STUDYPID,STUDYNUMBER,STUDYNUMBERMIG,STAGECODETEXT,PROJECTPID,PROJECTCODE,SHORTTITLE,STAGECODE,STANDARDSTUDYTYPECODE,STANDARDTYPENAME,CLINICALPHASE,CLINICALPHASETEXT,DETAILEDDESCRIPTION,EUDRACTNUMBER,EUDRACTNUMBERRECIEVEDDATE,STUDYTYPECODE,STUDYTYPENAME
1,0503-0101,503.101,Ended,3,0503-P01,Dose finding: 1.25 - 40 mg solution p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2,0503-0102,503.102,Ended,3,0503-P01,Dose titration: 2.5, 5, 10, 15mg i.v.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3,0503-0103,503.103,Ended,3,0503-P01,Absol. and rel. bioavail.(10mg p.o./i.v),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4,0503-0104,503.104,Unconfirmed,3,0503-P01,Metabolism and kinetics of 14C-lab.DKAH,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5,0503-0105,503.105,Ended,3,0503-P01,Kinetics, tolerance of 5,10,20mg p.o./7d,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6,0503-0106,503.106,Ended,3,0503-P01,Kinetics,tolerance comp.DKAH/ULFS49 p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7,0503-0107,503.107,Ended,3,0503-P01,Multiple p.o. administration (15 days),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8,0503-0201,503.201,Unconfirmed,3,0503-P01,Exercise duration - 1x10 mg p.o. ????,Unconfirmed,MIG,Migration,II,Phase II,Bisher noch keine Phase II-Genehmigung- ,,,000910,IS - Clin Study (MIGRATED)
9,0503-0202,503.202,Unconfirmed,3,0503-P01,Chron. treatment in stable angina,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10,0009-0070,9.70,Ended,4,0009-P01,ESPS-II,Ended,MIG,Migration,III,Phase III,- old contract, payed by BIGmbH*Biberach trial,,,000910,IS - Clin Study (MIGRATED)
11,0009-0105,9.105,Unconfirmed,4,0009-P01,Patients cerebrovascular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
12,0009-0123,9.123,Ended,4,0009-P01,Bioequivalence ESPS 2 - Production Batch,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13,0009-0124,9.124,Initiated,4,0009-P01,Bioequivalence Lower / Upper Limit,Initiated,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14,0009-0125,9.125,Ended,4,0009-P01,AS.TR.I.D.,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
15,0009-0126,9.126,Unconfirmed,4,0009-P01,RAD + ASA ex vivo study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
16,0009-0127,9.127,Ended,4,0009-P01,PK & PD Study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
17,0009-0128,9.128,Unconfirmed,4,0009-P01,ASA ex vivo study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
18,0009-0129,9.129,Unconfirmed,4,0009-P01,Pharmacokinetic Japanese patients,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
19,0009-0130,9.130,Ended,4,0009-P01,Thromboxane Inhibition,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
20,0009-0131,9.131,Ended,4,0009-P01,Clinical Pharmacology,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
21,0009-0132,9.132,Unconfirmed,4,0009-P01,Comparison of starting regimen,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
22,0009-0133,9.133,Unconfirmed,4,0009-P01,Clinical haematology,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
23,0009-0134,9.134,Unconfirmed,4,0009-P01,Clinical Outcome Study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
24,0009-0135,9.135,Ended,4,0009-P01,Driving/operating machinery (TUV),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
25,0009-0136,9.136,Ended,4,0009-P01,Food effect/dose dumping,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
26,0009-0137,9.137,Ended,4,0009-P01,Cohort Headaches Survey - Philipines,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
27,0009-0138,9.138,Ended,4,0009-P01,Comparison PK Aggrenox,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
28,0009-0139,9.139,Unconfirmed,4,0009-P01,Secondary prevention of stroke,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
29,0009-0140,9.140,Unconfirmed,4,0009-P01,ACE 2,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
30,0009-0141,9.141,Unconfirmed,4,0009-P01,Pilot study carotid stenting,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
31,0009-0142,9.142,Ended,4,0009-P01,VASP-PHOSPHORYLATION,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
32,0009-0143,9.143,Unconfirmed,4,0009-P01,ASASANTIN RETARD COHORT STUDY,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
33,0009-0144,9.144,Ended,4,0009-P01,in vivo batch comparison (new equipment),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
34,0009-0145,9.145,Unconfirmed,4,0009-P01,descriptive comp. of asa  retard v aspir,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
35,0009-0146,9.146,Ended,4,0009-P01,Absorption of DP from Aggrenox,Ended,MIG,Migration,IV,Phase IV,open-label/PhIV (no US IND for aggrenox) ,,,000910,IS - Clin Study (MIGRATED)
36,0009-0147,9.147,Preparing,4,0009-P01,Effects of Asa on cerebromicroembolism,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
37,0009-0148,9.148,Preparing,4,0009-P01,Headache dose titration study,Preparing,MIG,Migration,IV,Phase IV,,,,,
38,0009-0149,9.149,Ended,4,0009-P01,Bioequivalence new formulation,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
39,0009-0150,9.150,Ended,4,0009-P01,Dipyridamole headache prevention study,Ended,MIG,Migration,IV,Phase IV,,,,,
40,0009-0151,9.151,Unconfirmed,4,0009-P01,Aggrenox vs. Clopidogrel,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
41,0009-0152,9.152,Unconfirmed,4,0009-P01,Aggrenox clinical tolerance trial,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
42,0009-0153,9.153,Unconfirmed,4,0009-P01,Prevention/Reduction of Headache Trial,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
43,0009-0154,9.154,Unconfirmed,4,0009-P01,On demand treatment of Aggrenox Headache,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
44,0009-0155,9.155,Ended,4,0009-P01,Tolerability of Asa Ret 1 vs.2 caps/day,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
45,0009-0156,9.156,Ended,4,0009-P01,Study of Aggrenox induced headache,Ended,MIG,Migration,I,Phase I,,,,,
46,0009-0157,9.157,Ended,4,0009-P01,Vascular Access in Dialysis Patients,Ended,MIG,Migration,IV,Phase IV,,,,,
47,0009-0158,9.158,Ended,4,0009-P01,Bioequivalence "ideal release form",Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
48,0009-0159,9.159,Ended,4,0009-P01,PRoFESS,Ended,MIG,Migration,IV,Phase IV,average observation time approx. 3 years ,,,000910,IS - Clin Study (MIGRATED)
49,0009-0160,9.160,Ended,4,0009-P01,Pharmacology of DP induced headache,Ended,MIG,Migration,NONE,Not Classified,,,,,
50,0009-0161,9.161,Ended,4,0009-P01,Agg on Blood Rheol Oxid Stress/Rosensen,Ended,MIG,Migration,NONE,Not Classified,,,,,
51,0009-0162,9.162,Unconfirmed,4,0009-P01,A PK/PD Study of Clopidogrel,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
52,0009-0163,9.163,Ended,4,0009-P01,Bioavail' of various pharma' forms,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
53,0009-0165,9.165,Ended,4,0009-P01,PRCASA Trial/Smith,Ended,MIG,Migration,IV,Phase IV,,,,,
54,0009-0166,9.166,Ended,4,0009-P01,Tissue perfusion following Agg /Michaels,Ended,MIG,Migration,IV,Phase IV,,,,,
55,0009-0167,9.167,Ended,4,0009-P01,Adenosine and nitric Oxide/Biaggioni,Ended,MIG,Migration,IV,Phase IV,,,,,
56,0009-0168,9.168,Ended,4,0009-P01,Adenosine ind' h'che & blood flow/Olesen,Ended,MIG,Migration,NONE,Not Classified,,,,,
57,0009-0169,9.169,Ended,4,0009-P01,Aggrenox in aspirin resistance,Ended,MIG,Migration,IV,Phase IV,On behalf of BIPI ,,,000910,IS - Clin Study (MIGRATED)
58,0009-0170,9.170,Ended,4,0009-P01,ASSIST,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
59,0009-0171,9.171,Unconfirmed,4,0009-P01,Mngt of Dipyridamole-induced headache,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
60,0009-0172,9.172,Unconfirmed,4,0009-P01,Vascular Brain Injury Prevention,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
61,0009-0173,9.173,Preparing,4,0009-P01,Stroke Management Registry in France,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
62,0009-0174,9.174,Initiated,4,0009-P01,COG substudy PRoFESS,Initiated,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
63,0009-0175,9.175,Initiated,4,0009-P01,ProFESS Hemodynamic substudy,Initiated,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
64,0009-0176,9.176,Unconfirmed,4,0009-P01,PRoFESS Imaging Substudy, MRI,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
65,0009-0177,9.177,Unconfirmed,4,0009-P01,Aggrenox vs. ASS monotherapy,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
66,0009-0178,9.178,Ended,4,0009-P01,JASAP,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
67,0009-0182,9.182,Ended,4,0009-P01,EARLY treatment with Aggrenox/ASA,Ended,MIG,Migration,IV,Phase IV,,2006-004870-28,,000910,IS - Clin Study (MIGRATED)
68,0009-0183,9.183,Ended,4,0009-P01,Thrombin Receptors in Japanese Volunt,Ended,MIG,Migration,IV,Phase IV,,,,,
69,0009-0185,9.185,Unconfirmed,4,0009-P01,Endothelial Function study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
70,0009-0186,9.186,Unconfirmed,4,0009-P01,Aggrenox bridging Japan,Unconfirmed,MIG,Migration,III,Phase III,,,,,
71,0009-0187,9.187,Unconfirmed,4,0009-P01,pK in Elderly with Biomarkers,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
72,0009-0188,9.188,Unconfirmed,4,0009-P01,Inflammatory Biomarkers after Stroke,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
73,0009-0189,9.189,Preparing,4,0009-P01,pK-pD in Blood Compartments,Preparing,MIG,Migration,IV,Phase IV,,,,,
74,0009-0190,9.190,Unconfirmed,4,0009-P01,Retrospective Analysis of Heart transpla,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
75,0009-0191,9.191,Unconfirmed,4,0009-P01,Biomarkers of inflammation after stroke,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
76,0009-0192,9.192,Unconfirmed,4,0009-P01,Biomarkers of inflammation after stroke,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
77,0009-0193,9.193,Preparing,4,0009-P01,Bioequivalence study of mini capsules,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
78,0009-0194,9.194,Preparing,4,0009-P01,AGATE-J2,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
79,0009-0195,9.195,Preparing,4,0009-P01,AGGRENOX in vascular dementia,Preparing,MIG,Migration,IV,Phase IV,,,,,
80,0009-0196,9.196,Preparing,4,0009-P01,PMS Study of Aggrenox,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
81,0009-0197,9.197,Ended,4,0009-P01,Aggrenox and omeprazole DDI study,Ended,MIG,Migration,I,Phase I,Study will be outsourced to a U.S. CRO CRO to develop protocol & CRF, conduct study; analyze blood samples, provide written report,,,000910,IS - Clin Study (MIGRATED)
82,0009-0198,9.198,Unconfirmed,4,0009-P01,Smart Pill Device for Aggrenoz,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
83,0009-0199,9.199,Unconfirmed,4,0009-P01,Smart Pill Device for Aggrenox,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
84,0260-3135,260.3135,Ended,5,0260-P28,BEROTEC EMERGENCY ROOM TRIAL,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
85,0260-3139,260.3139,Ended,5,0260-P28,Emergency Room Study,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
86,0253-1000,253.1000,Ended,6,0253-P02,MILD ESS. HYPERTENSION,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
87,0253-1001,253.1001,Ended,6,0253-P02,SAFETY &, LONG TERM EFFECT,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
88,0253-1002,253.1002,Ended,6,0253-P02,MILD TO MODERATE ESS. HYPERTENSION,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
89,0253-1003,253.1003,Ended,6,0253-P02,MILD TO MODERATE ESS. HYPERTENSION,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
90,0253-1004,253.1004,Ended,6,0253-P02,SAFETY, LONG TERM EFFECT,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
91,0253-1005,253.1005,Ended,6,0253-P02,TOLERANCE, EFFICACY,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
92,0253-1006,253.1006,Ended,6,0253-P02,SAFETY & EFFICACY, STRATIFICATION: SEX,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
93,0253-1007,253.1007,Ended,6,0253-P02,BIOEQUIVALENCE, MULTIPLE DOSE,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
94,0253-1008,253.1008,Ended,6,0253-P02,KINETICS, DOSE LINEARITY,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
95,0253-1009,253.1009,Ended,6,0253-P02,CHANGE-OVER TTS>CPA, EFFICACY & SAFETY,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
96,0253-1010,253.1010,Ended,6,0253-P02,LOCAL TOLERANCE,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
97,0253-1011,253.1011,Preparing,6,0253-P02,EFFICACY & TOLERANCE,Preparing,MIG,Migration,III,Phase III,- , EStatus = X, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
98,0253-1012,253.1012,Unconfirmed,6,0253-P02,DIALYSE,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
99,0253-1013,253.1013,Ended,6,0253-P02,SAFETY & EFFICACY, CHANGE-OVER TTS>CPA,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
100,0253-1014,253.1014,Ended,6,0253-P02,PLASMA LEVEL, RENAL OUTPUT,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
101,0253-1015,253.1015,Unconfirmed,6,0253-P02,COMPARISON STANDARD,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
102,0253-1016,253.1016,Unconfirmed,6,0253-P02,MILD TO MODERATE ESS. HYPERTENSION,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
103,0253-1017,253.1017,Unconfirmed,6,0253-P02,MILD TO MODERATE ESS. HYPERTENSION,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
104,0253-1018,253.1018,Ended,6,0253-P02,SAFETY & EFFICACY,Ended,MIG,Migration,III,Phase III,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
105,0253-1019,253.1019,Unconfirmed,6,0253-P02,COMPLIANCE,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
106,0253-1020,253.1020,Ended,6,0253-P02,EFFICACY & TOLERANCE,Ended,MIG,Migration,III,Phase III,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
107,0253-1021,253.1021,Ended,6,0253-P02,SAFETY & EFFICACY,Ended,MIG,Migration,IIIB,Phase IIIb,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
108,0253-1022,253.1022,Ended,6,0253-P02,METHOD, ADHESIVENESS,Ended,MIG,Migration,I,Phase I,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
109,0253-1023,253.1023,Ended,6,0253-P02,SAFETY & EFFICACY,Ended,MIG,Migration,IIIB,Phase IIIb,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
110,0253-1024,253.1024,Unconfirmed,6,0253-P02,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
111,0253-1025,253.1025,Ended,6,0253-P02,TOLERANCE, EFFICACY,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
112,0253-1026,253.1026,Ended,6,0253-P02,SAFETY & EFFICACY,Ended,MIG,Migration,IIIB,Phase IIIb,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
113,0253-1081,253.1081,Unconfirmed,6,0253-P02,Compliance versus oral Catapres,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
114,0253-1082,253.1082,Unconfirmed,6,0253-P02,MILD TO MODERATE ESS. HYPERTENSION,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
115,0253-1083,253.1083,Unconfirmed,6,0253-P02,MILD TO MODERATE ESS. HYPERTENSION,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
116,0253-1084,253.1084,Unconfirmed,6,0253-P02,MILD TO MODERATE ESS. HYPERTENSION,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
117,0253-1085,253.1085,Unconfirmed,6,0253-P02,MILD TO MODERATE ESS. HYPERTENSION,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
118,0253-2001,253.2001,Preparing,6,0253-P02,Efficacy & safety, prophylaxis,Preparing,MIG,Migration,III,Phase III,- , EStatus = X, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
119,0253-2384,253.2384,Ended,6,0253-P02,Hypertension,Ended,MIG,Migration,III,Phase III,- Int'l by decision of Corp. Div. Med.,,,000910,IS - Clin Study (MIGRATED)
120,0253-2400,253.2400,Ended,6,0253-P02,CLONIDINE CPA vs PLACEBO IN ESSENTIAL Hy,Ended,MIG,Migration,II,Phase II,- Int'l by decision of Corp. Div. Med.,,,000500,Compassionate Use Program (CUP)
121,0253-2401,253.2401,Ended,6,0253-P02,24 h BP monitoring: Tablets vs CPA,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
122,0253-2413,253.2413,Ended,6,0253-P02,Perioperative anesthetic effect of cloni,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
123,0244-0301,244.301,Unconfirmed,7,0244-P02,Equivalence, Efficacy,Unconfirmed,MIG,Migration,NONE,Not Classified,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
124,0244-0302,244.302,Unconfirmed,7,0244-P02,Equivalence, Efficacy,Unconfirmed,MIG,Migration,NONE,Not Classified,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
125,0244-0303,244.303,Unconfirmed,7,0244-P02,Dose-Ranging, Efficacy,Unconfirmed,MIG,Migration,NONE,Not Classified,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
126,0244-0308,244.308,Unconfirmed,7,0244-P02,Cumul. dose-response,Unconfirmed,MIG,Migration,NONE,Not Classified,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
127,0244-0322,244.322,Unconfirmed,7,0244-P02,Safety, Efficacy,Unconfirmed,MIG,Migration,NONE,Not Classified,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
128,0236-0101,236.101,Ended,8,0236-P01,Tolerance, single dose (po),Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
129,0236-0103,236.103,Unconfirmed,8,0236-P01,Tolerance, multiple dose (po),Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
130,0236-0104,236.104,Unconfirmed,8,0236-P01,Tolerance, multiple dose (iv),Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
131,0236-0105,236.105,Unconfirmed,8,0236-P01,Kinetics & safety,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
132,0236-0106,236.106,Unconfirmed,8,0236-P01,Pain model I, evoked potential,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
133,0236-0107,236.107,Unconfirmed,8,0236-P01,Pain model II, evoked potential,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
134,0236-0108,236.108,Unconfirmed,8,0236-P01,Pain model III, evoked potential,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
135,0236-0111,236.111,Ended,8,0236-P01,Tolerance, single dose (iv),Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
136,0236-0113,236.113,Unconfirmed,8,0236-P01,NONE,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
137,0236-0114,236.114,Unconfirmed,8,0236-P01,PAIN POST OP,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
138,0236-0120,236.120,Ended,8,0236-P01,Tolerance, single dose (po),Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
139,0236-0121,236.121,Ended,8,0236-P01,Tolerance, single dose (iv),Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
140,0236-0122,236.122,Unconfirmed,8,0236-P01,Abs. bioavailability, single dose (po,iv,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
141,0236-0130,236.130,Ended,8,0236-P01,Pharmacokinetics, bioavailability,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
142,0236-0131,236.131,Unconfirmed,8,0236-P01,ADME,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
143,0236-0132,236.132,Unconfirmed,8,0236-P01,Bioequivalence, capsules/tablets,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
144,0236-0140,236.140,Ended,8,0236-P01,Respiratory effects, MR 2264 vs. morphin,Ended,MIG,Migration,I,Phase I,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
145,0236-0141,236.141,Unconfirmed,8,0236-P01,Histamine release, after single dose,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
146,0236-0142,236.142,Unconfirmed,8,0236-P01,Interaction / food, single dose p.o.,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
147,0236-0143,236.143,Unconfirmed,8,0236-P01,Drug abuse liability, human post addicts,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
148,0236-0150,236.150,Ended,8,0236-P01,Multiple dose p.o., cumulative charact.,Ended,MIG,Migration,I,Phase I,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
149,0236-0201,236.201,Ended,8,0236-P01,MR Single dose p.o., post tonsillectomy,Ended,MIG,Migration,II,Phase II,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
150,0236-0202,236.202,Unconfirmed,8,0236-P01,Single dose p.o., post episiotomy,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
151,0236-0211,236.211,Unconfirmed,8,0236-P01,PCA, abdominal surgery,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
152,0236-0212,236.212,Unconfirmed,8,0236-P01,Single dose i.v., abdom. hysterectomy,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
153,0236-0213,236.213,Unconfirmed,8,0236-P01,Single dose i.v., vs. morphine,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
154,0236-0214,236.214,Unconfirmed,8,0236-P01,Single dose i.v. /, multiple doses p.o.,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
155,0236-0220,236.220,Unconfirmed,8,0236-P01,Single dose i.m., post laparoskopy,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
156,0236-0250,236.250,Unconfirmed,8,0236-P01,PAIN,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
157,0236-0301,236.301,Unconfirmed,8,0236-P01,Multiple dose p.o., cancer pain,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
158,0236-0302,236.302,Unconfirmed,8,0236-P01,Multiple doses p.o., osteoarthritis,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
159,0236-0303,236.303,Unconfirmed,8,0236-P01,Multiple doses p.o., cancer / rheuma,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
160,0236-0304,236.304,Unconfirmed,8,0236-P01,Multiple doses p.o., liver insufficiency,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
161,0236-0305,236.305,Unconfirmed,8,0236-P01,Multiple dose p.o., kidney insufficiency,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
162,0236-0306,236.306,Unconfirmed,8,0236-P01,Multiple doses p.o., post OP,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
163,0527-0001,527.1,Ended,9,0527-P01,TAMSULOSIN VS PLACEBO IN MODERATE BPH,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
164,0527-0002,527.2,Ended,9,0527-P01,Long term safety F/U,Ended,MIG,Migration,IIIB,Phase IIIb,-  This trial is an open label safety study for which BIPI will be responsible. To be conducted at 14 VRG Int'l clinics, but field monitoring by BIPI. Pts enter trial after completing US93-04. drug not needed thru BIPI. Study initiation should begin 4Q94.   ,,,000910,IS - Clin Study (MIGRATED)
165,0527-0003,527.3,Ended,9,0527-P01,Pharmacodynamic study,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
166,0527-0004,527.4,Ended,9,0527-P01,Comparison with terazosin,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
167,0527-0005,527.5,Ended,9,0527-P01,Efficacy Tamsulosin,Ended,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
168,0527-0006,527.6,Ended,9,0527-P01,Food/Fasting pk in elderly volunteers,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
169,0527-0007,527.7,Ended,9,0527-P01,Pharmacoeconomic Study,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
170,0527-0008,527.8,Unconfirmed,9,0527-P01,Open to assess Tamsulosin,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
171,0527-0009,527.9,Ended,9,0527-P01,Mictional holter,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
172,0527-0010,527.10,Unconfirmed,9,0527-P01,Home Peak Flow Measurement ,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000980,Not Classified (MIGRATED)
173,0527-0011,527.11,Ended,9,0527-P01,PMS Study - Urologists,Ended,MIG,Migration,NONE,Not Classified,,,,000940,Post Marketing Study (MIGRATED)
174,0527-0012,527.12,Unconfirmed,9,0527-P01,Open,safety,efficacy,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
175,0527-0013,527.13,Ended,9,0527-P01,Tam vs Ter safety/efficacy,Ended,MIG,Migration,IIIB,Phase IIIb,Published in Urologia Feb.99 pp.6-13 ,,,000910,IS - Clin Study (MIGRATED)
176,0527-0014,527.14,Ended,9,0527-P01,PMS Study - Quality of Life,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
177,0527-0015,527.15,Ended,9,0527-P01,MICTUS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
178,0527-0016,527.16,Ended,9,0527-P01,Phase IV trial #1,Ended,MIG,Migration,IV,Phase IV,-This study consist of 50 sites The data management and site management will be performed by a CRO.     ,,,000940,Post Marketing Study (MIGRATED)
179,0527-0017,527.17,Ended,9,0527-P01,Open Label Comparator Trial,Ended,MIG,Migration,IV,Phase IV,-  The data management and site management will be performed by a CRO.     ,,,000940,Post Marketing Study (MIGRATED)
180,0527-0018,527.18,Unconfirmed,9,0527-P01,Phase IV trial #3,Unconfirmed,MIG,Migration,IV,Phase IV,        ,,,000940,Post Marketing Study (MIGRATED)
181,0527-0019,527.19,Ended,9,0527-P01,PMS - Alna in BPH-patients,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
182,0527-0020,527.20,Ended,9,0527-P01,Major irritative and obstructive LUTS,Ended,MIG,Migration,IV,Phase IV,Depending on Marketing requirements ,,,000940,Post Marketing Study (MIGRATED)
183,0527-0021,527.21,Unconfirmed,9,0527-P01,OIND prostatitis trial,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
184,0527-0022,527.22,Ended,9,0527-P01,Bioequivalence new production site,Ended,MIG,Migration,I,Phase I,Cato Research will manage the study ,,,000910,IS - Clin Study (MIGRATED)
185,0527-0023,527.23,Ended,9,0527-P01,Chronic Nonbacterial Prostatitis/ CPPS,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
186,0527-0024,527.24,Preparing,9,0527-P01,LUTS associated with Brachytherapy,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
187,0527-0025,527.25,Ended,9,0527-P01,Female LUTS,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
188,0527-0026,527.26,Ended,9,0527-P01,Acute Retention/BPH,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
189,0527-0027,527.27,Preparing,9,0527-P01,Tamsulosin vs. Doxazosin,Preparing,MIG,Migration,IV,Phase IV,Financial support by Yamanouchi/Japan ? ,,,000910,IS - Clin Study (MIGRATED)
190,0527-0028,527.28,Ended,9,0527-P01,JOSEPHINE,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
191,0527-0029,527.29,Ended,9,0527-P01,Chroncic Abacterial Prostatitis CPCRN,Ended,MIG,Migration,III,Phase III,See Extended Remark IOR-Study - BP responsible for supplying bulk drug -both active and matching placebo.
,,,,
192,0527-0030,527.30,Ended,9,0527-P01,Bladder Study,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
193,0527-0031,527.31,Unconfirmed,9,0527-P01,Tamsulosin in Parkinson Patient mit LUTS,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
194,0527-0032,527.32,Ended,9,0527-P01,Oberservational Study  in BPO and HBP,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
195,0527-0035,527.35,Unconfirmed,9,0527-P01,Flomax vs Placebo following TUNA or TUMT,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
196,0527-0036,527.36,Unconfirmed,9,0527-P01,Tamsulosin Acute Urinary Retention I,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
197,0527-0037,527.37,Unconfirmed,9,0527-P01,Tamsulosin Acute Urinary Retention II,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
198,0527-0038,527.38,Ended,9,0527-P01,Umstellungs-AWB,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
199,0527-0040,527.40,Ended,9,0527-P01,Alna AWB 2003,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
200,0527-0041,527.41,Ended,9,0527-P01,Pharmacovigillance Study Secotex,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
201,0527-0046,527.46,Ended,9,0527-P01,COUPLE, BPH Impact in daily life (URO),Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
202,0527-0047,527.47,Ended,9,0527-P01,Secotex PMS,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
203,0527-0052,527.52,Unconfirmed,9,0527-P01,Flomax in conjunction with antibiotics,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
204,0527-0053,527.53,Unconfirmed,9,0527-P01,Flomax in LUTS due to Multiple Sclerosis,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
205,0527-0056,527.56,Ended,9,0527-P01,ALNA AWB 2004,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
206,0527-0057,527.57,Ended,9,0527-P01,ECOUTE, BPH impact on daily life (GP),Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
207,0527-0058,527.58,Ended,9,0527-P01,Secotex Clinical Safety Evaluation,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
208,0527-0059,527.59,Preparing,9,0527-P01,SEXO_URO, Impact of BPH on sexuality,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
209,0527-0060,527.60,Unconfirmed,9,0527-P01,SEXO_GP,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
210,0527-0064,527.64,Ended,9,0527-P01,Secotex II Clinical Evaluation Programm,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
211,0527-0067,527.67,Preparing,9,0527-P01, WOW-TAB 0.4 mg vs Flomax 0.4mg,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
212,0527-0068,527.68,Ended,9,0527-P01,ALNA OCAS Nycturie AWB,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
213,0527-0069,527.69,Ended,9,0527-P01,Tolerability in different ages groups,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
214,0527-0070,527.70,Ended,9,0527-P01,Phenylephrine mydriasis interaction,Ended,MIG,Migration,I,Phase I,,2005-003025-10,,000910,IS - Clin Study (MIGRATED)
215,0527-0073,527.73,Ended,9,0527-P01,Tamsulosin mono or combination therapy,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
216,0527-0075,527.75,Ended,9,0527-P01,ALNA OCAS Long-term 6 months,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
217,0527-0076,527.76,Ended,9,0527-P01,Quality2 Study,Ended,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
218,0527-0077,527.77,Ended,9,0527-P01,Impact of Nocturia on QoL,Ended,MIG,Migration,IV,Phase IV,observational study ,,,000940,Post Marketing Study (MIGRATED)
219,0527-0078,527.78,Ended,9,0527-P01,CYP3A4 Interaction study Ketoconazole,Ended,MIG,Migration,I,Phase I,,2007-005293-31,,000910,IS - Clin Study (MIGRATED)
220,0527-0079,527.79,Ended,9,0527-P01,CYP2D6 Interaction Study Paroxetine,Ended,MIG,Migration,I,Phase I,,2007-005310-39,,000910,IS - Clin Study (MIGRATED)
221,0527-0080,527.80,Ended,9,0527-P01,QoL in patients with BPH and nocturia,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
222,0527-0081,527.81,Preparing,9,0527-P01,Self selction/self-recognition for OTC,Preparing,MIG,Migration,NONE,Not Classified,This is a CHC study. Trial dsign and Blinding is N/A.  Specialis-Urologists,,,000300,IS - Methodological Studies
223,0527-0084,527.84,Analysis,9,0527-P01,Flomax Relief,Analysis,MIG,Migration,NONE,Not Classified,,,,000920,NISnd - Study (MIGRATED)
224,1113-0001,1113.1,Ended,10,1113-P01,Single increasing dose tolerance study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
225,1113-0002,1113.2,Unconfirmed,10,1113-P01,Safety and Tolerability after mult. adm.,Unconfirmed,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
226,1113-0003,1113.3,Unconfirmed,10,1113-P01,Relative bioavailability tab.,Unconfirmed,MIG,Migration,I,Phase I,-  Study planning handled by Dr. Keirns. The investigator will be Dr Philip Leese, Innovex. The dose will be selected based on the results of the first trial.     ,,,000910,IS - Clin Study (MIGRATED)
227,0519-0001,519.1,Ended,11,0519-P01,Single dose tolerance of BIRM 270 BS,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
228,0519-0002,519.2,Ended,11,0519-P01,Multiple incr. dose tol. of BIRM 270 BS,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
229,0519-0003,519.3,Ended,11,0519-P01,Antigen challenge,Ended,MIG,Migration,IIIA,Phase IIIa,- ,,,000910,IS - Clin Study (MIGRATED)
230,0519-0004,519.4,Ended,11,0519-P01,Time and dose-effect on EIB,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
231,0519-0005,519.5,Ended,11,0519-P01,7 DAY ANTIGEN CHALLENGE,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
232,0519-0006,519.6,Unconfirmed,11,0519-P01,6 week efficacy,Unconfirmed,MIG,Migration,IIA,Phase IIa,-    Budget Explan: See memo to WM 10/27/92.   ,,,000910,IS - Clin Study (MIGRATED)
233,0519-0007,519.7,Ended,11,0519-P01,Pulmonary function study,Ended,MIG,Migration,II,Phase II,-  On internal clinical hold as a result of tox questions.   ON INTERNAL CLINICAL HOLD AS A RESULT OFTOX QUESTIONS. ,,,000910,IS - Clin Study (MIGRATED)
234,0519-0009,519.9,Unconfirmed,11,0519-P01,Nocturnal asthma,Unconfirmed,MIG,Migration,II,Phase II,-  WILL BE DELAYED DUE TO INTERNAL HOLD. MAY START 6-7/97 (TBD)     ,,,000910,IS - Clin Study (MIGRATED)
235,0519-0019,519.19,Preparing,11,0519-P01,Asthma,Preparing,MIG,Migration,IIIA,Phase IIIa,- ,,,000910,IS - Clin Study (MIGRATED)
236,0519-0024,519.24,Unconfirmed,11,0519-P01,Interaction trial,Unconfirmed,MIG,Migration,II,Phase II,-  Trial to be delayed at least 3 months as a result of tox questions.     ,,,000910,IS - Clin Study (MIGRATED)
237,0519-0101,519.101,Unconfirmed,11,0519-P01,Tolerability and PK,Unconfirmed,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
238,0519-0102,519.102,Unconfirmed,11,0519-P01,14 day dosing,Unconfirmed,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
239,0519-0103,519.103,Unconfirmed,11,0519-P01,SD antigen challenge,Unconfirmed,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
240,0519-0104,519.104,Unconfirmed,11,0519-P01,SD exercise,Unconfirmed,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
241,0519-1004,519.1004,Ended,11,0519-P01,Nocturnal Asthma,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
242,0231-0101,231.101,Ended,12,0231-P01,Single Dose Tolerance Study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
243,0231-0102,231.102,Ended,12,0231-P01,Multiple Dose Tolerance Study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
244,0231-0202,231.202,Ended,12,0231-P01,Effect & safety, long term treatment,Ended,MIG,Migration,III,Phase III,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
245,0231-0211,231.211,Ended,12,0231-P01,Effect & safety, long term treatment,Ended,MIG,Migration,III,Phase III,- inserted by pilnei at 21.06.93,,,000910,IS - Clin Study (MIGRATED)
246,0231-0213,231.213,Ended,12,0231-P01,Effect & safety, long term treatment,Ended,MIG,Migration,III,Phase III,- inserted by pilnei at 15.04.94,,,000910,IS - Clin Study (MIGRATED)
247,0231-0215,231.215,Ended,12,0231-P01,Effect & safety, long term treatment,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
248,0231-0220,231.220,Ended,12,0231-P01,Dose response,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
249,0231-0300,231.300,Ended,12,0231-P01,ABPM in out-patients (side study of OvA),Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
250,0231-0301,231.301,Ended,12,0231-P01,OPTIMO (periodically assessed tolerance),Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
251,0231-0302,231.302,Ended,12,0231-P01,Hypertensive with chronic renal complica,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
252,0231-0303,231.303,Ended,12,0231-P01,Influence on 24 h BP profile,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
253,0231-0304,231.304,Ended,12,0231-P01,Tolerability of Lacidipine in Elderly,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
254,0231-0305,231.305,Ended,12,0231-P01,Safety,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
255,0231-0306,231.306,Ended,12,0231-P01,Safety,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
256,0231-0307,231.307,Ended,12,0231-P01,effects under normal or hyposodic diet,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
257,0231-0308,231.308,Unconfirmed,12,0231-P01,24h BP-Control: Lacidipine compared to E,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
258,0231-0309,231.309,Ended,12,0231-P01,24h BP-Control: Lacidipine compared to E,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
259,0231-0310,231.310,Ended,12,0231-P01,Effect of dosing time,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
260,0231-0311,231.311,Ended,12,0231-P01,Effect on the 24 h ABPM - Side study OvA,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
261,0231-0312,231.312,Ended,12,0231-P01,Comparison with Adalat Oros - COMFORT,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
262,0231-0313,231.313,Ended,12,0231-P01,ABPM : Lacidipine vs Amlor - GP TEAM,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
263,0231-0315,231.315,Ended,12,0231-P01,Efficacy and safety of Lacidipine,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
264,0231-0316,231.316,Ended,12,0231-P01,EFFICACY/TOLERANCE 2MG & 4MG STARTING DO,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
265,0231-0320,231.320,Ended,12,0231-P01,Repeated doese po vs. Placebo,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
266,0231-0322,231.322,Ended,12,0231-P01,Ankle Study,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
267,0231-0324,231.324,Ended,12,0231-P01,Lacidipine in hypertension,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
268,0231-0326,231.326,Ended,12,0231-P01,LASTLHY,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
269,0231-0327,231.327,Ended,12,0231-P01,SWISH,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
270,0231-0328,231.328,Ended,12,0231-P01,Caldine and therapeutic compliance,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
271,0231-0329,231.329,Ended,12,0231-P01,Caldine epidemio-economic study,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
272,0231-0330,231.330,Ended,12,0231-P01,Caldine in elderly hypertensive patients,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
273,0231-0331,231.331,Ended,12,0231-P01,Efficacy and Safety of Lacidipine in Hyp,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
274,0231-0332,231.332,Ended,12,0231-P01,Hypertension education,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
275,0231-0333,231.333,Ended,12,0231-P01,Lacidipine vs Bendrofluozide in ISH,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
276,0231-0334,231.334,Ended,12,0231-P01,PMSS Caldine IV,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
277,0231-0335,231.335,Ended,12,0231-P01,Lacidipine in Ambulatory Hypertensives,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
278,0231-0336,231.336,Ended,12,0231-P01,Lac. vs BFZ on systemic markers LEOPARD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
279,0231-0338,231.338,Preparing,12,0231-P01,Asasantin + lacidipine in hypertension,Preparing,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
280,0231-0340,231.340,Ended,12,0231-P01,Tolerance checking early in treatment,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
281,0231-0342,231.342,Preparing,12,0231-P01,Patients's opinion and compliance,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
282,0509-0101,509.101,Ended,13,0509-P01,Dose finding: 10-150 mg drinksol. p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
283,0509-0102,509.102,Unconfirmed,13,0509-P01,Absol. and rel. bioavail.(10mg p.o./i.v),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
284,0509-0103,509.103,Ended,13,0509-P01,Multiple dose of 25,50,75,100 mg p.o./7d,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
285,0509-0104,509.104,Ended,13,0509-P01,C14 Adme Study (BIBU 104 XX/BIBU 52 ZW),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
286,0509-0105,509.105,Ended,13,0509-P01,Bioavailability 50mg capsule/solution,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
287,0509-0106,509.106,Ended,13,0509-P01,Bioavail.and toler.of various formulatio,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
288,0509-0107,509.107,Unconfirmed,13,0509-P01,Multiple parallel dose ??? over 7 days,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
289,0509-0108,509.108,Ended,13,0509-P01,Multiple dose 60mg and 90 mg t.i.d.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
290,0509-0109,509.109,Ended,13,0509-P01,Absorption Site Mapping,Ended,MIG,Migration,I,Phase I,- Identisches Datum f√ºr Final Draft und Final Protocol, aber unterschiedliche S.18! Eingang Final Protocol 11.04.95!!,,,000910,IS - Clin Study (MIGRATED)
291,0509-0110,509.110,Ended,13,0509-P01,Urine excretion,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
292,0509-0111,509.111,Ended,13,0509-P01,Rel. Bioavailability, Urinary excretion,Ended,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
293,0509-0112,509.112,Preparing,13,0509-P01,Bioavailability Study,Preparing,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
294,0509-0113,509.113,Ended,13,0509-P01,Influence of gastric pH on absorption,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
295,0509-0114,509.114,Preparing,13,0509-P01,Interaction with ticlopidin,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
296,0509-0115,509.115,Ended,13,0509-P01,PK of 10, 30 and 45 mg acid free Tablets,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
297,0509-0116,509.116,Ended,13,0509-P01,Pantoprazol Interact. with orange juice,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
298,0509-0117,509.117,Ended,13,0509-P01,Influence of food on the bioavailability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
299,0509-0118,509.118,Ended,13,0509-P01,Interaction Lefradafiban 30mg/Pantoprazo,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
300,0509-0119,509.119,Ended,13,0509-P01,Interaction Lefradafiban 20mg Pantoprazo,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
301,0509-0201,509.201,Ended,13,0509-P01,FRASCATI,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
302,0509-0202,509.202,Unconfirmed,13,0509-P01,Elective PTCA BIBU 104 vs. ASA,Unconfirmed,MIG,Migration,I,Phase I,-  This trial was entered based on CTU update information. Study was cancelled prior to entry.     ,,,000910,IS - Clin Study (MIGRATED)
303,0509-0203,509.203,Unconfirmed,13,0509-P01,Unstable Angina dose response,Unconfirmed,MIG,Migration,II,Phase II,-  This trial proposed is likely to be modified based on an FDA meeting (pre-IND, June 22 1995)     ,,,000910,IS - Clin Study (MIGRATED)
304,0509-0204,509.204,Ended,13,0509-P01,FROST,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
305,0509-0301,509.301,Preparing,13,0509-P01,FROST II,Preparing,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
306,0509-0302,509.302,Ended,13,0509-P01,Interaction with Clopidogrel,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
307,0509-0303,509.303,Preparing,13,0509-P01,BIBU52/104 comp. to IV Tirofiban in UA,Preparing,MIG,Migration,III,Phase III,See Extended Remark Three-month treatment is basis of NDA.  Follow-up data at 6 & 12 mos. will also be required.
,,,000910,IS - Clin Study (MIGRATED)
308,0509-0304,509.304,Unconfirmed,13,0509-P01,Interaction Telmi Clopidogrel + Aspirin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
309,0513-0101,513.101,Ended,14,0513-P01,Dose finding: 1, 3, 5, 10, 15 mg i.v.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
310,0513-0102,513.102,Ended,14,0513-P01,Pharmacokinetics of BIBU52 in Japanese,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
311,0513-0201,513.201,Ended,14,0513-P01,Reocclusion prophylaxis after PTCA,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
312,0513-0202,513.202,Ended,14,0513-P01,DOSE RANGING/PHARMACOKINETIC ASSESSMENT,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
313,0513-0203,513.203,Ended,14,0513-P01,Dose comparison and safety of BIBU PTCA,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
314,0513-0204,513.204,Ended,14,0513-P01,FRASCATI,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
315,0513-0301,513.301,Unconfirmed,14,0513-P01,PTCA phase III trial,Unconfirmed,MIG,Migration,III,Phase III,-  This protocol is likely to be done in conjunction with a European program. (another 2000 pts in a separate protocol)     ,,,000910,IS - Clin Study (MIGRATED)
316,1040-0001,1040.1,Ended,15,1040-P01,multiple dose tolerance i.v.,R,DB,PG,Ended,MIG,Migration,I,Phase I,- Proj. on hold will be cancelled most probably (15.7.96 Dr. D√ºttmann),,,000910,IS - Clin Study (MIGRATED)
317,1040-0002,1040.2,Ended,15,1040-P01,single dose tolerance i.v. DB,R,PG,Ended,MIG,Migration,I,Phase I,- Proj. on hold will be cancelled most probably (15.7.96 Dr. D√ºttmann),,,000910,IS - Clin Study (MIGRATED)
318,0518-0104,518.104,Ended,16,0518-P01,SAFETY,Ended,MIG,Migration,I,Phase I,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
319,0518-0105,518.105,Ended,16,0518-P01,TOLERABILITY P.O., SINGLE DOSE,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
320,0518-0106,518.106,Ended,16,0518-P01,TOLERABILITY P.O., MULTIPLE DOSE,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
321,0518-0107,518.107,Ended,16,0518-P01,Dose tolerance i.v. single dose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
322,0518-0108,518.108,Preparing,16,0518-P01,BIIP 20 XX vs. Koffein,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
323,0518-0109,518.109,Unconfirmed,16,0518-P01,Pharmacokinetics and bioavailability,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
324,0518-0110,518.110,Unconfirmed,16,0518-P01,Metabolism and pharmacokinetics (c14),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
325,0518-0113,518.113,Unconfirmed,16,0518-P01,Single administration in elderly volunte,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
326,0518-0114,518.114,Unconfirmed,16,0518-P01,Multiple administration,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
327,0518-0115,518.115,Unconfirmed,16,0518-P01,PHASE I STUDY ON BIIP 20 XX,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
328,0518-0202,518.202,Unconfirmed,16,0518-P01,Safety+tol. of mult. doses Apaxifylline,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000980,Not Classified (MIGRATED)
329,0518-0203,518.203,Unconfirmed,16,0518-P01,Dose ranging,Unconfirmed,MIG,Migration,II,Phase II,-  Intense CRO usage planned. Study dependent on FDA lifting the clinical hold. not pivotal     ,,,000910,IS - Clin Study (MIGRATED)
330,0506-0101,506.101,Ended,17,0506-P01,safety, single dose (po),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
331,0506-0102,506.102,Ended,17,0506-P01,increasing dose, safety study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
332,0506-0103,506.103,Ended,17,0506-P01,multiple increasing dose, safety,Ended,MIG,Migration,I,Phase I,trial discon. after 1st treat. period ,,,000910,IS - Clin Study (MIGRATED)
333,0506-0104,506.104,Ended,17,0506-P01,Mult.increas. dose safety,Ended,MIG,Migration,I,Phase I,Extended with two additional doses Due to good tolerability 2 add. dose groups (60, 80mg) tested; delay of following times lines app. 3 months,,,000910,IS - Clin Study (MIGRATED)
334,0506-0105,506.105,Preparing,17,0506-P01,NONE,Preparing,MIG,Migration,NONE,Not Classified,cancelled CANCELLED,,,000980,Not Classified (MIGRATED)
335,0506-0106,506.106,Unconfirmed,17,0506-P01,Kinetics in renal failure,Unconfirmed,MIG,Migration,I,Phase I,- *Ingelheim trial,,,000910,IS - Clin Study (MIGRATED)
336,0506-0107,506.107,Ended,17,0506-P01,i.v. safety, single ascend. dose steps,Ended,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
337,0506-0108,506.108,Ended,17,0506-P01,Bioavail. WAL 2014 iv. - po. ,Ended,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
338,0506-0109,506.109,Ended,17,0506-P01,Radiolabeled ADME study ,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
339,0506-0110,506.110,Preparing,17,0506-P01,Kinetics in reduced kidney function,Preparing,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
340,0506-0111,506.111,Ended,17,0506-P01,Single dose phase I,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
341,0506-0112,506.112,Ended,17,0506-P01,Multiple dose phase I,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
342,0506-0113,506.113,Unconfirmed,17,0506-P01,Food Interaction,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
343,0506-0114,506.114,Ended,17,0506-P01,Beta-Blocker Interaction,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
344,0506-0115,506.115,Preparing,17,0506-P01,Digoxine Interaction,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
345,0506-0116,506.116,Preparing,17,0506-P01,Diuretics Interaction I, furosemide,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
346,0506-0117,506.117,Unconfirmed,17,0506-P01,Diuretics Interaction II, thiazides,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
347,0506-0118,506.118,Unconfirmed,17,0506-P01,NSAIDs Interaction,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
348,0506-0119,506.119,Unconfirmed,17,0506-P01,Interaction with Antipsychotics,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
349,0506-0120,506.120,Unconfirmed,17,0506-P01,Kinetics with Antacids,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
350,0506-0121,506.121,Unconfirmed,17,0506-P01,Bioequivalence Final Formulation,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
351,0506-0122,506.122,Preparing,17,0506-P01,Safety in Broncho-Hypersensitivity,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
352,0506-0123,506.123,Unconfirmed,17,0506-P01,Safety in Patients with Arrhythmia,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
353,0506-0124,506.124,Unconfirmed,17,0506-P01,Safety in Patients with Cardiac Failure,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
354,0506-0201,506.201,Unconfirmed,17,0506-P01,APP, kinetics in CSF and plasma, safety,Unconfirmed,MIG,Migration,IIA,Phase IIa,trial not prepared either initiated trial not prepared and initiated, pending (only intended),,,000910,IS - Clin Study (MIGRATED)
355,0506-0202,506.202,Ended,17,0506-P01,Multiple dose safety patients ,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
356,0506-0203,506.203,Ended,17,0506-P01,3 months efficacy and safety,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
357,0506-0204,506.204,Unconfirmed,17,0506-P01,Efficacy/safety in Alzheimers,Unconfirmed,MIG,Migration,III,Phase III,-  CRO use not yet decided. Monitor and MRA TBD. Trial duration 15 mo. - 12 months for symptomatic claim and 3 addit ional months with randomized withdrawal for potential disease modifying claim. The 2 trials will be combined for the later claim if FDA agrees.   ,,,000910,IS - Clin Study (MIGRATED)
358,0506-0205,506.205,Unconfirmed,17,0506-P01,Efficacy/safety in Alzheimers,Unconfirmed,MIG,Migration,III,Phase III,-  CRO use not yet decided. Monitor and MRA TBD. Trial duration 15 mo. - 12 months for symptomatic claim and 3 addit ional months with randomized withdrawal for potential disease modifying claim. The 2 trials will be combined for the later claim if FDA agrees.   ,,,000910,IS - Clin Study (MIGRATED)
359,0506-0206,506.206,Ended,17,0506-P01,One year follow-up of safety of WAL 2014,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
360,0506-0207,506.207,Unconfirmed,17,0506-P01,Comparison against donepezil,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
361,0506-0208,506.208,Ended,17,0506-P01,Long-term safety in DAT,Ended,MIG,Migration,IIB,Phase IIb, FDA Clinical Hold removed ,,,000910,IS - Clin Study (MIGRATED)
362,0506-0209,506.209,Ended,17,0506-P01,Safety 48 and 60 mg for 3 months,Ended,MIG,Migration,IIB,Phase IIb,Study discontinued April 19, 2000 ,,,000910,IS - Clin Study (MIGRATED)
363,0135-0007,135.7,Ended,18,0135-P03,tiefe Venenthrombose, Prof. Zimmermann,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
364,0135-0023,135.23,Unconfirmed,18,0135-P03,tiefe Venenthrombose, multicenter,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
365,0135-0028,135.28,Ended,18,0135-P03,tiefe Venenthrombose, Frankfurt,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
366,0135-0040,135.40,Ended,18,0135-P03,Deep venous thrombosis, multicenter,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
367,0135-0052,135.52,Ended,18,0135-P03,Deep venous thrombosis, Bounameaux,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
368,0135-0065,135.65,Unconfirmed,18,0135-P03,Tiefe Venenthrombose, Prof. Wagner,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
369,0135-0068,135.68,Ended,18,0135-P03,Deep venous thrombosis (DVT),Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
370,0135-0113,135.113,Ended,18,0135-P03,Thrombosis deep venous,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
371,0135-0127,135.127,Unconfirmed,18,0135-P03,Thrombosis deep venous,Unconfirmed,MIG,Migration,II,Phase II,- OPU: Genentech USA ** *,,,000910,IS - Clin Study (MIGRATED)
372,0135-0128,135.128,Unconfirmed,18,0135-P03,Thrombosis deep venous,Unconfirmed,MIG,Migration,II,Phase II,- OPU: Genentech USA * *,,,000910,IS - Clin Study (MIGRATED)
373,0135-0129,135.129,Unconfirmed,18,0135-P03,Thrombosis deep venous,Unconfirmed,MIG,Migration,NONE,Not Classified,- OPU: Genentech USA, BI Canada monitoring ** *,,,000910,IS - Clin Study (MIGRATED)
374,0135-0161,135.161,Ended,18,0135-P03,Deep vein thrombosis,Ended,MIG,Migration,II,Phase II,- planned patients: 15-18 *,,,000910,IS - Clin Study (MIGRATED)
375,0135-0203,135.203,Ended,18,0135-P03,Central venous access cath thrombosis,Ended,MIG,Migration,II,Phase II,- planned patients: 5-10 * *,,,000910,IS - Clin Study (MIGRATED)
376,0135-0214,135.214,Ended,18,0135-P03,Deep vein thrombosis,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
377,0135-0285,135.285,Unconfirmed,18,0135-P03,rt-PA vs. Heparin in DVT,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
378,0135-0022,135.22,Ended,19,0135-P04,Beinarterienverschlu√ü, Wuppertal,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
379,0135-0024,135.24,Ended,19,0135-P04,Occlusion of leg arteries, Marburg,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
380,0135-0025,135.25,Ended,19,0135-P04,Occlusion of leg arteries, multicentre,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
381,0135-0027,135.27,Unconfirmed,19,0135-P04,Beinarterienverschlu√ü, Soest,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
382,0135-0033,135.33,Ended,19,0135-P04,Beinarterienverschlu√ü, K√∂ln,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
383,0135-0034,135.34,Ended,19,0135-P04,Bein- und Beckenarterienverschlu√ü, Hess,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
384,0135-0045,135.45,Ended,19,0135-P04,Bein- und Beckenarterienverschlu√ü,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
385,0135-0046,135.46,Unconfirmed,19,0135-P04,Bein-, Beckenarterienverschl., Stiegler,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
386,0135-0049,135.49,Ended,19,0135-P04,Beinarterienverschlu√ü, Hess,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
387,0135-0055,135.55,Unconfirmed,19,0135-P04,Beinarterienverschlu√ü, nicht operabel,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
388,0135-0056,135.56,Ended,19,0135-P04,Ulcus Cruris,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
389,0135-0062,135.62,Ended,19,0135-P04,rt-PA vs. Urokinase in patients with acu,Ended,MIG,Migration,III,Phase III,- *Biberach trial,,,000910,IS - Clin Study (MIGRATED)
390,0135-0119,135.119,Ended,19,0135-P04,Pilot study retinal arterial occlusion,Ended,MIG,Migration,II,Phase II,- No Report in prep. (Letter van Gellecum 22.09.92) / Report requested 30.03.93 (Letter EAG),,,,
391,0135-0136,135.136,Ended,19,0135-P04,open pilot dose-finding study with rt-PA,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
392,0135-0146,135.146,Ended,19,0135-P04,Retinal occlusion,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
393,0135-0188,135.188,Ended,19,0135-P04,PAO,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
394,0135-0212,135.212,Ended,19,0135-P04,rtPA, dose finding,Ended,MIG,Migration,III,Phase III,- Report expected 8/93,,,000910,IS - Clin Study (MIGRATED)
395,0135-0232,135.232,Ended,19,0135-P04,RT-PA V. SURGERY IN TREATM'T ON ACUTE OR,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
396,0135-0235,135.235,Ended,19,0135-P04,T.I.P.O.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
397,0135-0242,135.242,Ended,19,0135-P04,RT-PA IN PERIPHERAL ART. OCCLUSION,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
398,0135-0254,135.254,Ended,19,0135-P04,Peripheral Arterial Thrombosis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
399,0135-0271,135.271,Ended,19,0135-P04,Thrombosis, Arterial, Peripheral,Ended,MIG,Migration,IV,Phase IV,- ,,,,
400,0135-0296,135.296,Ended,19,0135-P04,coagulopathy in PAO using TEG,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
401,0135-0302,135.302,Unconfirmed,19,0135-P04,tPA vs STREPTOKINASE in PAO,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
402,0135-0304,135.304,Ended,19,0135-P04,coagulopathy in PAO using TEG (Sub-study,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
403,0135-0021,135.21,Ended,20,0135-P05,occlusion of cerebral artery,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
404,0135-0061,135.61,Ended,20,0135-P05,TTATTS,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
405,0135-0063,135.63,Ended,20,0135-P05,ECASS (Europ. coop. acute stroke study),Ended,MIG,Migration,III,Phase III,Ende Patientenrekrutierung: 09-MAR-94 ,,,000910,IS - Clin Study (MIGRATED)
406,0135-0071,135.71,Unconfirmed,20,0135-P05,Actylise in subarachnoid hemorrhage,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
407,0135-0158,135.158,Ended,20,0135-P05,Stroke,Ended,MIG,Migration,II,Phase II,- Trial stopped due to poor recruitment. *,,,000910,IS - Clin Study (MIGRATED)
408,0135-0159,135.159,Ended,20,0135-P05,Stroke,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
409,0135-0169,135.169,Ended,20,0135-P05,Stroke,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
410,0135-0173,135.173,Ended,20,0135-P05,Stroke,Ended,MIG,Migration,II,Phase II,- Published in Brit. Med. J. 297 (1988), 1571-1574. *,,,000910,IS - Clin Study (MIGRATED)
411,0135-0291,135.291,Ended,20,0135-P05,ECASS II,Ended,MIG,Migration,III,Phase III,ISC Approval: 13 SEP 96 ,,,000910,IS - Clin Study (MIGRATED)
412,0135-0295,135.295,Unconfirmed,20,0135-P05,Intraarterial Thrombolysis,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000980,Not Classified (MIGRATED)
413,0135-0297,135.297,Ended,20,0135-P05,NINDS Acute Stroke Trial,Ended,MIG,Migration,III,Phase III,- Trial was planned and conducted by Genentec,,,000910,IS - Clin Study (MIGRATED)
414,0135-0307,135.307,Ended,20,0135-P05,IST-3,Ended,MIG,Migration,III,Phase III,,,,,
415,0135-0309,135.309,Ended,20,0135-P05,EPITHET Study,Ended,MIG,Migration,III,Phase III,Sponsor is the academic group.  Not BI ,,,,
416,0135-0310,135.310,Unconfirmed,20,0135-P05,Prognostic Model,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
417,0135-0311,135.311,Preparing,20,0135-P05,ECASS III,Preparing,MIG,Migration,IV,Phase IV,3 to 4 hours after stroke onset ,,,000910,IS - Clin Study (MIGRATED)
418,0135-0312,135.312,Ended,20,0135-P05,ECASS-3, 3 -4.30 hours treatment window,Ended,MIG,Migration,IIIB,Phase IIIb,15 OPUs for 22 countries involved ,,,000910,IS - Clin Study (MIGRATED)
419,0135-0313,135.313,Ended,20,0135-P05,SITS-MOST,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
420,0135-0314,135.314,Analysis,20,0135-P05,Tele AVC Trial,Analysis,MIG,Migration,IV,Phase IV,management strategy of thrombolysis ,,,,
421,0135-0315,135.315,Ended,20,0135-P05,PMS for Actilyse (Stroke),Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
422,0135-0316,135.316,Ended,20,0135-P05,MIST2,Ended,MIG,Migration,III,Phase III,Intn'l marketing funding for drug supply ,2004-000658-22,,,
423,0135-0317,135.317,Ended,20,0135-P05,SITS - New Registry,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
424,0135-0319,135.319,Recruiting,20,0135-P05,EXTEND - Trial,Recruiting,MIG,Migration,III,Phase III,,,,,
425,0135-0320,135.320,Recruiting,20,0135-P05,PROFIL AVC,Recruiting,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
426,0135-0321,135.321,First Subject Randomised,20,0135-P05,ECASS-4: EXTEND,First Subject Randomised,MIG,Migration,III,Phase III,,2012-003609-80,03-APR-12,000150,IS - Clin Study - Explore
427,0135-0322,135.322,Analysis,20,0135-P05,SITS-UTMOST,Analysis,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
428,0135-0324,135.324,Preparing,20,0135-P05,QUICK,Preparing,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
429,0135-0330,135.330,Ended,20,0135-P05,Long term F-U impact by registry data,Ended,MIG,Migration,IV,Phase IV,,,,000930,NISed - Study (MIGRATED)
430,0135-0331,135.331,First Subject Randomised,20,0135-P05,TWE China,First Subject Randomised,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
431,0135-0332,135.332,Unconfirmed,20,0135-P05,Management of Pericarditis: IMPI-2,Unconfirmed,MIG,Migration,III,Phase III,,,,,
432,0135-0333,135.333,Unconfirmed,20,0135-P05,TEMPO-2 Minor stroke with proven occl.,Unconfirmed,MIG,Migration,III,Phase III,,,,,
433,1097-0010,1097.10,Ended,21,1097-P02,Bioavailability Study of Oramorph SR,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
434,1100-0742,1100.742,Ended,22,1100-P01,Adult oral single dose,Ended,MIG,Migration,I,Phase I,-  Pharmacokinetic levels necessary for choosing initial dose and escalation of doses for IIa-744. Non ACTG, BIPI funded. First study in man to assess safety, tolerance and pharmacokinetics. Necessary for choosing doses and escalation of doses for 744A.   ,,,000910,IS - Clin Study (MIGRATED)
435,1100-0744,1100.744,Ended,22,1100-P01,Adult mult. dose monotherapy,Ended,MIG,Migration,IIA,Phase IIa,-  First multiple dose study in patients to determine pharmacokinetics safety and activity profile. ACTG 164. To add 10 additional patients at 600 mg.   ,,,000910,IS - Clin Study (MIGRATED)
436,1100-0815,1100.815,Ended,22,1100-P01,SD bioavailability in 3 forms,Ended,MIG,Migration,I,Phase I,-  Absolute bioavailability and relative variability study.   Requires single oral dose and single IV dose tolerance studies in normal volunteers.   BUDGET EXPLAN: SEE MEMO TO WM 11/02/92   ,,,000910,IS - Clin Study (MIGRATED)
437,1100-0816,1100.816,Ended,22,1100-P01,Radiolabeled ADME,Ended,MIG,Migration,I,Phase I,-  There is a possibility that lab work may be done at R&D. Follows study 00815. To be conducted by a CRO. Mass distribution and accumulation. May be done open-label.     ,,,000910,IS - Clin Study (MIGRATED)
438,1100-0834,1100.834,Ended,22,1100-P01,Adult mult. dose combination,Ended,MIG,Migration,IIA,Phase IIa,-  Accrual to new dosing regimen of 200 mg/d for 2 wks then increasing to 400-600 mg/db till December 1993. First combination trial with A AZT in patients to determine pharmacokinetics, safety and activi profile. ACTG 168. To add 10 additional patients at 600 mg.   ,,,000910,IS - Clin Study (MIGRATED)
439,1100-0854,1100.854,Ended,22,1100-P01,Open label follow up,Ended,MIG,Migration,IIA,Phase IIa,-  Parexel will assume responsibilities for data entry, data review an d lock.     ,,,000910,IS - Clin Study (MIGRATED)
440,1100-0859,1100.859,Ended,22,1100-P01,Expanded access,Ended,MIG,Migration,III,Phase III,-  Initiation date will be revised following discussion of trial's design at the April FDA Advisory Committee meeting.  Lead time for contracts and clinical supplies will be considered. 5/16/95 ctrs,pts,complet date changes per maureen myers At the CPT mtg in 2/96, a date for final protocol and initiation wi ll be agreed upon.  Not clear who will be writing report. LAST ADULT SUBJECT COMPLETE ESTIMATED TO BE 10/17/96, PEDIATRIC PATIENTS WILL CO ,,,000910,IS - Clin Study (MIGRATED)
441,1100-0881,1100.881,Ended,22,1100-P01,Int'l adult comb./alt'g regim.,Ended,MIG,Migration,IIA,Phase IIa,-  Since this will be done in Europe the U.S. pays nothing. International trial involving investigation in Australia & Holland. Netherlands: 10 patients at 200 mg NVP + ZDV to stay at this dose. Australia:  All 4 pts will be on 400 mg NVP + ZDV. Examines use of NVP in drug naive patients. Parexel to prepare rpt.   ,,,000910,IS - Clin Study (MIGRATED)
442,1100-0891,1100.891,Ended,22,1100-P01,Adult I.V. single dose,Ended,MIG,Migration,I,Phase I,-  Conducted at Quincy.     ,,,000910,IS - Clin Study (MIGRATED)
443,1100-0896,1100.896,Ended,22,1100-P01,Relative bioavailability,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
444,1100-0922,1100.922,Unconfirmed,22,1100-P01,Concomitant med interaction,Unconfirmed,MIG,Migration,I,Phase I,-  May be done open-label.     ,,,000910,IS - Clin Study (MIGRATED)
445,1100-0934,1100.934,Ended,22,1100-P01,Bioequivalence final formul.,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
446,1100-0947,1100.947,Ended,22,1100-P01,Asympt adult mult ds monother.,Ended,MIG,Migration,IIA,Phase IIa,-  No randomization - all patients will receive 200 mg NVP QD for 28 day lead in period, then increased to 400 mg NVP QD. To add an additional 10 patients. Trial is 12 months duration. CRO to handle data review, data lock and report preparation.   ,,,000910,IS - Clin Study (MIGRATED)
447,1100-1009,1100.1009,Ended,22,1100-P01,M.D. comb. w/ ZDV ddC ddI,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
448,1100-1010,1100.1010,Ended,22,1100-P01,Adult mult. dose monotherapy,Ended,MIG,Migration,IIA,Phase IIa,-  5 patients per country. Patients may add nucleoside if P24 response is not durable. Clin comp is date last pt rolled into 1100.1036     ,,,000910,IS - Clin Study (MIGRATED)
449,1100-1011,1100.1011,Ended,22,1100-P01,Adult mult. dose combination,Ended,MIG,Migration,IIA,Phase IIa,-  TIMELINE FOR REPORT WRITING UNDER CONSIDERATION BY BIPI. Clin compl is date last pt rolled into 1100.1036. 14 patients per country.     ,,,000910,IS - Clin Study (MIGRATED)
450,1100-1031,1100.1031,Ended,22,1100-P01,Adult double vs triple therapy,Ended,MIG,Migration,IIA,Phase IIa,-  Data from this study will become part of the initial NDA submission     ,,,,
451,1100-1034,1100.1034,Unconfirmed,22,1100-P01,Stable disease- dbl vs triple,Unconfirmed,MIG,Migration,III,Phase III,        ,,,,
452,1100-1036,1100.1036,Ended,22,1100-P01,Open-label follow up Intl,Ended,MIG,Migration,IIA,Phase IIa,-  Other trials from which pts can roll into 1036: 1100.1046, 1100.104 7, 1100.1203 Regarding date for last pt. enrolled - trial is intended to contin ue until product registration in country or sponsor withdrawl   ,,,000910,IS - Clin Study (MIGRATED)
453,1100-1037,1100.1037,Ended,22,1100-P01,Immed vs. delayed in prev trea,Ended,MIG,Migration,IIA,Phase IIa,-  CR:  Parexel is tracking IRB expiration dates PXL is doing DM and safety portion of final report activity portion will be done by BIPI     ,,,000910,IS - Clin Study (MIGRATED)
454,1100-1038,1100.1038,Ended,22,1100-P01,Clinical efficacy pilot,Ended,MIG,Migration,IIA,Phase IIa,-  To evaluate the effect of 400 mg Nevirapine on virologic and immunologic endpoints. CBCT network pilot. Duration of treatment is 24 weeks. Naive patients: is NVP mono bet ter than placebo. In previously treated patients, is NVP plus AZT better than AZT. CRO for monitoring and data management.and report? Parexel is tracking IRB expiration dates.   ,,,000910,IS - Clin Study (MIGRATED)
455,1100-1044,1100.1044,Ended,22,1100-P01,Asymptomatic/codon 215,Ended,MIG,Migration,II,Phase II,-  289 of an expected 300 patients have entered the trial. 0 completed     ,,,,
456,1100-1045,1100.1045,Ended,22,1100-P01,Triple therapy arm to MP,Ended,MIG,Migration,II,Phase II,-  Enrollment closed to accrual as of 10/31/95.  1314 pts. enrolled. Clinical endpoint trial. Separate reports by BIPI & ACTG. We will receive data after clinic al completion.  The trial will end on 06/15/96, with patients being able to access ACTG 320 beginning on 04/15/96. BIPI/ACTG TO DO FIN REP. BIPI-NEG TSF OF DBASE FR ACTG.MAY IMPEDE FIN REP TIMELI ,,,,
457,1100-1046,1100.1046,Ended,22,1100-P01,Double, triple pilot,Ended,MIG,Migration,II,Phase II,-  4 countries. Signal on 2 double and 1 triple combo using intense virology, prelude to expansion with clin endpts. 27 pts per arm. Molfino will arrange to have CRO monitor Canadian site L.T. portion.  Trial could expand to an additional 200 patients. Canada trial #BO93NEV01. data management, analysis, and report are the responsibility of BIPI.   ,,,000910,IS - Clin Study (MIGRATED)
458,1100-1047,1100.1047,Ended,22,1100-P01,Triple therapy/late disease,Ended,MIG,Migration,II,Phase II, ISS study (Istituto Suepriore di Sanit√†) - Dr. Vella,,,000910,IS - Clin Study (MIGRATED)
459,1100-1048,1100.1048,Unconfirmed,22,1100-P01,Salvage in CPCRA,Unconfirmed,MIG,Migration,II,Phase II,-  Clinical endpoints for monotherapy comparison in AZT or ddI failures/intolerance.     ,,,,
460,1100-1049,1100.1049,Unconfirmed,22,1100-P01,Pilot early HIV mono/combo,Unconfirmed,MIG,Migration,II,Phase II,-  Virologic activity (using PCR) in early disease, signal for activit y >500 CD4.     ,,,,
461,1100-1051,1100.1051,Unconfirmed,22,1100-P01,clin endpoints/efficacy/MRC,Unconfirmed,MIG,Migration,III,Phase III,-  Clinical endpoint trial to accelerate approval. Initiation date will be revised following discussion of the trial's design at the April FDA advisory committee meeting CSR WILL BE CANCELLED 5/16/95 trial cancelled per maureen myers   ,,,000910,IS - Clin Study (MIGRATED)
462,1100-1055,1100.1055,Ended,22,1100-P01,SD with food or antacid,Ended,MIG,Migration,I,Phase I,-  AVC's Performed at a CRO     ,,,000910,IS - Clin Study (MIGRATED)
463,1100-1056,1100.1056,Ended,22,1100-P01,Single to mult. dose kinetics,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
464,1100-1062,1100.1062,Ended,22,1100-P01,Open label f/u for #854, 947,Ended,MIG,Migration,IIA,Phase IIa,-  Parexel to do field monitoring, data review, data lock and interim report. Parexel to track IRB expiration dates and reapprovals. PXL has been notified that we're winding this study down - study was due to close at registration anyway.   ,,,000910,IS - Clin Study (MIGRATED)
465,1100-1089,1100.1089,Ended,22,1100-P01,Triple comb. progressive dis.,Ended,MIG,Migration,II,Phase II,-  NCI trial T93-0093. 8 of an expected 8 patients have entered the trial. 0 completed. 1 patient discontinued the study in early March.  1 patient is sti ll on study. 1 ACT SUB W/REM ON DRUG. OPEN END STDY.  CONT W/1 PT AS LONG AS PTS BENEFIT ,,,,
466,1100-1090,1100.1090,Ended,22,1100-P01,Clinical Endpoint Study,Ended,MIG,Migration,III,Phase III,-please see extended remark Protocol accepted by Glaxo on 10/30/95. Participating countries are: Canada, France, Germany, Belgium, Italy, Australia, S. Africa, Spain, Netherlands, UK, Sweden and U.S.  1st invest. meet. held in U.S. with international meeting to follow.Enrollment and completion may be extended pending DSMB review. EARLY TERMINATION W/ LAST PT. VISIT 6/30/98. ,,,000910,IS - Clin Study (MIGRATED)
467,1100-1097,1100.1097,Ended,22,1100-P01,Triple comb.,Ended,MIG,Migration,I,Phase I,-  NCI trial. A request was made on 10/16/95 to close enrollment. Patients will be asked to stop drug.  The study has been terminated but the exact date in March, 1996 is not known.  Will be updated when information becomes available.   ,,,,
468,1100-1135,1100.1135,Ended,22,1100-P01,ICC study #1,Ended,MIG,Migration,II,Phase II,-  Nevirapine group to be added 1 month after study initiation. Roche holds IND for this trial. Trial conduct by Parexel.     ,,,000910,IS - Clin Study (MIGRATED)
469,1100-1136,1100.1136,Ended,22,1100-P01,ICC study #2,Ended,MIG,Migration,II,Phase II,-  Enrollment was completed at 158 patients on 2/15/96. Trial conducted by Parexel.     ,,,000910,IS - Clin Study (MIGRATED)
470,1100-1202,1100.1202,Unconfirmed,22,1100-P01,CPCRA Clinical Endpoint Trial,Unconfirmed,MIG,Migration,III,Phase III,-  This clinical trial was cancelled due to problems with impliment- ing the trial as currently designed.  Clinical trial 1100.1090 will take the place of this trial.     ,,,000910,IS - Clin Study (MIGRATED)
471,1100-1203,1100.1203,Ended,22,1100-P01,Protease PK interaction trial,Ended,MIG,Migration,I,Phase I,-  Trial is expected to begin patient enrollment by October 31, 1995. Drug is expected to be shipped to Roche (Canada) by October 18, 1995 but was delayed until Nov. 3, 1995 due to problem in obtaining export permit. BIPI involvement limited to Pk analysis, protocol review, and maybe AEs.  Patient screening began week of Nov. 13, 1995.   ,,,,
472,1100-1204,1100.1204,Ended,22,1100-P01,NVP/Indinavir interaction trial,Ended,MIG,Migration,I,Phase I,-  This trial is to be conducted by Harris labs. Duration extended.  Subjects to continue treatment as long as viral  count remains below level of detection.   COMPLETION FUZZY. TO CONTINUE AS LONG   AS VIRAL COUNT BELOW DETECTION LEVEL. ,,,000910,IS - Clin Study (MIGRATED)
473,1100-1205,1100.1205,Unconfirmed,22,1100-P01,ICC #3,Unconfirmed,MIG,Migration,IIB,Phase IIb,-  Inter-company collaborative study     ,,,000910,IS - Clin Study (MIGRATED)
474,1100-1206,1100.1206,Ended,22,1100-P01,Emergency use trial,Ended,MIG,Migration,II,Phase II,-  Emergency use trial which will allow patients access to NVP after accidental exposure to HIV-1. Study will continue until market approval of NVP. The study will be limited at this time to centers in Canada and the U.S.  No field monitoring required. Expected #cntrs/pts reduced due to lack of demand to-date.   ,,,000500,Compassionate Use Program (CUP)
475,1100-1208,1100.1208,Ended,22,1100-P01,Compassionate Use,Ended,MIG,Migration,III,Phase III,- ,,,000500,Compassionate Use Program (CUP)
476,1100-1212,1100.1212,Ended,22,1100-P01,NVP/Ritonavir interaction trial,Ended,MIG,Migration,I,Phase I,-  May start in the 1st half of 1996, dependent on negotiations with Harris labs. Duration extended.  Subjects to continue treatment as long as viral count remains below level of detection. COMPLETION DATE FUZZY. TO CONTINUE AS LONG AS VIRAL COUNT BELOW DETECTION. ,,,000910,IS - Clin Study (MIGRATED)
477,1100-1213,1100.1213,Ended,22,1100-P01,Bioequivalence,Ended,MIG,Migration,I,Phase I,-  Trial to be conducted by Harris in Phoenix, AZ (CRO), Data manageme nt to be done by Harris in Lincoln Nebraska.   LAST DOSE OF STUDY MEDICATION ON 3/17, CLINICAL COMPLETION ON 3/22/97 ,,,000910,IS - Clin Study (MIGRATED)
478,1100-1214,1100.1214,Ended,22,1100-P01,Pk - rifampin,Ended,MIG,Migration,I,Phase I,-      1ST SITE UNABLE TO ENROLL ALL PATIENTS, A 2ND SITE EXPECTED TO INITIATE APRIL 97 ,,,000910,IS - Clin Study (MIGRATED)
479,1100-1215,1100.1215,Ended,22,1100-P01,Pk - clarithromycin,Ended,MIG,Migration,I,Phase I,-  Group I: Clarithromycin will enroll into the study first, followed by Group II: ERMBT that will enroll last SFBC is encountering slower than expected enrollment, which will p ush out the expected clinical completion date. STUDY WILL BE CONDUCTED WITH CLARITHYROMYCIN AND ERYTHROMYCIN BREATH TEST ,,,000910,IS - Clin Study (MIGRATED)
480,1100-1216,1100.1216,Ended,22,1100-P01,Pk - ketoconazole,Ended,MIG,Migration,I,Phase I,-      1ST GROUP ENROLLED 21 PATIENTS, 2ND GROUP WILL ENROLL THE REMAINING PTS ,,,000910,IS - Clin Study (MIGRATED)
481,1100-1217,1100.1217,Ended,22,1100-P01,S. Dose PK of NVP in Hlthy Male Vol.,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
482,1100-1218,1100.1218,Ended,22,1100-P01,Bioequivalence,Ended,MIG,Migration,I,Phase I,-  Trial to be conducted by Harris in Lincoln, Nebraska (CRO) Harris labs to design CRFs.     ,,,000910,IS - Clin Study (MIGRATED)
483,1100-1219,1100.1219,Ended,22,1100-P01,TRIANON,Ended,MIG,Migration,IV,Phase IV,- ,,,,
484,1100-1223,1100.1223,Unconfirmed,22,1100-P01,START,Unconfirmed,MIG,Migration,NONE,Not Classified,        ,,,,
485,1100-1225,1100.1225,Ended,22,1100-P01,Expanded Access Program Europe,Ended,MIG,Migration,III,Phase III,- ,,,000500,Compassionate Use Program (CUP)
486,1100-1226,1100.1226,Ended,22,1100-P01,Post-mktg of NVP, Eff Sfty 6Mos Study,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
487,1100-1227,1100.1227,Unconfirmed,22,1100-P01,Expanded Access Trial of NVP,Unconfirmed,MIG,Migration,III,Phase III,NOTE:  THIS TRIAL HAS BEEN CANCELLED. ,,,000910,IS - Clin Study (MIGRATED)
488,1100-1228,1100.1228,Ended,22,1100-P01,Multi-dose PK of NVP in HIV-1 Inf Pts,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
489,1100-1229,1100.1229,Ended,22,1100-P01,ATLANTIC,Ended,MIG,Migration,IV,Phase IV,- ,,,,
490,1100-1230,1100.1230,Ended,22,1100-P01,Expanded access - Mexico,Ended,MIG,Migration,III,Phase III,-  Will use same protocol & CRFs as 1100.859. Conducted at Hospital de Infectologia, Centro Medico la Raza (Dr. Lavalle) and Instituto Nacional de la Nutricion (Dr. Sierra)     ,,,000910,IS - Clin Study (MIGRATED)
491,1100-1231,1100.1231,Ended,22,1100-P01,Repeat bioequivalence,Ended,MIG,Migration,I,Phase I,-  Trial to be conducted by Harris in Phoenix, AZ (CRO), Data manageme nt to be done by Harris in Lincoln Nebraska. The protocol is like 1100.1213, except that this will be a 2-way instead of a 3-way.   ,,,000910,IS - Clin Study (MIGRATED)
492,1100-1236,1100.1236,Ended,22,1100-P01,PK Study with NVP/RIT/SAQ,Ended,MIG,Migration,I,Phase I,Abbott Study ,,,,
493,1100-1239,1100.1239,Ended,22,1100-P01,VIRGO,Ended,MIG,Migration,IV,Phase IV,-  BIPI will supply drugs only to the France OPU Investigator is PR Raffi     ,,,,
494,1100-1250,1100.1250,Ended,22,1100-P01,FREEDOM,Ended,MIG,Migration,IV,Phase IV,-  Investigator is Johnson,M.     ,,,,
495,1100-1252,1100.1252,Unconfirmed,22,1100-P01,BMS Study,Unconfirmed,MIG,Migration,NONE,Not Classified,-  Investigator is Johnson,M.     ,,,000910,IS - Clin Study (MIGRATED)
496,1100-1258,1100.1258,Ended,22,1100-P01,PK Study-Viramune + Rifabutin,Ended,MIG,Migration,IV,Phase IV,        ,,,000910,IS - Clin Study (MIGRATED)
497,1100-1259,1100.1259,Ended,22,1100-P01,PK Study,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
498,1100-1260,1100.1260,Unconfirmed,22,1100-P01,Multiple Combination Study,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,,
499,1100-1262,1100.1262,Unconfirmed,22,1100-P01,Reversibility of PI-induced Lypodystroph,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,,
500,1100-1263,1100.1263,Unconfirmed,22,1100-P01,CSF Study,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,,
501,1100-1266,1100.1266,Ended,22,1100-P01,Efficacy and Safety in HIV infected Pat.,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
502,1100-1269,1100.1269,Unconfirmed,22,1100-P01,Unkown,Unconfirmed,MIG,Migration,NONE,Not Classified,Study # allocated, but trial source unk ,,,000980,Not Classified (MIGRATED)
503,1100-1270,1100.1270,Unconfirmed,22,1100-P01,Tetravir,Unconfirmed,MIG,Migration,III,Phase III,Study Cancelled on January 22, 1999 ,,,000910,IS - Clin Study (MIGRATED)
504,1100-1272,1100.1272,Unconfirmed,22,1100-P01,Safety Profile of all ARTs: SPAU,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,,
505,1100-1279,1100.1279,Preparing,22,1100-P01,ACTG 5015,Preparing,MIG,Migration,II,Phase II,,,,,
506,1100-1282,1100.1282,Ended,22,1100-P01,ACTG 5014: PI,ABT378-r+NVP/3RTI+ABC+NVP,Ended,MIG,Migration,IIB,Phase IIb,,,,,
507,1100-1283,1100.1283,Unconfirmed,22,1100-P01,PI Toxicity Switch,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
508,1100-1284,1100.1284,Ended,22,1100-P01,PI Switch1,Ended,MIG,Migration,IV,Phase IV,,,,,
509,1100-1286,1100.1286,Ended,22,1100-P01,Rash Avoidance NVP+PREDNISONE,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
510,1100-1287,1100.1287,Ended,22,1100-P01,South African Perinatal Transmission,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
511,1100-1288,1100.1288,Ended,22,1100-P01,Double non Nucleoside Study (2NN),Ended,MIG,Migration,III,Phase III,Trial Conducted by NATEC as IOR. ,,,,
512,1100-1289,1100.1289,Ended,22,1100-P01,CHARM,Ended,MIG,Migration,III,Phase III,Compact Highly-active AntiRetroviral Med ,,,,
513,1100-1290,1100.1290,Preparing,22,1100-P01,New Combo,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
514,1100-1291,1100.1291,Ended,22,1100-P01,NVP/MKC-442 PK Interaction,Ended,MIG,Migration,IA,Phase Ia,,,,,
515,1100-1292,1100.1292,Ended,22,1100-P01,The Brighton Compliance Study,Ended,MIG,Migration,IV,Phase IV,,,,,
516,1100-1293,1100.1293,Ended,22,1100-P01,Taylor Pregnancy PK,Ended,MIG,Migration,IV,Phase IV,,,,,
517,1100-1294,1100.1294,Ended,22,1100-P01,PI Toxicity Switch - Retrospective,Ended,MIG,Migration,IV,Phase IV,,,,,
518,1100-1299,1100.1299,Ended,22,1100-P01,EVITA,Ended,MIG,Migration,IV,Phase IV,,,,,
519,1100-1300,1100.1300,Initiated,22,1100-P01,FORTIMUNE,Initiated,MIG,Migration,IV,Phase IV,,,,,
520,1100-1301,1100.1301,Ended,22,1100-P01,Pr Katlama's GIGHAART study,Ended,MIG,Migration,IV,Phase IV,,,,,
521,1100-1302,1100.1302,Ended,22,1100-P01, NVP Effect on Reducing PI Lipodystrophy,Ended,MIG,Migration,IV,Phase IV,,,,,
522,1100-1304,1100.1304,Preparing,22,1100-P01,Resistance Testing in NVP Combo Failures,Preparing,MIG,Migration,IV,Phase IV,,,,,
523,1100-1305,1100.1305,Ended,22,1100-P01,PI SWITCH,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
524,1100-1306,1100.1306,Ended,22,1100-P01,Lymph Nodes,Ended,MIG,Migration,IV,Phase IV,,,,,
525,1100-1307,1100.1307,Initiated,22,1100-P01,Nucleoside Sparing,Initiated,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
526,1100-1308,1100.1308,Unconfirmed,22,1100-P01,NVP + Combivir in Naive Pts - Roxane,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
527,1100-1309,1100.1309,Unconfirmed,22,1100-P01,NVP + 3TC + d4T in Naive Pts - Roxane,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
528,1100-1310,1100.1310,Unconfirmed,22,1100-P01,NVP + 3TC + ddI, Naive Pts, QD - Roxane,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
529,1100-1311,1100.1311,Unconfirmed,22,1100-P01,PI Switch Toxicity - Roxane,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
530,1100-1312,1100.1312,Ended,22,1100-P01,London Baseline Resistance - UK OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
531,1100-1313,1100.1313,Ended,22,1100-P01,SCAN - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
532,1100-1314,1100.1314,Ended,22,1100-P01,PALMIRA - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,CANCELLED-NO PATIENTS ,,,,
533,1100-1315,1100.1315,Ended,22,1100-P01,GEN - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
534,1100-1316,1100.1316,Ended,22,1100-P01,COMPLI-1 - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
535,1100-1317,1100.1317,Ended,22,1100-P01,NELSANE - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
536,1100-1318,1100.1318,Ended,22,1100-P01,COMBINE - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
537,1100-1319,1100.1319,Ended,22,1100-P01,LIPODYSTROPHY - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
538,1100-1320,1100.1320,Ended,22,1100-P01,MOMA-02 - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
539,1100-1321,1100.1321,Ended,22,1100-P01,TAXI-3 - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
540,1100-1322,1100.1322,Ended,22,1100-P01,NORTE - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,Cancelled. No patients ,,,,
541,1100-1323,1100.1323,Ended,22,1100-P01,SAEI - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,CANCELLED-NO PATIENTS ,,,,
542,1100-1324,1100.1324,Ended,22,1100-P01,SAN PABLO - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
543,1100-1325,1100.1325,Unconfirmed,22,1100-P01,MALLO-1 - SPAIN OPU,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
544,1100-1326,1100.1326,Ended,22,1100-P01,PREVIHNE - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
545,1100-1327,1100.1327,Ended,22,1100-P01,ALICANTE - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
546,1100-1328,1100.1328,Ended,22,1100-P01,COST - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
547,1100-1329,1100.1329,Ended,22,1100-P01,BEGIN TO BEGIN - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
548,1100-1330,1100.1330,Ended,22,1100-P01,SAN CARLOS - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,CANCELLED-NO PATIENTS ,,,,
549,1100-1331,1100.1331,Ended,22,1100-P01,GOLF - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,CANCELLED-NO PATIENTS ,,,,
550,1100-1332,1100.1332,Preparing,22,1100-P01,AMADEUS - SPAIN OPU,Preparing,MIG,Migration,IV,Phase IV,,,,,
551,1100-1333,1100.1333,Preparing,22,1100-P01,SOLVENT - SPAIN OPU,Preparing,MIG,Migration,IV,Phase IV,,,,,
552,1100-1334,1100.1334,Ended,22,1100-P01,ROCA - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
553,1100-1335,1100.1335,Ended,22,1100-P01,TRAIOR - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
554,1100-1336,1100.1336,Ended,22,1100-P01,CORTICOIDES - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
555,1100-1337,1100.1337,Ended,22,1100-P01,METHADONE - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
556,1100-1338,1100.1338,Ended,22,1100-P01,RESISTENCIAS - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
557,1100-1339,1100.1339,Ended,22,1100-P01,SIMPLI - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
558,1100-1340,1100.1340,Ended,22,1100-P01,ANBA - SPAIN OPU,Ended,MIG,Migration,IV,Phase IV,,,,,
559,1100-1341,1100.1341,Preparing,22,1100-P01,CERVANTES - SPAIN OPU,Preparing,MIG,Migration,IV,Phase IV,CANCELLED-NO PATIENTS ,,,,
560,1100-1342,1100.1342,Unconfirmed,22,1100-P01,PEP - LARSEN,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
561,1100-1343,1100.1343,Ended,22,1100-P01,Sub of NVP for PI due to Intol (PitoN),Ended,MIG,Migration,IV,Phase IV,,,,,
562,1100-1345,1100.1345,Ended,22,1100-P01,NVP+ddI+Phosphazide, Pokrovskij - Moscow,Ended,MIG,Migration,IV,Phase IV,,,,,
563,1100-1346,1100.1346,Unconfirmed,22,1100-P01,PEP - TORRES - NYC,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
564,1100-1347,1100.1347,Unconfirmed,22,1100-P01,Tebas' PI Switch Cohort Pilot, Ongoing,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
565,1100-1348,1100.1348,Unconfirmed,22,1100-P01,PRICE CSF - Roxane Local Marketing,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
566,1100-1350,1100.1350,Preparing,22,1100-P01,Colebunders: PI Failure, NVP/2PIs/NRTIs,Preparing,MIG,Migration,IV,Phase IV,Local Trial ,,,,
567,1100-1352,1100.1352,Ended,22,1100-P01,Lipodystrophy Analysis - Cotton,Ended,MIG,Migration,IV,Phase IV,,,,,
568,1100-1353,1100.1353,Ended,22,1100-P01,HISTAVIR,Ended,MIG,Migration,IV,Phase IV,,,,,
569,1100-1354,1100.1354,Preparing,22,1100-P01,ddI/3TC/NVP vs. ddI/3TC/Fortovase,Preparing,MIG,Migration,IV,Phase IV,,,,,
570,1100-1355,1100.1355,Ended,22,1100-P01,VIZYR,Ended,MIG,Migration,IV,Phase IV,,,,,
571,1100-1359,1100.1359,Ended,22,1100-P01,NVP & METH IN HIV-1-INF PTS PHARMACOVIGI,Ended,MIG,Migration,IV,Phase IV,Phase Other, observation for local mktg ,,,,
572,1100-1362,1100.1362,Ended,22,1100-P01,Quality of life,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
573,1100-1363,1100.1363,Unconfirmed,22,1100-P01,NVP associated LFT changes in US cohort,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
574,1100-1364,1100.1364,Unconfirmed,22,1100-P01,NVP associated LFT changes US cohort 2,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
575,1100-1367,1100.1367,Ended,22,1100-P01,PI switch to NVP, EFV, or ABC--ACTG 5103,Ended,MIG,Migration,IIB,Phase IIb,Lipodystrophy parameters after rx switch ,,,,
576,1100-1374,1100.1374,Unconfirmed,22,1100-P01,ARV & in vitro adipocyte cell apoptosis,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
577,1100-1375,1100.1375,Unconfirmed,22,1100-P01,NVP vs EFV in naive patients (+ddI+d4T),Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
578,1100-1376,1100.1376,Ended,22,1100-P01,Prospective PI switch to NVP or EFV,Ended,MIG,Migration,IV,Phase IV,,,,,
579,1100-1377,1100.1377,Ended,22,1100-P01,Induction (PI) maintenance (NVP) Confort,Ended,MIG,Migration,IV,Phase IV,,,,,
580,1100-1378,1100.1378,Ended,22,1100-P01,ABC vs NVP vs EFV in PI switch (Nefa),Ended,MIG,Migration,IV,Phase IV,,,,,
581,1100-1379,1100.1379,Ended,22,1100-P01,Rash & liver tox on NVP (Nevexhe),Ended,MIG,Migration,IV,Phase IV,,,,,
582,1100-1380,1100.1380,Ended,22,1100-P01,Antihistamines & rash (RashGA),Ended,MIG,Migration,IV,Phase IV,,,,,
583,1100-1381,1100.1381,Unconfirmed,22,1100-P01,NVP + ABC vs EFV vs PI in PI failure,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
584,1100-1383,1100.1383,Preparing,22,1100-P01,PK Viramune Methadone Interaction,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
585,1100-1393,1100.1393,Ended,22,1100-P01,DDI, D4T and NVP in naive pts in China,Ended,MIG,Migration,IV,Phase IV,,,,,
586,1100-1395,1100.1395,Ended,22,1100-P01,AWB Rhine Area,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
587,1100-1416,1100.1416,Preparing,22,1100-P01,US NVP Optimized Tab BioEquivalent PK St,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
588,1100-1443,1100.1443,Preparing,22,1100-P01,Ingelheim NVP Optimized Tab Bioequiv PK,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
589,1100-1444,1100.1444,Ended,22,1100-P01,NVP Serum Levels with Diarrheal Illness,Ended,MIG,Migration,IV,Phase IV,,,,,
590,1100-1445,1100.1445,Ended,22,1100-P01,ACTG/ A5175,Ended,MIG,Migration,IV,Phase IV,,,,,
591,1100-1446,1100.1446,Ended,22,1100-P01,NVP Genomics,Ended,MIG,Migration,IV,Phase IV,,,,,
592,1100-1447,1100.1447,Ended,22,1100-P01,NVP-HAART/Preg-P Part.-Brstfeeding Women,Ended,MIG,Migration,IV,Phase IV,,,,,
593,1100-1492,1100.1492,Ended,22,1100-P01,AWB "Viramune-Truvada",Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
594,1100-1527,1100.1527,Ended,22,1100-P01,PMS Viramune,Ended,MIG,Migration,IV,Phase IV,PMS study Poland and Austria ,,,000940,Post Marketing Study (MIGRATED)
595,0248-0501,248.501,Ended,23,0248-P05,Tolerability in depressed patients,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
596,0248-0502,248.502,Ended,23,0248-P05,dose-finding 9 weeks,Ended,MIG,Migration,IIA,Phase IIa,- TUC Study,,,000910,IS - Clin Study (MIGRATED)
597,0248-0503,248.503,Ended,23,0248-P05,efficacy vs. comparator,Ended,MIG,Migration,IIA,Phase IIa,- TUC Study,,,000910,IS - Clin Study (MIGRATED)
598,0248-0504,248.504,Ended,23,0248-P05,Major depression,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
599,0248-0588,248.588,Unconfirmed,23,0248-P05,PPXAPD-0072-149,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
600,0248-0112,248.112,Ended,24,0248-P03,Pharmacokinetics age / gender,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
601,0248-0114,248.114,Ended,24,0248-P03,Drug interaction-probe-necid Pharmacok.,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
602,0248-0115,248.115,Ended,24,0248-P03,Food interaction,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
603,0248-0116,248.116,Ended,24,0248-P03,Bioequivalency & final formulation,Ended,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
604,0248-0118,248.118,Unconfirmed,24,0248-P03,Absolute oral bioavail.,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
605,0248-0120,248.120,Unconfirmed,24,0248-P03,in vitro dissolution specs.,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
606,0248-0122,248.122,Ended,24,0248-P03,Drug interaction-L-deprenyl,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
607,0248-0123,248.123,Ended,24,0248-P03,Tolerability in increasing doses,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
608,0248-0124,248.124,Ended,24,0248-P03,PHASE I STUDY ON SND919,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
609,0248-0125,248.125,Ended,24,0248-P03,PHASE I MULTIPLE DOSE STUDY ON SND919,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
610,0248-0301,248.301,Ended,24,0248-P03,MTD stages II-IV,Ended,MIG,Migration,IIA,Phase IIa,-  Part of international master plan.     ,,,000910,IS - Clin Study (MIGRATED)
611,0248-0302,248.302,Ended,24,0248-P03,MTD stage I and III,Ended,MIG,Migration,IIA,Phase IIa,-  Deprenyl, a MAO-B inhibitor, was shown to be effective in slowing the progression of Parkinson's disease and to delay the start of levodopa therapy. Since use of deprenyl will soon become the standard in early Parkinson's disease, this study will only enroll patients maintained on deprenyl.   ,,,000910,IS - Clin Study (MIGRATED)
612,0248-0303,248.303,Ended,24,0248-P03,Efficacy & safety, levodopa/DCI,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
613,0248-0304,248.304,Preparing,24,0248-P03,Efficacy, dose ranging,Preparing,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
614,0248-0305,248.305,Ended,24,0248-P03,Pramipexole in advanced Parkinson's,Ended,MIG,Migration,II,Phase II,- NZ Trial,,,000910,IS - Clin Study (MIGRATED)
615,0248-0306,248.306,Preparing,24,0248-P03,Efficacy & safety,Preparing,MIG,Migration,II,Phase II,- EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
616,0248-0307,248.307,Ended,24,0248-P03,EFFICACY/SAFETY OF ORAL DOSE,Ended,MIG,Migration,II,Phase II,- Discontinued due to low recruitment.,,,000910,IS - Clin Study (MIGRATED)
617,0248-0308,248.308,Ended,24,0248-P03,A Danish SND/Placebo Parkinson,Ended,MIG,Migration,II,Phase II,- To be reported by BIAS,,,000910,IS - Clin Study (MIGRATED)
618,0248-0309,248.309,Ended,24,0248-P03,open pilot trial Morbus Parkinson,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
619,0248-0310,248.310,Ended,24,0248-P03,Longterm effects, levodopa/DCI,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
620,0248-0320,248.320,Ended,24,0248-P03,LT safety/effic. stage III-IV,Ended,MIG,Migration,III,Phase III,-  Canadian trial #BO92SND02 Part of approved international master plan.     ,,,000910,IS - Clin Study (MIGRATED)
621,0248-0321,248.321,Ended,24,0248-P03,Efficacy & safety (pivotal) in adv. PD,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
622,0248-0322,248.322,Ended,24,0248-P03,Long term safety, 838.021 Follow-up,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
623,0248-0323,248.323,Ended,24,0248-P03,Early PD, DB, parallel, PBO-cont.,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
624,0248-0324,248.324,Ended,24,0248-P03,Efficacy & safety (pivotal), early PD,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
625,0248-0325,248.325,Ended,24,0248-P03,Safety - Follow-up,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
626,0248-0326,248.326,Ended,24,0248-P03,Efficacy & safety (Bromocriptine),Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
627,0248-0327,248.327,Ended,24,0248-P03,Open-label continuation,Ended,MIG,Migration,III,Phase III,-  Patient data from this ongoing trial will be collected on an interi m basis for inclusion in the NDA as of 01/31/95. This study will co ntinue until market launch. Canadian trial #BO92SND04. Canadian field monitoring by Endpoint Research   ,,,000910,IS - Clin Study (MIGRATED)
628,0248-0328,248.328,Ended,24,0248-P03,Open-Labelled, Cont. of 248.323 (/0001),Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
629,0248-0329,248.329,Unconfirmed,24,0248-P03,Acute efficacy & safety, advanced PD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
630,0248-0330,248.330,Ended,24,0248-P03,Efficacy & safety, fixed doses, early PD,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
631,0248-0331,248.331,Unconfirmed,24,0248-P03,Safety, follow-up of 838.026,Unconfirmed,MIG,Migration,III,Phase III,- *Ingelheim trial,,,000910,IS - Clin Study (MIGRATED)
632,0248-0332,248.332,Ended,24,0248-P03,Safety, follow-up of 838.026,Ended,MIG,Migration,III,Phase III,- Last Subject completed: extended to 31.12.1998 or until availability on the market - whatever comes first,,,000910,IS - Clin Study (MIGRATED)
633,0248-0333,248.333,Ended,24,0248-P03,Longterm safety, 838.030 Follow-up,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
634,0248-0334,248.334,Ended,24,0248-P03,Eval of Cardiov.&Biochem. effects of PPX,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
635,0248-0335,248.335,Ended,24,0248-P03,Effect on tremor in PD patients,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
636,0248-0336,248.336,Ended,24,0248-P03,LongTerm Open-Label Phase III b,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
637,0248-0337,248.337,Ended,24,0248-P03,Early Phase 2 Study in patients with PD,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
638,0248-0338,248.338,Ended,24,0248-P03,Maximal L-Dopa Reduction,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
639,0248-0339,248.339,Ended,24,0248-P03,Bromocriptine Switch Study,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000980,Not Classified (MIGRATED)
640,0248-0340,248.340,Unconfirmed,24,0248-P03,Pergolide comparison,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
641,0248-0341,248.341,Ended,24,0248-P03,Pramipexole/Levodopa Pet Study,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
642,0248-0342,248.342,Ended,24,0248-P03,Eye Safety Study,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
643,0248-0350,248.350,Ended,24,0248-P03,Levodopa Comparison (Calm PD),Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
644,0248-0351,248.351,Ended,24,0248-P03,adv. PD, on L-dopa - Ethnics (PRIME),Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
645,0248-0352,248.352,Ended,24,0248-P03,Multidose PPX,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
646,0248-0353,248.353,Ended,24,0248-P03,Chase study,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
647,0248-0354,248.354,Ended,24,0248-P03,Long term safety, extension of PRIME,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
648,0248-0355,248.355,Ended,24,0248-P03,Levodopa treated PD pat.in Latin America,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
649,0248-0356,248.356,Ended,24,0248-P03,imaging SPECT in CALM-PD Patients,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
650,0248-0357,248.357,Ended,24,0248-P03,P&U0097-Restless leg syndr.,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
651,0248-0358,248.358,Preparing,24,0248-P03,iv infusion L-dopa,Preparing,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
652,0248-0359,248.359,Preparing,24,0248-P03,Ropinirole Comparator,Preparing,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
653,0248-0360,248.360,Ended,24,0248-P03,Sifrol AWB 1:TIS,SHAPS,SPES,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
654,0248-0361,248.361,Ended,24,0248-P03,Levodopa treated pat-Cont.248.355(/0093),Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
655,0248-0362,248.362,Ended,24,0248-P03,Asian Study,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
656,0248-0363,248.363,Ended,24,0248-P03,Open label study in Russia,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
657,0248-0364,248.364,Unconfirmed,24,0248-P03,DB, PBO Cont., Flex. Dose Study in China,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
658,0248-0505,248.505,Ended,24,0248-P03,Comparative study in advanced PD,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
659,0248-0506,248.506,Ended,24,0248-P03,Longterm study in early and advanced PD,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
660,0248-0507,248.507,Ended,24,0248-P03,Effect of PPX on PD pts + conc. depress,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
661,0248-0508,248.508,Analysis,24,0248-P03,P&U Sleep laboratory study,Analysis,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
662,0248-0509,248.509,Preparing,24,0248-P03,P&U Epidemiol. study "sudden somnolence",Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
663,0248-0510,248.510,Ended,24,0248-P03,D-receptor polymorphism & sudden sleep,Ended,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
664,0248-0511,248.511,Ended,24,0248-P03,Sifrol AWB 2: Tremor, Depression,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
665,0248-0514,248.514,Unconfirmed,24,0248-P03,ascending dose in healthy volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
666,0248-0516,248.516,Ended,24,0248-P03,Bromcriptin comparator trial,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
667,0248-0517,248.517,Ended,24,0248-P03,Parkinson's Disease switching to PPX,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
668,0248-0527,248.527,Ended,24,0248-P03,Erstvorstellung 2003,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
669,0248-0533,248.533,Ended,24,0248-P03,PK and PD interaction study in adv. PD,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
670,0248-0534,248.534,Unconfirmed,24,0248-P03,Pilot, PK/PD after iv infusion L-dopa,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
671,0248-0535,248.535,Ended,24,0248-P03,Pilot, Progressive Supranuclear Palsy,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
672,0248-0536,248.536,Ended,24,0248-P03,OL switch Bormocriptine/pergolide PDpat.,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
673,0248-0537,248.537,Preparing,24,0248-P03,Efficacy & safety (DBT), early PD,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
674,0248-0538,248.538,Ended,24,0248-P03,Ophthalmologic Safety Study,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
675,0248-0539,248.539,Ended,24,0248-P03,Monotherapie 2004,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
676,0248-0544,248.544,Ended,24,0248-P03,Switch talipexole to pramipexole,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
677,0248-0547,248.547,Ended,24,0248-P03,Special Survey long-term use,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
678,0248-0548,248.548,Ended,24,0248-P03,Special survey renal dysfunction,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
679,0248-0549,248.549,Ended,24,0248-P03,Special survey non-combination of L-Dopa,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
680,0248-0550,248.550,Unconfirmed,24,0248-P03,Switching/Bromocriptine,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
681,0248-0551,248.551,Unconfirmed,24,0248-P03,Switching/t.b.d.,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
682,0248-0552,248.552,Unconfirmed,24,0248-P03,Switching/Cabergoline,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
683,0248-0553,248.553,Unconfirmed,24,0248-P03,Switching/t.b.d.,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
684,0248-0554,248.554,Unconfirmed,24,0248-P03,Switching/Cabergoline/Crossover fashion,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
685,0248-0555,248.555,Unconfirmed,24,0248-P03,Switching/Cabergoline t.b.d.,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
686,0248-0556,248.556,Unconfirmed,24,0248-P03,DBT/Placebo De novo Time to progression,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
687,0248-0558,248.558,Ended,24,0248-P03,Imaging regulation Dr. Marek,Ended,MIG,Migration,IV,Phase IV,,,,,
688,0248-0559,248.559,Ended,24,0248-P03,PMS Maintenance in PD,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
689,0248-0562,248.562,Unconfirmed,24,0248-P03,528E-CNS-0072-119,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
690,0248-0563,248.563,Unconfirmed,24,0248-P03,528E-CNS-0072-120,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
691,0248-0564,248.564,Unconfirmed,24,0248-P03,528E-CNS-0072-0122,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
692,0248-0565,248.565,Unconfirmed,24,0248-P03,528E-CNS-0072-123,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
693,0248-0566,248.566,Unconfirmed,24,0248-P03,528E-CNS-0072-0124,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
694,0248-0567,248.567,Unconfirmed,24,0248-P03,528E-CNS-0072-0125,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
695,0248-0568,248.568,Unconfirmed,24,0248-P03,528E-CNS-0072-0126,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
696,0248-0569,248.569,Unconfirmed,24,0248-P03,528E-CNS-0072-127,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
697,0248-0570,248.570,Unconfirmed,24,0248-P03,528E-CNS-0072-128,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
698,0248-0571,248.571,Unconfirmed,24,0248-P03,528E-CNS-0072-129,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
699,0248-0572,248.572,Unconfirmed,24,0248-P03,528E-CNS-0072-130,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
700,0248-0574,248.574,Unconfirmed,24,0248-P03,528E-CNS-0072-132,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
701,0248-0575,248.575,Unconfirmed,24,0248-P03,528E-CNS-0072-133,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
702,0248-0576,248.576,Unconfirmed,24,0248-P03,528E-CNS-0072-134,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
703,0248-0577,248.577,Unconfirmed,24,0248-P03,528E-CNS-0072-135,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
704,0248-0578,248.578,Unconfirmed,24,0248-P03,528E-CNS-0072-136,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
705,0248-0579,248.579,Unconfirmed,24,0248-P03,528E-CNS-0072-137,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
706,0248-0580,248.580,Unconfirmed,24,0248-P03,PPXAPD-0072-138,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
707,0248-0581,248.581,Unconfirmed,24,0248-P03,PPXAPD-0072-139,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
708,0248-0582,248.582,Preparing,24,0248-P03,PPXAPD-0072-142,Preparing,MIG,Migration,IV,Phase IV,,,,,
709,0248-0583,248.583,Preparing,24,0248-P03,PPXAPD-0072-143,Preparing,MIG,Migration,IV,Phase IV,,,,,
710,0248-0584,248.584,Preparing,24,0248-P03,PPXAPD-0072-144,Preparing,MIG,Migration,IV,Phase IV,,,,,
711,0248-0585,248.585,Preparing,24,0248-P03,PPXAPD-0072-145,Preparing,MIG,Migration,IV,Phase IV,,,,,
712,0248-0586,248.586,Preparing,24,0248-P03,PPXAPD-0072-147,Preparing,MIG,Migration,IV,Phase IV,,,,,
713,0248-0587,248.587,Preparing,24,0248-P03,PPXAPD-0072-148,Preparing,MIG,Migration,IV,Phase IV,,,,,
714,0248-0589,248.589,Preparing,24,0248-P03,Z/2730/0116,Preparing,MIG,Migration,IV,Phase IV,,,,,
715,0248-0590,248.590,Ended,24,0248-P03,France : Transversale study in PD,Ended,MIG,Migration,IV,Phase IV,epidemiological study without BI drug ,,,000940,Post Marketing Study (MIGRATED)
716,0248-0593,248.593,Preparing,24,0248-P03,Depressive symptoms in advanced PD,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
717,0248-0594,248.594,Unconfirmed,24,0248-P03,Depressive symptoms in late PD,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
718,0248-0595,248.595,Ended,24,0248-P03,pramipexole early start PD study,Ended,MIG,Migration,IV,Phase IV,Design similar to rasagiline model ,2005-004949-34,,000910,IS - Clin Study (MIGRATED)
719,0248-0596,248.596,Ended,24,0248-P03,Depressive symptoms in advanced PD,Ended,MIG,Migration,IV,Phase IV,,2005-003788-22,,000910,IS - Clin Study (MIGRATED)
720,0248-0597,248.597,Ended,24,0248-P03,Observational study in PD,Ended,MIG,Migration,IV,Phase IV,No EudraCT number is necessary. ,,,000940,Post Marketing Study (MIGRATED)
721,0248-0598,248.598,Ended,24,0248-P03,PMS Argentina 2005 titration schedule,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
722,0248-0599,248.599,Ended,24,0248-P03,PMS in Korea, requested by authority,Ended,MIG,Migration,IV,Phase IV,Study Report U Number: U08-3530-01 ,,,000940,Post Marketing Study (MIGRATED)
723,0248-0605,248.605,Preparing,24,0248-P03,neurol-psychophysiological study in PD,Preparing,MIG,Migration,IV,Phase IV,,,,,
724,0248-0606,248.606,Ended,24,0248-P03,Motor Function in Severe PD,Ended,MIG,Migration,IV,Phase IV,,,,,
725,0248-0611,248.611,Ended,24,0248-P03,Hedonia in PD,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
726,0248-0612,248.612,Ended,24,0248-P03,Parkinson Symptoms per disease severity,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
727,0248-0613,248.613,Ended,24,0248-P03,1st  Present of Mirapex in PD Patients,Ended,MIG,Migration,IV,Phase IV,no study drug administration ,,,000940,Post Marketing Study (MIGRATED)
728,0248-0614,248.614,Unconfirmed,24,0248-P03,Pramipexole and depression in PD,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
729,0248-0617,248.617,Ended,24,0248-P03,Epidemiology of depressive Sx in PD,Ended,MIG,Migration,IV,Phase IV,,,,,
730,0248-0619,248.619,Ended,24,0248-P03,DOMINION,Ended,MIG,Migration,IV,Phase IV,Observational Survey of PD patients No study medication supplied,,,000600,Survey Patient Questionnaire
731,0248-0620,248.620,Ended,24,0248-P03,Diagnostic criteria for early PD,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
732,0248-0621,248.621,Ended,24,0248-P03,Mexican Epidemiology of PD,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
733,0248-0622,248.622,Ended,24,0248-P03,BID study in early PD,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
734,0248-0625,248.625,Preparing,24,0248-P03,Evolution of Sx in early PD,Preparing,MIG,Migration,IV,Phase IV,,,,,
735,0248-0626,248.626,Preparing,24,0248-P03,Pramipexole PD Market Research,Preparing,MIG,Migration,NONE,Not Classified,Non clinical trial activit ,,,000980,Not Classified (MIGRATED)
736,0248-0628,248.628,Ended,24,0248-P03,PD and current treatm registry in Greece,Ended,MIG,Migration,IV,Phase IV,,,,,
737,0248-0631,248.631,Ended,24,0248-P03,Parkinson and non-motor symptoms,Ended,MIG,Migration,IV,Phase IV,trial type changed based on Degner/Busse sugestions  dated July, 22 2010,,,000600,Survey Patient Questionnaire
738,0248-0635,248.635,Ended,24,0248-P03,Jap PPX PMS in PD and Depression,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
739,0248-0639,248.639,Ended,24,0248-P03,Non-motor symptoms under PPX treatment,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
740,0248-0648,248.648,Ended,24,0248-P03,France PMS : PPX Target population in PD,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
741,0248-0649,248.649,Ended,24,0248-P03,Non-motor sympt of PD  under PPX treatm,Ended,MIG,Migration,IV,Phase IV,Observation of Therapeutic Use Anwendungsbeobachtung,,,000940,Post Marketing Study (MIGRATED)
742,0248-0651,248.651,Preparing,24,0248-P03,PPX open label 12-week study in China,Preparing,MIG,Migration,IV,Phase IV,it's a PMS study ,,,000940,Post Marketing Study (MIGRATED)
743,0248-0657,248.657,Ended,24,0248-P03,Kinetic tremor in PD and  PPX treatment,Ended,MIG,Migration,IV,Phase IV,Observation of Therapeutic Use ,,,000940,Post Marketing Study (MIGRATED)
744,0248-0658,248.658,Ended,24,0248-P03,WHO-5 application in PD,Ended,MIG,Migration,NONE,Not Classified,Survey (questionnaire application) Non-drug trial (survey trial),,,000920,NISnd - Study (MIGRATED)
745,0248-0661,248.661,Ended,24,0248-P03,MRI preclin PD,Ended,MIG,Migration,IV,Phase IV,None BI Drug experimental IIS (Poewe) ,,,,
746,0248-0670,248.670,Preparing,24,0248-P03,PREMYS Fr. obs. study in PD manag. care,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
747,0248-0672,248.672,Ended,24,0248-P03,Use of PPX and other DA and risks,Ended,MIG,Migration,IV,Phase IV,Epidemiology Study ,,,000980,Not Classified (MIGRATED)
748,0248-0673,248.673,Unconfirmed,24,0248-P03,MCIC on the UPDRS,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
749,0248-0679,248.679,Ended,24,0248-P03,NoMoFlu-PD Study,Ended,MIG,Migration,IV,Phase IV,,,,,
750,0248-0681,248.681,Ended,24,0248-P03,PDRT expr. in PD treated with ppx&L-dopa,Ended,MIG,Migration,IV,Phase IV,,,,,
751,0248-0682,248.682,Ended,24,0248-P03,Safety Study of PPX in Chinese PD,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
752,0248-0683,248.683,Preparing,24,0248-P03,Sifrol performance tracking study,Preparing,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
753,0248-0684,248.684,Preparing,24,0248-P03,Depression in PD patients in China,Preparing,MIG,Migration,NONE,Not Classified,  ,,,,
754,0248-0685,248.685,Unconfirmed,24,0248-P03,influence of depression on QOL,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000440,NISed ‚Äì Study - Case Control
755,0248-0101,248.101,Ended,25,0248-P02,Dose tolerance p.o., single dose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
756,0248-0102,248.102,Ended,25,0248-P02,Dose tolerance p.o., multiple dose,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
757,0248-0103,248.103,Ended,25,0248-P02,Dose tolerance i.v., single dose,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
758,0248-0104,248.104,Ended,25,0248-P02,Dose response, efficacy,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
759,0248-0105,248.105,Ended,25,0248-P02,Bioavailibility, p.o. vs. i.v.,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
760,0248-0106,248.106,Ended,25,0248-P02,ADME c14-SND 919, single dose,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
761,0248-0108,248.108,Ended,25,0248-P02,Kinetics, pilotstudy,Ended,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
762,0248-0109,248.109,Ended,25,0248-P02,Bioequivalence,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
763,0248-0110,248.110,Ended,25,0248-P02,Safety, cardiovascular data,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
764,0248-0111,248.111,Ended,25,0248-P02,Safety,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
765,0248-0113,248.113,Ended,25,0248-P02,Kinetics, renally impaired,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
766,0248-0117,248.117,Ended,25,0248-P02,Dose-proportionality Kinetics,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
767,0248-0119,248.119,Unconfirmed,25,0248-P02,Pharmacokinetics in hypertensives,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
768,0248-0121,248.121,Ended,25,0248-P02,Drug inferaction-levodopa Kinetics,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
769,0248-0201,248.201,Ended,25,0248-P02,Efficacy & safety,Ended,MIG,Migration,II,Phase II,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
770,0248-0202,248.202,Preparing,25,0248-P02,Efficacy & safety,Preparing,MIG,Migration,II,Phase II,Cancelled  10.90 ,,,000910,IS - Clin Study (MIGRATED)
771,0248-0203,248.203,Ended,25,0248-P02,Dose-efficacy of Pramipexole,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
772,0248-0204,248.204,Ended,25,0248-P02,Efficacy & safety vs. standard (open),Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
773,0248-0206,248.206,Preparing,25,0248-P02,Safety, pilotstudy,Preparing,MIG,Migration,II,Phase II,Cancelled 02.90 ,,,000910,IS - Clin Study (MIGRATED)
774,0248-0207,248.207,Ended,25,0248-P02,Safety & efficacy (HUN),Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
775,0248-0208,248.208,Ended,25,0248-P02,Safety & efficacy (chronic),Ended,MIG,Migration,II,Phase II,Discont. 09.92 ,,,000910,IS - Clin Study (MIGRATED)
776,0248-0209,248.209,Ended,25,0248-P02,Efficacy & safety, acute (TCH),Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
777,0248-0210,248.210,Ended,25,0248-P02,SND 919 in acute Schizophrenia,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
778,0248-0211,248.211,Unconfirmed,25,0248-P02,Pilot study add-on neuroleptics,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
779,0248-0212,248.212,Ended,25,0248-P02,efficacy and safety,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
780,0248-0213,248.213,Unconfirmed,25,0248-P02,Pos. symptom decision study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
781,0248-0214,248.214,Unconfirmed,25,0248-P02,Efficacy, add-on neuroleptics,Unconfirmed,MIG,Migration,IIB,Phase IIb,- *Ingelheim trial,,,000910,IS - Clin Study (MIGRATED)
782,0248-0215,248.215,Ended,25,0248-P02,Short term trial in residual pat.,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
783,0248-0216,248.216,Ended,25,0248-P02,Safety and pharmacokinetics,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
784,0248-0217,248.217,Ended,25,0248-P02,Safety, add-on to depot,Ended,MIG,Migration,III,Phase III,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
785,0248-0218,248.218,Unconfirmed,25,0248-P02,Long-term safety,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
786,0510-0955,510.955,Ended,26,0510-P05,<30% burn: pK/safety/efficacy,Ended,MIG,Migration,I,Phase I,-  Clinical completion is defined as one month follow-up.  Report delayed due to competing priorities in drug metabolism group.     ,,,000910,IS - Clin Study (MIGRATED)
787,0510-0972,510.972,Ended,26,0510-P05,< 30% burn: Safety & efficacy,Ended,MIG,Migration,IIA,Phase IIa,-  12 month follow-up expected 4/21/97. Completion date estimated pending exact information from CRFs.     ,,,000910,IS - Clin Study (MIGRATED)
788,0510-0978,510.978,Unconfirmed,26,0510-P05,>30% burn: pk/safety/efficacy,Unconfirmed,MIG,Migration,I,Phase I,-  Not on critical path for Pla filing for burn. Initiation depends upon demonstration of efficacy in trial 510.972.  Dates provisional.     ,,,000910,IS - Clin Study (MIGRATED)
789,0510-1040,510.1040,Unconfirmed,26,0510-P05,30%burn:saf./eff,Unconfirmed,MIG,Migration,III,Phase III,-  Endpoints will be wound healing. Systemic sequelae(ARDS) will be deferred per team recommendation and decision conference outcome.   TRIAL PREP ON HOLD PENDING IMC DECISION  ON RESTART OF ENLIMOMAB PROGRAM. ,,,000910,IS - Clin Study (MIGRATED)
790,0510-1061,510.1061,Unconfirmed,26,0510-P05,< 30% burn: Safety & efficacy,Unconfirmed,MIG,Migration,IIA,Phase IIa,-  Backup for US trial 00972 A (using different protocol)in Europe.   This trial is not a part of an approved international masterplan.     ,,,000910,IS - Clin Study (MIGRATED)
791,0510-1201,510.1201,Preparing,26,0510-P05,10-30% burn: pediatric,Preparing,MIG,Migration,I,Phase I,-  Data provisional. Trial will not initiate without long term mortality data from study 510.972.   INITIATION ON HOLD PENDING IMC DECISION. ,,,000910,IS - Clin Study (MIGRATED)
792,0510-0886,510.886,Ended,27,0510-P06,Rheumatoid arthritis,Ended,MIG,Migration,I,Phase I,        ,,,,
793,0510-0916,510.916,Ended,27,0510-P06,Safety - PLA/non-PLA,Ended,MIG,Migration,I,Phase I,-  This OIND study tracks 10 patients who received the PLA batch of BIRR1. Data will be used in renal submission. Due to the importance of this study it is being tracked as a BIPI trial. This trial is part of an approved international masterplan. Report to include brief summary of PK, safety and efficacy on PLA vs. non-PLA. The report will be an addenda to  510.886 REPT TO DISCUSS 10 PLA & 10 NON-PLA PTS. ,,,,
794,0510-1043,510.1043,Preparing,27,0510-P06,BIRR1 in early RA patients,Preparing,MIG,Migration,IIA,Phase IIa,-  One yr duration of treatment and observation. Includes retreatment. This trial is to be conducted under Dr. Lipsky's IND, with CRO (Clinimetrics).  CRFs to be done by Clinimetrics.  Initiation of trial is dependent on signing of contracts.   ,,,,
795,0510-1103,510.1103,Unconfirmed,27,0510-P06,Kinetic and tolerability,Unconfirmed,MIG,Migration,II,Phase II,- *Ingelheim trial,,,000910,IS - Clin Study (MIGRATED)
796,0510-0831,510.831,Ended,28,0510-P01,Liver pharmacokinetics,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
797,0510-1617,510.1617,Ended,28,0510-P01,Safety & pharmacokinetics,Ended,MIG,Migration,I,Phase I,-  This trial is part of an international masterplan. A date of the first draft of the report is TBD.     ,,,000910,IS - Clin Study (MIGRATED)
798,0510-1644,510.1644,Ended,28,0510-P01,Efficacy study, 3 mo.,Ended,MIG,Migration,II,Phase II,-  This trial involves 3-year follow-up of safety.  Last patient complete will be 1/16/98.  Follow-up discontinued after program terminated. Last subject completed date reflects date program term inated. PLANNED DATES NOT ACCURATE. SYSTEM DOES  NOT ALLOW INSERTION OF NEW DATES. ,,,000910,IS - Clin Study (MIGRATED)
799,0510-1682,510.1682,Ended,28,0510-P01,Pivotal PLA study (Europe),Ended,MIG,Migration,III,Phase III,- *Biberach trial,,,000910,IS - Clin Study (MIGRATED)
800,0510-1956,510.1956,Ended,28,0510-P01,Pivotal PLA study (U.S.),Ended,MIG,Migration,III,Phase III,-  Trial terminated with 209 patients enrolled/  Follow-up discontinued 3Q97.     ,,,000910,IS - Clin Study (MIGRATED)
801,0510-2617,510.2617,Ended,28,0510-P01,12 mo. safety & pharmaco.,Ended,MIG,Migration,I,Phase I,-  This trial is part of an international masterplan.     ,,,000910,IS - Clin Study (MIGRATED)
802,0510-2644,510.2644,Preparing,28,0510-P01,Efficacy, 1yr follow up,Preparing,MIG,Migration,II,Phase II,-  See comments regarding clinical completion dates of short term 644.   This trial is now part of 510.1644.     ,,,000910,IS - Clin Study (MIGRATED)
803,0510-2682,510.2682,Ended,28,0510-P01,Efficay, long term,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
804,0510-2956,510.2956,Preparing,28,0510-P01,Pivotal PLA 12mo F/P (US),Preparing,MIG,Migration,III,Phase III,-  This 'trial' is now included in 510.1956, as it does not meet the criteria of 'different treatments which will not be evaluated together'.     ,,,000910,IS - Clin Study (MIGRATED)
805,0510-1066,510.1066,Ended,29,0510-P07,Safety, pharmacok., biol. activ.- BIRR-1,Ended,MIG,Migration,IIA,Phase IIa,Insertion date: 09.09.94 ,,,000910,IS - Clin Study (MIGRATED)
806,0510-1067,510.1067,Ended,29,0510-P07,3 mo. efficacy,Ended,MIG,Migration,IIB,Phase IIb,-  Study sites in U.S., Norway, Denmark, Germany, Italy, Finland, Sweden and France. (additional OPU codes: ff, sf, sw, db wouldn't fit in field) LAST PT COMPL IS APPROXIMATE DATE PENDING DOCUMENTATION FROM OPUS Please enter actual when it becomes available - Pam PLANNED ENROLLED IN SUM OF MAX. NO. OF PATIENTS EACH CENTER COULD ENROLL. ,,,000910,IS - Clin Study (MIGRATED)
807,0510-1200,510.1200,Unconfirmed,29,0510-P07,Pilot safety & effic ICH,Unconfirmed,MIG,Migration,II,Phase II,-  Initiation depends upon demonstration of efficacy of enlimomab in trial 510.1067.Trial proposed to be conducted in U.S., Germany, and Finland (1 center in each country).   MILESTONES WILL BE ADJUSTED TO INITIATE  1Q97. CHANGE REQUIRES DIRECTOR APPROVAL ,,,000910,IS - Clin Study (MIGRATED)
808,0366-0001,366.1,Ended,30,0366-P01,Phase I of Tumor Vaccine MMIL-2,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
809,0366-0002,366.2,Unconfirmed,30,0366-P01,Sefety, tolerability,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
810,0366-0003,366.3,Unconfirmed,30,0366-P01,Relapse rate after curative surgery,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
811,0515-0001,515.1,Ended,31,0515-P01,Single incr. dose tol.- Omega Interferon,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
812,0515-0002,515.2,Ended,31,0515-P01,Double-blind rand. group comp. IFN(o+a),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
813,0515-0003,515.3,Ended,31,0515-P01,Group comp. of eff. of IFN-o - IFN-a 2b,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
814,0515-0004,515.4,Unconfirmed,31,0515-P01,Comparison of 2 doses IFN omega,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
815,0501-0001,501.1,Unconfirmed,32,0501-P01,Tolerability in patients,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
816,0501-0002,501.2,Unconfirmed,32,0501-P01,Max. tolerated dose (V.A.D. Protocol),Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
817,0501-0003,501.3,Unconfirmed,32,0501-P01,Safety, tolerability, pharmacokinetics,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
818,0528-0001,528.1,Ended,33,0528-P01,Single Rising Dose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
819,0528-0002,528.2,Ended,33,0528-P01,Rel. Bioavailab. oral solution/caps.50mg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
820,0528-0003,528.3,Ended,33,0528-P01,Single Rising Dose i.v. (1-25mg),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
821,0528-0004,528.4,Ended,33,0528-P01,C14-study BIBV 308 SE,Ended,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
822,0528-0005,528.5,Unconfirmed,33,0528-P01,C14-study BIBV 308 SE (i.v.),Unconfirmed,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
823,0528-0006,528.6,Ended,33,0528-P01,Multiple dose study BIBV 308 SE,Ended,MIG,Migration,I,Phase I,- Subject 25-32 acc. 1st Amendment,,,000910,IS - Clin Study (MIGRATED)
824,0528-0007,528.7,Unconfirmed,33,0528-P01,Dyn.,Safety and Kinetics in AP (no ASA),Unconfirmed,MIG,Migration,II,Phase II,,,,000980,Not Classified (MIGRATED)
825,0528-0008,528.8,Unconfirmed,33,0528-P01,Safety and Dyn of BIBV vs ASA post AMI,Unconfirmed,MIG,Migration,II,Phase II,,,,000980,Not Classified (MIGRATED)
826,0528-0009,528.9,Unconfirmed,33,0528-P01,Safety and Dyn. of BIBV vs ASA post stro,Unconfirmed,MIG,Migration,II,Phase II,,,,000980,Not Classified (MIGRATED)
827,0528-0010,528.10,Ended,33,0528-P01,BIBV 308 SE in anacidic volunteers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
828,0528-0011,528.11,Ended,33,0528-P01,Influence of food 100 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
829,0528-0012,528.12,Ended,33,0528-P01,Bioavailab. of new pharm. formulations,Ended,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
830,0528-0013,528.13,Ended,33,0528-P01,Mechanistic study of BIBV 308SE 25-200mg,Ended,MIG,Migration,II,Phase II,- before treatment for some subjects add. ASA-wash-out phase of 14 days,,,000910,IS - Clin Study (MIGRATED)
831,0528-0014,528.14,Ended,33,0528-P01,Kinetics and Safety of 200,400mg BIBV,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
832,0528-0016,528.16,Ended,33,0528-P01,Rel Bioavail.100mg tabl.vs capsule,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
833,0528-0017,528.17,Ended,33,0528-P01,Safety over 4 weeks with healthy subject,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
834,0528-0018,528.18,Ended,33,0528-P01,Influence of food of 100 mg tablet,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
835,0528-0020,528.20,Ended,33,0528-P01,Dose response - U.S.,Ended,MIG,Migration,II,Phase II,-  Delayed to 4Q97 due to FDA request for additional safety data. Germany will conduct a 1 month safety study in healthy volunteers.     ,,,000910,IS - Clin Study (MIGRATED)
836,0528-0022,528.22,Ended,33,0528-P01,Rel. bioavailability of sust. rel. forms,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
837,0528-0023,528.23,Ended,33,0528-P01,Interaction Study with Clopidogrel,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
838,0528-0201,528.201,Unconfirmed,33,0528-P01,Mechanistic study,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
839,0528-0202,528.202,Unconfirmed,33,0528-P01,Dose response - U.S.,Unconfirmed,MIG,Migration,II,Phase II,- Study renumbered by TMM Dr. Riedel. New Number is 528.15,,,000910,IS - Clin Study (MIGRATED)
840,0528-0203,528.203,Unconfirmed,33,0528-P01,Dose response - europe,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
841,0528-0204,528.204,Ended,33,0528-P01,Rel. BV of Sust. rel. Forms,Ended,MIG,Migration,I,Phase I,Fortsetzung 528.22 ,,,000910,IS - Clin Study (MIGRATED)
842,0528-0205,528.205,Unconfirmed,33,0528-P01,Terbogrel vs. Pentoxyfilin in PAOD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
843,0528-0206,528.206,Unconfirmed,33,0528-P01,Terbogrel vs. Cilostazol in PAOD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
844,0528-0207,528.207,Unconfirmed,33,0528-P01,Terbogrel vs. ASA,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
845,0528-0210,528.210,Unconfirmed,33,0528-P01,Interaction Terbogrel / Warfarin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
846,0528-0211,528.211,Unconfirmed,33,0528-P01,Interaction Terbogrel / Digoxin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
847,0528-0212,528.212,Unconfirmed,33,0528-P01,Interaction Terbogrel / Antidiabetics,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
848,0504-0101,504.101,Ended,34,0504-P01,Dose finding: 10 - 600mg suspension p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
849,0504-0102,504.102,Ended,34,0504-P01,Kinetics and safety of 10,50,100mg i.v.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
850,0504-0103,504.103,Unconfirmed,34,0504-P01,Absolute/relative bioavail. SI/KA/AMi.v.,Unconfirmed,MIG,Migration,I,Phase I,Pl. dates: Start 01-AUG-94 End 31-DEC-94 Trial on hold,,,000910,IS - Clin Study (MIGRATED)
851,0504-0104,504.104,Ended,34,0504-P01,Multiple applic.(p.o.) in healthy volunt,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
852,0504-0105,504.105,Ended,34,0504-P01,Relative bioavail. SI/different capsules,Ended,MIG,Migration,I,Phase I,- Obs.time: 2-3 days/treatment period;up to 5 treatm. periods,,,000910,IS - Clin Study (MIGRATED)
853,0504-0106,504.106,Ended,34,0504-P01,Dose finding:25-400mg as drinkg.solution,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
854,0504-0107,504.107,Ended,34,0504-P01,Tolerab.+kinetics 2-3x400mg/d over 7days,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
855,0504-0108,504.108,Ended,34,0504-P01,Metabolism and pharmacokin. of [14C]DTTX,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
856,0504-0109,504.109,Ended,34,0504-P01,Rel.bioav. of various pharm.formulations,Ended,MIG,Migration,I,Phase I,- Obs.time: 3 days/treatment period; 4 treatm. periods,,,000910,IS - Clin Study (MIGRATED)
857,0504-0110,504.110,Unconfirmed,34,0504-P01,Intraduodenal administration DTTX 30 SE,Unconfirmed,MIG,Migration,I,Phase I,Trial on hold  (ident.352.051.030) Notice Dr. Narjes - 12.05.95,,,000910,IS - Clin Study (MIGRATED)
858,0531-0001,531.1,Ended,35,0531-P01,Tolerab./Kinetics: increasing doses p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
859,0531-0002,531.2,Ended,35,0531-P01,PD, PK, Tolerability of 5,10,20,40 mg po,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
860,0531-0003,531.3,Ended,35,0531-P01,Kinetics/Safety of 5,20,80 mg p.o. 7days,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
861,0531-0004,531.4,Ended,35,0531-P01,Single rising dose (5,10,20,40mg) i.v.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
862,0531-0005,531.5,Ended,35,0531-P01,Absolute /relative bioavailability,Ended,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
863,0531-0006,531.6,Unconfirmed,35,0531-P01,4 week dose response:efficacy and safety,Unconfirmed,MIG,Migration,II,Phase II,,,,000980,Not Classified (MIGRATED)
864,0531-0007,531.7,Unconfirmed,35,0531-P01,Absolute Bioavailability,Unconfirmed,MIG,Migration,I,Phase I,Trial canceled on 08NOV95 Trial canceled on 08NOV95 - 5mg dose will be tested in Trial No. 531.5,,,000980,Not Classified (MIGRATED)
865,0193-0001,193.1,Ended,36,0193-P01,Dose finding: 0.5 - 2 mg tablet p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
866,0193-0002,193.2,Ended,36,0193-P01,Dose response study: 0.5,1,2mg tabl. p.o,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
867,0193-0003,193.3,Unconfirmed,36,0193-P01,Saf.,effic.in sulphonylur.-trea.diab.pat,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
868,0193-0004,193.4,Unconfirmed,36,0193-P01,Eintrag fehlt; bitte updaten,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
869,0193-0005,193.5,Unconfirmed,36,0193-P01,Eintrag fehlt; bitte updaten,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
870,0193-0006,193.6,Unconfirmed,36,0193-P01,Multiple dose,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
871,0193-0009,193.9,Unconfirmed,36,0193-P01,Three months comparison,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
872,0193-0050,193.50,Ended,36,0193-P01,Abs. bioavail. of 2mg p.o/i.v.,Ended,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
873,0502-0101,502.101,Ended,37,0502-P01,Dose finding: 1-160 mg drink. sol. p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
874,0502-0102,502.102,Ended,37,0502-P01,Bioavailab.: 20mg/160mg dr.sol./KAH p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
875,0502-0103,502.103,Ended,37,0502-P01,Pharmacodynamics,-kinetics 20-80 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
876,0502-0104,502.104,Unconfirmed,37,0502-P01,Kinetics: 10, 40 mg KAH over 7 days p.o.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
877,0502-0105,502.105,Ended,37,0502-P01,Dose finding: 10 - 80 mg ampoule i.v.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
878,0502-0106,502.106,Ended,37,0502-P01,Bioavailab.: 40mg i.v./dr.sol./TA p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
879,0502-0107,502.107,Unconfirmed,37,0502-P01,Kinetics: 1x10 mg capsule - tablet p.o.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
880,0502-0108,502.108,Unconfirmed,37,0502-P01,Kinetics: increasing multiple dose p.o.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
881,0502-0109,502.109,Ended,37,0502-P01,Kinetics: 20 and 80 mg of TA or KAH p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
882,0502-0110,502.110,Ended,37,0502-P01,ADME of 14C labelled substance,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
883,0502-0111,502.111,Ended,37,0502-P01,Dose finding: 60 and 80 mg ampoule i.v.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
884,0502-0112,502.112,Ended,37,0502-P01,Bioavailab.:160mg i.v./dr.sol./TA p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
885,0502-0113,502.113,Ended,37,0502-P01,Food interaction: 40 and 160 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
886,0502-0114,502.114,Ended,37,0502-P01,Pk interaction with HCTZ,Ended,MIG,Migration,I,Phase I,-  Trial to be conducted with Innovex.     ,,,000910,IS - Clin Study (MIGRATED)
887,0502-0115,502.115,Ended,37,0502-P01,Tolerance and kinetics: 320 mg TA p.o.,Ended,MIG,Migration,I,Phase I,L.A.B.; Investigator Baedeker ,,,000910,IS - Clin Study (MIGRATED)
888,0502-0116,502.116,Unconfirmed,37,0502-P01,Bioavailab.: 25mg TA/caps / 2x12.5g caps,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
889,0502-0117,502.117,Unconfirmed,37,0502-P01,Dose proportionality,Unconfirmed,MIG,Migration,II,Phase II,-  Trial conduct with Innovex. Study cancelled 10/94.     ,,,000910,IS - Clin Study (MIGRATED)
890,0502-0118,502.118,Ended,37,0502-P01,Pharmacokinetic: in renal insuff.patient,Ended,MIG,Migration,I,Phase I,wash-out period 14 days ,,,000910,IS - Clin Study (MIGRATED)
891,0502-0119,502.119,Ended,37,0502-P01,Interact.:BIBR/cardia glycoside Digoxin,Ended,MIG,Migration,I,Phase I,- Screening about 14 days, follow up about 7 to 14 days,,,000910,IS - Clin Study (MIGRATED)
892,0502-0120,502.120,Ended,37,0502-P01,BIBR 277 SE / WARFARIN interaction study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
893,0502-0121,502.121,Ended,37,0502-P01,Interaction: BIBR SE 277 / Paracetamol,Ended,MIG,Migration,I,Phase I,wash-out period 14 days ,,,000910,IS - Clin Study (MIGRATED)
894,0502-0122,502.122,Ended,37,0502-P01,Interaction: Telmisartan / Glibenclamid,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
895,0502-0123,502.123,Ended,37,0502-P01,PK in hepatic insuff. and healthy subj.,Ended,MIG,Migration,I,Phase I,Obs.tdurat: 5d(for i.v.-dosis)=+3visits Due to Amendment No. 5 and 6: additional i.v.-treatment for 5 subjects and 2 (as doseleaders) with hepatic insuff., who already received the 20 and 120mg p.o.-dose,,,000910,IS - Clin Study (MIGRATED)
896,0502-0124,502.124,Ended,37,0502-P01,Kinetics: 20/120mg TA in elderly/ 7 days,Ended,MIG,Migration,I,Phase I,wash-out period: 14 days ,,,000910,IS - Clin Study (MIGRATED)
897,0502-0125,502.125,Ended,37,0502-P01,Interaction: Telmisartan / Ibuprofen,Ended,MIG,Migration,I,Phase I,wash-out period >= 13 days ,,,000910,IS - Clin Study (MIGRATED)
898,0502-0126,502.126,Ended,37,0502-P01,Interaction: Telmisartan / Amlodipine,Ended,MIG,Migration,I,Phase I,wash-out period >= 13 days ,,,000910,IS - Clin Study (MIGRATED)
899,0502-0127,502.127,Ended,37,0502-P01,Pivotal BA/BE study,Ended,MIG,Migration,I,Phase I,-  Final sample size dependent on pk variability. Trial may be conducted by Phoenix Asking FDA for an exemption, trial may not be performed.     ,,,000910,IS - Clin Study (MIGRATED)
900,0502-0128,502.128,Ended,37,0502-P01,Rel.Bioavail. 120 mg oblong/round tabl.,Ended,MIG,Migration,I,Phase I,wash-out period >= 7 days ,,,000910,IS - Clin Study (MIGRATED)
901,0502-0129,502.129,Ended,37,0502-P01,Single administration / Japan,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
902,0502-0130,502.130,Ended,37,0502-P01,Multiple administration,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
903,0502-0131,502.131,Ended,37,0502-P01,Effect of food,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
904,0502-0132,502.132,Ended,37,0502-P01,Biological equivale-nce,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
905,0502-0134,502.134,Unconfirmed,37,0502-P01,Pivotal BE study for fixed dose comb.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
906,0502-0135,502.135,Unconfirmed,37,0502-P01,PK interactions Telmisartan/Maaloxan,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
907,0502-0201,502.201,Ended,37,0502-P01,Efficacy: 10-160mg KAH over 7 days p.o.,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
908,0502-0202,502.202,Ended,37,0502-P01,4w dose range w/capsule,Ended,MIG,Migration,II,Phase II,-  Preliminary results presented to IMC April 21, 1994     ,,,000910,IS - Clin Study (MIGRATED)
909,0502-0203,502.203,Ended,37,0502-P01,Dose response,Ended,MIG,Migration,II,Phase II,-  First route of synthesis, round tablet.Patients discontinued are included as "complete per protocol".     ,,,000910,IS - Clin Study (MIGRATED)
910,0502-0205,502.205,Unconfirmed,37,0502-P01,Dose Response,Higher Doses(vs.Enalapril),Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
911,0502-0206,502.206,Ended,37,0502-P01,Safety/effic:12wk vs enalapril,Ended,MIG,Migration,III,Phase III,-  Number patients changed from 500 to 420 per new master plan 6/22/94 Number of centers increased per Dr. Urquilla. Monitor name change (planning) per Dr. Urquilla 1/6/95 JMP.Drug supplies will be shi pped July 17.   ,,,000910,IS - Clin Study (MIGRATED)
912,0502-0207,502.207,Ended,37,0502-P01,PROOF OF EFFICACY: 8 WK VS ATENOLOL,Ended,MIG,Migration,IIIA,Phase IIIa,- ,,,000910,IS - Clin Study (MIGRATED)
913,0502-0208,502.208,Ended,37,0502-P01,Amlodipine Comparison,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
914,0502-0209,502.209,Ended,37,0502-P01,Severe hypertension, vs Elanapril,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
915,0502-0210,502.210,Ended,37,0502-P01,Elderly(>65yr)Hypertensives(vs.Enalapr.),Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
916,0502-0211,502.211,Ended,37,0502-P01,OTAHRI,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
917,0502-0212,502.212,Unconfirmed,37,0502-P01,Renal impairment 2.,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
918,0502-0213,502.213,Ended,37,0502-P01,Renal Hemodynamics in HTN,Ended,MIG,Migration,III,Phase III,-  Semi-final route of synthesis, round tablet. First subject enrolled in June.     ,,,000910,IS - Clin Study (MIGRATED)
919,0502-0214,502.214,Ended,37,0502-P01,LT safety: 52wk vs lisinopril,Ended,MIG,Migration,III,Phase III,-  Will include pharmacoeconomic parameters. Semi-final route of synthesis, round tablet. 450 (75%) patients must be randomized by August 31, 1995 to achieve database lock of December 31, 1996 for interim analysis. previous clin comp date was for 75% pts for interim analysis.   ,,,000910,IS - Clin Study (MIGRATED)
920,0502-0216,502.216,Ended,37,0502-P01,Telmisartan Hypertension vs. Atenolol,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
921,0502-0219,502.219,Ended,37,0502-P01,OL extension,Ended,MIG,Migration,III,Phase III,-  Trial to continue through NDA approval. Interim analysis for NDA submission.Conducted in US, UK, Europe, and Canada. Open label extension of phase IIb protocols. Upgraded to probable per Dr. Urquilla.  Monitor name change (planni ng) per Dr. Urquilla 1/6/95,JMP.  7 centers are from 502.203; safety database:  will continue until time of registration.   ,,,000910,IS - Clin Study (MIGRATED)
922,0502-0220,502.220,Ended,37,0502-P01,Open-label follow-up / Europe,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
923,0502-0221,502.221,Ended,37,0502-P01,Open-label de novo,Ended,MIG,Migration,III,Phase III,-  To be conducted with Dr. Neutel Safety database:  will continue until time of registration.     ,,,000910,IS - Clin Study (MIGRATED)
924,0502-0222,502.222,Ended,37,0502-P01,European no-cough study,Ended,MIG,Migration,IIIA,Phase IIIa,- ,,,000910,IS - Clin Study (MIGRATED)
925,0502-0223,502.223,Ended,37,0502-P01,Cough Study,Ended,MIG,Migration,III,Phase III,-  Conduct, analysis and reporting performed by COROMED.  One center in Canada. 11/1/96 cutoff for safety data to be submitted with NDA. Enrollment closed 4/16/97 due to slow enrollment. 92 patients randomized.   ,,,000910,IS - Clin Study (MIGRATED)
926,0502-0224,502.224,Ended,37,0502-P01,TELLOS,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
927,0502-0225,502.225,Ended,37,0502-P01,Pilot study,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
928,0502-0226,502.226,Ended,37,0502-P01,Pre-pilot study,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
929,0502-0228,502.228,Ended,37,0502-P01,De novo open-label study,Ended,MIG,Migration,III,Phase III,Long-term study Treatment duration of min. 52 weeks, interim visits possible, max. duration until registration, Run-in phase single blind,,,000910,IS - Clin Study (MIGRATED)
930,0502-0233,502.233,Ended,37,0502-P01,diurnal blood pressure variation,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
931,0502-0234,502.234,Preparing,37,0502-P01,Safety & eff: 8wk vs enalapri,Preparing,MIG,Migration,III,Phase III,-  replaced by 502.238. Req new AD and 50% SWF MRA.     ,,,000910,IS - Clin Study (MIGRATED)
932,0502-0235,502.235,Ended,37,0502-P01,Food Interaction Study,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
933,0502-0236,502.236,Ended,37,0502-P01,'DETAIL',Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
934,0502-0237,502.237,Ended,37,0502-P01,Telmisartan vs. Losartan (LVH),Ended,MIG,Migration,III,Phase III,-  Enalapril rejected as active control at LVH experts meeting. Delayed by decision on comparator drug. Initiation pending availability of drug supplies. Unable to obtain Ramipril and matching placebo - 1/20/97. INITIATION PENDING AVAILABILITY OF DRUG SUPPLIES ,,,000910,IS - Clin Study (MIGRATED)
935,0502-0238,502.238,Ended,37,0502-P01,Safety & eff: 8wk vs enalapri,Ended,MIG,Migration,III,Phase III,-  Replaces 502.234 same trial except this one is open label Patients for NDA report completed 03Jan97.   PATIENTS FOR NDA REPORT COMPLETED       03JAN97. ,,,000910,IS - Clin Study (MIGRATED)
936,0502-0239,502.239,Unconfirmed,37,0502-P01,? / Japan,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
937,0502-0240,502.240,Unconfirmed,37,0502-P01,? / Japan,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
938,0502-0242,502.242,Ended,37,0502-P01,Long-term trial for 52 weeks,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
939,0502-0243,502.243,Ended,37,0502-P01,Dose-Response by monotherapy,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
940,0502-0244,502.244,Ended,37,0502-P01,Dose-Response by combination therapy,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
941,0502-0245,502.245,Preparing,37,0502-P01,Severe Hypertension,Preparing,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
942,0502-0248,502.248,Unconfirmed,37,0502-P01,Aortic Compliance,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,trial design under discussion ,,,000910,IS - Clin Study (MIGRATED)
943,0502-0251,502.251,Preparing,37,0502-P01,Trial for severe Hypertension,Preparing,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
944,0502-0252,502.252,Preparing,37,0502-P01,Hamacocinetic study in Hypertension,Preparing,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
945,0502-0253,502.253,Preparing,37,0502-P01,Long-term trial essential Hypertension,Preparing,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
946,0502-0254,502.254,Ended,37,0502-P01,ARAMIS (ISH-Study),Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
947,0502-0255,502.255,Ended,37,0502-P01,Evaluat. of Diuretic/Natriuretic Effects,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
948,0502-0256,502.256,Ended,37,0502-P01,TELMISARTAN VS. VALSARTAN,Ended,MIG,Migration,IIIB,Phase IIIb,-  dg chgd to possible as a result of 98 budget discussions 11/7/97     ,,,000910,IS - Clin Study (MIGRATED)
949,0502-0257,502.257,Ended,37,0502-P01,Telmisartan vs. Losartan/HCTZ (OTELLOH),Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
950,0502-0258,502.258,Ended,37,0502-P01,TELMISARTAN VS AMLODIPINE,Ended,MIG,Migration,IIIB,Phase IIIb,ABPM TRIAL dg chgd to possible as a result of 98 budget discussions, 11/7/97 dg chgd to cc212 as arranging with Marketing to pay in total ($1M budgeted in Mkt in 1998)     ,,,000910,IS - Clin Study (MIGRATED)
951,0502-0260,502.260,Ended,37,0502-P01,Open-label FU Europe/South Africa (IIIb),Ended,MIG,Migration,IIIB,Phase IIIb,Follow up of 502.257 ,,,000910,IS - Clin Study (MIGRATED)
952,0502-0263,502.263,Ended,37,0502-P01,PHASEII TRIAL FOR SEVERE HYPERTENSION,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
953,0502-0264,502.264,Ended,37,0502-P01,PK study in renal failure patients,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
954,0502-0265,502.265,Ended,37,0502-P01,Phamacokinetic study in Hypertension,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
955,0502-0266,502.266,Ended,37,0502-P01,Phase IIb trial in renal insufficiency,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
956,0502-0267,502.267,Ended,37,0502-P01,Enarapril comparison,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
957,0502-0268,502.268,Ended,37,0502-P01,PK study for PPK ana-lysis,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
958,0502-0270,502.270,Ended,37,0502-P01,Telmisartan vs. Losartan,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
959,0502-0271,502.271,Ended,37,0502-P01,DB, placebo contr. study to test efficac,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
960,0502-0272,502.272,Ended,37,0502-P01,Long term trial,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
961,0502-0273,502.273,Preparing,37,0502-P01,Bioavairability : KAH vs TA,Preparing,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
962,0502-0306,502.306,Ended,37,0502-P01,de novo safety eval.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
963,0502-0311,502.311,Ended,37,0502-P01,Long-term safety,Ended,MIG,Migration,IIIA,Phase IIIa,- ,,,000910,IS - Clin Study (MIGRATED)
964,0502-0312,502.312,Ended,37,0502-P01,52-week comp. with HCTZ, long-term safet,Ended,MIG,Migration,IIIA,Phase IIIa,- ,,,000910,IS - Clin Study (MIGRATED)
965,0502-0313,502.313,Unconfirmed,37,0502-P01,Add-on to HCTZ background,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,- ,,,000910,IS - Clin Study (MIGRATED)
966,0502-0314,502.314,Ended,37,0502-P01,PMS Study,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
967,0502-0316,502.316,Ended,37,0502-P01,Telmisartan vs losartan,Ended,MIG,Migration,IIIB,Phase IIIb,The clinical phase has been changed to phase IV because the study drug which was registered on June '99 with central procedure, has been marketed in Italy on August 29,1999.,,,000910,IS - Clin Study (MIGRATED)
968,0502-0317,502.317,Ended,37,0502-P01,Telmisartan vs enalapril in elderly,Ended,MIG,Migration,IIIB,Phase IIIb,The clinical Phase has been changed to phase IV because the study drug which was registered on June '99 with central procedure, has been marketed in Italy on August 29,1999.,,,000910,IS - Clin Study (MIGRATED)
969,0502-0318,502.318,Unconfirmed,37,0502-P01,Telmisartan vs lisinopril type 2 diabet.,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
970,0502-0320,502.320,Preparing,37,0502-P01,Telmisartan vs losartan in LVH,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
971,0502-0322,502.322,Ended,37,0502-P01,Hospital PMS study (Germany),Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
972,0502-0325,502.325,Unconfirmed,37,0502-P01,Flexibility of use,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
973,0502-0326,502.326,Unconfirmed,37,0502-P01,Telm. vs valsartan, high-risk pats. LVA,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
974,0502-0327,502.327,Ended,37,0502-P01,Telmisartan vs valsartan missed dose,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
975,0502-0339,502.339,Ended,37,0502-P01,ESPRIT (Micardis/renal impairment),Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
976,0502-0340,502.340,Unconfirmed,37,0502-P01,telmisartan vs candesartan AII challenge,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
977,0502-0341,502.341,Ended,37,0502-P01,telmisartan/simvastatin interaction,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
978,0502-0343,502.343,Ended,37,0502-P01,Micardis vs losartan efficacy,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
979,0502-0344,502.344,Ended,37,0502-P01,TOPAS - Micardis vs losartan efficacy,Ended,MIG,Migration,IV,Phase IV,U-number: U01-1723 ,,,000910,IS - Clin Study (MIGRATED)
980,0502-0345,502.345,Unconfirmed,37,0502-P01,Micardis vs Hyzaar efficacy,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
981,0502-0346,502.346,Unconfirmed,37,0502-P01,Community based study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
982,0502-0347,502.347,Unconfirmed,37,0502-P01,Community based study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
983,0502-0350,502.350,Ended,37,0502-P01,Telmisartan and endothelial dysfunction,Ended,MIG,Migration,IV,Phase IV,Stopped due to difficult recruiment ,,,000910,IS - Clin Study (MIGRATED)
984,0502-0351,502.351,Unconfirmed,37,0502-P01,PMS study with ABPM,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
985,0502-0352,502.352,Unconfirmed,37,0502-P01,telmisartan vs ACEI in diabetics,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
986,0502-0353,502.353,Ended,37,0502-P01,24 hour blood pressure control,Ended,MIG,Migration,IV,Phase IV,,,,,
987,0502-0354,502.354,Ended,37,0502-P01,Telmisartan vs standard practice,Ended,MIG,Migration,IV,Phase IV,Run by Glaxo Welcome ,,,000910,IS - Clin Study (MIGRATED)
988,0502-0355,502.355,Ended,37,0502-P01,Non-comparative ABPM,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
989,0502-0356,502.356,Ended,37,0502-P01,Telmisartan vs losartan in Taiwanese,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
990,0502-0357,502.357,Ended,37,0502-P01,Telmisartan vs enalapril in Taiwanese,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
991,0502-0358,502.358,Preparing,37,0502-P01,Digoxin interaction,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
992,0502-0359,502.359,Ended,37,0502-P01,Micardis PMS study,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
993,0502-0360,502.360,Unconfirmed,37,0502-P01,Micardis PMS study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
994,0502-0361,502.361,Ended,37,0502-P01,Micardis PMS study,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
995,0502-0362,502.362,Ended,37,0502-P01,Micardis PMS study (EXCALIBUR),Ended,MIG,Migration,NONE,Not Classified,,,,000940,Post Marketing Study (MIGRATED)
996,0502-0363,502.363,Ended,37,0502-P01,Open phase IV study vs placebo,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
997,0502-0364,502.364,Ended,37,0502-P01,Open label titration in Thai patients,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
998,0502-0365,502.365,Ended,37,0502-P01,Telmisartan vs losartan in Chinese,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
999,0502-0366,502.366,Ended,37,0502-P01,Non-comparative trial in Korean patients,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1000,0502-0367,502.367,Ended,37,0502-P01,Open label ABPM Telmisartan 40 mg,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1001,0502-0372,502.372,Preparing,37,0502-P01,Missed dose trial with ABPM,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1002,0502-0373,502.373,Ended,37,0502-P01,Outcome Study ONTARGET,Ended,MIG,Migration,IV,Phase IV,Endpoint Cardiov. morbidity/mortality ,,,000910,IS - Clin Study (MIGRATED)
1003,0502-0374,502.374,Ended,37,0502-P01,Efficacy in clinical patients Germany,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1004,0502-0375,502.375,Preparing,37,0502-P01,Evaluation of QT Effect,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1005,0502-0376,502.376,Ended,37,0502-P01,Valsartan miss a dose - MICADO,Ended,MIG,Migration,IV,Phase IV,missed dose trial ,,,000910,IS - Clin Study (MIGRATED)
1006,0502-0377,502.377,Unconfirmed,37,0502-P01,Microemboly signal study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1007,0502-0378,502.378,Ended,37,0502-P01,Telmisartan and Lacidipine QT interval,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1008,0502-0379,502.379,Ended,37,0502-P01,ABPM Mexico,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1009,0502-0380,502.380,Unconfirmed,37,0502-P01,Telmisartan in Caucasian Nondippers,Unconfirmed,MIG,Migration,IV,Phase IV,pilot ,,,000910,IS - Clin Study (MIGRATED)
1010,0502-0383,502.383,Ended,37,0502-P01,Dose finding for Vietnamese patients,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1011,0502-0384,502.384,Unconfirmed,37,0502-P01,LVH-Study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1012,0502-0385,502.385,Ended,37,0502-P01,Telmisartan in CAD,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1013,0502-0386,502.386,Ended,37,0502-P01,Praxis PMS study (Germany),Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1014,0502-0389,502.389,Unconfirmed,37,0502-P01,Telmisartan vs Amlodipine in Japanese,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1015,0502-0391,502.391,Ended,37,0502-P01,PRISMA -  vs. Ramipril,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1016,0502-0392,502.392,Ended,37,0502-P01,Superior BP control vs. Ramipril (US),Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1017,0502-0393,502.393,Ended,37,0502-P01,Micardis reduces LVH (MRI) TELMAR,Ended,MIG,Migration,IV,Phase IV,Summary Report S,,,000910,IS - Clin Study (MIGRATED)
1018,0502-0394,502.394,Preparing,37,0502-P01,Micardis reduces LVH (Echo),Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1019,0502-0395,502.395,Preparing,37,0502-P01,Micardis silent ischemic episodes,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1020,0502-0396,502.396,Ended,37,0502-P01,VIVALDI - diabetic nephropathy,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1021,0502-0397,502.397,Ended,37,0502-P01,AMADEO - Reduction of Proteinuria,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1022,0502-0398,502.398,Ended,37,0502-P01,TRENDY - renal endothelial dysfunction,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1023,0502-0401,502.401,Preparing,37,0502-P01,Efficacy and Safety in Korean Patients,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1024,0502-0402,502.402,Ended,37,0502-P01,Telmisartan vs Candesartan AII-challenge,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1025,0502-0412,502.412,Preparing,37,0502-P01,ABPM comparison versus Losartan (Nippon),Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1026,0502-0413,502.413,Ended,37,0502-P01,INNOVATION study,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1027,0502-0414,502.414,Ended,37,0502-P01,Convert to tablet from capsule (Nippon),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1028,0502-0417,502.417,Ended,37,0502-P01,Tabl developm (Manitol based),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1029,0502-0418,502.418,Preparing,37,0502-P01,Tabl developm (modified Manitol based),Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1030,0502-0419,502.419,Preparing,37,0502-P01,Tabl developm (add. for Manitol based),Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1031,0502-0420,502.420,Unconfirmed,37,0502-P01,Ischemia and Blood Pressure Monitoring,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1032,0502-0423,502.423,Unconfirmed,37,0502-P01,Expansion Dose Range Study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1033,0502-0424,502.424,Ended,37,0502-P01,MICCAT II,Ended,MIG,Migration,IV,Phase IV,,,,,
1034,0502-0425,502.425,Ended,37,0502-P01,VAMI PMS,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1035,0502-0426,502.426,Ended,37,0502-P01,SURGE observational,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1036,0502-0428,502.428,Ended,37,0502-P01,AWB Reha (cardio),Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1037,0502-0429,502.429,Ended,37,0502-P01,AWB Reha (nephro),Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1038,0502-0430,502.430,Ended,37,0502-P01,AWB Reha (diabetes),Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1039,0502-0431,502.431,Ended,37,0502-P01,AWB Reha (pulmo),Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1040,0502-0433,502.433,Ended,37,0502-P01,telmisartan adipocyte,Ended,MIG,Migration,IV,Phase IV,,,,,
1041,0502-0435,502.435,Ended,37,0502-P01,Micardis 80 mg ABPM,Ended,MIG,Migration,IV,Phase IV,,,,,
1042,0502-0440,502.440,Ended,37,0502-P01,Micardis migraine,Ended,MIG,Migration,II,Phase II,,,,,
1043,0502-0441,502.441,Ended,37,0502-P01,AWB Fach AD (cardio),Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1044,0502-0442,502.442,Ended,37,0502-P01,AWB Fach AD (nephro),Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1045,0502-0443,502.443,Ended,37,0502-P01,AWB Fach AD (diabetes),Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1046,0502-0444,502.444,Unconfirmed,37,0502-P01,AWB Fach AD (pulmo),Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1047,0502-0445,502.445,Ended,37,0502-P01,Efficacy and Safety of Micardis ABPM PMS,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1048,0502-0446,502.446,Preparing,37,0502-P01,CICLADES I,Preparing,MIG,Migration,IV,Phase IV,Study Cancelled ,,,000940,Post Marketing Study (MIGRATED)
1049,0502-0447,502.447,Ended,37,0502-P01,CICLADES II,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1050,0502-0448,502.448,Ended,37,0502-P01,TELETENSION,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1051,0502-0449,502.449,Preparing,37,0502-P01,TELETENSION Cardio,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1052,0502-0450,502.450,Ended,37,0502-P01,PROTECT,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1053,0502-0451,502.451,Preparing,37,0502-P01,PROTECT Cardio,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1054,0502-0452,502.452,Preparing,37,0502-P01,VARNA,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1055,0502-0456,502.456,Preparing,37,0502-P01,Micardis in patients with COPD,Preparing,MIG,Migration,IV,Phase IV,,,,,
1056,0502-0457,502.457,Ended,37,0502-P01,Interact. Telmi - Clopidogrel,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1057,0502-0458,502.458,Ended,37,0502-P01,Interact. Telmi / Aggrenox,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1058,0502-0460,502.460,Ended,37,0502-P01,Matthew Weir Kidney Transplant Study,Ended,MIG,Migration,III,Phase III,Kidney Graft Survival Study ,,,,
1059,0502-0461,502.461,Ended,37,0502-P01,MICCAT I,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1060,0502-0462,502.462,Ended,37,0502-P01,6 m compliance antihypertensive regimens,Ended,MIG,Migration,IV,Phase IV,,,,,
1061,0502-0464,502.464,Ended,37,0502-P01,Telmisartan Ruilope Study,Ended,MIG,Migration,IV,Phase IV,,2004-001238-18,,,
1062,0502-0465,502.465,Ended,37,0502-P01,5 Steps Micardis PMS Program in CEE,Ended,MIG,Migration,IV,Phase IV,This study was divided into 5 steps ,,,000940,Post Marketing Study (MIGRATED)
1063,0502-0466,502.466,Unconfirmed,37,0502-P01,Micardis / Micardis Plus PMS study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1064,0502-0467,502.467,Ended,37,0502-P01,Micardis / Micardis Plus PMS Study,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1065,0502-0468,502.468,Ended,37,0502-P01,Vigimatin,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1066,0502-0469,502.469,Ended,37,0502-P01,Insulin Resistance Study,Ended,MIG,Migration,II,Phase II,,2004-003986-34,,000910,IS - Clin Study (MIGRATED)
1067,0502-0471,502.471,Ended,37,0502-P01,Halt Progr. of Polycystic Kidney Disease,Ended,MIG,Migration,IV,Phase IV,,,,,
1068,0502-0473,502.473,Preparing,37,0502-P01,CESNA Study,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1069,0502-0474,502.474,Ended,37,0502-P01,Antihypertensive treatment &  morning BP,Ended,MIG,Migration,IV,Phase IV,,,,,
1070,0502-0477,502.477,Unconfirmed,37,0502-P01,Micardis vs. Benicar,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1071,0502-0478,502.478,Ended,37,0502-P01,Telmisartan in pat with renal impairment,Ended,MIG,Migration,IV,Phase IV,,,,,
1072,0502-0479,502.479,Ended,37,0502-P01,PMS of Micardis,Ended,MIG,Migration,IV,Phase IV,Study Report U Number: U08-3529-01 ,,,000940,Post Marketing Study (MIGRATED)
1073,0502-0481,502.481,Ended,37,0502-P01,ODYSSEE,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1074,0502-0482,502.482,Ended,37,0502-P01,PRODIGE,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1075,0502-0483,502.483,Ended,37,0502-P01,CIBLE,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1076,0502-0484,502.484,Ended,37,0502-P01,AURORA,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1077,0502-0485,502.485,Ended,37,0502-P01,Morning hypertension, metabolism,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1078,0502-0486,502.486,Ended,37,0502-P01,PPAR gamma,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1079,0502-0487,502.487,Ended,37,0502-P01,Observational study of Mic and Mic Plus,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1080,0502-0488,502.488,Ended,37,0502-P01,Micardis plus ABPM study in China,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1081,0502-0489,502.489,Ended,37,0502-P01,DYNAMIC,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1082,0502-0490,502.490,Ended,37,0502-P01,Microalbuminurie-Reduktion - MicMic,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1083,0502-0492,502.492,Ended,37,0502-P01,Diamond,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1084,0502-0493,502.493,Ended,37,0502-P01,PMS in specialists,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1085,0502-0494,502.494,Ended,37,0502-P01,observational study Micardis prescript,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1086,0502-0496,502.496,Ended,37,0502-P01,SURGE II,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1087,0502-0497,502.497,Unconfirmed,37,0502-P01,Dose finding for Metabolic,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1088,0502-0498,502.498,Ended,37,0502-P01,PRIMA,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1089,0502-0499,502.499,Preparing,37,0502-P01,Metabolic Syndrom Cardio,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1090,0502-0500,502.500,Ended,37,0502-P01,Survey in routine clinical settings,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
1091,0502-0501,502.501,Preparing,37,0502-P01,observational - ADMA level,Preparing,MIG,Migration,IV,Phase IV,,,,,
1092,0502-0502,502.502,Preparing,37,0502-P01,PORTHOS: Telmi in older pat with ISC,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1093,0502-0503,502.503,Ended,37,0502-P01,Lifestyle eff in lowering BP in Greece,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1094,0502-0504,502.504,Ended,37,0502-P01,BPreduction in Danish general practice,Ended,MIG,Migration,IV,Phase IV,,,,,
1095,0502-0505,502.505,Ended,37,0502-P01,Morning hypertension and metabolism 2-a,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1096,0502-0506,502.506,Ended,37,0502-P01,Morning hypertension and metabolism 2-b,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1097,0502-0507,502.507,Preparing,37,0502-P01,TELMET: HBP + Metabolic Syndrome,Preparing,MIG,Migration,IV,Phase IV,,,,,
1098,0502-0508,502.508,Ended,37,0502-P01,Protect Plus,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1099,0502-0509,502.509,Preparing,37,0502-P01,HTA and renal impairment reduction,Preparing,MIG,Migration,IV,Phase IV,,,,,
1100,0502-0510,502.510,Ended,37,0502-P01,TELSYS,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1101,0502-0511,502.511,Ended,37,0502-P01,cerebro and cardiovasc survey,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
1102,0502-0512,502.512,Ended,37,0502-P01,Endothelial dysfunction-doppler+CV risk,Ended,MIG,Migration,IV,Phase IV,,,,,
1103,0502-0513,502.513,Ended,37,0502-P01,Morning HTN and home BP measurement,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1104,0502-0514,502.514,Ended,37,0502-P01,HBP+renal transplant/glucose homeostasis,Ended,MIG,Migration,IV,Phase IV,,,,,
1105,0502-0517,502.517,Unconfirmed,37,0502-P01,Survey in hypertensive patients,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1106,0502-0518,502.518,Ended,37,0502-P01,Effect on Central Arterial Pressure/Alx,Ended,MIG,Migration,IV,Phase IV,,,,,
1107,0502-0519,502.519,Ended,37,0502-P01,Telmisartan Tab Hypertension,Ended,MIG,Migration,IV,Phase IV,,,,000930,NISed - Study (MIGRATED)
1108,0502-0520,502.520,Ended,37,0502-P01,Micardis tablet 2nd generation developm.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1109,0502-0521,502.521,Ended,37,0502-P01,TELMA (HTN and Proteinuria),Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1110,0502-0522,502.522,Preparing,37,0502-P01,Telm in HBP + chronic renal disease + MS,Preparing,MIG,Migration,IV,Phase IV,,,,,
1111,0502-0523,502.523,Ended,37,0502-P01,Risc treat (Germany),Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1112,0502-0524,502.524,Ended,37,0502-P01,Cardio-Sis,Ended,MIG,Migration,IV,Phase IV,,,,,
1113,0502-0525,502.525,Preparing,37,0502-P01,Macro (France),Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1114,0502-0526,502.526,Preparing,37,0502-P01,Risc Treat (France),Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1115,0502-0527,502.527,Analysis,37,0502-P01,PARTAGE,Analysis,MIG,Migration,NONE,Not Classified,,,,,
1116,0502-0529,502.529,Ended,37,0502-P01,HBP+Chronic Renal Failure+Haemodialysis,Ended,MIG,Migration,IV,Phase IV,,,,,
1117,0502-0530,502.530,Ended,37,0502-P01,HBP control and retinal microcirculation,Ended,MIG,Migration,IV,Phase IV,,,,,
1118,0502-0531,502.531,Preparing,37,0502-P01,Treatment Resistance Predictors in ISH,Preparing,MIG,Migration,IV,Phase IV,,,,,
1119,0502-0533,502.533,Ended,37,0502-P01,Telmisartan neurovas protect-post stroke,Ended,MIG,Migration,IV,Phase IV,IIS study ,,,,
1120,0502-0534,502.534,Ended,37,0502-P01,Hypertension Management in Greece,Ended,MIG,Migration,IV,Phase IV,Four visits per patient, for a time period defined by the investigator,,,,
1121,0502-0535,502.535,Unconfirmed,37,0502-P01,IIS: T320 vs T80 in nephropathy,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
1122,0502-0536,502.536,Ended,37,0502-P01,CARAVAGE,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
1123,0502-0537,502.537,Preparing,37,0502-P01,Efficacy/safety Micardis in Treatment,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1124,0502-0538,502.538,Ended,37,0502-P01,Telmi. on albuminuria: HTA + diabetes,Ended,MIG,Migration,IV,Phase IV,,,,,
1125,0502-0539,502.539,Ended,37,0502-P01,DIPROTEL Study,Ended,MIG,Migration,IV,Phase IV,,,,,
1126,0502-0540,502.540,Ended,37,0502-P01,CONTROL,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1127,0502-0541,502.541,Ended,37,0502-P01,ATLANTIQUE,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
1128,0502-0543,502.543,Unconfirmed,37,0502-P01,Long-term observation PMS for DN,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
1129,0502-0544,502.544,Unconfirmed,37,0502-P01,Long-term observ PMS for DN of Normotens,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
1130,0502-0545,502.545,Ended,37,0502-P01,Telmisartan and Adiponectin,Ended,MIG,Migration,IV,Phase IV,,,,,
1131,0502-0546,502.546,Unconfirmed,37,0502-P01,MIC3G pilot PK,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1132,0502-0547,502.547,Unconfirmed,37,0502-P01,MIC3G BE,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1133,0502-0548,502.548,Ended,37,0502-P01,Changes non Dipper a. Risser to Dipper,Ended,MIG,Migration,IV,Phase IV,,,,,
1134,0502-0549,502.549,Preparing,37,0502-P01,Changes PWV-ABP in hypertensive patients,Preparing,MIG,Migration,IV,Phase IV,,,,,
1135,0502-0555,502.555,Analysis,37,0502-P01,Identification of CV risk groups,Analysis,MIG,Migration,IV,Phase IV,One ambulatory visit per patient One ambulatory visit per patient in order to collect the information needed for the study,,,000920,NISnd - Study (MIGRATED)
1136,0502-0556,502.556,Unconfirmed,37,0502-P01,MIC PRoFESS BE,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1137,0502-0557,502.557,Ended,37,0502-P01,MIC T80 BE,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1138,0502-0559,502.559,Unconfirmed,37,0502-P01,HTN in Renal Post Transplant Children,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1139,0502-0560,502.560,Preparing,37,0502-P01,Telmisartan in Human Milk,Preparing,MIG,Migration,I,Phase I,,2008-006859-41,,000910,IS - Clin Study (MIGRATED)
1140,0502-0562,502.562,Ended,37,0502-P01,COSTANT-HTN in Renal Transplant patients,Ended,MIG,Migration,IV,Phase IV,,2008-000822-38,,,
1141,0502-0567,502.567,Unconfirmed,37,0502-P01,MIC T20 BE,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1142,0502-0568,502.568,Unconfirmed,37,0502-P01,MIC T40 BE,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1143,0502-0570,502.570,Preparing,37,0502-P01,PROTECT MAROC,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1144,0502-0572,502.572,Ended,37,0502-P01,Markers of CV risk in diabetics hyper.,Ended,MIG,Migration,IV,Phase IV,,,,,
1145,0502-0573,502.573,Ended,37,0502-P01,HIGHCARE,Ended,MIG,Migration,IV,Phase IV,,,,,
1146,0502-0574,502.574,Ended,37,0502-P01,PUISSANCE HTA,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1147,0502-0575,502.575,Unconfirmed,37,0502-P01,Telmisartan 80 vs Ramipril 20 (study1),Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1148,0502-0576,502.576,Unconfirmed,37,0502-P01,Telmisartan 80 vs Ramipril 20 (study2),Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1149,0502-0579,502.579,Ended,37,0502-P01,Telmisartan & effect life style progr.,Ended,MIG,Migration,IV,Phase IV,PMSS in Slovakia only ,,,000940,Post Marketing Study (MIGRATED)
1150,0502-0580,502.580,Ended,37,0502-P01,Hypertension in the over 70s,Ended,MIG,Migration,IV,Phase IV,,,,,
1151,0502-0581,502.581,Ended,37,0502-P01,Belgian PMS in high risk patients,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1152,0502-0582,502.582,Ended,37,0502-P01,24h BP under Micardis in daily practice,Ended,MIG,Migration,IV,Phase IV,PMS Switzerland ,,,000940,Post Marketing Study (MIGRATED)
1153,0502-0584,502.584,Ended,37,0502-P01,PRO-POWER HTN with risk factor 24 weeks,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1154,0502-0585,502.585,Ended,37,0502-P01,Effect of Telmisartan on BP and CRFI,Ended,MIG,Migration,IV,Phase IV,Observation of therapeutic use ,,,000940,Post Marketing Study (MIGRATED)
1155,0502-0586,502.586,Unconfirmed,37,0502-P01,CV risk evaluation by Greek physicians,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
1156,0502-0587,502.587,Ended,37,0502-P01,Modification of CV risk,Ended,MIG,Migration,IV,Phase IV,,,,,
1157,0502-0588,502.588,Ended,37,0502-P01,A PMS on safety and tolerability of ARBs,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1158,0502-0589,502.589,Ended,37,0502-P01,Bone remodel. markers,Ended,MIG,Migration,IV,Phase IV,,,,,
1159,0502-0590,502.590,Ended,37,0502-P01,Epidemiol study: Antihypert. and sepsis,Ended,MIG,Migration,IV,Phase IV,,,,000980,Not Classified (MIGRATED)
1160,0502-0591,502.591,Ended,37,0502-P01,Real case studies ONTARGET pats.,Ended,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
1161,0502-0593,502.593,Analysis,37,0502-P01,bicuspid aortic valve disease,Analysis,MIG,Migration,III,Phase III,,,,,
1162,0502-0594,502.594,Unconfirmed,37,0502-P01,PMS Safety&Eff in India,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000940,Post Marketing Study (MIGRATED)
1163,0502-0595,502.595,Unconfirmed,37,0502-P01,BAV Study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
1164,0502-0596,502.596,Ended,37,0502-P01,Impact of ARBs on QoL in HT-DM2 pat.,Ended,MIG,Migration,IV,Phase IV,,,,,
1165,0502-0597,502.597,Ended,37,0502-P01,Surv of Safety Info w.ACEs inh. a. ARBs,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
1166,0502-0598,502.598,Ended,37,0502-P01,TWINS NTA Belgium,Ended,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
1167,0502-0599,502.599,Ended,37,0502-P01,Epidemiolog.antihypert a. cancer risk,Ended,MIG,Migration,IV,Phase IV,observational study, existing data  Values from CTMS: Planned Subjects Screened: 1165781, Planned Subjects Randomized: 1165781, Planned Subjects Completed Treatment: 1165781,,,000980,Not Classified (MIGRATED)
1168,0502-0600,502.600,Ended,37,0502-P01,Protection K Survey,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
1169,0502-0601,502.601,Analysis,37,0502-P01,cardiometabolic project,Analysis,MIG,Migration,IV,Phase IV,,,,,
1170,0502-0602,502.602,Ended,37,0502-P01,Treatment Adherence in Middle East,Ended,MIG,Migration,IV,Phase IV,,,,000930,NISed - Study (MIGRATED)
1171,0502-0603,502.603,Ended,37,0502-P01,Surv-Gap Risk,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
1172,0502-0604,502.604,Ended,37,0502-P01,IIS - Indiapres,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
1173,0502-0605,502.605,Ended,37,0502-P01,Telmisartan Substitution Research,Ended,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
1174,0502-0606,502.606,Analysis,37,0502-P01,CV Risk Factor Survey,Analysis,MIG,Migration,IV,Phase IV,,,,000930,NISed - Study (MIGRATED)
1175,0502-0607,502.607,Ended,37,0502-P01,Micardis Performance Tracking,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
1176,0502-0610,502.610,Preparing,37,0502-P01,Oral disintegrating (OD) 40mg Tab dev,Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
1177,0502-0611,502.611,Preparing,37,0502-P01,Oral disintegrating (OD) 40mg Tab dev W,Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
1178,1028-0001,1028.1,Ended,38,1028-P01,CMC Placebo Tolerance,Ended,MIG,Migration,I,Phase I,-  Trial performed, and report prepared by Phase I unit at GmbH.     ,,,000910,IS - Clin Study (MIGRATED)
1179,1028-0002,1028.2,Ended,38,1028-P01,Single dose tolerance,Ended,MIG,Migration,I,Phase I,-  Review of tolerance data needs to occur soon after patient comple- tion in order to proceed to Trial 00843. CRO for SITE anticipated (e.g., BioClin). CRO for SITE changed to IMTCI   ,,,000910,IS - Clin Study (MIGRATED)
1180,1028-0003,1028.3,Ended,38,1028-P01,Multiple dose tolerance,Ended,MIG,Migration,I,Phase I,-  Report timeline shifted due to shift in priorities: 1028.4 and 10 28.5 to be analyzed first.   REPORT DELAYED DUE TO SHIFT IN PRIORITIES ,,,000910,IS - Clin Study (MIGRATED)
1181,1028-0004,1028.4,Ended,38,1028-P01,Prophylactic activity,Ended,MIG,Migration,IIA,Phase IIa,-  Preferred dose form (i.e. solution vs. powder) will be selected following this trial.  Exact dates depend on school calendar of student volunteers.     ,,,000910,IS - Clin Study (MIGRATED)
1182,1028-0005,1028.5,Ended,38,1028-P01,Therapeutic activity,Ended,MIG,Migration,IIA,Phase IIa,-  Initiation of trial accelerated to run in parallel with trial 1028.4. Monitoring guide will be issued in conjunction with 1028.4     ,,,000910,IS - Clin Study (MIGRATED)
1183,1028-0006,1028.6,Ended,38,1028-P01,Safety of BIRR 4 (4.4 mg, QID),Ended,MIG,Migration,I,Phase I,-  Initiation date dependent on approval of Masterplan. Inclusion of asthmatics awaits discussion with CBER.   DEPENDENT ON APPROVAL OF MASTERPLAN ,,,000910,IS - Clin Study (MIGRATED)
1184,1028-0007,1028.7,Unconfirmed,38,1028-P01,Define dosing frequency,Unconfirmed,MIG,Migration,II,Phase II,-  Initiation dependent on obtaining results of 1028.6, and rhinovirus  season.   PENDING APPROVAL OF MASTERPLAN ,,,000910,IS - Clin Study (MIGRATED)
1185,1028-0009,1028.9,Ended,38,1028-P01,Radioscintigraphy study,Ended,MIG,Migration,II,Phase II,-  Initiation date and number of subjects to be determined by UK. No CRO usage planned. UK will do contracts.  BIPI to supply cor e CRFs, but no PIM by BIPI.     ,,,000910,IS - Clin Study (MIGRATED)
1186,1028-0010,1028.10,Unconfirmed,38,1028-P01,Pilot Trial in Natural Colds,Unconfirmed,MIG,Migration,II,Phase II,-  Pending approval of IMC   PENDING APPROVAL OF IMC ,,,000910,IS - Clin Study (MIGRATED)
1187,1028-0011,1028.11,Preparing,38,1028-P01,Dose ranging,Preparing,MIG,Migration,II,Phase II,-  Initiation date depends on stability data from pharmaceutics.     ,,,000910,IS - Clin Study (MIGRATED)
1188,1028-0012,1028.12,Unconfirmed,38,1028-P01,Dose freqency trial,Unconfirmed,MIG,Migration,II,Phase II,-      PENDING APPROVAL ,,,000910,IS - Clin Study (MIGRATED)
1189,1028-0013,1028.13,Unconfirmed,38,1028-P01,Induced cold in asthmatics,Unconfirmed,MIG,Migration,II,Phase II,-  Pending approval   PENDING APPROVAL ,,,000910,IS - Clin Study (MIGRATED)
1190,0244-1501,244.1501,Unconfirmed,39,0244-P15,Kinetics,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1191,0244-1502,244.1502,Unconfirmed,39,0244-P15,Safety comparison vs placebo,Unconfirmed,MIG,Migration,III,Phase III,-  Protocol similar to Atrovent Lactose Inhalet # 01023A. Previously known as 244.2455 Will only conduct trial if second Phase III trial is required.     ,,,000910,IS - Clin Study (MIGRATED)
1192,0244-1503,244.1503,Unconfirmed,39,0244-P15,3 months efficacy/safety in asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1193,0244-1504,244.1504,Ended,39,0244-P15,Cumulative Dose-response in COPD,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
1194,0244-1505,244.1505,Ended,39,0244-P15,BINEB Pilot Cum Dose Response Atrovent,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
1195,0244-1506,244.1506,Unconfirmed,39,0244-P15,Safety comparison vs placebo,Unconfirmed,MIG,Migration,III,Phase III,Protocol similar to Tiotropium inhalet # 205.114 Replaced 244.2454.     ,,,000910,IS - Clin Study (MIGRATED)
1196,0244-1509,244.1509,Unconfirmed,39,0244-P15,1 month efficacy/safety in children with,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1197,0244-2447,244.2447,Ended,39,0244-P15,Dose-ranging in COPD (+PK),Ended,MIG,Migration,IIB,Phase IIb,-  Original CSR submitted to Pharmaceutics 5/26/94, updated CSR 10/17/ 94. Due to delay in receipt of devices, start of this trial has been delayed until 4Q95, then again due to snow.     ,,,000910,IS - Clin Study (MIGRATED)
1198,0244-2454,244.2454,Unconfirmed,39,0244-P15,Safety comparison vs placebo,Unconfirmed,MIG,Migration,III,Phase III,-  Protocol similar to Atrovent Lactose Inhalet #01022A. Replaced by 244.1506.     ,,,000910,IS - Clin Study (MIGRATED)
1199,0244-2455,244.2455,Preparing,39,0244-P15,Safety comparison vs placebo,Preparing,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1200,0244-2466,244.2466,Unconfirmed,39,0244-P15,Long term safety 244.1506,Unconfirmed,MIG,Migration,III,Phase III,3 month extension to 244.1506 3 month extension following 244.1506.  Will use same patients as enrolled in 244.1506.,,,000910,IS - Clin Study (MIGRATED)
1201,0244-2483,244.2483,Unconfirmed,39,0244-P15,Long term safety,Unconfirmed,MIG,Migration,III,Phase III,-  9 month extension following 244.1502.  Will use same patients as enrolled in 244.1502.     ,,,000910,IS - Clin Study (MIGRATED)
1202,0244-2484,244.2484,Ended,39,0244-P15,3 mo theraputic equiv. dose + 3 mo ext.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1203,0244-2485,244.2485,Unconfirmed,39,0244-P15,3 month extension of 244.2484,Unconfirmed,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
1204,0244-2489,244.2489,Ended,39,0244-P15,Safety comparison vs placebo,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
1205,0244-2494,244.2494,Initiated,39,0244-P15,Scintigraphy in pts with poor MDI techn.,Initiated,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1206,0244-2495,244.2495,Initiated,39,0244-P15,Insp Flow Rate on Lung/Oroph deposition,Initiated,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1207,0215-1101,215.1101,Unconfirmed,40,0215-P11,Kinetics,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1208,0215-1102,215.1102,Ended,40,0215-P11,Dose ranging (5-way crossover),Ended,MIG,Migration,II,Phase II,Title incomplete ,,,000910,IS - Clin Study (MIGRATED)
1209,0215-1103,215.1103,Ended,40,0215-P11,Cumulative dose-response,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1210,0215-1104,215.1104,Ended,40,0215-P11,3 months efficacy and safety in asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1211,0215-1105,215.1105,Ended,40,0215-P11,Berodual Respimat Pediatric Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1212,0215-1349,215.1349,Ended,40,0215-P11,3 month safety/efficacy in COPD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1213,0215-1354,215.1354,Unconfirmed,40,0215-P11,Bronchial hyperreactivity in asthma,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1214,0215-1355,215.1355,Unconfirmed,40,0215-P11,Bronchial Hyperreactivity in asthma,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1215,0215-1356,215.1356,Preparing,40,0215-P11,Berodual Respimat vs Duovent MDI,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1216,0215-1357,215.1357,Ended,40,0215-P11,Patient Preference, Respimat vs HFA,Ended,MIG,Migration,IIIB,Phase IIIb,participants: Germany only ,,,000910,IS - Clin Study (MIGRATED)
1217,0215-1359,215.1359,Preparing,40,0215-P11,Bridging study,Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
1218,0215-1360,215.1360,Ended,40,0215-P11,Scintigraphy in pts with poor MDI techn,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1219,0215-1361,215.1361,Ended,40,0215-P11,Insp Flow rate on Lung/Oroph deposition,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1220,0215-1362,215.1362,Ended,40,0215-P11,Berodual Resp., safety,efficacy,handling,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1221,0215-1363,215.1363,Ended,40,0215-P11,Berodual Resp., safety,efficacy,handling,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1222,0215-1364,215.1364,Ended,40,0215-P11,Scintigraphy inspiratory flow,Ended,MIG,Migration,IV,Phase IV,,2005-000841-12,,000910,IS - Clin Study (MIGRATED)
1223,0215-1365,215.1365,Ended,40,0215-P11,Scintigraphy bad MDI users,Ended,MIG,Migration,IV,Phase IV,,2005-000844-10,,000910,IS - Clin Study (MIGRATED)
1224,0215-1366,215.1366,Ended,40,0215-P11,AWB, Safety, Efficacy & Handling,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1225,0215-1367,215.1367,Ended,40,0215-P11,AWB, Safety, Efficacy and Handling,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1226,0260-1507,260.1507,Ended,41,0260-P27,Cumulative doses in Asthma,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
1227,0260-2702,260.2702,Unconfirmed,41,0260-P27,50/100 mcg qid Respimat vs 2x100 qid MDI,Unconfirmed,MIG,Migration,III,Phase III,- Ingelheim trial before,,,000910,IS - Clin Study (MIGRATED)
1228,0260-2703,260.2703,Unconfirmed,41,0260-P27,Small airway function,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1229,0260-2704,260.2704,Unconfirmed,41,0260-P27,Asthma in children / 1 month,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1230,0260-2705,260.2705,Ended,41,0260-P27,BINEB Pilot I Cum Dose-Response,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
1231,0260-2706,260.2706,Ended,41,0260-P27,HEALTHY VOLUNTEER DEPOSITION,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1232,0260-2707,260.2707,Ended,41,0260-P27,Effect of beta 2 onventilation,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
1233,0260-2708,260.2708,Ended,41,0260-P27,Berotec BINEB Dose Ranging Study,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
1234,0260-2709,260.2709,Ended,41,0260-P27,Healthy volunteers deposition,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1235,0260-2710,260.2710,Unconfirmed,41,0260-P27,Kinetics in volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1236,0260-3164,260.3164,Unconfirmed,41,0260-P27,Characterising mode of inhalation,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1237,0260-3165,260.3165,Unconfirmed,41,0260-P27,Characterising mode of inhaltation.,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1238,0260-3170,260.3170,Ended,41,0260-P27,Dose finding study (6-way Crossover),Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
1239,0260-3172,260.3172,Unconfirmed,41,0260-P27,Open Trial 1 ...,Unconfirmed,MIG,Migration,III,Phase III,created by Till Mey BI Germany ,,,000910,IS - Clin Study (MIGRATED)
1240,0260-3173,260.3173,Unconfirmed,41,0260-P27,Open Trial 2 ...,Unconfirmed,MIG,Migration,III,Phase III,created by Till Mey BI Germany ,,,000910,IS - Clin Study (MIGRATED)
1241,1047-0001,1047.1,Ended,42,1047-P01,Comparative clinical Equivalence of Bude,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1242,1047-0022,1047.22,Ended,42,1047-P01,PMS in Asthmatics, Columbia,Ended,MIG,Migration,IV,Phase IV,Study created according to Dr. Viel ,,,000940,Post Marketing Study (MIGRATED)
1243,0212-0701,212.701,Ended,43,0212-P07,Effect on HPA axis volunteers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1244,0212-0702,212.702,Unconfirmed,43,0212-P07,Safety and efficacy,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1245,0212-0703,212.703,Unconfirmed,43,0212-P07,Asthma in children,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1246,0212-0704,212.704,Ended,43,0212-P07,LUNG DEPOSITION OF FLUNISOLIDE,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1247,0212-0803,212.803,Ended,43,0212-P07,DEPOSITION 3 WAY CROSS OVER,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1248,0525-0001,525.1,Ended,44,0525-P01,Single rising dose p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1249,0525-0002,525.2,Unconfirmed,44,0525-P01,missing,Unconfirmed,MIG,Migration,I,Phase I,manually entered ,,,000910,IS - Clin Study (MIGRATED)
1250,0525-0003,525.3,Ended,44,0525-P01,BIBB 515 trial of 2 weeks in volunteers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1251,0525-0004,525.4,Ended,44,0525-P01,Single dose PK,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1252,0260-2501,260.2501,Ended,45,0260-P25,SD-Pharmacokinetics,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1253,0260-2502,260.2502,Ended,45,0260-P25,Efficacy and Safety,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1254,0260-2503,260.2503,Ended,45,0260-P25,ALT.PROP./B100 DOSE CONFIRMATION,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1255,0260-2504,260.2504,Ended,45,0260-P25,Alt. prop.,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1256,0260-2505,260.2505,Unconfirmed,45,0260-P25,Efficacy, act.cont.db.par.gr.,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
1257,0260-2506,260.2506,Ended,45,0260-P25,pediatric study - HFA-HDI,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1258,0260-3158,260.3158,Ended,45,0260-P25,Fenoterol HFA dose-confirmation,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1259,0260-3171,260.3171,Ended,45,0260-P25,Ethylometer,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1260,0260-3174,260.3174,Ended,45,0260-P25,Bioequivalence ...,Ended,MIG,Migration,I,Phase I,created by Till Mey BI Germany ,,,000910,IS - Clin Study (MIGRATED)
1261,0260-3175,260.3175,Unconfirmed,45,0260-P25,Open label study in Asthma,Unconfirmed,MIG,Migration,III,Phase III,created by Till Mey BI Germany ,,,000910,IS - Clin Study (MIGRATED)
1262,0260-3176,260.3176,Unconfirmed,45,0260-P25,Open label study in COPD,Unconfirmed,MIG,Migration,III,Phase III,created by Till Mey BI Germany ,,,000910,IS - Clin Study (MIGRATED)
1263,0260-3177,260.3177,Ended,45,0260-P25,Bhr placebo HFA,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1264,0260-3178,260.3178,Ended,45,0260-P25,German PMS Berotec N 100,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1265,0212-0601,212.601,Ended,46,0212-P06,Efficacy, Safety,Ended,MIG,Migration,III,Phase III,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1266,0212-0602,212.602,Ended,46,0212-P06,HPA-axis,Ended,MIG,Migration,I,Phase I,- Titel ist nicht komplett erfasst !,,,000910,IS - Clin Study (MIGRATED)
1267,0137-0001,137.1,Ended,47,0137-P01,Augentropfen,Vertr√§glichkeit, Sundmacher,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1268,0137-0002,137.2,Ended,47,0137-P01,Nasenspray, Vertr√§glichkeit, Biodesign,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1269,0137-0003,137.3,Ended,47,0137-P01,Lymphomas, Plasmocytomas, Solid Tumors,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1270,0137-0004,137.4,Ended,47,0137-P01,Orient. Kinetik nach Einmalappl. am Auge,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1271,0137-0005,137.5,Ended,47,0137-P01,Orient. Kinetik nach Applikation am Auge,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1272,0137-0006,137.6,Ended,47,0137-P01,Chronic hepatitis B,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1273,0137-0007,137.7,Ended,47,0137-P01,Non-Hodgkin-Lymphoma, Dr. Ho,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1274,0137-0008,137.8,Ended,47,0137-P01,Non-Hodgkin-Lymphoma, Dr. Bergmann, rand,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1275,0137-0009,137.9,Ended,47,0137-P01,Non-Hodgkin-Lymphome, Dr.Bergmann,n.rand,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1276,0137-0010,137.10,Ended,47,0137-P01,Casuistries - tumors / comp. use.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1277,0137-0011,137.11,Unconfirmed,47,0137-P01,Hypernephrom-adjuvante Ther.,Multicenter,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1278,0137-0012,137.12,Ended,47,0137-P01,Chronisch myeloische Leuk√§mie - chron.,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1279,0137-0013,137.13,Ended,47,0137-P01,Chronisch myeloische Leuk√§mie - akzel.,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1280,0137-0014,137.14,Unconfirmed,47,0137-P01,K. Dendritica Vergleich Gamma - Alpha,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1281,0137-0015,137.15,Ended,47,0137-P01,Anogenital papillomatosis - Prof. Gross,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1282,0137-0016,137.16,Unconfirmed,47,0137-P01,chron. Polyarthritis,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1283,0137-0017,137.17,Unconfirmed,47,0137-P01,Juvenile Polyarthritis,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1284,0137-0018,137.18,Unconfirmed,47,0137-P01,Hypernephrom ohne Lymphknoten-Metastasen,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1285,0137-0019,137.19,Unconfirmed,47,0137-P01,Hypernephrom mit Lymphknoten-Metastasen,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1286,0137-0020,137.20,Unconfirmed,47,0137-P01,metastasierendes Melanom,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1287,0137-0021,137.21,Unconfirmed,47,0137-P01,HPV-Infektionen, Prof. zur Hausen,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1288,0137-0022,137.22,Unconfirmed,47,0137-P01,Ovarialkarzinom,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1289,0137-0023,137.23,Unconfirmed,47,0137-P01,Kasuistiken - h√§matogene Tumoren,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1290,0137-0024,137.24,Ended,47,0137-P01,Kasuistiken - virale Indikationen,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1291,0137-0025,137.25,Ended,47,0137-P01,Immune dysfunctions,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1292,0137-0026,137.26,Ended,47,0137-P01,Malignant melanoma, Stadium III,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1293,0137-0027,137.27,Unconfirmed,47,0137-P01,high risk-Melanom, Multicenter,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1294,0137-0028,137.28,Ended,47,0137-P01,kutane Lymphome, Prof. Burg,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1295,0137-0029,137.29,Unconfirmed,47,0137-P01,Myelodysplasiesyndrom,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1296,0137-0030,137.30,Ended,47,0137-P01,Akute und chron. Leuk√§mie, Dr. Bartsch,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1297,0137-0031,137.31,Unconfirmed,47,0137-P01,Papillome bei Immunsuppression,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1298,0137-0032,137.32,Ended,47,0137-P01,HPV-associated bowens desease,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1299,0137-0033,137.33,Ended,47,0137-P01,RCC,Ended,MIG,Migration,II,Phase II,- started int'l,,,000910,IS - Clin Study (MIGRATED)
1300,0137-0034,137.34,Unconfirmed,47,0137-P01,metast. Hypernephrom - Multicenter,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1301,0137-0035,137.35,Unconfirmed,47,0137-P01,Bio√§quivalenz - Dr. Porzolt/Ulm,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1302,0137-0036,137.36,Ended,47,0137-P01,Bioequiv. IFN Gamma-1b (Genent./Bender),Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1303,0137-0037,137.37,Ended,47,0137-P01,Malignant Melanoma, Prof. Kleeberg EORTC,Ended,MIG,Migration,III,Phase III,- 3rd treatment group with IFN-Alpha of other company / local no BE:804 * old contract, payed by BIGmbH,,,000910,IS - Clin Study (MIGRATED)
1304,0137-0038,137.38,Ended,47,0137-P01,Immunther.i.v mit IFN-aktiv.Makrophagen,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1305,0137-0039,137.39,Ended,47,0137-P01,Immunther.i.p.mit IFN-aktiv.Makrophagen,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1306,0137-0040,137.40,Unconfirmed,47,0137-P01,Wegenersche Granulomatose,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1307,0137-0041,137.41,Ended,47,0137-P01,Chronic granulomatous disease GENENTECH,Ended,MIG,Migration,II,Phase II,Numbers of patients not acc. to protocol ,,,000910,IS - Clin Study (MIGRATED)
1308,0137-0042,137.42,Unconfirmed,47,0137-P01,Lungenfibrose, idiopath. CIS,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1309,0137-0043,137.43,Ended,47,0137-P01,Imukin with dose reduct. in RA,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1310,0137-0044,137.44,Ended,47,0137-P01,Burns-Related Infections,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1311,0137-0045,137.45,Ended,47,0137-P01,Wegener's granulomatosis,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1312,0137-0046,137.46,Ended,47,0137-P01,Bioequiv. IFN Gamma-1b (Genent./Bender),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1313,0137-0047,137.47,Ended,47,0137-P01,Immuneparalysis,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1314,0137-0048,137.48,Ended,47,0137-P01,High risk of infectious diseases,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1315,0137-0049,137.49,Ended,47,0137-P01,Immunology in Chronic Osteitis,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1316,0137-0050,137.50,Ended,47,0137-P01,Atopic dermatitis,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1317,0137-0051,137.51,Unconfirmed,47,0137-P01,Pre-study immunoparalysis in Sepsis,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000980,Not Classified (MIGRATED)
1318,0137-0052,137.52,Unconfirmed,47,0137-P01,Immunoparalysis in Sepsis,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000980,Not Classified (MIGRATED)
1319,0137-0104,137.104,Ended,47,0137-P01,Intraperitoneal administration,Ended,MIG,Migration,II,Phase II,- old contract, payed by BIGmbH / Report expected 12/92,,,000910,IS - Clin Study (MIGRATED)
1320,0137-0110,137.110,Ended,47,0137-P01,Malignant melanoma,Ended,MIG,Migration,II,Phase II,- 12-8-90: Study ongoing in follow-up periode * *,,,000910,IS - Clin Study (MIGRATED)
1321,0137-0124,137.124,Ended,47,0137-P01,Leishmaniasis cut.,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1322,0137-0129,137.129,Ended,47,0137-P01,INTRATUMORAL IFN-GAMMA IN GLIOBLASTOMA,Ended,MIG,Migration,II,Phase II,- Rep. Nahlen (CIS-Wien),,,000910,IS - Clin Study (MIGRATED)
1323,0137-0133,137.133,Ended,47,0137-P01,Hypertrophic scars,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1324,0137-0134,137.134,Ended,47,0137-P01,Chronic granulomatous disease,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1325,0137-0143,137.143,Ended,47,0137-P01,SCLC,Ended,MIG,Migration,III,Phase III,- old contract, payed by BIGmbH,,,000910,IS - Clin Study (MIGRATED)
1326,0137-0148,137.148,Ended,47,0137-P01,Leishmaniasis cut.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1327,0137-0154,137.154,Ended,47,0137-P01,IFN-GAMMA IN RHEUMATOID ARTHRITIS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1328,0137-0156,137.156,Ended,47,0137-P01,Leishmaniasis, cutaneous,Ended,MIG,Migration,III,Phase III,- Info. that study is finished from Prof.Steinmann, Biberach: 29.1.96,,,000910,IS - Clin Study (MIGRATED)
1329,0137-0158,137.158,Ended,47,0137-P01,Recombinant Human Interferongamma in CGD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1330,0137-0163,137.163,Ended,47,0137-P01,IFN-gamma effect on CGD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1331,0137-0175,137.175,Ended,47,0137-P01,EFFICACY/SAFETY STUDY IN ADVANCED HIV,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1332,0137-0176,137.176,Ended,47,0137-P01,MAC infection in HIV,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1333,0137-0187,137.187,Unconfirmed,47,0137-P01,Locoregional imunotherapy,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1334,0137-0188,137.188,Unconfirmed,47,0137-P01,Locoregional immunostimulation,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1335,0137-0189,137.189,Unconfirmed,47,0137-P01,Locoregional immunostimulation,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1336,0137-0190,137.190,Preparing,47,0137-P01,Locoregional immunostumulation,Preparing,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1337,0137-0191,137.191,Unconfirmed,47,0137-P01,Chemoembolization - immunostimulation,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1338,0137-0192,137.192,Unconfirmed,47,0137-P01,Locoregional immunotherapy,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1339,0137-0193,137.193,Unconfirmed,47,0137-P01,Chemoembolisation - immunostimulation,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1340,0137-0194,137.194,Ended,47,0137-P01,Prevention of trauma related infections,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1341,0137-0195,137.195,Ended,47,0137-P01,Prophylaxis of infections in HIV,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1342,0137-0196,137.196,Preparing,47,0137-P01,Atopic dermatitis, in vitro & study,Preparing,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
1343,0137-0200,137.200,Ended,47,0137-P01,Inf. foll. aut. stern. Transplantations,Ended,MIG,Migration,IIA,Phase IIa,Recruitment stop 30.05.98 due to... Recruitment was stopped on 30 May 98 due to low recruitment. Abbrev. stat. report was made by Dr. Glancszpigel (CRO),,,000910,IS - Clin Study (MIGRATED)
1344,0137-0201,137.201,Unconfirmed,47,0137-P01,Immunoparalysis in Sepsis, Dosefinding,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
1345,0137-0202,137.202,Unconfirmed,47,0137-P01,Immunoparalysis in Sepsis,Unconfirmed,MIG,Migration,II,Phase II,,,,000980,Not Classified (MIGRATED)
1346,0137-1201,137.1201,Preparing,47,0137-P01,Prevention of, Major Infections,Preparing,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1347,0152-0011,152.11,Ended,48,0152-P01,IL8-induction,intradermal, IOR,Ended,MIG,Migration,I,Phase I,,,,,
1348,0152-0013,152.13,Ended,48,0152-P01,ILP TNFa and Melphalan in MM - IOR,Ended,MIG,Migration,II,Phase II,,,,,
1349,0152-0056,152.56,Ended,48,0152-P01,Trt of metastatic melanoma pat. (pilot),Ended,MIG,Migration,II,Phase II,- Originally planned in indication Melanoma/Sarcoma/Limb tumor became an own trial (920300),,,000910,IS - Clin Study (MIGRATED)
1350,0152-0061,152.61,Ended,48,0152-P01,Perfusion in malignant melanoma,Ended,MIG,Migration,IIB,Phase IIb,- Trial first started in Belgium, then investigator went to     Switzerland, there the trial continued.,,,000910,IS - Clin Study (MIGRATED)
1351,0152-0067,152.67,Ended,48,0152-P01,ILP therapy (pilot trial),Ended,MIG,Migration,II,Phase II,- ,,,000500,Compassionate Use Program (CUP)
1352,0152-0070,152.70,Ended,48,0152-P01,Open randomised prospective study,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1353,0152-0071,152.71,Ended,48,0152-P01,Extremity melanoma,Ended,MIG,Migration,III,Phase III,-  The NCI will hold the IND and will conduct the trial we will review  protocol (to be written by Dr. D. Fraker of U.Penn) Number of patients reduced to 120 per Dr. Clarke (UK) via A. geller  gmbh- drug to be shipped from vienna to nci for storage and distribution to investigators   ,,,,
1354,0152-0072,152.72,Unconfirmed,48,0152-P01,Phase III study - TBD,Unconfirmed,MIG,Migration,III,Phase III,-  The NCI will hold the IND and will conduct the trial we will review  protocol (to be written by Dr. D. Fraker of U.Penn) Cancelled per Dr. Clarke (UK) via A. Geller, GmbH     ,,,000910,IS - Clin Study (MIGRATED)
1355,0152-0012,152.12,Ended,49,0152-P02,ILP TNFa and Melphalan in STS - IOR,Ended,MIG,Migration,IIB,Phase IIb,,,,,
1356,0152-0062,152.62,Ended,49,0152-P02,Trt of irresectable sarcoma,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000500,Compassionate Use Program (CUP)
1357,0152-0063,152.63,Ended,49,0152-P02,ILP therapy (Pilot trial),Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1358,0152-0066,152.66,Ended,49,0152-P02,ILP TNF-alpha and melphalan in STS,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
1359,0152-0073,152.73,Unconfirmed,49,0152-P02,Pat.Data Managem.System,ILP advanced STS,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1360,0511-0001,511.1,Ended,50,0511-P01,SD-Tolerability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1361,0511-0002,511.2,Ended,50,0511-P01,MD-Tolerability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1362,0511-0003,511.3,Ended,50,0511-P01,PHARMACODYNAMICS,DB, SINGLE DOSE,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
1363,0511-0004,511.4,Ended,50,0511-P01,Paroxetine PET/QEEG,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
1364,0511-0005,511.5,Ended,50,0511-P01,BIMT 17 PET/QEEG,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
1365,0511-0006,511.6,Unconfirmed,50,0511-P01,Phase IIb depression,Unconfirmed,MIG,Migration,IIB,Phase IIb,-  This possible phase IIb study may be pivotal.     ,,,000910,IS - Clin Study (MIGRATED)
1366,0511-0007,511.7,Unconfirmed,50,0511-P01,Phase II depression,Unconfirmed,MIG,Migration,IIA,Phase IIa,-  Differs from 511.06 only in the active comparator substance. 270-300 subjects Trial delayed to agree with 4Q96 IND filing date from DRA.     ,,,000910,IS - Clin Study (MIGRATED)
1367,0511-0008,511.8,Unconfirmed,50,0511-P01,random, db, dosing regimen,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1368,0511-0009,511.9,Ended,50,0511-P01,Single incr. dose toler. study - BIMT 17,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1369,0511-0010,511.10,Ended,50,0511-P01,Pharmacodynamic study,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
1370,0511-0011,511.11,Ended,50,0511-P01,Phase II depression,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
1371,0511-0012,511.12,Ended,50,0511-P01,Phase II depression,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
1372,0511-0013,511.13,Unconfirmed,50,0511-P01,PET binding,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1373,0511-0014,511.14,Ended,50,0511-P01,I.V. Safety and Tolerability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1374,0511-0015,511.15,Ended,50,0511-P01,14C ADME,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1375,0511-0016,511.16,Unconfirmed,50,0511-P01,Absolute Bioavailability,Unconfirmed,MIG,Migration,I,Phase I,To be planned when 511.33 results in. ,,,000910,IS - Clin Study (MIGRATED)
1376,0511-0017,511.17,Ended,50,0511-P01,Comparative bioavail. study - BIMT 17 ,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1377,0511-0018,511.18,Ended,50,0511-P01,Dosing Regimen,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1378,0511-0019,511.19,Ended,50,0511-P01,Rel. bioavailability BIMT 17 BS tab-cap ,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1379,0511-0020,511.20,Unconfirmed,50,0511-P01,Efficacy study,Unconfirmed,MIG,Migration,III,Phase III,-  Approved by the IMC. Start date dependent on availability of final formulation. dg chgd init date on 11/5/97 to 1/1/99 as a result of budget discu ssions. NOT YET APPROVED BY IMC ,,,000910,IS - Clin Study (MIGRATED)
1380,0511-0021,511.21,Unconfirmed,50,0511-P01,Efficacy study,Unconfirmed,MIG,Migration,III,Phase III,-  Not yet approved by thhe IMC. Start date dependent on availability of final formulation. dg chgd init date on 11/5/97 to 1/1/99 as a result of budget discu ssions. NOT YET APPROVED BY IMC ,,,000910,IS - Clin Study (MIGRATED)
1381,0511-0022,511.22,Unconfirmed,50,0511-P01,Depression,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1382,0511-0023,511.23,Unconfirmed,50,0511-P01,Moderate depression - paroxetine,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
1383,0511-0024,511.24,Unconfirmed,50,0511-P01,Long term safety,Unconfirmed,MIG,Migration,III,Phase III,-  Not yet approved by the IMC. Start date dependent on availability of final formulation. dg chgd init date on 11/5/97 to 1/1/99 as a result of budget discu ssions. NOT YET APPROVED BY IMC ,,,000910,IS - Clin Study (MIGRATED)
1384,0511-0025,511.25,Unconfirmed,50,0511-P01,Safety study,Unconfirmed,MIG,Migration,III,Phase III,-  Not yet approved by the IMC. Start date dependent on availability of final formulation. Trial may be cancelled.   NOT YET APPROVED BY IMC ,,,000910,IS - Clin Study (MIGRATED)
1385,0511-0026,511.26,Ended,50,0511-P01,Food Interaction Study,Ended,MIG,Migration,I,Phase I,HPZ will have monitoring responsibility ,,,000910,IS - Clin Study (MIGRATED)
1386,0511-0027,511.27,Unconfirmed,50,0511-P01,Alcohol interaction study,Unconfirmed,MIG,Migration,I,Phase I,manually entered ,,,000910,IS - Clin Study (MIGRATED)
1387,0511-0028,511.28,Ended,50,0511-P01,Safety and tolerability,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
1388,0511-0029,511.29,Unconfirmed,50,0511-P01,Severe depression,Unconfirmed,MIG,Migration,III,Phase III,Patient numbers TBD ,,,000910,IS - Clin Study (MIGRATED)
1389,0511-0030,511.30,Unconfirmed,50,0511-P01,Relapse study,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1390,0511-0031,511.31,Unconfirmed,50,0511-P01,Efficacy in severely depressed in-pats,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1391,0511-0032,511.32,Unconfirmed,50,0511-P01,EURAT,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1392,0511-0033,511.33,Ended,50,0511-P01,Rel. Bioavailability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1393,0511-0034,511.34,Unconfirmed,50,0511-P01,MAD efficacy study,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,        ,,,000910,IS - Clin Study (MIGRATED)
1394,0511-0035,511.35,Unconfirmed,50,0511-P01,Interaction with oral contraceptives,Unconfirmed,MIG,Migration,I,Phase I,manually entered ,,,000910,IS - Clin Study (MIGRATED)
1395,0511-0036,511.36,Unconfirmed,50,0511-P01,Interaction with Pantoprazol,Unconfirmed,MIG,Migration,I,Phase I,manually entered ,,,000910,IS - Clin Study (MIGRATED)
1396,0511-0037,511.37,Ended,50,0511-P01,Interaction with Itraconazole,Ended,MIG,Migration,I,Phase I,manually entered ,,,000910,IS - Clin Study (MIGRATED)
1397,0511-0038,511.38,Preparing,50,0511-P01,Interaction with Rifampicin,Preparing,MIG,Migration,I,Phase I,manually entered ,,,000910,IS - Clin Study (MIGRATED)
1398,0511-0039,511.39,Unconfirmed,50,0511-P01,MDD-Flibanserin & Fluoxetine,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
1399,0511-0040,511.40,Unconfirmed,50,0511-P01,BIMT,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
1400,0511-0041,511.41,Ended,50,0511-P01,MDD-Flibanserin & Fluoxetine,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
1401,0511-0042,511.42,Ended,50,0511-P01,CAF√â,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
1402,0511-0043,511.43,Ended,50,0511-P01,MDD-Flibanserin & Fluoxetine,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
1403,0511-0044,511.44,Ended,50,0511-P01,Follow-NAA,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
1404,0511-0045,511.45,Ended,50,0511-P01,Open Label  Follow-EU,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
1405,0511-0046,511.46,Unconfirmed,50,0511-P01,MDD-Placebo & paroxetine,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1406,0511-0047,511.47,Unconfirmed,50,0511-P01,MDD-Placebo & paroxetine,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1407,0511-0048,511.48,Unconfirmed,50,0511-P01,MDD-Placebo & paroxetine,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1408,0511-0049,511.49,Ended,50,0511-P01,WEST MDD-Placebo and Paroxetine,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
1409,0511-0050,511.50,Preparing,50,0511-P01,OL/DB Geriatric Study,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1410,0511-0051,511.51,Unconfirmed,50,0511-P01,Flibanserin PK/Safety-Pediatric,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
1411,0511-0052,511.52,Unconfirmed,50,0511-P01,OL-Flibansvs Parox/Young Adults,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1412,0511-0053,511.53,Unconfirmed,50,0511-P01,OL-Flib vs. Parox-Elderly Population,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1413,0511-0054,511.54,Preparing,50,0511-P01,PK safety interaction - benzodiazepines,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1414,0511-0055,511.55,Unconfirmed,50,0511-P01,Japanese Phase 1 Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1415,0208-0301,208.301,Unconfirmed,51,0208-P02,EFFICACY & SAFETY,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1416,0208-0302,208.302,Ended,51,0208-P02,INT'L EFFICACY STUDY IN ANXIETY,Ended,MIG,Migration,IIA,Phase IIa,- *Ingelheim trial,,,000910,IS - Clin Study (MIGRATED)
1417,0244-2344,244.2344,Ended,52,0244-P20,Assess APR indication,Ended,MIG,Migration,II,Phase II,-  Interim analysis suggests will require higher doses (42/84mcg/nostr il) tid for 8 weeks. Will need 2nd phase II dose response study. Review will take aproximately 60 days.     ,,,000910,IS - Clin Study (MIGRATED)
1418,0244-2348,244.2348,Ended,52,0244-P20,Dose ranging NAPR patients,Ended,MIG,Migration,II,Phase II,-  Based on interim analysis phase III dose of 42mcg tid for 8 weeks selected for double blind portion using .03% solution.     ,,,000910,IS - Clin Study (MIGRATED)
1419,0244-2361,244.2361,Ended,52,0244-P20,Double-blind safety & efficacy,Ended,MIG,Migration,III,Phase III,-  Each site will enroll 30 patients; they may enroll up to 40 (with  the monitor's permission).  Duration for double-blind portion of study is 3 months and 12 months for open-label portion.     ,,,000910,IS - Clin Study (MIGRATED)
1420,0244-2362,244.2362,Ended,52,0244-P20,Optimal dose response/APR pts.,Ended,MIG,Migration,II,Phase II,-  Each site will enroll 30 patients; up to 40 patients or more may be enrolled (with the monitors permission). 4 months duration for double-blind portion and 12 months duration for open-label portion     ,,,000910,IS - Clin Study (MIGRATED)
1421,0244-2373,244.2373,Ended,52,0244-P20,Dose response,Ended,MIG,Migration,II,Phase II,-  The model will be used in assessing future combination products. Academic draft report has been received from Drs. Naclerio and Baroody on 10/8/90.     ,,,000910,IS - Clin Study (MIGRATED)
1422,0244-2387,244.2387,Ended,52,0244-P20,double-blind safety & efficacy,Ended,MIG,Migration,III,Phase III,-  Duration of double-blind portion of study is 12 weeks and 12 months for open-label portion.  Dates reported for open label are for 6 month data only. Date changes due to medical management decision to pursue NAPR/APR NDA. (difficult NDA strategy) Target for November '91 instead of July '91. All date changes are contingent upon this decision.   ,,,000910,IS - Clin Study (MIGRATED)
1423,0244-2391,244.2391,Ended,52,0244-P20,Pharmacokinetics,Ended,MIG,Migration,I,Phase I,-  Integrated report pending pharmacokinetic standardization. Safety data has been locked, with information presented to upper BIPI management on 9/20/90.     ,,,000910,IS - Clin Study (MIGRATED)
1424,0244-2400,244.2400,Ended,52,0244-P20,Pharmacokinetics,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
1425,0244-2402,244.2402,Ended,52,0244-P20,Onset & dur of drug activity,Ended,MIG,Migration,II,Phase II,-  Study results will now be included in the .03% NDA.     ,,,000910,IS - Clin Study (MIGRATED)
1426,0244-2415,244.2415,Ended,52,0244-P20,O.L. safety,Ended,MIG,Migration,II,Phase II,-  Each site will enroll 30 patients; up to 40 patients or more may be enrolled (with the monitors permission). 4 months duration for double-blind portion and 12 months duration for open-label portion.   ,,,000910,IS - Clin Study (MIGRATED)
1427,0244-2416,244.2416,Ended,52,0244-P20,open-label safety & efficacy,Ended,MIG,Migration,III,Phase III,-  Each site will enroll 30 patients; they may enroll up to 40 (with  the monitor's permission).  Duration for double-blind portion of study is 3 months and 12 months for open-label portion. 7/22/91-No target date established for doing final patient reviews. Lower priority than NDA and higher straight fall trial program.   ,,,000910,IS - Clin Study (MIGRATED)
1428,0244-2417,244.2417,Ended,52,0244-P20,open-label safety & efficacy,Ended,MIG,Migration,III,Phase III,-  Duration of double-blind portion of study is 12 weeks and 12 months for open-label portion.  Dates reported for open label are for 6 month data only. Date changes due to medical management decision to pursue NAPR/APR NDA. (difficult NDA strategy) Target for November '91 instead of July '91. All date changes are contingent upon this decision.   ,,,000910,IS - Clin Study (MIGRATED)
1429,0244-2423,244.2423,Ended,52,0244-P20,BID perennial rhinitis,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
1430,0244-2434,244.2434,Ended,52,0244-P20,Antihistamine comparison,Ended,MIG,Migration,IIIB,Phase IIIb,-  Enrollment problem addressed with opening of new site.  Internal manpower constraints and priority for lock of pediatric trial do not allow for this report to be completed at an accelerated schedule, therefore data set lock remains targeted for 10/17/94.   ,,,000910,IS - Clin Study (MIGRATED)
1431,0244-2435,244.2435,Ended,52,0244-P20,Seasonal antihistamine,Ended,MIG,Migration,IIIB,Phase IIIb,-  Internal manpower constraints require data set lock to remain at 11/30/94.     ,,,000910,IS - Clin Study (MIGRATED)
1432,0244-2439,244.2439,Ended,52,0244-P20,Intranasal steroid,Ended,MIG,Migration,IIIB,Phase IIIb,-  Trial will be done using CRO.     ,,,000910,IS - Clin Study (MIGRATED)
1433,0244-2446,244.2446,Ended,52,0244-P20,Intranasal steroid - LONG TERM,Ended,MIG,Migration,IIIB,Phase IIIb,-  Trial will be done using Innovex.     ,,,000910,IS - Clin Study (MIGRATED)
1434,0244-2478,244.2478,Unconfirmed,52,0244-P20,Antigen challenge,Unconfirmed,MIG,Migration,IV,Phase IV,        ,,,000910,IS - Clin Study (MIGRATED)
1435,0244-2504,244.2504,Preparing,52,0244-P20,Pediatric Perennial Allergic Rhinitis St,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1436,0244-2291,244.2291,Ended,53,0244-P19,COMMON COLD,Ended,MIG,Migration,I,Phase I,-  Formerly IIa1     ,,,000910,IS - Clin Study (MIGRATED)
1437,0244-2386,244.2386,Ended,53,0244-P19,pilot evaluation - qid,Ended,MIG,Migration,II,Phase II,-  Dr. Tinkleman's site (center 5) terminated due to poor entrollment.   The 40 patients from center 5 will be completed by Dr. Posner (24 pts), Dr. Zinny (8 pts) and Dr. Dockhorn (8 pts).     ,,,000910,IS - Clin Study (MIGRATED)
1438,0244-2399,244.2399,Ended,53,0244-P19,Dose ranging - tid,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
1439,0244-2422,244.2422,Ended,53,0244-P19,pharmacokinetic study,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
1440,0244-2436,244.2436,Ended,53,0244-P19,Global Assessment/Natural cold,Ended,MIG,Migration,IIIB,Phase IIIb,        ,,,000910,IS - Clin Study (MIGRATED)
1441,0244-2442,244.2442,Unconfirmed,53,0244-P19,ANS vs Seldane-D OR Deconamine,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,-  A meeting is scheduled Jan. '96 between Regulatory, Legal and Marketing to determine if this trial should be performed.     ,,,000910,IS - Clin Study (MIGRATED)
1442,0244-2448,244.2448,Ended,53,0244-P19,Pediatric pharmacokinetic tria,Ended,MIG,Migration,II,Phase II,-  Due to enrollment concerns, this trial has been postponed until cold season of 95-96.   FINAL RPT. DELAYED. DMPK NOT ABLE TO CALC. WHEN PK SECTION WILL BE COMPLETED. ,,,000910,IS - Clin Study (MIGRATED)
1443,0244-2460,244.2460,Unconfirmed,53,0244-P19,Conditions-of-use study,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,-  Trial delayed until strategy for OTC is clarified.     ,,,000910,IS - Clin Study (MIGRATED)
1444,0244-2465,244.2465,Ended,53,0244-P19,Pediatric Safety,Ended,MIG,Migration,III,Phase III,-  Study dependent on FDA response to package.     ,,,000910,IS - Clin Study (MIGRATED)
1445,0244-2477,244.2477,Unconfirmed,53,0244-P19,Rhinovirus transmission trial,Unconfirmed,MIG,Migration,IV,Phase IV,-  Hope to initiate in 1996. Timing dependent on investigator's schedule. Trial cancelled on 10/21/96 due to cost and low possibility of a positive result.   ,,,000940,Post Marketing Study (MIGRATED)
1446,0244-2503,244.2503,Ended,53,0244-P19,Pediatric Common Cold  and Allergy Study,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1447,0244-2405,244.2405,Ended,54,0244-P18,Short term safety & efficacy,Ended,MIG,Migration,III,Phase III,-  Estimated per patient costs are for the complete protocol, includ- ing the one year portion. All sites (except one) were allowed to enroll as of January 25, l99l. Dr. Hampel's site was opened February l9, l99l.   ,,,000910,IS - Clin Study (MIGRATED)
1448,0244-2406,244.2406,Ended,54,0244-P18,Short term safety & efficacy,Ended,MIG,Migration,III,Phase III,-  Estimated per patient costs are for the complete protocol including  the one year portion.     ,,,000910,IS - Clin Study (MIGRATED)
1449,0244-2418,244.2418,Ended,54,0244-P18,Long term safety & efficacy,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
1450,0244-2419,244.2419,Ended,54,0244-P18,Long term safety & efficacy,Ended,MIG,Migration,III,Phase III,-  Dr. Lockey is last site enrolling patients. Clinical participation will be done by 9/31/92 as trial will be closed early.     ,,,000910,IS - Clin Study (MIGRATED)
1451,0244-2461,244.2461,Unconfirmed,54,0244-P18,Dose-escalation P.R.,Unconfirmed,MIG,Migration,III,Phase III,-  Study design specifics will depend on results of short-term 847A and 848A and meeting with FDA.  FDA meeting targeted for 1994.     ,,,000910,IS - Clin Study (MIGRATED)
1452,0244-2464,244.2464,Unconfirmed,54,0244-P18,Chronic sinusitis,Unconfirmed,MIG,Migration,III,Phase III,-  Another replicate trial would be required to support an NDA indication.     ,,,000910,IS - Clin Study (MIGRATED)
1453,0107-0053,107.53,Ended,55,0107-P05,Tolerab., kinetics of 30 mg Gel topical,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1454,0107-0079,107.79,Ended,55,0107-P05,Acute antiphlog.effect with NSE-test/Gel,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1455,0107-0088,107.88,Ended,55,0107-P05,Meloxicam top. vs. Voltaren and Felden,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1456,0107-0091,107.91,Ended,55,0107-P05,Meloxicam top. vs. Diclofenac +Piroxicam,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1457,0107-0108,107.108,Ended,55,0107-P05,Kinetics and tolerability, 30 mg topical,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1458,0107-0161,107.161,Unconfirmed,55,0107-P05,Efficacy on Gonarthritis vs.NSAID topic.,Unconfirmed,MIG,Migration,III,Phase III,Planned dates to be determined ,,,000910,IS - Clin Study (MIGRATED)
1459,0107-0214,107.214,Ended,55,0107-P05,PK & tolerability 30mg Mel. topical gel,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1460,0107-0034,107.34,Ended,56,0107-P03,Pilot study: Meloxicam 30 mg i.v. Bolus,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1461,0107-0057,107.57,Ended,56,0107-P03,Meloxicam 15 mg vs placebo: 107.057-TH,Ended,MIG,Migration,II,Phase II,- Report expected end 92 (Letter Gulinck 11/92) / Report Date requested (Letter DI 10/92),,,000910,IS - Clin Study (MIGRATED)
1462,0107-0058,107.58,Preparing,56,0107-P03,15mg Meloxicam vs. Comparator,Preparing,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1463,0107-0059,107.59,Ended,56,0107-P03,Efficacy trial of meloxicam ampoules sci,Ended,MIG,Migration,III,Phase III,- *Biberach trial,,,000910,IS - Clin Study (MIGRATED)
1464,0107-0100,107.100,Ended,56,0107-P03,meloxicam 15mg vs diclofenac 100mg lumb.,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1465,0107-0101,107.101,Ended,56,0107-P03,meloxicam 15mg vs piroxicam 20mg lumbago,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1466,0107-0104,107.104,Unconfirmed,56,0107-P03,Meloxicam 15 mg vs placebo in sciatica,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1467,0107-0132,107.132,Ended,56,0107-P03,Phase III trialcontrol:Indomethacin,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1468,0107-0160,107.160,Ended,56,0107-P03,Efficacy,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
1469,0107-0165,107.165,Ended,56,0107-P03,PHASE III open study,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1470,0107-0177,107.177,Ended,56,0107-P03,Efficacy and safety,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1471,0107-0001,107.1,Ended,57,0107-P01,Tolerability and Kinetics: IPHAR,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1472,0107-0002,107.2,Ended,57,0107-P01,Cumul. Dose up to 100 mg p.o.: IPHAR,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1473,0107-0003,107.3,Ended,57,0107-P01,1. Efficacy Trial: BIODESIGN,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1474,0107-0004,107.4,Ended,57,0107-P01,Synovialkinetics,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1475,0107-0005,107.5,Ended,57,0107-P01,2. Efficacy Trial: Dr. Josenhans,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1476,0107-0006,107.6,Ended,57,0107-P01,3. Efficacy Trial: multicenter,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1477,0107-0007,107.7,Ended,57,0107-P01,4. Efficacy Trial: Prof. Bach,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1478,0107-0008,107.8,Ended,57,0107-P01,Rheumatoid Arthritis: Dr. Wittenborg,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1479,0107-0011,107.11,Ended,57,0107-P01,Rheumatoid Arthritis: ,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1480,0107-0013,107.13,Ended,57,0107-P01,Extraarticular disease: multicenter,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1481,0107-0014,107.14,Ended,57,0107-P01,Efficacy&Tolerance: Meloxicam/Piroxicam,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1482,0107-0015,107.15,Ended,57,0107-P01,Transsynovial kinetics: Prof. Bach,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1483,0107-0016,107.16,Unconfirmed,57,0107-P01,Bioaequivalence: 30 mg capsule,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1484,0107-0017,107.17,Unconfirmed,57,0107-P01,Traumatologie,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1485,0107-0018,107.18,Ended,57,0107-P01,Interferenz mit Aspirin und Tagamet,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1486,0107-0021,107.21,Ended,57,0107-P01,Vertr√§glichkeit bis 60 mg i.v. Bolus,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1487,0107-0022,107.22,Ended,57,0107-P01,Resorption durch Antacida und Nahrung,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1488,0107-0023,107.23,Unconfirmed,57,0107-P01,Vertr√§glichkeit bei kumul. Dosierung,Unconfirmed,MIG,Migration,I,Phase I,Transferred from CTMD: status x means trial probably cancelled. 
Phone call with Ms. Hertl on March 24, 1999,,,000910,IS - Clin Study (MIGRATED)
1489,0107-0024,107.24,Unconfirmed,57,0107-P01,Abh√§ngigkeit von Alter und Geschlecht,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1490,0107-0025,107.25,Ended,57,0107-P01,Bioavail. and pharmacok. 30 mg UHAC i.v.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1491,0107-0026,107.26,Ended,57,0107-P01,Metaboliten im Urin,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1492,0107-0027,107.27,Ended,57,0107-P01,Kinetik nach 14C-Markierung,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1493,0107-0028,107.28,Unconfirmed,57,0107-P01,Gewebekinetik bei Rheumatoider Arthritis,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1494,0107-0029,107.29,Ended,57,0107-P01,Hemmung der Pl√§ttchenaggregation,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1495,0107-0030,107.30,Ended,57,0107-P01,Efficacy&Tolerance: 7.5mg vs 15mg Melo,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1496,0107-0031,107.31,Ended,57,0107-P01,Bioverf√ºgb.:30mg Kaps/Supposi/Suspension,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1497,0107-0032,107.32,Ended,57,0107-P01,Bioavailability: 30mg p.o./rectal,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1498,0107-0033,107.33,Ended,57,0107-P01,Tolerability up to 30mg p.o.: BIODESIGN,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1499,0107-0035,107.35,Ended,57,0107-P01,Efficacy&Tolerance: Meloxicam vs Placebo,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1500,0107-0036,107.36,Ended,57,0107-P01,Long term study: Meloxicam/Piroxicam,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1501,0107-0037,107.37,Ended,57,0107-P01,Long term study: Meloxicam/Naproxen,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1502,0107-0038,107.38,Ended,57,0107-P01,SINGLE DOSE PHARMACOKINETIC STUDY IN ELD,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1503,0107-0039,107.39,Ended,57,0107-P01,MULTIDOSE PHARMACOKINETIC STUDY IN ELDER,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1504,0107-0040,107.40,Ended,57,0107-P01,Open long term study: Meloxicam 15 mg,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1505,0107-0041,107.41,Ended,57,0107-P01,Open long term study: Meloxicam 30 mg,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1506,0107-0049,107.49,Ended,57,0107-P01,Cholestyramine: Reabsorption of Melo i.v,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1507,0107-0050,107.50,Ended,57,0107-P01,Tolerability and kinetics 5-30 mg i.m.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1508,0107-0051,107.51,Ended,57,0107-P01,Kinetics in patients with renal failure,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1509,0107-0052,107.52,Ended,57,0107-P01,Kinetics in patients with liver insuff.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1510,0107-0054,107.54,Unconfirmed,57,0107-P01,Bioavailibility of 1x30 mg p.o. TA / KAH,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1511,0107-0055,107.55,Ended,57,0107-P01,Bioavailibility of 1x15 mg p.o. TA / KAH,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1512,0107-0056,107.56,Ended,57,0107-P01,Kinetics, tolerabil. of 1x15mg i.m./i.v.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1513,0107-0060,107.60,Ended,57,0107-P01,safety inj. and piroxicam,Ended,MIG,Migration,III,Phase III,- *Biberach trial,,,000910,IS - Clin Study (MIGRATED)
1514,0107-0061,107.61,Ended,57,0107-P01,Long term study: Meloxicam 7.5/Naproxen,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1515,0107-0062,107.62,Ended,57,0107-P01,Bioequivalence of 1x15 mg Suppos./Caps.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1516,0107-0064,107.64,Ended,57,0107-P01,Bioequival.: 15mg SU(gly,wax),KAH /7days,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1517,0107-0065,107.65,Ended,57,0107-P01,EVALUATION OF GASTROINTESTINAL EFFECTS,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1518,0107-0066,107.66,Ended,57,0107-P01,Pilot-Study: Bioequiv.1x15mg(Ts/Tns/KAH),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1519,0107-0067,107.67,Unconfirmed,57,0107-P01,Interaction Meloxicam/Glibenclamid p.o.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1520,0107-0068,107.68,Ended,57,0107-P01,PHARMACOKINETICS OF 15MG AT STEADY STATE,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1521,0107-0069,107.69,Ended,57,0107-P01,Follow-up treatment,Ended,MIG,Migration,III,Phase III,Treatment until registration Subjects planned to be enrolled/entered: open (all patients requiring follow up treatment),,,000500,Compassionate Use Program (CUP)
1522,0107-0070,107.70,Ended,57,0107-P01,Interaction with Methotrexate 908,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1523,0107-0071,107.71,Ended,57,0107-P01,Effect of food on bioavail.of 1x15mg p.o,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1524,0107-0072,107.72,Ended,57,0107-P01,Interact. of Meloxicam with Digitalis,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1525,0107-0073,107.73,Unconfirmed,57,0107-P01,Biliary excretion/metabolites 15 mg i.v.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1526,0107-0074,107.74,Ended,57,0107-P01,Bioavailability of 1x15mg(TA/KAH) /7days,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1527,0107-0075,107.75,Ended,57,0107-P01,Safety in renal impairment, RA/OA CT635,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1528,0107-0078,107.78,Ended,57,0107-P01,Kinetics 7.5mg caps.: single/mult., m/f,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1529,0107-0080,107.80,Ended,57,0107-P01,Tolerance of Meloxicam,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1530,0107-0081,107.81,Ended,57,0107-P01,Urinary excretion of PGE2/PGF1alpha,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1531,0107-0082,107.82,Ended,57,0107-P01,Rel.bioavailab. 7.5mg TA/KAH,15mg KAH/7d,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1532,0107-0083,107.83,Ended,57,0107-P01,Safety study RA, high dose,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1533,0107-0084,107.84,Ended,57,0107-P01,Efficacy study RA, high dose,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1534,0107-0085,107.85,Ended,57,0107-P01,Effect of age & sex on pharmacokinetics,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1535,0107-0087,107.87,Ended,57,0107-P01,30 mg Kinetik bei √§lteren Probanden,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1536,0107-0089,107.89,Ended,57,0107-P01,Meloxicam and Furosemide interaction,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1537,0107-0092,107.92,Ended,57,0107-P01,G.I. Tolerability in R.A.,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
1538,0107-0105,107.105,Ended,57,0107-P01,Gastric mucosal blood flow study,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1539,0107-0109,107.109,Ended,57,0107-P01,Follow-up 22,5 mg (High dose),Ended,MIG,Migration,III,Phase III,End date: open (up to registration) ,,,000500,Compassionate Use Program (CUP)
1540,0107-0111,107.111,Ended,57,0107-P01,Incidence of GI hemorrhage / ulcer,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1541,0107-0114,107.114,Ended,57,0107-P01,Furosemide Interaction,Ended,MIG,Migration,II,Phase II,- Follow-up to ZA031.,,,000910,IS - Clin Study (MIGRATED)
1542,0107-0116,107.116,Ended,57,0107-P01,Suppositories 7.5 mg Bioequivalence,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1543,0107-0117,107.117,Ended,57,0107-P01,Tolerability,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1544,0107-0118,107.118,Ended,57,0107-P01,skin tolerance of UH-AC 62XX CreSa,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1545,0107-0119,107.119,Ended,57,0107-P01,Tolerability,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1546,0107-0120,107.120,Ended,57,0107-P01,Expl. study,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1547,0107-0121,107.121,Ended,57,0107-P01,Efficacy and tolerability of UH-AC 62 xx,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1548,0107-0122,107.122,Ended,57,0107-P01,Efficacy and tolerability,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1549,0107-0123,107.123,Ended,57,0107-P01,Efficacy in ECCS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1550,0107-0124,107.124,Ended,57,0107-P01,single administration,Ended,MIG,Migration,I,Phase I,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
1551,0107-0125,107.125,Ended,57,0107-P01,SINGLE ADMINISTRATION TRIAL,Ended,MIG,Migration,I,Phase I,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
1552,0107-0126,107.126,Ended,57,0107-P01,ADDITIONAL MULTIPLEADMINISTRATION TRIAL,Ended,MIG,Migration,I,Phase I,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
1553,0107-0127,107.127,Ended,57,0107-P01,MULTIPLE ADMINISTRATION TRIAL,Ended,MIG,Migration,I,Phase I,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
1554,0107-0128,107.128,Ended,57,0107-P01,EARLY PHASE II TRIAL (RA),Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
1555,0107-0130,107.130,Ended,57,0107-P01,LATE PHASE II TRIAL(RA),Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
1556,0107-0133,107.133,Ended,57,0107-P01,LONG-TERM,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
1557,0107-0134,107.134,Ended,57,0107-P01,PHASE III DBT (RA),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1558,0107-0136,107.136,Ended,57,0107-P01,LATE PHASE II TRIAL(RA),Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
1559,0107-0137,107.137,Ended,57,0107-P01,Efficacy in daily dose of 1mg and 10mg,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
1560,0107-0138,107.138,Ended,57,0107-P01,EFFICACY/SAFETY USING THERMOGRAPHIC ASS',Ended,MIG,Migration,II,Phase II,- Interim report sent,,,000910,IS - Clin Study (MIGRATED)
1561,0107-0139,107.139,Analysis,57,0107-P01,Follow-up of the dose-response trial,Analysis,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1562,0107-0140,107.140,Ended,57,0107-P01,Meloxicam - Postmarketing Study,Ended,MIG,Migration,IV,Phase IV,107.140 covers 107.175 + 107.176 ,,,000940,Post Marketing Study (MIGRATED)
1563,0107-0141,107.141,Ended,57,0107-P01,Interaction betw. Meloxicam and Warfarin,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1564,0107-0143,107.143,Unconfirmed,57,0107-P01,Prostaglandins in various tissues,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1565,0107-0144,107.144,Ended,57,0107-P01,Meloxicam / Lithium Interaction,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1566,0107-0150,107.150,Ended,57,0107-P01,Prostanoid-Synthesis in healthy volunt.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1567,0107-0151,107.151,Ended,57,0107-P01,influence of fast,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1568,0107-0152,107.152,Ended,57,0107-P01,Bioequivalence of 5mgx2 vs 10mgx1,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1569,0107-0164,107.164,Ended,57,0107-P01,Economic and med. evaluation,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
1570,0107-0167,107.167,Ended,57,0107-P01,Mel./Warfarin-Piroxicam interaction,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1571,0107-0168,107.168,Ended,57,0107-P01,Dose-finding in ECCS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1572,0107-0170,107.170,Ended,57,0107-P01,Effects of Meloxicam on Cyclo-oxygenase,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1573,0107-0173,107.173,Ended,57,0107-P01,Interaction: Meloxicam and Acenocoumarol,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1574,0107-0175,107.175,Preparing,57,0107-P01,PMS-Study Mobec,Preparing,MIG,Migration,IV,Phase IV,see 107.140 ,,,000980,Not Classified (MIGRATED)
1575,0107-0176,107.176,Preparing,57,0107-P01,PMS-Study NSAIDS,Preparing,MIG,Migration,IV,Phase IV,see 107.140 ,,,000980,Not Classified (MIGRATED)
1576,0107-0178,107.178,Ended,57,0107-P01,40 g fat food interaction,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1577,0107-0180,107.180,Preparing,57,0107-P01,Bioequivalence US Tablet vs. Capsule,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1578,0107-0183,107.183,Ended,57,0107-P01,Dose Ranging,Ended,MIG,Migration,III,Phase III,-  Full CRO (Pharmaco) - to include IND, clinical studies, NDA. Second investigator meeting will be the weekend of 10/24/97. Last patient complete date under review.     ,,,000910,IS - Clin Study (MIGRATED)
1579,0107-0184,107.184,Preparing,57,0107-P01,Efficacy Meloxicam in RA vs NSAID,Preparing,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1580,0107-0185,107.185,Preparing,57,0107-P01,Meloxicam comparison versus NSAID,Preparing,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1581,0107-0188,107.188,Ended,57,0107-P01,7.5 mg Meloxicam versus other NSAID,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
1582,0107-0194,107.194,Ended,57,0107-P01,Efficacy and safety among Filipino Pat.,Ended,MIG,Migration,NONE,Not Classified,- ,,,000940,Post Marketing Study (MIGRATED)
1583,0107-0195,107.195,Ended,57,0107-P01,Observational Cohort Evaluation,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1584,0107-0206,107.206,Unconfirmed,57,0107-P01,Prostanoid-Synthesis in volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1585,0107-0211,107.211,Unconfirmed,57,0107-P01,Marketing study - RA,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,-  These dates are 'place holders' pending further discussion with con sultants.     ,,,000910,IS - Clin Study (MIGRATED)
1586,0107-0212,107.212,Ended,57,0107-P01,Efficacy and Safety, RA,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
1587,0107-0226,107.226,Ended,57,0107-P01,BE 15 mg tbl. (US) vs. 2x7.5 mg (US),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1588,0107-0227,107.227,Preparing,57,0107-P01,Meloxicam BE instamelt vs current tab,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1589,0107-0230,107.230,Preparing,57,0107-P01,Bioequivalence meloxicam Zydis/cur tab,Preparing,MIG,Migration,I,Phase I,3x cross-over ,,,000910,IS - Clin Study (MIGRATED)
1590,0107-0231,107.231,Unconfirmed,57,0107-P01,meloxicam on fever induced by LPS,Unconfirmed,MIG,Migration,IIA,Phase IIa,cancelled pending IMC review and approv ,,,000910,IS - Clin Study (MIGRATED)
1591,0107-0232,107.232,Preparing,57,0107-P01,BE 22.5vs 7.5 mg meloxicam,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1592,0107-0234,107.234,Ended,57,0107-P01,BE Chinese tablet versus BI KG tablet,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1593,0107-0236,107.236,Ended,57,0107-P01,Evaluation of meloxicam on bleeding time,Ended,MIG,Migration,IV,Phase IV,accelerated timelines due launch timing ,,,000910,IS - Clin Study (MIGRATED)
1594,0107-0238,107.238,Preparing,57,0107-P01,BE sd. 15 Zydis vs. 15 cur tab/food int.,Preparing,MIG,Migration,I,Phase I,3 way cross-over ,,,000910,IS - Clin Study (MIGRATED)
1595,0107-0239,107.239,Preparing,57,0107-P01,dose proportiona. Zydis 7.5 vs. Zydis 15,Preparing,MIG,Migration,I,Phase I,3 way cross-over ,,,000910,IS - Clin Study (MIGRATED)
1596,0107-0240,107.240,Preparing,57,0107-P01,BE multiple dose 15mg Zydis / cur tablet,Preparing,MIG,Migration,I,Phase I,2 way cross-over ,,,000910,IS - Clin Study (MIGRATED)
1597,0107-0241,107.241,Unconfirmed,57,0107-P01,Bioavail. 7.5mg suppo vs. 7.5mg tablet,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1598,0107-0245,107.245,Ended,57,0107-P01,PMS meloxicam 15 mg tablet,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1599,0107-0246,107.246,Ended,57,0107-P01,Cohort Study of Mobic Capsule,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
1600,0107-0248,107.248,Preparing,57,0107-P01,BE sd Japan tablet versus Japan capsule,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1601,0107-0249,107.249,Ended,57,0107-P01,Clinical therapeutic evaluation of melox,Ended,MIG,Migration,NONE,Not Classified,national CTE in Mexico ,,,000940,Post Marketing Study (MIGRATED)
1602,0107-0251,107.251,Ended,57,0107-P01,Preliminary BE trial of UHAC62,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1603,0107-0252,107.252,Ended,57,0107-P01,BE trial of UHAC62 TAB.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1604,0107-0253,107.253,Ended,57,0107-P01,efficacy in acute muscle damage,Ended,MIG,Migration,IV,Phase IV,investigator initiated study ,,,,
1605,0107-0255,107.255,Ended,57,0107-P01,PD interaction meloxicam / aspirin,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1606,0107-0258,107.258,Ended,57,0107-P01,RA, 7.5mg, 15 mg, 22.5 mg vs placebo,Ended,MIG,Migration,III,Phase III,Phase IIIb/Phase IV ,,,000910,IS - Clin Study (MIGRATED)
1607,0107-0259,107.259,Ended,57,0107-P01,Multiple dose BE tablet versus capsule,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1608,0107-0260,107.260,Ended,57,0107-P01,BE trial of UHAC tablet(TF4),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1609,0107-0262,107.262,Unconfirmed,57,0107-P01,COX-2 AWB Rheuma 15 mg,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1610,0107-0264,107.264,Ended,57,0107-P01,Mobic PMS Study Mexico (CTE booklets),Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1611,0107-0272,107.272,Ended,57,0107-P01,Meloxicam response in diff.  groups,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1612,0107-0010,107.10,Ended,58,0107-P06,Spondylitis Ankylosans:,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1613,0107-0098,107.98,Ended,58,0107-P06,Efficacy and safety in AS,Ended,MIG,Migration,III,Phase III,-1 report after 6 weeks / 1 report year *Biberach trial,,,000910,IS - Clin Study (MIGRATED)
1614,0107-0237,107.237,Ended,58,0107-P06,AS  in Chinese patients,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1615,0116-0001,116.1,Ended,59,0116-P01,1. Vertr√§glichkeitspr√ºfung, Kinetik,p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1616,0116-0002,116.2,Ended,59,0116-P01,Pr√ºfg. Kinetik u. Vertr√§glichk.neue Gal.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1617,0116-0003,116.3,Ended,59,0116-P01,Vertr√§glichkeit,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1618,0116-0004,116.4,Ended,59,0116-P01,Pellets/Trinkl√∂sung, Vertr√§gl., Kinetik,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1619,0116-0005,116.5,Ended,59,0116-P01,Systolische Zeitintervalle, Freiburg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1620,0116-0006,116.6,Ended,59,0116-P01,erh√∂hte F√ºllungsdrucke, Dr. Spitzer,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1621,0116-0007,116.7,Ended,59,0116-P01,KH-Stoffwechsel, Glucosebelastung,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1622,0116-0008,116.8,Unconfirmed,59,0116-P01,Pilotstudie p.o., Dr. Alber,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1623,0116-0009,116.9,Ended,59,0116-P01,Pilotstudie p.o., Dr. Borgolte,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1624,0116-0010,116.10,Ended,59,0116-P01,Dosis-Wirkungsvergleich, Dr. Rose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1625,0116-0011,116.11,Unconfirmed,59,0116-P01,Mehrfachapplikation, Dr. Thormann,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1626,0116-0012,116.12,Ended,59,0116-P01,KH-Stoffwechsel, Dr. Nebel,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1627,0116-0013,116.13,Unconfirmed,59,0116-P01,Kombination mit Impromidin, Dr.Baumann,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1628,0116-0014,116.14,Unconfirmed,59,0116-P01,Linksherzkatheter, Dr. Weikl,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1629,0116-0015,116.15,Ended,59,0116-P01,i.v. Vertr√§glichkeit, Kinetik, Thomae,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1630,0116-0016,116.16,Ended,59,0116-P01,4 Wochen Anwendung, Prof. Hagemeijer,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1631,0116-0017,116.17,Ended,59,0116-P01,Dosis-Wirkung oral, Dr. Kayali,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1632,0116-0018,116.18,Ended,59,0116-P01,Thrombozytenaggregation, Dr. Rose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1633,0116-0019,116.19,Ended,59,0116-P01,Heart failure,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1634,0116-0020,116.20,Ended,59,0116-P01,24 Stunden H√§modynamik, Prof. Stauch,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1635,0116-0021,116.21,Ended,59,0116-P01,Dosis-Wirkungs-Relation, IPHAR-Institut,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1636,0116-0022,116.22,Ended,59,0116-P01,i.v. Einmalapplikation, Dr. Spitzer,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1637,0116-0023,116.23,Ended,59,0116-P01,Dosis-Findung, IPHAR-Institut,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1638,0116-0024,116.24,Ended,59,0116-P01,Vertr√§glichkeit, 2.5-7.5 mg, Vorversuch,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1639,0116-0025,116.25,Unconfirmed,59,0116-P01,Pilotversuch zu 116.26, Dr. Baumann,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1640,0116-0026,116.26,Ended,59,0116-P01,Langzeitbehandlung, Dr. Permanetter,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1641,0116-0027,116.27,Ended,59,0116-P01,BORN-Test, 2.5 und 5 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1642,0116-0028,116.28,Ended,59,0116-P01,Vergleich mit Captopril, Dr. Hauf,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1643,0116-0029,116.29,Ended,59,0116-P01,absolute Bioverf√ºgbarkeit, Dr. Haehl,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1644,0116-0030,116.30,Ended,59,0116-P01,2x 5 bzw. 10 mg √ºber 4 Wochen,Dr. Hirsch,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1645,0116-0031,116.31,Unconfirmed,59,0116-P01,pos.inotr. Wirkg., LH-Kath., Dr. Pouleur,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1646,0116-0032,116.32,Ended,59,0116-P01,none,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1647,0116-0033,116.33,Ended,59,0116-P01,Heart failure,Ended,MIG,Migration,II,Phase II,- old contract -> I (EWOE discussed with Dr. wald Oct 91),,,000910,IS - Clin Study (MIGRATED)
1648,0116-0034,116.34,Ended,59,0116-P01,Heart failure,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1649,0116-0036,116.36,Ended,59,0116-P01,Case control studies,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1650,0116-0037,116.37,Ended,59,0116-P01,Ergometriebelastbarkeit, Prof. Uglesic,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1651,0116-0038,116.38,Ended,59,0116-P01,p.o., Dr. Borja-Martinez,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1652,0116-0039,116.39,Unconfirmed,59,0116-P01,Heart failure chronic congestive,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1653,0116-0041,116.41,Unconfirmed,59,0116-P01,Lungenfunktion, 5 mg p.o., Dr. B√∂lcskei,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1654,0116-0042,116.42,Ended,59,0116-P01,Infusionskinetik (8 Std.), Vorversuch,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1655,0116-0043,116.43,Ended,59,0116-P01,i.v. single administration, Dr. Sauer,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1656,0116-0044,116.44,Ended,59,0116-P01,4 Wochen, kontrolliert, Prof. Hagemeijer,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1657,0116-0045,116.45,Unconfirmed,59,0116-P01,Heart failure,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1658,0116-0046,116.46,Ended,59,0116-P01,Plasmaspiegel n√ºchtern <-> postprandial,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1659,0116-0047,116.47,Ended,59,0116-P01,Vorversuch: Infusionskinetik 2.5 mg/h,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1660,0116-0048,116.48,Unconfirmed,59,0116-P01,Kontraktilit√§tspr√ºfung, Prof. Seipel,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1661,0116-0049,116.49,Ended,59,0116-P01,Hepatic Failure,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1662,0116-0050,116.50,Unconfirmed,59,0116-P01,Vergleich 5/10 mg sid i.v., Dr. G√ºlker,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1663,0116-0051,116.51,Ended,59,0116-P01,Plasmaspiegel, 5 mg i.v.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1664,0116-0052,116.52,Ended,59,0116-P01,Effects heart conduction,Ended,MIG,Migration,II,Phase II,- Follow-up for trial 116-53 *,,,000910,IS - Clin Study (MIGRATED)
1665,0116-0053,116.53,Ended,59,0116-P01,Heart failure,Ended,MIG,Migration,II,Phase II,- No report: Randomization has not been followed. Unbalance in  groups. * *,,,000910,IS - Clin Study (MIGRATED)
1666,0116-0054,116.54,Ended,59,0116-P01,Renal failure, Dr.Ehninger,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1667,0116-0055,116.55,Ended,59,0116-P01,Vergleich mit Dobutamin, Dr. Baumann,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1668,0116-0056,116.56,Ended,59,0116-P01,2x5 mg p.o. √ºber 4 Wochen, Dr. Weikl,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1669,0116-0057,116.57,Ended,59,0116-P01,Comparison 5/10 mg, i.v., Prof. Sebening,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1670,0116-0058,116.58,Ended,59,0116-P01,10 mg p.o. √ºber 2 Wochen, Prof. Bischoff,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1671,0116-0059,116.59,Ended,59,0116-P01,Heart failure,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1672,0116-0060,116.60,Unconfirmed,59,0116-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1673,0116-0061,116.61,Unconfirmed,59,0116-P01,Kombination mit Nitroglycerin, Simoons,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1674,0116-0062,116.62,Ended,59,0116-P01,Langzeitinfusion, Dr. El Allaf,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1675,0116-0063,116.63,Ended,59,0116-P01,Long term treatment, intern. multicenter,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1676,0116-0064,116.64,Ended,59,0116-P01,Hemodynamics,Ended,MIG,Migration,II,Phase II,- No report due to poor recruitment. * *,,,000910,IS - Clin Study (MIGRATED)
1677,0116-0065,116.65,Ended,59,0116-P01,Hochverst√§rktes Oberfl√§chen-EKG, Hombach,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1678,0116-0066,116.66,Unconfirmed,59,0116-P01,Vergleich gegen Enalapril, Dr. Steinmann,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1679,0116-0067,116.67,Ended,59,0116-P01,Skelettmuskelstoffwechsel, Dr. Peters,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1680,0116-0068,116.68,Ended,59,0116-P01,Wirkungsdauer i.v., Dr. Peters,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1681,0116-0069,116.69,Ended,59,0116-P01,Rechtsherzkatheter i.v., Dr. Baumann,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1682,0116-0070,116.70,Ended,59,0116-P01,Bioverf√ºgbark. v. 5 mg p.o. "alt/neu",Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1683,0116-0071,116.71,Ended,59,0116-P01,Bioverf√ºgbarkeit 2.5 mg Enalapril TA/KAH,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1684,0116-0072,116.72,Ended,59,0116-P01,Long term efficacy, multicentre GDR,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1685,0116-0073,116.73,Unconfirmed,59,0116-P01,Bioverf√ºgbark. 2.5 mg i.v. "PVP/Mannit",Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1686,0116-0074,116.74,Ended,59,0116-P01,i.v. -> p.o., Dr. Mendiola-Garcia,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1687,0116-0075,116.75,Ended,59,0116-P01,6 months p.o., Dr. Borja-Martinez,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1688,0116-0076,116.76,Ended,59,0116-P01,Myocardial energetics, Prof. Just,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1689,0116-0077,116.77,Unconfirmed,59,0116-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1690,0116-0079,116.79,Ended,59,0116-P01,Platelet behavior, Prof. Mitchell,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1691,0116-0080,116.80,Unconfirmed,59,0116-P01,Rechtsherzkatheter i.v., Dr. Baumann,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1692,0116-0081,116.81,Ended,59,0116-P01,4 Wochen p.o., Dr. Keck,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1693,0116-0082,116.82,Unconfirmed,59,0116-P01,Elektromechan. Entkoppelung, Dr. Baumann,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1694,0116-0083,116.83,Unconfirmed,59,0116-P01,Terminale Herzinsuff., Prof. Hagemeijer,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1695,0116-0084,116.84,Ended,59,0116-P01,Pharmacokinetics,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1696,0116-0085,116.85,Ended,59,0116-P01,Cardiac Failure,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1697,0116-0086,116.86,Ended,59,0116-P01,Rechtsherzkatheter i.v., Prof. Hoffman,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1698,0116-0087,116.87,Ended,59,0116-P01,Right heart catheter i.v., Prof. Effert,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1699,0116-0088,116.88,Unconfirmed,59,0116-P01,Pharmacokinetics, Prof. Akio Shigematsu,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1700,0116-0089,116.89,Ended,59,0116-P01,Dose response,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1701,0116-0090,116.90,Ended,59,0116-P01,Withdrawal of Dobutamine,Ended,MIG,Migration,II,Phase II,- old contract -> I (EWOE see CTU III/91 letter),,,000910,IS - Clin Study (MIGRATED)
1702,0116-0091,116.91,Ended,59,0116-P01,2.5 mg p.o., Prof. Granic,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1703,0116-0092,116.92,Ended,59,0116-P01,Heart failure,Ended,MIG,Migration,I,Phase I,- OPU changed from TH to AU. Monitored in AU. TH just did      kinetic report.,,,000910,IS - Clin Study (MIGRATED)
1704,0116-0093,116.93,Ended,59,0116-P01,Elektrophysiologie, Multicenter F,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1705,0116-0094,116.94,Ended,59,0116-P01,ASSESSM'T OF RENAL & PLATELET FUNCTION I,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1706,0116-0095,116.95,Unconfirmed,59,0116-P01,Longterm treatment, Dr. Pehrsson,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1707,0116-0098,116.98,Ended,59,0116-P01,Pharmacokinetics of 2.5mg tablet/capsule,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1708,0116-0099,116.99,Unconfirmed,59,0116-P01,Multiple oral admin., Prof. Shishido,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1709,0116-0100,116.100,Unconfirmed,59,0116-P01,Koronare Herzkrankheit, Prof. Schlepper,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1710,0116-0101,116.101,Unconfirmed,59,0116-P01,Metabolism, Pharmacokin. of 14C-labelled,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1711,0116-0102,116.102,Ended,59,0116-P01,Efficacy in CHF,add.to ACE-inhib.(PICO),Ended,MIG,Migration,III,Phase III,CRO= SOCAR ,,,000910,IS - Clin Study (MIGRATED)
1712,0116-0103,116.103,Ended,59,0116-P01,Kinetics, interaction with digoxin,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1713,0116-0104,116.104,Ended,59,0116-P01,Kinetics, patients with liver insuffic.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1714,0116-0105,116.105,Ended,59,0116-P01,Kinetics,interaction with furosemid,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1715,0116-0106,116.106,Ended,59,0116-P01,Kinetics,interaction with enalapril,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1716,0116-0107,116.107,Ended,59,0116-P01,Kinetics,interaction with warfarin,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1717,0116-0108,116.108,Ended,59,0116-P01,Kinetics, dose proportionality,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1718,0116-0109,116.109,Ended,59,0116-P01,Mortality trial,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1719,0116-0110,116.110,Ended,59,0116-P01,Follow-up of the PICO trial,Ended,MIG,Migration,III,Phase III,CRO SOCAR ,,,000910,IS - Clin Study (MIGRATED)
1720,0116-0111,116.111,Ended,59,0116-P01,Compassionate use (after PICO),Ended,MIG,Migration,III,Phase III,,,,000500,Compassionate Use Program (CUP)
1721,0116-0120,116.120,Ended,59,0116-P01,Heart failure chronic,Ended,MIG,Migration,II,Phase II,- Status E agreed by Dr. Hertkorn, 10.06.1997.,,,000910,IS - Clin Study (MIGRATED)
1722,0116-0122,116.122,Ended,59,0116-P01,PHASE I STUDY (SINGLE ADMIN.),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1723,0116-0123,116.123,Ended,59,0116-P01,Pharmacokinetics,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1724,0116-0124,116.124,Ended,59,0116-P01,PHASE I STUDY (MULTIPLE ADMIN.),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1725,0116-0125,116.125,Ended,59,0116-P01,EARLY PHASE II STUDY,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1726,0116-0128,116.128,Ended,59,0116-P01,CLINICAL PHARMACOLOGICAL TRIAL,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1727,0116-0129,116.129,Ended,59,0116-P01,PHASE I STUDY(SINGLE ADMIN.),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1728,0116-0130,116.130,Ended,59,0116-P01,DTS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1729,0116-0138,116.138,Ended,59,0116-P01,LONG TERM OT,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1730,0116-0141,116.141,Ended,59,0116-P01,CLINICAL PHARMACOLOGICAL TRIAL,Ended,MIG,Migration,II,Phase II,- Only single administration study was done.,,,000910,IS - Clin Study (MIGRATED)
1731,0116-0142,116.142,Ended,59,0116-P01,LONG TERM DBT,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1732,0116-0143,116.143,Ended,59,0116-P01,CLIN. EVAL. OF PIMOBENDAN ON CHF BY DBT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1733,0116-0146,116.146,Ended,59,0116-P01,AT. DBT,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1734,0116-0147,116.147,Ended,59,0116-P01,Long term safety,Ended,MIG,Migration,III,Phase III,-  IND to be inactivated. Drafting letter to investigators. The last center, Dr. Lindenfeld, was closed out 12/20/96.     ,,,000910,IS - Clin Study (MIGRATED)
1735,0116-0148,116.148,Ended,59,0116-P01,Sustained efficacy,Ended,MIG,Migration,III,Phase III,-  Pivotal trial.     ,,,000910,IS - Clin Study (MIGRATED)
1736,0116-0151,116.151,Ended,59,0116-P01,PHASE I STUDY (MEAL),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1737,0116-0152,116.152,Ended,59,0116-P01,PHASE I STUDY (BIOEQUIVALENCE),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1738,0116-0166,116.166,Ended,59,0116-P01,Hemodynamics,Ended,MIG,Migration,II,Phase II,-  Final integrated report for IIa3 delayed to avoid conflict with IIIb20.     ,,,000910,IS - Clin Study (MIGRATED)
1739,0116-0167,116.167,Ended,59,0116-P01,Influence of UDCG115 on ADME of Lasix,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
1740,0116-0169,116.169,Ended,59,0116-P01,Effect of UDCG115 on morbidity in CHF,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
1741,0116-0170,116.170,Ended,59,0116-P01,Long-term efficacy of AC (cardiac functi,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
1742,0116-0172,116.172,Ended,59,0116-P01,efficacy regarding myocardial metabolism,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
1743,0116-0175,116.175,Ended,59,0116-P01,Effect of Acardi on Cardiopulmonary Exer,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
1744,0116-0176,116.176,Ended,59,0116-P01,Efficacy of Acardi on cardiac function,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
1745,0116-0177,116.177,Ended,59,0116-P01,To assess the clinical efficacy of,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
1746,0116-0178,116.178,Ended,59,0116-P01,Efficacy of Acardi on cardiac function,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
1747,1012-0003,1012.3,Ended,60,1012-P01,Pharmacokinetic Trial,Ended,MIG,Migration,I,Phase I,-  QA data review scheduled for completion by 10/11/91; database lock = 6 weeks after QA review (11/22/91).     ,,,000910,IS - Clin Study (MIGRATED)
1748,1012-0005,1012.5,Ended,60,1012-P01,Comp. w/ albuterol & Atrovent,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
1749,1012-0006,1012.6,Unconfirmed,60,1012-P01,Clinical Outcome Study,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,-  The investigators will be identified for this study in Mid- March.  Buy in from Marketing needed before protocol can be finalized.  Decision to be made probably in January, 1995 when Marketing will be able to review the preliminary results fro the ATROVENT 1095 exercise study.   ,,,000910,IS - Clin Study (MIGRATED)
1750,1012-0007,1012.7,Ended,60,1012-P01,Bioequivalence trial,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
1751,1012-0008,1012.8,Ended,60,1012-P01,Comp. w/ albuterol & Atrovent,Ended,MIG,Migration,III,Phase III,-  This multi-center trial was contracted to G. H. Besselaar Associates     ,,,000910,IS - Clin Study (MIGRATED)
1752,1012-0012,1012.12,Ended,60,1012-P01,Combivent Vs. Ventolin,Ended,MIG,Migration,IIIB,Phase IIIb,-  A few patients in some sites may complete after 4/29, however, this is not expected to affect the date of Data Lock.     ,,,000910,IS - Clin Study (MIGRATED)
1753,1012-0014,1012.14,Ended,60,1012-P01,Combivent Vs. Ventolin,Ended,MIG,Migration,IIIB,Phase IIIb,-  A few patients is some sites may complete after 4/29, however, this is not expected to affect the date of Data Lock.     ,,,000910,IS - Clin Study (MIGRATED)
1754,1012-0021,1012.21,Ended,60,1012-P01,Combivent MDI vs Sabutamol MDI in COPD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
1755,1012-0022,1012.22,Ended,60,1012-P01,Comparison with Berodual,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
1756,1012-0023,1012.23,Ended,60,1012-P01,Effect on Lung vol/hyperinflation,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1757,1012-0031,1012.31,Unconfirmed,60,1012-P01,EVANS,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
1758,1012-0032,1012.32,Ended,60,1012-P01,Asthma-Adults,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1759,1012-0033,1012.33,Ended,60,1012-P01,Acute Asthma-Mod. to Severe,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
1760,1012-0035,1012.35,Ended,60,1012-P01,BRONCHOSPASP INDUCED BY EXERCISE,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
1761,1012-0036,1012.36,Ended,60,1012-P01,Bronchospasm induced by Methacholine,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
1762,1012-0054,1012.54,Ended,60,1012-P01,EOLE,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1763,1012-0057,1012.57,Ended,60,1012-P01,Combivent CFC/Respimat Asthma,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1764,1012-0058,1012.58,Analysis,60,1012-P01,Hyperinflation with Tachypnea,Analysis,MIG,Migration,IV,Phase IV,,,,,
1765,1012-0063,1012.63,Unconfirmed,60,1012-P01,Lebanon - COPD Epidemiology Survey,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
1766,1024-0001,1024.1,Ended,61,1024-P01,Soft tissue trauma,Ended,MIG,Migration,III,Phase III,- planned patients: 250-330 * *,,,000910,IS - Clin Study (MIGRATED)
1767,1012-0010,1012.10,Unconfirmed,63,1012-P02,Dose confirmation study,Unconfirmed,MIG,Migration,II,Phase II,-  Schedule will depend on when final formulation, manufacturing proce ss and delivery system available.  An international development program is planned in which BIPI is planning to participate.  Dose selection to follow selection for ATROVENT and albuterol.   ,,,000910,IS - Clin Study (MIGRATED)
1768,1012-0011,1012.11,Ended,63,1012-P02,Safety comparison vs aerosol,Ended,MIG,Migration,III,Phase III,-CTR Delayed .  Error found in AE tables Schedule will depend on when final formulation, manufacturing process and delivery system are available.     ,,,000910,IS - Clin Study (MIGRATED)
1769,1012-0013,1012.13,Ended,63,1012-P02,COMBIVENT PED. BIOEQUIVALENCE,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1770,1012-0015,1012.15,Ended,63,1012-P02,alt.prop./eff. safety,Ended,MIG,Migration,III,Phase III,- = 1012.4,,,000910,IS - Clin Study (MIGRATED)
1771,1012-0024,1012.24,Ended,63,1012-P02,3-way crossover, one day dose,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
1772,1012-0025,1012.25,Ended,63,1012-P02,COMBIVENT HFA dose confirmation study,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
1773,1012-0026,1012.26,Preparing,63,1012-P02,9 month ext. 1012.11,Preparing,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
1774,1012-0034,1012.34,Unconfirmed,63,1012-P02,BRONCHOSPASM INDUCED BY METHACHOLINE,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
1775,1012-0037,1012.37,Unconfirmed,63,1012-P02,Cumulative dose response,Unconfirmed,MIG,Migration,II,Phase II,-  This trial has been cancelled.     ,,,000910,IS - Clin Study (MIGRATED)
1776,1012-0040,1012.40,Ended,63,1012-P02,BPCO & assorted inhaled bronchodilators,Ended,MIG,Migration,NONE,Not Classified,,,,000940,Post Marketing Study (MIGRATED)
1777,1012-0042,1012.42,Preparing,63,1012-P02,Combivent BHR study,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1778,1012-0043,1012.43,Ended,63,1012-P02,Cummulative dose-response study,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
1779,1012-0047,1012.47,Preparing,63,1012-P02,Long term safety and efficacy,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1780,1012-0049,1012.49,Preparing,63,1012-P02,Cumulative Dose Response - repeat,Preparing,MIG,Migration,II,Phase II,Repeat of the terminated study 1012.43 ,,,000910,IS - Clin Study (MIGRATED)
1781,1012-0051,1012.51,Preparing,63,1012-P02,Dose confirmation study,Preparing,MIG,Migration,II,Phase II,repeat of dose confirmation, final valve ,,,000910,IS - Clin Study (MIGRATED)
1782,1012-0059,1012.59,Preparing,63,1012-P02,Safety, Tolerability in Healthy Subjects,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1783,1012-0060,1012.60,Preparing,63,1012-P02,Dose Confirmation in COPD,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1784,1012-0061,1012.61,Preparing,63,1012-P02,Safety and Efficacy in COPD,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1785,1107-0001,1107.1,Ended,69,1107-P01,Perlutan vs Microdiol in contraception.,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
1786,1107-0002,1107.2,Ended,69,1107-P01,Safety assessment of Perlutal,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
1787,1107-0003,1107.3,Ended,69,1107-P01,DHPA + EEn/Contraception,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
1788,1107-0004,1107.4,Ended,69,1107-P01,Metabolic effect perlutal vs Minulet,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1789,1107-0005,1107.5,Ended,69,1107-P01,Dose finding Perlutal,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1790,1107-0006,1107.6,Ended,69,1107-P01,Inf. on hemost. & Lipid met.,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
1791,1107-0007,1107.7,Ended,69,1107-P01,Perlutan (150/10) vs Perlutan (90/6) in,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
1792,1107-0008,1107.8,Ended,69,1107-P01,Perlutal in adolescence,Ended,MIG,Migration,IV,Phase IV,- national according to Dr. Breviglieri (24.4.96),,,,
1793,1107-0009,1107.9,Ended,69,1107-P01,Perlutal 90/6mg in Contraception,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
1794,1107-0010,1107.10,Ended,69,1107-P01,Dose finding Perlutal,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1795,1107-0011,1107.11,Ended,69,1107-P01,Acumolation in tussu,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1796,1107-0012,1107.12,Ended,69,1107-P01,Perlutal 90/6 vs. 150/10 mg.,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
1797,0244-2486,244.2486,Unconfirmed,71,0244-P16,Efficacy study,Unconfirmed,MIG,Migration,III,Phase III,-  Approved by ISC. Dates and BIPI involvement tentative     ,,,000910,IS - Clin Study (MIGRATED)
1798,0244-1401,244.1401,Ended,72,0244-P14,Tolerability,Multiple Dose,Pharmacokin.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1799,0244-1402,244.1402,Ended,72,0244-P14,Kinetics, Single Dose, Tolerability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1800,0244-1403,244.1403,Ended,72,0244-P14,Dose confirmation study,Ended,MIG,Migration,II,Phase II,-  This is an accelerated timeline in response to BIGmbH's request to expedite this trial contingent upon the availability of invest. and  rapid enrollment.     ,,,000910,IS - Clin Study (MIGRATED)
1801,0244-1404,244.1404,Ended,72,0244-P14,Cumulative doses Iprat. alt. prop.,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1802,0244-1405,244.1405,Ended,72,0244-P14,Safety vs Std. MDI & placebo,Ended,MIG,Migration,III,Phase III,-  Schedule will depend on when Germany has final formulation, manufacturing process and delivery system available.  Delay because results of French and German studies are needed before initiating the safety studies.   ,,,000910,IS - Clin Study (MIGRATED)
1803,0244-1406,244.1406,Preparing,72,0244-P14,Safety vs Placebo HFA,Preparing,MIG,Migration,III,Phase III,-  Schedule will depend on when Germany has final formulation, manufacturing process and delivery system available.     ,,,000910,IS - Clin Study (MIGRATED)
1804,0244-1407,244.1407,Ended,72,0244-P14,ALT.PROP./EFFICACY AND SAFETY 6 MONTHS,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1805,0244-1408,244.1408,Ended,72,0244-P14,ALT.PROP./EFFICACY AND SAFETY 1 YEAR,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1806,0244-1409,244.1409,Ended,72,0244-P14,IPRA.BRO. HFA IN PAEDIATRIC BR. ASTHMA,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
1807,0244-2453,244.2453,Ended,72,0244-P14,Long term safety,Ended,MIG,Migration,III,Phase III,-  This study will be conducted by a CRO. Study will be initially supplied with existing product and resuppli ed when the final NDA batch is available.  Final protocol and stud y initiation delayed in order to include FDAs recommendations. Study closed to enrollment.   ,,,000910,IS - Clin Study (MIGRATED)
1808,0244-2469,244.2469,Ended,72,0244-P14,HFA 134a nasal mucociliary clearance,Ended,MIG,Migration,IV,Phase IV,- IPACT I,,,000910,IS - Clin Study (MIGRATED)
1809,0244-2470,244.2470,Ended,72,0244-P14,HFA 227 nasal nucociliary clearance,Ended,MIG,Migration,IV,Phase IV,- IPACT II,,,000910,IS - Clin Study (MIGRATED)
1810,0244-2480,244.2480,Ended,72,0244-P14,Kinetics in COPD,Ended,MIG,Migration,IIB,Phase IIb,This is a BIOAVAILABILITY study       ,,,000910,IS - Clin Study (MIGRATED)
1811,0244-2498,244.2498,Ended,72,0244-P14,final valve dose comparison in copd,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
1812,0244-2507,244.2507,Ended,72,0244-P14,dose counter,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1813,0244-2509,244.2509,Ended,72,0244-P14,Atrovent Inhaler CFC Free PEM study,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1814,0244-2512,244.2512,Unconfirmed,72,0244-P14,test 1 jljn,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
1815,0244-0601,244.601,Ended,73,0244-P13,Efficacy, Childre (4-12y),Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1816,0244-0690,244.690,Unconfirmed,73,0244-P13,Efficacy,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = X, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1817,0244-0870,244.870,Preparing,73,0244-P13,single-dose, equivalence,Preparing,MIG,Migration,III,Phase III,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1818,0244-1301,244.1301,Ended,73,0244-P13,DOSE CONFIRMATION STUDY,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1819,0244-1302,244.1302,Ended,73,0244-P13,Lactose Inhalets (4 week Efficacy ),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1820,0244-1303,244.1303,Ended,73,0244-P13,Cumulative doses Iprat. lactose inhalets,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1821,0244-1304,244.1304,Ended,73,0244-P13,lac.inh./Efficacy and safety, 4 weeks,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1822,0244-1305,244.1305,Ended,73,0244-P13,Lactose Inhalet (12 week Safety),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1823,0244-1306,244.1306,Ended,73,0244-P13,Lactose Inhalet (12 week safety),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1824,0244-1307,244.1307,Ended,73,0244-P13,Dose ranging,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
1825,0244-1308,244.1308,Ended,73,0244-P13,Safety comparison vs placebo,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
1826,0244-1309,244.1309,Preparing,73,0244-P13,Safety comparison vs placebo,Preparing,MIG,Migration,III,Phase III,-  Schedule will depend on when Germany has final formulation, manufacturing process and delivery system available.     ,,,000910,IS - Clin Study (MIGRATED)
1827,0244-1310,244.1310,Ended,73,0244-P13,Lactose Inhalets Flow Rate Study,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
1828,0244-1311,244.1311,Unconfirmed,73,0244-P13,pediatric study,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
1829,0244-1312,244.1312,Unconfirmed,73,0244-P13,Dose-Confirmation,Unconfirmed,MIG,Migration,III,Phase III,,,,000980,Not Classified (MIGRATED)
1830,0244-2452,244.2452,Preparing,73,0244-P13,Long term safety,Preparing,MIG,Migration,IIIB,Phase IIIb,-  This study will be conducted by BI Canada. Study initiation has been delayed due to the low respirable fraction of Atrovent Lactose Inhalants and remanufacturing of the drug supply.     ,,,000910,IS - Clin Study (MIGRATED)
1831,0244-2456,244.2456,Ended,73,0244-P13,Single dose device comparison,Ended,MIG,Migration,I,Phase I,-  If this study is needed, it will be conducted after the NDA is filed.     ,,,000910,IS - Clin Study (MIGRATED)
1832,0244-2457,244.2457,Ended,73,0244-P13,Flow rate,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
1833,0244-2463,244.2463,Ended,73,0244-P13,Back-up study Atrovent in Asthma 5xcross,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1834,0260-2401,260.2401,Ended,75,0260-P24,Dose Confirmation Fenoterol 200 Lactose,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1835,0260-2301,260.2301,Ended,76,0260-P23,lac.inh./five-period dose ranging study,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1836,0260-2302,260.2302,Ended,76,0260-P23,lac.inh./Long term safety+effic. 4 weeks,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1837,0260-2303,260.2303,Ended,76,0260-P23,Cumulative doses Fenoterol, lactose inh.,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1838,0260-2304,260.2304,Ended,76,0260-P23,lac.inh./Long term safety+effic. 4 weeks,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1839,0260-2305,260.2305,Ended,76,0260-P23,Lac. inh./longt. (12 weeks),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1840,0260-2306,260.2306,Ended,76,0260-P23,Pediatric study,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1841,0260-2307,260.2307,Unconfirmed,76,0260-P23,lac.inh./B100/ flow,child.,Unconfirmed,MIG,Migration,II,Phase II,- Confirm,,,000910,IS - Clin Study (MIGRATED)
1842,0215-0401,215.401,Preparing,77,0215-P08,Efficacy, handling,Preparing,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1843,0215-0402,215.402,Ended,77,0215-P08,Therap. comparison, handling,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1844,0215-0403,215.403,Preparing,77,0215-P08,Efficacy, Safety,Preparing,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1845,0215-0801,215.801,Ended,77,0215-P08,Dose confirmation/lactose powder capsule,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1846,0215-0802,215.802,Ended,77,0215-P08,Safety, Acceptance,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1847,0215-0803,215.803,Ended,77,0215-P08,Cumulative dose, lactose inhalets,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1848,0215-0804,215.804,Ended,77,0215-P08,Different inh. fractions equivalence,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1849,0215-0805,215.805,Ended,77,0215-P08,Lactose inhalets - safety in children,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1850,0215-0806,215.806,Ended,77,0215-P08,Cumulative dose, lactose inhalets,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1851,0215-0901,215.901,Ended,78,0215-P09,SD-Pharmakokinetics,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1852,0215-0902,215.902,Ended,78,0215-P09,Alt. prop. - 3 months safety,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1853,0215-0903,215.903,Ended,78,0215-P09,Alt. Prop. Dose Confirmation study,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1854,0215-0904,215.904,Ended,78,0215-P09,New propellants in infants,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1855,0215-0905,215.905,Ended,78,0215-P09,LUNG DEPOSITION OF HFA-134A/HFA-227/CFC,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1856,0215-0906,215.906,Ended,78,0215-P09,LUNG DEPOSITION OF BERODUAL,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1857,0215-1347,215.1347,Ended,78,0215-P09,HFA 3-months large-scale safety,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
1858,1012-0002,1012.2,Ended,79,1012-P03,Pharmacokinetics Trial,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
1859,1012-0009,1012.9,Ended,79,1012-P03,Efficacy and Safety Comparison,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
1860,1012-0029,1012.29,Preparing,79,1012-P03,Registration Support / Marketing,Preparing,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1861,1012-0041,1012.41,Ended,79,1012-P03,Efficacy & safety, Attack of asthma,Ended,MIG,Migration,IIIB,Phase IIIb,BI China ,,,000910,IS - Clin Study (MIGRATED)
1862,1012-0045,1012.45,Ended,79,1012-P03,Combiv.vs.salbutamol UDV Asthma children,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
1863,0212-0309,212.309,Unconfirmed,80,0212-P08,Efficacy,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1864,0212-0802,212.802,Preparing,80,0212-P08,alt.prop./HPA axis,Preparing,MIG,Migration,II,Phase II,- *Ingelheim trial,,,000910,IS - Clin Study (MIGRATED)
1865,0212-0811,212.811,Preparing,80,0212-P08,Efficacy and Safety,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
1866,0212-9999,212.9999,Preparing,80,0212-P08,alt.prop./Safety, Effic.,Preparing,MIG,Migration,III,Phase III,high study number for historical reasons *Ingelheim trial,,,000910,IS - Clin Study (MIGRATED)
1867,0208-0101,208.101,Ended,81,0208-P01,Dose tolerance i.v., single dose,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1868,0208-0102,208.102,Ended,81,0208-P01,Dose tolerance p.o., single dose,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1869,0208-0103,208.103,Ended,81,0208-P01,Dose tolerance, multiple dose, po,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1870,0208-0104,208.104,Ended,81,0208-P01,Kinetics, bioavailability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1871,0208-0105,208.105,Ended,81,0208-P01,Dose tolerance, multiple dose, po,Ended,MIG,Migration,I,Phase I,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1872,0208-0107,208.107,Ended,81,0208-P01,Rel. Bioavailability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1873,0208-0109,208.109,Ended,81,0208-P01,14C study Kinetics Metabolism,Ended,MIG,Migration,I,Phase I,- inserted by claus 16.07.93,,,000910,IS - Clin Study (MIGRATED)
1874,0208-0201,208.201,Ended,81,0208-P01,Safety & efficacy,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1875,0208-0202,208.202,Unconfirmed,81,0208-P01,EFFICACY & SAFETY, DOSE RANGING AGAINST,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1876,0208-0203,208.203,Unconfirmed,81,0208-P01,EFFICACY & SAFETY,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1877,0208-0501,208.501,Ended,81,0208-P01,EFFICACY AS ANTIEMETIC,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1878,0208-0502,208.502,Ended,81,0208-P01,IV DAU 6215 in acute cisplatin induced,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1879,0208-0503,208.503,Unconfirmed,81,0208-P01,EFFICACY & SAFETY,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1880,0208-0504,208.504,Unconfirmed,81,0208-P01,EFFICACY & SAFETY,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1881,0208-0600,208.600,Ended,81,0208-P01,SINGLE ADMINISTRATION,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1882,0208-0601,208.601,Ended,81,0208-P01,SINGLE ADMINISTRATION,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1883,0208-0602,208.602,Ended,81,0208-P01,MULTIPLE ADMINISTRATION,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1884,0208-0603,208.603,Ended,81,0208-P01,ARIYOSHI, DTS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1885,0208-0604,208.604,Ended,81,0208-P01,ARIYOSHI, DTS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1886,0208-0605,208.605,Ended,81,0208-P01,Preventive administ-ration,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1887,0208-0607,208.607,Unconfirmed,81,0208-P01,EFFICACY & SAFETY,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1888,0208-0608,208.608,Ended,81,0208-P01,Itaset. (iv) in cisplatin chemo. (US),Ended,MIG,Migration,III,Phase III,conducted, analyzed and reported by CRO ,,,000910,IS - Clin Study (MIGRATED)
1889,0208-0609,208.609,Ended,81,0208-P01,Itaset. (po) in moder. emet. chemo. (US),Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1890,0208-0610,208.610,Ended,81,0208-P01,PK study cancer patients,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1891,0208-0611,208.611,Ended,81,0208-P01,PK in renal impaired patients,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1892,0208-0612,208.612,Ended,81,0208-P01,Itaset.(iv)+Dexa. in cisplatin chemo(EU),Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1893,0208-0613,208.613,Ended,81,0208-P01,Itaset. (po) in moder. emet. chemo. (EU),Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1894,0208-0614,208.614,Ended,81,0208-P01,Itaset. (po) cisplatin chemo. (US),Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1895,0208-0615,208.615,Ended,81,0208-P01,Itaset. (po) repeated courses (EU),Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1896,0208-0616,208.616,Ended,81,0208-P01,2.5mg DAU 6215 CL,i.v. inj vs short inj,Ended,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
1897,0208-0617,208.617,Unconfirmed,81,0208-P01,Bioequiv. 2.5 mg filmtabl. versus final,Unconfirmed,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
1898,0208-0618,208.618,Ended,81,0208-P01,Abs. bioavailability 2.5 mg filmtabl.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1899,0208-0619,208.619,Ended,81,0208-P01,ARIYOSI DBT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1900,0208-0620,208.620,Ended,81,0208-P01,NAGAO-OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1901,0208-0621,208.621,Ended,81,0208-P01,TANAKA-OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1902,0208-0622,208.622,Ended,81,0208-P01,OHNO-OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1903,0208-0623,208.623,Ended,81,0208-P01,KUDO-OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1904,0208-0624,208.624,Ended,81,0208-P01,Bioequivalency test 8mg cap vs 16mg cap.,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1905,0208-0625,208.625,Ended,81,0208-P01,Abs. bioavailab. 1 mg filmtablet,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1906,0208-0626,208.626,Ended,81,0208-P01,OL pediatric tial - oral,Ended,MIG,Migration,III,Phase III,-  Approved by IMC 4/97. Parexel to handle monitoring, data management, data entry etc. as in previous itasetron trials.     ,,,000910,IS - Clin Study (MIGRATED)
1907,0208-0627,208.627,Ended,81,0208-P01,OL pediatric tial - IV,Ended,MIG,Migration,III,Phase III,-  Approved by IMC 4/97. Parexel to handle monitoring, data management, data entry etc. as in previous itasetron trials.     ,,,000910,IS - Clin Study (MIGRATED)
1908,0208-0628,208.628,Ended,81,0208-P01,Bioequiv. 1mg FCT final formulat.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1909,0208-0629,208.629,Ended,81,0208-P01,Food Interaction,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1910,0208-0630,208.630,Unconfirmed,81,0208-P01,Ondansetron 4/8 mg Bioequivalenz,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1911,0208-0631,208.631,Unconfirmed,81,0208-P01,2.5 mg - FCT vs short infusion,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1912,0208-0632,208.632,Unconfirmed,81,0208-P01,2,5 mg - bolus vs short infusion,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1913,1097-0001,1097.1,Ended,82,1097-P01,none,Ended,MIG,Migration,I,Phase I,- Report finished, re-signment UK (Letter Griffith 01.10.92),,,000910,IS - Clin Study (MIGRATED)
1914,1097-0002,1097.2,Ended,82,1097-P01,BIOAVAILABILITY,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1915,1097-0003,1097.3,Ended,82,1097-P01,PAIN,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1916,1097-0005,1097.5,Ended,82,1097-P01,COMPARATIVE BIOAVAILABILITY STUDY,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1917,1097-0007,1097.7,Unconfirmed,82,1097-P01,S.C., I.M. Bioavailability,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
1918,1097-0008,1097.8,Unconfirmed,82,1097-P01,Bioavailability,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1919,1097-0009,1097.9,Ended,82,1097-P01,Flavour palatability study - TASTE,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
1920,0205-0101,205.101,Ended,83,0205-P01,SD-tolerance,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1921,0205-0102,205.102,Ended,83,0205-P01,SD-tolerance,Ended,MIG,Migration,I,Phase I,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1922,0205-0103,205.103,Ended,83,0205-P01,Dose Tolerance, Multiple Dose,Ended,MIG,Migration,I,Phase I,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1923,0205-0104,205.104,Ended,83,0205-P01,Dose Tolerance, Multiple Dose,Ended,MIG,Migration,I,Phase I,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
1924,0205-0105,205.105,Ended,83,0205-P01,Abs. Bioavailability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1925,0205-0106,205.106,Ended,83,0205-P01,Single dose p.o. tolerability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1926,0205-0107,205.107,Ended,83,0205-P01,Increasing dose tolerance of BA 679 BR,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1927,0205-0108,205.108,Ended,83,0205-P01,Chronic dosing,Ended,MIG,Migration,IIB,Phase IIb,-  Although the date for database lock will remain as 12/15/95 every effort is being made to lock on 11/21/95 to have results available for Dr. Barner's visit on 11/30/95     ,,,000910,IS - Clin Study (MIGRATED)
1928,0205-0113,205.113,Ended,83,0205-P01,COMPARISON BINEB WITH LACT.INHALETS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1929,0205-0114,205.114,Ended,83,0205-P01,3 month safety and efficacy,Ended,MIG,Migration,III,Phase III,-  the dates for this trial have been adjusted to reflect the delay in  drug supply     ,,,000910,IS - Clin Study (MIGRATED)
1930,0205-0115,205.115,Ended,83,0205-P01,3 month study replicate,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
1931,0205-0116,205.116,Ended,83,0205-P01,Safety mucociliary clearance,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
1932,0205-0117,205.117,Ended,83,0205-P01,Nine month safety extension,Ended,MIG,Migration,III,Phase III,-  trial is noted to be initiated 3 months after 205.114 however drug supplies and crfs will included in supplies for 13-week trials.   Patients will not enter extension until they have completed the short term trial Drug supplies have been included in CSRs for 205.114   ,,,000910,IS - Clin Study (MIGRATED)
1933,0205-0118,205.118,Ended,83,0205-P01,Quality of live.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1934,0205-0119,205.119,Ended,83,0205-P01,Pilot dose-escalation study in COPD pati,Ended,MIG,Migration,II,Phase II,- Report exp. end '92,,,000910,IS - Clin Study (MIGRATED)
1935,0205-0120,205.120,Ended,83,0205-P01,Dose and Time Response (placebo control),Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
1936,0205-0122,205.122,Ended,83,0205-P01,Comparative Efficacy/Safety Vs. Atrovent,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1937,0205-0123,205.123,Ended,83,0205-P01,Effect of AM/PM dosing,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1938,0205-0124,205.124,Ended,83,0205-P01,Quality of sleep in COPD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1939,0205-0125,205.125,Unconfirmed,83,0205-P01,Efficacy and safety in sleep,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1940,0205-0126,205.126,Ended,83,0205-P01,One year efficacy/safety in COPD,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
1941,0205-0128,205.128,Ended,83,0205-P01,Nine month safety ext. #2,Ended,MIG,Migration,III,Phase III,-  Trial is noted to be initiated 3 months after 205.115 however drug supplies and crfs will included in supplies for 13-week trials.   Patients will not enter extension until they have completed the short term trial Drug supplies have been included in CSR for 205.115 Final protocol date is an estimate, please confirm date - Pam.   ,,,000910,IS - Clin Study (MIGRATED)
1942,0205-0129,205.129,Ended,83,0205-P01,Onset of steady state in COPD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1943,0205-0130,205.130,Ended,83,0205-P01,Tiotropium compared with Salmeterol I,Ended,MIG,Migration,III,Phase III,- First comparison study of Tiotropium with Salmeterol 12h PFT(Second study = 205.137),,,000910,IS - Clin Study (MIGRATED)
1944,0205-0131,205.131,Ended,83,0205-P01,Tiotropium exercise tolerance,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
1945,0205-0132,205.132,Ended,83,0205-P01,Handihaler flow rate,Ended,MIG,Migration,I,Phase I,-  Being conducted by Dr. Chodosh. Placebo only, no active drug. The study is to determine if COPD patients with a wide range of disease severity can generate the minimal required inspiratory flow rate through the Handihaler necessary to vibrate the capsule and evacuate the powder from the capsules.   ,,,000910,IS - Clin Study (MIGRATED)
1946,0205-0133,205.133,Ended,83,0205-P01,Pharmacokinetics/Tiotropium/Elderly Pts,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
1947,0205-0135,205.135,Unconfirmed,83,0205-P01,Single-dose tolerance,Unconfirmed,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
1948,0205-0136,205.136,Unconfirmed,83,0205-P01,Multi-dose tolerance,Unconfirmed,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
1949,0205-0137,205.137,Ended,83,0205-P01,Tiotropium compared with Salmeterol II,Ended,MIG,Migration,IIIA,Phase IIIa,- Second comparison study of Tiotropium with Salmeterol 3h PFT (First study = 205.130),,,000910,IS - Clin Study (MIGRATED)
1950,0205-0139,205.139,Ended,83,0205-P01,Dose finding study of BA 679 BR,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
1951,0205-0140,205.140,Unconfirmed,83,0205-P01,cLINICAL CONFIRMATION,Unconfirmed,MIG,Migration,NONE,Not Classified,        ,,,000910,IS - Clin Study (MIGRATED)
1952,0205-0211,205.211,Unconfirmed,83,0205-P01,Hyperinflation in COPD Patients,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1953,0205-0214,205.214,Ended,83,0205-P01,MISTRAL,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1954,0205-0215,205.215,Ended,83,0205-P01,Tiotropium-Static lung volumes,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1955,0205-0216,205.216,Unconfirmed,83,0205-P01,Multi dose DPI placeholder,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
1956,0205-0217,205.217,Unconfirmed,83,0205-P01,Belgium national (number 1),Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1957,0205-0218,205.218,Ended,83,0205-P01,US National (Inspiratory Capacity),Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1958,0205-0219,205.219,Unconfirmed,83,0205-P01,US National (elastic recoil),Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1959,0205-0220,205.220,Ended,83,0205-P01,Denmark  (learning and retention),Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1960,0205-0221,205.221,Unconfirmed,83,0205-P01,US National (compliance or 6 min walk),Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1961,0205-0222,205.222,Ended,83,0205-P01,Renal Excretion Interaction,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1962,0205-0223,205.223,Ended,83,0205-P01,Exercise Tolerance Study,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1963,0205-0224,205.224,Unconfirmed,83,0205-P01,Sleep Study,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1964,0205-0226,205.226,Ended,83,0205-P01,Tiotropium versus Oxitropium,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1965,0205-0227,205.227,Ended,83,0205-P01,Long Term Trial,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1966,0205-0228,205.228,Preparing,83,0205-P01,Dyspnea I,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1967,0205-0229,205.229,Preparing,83,0205-P01,Dyspnea II,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1968,0205-0230,205.230,Ended,83,0205-P01,Tiotropium rehabilitation study,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1969,0205-0231,205.231,Ended,83,0205-P01,Mechanisms of Exertional Dyspnea,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1970,0205-0232,205.232,Ended,83,0205-P01,Taiwan Efficacy Confirmation,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1971,0205-0233,205.233,Unconfirmed,83,0205-P01,Comparison with Theophylline,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1972,0205-0234,205.234,Ended,83,0205-P01,ABG,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1973,0205-0235,205.235,Ended,83,0205-P01,UPLIFT,Ended,MIG,Migration,IIIB,Phase IIIb,Monitoring Q3mo. for 1st year then Q6 mo changed to covered study,,,000910,IS - Clin Study (MIGRATED)
1974,0205-0236,205.236,Unconfirmed,83,0205-P01,Large Scale II,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1975,0205-0237,205.237,Unconfirmed,83,0205-P01,High Resource Utilizers,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1976,0205-0238,205.238,Ended,83,0205-P01,Deposition Study in COPD Patients,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1977,0205-0239,205.239,Ended,83,0205-P01,Human Pharmacology Study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
1978,0205-0240,205.240,Preparing,83,0205-P01,Formoterol Trial,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1979,0205-0241,205.241,Preparing,83,0205-P01,UK GP Trial,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1980,0205-0242,205.242,Preparing,83,0205-P01,Patient Compliance: Tio vs. Formoterol,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1981,0205-0243,205.243,Ended,83,0205-P01,Efficacy confirmation - Philippines,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1982,0205-0244,205.244,Ended,83,0205-P01,Efficacy confirmation  Korea,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1983,0205-0245,205.245,Ended,83,0205-P01,Efficacy confirmation  China,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1984,0205-0246,205.246,Unconfirmed,83,0205-P01,Canadian Usual Care Trial,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
1985,0205-0247,205.247,Ended,83,0205-P01,Effect of tio in pul rehab patients,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1986,0205-0256,205.256,Ended,83,0205-P01,TIPHON - french national,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1987,0205-0257,205.257,Ended,83,0205-P01,Large Scale Study III in pneum. practice,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1988,0205-0258,205.258,Ended,83,0205-P01,Effect of ipr BR and fenoterol on SS tio,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1989,0205-0259,205.259,Ended,83,0205-P01,Spiriva Assessment of FEV1 (SAFE),Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1990,0205-0261,205.261,Ended,83,0205-P01,Effect on muscular efficiency,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1991,0205-0262,205.262,Preparing,83,0205-P01,endurance capacity/work of breathing,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1992,0205-0263,205.263,Preparing,83,0205-P01,Tiotropium vs Atrovent - TACTIC study,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1993,0205-0264,205.264,Ended,83,0205-P01,Salmeterol comparison study,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1994,0205-0265,205.265,Preparing,83,0205-P01,Atrovent comparison in managed care,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1995,0205-0266,205.266,Ended,83,0205-P01,Exacerbation of COPD in the VA setting,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1996,0205-0267,205.267,Preparing,83,0205-P01,Long term care study,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
1997,0205-0268,205.268,Unconfirmed,83,0205-P01,Primary care study,Unconfirmed,MIG,Migration,IV,Phase IV, Values from CTMS: Planned Subjects Screened: 100000, Planned Subjects Randomized: 100000, Planned Subjects Completed Treatment: ,,,000910,IS - Clin Study (MIGRATED)
1998,0205-0269,205.269,Ended,83,0205-P01,Accelerometer study,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
1999,0205-0270,205.270,Ended,83,0205-P01,Tiotropium Sputum Study,Ended,MIG,Migration,IIIB,Phase IIIb,explorative study journal requirement to include in registry - retrospective project team decision,,,000910,IS - Clin Study (MIGRATED)
2000,0205-0271,205.271,Unconfirmed,83,0205-P01,Tiotropium switch trial (LABA/ICS),Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2001,0205-0272,205.272,Unconfirmed,83,0205-P01,MDPI Phase I,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2002,0205-0273,205.273,Ended,83,0205-P01,Tiotropium vs. Salmeterol/Fluticasone,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2003,0205-0274,205.274,Preparing,83,0205-P01,Eight-week efficacy trial of tio,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2004,0205-0275,205.275,Unconfirmed,83,0205-P01,AM/PM study in Netherlands,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2005,0205-0276,205.276,Ended,83,0205-P01,UK Primary Care Efficacy Study,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2006,0205-0277,205.277,Ended,83,0205-P01,Spiriva Inh., 4 weeks, Safety and Effic.,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2007,0205-0278,205.278,Ended,83,0205-P01,Spiriva Inh., 4 weeks, Safety and Effic.,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2008,0205-0279,205.279,Ended,83,0205-P01,Atrovent comparrison study in Taiwan,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2009,0205-0280,205.280,Ended,83,0205-P01,Post marketing in the Philippines,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2010,0205-0281,205.281,Ended,83,0205-P01,Swedish study of untreated COPD patients,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2011,0205-0282,205.282,Ended,83,0205-P01,Effect of tio on the change in FEV1,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2012,0205-0283,205.283,Unconfirmed,83,0205-P01,Portugese smoking status trial,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2013,0205-0284,205.284,Ended,83,0205-P01,Holter Study,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2014,0205-0285,205.285,Ended,83,0205-P01,URG BPCO 2003,Ended,MIG,Migration,IV,Phase IV,No drug is used is this trial ,,,000940,Post Marketing Study (MIGRATED)
2015,0205-0286,205.286,Preparing,83,0205-P01,AM/PM Netherlands,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2016,0205-0287,205.287,Ended,83,0205-P01,Seretide II Comparison Study,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2017,0205-0288,205.288,Unconfirmed,83,0205-P01,Low delivered dose,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2018,0205-0289,205.289,Ended,83,0205-P01,Effect of tio on training,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2019,0205-0290,205.290,Ended,83,0205-P01,Spiriva PEM,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2020,0205-0292,205.292,Ended,83,0205-P01,Measurement of tio on lung volumes,Ended,MIG,Migration,IV,Phase IV,,,,,
2021,0205-0293,205.293,Unconfirmed,83,0205-P01,One Year Exacerbation Trial,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2022,0205-0294,205.294,Ended,83,0205-P01,Tio in Patients of African descent,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2023,0205-0295,205.295,Unconfirmed,83,0205-P01,Mild-Mioderate COPD and IC,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
2024,0205-0296,205.296,Unconfirmed,83,0205-P01,Renal dysfunction,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2025,0205-0297,205.297,Ended,83,0205-P01,IIS-Epidemiology/EMMEPOC, non-intervent.,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000600,Survey Patient Questionnaire
2026,0205-0298,205.298,Ended,83,0205-P01,IIS-Daily life activities,non-intervent.,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000600,Survey Patient Questionnaire
2027,0205-0299,205.299,Ended,83,0205-P01,IIS-Risk factors hospitalis./non-interv.,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2028,0205-0300,205.300,Ended,83,0205-P01,NL-Pedometer, non-Tiotropium,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2029,0205-0301,205.301,Ended,83,0205-P01,Tiotropium in COPD and concomit. asthma,Ended,MIG,Migration,IV,Phase IV,,2004-002166-38,,000910,IS - Clin Study (MIGRATED)
2030,0205-0302,205.302,Ended,83,0205-P01,QTc anal  tio 18 & 72 . pbo & act cont,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2031,0205-0303,205.303,Ended,83,0205-P01,Effect of Tio on Neural Resp. Drive,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,,
2032,0205-0304,205.304,Ended,83,0205-P01,QoL in COPD patients in Greece, non-int.,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2033,0205-0305,205.305,Ended,83,0205-P01,"Diagnostic tree" in COPD,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2034,0205-0306,205.306,Unconfirmed,83,0205-P01,LARGE Study - Tiotropium in Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
2035,0205-0307,205.307,Ended,83,0205-P01,Funct. mechanisms of lung vol. reduction,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,,
2036,0205-0308,205.308,Unconfirmed,83,0205-P01,Dyspnea I,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2037,0205-0309,205.309,Unconfirmed,83,0205-P01,Dyspnea II,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2038,0205-0311,205.311,Ended,83,0205-P01,COPD Chart Review, non-interv., Belgium,Ended,MIG,Migration,IV,Phase IV,CRO = HEDM ,,,000940,Post Marketing Study (MIGRATED)
2039,0205-0312,205.312,Ended,83,0205-P01,QUOTAS - CES 2,Ended,MIG,Migration,IV,Phase IV,copd prevalence estimation ,,,000940,Post Marketing Study (MIGRATED)
2040,0205-0313,205.313,Recruiting,83,0205-P01,Initiatives BPCO Study,Recruiting,MIG,Migration,NONE,Not Classified,Alliance study ,,,,
2041,0205-0314,205.314,Ended,83,0205-P01,Drug Use Result Survey,Ended,MIG,Migration,IV,Phase IV,BI only ,,,000920,NISnd - Study (MIGRATED)
2042,0205-0315,205.315,Ended,83,0205-P01,Special Survey Long-term Treatment,Ended,MIG,Migration,IV,Phase IV,BI only ,,,000920,NISnd - Study (MIGRATED)
2043,0205-0316,205.316,Unconfirmed,83,0205-P01,Tio during acute COPD exacerbation,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
2044,0205-0317,205.317,Ended,83,0205-P01,Non-interventional EQ-5D Survey,Ended,MIG,Migration,IV,Phase IV,BI only,  GPV # 188 and # 5409 (Extensio n Latvia),,,000600,Survey Patient Questionnaire
2045,0205-0318,205.318,Ended,83,0205-P01,IIS Tio + HV induced HI in mild/mod COPD,Ended,MIG,Migration,IV,Phase IV,,,,,
2046,0205-0319,205.319,Ended,83,0205-P01,QoL in COPD patients, non interventional,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000600,Survey Patient Questionnaire
2047,0205-0320,205.320,Ended,83,0205-P01,AWB Spiriva,  Hyperinflation in COPD,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2048,0205-0321,205.321,Ended,83,0205-P01,Step test development,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,,
2049,0205-0322,205.322,Preparing,83,0205-P01,Tio vs. Roflumilast withdrawal-study,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2050,0205-0323,205.323,Ended,83,0205-P01,IIS: Impact of Tio on Hemodynamics,Ended,MIG,Migration,IV,Phase IV,IIS Trial, Alliance study ,,,,
2051,0205-0324,205.324,Ended,83,0205-P01,Impact of Tio on Gas Exchange,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,,
2052,0205-0325,205.325,Ended,83,0205-P01,Combivent Comparison Trial,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2053,0205-0326,205.326,Ended,83,0205-P01,CAGE Study,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2054,0205-0327,205.327,Preparing,83,0205-P01,Tio + Roflu vs. max. Bronchodilatation,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2055,0205-0328,205.328,Preparing,83,0205-P01,ICS Withdrawal Study,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2056,0205-0329,205.329,Ended,83,0205-P01,IIS:Tio and elastin degradation in COPD,Ended,MIG,Migration,IV,Phase IV,,,,,
2057,0205-0330,205.330,Unconfirmed,83,0205-P01,Early PM-Pharmacovigilance Japan,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2058,0205-0331,205.331,Ended,83,0205-P01,Non-intervent., FOT + bodybox in COPD,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2059,0205-0332,205.332,Ended,83,0205-P01,Kvasimodo, non-interventional,Ended,MIG,Migration,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
2060,0205-0333,205.333,Unconfirmed,83,0205-P01,Active controlled hyperinflation I,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2061,0205-0334,205.334,Ended,83,0205-P01,Tio + Salmeterol vs. Seretide, EET + FRC,Ended,MIG,Migration,IV,Phase IV,eCRF pages are total - rescheduled pages Alliance study,2006-004086-33,,000910,IS - Clin Study (MIGRATED)
2062,0205-0335,205.335,Ended,83,0205-P01,PIKO NEO, non-interv, transv, GP's,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000940,Post Marketing Study (MIGRATED)
2063,0205-0336,205.336,Unconfirmed,83,0205-P01,Non-interventional spirometry,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2064,0205-0337,205.337,Ended,83,0205-P01,Spiriva PMS Study in Korea,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000940,Post Marketing Study (MIGRATED)
2065,0205-0340,205.340,Ended,83,0205-P01,EVADE - diagnostic questionnaire,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2066,0205-0343,205.343,Analysis,83,0205-P01,EXACO non-interventional,Analysis,MIG,Migration,NONE,Not Classified,Alliance study ,,,,
2067,0205-0344,205.344,Ended,83,0205-P01,INSPIRE, non-interv, trans, PNEUMO,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2068,0205-0345,205.345,Ended,83,0205-P01,Spirometry, non-interventional,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2069,0205-0346,205.346,Ended,83,0205-P01,Combivent Comparison Trial II,Ended,MIG,Migration,IV,Phase IV,,2006-000822-30,,000910,IS - Clin Study (MIGRATED)
2070,0205-0347,205.347,Ended,83,0205-P01,Non-interv. - Optoelectron. lung volumes,Ended,MIG,Migration,IV,Phase IV,,,,,
2071,0205-0348,205.348,Ended,83,0205-P01,Tio in cough,Ended,MIG,Migration,III,Phase III,,,,,
2072,0205-0349,205.349,Unconfirmed,83,0205-P01,Tio in sarcoidosis,Unconfirmed,MIG,Migration,III,Phase III,,,,,
2073,0205-0350,205.350,Ended,83,0205-P01,Hyperinflation in Low Exercise,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,,
2074,0205-0351,205.351,Ended,83,0205-P01,Tiotropium and walking capacity,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,,
2075,0205-0352,205.352,Ended,83,0205-P01,non-intervent., dynamic hyperinflation,Ended,MIG,Migration,IV,Phase IV,,,,,
2076,0205-0354,205.354,Unconfirmed,83,0205-P01,IPAG spirometry screening,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2077,0205-0355,205.355,Ended,83,0205-P01,BILAN, non-interv, transv, pneumo,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2078,0205-0356,205.356,Ended,83,0205-P01,Market Research Canada,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2079,0205-0357,205.357,Ended,83,0205-P01,Non-tiotropium physiotherapy,Ended,MIG,Migration,IV,Phase IV,BI only ,,,,
2080,0205-0358,205.358,Ended,83,0205-P01,COPD epidemiology in Asia/Pacific,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2081,0205-0359,205.359,Ended,83,0205-P01,Argentina COPD questionnaire,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2082,0205-0360,205.360,Ended,83,0205-P01,COPD: Impairment in daily activities,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2083,0205-0361,205.361,Ended,83,0205-P01,Non-drug training program in COPD,Ended,MIG,Migration,IV,Phase IV,BI only ,,,000600,Survey Patient Questionnaire
2084,0205-0362,205.362,Ended,83,0205-P01,Psychologic impacts of COPD,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2085,0205-0363,205.363,Ended,83,0205-P01,Exacerbation screening,Ended,MIG,Migration,IV,Phase IV,No clinical study - Screening program!!! ,,,000600,Survey Patient Questionnaire
2086,0205-0364,205.364,Ended,83,0205-P01,AWB, Spiriva in early COPD,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2087,0205-0365,205.365,Ended,83,0205-P01,Maintenance treatment naive patients,Ended,MIG,Migration,IV,Phase IV,Pfizer conducted study ,2006-006276-38,,000910,IS - Clin Study (MIGRATED)
2088,0205-0366,205.366,Ended,83,0205-P01,Respiratory muscle strength, non-int.,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000600,Survey Patient Questionnaire
2089,0205-0367,205.367,Ended,83,0205-P01,Danish KOLibri survey,Ended,MIG,Migration,IV,Phase IV,No EdraCT number ,,,000930,NISed - Study (MIGRATED)
2090,0205-0368,205.368,Ended,83,0205-P01,EXACTT - Long-term Exercise,Ended,MIG,Migration,IV,Phase IV,Alliance study ,2006-004610-41,,000910,IS - Clin Study (MIGRATED)
2091,0205-0369,205.369,Unconfirmed,83,0205-P01,Non-interv. differential questionnaire,Unconfirmed,MIG,Migration,IV,Phase IV,Alliance study ,,,000600,Survey Patient Questionnaire
2092,0205-0370,205.370,Ended,83,0205-P01,Non-interv. diagnostic questionnaire,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2093,0205-0371,205.371,Ended,83,0205-P01,Tio and gas exchange,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,,
2094,0205-0373,205.373,Ended,83,0205-P01,China - open label 8 week study,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000940,Post Marketing Study (MIGRATED)
2095,0205-0374,205.374,Ended,83,0205-P01,Mexican Patients Program,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000600,Survey Patient Questionnaire
2096,0205-0375,205.375,Ended,83,0205-P01,Inhaled Medication Compliance,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000600,Survey Patient Questionnaire
2097,0205-0376,205.376,Ended,83,0205-P01,Kvasimodo 2,Ended,MIG,Migration,IV,Phase IV,No EudraCT number ,,,000930,NISed - Study (MIGRATED)
2098,0205-0377,205.377,Ended,83,0205-P01,Cardiac limitations in COPD,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,,
2099,0205-0378,205.378,Preparing,83,0205-P01,CAGE 2 Study,Preparing,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2100,0205-0379,205.379,Ended,83,0205-P01,Tiotropium and Mucins in COPD,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,,
2101,0205-0381,205.381,Ended,83,0205-P01,Tio in asthma,Ended,MIG,Migration,III,Phase III,BI only ,,,,
2102,0205-0382,205.382,Ended,83,0205-P01,PIKO-6 Device: Validation in COPD,Ended,MIG,Migration,IV,Phase IV,,,,,
2103,0205-0383,205.383,Ended,83,0205-P01,Peer-review supported QA,Ended,MIG,Migration,IV,Phase IV,no clin. study; review of patient files of pneumologists by peers,,,000600,Survey Patient Questionnaire
2104,0205-0384,205.384,Ended,83,0205-P01,Meteorological parameter in COPD,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2105,0205-0385,205.385,Ended,83,0205-P01,Austrian Epidemiologic Survey COPD,Ended,MIG,Migration,IV,Phase IV,no drug involved or provided; GPV # 0 supported by the Austrian Ludwig Boltzmann Institute COPD, Alliance study,,,000600,Survey Patient Questionnaire
2106,0205-0386,205.386,Ended,83,0205-P01,Prevalence of COPD at Cincinnati VAMC,Ended,MIG,Migration,IV,Phase IV,,,,,
2107,0205-0387,205.387,Initiated,83,0205-P01,Disease Management COPD,Initiated,MIG,Migration,IV,Phase IV,Alliance study ,,,000600,Survey Patient Questionnaire
2108,0205-0388,205.388,Ended,83,0205-P01,Distribution of ventilation in COPD,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,,
2109,0205-0389,205.389,Ended,83,0205-P01,POET-COPD (Tio vs. Sal 1 yr trial),Ended,MIG,Migration,IV,Phase IV,Alliance study ,2007-001840-33,,000910,IS - Clin Study (MIGRATED)
2110,0205-0390,205.390,Ended,83,0205-P01,COPD Diagn. Software Evaluation - PILOT,Ended,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
2111,0205-0391,205.391,Ended,83,0205-P01,COPD Diagnostic Software Evaluation,Ended,MIG,Migration,NONE,Not Classified,Alliance study ,,,000300,IS - Methodological Studies
2112,0205-0393,205.393,Ended,83,0205-P01,Tio volume protection in milder COPD,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,,
2113,0205-0394,205.394,Ended,83,0205-P01,Tiotropium and cough in COPD,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,,
2114,0205-0395,205.395,Recruiting,83,0205-P01,Lung mechanics, HRCT - tiotropium,Recruiting,MIG,Migration,IV,Phase IV,Alliance study ,,,,
2115,0205-0396,205.396,Ended,83,0205-P01,RUSSE: Tiotropium Efficacy and Safety,Ended,MIG,Migration,IV,Phase IV,Alliance study NO,,,000940,Post Marketing Study (MIGRATED)
2116,0205-0397,205.397,Ended,83,0205-P01,COPD Differential Diagnosis,Ended,MIG,Migration,IV,Phase IV,Survey in Austria only 50 GP, supported by 9 pulmonologists, BI only study,,,000600,Survey Patient Questionnaire
2117,0205-0398,205.398,Ended,83,0205-P01,Austria - ADLs and tiotropium,Ended,MIG,Migration,IV,Phase IV,Spiriva AWB Austria, GPV # 0 Post Marketing Surveillance Study, Alliance study,,,000940,Post Marketing Study (MIGRATED)
2118,0205-0399,205.399,Ended,83,0205-P01,Fresh Air,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000940,Post Marketing Study (MIGRATED)
2119,0205-0400,205.400,Ended,83,0205-P01,FRANCE - preSPIRO,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2120,0205-0401,205.401,Ended,83,0205-P01,Germany - COPD Screening,Ended,MIG,Migration,NONE,Not Classified,patient screening program - no drug trea tment involved,,,000600,Survey Patient Questionnaire
2121,0205-0402,205.402,Ended,83,0205-P01,Germany - Hyperinflation and Tio in COPD,Ended,MIG,Migration,IV,Phase IV,BI only ,,,000940,Post Marketing Study (MIGRATED)
2122,0205-0403,205.403,Ended,83,0205-P01,Depression in COPD patients in Rehab,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000600,Survey Patient Questionnaire
2123,0205-0404,205.404,Ended,83,0205-P01,Tio and NK A bronchospasm in asthma,Ended,MIG,Migration,IV,Phase IV,BI only the entire safety reporting is with the investigator,2007-001858-70,,,
2124,0205-0405,205.405,Unconfirmed,83,0205-P01,Cystic Fibrosis Survey,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
2125,0205-0406,205.406,Ended,83,0205-P01,UK - HEALTH Study,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,,
2126,0205-0407,205.407,Ended,83,0205-P01,Spain - E+C Study,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000600,Survey Patient Questionnaire
2127,0205-0408,205.408,Ended,83,0205-P01,Spain - EDIP EPOC,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000600,Survey Patient Questionnaire
2128,0205-0409,205.409,Unconfirmed,83,0205-P01,UAE - Differential Diagnosis,Unconfirmed,MIG,Migration,IV,Phase IV,Alliance study, GPV # 51 ,,,000600,Survey Patient Questionnaire
2129,0205-0410,205.410,Ended,83,0205-P01,TALC Study,Ended,MIG,Migration,IV,Phase IV,BI only ,,,,
2130,0205-0412,205.412,Ended,83,0205-P01,France - Daily Activities and COPD,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2131,0205-0413,205.413,Ended,83,0205-P01,Spain - EDIP-EPOC II,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000600,Survey Patient Questionnaire
2132,0205-0414,205.414,Preparing,83,0205-P01,Portugal - V/Q and tiotropium,Preparing,MIG,Migration,IV,Phase IV,Alliance study ,,,,
2133,0205-0415,205.415,Ended,83,0205-P01,Greece - COPD screening,Ended,MIG,Migration,IV,Phase IV,Post marketing surveillance study BI only,,,,
2134,0205-0421,205.421,Ended,83,0205-P01,France - DepisTRA BPCO,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2135,0205-0427,205.427,Ended,83,0205-P01,Glasgow Supported Self Management Trial,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,,
2136,0205-0428,205.428,Ended,83,0205-P01,Spain - COMEPOC study,Ended,MIG,Migration,IV,Phase IV,Alliance study, GPV # 3 ,,,,
2137,0205-0429,205.429,Analysis,83,0205-P01,France - Early detection of COPD,Analysis,MIG,Migration,IV,Phase IV,Alliance study, GPV # 5 observationa, non internventional, non product study,,,,
2138,0205-0430,205.430,Unconfirmed,83,0205-P01,Screening project in Egypt,Unconfirmed,MIG,Migration,IV,Phase IV,Alliance study ,,,000600,Survey Patient Questionnaire
2139,0205-0431,205.431,Recruiting,83,0205-P01,French educational program for COPD,Recruiting,MIG,Migration,NONE,Not Classified,Alliance study, GPV # 77 ,,,,
2140,0205-0432,205.432,Ended,83,0205-P01,Cost analysis in ambul. COPD patients,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000940,Post Marketing Study (MIGRATED)
2141,0205-0433,205.433,Ended,83,0205-P01,Patient Flow Quantification,Ended,MIG,Migration,NONE,Not Classified,NTA.J D. Delcl√≥s (business Intelligence) ting, GPV # 69,,,000940,Post Marketing Study (MIGRATED)
2142,0205-0434,205.434,Ended,83,0205-P01,COPD and ADL France,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000940,Post Marketing Study (MIGRATED)
2143,0205-0435,205.435,Ended,83,0205-P01,Denmark - Early detection of COPD,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,,
2144,0205-0436,205.436,Ended,83,0205-P01,COPD Severity,Ended,MIG,Migration,IV,Phase IV,observational only, Alliance study, GP and Pulmonologists,  GPV # 128,,,000600,Survey Patient Questionnaire
2145,0205-0437,205.437,Analysis,83,0205-P01,SCOP-cardio,Analysis,MIG,Migration,NONE,Not Classified,Alliance study ,,,,
2146,0205-0439,205.439,Ended,83,0205-P01,Lung-age study - France,Ended,MIG,Migration,IV,Phase IV,observational non product study Alliance study,  GPV # 201,,,000940,Post Marketing Study (MIGRATED)
2147,0205-0440,205.440,Ended,83,0205-P01,Spiriva and exercise in early stage COPD,Ended,MIG,Migration,IV,Phase IV,Alliance study Expansion in earlier stages of COPD,,,000910,IS - Clin Study (MIGRATED)
2148,0205-0447,205.447,Ended,83,0205-P01,COPD population screener study SEARCH I,Ended,MIG,Migration,NONE,Not Classified,No treatment, hence cells are blank Primary care Physician (PCPs) sites will be randomized,,,000300,IS - Methodological Studies
2149,0205-0448,205.448,Unconfirmed,83,0205-P01,COPD population screener study SEARCH II,Unconfirmed,MIG,Migration,NONE,Not Classified,No drug intervention ,,,000300,IS - Methodological Studies
2150,0205-0449,205.449,Ended,83,0205-P01,Diagnostics COPD market and Spiriva,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000940,Post Marketing Study (MIGRATED)
2151,0205-0450,205.450,Ended,83,0205-P01,SOSPES trial - SGRQ in CEE region,Ended,MIG,Migration,IV,Phase IV,SOSPES trial, GPV # 25409 ,,,000940,Post Marketing Study (MIGRATED)
2152,0205-0451,205.451,Ended,83,0205-P01,COPD risks in smokers (questionnaire),Ended,MIG,Migration,IV,Phase IV,BI only ,,,000940,Post Marketing Study (MIGRATED)
2153,0205-0453,205.453,Ended,83,0205-P01,EXTREPOC: COPD Prevalence in Extremadura,Ended,MIG,Migration,IV,Phase IV,Alliance study,  GPV # 9309 ,,,,
2154,0205-0454,205.454,Ended,83,0205-P01,ECME Characteristics of Women in Spain,Ended,MIG,Migration,IV,Phase IV,Alliance study,  GPV # 9209 ,,,000940,Post Marketing Study (MIGRATED)
2155,0205-0455,205.455,Ended,83,0205-P01,Assessment of COPD therapy (Tiotropium),Ended,MIG,Migration,IV,Phase IV,Alliance study, GPV # 21509 ,,,000940,Post Marketing Study (MIGRATED)
2156,0205-0459,205.459,Ended,83,0205-P01,Pulmo prescriptions in COPD wave 2,Ended,MIG,Migration,IV,Phase IV,BI only ,,,000600,Survey Patient Questionnaire
2157,0205-0460,205.460,Ended,83,0205-P01,Low frequency ultrasound,Ended,MIG,Migration,IV,Phase IV,Alliance study, GPV # 22709 ,,,,
2158,0205-0461,205.461,Ended,83,0205-P01,EPOCAN - Epidemiology (Can. Islands),Ended,MIG,Migration,IV,Phase IV,Alliance Study, GPV # 22209 ,,,000940,Post Marketing Study (MIGRATED)
2159,0205-0462,205.462,Analysis,83,0205-P01,French COPD Educational Programme,Analysis,MIG,Migration,IV,Phase IV,Alliance Study,  GPV # 21209 ,,,,
2160,0205-0465,205.465,Ended,83,0205-P01,ACTIVE program - Canada,Ended,MIG,Migration,IV,Phase IV,BI only ,,,,
2161,0205-0466,205.466,Analysis,83,0205-P01,STST Sit To Stand Test - Pilot (France),Analysis,MIG,Migration,IV,Phase IV,No drug product involved Intervention is sit-to-stand test; Alliance study,,,,
2162,0205-0467,205.467,Recruiting,83,0205-P01,Early intervention in COPD - China,Recruiting,MIG,Migration,IV,Phase IV,Alliance study ,,,,
2163,0205-0468,205.468,Ended,83,0205-P01,French COPD prescriptions,Ended,MIG,Migration,IV,Phase IV,BI only ,,,000600,Survey Patient Questionnaire
2164,0205-0469,205.469,Ended,83,0205-P01,Wii in home exercise,Ended,MIG,Migration,IV,Phase IV,BI only ,,,,
2165,0205-0470,205.470,Ended,83,0205-P01,Patient Portraits and Insights,Ended,MIG,Migration,IV,Phase IV,Alliance Study, GPV # 10166; NTA with so licited reporting // project owner: Eric Chang (Corp. Dept. Business Analysis).,,,000600,Survey Patient Questionnaire
2166,0205-0472,205.472,Ended,83,0205-P01,Dyspnoea during exercise PRO,Ended,MIG,Migration,IV,Phase IV,BI only, GPV # 10233; NTA with solicited  reporting // Project owner: Brigitta Monz (Corp. Dept. MAPOR),,,000600,Survey Patient Questionnaire
2167,0205-0473,205.473,Unconfirmed,83,0205-P01,Ireland - Consumer mobilisation program,Unconfirmed,MIG,Migration,IV,Phase IV,Alliance Study, GPV # 10258 ,,,000600,Survey Patient Questionnaire
2168,0205-0474,205.474,Ended,83,0205-P01,SMS reminder to assess adherence,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000940,Post Marketing Study (MIGRATED)
2169,0205-0475,205.475,Recruiting,83,0205-P01,Belgium - AMICE,Recruiting,MIG,Migration,IV,Phase IV,IIS study with mono-arm tiotropium; Alliance study,,,,
2170,0205-0476,205.476,Ended,83,0205-P01,Spain - FENCLINE,Ended,MIG,Migration,IV,Phase IV,Alliance study, GPV # 10151 ,,,000300,IS - Methodological Studies
2171,0205-0477,205.477,Ended,83,0205-P01,Hospital discharge study 1,Ended,MIG,Migration,IV,Phase IV, BI only,,,000910,IS - Clin Study (MIGRATED)
2172,0205-0478,205.478,Ended,83,0205-P01,Hospital discharge study 2,Ended,MIG,Migration,IV,Phase IV, BI only,,,000910,IS - Clin Study (MIGRATED)
2173,0205-0479,205.479,Ended,83,0205-P01,COPD & acute respiratory infection 1,Ended,MIG,Migration,IV,Phase IV, BI only,,,000910,IS - Clin Study (MIGRATED)
2174,0205-0480,205.480,Preparing,83,0205-P01,COPD & acute respiratory infection 2,Preparing,MIG,Migration,IV,Phase IV,Trial conceptually approved pending CTP,  BI only,,,000910,IS - Clin Study (MIGRATED)
2175,0205-0481,205.481,Preparing,83,0205-P01,Healthcare COPD program in pharmacy,Preparing,MIG,Migration,IV,Phase IV,Alliance study, GPV # 10371 ,,,000600,Survey Patient Questionnaire
2176,0205-0482,205.482,Ended,83,0205-P01,COPD among smoking asthmatics,Ended,MIG,Migration,NONE,Not Classified,BI only, GPV # 11004 ,,,000300,IS - Methodological Studies
2177,0205-0483,205.483,Ended,83,0205-P01,Adherence to Spiriva in COPD Pat. ADESPI,Ended,MIG,Migration,IV,Phase IV,Alliance Study ,,,000940,Post Marketing Study (MIGRATED)
2178,0205-0484,205.484,Ended,83,0205-P01,Monitoring of COPD prescriptions,Ended,MIG,Migration,NONE,Not Classified,Alliance study, GPV # 10365 ,,,000600,Survey Patient Questionnaire
2179,0205-0485,205.485,Unconfirmed,83,0205-P01,Patient adherence study,Unconfirmed,MIG,Migration,IV,Phase IV,Alliance study, GPV # 10346 ,,,000600,Survey Patient Questionnaire
2180,0205-0486,205.486,Ended,83,0205-P01,TOP GOLD / Early detection and diagnosis,Ended,MIG,Migration,NONE,Not Classified,GPV # 10060 / Alliance program ,,,000930,NISed - Study (MIGRATED)
2181,0205-0487,205.487,Ended,83,0205-P01,Predictors of activity in COPD - NL,Ended,MIG,Migration,NONE,Not Classified,investigator initiated activity, investi gator: Prof. ten Hacken, contact: Bregt Kappelhoff), no drug product involved. // Alliance study,,,000600,Survey Patient Questionnaire
2182,0205-0488,205.488,Ended,83,0205-P01,COPD Management Review Service,Ended,MIG,Migration,NONE,Not Classified,BI only ,,,000600,Survey Patient Questionnaire
2183,0205-0489,205.489,Ended,83,0205-P01,Singapore - IMPACT Program,Ended,MIG,Migration,NONE,Not Classified,BI only ,,,000940,Post Marketing Study (MIGRATED)
2184,0205-0490,205.490,Unconfirmed,83,0205-P01,Greece - Patient compliance,Unconfirmed,MIG,Migration,NONE,Not Classified,Alliance study ,,,000600,Survey Patient Questionnaire
2185,0205-0491,205.491,Ended,83,0205-P01,COPD prevalence in Zaragoza,Ended,MIG,Migration,NONE,Not Classified,CTMS n¬∫ allocated retrospec.NTA ext tively. Due to Xavier Ribera¬øs email from July 7th, 2011, (¬øAll these studies were sent to medical affairs corporate and evaluated by the IIB/IV W group. The problem is that some of them (most) were sent to Steven Kesten and endorsed out of the IIB/IV WG meeting (of-line?) , others to Armin or  Fee and the endorsement answer has been always by e-mail (some of them in the middle of other subjects). Also some of them have been managed  by Pfizer Spain. The result is that I did not keep the e-mails and I do not have written (official) confirmation of the endorsement. I have all the protocols in English because we sent them to corporate for evaluation (all of them). I do not know if Steven kept the records or some of them are in the 3b4 minutes.¬ø) and records retention it is not possible to prove whether the NTA is officially released by Corporate and the Spiriva IIIb/IV Working Group, respectively.,,,,
2186,0205-0492,205.492,Ended,83,0205-P01,COPD prevalence in Colloto,Ended,MIG,Migration,NONE,Not Classified,CTMS number has been allocated retrospec tively. Due to Xavier Ribera¬øs email from July 7th, 2011, (¬øAll these studies were sent to medical affairs corporate and evaluated by the IIB/IV W group. The problem is that some of them (most) were sent to Steven Kesten and endorsed out of the IIB/IV WG meeting (of-line?) , others to Armin or  Fee and the endorsement answer has been always by e-mail (some of them in the middle of other subjects). Also some of them have been managed  by Pfizer Spain. The result is that I did not keep the e-mails and I do not have written (official) confirmation of the endorsement. I have all the protocols in English because we sent them to corporate for evaluation (all of them). I do not know if Steven kept the records or some of them are in the 3b4 minutes.¬ø) and records retention it is not possible to prove whether the NTA is officially released by Corporate and the Spiriva IIIb/IV Working Group, respectively.,,,,
2187,0205-0493,205.493,Ended,83,0205-P01,COPD prevalence in Najera-La Rioja,Ended,MIG,Migration,NONE,Not Classified,CTMS number has been allocated retrospec tively. Due to Xavier Ribera¬øs email from July 7th, 2011, (¬øAll these studies were sent to medical affairs corporate and evaluated by the IIB/IV W group. The problem is that some of them (most) were sent to Steven Kesten and endorsed out of the IIB/IV WG meeting (of-line?) , others to Armin or  Fee and the endorsement answer has been always by e-mail (some of them in the middle of other subjects). Also some of them have been managed  by Pfizer Spain. The result is that I did not keep the e-mails and I do not have written (official) confirmation of the endorsement. I have all the protocols in English because we sent them to corporate for evaluation (all of them). I do not know if Steven kept the records or some of them are in the 3b4 minutes.¬ø) and records retention it is not possible to prove whether the NTA is officially released by Corporate and the Spiriva IIIb/IV Working Group, respectively.,,,,
2188,0205-0494,205.494,Ended,83,0205-P01,Disease management in local area,Ended,MIG,Migration,NONE,Not Classified,CTMS number has been allocated retrospec tively. Due to Xavier Ribera¬øs email from July 7th, 2011, (¬øAll these studies were sent to medical affairs corporate and evaluated by the IIB/IV W group. The problem is that some of them (most) were sent to Steven Kesten and endorsed out of the IIB/IV WG meeting (of-line?) , others to Armin or  Fee and the endorsement answer has been always by e-mail (some of them in the middle of other subjects). Also some of them have been managed  by Pfizer Spain. The result is that I did not keep the e-mails and I do not have written (official) confirmation of the endorsement. I have all the protocols in English because we sent them to corporate for evaluation (all of them). I do not know if Steven kept the records or some of them are in the 3b4 minutes.¬ø) and records retention it is not possible to prove whether the NTA is officially released by Corporate and the Spiriva IIIb/IV Working Group, respectively.,,,,
2189,0205-0495,205.495,Analysis,83,0205-P01,Spain - QoL in COPD patients,Analysis,MIG,Migration,NONE,Not Classified,CTMS number has been allocated retrospec tively. Due to Xavier Ribera¬øs email from July 7th, 2011, (¬øAll these studies were sent to medical affairs corporate and evaluated by the IIB/IV W group. The problem is that some of them (most) were sent to Steven Kesten and endorsed out of the IIB/IV WG meeting (of-line?) , others to Armin or  Fee and the endorsement answer has been always by e-mail (some of them in the middle of other subjects). Also some of them have been managed  by Pfizer Spain. The result is that I did not keep the e-mails and I do not have written (official) confirmation of the endorsement. I have all the protocols in English because we sent them to corporate for evaluation (all of them). I do not know if Steven kept the records or some of them are in the 3b4 minutes.¬ø) and records retention it is not possible to prove whether the NTA is officially released by Corporate and the Spiriva IIIb/IV Working Group, respectively.,,,000420,NISnd ‚Äì Study - Cohort
2190,0205-0496,205.496,Ended,83,0205-P01,QoL in COPD patients in primary care,Ended,MIG,Migration,NONE,Not Classified,CTMS number has been allocated retrospec tively. Due to Xavier Ribera¬øs email from July 7th, 2011, (¬øAll these studies were sent to medical affairs corporate and evaluated by the IIB/IV W group. The problem is that some of them (most) were sent to Steven Kesten and endorsed out of the IIB/IV WG meeting (of-line?) , others to Armin or  Fee and the endorsement answer has been always by e-mail (some of them in the middle of other subjects). Also some of them have been managed  by Pfizer Spain. The result is that I did not keep the e-mails and I do not have written (official) confirmation of the endorsement. I have all the protocols in English because we sent them to corporate for evaluation (all of them). I do not know if Steven kept the records or some of them are in the 3b4 minutes.¬ø) and records retention it is not possible to prove whether the NTA is officially released by Corporate and the Spiriva IIIb/IV Working Group, respectively.,,,,
2191,0205-0497,205.497,Ended,83,0205-P01,Spain - ADEPOC study,Ended,MIG,Migration,NONE,Not Classified,CTMS n¬∫ allocated retrospec.NTA ext. tively. Due to Xavier Ribera¬øs email from July 7th, 2011, (¬øAll these studies were sent to medical affairs corporate and evaluated by the IIB/IV W group. The problem is that some of them (most) were sent to Steven Kesten and endorsed out of the IIB/IV WG meeting (of-line?) , others to Armin or  Fee and the endorsement answer has been always by e-mail (some of them in the middle of other subjects). Also some of them have been managed  by Pfizer Spain. The result is that I did not keep the e-mails and I do not have written (official) confirmation of the endorsement. I have all the protocols in English because we sent them to corporate for evaluation (all of them). I do not know if Steven kept the records or some of them are in the 3b4 minutes.¬ø) and records retention it is not possible to prove whether the NTA is officially released by Corporate and the Spiriva IIIb/IV Working Group, respectively.,,,,
2192,0205-0498,205.498,Ended,83,0205-P01,Spain - FUMEPOC study,Ended,MIG,Migration,NONE,Not Classified,CTMS number has been allocated retrospec tively. Due to Xavier Ribera¬øs email from July 7th, 2011, (¬øAll these studies were sent to medical affairs corporate and evaluated by the IIB/IV W group. The problem is that some of them (most) were sent to Steven Kesten and endorsed out of the IIB/IV WG meeting (of-line?) , others to Armin or  Fee and the endorsement answer has been always by e-mail (some of them in the middle of other subjects). Also some of them have been managed  by Pfizer Spain. The result is that I did not keep the e-mails and I do not have written (official) confirmation of the endorsement. I have all the protocols in English because we sent them to corporate for evaluation (all of them). I do not know if Steven kept the records or some of them are in the 3b4 minutes.¬ø) and records retention it is not possible to prove whether the NTA is officially released by Corporate and the Spiriva IIIb/IV Working Group, respectively.,,,,
2193,0205-0499,205.499,Ended,83,0205-P01,Spain - AEPOC,Ended,MIG,Migration,NONE,Not Classified,CTMS number has been allocated retrospec tively. Due to Xavier Ribera¬øs email from July 7th, 2011, (¬øAll these studies were sent to medical affairs corporate and evaluated by the IIB/IV W group. The problem is that some of them (most) were sent to Steven Kesten and endorsed out of the IIB/IV WG meeting (of-line?) , others to Armin or  Fee and the endorsement answer has been always by e-mail (some of them in the middle of other subjects). Also some of them have been managed  by Pfizer Spain. The result is that I did not keep the e-mails and I do not have written (official) confirmation of the endorsement. I have all the protocols in English because we sent them to corporate for evaluation (all of them). I do not know if Steven kept the records or some of them are in the 3b4 minutes.¬ø) and records retention it is not possible to prove whether the NTA is officially released by Corporate and the Spiriva IIIb/IV Working Group, respectively.,,,,
2194,0205-0500,205.500,Unconfirmed,83,0205-P01,Spiriva U&A study,Unconfirmed,MIG,Migration,NONE,Not Classified,BI only ,,,000600,Survey Patient Questionnaire
2195,0205-0501,205.501,Ended,83,0205-P01,ICEBERG,Ended,MIG,Migration,NONE,Not Classified,Alliance study ,,,000300,IS - Methodological Studies
2196,0205-0502,205.502,Ended,83,0205-P01,MATHS,Ended,MIG,Migration,IV,Phase IV,Alliance study ,,,000940,Post Marketing Study (MIGRATED)
2197,0205-0503,205.503,Analysis,83,0205-P01,COPD Comorbidities: Real Life Snapshot,Analysis,MIG,Migration,NONE,Not Classified,Alliance study ,,,,
2198,0205-0504,205.504,Recruiting,83,0205-P01,VSRQ and rehabilitation in COPD,Recruiting,MIG,Migration,NONE,Not Classified,Alliance study ,,,,
2199,0205-0505,205.505,Unconfirmed,83,0205-P01,Sweden - Adherence,Unconfirmed,MIG,Migration,NONE,Not Classified,Alliance program ,,,000600,Survey Patient Questionnaire
2200,0205-0506,205.506,Ended,83,0205-P01,Netherlands - TASMAN,Ended,MIG,Migration,NONE,Not Classified,BI only ,,,000600,Survey Patient Questionnaire
2201,0205-0507,205.507,Recruiting,83,0205-P01,SIMPLE study - Portugal,Recruiting,MIG,Migration,NONE,Not Classified,Alliance study ,,,,
2202,0205-0508,205.508,Ended,83,0205-P01,ANDES study,Ended,MIG,Migration,NONE,Not Classified,BI only ,,,000600,Survey Patient Questionnaire
2203,0205-0512,205.512,Unconfirmed,83,0205-P01,Spiriva Performance Tracking Study I,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
2204,0205-0513,205.513,Unconfirmed,83,0205-P01,Spiriva Performance Tracking Study II,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
2205,0205-0515,205.515,Ended,83,0205-P01,Spirimetry Clinic Day,Ended,MIG,Migration,NONE,Not Classified,,,,000980,Not Classified (MIGRATED)
2206,0205-0516,205.516,Analysis,83,0205-P01,COPD and CHF prevalence (SUSPIRO),Analysis,MIG,Migration,NONE,Not Classified,NTA ,,,000600,Survey Patient Questionnaire
2207,0205-0517,205.517,Analysis,83,0205-P01,LABA/LAMA Adherence in COPD,Analysis,MIG,Migration,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
2208,0205-0518,205.518,Ended,83,0205-P01,Tio in the Immediate Post-Hosp. Period,Ended,MIG,Migration,IV,Phase IV,Retrospective database analysis ,,,,
2209,0205-0519,205.519,Recruiting,83,0205-P01,Colibri COPD Cohort,Recruiting,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
2210,0205-0520,205.520,Unconfirmed,83,0205-P01,Tiotropium in non-smokers COPD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2211,0205-0526,205.526,Ended,83,0205-P01,Comb Bronchodil in COPD and CardPulm AEs,Ended,MIG,Migration,IV,Phase IV,,,,,
2212,0205-0528,205.528,Recruiting,83,0205-P01,RADICALS,Recruiting,MIG,Migration,NONE,Not Classified,,,,,
2213,0205-0529,205.529,Ended,83,0205-P01,POPE Study,Ended,MIG,Migration,NONE,Not Classified,,,,,
2214,0205-0530,205.530,Preparing,83,0205-P01,Exacerbation and fatigue in COPD,Preparing,MIG,Migration,NONE,Not Classified,,,,,
2215,0205-0531,205.531,Analysis,83,0205-P01,COPD progression in early COPD,Analysis,MIG,Migration,IV,Phase IV,,,,,
2216,0205-0534,205.534,Ended,83,0205-P01,Velocity of Respimat Cloud,Ended,MIG,Migration,NONE,Not Classified,This study is not clinical. ,,,,
2217,0107-0009,107.9,Ended,84,0107-P02,Efficacy and Safety UH-AC 62 vs. Pirox.,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2218,0107-0012,107.12,Unconfirmed,84,0107-P02,Arthrosen,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2219,0107-0019,107.19,Ended,84,0107-P02,Activat. (exacerb.) OA knee: multicenter,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2220,0107-0020,107.20,Ended,84,0107-P02,Tissue kinetics / coxarthrosis,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2221,0107-0042,107.42,Ended,84,0107-P02,OA: Dosefinding: 7.5-15-30mg-Placebo 951,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2222,0107-0043,107.43,Ended,84,0107-P02,OA: Hip: 15-30mg Melo vs. 20mg Piro 952,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2223,0107-0044,107.44,Ended,84,0107-P02,OA: Knee: 15-30mg Melo vs.100mgDiclo 953,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2224,0107-0045,107.45,Ended,84,0107-P02,OA: Long term study: 15mg Mel.vs.Pir.954,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2225,0107-0046,107.46,Ended,84,0107-P02,OA: Longterm study: 30mg Mel.vs.Dicl.955,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2226,0107-0047,107.47,Ended,84,0107-P02,OA: Open longterm study: 15mgMelo 956/15,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2227,0107-0048,107.48,Ended,84,0107-P02,OA: Open longterm study: 30mgMelo 956/30,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2228,0107-0063,107.63,Ended,84,0107-P02,OA: Longterm study: 7.5mgMel.vs.Dicl.966,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2229,0107-0076,107.76,Ended,84,0107-P02,SAFETY AND EFFICACY OF MELOXICAM,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2230,0107-0077,107.77,Ended,84,0107-P02,OSTEOARTHRITIS IN HIP OR KNEE,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2231,0107-0090,107.90,Ended,84,0107-P02,Articular diffusion of Meloxicam,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2232,0107-0093,107.93,Unconfirmed,84,0107-P02,Leucocyte emigration,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,No. of patients to be determined ,,,000910,IS - Clin Study (MIGRATED)
2233,0107-0094,107.94,Ended,84,0107-P02,OA of the spine,Ended,MIG,Migration,IIIB,Phase IIIb,- *Biberach trial,,,000910,IS - Clin Study (MIGRATED)
2234,0107-0099,107.99,Ended,84,0107-P02,Melox.15mg vs diclof. 100mg qual.of life,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2235,0107-0112,107.112,Unconfirmed,84,0107-P02,DB Endoscopic Trial - Melo vs. Piroxicam,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,Trial cancelled (Med.Team Meeting 03/94) ,,,000910,IS - Clin Study (MIGRATED)
2236,0107-0113,107.113,Ended,84,0107-P02,DB Endoscopic Trial - Meloxicam vs Diclo,Ended,MIG,Migration,IIIB,Phase IIIb,Trial cancelled (April 95) ,,,000910,IS - Clin Study (MIGRATED)
2237,0107-0129,107.129,Ended,84,0107-P02,PHASE IIb(OA),Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2238,0107-0131,107.131,Ended,84,0107-P02,PHASE III DBT (OA),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2239,0107-0135,107.135,Ended,84,0107-P02,PHASE IIa(OA),Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
2240,0107-0149,107.149,Ended,84,0107-P02,Efficacy, Safety and Tolerance in OA,Ended,MIG,Migration,III,Phase III,,,,000980,Not Classified (MIGRATED)
2241,0107-0153,107.153,Ended,84,0107-P02,Large scale safety 7.5mg Melo vs. Diclo,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2242,0107-0154,107.154,Ended,84,0107-P02,Large scale safety 7.5mg Melo vs. Pirox,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2243,0107-0155,107.155,Unconfirmed,84,0107-P02,Osteoarthritis,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
2244,0107-0166,107.166,Ended,84,0107-P02,Dose escalation in OA, Model study,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2245,0107-0169,107.169,Ended,84,0107-P02,OA of the knee,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2246,0107-0181,107.181,Ended,84,0107-P02,Dose Ranging,Ended,MIG,Migration,III,Phase III,-  Full CRO (Pharmaco) - to include IND, clinical studies, NDA.  No investigator meeting for trial planned.     ,,,000910,IS - Clin Study (MIGRATED)
2247,0107-0182,107.182,Preparing,84,0107-P02,Meloxicam comparison versus Nabumetone,Preparing,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2248,0107-0189,107.189,Ended,84,0107-P02,Safety and Efficacy of 7.5 mg Meloxicam,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
2249,0107-0190,107.190,Ended,84,0107-P02,Safety/Efficacy Meloxicam vs. Piroxicam,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2250,0107-0192,107.192,Unconfirmed,84,0107-P02,Safety and efficacy of oral Melox. 7.5mg,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
2251,0107-0196,107.196,Ended,84,0107-P02,Oral Melox. 7.5mg vs. Diclo. Taiwan,Ended,MIG,Migration,IV,Phase IV,- Socpe is National (TMM 5/97),,,000910,IS - Clin Study (MIGRATED)
2252,0107-0207,107.207,Ended,84,0107-P02,Safety & Efficacy oral Mel7.5mg vs. Dicl,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000980,Not Classified (MIGRATED)
2253,0107-0209,107.209,Preparing,84,0107-P02,Endoscopy study,Preparing,MIG,Migration,IIIB,Phase IIIb,-  actual initiation pending results of 107.181 trial.     ,,,000910,IS - Clin Study (MIGRATED)
2254,0107-0210,107.210,Ended,84,0107-P02,Marketing study - OA,Ended,MIG,Migration,IIIB,Phase IIIb,-  ,,,000910,IS - Clin Study (MIGRATED)
2255,0107-0213,107.213,Ended,84,0107-P02,4 weeks treat. in OA of knee vs. Dic. SR,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2256,0107-0216,107.216,Preparing,84,0107-P02,Endoscopy study,Preparing,MIG,Migration,IIIB,Phase IIIb,-  actual initiation pending results of 107.181 trial.     ,,,000910,IS - Clin Study (MIGRATED)
2257,0107-0225,107.225,Preparing,84,0107-P02,OA in Chinese Patients,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2258,0107-0228,107.228,Ended,84,0107-P02,Meloxicam in Corean,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2259,0107-0229,107.229,Ended,84,0107-P02,Comparison meloxicam in Corean OA,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2260,0107-0233,107.233,Ended,84,0107-P02,PMS meloxicam 7.5 mg in OA,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2261,0107-0269,107.269,Ended,84,0107-P02,Mobic Capsule in Korea,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2262,0107-0275,107.275,Ended,84,0107-P02,Bioequivalence with generics,Ended,MIG,Migration,I,Phase I,,,,,
2263,0107-0086,107.86,Ended,85,0107-P04,Meloxicam in renal colic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2264,0107-0095,107.95,Unconfirmed,85,0107-P04,i.v. onset of action,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2265,0107-0096,107.96,Unconfirmed,85,0107-P04,i.v. safety and tolerance,Unconfirmed,MIG,Migration,III,Phase III,Study on hold (Med. Team Meeting 03/94) ,,,000910,IS - Clin Study (MIGRATED)
2266,0107-0097,107.97,Unconfirmed,85,0107-P04,Parent.as init.ther.in acute flares ofOA,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,Trial cancelled (09-APR-94) ,,,000910,IS - Clin Study (MIGRATED)
2267,0107-0106,107.106,Ended,85,0107-P04,s.c. tolerance, rising dose,Ended,MIG,Migration,I,Phase I,- Duration of observ.: 2 days or 3 days (15mg dose group only),,,000910,IS - Clin Study (MIGRATED)
2268,0107-0107,107.107,Ended,85,0107-P04,s.c. bioavailability vs. i.v.,Ended,MIG,Migration,I,Phase I,- 12 days obs.: 1 day treatment, 6 days wash-out (incl.4 days          kinetics), 1 day treatement, 4 days kinetics,,,000910,IS - Clin Study (MIGRATED)
2269,0107-0145,107.145,Unconfirmed,85,0107-P04,15 mg iv multiple application,Unconfirmed,MIG,Migration,I,Phase I,Pl. dates: Start 01-MAY-95 End 30-JUN-95 Trial on hold,,,000910,IS - Clin Study (MIGRATED)
2270,0107-0146,107.146,Unconfirmed,85,0107-P04,i.v. 7.5 mg vs 15 mg vs Placebo vs oral,Unconfirmed,MIG,Migration,III,Phase III,Trial cancelled (Decision 26-JUL-95) ,,,000910,IS - Clin Study (MIGRATED)
2271,0107-0147,107.147,Unconfirmed,85,0107-P04,i.m. 7.5 mg vs 15 mg vs Placebo vs oral,Unconfirmed,MIG,Migration,II,Phase II,Trial cancelled ,,,000910,IS - Clin Study (MIGRATED)
2272,0107-0148,107.148,Unconfirmed,85,0107-P04,IM 15 mg vs oral 15 mg,Unconfirmed,MIG,Migration,III,Phase III,Trial on hold ,,,000910,IS - Clin Study (MIGRATED)
2273,0107-0157,107.157,Ended,85,0107-P04,7 days safety of 15mg IM Meloxicam in RA,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2274,0107-0158,107.158,Ended,85,0107-P04,IM meloxicam in OA,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2275,0107-0159,107.159,Unconfirmed,85,0107-P04,15mg IM versus comparator IM in Sciatica,Unconfirmed,MIG,Migration,III,Phase III,Planned dates to be determined ,,,000910,IS - Clin Study (MIGRATED)
2276,0107-0171,107.171,Ended,85,0107-P04,Bioavailability: 7.5mg i.m. vs i.v.,Ended,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
2277,0107-0199,107.199,Unconfirmed,85,0107-P04,Arthroscopy dose-finding postop. pain,Unconfirmed,MIG,Migration,II,Phase II,,,,000980,Not Classified (MIGRATED)
2278,0107-0200,107.200,Unconfirmed,85,0107-P04,Hysterectomy - postop. pain meloxicam,Unconfirmed,MIG,Migration,II,Phase II,,,,000980,Not Classified (MIGRATED)
2279,0107-0217,107.217,Ended,85,0107-P04,PK comparison of 15 mg i.m./oral,Ended,MIG,Migration,I,Phase I,created by Till Mey BI Germany ,,,000910,IS - Clin Study (MIGRATED)
2280,0107-0242,107.242,Preparing,85,0107-P04,Meloxicam ampoules in OA in Chinese Pati,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2281,0107-0247,107.247,Unconfirmed,85,0107-P04,Mobec-Ampulle AWB,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2282,0107-0265,107.265,Ended,85,0107-P04,OA Registration study China,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2283,0107-0266,107.266,Ended,85,0107-P04,Registration study RA in China,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2284,0107-0267,107.267,Ended,85,0107-P04,PMS Philippines ampoules,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2285,0107-0270,107.270,Ended,85,0107-P04,PMS study of Mobic injection in Korea,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2286,0107-0271,107.271,Preparing,85,0107-P04,Effects of 15 mg amps followed by tablts,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2287,0107-0273,107.273,Ended,85,0107-P04,Impact of Movalis on Health Related QoL,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2288,0140-0001,140.1,Ended,86,0140-P01,Dosisfindung und Kinetik bis 20 mg p.o.,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2289,0140-0002,140.2,Ended,86,0140-P01,Dosis-Wirkung, Kinetik bis 10 mg p.o.,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2290,0140-0003,140.3,Ended,86,0140-P01,none,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2291,0140-0004,140.4,Ended,86,0140-P01,Vertr√§glichk., Kinetik b. Mehrfach-Appl.,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2292,0140-0005,140.5,Ended,86,0140-P01,Wirkung u. Vertr√§glichk. b. 7tg. Anwendg,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2293,0140-0006,140.6,Ended,86,0140-P01,Dosiswirkung b. Belastung i.v., Dr. Hauf,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2294,0140-0007,140.7,Ended,86,0140-P01,Dosiswirkg. b. Belastg. 4Wo p.o./Uglesic,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2295,0140-0008,140.8,Unconfirmed,86,0140-P01,Wirkung 2x5 mg p.o. 4 Wo./ Prof. Uglesic,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2296,0140-0009,140.9,Ended,86,0140-P01,Exercise effects of 2.5/5 mg i.v./Mult.C,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2297,0140-0010,140.10,Ended,86,0140-P01,Bioverf√ºgbarkeit 10 mg p.o./i.v. (Prob),Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2298,0140-0011,140.11,Ended,86,0140-P01,Haemodynamics,left-ventr.Cont. i.v./Mult,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2299,0140-0012,140.12,Ended,86,0140-P01,Cardiac conduction system(i.v.)Steinbeck,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2300,0140-0013,140.13,Ended,86,0140-P01,Katecholamin, Renin b. 3tg. p.o. Anwendg,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2301,0140-0014,140.14,Ended,86,0140-P01,Cardiac conduction system (i.v.) /Senges,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2302,0140-0015,140.15,Unconfirmed,86,0140-P01,Asthma bronchiale 1x5 mg i.v./ Dr. Boos,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2303,0140-0016,140.16,Ended,86,0140-P01,Dose response 2 weeks p.o. / Multicenter,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2304,0140-0017,140.17,Unconfirmed,86,0140-P01,Antiang. efficacy 2x2.5mg p.o. 4Wo /Mosc,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2305,0140-0018,140.18,Ended,86,0140-P01,Einflu√ü auf Fahrt√ºchtigkeit 1 Woche/T√úV,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2306,0140-0019,140.19,Ended,86,0140-P01,Pharmacokinetics,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2307,0140-0020,140.20,Ended,86,0140-P01,Safety in asthmatic patients 140.020-TH,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2308,0140-0021,140.21,Ended,86,0140-P01,Asthma bronch. 1x5 mg p.o./Prof. Virchow,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2309,0140-0022,140.22,Ended,86,0140-P01,Bio√§quivalenz 5 mg Tabl./Kaps. (Prob),Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2310,0140-0023,140.23,Ended,86,0140-P01,Kinetics, dose dependency 5-20 mg p.o.,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2311,0140-0024,140.24,Ended,86,0140-P01,Influence of food on kinetics, 5 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2312,0140-0025,140.25,Ended,86,0140-P01,Dose confirmation,Ended,MIG,Migration,III,Phase III,-  IP No. 140.25 This is one of the two adequate and well-controlled trials intended to support the NDA for ULFS 49.     ,,,000910,IS - Clin Study (MIGRATED)
2313,0140-0026,140.26,Unconfirmed,86,0140-P01,Comparison to nifedipine, multicenter/D,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2314,0140-0027,140.27,Ended,86,0140-P01,Comparison with atenolol 140.027-TH,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2315,0140-0028,140.28,Unconfirmed,86,0140-P01,Combination with ISMN, multicenter/NL,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2316,0140-0029,140.29,Ended,86,0140-P01,Nifedepine background,Ended,MIG,Migration,III,Phase III,-  IP No. 140.29. This is one of the two adequate and well-controlled trials intended to support the NDA for UL-FS 49.     ,,,000910,IS - Clin Study (MIGRATED)
2317,0140-0030,140.30,Ended,86,0140-P01,ZAT.I.M.S.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2318,0140-0031,140.31,Unconfirmed,86,0140-P01,Holter monitoring, multicenter,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2319,0140-0033,140.33,Ended,86,0140-P01,STUDY OF ZATEBRADINE IN RENAL IMPAIRMENT,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2320,0140-0034,140.34,Ended,86,0140-P01,PHARMACOKINETICS IN HEPATIC IMPAIRMENT,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2321,0140-0035,140.35,Ended,86,0140-P01,Kinetics in elderly volunt. 2x5mg p.o.,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2322,0140-0036,140.36,Ended,86,0140-P01,Kinetics of 1x50mg Atenolol CAPS/TA p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2323,0140-0037,140.37,Ended,86,0140-P01,SWEZAT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2324,0140-0038,140.38,Unconfirmed,86,0140-P01,Sinus node disfunction (S),Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2325,0140-0039,140.39,Ended,86,0140-P01,Danozat, nitrates add-on,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2326,0140-0040,140.40,Ended,86,0140-P01,UL-FS 49 with √ü-Blocker coadministration,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2327,0140-0041,140.41,Ended,86,0140-P01,DILTIAZEM EFFICACY STUDY,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2328,0140-0042,140.42,Unconfirmed,86,0140-P01,UL-FS 49 versus acebutolol,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2329,0140-0043,140.43,Unconfirmed,86,0140-P01,Comparison to metoprolol (D/A),Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2330,0140-0044,140.44,Ended,86,0140-P01,EFFICACY ANGINA PECTORIS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2331,0140-0045,140.45,Ended,86,0140-P01,LV hemodynamics/Germany,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2332,0140-0046,140.46,Unconfirmed,86,0140-P01,LV hemodynamics (USA),Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2333,0140-0047,140.47,Ended,86,0140-P01,Interaction with oral anticoagulants,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2334,0140-0048,140.48,Ended,86,0140-P01,7.5mg: interaction with 3.5mg Glibencl.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2335,0140-0049,140.49,Ended,86,0140-P01,PHARMACOKINETICS/QUINIDINE,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2336,0140-0050,140.50,Ended,86,0140-P01,UL-FS 49 with Digitalis,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2337,0140-0051,140.51,Unconfirmed,86,0140-P01,Safety in unstable angina pectoris,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2338,0140-0052,140.52,Unconfirmed,86,0140-P01,Safety in post-MI,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2339,0140-0053,140.53,Ended,86,0140-P01,Increasing doses:20,30,40,50mg p.o./caps,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2340,0140-0054,140.54,Unconfirmed,86,0140-P01,Kinetics of 1x50mg Metoprolol CAP/TA p.o,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2341,0140-0055,140.55,Ended,86,0140-P01,Tolerance,kinetic of 10mg i.v./bol.+inf.,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2342,0140-0056,140.56,Ended,86,0140-P01,Silent ischemia, multicenter/Germany,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2343,0140-0057,140.57,Unconfirmed,86,0140-P01,steady state,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2344,0140-0058,140.58,Ended,86,0140-P01,Up-titration of UL-FS 49,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2345,0140-0059,140.59,Unconfirmed,86,0140-P01,Diurnal influence on kinetics,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2346,0140-0060,140.60,Ended,86,0140-P01,Open-label safety:2x5/7.5 mg p.o./Germ.,Ended,MIG,Migration,III,Phase III,until drug market.or premature terminat. ,,,000910,IS - Clin Study (MIGRATED)
2347,0140-0061,140.61,Ended,86,0140-P01,Long-term safety,Ended,MIG,Migration,III,Phase III,-  data cutoff for NDA will be 12/1/95. Investigators told to terminate study. All patients to come in for their final visit by the end of May.     ,,,000910,IS - Clin Study (MIGRATED)
2348,0140-0062,140.62,Ended,86,0140-P01,Open-label follow-up program/Europe,Ended,MIG,Migration,III,Phase III,until drug market.or premature terminat. ,,,000910,IS - Clin Study (MIGRATED)
2349,0140-0063,140.63,Ended,86,0140-P01,Bioequ.clin./market.TA/clin.KAH 5mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2350,0140-0064,140.64,Ended,86,0140-P01,Bioequ. clinical/marketed TA 7.5 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2351,0140-0065,140.65,Ended,86,0140-P01,ELECTROPHYSIOLOGY-SINUS NODE ACTIVITY,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
2352,0140-0066,140.66,Ended,86,0140-P01,Long-term efficacy,Ended,MIG,Migration,III,Phase III,-  Cardio data costs included in labs. Investigator told to terminate the study. All patients are to come in for the final visit by the end of May.     ,,,000910,IS - Clin Study (MIGRATED)
2353,0140-0067,140.67,Ended,86,0140-P01,PHARMACOKINETICS/DILTIAZEM,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2354,0140-0068,140.68,Unconfirmed,86,0140-P01,Interaction with Digoxin/CDN,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2355,0140-0069,140.69,Ended,86,0140-P01,INTERACTION WITH NIFEDIPINE,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2356,0140-0070,140.70,Ended,86,0140-P01,7.5 mg: Interaction with 20 mg ISDN p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2357,0140-0071,140.71,Ended,86,0140-P01,7.5 mg: Interaction with Cimetidine,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2358,0140-0072,140.72,Ended,86,0140-P01,Int'l Long-term safety,Ended,MIG,Migration,III,Phase III,-  BIPI will provide CRFs and data management. Thomae will package and supply drug. Study being terminated. All patients will come in for a final visit by the end of May.   ,,,000910,IS - Clin Study (MIGRATED)
2359,0140-0073,140.73,Unconfirmed,86,0140-P01,Open-label follow-up 2.5, 5, 7.5 bid/CDN,Unconfirmed,MIG,Migration,III,Phase III,For pats not prev. enroll. in Zat trials No protocol has been received here at BID hence there is very little information about this trial,,,000910,IS - Clin Study (MIGRATED)
2360,0140-0074,140.74,Ended,86,0140-P01,Retinal electrophysiology in healthy vol,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2361,0140-0075,140.75,Ended,86,0140-P01,Long-term safety,Ended,MIG,Migration,III,Phase III,-  Trial protocol and CRFs based on trial 00968A. Investigators notified to bring in all patients for a final visit and terminate the study by the end of May.     ,,,000910,IS - Clin Study (MIGRATED)
2362,0140-0077,140.77,Unconfirmed,86,0140-P01,Single dose asthma/CDN,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2363,0140-0078,140.78,Unconfirmed,86,0140-P01,Electrophysiology AV-Block/CDN,Unconfirmed,MIG,Migration,II,Phase II,- There is currently no protocol here at BID hence there is little information in CTMD,,,000910,IS - Clin Study (MIGRATED)
2364,0140-0079,140.79,Unconfirmed,86,0140-P01,Effects on driving ability,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2365,0140-0080,140.80,Preparing,86,0140-P01,Dose ranging study/D,Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
2366,0140-0081,140.81,Unconfirmed,86,0140-P01,Bioequivalence trial formul.-market tab.,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2367,0140-0082,140.82,Unconfirmed,86,0140-P01,Relative and absolute bioavailability,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2368,0140-0084,140.84,Ended,86,0140-P01,none,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2369,0140-0085,140.85,Ended,86,0140-P01,PHASE I STUDY (MULTIPLE DOSE),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2370,0140-0086,140.86,Ended,86,0140-P01,SINGLE INCREASING DOSE PHASE I STUDY,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2371,0140-0087,140.87,Ended,86,0140-P01,PHASE I STUDY (MEAL),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2372,0140-0088,140.88,Ended,86,0140-P01,Effects of ULFS 49 Cl for angina pectori,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2373,0140-0089,140.89,Ended,86,0140-P01,early phaseII,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
2374,0140-0090,140.90,Ended,86,0140-P01,Clinical Pharmacological Trial,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
2375,0140-0091,140.91,Ended,86,0140-P01,IV HEMODYNAMICS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2376,0140-0093,140.93,Unconfirmed,86,0140-P01,Bioequivalence test,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2377,0140-0094,140.94,Unconfirmed,86,0140-P01,OT,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2378,0140-0095,140.95,Unconfirmed,86,0140-P01,DBT,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2379,0140-0096,140.96,Ended,86,0140-P01,Long Term Study,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2380,0140-0097,140.97,Ended,86,0140-P01,DTS,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
2381,0140-0098,140.98,Ended,86,0140-P01,Clinical Pharmacological trial,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
2382,0140-0099,140.99,Ended,86,0140-P01,TREADMILL TEST,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
2383,0140-0100,140.100,Ended,86,0140-P01,MYOCARDIAL IMAGING,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
2384,0135-0070,135.70,Ended,87,0135-P06,COBALT,Ended,MIG,Migration,IIIB,Phase IIIb,- *Biberach trial,,,000910,IS - Clin Study (MIGRATED)
2385,0135-0245,135.245,Ended,87,0135-P06,PILOT DOUBLE INTRAVENOUS BOLUS STUDY IN,Ended,MIG,Migration,II,Phase II,- publication available, report expected - no date (CTU letter 12/92),,,000910,IS - Clin Study (MIGRATED)
2386,0231-0212,231.212,Ended,88,0231-P02,ELSA,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2387,0231-0325,231.325,Ended,88,0231-P02,ELSA substudy on lipids profile,Ended,MIG,Migration,IV,Phase IV,Stat and DM performed by Glaxo Italy ,,,000910,IS - Clin Study (MIGRATED)
2388,0231-0341,231.341,Unconfirmed,88,0231-P02,Elsa-Substudie: Genotypisierung,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2389,0021-0030,21.30,Unconfirmed,89,0021-P01,Prevent.of acut.complic.of PTCA B 143/88,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2390,0021-0052,21.52,Ended,89,0021-P01,Efficacy in prevention vs placebo,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2391,0021-0375,21.375,Ended,89,0021-P01,Prevention of acute complications,Ended,MIG,Migration,III,Phase III,- old contract, payed by BIGmbH,,,000910,IS - Clin Study (MIGRATED)
2392,0021-0442,21.442,Ended,89,0021-P01,MI pre-conditioning,Ended,MIG,Migration,III,Phase III,-  Investigator will be Dr. C. Wolf at the University of California. To be monitored by Innovex. This trial may be terminated. Awaiting IMC approval to terminate. Trial terminated 10/23/95   ,,,000910,IS - Clin Study (MIGRATED)
2393,0135-0156,135.156,Ended,90,0135-P07,Thrombolytic treatment of acute coronary,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2394,0135-0210,135.210,Unconfirmed,90,0135-P07,Retinal arterial occlusion,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2395,0135-0279,135.279,Ended,90,0135-P07,rt-PA in cataract surgery,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2396,0135-0282,135.282,Ended,90,0135-P07,rt-pa in intraocular fibrin formation,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2397,0135-0283,135.283,Ended,90,0135-P07,Locally dissolve cent.retinal occlusion,Ended,MIG,Migration,III,Phase III,- ,,,,
2398,0135-0288,135.288,Ended,90,0135-P07,IOR-Study rt-PA,Ended,MIG,Migration,II,Phase II,- ,,,,
2399,0135-0289,135.289,Ended,90,0135-P07,Lysis of intraocular therapyres. fibrin,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2400,0018-0204,18.204,Unconfirmed,91,0018-P01,Bronchitis acute,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2401,0018-0205,18.205,Ended,91,0018-P01,Bronchitis acute,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2402,0018-0246,18.246,Ended,91,0018-P01,Bronchitis acute,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2403,0018-0268,18.268,Ended,91,0018-P01,none,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2404,0018-0321,18.321,Unconfirmed,91,0018-P01,Bronchitis chronic;Bronchitis acute,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2405,0018-0322,18.322,Unconfirmed,91,0018-P01,Bronchitis chronic;Bronchitis acute,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2406,0018-0323,18.323,Unconfirmed,91,0018-P01,Bronchitis acute;Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2407,0018-0324,18.324,Unconfirmed,91,0018-P01,Bronchitis acute;Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2408,0018-0325,18.325,Unconfirmed,91,0018-P01,Bronchitis acute;Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2409,0018-0326,18.326,Unconfirmed,91,0018-P01,Bronchitis acute;Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2410,0018-0327,18.327,Unconfirmed,91,0018-P01,Bronchitis,Unconfirmed,MIG,Migration,IV,Phase IV,- OPU: DPT FHER YV ** *,,,000910,IS - Clin Study (MIGRATED)
2411,0018-0339,18.339,Unconfirmed,91,0018-P01,Bronchitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2412,0018-0341,18.341,Unconfirmed,91,0018-P01,Bronchitis acute,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2413,0018-0342,18.342,Unconfirmed,91,0018-P01,Bronchitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2414,0018-0354,18.354,Unconfirmed,91,0018-P01,Bronchitis acute;Bronchitis chronic;Rhin,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
2415,0018-0356,18.356,Unconfirmed,91,0018-P01,Bronchitis acute;Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2416,0018-0357,18.357,Unconfirmed,91,0018-P01,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2417,0018-0361,18.361,Ended,91,0018-P01,Bronchitis acute,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2418,0018-0362,18.362,Ended,91,0018-P01,Liver insufficiency,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2419,0018-0367,18.367,Ended,91,0018-P01,BRONCHITIS,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
2420,0018-0368,18.368,Unconfirmed,91,0018-P01,Bronchitis acute,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2421,0018-0383,18.383,Ended,91,0018-P01,Bronchitis acute,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2422,0018-0384,18.384,Ended,91,0018-P01,Bronchitis acute,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2423,0018-0385,18.385,Ended,91,0018-P01,Bronchitis acute,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2424,0018-0386,18.386,Ended,91,0018-P01,Bronchitis acute,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2425,0018-0388,18.388,Unconfirmed,91,0018-P01,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2426,0018-0399,18.399,Ended,91,0018-P01,Bronchitis, acute,Ended,MIG,Migration,III,Phase III,- EE Study,,,000910,IS - Clin Study (MIGRATED)
2427,0018-0425,18.425,Ended,91,0018-P01,TAMURA OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2428,0018-0444,18.444,Ended,91,0018-P01,NIIZU OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2429,0018-0460,18.460,Ended,91,0018-P01,Ambroxol-QoL-Study,Ended,MIG,Migration,III,Phase III,- Study performed by Innovex in UK,,,000910,IS - Clin Study (MIGRATED)
2430,0018-0461,18.461,Ended,91,0018-P01,Ambroxol-Acute Bronchitis Study,Ended,MIG,Migration,III,Phase III,- *Ingelheim trial,,,000910,IS - Clin Study (MIGRATED)
2431,0018-0467,18.467,Unconfirmed,91,0018-P01,Dose-Finding Pediatric,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2432,0018-0470,18.470,Unconfirmed,91,0018-P01,Obstructive Bronchitis in Children,Unconfirmed,MIG,Migration,III,Phase III,,,,000980,Not Classified (MIGRATED)
2433,0135-0001,135.1,Ended,92,0135-P01,Cooperative study I in myocard. infarct.,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2434,0135-0002,135.2,Ended,92,0135-P01,Cooperative study II in myocard.infarct.,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2435,0135-0003,135.3,Unconfirmed,92,0135-P01,Verschlu√ü arterioven√∂ser Shunts,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2436,0135-0004,135.4,Ended,92,0135-P01,Plasmaspiegel: 70/90 mg bei 7.50h Infus.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2437,0135-0005,135.5,Ended,92,0135-P01,Infarction myocardial acute,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2438,0135-0006,135.6,Ended,92,0135-P01,Pharmacokinetics, Prof. Verstraete,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2439,0135-0008,135.8,Ended,92,0135-P01,G.A.U.S.,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2440,0135-0009,135.9,Ended,92,0135-P01,form.1 + form.2 rt-PA 0.25 mg/kg body-wt,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2441,0135-0010,135.10,Unconfirmed,92,0135-P01,Cooperative study IV,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2442,0135-0011,135.11,Ended,92,0135-P01,Cooperative study V,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2443,0135-0014,135.14,Ended,92,0135-P01,Instable angina pectoris, Hamburg,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2444,0135-0015,135.15,Ended,92,0135-P01,Kinetik: 0.25 + 0.50 mg/kgKG (1h Infus.),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2445,0135-0017,135.17,Ended,92,0135-P01,Methodenfindung: rt-PA Plasmaspiegel,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2446,0135-0020,135.20,Ended,92,0135-P01,Kinetik/H√§most.:0.25,0.5 mg/kgKG (30min),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2447,0135-0026,135.26,Ended,92,0135-P01,Dose comp., myocard infarct, multicenter,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2448,0135-0029,135.29,Unconfirmed,92,0135-P01,Kardiogener Schock, Mainz,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2449,0135-0030,135.30,Ended,92,0135-P01,Acute myocardial infarction, Pharmaco.,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2450,0135-0032,135.32,Ended,92,0135-P01,100 mg rt-PA bei akutem Myocardinfarkt,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2451,0135-0035,135.35,Ended,92,0135-P01,Vergleichende Kinetik von p.l.1, 2 und 3,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2452,0135-0036,135.36,Unconfirmed,92,0135-P01,Dosisfindung, BII Proj.-No 91 219, PI,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2453,0135-0037,135.37,Ended,92,0135-P01,Ambulance-study in emergency patients/U.,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2454,0135-0038,135.38,Ended,92,0135-P01,Ambulance-study in emergency patients/B.,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2455,0135-0039,135.39,Unconfirmed,92,0135-P01,Emergency PTCA, Rotterdam,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2456,0135-0043,135.43,Ended,92,0135-P01,AMI (Heparin),Ended,MIG,Migration,III,Phase III,- old contract, payed by BIGmbH / Report Dr. EAG, no date yet (EAG)/Rep.exp. 12/92 (CTIS page3),,,000910,IS - Clin Study (MIGRATED)
2457,0135-0044,135.44,Unconfirmed,92,0135-P01,AMI,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2458,0135-0053,135.53,Ended,92,0135-P01,TAPS (rt-PA - APSAC - Patency - Study),Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2459,0135-0054,135.54,Unconfirmed,92,0135-P01,MI - Heparin, UDSSR BIZ-Nr. 92002,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2460,0135-0057,135.57,Ended,92,0135-P01,Comparative kinetics old/new,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2461,0135-0058,135.58,Ended,92,0135-P01,Late assessment of thrombolytic efficacy,Ended,MIG,Migration,IV,Phase IV,- To be reported by BIL UK*Biberach trial,,,000910,IS - Clin Study (MIGRATED)
2462,0135-0059,135.59,Unconfirmed,92,0135-P01,ECCAPPIF, Frankreich,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2463,0135-0060,135.60,Unconfirmed,92,0135-P01,Reanimation,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2464,0135-0064,135.64,Ended,92,0135-P01,GUSTO trial,Ended,MIG,Migration,III,Phase III,- No monitoring in NL, centers monitored by Genentech.*Biberach trial,,,000910,IS - Clin Study (MIGRATED)
2465,0135-0067,135.67,Ended,92,0135-P01,Bioequival.of current/modified process,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2466,0135-0069,135.69,Ended,92,0135-P01,Safety and efficacy of KY-variant rt-PA,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2467,0135-0100,135.100,Ended,92,0135-P01,Infarction myocardial acute,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2468,0135-0101,135.101,Ended,92,0135-P01,THROMBOLYSIS,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2469,0135-0104,135.104,Ended,92,0135-P01,AMI,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2470,0135-0105,135.105,Ended,92,0135-P01,AMI,Ended,MIG,Migration,III,Phase III,- Dev.Prot.: FROM 1/1/87, RANDOM ALLOCATION TO PLACEBO ADMINISTRATION IN PATIENTS ADMITTED UNDER 2 HOURS WAS OMITTED BECA *,,,000910,IS - Clin Study (MIGRATED)
2471,0135-0107,135.107,Unconfirmed,92,0135-P01,Infarction myocardial,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
2472,0135-0108,135.108,Ended,92,0135-P01,Infarction myocardial acute,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2473,0135-0109,135.109,Unconfirmed,92,0135-P01,Infarction myocardial,Unconfirmed,MIG,Migration,NONE,Not Classified,- OPU: Genentech USA ** *,,,000910,IS - Clin Study (MIGRATED)
2474,0135-0110,135.110,Ended,92,0135-P01,Infarction myocardial,Ended,MIG,Migration,I,Phase I,- OPU: Genentech USA ** *,,,000910,IS - Clin Study (MIGRATED)
2475,0135-0114,135.114,Ended,92,0135-P01,Infarction myocardial acute,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2476,0135-0115,135.115,Ended,92,0135-P01,AMI, European trial,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2477,0135-0117,135.117,Ended,92,0135-P01,AMI (ASSET),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2478,0135-0120,135.120,Ended,92,0135-P01,Infarction myocardial acute,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2479,0135-0124,135.124,Unconfirmed,92,0135-P01,Infarction myocardial acute,Unconfirmed,MIG,Migration,NONE,Not Classified,- OPU: Genentech USA * *,,,000910,IS - Clin Study (MIGRATED)
2480,0135-0125,135.125,Unconfirmed,92,0135-P01,Infarction myocardial,Unconfirmed,MIG,Migration,I,Phase I,- OPU: Genentech USA ** *,,,000910,IS - Clin Study (MIGRATED)
2481,0135-0130,135.130,Unconfirmed,92,0135-P01,Infarction myocardial,Unconfirmed,MIG,Migration,NONE,Not Classified,- OPU: Genentech USA ** *,,,000910,IS - Clin Study (MIGRATED)
2482,0135-0131,135.131,Unconfirmed,92,0135-P01,Infarction myocardial,Unconfirmed,MIG,Migration,NONE,Not Classified,- OPU: Genentech USA * *,,,000910,IS - Clin Study (MIGRATED)
2483,0135-0134,135.134,Unconfirmed,92,0135-P01,Infarction myocardial,Unconfirmed,MIG,Migration,NONE,Not Classified,- OPU: Genentech USA * *,,,000910,IS - Clin Study (MIGRATED)
2484,0135-0135,135.135,Unconfirmed,92,0135-P01,Infarction myocardial,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
2485,0135-0137,135.137,Ended,92,0135-P01,AMI,Ended,MIG,Migration,IV,Phase IV,- OPU: Genentech USA, BI Canada monitoring, Contract cancelled, status is analysing, but set to 'ended without report' *,,,000910,IS - Clin Study (MIGRATED)
2486,0135-0139,135.139,Ended,92,0135-P01,AMI,Ended,MIG,Migration,III,Phase III,- NZ Trial,,,000910,IS - Clin Study (MIGRATED)
2487,0135-0141,135.141,Unconfirmed,92,0135-P01,Infarction myocardial acute,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
2488,0135-0142,135.142,Unconfirmed,92,0135-P01,Infarction myocardial acute,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2489,0135-0143,135.143,Ended,92,0135-P01,AMI,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2490,0135-0144,135.144,Ended,92,0135-P01,Infarction myocardial/AMI Ambulance stud,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2491,0135-0145,135.145,Ended,92,0135-P01,AMI ambulance study,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2492,0135-0147,135.147,Ended,92,0135-P01,Infarction myocardial,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2493,0135-0148,135.148,Unconfirmed,92,0135-P01,Angina-Pectoris unstable,Unconfirmed,MIG,Migration,NONE,Not Classified,- OPU: Genentech USA * *,,,000910,IS - Clin Study (MIGRATED)
2494,0135-0150,135.150,Ended,92,0135-P01,AMI,Ended,MIG,Migration,II,Phase II,- Report requested 30.03.93 (Letter EAG),,,000910,IS - Clin Study (MIGRATED)
2495,0135-0153,135.153,Ended,92,0135-P01,AMI,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2496,0135-0154,135.154,Ended,92,0135-P01,AMI,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2497,0135-0155,135.155,Unconfirmed,92,0135-P01,Infarction myocard. acute;Arterial occl.,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
2498,0135-0162,135.162,Ended,92,0135-P01,Infarction myocardial,Ended,MIG,Migration,III,Phase III,- planned patients: 25-40 ** *,,,000910,IS - Clin Study (MIGRATED)
2499,0135-0163,135.163,Ended,92,0135-P01,TEAHAT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2500,0135-0164,135.164,Ended,92,0135-P01,AMI,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2501,0135-0165,135.165,Ended,92,0135-P01,AMI,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2502,0135-0166,135.166,Ended,92,0135-P01,AMI,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2503,0135-0168,135.168,Ended,92,0135-P01,Infarction myocardial acute,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2504,0135-0172,135.172,Ended,92,0135-P01,EFFECTS ON FIBRINOLYTIC PROCESS ON PATIE,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2505,0135-0174,135.174,Ended,92,0135-P01,AMI ambulance study,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2506,0135-0176,135.176,Ended,92,0135-P01,AMI (ambulance REPAIR),Ended,MIG,Migration,IV,Phase IV,- planned patients: 200-300 * *,,,000910,IS - Clin Study (MIGRATED)
2507,0135-0178,135.178,Ended,92,0135-P01,Thrombolytic and cardioprotective therap,Ended,MIG,Migration,II,Phase II,- old contract, payed by BIGmbH /                               Report expected 12/92 (T. Goethals - EAG),,,000910,IS - Clin Study (MIGRATED)
2508,0135-0179,135.179,Ended,92,0135-P01,GISSI 2,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2509,0135-0180,135.180,Ended,92,0135-P01,AMI ambulance study,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2510,0135-0181,135.181,Ended,92,0135-P01,AMI,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2511,0135-0182,135.182,Ended,92,0135-P01,AMI,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2512,0135-0183,135.183,Unconfirmed,92,0135-P01,AMI,Unconfirmed,MIG,Migration,IV,Phase IV,- OPU: Genentech USA, BI Canada monitoring, Contract cancelled, status is analysing, but set to 'ended without report' *,,,000910,IS - Clin Study (MIGRATED)
2513,0135-0184,135.184,Ended,92,0135-P01,AMI,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2514,0135-0185,135.185,Ended,92,0135-P01,AMI,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2515,0135-0186,135.186,Ended,92,0135-P01,rt-PA and positron emission tomography,Ended,MIG,Migration,IV,Phase IV,- Safety summary expected,,,000910,IS - Clin Study (MIGRATED)
2516,0135-0187,135.187,Ended,92,0135-P01,AMI,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2517,0135-0189,135.189,Ended,92,0135-P01,AMI,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2518,0135-0191,135.191,Ended,92,0135-P01,AMI,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2519,0135-0192,135.192,Unconfirmed,92,0135-P01,AMI,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2520,0135-0194,135.194,Ended,92,0135-P01,Dipyridamole and rt-PA in AMI,Ended,MIG,Migration,III,Phase III,- Nat. cf. CTU III/91 letter,,,000910,IS - Clin Study (MIGRATED)
2521,0135-0197,135.197,Ended,92,0135-P01,ASSESSING FACTORS AFFECTING TIME TO THRO,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2522,0135-0201,135.201,Ended,92,0135-P01,AMI,Ended,MIG,Migration,III,Phase III,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
2523,0135-0202,135.202,Ended,92,0135-P01,AMI,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2524,0135-0205,135.205,Ended,92,0135-P01,PILOT STUDY IN PATIENTS WITH MI,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2525,0135-0206,135.206,Ended,92,0135-P01,Infarction, myocardial, acute,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2526,0135-0207,135.207,Ended,92,0135-P01,AMI,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2527,0135-0208,135.208,Ended,92,0135-P01,South African TPA Trial,Ended,MIG,Migration,IV,Phase IV,- Safety Report in '93 * Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
2528,0135-0211,135.211,Ended,92,0135-P01,AMI,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2529,0135-0216,135.216,Ended,92,0135-P01,Anticoagulation or platelet aggreg.inhi.,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2530,0135-0217,135.217,Ended,92,0135-P01,AMI,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2531,0135-0218,135.218,Ended,92,0135-P01,AMI,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2532,0135-0219,135.219,Unconfirmed,92,0135-P01,AMI,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2533,0135-0220,135.220,Ended,92,0135-P01,P.T.C.A.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2534,0135-0227,135.227,Ended,92,0135-P01,Actilyse Myocardial Infarction,Ended,MIG,Migration,III,Phase III,- national interest ("Assistance Public de Paris"),,,000910,IS - Clin Study (MIGRATED)
2535,0135-0228,135.228,Ended,92,0135-P01,AMI (ambulance I),Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2536,0135-0229,135.229,Ended,92,0135-P01,AMI (ambulance II),Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2537,0135-0230,135.230,Ended,92,0135-P01,AMI (ambulance III),Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2538,0135-0234,135.234,Ended,92,0135-P01,L.A.T.I.M.S.,Ended,MIG,Migration,IV,Phase IV,- Discontinued due to low recruitment rate.,,,000910,IS - Clin Study (MIGRATED)
2539,0135-0236,135.236,Ended,92,0135-P01,SINGLE INTRAVENOUS BOLUS IN EARLY PHASE,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2540,0135-0238,135.238,Ended,92,0135-P01,PILOT BOLUS STUDY IN ACUTE MI,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2541,0135-0239,135.239,Ended,92,0135-P01,MYOC.INFARCTION,Ended,MIG,Migration,III,Phase III,- Arm of the study C87-0645 (local-no.: CT0379) same patients  as there (see no fault insurance '89) * *,,,000910,IS - Clin Study (MIGRATED)
2542,0135-0240,135.240,Ended,92,0135-P01,AMI,Ended,MIG,Migration,II,Phase II,- To be reported by BIAS,,,000910,IS - Clin Study (MIGRATED)
2543,0135-0241,135.241,Ended,92,0135-P01,Clinical trial of rt-PA,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2544,0135-0244,135.244,Ended,92,0135-P01,Myocardial infarction,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2545,0135-0246,135.246,Ended,92,0135-P01,rt-PA Thrombolysis and Reinfarction rate,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2546,0135-0247,135.247,Ended,92,0135-P01,MI,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2547,0135-0248,135.248,Ended,92,0135-P01,Prehospital treatment of AMI with throm,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2548,0135-0252,135.252,Ended,92,0135-P01,DOUBLE-BOLUS IN MI,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2549,0135-0255,135.255,Ended,92,0135-P01,AMI,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2550,0135-0256,135.256,Ended,92,0135-P01,Alteplase in acute myocardial infarction,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2551,0135-0259,135.259,Ended,92,0135-P01,LVF after late thombolysis with rt-PA,Ended,MIG,Migration,III,Phase III,- Intended for publication (Am. Coll. Cardiol. 42nd Annual    Sci. Session.,,,000910,IS - Clin Study (MIGRATED)
2552,0135-0260,135.260,Unconfirmed,92,0135-P01,Infarction, myocardial, acute,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2553,0135-0262,135.262,Ended,92,0135-P01,Failure coronary reperfus'n after strep.,Ended,MIG,Migration,III,Phase III,- ,,,,
2554,0135-0263,135.263,Ended,92,0135-P01,Repeated tpa administration,Ended,MIG,Migration,IV,Phase IV,- ,,,,
2555,0135-0265,135.265,Ended,92,0135-P01,Vector-ECG, GISSI protocol,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2556,0135-0266,135.266,Ended,92,0135-P01,DOUBLE BOLUS IV. IN ACUTE MI,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2557,0135-0268,135.268,Ended,92,0135-P01,B.A.M.I.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2558,0135-0269,135.269,Ended,92,0135-P01,A.M.I.P.,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2559,0135-0275,135.275,Ended,92,0135-P01,OT of rt-PA,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2560,0135-0276,135.276,Ended,92,0135-P01,GUSTO (135.64) angiographic substudy,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2561,0135-0277,135.277,Ended,92,0135-P01,Post marketing surveillance with Actilys,Ended,MIG,Migration,NONE,Not Classified,- ,,,000940,Post Marketing Study (MIGRATED)
2562,0135-0280,135.280,Ended,92,0135-P01,ANGIOGRAPHIC PATENCY OF BOLUS V 90 MIN,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2563,0135-0284,135.284,Ended,92,0135-P01,Accelerating rt-PA Regimen in the Chines,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2564,0135-0290,135.290,Ended,92,0135-P01,Continuos Vs Double Boulus,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2565,0135-0292,135.292,Ended,92,0135-P01,Angioplasty Compatibility Trial (PAACT),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2566,0135-0298,135.298,Ended,92,0135-P01,TUCC pilot study,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2567,0135-0299,135.299,Ended,92,0135-P01,TUCC,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2568,0135-0301,135.301,Ended,92,0135-P01,PHARAOH,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2569,0135-0303,135.303,Unconfirmed,92,0135-P01,rt-PA and 40 hrs inf. vs. dalteparin,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,The study was given a new st.no. 1174.1 ,,,000910,IS - Clin Study (MIGRATED)
2570,0135-0305,135.305,Unconfirmed,92,0135-P01,Actilyse - Myocardinfarkt,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2571,0135-0306,135.306,Unconfirmed,92,0135-P01,Actilyse - Myocardinfarkt,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2572,0135-0308,135.308,Recruiting,92,0135-P01,ESTIM Study,Recruiting,MIG,Migration,IV,Phase IV,,,,,
2573,0135-0325,135.325,Unconfirmed,92,0135-P01,EARLY-MYO,Unconfirmed,MIG,Migration,III,Phase III,,,,,
2574,0135-0326,135.326,Recruiting,92,0135-P01,Early-MYO,Recruiting,MIG,Migration,IV,Phase IV,,,,,
2575,0135-0328,135.328,Recruiting,92,0135-P01,Actilyse during PCI in STEMI patients,Recruiting,MIG,Migration,II,Phase II,,,,,
2576,0135-0334,135.334,First Subject Randomised,92,0135-P01,OPTIMAL Opt cor flow after PCI for STEMI,First Subject Randomised,MIG,Migration,II,Phase II,,,,,
2577,0502-0133,502.133,Unconfirmed,93,0502-P03,PK/Bioavailability for fixed dose comb.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2578,0502-0136,502.136,Ended,93,0502-P03,BA fixed dose vs components,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2579,0502-0204,502.204,Ended,93,0502-P03,HCTZ factorial design,Ended,MIG,Migration,III,Phase III,-  Will use tablet formulation. Planned for conduct in U.S. Number of centers, patients and initiation date changed per Dr. Urquilla. FDA commenting on protocol (Jan.-Feb 95).     ,,,000910,IS - Clin Study (MIGRATED)
2580,0502-0215,502.215,Ended,93,0502-P03,Long-Term Comp. (HCTZ add-on),Ended,MIG,Migration,III,Phase III,- *Biberach trial,,,000910,IS - Clin Study (MIGRATED)
2581,0502-0229,502.229,Unconfirmed,93,0502-P03,Fixed Dose Combination,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
2582,0502-0230,502.230,Unconfirmed,93,0502-P03,de novo open-label safety,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2583,0502-0231,502.231,Unconfirmed,93,0502-P03,de novo OL safety,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,- ,,,000910,IS - Clin Study (MIGRATED)
2584,0502-0232,502.232,Unconfirmed,93,0502-P03,Clinical pharmacolo-gy,Unconfirmed,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
2585,0502-0246,502.246,Unconfirmed,93,0502-P03,Telmisartan vs. Losartan / Mexico,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2586,0502-0247,502.247,Unconfirmed,93,0502-P03,Telmisartan vs. Active Control / Mexico,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2587,0502-0250,502.250,Unconfirmed,93,0502-P03,Confirmatory effic. study FDC Telmi/HCTZ,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2588,0502-0261,502.261,Ended,93,0502-P03,Telmisartan FDC Pivotal Efficacy 80/12.5,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2589,0502-0262,502.262,Unconfirmed,93,0502-P03,Confirmatory effic./factorial design FDC,Unconfirmed,MIG,Migration,NONE,Not Classified,was formerly 502.229, which appear canc. ,,,000910,IS - Clin Study (MIGRATED)
2590,0502-0315,502.315,Preparing,93,0502-P03,FDC vs Amlodipine in Blacks,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2591,0502-0321,502.321,Ended,93,0502-P03,FDC long term follow up,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2592,0502-0323,502.323,Ended,93,0502-P03,40/12.5 pivotal efficacy,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2593,0502-0324,502.324,Ended,93,0502-P03,PK/BE study 40/12.5,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2594,0502-0342,502.342,Preparing,93,0502-P03,MicHCT in Blk Htn pts (20%diabetic),Preparing,MIG,Migration,IV,Phase IV,pilot ,,,000910,IS - Clin Study (MIGRATED)
2595,0502-0349,502.349,Unconfirmed,93,0502-P03,Micardis FDC in Blacks,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2596,0502-0387,502.387,Ended,93,0502-P03,Telmisartan HCTZ vs HYZAAR,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2597,0502-0388,502.388,Unconfirmed,93,0502-P03,Telm HCTZ in non-responders,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2598,0502-0390,502.390,Ended,93,0502-P03,Praxis PMS study,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2599,0502-0399,502.399,Ended,93,0502-P03,SMOOTH - BP control in Diabetic/Obese,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2600,0502-0400,502.400,Ended,93,0502-P03,ATHOS: elderly/systolic hypertension,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2601,0502-0404,502.404,Unconfirmed,93,0502-P03,Micardis in home blood pressure control,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2602,0502-0406,502.406,Ended,93,0502-P03,S/E Telmisartan 40+ vs Losartan 50+ HCTZ,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2603,0502-0409,502.409,Unconfirmed,93,0502-P03,PROFILE,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000940,Post Marketing Study (MIGRATED)
2604,0502-0410,502.410,Ended,93,0502-P03,Follow-up PROFILE,Ended,MIG,Migration,NONE,Not Classified,,,,000940,Post Marketing Study (MIGRATED)
2605,0502-0427,502.427,Ended,93,0502-P03,MH AWB 2003, Germany,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2606,0502-0436,502.436,Ended,93,0502-P03,Non-responder study to Telmisartan 40mg,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
2607,0502-0437,502.437,Ended,93,0502-P03,BE between Int-combo and J-FDC 40 /12.5,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2608,0502-0438,502.438,Ended,93,0502-P03,BE between Int-combo and J-FDC 80 /12.5,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2609,0502-0439,502.439,Ended,93,0502-P03,Factorial Study,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
2610,0502-0453,502.453,Ended,93,0502-P03,MIC PLUS Phase I,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2611,0502-0454,502.454,Preparing,93,0502-P03,Ph I multiple dose,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2612,0502-0455,502.455,Preparing,93,0502-P03,DESPERTAR,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2613,0502-0459,502.459,Preparing,93,0502-P03,Efficacy & Safety of Micardis Plus,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2614,0502-0463,502.463,Ended,93,0502-P03,IMPROVE,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2615,0502-0472,502.472,Ended,93,0502-P03,Saf & Eff of MicardisPlus 80/12.5,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2616,0502-0475,502.475,Ended,93,0502-P03,MicardisPlus PMS Study in Korea,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2617,0502-0495,502.495,Ended,93,0502-P03,BE Int-combo vs J-FDC 80/12.5 II,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2618,0502-0515,502.515,Ended,93,0502-P03,PK T 80 / H 12.5 tablet in China,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2619,0502-0516,502.516,Ended,93,0502-P03,Long term safety for 80/12.5 & 40/12.5,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2620,0502-0532,502.532,Ended,93,0502-P03,CENTER,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2621,0502-0542,502.542,Ended,93,0502-P03,Long-term observation PMS for Micombi,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
2622,0502-0554,502.554,Unconfirmed,93,0502-P03,Telmi alone in comp to Telmi and LSC,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2623,0502-0569,502.569,Ended,93,0502-P03,Food effect of Telmisartan/HCTZ,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2624,0502-0571,502.571,Ended,93,0502-P03,BE between J-T80(T40*2)+J-FDC T80/H12.5,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2625,0534-0003,534.3,Unconfirmed,94,0534-P01,Escalating doses,Unconfirmed,MIG,Migration,I,Phase I,- No BI Trial (CNSI),,,000910,IS - Clin Study (MIGRATED)
2626,0534-0008,534.8,Unconfirmed,94,0534-P01,Stroke,Unconfirmed,MIG,Migration,IIA,Phase IIa,- No BI Trial: CNSI in USA, Canada and Europe. End of Treatment: 12/95,,,000910,IS - Clin Study (MIGRATED)
2627,0534-0010,534.10,Unconfirmed,94,0534-P01,Stroke,Unconfirmed,MIG,Migration,I,Phase I,- No BI Study: CNSI in USA and UK. End of Treatment: 11/95,,,000910,IS - Clin Study (MIGRATED)
2628,0534-0011,534.11,Ended,94,0534-P01,Definitive Phase II/III Stroke,Ended,MIG,Migration,IIB,Phase IIb,-  A full service CRO will conduct the trial and perform data manageme nt. A final decision regarding whether or not to continue the trial will be made no later than 3 months after data lock for the interim report. Clin comp date assumes June start date and .5 pt/mo accrual. UK will also participate.   ,,,000910,IS - Clin Study (MIGRATED)
2629,0534-0013,534.13,Unconfirmed,94,0534-P01,Definitive Phase III Stroke,Unconfirmed,MIG,Migration,III,Phase III,-  An interim report is unlikely. CRO usage TBD. This trial will be like 534.11 except there will be one ac tive dose. It will use the same investigetors a 534.11, and will b egin when patient enrollment is completed on 534.11. UK will also participate.   ,,,000910,IS - Clin Study (MIGRATED)
2630,0534-0014,534.14,Ended,94,0534-P01,Proof of Safety,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2631,0534-0015,534.15,Unconfirmed,94,0534-P01,DWI in acute stroke,Unconfirmed,MIG,Migration,III,Phase III,-  A full service CRO will conduct the trial and perform data manageme nt. This trial will be similar to 534.13 except that it will use an  anatomical (DWI) rather than functional endpoint. Trial is ON-HOLD.   ,,,000910,IS - Clin Study (MIGRATED)
2632,0534-0017,534.17,Unconfirmed,94,0534-P01,PhaseIIa study of CNS1102,Unconfirmed,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
2633,0534-0020,534.20,Ended,94,0534-P01,Phase I of CNS1102 (single i.v. admin.),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2634,0502-0217,502.217,Ended,95,0502-P02,ARCTIC Study (Acute Hemodynamics),Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
2635,0502-0218,502.218,Ended,95,0502-P02,Repl.Angiotensin conv. enzyme in CHF,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2636,0502-0227,502.227,Ended,95,0502-P02,Early phase II(dose-escalation design,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
2637,0502-0249,502.249,Unconfirmed,95,0502-P02,CHF study vs captopril,Unconfirmed,MIG,Migration,III,Phase III,-  Min 12 mo. duration per patient may be extended to 18 mo. 2/4/98: if a decision is made to pursue this study, a new trial num ber will be assigned.     ,,,000910,IS - Clin Study (MIGRATED)
2638,0502-0348,502.348,Preparing,95,0502-P02,Micardis in CHF pilot,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2639,0135-0016,135.16,Unconfirmed,96,0135-P02,Major Pulmonary Embolism - multicenter,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2640,0135-0031,135.31,Ended,96,0135-P02,Pulmonary embolism,Ended,MIG,Migration,III,Phase III,- old contract, payed by BIGmbH*Biberach trial,,,000910,IS - Clin Study (MIGRATED)
2641,0135-0103,135.103,Ended,96,0135-P02,Embolism pulmonary,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2642,0135-0126,135.126,Ended,96,0135-P02,Embolism pulmonary,Ended,MIG,Migration,NONE,Not Classified,- OPU: Genentech USA * *,,,000910,IS - Clin Study (MIGRATED)
2643,0135-0151,135.151,Unconfirmed,96,0135-P02,Embolism pulmonary,Unconfirmed,MIG,Migration,NONE,Not Classified,- OPU: Genentech USA * *,,,000910,IS - Clin Study (MIGRATED)
2644,0135-0152,135.152,Ended,96,0135-P02,Embolism pulmonary,Ended,MIG,Migration,NONE,Not Classified,- OPU: Genentech USA * *,,,000910,IS - Clin Study (MIGRATED)
2645,0135-0200,135.200,Ended,96,0135-P02,P.A.I.M.S. 2,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2646,0135-0209,135.209,Ended,96,0135-P02,Pulmonary embolism,Ended,MIG,Migration,III,Phase III,- old contract, payed by BIGmbH,,,000910,IS - Clin Study (MIGRATED)
2647,0135-0253,135.253,Ended,96,0135-P02,PULMONARY EMBOLISM,Ended,MIG,Migration,IV,Phase IV,- Monitoring in Canada and US by Genentech,,,000910,IS - Clin Study (MIGRATED)
2648,0135-0272,135.272,Ended,96,0135-P02,Actilyse, pulmonary embolism, hemodynami,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
2649,0135-0294,135.294,Ended,96,0135-P02,Effect of Actilyse on pulmonary embolism,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2650,1123-0001,1123.1,Ended,97,1123-P01,Open-Label, MC, Dose-Escalation,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2651,1123-0002,1123.2,Ended,97,1123-P01,Open-Label,MC,Rand.,Angiographic Trial,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2652,1123-0003,1123.3,Ended,97,1123-P01,ASSENT-1, MC,OL,Rand.,Safety Trial,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2653,1123-0004,1123.4,Ended,97,1123-P01,ASSENT 2 Efficacy, Safety and Mortality,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2654,1123-0005,1123.5,Ended,97,1123-P01,Procoagulant effect of TNK,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2655,1123-0006,1123.6,Unconfirmed,97,1123-P01,Combination study with ReoPro,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2656,1123-0007,1123.7,Preparing,97,1123-P01,Early Thrombolysis,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2657,1123-0008,1123.8,Ended,97,1123-P01,Asian TNK Study,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2658,1123-0009,1123.9,Ended,97,1123-P01,TEMA24h ECG Monitoring Assent2 sub-popul,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2659,1123-0010,1123.10,Ended,97,1123-P01,ASSENT 3,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2660,1123-0011,1123.11,Ended,97,1123-P01,Assent 3 Plus,Ended,MIG,Migration,IIIB,Phase IIIb,Further documentation see Assent 3 ,,,000910,IS - Clin Study (MIGRATED)
2661,1123-0012,1123.12,Ended,97,1123-P01,ASSENT IV - Thrombolysis + PCI,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2662,1123-0013,1123.13,Unconfirmed,97,1123-P01,FACILITATED PCI,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
2663,1123-0014,1123.14,Unconfirmed,97,1123-P01,ASSENT 3 Bis,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
2664,1123-0015,1123.15,Ended,97,1123-P01,Vermont University,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2665,1123-0016,1123.16,Ended,97,1123-P01,Metalyse Used in Emergency Ambulance,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2666,1123-0017,1123.17,Preparing,97,1123-P01,Stim 2002,Preparing,MIG,Migration,NONE,Not Classified,,,,000940,Post Marketing Study (MIGRATED)
2667,1123-0019,1123.19,Ended,97,1123-P01,BERAMI-I,Ended,MIG,Migration,IV,Phase IV,,,,,
2668,1123-0021,1123.21,Ended,97,1123-P01,OPTIMAL,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2669,1123-0022,1123.22,Ended,97,1123-P01,Metalyse PRTOSinRF,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2670,1123-0025,1123.25,Ended,97,1123-P01,PMS for Metalyse,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2671,1123-0026,1123.26,Ended,97,1123-P01,Pan-Hellenic Registry of Acute MI,Ended,MIG,Migration,IV,Phase IV,,,,,
2672,1123-0027,1123.27,Ended,97,1123-P01,Myocardial Infarction Registry,Ended,MIG,Migration,IV,Phase IV,,,,,
2673,1123-0028,1123.28,Ended,97,1123-P01,STREAM,Ended,MIG,Migration,IIIB,Phase IIIb,,2007-001219-44,,000910,IS - Clin Study (MIGRATED)
2674,1123-0029,1123.29,Preparing,97,1123-P01,Europ.registry AMII treat community hosp,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
2675,1123-0030,1123.30,Ended,97,1123-P01,BLITZ 3,Ended,MIG,Migration,IV,Phase IV,National register conducted by ANMCO Epidemiological study,,,000940,Post Marketing Study (MIGRATED)
2676,1123-0033,1123.33,Unconfirmed,97,1123-P01,STREAM 2,Unconfirmed,MIG,Migration,III,Phase III,,,,,
2677,0265-0101,265.101,Ended,98,0265-P01,Tolerance, increasing SD, p.o.,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2678,0265-0102,265.102,Ended,98,0265-P01,Efficacy, Plasma levels,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2679,0265-0103,265.103,Ended,98,0265-P01,Tolerance, increasing SD, i.v.,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2680,0265-0104,265.104,Ended,98,0265-P01,Tolerance,, increasing SD, i.h.,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2681,0265-0105,265.105,Ended,98,0265-P01,Tolerance, efficacy, MD,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2682,0265-0106,265.106,Ended,98,0265-P01,Tolerance, efficacy, MD,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2683,0265-0107,265.107,Ended,98,0265-P01,Plasma levels, Urine excretion,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2684,0265-0108,265.108,Unconfirmed,98,0265-P01,No Legacy Data,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2685,0265-0110,265.110,Ended,98,0265-P01,Pharmacokinetics, Bioavailability,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2686,0265-0112,265.112,Ended,98,0265-P01,Bronchoconstriction, PAF-induced,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2687,0265-0113,265.113,Ended,98,0265-P01,Pharmacokinetics, Metabolism,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2688,0265-0114,265.114,Ended,98,0265-P01,safety and tolerab., after multiple nasa,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2689,0265-0116,265.116,Ended,98,0265-P01,Effect of WEB 2086 on bleeding time,Ended,MIG,Migration,I,Phase I,- Report requested (Letter LV 11/93),,,000910,IS - Clin Study (MIGRATED)
2690,0265-0117,265.117,Ended,98,0265-P01,WEB 2086/ASA:interact. on bleeding time,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2691,0265-0118,265.118,Unconfirmed,98,0265-P01,WEB2086 bioequival., caps. vs filmtablet,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2692,0265-0119,265.119,Ended,98,0265-P01,Hemodynamic effects,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2693,0265-0120,265.120,Ended,98,0265-P01,Phase I study (single administration),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2694,0265-0121,265.121,Preparing,98,0265-P01,multiple dose, safety,tol.,kinetics,Preparing,MIG,Migration,I,Phase I,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2695,0265-0122,265.122,Ended,98,0265-P01,EFFICACY ON PAF IND.CUT.RESP. VOLUNTEERS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2696,0265-0201,265.201,Ended,98,0265-P01,EFFECTS ON ASTHMATICS REQ.INH.CORTICOSTE,Ended,MIG,Migration,II,Phase II,- started int'l / 3/93 (verbal communication),,,000910,IS - Clin Study (MIGRATED)
2697,0265-0206,265.206,Ended,98,0265-P01,Antigen-ind. bronch., hyperresponsivenes,Ended,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2698,0265-0209,265.209,Ended,98,0265-P01,Asthma, hyperreaction,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2699,0265-0211,265.211,Preparing,98,0265-P01,Cutaneous allergen, oral WEB 2086 40 mg,Preparing,MIG,Migration,II,Phase II,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2700,0265-0212,265.212,Ended,98,0265-P01,ORAL ALLERGEN CHALLENGE STUDY,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2701,0265-0213,265.213,Ended,98,0265-P01,Open label of WEB 2086 for asthma,Ended,MIG,Migration,II,Phase II,- ,,,,
2702,0265-0214,265.214,Unconfirmed,98,0265-P01,BRONCHIAL ASTHMA,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2703,0265-1401,265.1401,Ended,98,0265-P01,Efficacy & safety, system. mastocytosis,Ended,MIG,Migration,II,Phase II,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2704,0265-2000,265.2000,Ended,98,0265-P01,Efficacy in ITP,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2705,0265-2001,265.2001,Ended,98,0265-P01,Not yet coded,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2706,0265-2002,265.2002,Ended,98,0265-P01,Phase I study (multiple administration),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2707,0265-2003,265.2003,Ended,98,0265-P01,ORAL/INHALED WEB2086 ON PAF INDUCED BRON,Ended,MIG,Migration,I,Phase I,- Report exp. end '92 (T. LV),,,000910,IS - Clin Study (MIGRATED)
2708,0265-2004,265.2004,Ended,98,0265-P01,Dose finding study compared with placebo,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2709,0265-2007,265.2007,Ended,98,0265-P01,Additional phase I study (Multiple adm.),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2710,0265-2008,265.2008,Ended,98,0265-P01,Additional dose finding study,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2711,0265-2009,265.2009,Ended,98,0265-P01,DBT compared with active drug,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2712,0265-2010,265.2010,Ended,98,0265-P01,Long term study,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2713,0265-2011,265.2011,Ended,98,0265-P01,Long term study,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2714,0265-2012,265.2012,Ended,98,0265-P01,Effects on bronchial hyperresponsiveness,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2715,0265-2013,265.2013,Ended,98,0265-P01,Influence of food on bioavailability,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2716,0265-2014,265.2014,Ended,98,0265-P01,Skin tolerability,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2717,0265-2015,265.2015,Ended,98,0265-P01,Tolerability of WEB eye drops,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2718,0265-2016,265.2016,Ended,98,0265-P01,Phototoxicity of WEB 2086 Cream 3%,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2719,0265-2017,265.2017,Ended,98,0265-P01,Anti-inflamatory effects of web2086,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2720,0265-0109,265.109,Ended,99,0265-P02,Plasma level after, SD inhalation,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2721,0265-0123,265.123,Ended,99,0265-P02,EFFICACY AGAINST PAF IND.BRONCHOCONSTR.,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2722,0265-0124,265.124,Preparing,99,0265-P02,Efficacy, inhaled PAF,Preparing,MIG,Migration,I,Phase I,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2723,0265-0801,265.801,Ended,99,0265-P02,Antigen-induced, hyperresponsivness,Ended,MIG,Migration,II,Phase II,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2724,0265-0403,265.403,Preparing,100,0265-P03,Efficacy, Safety,Preparing,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2725,0265-0404,265.404,Unconfirmed,100,0265-P03,RHINITIS,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2726,0265-0405,265.405,Unconfirmed,100,0265-P03,RHINITIS,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2727,0265-0901,265.901,Ended,100,0265-P03,Nasal provocation,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
2728,0265-0902,265.902,Ended,100,0265-P03,Cedar pollen trial,Ended,MIG,Migration,II,Phase II,-  Formerly IIb3     ,,,000910,IS - Clin Study (MIGRATED)
2729,0265-0115,265.115,Ended,101,0265-P04,Tolerance,intranasal, SD,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2730,0265-0401,265.401,Ended,101,0265-P04,Nasal provocation trial,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
2731,0265-0402,265.402,Ended,101,0265-P04,Ragweed trial,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
2732,0265-2005,265.2005,Ended,101,0265-P04,Nasal provocation study of WEB 2086,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2733,0265-2006,265.2006,Ended,101,0265-P04,Nasal provocation study of WEB 2086,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2734,0265-0701,265.701,Ended,102,0265-P05,Efficacy & safety, basic treatment,Ended,MIG,Migration,II,Phase II,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2735,0265-1001,265.1001,Preparing,102,0265-P05,Efficacy & safety in, proctosigmoiditis,Preparing,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2736,0265-1002,265.1002,Preparing,102,0265-P05,safety &tolerability,Preparing,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2737,0265-1101,265.1101,Ended,103,0265-P07,Efficacy and Safety of WEB 2086 in Psori,Ended,MIG,Migration,II,Phase II,- started int'l / Report requested (Letter RK 11.08.92) no ans wer / (Letter Dr. Woerner),,,000910,IS - Clin Study (MIGRATED)
2738,0265-2018,265.2018,Unconfirmed,103,0265-P07,Efficacy and tolerability,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2739,0265-2019,265.2019,Unconfirmed,103,0265-P07,Efficacy in prev. ecz. infl. after aller,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2740,0266-0101,266.101,Ended,104,0266-P01,Increasing doses, single dose p.o.,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2741,0266-0102,266.102,Ended,104,0266-P01,Dose-response, single dose p.o.,Ended,MIG,Migration,I,Phase I,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2742,0266-0103,266.103,Ended,104,0266-P01,Multiple dose, oral, tolerance,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2743,0266-0104,266.104,Ended,104,0266-P01,Protective effect of, single oral dose,Ended,MIG,Migration,I,Phase I,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2744,0266-0105,266.105,Unconfirmed,104,0266-P01,NONE,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2745,0266-0106,266.106,Ended,104,0266-P01,Increasing doses, single dose i.v.,Ended,MIG,Migration,I,Phase I,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2746,0266-0107,266.107,Ended,104,0266-P01,Abs. bioavailability,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2747,0266-0108,266.108,Ended,104,0266-P01,Increasing doses, single dose p.o.,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2748,0266-0109,266.109,Ended,104,0266-P01,Multiple dose, oral, tolerance,Ended,MIG,Migration,I,Phase I,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2749,0266-0110,266.110,Ended,104,0266-P01,Kinetics-male/female, tolerance,Ended,MIG,Migration,I,Phase I,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2750,0266-0112,266.112,Unconfirmed,104,0266-P01,Protective effect, PAF-provocation,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2751,0264-0101,264.101,Ended,105,0264-P01,Safety, titration,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2752,0264-0102,264.102,Ended,105,0264-P01,Tolerance, safety,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2753,0264-0103,264.103,Ended,105,0264-P01,Heart function, skin humidity,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2754,0264-0104,264.104,Ended,105,0264-P01,Scopolamin, dementia test,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2755,0264-0105,264.105,Ended,105,0264-P01,i.v. safety, single dose,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2756,0264-0106,264.106,Ended,105,0264-P01,Safety & kinetics, bioavailability,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2757,0264-0107,264.107,Ended,105,0264-P01,Bioavailability, elderly volunteers,Ended,MIG,Migration,I,Phase I,- , Alter > 60, EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2758,0264-0108,264.108,Ended,105,0264-P01,Safety, multiple dose,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2759,0264-0109,264.109,Ended,105,0264-P01,Hypoxic Hypoxia, dose finding,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2760,0264-0110,264.110,Unconfirmed,105,0264-P01,Safety, elderly volunteers,Unconfirmed,MIG,Migration,I,Phase I,- , Alter > 60, EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2761,0264-0111,264.111,Ended,105,0264-P01,Event-related-brain-, potentials,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2762,0264-0112,264.112,Ended,105,0264-P01,Titration & safety, elderly volunteers,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2763,0264-0113,264.113,Ended,105,0264-P01,Pharmacokinetics, metabolism,Ended,MIG,Migration,I,Phase I,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2764,0264-0114,264.114,Unconfirmed,105,0264-P01,Safety, single dose,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2765,0264-0115,264.115,Unconfirmed,105,0264-P01,Safety, multiple dose,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2766,0264-0116,264.116,Unconfirmed,105,0264-P01,Pharmacodynamic, single dose,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2767,0264-0117,264.117,Unconfirmed,105,0264-P01,Pharmacokinetics, bioequivalence,Unconfirmed,MIG,Migration,I,Phase I,- , Alter > 60, EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2768,0264-0201,264.201,Ended,105,0264-P01,Safety,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2769,0264-0202,264.202,Preparing,105,0264-P01,Nootropic action, safety,Preparing,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2770,0264-0203,264.203,Preparing,105,0264-P01,Mode of action, safety,Preparing,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2771,0264-0204,264.204,Ended,105,0264-P01,Safety & efficacy, multiple dose,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2772,0264-0205,264.205,Preparing,105,0264-P01,Safety, nootropic, action,Preparing,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2773,0264-0206,264.206,Ended,105,0264-P01,Mode of action, safety,Ended,MIG,Migration,II,Phase II,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2774,0264-0207,264.207,Preparing,105,0264-P01,Safety & efficacy,Preparing,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2775,0264-0208,264.208,Preparing,105,0264-P01,Safety & efficacy, multiple dose,Preparing,MIG,Migration,II,Phase II,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2776,0264-0209,264.209,Preparing,105,0264-P01,Efficacy & safety, Cerebro spinal,Preparing,MIG,Migration,II,Phase II,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2777,0264-0210,264.210,Preparing,105,0264-P01,Safety & Efficacy,Preparing,MIG,Migration,II,Phase II,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2778,0264-0211,264.211,Ended,105,0264-P01,Safety & efficacy,Ended,MIG,Migration,II,Phase II,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2779,0264-0212,264.212,Unconfirmed,105,0264-P01,Safety & efficay,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2780,0264-0213,264.213,Unconfirmed,105,0264-P01,Safety & efficay,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2781,0264-0214,264.214,Unconfirmed,105,0264-P01,Safety & efficay,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2782,0264-0215,264.215,Unconfirmed,105,0264-P01,Safety & efficay,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2783,0264-0216,264.216,Unconfirmed,105,0264-P01,Organic mental disorder,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2784,0264-0220,264.220,Preparing,105,0264-P01,Safety & efficacy,Preparing,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2785,0264-0300,264.300,Unconfirmed,105,0264-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2786,0264-0301,264.301,Unconfirmed,105,0264-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2787,0264-0302,264.302,Unconfirmed,105,0264-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2788,0264-0303,264.303,Ended,105,0264-P01,Depression,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2789,0264-0304,264.304,Ended,105,0264-P01,CEREBROVASCULAR DISEASE,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2790,0264-0305,264.305,Ended,105,0264-P01,PHARMACOKINETICS,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2791,0264-0306,264.306,Ended,105,0264-P01,--,Ended,MIG,Migration,II,Phase II,- Only publication planned. * *,,,000910,IS - Clin Study (MIGRATED)
2792,0264-0307,264.307,Ended,105,0264-P01,DEMENTIA, SENILE,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2793,0264-0308,264.308,Ended,105,0264-P01,Morbus Meniere,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2794,0264-0309,264.309,Ended,105,0264-P01,CEREBROVASCULAR DISEASE,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2795,0264-0310,264.310,Ended,105,0264-P01,DBT VS AVAN,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2796,0264-0312,264.312,Ended,105,0264-P01,LONG TERM TREATMENT OF WEB1881,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2797,0264-0313,264.313,Ended,105,0264-P01,EFFECT OF WEB 1881 ON CEREBROSP. FLUID,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2798,0264-0314,264.314,Ended,105,0264-P01,Biological equivalence study of WEB 1881,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2799,0264-0315,264.315,Ended,105,0264-P01,WEB 1881 open trial (capsule form),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2800,0264-0316,264.316,Ended,105,0264-P01,WEB 1881 open trial (200 and 400 mg/day),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2801,0264-0317,264.317,Ended,105,0264-P01,WEB 1881 open trial,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2802,0264-0318,264.318,Ended,105,0264-P01,WEB 1881 open trial (capsule form),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2803,0264-0319,264.319,Ended,105,0264-P01,WEB 1881 open trial (capsule form),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2804,0072-0001,72.1,Ended,106,0072-P01,Kreislaufwirkung bei Probanden, I,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2805,0072-0002,72.2,Ended,106,0072-P01,Kreislaufwirkung bei Probanden, II,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
2806,0072-0101,72.101,Ended,106,0072-P01,Tolerancestudy, single dose,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2807,0072-0102,72.102,Unconfirmed,106,0072-P01,Tolerancestudy, single dose,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2808,0072-0103,72.103,Ended,106,0072-P01,Tolerancestudy, multiple dose,Ended,MIG,Migration,I,Phase I,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2809,0072-0104,72.104,Ended,106,0072-P01,Kinetics, single dose,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2810,0072-0105,72.105,Ended,106,0072-P01,Bioavailability, single dose,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2811,0072-0106,72.106,Ended,106,0072-P01,Pharmacokinetics,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2812,0072-0107,72.107,Ended,106,0072-P01,Pilotstudy, kinetics,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2813,0072-0108,72.108,Unconfirmed,106,0072-P01,Tolerance, single dose,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2814,0072-0109,72.109,Ended,106,0072-P01,Pharmacokinetics, metabolism,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2815,0072-0110,72.110,Unconfirmed,106,0072-P01,Kinetics, single dose,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2816,0072-0111,72.111,Unconfirmed,106,0072-P01,Kinetics, multiple dose,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2817,0072-0401,72.401,Unconfirmed,106,0072-P01,Parkinson-Syndrome,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2818,0072-0402,72.402,Ended,106,0072-P01,Efficacy, Hoehn&Yahr III-V,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2819,0072-0403,72.403,Unconfirmed,106,0072-P01,Efficacy, Hoehn & Yahr III-V,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2820,0072-0404,72.404,Ended,106,0072-P01,B-HT 920 vs. Madopar,Ended,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2821,0072-0405,72.405,Unconfirmed,106,0072-P01,Efficacy, Hoehn & Yahr I-III,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2822,0072-0406,72.406,Ended,106,0072-P01,Efficacy, Hoehn & Yahr II-IV,Ended,MIG,Migration,II,Phase II,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2823,0072-0407,72.407,Unconfirmed,106,0072-P01,Efficacy,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2824,0072-0408,72.408,Unconfirmed,106,0072-P01,Efficacy,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2825,0072-0409,72.409,Unconfirmed,106,0072-P01,Parkinson-Syndrome,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2826,0072-0410,72.410,Ended,106,0072-P01,Parkinson's Disease,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2827,0072-0411,72.411,Preparing,106,0072-P01,Efficacy, on-off symptoms,Preparing,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2828,0072-0412,72.412,Unconfirmed,106,0072-P01,Efficacy, 'de novo',Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2829,0072-0413,72.413,Unconfirmed,106,0072-P01,Efficacy,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2830,0072-0414,72.414,Unconfirmed,106,0072-P01,Efficacy,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2831,0072-0415,72.415,Unconfirmed,106,0072-P01,Efficacy, on-off symptoms,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2832,0072-0416,72.416,Unconfirmed,106,0072-P01,Efficacy, on-off symptoms,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2833,0072-0417,72.417,Ended,106,0072-P01,Efficacy, Hoehn&Yahr II-IV,Ended,MIG,Migration,II,Phase II,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2834,0072-0418,72.418,Unconfirmed,106,0072-P01,Efficacy, Hoehn&Yahr I-II,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2835,0072-0419,72.419,Preparing,106,0072-P01,Efficacy, Hoehn&Yahr II-IV,Preparing,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2836,0072-0421,72.421,Unconfirmed,106,0072-P01,Efficacy&safety,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2837,0072-0422,72.422,Unconfirmed,106,0072-P01,Efficacy & safety, pilotstudy,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2838,0072-0423,72.423,Ended,106,0072-P01,Efficacy&safety,Ended,MIG,Migration,II,Phase II,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2839,0072-0425,72.425,Ended,106,0072-P01,Efficacy, Hoehn&Yahr II-IV,Ended,MIG,Migration,II,Phase II,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2840,0072-0426,72.426,Ended,106,0072-P01,Efficacy, Hoehn&Yahr II-IV,Ended,MIG,Migration,II,Phase II,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2841,0072-0601,72.601,Unconfirmed,106,0072-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2842,0072-0603,72.603,Ended,106,0072-P01,PHARMACOKINETICS,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2843,0072-0604,72.604,Ended,106,0072-P01,none,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2844,0072-0606,72.606,Unconfirmed,106,0072-P01,000,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2845,0072-0608,72.608,Ended,106,0072-P01,ANTI-PARKINSON EFFECT OF B-HT 920,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2846,0072-0614,72.614,Ended,106,0072-P01,DBT of B-HT 920 (Phase III),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2847,0072-0615,72.615,Ended,106,0072-P01,Taniguchi OT of B-HT 920 (Phase III),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2848,0072-0616,72.616,Ended,106,0072-P01,Tone OT of B-HT 920 (Phase III),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2849,0072-0617,72.617,Ended,106,0072-P01,Mizuno OT of B-HT 920 (Phase III),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2850,0072-0618,72.618,Ended,106,0072-P01,Tamaki Ot of B-HT 920 (Phase III),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2851,0072-0619,72.619,Ended,106,0072-P01,Clinical pharmacology of B-HT 920,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2852,0072-0622,72.622,Ended,106,0072-P01,Ocular haemodynamic and B-HT 920 Cl2,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
2853,0072-0623,72.623,Ended,106,0072-P01,FOLLOW-UP,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2854,0072-0625,72.625,Ended,106,0072-P01,Additional indication,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
2855,0072-0629,72.629,Preparing,106,0072-P01,To research efficacyand safety of Domin,Preparing,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
2856,0072-0630,72.630,Unconfirmed,106,0072-P01,change of other dopamine againsts,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
2857,0260-0301,260.301,Preparing,107,0260-P08,Equivalence, efficacy,Preparing,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2858,0260-0303,260.303,Unconfirmed,107,0260-P08,Dose-Ranging, Efficacy,Unconfirmed,MIG,Migration,NONE,Not Classified,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2859,0260-0305,260.305,Preparing,107,0260-P08,lung deposition,Preparing,MIG,Migration,I,Phase I,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2860,0260-0306,260.306,Unconfirmed,107,0260-P08,flow rate,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2861,0260-0308,260.308,Unconfirmed,107,0260-P08,Cumul. dose-response,Unconfirmed,MIG,Migration,NONE,Not Classified,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2862,0260-0311,260.311,Unconfirmed,107,0260-P08,Safety, Efficacy,Unconfirmed,MIG,Migration,NONE,Not Classified,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2863,0260-0355,260.355,Unconfirmed,107,0260-P08,lung deposition,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2864,0260-0366,260.366,Unconfirmed,107,0260-P08,flow rate,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2865,0260-0391,260.391,Preparing,107,0260-P08,Pilot Study, Seq./Synchr. Inhal.,Preparing,MIG,Migration,NONE,Not Classified,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2866,0260-3146,260.3146,Ended,107,0260-P08,MDI vs MDPI1 masterplan 684.901,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2867,0260-3148,260.3148,Ended,107,0260-P08,MDPI-1 deposition study 684.005,Ended,MIG,Migration,II,Phase II,- Data analysis ongoing at BIKG.,,,000910,IS - Clin Study (MIGRATED)
2868,0260-3167,260.3167,Preparing,107,0260-P08,4 weeks efficacy in Asthma of 1 puff,Preparing,MIG,Migration,III,Phase III,- ,,,000980,Not Classified (MIGRATED)
2869,0260-3168,260.3168,Preparing,107,0260-P08,Protect. against methachol. challenge iA,Preparing,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
2870,0260-3169,260.3169,Unconfirmed,107,0260-P08,Protection against EIB in asthma,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
2871,0244-0801,244.801,Ended,108,0244-P01,Glucose-filling, particle size,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2872,0244-0802,244.802,Ended,108,0244-P01,Glucose-filling, particle size,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2873,0244-0803,244.803,Ended,108,0244-P01,Glucose-filling, particle size,Ended,MIG,Migration,IV,Phase IV,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2874,0244-0804,244.804,Ended,108,0244-P01,Glucose-filling, particle size,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2875,0244-2481,244.2481,Ended,108,0244-P01,In-vitro ocular and facial deposition,Ended,MIG,Migration,II,Phase II,- ,,,000300,IS - Methodological Studies
2876,0260-0970,260.970,Ended,109,0260-P06,Single-dose, equivalence,Ended,MIG,Migration,III,Phase III,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2877,0260-3147,260.3147,Ended,109,0260-P06,Powder Capsule - New Technology Glucose,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
2878,0260-0103,260.103,Ended,110,0260-P01,Safety,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2879,0260-1301,260.1301,Ended,110,0260-P01,Efficacy, single dose,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2880,0260-1302,260.1302,Ended,110,0260-P01,Efficacy, single dose,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2881,0260-1303,260.1303,Ended,110,0260-P01,Efficacy, single dose,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2882,0260-1304,260.1304,Ended,110,0260-P01,Acceptance, handling, safety,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2883,0260-1305,260.1305,Unconfirmed,110,0260-P01,Children,Unconfirmed,MIG,Migration,III,Phase III,- , Kinder, EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2884,0260-1401,260.1401,Ended,110,0260-P01,Piezosystem im KHz-, bzw. MHz.-Bereich,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2885,0260-1402,260.1402,Ended,110,0260-P01,Efficacy, equivalence,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2886,0260-1403,260.1403,Ended,110,0260-P01,Efficacy, equivalence,Ended,MIG,Migration,II,Phase II,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2887,0260-1404,260.1404,Ended,110,0260-P01,Acceptance, handling, multiple dose,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2888,0260-1405,260.1405,Ended,110,0260-P01,Lung deposition, 99m-Tc-labelled,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2889,0260-1406,260.1406,Preparing,110,0260-P01,Efficacy,Preparing,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2890,0260-1407,260.1407,Unconfirmed,110,0260-P01,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2891,0215-0201,215.201,Ended,111,0215-P02,Dose confirmation,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2892,0215-0202,215.202,Unconfirmed,111,0215-P02,3 month Safety and Acceptance,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2893,0215-0203,215.203,Ended,111,0215-P02,Cumulative dose response,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
2894,0215-0208,215.208,Unconfirmed,111,0215-P02,Cumul. dose-response,Unconfirmed,MIG,Migration,NONE,Not Classified,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2895,0215-0211,215.211,Unconfirmed,111,0215-P02,Safety, Efficacy,Unconfirmed,MIG,Migration,NONE,Not Classified,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2896,0220-0101,220.101,Ended,112,0220-P02,Safety,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2897,0220-0201,220.201,Preparing,112,0220-P02,Efficacy, equivalence,Preparing,MIG,Migration,III,Phase III,- , EStatus = X, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2898,0220-0301,220.301,Ended,112,0220-P02,Efficacy, single dose,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2899,0220-0302,220.302,Ended,112,0220-P02,Efficacy, single dose,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2900,0220-0303,220.303,Ended,112,0220-P02,Acceptance, handling, safety,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2901,0220-0304,220.304,Ended,112,0220-P02,Equivalence, therapeut. comparis.,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2902,0220-0305,220.305,Ended,112,0220-P02,Equivalence, therapeut. comparis.,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2903,0220-0306,220.306,Unconfirmed,112,0220-P02,Equivalence, therap. comparison,Unconfirmed,MIG,Migration,III,Phase III,- , Kinder, EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2904,0244-0103,244.103,Ended,113,0244-P04,Safety,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2905,0244-1101,244.1101,Ended,113,0244-P04,Efficacy, equivalence,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2906,0244-1102,244.1102,Ended,113,0244-P04,Acceptance, handling,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2907,0244-1103,244.1103,Unconfirmed,113,0244-P04,Children,Unconfirmed,MIG,Migration,III,Phase III,- , Kinder, EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2908,0243-0001,243.1,Ended,114,0243-P05,Asthma,Ended,MIG,Migration,II,Phase II,- Summary expected 01/93 (Letter Sommar 10/92),,,000910,IS - Clin Study (MIGRATED)
2909,0243-0301,243.301,Preparing,114,0243-P05,Equivalence,Preparing,MIG,Migration,II,Phase II,- , EStatus = X, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2910,0054-0104,54.104,Ended,115,0054-P06,Safety,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2911,0054-0302,54.302,Unconfirmed,115,0054-P06,Equivalence,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = X, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
2912,0054-0517,54.517,Ended,115,0054-P06,Bio-equivalence of PED in COPD patients,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2913,0114-0001,114.1,Ended,116,0114-P01,Pilotstudie,Therapiedauervergleich IFN,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2914,0114-0002,114.2,Ended,116,0114-P01,Bladder-Carcinoma in situ,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2915,0114-0003,114.3,Ended,116,0114-P01,Urinary bladder carcinoma - instill.,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2916,0114-0004,114.4,Ended,116,0114-P01,Laryngeal Papillomatosis, Multicenter,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2917,0114-0005,114.5,Unconfirmed,116,0114-P01,Herpes-simplex,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2918,0114-0006,114.6,Ended,116,0114-P01,HPV-6 Trachealpapillomatose Wolfart,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2919,0114-0007,114.7,Ended,116,0114-P01,K. Dendritica Vergleich Alpha - Gamma,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2920,0114-0008,114.8,Ended,116,0114-P01,Kontaktprophylaxe, fortlfd. Random.,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2921,0114-0009,114.9,Ended,116,0114-P01,HPV-associated genital papillomatosis,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2922,0114-0010,114.10,Ended,116,0114-P01,Herpes zoster, Vorstudie, Prof. R√∂ckl,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2923,0114-0011,114.11,Unconfirmed,116,0114-P01,Kontaktprophylaxe, Familien-Random.,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2924,0114-0012,114.12,Ended,116,0114-P01,Advanced metastasizing melanoma,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2925,0114-0013,114.13,Unconfirmed,116,0114-P01,K. Dendritica, OR,Bijsterveld,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2926,0114-0014,114.14,Ended,116,0114-P01,HPV-associated genital papillomatosa,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2927,0114-0015,114.15,Ended,116,0114-P01,Herpes genitalis, Dr. Meisel,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2928,0114-0016,114.16,Ended,116,0114-P01,Casuistics of therapy-resistant diseases,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2929,0114-0017,114.17,Ended,116,0114-P01,Probandenversuch, Dr. Duong,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2930,0114-0018,114.18,Ended,116,0114-P01,Hairy cell leukemia, multicenter,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2931,0114-0019,114.19,Unconfirmed,116,0114-P01,Ovarialkarzinom, Prof. Mosler,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2932,0114-0020,114.20,Unconfirmed,116,0114-P01,Adenokarzinom der Niere - Ackermann,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2933,0114-0021,114.21,Ended,116,0114-P01,Orient. Plasmakinetik nach rekt. Applik.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2934,0114-0022,114.22,Ended,116,0114-P01,Metastasing hypernephroma,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2935,0114-0023,114.23,Ended,116,0114-P01,Herpes genitalis, Multicenter,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2936,0114-0024,114.24,Ended,116,0114-P01,Herpes labialis, Multicenter,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2937,0114-0025,114.25,Ended,116,0114-P01,IFN-gel by HPV-caused genital infections,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2938,0114-0026,114.26,Ended,116,0114-P01,Gel-Anwendungstest bei Psoriasis, Thomae,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2939,0114-0027,114.27,Ended,116,0114-P01,high risk-melanoma, Multicenter,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2940,0114-0028,114.28,Unconfirmed,116,0114-P01,Nasopharynxkarzinom - Dr. Fink,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2941,0114-0029,114.29,Unconfirmed,116,0114-P01,Schnupfenprophylaxe, Biodesign,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2942,0114-0030,114.30,Ended,116,0114-P01,low risk-Mamma-Karzinom,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2943,0114-0031,114.31,Ended,116,0114-P01,Chron. Hepatitis B, Prof. Hopf,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2944,0114-0032,114.32,Unconfirmed,116,0114-P01,K. Dendritica, OR,Bijsterveld NL 29/85,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2945,0114-0033,114.33,Unconfirmed,116,0114-P01,Nasopharynxkarzinom - Dr. Bertram,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2946,0114-0034,114.34,Ended,116,0114-P01,Keratitis Dendritica E 206/85,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2947,0114-0035,114.35,Unconfirmed,116,0114-P01,Herpes Zoster ophthalmicus,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2948,0114-0036,114.36,Unconfirmed,116,0114-P01,Immunozytom,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2949,0114-0037,114.37,Unconfirmed,116,0114-P01,Warzen - Pilotstudie Prof.Haneke,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2950,0114-0038,114.38,Unconfirmed,116,0114-P01,Hepatitis - Prof.Hopf, Berlin,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2951,0114-0039,114.39,Unconfirmed,116,0114-P01,Melanom - Dr. Hesse, Ulm,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2952,0114-0040,114.40,Unconfirmed,116,0114-P01,Keratitis Dendritica E 26/86,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2953,0114-0041,114.41,Unconfirmed,116,0114-P01,low risk-Mamma-Karzinom (Multicenter),Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2954,0114-0042,114.42,Ended,116,0114-P01,Metastasising Carcinoid Tumors,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2955,0114-0043,114.43,Unconfirmed,116,0114-P01,Vorstudie Hypernephrom - hoch dosiert,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2956,0114-0044,114.44,Unconfirmed,116,0114-P01,Pharmakokinetik,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2957,0114-0045,114.45,Unconfirmed,116,0114-P01,Akute lymphatische Leuk√§mie bei Kindern,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2958,0114-0046,114.46,Unconfirmed,116,0114-P01,Genitalpapillomatose - Dr.Schneider,Ulm,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2959,0114-0047,114.47,Ended,116,0114-P01,Hepatitis Non-A-Non-B, randomised,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2960,0114-0048,114.48,Ended,116,0114-P01,Hepatitis Non-A-Non-B (sporadisch),Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2961,0114-0050,114.50,Ended,116,0114-P01,Pharmacocinetics, Dr. Nerl, M√ºnchen,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
2962,0114-0051,114.51,Ended,116,0114-P01,Hairy cell leukemia, Dr.Nerl, M√ºnchen,Ended,MIG,Migration,II,Phase II,- Trial dates: 10/84 to 07/89 (intermediate results at 26.07.89), cut- off date,,,000910,IS - Clin Study (MIGRATED)
2963,0114-0052,114.52,Unconfirmed,116,0114-P01,CML Dr. Nerl, M√ºnchen,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
2964,0114-0053,114.53,Ended,116,0114-P01,CML,Ended,MIG,Migration,III,Phase III,- old contract, payed by BIGmbH,,,000910,IS - Clin Study (MIGRATED)
2965,0114-0054,114.54,Ended,116,0114-P01,CML (EORTC),Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2966,0114-0100,114.100,Unconfirmed,116,0114-P01,Scleroderma systemic,Unconfirmed,MIG,Migration,II,Phase II,- planned patients:12-16 ** *,,,000910,IS - Clin Study (MIGRATED)
2967,0114-0101,114.101,Ended,116,0114-P01,Carcinoma renal cell,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2968,0114-0102,114.102,Unconfirmed,116,0114-P01,Melanoma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2969,0114-0103,114.103,Ended,116,0114-P01,Leukaemia hairy cell,Ended,MIG,Migration,II,Phase II,- planned patients: 20-40 * *,,,000910,IS - Clin Study (MIGRATED)
2970,0114-0104,114.104,Unconfirmed,116,0114-P01,Lymphoma non-Hodgkin,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2971,0114-0105,114.105,Unconfirmed,116,0114-P01,Carcinoma renal cell,Unconfirmed,MIG,Migration,II,Phase II,- planned patients: 10-20 * *,,,000910,IS - Clin Study (MIGRATED)
2972,0114-0106,114.106,Ended,116,0114-P01,Carcinoma renal cell,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2973,0114-0107,114.107,Unconfirmed,116,0114-P01,Carcinoid,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2974,0114-0108,114.108,Unconfirmed,116,0114-P01,Fulminant hepatitis,Unconfirmed,MIG,Migration,II,Phase II,- Dev.Prot.: PATIENTS OF THIS REPORT PROCEED ALL OF THE SECOND CLINIC CENTER (CHIEF OF THE LIVER CARE-UNIT: DR. J. RODES, *,,,000910,IS - Clin Study (MIGRATED)
2975,0114-0109,114.109,Unconfirmed,116,0114-P01,Multiple myeloma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2976,0114-0110,114.110,Unconfirmed,116,0114-P01,Herpes kerat. dendr.,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2977,0114-0111,114.111,Unconfirmed,116,0114-P01,CAHB (adults),Unconfirmed,MIG,Migration,II,Phase II,- Dev.Prot.: AS 1 PATIENT DIED DUE TO AN AUTO CRASH, ONLY 9 PATIENTS WITH VERUM AND 10 PATIENTS WITHOUT, AS CONTROL. NO P *,,,000910,IS - Clin Study (MIGRATED)
2978,0114-0112,114.112,Unconfirmed,116,0114-P01,HPV (JLP),Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2979,0114-0113,114.113,Ended,116,0114-P01,Infection respiratory,Ended,MIG,Migration,II,Phase II,- Letter 26/6/89 Bevis->Lander study discont (not cancelled) *,,,000910,IS - Clin Study (MIGRATED)
2980,0114-0114,114.114,Unconfirmed,116,0114-P01,Papillomatosis laryngeal,Unconfirmed,MIG,Migration,NONE,Not Classified,- planned patients: 6-10 * *,,,000910,IS - Clin Study (MIGRATED)
2981,0114-0115,114.115,Unconfirmed,116,0114-P01,Carcinoma,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
2982,0114-0116,114.116,Unconfirmed,116,0114-P01,Leukaemia myelocytic;Thrombocythaemia;Po,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
2983,0114-0117,114.117,Unconfirmed,116,0114-P01,CAHB (adults),Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2984,0114-0118,114.118,Ended,116,0114-P01,CAHB (Delta),Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2985,0114-0119,114.119,Unconfirmed,116,0114-P01,Herpes-keratitis dendritic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2986,0114-0120,114.120,Unconfirmed,116,0114-P01,Malignant melanoma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2987,0114-0121,114.121,Unconfirmed,116,0114-P01,CAHB (children),Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2988,0114-0122,114.122,Ended,116,0114-P01,CLL,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2989,0114-0123,114.123,Ended,116,0114-P01,CAHB (Delta),Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2990,0114-0124,114.124,Ended,116,0114-P01,CAHB,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2991,0114-0125,114.125,Ended,116,0114-P01,HCL,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2992,0114-0126,114.126,Unconfirmed,116,0114-P01,Herpes Zoster,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
2993,0114-0127,114.127,Unconfirmed,116,0114-P01,Osteomyelosclerosis,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2994,0114-0128,114.128,Ended,116,0114-P01,Condylomata accuminata,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2995,0114-0129,114.129,Ended,116,0114-P01,Hepatitis, CAHB (children),Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2996,0114-0130,114.130,Ended,116,0114-P01,Myeloproliferative disorders chronic,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2997,0114-0131,114.131,Unconfirmed,116,0114-P01,Thrombocytosis,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2998,0114-0132,114.132,Unconfirmed,116,0114-P01,Carcinoma bladder,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
2999,0114-0133,114.133,Ended,116,0114-P01,Behcet's disease, oral, ulceration,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3000,0114-0134,114.134,Ended,116,0114-P01,Hepatitis, CAHB (adults),Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3001,0114-0135,114.135,Ended,116,0114-P01,Hepatitis, NANB,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3002,0114-0136,114.136,Ended,116,0114-P01,Hepatitis, CAHB (delta),Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3003,0114-0137,114.137,Ended,116,0114-P01,IFN AND CHEMOTHERAPY IN NSCLC,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3004,0114-0138,114.138,Ended,116,0114-P01,Malignant melanoma,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
3005,0114-0139,114.139,Ended,116,0114-P01,Leukaemia myelocytic,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3006,0114-0140,114.140,Ended,116,0114-P01,Thrombocythaemia,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3007,0114-0141,114.141,Unconfirmed,116,0114-P01,Plasmacytoma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3008,0114-0142,114.142,Unconfirmed,116,0114-P01,Cytomegalic inclusion disease,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3009,0114-0143,114.143,Unconfirmed,116,0114-P01,Carcinoma nasopharyngeal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3010,0114-0144,114.144,Ended,116,0114-P01,CML,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3011,0114-0145,114.145,Unconfirmed,116,0114-P01,HCL,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3012,0114-0146,114.146,Unconfirmed,116,0114-P01,Cancer, ovarian (+Etop.),Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3013,0114-0147,114.147,Ended,116,0114-P01,HCL,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3014,0114-0148,114.148,Ended,116,0114-P01,RCC,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
3015,0114-0149,114.149,Ended,116,0114-P01,Alopecia-areata,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3016,0114-0150,114.150,Ended,116,0114-P01,Malignant lymphoma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3017,0114-0151,114.151,Ended,116,0114-P01,Thrombocythaemia,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3018,0114-0152,114.152,Ended,116,0114-P01,RCC,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3019,0114-0153,114.153,Ended,116,0114-P01,MDS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3020,0114-0154,114.154,Ended,116,0114-P01,EORTC Genito-urinary tract cancer group,Ended,MIG,Migration,III,Phase III,- old contract, payed by BIGmbH,,,000910,IS - Clin Study (MIGRATED)
3021,0114-0155,114.155,Ended,116,0114-P01,Behcet's disease (oral),Ended,MIG,Migration,III,Phase III,- old contract, payed by BIGmbH,,,000910,IS - Clin Study (MIGRATED)
3022,0114-0156,114.156,Ended,116,0114-P01,Acute NANB hepatitis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3023,0114-0157,114.157,Ended,116,0114-P01,Behcet's disease (genital),Ended,MIG,Migration,II,Phase II,- old contract, payed by BIGmbH,,,000910,IS - Clin Study (MIGRATED)
3024,0114-0158,114.158,Ended,116,0114-P01,Epidemic Keratoconjunctivitis,Ended,MIG,Migration,III,Phase III,- Subjects: Persones in hosp. withoutsymptoms of Keratitis epid who had contact with patients, suffering from Keratitis ep,,,000910,IS - Clin Study (MIGRATED)
3025,0114-0159,114.159,Ended,116,0114-P01,Epidemic Keratokonjunktivitis,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3026,0114-0161,114.161,Ended,116,0114-P01,Essential thrombocytemia - Follow-up,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3027,0114-0162,114.162,Ended,116,0114-P01,Colon-Adjuvant,Ended,MIG,Migration,III,Phase III,- ,,,,
3028,0114-0163,114.163,Ended,116,0114-P01,Mamma,Ended,MIG,Migration,III,Phase III,- Total Observation Time: until progression of disease,,,,
3029,0114-0164,114.164,Ended,116,0114-P01,Colon Palliativ,Ended,MIG,Migration,III,Phase III,- ,,,,
3030,0114-0165,114.165,Ended,116,0114-P01,CML,Ended,MIG,Migration,III,Phase III,- ,,,,
3031,0114-0166,114.166,Ended,116,0114-P01,small cell - limited,Ended,MIG,Migration,III,Phase III,- ,,,,
3032,0114-0167,114.167,Ended,116,0114-P01,M.M.,Ended,MIG,Migration,III,Phase III,- ,,,,
3033,0114-0168,114.168,Ended,116,0114-P01,small cell,Ended,MIG,Migration,III,Phase III,- ,,,,
3034,0114-0169,114.169,Ended,116,0114-P01,Non Hodgkin,Ended,MIG,Migration,III,Phase III,- ,,,,
3035,0114-0170,114.170,Ended,116,0114-P01,HepCa,Ended,MIG,Migration,II,Phase II,- ,,,,
3036,0114-0171,114.171,Ended,116,0114-P01,Adjuvant therapy in colorectal cancer,Ended,MIG,Migration,II,Phase II,- ,,,,
3037,0114-0172,114.172,Ended,116,0114-P01,chron HCV,Ended,MIG,Migration,II,Phase II,- ,,,,
3038,0114-0173,114.173,Ended,116,0114-P01,Inhalation/Pharmacikinetics,Ended,MIG,Migration,I,Phase I,- old CTIS No. 900468 had been deleted due to an error, with CTU 3/93 reentered as IOR-study.,,,,
3039,0114-0174,114.174,Ended,116,0114-P01,Metastatic RCC,Ended,MIG,Migration,II,Phase II,- ,,,,
3040,0163-0001,163.1,Ended,117,0163-P01,Pilot-Studie: Nat√ºrliches Surfactant,Ended,MIG,Migration,II,Phase II,dose finding ,,,000910,IS - Clin Study (MIGRATED)
3041,0163-0002,163.2,Ended,117,0163-P01,Nat√ºrliches Surfactant beim IRDS,Ended,MIG,Migration,II,Phase II,Prevention study ,,,000910,IS - Clin Study (MIGRATED)
3042,0163-0003,163.3,Ended,117,0163-P01,Intervention treatment,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3043,0163-0004,163.4,Ended,117,0163-P01,Comparative dose-study SF-RI 1,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3044,0163-0005,163.5,Ended,117,0163-P01,Interventionsstudie mit SF-RI 1,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3045,0163-0006,163.6,Ended,117,0163-P01,Behandlung mit nat√ºrlichem Surfactant,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3046,0163-0007,163.7,Ended,117,0163-P01,Intervention treatment with SF-RI 1,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3047,0163-0008,163.8,Ended,117,0163-P01,Natural Surfactant - Follow up,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3048,0163-0009,163.9,Ended,117,0163-P01,SF-RI 1 in term infants,Ended,MIG,Migration,IIA,Phase IIa,clin. coordimator: Prof. B. Roth, K√∂ln ,,,000910,IS - Clin Study (MIGRATED)
3049,0163-0010,163.10,Ended,117,0163-P01,Nebulization by pharyngeal CPAP,Ended,MIG,Migration,II,Phase II,feasibility study ,,,000910,IS - Clin Study (MIGRATED)
3050,0163-0011,163.11,Ended,117,0163-P01,Pilot study with Alveofact in ARDS,Ended,MIG,Migration,IIA,Phase IIa,clin. coordinator: Prof. W. Seeger Coordinating investigator, Leiter der klinischen Pr√ºfung and on-site monitor: Prof. Seeger, Gie√üen,,,,
3051,0163-0020,163.20,Ended,117,0163-P01,PREVENTION IRDS,Ended,MIG,Migration,III,Phase III,- Safety summary expected,,,000910,IS - Clin Study (MIGRATED)
3052,0163-0021,163.21,Ended,117,0163-P01,Efficacy and safety in IRDS + long term,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3053,0163-0022,163.22,Ended,117,0163-P01,IRDS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3054,0163-0023,163.23,Ended,117,0163-P01,Efficacy/safety in neonatal RDS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3055,0163-0024,163.24,Ended,117,0163-P01,Alveofact in RDS, prematures 500-600 g,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3056,0163-0025,163.25,Ended,117,0163-P01,Alveofact/Exosurf trial,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3057,0163-0026,163.26,Ended,117,0163-P01,Post-marketing surveillance,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
3058,0163-0027,163.27,Ended,117,0163-P01,Alveofact in RDS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3059,0163-0028,163.28,Ended,117,0163-P01,Pediatric ARDS,Ended,MIG,Migration,IIA,Phase IIa,clin. coordinator: Prof. J. M√∂ller Participating countries: Germany and Austria,,,000910,IS - Clin Study (MIGRATED)
3060,0163-0029,163.29,Unconfirmed,117,0163-P01,Alveofact - RDS,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
3061,0163-0030,163.30,Unconfirmed,117,0163-P01,IOR - Gortner,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
3062,0163-0031,163.31,Preparing,117,0163-P01,Alveofact in Meconium Aspiration,Preparing,MIG,Migration,II,Phase II,,,,,
3063,0248-0107,248.107,Ended,118,0248-P04,Dose tolerance t.o., single CPA,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3064,0248-0512,248.512,Unconfirmed,118,0248-P04,single dose PK and tol. in volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3065,0248-0513,248.513,Unconfirmed,118,0248-P04,multiple dose and tol. in volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3066,0248-0540,248.540,Unconfirmed,118,0248-P04,POC Study in obese patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
3067,1116-0001,1116.1,Unconfirmed,119,1116-P01,Pk study - RA,Unconfirmed,MIG,Migration,I,Phase I,-  Program on hold; unlikely to proceed.   PLANNED DATES NOT ACCURATE. SYSTEM DOES  NOT ALLOW INSERTION OF NEW DATES. ,,,000910,IS - Clin Study (MIGRATED)
3068,1116-0002,1116.2,Unconfirmed,119,1116-P01,Pk - indication TBD,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
3069,1116-0003,1116.3,Ended,119,1116-P01,Pk study - RA,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
3070,1047-0002,1047.2,Preparing,120,1047-P02,Dose ranging,Preparing,MIG,Migration,IIB,Phase IIb,-  This trial is scheduled to have data management and monitoring outsourced to a CRO     ,,,000910,IS - Clin Study (MIGRATED)
3071,1047-0003,1047.3,Unconfirmed,120,1047-P02,Safety comparison vs placebo,Unconfirmed,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3072,1047-0004,1047.4,Preparing,120,1047-P02,Long term safety and efficacy,Preparing,MIG,Migration,III,Phase III,-  This trial is planned to be monitored and have data management outsource to a CRO     ,,,000910,IS - Clin Study (MIGRATED)
3073,1047-0005,1047.5,Ended,120,1047-P02,Effects on HPA-axis,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3074,1047-0006,1047.6,Ended,120,1047-P02,ETHANOL SAFETY BINEB STUDY,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
3075,1047-0007,1047.7,Unconfirmed,120,1047-P02,Methacholine Challenge in Asthma,Unconfirmed,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
3076,1047-0008,1047.8,Ended,120,1047-P02,Budesonide SWITCH study,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3077,1047-0009,1047.9,Preparing,120,1047-P02,Pediatric,Multiple Dose, Dose Ranging,Preparing,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3078,1047-0010,1047.10,Preparing,120,1047-P02,9-month extension of 1047.9,Preparing,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3079,1047-0011,1047.11,Ended,120,1047-P02,Deposition study in asthma vs.Turbohaler,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3080,1047-0013,1047.13,Unconfirmed,120,1047-P02,Oral steroid dependent,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3081,1047-0014,1047.14,Preparing,120,1047-P02,1 Year adult extension of 1047.8,Preparing,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
3082,1047-0015,1047.15,Preparing,120,1047-P02,Steroid sparing study,Preparing,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3083,1047-0016,1047.16,Ended,120,1047-P02,3 Months Safety/Efficacy Moderate Asthma,Ended,MIG,Migration,IIIA,Phase IIIa,- ,,,000910,IS - Clin Study (MIGRATED)
3084,1047-0017,1047.17,Preparing,120,1047-P02,3 Months Safety/Efficacy Severe Asthma,Preparing,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3085,1047-0018,1047.18,Preparing,120,1047-P02,Effectiveness in asthma vs turbuhaler,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
3086,1047-0019,1047.19,Unconfirmed,120,1047-P02,Once/day dosing in asthma,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3087,1047-0020,1047.20,Preparing,120,1047-P02,Pilot study for Health Economics in asth,Preparing,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
3088,1047-0021,1047.21,Preparing,120,1047-P02,Ethanolic formulations taste study,Preparing,MIG,Migration,IIA,Phase IIa,No active drug - both placebo ,,,000910,IS - Clin Study (MIGRATED)
3089,0243-0002,243.2,Ended,121,0243-P06,BINEB (Sal) Dose Ranging Study,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
3090,0243-0003,243.3,Ended,121,0243-P06,Cumulative dose response, 3 way CO,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3091,0243-0004,243.4,Preparing,121,0243-P06,Safety comparison vs placebo,Preparing,MIG,Migration,III,Phase III,- This trial will have a  pharmacokinetic assessment     ,,,000910,IS - Clin Study (MIGRATED)
3092,0243-0005,243.5,Unconfirmed,121,0243-P06,Safety comparison vs placebo,Unconfirmed,MIG,Migration,III,Phase III,-  The program will be refined as the development strategies are put f orward by the medical subteam and approved by the CEG/IMC.     ,,,000910,IS - Clin Study (MIGRATED)
3093,0243-0006,243.6,Unconfirmed,121,0243-P06,Dose ranging,Unconfirmed,MIG,Migration,II,Phase II,-  Was duplicate of Canadian study 243.2     ,,,000910,IS - Clin Study (MIGRATED)
3094,0243-0007,243.7,Ended,121,0243-P06,Dose range finding in COPD,Ended,MIG,Migration,IIB,Phase IIb,        ,,,000910,IS - Clin Study (MIGRATED)
3095,0243-0008,243.8,Unconfirmed,121,0243-P06,Pediatric Safety & Efficacy,Unconfirmed,MIG,Migration,III,Phase III,-Trial on HOLD per TMM D.Pavia This trial is planned to go to a CRO.  We will look to outsource all aspects of this trial. This trial will incorporate pharmacokinetic assessments     ,,,000910,IS - Clin Study (MIGRATED)
3096,0243-0009,243.9,Unconfirmed,121,0243-P06,6 mo safety extension (243.4),Unconfirmed,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3097,0243-0010,243.10,Ended,121,0243-P06,Methacholine Challenge,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
3098,0243-0011,243.11,Preparing,121,0243-P06,Exercise Induced Bronchoconstriction,Preparing,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
3099,0243-0012,243.12,Preparing,121,0243-P06,prn use in Asthma: 2x4 weeks,Preparing,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
3100,0243-0013,243.13,Unconfirmed,121,0243-P06,3 months safety/efficacy, 2x100mcg,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3101,0243-0014,243.14,Unconfirmed,121,0243-P06,Pediatric Safety & Efficacy,Unconfirmed,MIG,Migration,III,Phase III,-  This is the long term extension to trial 243.8.  This trial is planned for outsourcing of all aspects     ,,,000910,IS - Clin Study (MIGRATED)
3102,0243-0302,243.302,Preparing,121,0243-P06,Pharmacokinetic in Paediatric Asthma,Preparing,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
3103,1127-0001,1127.1,Ended,124,1127-P01,Murine anti CD44v6 Imaging/Biodistrib.,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
3104,1128-0001,1128.1,Unconfirmed,125,1128-P01,Safety single dose p.o. in volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
3105,1128-0002,1128.2,Ended,125,1128-P01,Efficacy and safety single dose p.o.,Ended,MIG,Migration,II,Phase II,- ISC Protocol 15.2.96 study cancelled,,,000910,IS - Clin Study (MIGRATED)
3106,1012-0016,1012.16,Unconfirmed,126,1012-P05,Safety comparison vs placebo,Unconfirmed,MIG,Migration,III,Phase III,-  The program will be refined as the development strategies are put forward by the medical subteam and approved by the CEG/IMC.     ,,,000910,IS - Clin Study (MIGRATED)
3107,1012-0017,1012.17,Unconfirmed,126,1012-P05,Safety comparison vs placebo,Unconfirmed,MIG,Migration,III,Phase III,-  The program will be refined as the development strategies are put f orward by the medical subteam and approved by the CEG/IMC. Replaced by 1012.20.     ,,,000910,IS - Clin Study (MIGRATED)
3108,1012-0018,1012.18,Unconfirmed,126,1012-P05,Dose ranging,Unconfirmed,MIG,Migration,II,Phase II,-  Awaiting FDA response concerning going right into Phase III using doses from Phase II ATROVENT + Salbutamol.     ,,,000910,IS - Clin Study (MIGRATED)
3109,1012-0020,1012.20,Unconfirmed,126,1012-P05,Safety comparison vs placebo,Unconfirmed,MIG,Migration,III,Phase III,-  The program will be refined as the development strategies are put f orward by the medical subteam and approved by the CEG/IMC. Replaced 1012.17.     ,,,000910,IS - Clin Study (MIGRATED)
3110,1012-0044,1012.44,Preparing,126,1012-P05,Cumulative dose response safety in COPD,Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
3111,1012-0046,1012.46,Ended,126,1012-P05,12 week safety & efficacy in COPD,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
3112,1012-0048,1012.48,Preparing,126,1012-P05,Comparison of combivent vs ipratropium b,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3113,1012-0055,1012.55,Preparing,126,1012-P05,Dose finding in COPD,Preparing,MIG,Migration,IIB,Phase IIb,,2005-002730-35,,000910,IS - Clin Study (MIGRATED)
3114,1012-0056,1012.56,Ended,126,1012-P05,Safety&Efficacy of Comb. Respimat  COPD,Ended,MIG,Migration,IIIA,Phase IIIa,,2006-002694-52,,000910,IS - Clin Study (MIGRATED)
3115,1012-0062,1012.62,Ended,126,1012-P05,Combivent Respimat 1-year study,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
3116,1012-0065,1012.65,Ended,126,1012-P05,Ventilator Adapter for CVT-Respimat,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
3117,1012-0066,1012.66,Preparing,126,1012-P05,CVT RMT vs albuterol & ipratropium,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
3118,1012-0067,1012.67,Preparing,126,1012-P05,CVT RMT vs albuterol & ipratropium,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
3119,1012-0068,1012.68,Unconfirmed,126,1012-P05,Combivent Respimat Trial in China,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3120,0534-0002,534.2,Unconfirmed,127,0534-P02,Traumatic Brain injury,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
3121,0534-0005,534.5,Unconfirmed,127,0534-P02,Traumatic Brain Injury,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
3122,0534-0012,534.12,Analysis,127,0534-P02,Traumatic brain injury,Analysis,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3123,0534-0016,534.16,Unconfirmed,127,0534-P02,single dose ADME,Unconfirmed,MIG,Migration,I,Phase I,-  A PRA will do everything but protocol.   This trial has no BIPI involvement.  It has been added for what-if analysis for J. Wecker.   ,,,000910,IS - Clin Study (MIGRATED)
3124,0535-0001,535.1,Ended,128,0535-P01,Single rising dose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3125,1136-0001,1136.1,Ended,130,1136-P01,Airway Expression Candidate Asthma Gene,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3126,1136-0002,1136.2,Ended,130,1136-P01,Expression of Asthma Gene in Families,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3127,1136-0003,1136.3,Ended,130,1136-P01,DNA in asthmatics from Aberdeen cohort,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
3128,0537-0001,537.1,Ended,131,0537-P01,Single rising dose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3129,0537-0002,537.2,Ended,131,0537-P01,Influence on cholesterol biosynthesis,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3130,0537-0003,537.3,Ended,131,0537-P01,Plasma levels of 160 mg BIBX 245 CL s.d.,Ended,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
3131,0537-0004,537.4,Unconfirmed,131,0537-P01,Two week study in vol. with high cholest,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3132,0537-0006,537.6,Preparing,131,0537-P01,Dose finding 6 week study,Preparing,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3133,0537-0007,537.7,Ended,131,0537-P01,Single dose food-fasting,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3134,1105-0002,1105.2,Ended,132,1105-P01,none,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3135,1105-0014,1105.14,Unconfirmed,132,1105-P01,Asthma,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3136,1105-0021,1105.21,Ended,132,1105-P01,Dose ranging,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3137,1105-0026,1105.26,Unconfirmed,132,1105-P01,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3138,1105-0027,1105.27,Ended,132,1105-P01,Asthma,Ended,MIG,Migration,III,Phase III,-  2) 13 MALE PATIENTS *,,,000910,IS - Clin Study (MIGRATED)
3139,1105-0028,1105.28,Ended,132,1105-P01,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3140,1105-0032,1105.32,Ended,132,1105-P01,Low Resp. fraction vs std,Ended,MIG,Migration,IV,Phase IV,-  This study must be completed quickly in order to have any value.     ,,,000940,Post Marketing Study (MIGRATED)
3141,1105-0033,1105.33,Unconfirmed,132,1105-P01,Absolute Bioavailability,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3142,1105-0022,1105.22,Ended,133,1105-P02,Pediatric maintenance therapy,Ended,MIG,Migration,III,Phase III,-  Drs. Berman, Chervinsky and Kemp studies never initiated.     ,,,000910,IS - Clin Study (MIGRATED)
3143,1105-0001,1105.1,Ended,134,1105-P03,ASTHMA,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
3144,1105-0015,1105.15,Ended,134,1105-P03,ASTHMA,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
3145,1105-0016,1105.16,Unconfirmed,134,1105-P03,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3146,1105-0017,1105.17,Unconfirmed,134,1105-P03,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3147,1105-0018,1105.18,Ended,134,1105-P03,ASTHMA,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
3148,1105-0020,1105.20,Ended,134,1105-P03,ASTHMA,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
3149,1105-0030,1105.30,Ended,134,1105-P03,Emergency room eval.,Ended,MIG,Migration,II,Phase II,-  Changed from IIIb2.  Study being done under investigator's own IND     ,,,000910,IS - Clin Study (MIGRATED)
3150,1105-0031,1105.31,Ended,134,1105-P03,ASTHMA,Ended,MIG,Migration,IV,Phase IV,        ,,,000940,Post Marketing Study (MIGRATED)
3151,1105-0005,1105.5,Ended,136,1105-P05,Efficacy & dosage in children,Ended,MIG,Migration,III,Phase III,-  Part II of Study.     ,,,000910,IS - Clin Study (MIGRATED)
3152,1105-0006,1105.6,Unconfirmed,136,1105-P05,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3153,1105-0023,1105.23,Ended,136,1105-P05,Common-Cold,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3154,1105-0024,1105.24,Unconfirmed,136,1105-P05,Common-Cold,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3155,1105-0029,1105.29,Ended,136,1105-P05,ALUPENT IN PEDIATRIC ASTHMA,Ended,MIG,Migration,II,Phase II,- Safety only,,,000910,IS - Clin Study (MIGRATED)
3156,1105-0007,1105.7,Unconfirmed,137,1105-P06,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3157,1105-0010,1105.10,Unconfirmed,137,1105-P06,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
3158,1105-0012,1105.12,Ended,137,1105-P06,none,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3159,1105-0019,1105.19,Ended,137,1105-P06,Bronchitis chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3160,1105-0034,1105.34,Unconfirmed,137,1105-P06,Relative Bioavailability,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3161,0244-0703,244.703,Unconfirmed,138,0244-P21,Infants,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3162,0244-2440,244.2440,Ended,138,0244-P21,Pediatric P.R.: Short-term,Ended,MIG,Migration,III,Phase III,-  To show efficacy & safety of Atrovent Nasal Spray 0.03% in pediatric patients with perennial rhinitis.     ,,,000910,IS - Clin Study (MIGRATED)
3163,0244-2441,244.2441,Ended,138,0244-P21,Pediatric P.R.: Long-term,Ended,MIG,Migration,III,Phase III,-  Will try for six-month duration instead of one-year or use adult data instead pending discussion with FDA.     ,,,000910,IS - Clin Study (MIGRATED)
3164,0244-2462,244.2462,Unconfirmed,138,0244-P21,Pediatric P.R.: Short-term,Unconfirmed,MIG,Migration,III,Phase III,-  Confirmatory trial to show efficacy & safety of Atrovent Nasal Spray 0.03% in pediatric patients with perennial rhinitis. Only to be done if required by FDA. FDA has not commented on 1st p rotocol or need for second although DRA has made repeated requests. Will need results of 903A/1 and 903A/2 which will not be available until Fall 1994.   ,,,000910,IS - Clin Study (MIGRATED)
3165,0244-0701,244.701,Ended,139,0244-P22,Bronchokonstriction, Benzalkoniumchlorid,Ended,MIG,Migration,III,Phase III,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3166,0244-0702,244.702,Ended,139,0244-P22,pH-influence, efficacy,Ended,MIG,Migration,III,Phase III,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3167,0244-2070,244.2070,Ended,139,0244-P22,Dose ranging,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
3168,0244-2347,244.2347,Ended,139,0244-P22,Use with beta-agonist: Alupent,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
3169,0244-2349,244.2349,Ended,139,0244-P22,Comparison with metaproterenol,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
3170,0244-2384,244.2384,Ended,139,0244-P22,Comparison with albuterol,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3171,0244-2388,244.2388,Ended,139,0244-P22,Use with beta-agonist: albuter,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3172,0244-2403,244.2403,Ended,139,0244-P22,Pharmacokinetics,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
3173,0244-2428,244.2428,Ended,139,0244-P22,Clinical Outcome,Ended,MIG,Migration,IV,Phase IV,-  Marketing study -- ATROVENT UDV on sleep patterns.     ,,,000940,Post Marketing Study (MIGRATED)
3174,0244-2450,244.2450,Unconfirmed,139,0244-P22,Compassionate use,Unconfirmed,MIG,Migration,III,Phase III,-  BI Pharma is supplying drug only. No target date for completion available due to this being an ongoing trial.     ,,,000500,Compassionate Use Program (CUP)
3175,0065-0001,65.1,Ended,140,0065-P01,Sj√∂gren-Syndrom, Ungarn,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
3176,0065-0015,65.15,Ended,140,0065-P01,Einzelfallpr√ºfung bei Sj√∂gren-Syndrom,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3177,0065-0063,65.63,Unconfirmed,140,0065-P01,Sjogren-Syndrome,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3178,0065-0064,65.64,Ended,140,0065-P01,Sjogren-Syndrome,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3179,0065-0082,65.82,Unconfirmed,140,0065-P01,Sjogren-Syndrome,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3180,0065-0083,65.83,Unconfirmed,140,0065-P01,Sjogren-Syndrome,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3181,0065-0084,65.84,Unconfirmed,140,0065-P01,Sjogren-Syndrome,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3182,0065-0085,65.85,Unconfirmed,140,0065-P01,Sjogren-Syndrome,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3183,0065-0086,65.86,Unconfirmed,140,0065-P01,Sjogren-Syndrome,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3184,0065-0087,65.87,Unconfirmed,140,0065-P01,Sjogren-Syndrome,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3185,0065-0088,65.88,Unconfirmed,140,0065-P01,Sjogren-Syndrome,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3186,0065-0089,65.89,Unconfirmed,140,0065-P01,Sjogren-Syndrome,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3187,0065-0090,65.90,Unconfirmed,140,0065-P01,Sjogren-Syndrome,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3188,0065-0091,65.91,Unconfirmed,140,0065-P01,Sjogren-Syndrome,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3189,0065-0123,65.123,Ended,140,0065-P01,Safety & efficacy,Ended,MIG,Migration,II,Phase II,-  Report will now only address safety issues since the Bromhexine development program has been stopped.     ,,,000910,IS - Clin Study (MIGRATED)
3190,0065-0126,65.126,Ended,140,0065-P01,Dose proportionality study,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
3191,0253-0905,253.905,Ended,141,0253-P04,Safety & efficacy, TTS/6-1st follow-up,Ended,MIG,Migration,III,Phase III,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3192,0253-0906,253.906,Ended,141,0253-P04,Safety, dosage, TTS/6-2nd follow-up,Ended,MIG,Migration,III,Phase III,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3193,0253-0907,253.907,Ended,141,0253-P04,Safety, TTS/6-3rd follow-up,Ended,MIG,Migration,III,Phase III,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3194,0253-0908,253.908,Ended,141,0253-P04,Safety, TTS/6-4th follow-up,Ended,MIG,Migration,III,Phase III,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3195,0253-0909,253.909,Ended,141,0253-P04,Safety, TTS/6-5th follow-up,Ended,MIG,Migration,III,Phase III,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3196,0253-0912,253.912,Ended,141,0253-P04,Safety, TTS/10 - indiv. case,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3197,0253-0914,253.914,Ended,141,0253-P04,Safety & efficacy,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3198,0253-0915,253.915,Ended,141,0253-P04,Safety,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3199,0253-0916,253.916,Ended,141,0253-P04,Safety, Dosage, follow-up,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3200,0253-0917,253.917,Ended,141,0253-P04,Case control study,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3201,0253-0918,253.918,Ended,141,0253-P04,Efficacy & safety, malabsorption,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3202,0253-0919,253.919,Ended,141,0253-P04,Case control study,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3203,0253-0920,253.920,Ended,141,0253-P04,Safety, dosage, follow-up,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3204,0253-0921,253.921,Ended,141,0253-P04,Safety, 260.616 1. follow-up,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3205,0253-0922,253.922,Ended,141,0253-P04,safety, 260.616 2. follow up,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3206,0253-0923,253.923,Ended,141,0253-P04,Case control study,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3207,0253-2013,253.2013,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3208,0253-2014,253.2014,Unconfirmed,141,0253-P04,Hypertension mild,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3209,0253-2015,253.2015,Unconfirmed,141,0253-P04,Hypertension mild,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3210,0253-2016,253.2016,Unconfirmed,141,0253-P04,Hypertension mild,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3211,0253-2017,253.2017,Unconfirmed,141,0253-P04,Hypertension,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3212,0253-2018,253.2018,Ended,141,0253-P04,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3213,0253-2019,253.2019,Ended,141,0253-P04,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3214,0253-2020,253.2020,Ended,141,0253-P04,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3215,0253-2021,253.2021,Ended,141,0253-P04,Hypertension,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3216,0253-2022,253.2022,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3217,0253-2023,253.2023,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3218,0253-2024,253.2024,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3219,0253-2025,253.2025,Unconfirmed,141,0253-P04,Hypertension mild,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3220,0253-2026,253.2026,Ended,141,0253-P04,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3221,0253-2027,253.2027,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3222,0253-2028,253.2028,Ended,141,0253-P04,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3223,0253-2029,253.2029,Ended,141,0253-P04,Hypertension,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3224,0253-2030,253.2030,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3225,0253-2031,253.2031,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3226,0253-2032,253.2032,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3227,0253-2033,253.2033,Unconfirmed,141,0253-P04,Hypertension mild cold;Hypertension mode,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3228,0253-2034,253.2034,Unconfirmed,141,0253-P04,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3229,0253-2035,253.2035,Ended,141,0253-P04,Hypertension,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3230,0253-2036,253.2036,Ended,141,0253-P04,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3231,0253-2037,253.2037,Ended,141,0253-P04,Hypertension,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3232,0253-2038,253.2038,Unconfirmed,141,0253-P04,Hypertension mild, moderate;Diabetes-mel,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3233,0253-2040,253.2040,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3234,0253-2041,253.2041,Ended,141,0253-P04,Hypertension,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3235,0253-2042,253.2042,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3236,0253-2043,253.2043,Unconfirmed,141,0253-P04,Hypertension mild,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3237,0253-2044,253.2044,Unconfirmed,141,0253-P04,Hypertension mild,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3238,0253-2045,253.2045,Ended,141,0253-P04,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3239,0253-2046,253.2046,Ended,141,0253-P04,Geriatric HTN,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3240,0253-2047,253.2047,Ended,141,0253-P04,Hypertension mild,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3241,0253-2048,253.2048,Ended,141,0253-P04,HTN and chronic renal failure,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3242,0253-2050,253.2050,Ended,141,0253-P04,Hypertension mild;Diabetes-Mellitus mino,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3243,0253-2051,253.2051,Unconfirmed,141,0253-P04,Hypertension mild;Diabetes-Mellitus mino,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3244,0253-2052,253.2052,Ended,141,0253-P04,Geriatric HTN,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3245,0253-2054,253.2054,Ended,141,0253-P04,Adolescent HTN,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3246,0253-2055,253.2055,Unconfirmed,141,0253-P04,Hypertension mild,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3247,0253-2056,253.2056,Ended,141,0253-P04,Long-term efficacy,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3248,0253-2057,253.2057,Ended,141,0253-P04,Sexual dysfunction,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3249,0253-2058,253.2058,Ended,141,0253-P04,Insulin tolerance,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3250,0253-2062,253.2062,Ended,141,0253-P04,Comp. w/ propranolol,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3251,0253-2064,253.2064,Ended,141,0253-P04,Comp. w/ Atenolol: exercise,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3252,0253-2143,253.2143,Unconfirmed,141,0253-P04,Hypertension,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3253,0253-2144,253.2144,Unconfirmed,141,0253-P04,Hypertension,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3254,0253-2145,253.2145,Unconfirmed,141,0253-P04,Hypertension severe;Hypertension,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3255,0253-2146,253.2146,Unconfirmed,141,0253-P04,Hypertension,Unconfirmed,MIG,Migration,III,Phase III,- planned patients: 15-20 ** *,,,000910,IS - Clin Study (MIGRATED)
3256,0253-2147,253.2147,Unconfirmed,141,0253-P04,Hypertension mild,Unconfirmed,MIG,Migration,II,Phase II,- planned patients: 60-120 * *,,,000910,IS - Clin Study (MIGRATED)
3257,0253-2148,253.2148,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3258,0253-2149,253.2149,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- Dev.Prot.: 34 PATIENTS ENTERED, 24 ANALYSED, ONLY 5 OF THOSE WITH BASELINE, POST FIRST TREATMENT AND POST SECOND TREATM *,,,000910,IS - Clin Study (MIGRATED)
3259,0253-2150,253.2150,Unconfirmed,141,0253-P04,none,Unconfirmed,MIG,Migration,II,Phase II,- Dev.Prot.: 34 PATIENTS ENTERED, 24 ANALYSED, ONLY 5 OF THOSE WITH BASELINE, POST FIRST TREATMENT AND POST SECOND TREATM *,,,000910,IS - Clin Study (MIGRATED)
3260,0253-2152,253.2152,Unconfirmed,141,0253-P04,Hypertension mild,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3261,0253-2153,253.2153,Unconfirmed,141,0253-P04,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3262,0253-2154,253.2154,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,II,Phase II,- MED-BI-BV-84-5 * *,,,000910,IS - Clin Study (MIGRATED)
3263,0253-2156,253.2156,Unconfirmed,141,0253-P04,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3264,0253-2158,253.2158,Unconfirmed,141,0253-P04,none,Unconfirmed,MIG,Migration,II,Phase II,- reports from BIPI USA. *,,,000910,IS - Clin Study (MIGRATED)
3265,0253-2160,253.2160,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3266,0253-2162,253.2162,Unconfirmed,141,0253-P04,Hypertension moderate;Hypertension mild,Unconfirmed,MIG,Migration,II,Phase II,- CT-82-1 * *,,,000910,IS - Clin Study (MIGRATED)
3267,0253-2163,253.2163,Ended,141,0253-P04,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3268,0253-2164,253.2164,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3269,0253-2165,253.2165,Ended,141,0253-P04,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3270,0253-2167,253.2167,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3271,0253-2169,253.2169,Unconfirmed,141,0253-P04,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3272,0253-2170,253.2170,Unconfirmed,141,0253-P04,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3273,0253-2171,253.2171,Ended,141,0253-P04,none,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3274,0253-2172,253.2172,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3275,0253-2173,253.2173,Ended,141,0253-P04,Hypertension,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3276,0253-2174,253.2174,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3277,0253-2175,253.2175,Ended,141,0253-P04,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3278,0253-2176,253.2176,Ended,141,0253-P04,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3279,0253-2177,253.2177,Ended,141,0253-P04,Hypertension,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3280,0253-2178,253.2178,Unconfirmed,141,0253-P04,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
3281,0253-2217,253.2217,Unconfirmed,141,0253-P04,Hypertension,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3282,0253-2218,253.2218,Unconfirmed,141,0253-P04,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- BIBV-83-12 *,,,000910,IS - Clin Study (MIGRATED)
3283,0253-2242,253.2242,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3284,0253-2243,253.2243,Unconfirmed,141,0253-P04,Hypertension mild,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3285,0253-2244,253.2244,Unconfirmed,141,0253-P04,Hypertension mild,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3286,0253-2245,253.2245,Ended,141,0253-P04,Hypertension mild,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3287,0253-2246,253.2246,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3288,0253-2253,253.2253,Ended,141,0253-P04,Sauna study,Ended,MIG,Migration,III,Phase III,- Summary,,,000910,IS - Clin Study (MIGRATED)
3289,0253-2259,253.2259,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3290,0253-2260,253.2260,Ended,141,0253-P04,Hypertension moderate;Hypertension sever,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3291,0253-2266,253.2266,Ended,141,0253-P04,HYPERTENSION,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3292,0253-2269,253.2269,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- NZ Trial,,,000910,IS - Clin Study (MIGRATED)
3293,0253-2270,253.2270,Unconfirmed,141,0253-P04,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
3294,0253-2273,253.2273,Unconfirmed,141,0253-P04,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3295,0253-2279,253.2279,Ended,141,0253-P04,Hypertension mild,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3296,0253-2280,253.2280,Ended,141,0253-P04,Hypertension mild,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3297,0253-2282,253.2282,Ended,141,0253-P04,Eval. w/ impaired renal fcn,Ended,MIG,Migration,IV,Phase IV,-  (DUPLICATE OF LOWENTHAL STUDY) Lack of patient enrollment.  Study design has been changed to a retrospective review of   Catapres-TTS use in 30 pts with impaired renal function. Estimated cost is $5,000.   ,,,000940,Post Marketing Study (MIGRATED)
3298,0253-2284,253.2284,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,II,Phase II,- BIBV-84-05 * *,,,000910,IS - Clin Study (MIGRATED)
3299,0253-2285,253.2285,Ended,141,0253-P04,Effect on LV mass,Ended,MIG,Migration,IV,Phase IV,-  FORMERLY CATAPRES TABLETS IVWW1.  AT INVESTIGATOR'S REQUEST THE  STUDY DRUG WAS SWITCHED FROM ORAL TO CATAPRES TTS.  LACK OF PATIENT ENROLLMENT.     ,,,000940,Post Marketing Study (MIGRATED)
3300,0253-2286,253.2286,Ended,141,0253-P04,Comp. w/ thiazide in elderly,Ended,MIG,Migration,IV,Phase IV,        ,,,000940,Post Marketing Study (MIGRATED)
3301,0253-2287,253.2287,Ended,141,0253-P04,Hypertension,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3302,0253-2288,253.2288,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3303,0253-2293,253.2293,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3304,0253-2294,253.2294,Ended,141,0253-P04,Hypertension,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3305,0253-2298,253.2298,Unconfirmed,141,0253-P04,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3306,0253-2303,253.2303,Ended,141,0253-P04,Comp. w/ chlorthal. in elderly,Ended,MIG,Migration,III,Phase III,-  Formerly IVl1  Converted from phase IV to phase III due to unapproved dose of   chlorthalidone     ,,,000910,IS - Clin Study (MIGRATED)
3307,0253-2337,253.2337,Ended,141,0253-P04,Comparison w/ captopril,Ended,MIG,Migration,IV,Phase IV,-  Formerly IVe1 Data presented South Med. Assoc. meeting 11/7/89. Manuscript in review by investigators. Submitted to Clinical Therapeutics 1/15/90.   ,,,000940,Post Marketing Study (MIGRATED)
3308,0253-2338,253.2338,Ended,141,0253-P04,HYPERTENSION,Ended,MIG,Migration,IV,Phase IV,-  FORMERLY IVh6.  Trial terminated.  Report to summarize safety only.     ,,,000940,Post Marketing Study (MIGRATED)
3309,0253-2344,253.2344,Unconfirmed,141,0253-P04,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3310,0253-2347,253.2347,Ended,141,0253-P04,ANTIHYPERT.PATCH ITALIAN STUDY,Ended,MIG,Migration,III,Phase III,- Report expected 12/92 (Letter Daniotti 06.10.92),,,000910,IS - Clin Study (MIGRATED)
3311,0253-2348,253.2348,Ended,141,0253-P04,Comparison w/ verapamil SR,Ended,MIG,Migration,IV,Phase IV,-  Preliminary review of the data indicated the comparable efficacy of the two antihypertensives. Manuscript in preparation.     ,,,000940,Post Marketing Study (MIGRATED)
3312,0253-2349,253.2349,Ended,141,0253-P04,Patch rotation,Ended,MIG,Migration,IV,Phase IV,-  A preliminary analysis of this trial was completed via market research.  Additional information requested of MDS 12/89. Report to follow within 3 weeks of receipt of information from MDS.   ,,,000940,Post Marketing Study (MIGRATED)
3313,0253-2351,253.2351,Ended,141,0253-P04,bioequiv. rotation / 7day,Ended,MIG,Migration,I,Phase I,-  May publish manuscript. Abstract published 9/89.     ,,,000910,IS - Clin Study (MIGRATED)
3314,0253-2354,253.2354,Unconfirmed,141,0253-P04,24 hr efficacy,Unconfirmed,MIG,Migration,IV,Phase IV,        ,,,,
3315,0253-2356,253.2356,Ended,141,0253-P04,HYPERTENSION,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3316,0253-2374,253.2374,Ended,141,0253-P04,Longterm efficacy and safety,Ended,MIG,Migration,III,Phase III,- old contract -> I (EWOE discussed Oct.91 with Dr. Wald) / Report requested 7/93 Dr. Gladigau,,,,
3317,0253-2382,253.2382,Ended,141,0253-P04,Adjunct to enalapril,Ended,MIG,Migration,IV,Phase IV,-  FORMERLY IVo2 All centers are complete. Manuscript submitted 5/91 to the Journal of Clinical Pharmacology     ,,,000940,Post Marketing Study (MIGRATED)
3318,0253-2383,253.2383,Ended,141,0253-P04,Adjuvant to diltiazem SR,Ended,MIG,Migration,IV,Phase IV,-  Compliance to oral regimens will be evaluated using the MEMS monitor.  An attempt to correlate poor compliance to a pattern of Rx refills and lack of blood pressure control will be undertaken. Manuscript submitted 5/91 to Clinical Therapeutics   ,,,000940,Post Marketing Study (MIGRATED)
3319,0253-2395,253.2395,Ended,141,0253-P04,Adjunct to nifedipine,Ended,MIG,Migration,IV,Phase IV,-  Nifedipine XL is anticipated to become the most widely prescribed calcium channel blocker within the next several years.     ,,,000940,Post Marketing Study (MIGRATED)
3320,0253-2399,253.2399,Ended,141,0253-P04,HYPERTENSION,Ended,MIG,Migration,II,Phase II,-  Estimated grant totals only for Drs. Hamburger and Shah.     ,,,000910,IS - Clin Study (MIGRATED)
3321,0253-2420,253.2420,Ended,141,0253-P04,EFFECTS ON 24H BLOOD PRESSURE,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3322,0253-2421,253.2421,Ended,141,0253-P04,CLONIDINE LONG TERM TREATMENT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3323,0253-2428,253.2428,Ended,141,0253-P04,Inner city seeding program,Ended,MIG,Migration,IV,Phase IV,-  Field monitoring to be conducted by telephone, CRFs to be mailed in to BIPI by the investigators. Initial slow enrollment due to back ordered product. 9/20/94:DRS.HILLIARD AND RENYOLDS SITES ARE CLOSED.  DR.TORRES SITE NEVER RETURNS MS. SNARR'S MESSAGES. EVERETEZE(04) & OPARIL(09) ARE COMPLETE & HAVE BEEN INITIATED AS NEW INVESTIGATORS (12 & 13).   ,,,000940,Post Marketing Study (MIGRATED)
3324,0253-2430,253.2430,Unconfirmed,141,0253-P04,Arterial Compliance,Unconfirmed,MIG,Migration,I,Phase I,-  study has been completed by Dr Weber. 310/ 595-9366     ,,,,
3325,0253-2434,253.2434,Unconfirmed,141,0253-P04,Circadian BP variation,Unconfirmed,MIG,Migration,IV,Phase IV,-  THIS IS THE SECOND PHASE OF DR. BRANCHE'S STUDY IN BLACK INNER CITY HYPERTENSIVES.  PHASE I WAS PUBLISHED IN AJM (JULY 1991). STUDY IS COMPLETE. Phone 212/939-1449   ,,,,
3326,0253-2437,253.2437,Unconfirmed,141,0253-P04,Alcoholic hypertensives,Unconfirmed,MIG,Migration,IV,Phase IV,-  Investigator informed that the final clinical drug resuply would be sent, and no additional shipments will be made.     ,,,,
3327,0253-2445,253.2445,Ended,141,0253-P04,Comparison with Amlodipine,Ended,MIG,Migration,IV,Phase IV,-  Initiation visit took place 10/93, but investigator was unable to begin until 3/94 for lack of signed contracts and final protocol.     ,,,000940,Post Marketing Study (MIGRATED)
3328,0253-2446,253.2446,Ended,141,0253-P04,Atrial fibrillation (I),Ended,MIG,Migration,IV,Phase IV,-  THE PLASMA SAMPLE RESULTS HAVE BEEN GIVEN TO DR. URQUILLA AS OF 9/1 9/94. Trial terminated 10/20/95.     ,,,000940,Post Marketing Study (MIGRATED)
3329,0253-2460,253.2460,Unconfirmed,141,0253-P04,Comp w ACE & CA blocker,Unconfirmed,MIG,Migration,IV,Phase IV,-  Publication is unlikely to be completed prior to patent expiry. Therefore trial cancelled.     ,,,000940,Post Marketing Study (MIGRATED)
3330,0253-2464,253.2464,Unconfirmed,141,0253-P04,ACE inhibitor cough,Unconfirmed,MIG,Migration,IV,Phase IV,-  pts completed. Abstract submitted to ATS. Clincally complete. 415/750-2007     ,,,,
3331,0253-2466,253.2466,Unconfirmed,141,0253-P04,Post-op hemodynamics,Unconfirmed,MIG,Migration,IV,Phase IV,-  312 633-7923 (or  6167 -OR) Called 2/22/95.  Unable to reach. 80 patients enrolled/completed per phone call to Dr. Pertel on 4/25/95.  Drug did not appear to be effective at 0.1 mg dose. Dr. Pertel would like to repeat study with 0.2 mg. 6/14: request for more drug on hold-awaiting summary results from Dr. Pertel.   ,,,,
3332,0253-2467,253.2467,Unconfirmed,141,0253-P04,Renal protective effects,Unconfirmed,MIG,Migration,IV,Phase IV,-  Call Dr Amidon 415/476-1326 CA. 1pt enroll. as of 11/28/94. Expecting 8 pts to complete (originally 20). 6/2: Center requests 40 patches to replace dropouts. Have 5 scr; 2 scr drops; 2 drop in active. 6/12: drug shipped. 11/20: Per Cindy Klinski, status= 8 consented; 5 drops(3 screen/2 active);2 compl;1 active. 6/96: 6 subj completed. study stopped - no evidence of benefit   ,,,,
3333,0253-2469,253.2469,Ended,141,0253-P04,COMPLIANCE IN HYPERTENSIVE PATIENTS,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
3334,0253-2472,253.2472,Ended,141,0253-P04,PROACT Trial,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3335,0253-2475,253.2475,Ended,141,0253-P04,isolated systolic hypertension,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
3336,0253-2476,253.2476,Ended,141,0253-P04,Clonidine TTS vs enalapril in LVH,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3337,0253-2477,253.2477,Ended,141,0253-P04,Trough: peak ratio,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
3338,0253-2478,253.2478,Ended,141,0253-P04,clonidine cross-over study,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
3339,0253-2486,253.2486,Ended,141,0253-P04,TTS BE and adhesion,Ended,MIG,Migration,I,Phase I,Formulation with new source PIB ,,,000910,IS - Clin Study (MIGRATED)
3340,0253-2487,253.2487,Unconfirmed,141,0253-P04,Skin Irritation Sensitization & Adhesion,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
3341,0253-2489,253.2489,Preparing,141,0253-P04,Catapres-TTS Bioequivalence,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3342,0253-0301,253.301,Ended,142,0253-P01,Thromozytenaggregat., spontan&stimuliert,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3343,0253-0302,253.302,Ended,142,0253-P01,Thromozytenaggregat., spontan&stimuliert,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3344,0253-0304,253.304,Ended,142,0253-P01,No Legacy Data,Ended,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3345,0253-0307,253.307,Ended,142,0253-P01,Efficacy, LH-hypertrophy,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3346,0253-0308,253.308,Preparing,142,0253-P01,Exercise tolerance,Preparing,MIG,Migration,IV,Phase IV,- , EStatus = X, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3347,0253-0309,253.309,Preparing,142,0253-P01,Exercise tolerance, male patients,Preparing,MIG,Migration,IV,Phase IV,- , EStatus = X, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3348,0253-1161,253.1161,Ended,142,0253-P01,Bioequivalence, serum level,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3349,0253-2000,253.2000,Unconfirmed,142,0253-P01,None,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3350,0253-2002,253.2002,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3351,0253-2007,253.2007,Unconfirmed,142,0253-P01,Hypertension mild,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3352,0253-2011,253.2011,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3353,0253-2012,253.2012,Ended,142,0253-P01,none,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
3354,0253-2068,253.2068,Ended,142,0253-P01,Hypertension mild,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3355,0253-2069,253.2069,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3356,0253-2070,253.2070,Unconfirmed,142,0253-P01,Hypertension moderate;Hypertension sever,Unconfirmed,MIG,Migration,NONE,Not Classified,- 41 PATIENTS CONTINUED, 12 DROP OUTS. 29 PATIENTS COMPLETED THE WHOLE STUD *,,,000910,IS - Clin Study (MIGRATED)
3357,0253-2071,253.2071,Ended,142,0253-P01,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3358,0253-2072,253.2072,Unconfirmed,142,0253-P01,Hypertension moderate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3359,0253-2073,253.2073,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3360,0253-2074,253.2074,Ended,142,0253-P01,Hypertension,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3361,0253-2075,253.2075,Ended,142,0253-P01,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3362,0253-2076,253.2076,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3363,0253-2077,253.2077,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3364,0253-2078,253.2078,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3365,0253-2079,253.2079,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3366,0253-2080,253.2080,Unconfirmed,142,0253-P01,Hypertension moderate;Hypertension sever,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3367,0253-2081,253.2081,Unconfirmed,142,0253-P01,Hypertension surgery postoperative,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3368,0253-2082,253.2082,Unconfirmed,142,0253-P01,Angina-Pectoris stable,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3369,0253-2083,253.2083,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3370,0253-2085,253.2085,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3371,0253-2086,253.2086,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3372,0253-2087,253.2087,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3373,0253-2088,253.2088,Ended,142,0253-P01,HYPERTENSION,Ended,MIG,Migration,IV,Phase IV,-  Grant of $32,060.00 was issued in 1982 and is included in estimated  grant total.     ,,,000940,Post Marketing Study (MIGRATED)
3374,0253-2089,253.2089,Unconfirmed,142,0253-P01,Hypertension mild cold,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3375,0253-2090,253.2090,Unconfirmed,142,0253-P01,Hypertension moderate;Hypertension sever,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3376,0253-2091,253.2091,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3377,0253-2093,253.2093,Ended,142,0253-P01,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3378,0253-2094,253.2094,Unconfirmed,142,0253-P01,Hypertension mild,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3379,0253-2095,253.2095,Ended,142,0253-P01,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3380,0253-2097,253.2097,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,NONE,Not Classified,- / trial performed by: BI Div. Pfizer, Kenya *,,,000910,IS - Clin Study (MIGRATED)
3381,0253-2099,253.2099,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate;,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3382,0253-2100,253.2100,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate;,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3383,0253-2104,253.2104,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3384,0253-2107,253.2107,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3385,0253-2109,253.2109,Ended,142,0253-P01,Hypertension moderate;Hypertension sever,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3386,0253-2110,253.2110,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3387,0253-2111,253.2111,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3388,0253-2113,253.2113,Ended,142,0253-P01,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3389,0253-2114,253.2114,Unconfirmed,142,0253-P01,Hypertension moderate;Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3390,0253-2118,253.2118,Unconfirmed,142,0253-P01,Hypertension mild,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3391,0253-2120,253.2120,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3392,0253-2127,253.2127,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3393,0253-2128,253.2128,Unconfirmed,142,0253-P01,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3394,0253-2134,253.2134,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3395,0253-2135,253.2135,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3396,0253-2136,253.2136,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3397,0253-2138,253.2138,Ended,142,0253-P01,HYPERTENSION,Ended,MIG,Migration,IV,Phase IV,-  Terminated due to slow enrollment.     ,,,000940,Post Marketing Study (MIGRATED)
3398,0253-2139,253.2139,Ended,142,0253-P01,Comp. w/ propranolol,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3399,0253-2141,253.2141,Ended,142,0253-P01,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3400,0253-2157,253.2157,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3401,0253-2159,253.2159,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,II,Phase II,- MED-BIBV-83-8 * *,,,000910,IS - Clin Study (MIGRATED)
3402,0253-2161,253.2161,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3403,0253-2166,253.2166,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3404,0253-2168,253.2168,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3405,0253-2179,253.2179,Ended,142,0253-P01,Hypertension mild,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3406,0253-2180,253.2180,Ended,142,0253-P01,Hypertension,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3407,0253-2187,253.2187,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3408,0253-2188,253.2188,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3409,0253-2191,253.2191,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3410,0253-2205,253.2205,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3411,0253-2206,253.2206,Ended,142,0253-P01,Hypertension, elderly,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3412,0253-2210,253.2210,Ended,142,0253-P01,HYPERTENSION,Ended,MIG,Migration,IV,Phase IV,        ,,,000940,Post Marketing Study (MIGRATED)
3413,0253-2211,253.2211,Ended,142,0253-P01,HYPERTENSION,Ended,MIG,Migration,IV,Phase IV,-  Drs. Robie and Stein are performing special laboratory analyses.     ,,,000940,Post Marketing Study (MIGRATED)
3414,0253-2212,253.2212,Ended,142,0253-P01,HYPERTENSION,Ended,MIG,Migration,IV,Phase IV,        ,,,000940,Post Marketing Study (MIGRATED)
3415,0253-2213,253.2213,Ended,142,0253-P01,HYPERTENSION,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
3416,0253-2214,253.2214,Ended,142,0253-P01,HYPERTENSION,Ended,MIG,Migration,IV,Phase IV,-  Submitted for publication.     ,,,000940,Post Marketing Study (MIGRATED)
3417,0253-2215,253.2215,Unconfirmed,142,0253-P01,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3418,0253-2228,253.2228,Unconfirmed,142,0253-P01,Hypertension moderate;Hypertension sever,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3419,0253-2229,253.2229,Unconfirmed,142,0253-P01,Hypertension renal failure minor dialysi,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3420,0253-2230,253.2230,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3421,0253-2231,253.2231,Unconfirmed,142,0253-P01,Hypertension renal failure minor dialysi,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
3422,0253-2232,253.2232,Ended,142,0253-P01,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3423,0253-2233,253.2233,Unconfirmed,142,0253-P01,Hypertension moderate;Hypertension sever,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3424,0253-2234,253.2234,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3425,0253-2235,253.2235,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3426,0253-2236,253.2236,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3427,0253-2237,253.2237,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3428,0253-2238,253.2238,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3429,0253-2239,253.2239,Unconfirmed,142,0253-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3430,0253-2240,253.2240,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3431,0253-2252,253.2252,Unconfirmed,142,0253-P01,Hypertension mild,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3432,0253-2257,253.2257,Ended,142,0253-P01,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3433,0253-2258,253.2258,Ended,142,0253-P01,HYPERTENSION,Ended,MIG,Migration,IV,Phase IV,        ,,,000940,Post Marketing Study (MIGRATED)
3434,0253-2261,253.2261,Ended,142,0253-P01,Hypertension,Ended,MIG,Migration,II,Phase II,- Study material administered for 14 days, with washout period  between treatments of 7 days. * *,,,000910,IS - Clin Study (MIGRATED)
3435,0253-2263,253.2263,Ended,142,0253-P01,Hypertension,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3436,0253-2267,253.2267,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3437,0253-2271,253.2271,Ended,142,0253-P01,CLONIDINE IN ELDERLY HYPERTENSION,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3438,0253-2277,253.2277,Ended,142,0253-P01,Hypertension phaeochromocytoma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3439,0253-2283,253.2283,Ended,142,0253-P01,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3440,0253-2290,253.2290,Unconfirmed,142,0253-P01,Hypertension phaeochromocytoma minor,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3441,0253-2291,253.2291,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3442,0253-2297,253.2297,Ended,142,0253-P01,none,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3443,0253-2299,253.2299,Ended,142,0253-P01,Hypertensive crisis,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3444,0253-2300,253.2300,Ended,142,0253-P01,Hypertension,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3445,0253-2301,253.2301,Unconfirmed,142,0253-P01,Hypertensive crisis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3446,0253-2309,253.2309,Ended,142,0253-P01,Hypertension, pregnancy,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3447,0253-2310,253.2310,Ended,142,0253-P01,Hypertension,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3448,0253-2314,253.2314,Unconfirmed,142,0253-P01,Tremor/Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3449,0253-2316,253.2316,Ended,142,0253-P01,Hypertension,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3450,0253-2320,253.2320,Ended,142,0253-P01,Left ventricular mass,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3451,0253-2322,253.2322,Ended,142,0253-P01,Hypertension,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3452,0253-2323,253.2323,Ended,142,0253-P01,Acute antihypertensive effects during op,Ended,MIG,Migration,IV,Phase IV,- Own IND trial *,,,000910,IS - Clin Study (MIGRATED)
3453,0253-2325,253.2325,Ended,142,0253-P01,Hypertension,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3454,0253-2326,253.2326,Ended,142,0253-P01,CLONIDINE IN ACOUSTIC STRESS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3455,0253-2328,253.2328,Unconfirmed,142,0253-P01,CLONIDINE IL ELDERLY HYPERTENSION,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3456,0253-2334,253.2334,Ended,142,0253-P01,Pharmacokil.,Ended,MIG,Migration,IV,Phase IV,- planned patients: 4-6 ** *,,,000910,IS - Clin Study (MIGRATED)
3457,0253-2335,253.2335,Ended,142,0253-P01,Hypertension,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3458,0253-2340,253.2340,Ended,142,0253-P01,Hypertension,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3459,0253-2341,253.2341,Ended,142,0253-P01,Hypertension,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3460,0253-2343,253.2343,Ended,142,0253-P01,Submax excercise in hypertensive pat.,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3461,0253-2355,253.2355,Ended,142,0253-P01,Hypertensive urgency,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3462,0253-2364,253.2364,Unconfirmed,142,0253-P01,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3463,0253-2365,253.2365,Ended,142,0253-P01,ANTHYPERT.EFFECTS CLONIDINE/CAPTOPRIL,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3464,0253-2366,253.2366,Ended,142,0253-P01,ANTIHYPERT.OF CLONIDINE/NIFEDIPINE,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3465,0253-2368,253.2368,Ended,142,0253-P01,CDN AND US FORMULATION COMPARISON,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3466,0253-2379,253.2379,Ended,142,0253-P01,LVH Reversal with Clonidine Monotherapy,Ended,MIG,Migration,IV,Phase IV,- Report requested 7/93 Dr.GLA,,,000910,IS - Clin Study (MIGRATED)
3467,0253-2385,253.2385,Ended,142,0253-P01,Hypertension,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3468,0253-2387,253.2387,Ended,142,0253-P01,Clonidine and blood pressure fluctuation,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3469,0253-2394,253.2394,Ended,142,0253-P01,Hydrochlorothiazide and clonidine in add,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3470,0253-2398,253.2398,Ended,142,0253-P01,HYPERTENSION,Ended,MIG,Migration,III,Phase III,-  Terminated due to inability to recruit study patients.     ,,,000910,IS - Clin Study (MIGRATED)
3471,0253-2402,253.2402,Ended,142,0253-P01,Hypertension,Ended,MIG,Migration,IV,Phase IV,- Report available 12/92 (Letter Maria 09.10.92),,,000910,IS - Clin Study (MIGRATED)
3472,0253-2415,253.2415,Ended,142,0253-P01,Bioequivalence study of Clonidine 0.1 mg,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
3473,0253-2440,253.2440,Unconfirmed,142,0253-P01,Role of BP in renal failure,Unconfirmed,MIG,Migration,IV,Phase IV,        ,,,,
3474,0253-2443,253.2443,Ended,142,0253-P01,Effect on Ventil.response to hypoxia,Ended,MIG,Migration,I,Phase I,- ,,,,
3475,0253-2444,253.2444,Ended,142,0253-P01,Effects of epidual on fentanyl anesthesi,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
3476,0253-2458,253.2458,Ended,142,0253-P01,Effect of epidural clonidine on the pai,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
3477,0253-2480,253.2480,Ended,142,0253-P01,Bioequivalence new form to current form.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3478,0253-2485,253.2485,Analysis,142,0253-P01,POISE II,Analysis,MIG,Migration,IV,Phase IV,IIS - NO SAE REPORTING RESPONSIBILITIES ,,,,
3479,0219-0001,219.1,Unconfirmed,143,0219-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3480,0219-0002,219.2,Unconfirmed,143,0219-P01,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3481,0219-0003,219.3,Unconfirmed,143,0219-P01,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3482,0219-0004,219.4,Ended,143,0219-P01,Hypertension,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3483,0219-0005,219.5,Unconfirmed,143,0219-P01,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3484,0219-0006,219.6,Ended,143,0219-P01,HYPERTENSION,Ended,MIG,Migration,I,Phase I,-  Formerly Ia1.     ,,,000910,IS - Clin Study (MIGRATED)
3485,0219-0007,219.7,Unconfirmed,143,0219-P01,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3486,0228-0109,228.109,Unconfirmed,147,0228-P01,clinic. pharmacology, pharmacokinetics,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3487,0228-0211,228.211,Ended,147,0228-P01,Wirksamkeit-150 bol, Plasmaspiegel,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3488,0228-0426,228.426,Ended,147,0228-P01,Electro-physiology,Ended,MIG,Migration,IV,Phase IV,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3489,0228-0427,228.427,Ended,147,0228-P01,Efficacy, Inotropic effect,Ended,MIG,Migration,IV,Phase IV,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3490,0228-0428,228.428,Ended,147,0228-P01,ESPVR, Mexiletine,Ended,MIG,Migration,IV,Phase IV,- , EStatus = S, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3491,0228-0491,228.491,Analysis,147,0228-P01,Drug monitoring, Mexitil i.v.,Analysis,MIG,Migration,IV,Phase IV,- , EStatus = I, inserted by gerken at 22.03.93,,,000940,Post Marketing Study (MIGRATED)
3492,0228-0700,228.700,Unconfirmed,147,0228-P01,Arrhythmia ventricular infarction myocar,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3493,0228-0710,228.710,Unconfirmed,147,0228-P01,Arrhythmia ventricular,Unconfirmed,MIG,Migration,I,Phase I,- Phase I-II * *,,,000910,IS - Clin Study (MIGRATED)
3494,0228-0711,228.711,Unconfirmed,147,0228-P01,Arrhythmia ventricular infarction myocar,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3495,0228-0712,228.712,Ended,147,0228-P01,Arrhythmia ventricular;Extrasystoles;Tac,Ended,MIG,Migration,NONE,Not Classified,- Dev.Prot.: 140 PATIENTS WERE PLANNED. 9 OF THE 108 PATIENTS TREATED IN THE PLACEBO GROUP WHO HAD PLASMA MEXITIL LEVELS *,,,000910,IS - Clin Study (MIGRATED)
3496,0228-0718,228.718,Unconfirmed,147,0228-P01,Arrhythmia ventricular;Extrasystoles,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3497,0228-0720,228.720,Unconfirmed,147,0228-P01,Arrhythmia ventricular,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3498,0228-0721,228.721,Unconfirmed,147,0228-P01,Tachycardia ventricular;Extrasystoles,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3499,0228-0722,228.722,Unconfirmed,147,0228-P01,Tachycardia ventricular;Extrasystoles,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3500,0228-0723,228.723,Unconfirmed,147,0228-P01,Tachycardia ventricular;Extrasystoles,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3501,0228-0724,228.724,Unconfirmed,147,0228-P01,Arrhythmia ventricular,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3502,0228-0734,228.734,Unconfirmed,147,0228-P01,Arrhythmia ventricular acute,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3503,0228-0748,228.748,Unconfirmed,147,0228-P01,Arrhythmia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3504,0228-0761,228.761,Unconfirmed,147,0228-P01,Arrhythmia ventricular acute,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3505,0228-0762,228.762,Unconfirmed,147,0228-P01,Arrhythmia ventricular acute,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3506,0228-0763,228.763,Unconfirmed,147,0228-P01,Arrhythmia ventricular,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3507,0228-0766,228.766,Unconfirmed,147,0228-P01,Tachycardia supraventricular,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3508,0228-0767,228.767,Unconfirmed,147,0228-P01,Tachycardia ventricular,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3509,0228-0768,228.768,Unconfirmed,147,0228-P01,Arrhythmia ventricular,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3510,0228-0769,228.769,Unconfirmed,147,0228-P01,Arrhythmia ventricular,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3511,0228-0770,228.770,Unconfirmed,147,0228-P01,Tachycardia supraventricular,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3512,0228-0771,228.771,Unconfirmed,147,0228-P01,Arrhythmia ventricular,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3513,0228-0775,228.775,Unconfirmed,147,0228-P01,Arrhythmia supraventricular,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3514,0228-0782,228.782,Unconfirmed,147,0228-P01,Arrhythmia ventricular;Arrhythmia suprav,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3515,0228-0783,228.783,Unconfirmed,147,0228-P01,Arrhythmia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3516,0228-0786,228.786,Unconfirmed,147,0228-P01,Infarction myocardial;Arrhythmia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3517,0228-0805,228.805,Unconfirmed,147,0228-P01,Arrhythmia ventricular;Arrhythmia suprav,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3518,0228-0820,228.820,Ended,147,0228-P01,Long term follow-up study,Ended,MIG,Migration,II,Phase II,-  Double-blind part of study completed 1982.     ,,,000910,IS - Clin Study (MIGRATED)
3519,0228-0822,228.822,Unconfirmed,147,0228-P01,Coronary disease;Arrhythmia ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- Dev.Prot.: 1. PATIENTS WHO WERE ON MEXITIL FOR ONE YEAR FOLLOWING THE CONTROLLED PORTION OF THE STUDY MAY CONTINUE ON MEXI TIL FOR AN ADDITIONAL YEAR PROVIDED THAT THE INVESTIGATOR CONTINUED TO FILL OUT AND RETURN TO B.I.L. CASE REPORT FORMS EV,,,000910,IS - Clin Study (MIGRATED)
3520,0228-0825,228.825,Unconfirmed,147,0228-P01,Arrhythmia supraventricular,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3521,0228-0827,228.827,Unconfirmed,147,0228-P01,Arrhythmia ventricular,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3522,0228-0829,228.829,Ended,147,0228-P01,Q12h dosing,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
3523,0228-0830,228.830,Unconfirmed,147,0228-P01,Arrhythmia ventricular infarction acute,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3524,0228-0831,228.831,Unconfirmed,147,0228-P01,Arrhythmia ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3525,0228-0842,228.842,Ended,147,0228-P01,VENTRICULAR ARRHYTHMIAS,Ended,MIG,Migration,IIIB,Phase IIIb,-  Study terminated due to departure of investigator  from institution where study is being conducted.     ,,,000910,IS - Clin Study (MIGRATED)
3526,0228-0843,228.843,Ended,147,0228-P01,VENTRICULAR ARRHYTHMIAS,Ended,MIG,Migration,III,Phase III,-  Publication in preparation.     ,,,000910,IS - Clin Study (MIGRATED)
3527,0228-0845,228.845,Unconfirmed,147,0228-P01,Arrhythmia ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3528,0228-0849,228.849,Unconfirmed,147,0228-P01,Arrhythmia ventricular infarction myocar,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3529,0228-0850,228.850,Unconfirmed,147,0228-P01,Arrhythmia ventricular;Surgery cardiovas,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3530,0228-0852,228.852,Ended,147,0228-P01,VENTRICULAR ARRHYTHMIAS,Ended,MIG,Migration,IIIB,Phase IIIb,-  THE SHORT TERM PHASE WAS COMPLETED 12/87     ,,,000910,IS - Clin Study (MIGRATED)
3531,0228-0854,228.854,Ended,147,0228-P01,VENTRICULAR ARRHYTHMIAS,Ended,MIG,Migration,IIIB,Phase IIIb,-  Study terminated due to slow enrollment.     ,,,000910,IS - Clin Study (MIGRATED)
3532,0228-0855,228.855,Unconfirmed,147,0228-P01,Arrhythmia ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3533,0228-0857,228.857,Ended,147,0228-P01,VENTRICULAR ARRHYTHMIAS,Ended,MIG,Migration,IIIB,Phase IIIb,-  Study terminated due to slow enrollment.     ,,,000910,IS - Clin Study (MIGRATED)
3534,0228-0865,228.865,Ended,147,0228-P01,VENTRICULAR ARRHYTHMIAS,Ended,MIG,Migration,I,Phase I,-  The final manuscript is being submitted to ACC pending approval. The final manuscript served as the final report for this study and final safety summary was submited 01/17/91. Report sent to Germany     ,,,000910,IS - Clin Study (MIGRATED)
3535,0228-0868,228.868,Ended,147,0228-P01,VENTRICULAR ARRHYTHMIAS,Ended,MIG,Migration,IV,Phase IV,-  Final statistical report and abstract received 12/90. A manuscript will be submitted first quarter 1991. Draft manuscript received 02/20/91. To date 06-21-91 we have not recieved a manuscrpt from investigator.   ,,,000940,Post Marketing Study (MIGRATED)
3536,0228-0869,228.869,Ended,147,0228-P01,VENTRICULAR ARRHYTHMIAS,Ended,MIG,Migration,IV,Phase IV,-  Formerly IVe1 Study terminated no new patients to be enrolled-10/89.     ,,,000940,Post Marketing Study (MIGRATED)
3537,0228-0870,228.870,Ended,147,0228-P01,VENTRICULAR ARRHYTHMIAS,Ended,MIG,Migration,IV,Phase IV,-  Two sites, Drs. Tonkon & Navartil were terminated. Close out visits were both 02/08/90. Dr. Tonkon enrollment terminated 11/89.     ,,,000940,Post Marketing Study (MIGRATED)
3538,0228-0871,228.871,Ended,147,0228-P01,VENTRICULAR ARRHYTHMIAS,Ended,MIG,Migration,IIIB,Phase IIIb,-  FORMERLY IVc1.  Study terminated due to slow enrollment. Draft safety summary issued 12/8/89.     ,,,000910,IS - Clin Study (MIGRATED)
3539,0228-0875,228.875,Ended,147,0228-P01,VENTRICULAR ARRHYTHMIAS,Ended,MIG,Migration,IIIB,Phase IIIb,-  Second site initiation visit was performed on 9/18/90. Study terminated-no additional payments needed.     ,,,000910,IS - Clin Study (MIGRATED)
3540,0228-0876,228.876,Ended,147,0228-P01,VENTRICULAR ARRHYTHMIAS,Ended,MIG,Migration,IV,Phase IV,-  FORMERLY IIIr2. Study close-out to occur late January. Study terminated-no additional payments needed.     ,,,000940,Post Marketing Study (MIGRATED)
3541,0228-0882,228.882,Ended,147,0228-P01,VENTRICULAR ARRHYTHMIAS,Ended,MIG,Migration,IV,Phase IV,-  A final statistical report was issued 2/28/90.     ,,,000940,Post Marketing Study (MIGRATED)
3542,0228-0888,228.888,Ended,147,0228-P01,Emergency Mexitil,Ended,MIG,Migration,IV,Phase IV,-  Study ended 1986 with NDA approval. Some patients continued to receive drug due to difference in strength between this and marketed capsules. In 8/91 investigators were notified of termination of the program.   ,,,000500,Compassionate Use Program (CUP)
3543,0228-0889,228.889,Ended,147,0228-P01,VENTRICULAR ARRHYTHMIAS,Ended,MIG,Migration,IV,Phase IV,-  Trial to continue with commercial product. The investigator will write 2 manuscripts concerning the results which will serve as a final report. Called investigator 06-21 no answer.     ,,,000940,Post Marketing Study (MIGRATED)
3544,0228-0905,228.905,Ended,147,0228-P01,Effic.& Safety on Ventic. Arrhyth.(AMI),Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
3545,0228-0906,228.906,Unconfirmed,147,0228-P01,Efficacy and Safety Ventric. arrhythimia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
3546,0228-0907,228.907,Ended,147,0228-P01,Efficacy and safety ventric. arrhythmia,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
3547,0228-0908,228.908,Ended,147,0228-P01,Efficacy and safety ventric. arrhythmia,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
3548,0228-0910,228.910,Ended,147,0228-P01,Efficacy and safety on tachyarrhythmia,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
3549,0228-0911,228.911,Ended,147,0228-P01,MUSTT trial,Ended,MIG,Migration,IV,Phase IV,-  Dr. Buxton received NIH funding for continuation of the trial in additional patients in August 91. Final payment to be made by end of 94. MUSTT TRIAL call Victoria Christian DUKE Univ. Clinical Coord. 919/286-8876.   ,,,,
3550,0228-0912,228.912,Unconfirmed,147,0228-P01,Ventricular Arrhythmias,Unconfirmed,MIG,Migration,IV,Phase IV,-  Study recruitment over 36 months. Four enrolled two active; two screened as of 5/16/91. # 215/662-9002 Kim Quoronta     ,,,,
3551,0228-0927,228.927,Ended,147,0228-P01,Mexitil & Sotalol,Ended,MIG,Migration,IV,Phase IV,-  Number of patients and centers reduced by Dr. Urquilla to ensure timely availability of study results. Letters sent to investigators to terminate the trial 6/7/94. no patients were active at the time of termination.Requesed date f or data lock and report issue from Dr. Dias on 1/23/95.  Abbreviate d report to be written:timeline undecided at this time.   ,,,000940,Post Marketing Study (MIGRATED)
3552,0228-0928,228.928,Ended,147,0228-P01,the comparison MX & Lidocaine of Ventri.,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
3553,0228-0929,228.929,Ended,147,0228-P01,Efficacy & safety ofMX-i on ventric. arr,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
3554,0228-0930,228.930,Ended,147,0228-P01,Efficacy & safety ofMX-i on ventric. arr,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
3555,0228-0932,228.932,Ended,147,0228-P01,Effic. & safety MX-ion ventric. arrhythm,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
3556,0228-0101,228.101,Unconfirmed,148,0228-P02,Vertraeglichkeit, Einzeldosis,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3557,0228-0103,228.103,Unconfirmed,148,0228-P02,Vertraeglichkeit, Dauermedikation,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3558,0228-0107,228.107,Unconfirmed,148,0228-P02,Plasmaspiegel, In-Vivo,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3559,0228-0108,228.108,Unconfirmed,148,0228-P02,Leberfunktionswerte, intrahepatische,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3560,0228-0114,228.114,Unconfirmed,148,0228-P02,Pilot Study, Plasma+urine levels,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3561,0228-0116,228.116,Unconfirmed,148,0228-P02,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3562,0228-0117,228.117,Unconfirmed,148,0228-P02,Plasma concentration, Pharmacokinetics,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3563,0228-0118,228.118,Unconfirmed,148,0228-P02,Plasma concentration, Multiple dose,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3564,0228-0119,228.119,Unconfirmed,148,0228-P02,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3565,0228-0120,228.120,Unconfirmed,148,0228-P02,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3566,0228-0121,228.121,Unconfirmed,148,0228-P02,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3567,0228-0202,228.202,Ended,148,0228-P02,No Legacy Data,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3568,0228-0207,228.207,Ended,148,0228-P02,Wirkung, Nebenwirk., Blutspiegel,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3569,0228-0208,228.208,Preparing,148,0228-P02,Red. Dosis, Umstellung,Preparing,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3570,0228-0209,228.209,Ended,148,0228-P02,No Legacy Data,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3571,0228-0210,228.210,Ended,148,0228-P02,No Legacy Data,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3572,0228-0401,228.401,Ended,148,0228-P02,No Legacy Data,Ended,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3573,0228-0402,228.402,Ended,148,0228-P02,No Legacy Data,Ended,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3574,0228-0403,228.403,Ended,148,0228-P02,No Legacy Data,Ended,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3575,0228-0404,228.404,Ended,148,0228-P02,No Legacy Data,Ended,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3576,0228-0405,228.405,Ended,148,0228-P02,No Legacy Data,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3577,0228-0406,228.406,Ended,148,0228-P02,Antiarrhythm.Wirkung, Einzelpraeparate,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3578,0228-0407,228.407,Ended,148,0228-P02,Wirksamkeit, Kombination/Soltalol,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3579,0228-0408,228.408,Ended,148,0228-P02,Efficacy, inotropic effect,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3580,0228-0409,228.409,Analysis,148,0228-P02,Wirksamkeit,Analysis,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3581,0228-0410,228.410,Analysis,148,0228-P02,Antiarrhythm.Wirkung,Analysis,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3582,0228-0411,228.411,Analysis,148,0228-P02,Antiarrhythm.Wirkung,Analysis,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3583,0228-0412,228.412,Analysis,148,0228-P02,Efficacy & safety,Analysis,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3584,0228-0413,228.413,Analysis,148,0228-P02,antiarrhythm.Wirkung, Vertraeglichkeit,Analysis,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3585,0228-0414,228.414,Analysis,148,0228-P02,Efficacy & safety,Analysis,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3586,0228-0415,228.415,Unconfirmed,148,0228-P02,antiarrhythm.Wirkung,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3587,0228-0416,228.416,Unconfirmed,148,0228-P02,Efficacy, safety,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3588,0228-0417,228.417,Ended,148,0228-P02,antiarrhythm.Wirkung, vertraeglichkeit,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3589,0228-0418,228.418,Ended,148,0228-P02,antiarrhythm.Wirkung,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3590,0228-0419,228.419,Ended,148,0228-P02,antiarrhythm.Wirkung,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3591,0228-0420,228.420,Ended,148,0228-P02,antiarrhythm.Wirkung, lown-index,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3592,0228-0421,228.421,Analysis,148,0228-P02,antiarrhythm.Wirkung, Plasmakonzentarati,Analysis,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3593,0228-0422,228.422,Unconfirmed,148,0228-P02,antiarrhythm.Wirkung, bioverfuegbarkeit,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3594,0228-0423,228.423,Analysis,148,0228-P02,antiarrhythm.Wirkung, mexitilserumspiege,Analysis,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3595,0228-0424,228.424,Analysis,148,0228-P02,antiarrhythm.Wirkung, Langzeittherapie,Analysis,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3596,0228-0425,228.425,Ended,148,0228-P02,antiarrhythm.Wirkung,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3597,0228-0429,228.429,Unconfirmed,148,0228-P02,VENTR. EXTRASYSTOLES,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3598,0228-0430,228.430,Unconfirmed,148,0228-P02,VENTR. EXTRASYSTOLES,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3599,0228-0431,228.431,Unconfirmed,148,0228-P02,VENTR. EXTRASYSTOLES,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3600,0228-0432,228.432,Ended,148,0228-P02,Efficacy, Serial signal-averaged ECG,Ended,MIG,Migration,IV,Phase IV,,,,,
3601,0228-0499,228.499,Ended,148,0228-P02,Pharmakocinetics, arrhythmia,Ended,MIG,Migration,IV,Phase IV,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3602,0228-0501,228.501,Ended,148,0228-P02,Efficacy, diabetic neuropathy,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3603,0228-0502,228.502,Ended,148,0228-P02,Efficacy, Thermosensitivity,Ended,MIG,Migration,II,Phase II,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3604,0228-0505,228.505,Unconfirmed,148,0228-P02,Efficacy,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = S, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3605,0228-0506,228.506,Unconfirmed,148,0228-P02,NONE,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3606,0228-0507,228.507,Unconfirmed,148,0228-P02,DIABETIC NEUROPATHY,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3607,0228-0508,228.508,Unconfirmed,148,0228-P02,DIABETIC NEUROPATHY,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3608,0228-0598,228.598,Analysis,148,0228-P02,Mexiletine, diabetic neuropathy,Analysis,MIG,Migration,IV,Phase IV,- , EStatus = I, inserted by gerken at 22.03.93,,,000940,Post Marketing Study (MIGRATED)
3609,0228-0599,228.599,Analysis,148,0228-P02,No Legacy Data,Analysis,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3610,0228-0701,228.701,Unconfirmed,148,0228-P02,Infarction myocardial,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3611,0228-0702,228.702,Unconfirmed,148,0228-P02,Tachycardia ventricular chagas-Disease m,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3612,0228-0703,228.703,Unconfirmed,148,0228-P02,Arrhythmia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3613,0228-0704,228.704,Ended,148,0228-P02,Arrhythmia ventricular,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3614,0228-0706,228.706,Unconfirmed,148,0228-P02,Arrhythmia ventricular;Extrasystoles,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3615,0228-0727,228.727,Unconfirmed,148,0228-P02,Arrhythmia ventricular;Extrasystoles,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3616,0228-0728,228.728,Unconfirmed,148,0228-P02,Arrhythmia ventricular;Extrasystoles,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3617,0228-0729,228.729,Unconfirmed,148,0228-P02,Arrhythmia ventricular;Extrasystoles;Tac,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3618,0228-0730,228.730,Unconfirmed,148,0228-P02,Tachycardia ventricular,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3619,0228-0731,228.731,Ended,148,0228-P02,Arrhythmia ventricular;Extrasystoles;Tac,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3620,0228-0732,228.732,Unconfirmed,148,0228-P02,Arrhythmia ventricular extrasystoles,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3621,0228-0735,228.735,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3622,0228-0736,228.736,Ended,148,0228-P02,Arrhythmia ventricular,Ended,MIG,Migration,II,Phase II,- planned patients:30-40 * *,,,000910,IS - Clin Study (MIGRATED)
3623,0228-0737,228.737,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3624,0228-0738,228.738,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3625,0228-0739,228.739,Ended,148,0228-P02,Tinnitus minor,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3626,0228-0740,228.740,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3627,0228-0743,228.743,Unconfirmed,148,0228-P02,Arrhythmia ventricular infarction myocar,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3628,0228-0744,228.744,Unconfirmed,148,0228-P02,Arrhythmia ventricular infarction myocar,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3629,0228-0746,228.746,Ended,148,0228-P02,Arrhythmia ventricular,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3630,0228-0747,228.747,Unconfirmed,148,0228-P02,Arrhythmia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3631,0228-0749,228.749,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3632,0228-0750,228.750,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3633,0228-0751,228.751,Unconfirmed,148,0228-P02,Arrhythmia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3634,0228-0755,228.755,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3635,0228-0756,228.756,Unconfirmed,148,0228-P02,Arrhythmia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3636,0228-0757,228.757,Unconfirmed,148,0228-P02,Arrhythmia ventricular coronary disease,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3637,0228-0758,228.758,Unconfirmed,148,0228-P02,Arrhythmia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3638,0228-0759,228.759,Unconfirmed,148,0228-P02,Extrasystoles ventricular infarction myo,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3639,0228-0760,228.760,Unconfirmed,148,0228-P02,Arrhythmia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3640,0228-0764,228.764,Unconfirmed,148,0228-P02,Arrhythmia ventricular heart failure con,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3641,0228-0765,228.765,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3642,0228-0774,228.774,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3643,0228-0777,228.777,Unconfirmed,148,0228-P02,Arrhythmia infarction myocardial,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3644,0228-0784,228.784,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3645,0228-0788,228.788,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3646,0228-0789,228.789,Unconfirmed,148,0228-P02,Arrhythmia ventricular chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3647,0228-0790,228.790,Unconfirmed,148,0228-P02,Arrhythmia ventricular chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3648,0228-0791,228.791,Unconfirmed,148,0228-P02,Arrhythmia ventricular chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3649,0228-0792,228.792,Unconfirmed,148,0228-P02,Arrhythmia ventricular chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3650,0228-0798,228.798,Ended,148,0228-P02,Arrhythmia ventricular,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3651,0228-0799,228.799,Unconfirmed,148,0228-P02,Arrhythmia ventricular;Arrhythmia suprav,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3652,0228-0800,228.800,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3653,0228-0801,228.801,Ended,148,0228-P02,Arrhythmia ventricular,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3654,0228-0802,228.802,Ended,148,0228-P02,Arrhythmia ventricular,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3655,0228-0803,228.803,Unconfirmed,148,0228-P02,Arrhythmia ventricular;Arrhythmia suprav,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3656,0228-0804,228.804,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3657,0228-0806,228.806,Unconfirmed,148,0228-P02,Arrhythmia ventricular;Coronary disease,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3658,0228-0807,228.807,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3659,0228-0809,228.809,Unconfirmed,148,0228-P02,Arrhythmia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3660,0228-0812,228.812,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3661,0228-0813,228.813,Unconfirmed,148,0228-P02,Bradycardia sinus;Arrhythmia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3662,0228-0815,228.815,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3663,0228-0816,228.816,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3664,0228-0817,228.817,Unconfirmed,148,0228-P02,Arrhythmia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3665,0228-0818,228.818,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,III,Phase III,- 2. REDUCED LOWER AGE LIMIT TO 18 YEARS TO IMPROVE R *,,,000910,IS - Clin Study (MIGRATED)
3666,0228-0819,228.819,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,III,Phase III,- A) PATIENTS WHO HAVE BEEN IN HEART FAILURE - USE OF NORPA *,,,000910,IS - Clin Study (MIGRATED)
3667,0228-0821,228.821,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3668,0228-0836,228.836,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3669,0228-0837,228.837,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3670,0228-0839,228.839,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3671,0228-0840,228.840,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3672,0228-0844,228.844,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3673,0228-0846,228.846,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
3674,0228-0848,228.848,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3675,0228-0860,228.860,Ended,148,0228-P02,Arrhythmia ventricular,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3676,0228-0861,228.861,Unconfirmed,148,0228-P02,Arrhythmia ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3677,0228-0867,228.867,Ended,148,0228-P02,Arrhythmia, ventricular,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3678,0228-0877,228.877,Unconfirmed,148,0228-P02,Arrhythmias, ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3679,0228-0878,228.878,Unconfirmed,148,0228-P02,Arrhythmias, ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3680,0228-0879,228.879,Unconfirmed,148,0228-P02,Arrhythmias, ventricular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3681,0228-0881,228.881,Ended,148,0228-P02,VENTRICULAR ARRYTHMIAS STUDY,Ended,MIG,Migration,IV,Phase IV,- Report expected 3/93 (Letter Daniotti 06.10.92),,,000910,IS - Clin Study (MIGRATED)
3682,0228-0893,228.893,Ended,148,0228-P02,Mexilen perlonguets,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3683,0228-0895,228.895,Ended,148,0228-P02,Arrhythmias, ventricular,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3684,0228-0896,228.896,Ended,148,0228-P02,Atthythmias, ventricular,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3685,0228-0899,228.899,Ended,148,0228-P02,MX-L early phase IIstudy,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
3686,0228-0904,228.904,Unconfirmed,148,0228-P02,Efficacy and safety ventrithm,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
3687,0228-0909,228.909,Ended,148,0228-P02,KATO DTS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3688,0228-0916,228.916,Ended,148,0228-P02,Ventricular tachycardia,Ended,MIG,Migration,IV,Phase IV,-  asof 05/17/95 site has 17pts enrolled. Call Dr. Langeri or Fred Ces na, RN: 610/645-2900 for updates. has enough supplies (exp date:10/96) for approx 32 more pts.     ,,,,
3689,0228-0917,228.917,Unconfirmed,148,0228-P02,Ventricular Arrhythmias,Unconfirmed,MIG,Migration,IV,Phase IV,-  Mexitil supplies only. Open-ended study. Status letter sent 3/13/90. No response to date-3/23/90.     ,,,,
3690,0228-0918,228.918,Ended,148,0228-P02,effect of MX hydrochrolide on heart rate,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
3691,0228-0924,228.924,Ended,148,0228-P02,KATO DBT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3692,0228-0925,228.925,Ended,148,0228-P02,YAMADA,LONG OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3693,0228-0926,228.926,Ended,148,0228-P02,Ogawa OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3694,0228-0931,228.931,Ended,148,0228-P02,Effect of combined administration of MX,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
3695,0228-0933,228.933,Ended,148,0228-P02,Efficacy & safety of MX on VPC with MI,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
3696,0228-0936,228.936,Ended,148,0228-P02,Mexitil Perlonget Bioavailability,Ended,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
3697,0021-0004,21.4,Ended,149,0021-P02,Felix - Myokard - Scanning,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
3698,0021-0189,21.189,Unconfirmed,149,0021-P02,Thallium imaging,ischaemic heart disease,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3699,0021-0304,21.304,Unconfirmed,149,0021-P02,Thallium imaging,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
3700,0021-0313,21.313,Unconfirmed,149,0021-P02,Angina-pectoris, thallium imaging,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3701,0021-0343,21.343,Unconfirmed,149,0021-P02,Thallium imaging,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3702,0021-0003,21.3,Ended,150,0021-P03,Blutspiegel-Vergleich geg. Anginal,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
3703,0021-0006,21.6,Unconfirmed,150,0021-P03,Schweden S 254/79,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
3704,0021-0008,21.8,Unconfirmed,150,0021-P03,Depotentwicklung, Versuche Biochemie,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3705,0021-0009,21.9,Unconfirmed,150,0021-P03,Depot, Pharmakokinetik, Dresse B /80,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3706,0021-0010,21.10,Unconfirmed,150,0021-P03,Depot, Universit√§t L√ºttich B 714/80,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3707,0021-0011,21.11,Ended,150,0021-P03,Depot, BTG-Spiegel, Kutti,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
3708,0021-0012,21.12,Unconfirmed,150,0021-P03,Depot, Thrombosis-Prevention B 324/81,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3709,0021-0013,21.13,Ended,150,0021-P03,Depot, HaF - induzierter TFW, Breddin,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3710,0021-0014,21.14,Unconfirmed,150,0021-P03,Depot, Herzinsufizienz, Lausanne 505/82,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
3711,0021-0015,21.15,Unconfirmed,150,0021-P03,Depot, verk√ºrzte PLZ, Herzog/Budde,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
3712,0021-0016,21.16,Unconfirmed,150,0021-P03,Depot, Pr√ºfg. auf Tachyphylaxie, Breddin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3713,0021-0017,21.17,Ended,150,0021-P03,Depot, 200 mg / 150 mg, Breddin,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3714,0021-0018,21.18,Ended,150,0021-P03,Depot, 150 mg / 75 mg Dragee Breddin,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3715,0021-0019,21.19,Unconfirmed,150,0021-P03,Dos.-Titrat. Pers.pHi 75-225 mg, Breddin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3716,0021-0020,21.20,Unconfirmed,150,0021-P03,Depot, Persantin pHi 200 mg, Breddin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3717,0021-0021,21.21,Unconfirmed,150,0021-P03,Depot, 200 mg S 980/83,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3718,0021-0022,21.22,Unconfirmed,150,0021-P03,Depot, 200 mg S 58/84,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3719,0021-0023,21.23,Ended,150,0021-P03,Persantin-Depot 200 mg, Vollblutaggreg.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3720,0021-0024,21.24,Unconfirmed,150,0021-P03,Retard,200 mg-Asas.Ret.,200/25 mg,Bremer,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3721,0021-0025,21.25,Unconfirmed,150,0021-P03,Retard, 200 mg Thrombo-embol. B 203/84,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3722,0021-0026,21.26,Unconfirmed,150,0021-P03,Ret., Vollblutaggreg.,Pilotst. CH /84,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3723,0021-0027,21.27,Ended,150,0021-P03,Toler.Study 1, Tabl./Perlg./Plac. 682/84,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3724,0021-0031,21.31,Ended,150,0021-P03,Kinetic Instant-Form, acid /Breddin,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3725,0021-0032,21.32,Unconfirmed,150,0021-P03,Dragees 75,100 mg, Prof.Chen,China 46/85,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3726,0021-0033,21.33,Unconfirmed,150,0021-P03,Depot, 200 mg S 145/85,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3727,0021-0034,21.34,Ended,150,0021-P03,Plasmaspiegel - DR/KAR/LOK,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3728,0021-0035,21.35,Ended,150,0021-P03,Plasmaspiegel (Anginal),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3729,0021-0036,21.36,Unconfirmed,150,0021-P03,Depot, 200 mg S 222/85,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3730,0021-0037,21.37,Ended,150,0021-P03,Plasmaspiegel - Dragee (400 mg/Tag),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3731,0021-0038,21.38,Ended,150,0021-P03,Indukt. v. Interferon durch Persantin I,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3732,0021-0039,21.39,Ended,150,0021-P03,Indukt. v. Interferon durch Persantin II,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3733,0021-0040,21.40,Unconfirmed,150,0021-P03,Occlusion after Bypass surgery S 495/85,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3734,0021-0041,21.41,Unconfirmed,150,0021-P03,Pharmacokinetic Study F 268/86,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3735,0021-0042,21.42,Unconfirmed,150,0021-P03,Depot 200 mg, Pharmakologie CH 58/87,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
3736,0021-0043,21.43,Unconfirmed,150,0021-P03,Depot 200 mg, Claudic.interm. CH 569/86,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
3737,0021-0045,21.45,Ended,150,0021-P03,CABADAS,Ended,MIG,Migration,III,Phase III,- Letter Dr. Feuerer (4.10.94) no report, just publication and summary*Biberach trial,,,000910,IS - Clin Study (MIGRATED)
3738,0021-0046,21.46,Ended,150,0021-P03,ADME-Pr√ºfung, Dr. Brickl,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3739,0021-0047,21.47,Ended,150,0021-P03,Pharmakokinetik versch. Freisetzung,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3740,0021-0048,21.48,Ended,150,0021-P03,Pharmakokinetik versch. Freisetzung II,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3741,0021-0049,21.49,Unconfirmed,150,0021-P03,DIPACTI study Belgien,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
3742,0021-0050,21.50,Unconfirmed,150,0021-P03,APPI study B 401/88,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
3743,0021-0051,21.51,Ended,150,0021-P03,Pharmakokin. versch. Freisetz.400mg/Tag,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3744,0021-0217,21.217,Unconfirmed,150,0021-P03,Platelet cerebrovascular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3745,0021-0241,21.241,Unconfirmed,150,0021-P03,Platelet cerebrovascular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3746,0021-0267,21.267,Unconfirmed,150,0021-P03,Platelet cerebrovascular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3747,0021-0286,21.286,Unconfirmed,150,0021-P03,Platelet renal dialysis haemo survival V,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3748,0021-0287,21.287,Ended,150,0021-P03,PLATELET INDICATIONS,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
3749,0021-0288,21.288,Ended,150,0021-P03,PLATELET INDICATIONS,Ended,MIG,Migration,III,Phase III,-  Formerly IIIb2. Study report is pending.  Preliminary examination of graft occlusion data indicates that Persantine/aspirin is not superior to placebo.     ,,,000910,IS - Clin Study (MIGRATED)
3750,0021-0336,21.336,Ended,150,0021-P03,PLATELET INDICATIONS,Ended,MIG,Migration,II,Phase II,-  Because trialist has not met previously agreed to enrollment goal;  the study was terminated.   Study report is pending. Dates for Draft and Final Reports were changed recently due to priority changes in MDAS.   ,,,000910,IS - Clin Study (MIGRATED)
3751,0021-0350,21.350,Ended,150,0021-P03,PLATELET INDICATIONS,Ended,MIG,Migration,II,Phase II,-  Because the trialist has not met the previously agreed to enrollment goal, the trial was terminated with only 8 completed patients in the Persantine group and six in the placebo group. No statistically significant differences were seen in platelet surviv- al time lengthening or platelet deposition comparing the two treat- ment groups.   ,,,000910,IS - Clin Study (MIGRATED)
3752,0021-0366,21.366,Ended,150,0021-P03,PLATELET INDICATIONS,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
3753,0021-0387,21.387,Ended,150,0021-P03,PLATELET INDICATIONS,Ended,MIG,Migration,I,Phase I,-  Bioequivalence trial scheduled for submission to the FDA  March 1989.     ,,,000910,IS - Clin Study (MIGRATED)
3754,0021-0389,21.389,Ended,150,0021-P03,Antiplatelet,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3755,0021-0396,21.396,Ended,150,0021-P03,Dipyridamole retard on platelet aggregat,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3756,0021-0447,21.447,Ended,150,0021-P03,PISA,Ended,MIG,Migration,III,Phase III,- previously named PACT,,,000910,IS - Clin Study (MIGRATED)
3757,0021-0449,21.449,Ended,150,0021-P03,Bioequivalence study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3758,1100-0853,1100.853,Ended,151,1100-P02,Pediatric single dose,Ended,MIG,Migration,I,Phase I,-  Depends on IND submission in early May 1991 and FDA approval. There are no investigator costs, as the trial is being done with the ACTG. If we were to do it elsewhere, estimated investigator cost is $5,000/pt.   ,,,000910,IS - Clin Study (MIGRATED)
3759,1100-0882,1100.882,Ended,151,1100-P02,Pediatric multiple dose,Ended,MIG,Migration,IIA,Phase IIa,-  Multiple dose study to assess safety/tolerance and pharmacokinetics in children. CRO for field monitoring, data review, data lock and report. Enrollment closed as of 10/31/95.   EXPECTED TO COMPLETE BY 6/18/96. ,,,000910,IS - Clin Study (MIGRATED)
3760,1100-0892,1100.892,Ended,151,1100-P02,Pediatric open label extension,Ended,MIG,Migration,IIA,Phase IIa,-  Protocol changed to 400 mg/m2 NVP or 400 mg/m2 NVP + ddI. As of 3/93 patients may add ddI.     ,,,000910,IS - Clin Study (MIGRATED)
3761,1100-1030,1100.1030,Ended,151,1100-P02,Pediatric SD PK in Mom/neonate,Ended,MIG,Migration,I,Phase I,-  There are 4 patients enrolled in cohort IA and 6 patients enrolled in cohort IB.  Cohort II opened on 12/18/95 and 7 patients have enrolled. As of 8/97, Cohort III has 13 mother/infant pairs and is due to complete in Feb 98 after a 6 month follow-up COHRTS 1A & 1B COMP. COHRT 2 W/START 8/96SING DOSE IN MO & NEWBRN. 1 MO NEV DOSE ,,,,
3762,1100-1032,1100.1032,Ended,151,1100-P02,Pedi comb therapy/advanced HIV,Ended,MIG,Migration,IIA,Phase IIa,-  Patients must have shown disease progression despite a minimum of 6 mo. previous single or combination antiretroviral therapy. Duration of treatment 2 yrs. Convert to triple therapy after 24 weeks. As of 02/21/96, enrolled 402 and closed stage I of trial. ACTG will probably do executive summary then turn over data to BIPI  for locking and report.Study closed accural on 3/15/96 w/ 432 p STAGE 2 OPENED 7/13/95. ,,,,
3763,1100-1033,1100.1033,Ended,151,1100-P02,W.H.O. Perinatal Trans.,Ended,MIG,Migration,III,Phase III,-  ACTG funded. Study to be conducted in Africa. ON-HOLD indefinitely.     ,,,000910,IS - Clin Study (MIGRATED)
3764,1100-1207,1100.1207,Ended,151,1100-P02,Perinatal transmission,Ended,MIG,Migration,IIB,Phase IIb,-  Tentative initiation 10/96 - Dr. Sullivan wants to start ASAP.     ,,,,
3765,1100-1209,1100.1209,Ended,151,1100-P02,HIVNET 006 - Ugandan pediatric trial,Ended,MIG,Migration,I,Phase I,-  Best estimate of study initiation is 04/15/96. Currently enrolling into cohort II. Brooks Jackson, investigator. FHI (Family Health International), Missy Allen, study coordinator.     ,,,,
3766,1100-1241,1100.1241,Unconfirmed,151,1100-P02,DURBIN perinatal trial,Unconfirmed,MIG,Migration,II,Phase II,-  BIPI will supply drugs and possible virology support. Investigator is John Sullivan     ,,,,
3767,1100-1257,1100.1257,Ended,151,1100-P02,Pediatric Expanded Access - Europe,Ended,MIG,Migration,II,Phase II,,,,000500,Compassionate Use Program (CUP)
3768,1100-1261,1100.1261,Unconfirmed,151,1100-P02,PENTA VII - d4T+ddI+NVP+NFV in Newborns,Unconfirmed,MIG,Migration,NONE,Not Classified,NOTE:  THIS STUDY HAS BEEN CANCELLED. ,,,,
3769,1100-1278,1100.1278,Ended,151,1100-P02,Peds. Compassionate Use - France,Ended,MIG,Migration,NONE,Not Classified,This study will take the place of 1257 ,,,000500,Compassionate Use Program (CUP)
3770,1100-1295,1100.1295,Preparing,151,1100-P02,Pediatric Late Infection,Preparing,MIG,Migration,IV,Phase IV,,,,,
3771,1100-1296,1100.1296,Preparing,151,1100-P02,Pediatric Early Infection,Preparing,MIG,Migration,IV,Phase IV,,,,,
3772,1100-1351,1100.1351,Ended,151,1100-P02,MRC Pediatrics HIV Cohort - Cotton,Ended,MIG,Migration,IV,Phase IV,Restrospective study looking at data ,,,,
3773,1100-1368,1100.1368,Ended,151,1100-P02,Registrational study for 150 mg/m2 dose,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
3774,0107-0110,107.110,Unconfirmed,152,0107-P07,Bioequiv. suspension vs.capsules/tablets,Unconfirmed,MIG,Migration,I,Phase I,Pl. dates: start 01-JUN-94 end 15-JUL-94 Trial on hold,,,000910,IS - Clin Study (MIGRATED)
3775,0107-0162,107.162,Ended,152,0107-P07,Oral Suspension in JRA,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
3776,0107-0163,107.163,Unconfirmed,152,0107-P07,Syrup in RA and OA vs. Meloxicam tablets,Unconfirmed,MIG,Migration,III,Phase III,Planned dates to be determined ,,,000910,IS - Clin Study (MIGRATED)
3777,0107-0172,107.172,Ended,152,0107-P07,Rel. Bioavailability syrup vs. capsule,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3778,0107-0179,107.179,Ended,152,0107-P07,Melox. Syrup vs. Melox. Tabl. in OA,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3779,0107-0208,107.208,Ended,152,0107-P07,Oral Suspension in JRA,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3780,0107-0235,107.235,Ended,152,0107-P07,Meloxicam in JRA,Ended,MIG,Migration,IIIA,Phase IIIa,.208 split into 2 trials;235 is NA part ,,,000910,IS - Clin Study (MIGRATED)
3781,0107-0243,107.243,Ended,152,0107-P07,dose proportionality suspension,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3782,0107-0244,107.244,Ended,152,0107-P07,Compasionate Use,Ended,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
3783,0107-0254,107.254,Ended,152,0107-P07,dose-proprotionality,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3784,0107-0102,107.102,Unconfirmed,153,0107-P08,Melox.15mg vs diclofen.100mg tendinitis,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
3785,0107-0103,107.103,Unconfirmed,153,0107-P08,Meloxicam 15mg vs diclofen.100mg sprains,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
3786,0107-0156,107.156,Ended,153,0107-P08,Meloxicam in acute shoulder pain,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3787,0107-0187,107.187,Ended,153,0107-P08,Melo./Placebo in acute painful shoulder,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3788,0538-0001,538.1,Ended,154,0538-P01,Arnika-Gel, Tolerability,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
3789,0064-0001,64.1,Ended,155,0064-P00,Dysphonia,Ended,MIG,Migration,IV,Phase IV,- No Report will be written, Protocol violations. No conclusion can be drawn. *,,,000910,IS - Clin Study (MIGRATED)
3790,0064-0002,64.2,Ended,155,0064-P00,Clobutinol in chronic cough,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3791,0064-0003,64.3,Ended,155,0064-P00,Bioavailability of 3x40mg s.c.TA/Solut.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3792,0064-0004,64.4,Ended,155,0064-P00,Orient. Kinetik v. Silomat-Dragee 80 mg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3793,0064-0005,64.5,Unconfirmed,155,0064-P00,Wirksamkeit Silomat vs. Codein,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
3794,0064-0006,64.6,Ended,155,0064-P00,Bioavailability of solution, tabl., amp.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3795,0064-0007,64.7,Ended,155,0064-P00,Safety + Efficacy in dry+tickling cough,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3796,0064-0008,64.8,Unconfirmed,155,0064-P00,Study to assess the relative bioavailabi,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3797,0064-0009,64.9,Ended,155,0064-P00,Pharmacokinetic trial, rising dose,Ended,MIG,Migration,I,Phase I,Design:single-centre, multiple rising dose,placebo-controlled within treatment groups,2006-006036-21,,000910,IS - Clin Study (MIGRATED)
3798,0064-0010,64.10,Unconfirmed,155,0064-P00,Thorough QT,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3799,0064-0011,64.11,Unconfirmed,155,0064-P00,Pharmacokinetic trial,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3800,0541-0001,541.1,Unconfirmed,159,0541-P00,New formulation,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
3801,0514-0201,514.201,Ended,160,0514-P00,Pilot Study in Acute Pharyngitis,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3802,1024-0002,1024.2,Ended,161,1024-P02,Relative bioavailability of ibuprofen,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3803,1024-0003,1024.3,Ended,161,1024-P02,Relative bioavailability of ibuprofen,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3804,1024-0004,1024.4,Preparing,161,1024-P02,Relative Bioavailability,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3805,1124-0001,1124.1,Ended,162,1124-P01,Dose-finding of c.m. nasal spray,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
3806,1124-0002,1124.2,Ended,162,1124-P01,Efficacy and Safety,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3807,1124-0003,1124.3,Ended,162,1124-P01,Alergic Rhinitis - Nasal Spray,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3808,1124-0004,1124.4,Ended,162,1124-P01,Dose-finding Study of c.m. eye drops,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
3809,1124-0005,1124.5,Ended,162,1124-P01,I.Sequ. Dose Rising and II.Top Dose Tol.,Ended,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
3810,1124-0006,1124.6,Preparing,162,1124-P01,Seasonal allergic conjunctivitis,Preparing,MIG,Migration,II,Phase II,- According BE Ini OPU switched to ZA (CTU 0397),,,000910,IS - Clin Study (MIGRATED)
3811,1124-0007,1124.7,Ended,162,1124-P01,Chlorpheniaramine (Eye drops),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3812,1124-0008,1124.8,Ended,162,1124-P01,Duration of efficay of c.m. 4%,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3813,1124-0009,1124.9,Unconfirmed,162,1124-P01,p-c, d-b Efficacy and tol. 0,4 % C.M.,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3814,1124-0010,1124.10,Ended,162,1124-P01,Tolerance,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3815,1124-0011,1124.11,Ended,162,1124-P01,Chlorpheniramine - eye drops,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3816,1124-0012,1124.12,Ended,162,1124-P01,Relative bioavailability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3817,1124-0013,1124.13,Unconfirmed,162,1124-P01,Efficacy versus Placebo,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3818,1134-0001,1134.1,Ended,163,1134-P01,Rel. Bioavailability of Dextromethorphan,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3819,0018-0173,18.173,Ended,164,0018-P03,Ambroxol Lozenges - Sore throat pain 20,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
3820,0018-0174,18.174,Ended,164,0018-P03,Acute virale pharyngitis,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
3821,0018-0466,18.466,Ended,164,0018-P03,Efficacy and tolerance,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3822,0018-0468,18.468,Ended,164,0018-P03,Safety and Efficacy,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3823,0018-0479,18.479,Ended,164,0018-P03,Rel.bioav.of Ambroxol Lozenges vs Syrup,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3824,0018-0481,18.481,Unconfirmed,164,0018-P03,Sore throat after tonsillectomy,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3825,0018-0487,18.487,Ended,164,0018-P03,Adolescent patients,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3826,0018-0489,18.489,Ended,164,0018-P03,Placebo and active control study,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3827,0018-0490,18.490,Ended,164,0018-P03,Mucoangin Study China,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
3828,0018-0491,18.491,Preparing,164,0018-P03,20 mg in relieving  pain of sore throat,Preparing,MIG,Migration,III,Phase III,Protocol to be discussed with FDA ,,,000910,IS - Clin Study (MIGRATED)
3829,0018-0492,18.492,Unconfirmed,164,0018-P03,DDI Phase I,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3830,0018-0493,18.493,Ended,164,0018-P03,5-7 Day repeated dose PK,Ended,MIG,Migration,I,Phase I,,2009-014822-40,,000910,IS - Clin Study (MIGRATED)
3831,0018-0494,18.494,Ended,164,0018-P03,ADME,Ended,MIG,Migration,I,Phase I,,2008-005114-52,,000910,IS - Clin Study (MIGRATED)
3832,0018-0495,18.495,Unconfirmed,164,0018-P03,Label Comprehension Questionnaire,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3833,0018-0496,18.496,Unconfirmed,164,0018-P03,Actual use,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3834,0018-0497,18.497,Preparing,164,0018-P03,Renal impairment PK,Preparing,MIG,Migration,I,Phase I,Study initiation to be discussed with AJ ,,,000910,IS - Clin Study (MIGRATED)
3835,0018-0498,18.498,Preparing,164,0018-P03,Hepatic impairment PK,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3836,0018-0499,18.499,Preparing,164,0018-P03,Safety trial (phase I),Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3837,0018-0500,18.500,Preparing,164,0018-P03,QTc study,Preparing,MIG,Migration,I,Phase I,Protocol to be discussed with the FDA ,2010-022426-32,,000910,IS - Clin Study (MIGRATED)
3838,0018-0501,18.501,Preparing,164,0018-P03,Phase II single dose,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
3839,0018-0507,18.507,Preparing,164,0018-P03,Phase III trial (parallel to 18.491),Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3840,0018-0508,18.508,Preparing,164,0018-P03,Chinese Registration,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3841,0543-0001,543.1,Ended,165,0543-P01,Safety, Tolerability and preliminary PK,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3842,0543-0002,543.2,Ended,165,0543-P01,Methodology Study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3843,0543-0003,543.3,Ended,165,0543-P01,Bioavailability Comparison Study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3844,0543-0004,543.4,Ended,165,0543-P01,Safety,tolerability, PK, multiple dose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3845,0543-0005,543.5,Ended,165,0543-P01,The effect of food intake,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3846,0543-0006,543.6,Unconfirmed,165,0543-P01,Effect of gender on MAC-1 expression,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3847,0543-0007,543.7,Ended,165,0543-P01,Drug interaction - theophylline,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3848,0543-0008,543.8,Unconfirmed,165,0543-P01,Drug interaction - cimetidine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3849,0543-0009,543.9,Unconfirmed,165,0543-P01,Drug interaction - diuretics,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3850,0543-0010,543.10,Ended,165,0543-P01,Effect of BIIL284 BS in COPD patients,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
3851,0543-0011,543.11,Ended,165,0543-P01,Effect of BIIL284 pre-treatment,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
3852,0543-0012,543.12,Unconfirmed,165,0543-P01,BIIL 284 antigen challenge,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
3853,0543-0013,543.13,Preparing,165,0543-P01,Severe persistent asthma (Noctur Asthma),Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
3854,0543-0014,543.14,Ended,165,0543-P01,PK/PD of BIIL 284 BS in RA,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
3855,0543-0016,543.16,Ended,165,0543-P01,14C-ADME Study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3856,0543-0017,543.17,Ended,165,0543-P01,Chronic Obstructive Bronchitis,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
3857,0543-0018,543.18,Unconfirmed,165,0543-P01,Simple Chronic Bronchitis,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
3858,0543-0019,543.19,Unconfirmed,165,0543-P01,COPD - Acute Exacerbation,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
3859,0543-0020,543.20,Unconfirmed,165,0543-P01,Antitrypsin Deficiency,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
3860,0543-0021,543.21,Unconfirmed,165,0543-P01,Drug Interaction - Digoxin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3861,0543-0022,543.22,Unconfirmed,165,0543-P01,Drug Interaction - Antacid,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3862,0543-0023,543.23,Unconfirmed,165,0543-P01,Drug Interaction - Warfarin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3863,0543-0024,543.24,Ended,165,0543-P01,Drug Interaction - Oral Steroids,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3864,0543-0025,543.25,Unconfirmed,165,0543-P01,Drug Interaction - Antibiotic,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3865,0543-0026,543.26,Ended,165,0543-P01,PK in hepatic Impairment,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3866,0543-0028,543.28,Ended,165,0543-P01,Rel. Bioavailability of Boli formulation,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3867,0543-0031,543.31,Ended,165,0543-P01,Relative Bioavailibility of 5mg Tablet,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3868,0543-0038,543.38,Unconfirmed,165,0543-P01,Phase III pivotal #1,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3869,0543-0039,543.39,Unconfirmed,165,0543-P01,Phase III pivotal #2,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3870,0543-0040,543.40,Unconfirmed,165,0543-P01,Anti-inflammatory profiling study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3871,0543-0041,543.41,Unconfirmed,165,0543-P01,Head to head vs PDE4 antagonist,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
3872,0543-0042,543.42,Unconfirmed,165,0543-P01,Head to head vs ICS,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
3873,0543-0043,543.43,Unconfirmed,165,0543-P01,Phase IIIb FEV1 decline #1,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
3874,0543-0044,543.44,Unconfirmed,165,0543-P01,Phase IIIb FEV1 decline #2,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
3875,0545-0001,545.1,Unconfirmed,167,0545-P01,Tolerability and Safety, 1 hour iv infus,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3876,0545-0002,545.2,Unconfirmed,167,0545-P01,Maintenance Dose in healthy volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3877,0545-0003,545.3,Unconfirmed,167,0545-P01,Tolerability in Patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
3878,0545-0004,545.4,Unconfirmed,167,0545-P01,ADME in Man,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3879,0542-0001,542.1,Ended,168,0542-P01,Hamamelis Cream Tolerance Study,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
3880,0040-0003,40.3,Unconfirmed,169,0040-P00,Tagesprofil, Schnupfen-Gel,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
3881,0040-0004,40.4,Ended,169,0040-P00,Wirkungsdauer-Vergleich,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
3882,0040-0008,40.8,Ended,169,0040-P00,Dexa-Rhinospray N in Rhinitis allergica,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
3883,1104-0001,1104.1,Unconfirmed,170,1104-P01,Comparison with standard diagnostic test,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3884,1097-0011,1097.11,Ended,175,1097-P03,Morphin OD versus MST continus BID,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3885,0212-0201,212.201,Preparing,176,0212-P10,Efficacy, Safety,Preparing,MIG,Migration,III,Phase III,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3886,0212-0205,212.205,Unconfirmed,176,0212-P10,Deposition,Unconfirmed,MIG,Migration,NONE,Not Classified,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3887,0212-0206,212.206,Unconfirmed,176,0212-P10,Flow Rate,Unconfirmed,MIG,Migration,NONE,Not Classified,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3888,0212-0291,212.291,Preparing,176,0212-P10,Taste,Preparing,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3889,0212-0301,212.301,Ended,176,0212-P10,Efficacy,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
3890,0212-0302,212.302,Ended,176,0212-P10,Efficacy, Cortisol levels,Ended,MIG,Migration,IV,Phase IV,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3891,0212-0303,212.303,Ended,176,0212-P10,Therapeutic comparison of efficacy,Ended,MIG,Migration,III,Phase III,- , Kinder, EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3892,0212-0304,212.304,Unconfirmed,176,0212-P10,NONE,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3893,0212-0305,212.305,Unconfirmed,176,0212-P10,NONE,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3894,0212-0306,212.306,Ended,176,0212-P10,Efficacy,Ended,MIG,Migration,IV,Phase IV,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3895,0212-0310,212.310,Unconfirmed,176,0212-P10,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3896,0212-0312,212.312,Preparing,176,0212-P10,Taste,Preparing,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3897,0212-0314,212.314,Unconfirmed,176,0212-P10,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3898,0212-0315,212.315,Unconfirmed,176,0212-P10,Flunisolide Spacer vs. Budesonid Turboha,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
3899,0212-0501,212.501,Ended,176,0212-P10,Efficacy and tolerability,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
3900,0212-0502,212.502,Ended,176,0212-P10,Efficacy and tolerability,Ended,MIG,Migration,IV,Phase IV,- inserted by gerken at 22.06.93,,,000940,Post Marketing Study (MIGRATED)
3901,0212-0503,212.503,Ended,176,0212-P10,Efficacy and tolerability,Ended,MIG,Migration,IV,Phase IV,- inserted by gerken at 22.06.93,,,000940,Post Marketing Study (MIGRATED)
3902,0212-0504,212.504,Ended,176,0212-P10,Efficacy and tolerability,Ended,MIG,Migration,IV,Phase IV,- inserted by gerken at 22.06.93,,,000940,Post Marketing Study (MIGRATED)
3903,0212-0505,212.505,Ended,176,0212-P10,Efficacy and tolerability,Ended,MIG,Migration,IV,Phase IV,- inserted by gerken at 22.06.93,,,000940,Post Marketing Study (MIGRATED)
3904,0212-0506,212.506,Preparing,176,0212-P10,Tolerance and Efficacy,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
3905,0212-0801,212.801,Analysis,176,0212-P10,Inhalation of irritant substances,Analysis,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
3906,0212-0807,212.807,Ended,176,0212-P10,Aerosol Lung Deposition,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3907,0212-0808,212.808,Ended,176,0212-P10,Pilot study on aerosol lung deposition,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3908,0212-0810,212.810,Unconfirmed,176,0212-P10,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
3909,0107-0191,107.191,Ended,177,0107-P09,Safety/Efficacy Meloxicam vs. Mefenamic,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
3910,0107-0174,107.174,Ended,178,0107-P10,Rel. Bioavail. quick tablet vs. capsule,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3911,0107-0197,107.197,Ended,178,0107-P10,Dosefind. 1.875,3.75,7.5,15 mg quick tab,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3912,0107-0198,107.198,Preparing,178,0107-P10,Third molar (2nd trial),Preparing,MIG,Migration,III,Phase III,cancelled ,,,000910,IS - Clin Study (MIGRATED)
3913,0107-0201,107.201,Preparing,178,0107-P10,Ankle sprain,Preparing,MIG,Migration,III,Phase III,Formulation issues ,,,000910,IS - Clin Study (MIGRATED)
3914,0107-0202,107.202,Preparing,178,0107-P10,Sport injury: ankle sprain,Preparing,MIG,Migration,III,Phase III,on hold ,,,000910,IS - Clin Study (MIGRATED)
3915,0107-0203,107.203,Preparing,178,0107-P10,Headache type tensive headache,Preparing,MIG,Migration,III,Phase III,Formulation Issues ,,,000910,IS - Clin Study (MIGRATED)
3916,0107-0204,107.204,Preparing,178,0107-P10,Headache type migraine,Preparing,MIG,Migration,III,Phase III,on-hold ,,,000910,IS - Clin Study (MIGRATED)
3917,0107-0215,107.215,Preparing,178,0107-P10,Efficacy in minor surgery pain,Preparing,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
3918,0107-0218,107.218,Preparing,178,0107-P10,Bioequivalence Study,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3919,0107-0219,107.219,Preparing,178,0107-P10,Chronic Pain Study,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3920,0107-0220,107.220,Unconfirmed,178,0107-P10,Endoscopy Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3921,0107-0221,107.221,Unconfirmed,178,0107-P10,Phase I study single administration,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3922,0107-0222,107.222,Unconfirmed,178,0107-P10,Second minor surgery study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3923,0107-0223,107.223,Unconfirmed,178,0107-P10,Dose-proportionality/multiple dose PK,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3924,0107-0224,107.224,Ended,178,0107-P10,Food-effect study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3925,0107-0193,107.193,Ended,179,0107-P11,Safety/efficacy of oral Melox. 7.5/15mg,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
3926,0107-0250,107.250,Ended,179,0107-P11,Meloxicam oral susp. in ENT children,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
3927,1020-0001,1020.1,Ended,180,1020-P01,Single blind G115 for the potent. of vac,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
3928,1020-0002,1020.2,Ended,180,1020-P01,G115 on maximal oxygen uptake and maxima,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3929,1020-0003,1020.3,Ended,180,1020-P01,The effect of G115 on the non-insulin de,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3930,1020-0004,1020.4,Ended,180,1020-P01,Effects of G115 on pulmon. functs, gen.,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3931,1020-0005,1020.5,Ended,180,1020-P01,Quality of Life,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3932,1020-0006,1020.6,Ended,180,1020-P01,Safety and efficacy of G115 for the pote,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3933,1020-0007,1020.7,Ended,180,1020-P01,Comparison of the effect on QoL with G11,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3934,1020-0008,1020.8,Ended,180,1020-P01,Ginsana in physical endurance,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3935,1020-0009,1020.9,Ended,180,1020-P01,Efficacy of Ginsana in relieving stress,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3936,1020-0010,1020.10,Ended,180,1020-P01,Efficacy of G115 on half-time haemoglob.,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3937,1020-0011,1020.11,Ended,180,1020-P01,Efficacy of G115 on half-time haemoglob,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
3938,1020-0012,1020.12,Unconfirmed,180,1020-P01,Ginsana Immunology,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3939,1020-0013,1020.13,Unconfirmed,180,1020-P01,COPD,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,,
3940,1139-0001,1139.1,Ended,181,1139-P01,Use of Synvisc,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
3941,1139-0002,1139.2,Ended,181,1139-P01,Synvisc medicoeconomic impact,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3942,1139-0003,1139.3,Unconfirmed,181,1139-P01,Comparison Synvisc (orthopedic),Unconfirmed,MIG,Migration,IV,Phase IV,-Study cancelled ,,,000910,IS - Clin Study (MIGRATED)
3943,1139-0004,1139.4,Ended,181,1139-P01,Comparison Synvisc vs usual treatments,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
3944,1139-0005,1139.5,Ended,181,1139-P01,Use of synvisc in gonoarthrosis,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
3945,1139-0006,1139.6,Ended,181,1139-P01,SENIOR,Ended,MIG,Migration,NONE,Not Classified,,,,000940,Post Marketing Study (MIGRATED)
3946,1139-0007,1139.7,Ended,181,1139-P01,ACTIVE,Ended,MIG,Migration,NONE,Not Classified,,,,000940,Post Marketing Study (MIGRATED)
3947,0107-0274,107.274,Ended,182,0107-P00,Meloxicam cap 15 mg bioequiv study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3948,0107-0276,107.276,Preparing,182,0107-P00,Bioequiv Movalis caps vs tabs Russia,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3949,0218-0101,218.101,Ended,183,0218-P00,Bioavailability,Ended,MIG,Migration,I,Phase I,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3950,0218-0201,218.201,Ended,183,0218-P00,Efficacy & safety,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3951,0218-0202,218.202,Ended,183,0218-P00,Efficacy and tolerance of tablets,Ended,MIG,Migration,II,Phase II,-  Observation Duration: maximum of possible days entered; minimum for total=28 days, minimum for screening=7 days,,,000910,IS - Clin Study (MIGRATED)
3952,0218-0301,218.301,Ended,183,0218-P00,Efficacy & safety,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3953,0218-0601,218.601,Ended,183,0218-P00,Combination rationale,Ended,MIG,Migration,IV,Phase IV,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3954,0218-0700,218.700,Ended,183,0218-P00,Pain,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
3955,0218-0701,218.701,Unconfirmed,183,0218-P00,Dose rationale,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3956,0218-0702,218.702,Unconfirmed,183,0218-P00,Combination rationale,Unconfirmed,MIG,Migration,III,Phase III,To be performed by CRO ,,,000910,IS - Clin Study (MIGRATED)
3957,0218-0703,218.703,Unconfirmed,183,0218-P00,Proctalgia fugax,Unconfirmed,MIG,Migration,II,Phase II,To be performed by CRO ,,,000910,IS - Clin Study (MIGRATED)
3958,0218-0705,218.705,Analysis,183,0218-P00,PASS for Peru,Analysis,MIG,Migration,IV,Phase IV,,,,000410,NISnd ‚Äì Study - Other
3959,0201-0201,201.201,Ended,184,0201-P01,Efficacy & safety,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3960,0201-0202,201.202,Ended,184,0201-P01,Efficacy, acute, right-left comparis.,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3961,0201-0401,201.401,Ended,184,0201-P01,Kinetics,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3962,0201-0402,201.402,Ended,184,0201-P01,Prophylaxis, mode of action,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3963,0201-0403,201.403,Ended,184,0201-P01,Prophylaxis, mode of action,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3964,0201-0404,201.404,Ended,184,0201-P01,Capillarflow, pilotstudy,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
3965,0201-0501,201.501,Ended,184,0201-P01,Efficacy and Tolerability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
3966,0559-0001,559.1,Ended,185,0559-P01,Insulin sensitivity in diabetic patients,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
3967,0559-0002,559.2,Unconfirmed,185,0559-P01,Proof of concept study,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
3968,0559-0003,559.3,Ended,185,0559-P01,Single escalating dose,5-160mg sol.,Ended,MIG,Migration,I,Phase I,Run as 201 at Pfizer Inc. ,,,000910,IS - Clin Study (MIGRATED)
3969,0559-0004,559.4,Ended,185,0559-P01,Single escalating dose, food+interaction,Ended,MIG,Migration,I,Phase I,Run as 001 at Pfizer Inc ,,,000910,IS - Clin Study (MIGRATED)
3970,0559-0005,559.5,Ended,185,0559-P01,Multiple dose up to 600 mg,Ended,MIG,Migration,I,Phase I,Run as 002 at Pfizer Inc. ,,,000910,IS - Clin Study (MIGRATED)
3971,1100-1396,1100.1396,Ended,190,1100-P00,NONNUKE Katlama,Ended,MIG,Migration,III,Phase III,,,,,
3972,1100-1399,1100.1399,Unconfirmed,190,1100-P00,SPARTAK,Unconfirmed,MIG,Migration,III,Phase III,,,,,
3973,1100-1400,1100.1400,Preparing,190,1100-P00,TDM,Preparing,MIG,Migration,IV,Phase IV,,,,,
3974,1100-1401,1100.1401,Unconfirmed,190,1100-P00,BANA CS,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
3975,1100-1402,1100.1402,Ended,190,1100-P00,AWB Long Term Switch,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
3976,1100-1403,1100.1403,Unconfirmed,190,1100-P00,NVP and Kaletra Switch (Lange),Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
3977,1100-1404,1100.1404,Ended,190,1100-P00,NVP and Kaletra Naive (Danner),Ended,MIG,Migration,IV,Phase IV,,,,,
3978,1100-1405,1100.1405,Unconfirmed,190,1100-P00,mtDNA Freezer Study (Reiss Primagen),Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
3979,1100-1406,1100.1406,Ended,190,1100-P00,HCV/HIV Infect & Insulin,Ended,MIG,Migration,IV,Phase IV,,,,,
3980,1100-1407,1100.1407,Ended,190,1100-P00,Nucleosides/Sustiva,Ended,MIG,Migration,IV,Phase IV,,,,,
3981,1100-1483,1100.1483,Ended,190,1100-P00,DOT for HIV+ Community-Rel. Prisoners,Ended,MIG,Migration,IV,Phase IV,,,,,
3982,0244-2473,244.2473,Unconfirmed,192,0244-P23,SAR Park study,Unconfirmed,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
3983,0244-2474,244.2474,Preparing,192,0244-P23,SAR - CEDAR,Preparing,MIG,Migration,II,Phase II,-  Prepare all three strengths (0.03, 0.06, 0.12) for the trial due to timelines. Only 0.06% to be packaged for use.  Dosing frequency to be determined depending upon results of 244.2475.     ,,,000910,IS - Clin Study (MIGRATED)
3984,0244-2475,244.2475,Ended,192,0244-P23,SAR Rag weed,Ended,MIG,Migration,III,Phase III,-  Prepare all three strengths (0.03, 0.06, 0.12) for trial due to timelines.     ,,,000910,IS - Clin Study (MIGRATED)
3985,0244-2172,244.2172,Ended,193,0244-P24,COPD,Ended,MIG,Migration,IV,Phase IV,-  Total enrollment will exceed 72 due to mouthpiece error.     ,,,000940,Post Marketing Study (MIGRATED)
3986,0244-2245,244.2245,Ended,193,0244-P24,COPD,Ended,MIG,Migration,IV,Phase IV,        ,,,000940,Post Marketing Study (MIGRATED)
3987,0244-2254,244.2254,Ended,193,0244-P24,COPD,Ended,MIG,Migration,IV,Phase IV,-  Dr. Davies  co-investigator with Dr. Niewoehner.     ,,,000940,Post Marketing Study (MIGRATED)
3988,0244-2368,244.2368,Ended,193,0244-P24,QOL comp. w/ theophylline,Ended,MIG,Migration,IV,Phase IV,-  High priority of Marketing. Phase IV Marketing study.     ,,,000940,Post Marketing Study (MIGRATED)
3989,0244-2369,244.2369,Ended,193,0244-P24,Cost-effectiveness,Ended,MIG,Migration,NONE,Not Classified,-  Being handled by Policy Analysis, Inc. (Dr. G. Coster) a contract house specializing in these areas.  No drugs required-retrospective  analysis of data.     ,,,000980,Not Classified (MIGRATED)
3990,0244-2385,244.2385,Ended,193,0244-P24,Comp. w/ albuterol & theoph.,Ended,MIG,Migration,IV,Phase IV,        ,,,000940,Post Marketing Study (MIGRATED)
3991,0244-2410,244.2410,Ended,193,0244-P24,Single dose Topcithin +/- -/-,Ended,MIG,Migration,IV,Phase IV,        ,,,000940,Post Marketing Study (MIGRATED)
3992,0244-2437,244.2437,Unconfirmed,193,0244-P24,Anti-inflammatory effect,Unconfirmed,MIG,Migration,NONE,Not Classified,        ,,,,
3993,0244-2438,244.2438,Unconfirmed,193,0244-P24,NIH study in COPD,Unconfirmed,MIG,Migration,IV,Phase IV,-  BIPHARMA is supplying drugs only.     ,,,,
3994,0244-2443,244.2443,Ended,193,0244-P24,Clinical Outcome Study,Ended,MIG,Migration,IV,Phase IV,-  Results from interim analysis expected 3/94.  Identical to 00967A (except for use in ATROVENT).     ,,,000940,Post Marketing Study (MIGRATED)
3995,0244-2445,244.2445,Ended,193,0244-P24,New canister valve vs mktd,Ended,MIG,Migration,IV,Phase IV,        ,,,000940,Post Marketing Study (MIGRATED)
3996,0244-2451,244.2451,Ended,193,0244-P24,Anti-inflammatory effect,Ended,MIG,Migration,IV,Phase IV,-  Study terminated by investyigator due to poor enrollment.     ,,,,
3997,0244-2467,244.2467,Ended,193,0244-P24,PERCEPTION OF BRONCHODILATATION,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
3998,0244-2468,244.2468,Ended,193,0244-P24,PERCEPTION OF BRONCHODILATATION,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
3999,0244-2479,244.2479,Ended,193,0244-P24,EGE (Effets on Gas Exchange),Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4000,0244-2487,244.2487,Preparing,193,0244-P24,Flow rate study,Preparing,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4001,1150-0001,1150.1,Ended,194,1150-P01,Single dose tolerability in volunteers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4002,1150-0002,1150.2,Unconfirmed,194,1150-P01,Methacholine challenge in volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
4003,1150-0003,1150.3,Ended,194,1150-P01,Multiple dose tolerability in volunteers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4004,1150-0004,1150.4,Preparing,194,1150-P01,Exercise challenge in asthmatics,Preparing,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
4005,1150-0005,1150.5,Preparing,194,1150-P01,Allergen chanllenge in asthmatics,Preparing,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
4006,1150-0006,1150.6,Preparing,194,1150-P01,Pulmonary function in asthmatics,Preparing,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
4007,1150-0007,1150.7,Ended,194,1150-P01,Dose extension, safety, tolerability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4008,1150-0008,1150.8,Preparing,194,1150-P01,Protect. Methacholine Challenge in Astma,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
4009,0222-0501,222.501,Ended,195,0222-P02,Ditec HFA/Pharmacokinetic,Ended,MIG,Migration,I,Phase I,Study starts when dir batch is available inserted by gerken at 22.06.93,,,000910,IS - Clin Study (MIGRATED)
4010,0222-0502,222.502,Ended,195,0222-P02,Dose-Confirmation Study,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
4011,0222-0503,222.503,Unconfirmed,195,0222-P02,Dose-Confirmation Study of Ditec,Unconfirmed,MIG,Migration,III,Phase III,no. of pat. not yet exactly determined inserted by gerken at 22.06.93,,,000910,IS - Clin Study (MIGRATED)
4012,0222-0604,222.604,Ended,195,0222-P02,Dose-Confirmation Study in Br. Asthma ,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
4013,0222-0605,222.605,Ended,195,0222-P02,Ditec HFA: Safety and efficacy in asthma,Ended,MIG,Migration,III,Phase III,Study on hold 06-Oct-1998 to 01-Nov-1998 ,,,000910,IS - Clin Study (MIGRATED)
4014,0222-0606,222.606,Unconfirmed,195,0222-P02,Safety and efficacy in asthma/children,Unconfirmed,MIG,Migration,III,Phase III,Planned  study start: Octobre 1999 ,,,000910,IS - Clin Study (MIGRATED)
4015,0222-0607,222.607,Unconfirmed,195,0222-P02,Rational for drug combination in  EIA,Unconfirmed,MIG,Migration,III,Phase III,Final decision on study pending! ,,,000910,IS - Clin Study (MIGRATED)
4016,0253-1401,253.1401,Ended,210,0253-P05,Efficacy & tolerance, pilot study,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
4017,0253-1402,253.1402,Ended,210,0253-P05,Efficacy & tolerance,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
4018,0253-1403,253.1403,Ended,210,0253-P05,Efficacy & tolerance, tablet vs. TTS,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
4019,0253-1404,253.1404,Preparing,210,0253-P05,Efficacy&feasibility, nicotine withdrawa,Preparing,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
4020,0253-2336,253.2336,Ended,210,0253-P05,Efficacy & safety - 7wk,Ended,MIG,Migration,III,Phase III,-  Study results inconclusive, with marked intercenter variability. Program on hold.     ,,,000910,IS - Clin Study (MIGRATED)
4021,0253-2339,253.2339,Ended,210,0253-P05,Nicotine withdrawal,Ended,MIG,Migration,III,Phase III,- Report expected 12/92 (Letter Sommar 10/92),,,000910,IS - Clin Study (MIGRATED)
4022,0253-2367,253.2367,Ended,210,0253-P05,Efficacy & safety - 5wk,Ended,MIG,Migration,III,Phase III,-  All work on this project stopped 4/11/90 per management orders with  work (data base lock analysis) to resume at a later date as priorities permit. All final patient reviews completed 4/8/90 and close-out visits completed. Program on hold.   ,,,000910,IS - Clin Study (MIGRATED)
4023,0253-2432,253.2432,Unconfirmed,210,0253-P05,Smoking cessation,Unconfirmed,MIG,Migration,II,Phase II,-  8/92 64 patients have completed.  We will be paying for data analysis. Results of the analysis will determine if the study will be continued to 120 patients.  Earliest trial would resume is 2/93 .   ,,,,
4024,1118-0001,1118.1,Unconfirmed,211,1118-P01,Effic. & saf. of Ginkgo biloba b.i.d.,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4025,1118-0002,1118.2,Ended,211,1118-P01,Ginkgo in neuropsychological functions,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
4026,1118-0003,1118.3,Unconfirmed,211,1118-P01,Ginkgo GK501 Efficacy,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
4027,0228-0504,228.504,Ended,212,0228-P00,Quality of life,Ended,MIG,Migration,II,Phase II,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
4028,0228-0705,228.705,Ended,212,0228-P00,Cardiopathy ischaemic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4029,0228-0707,228.707,Unconfirmed,212,0228-P00,Cardiopathy ischaemic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4030,0228-0708,228.708,Ended,212,0228-P00,Infarction myocardial acute,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4031,0228-0709,228.709,Unconfirmed,212,0228-P00,Infarction myocardial acute,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4032,0228-0713,228.713,Unconfirmed,212,0228-P00,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4033,0228-0714,228.714,Ended,212,0228-P00,No Legacy Data,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4034,0228-0715,228.715,Unconfirmed,212,0228-P00,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4035,0228-0716,228.716,Unconfirmed,212,0228-P00,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4036,0228-0717,228.717,Unconfirmed,212,0228-P00,Coronary disease,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4037,0228-0719,228.719,Unconfirmed,212,0228-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4038,0228-0725,228.725,Unconfirmed,212,0228-P00,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4039,0228-0726,228.726,Unconfirmed,212,0228-P00,Cardiopathy ischaemic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4040,0228-0733,228.733,Ended,212,0228-P00,Arrhythmia ventricular,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4041,0228-0741,228.741,Unconfirmed,212,0228-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4042,0228-0742,228.742,Unconfirmed,212,0228-P00,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4043,0228-0745,228.745,Unconfirmed,212,0228-P00,Infarction myocardial,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4044,0228-0752,228.752,Unconfirmed,212,0228-P00,Infarction myocardial,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4045,0228-0753,228.753,Unconfirmed,212,0228-P00,Infarction myocardial,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4046,0228-0754,228.754,Unconfirmed,212,0228-P00,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4047,0228-0772,228.772,Unconfirmed,212,0228-P00,Myotonia congenital,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4048,0228-0773,228.773,Unconfirmed,212,0228-P00,Smoking minor,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4049,0228-0776,228.776,Unconfirmed,212,0228-P00,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4050,0228-0778,228.778,Unconfirmed,212,0228-P00,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4051,0228-0779,228.779,Unconfirmed,212,0228-P00,Infarction myocardial,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4052,0228-0780,228.780,Unconfirmed,212,0228-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4053,0228-0781,228.781,Ended,212,0228-P00,Myotonia congenital,Ended,MIG,Migration,II,Phase II,- only stat. Report, no clin. Report because of negative      results. ** *,,,000910,IS - Clin Study (MIGRATED)
4054,0228-0785,228.785,Unconfirmed,212,0228-P00,Chagas-Disease,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4055,0228-0787,228.787,Ended,212,0228-P00,Chagas-Disease,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4056,0228-0793,228.793,Unconfirmed,212,0228-P00,Heart failure congestive;Arrhythmia vent,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4057,0228-0794,228.794,Unconfirmed,212,0228-P00,Infarction myocardial acute,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4058,0228-0795,228.795,Unconfirmed,212,0228-P00,Infarction myocardial acute,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4059,0228-0796,228.796,Unconfirmed,212,0228-P00,Liver cirrhosis minor,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4060,0228-0797,228.797,Unconfirmed,212,0228-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4061,0228-0808,228.808,Unconfirmed,212,0228-P00,Chagas-Disease,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4062,0228-0810,228.810,Unconfirmed,212,0228-P00,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4063,0228-0811,228.811,Ended,212,0228-P00,No Legacy Data,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4064,0228-0814,228.814,Unconfirmed,212,0228-P00,Chagas-Disease,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4065,0228-0823,228.823,Unconfirmed,212,0228-P00,Renal failure minor,Unconfirmed,MIG,Migration,IV,Phase IV,- Dev.Prot.: 1. PATIENTS WHO WERE ON MEXITIL FOR ONE YEAR FOLLOWING THE CONTROLLED PORTION OF THE STUDY MAY CONTINUE ON MEXI TIL FOR AN ADDITIONAL YEAR PROVIDED THAT THE INVESTIGATOR CONTINUED TO FILL OUT AND RETURN TO B.I.L. CASE REPORT FORMS EV,,,000910,IS - Clin Study (MIGRATED)
4066,0228-0824,228.824,Unconfirmed,212,0228-P00,Coronary disease,Unconfirmed,MIG,Migration,IV,Phase IV,- Dev.Prot.: 1. PATIENTS WHO WERE ON MEXITIL FOR ONE YEAR FOLLOWING THE CONTROLLED PORTION OF THE STUDY MAY CONTINUE ON MEXI TIL FOR AN ADDITIONAL YEAR PROVIDED THAT THE INVESTIGATOR CONTINUED TO FILL OUT AND RETURN TO B.I.L. CASE REPORT FORMS EV,,,000910,IS - Clin Study (MIGRATED)
4067,0228-0826,228.826,Unconfirmed,212,0228-P00,Cardiovascular diseases,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4068,0228-0828,228.828,Unconfirmed,212,0228-P00,Renal failure dialysis minor,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4069,0228-0832,228.832,Unconfirmed,212,0228-P00,Liver failure,Unconfirmed,MIG,Migration,IV,Phase IV,- planned patients: 12-16 ** *,,,000910,IS - Clin Study (MIGRATED)
4070,0228-0833,228.833,Unconfirmed,212,0228-P00,Infarction myocardial acute,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4071,0228-0834,228.834,Unconfirmed,212,0228-P00,Arrhythmia ventricular,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4072,0228-0835,228.835,Unconfirmed,212,0228-P00,Arrhythmia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4073,0228-0838,228.838,Ended,212,0228-P00,Polyneuropathy diabetes-Mellitus,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4074,0228-0841,228.841,Unconfirmed,212,0228-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4075,0228-0847,228.847,Unconfirmed,212,0228-P00,Angina-Pectoris,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4076,0228-0851,228.851,Unconfirmed,212,0228-P00,Heart conduction disturbance,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4077,0228-0853,228.853,Unconfirmed,212,0228-P00,Arrhythmia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4078,0228-0856,228.856,Ended,212,0228-P00,Infarction myocardial,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4079,0228-0858,228.858,Unconfirmed,212,0228-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4080,0228-0859,228.859,Ended,212,0228-P00,Infarction myocardial,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4081,0228-0862,228.862,Ended,212,0228-P00,Pancreatitis chronic,Ended,MIG,Migration,III,Phase III,- Status requested (Letter HK 11.08.92) no answer,,,000910,IS - Clin Study (MIGRATED)
4082,0228-0863,228.863,Ended,212,0228-P00,Infarction myocardial acute,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4083,0228-0864,228.864,Ended,212,0228-P00,Cardiopathies,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4084,0228-0866,228.866,Ended,212,0228-P00,DETERMINATION OF ENANTIOMERS,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4085,0228-0873,228.873,Ended,212,0228-P00,Effect of mexiletine on pain/fibromyalgi,Ended,MIG,Migration,III,Phase III,- report requested 8/93 Dr. HK,,,000910,IS - Clin Study (MIGRATED)
4086,0228-0874,228.874,Ended,212,0228-P00,Pharmacokinetics,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4087,0228-0880,228.880,Ended,212,0228-P00,Mexiletine, pain, diabetic neuropathy,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4088,0228-0884,228.884,Ended,212,0228-P00,SINGLE ORAL ADMINISTRATION,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4089,0228-0885,228.885,Ended,212,0228-P00,MULTIPLE ORAL ADMINISTRATION,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4090,0228-0886,228.886,Ended,212,0228-P00,MULTIPLE ORAL ADMINISTRATION,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
4091,0228-0887,228.887,Ended,212,0228-P00,PAIN-RELIEVER EFFECT OF PDN,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
4092,0228-0890,228.890,Ended,212,0228-P00,PHARMACOKINETICS OF MX-L,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4093,0228-0891,228.891,Ended,212,0228-P00,PHARMACOKINETICS OF MX-L,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4094,0228-0892,228.892,Ended,212,0228-P00,PHARMACOKINETICS OF MX-L,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4095,0228-0894,228.894,Ended,212,0228-P00,PHARMACOKINETICS OF MX-L,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4096,0228-0897,228.897,Ended,212,0228-P00,PHARMACOKINETICS OF MX-L,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4097,0228-0898,228.898,Ended,212,0228-P00,Mexiletine-Pain in diab. Polyneuropathy,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4098,0228-0900,228.900,Ended,212,0228-P00,Pain, chronic neuropathy,Ended,MIG,Migration,III,Phase III,- ,,,,
4099,0228-0901,228.901,Ended,212,0228-P00,EFFECTS OF FOOD,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4100,0228-0902,228.902,Ended,212,0228-P00,BIOEQUIVALENCE (85vs170),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4101,0228-0903,228.903,Ended,212,0228-P00,Mexiletine in chronic neuropathic pain,Ended,MIG,Migration,NONE,Not Classified,- ,,,,
4102,0228-0913,228.913,Unconfirmed,212,0228-P00,Neuropathic pain,Unconfirmed,MIG,Migration,IV,Phase IV,-  60 pt. placebo controlled study conducted at 5 study sites (3 U.S. and 2 Canada proposed). AS OF 10/20/95, 4 PTS COMPL 10 PTS COMPLETED IN MONTREAL.I CENTER OPENED IN TORONTO 712/467-7423.   ,,,,
4103,0228-0914,228.914,Unconfirmed,212,0228-P00,Peripheral Neuropathy,Unconfirmed,MIG,Migration,III,Phase III,-  Product shipped 8/90. LM on 7/20 phone call not returned. LM on 8/19/94 Carol Kemper. # 408/885-4300-Ronnie? 9/15/94 LM, NO REPLY BY 9/20/94.   ,,,,
4104,0228-0915,228.915,Unconfirmed,212,0228-P00,Peripheral neuropathy,Unconfirmed,MIG,Migration,IV,Phase IV,-  26 patients enrolled AS OF 10/94.  816/235-5249.  31 patients compl eted. Dr. Wright writing results and will send to BIPI when complet e.     ,,,,
4105,0228-0919,228.919,Ended,212,0228-P00,DTS,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
4106,0228-0920,228.920,Ended,212,0228-P00,Long-Termed Traial,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
4107,0228-0921,228.921,Ended,212,0228-P00,ClinicalPharmacology,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4108,0228-0922,228.922,Ended,212,0228-P00,DBT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4109,0228-0923,228.923,Ended,212,0228-P00,ClinicalPharmacology,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4110,0228-0934,228.934,Unconfirmed,212,0228-P00,Analgesia,Unconfirmed,MIG,Migration,IV,Phase IV,-  as of 10/20/94 site has 5 pts enrolled. # 901/448-8353 Linda Horner.     ,,,,
4111,0228-0935,228.935,Unconfirmed,212,0228-P00,ACTG neuropathy study,Unconfirmed,MIG,Migration,II,Phase II,-  ACTG sponsored. As of 10/20/94 27 PTS ENROLLED. Drug shipped 12/13/94.     ,,,,
4112,0228-0937,228.937,Ended,212,0228-P00,Bioequivalence(85 vs170),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4113,0228-0938,228.938,Unconfirmed,212,0228-P00,HIV associated neuropathy,Unconfirmed,MIG,Migration,IV,Phase IV,        ,,,,
4114,0228-0939,228.939,Unconfirmed,212,0228-P00,MX-PHN Phase IIb study,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
4115,0228-0940,228.940,Unconfirmed,212,0228-P00,MX-PHN long-term study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
4116,0253-1701,253.1701,Ended,213,0253-P00,Efficacy,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
4117,0253-1703,253.1703,Ended,213,0253-P00,Efficacy, Dixarit-Combination,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
4118,0253-2003,253.2003,Unconfirmed,213,0253-P00,Schizophrenia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4119,0253-2004,253.2004,Unconfirmed,213,0253-P00,Menopausal flushing,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4120,0253-2005,253.2005,Unconfirmed,213,0253-P00,none,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4121,0253-2008,253.2008,Unconfirmed,213,0253-P00,Menopausal flushing,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4122,0253-2009,253.2009,Unconfirmed,213,0253-P00,Menopausal flushing,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4123,0253-2039,253.2039,Unconfirmed,213,0253-P00,No Legacy Data,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4124,0253-2059,253.2059,Unconfirmed,213,0253-P00,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4125,0253-2060,253.2060,Unconfirmed,213,0253-P00,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4126,0253-2061,253.2061,Unconfirmed,213,0253-P00,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4127,0253-2065,253.2065,Ended,213,0253-P00,MENOPAUSAL SYNDROME,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
4128,0253-2066,253.2066,Ended,213,0253-P00,Obsessive behaviour,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4129,0253-2067,253.2067,Ended,213,0253-P00,Raynaud-disease;Raynaud-syndrome;Sympath,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4130,0253-2084,253.2084,Ended,213,0253-P00,Angina-Pectoris stable,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4131,0253-2092,253.2092,Ended,213,0253-P00,CHF,Ended,MIG,Migration,II,Phase II,-  Dr. Fouad replaced Dr. Cressman; only one center.     ,,,000910,IS - Clin Study (MIGRATED)
4132,0253-2098,253.2098,Unconfirmed,213,0253-P00,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4133,0253-2101,253.2101,Unconfirmed,213,0253-P00,Hypertension mild,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4134,0253-2106,253.2106,Unconfirmed,213,0253-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4135,0253-2108,253.2108,Unconfirmed,213,0253-P00,Trauma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4136,0253-2115,253.2115,Ended,213,0253-P00,Hypertension severe,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4137,0253-2117,253.2117,Unconfirmed,213,0253-P00,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4138,0253-2119,253.2119,Unconfirmed,213,0253-P00,Brain dysfunction syndrome;Hyperkinesis,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4139,0253-2121,253.2121,Unconfirmed,213,0253-P00,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4140,0253-2122,253.2122,Unconfirmed,213,0253-P00,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4141,0253-2123,253.2123,Unconfirmed,213,0253-P00,Convulsions,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4142,0253-2126,253.2126,Unconfirmed,213,0253-P00,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4143,0253-2130,253.2130,Unconfirmed,213,0253-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4144,0253-2133,253.2133,Ended,213,0253-P00,Migraine,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4145,0253-2137,253.2137,Unconfirmed,213,0253-P00,Gilles-de-la-tourette-syndrome,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4146,0253-2140,253.2140,Unconfirmed,213,0253-P00,Hypertension/Stress,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4147,0253-2142,253.2142,Ended,213,0253-P00,MENOPAUSAL SYNDROME,Ended,MIG,Migration,II,Phase II,-  Grant paid to IBRD.     ,,,000910,IS - Clin Study (MIGRATED)
4148,0253-2151,253.2151,Unconfirmed,213,0253-P00,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4149,0253-2155,253.2155,Unconfirmed,213,0253-P00,Menopausal flushing,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4150,0253-2189,253.2189,Unconfirmed,213,0253-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4151,0253-2190,253.2190,Ended,213,0253-P00,Migraine,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4152,0253-2193,253.2193,Unconfirmed,213,0253-P00,Torticollis,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4153,0253-2200,253.2200,Unconfirmed,213,0253-P00,Surgery,Unconfirmed,MIG,Migration,III,Phase III,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4154,0253-2202,253.2202,Ended,213,0253-P00,Surgery postoperative,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4155,0253-2204,253.2204,Unconfirmed,213,0253-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4156,0253-2208,253.2208,Unconfirmed,213,0253-P00,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4157,0253-2216,253.2216,Unconfirmed,213,0253-P00,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4158,0253-2219,253.2219,Unconfirmed,213,0253-P00,Migraine,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4159,0253-2220,253.2220,Unconfirmed,213,0253-P00,Menopausal Flushing,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4160,0253-2221,253.2221,Unconfirmed,213,0253-P00,Migraine,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4161,0253-2222,253.2222,Unconfirmed,213,0253-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4162,0253-2223,253.2223,Unconfirmed,213,0253-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4163,0253-2226,253.2226,Unconfirmed,213,0253-P00,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4164,0253-2227,253.2227,Unconfirmed,213,0253-P00,Hypertension renal failure minor,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4165,0253-2241,253.2241,Unconfirmed,213,0253-P00,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4166,0253-2247,253.2247,Unconfirmed,213,0253-P00,none,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4167,0253-2250,253.2250,Unconfirmed,213,0253-P00,Menopausal flushing,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4168,0253-2262,253.2262,Ended,213,0253-P00,Includes study 105, 852292,Ended,MIG,Migration,III,Phase III,- Report requested 8/93 Dr. HK,,,000910,IS - Clin Study (MIGRATED)
4169,0253-2264,253.2264,Unconfirmed,213,0253-P00,Nephropathy diabetes-Mellitus hypertensi,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4170,0253-2265,253.2265,Unconfirmed,213,0253-P00,Surgery,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4171,0253-2268,253.2268,Unconfirmed,213,0253-P00,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4172,0253-2272,253.2272,Ended,213,0253-P00,Diuresis,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4173,0253-2275,253.2275,Ended,213,0253-P00,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,NONE,Not Classified,-  GREEN LANE HOSPITAL WAS RESPONSIBLE FOR DATA ENTRY BUT DID NOT RECRUIT PATIENTS. AFTER CO *,,,000910,IS - Clin Study (MIGRATED)
4174,0253-2276,253.2276,Ended,213,0253-P00,Liver cirrhosis minor,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4175,0253-2278,253.2278,Unconfirmed,213,0253-P00,Hypertension infarction myocardial acute,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4176,0253-2289,253.2289,Ended,213,0253-P00,Manic disorders,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4177,0253-2292,253.2292,Unconfirmed,213,0253-P00,Trauma;Pain,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4178,0253-2295,253.2295,Ended,213,0253-P00,Menopausal,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4179,0253-2296,253.2296,Ended,213,0253-P00,Surgery cardiovascular,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4180,0253-2302,253.2302,Ended,213,0253-P00,Surgery,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4181,0253-2304,253.2304,Ended,213,0253-P00,Surgery orthopaedic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4182,0253-2307,253.2307,Unconfirmed,213,0253-P00,Migraine,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4183,0253-2308,253.2308,Ended,213,0253-P00,Hypertension,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4184,0253-2311,253.2311,Unconfirmed,213,0253-P00,Growth disorders,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4185,0253-2312,253.2312,Unconfirmed,213,0253-P00,Constitutional growth delay (CGD),Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4186,0253-2315,253.2315,Unconfirmed,213,0253-P00,Growth hormone release,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4187,0253-2321,253.2321,Ended,213,0253-P00,Surgery,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4188,0253-2324,253.2324,Ended,213,0253-P00,Effect of Clonidine on anesthetic stabil,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4189,0253-2327,253.2327,Ended,213,0253-P00,HTA no responding to Captopril,Ended,MIG,Migration,IV,Phase IV,- Incomplete data, patients did not comply with the protocol,,,000910,IS - Clin Study (MIGRATED)
4190,0253-2329,253.2329,Ended,213,0253-P00,Menopausal Flushing,Ended,MIG,Migration,IV,Phase IV,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
4191,0253-2330,253.2330,Ended,213,0253-P00,Surgery pre-Operative,Ended,MIG,Migration,IV,Phase IV,- Own IND study. *,,,000910,IS - Clin Study (MIGRATED)
4192,0253-2332,253.2332,Ended,213,0253-P00,Postoperative,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4193,0253-2333,253.2333,Ended,213,0253-P00,Hepatic Failure,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4194,0253-2342,253.2342,Ended,213,0253-P00,Hyperkinesia syndr.,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4195,0253-2345,253.2345,Ended,213,0253-P00,Stuttering,Ended,MIG,Migration,IV,Phase IV,- ,,,,
4196,0253-2346,253.2346,Unconfirmed,213,0253-P00,Pain,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4197,0253-2352,253.2352,Ended,213,0253-P00,Analgesy and clonidine (human pharmacody,Ended,MIG,Migration,IV,Phase IV,- Own IND study. published *,,,000910,IS - Clin Study (MIGRATED)
4198,0253-2353,253.2353,Unconfirmed,213,0253-P00,Cardiomyopathy,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4199,0253-2357,253.2357,Ended,213,0253-P00,Hypertension, Gestosis,Ended,MIG,Migration,IV,Phase IV,- -compassionate use-,,,000500,Compassionate Use Program (CUP)
4200,0253-2358,253.2358,Ended,213,0253-P00,Anesthesia in ORL surgery,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4201,0253-2369,253.2369,Ended,213,0253-P00,Clonidine and suppr. of the mech. vent.,Ended,MIG,Migration,IV,Phase IV,- No report, for 5 patients out of 14 randomization has not    been respected.,,,000910,IS - Clin Study (MIGRATED)
4202,0253-2370,253.2370,Ended,213,0253-P00,Clonidine prem.,Etomidate, Fentanyl ind.,Ended,MIG,Migration,IV,Phase IV,- 'Puplication planned for II/93 (Letter Maria 09.10.92)      study summary,,,000910,IS - Clin Study (MIGRATED)
4203,0253-2371,253.2371,Ended,213,0253-P00,Clonidine in peri-operative period,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4204,0253-2372,253.2372,Ended,213,0253-P00,Effect of Clonidine on stereotypies,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4205,0253-2373,253.2373,Ended,213,0253-P00,Preoperative use a. prevent. of ischemic,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4206,0253-2376,253.2376,Ended,213,0253-P00,Pharmacokinetics, epidural,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4207,0253-2377,253.2377,Ended,213,0253-P00,Clinical pharmacology,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4208,0253-2380,253.2380,Ended,213,0253-P00,Migraine,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4209,0253-2381,253.2381,Ended,213,0253-P00,TOURETTE SYNDROME,Ended,MIG,Migration,III,Phase III,-  Awaiting statistical analysis. Ongoing reviews with investigator.     ,,,000910,IS - Clin Study (MIGRATED)
4210,0253-2386,253.2386,Ended,213,0253-P00,Comparison Clonidine - Nifedipine LP,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4211,0253-2389,253.2389,Ended,213,0253-P00,Epidural Clonidine in back pain,Ended,MIG,Migration,III,Phase III,- ,,,,
4212,0253-2390,253.2390,Ended,213,0253-P00,Effect of Clonidine on Lumbar block,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4213,0253-2391,253.2391,Ended,213,0253-P00,HOW DOES ECT WORK,Ended,MIG,Migration,II,Phase II,- ,,,,
4214,0253-2392,253.2392,Ended,213,0253-P00,VAR. AFFECTING GH RESPONSE TO CLONIDINE,Ended,MIG,Migration,II,Phase II,- Own IND-study * *  / Report for invest. no date,,,,
4215,0253-2393,253.2393,Unconfirmed,213,0253-P00,Cardiomyopathy, hypertrophic,Unconfirmed,MIG,Migration,III,Phase III,- NZ Trial,,,000910,IS - Clin Study (MIGRATED)
4216,0253-2403,253.2403,Ended,213,0253-P00,Prevention of post-operative shivering,Ended,MIG,Migration,II,Phase II,- ,,,,
4217,0253-2404,253.2404,Ended,213,0253-P00,Postoperative analgesia with clonidine,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4218,0253-2405,253.2405,Ended,213,0253-P00,Clonidine postop abstinence symptoms,Ended,MIG,Migration,III,Phase III,- ,,,,
4219,0253-2406,253.2406,Ended,213,0253-P00,None,Ended,MIG,Migration,III,Phase III,- ,,,,
4220,0253-2407,253.2407,Ended,213,0253-P00,Hypertension,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4221,0253-2408,253.2408,Ended,213,0253-P00,Hypertension,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4222,0253-2409,253.2409,Ended,213,0253-P00,Epidural clonidine in labour,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4223,0253-2410,253.2410,Ended,213,0253-P00,Clonidine in Ulcerative Colitis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4224,0253-2411,253.2411,Ended,213,0253-P00,Eclampsia,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4225,0253-2412,253.2412,Ended,213,0253-P00,Analgesia,Ended,MIG,Migration,III,Phase III,- ,,,,
4226,0253-2414,253.2414,Ended,213,0253-P00,Effect on HGH secretion,Ended,MIG,Migration,III,Phase III,- ,,,,
4227,0253-2416,253.2416,Ended,213,0253-P00,Clonidine in PCA,Ended,MIG,Migration,IV,Phase IV,- ,,,,
4228,0253-2418,253.2418,Unconfirmed,213,0253-P00,Clonidine Compassionate use,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000500,Compassionate Use Program (CUP)
4229,0253-2419,253.2419,Ended,213,0253-P00,Cauda anaesthesie,Ended,MIG,Migration,III,Phase III,- ,,,,
4230,0253-2422,253.2422,Ended,213,0253-P00,Postoperative Analgesia,Ended,MIG,Migration,IV,Phase IV,- ,,,,
4231,0253-2423,253.2423,Preparing,213,0253-P00,IN TAMOXIFEN INDUCED VASOMOTOR SYMPTOMS,Preparing,MIG,Migration,IV,Phase IV,- ,,,,
4232,0253-2424,253.2424,Ended,213,0253-P00,EFFECTS ON SLEEP DISORDER IN PANIC DISOR,Ended,MIG,Migration,IV,Phase IV,- ,,,,
4233,0253-2425,253.2425,Ended,213,0253-P00,EFFECTS OF CLONIDINE ON ANAESTHESIA,Ended,MIG,Migration,IV,Phase IV,- ,,,,
4234,0253-2426,253.2426,Ended,213,0253-P00,Intrathecal clon.- lower segment caesar.,Ended,MIG,Migration,I,Phase I,- ,,,,
4235,0253-2427,253.2427,Ended,213,0253-P00,Caudal anaestesia,Ended,MIG,Migration,III,Phase III,- ,,,,
4236,0253-2429,253.2429,Ended,213,0253-P00,Regional Anaesthesia,Ended,MIG,Migration,III,Phase III,- ,,,,
4237,0253-2431,253.2431,Unconfirmed,213,0253-P00,Analgesia in neuropathy,Unconfirmed,MIG,Migration,II,Phase II,-  Catapres-TTS use in diabetic neuropathy.  Prelim. results were sent  to K. Matzek 1 yr ago. Study has been published.     ,,,,
4238,0253-2433,253.2433,Unconfirmed,213,0253-P00,Naltrexone induction symptoms,Unconfirmed,MIG,Migration,II,Phase II,-  44pts active as of 9/92.  62 patients completed trial. Trial comple ted to date.     ,,,,
4239,0253-2435,253.2435,Unconfirmed,213,0253-P00,Perioperative Myocardial Inf.,Unconfirmed,MIG,Migration,III,Phase III,-  IRB approvals received 1/90. This study is on hold and may be canceled.  We are not planning on resupplying with study drug at this time.     ,,,,
4240,0253-2436,253.2436,Unconfirmed,213,0253-P00,Perioperative use,Unconfirmed,MIG,Migration,II,Phase II,-  Dr. Hoff/Judy West,RN are running study; call them 415/476-0410 or Judy-0403. 5/24/95: Dr. Hoff on sabbatical. Phone contact-call not returnedfrom J.West. 6/19: No enrollment the prev. 8 mos (supplier problem). To begin recruitment mid july '95. Data for 20+ pts has been analyzed. 9/25: letter sent in July re: expired drug. 11/20:still no request from ctr for resupply. 2/23/96:message lef   ,,,,
4241,0253-2438,253.2438,Unconfirmed,213,0253-P00,Catecholemine function,Unconfirmed,MIG,Migration,II,Phase II,        ,,,,
4242,0253-2439,253.2439,Unconfirmed,213,0253-P00,Spinal cord damage & CVA,Unconfirmed,MIG,Migration,II,Phase II,        ,,,,
4243,0253-2441,253.2441,Unconfirmed,213,0253-P00,Noradrenergic rel. & metab.,Unconfirmed,MIG,Migration,I,Phase I,-  115 patients completed study to date. Termination letter sent 1/16/91, as U.S. supplies expired 3/31/91. Investigator subsequently called Germany. The study will continue using supplies from Germany.   ,,,,
4244,0253-2442,253.2442,Ended,213,0253-P00,Effect on hyperoxia,Ended,MIG,Migration,NONE,Not Classified,- ,,,,
4245,0253-2447,253.2447,Ended,213,0253-P00,Ease form birth pains,Ended,MIG,Migration,NONE,Not Classified,- ,,,,
4246,0253-2448,253.2448,Ended,213,0253-P00,Postoperative apnoea,Ended,MIG,Migration,III,Phase III,- ,,,,
4247,0253-2449,253.2449,Ended,213,0253-P00,Thoracothomy and Clonidine,Ended,MIG,Migration,III,Phase III,- ,,,,
4248,0253-2450,253.2450,Ended,213,0253-P00,Intrathecal spinal anaesthesia,Ended,MIG,Migration,III,Phase III,- ,,,,
4249,0253-2451,253.2451,Ended,213,0253-P00,Analgesia,Ended,MIG,Migration,III,Phase III,- ,,,,
4250,0253-2452,253.2452,Ended,213,0253-P00,CLONIDINE IN SPINAL CORD INJURY,Ended,MIG,Migration,II,Phase II,- ,,,,
4251,0253-2453,253.2453,Ended,213,0253-P00,CLONIDINE IN CHF,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4252,0253-2454,253.2454,Unconfirmed,213,0253-P00,EVALUATION OF EPIDURAL ADMIN IN LABOUR,Unconfirmed,MIG,Migration,I,Phase I,- ,,,,
4253,0253-2455,253.2455,Ended,213,0253-P00,Intrathecal Clonidine,Ended,MIG,Migration,III,Phase III,- ,,,,
4254,0253-2457,253.2457,Ended,213,0253-P00,Growth Hormaone Levels,Ended,MIG,Migration,NONE,Not Classified,- ,,,,
4255,0253-2459,253.2459,Ended,213,0253-P00,Bupivacaine-clon. vs Bup.-morphine,Ended,MIG,Migration,III,Phase III,- ,,,,
4256,0253-2461,253.2461,Ended,213,0253-P00,Effect on duration of caudal analgesia,Ended,MIG,Migration,NONE,Not Classified,- ,,,,
4257,0253-2462,253.2462,Ended,213,0253-P00,Postoperative Analgesia,Ended,MIG,Migration,NONE,Not Classified,- ,,,,
4258,0253-2463,253.2463,Ended,213,0253-P00,Tourette Syndrome,Ended,MIG,Migration,II,Phase II,-  10 centers are expected to participate.  (312) 942-4500. Will need 12000 0.1mg tabs.  Approved for NIH funding; Dr. Dias checked with management - OK to supply drug.,,,,
4259,0253-2465,253.2465,Unconfirmed,213,0253-P00,Sympathetic mediated pain,Unconfirmed,MIG,Migration,II,Phase II,-  BI providing $25,000 grant funding for the analysis of Catapres samples and clinical supplies. AKA Dr. Derasari 813/251-7438 (Pat Pinkham). 6/22/95: phone call to center not returned. Pat on vacation until June 28. 7/14: 5 pts. enrolled. Center evaluating for continuation. 7/13: letter to center re: expired drug. 9/25: Still no request for resupply. 11/20: still no request from center   ,,,,
4260,0253-2468,253.2468,Unconfirmed,213,0253-P00,Sympathetic mediated pain,Unconfirmed,MIG,Migration,IV,Phase IV,-  Providing placebo-TTS only. # 414/257-6259... 11/28/94: Study Terminated, 12 volunteers completed study.     ,,,,
4261,0253-2474,253.2474,Preparing,213,0253-P00,Bioequivalence,Preparing,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4262,0253-2479,253.2479,Ended,213,0253-P00,Congestive Heart Failure add. Enalapril,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
4263,0253-2483,253.2483,Ended,213,0253-P00,Postoperative Stress Reaction,Ended,MIG,Migration,NONE,Not Classified,,,,,
4264,0253-2484,253.2484,Ended,213,0253-P00,Clonidine pediatric analgesia,Ended,MIG,Migration,III,Phase III,,,,,
4265,0253-2488,253.2488,Unconfirmed,213,0253-P00,clonidine + ropivacaine for loc anesth,Unconfirmed,MIG,Migration,NONE,Not Classified,entered for purchase of drug supply Study ongoing since 2008. Original Clonidine ampoules are expiring. Investigator wishes to continue study after purchase of new drug supply from BI.,,,,
4266,1071-0009,1071.9,Unconfirmed,217,1071-P01,Brontheo - obstruktive Atemwegserkrank.,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
4267,0054-0001,54.1,Ended,218,0054-P00,Langzeitpr√ºfung,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
4268,0054-0002,54.2,Unconfirmed,218,0054-P00,BA 253 / NAB 365 - Kombination, Ulmer,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
4269,0054-0003,54.3,Unconfirmed,218,0054-P00,Chron. Bronch. und Augenvertr√§glichkeit,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
4270,0054-0004,54.4,Ended,218,0054-P00,Vergleich Bronchospasmolytika,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
4271,0054-0005,54.5,Unconfirmed,218,0054-P00,Als Mydriatikum / Cycloplegikum,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
4272,0054-0006,54.6,Ended,218,0054-P00,BR Akutversuch, Dorow,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
4273,0054-0007,54.7,Unconfirmed,218,0054-P00,Vertr√§glichkeit bei Kindern,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
4274,0054-0008,54.8,Ended,218,0054-P00,Mucoziliare Clearance, Nakhosteen,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
4275,0054-0009,54.9,Ended,218,0054-P00,Pupillenerweiterung, Probanden,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
4276,0054-0010,54.10,Ended,218,0054-P00,Antihydrotische Wirksamkeit,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
4277,0054-0011,54.11,Unconfirmed,218,0054-P00,Antihidrot. Wirkung (abh√§ngig v.P-Dauer),Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
4278,0054-0012,54.12,Unconfirmed,218,0054-P00,Antihidrot.Wirkung (abh√§ngig v.Konzentr),Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
4279,0054-0013,54.13,Unconfirmed,218,0054-P00,Vertr√§gl.u.Akzeptanz b.Prob.,Braun-Falco,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
4280,0054-0014,54.14,Ended,218,0054-P00,Dosiswirkung d. Kombin. NAB 365 / BA 253,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
4281,0054-0402,54.402,Ended,218,0054-P00,Bronchitis chronic obstructive,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4282,0054-0403,54.403,Ended,218,0054-P00,Bronchospasm,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4283,0054-0404,54.404,Ended,218,0054-P00,Bronchitis chronic,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4284,0054-0406,54.406,Ended,218,0054-P00,Asthma exercise induced,Ended,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4285,0054-0407,54.407,Unconfirmed,218,0054-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4286,0054-0408,54.408,Unconfirmed,218,0054-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4287,0054-0410,54.410,Unconfirmed,218,0054-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4288,0054-0412,54.412,Unconfirmed,218,0054-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4289,0054-0413,54.413,Unconfirmed,218,0054-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- planned patients: 8-10 * *,,,000910,IS - Clin Study (MIGRATED)
4290,0054-0414,54.414,Unconfirmed,218,0054-P00,Asthma;Bronchitis chronic,Unconfirmed,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4291,0054-0415,54.415,Unconfirmed,218,0054-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4292,0054-0416,54.416,Unconfirmed,218,0054-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4293,0054-0417,54.417,Unconfirmed,218,0054-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4294,0054-0418,54.418,Unconfirmed,218,0054-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4295,0054-0419,54.419,Unconfirmed,218,0054-P00,Asthma allergic,Unconfirmed,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4296,0054-0420,54.420,Unconfirmed,218,0054-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4297,0054-0421,54.421,Unconfirmed,218,0054-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4298,0054-0422,54.422,Unconfirmed,218,0054-P00,Bronchitis,Unconfirmed,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4299,0054-0423,54.423,Unconfirmed,218,0054-P00,Asthma acute,Unconfirmed,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4300,0054-0424,54.424,Unconfirmed,218,0054-P00,Asthma acute,Unconfirmed,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4301,0054-0425,54.425,Unconfirmed,218,0054-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4302,0054-0426,54.426,Unconfirmed,218,0054-P00,Asthma allergic,Unconfirmed,MIG,Migration,III,Phase III,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4303,0054-0427,54.427,Unconfirmed,218,0054-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4304,0054-0428,54.428,Unconfirmed,218,0054-P00,Rhinitis perennial,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4305,0054-0429,54.429,Unconfirmed,218,0054-P00,Rhinitis perennial,Unconfirmed,MIG,Migration,III,Phase III,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4306,0054-0430,54.430,Unconfirmed,218,0054-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4307,0054-0431,54.431,Ended,218,0054-P00,Asthma exercise induced,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4308,0054-0432,54.432,Unconfirmed,218,0054-P00,Asthma exercise induced,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4309,0054-0433,54.433,Unconfirmed,218,0054-P00,Asthma nocturnal,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4310,0054-0434,54.434,Ended,218,0054-P00,Asthma nocturnal,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4311,0054-0435,54.435,Unconfirmed,218,0054-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4312,0054-0436,54.436,Unconfirmed,218,0054-P00,Asthma nocturnal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4313,0054-0437,54.437,Ended,218,0054-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4314,0054-0438,54.438,Unconfirmed,218,0054-P00,Bronchitis chronic;Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4315,0054-0439,54.439,Unconfirmed,218,0054-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4316,0054-0440,54.440,Unconfirmed,218,0054-P00,Asthma;Bronchitis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4317,0054-0441,54.441,Ended,218,0054-P00,Asthma;Bronchitis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4318,0054-0442,54.442,Unconfirmed,218,0054-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4319,0054-0443,54.443,Ended,218,0054-P00,Asthma,Ended,MIG,Migration,II,Phase II,- End of Trial data indicate Ipratropium-bromide as second trialsubstance (CTIS page 3). * *,,,000910,IS - Clin Study (MIGRATED)
4320,0054-0444,54.444,Unconfirmed,218,0054-P00,Bronchitis chronic bronchospasm,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4321,0054-0445,54.445,Ended,218,0054-P00,Asthma - Children,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4322,0054-0447,54.447,Ended,218,0054-P00,Asthma chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4323,0054-0448,54.448,Ended,218,0054-P00,CHRONIC ASTHMA,Ended,MIG,Migration,III,Phase III,- Summary,,,000910,IS - Clin Study (MIGRATED)
4324,0054-0449,54.449,Ended,218,0054-P00,Asthma;Bronchitis chronic,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4325,0054-0450,54.450,Ended,218,0054-P00,ASTHMA,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4326,0054-0451,54.451,Unconfirmed,218,0054-P00,Rhinitis vasomotor,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4327,0054-0452,54.452,Unconfirmed,218,0054-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4328,0054-0453,54.453,Unconfirmed,218,0054-P00,Rhinitis allergic perennial,Unconfirmed,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4329,0054-0454,54.454,Unconfirmed,218,0054-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4330,0054-0455,54.455,Ended,218,0054-P00,Bronchitis chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4331,0054-0456,54.456,Ended,218,0054-P00,Bronchitis chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4332,0054-0457,54.457,Ended,218,0054-P00,Asthma, Bronchitis,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4333,0054-0458,54.458,Unconfirmed,218,0054-P00,Rhinitis vasomotor,Unconfirmed,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4334,0054-0459,54.459,Unconfirmed,218,0054-P00,Rhinitis allergic,Unconfirmed,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
4335,0054-0461,54.461,Ended,218,0054-P00,Bronchitis chronic,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4336,0054-0462,54.462,Ended,218,0054-P00,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4337,0054-0463,54.463,Ended,218,0054-P00,Pharmacodynamics - Dose response study,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4338,0054-0464,54.464,Unconfirmed,218,0054-P00,Bronchitis, chronic,Unconfirmed,MIG,Migration,II,Phase II,- Status E agreed by Dr. Hertkorn, 10.06.1997.,,,000910,IS - Clin Study (MIGRATED)
4339,0054-0465,54.465,Unconfirmed,218,0054-P00,Emphysema,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4340,0054-0466,54.466,Ended,218,0054-P00,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4341,0054-0467,54.467,Unconfirmed,218,0054-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4342,0054-0468,54.468,Ended,218,0054-P00,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4343,0054-0469,54.469,Ended,218,0054-P00,none,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4344,0054-0470,54.470,Ended,218,0054-P00,Hypersensitivity respiratory,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4345,0054-0471,54.471,Unconfirmed,218,0054-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4346,0054-0472,54.472,Ended,218,0054-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4347,0054-0473,54.473,Ended,218,0054-P00,none,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4348,0054-0474,54.474,Ended,218,0054-P00,ASTHMA,Ended,MIG,Migration,II,Phase II,- Report requested (Letter LV 11/93),,,000910,IS - Clin Study (MIGRATED)
4349,0054-0475,54.475,Ended,218,0054-P00,Polyposis, nasal,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4350,0054-0476,54.476,Ended,218,0054-P00,Rhinitis vasomotor perennial,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4351,0054-0477,54.477,Ended,218,0054-P00,Bronchitis chronic;Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4352,0054-0478,54.478,Ended,218,0054-P00,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4353,0054-0479,54.479,Ended,218,0054-P00,none,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4354,0054-0480,54.480,Unconfirmed,218,0054-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4355,0054-0481,54.481,Ended,218,0054-P00,Hyperhidrosis,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4356,0054-0483,54.483,Ended,218,0054-P00,STUDY IN MANAGEMENT OF CHRONIC BRONCHITI,Ended,MIG,Migration,III,Phase III,- (Summary),,,000910,IS - Clin Study (MIGRATED)
4357,0054-0484,54.484,Ended,218,0054-P00,PLACEBO COMPARISON TO DETERMINE PHAMACOL,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4358,0054-0485,54.485,Ended,218,0054-P00,STUDY IN MANAGEMENT OF ASTHMA,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4359,0054-0486,54.486,Ended,218,0054-P00,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4360,0054-0487,54.487,Ended,218,0054-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4361,0054-0488,54.488,Ended,218,0054-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4362,0054-0489,54.489,Ended,218,0054-P00,Emphysema,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4363,0054-0490,54.490,Ended,218,0054-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4364,0054-0491,54.491,Ended,218,0054-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4365,0054-0492,54.492,Ended,218,0054-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4366,0054-0493,54.493,Ended,218,0054-P00,Emphysema,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4367,0054-0494,54.494,Ended,218,0054-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4368,0054-0495,54.495,Ended,218,0054-P00,Emphysema,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4369,0054-0496,54.496,Unconfirmed,218,0054-P00,Asthma (pediatric),Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4370,0054-0498,54.498,Ended,218,0054-P00,TREATMENT OF COUGH DURING URTI,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4371,0054-0500,54.500,Ended,218,0054-P00,Rhinitis, perennial,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4372,0054-0501,54.501,Ended,218,0054-P00,Nasal polyposis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4373,0054-0502,54.502,Ended,218,0054-P00,Allergen nasal test,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4374,0054-0503,54.503,Ended,218,0054-P00,Evaluation of the efficacy of Oxitropium,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4375,0054-0506,54.506,Ended,218,0054-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4376,0054-0507,54.507,Ended,218,0054-P00,EFFICACY/ACCEPTABILITY STUDY,Ended,MIG,Migration,III,Phase III,- Report requested (Letter LV 11/93),,,000910,IS - Clin Study (MIGRATED)
4377,0054-0508,54.508,Ended,218,0054-P00,Asthma,Ended,MIG,Migration,III,Phase III,- Report available 3/93 (Letter Maria 09.10.92)/ Report expected 9/93,,,000910,IS - Clin Study (MIGRATED)
4378,0054-0509,54.509,Unconfirmed,218,0054-P00,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4379,0054-0510,54.510,Ended,218,0054-P00,Dose-response in BPCO patients,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4380,0054-0515,54.515,Ended,218,0054-P00,Asthma, Bronchitis,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4381,0054-0516,54.516,Ended,218,0054-P00,EFFECT OF LONG TERM TREATMENT ON LUNG FU,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4382,0054-0520,54.520,Ended,218,0054-P00,WITH/WITHOUT SALBUTAMOL IN ACUTE ASTHMA,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4383,0054-0521,54.521,Ended,218,0054-P00,BRONCHOCON.INDUCED BY PROSTAGLANDIN D2,Ended,MIG,Migration,IV,Phase IV,- ,,,,
4384,0054-0522,54.522,Unconfirmed,218,0054-P00,REVERSIBILITY OF LUNG FUNCTION AFTER TRA,Unconfirmed,MIG,Migration,III,Phase III,- ,,,,
4385,0054-0527,54.527,Ended,218,0054-P00,TER-Fukuda trial,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
4386,0054-0529,54.529,Ended,218,0054-P00,TER-long term therapy in COPD,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
4387,0054-0534,54.534,Ended,218,0054-P00,TER-secretion study,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
4388,0054-0535,54.535,Ended,218,0054-P00,Dose-finding in asthmatic children,Ended,MIG,Migration,II,Phase II,- ,,,,
4389,0054-0536,54.536,Ended,218,0054-P00,BRONCHIAL HYPERRESPONSIVENESS IN ASTHMA,Ended,MIG,Migration,IV,Phase IV,- ,,,,
4390,0054-0537,54.537,Unconfirmed,218,0054-P00,TER-Asamoto trial,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4391,0054-0538,54.538,Ended,218,0054-P00,TER-CHIBA trial,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
4392,0054-0539,54.539,Unconfirmed,218,0054-P00,TER-HIROSHIMA trial,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
4393,0054-0540,54.540,Ended,218,0054-P00,Efficacy in bronchitic children,Ended,MIG,Migration,III,Phase III,- ,,,,
4394,0054-0541,54.541,Ended,218,0054-P00,Elder patient with Bronchial Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
4395,0054-0542,54.542,Ended,218,0054-P00,Biav. vs. MDI,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4396,0054-0543,54.543,Ended,218,0054-P00,DTS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4397,0054-0544,54.544,Ended,218,0054-P00,DBT vs. MDI,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4398,0054-0545,54.545,Ended,218,0054-P00,DBT vs. MDI,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4399,0054-0546,54.546,Ended,218,0054-P00,OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4400,0054-0547,54.547,Ended,218,0054-P00,OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4401,0054-0548,54.548,Ended,218,0054-P00,ORAL CORTICOSTEROIDS ON BRONCHOD. RESPON,Ended,MIG,Migration,I,Phase I,- ,,,,
4402,0054-0550,54.550,Ended,218,0054-P00,Chronic emphysem,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
4403,0054-0553,54.553,Ended,218,0054-P00,Bioequivalence studyof Ba253 HFA134a MDI,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4404,0054-0557,54.557,Ended,218,0054-P00,Long-term vs. theophylline in COPD,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
4405,0054-0558,54.558,Ended,218,0054-P00,Dose confiramation study of BA253BINEB,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
4406,0054-0559,54.559,Unconfirmed,218,0054-P00,Ventilat - chronische Bronchitis,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
4407,0054-0560,54.560,Ended,218,0054-P00,Double Blind Trial COPD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4408,0054-0561,54.561,Ended,218,0054-P00,Long Term Trial COPD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4409,0054-0562,54.562,Ended,218,0054-P00,Long Term Trial Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4410,0054-0563,54.563,Ended,218,0054-P00,Ventilat DA, 12 month, Safety + Efficacy,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
4411,0054-0564,54.564,Ended,218,0054-P00,Ventilat DA, 4 weeks, Safety +  Efficacy,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
4412,0054-0565,54.565,Unconfirmed,218,0054-P00,Bioequivalence of HFA-Oxivent,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
4413,0054-0566,54.566,Ended,218,0054-P00,Hypertonic Saline Provocation in COPD,Ended,MIG,Migration,IV,Phase IV,Investigator Initiated Study (IIS) Investigator Initiated Study: no study monitoring planned; analysis will be done by site,,,,
4414,0054-0567,54.567,Ended,218,0054-P00,Breathing pattern with anticholinergic,Ended,MIG,Migration,IV,Phase IV,Monocenter Study ,,,,
4415,0202-0501,202.501,Preparing,219,0202-P01,Efficacy & safety,Preparing,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
4416,0202-0809,202.809,Ended,219,0202-P01,Buscapina-Ibuprofen in dysmenorrhea,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4417,0202-0810,202.810,Ended,219,0202-P01,Buscapina-Ibuprofen in dysmenorrhea,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4418,0202-0811,202.811,Ended,219,0202-P01,Buscapina Ibuprofen in Dysmenorrhea,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4419,0202-0812,202.812,Ended,219,0202-P01,Abdominal colic pain children,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4420,0202-0813,202.813,Ended,219,0202-P01,Abdominal colic pain children,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4421,0202-0815,202.815,Ended,219,0202-P01,Efficacy and safety of Buscapina-Ibuprof,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4422,0202-0816,202.816,Ended,219,0202-P01,Buscopan + Ibuprofen Suspension bioavail,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4423,0202-0821,202.821,Unconfirmed,219,0202-P01,Efficacy in PMS and dysmenorrhoea,Unconfirmed,MIG,Migration,III,Phase III,To be done by CRO ,,,000910,IS - Clin Study (MIGRATED)
4424,0202-0837,202.837,Unconfirmed,219,0202-P01,Proof of concept study in menstrual pain,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
4425,1012-0001,1012.1,Ended,220,1012-P00,COMBIVENT UDV-ASTHMA, EMERGENCY ROOM,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4426,1012-0004,1012.4,Ended,220,1012-P00,UDV - Emergency Room,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4427,1012-0019,1012.19,Ended,220,1012-P00,Combivent phase IV trial in COPD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4428,1012-0027,1012.27,Unconfirmed,220,1012-P00,Combivent/Salbutamol ER Study,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
4429,1012-0028,1012.28,Unconfirmed,220,1012-P00,High Dose Combivent/Salbutamol,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
4430,1012-0030,1012.30,Unconfirmed,220,1012-P00,Not updated in CTMS,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4431,1012-0038,1012.38,Ended,220,1012-P00,Bonchodilator effect vs. Atrovent,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4432,1012-0039,1012.39,Ended,220,1012-P00,Art. O2 desaturation in COPD, (EVANS II),Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4433,1012-0050,1012.50,Ended,220,1012-P00,Combivent MDI in Mod. to Sev. Asthma,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
4434,1012-0052,1012.52,Recruiting,220,1012-P00,PMS Combivent, Columbia,Recruiting,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
4435,1012-0053,1012.53,Preparing,220,1012-P00,PMS in moderate to severe asthma,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
4436,1012-0064,1012.64,Preparing,220,1012-P00,Combivent HFA and CFC MDI PK study,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4437,1012-0069,1012.69,Analysis,220,1012-P00,SENSITIVITY OF THE STEP TEST IN COPD,Analysis,MIG,Migration,IV,Phase IV,,,,,
4438,0107-0205,107.205,Unconfirmed,221,0107-P12,Phase III study #1,Unconfirmed,MIG,Migration,III,Phase III,-  Approved by the IMC 4/97. On-hold - haven't received ISC approval. Tabled discussion until June ISC meeting. Number of centers may drop by 1/3 to 1/2.   NOT YET APPROVED BY IMC ,,,000910,IS - Clin Study (MIGRATED)
4439,1152-0001,1152.1,Ended,222,1152-P01,Phase I study #1,Ended,MIG,Migration,I,Phase I,-One patient in TSH follow-up Approved by the IMC 4/97 & ISC. To be performed by the Ludwig Institute at the Memorial Sloan Kettering Cancer Center in NYC and their affiliated center at the Mayo clinic, and Austin & Reparation in Melbourne, Australia. A labor intensive study with imaging & PK/PD.   ,,,000910,IS - Clin Study (MIGRATED)
4440,1152-0002,1152.2,Initiated,222,1152-P01,Phase I study #2,Initiated,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4441,1152-0003,1152.3,Ended,222,1152-P01,Phase I study #3,Ended,MIG,Migration,I,Phase I,Database will not be locked. ,,,000910,IS - Clin Study (MIGRATED)
4442,1152-0004,1152.4,Preparing,222,1152-P01,Phase I study #4,Preparing,MIG,Migration,I,Phase I,-  Approved by the IMC 4/97 & ISC. To be performed by the Ludwig Institute at the the Mayo Clinic. A labor intensive study with imaging, PK/PD and tumor biopsies.   ,,,000910,IS - Clin Study (MIGRATED)
4443,1152-0005,1152.5,Ended,222,1152-P01,Phase I study #5,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
4444,1152-0006,1152.6,Ended,222,1152-P01,Phase I Study Non-Small Cell Lung Cancer,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4445,1152-0007,1152.7,Preparing,222,1152-P01,Phase II in Breast Cancer,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
4446,1152-0008,1152.8,Preparing,222,1152-P01,Phase II in Pancreatic Cancer,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
4447,1152-0009,1152.9,Preparing,222,1152-P01,Phase I Study in Colorectal Cancer,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4448,1152-0010,1152.10,Ended,222,1152-P01,Phase II Unconjugated Study,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
4449,1152-0011,1152.11,Preparing,222,1152-P01,Open Label Extention of BIBH-1,Preparing,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
4450,1152-0012,1152.12,Preparing,222,1152-P01,Open Label Extention of 131-I BIBH-1,Preparing,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
4451,1152-0013,1152.13,Unconfirmed,222,1152-P01,Continued use trial,Unconfirmed,MIG,Migration,I,Phase I,After trials  with 131 I-BIBH-1 ,,,000500,Compassionate Use Program (CUP)
4452,1152-0014,1152.14,Ended,222,1152-P01,Phase I in colorectal cancer,Ended,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
4453,1152-0015,1152.15,Unconfirmed,222,1152-P01,Phase I combination gemcitabine,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
4454,1152-0016,1152.16,Preparing,222,1152-P01,Phase I CRC 25 and 100mg BIBH 1,Preparing,MIG,Migration,IB,Phase Ib, CLIN HOLD 2/15/02-Colorectal cancer pts ,,,000910,IS - Clin Study (MIGRATED)
4455,1152-0017,1152.17,Preparing,222,1152-P01,Phase I Double Dose Colorectal Cancer,Preparing,MIG,Migration,IB,Phase Ib,f/u until interim: 16 w ,,,000910,IS - Clin Study (MIGRATED)
4456,1152-0018,1152.18,Preparing,222,1152-P01,Phase II Single Dose Colorectal Cancer,Preparing,MIG,Migration,II,Phase II,f/u until interim 3 m ,,,000910,IS - Clin Study (MIGRATED)
4457,1152-0019,1152.19,Preparing,222,1152-P01,Phase I Double Dose NSCLC,Preparing,MIG,Migration,IB,Phase Ib,f/u until interim 16 w ,,,000910,IS - Clin Study (MIGRATED)
4458,1152-0020,1152.20,Preparing,222,1152-P01,Phase I combination paclitaxel,Preparing,MIG,Migration,IB,Phase Ib,f/u until interim 8 w ,,,000910,IS - Clin Study (MIGRATED)
4459,1152-0021,1152.21,Unconfirmed,222,1152-P01,Phase II Single Dose NSCLC,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
4460,1152-0022,1152.22,Unconfirmed,222,1152-P01,Phase II Single Dose Breast Cancer,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
4461,1152-0023,1152.23,Unconfirmed,222,1152-P01,Phase II in Pancreas Cancer,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
4462,1152-0024,1152.24,Unconfirmed,222,1152-P01,Phase II in colorectal cancer (confirm.),Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
4463,1152-0025,1152.25,Unconfirmed,222,1152-P01,Phase I combination irinotecan,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
4464,1154-0001,1154.1,Ended,224,1154-P01,Phase I safety, PK & MTD,Ended,MIG,Migration,I,Phase I,Trial performed by EORTC, Data managment ,,,000910,IS - Clin Study (MIGRATED)
4465,1154-0002,1154.2,Unconfirmed,224,1154-P01,Phase IIa in HNSCC,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
4466,1154-0003,1154.3,Unconfirmed,224,1154-P01,Phase IIa in NSCLC,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
4467,1154-0004,1154.4,Unconfirmed,224,1154-P01,Phase IIa in glioblastoma,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
4468,1154-0005,1154.5,Unconfirmed,224,1154-P01,Phase IIa in Ca. oesophagus,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
4469,1154-0006,1154.6,Unconfirmed,224,1154-P01,Phase IIa in Ca. cervix,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
4470,1154-0007,1154.7,Unconfirmed,224,1154-P01,Phase IIa in breast cancer,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
4471,1154-0008,1154.8,Unconfirmed,224,1154-P01,Comb. therapy with paclitaxel (Phase I),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4472,1155-0001,1155.1,Unconfirmed,225,1155-P01,Allogeneic Tumor Vaccine / Dose-Finding,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
4473,1155-0002,1155.2,Ended,225,1155-P01,Allogeneic Tumor Vaccine / Safety, Toler,Ended,MIG,Migration,I,Phase I,additional CRFpages extended phase... original and extended phase: 
change of CRF pages, 17-jul-2001
according to telephone information of Mr. Markou 
(21 visits, 188 CRF pages)


according to amendment 2, an open end is defined for patient 1001

change of CRF pages, 9-dec-99
according to mail- Mr.Markou, 
CRF Part V, for patient no. 1001
(last visit 48, last page: 422)

new CRF pages, 12-jul-00 mail - Mr. Markou
CRF part VI, for patient no. 1001
(no. of visits: 57, CRF-pages: 500)
,,,000910,IS - Clin Study (MIGRATED)
4474,0573-0001,573.1,Ended,226,0573-P01,ISIS 2302 in Crohn's Disease,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
4475,0205-0121,205.121,Ended,227,0205-P02,EFFECT ON METHACHOLINE RESPONSIVENESS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4476,0205-0201,205.201,Ended,227,0205-P02,Bronchodilator study,Ended,MIG,Migration,II,Phase II,-  Delay due to drug.     ,,,000910,IS - Clin Study (MIGRATED)
4477,0205-0202,205.202,Ended,227,0205-P02,Nocturnal asthma,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
4478,0205-0203,205.203,Ended,227,0205-P02,Efficacy in EIB,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
4479,0205-0204,205.204,Preparing,227,0205-P02,Rebound hyperreactivity,Preparing,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4480,0205-0205,205.205,Preparing,227,0205-P02,Nocturnal asthma,Preparing,MIG,Migration,III,Phase III,-  1999 master list from b. nothhelfer lists this trial as BII budget this trial shold be included in 1999 resource estimations only     ,,,000910,IS - Clin Study (MIGRATED)
4481,0205-0206,205.206,Unconfirmed,227,0205-P02,Nocturnal asthma,Unconfirmed,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
4482,0205-0207,205.207,Unconfirmed,227,0205-P02,Salmeterol / Nocturnal asthma,Unconfirmed,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
4483,0205-0208,205.208,Unconfirmed,227,0205-P02,Maintenance dose steroid,Unconfirmed,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
4484,1157-0001,1157.1,Preparing,228,1157-P01,IV dose-escalating in HV,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4485,1157-0002,1157.2,Ended,228,1157-P01,First-step oral single dose study in HV,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4486,1157-0003,1157.3,Ended,228,1157-P01,9-day oral repeated dose in HV,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4487,1157-0004,1157.4,Ended,228,1157-P01,Extension oral single-dose in HV,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4488,1157-0005,1157.5,Preparing,228,1157-P01,Cough-challenge single dose study,Preparing,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
4489,1157-0006,1157.6,Preparing,228,1157-P01,Ozone-challenge single dose study,Preparing,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
4490,1157-0007,1157.7,Preparing,228,1157-P01,6-week study in COPD,Preparing,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
4491,1157-0008,1157.8,Preparing,228,1157-P01,ADME study in man,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4492,1157-0009,1157.9,Preparing,228,1157-P01,Drug interaction study - Theophylline,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4493,1157-0010,1157.10,Preparing,228,1157-P01,Food interaction study,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4494,1157-0013,1157.13,Preparing,228,1157-P01,Drug interaction - OP contraceptives,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4495,1157-0014,1157.14,Preparing,228,1157-P01,Drug interaction - Itraconazole,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4496,1157-0015,1157.15,Unconfirmed,228,1157-P01,Acute non-bacterial exacerbations of CB,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
4497,1157-0016,1157.16,Preparing,228,1157-P01,Oral repeated dose in elderly,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4498,1157-0017,1157.17,Unconfirmed,228,1157-P01,PK in renal insufficiency,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4499,1157-0018,1157.18,Unconfirmed,228,1157-P01,PK in hepatic insufficiency,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4500,1157-0019,1157.19,Unconfirmed,228,1157-P01,Absolute bioavailability study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4501,1157-0020,1157.20,Unconfirmed,228,1157-P01,Mucociliary clearance,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4502,1157-0021,1157.21,Unconfirmed,228,1157-P01,Drug interaction - Digoxine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4503,1157-0022,1157.22,Unconfirmed,228,1157-P01,Drug interaction - Warfarine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4504,1157-0023,1157.23,Unconfirmed,228,1157-P01,Drug interaction - Anti-acids,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4505,1157-0024,1157.24,Unconfirmed,228,1157-P01,Drug interaction - statine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4506,1157-0025,1157.25,Unconfirmed,228,1157-P01,Drug interaction - Alcohol,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4507,1157-0026,1157.26,Unconfirmed,228,1157-P01,Safety, PK study in COPD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4508,1157-0030,1157.30,Preparing,228,1157-P01,Single-dose study in females,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4509,1157-0031,1157.31,Preparing,228,1157-P01,Single-dose study in elderly,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4510,1157-0032,1157.32,Preparing,228,1157-P01,repeated dosing in females,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4511,0018-0475,18.475,Unconfirmed,229,0018-P04,missing,Unconfirmed,MIG,Migration,III,Phase III,manually entered ,,,000910,IS - Clin Study (MIGRATED)
4512,0584-0001,584.1,Unconfirmed,230,0584-P01,Asthma bronchiale,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000980,Not Classified (MIGRATED)
4513,1120-0001,1120.1,Ended,231,1120-P01,Hypno-sedative effect and tolerability,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4514,1120-0002,1120.2,Ended,231,1120-P01,Eschscholtzia in primary insomnia,Ended,MIG,Migration,IIIA,Phase IIIa,- ,,,000910,IS - Clin Study (MIGRATED)
4515,1120-0004,1120.4,Unconfirmed,231,1120-P01,Sleep labor,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4516,1149-0001,1149.1,Ended,232,1149-P01,Safety and Tolerability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4517,1149-0002,1149.2,Ended,232,1149-P01,Proof of Concept,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4518,1149-0003,1149.3,Ended,232,1149-P01,Tolerability PK,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4519,1149-0004,1149.4,Unconfirmed,232,1149-P01,Bioeq.Study: IV vs. intranasal,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4520,1149-0005,1149.5,Preparing,232,1149-P01,Tolerability/ Safety/ Pharmacokinetics,Preparing,MIG,Migration,IIB,Phase IIb,HOLD-1 dose,at home during H/A ,,,000910,IS - Clin Study (MIGRATED)
4521,1149-0006,1149.6,Unconfirmed,232,1149-P01,Cardiac Hemodynamic Effects,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4522,1149-0007,1149.7,Unconfirmed,232,1149-P01,Safety/Tolerance/Efficacy in Migraine,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
4523,1149-0008,1149.8,Unconfirmed,232,1149-P01,Safety/Tol.Effic. Migraine multip. attac,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
4524,1149-0009,1149.9,Unconfirmed,232,1149-P01,Safety/Tol./Effic. Migraine Recurrence,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
4525,1149-0010,1149.10,Unconfirmed,232,1149-P01,Safety/Tol./Effic. Migraine Long Term,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
4526,1149-0011,1149.11,Unconfirmed,232,1149-P01,Comparison Lacidipine vs Bendrofluacine,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
4527,1149-0012,1149.12,Unconfirmed,232,1149-P01,Safety/PK/MD[intranasal],Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4528,1149-0013,1149.13,Unconfirmed,232,1149-P01,ADME [intransal],Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4529,1149-0014,1149.14,Unconfirmed,232,1149-P01,Hepatic Impairment [intransal],Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4530,1149-0015,1149.15,Unconfirmed,232,1149-P01,Hypertension [intrasanal],Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4531,1149-0016,1149.16,Unconfirmed,232,1149-P01,Drug/Drug Interaction Sumatriptan,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4532,1149-0017,1149.17,Unconfirmed,232,1149-P01,Drug/Drug Interaction Ergotamine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4533,1149-0018,1149.18,Unconfirmed,232,1149-P01,Drug/Drug Interaction Dihydroergotamine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4534,1149-0019,1149.19,Unconfirmed,232,1149-P01,Drug/Drug Interaction Paracet & Metaclop,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4535,1149-0020,1149.20,Unconfirmed,232,1149-P01,Drug/Drug Interaction and ETOH,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4536,1149-0021,1149.21,Unconfirmed,232,1149-P01,Safety/Tolerance/Efficacy in Migraine,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
4537,1149-0022,1149.22,Unconfirmed,232,1149-P01,Safety/Tol/Eff. Migraine multip. attacks,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
4538,1149-0023,1149.23,Unconfirmed,232,1149-P01,Neuroendocrine Effects,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4539,1149-0024,1149.24,Unconfirmed,232,1149-P01,Psychometric Testing,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4540,1149-0025,1149.25,Unconfirmed,232,1149-P01,Safety/Tol/PK in Elderly,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4541,1149-0026,1149.26,Unconfirmed,232,1149-P01,Potential for Abuse,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4542,1149-0027,1149.27,Unconfirmed,232,1149-P01,Safety/Tol/Efficacy in Adolescents,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4543,1149-0028,1149.28,Ended,232,1149-P01,Effect of BIBN on CNS arteries and hemod,Ended,MIG,Migration,I,Phase I,To be performed by Olesen in Denmark ,,,,
4544,1149-0029,1149.29,Ended,232,1149-P01,BIBN 4096 inhibition of iv CGRP,Ended,MIG,Migration,I,Phase I,Performed by Prf. Olesen in Denmark ,,,,
4545,1149-0030,1149.30,Ended,232,1149-P01,Effect of BIBN on CGRP -pre-tx with NTG,Ended,MIG,Migration,I,Phase I,Performed by Prof Olesen in Denmark ,,,,
4546,1149-0034,1149.34,Ended,232,1149-P01,Safety and Tolerability: oral BIBN 4096,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4547,1149-0035,1149.35,Ended,232,1149-P01,Safety,Tolerability:new intranasal form,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4548,1149-0036,1149.36,Unconfirmed,232,1149-P01,Bioeq. Study: IV vs new in formulation,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4549,1149-0041,1149.41,Unconfirmed,232,1149-P01,Safety/Tolerability/PK: in/Japan,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4550,1149-0043,1149.43,Unconfirmed,232,1149-P01,Forearm trial,Unconfirmed,MIG,Migration,I,Phase I,CRO: Phase I unit in a University ,,,000910,IS - Clin Study (MIGRATED)
4551,1031-0008,1031.8,Unconfirmed,233,1031-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4552,1031-0009,1031.9,Ended,233,1031-P01,HYPERTENSION,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
4553,1031-0020,1031.20,Unconfirmed,233,1031-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4554,1031-0022,1031.22,Unconfirmed,233,1031-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4555,1031-0023,1031.23,Unconfirmed,233,1031-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4556,1031-0024,1031.24,Ended,233,1031-P01,none,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4557,1031-0025,1031.25,Unconfirmed,233,1031-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4558,1031-0026,1031.26,Unconfirmed,233,1031-P01,Hypertension,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4559,1031-0028,1031.28,Unconfirmed,233,1031-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4560,1055-0539,1055.539,Ended,234,1055-P00,ALLERGIC RHINITIS,Ended,MIG,Migration,I,Phase I,-  Part A of study has 16 patients and Part B has 10 patients.     ,,,000910,IS - Clin Study (MIGRATED)
4561,1072-0001,1072.1,Unconfirmed,235,1072-P00,Heart failure,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4562,1072-0002,1072.2,Ended,235,1072-P00,NAUSEA & VOMITING,Ended,MIG,Migration,I,Phase I,-  No prior data on Kinetics available; study clinically complete.  Validated assay with required sensitivity under development.     ,,,000910,IS - Clin Study (MIGRATED)
4563,0012-0203,12.203,Unconfirmed,236,0012-P03,Oesophagitis reflux,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4564,0012-0212,12.212,Unconfirmed,236,0012-P03,Oesophagitis reflux,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4565,0012-0223,12.223,Unconfirmed,236,0012-P03,Oesophagitis reflux,Unconfirmed,MIG,Migration,III,Phase III,- planned patients: 60-120 * *,,,000910,IS - Clin Study (MIGRATED)
4566,0012-0382,12.382,Unconfirmed,236,0012-P03,Oesophagitis reflux,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4567,0012-0410,12.410,Unconfirmed,236,0012-P03,Oesophagitis reflux,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4568,0012-0466,12.466,Unconfirmed,236,0012-P03,Oesophagitis reflux,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4569,0012-0489,12.489,Unconfirmed,236,0012-P03,Oesophagitis reflux,Unconfirmed,MIG,Migration,IV,Phase IV,- NZ Trial,,,000910,IS - Clin Study (MIGRATED)
4570,0012-0507,12.507,Ended,236,0012-P03,Oesophagitis reflux,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4571,0012-0542,12.542,Unconfirmed,236,0012-P03,Oesophagitis reflux;Dyspepsia;Ulcer pept,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4572,0012-0556,12.556,Unconfirmed,236,0012-P03,Oesophagitis reflux,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4573,0012-0570,12.570,Unconfirmed,236,0012-P03,Oesophagitis reflux,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4574,0012-0587,12.587,Unconfirmed,236,0012-P03,Oesophagitis reflux,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4575,0012-0603,12.603,Unconfirmed,236,0012-P03,Oesophagitis reflux;Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4576,0012-0649,12.649,Unconfirmed,236,0012-P03,Oesophagitis reflux,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4577,0012-0651,12.651,Ended,236,0012-P03,Reflux oesophagitis,Ended,MIG,Migration,III,Phase III,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
4578,0012-0662,12.662,Ended,236,0012-P03,Oesophagitis reflux,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4579,0012-0663,12.663,Ended,236,0012-P03,Oesophagitis reflux,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4580,0012-0664,12.664,Ended,236,0012-P03,Oesophagitis reflux,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4581,0012-0670,12.670,Ended,236,0012-P03,GASTROESOPHAGEAL REFLUX,Ended,MIG,Migration,II,Phase II,-  Changed from IIk1.     ,,,000910,IS - Clin Study (MIGRATED)
4582,0012-0143,12.143,Ended,237,0012-P01,gegen Ranitidine, Wirksamkeit, Dr.Klinge,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
4583,0012-0201,12.201,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4584,0012-0202,12.202,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4585,0012-0204,12.204,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4586,0012-0206,12.206,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4587,0012-0207,12.207,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4588,0012-0208,12.208,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4589,0012-0210,12.210,Ended,237,0012-P01,Ulcer duodenal;Ulcer gastric,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4590,0012-0211,12.211,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4591,0012-0215,12.215,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,III,Phase III,- planned patients: 220-250 * *,,,000910,IS - Clin Study (MIGRATED)
4592,0012-0217,12.217,Unconfirmed,237,0012-P01,Ulcer gastric;Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4593,0012-0219,12.219,Unconfirmed,237,0012-P01,Ulcer peptic;Dyspepsia;Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4594,0012-0222,12.222,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4595,0012-0224,12.224,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4596,0012-0225,12.225,Unconfirmed,237,0012-P01,Ulcer duodenal;Duodenitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4597,0012-0228,12.228,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4598,0012-0229,12.229,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4599,0012-0230,12.230,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4600,0012-0231,12.231,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4601,0012-0232,12.232,Ended,237,0012-P01,Ulcer duodenal,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4602,0012-0233,12.233,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4603,0012-0234,12.234,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4604,0012-0235,12.235,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4605,0012-0236,12.236,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4606,0012-0244,12.244,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4607,0012-0249,12.249,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4608,0012-0251,12.251,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4609,0012-0255,12.255,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4610,0012-0257,12.257,Unconfirmed,237,0012-P01,Ulcer gastric;Ulcer duodenal;Dyspepsia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4611,0012-0259,12.259,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4612,0012-0261,12.261,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4613,0012-0262,12.262,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4614,0012-0265,12.265,Unconfirmed,237,0012-P01,Ulcer gastric;Ulcer duodenal;Dyspepsia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4615,0012-0268,12.268,Unconfirmed,237,0012-P01,Ulcer gastric;Ulcer duodenal;Dyspepsia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4616,0012-0269,12.269,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4617,0012-0271,12.271,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4618,0012-0275,12.275,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4619,0012-0277,12.277,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4620,0012-0278,12.278,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4621,0012-0279,12.279,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4622,0012-0280,12.280,Unconfirmed,237,0012-P01,Ulcer duodenal;Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4623,0012-0281,12.281,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4624,0012-0282,12.282,Unconfirmed,237,0012-P01,Ulcer gastric;Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4625,0012-0283,12.283,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4626,0012-0284,12.284,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4627,0012-0285,12.285,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4628,0012-0286,12.286,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4629,0012-0287,12.287,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4630,0012-0292,12.292,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4631,0012-0293,12.293,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4632,0012-0294,12.294,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4633,0012-0298,12.298,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4634,0012-0303,12.303,Unconfirmed,237,0012-P01,Ulcer gastric;Ulcer duodenal;Dyspepsia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4635,0012-0305,12.305,Ended,237,0012-P01,Ulcer duodenal;Ulcer gastric,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4636,0012-0306,12.306,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric;Dyspepsia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4637,0012-0307,12.307,Ended,237,0012-P01,Ulcer duodenal;Ulcer gastric,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4638,0012-0308,12.308,Unconfirmed,237,0012-P01,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4639,0012-0310,12.310,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4640,0012-0318,12.318,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4641,0012-0319,12.319,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4642,0012-0320,12.320,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4643,0012-0321,12.321,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4644,0012-0322,12.322,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4645,0012-0323,12.323,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4646,0012-0324,12.324,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4647,0012-0325,12.325,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4648,0012-0326,12.326,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric;Dyspepsia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4649,0012-0330,12.330,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4650,0012-0331,12.331,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4651,0012-0332,12.332,Unconfirmed,237,0012-P01,Dyspepsia;Ulcer gastric;Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4652,0012-0333,12.333,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4653,0012-0334,12.334,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4654,0012-0335,12.335,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4655,0012-0336,12.336,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4656,0012-0337,12.337,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4657,0012-0347,12.347,Unconfirmed,237,0012-P01,Ulcer gastric;Ulcer duodenal;Dyspepsia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4658,0012-0353,12.353,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4659,0012-0354,12.354,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4660,0012-0356,12.356,Unconfirmed,237,0012-P01,Ulcer gastric;Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4661,0012-0377,12.377,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4662,0012-0379,12.379,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4663,0012-0380,12.380,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4664,0012-0381,12.381,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4665,0012-0383,12.383,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4666,0012-0384,12.384,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric;Oesophagiti,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4667,0012-0385,12.385,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4668,0012-0387,12.387,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4669,0012-0388,12.388,Unconfirmed,237,0012-P01,Ulcer peptic;Ulcer gastric;Ulcer duodena,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4670,0012-0389,12.389,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4671,0012-0390,12.390,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4672,0012-0393,12.393,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4673,0012-0395,12.395,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4674,0012-0402,12.402,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4675,0012-0403,12.403,Unconfirmed,237,0012-P01,Ulcer gastric;Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4676,0012-0404,12.404,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4677,0012-0406,12.406,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric;Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4678,0012-0407,12.407,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4679,0012-0408,12.408,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4680,0012-0409,12.409,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4681,0012-0411,12.411,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,II,Phase II,- Phase II-III * *,,,000910,IS - Clin Study (MIGRATED)
4682,0012-0413,12.413,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4683,0012-0415,12.415,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4684,0012-0416,12.416,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4685,0012-0417,12.417,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric;dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4686,0012-0419,12.419,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4687,0012-0420,12.420,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4688,0012-0422,12.422,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4689,0012-0423,12.423,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4690,0012-0424,12.424,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4691,0012-0432,12.432,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4692,0012-0436,12.436,Unconfirmed,237,0012-P01,Ulcer duodenal healed;Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4693,0012-0438,12.438,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4694,0012-0439,12.439,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4695,0012-0440,12.440,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4696,0012-0441,12.441,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4697,0012-0442,12.442,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4698,0012-0443,12.443,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4699,0012-0449,12.449,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4700,0012-0450,12.450,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4701,0012-0451,12.451,Unconfirmed,237,0012-P01,Ulcer gastric;Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4702,0012-0452,12.452,Unconfirmed,237,0012-P01,Ulcer gastric;Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4703,0012-0453,12.453,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4704,0012-0454,12.454,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4705,0012-0456,12.456,Unconfirmed,237,0012-P01,Ulcer gastric;Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4706,0012-0458,12.458,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4707,0012-0469,12.469,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4708,0012-0470,12.470,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4709,0012-0471,12.471,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4710,0012-0477,12.477,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4711,0012-0480,12.480,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric;Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4712,0012-0484,12.484,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4713,0012-0486,12.486,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4714,0012-0487,12.487,Unconfirmed,237,0012-P01,Ulcer gastric;Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4715,0012-0488,12.488,Unconfirmed,237,0012-P01,Ulcer gastric;Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4716,0012-0495,12.495,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4717,0012-0497,12.497,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4718,0012-0498,12.498,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4719,0012-0499,12.499,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4720,0012-0500,12.500,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4721,0012-0501,12.501,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4722,0012-0502,12.502,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4723,0012-0511,12.511,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4724,0012-0514,12.514,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4725,0012-0515,12.515,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4726,0012-0517,12.517,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4727,0012-0521,12.521,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4728,0012-0523,12.523,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4729,0012-0525,12.525,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4730,0012-0530,12.530,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- OPU: Boots GB * *,,,000910,IS - Clin Study (MIGRATED)
4731,0012-0537,12.537,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4732,0012-0538,12.538,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4733,0012-0539,12.539,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4734,0012-0541,12.541,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4735,0012-0544,12.544,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4736,0012-0545,12.545,Unconfirmed,237,0012-P01,Ulcer duodenal;Duodenitis;Oesophagitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4737,0012-0546,12.546,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4738,0012-0547,12.547,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4739,0012-0550,12.550,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4740,0012-0551,12.551,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4741,0012-0557,12.557,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4742,0012-0558,12.558,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4743,0012-0567,12.567,Ended,237,0012-P01,Duodenal ulcer,Ended,MIG,Migration,IV,Phase IV,- No report, negative results.,,,000910,IS - Clin Study (MIGRATED)
4744,0012-0579,12.579,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4745,0012-0580,12.580,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4746,0012-0581,12.581,Ended,237,0012-P01,Ulcer duodenal,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4747,0012-0584,12.584,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4748,0012-0585,12.585,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4749,0012-0588,12.588,Unconfirmed,237,0012-P01,Ulcer duodenal;Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4750,0012-0589,12.589,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4751,0012-0590,12.590,Unconfirmed,237,0012-P01,Ulcer duodenal recurrent,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4752,0012-0591,12.591,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4753,0012-0592,12.592,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4754,0012-0594,12.594,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4755,0012-0595,12.595,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- NZ Trial,,,000910,IS - Clin Study (MIGRATED)
4756,0012-0599,12.599,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4757,0012-0600,12.600,Ended,237,0012-P01,DUODENAL ULCER,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
4758,0012-0605,12.605,Unconfirmed,237,0012-P01,Ulcer duodenal healed,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4759,0012-0612,12.612,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4760,0012-0615,12.615,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4761,0012-0616,12.616,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4762,0012-0624,12.624,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- planned patients: 20-30 ** Dev.Prot.: NO CIMETIDINE  COMPARISON, BUT COMPARISON WITH ISOTONIC SALINE SOLUTION (AS PLACEBO). ONLY THE ACUTE TEST WA *,,,000910,IS - Clin Study (MIGRATED)
4763,0012-0628,12.628,Unconfirmed,237,0012-P01,Ulcer gastric;Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- NZ Trial,,,000910,IS - Clin Study (MIGRATED)
4764,0012-0629,12.629,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- planned patients:80-100 * *,,,000910,IS - Clin Study (MIGRATED)
4765,0012-0634,12.634,Ended,237,0012-P01,Duodenal ulcer,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4766,0012-0635,12.635,Ended,237,0012-P01,Duodenal ulcer,Ended,MIG,Migration,IV,Phase IV,- Published in: Philipp J Intern Med 27 (1989), 107-117. ** *,,,000910,IS - Clin Study (MIGRATED)
4767,0012-0636,12.636,Ended,237,0012-P01,Ulcer duodenal,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4768,0012-0653,12.653,Ended,237,0012-P01,Ulcer duodenal,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4769,0012-0655,12.655,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- OPU: Boots GB ** *,,,000910,IS - Clin Study (MIGRATED)
4770,0012-0659,12.659,Ended,237,0012-P01,DUODENAL ULCER,Ended,MIG,Migration,III,Phase III,-  Formerly IIIa15, IIIa20.  This study was terminated due to  discontinuation of the Gastrozepin program.     ,,,000910,IS - Clin Study (MIGRATED)
4771,0012-0660,12.660,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- OPU:Boots GB ** *,,,000910,IS - Clin Study (MIGRATED)
4772,0012-0666,12.666,Unconfirmed,237,0012-P01,Duodenal ulcer,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4773,0012-0668,12.668,Ended,237,0012-P01,Duodenal ulcer,Ended,MIG,Migration,III,Phase III,- planned patients: 400-500 ** *,,,000910,IS - Clin Study (MIGRATED)
4774,0012-0671,12.671,Unconfirmed,237,0012-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4775,0012-0672,12.672,Ended,237,0012-P01,Ulcer duodenal,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4776,0012-0674,12.674,Ended,237,0012-P01,HEALING IN COMBINATION WITH RANITIDINE,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4777,0012-0689,12.689,Ended,237,0012-P01,DUODENAL ULCER,Ended,MIG,Migration,III,Phase III,-  Formerly IIIa15, IIIa20.  This study was terminated due to  discontinuation of the Gastrozepin program.     ,,,000910,IS - Clin Study (MIGRATED)
4778,0021-0001,21.1,Ended,238,0021-P00,bei Plazenta-Insuffizienz 1,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
4779,0021-0002,21.2,Ended,238,0021-P00,bei Plazenta-Insuffizienz 2,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
4780,0021-0005,21.5,Ended,238,0021-P00,bei Placenta-Insuffizienz 3,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
4781,0021-0007,21.7,Ended,238,0021-P00,Provokation A.Pectoris-Schmerz,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
4782,0021-0028,21.28,Ended,238,0021-P00,Persantin pHi 21-28,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4783,0021-0044,21.44,Ended,238,0021-P00,Leukotriensynth. of Leucozytes ,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
4784,0021-0100,21.100,Unconfirmed,238,0021-P00,Arterial disease, peripheral,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4785,0021-0101,21.101,Ended,238,0021-P00,none,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4786,0021-0102,21.102,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4787,0021-0103,21.103,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4788,0021-0104,21.104,Unconfirmed,238,0021-P00,Pagets disease,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4789,0021-0105,21.105,Unconfirmed,238,0021-P00,Glomerulonephritis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4790,0021-0106,21.106,Unconfirmed,238,0021-P00,Ischaemic heart disease,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4791,0021-0107,21.107,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4792,0021-0108,21.108,Ended,238,0021-P00,Dipyridamole and ASA in DVT,Ended,MIG,Migration,III,Phase III,- Status E agreed by Dr. Hertkorn, 10.06.1997.,,,000910,IS - Clin Study (MIGRATED)
4793,0021-0109,21.109,Unconfirmed,238,0021-P00,Coronary bypass,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4794,0021-0110,21.110,Unconfirmed,238,0021-P00,Deep vein thrombosis, recurrent,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4795,0021-0111,21.111,Unconfirmed,238,0021-P00,Respiratory distress syndrome,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4796,0021-0112,21.112,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4797,0021-0113,21.113,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4798,0021-0114,21.114,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4799,0021-0115,21.115,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4800,0021-0116,21.116,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4801,0021-0117,21.117,Ended,238,0021-P00,No Legacy Data,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4802,0021-0118,21.118,Unconfirmed,238,0021-P00,Deep vein thrombosis, Coronary bypass,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4803,0021-0119,21.119,Unconfirmed,238,0021-P00,Haemodialysis,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4804,0021-0120,21.120,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4805,0021-0121,21.121,Unconfirmed,238,0021-P00,Ischaemic heart disease,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4806,0021-0122,21.122,Ended,238,0021-P00,Transluminal angiopl.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4807,0021-0123,21.123,Unconfirmed,238,0021-P00,Cardiac valve replacement,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4808,0021-0124,21.124,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4809,0021-0125,21.125,Unconfirmed,238,0021-P00,Platelet cerebrovascular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4810,0021-0126,21.126,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4811,0021-0127,21.127,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4812,0021-0128,21.128,Unconfirmed,238,0021-P00,Platelet cerebrovascular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4813,0021-0129,21.129,Unconfirmed,238,0021-P00,Glomerulosclerosis, Focal segmenta,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4814,0021-0130,21.130,Unconfirmed,238,0021-P00,Coagulation disorders,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4815,0021-0131,21.131,Unconfirmed,238,0021-P00,Arterial angioplasty, peripheral,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4816,0021-0132,21.132,Ended,238,0021-P00,FEMPOP. PREVENTION VASC. GRAFT FAILURE,Ended,MIG,Migration,IV,Phase IV,- intern'l? / Report requested 30.03.93 (Letter Dr. EAG) / IOR-Study waiting for report from investigator (fax 5-7-93),,,,
4817,0021-0133,21.133,Ended,238,0021-P00,ASA and Dipyridamole following PTCA,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4818,0021-0134,21.134,Ended,238,0021-P00,Coronary bypass,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4819,0021-0135,21.135,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4820,0021-0136,21.136,Unconfirmed,238,0021-P00,Cardiovascular surgery,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4821,0021-0137,21.137,Unconfirmed,238,0021-P00,Deep vein thrombosis,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4822,0021-0138,21.138,Unconfirmed,238,0021-P00,Deep vein thrombosis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4823,0021-0139,21.139,Unconfirmed,238,0021-P00,Intensive-care,Unconfirmed,MIG,Migration,NONE,Not Classified,- planned patients:50-60 * *,,,000910,IS - Clin Study (MIGRATED)
4824,0021-0140,21.140,Unconfirmed,238,0021-P00,Deep vein thrombosis,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4825,0021-0141,21.141,Ended,238,0021-P00,Blood cardioplegia,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4826,0021-0142,21.142,Unconfirmed,238,0021-P00,Endarterectomy, carotid,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4827,0021-0143,21.143,Unconfirmed,238,0021-P00,Cardiac surgery,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4828,0021-0144,21.144,Ended,238,0021-P00,aorto-coronary bypass-operation,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4829,0021-0145,21.145,Ended,238,0021-P00,Asasantin Depot after PTA vs. Anticoagul,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4830,0021-0146,21.146,Ended,238,0021-P00,Cardiac insufficiency,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4831,0021-0147,21.147,Ended,238,0021-P00,is Persantin + ISDN more effective than,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4832,0021-0148,21.148,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4833,0021-0149,21.149,Ended,238,0021-P00,Persantin in therapyresistant nephrotic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4834,0021-0150,21.150,Unconfirmed,238,0021-P00,Nephropathy, diabetes-mellitus,Unconfirmed,MIG,Migration,I,Phase I,- OPU: BI GCA * *,,,000910,IS - Clin Study (MIGRATED)
4835,0021-0151,21.151,Ended,238,0021-P00,none,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4836,0021-0152,21.152,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4837,0021-0153,21.153,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4838,0021-0154,21.154,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4839,0021-0155,21.155,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4840,0021-0156,21.156,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4841,0021-0157,21.157,Unconfirmed,238,0021-P00,Arterial disease, peripheral,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4842,0021-0158,21.158,Ended,238,0021-P00,none,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4843,0021-0159,21.159,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4844,0021-0160,21.160,Ended,238,0021-P00,Coronary angioplasty,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4845,0021-0161,21.161,Ended,238,0021-P00,Coronary bypass,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4846,0021-0162,21.162,Ended,238,0021-P00,none,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4847,0021-0163,21.163,Ended,238,0021-P00,Coronary artery bypass graft,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4848,0021-0164,21.164,Unconfirmed,238,0021-P00,Arterial disease, peripheral,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4849,0021-0165,21.165,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4850,0021-0166,21.166,Unconfirmed,238,0021-P00,Cardiovascular,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4851,0021-0167,21.167,Unconfirmed,238,0021-P00,Cardiac,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4852,0021-0168,21.168,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4853,0021-0169,21.169,Ended,238,0021-P00,Cardiac,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4854,0021-0170,21.170,Unconfirmed,238,0021-P00,Cardiac,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4855,0021-0171,21.171,Unconfirmed,238,0021-P00,Cardiac insufficiency,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4856,0021-0172,21.172,Unconfirmed,238,0021-P00,RIND,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4857,0021-0173,21.173,Ended,238,0021-P00,none,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4858,0021-0174,21.174,Ended,238,0021-P00,Safety, efficacy,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4859,0021-0175,21.175,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4860,0021-0176,21.176,Ended,238,0021-P00,Coronary bypass,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4861,0021-0177,21.177,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4862,0021-0178,21.178,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4863,0021-0179,21.179,Unconfirmed,238,0021-P00,Diabetes-mellitus,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4864,0021-0180,21.180,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4865,0021-0181,21.181,Unconfirmed,238,0021-P00,Platelet arterial disease peripheral ulc,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4866,0021-0182,21.182,Unconfirmed,238,0021-P00,Platelet arterial disease peripheral ulc,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4867,0021-0183,21.183,Unconfirmed,238,0021-P00,Coronary bypass,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4868,0021-0184,21.184,Unconfirmed,238,0021-P00,Glomerulonephritis,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4869,0021-0185,21.185,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4870,0021-0186,21.186,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4871,0021-0187,21.187,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4872,0021-0188,21.188,Unconfirmed,238,0021-P00,Infarction,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4873,0021-0190,21.190,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4874,0021-0191,21.191,Unconfirmed,238,0021-P00,Cerebrovascular,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4875,0021-0192,21.192,Unconfirmed,238,0021-P00,Valve replacement,Unconfirmed,MIG,Migration,IV,Phase IV,- Evaluation made in USA No: E-81-1436 ** *,,,000910,IS - Clin Study (MIGRATED)
4876,0021-0193,21.193,Unconfirmed,238,0021-P00,Cardiovascular,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4877,0021-0194,21.194,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4878,0021-0195,21.195,Ended,238,0021-P00,Thallium imaging,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4879,0021-0196,21.196,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4880,0021-0197,21.197,Unconfirmed,238,0021-P00,Coronary bypass,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4881,0021-0198,21.198,Unconfirmed,238,0021-P00,Arterial construction,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4882,0021-0199,21.199,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4883,0021-0200,21.200,Unconfirmed,238,0021-P00,Arterial reconstruction,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4884,0021-0201,21.201,Ended,238,0021-P00,Subarachnoidal bleeding,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4885,0021-0202,21.202,Ended,238,0021-P00,Subarachnoidal bleeding,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4886,0021-0203,21.203,Ended,238,0021-P00,MRC STUDY IN FEM.POP.GRAFTS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4887,0021-0204,21.204,Unconfirmed,238,0021-P00,Coronary bypass,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4888,0021-0205,21.205,Unconfirmed,238,0021-P00,Valve replacement,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4889,0021-0206,21.206,Unconfirmed,238,0021-P00,Valve replacement,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4890,0021-0207,21.207,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4891,0021-0208,21.208,Unconfirmed,238,0021-P00,Ischaemic heart disease,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4892,0021-0209,21.209,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4893,0021-0210,21.210,Unconfirmed,238,0021-P00,Angina pectoris,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4894,0021-0211,21.211,Unconfirmed,238,0021-P00,Ischaemic heart disease,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4895,0021-0212,21.212,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4896,0021-0213,21.213,Unconfirmed,238,0021-P00,Endarterectomy, carotid, TIA,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4897,0021-0214,21.214,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4898,0021-0215,21.215,Unconfirmed,238,0021-P00,Glomerulonephritis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4899,0021-0216,21.216,Unconfirmed,238,0021-P00,Arterial disease, peripheral,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4900,0021-0218,21.218,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4901,0021-0219,21.219,Unconfirmed,238,0021-P00,Patients cerebrovascular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4902,0021-0220,21.220,Ended,238,0021-P00,COCP,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4903,0021-0221,21.221,Unconfirmed,238,0021-P00,Ischaemic heart disease,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4904,0021-0222,21.222,Ended,238,0021-P00,Ischaemic heart disease,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4905,0021-0223,21.223,Unconfirmed,238,0021-P00,Infarction,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4906,0021-0224,21.224,Unconfirmed,238,0021-P00,Infarction,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4907,0021-0225,21.225,Unconfirmed,238,0021-P00,Diabetes-mellitus, retinopathy,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4908,0021-0226,21.226,Unconfirmed,238,0021-P00,Spherocytosis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4909,0021-0227,21.227,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- DOSAGE: 400 MG/DA *,,,000910,IS - Clin Study (MIGRATED)
4910,0021-0228,21.228,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4911,0021-0229,21.229,Ended,238,0021-P00,Placental insufficiency,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4912,0021-0230,21.230,Ended,238,0021-P00,none,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4913,0021-0231,21.231,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4914,0021-0232,21.232,Ended,238,0021-P00,Chronic glomerulonephritis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4915,0021-0233,21.233,Ended,238,0021-P00,Ischaemic heart disease,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4916,0021-0234,21.234,Ended,238,0021-P00,Nephrotic syndrome, glomerulonephritis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4917,0021-0235,21.235,Ended,238,0021-P00,Valve replacement,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4918,0021-0236,21.236,Unconfirmed,238,0021-P00,Valve replacement,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4919,0021-0237,21.237,Unconfirmed,238,0021-P00,Nephrotic syndrome,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4920,0021-0238,21.238,Unconfirmed,238,0021-P00,Ischaemic heart disease,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4921,0021-0239,21.239,Unconfirmed,238,0021-P00,Nephrotic syndrome, glomerulonephritis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4922,0021-0240,21.240,Unconfirmed,238,0021-P00,Lupus nephritis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4923,0021-0242,21.242,Ended,238,0021-P00,Coronary by-pass,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4924,0021-0243,21.243,Unconfirmed,238,0021-P00,Coronary bypass,Unconfirmed,MIG,Migration,II,Phase II,- Phase II-III * *,,,000910,IS - Clin Study (MIGRATED)
4925,0021-0244,21.244,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4926,0021-0245,21.245,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4927,0021-0246,21.246,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4928,0021-0247,21.247,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4929,0021-0248,21.248,Ended,238,0021-P00,No Legacy Data,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4930,0021-0249,21.249,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4931,0021-0250,21.250,Unconfirmed,238,0021-P00,Raynaud-disease, -syndrome,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4932,0021-0251,21.251,Ended,238,0021-P00,Infarction, acute,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4933,0021-0252,21.252,Unconfirmed,238,0021-P00,Renal insufficiency, chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4934,0021-0253,21.253,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4935,0021-0254,21.254,Unconfirmed,238,0021-P00,Nephrotic syndrome,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4936,0021-0255,21.255,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4937,0021-0256,21.256,Ended,238,0021-P00,No Legacy Data,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4938,0021-0257,21.257,Ended,238,0021-P00,No Legacy Data,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4939,0021-0258,21.258,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4940,0021-0259,21.259,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4941,0021-0260,21.260,Unconfirmed,238,0021-P00,Diabetes-mellitus, retinopathy,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4942,0021-0261,21.261,Unconfirmed,238,0021-P00,Hyperlipidaemia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4943,0021-0262,21.262,Ended,238,0021-P00,Angina-pectoris,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4944,0021-0263,21.263,Unconfirmed,238,0021-P00,Disseminated intravascular coagulation,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4945,0021-0264,21.264,Unconfirmed,238,0021-P00,Peritoneal dialysis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4946,0021-0265,21.265,Unconfirmed,238,0021-P00,Infarction,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4947,0021-0266,21.266,Unconfirmed,238,0021-P00,Stroke,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4948,0021-0268,21.268,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4949,0021-0269,21.269,Ended,238,0021-P00,Ulcus cruris,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4950,0021-0270,21.270,Unconfirmed,238,0021-P00,Ischaemic heart disease,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4951,0021-0271,21.271,Ended,238,0021-P00,Angina pectoris,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4952,0021-0272,21.272,Ended,238,0021-P00,Coronary bypass,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4953,0021-0273,21.273,Ended,238,0021-P00,Coronary artery bypass graft,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4954,0021-0274,21.274,Unconfirmed,238,0021-P00,Arterial disease, peripheral,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4955,0021-0275,21.275,Ended,238,0021-P00,Subarachnoidal bleeding,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4956,0021-0276,21.276,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4957,0021-0277,21.277,Unconfirmed,238,0021-P00,Coronary bypass,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4958,0021-0278,21.278,Unconfirmed,238,0021-P00,Cerebral aneurysm,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4959,0021-0279,21.279,Unconfirmed,238,0021-P00,Deep vein thrombosis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4960,0021-0280,21.280,Ended,238,0021-P00,Pharmacokinetics,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4961,0021-0281,21.281,Ended,238,0021-P00,No Legacy Data,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4962,0021-0282,21.282,Unconfirmed,238,0021-P00,Coronary bypass,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4963,0021-0283,21.283,Unconfirmed,238,0021-P00,Coronary bypass,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4964,0021-0284,21.284,Unconfirmed,238,0021-P00,Peritoneal dialysis,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4965,0021-0285,21.285,Unconfirmed,238,0021-P00,Arterial reconstruction, prostetic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4966,0021-0289,21.289,Unconfirmed,238,0021-P00,Peritoneal dialysis,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4967,0021-0290,21.290,Ended,238,0021-P00,RENAL INDICATIONS,Ended,MIG,Migration,II,Phase II,-  Report available.     ,,,000910,IS - Clin Study (MIGRATED)
4968,0021-0291,21.291,Ended,238,0021-P00,none,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4969,0021-0292,21.292,Unconfirmed,238,0021-P00,Peritoneal dialysis,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4970,0021-0293,21.293,Unconfirmed,238,0021-P00,Peritoneal dialysis,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4971,0021-0294,21.294,Ended,238,0021-P00,RENAL INDICATIONS,Ended,MIG,Migration,II,Phase II,-  Due to numerous protocol violations which effect the efficacy  data only a safety report was issued.     ,,,000910,IS - Clin Study (MIGRATED)
4972,0021-0295,21.295,Unconfirmed,238,0021-P00,Angina pectoris,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4973,0021-0296,21.296,Ended,238,0021-P00,Renal,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4974,0021-0297,21.297,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4975,0021-0298,21.298,Ended,238,0021-P00,none,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4976,0021-0299,21.299,Ended,238,0021-P00,none,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4977,0021-0300,21.300,Unconfirmed,238,0021-P00,Carcinoma, melanoma/ colon CA,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4978,0021-0301,21.301,Unconfirmed,238,0021-P00,Angina-pectoris,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4979,0021-0302,21.302,Unconfirmed,238,0021-P00,Angina-pectoris,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4980,0021-0303,21.303,Unconfirmed,238,0021-P00,Peritoneal dialysis,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4981,0021-0305,21.305,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4982,0021-0306,21.306,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4983,0021-0308,21.308,Unconfirmed,238,0021-P00,Ischaemic heart disease,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4984,0021-0309,21.309,Unconfirmed,238,0021-P00,Coronary bypass,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4985,0021-0310,21.310,Unconfirmed,238,0021-P00,Glomerulonephritis, membranproliferative,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4986,0021-0311,21.311,Ended,238,0021-P00,CORONARY DISEASE,Ended,MIG,Migration,I,Phase I,-  Statistical report available.     ,,,000910,IS - Clin Study (MIGRATED)
4987,0021-0312,21.312,Unconfirmed,238,0021-P00,Positive ECG, ischaemia,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
4988,0021-0314,21.314,Unconfirmed,238,0021-P00,Ventricular hypertrophy,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4989,0021-0315,21.315,Unconfirmed,238,0021-P00,Diabetes-mellitus, retinopathy,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
4990,0021-0316,21.316,Unconfirmed,238,0021-P00,diabetes-mellitus, retinopathy,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4991,0021-0317,21.317,Unconfirmed,238,0021-P00,Ischaemic heart disease,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4992,0021-0318,21.318,Unconfirmed,238,0021-P00,Valve replacement,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4993,0021-0319,21.319,Unconfirmed,238,0021-P00,Coronary bypass,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4994,0021-0320,21.320,Unconfirmed,238,0021-P00,Angioplasty, coronary,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4995,0021-0321,21.321,Unconfirmed,238,0021-P00,Arterial reconstruction,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
4996,0021-0322,21.322,Unconfirmed,238,0021-P00,Glomerulonephritis, membranproliferative,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
4997,0021-0323,21.323,Unconfirmed,238,0021-P00,Scleroderma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
4998,0021-0324,21.324,Unconfirmed,238,0021-P00,Coronary bypass,Unconfirmed,MIG,Migration,IV,Phase IV,- Dev.Prot.: TRIAL HALTED WITH NO BENEFIT SEEN WITH ANTIPLATELET THERAPY. 28 PATIENTS COMPLETED 1 YEAR AND 21 COMPLETED 2 *,,,000910,IS - Clin Study (MIGRATED)
4999,0021-0325,21.325,Unconfirmed,238,0021-P00,Ischaemic heart disease,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5000,0021-0326,21.326,Unconfirmed,238,0021-P00,Cancer,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5001,0021-0327,21.327,Unconfirmed,238,0021-P00,Arterial reconstruction, peripheral,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5002,0021-0328,21.328,Ended,238,0021-P00,RENAL INDICATIONS,Ended,MIG,Migration,II,Phase II,-  Aspirin/Persantine significantly delayed the progression of renal dysfunction compared with the placebo group.     ,,,000910,IS - Clin Study (MIGRATED)
5003,0021-0329,21.329,Unconfirmed,238,0021-P00,Diabetes-mellitus,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5004,0021-0330,21.330,Unconfirmed,238,0021-P00,Peritoneal dialysis,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5005,0021-0331,21.331,Unconfirmed,238,0021-P00,Peritoneal dialysis,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5006,0021-0332,21.332,Unconfirmed,238,0021-P00,Cancer,Unconfirmed,MIG,Migration,I,Phase I,- Dev.Prot.: 8503: HIGHER DOSE LEVELS AS ORIGINALLY INTENDED HAVE BEEN REACHED (DOSE LEVEL 11=7.7 MG/KG/DAY PERSANTIN OVE *,,,000910,IS - Clin Study (MIGRATED)
5007,0021-0333,21.333,Ended,238,0021-P00,Infarction,Ended,MIG,Migration,IV,Phase IV,- Dev.Prot.: 8503: HIGHER DOSE LEVELS AS ORIGINALLY INTENDED HAVE BEEN REACHED (DOSE LEVEL 11=7.7 MG/KG/DAY PERSANTIN OVER 3  DAYS) WITHOUT SIGNIFICANT INCREASE IN ADVERSE EFFECTS. THIS MIGHT BE DUE TO HIGHER ALPHA-1-GLYCOPROTEIN CONCENTRATIONS I,,,000910,IS - Clin Study (MIGRATED)
5008,0021-0334,21.334,Unconfirmed,238,0021-P00,Arterial disease, peripheral,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5009,0021-0335,21.335,Unconfirmed,238,0021-P00,Cardiac,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5010,0021-0337,21.337,Unconfirmed,238,0021-P00,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
5011,0021-0338,21.338,Unconfirmed,238,0021-P00,Cerebrovascular disorders,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5012,0021-0339,21.339,Ended,238,0021-P00,Femoralis pop.by-pass op.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5013,0021-0340,21.340,Ended,238,0021-P00,fem.pop.bypass,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5014,0021-0341,21.341,Ended,238,0021-P00,No indication,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5015,0021-0342,21.342,Ended,238,0021-P00,Coronary bypass,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5016,0021-0344,21.344,Unconfirmed,238,0021-P00,Infarction,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5017,0021-0345,21.345,Ended,238,0021-P00,Arterial, angioplasty, peripheral,Ended,MIG,Migration,III,Phase III,- ,,,,
5018,0021-0346,21.346,Ended,238,0021-P00,Persantin in patients with claudication,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5019,0021-0347,21.347,Ended,238,0021-P00,Micro Albuminuria,Ended,MIG,Migration,IV,Phase IV,- Report available in Ingelheim. *,,,000910,IS - Clin Study (MIGRATED)
5020,0021-0348,21.348,Ended,238,0021-P00,No Legacy Data,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5021,0021-0349,21.349,Ended,238,0021-P00,Thrombosis,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5022,0021-0351,21.351,Ended,238,0021-P00,Carcinoma,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5023,0021-0352,21.352,Ended,238,0021-P00,CORONARY DISEASE,Ended,MIG,Migration,I,Phase I,-  Dr. Cass study was terminated 12/30/86. Dr. Nagel's not initiated.  Management decision to halt clinical development of Persantine   pHI study.     ,,,000910,IS - Clin Study (MIGRATED)
5024,0021-0353,21.353,Ended,238,0021-P00,No Legacy Data,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5025,0021-0354,21.354,Unconfirmed,238,0021-P00,Reconstructive vascular surgery,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5026,0021-0355,21.355,Unconfirmed,238,0021-P00,Diabetes (smokers),Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5027,0021-0356,21.356,Ended,238,0021-P00,Proteinuria,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5028,0021-0357,21.357,Unconfirmed,238,0021-P00,Membranous glomerulonephritis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5029,0021-0358,21.358,Unconfirmed,238,0021-P00,Venous or arterial pathology,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5030,0021-0359,21.359,Ended,238,0021-P00,Persantin pHi,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5031,0021-0360,21.360,Ended,238,0021-P00,Micro Proteinuria,Ended,MIG,Migration,IV,Phase IV,- Summary,,,000910,IS - Clin Study (MIGRATED)
5032,0021-0361,21.361,Ended,238,0021-P00,Critical limb ischaemia,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5033,0021-0362,21.362,Ended,238,0021-P00,PERGAR (Pregnancy, high risk),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5034,0021-0363,21.363,Ended,238,0021-P00,Deep vein thrombosis,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5035,0021-0364,21.364,Ended,238,0021-P00,Macro Proteinuria,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5036,0021-0365,21.365,Ended,238,0021-P00,No Legacy Data,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5037,0021-0367,21.367,Ended,238,0021-P00,IV and oral administration,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5038,0021-0368,21.368,Ended,238,0021-P00,Coronary bypass,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5039,0021-0369,21.369,Ended,238,0021-P00,PET (Pre-eclamptic Toxemia),Ended,MIG,Migration,III,Phase III,- No Report date yet available (Letter deWet 7.10.92).,,,000910,IS - Clin Study (MIGRATED)
5040,0021-0370,21.370,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5041,0021-0371,21.371,Ended,238,0021-P00,none,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5042,0021-0372,21.372,Unconfirmed,238,0021-P00,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5043,0021-0374,21.374,Ended,238,0021-P00,Intermittent claudication,Ended,MIG,Migration,III,Phase III,- Follow-up study of multicenter study no.1/87. No.of pat.depe ds on study No.1/87. *,,,000910,IS - Clin Study (MIGRATED)
5044,0021-0376,21.376,Ended,238,0021-P00,Pharmacokinetics,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5045,0021-0377,21.377,Ended,238,0021-P00,Pharmacokinetics,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5046,0021-0378,21.378,Ended,238,0021-P00,Thrombolytic and cardioprotective therap,Ended,MIG,Migration,II,Phase II,- Report expected 12/92 (T. Goethals - EAG),,,000910,IS - Clin Study (MIGRATED)
5047,0021-0379,21.379,Ended,238,0021-P00,EFFECTS ON WHOLE BLOOD PLATELET AGGREGAT,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5048,0021-0380,21.380,Unconfirmed,238,0021-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5049,0021-0381,21.381,Ended,238,0021-P00,D.I.P.A.P.,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5050,0021-0382,21.382,Ended,238,0021-P00,Deep vein thrombosis,Ended,MIG,Migration,IV,Phase IV,- Study discontinuedn due to difficulties in recruitment. * *,,,000910,IS - Clin Study (MIGRATED)
5051,0021-0383,21.383,Ended,238,0021-P00,Influence of Persantin on bleeding time,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5052,0021-0384,21.384,Ended,238,0021-P00,TOJO,DBT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5053,0021-0385,21.385,Ended,238,0021-P00,Development of a method of measurement,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5054,0021-0386,21.386,Ended,238,0021-P00,D.I.V.A.T.,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5055,0021-0388,21.388,Unconfirmed,238,0021-P00,Infarction myocardial, acute,Unconfirmed,MIG,Migration,IV,Phase IV,- Published in: Minerva Cardiologica 36 (1988), 347-350. *,,,000910,IS - Clin Study (MIGRATED)
5056,0021-0390,21.390,Ended,238,0021-P00,ISHIKAWA,OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5057,0021-0391,21.391,Ended,238,0021-P00,NARITA,OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5058,0021-0392,21.392,Ended,238,0021-P00,Ventricular Function, elderly,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5059,0021-0393,21.393,Ended,238,0021-P00,Intermittent claudication,Ended,MIG,Migration,IV,Phase IV,- Intermittent claudication.,,,000910,IS - Clin Study (MIGRATED)
5060,0021-0394,21.394,Unconfirmed,238,0021-P00,Peripheral Arterial Thrombosis,Unconfirmed,MIG,Migration,IV,Phase IV,- Report requested (Letter EAG 30.03.93),,,000910,IS - Clin Study (MIGRATED)
5061,0021-0399,21.399,Ended,238,0021-P00,Combination with PALA,Ended,MIG,Migration,II,Phase II,-  The study is clinically complete with 19 completed patients. Only one patient evidenced a partial response to treatment. Dates of Draft and Final Reports were changed recently due to priority changes in MDAS.   ,,,000910,IS - Clin Study (MIGRATED)
5062,0021-0400,21.400,Ended,238,0021-P00,SUGIZAKI,OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5063,0021-0402,21.402,Ended,238,0021-P00,Pilot study in colorectal cancer,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5064,0021-0404,21.404,Ended,238,0021-P00,Diabetes mellitus,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5065,0021-0406,21.406,Unconfirmed,238,0021-P00,Eco-test,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5066,0021-0408,21.408,Ended,238,0021-P00,SINGLE ADMINISTRATION,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5067,0021-0409,21.409,Ended,238,0021-P00,SINGLE ADMINISTRATION,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5068,0021-0410,21.410,Unconfirmed,238,0021-P00,Nephropathy, glomerular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5069,0021-0412,21.412,Ended,238,0021-P00,Thrombolysis effect of Dipyridamole,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5070,0021-0415,21.415,Ended,238,0021-P00,Pers./Pentoxiphyl.,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5071,0021-0417,21.417,Ended,238,0021-P00,Arrhythmias, postthrombolytic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5072,0021-0420,21.420,Ended,238,0021-P00,NONE,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5073,0021-0421,21.421,Ended,238,0021-P00,Pilotstudie mit III Indium markierten Th,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5074,0021-0422,21.422,Ended,238,0021-P00,Pharmacokinetic of dipyridamole 150.,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5075,0021-0423,21.423,Ended,238,0021-P00,SINGLE ORAL ADMINISTRATION(EFFECT OF FOO,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5076,0021-0424,21.424,Ended,238,0021-P00,MULTIPLE ORAL ADMINISTRATION,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5077,0021-0425,21.425,Unconfirmed,238,0021-P00,Atherosclerosis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5078,0021-0426,21.426,Ended,238,0021-P00,Haemoreologic efects of Dipyridamole,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5079,0021-0428,21.428,Ended,238,0021-P00,Influence of Persantine on high risk pre,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5080,0021-0429,21.429,Ended,238,0021-P00,zzz,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5081,0021-0430,21.430,Ended,238,0021-P00,EFFECT IN COMBINATION WITH AZT,Ended,MIG,Migration,II,Phase II,- Summary,,,000910,IS - Clin Study (MIGRATED)
5082,0021-0431,21.431,Ended,238,0021-P00,EFFECT ON COMBINATION WITH AZT IN AIDS,Ended,MIG,Migration,II,Phase II,- Summary,,,000910,IS - Clin Study (MIGRATED)
5083,0021-0432,21.432,Ended,238,0021-P00,Regional blood flow and metabolism,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5084,0021-0433,21.433,Unconfirmed,238,0021-P00,CORONARY DISEASE,Unconfirmed,MIG,Migration,I,Phase I,-  Study terminated per physician monitor due to lack of enrollment.     ,,,000910,IS - Clin Study (MIGRATED)
5085,0021-0434,21.434,Ended,238,0021-P00,CORONARY DISEASE,Ended,MIG,Migration,I,Phase I,-  No longer planning to repeat McMahon and Buchman studies.  This  study was to test concepts in re: absorption seen previously   in Hurwitz/Darrogh studies.     ,,,000910,IS - Clin Study (MIGRATED)
5086,0021-0435,21.435,Ended,238,0021-P00,Dipyridamole and asthma,Ended,MIG,Migration,IV,Phase IV,- Report expected 10/92 (Letter Lessner 10/92),,,000910,IS - Clin Study (MIGRATED)
5087,0021-0436,21.436,Unconfirmed,238,0021-P00,Vascular eccidents, prophylaxis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5088,0021-0437,21.437,Ended,238,0021-P00,SINGLE ADMINISTRATION,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5089,0021-0438,21.438,Ended,238,0021-P00,RA-SP VOLUNTEER STUDY - CONSECUTIVE,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5090,0021-0439,21.439,Ended,238,0021-P00,Effect of Aspirin/Dipyridamole on PGI 2,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5091,0021-0440,21.440,Ended,238,0021-P00,Combination dipyridamole - Zidovudine,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5092,0021-0443,21.443,Ended,238,0021-P00,STABLE CORONARY ANGIOPLASTY,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5093,0021-0444,21.444,Ended,238,0021-P00,DBT study of PE tab. on angina pectoris,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5094,0021-0445,21.445,Ended,238,0021-P00,open trial study of PE tab. on SMI,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
5095,0021-0446,21.446,Ended,238,0021-P00,DOHI,OT,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
5096,0021-0448,21.448,Unconfirmed,238,0021-P00,Persantine Pharmacokinetic Study,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5097,0021-0450,21.450,Preparing,238,0021-P00,Vascular Biology of DP/Agg (Fitzgerald),Preparing,MIG,Migration,IV,Phase IV,,,,,
5098,0244-0306,244.306,Ended,239,0244-P00,Atrovent+Theophyllin, different multiinh,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5099,0244-0901,244.901,Unconfirmed,239,0244-P00,CHRONIC OBSTRUCTIVE AIRWAYS DISEASE,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5100,0244-1001,244.1001,Preparing,239,0244-P00,Efficacy, infants,Preparing,MIG,Migration,NONE,Not Classified,- , Kinder, EStatus = X, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5101,0244-1051,244.1051,Preparing,239,0244-P00,Cost effectiveness,Preparing,MIG,Migration,IV,Phase IV,- , EStatus = X, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5102,0244-1052,244.1052,Preparing,239,0244-P00,Efficacy,Preparing,MIG,Migration,IV,Phase IV,- , EStatus = X, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5103,0244-2005,244.2005,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5104,0244-2006,244.2006,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5105,0244-2007,244.2007,Unconfirmed,239,0244-P00,Asthma chronic;Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5106,0244-2008,244.2008,Unconfirmed,239,0244-P00,Fibrosis cystic;Asthma;Hypersensitivity,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5107,0244-2009,244.2009,Unconfirmed,239,0244-P00,Bronchitis chronic;Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5108,0244-2011,244.2011,Unconfirmed,239,0244-P00,Bronchospasm,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5109,0244-2012,244.2012,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5110,0244-2014,244.2014,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5111,0244-2020,244.2020,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5112,0244-2021,244.2021,Unconfirmed,239,0244-P00,Asthma;Cold,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5113,0244-2022,244.2022,Unconfirmed,239,0244-P00,Rhinitis vasomotor,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5114,0244-2024,244.2024,Unconfirmed,239,0244-P00,Rhinitis vasomotor,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5115,0244-2025,244.2025,Ended,239,0244-P00,Bronchitis smoking,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5116,0244-2026,244.2026,Unconfirmed,239,0244-P00,Bronchitis chronic obstructive,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5117,0244-2027,244.2027,Unconfirmed,239,0244-P00,Rhinitis vasomotor,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5118,0244-2033,244.2033,Unconfirmed,239,0244-P00,Bronchitis acute,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5119,0244-2036,244.2036,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- Part one of a trial. Part two is 850176* *,,,000910,IS - Clin Study (MIGRATED)
5120,0244-2040,244.2040,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5121,0244-2041,244.2041,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5122,0244-2042,244.2042,Ended,239,0244-P00,Rhinitis vasomotor,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5123,0244-2043,244.2043,Ended,239,0244-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5124,0244-2044,244.2044,Ended,239,0244-P00,Rhinitis vasomotor,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5125,0244-2046,244.2046,Ended,239,0244-P00,Bronchitis chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5126,0244-2047,244.2047,Unconfirmed,239,0244-P00,Prostatic hypertrophy minor,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5127,0244-2048,244.2048,Unconfirmed,239,0244-P00,Rhinitis perennial,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5128,0244-2049,244.2049,Unconfirmed,239,0244-P00,Rhinitis perennial,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5129,0244-2050,244.2050,Ended,239,0244-P00,COLD,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5130,0244-2052,244.2052,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5131,0244-2053,244.2053,Ended,239,0244-P00,Asthma;Bronchitis chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5132,0244-2054,244.2054,Ended,239,0244-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- Summary + publ. abstract expected 12/92 (Letter Sommar 10/92) Report requested (Letter LV 11/93),,,000910,IS - Clin Study (MIGRATED)
5133,0244-2055,244.2055,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5134,0244-2056,244.2056,Ended,239,0244-P00,Rhinitis vasomotor,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5135,0244-2057,244.2057,Unconfirmed,239,0244-P00,Rhinitis vasomotor,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5136,0244-2058,244.2058,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- (Letter LV. no reply)  / Summary expected 12/92 (Letter Sommar 10/92),,,000910,IS - Clin Study (MIGRATED)
5137,0244-2059,244.2059,Unconfirmed,239,0244-P00,Asthma acute,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5138,0244-2060,244.2060,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5139,0244-2061,244.2061,Unconfirmed,239,0244-P00,Rhinitis vasomotor,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5140,0244-2062,244.2062,Ended,239,0244-P00,Rhinitis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5141,0244-2063,244.2063,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5142,0244-2064,244.2064,Unconfirmed,239,0244-P00,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5143,0244-2065,244.2065,Unconfirmed,239,0244-P00,Bronchitis chronic smoking,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5144,0244-2066,244.2066,Unconfirmed,239,0244-P00,Bronchitis chronic smoking,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5145,0244-2067,244.2067,Unconfirmed,239,0244-P00,Bronchitis chronic smoking,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5146,0244-2068,244.2068,Unconfirmed,239,0244-P00,Bronchitis chronic smoking,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5147,0244-2069,244.2069,Unconfirmed,239,0244-P00,Bronchitis chronic smoking,Unconfirmed,MIG,Migration,II,Phase II,- planned patients: 16-20 * *,,,000910,IS - Clin Study (MIGRATED)
5148,0244-2071,244.2071,Unconfirmed,239,0244-P00,Bronchiolitis;Bronchitis;Pneumonia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5149,0244-2072,244.2072,Unconfirmed,239,0244-P00,Rhinitis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5150,0244-2073,244.2073,Unconfirmed,239,0244-P00,Glaucoma narrow angle minor;Glaucoma ang,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5151,0244-2074,244.2074,Unconfirmed,239,0244-P00,Rhinitis vasomotor,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5152,0244-2075,244.2075,Unconfirmed,239,0244-P00,Rhinitis vasomotor,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5153,0244-2076,244.2076,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5154,0244-2077,244.2077,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5155,0244-2078,244.2078,Unconfirmed,239,0244-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5156,0244-2079,244.2079,Unconfirmed,239,0244-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5157,0244-2085,244.2085,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5158,0244-2087,244.2087,Unconfirmed,239,0244-P00,Bronchitis chronic;Cold,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5159,0244-2088,244.2088,Unconfirmed,239,0244-P00,Bronchitis chronic;Cold,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5160,0244-2090,244.2090,Unconfirmed,239,0244-P00,COLD;Bronchitis chronic;Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5161,0244-2092,244.2092,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5162,0244-2093,244.2093,Unconfirmed,239,0244-P00,Rhinitis vasomotor,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5163,0244-2095,244.2095,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5164,0244-2097,244.2097,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- planned patients: 12-15 ** *,,,000910,IS - Clin Study (MIGRATED)
5165,0244-2098,244.2098,Unconfirmed,239,0244-P00,Rhinitis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5166,0244-2099,244.2099,Ended,239,0244-P00,Rhinitis vasomotor,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5167,0244-2100,244.2100,Ended,239,0244-P00,Rhinitis vasomotor,Ended,MIG,Migration,III,Phase III,- planned patients: 20-40 * *,,,000910,IS - Clin Study (MIGRATED)
5168,0244-2101,244.2101,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5169,0244-2102,244.2102,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5170,0244-2103,244.2103,Ended,239,0244-P00,Bronchitis chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5171,0244-2105,244.2105,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5172,0244-2107,244.2107,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5173,0244-2108,244.2108,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5174,0244-2109,244.2109,Ended,239,0244-P00,Cough irritative;Laryngitis viral,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5175,0244-2110,244.2110,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5176,0244-2111,244.2111,Ended,239,0244-P00,Bronchitis chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5177,0244-2113,244.2113,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5178,0244-2114,244.2114,Unconfirmed,239,0244-P00,Bronchitis,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5179,0244-2115,244.2115,Unconfirmed,239,0244-P00,Cough chronic,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5180,0244-2116,244.2116,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- planned patients: 16-30 * *,,,000910,IS - Clin Study (MIGRATED)
5181,0244-2117,244.2117,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5182,0244-2118,244.2118,Unconfirmed,239,0244-P00,Bronchospasm allergic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5183,0244-2119,244.2119,Ended,239,0244-P00,Bronchitis chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5184,0244-2120,244.2120,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5185,0244-2122,244.2122,Unconfirmed,239,0244-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5186,0244-2123,244.2123,Unconfirmed,239,0244-P00,Asthma;Bronchitis,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5187,0244-2124,244.2124,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5188,0244-2125,244.2125,Ended,239,0244-P00,Bronchitis chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5189,0244-2133,244.2133,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5190,0244-2134,244.2134,Ended,239,0244-P00,Rhinitis vasomotor,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5191,0244-2137,244.2137,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5192,0244-2138,244.2138,Ended,239,0244-P00,Asthma chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5193,0244-2139,244.2139,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- planned patients: 16-20 ** *,,,000910,IS - Clin Study (MIGRATED)
5194,0244-2140,244.2140,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5195,0244-2141,244.2141,Ended,239,0244-P00,Asthma;Hypersensitivity respiratory,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5196,0244-2142,244.2142,Ended,239,0244-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5197,0244-2144,244.2144,Ended,239,0244-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5198,0244-2145,244.2145,Ended,239,0244-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5199,0244-2146,244.2146,Unconfirmed,239,0244-P00,Asthma allergic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5200,0244-2147,244.2147,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5201,0244-2148,244.2148,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5202,0244-2150,244.2150,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5203,0244-2151,244.2151,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5204,0244-2154,244.2154,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5205,0244-2155,244.2155,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5206,0244-2156,244.2156,Unconfirmed,239,0244-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5207,0244-2158,244.2158,Unconfirmed,239,0244-P00,Fibrosis cystic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5208,0244-2159,244.2159,Ended,239,0244-P00,Cough, postivral,Ended,MIG,Migration,IV,Phase IV,- planned patients: 10-20 * *,,,000910,IS - Clin Study (MIGRATED)
5209,0244-2160,244.2160,Unconfirmed,239,0244-P00,Wheezing,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5210,0244-2161,244.2161,Ended,239,0244-P00,Rhinitis vasomotor,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5211,0244-2162,244.2162,Unconfirmed,239,0244-P00,Rhinitis perennial,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5212,0244-2163,244.2163,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5213,0244-2164,244.2164,Ended,239,0244-P00,Common-Cold,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5214,0244-2165,244.2165,Unconfirmed,239,0244-P00,Hypersensitivity respiratory,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5215,0244-2166,244.2166,Unconfirmed,239,0244-P00,Respiratory tract diseases,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5216,0244-2167,244.2167,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5217,0244-2168,244.2168,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- Dev.Prot.: 18 PATIENTS (6 F, 12 M). TWO PATIENTS WERE EXCLUDED FROM THE EVALUATION, BECAUSE THE DIFFERENCE FROM THE FEV *,,,000910,IS - Clin Study (MIGRATED)
5218,0244-2170,244.2170,Unconfirmed,239,0244-P00,Rhinitis vasomotor,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5219,0244-2171,244.2171,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5220,0244-2173,244.2173,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5221,0244-2174,244.2174,Ended,239,0244-P00,Fibrosis cystic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5222,0244-2175,244.2175,Unconfirmed,239,0244-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5223,0244-2176,244.2176,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5224,0244-2177,244.2177,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5225,0244-2178,244.2178,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5226,0244-2180,244.2180,Unconfirmed,239,0244-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5227,0244-2181,244.2181,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5228,0244-2182,244.2182,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- planned patients: 20-30 ** *,,,000910,IS - Clin Study (MIGRATED)
5229,0244-2184,244.2184,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5230,0244-2185,244.2185,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5231,0244-2186,244.2186,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5232,0244-2187,244.2187,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5233,0244-2188,244.2188,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5234,0244-2191,244.2191,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5235,0244-2193,244.2193,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5236,0244-2194,244.2194,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5237,0244-2196,244.2196,Ended,239,0244-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5238,0244-2197,244.2197,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5239,0244-2198,244.2198,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5240,0244-2199,244.2199,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5241,0244-2200,244.2200,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5242,0244-2201,244.2201,Unconfirmed,239,0244-P00,Bronchospasm,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5243,0244-2202,244.2202,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5244,0244-2203,244.2203,Unconfirmed,239,0244-P00,Hypersensitivity respiratory,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5245,0244-2204,244.2204,Unconfirmed,239,0244-P00,Hypersensitivity respiratory,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5246,0244-2205,244.2205,Unconfirmed,239,0244-P00,Hypersensitivity respiratory,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5247,0244-2207,244.2207,Unconfirmed,239,0244-P00,Bronchospasm;Bronchitis chronic;Bronchit,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5248,0244-2210,244.2210,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5249,0244-2212,244.2212,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5250,0244-2214,244.2214,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5251,0244-2215,244.2215,Ended,239,0244-P00,Bronchitis;Bronchitis chronic,Ended,MIG,Migration,III,Phase III,- No Report, data doubtful *,,,000910,IS - Clin Study (MIGRATED)
5252,0244-2216,244.2216,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5253,0244-2218,244.2218,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5254,0244-2219,244.2219,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5255,0244-2220,244.2220,Ended,239,0244-P00,Bronchitis chronic,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5256,0244-2221,244.2221,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5257,0244-2223,244.2223,Ended,239,0244-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5258,0244-2224,244.2224,Ended,239,0244-P00,Rhinitis perennial,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5259,0244-2227,244.2227,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5260,0244-2228,244.2228,Unconfirmed,239,0244-P00,Bronchitis chronic obstructive,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5261,0244-2229,244.2229,Unconfirmed,239,0244-P00,Bronchitis chronic obstructive,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5262,0244-2234,244.2234,Ended,239,0244-P00,Asthma;Bronchitis chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5263,0244-2235,244.2235,Ended,239,0244-P00,Rhinitis perennial,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5264,0244-2236,244.2236,Ended,239,0244-P00,Atrovent nasal vs steroid,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5265,0244-2237,244.2237,Ended,239,0244-P00,Rhinitis allergic perennial,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5266,0244-2238,244.2238,Unconfirmed,239,0244-P00,BPCO,Unconfirmed,MIG,Migration,III,Phase III,- Status E agreed by Dr. Hertkorn, 10.06.1997.,,,000910,IS - Clin Study (MIGRATED)
5267,0244-2239,244.2239,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5268,0244-2242,244.2242,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5269,0244-2243,244.2243,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5270,0244-2246,244.2246,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5271,0244-2248,244.2248,Ended,239,0244-P00,Bronchitis chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5272,0244-2250,244.2250,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5273,0244-2251,244.2251,Unconfirmed,239,0244-P00,Common-Cold,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5274,0244-2252,244.2252,Unconfirmed,239,0244-P00,none,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5275,0244-2253,244.2253,Unconfirmed,239,0244-P00,Common-Cold,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5276,0244-2255,244.2255,Unconfirmed,239,0244-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5277,0244-2258,244.2258,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5278,0244-2260,244.2260,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5279,0244-2261,244.2261,Ended,239,0244-P00,Rhinitis vasomotor,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5280,0244-2265,244.2265,Ended,239,0244-P00,COPD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5281,0244-2266,244.2266,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5282,0244-2268,244.2268,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5283,0244-2269,244.2269,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5284,0244-2270,244.2270,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5285,0244-2271,244.2271,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5286,0244-2272,244.2272,Ended,239,0244-P00,Bronchitis chronic;Asthma,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
5287,0244-2273,244.2273,Ended,239,0244-P00,COLD,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
5288,0244-2275,244.2275,Unconfirmed,239,0244-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5289,0244-2278,244.2278,Ended,239,0244-P00,COLD,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
5290,0244-2279,244.2279,Ended,239,0244-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5291,0244-2280,244.2280,Ended,239,0244-P00,Rhinitis allergic;Rhinitis vasomotor,Ended,MIG,Migration,III,Phase III,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
5292,0244-2281,244.2281,Ended,239,0244-P00,Airway obstruction,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5293,0244-2282,244.2282,Ended,239,0244-P00,Rhinitis allergic;Rhinitis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5294,0244-2286,244.2286,Ended,239,0244-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5295,0244-2289,244.2289,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5296,0244-2293,244.2293,Ended,239,0244-P00,IPRATROPIUM VS VENTOLINE IN ACUTE ASTHMA,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5297,0244-2295,244.2295,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5298,0244-2296,244.2296,Unconfirmed,239,0244-P00,Asthma acute,Unconfirmed,MIG,Migration,IV,Phase IV,- OPU: DPT FHER YV ** Dev.Prot.: ONLY SIX PATIENTS WERE INCLUDED. ONE PATIENT IS NOT INCLUDED IN THE ANALYSIS BECAUSE HE DID NOT RECEIVE PROP *,,,000910,IS - Clin Study (MIGRATED)
5299,0244-2298,244.2298,Ended,239,0244-P00,Obstructive bronchitis,Ended,MIG,Migration,IV,Phase IV,- Data analysis by investigator. No report date yet available.,,,000910,IS - Clin Study (MIGRATED)
5300,0244-2299,244.2299,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5301,0244-2300,244.2300,Ended,239,0244-P00,none,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5302,0244-2302,244.2302,Ended,239,0244-P00,Rhinitis allergic;Rhinitis vasomotor,Ended,MIG,Migration,III,Phase III,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
5303,0244-2303,244.2303,Ended,239,0244-P00,LONG TERM OPEN STUDY,Ended,MIG,Migration,III,Phase III,- Summary,,,000910,IS - Clin Study (MIGRATED)
5304,0244-2304,244.2304,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5305,0244-2305,244.2305,Ended,239,0244-P00,Asthma;Bronchitis chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5306,0244-2306,244.2306,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5307,0244-2307,244.2307,Ended,239,0244-P00,Asthma/Inhalator vs DA,Ended,MIG,Migration,III,Phase III,- Report requested (Letter LV 11/93) Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
5308,0244-2308,244.2308,Ended,239,0244-P00,Asthma/Inhalator,Ended,MIG,Migration,III,Phase III,- Report requested (Letter LV 11/93) Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
5309,0244-2309,244.2309,Ended,239,0244-P00,Rhinitis allergic perennial;Fever;Rhinit,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5310,0244-2310,244.2310,Ended,239,0244-P00,Asthma (pediatric),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5311,0244-2313,244.2313,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5312,0244-2314,244.2314,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5313,0244-2315,244.2315,Ended,239,0244-P00,Bronchitis,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5314,0244-2316,244.2316,Ended,239,0244-P00,Rhinitis perennial,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5315,0244-2317,244.2317,Ended,239,0244-P00,COLD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5316,0244-2318,244.2318,Unconfirmed,239,0244-P00,Airways obstruction,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5317,0244-2319,244.2319,Ended,239,0244-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5318,0244-2320,244.2320,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5319,0244-2321,244.2321,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5320,0244-2322,244.2322,Ended,239,0244-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5321,0244-2323,244.2323,Ended,239,0244-P00,Rhinitis allergic;Rhinitis vasomotor,Ended,MIG,Migration,III,Phase III,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
5322,0244-2324,244.2324,Unconfirmed,239,0244-P00,Rhinitis allergic;Rhinitis,Unconfirmed,MIG,Migration,II,Phase II,- Report available 12/92 (Letter Maria 09.10.92)/ Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
5323,0244-2326,244.2326,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5324,0244-2327,244.2327,Ended,239,0244-P00,none,Ended,MIG,Migration,I,Phase I,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
5325,0244-2328,244.2328,Unconfirmed,239,0244-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5326,0244-2329,244.2329,Ended,239,0244-P00,COPD,Ended,MIG,Migration,III,Phase III,- 30 pat. according protocol,20 pat.acc.simplified protocol.  only 2 study days. *,,,000910,IS - Clin Study (MIGRATED)
5327,0244-2330,244.2330,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5328,0244-2331,244.2331,Ended,239,0244-P00,Bronchitis chronic;Emphysema pulmonary,Ended,MIG,Migration,IV,Phase IV,- planned patients:20-30 * */ Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
5329,0244-2332,244.2332,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5330,0244-2333,244.2333,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5331,0244-2335,244.2335,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- planned patients: 25-30 * *,,,000910,IS - Clin Study (MIGRATED)
5332,0244-2336,244.2336,Ended,239,0244-P00,Rhinitis,Ended,MIG,Migration,IV,Phase IV,- planned patients: 30-40 * *,,,000910,IS - Clin Study (MIGRATED)
5333,0244-2337,244.2337,Unconfirmed,239,0244-P00,Bronchitis chronic;Emphysema pulmonary,Unconfirmed,MIG,Migration,NONE,Not Classified,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
5334,0244-2338,244.2338,Ended,239,0244-P00,Rhinitis, allergic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5335,0244-2339,244.2339,Unconfirmed,239,0244-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5336,0244-2340,244.2340,Ended,239,0244-P00,Airways obstruction,Ended,MIG,Migration,IV,Phase IV,- Report requested (Fax 1/93 Dr. LV),,,000910,IS - Clin Study (MIGRATED)
5337,0244-2341,244.2341,Ended,239,0244-P00,Safety,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5338,0244-2342,244.2342,Ended,239,0244-P00,Rhinitis perennial,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5339,0244-2343,244.2343,Ended,239,0244-P00,Safety,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5340,0244-2350,244.2350,Ended,239,0244-P00,Dose response,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5341,0244-2351,244.2351,Ended,239,0244-P00,Asthma, exercise induced,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5342,0244-2352,244.2352,Ended,239,0244-P00,Rhinitis in tracheotomia,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5343,0244-2353,244.2353,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5344,0244-2354,244.2354,Ended,239,0244-P00,Tolerance of ipratropium bromide powder.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5345,0244-2355,244.2355,Ended,239,0244-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5346,0244-2356,244.2356,Ended,239,0244-P00,Chronic bronchitis,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5347,0244-2357,244.2357,Ended,239,0244-P00,High dose,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5348,0244-2358,244.2358,Ended,239,0244-P00,Comparison MDI vs MDI+aerochamber,Ended,MIG,Migration,IV,Phase IV,- Aerochamber * *,,,000910,IS - Clin Study (MIGRATED)
5349,0244-2359,244.2359,Ended,239,0244-P00,Spirometry vs impedance,Ended,MIG,Migration,IV,Phase IV,- Study will be repeated because of protocol violations. * *,,,000910,IS - Clin Study (MIGRATED)
5350,0244-2363,244.2363,Ended,239,0244-P00,COLD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5351,0244-2364,244.2364,Ended,239,0244-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5352,0244-2365,244.2365,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5353,0244-2367,244.2367,Ended,239,0244-P00,ADJUNCT TREATMENT DYSPNEA COPD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5354,0244-2370,244.2370,Ended,239,0244-P00,nasal/marketing study,Ended,MIG,Migration,IV,Phase IV,- EF Study,,,000910,IS - Clin Study (MIGRATED)
5355,0244-2371,244.2371,Ended,239,0244-P00,Asthma, exercise induced,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5356,0244-2372,244.2372,Ended,239,0244-P00,FO2-Study,Ended,MIG,Migration,III,Phase III,- Summary expected 12/92  / Report requested (Letter LV 11/93),,,000910,IS - Clin Study (MIGRATED)
5357,0244-2374,244.2374,Ended,239,0244-P00,Rhinitis, vasomotor,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5358,0244-2375,244.2375,Ended,239,0244-P00,HEMODYNAMICS ATROVENT/VENTOLIN IN COPD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5359,0244-2376,244.2376,Ended,239,0244-P00,Atrovent vs salbutamol,Ended,MIG,Migration,IV,Phase IV,- ,,,,
5360,0244-2377,244.2377,Ended,239,0244-P00,Atrovent in CAL-QOL,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5361,0244-2378,244.2378,Ended,239,0244-P00,Cough induced by bronchoscopy,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5362,0244-2379,244.2379,Ended,239,0244-P00,Fenot., Duovent and Teophylline in COPD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5363,0244-2380,244.2380,Unconfirmed,239,0244-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,,
5364,0244-2381,244.2381,Ended,239,0244-P00,COPD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5365,0244-2382,244.2382,Unconfirmed,239,0244-P00,SPICY FOOD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5366,0244-2383,244.2383,Ended,239,0244-P00,SALIVATION IN NORMAL SUBJECTS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5367,0244-2389,244.2389,Ended,239,0244-P00,Laryngotracheobronchitis,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
5368,0244-2392,244.2392,Ended,239,0244-P00,ATROVENT IN COPD,Ended,MIG,Migration,IV,Phase IV,- Theophylline, salbutamol, and beclomethasone wre also tested for efficacy in individual patients using the N-of-1 method,,,,
5369,0244-2393,244.2393,Ended,239,0244-P00,PREVENTION OF COPD BY ATROVENT,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5370,0244-2394,244.2394,Unconfirmed,239,0244-P00,Clinical trial of Atrovent aerosol,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5371,0244-2395,244.2395,Ended,239,0244-P00,ATROVENT/VENTOLIN IN BRONCHIOLITIS,Ended,MIG,Migration,III,Phase III,- Due to very slow enrollment the study was terminated early with 62 patients completing the study out of the planned 360.,,,,
5372,0244-2396,244.2396,Ended,239,0244-P00,EFFECT ON PEAK INSPIRATORY PRESSURE IN C,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5373,0244-2397,244.2397,Ended,239,0244-P00,Bronchitis, chronic,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
5374,0244-2398,244.2398,Ended,239,0244-P00,Bronchitis, chronic,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
5375,0244-2401,244.2401,Unconfirmed,239,0244-P00,COPD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5376,0244-2404,244.2404,Ended,239,0244-P00,Comp. Atr/decong/combination,Ended,MIG,Migration,II,Phase II,-  Investigator needs initiation by Jan. 7, 1993 to accept protocol. Will review priorities with Pharmaceutics to try to accomodate.     ,,,000910,IS - Clin Study (MIGRATED)
5377,0244-2407,244.2407,Ended,239,0244-P00,Ipratropium Bromide in chronic cough,Ended,MIG,Migration,IV,Phase IV,- Report date requested (Brf. LV 10/92),,,000910,IS - Clin Study (MIGRATED)
5378,0244-2408,244.2408,Unconfirmed,239,0244-P00,COPD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5379,0244-2409,244.2409,Ended,239,0244-P00,Atrovent - cost effective study,Ended,MIG,Migration,IV,Phase IV,- Final Report end 1992,,,000910,IS - Clin Study (MIGRATED)
5380,0244-2411,244.2411,Ended,239,0244-P00,Nebulized combination of ipratr.bro. and,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5381,0244-2412,244.2412,Ended,239,0244-P00,Nebulized ipratropium-bromide in acute,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5382,0244-2420,244.2420,Ended,239,0244-P00,Wheeze, Symptomatic,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5383,0244-2421,244.2421,Ended,239,0244-P00,Ipratropium bromide in acute asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,,
5384,0244-2424,244.2424,Ended,239,0244-P00,SEVERE ACUTE ASTHMA,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5385,0244-2425,244.2425,Ended,239,0244-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,,
5386,0244-2426,244.2426,Ended,239,0244-P00,Electric vagal stimulation in humans,Ended,MIG,Migration,NONE,Not Classified,- ,,,,
5387,0244-2427,244.2427,Ended,239,0244-P00,Single dose-emergency,Ended,MIG,Migration,IIIB,Phase IIIb,-    BUDGET EXPLAN: SEE MEMO TO WM 11/02/92   ,,,000910,IS - Clin Study (MIGRATED)
5388,0244-2429,244.2429,Ended,239,0244-P00,Bronchiolitis,Ended,MIG,Migration,IV,Phase IV,- ,,,,
5389,0244-2430,244.2430,Ended,239,0244-P00,ATROVENT/SALBUTAMOL PEDIATRIC STUDY,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5390,0244-2432,244.2432,Ended,239,0244-P00,IPRATROPIUM-BROMIDE IN ELDERLY PATIENTS,Ended,MIG,Migration,III,Phase III,- (Letter SCH),,,000910,IS - Clin Study (MIGRATED)
5391,0244-2433,244.2433,Ended,239,0244-P00,Airway Echogram,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
5392,0244-2444,244.2444,Ended,239,0244-P00,Therap. equivalence of Atrovent forte,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5393,0244-2449,244.2449,Ended,239,0244-P00,UDVs,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5394,0244-2458,244.2458,Ended,239,0244-P00,COPD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5395,0244-2459,244.2459,Ended,239,0244-P00,Vasomotor Rhinitis,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5396,0244-2471,244.2471,Ended,239,0244-P00,Severe acute bronchial obstruction,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
5397,0244-2476,244.2476,Initiated,239,0244-P00,Metacholine-induced bronchoconstriction,Initiated,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
5398,0244-2488,244.2488,Preparing,239,0244-P00,Atrovent UDV in VCD,Preparing,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5399,0244-2490,244.2490,Ended,239,0244-P00,COPD - PMS-I,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5400,0244-2491,244.2491,Ended,239,0244-P00,COPD - PMS-II,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5401,0244-2492,244.2492,Ended,239,0244-P00,COPD, PMS III,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5402,0244-2493,244.2493,Ended,239,0244-P00,Tolerability and Efficacy,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5403,0244-2496,244.2496,Ended,239,0244-P00,Atrovent Inh., 12 month, Safety+Efficacy,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5404,0244-2497,244.2497,Ended,239,0244-P00,Atrovent Inh., 4 weeks, Safety + Effic.,Ended,MIG,Migration,IV,Phase IV,Generated on request from Ms. B. Weeser ,,,000940,Post Marketing Study (MIGRATED)
5405,0244-2499,244.2499,Ended,239,0244-P00,Atrov.UDV/Ventilat Inh.-Prescr.Antichol.,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5406,0244-2500,244.2500,Ended,239,0244-P00,Atrovent UDV, 4 weeks, Safety + Efficacy,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5407,0244-2501,244.2501,Ended,239,0244-P00,Atrovent Inh., 4 weeks, Safety + Effic.,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5408,0244-2502,244.2502,Ended,239,0244-P00,Atrovent Inh., 3 month, Safety +Efficacy,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5409,0244-2505,244.2505,Ended,239,0244-P00,Grimfeld,Ended,MIG,Migration,NONE,Not Classified,,,,000940,Post Marketing Study (MIGRATED)
5410,0244-2506,244.2506,Ended,239,0244-P00,IIS: Acute bronchitis,Ended,MIG,Migration,IV,Phase IV,,,,,
5411,0244-2508,244.2508,Ended,239,0244-P00,IIS:Anticholinergics in Tetraplegia,Ended,MIG,Migration,IV,Phase IV,,,,,
5412,0244-2511,244.2511,Ended,239,0244-P00,Comparison of exercise challenges,Ended,MIG,Migration,IV,Phase IV,This is an IIS (Dr. Maltais, Montreal) ,,,,
5413,0244-2513,244.2513,Ended,239,0244-P00,Step-test and ESWT responsiveness,Ended,MIG,Migration,II,Phase II,IIS study To determine sensitivity of step test and shuttle walk test using nebulised placebo and Atrovent,,,,
5414,0244-2514,244.2514,Ended,239,0244-P00,IPO-COPD study,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
5415,0244-0502,244.502,Unconfirmed,240,0244-P25,Acute asthma,Unconfirmed,MIG,Migration,III,Phase III,- inserted by gerken at 22.06.93,,,000910,IS - Clin Study (MIGRATED)
5416,0244-2000,244.2000,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5417,0244-2001,244.2001,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5418,0244-2002,244.2002,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5419,0244-2003,244.2003,Ended,240,0244-P25,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5420,0244-2004,244.2004,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5421,0244-2010,244.2010,Unconfirmed,240,0244-P25,Asthma;Cold,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5422,0244-2013,244.2013,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5423,0244-2015,244.2015,Ended,240,0244-P25,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5424,0244-2016,244.2016,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- Planned patients:15-20 * *,,,000910,IS - Clin Study (MIGRATED)
5425,0244-2017,244.2017,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5426,0244-2018,244.2018,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5427,0244-2019,244.2019,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5428,0244-2023,244.2023,Unconfirmed,240,0244-P25,Asthma chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5429,0244-2028,244.2028,Unconfirmed,240,0244-P25,Asthma;Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5430,0244-2029,244.2029,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5431,0244-2030,244.2030,Ended,240,0244-P25,Asthma;Bronchitis chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5432,0244-2031,244.2031,Ended,240,0244-P25,Asthma;Bronchitis chronic obstructive,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5433,0244-2032,244.2032,Ended,240,0244-P25,Asthma nocturnal,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5434,0244-2034,244.2034,Unconfirmed,240,0244-P25,Asthma chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5435,0244-2035,244.2035,Ended,240,0244-P25,Asthma chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5436,0244-2037,244.2037,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- Part two of a trial. Part one is 850175 *,,,000910,IS - Clin Study (MIGRATED)
5437,0244-2038,244.2038,Ended,240,0244-P25,Asthma;Bronchitis chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5438,0244-2039,244.2039,Unconfirmed,240,0244-P25,Asthma;Bronchial chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5439,0244-2045,244.2045,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5440,0244-2051,244.2051,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5441,0244-2080,244.2080,Unconfirmed,240,0244-P25,Asthma;Cold,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5442,0244-2081,244.2081,Unconfirmed,240,0244-P25,Asthma;Cold,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5443,0244-2082,244.2082,Unconfirmed,240,0244-P25,Asthma;Cold,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5444,0244-2083,244.2083,Ended,240,0244-P25,Asthma;Cold,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5445,0244-2084,244.2084,Unconfirmed,240,0244-P25,Asthma;Cold,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5446,0244-2086,244.2086,Unconfirmed,240,0244-P25,COLD;Asthma;Bronchitis,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5447,0244-2089,244.2089,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5448,0244-2091,244.2091,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5449,0244-2094,244.2094,Unconfirmed,240,0244-P25,Asthma allergic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5450,0244-2096,244.2096,Unconfirmed,240,0244-P25,Asthma;Rhinitis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5451,0244-2104,244.2104,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5452,0244-2106,244.2106,Unconfirmed,240,0244-P25,Bronchitis chronic;Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5453,0244-2112,244.2112,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5454,0244-2121,244.2121,Unconfirmed,240,0244-P25,Asthma;Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5455,0244-2126,244.2126,Ended,240,0244-P25,Asthma chronic;Bronchitis,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5456,0244-2127,244.2127,Ended,240,0244-P25,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5457,0244-2128,244.2128,Unconfirmed,240,0244-P25,Asthma;Bronchitis chronic;Emphysema pulm,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5458,0244-2129,244.2129,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5459,0244-2130,244.2130,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5460,0244-2131,244.2131,Ended,240,0244-P25,Asthma chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5461,0244-2132,244.2132,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5462,0244-2135,244.2135,Ended,240,0244-P25,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5463,0244-2136,244.2136,Ended,240,0244-P25,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5464,0244-2143,244.2143,Ended,240,0244-P25,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5465,0244-2149,244.2149,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5466,0244-2152,244.2152,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5467,0244-2153,244.2153,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5468,0244-2157,244.2157,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5469,0244-2179,244.2179,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5470,0244-2183,244.2183,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5471,0244-2189,244.2189,Unconfirmed,240,0244-P25,Asthma chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5472,0244-2190,244.2190,Unconfirmed,240,0244-P25,Asthma;Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5473,0244-2192,244.2192,Unconfirmed,240,0244-P25,Asthma allergic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5474,0244-2195,244.2195,Ended,240,0244-P25,Bronchitis chronic;Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5475,0244-2206,244.2206,Unconfirmed,240,0244-P25,Asthma;Bronchitis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5476,0244-2208,244.2208,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5477,0244-2209,244.2209,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5478,0244-2211,244.2211,Ended,240,0244-P25,Asthma,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5479,0244-2213,244.2213,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5480,0244-2217,244.2217,Unconfirmed,240,0244-P25,Asthma chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5481,0244-2222,244.2222,Ended,240,0244-P25,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5482,0244-2225,244.2225,Ended,240,0244-P25,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5483,0244-2233,244.2233,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5484,0244-2240,244.2240,Ended,240,0244-P25,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5485,0244-2241,244.2241,Ended,240,0244-P25,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5486,0244-2244,244.2244,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5487,0244-2247,244.2247,Unconfirmed,240,0244-P25,Asthma chronic,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
5488,0244-2249,244.2249,Unconfirmed,240,0244-P25,Asthma exercise induced,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
5489,0244-2256,244.2256,Unconfirmed,240,0244-P25,Asthma;Bronchiectasis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5490,0244-2257,244.2257,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5491,0244-2259,244.2259,Ended,240,0244-P25,Asthma,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5492,0244-2262,244.2262,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5493,0244-2263,244.2263,Ended,240,0244-P25,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5494,0244-2267,244.2267,Unconfirmed,240,0244-P25,Asthma chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5495,0244-2274,244.2274,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
5496,0244-2276,244.2276,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
5497,0244-2277,244.2277,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5498,0244-2283,244.2283,Ended,240,0244-P25,Asthma chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5499,0244-2284,244.2284,Ended,240,0244-P25,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5500,0244-2285,244.2285,Ended,240,0244-P25,Asthma;Bronchitis chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5501,0244-2287,244.2287,Ended,240,0244-P25,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5502,0244-2288,244.2288,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5503,0244-2290,244.2290,Ended,240,0244-P25,Viral & post viral bronchitis,Ended,MIG,Migration,III,Phase III,-  Dr. J. Golden is co-investigator with Dr. Baron.     ,,,000910,IS - Clin Study (MIGRATED)
5504,0244-2292,244.2292,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5505,0244-2294,244.2294,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5506,0244-2297,244.2297,Ended,240,0244-P25,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5507,0244-2301,244.2301,Unconfirmed,240,0244-P25,Asthma bronchitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5508,0244-2311,244.2311,Ended,240,0244-P25,Asthma exercise induced,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5509,0244-2312,244.2312,Ended,240,0244-P25,Comp. w/ Alupent,Ended,MIG,Migration,III,Phase III,-  Formerly IIId1.     ,,,000910,IS - Clin Study (MIGRATED)
5510,0244-2325,244.2325,Ended,240,0244-P25,Asthma, gastroesophageal reflux,Ended,MIG,Migration,IV,Phase IV,- Report expected 12/92 (Letter Maria 09.10.92),,,000910,IS - Clin Study (MIGRATED)
5511,0244-2334,244.2334,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5512,0244-2345,244.2345,Ended,240,0244-P25,Comp. w/ theophylline,Ended,MIG,Migration,III,Phase III,-  Formerly IIIh2.     ,,,000910,IS - Clin Study (MIGRATED)
5513,0244-2346,244.2346,Ended,240,0244-P25,Add-on for chronic asthma,Ended,MIG,Migration,III,Phase III,-  Report on "hold" pending availability of statistician.     ,,,000910,IS - Clin Study (MIGRATED)
5514,0244-2360,244.2360,Ended,240,0244-P25,3-week pivotal trial,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
5515,0244-2366,244.2366,Ended,240,0244-P25,Pediatric dosing,Ended,MIG,Migration,III,Phase III,-  As of 9/24/91, no statistician has been assigned.     ,,,000910,IS - Clin Study (MIGRATED)
5516,0244-2390,244.2390,Unconfirmed,240,0244-P25,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5517,0244-2413,244.2413,Ended,240,0244-P25,Nebulized ipratropium in young children,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5518,0244-2414,244.2414,Unconfirmed,240,0244-P25,The Effect of age on the efficacy of ast,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5519,0244-2431,244.2431,Ended,240,0244-P25,beta-agonist sparing effect of Atrovent,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5520,0244-2472,244.2472,Unconfirmed,240,0244-P25,Tolerance and efficacy ,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5521,0244-2510,244.2510,Ended,240,0244-P25,IIS: LARGE-LABA Response by Genotype,Ended,MIG,Migration,III,Phase III,,,,,
5522,0246-0206,246.206,Unconfirmed,241,0246-P00,Efficacy, low purin diat,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5523,0246-0207,246.207,Unconfirmed,241,0246-P00,Efficacy, duration of effect,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5524,0246-0208,246.208,Unconfirmed,241,0246-P00,Efficacy, duration of effect,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5525,0246-0209,246.209,Unconfirmed,241,0246-P00,Efficacy, low purin diat,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5526,0246-0210,246.210,Unconfirmed,241,0246-P00,Efficacy, low purin diat,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5527,0246-0211,246.211,Unconfirmed,241,0246-P00,Efficacy, low purin diat,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5528,0246-0213,246.213,Ended,241,0246-P00,Efficay,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5529,0246-0300,246.300,Ended,241,0246-P00,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5530,0246-0301,246.301,Unconfirmed,241,0246-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5531,0246-0302,246.302,Unconfirmed,241,0246-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5532,0246-0303,246.303,Unconfirmed,241,0246-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5533,0246-0304,246.304,Unconfirmed,241,0246-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5534,0246-0305,246.305,Unconfirmed,241,0246-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5535,0246-0306,246.306,Ended,241,0246-P00,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5536,0246-0307,246.307,Ended,241,0246-P00,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5537,0246-0308,246.308,Unconfirmed,241,0246-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5538,0246-0309,246.309,Unconfirmed,241,0246-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5539,0246-0310,246.310,Unconfirmed,241,0246-P00,Rhinitis allergic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5540,0246-0311,246.311,Unconfirmed,241,0246-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5541,0246-0312,246.312,Unconfirmed,241,0246-P00,Asthma;Bronchitis chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5542,0246-0313,246.313,Unconfirmed,241,0246-P00,Rhinitis allergic perennial,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5543,0246-0314,246.314,Unconfirmed,241,0246-P00,Rhinitis allergic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5544,0246-0315,246.315,Unconfirmed,241,0246-P00,gegen Placebo (Multicenter),Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5545,0246-0316,246.316,Unconfirmed,241,0246-P00,Rhinitis allergic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5546,0246-0317,246.317,Unconfirmed,241,0246-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5547,0246-0318,246.318,Unconfirmed,241,0246-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5548,0246-0319,246.319,Ended,241,0246-P00,Asthma allergic,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5549,0246-0320,246.320,Unconfirmed,241,0246-P00,Asthma allergic;Bronchitis,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5550,0246-0321,246.321,Unconfirmed,241,0246-P00,Asthma allergic;Bronchitis,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5551,0246-0322,246.322,Ended,241,0246-P00,Allergie-Prophylaxe, Multicenterpr√ºfung,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5552,0246-0323,246.323,Unconfirmed,241,0246-P00,Rhinitis allergic seasonal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
5553,0246-0324,246.324,Unconfirmed,241,0246-P00,Dermatitis allergic contact,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
5554,0246-0325,246.325,Ended,241,0246-P00,Asthma allergic;Bronchitis,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5555,0246-0326,246.326,Unconfirmed,241,0246-P00,Asthma allergic;Bronchitis;Rhinitis alle,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5556,0246-0327,246.327,Unconfirmed,241,0246-P00,Bronchospasm allergen induced;Asthma all,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5557,0246-0328,246.328,Unconfirmed,241,0246-P00,Asthma allergic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5558,0246-0329,246.329,Unconfirmed,241,0246-P00,Asthma allergic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5559,0246-0330,246.330,Ended,241,0246-P00,ALLERGIC RHINITIS,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
5560,0246-0331,246.331,Ended,241,0246-P00,ALLERGIC RHINITIS,Ended,MIG,Migration,II,Phase II,-  Dr. Marcoux is co-investigator.     ,,,000910,IS - Clin Study (MIGRATED)
5561,0246-0332,246.332,Ended,241,0246-P00,Conjunctivitis allergic seasonal,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5562,0246-0333,246.333,Ended,241,0246-P00,Hyperuricemia,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5563,0246-0334,246.334,Unconfirmed,241,0246-P00,Rhinitis allergic seasonal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5564,0246-0335,246.335,Unconfirmed,241,0246-P00,(KG-trial, see S255 in CICS2),Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5565,0246-0336,246.336,Unconfirmed,241,0246-P00,(KG-trial, see S255 in CICS2),Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5566,0246-0337,246.337,Ended,241,0246-P00,Efficacy ,low purin diat,Ended,MIG,Migration,II,Phase II,- *Ingelheim trial,,,000910,IS - Clin Study (MIGRATED)
5567,0246-0339,246.339,Ended,241,0246-P00,Allergie-Prophylaxe, 12-Wochen-Studie,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5568,0246-0340,246.340,Unconfirmed,241,0246-P00,Vertr√§glichk. (Augentr.) bei Probanden,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5569,0246-0341,246.341,Ended,241,0246-P00,Pilotstudie: Wirks. w√§√ürige 5% L√∂sung,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5570,0246-0342,246.342,Unconfirmed,241,0246-P00,Internat.multizentr. Studie (Nasalspray),Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5571,0246-0343,246.343,Ended,241,0246-P00,Pilotstudie: Wirks. 2% L√∂sung,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5572,0246-0344,246.344,Ended,241,0246-P00,Nasenspray bei allergischer Rhinitis,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5573,0246-0345,246.345,Ended,241,0246-P00,Vertr√§glichk. (Nasenspray) bei Probanden,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5574,0253-2112,253.2112,Unconfirmed,242,0253-P06,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5575,0253-2125,253.2125,Unconfirmed,242,0253-P06,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5576,0253-2131,253.2131,Ended,242,0253-P06,Schizophrenia/Dyskinesia,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5577,0253-2132,253.2132,Ended,242,0253-P06,Menopausal flushing,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5578,0253-2192,253.2192,Ended,242,0253-P06,Hypertension,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5579,0253-2203,253.2203,Unconfirmed,242,0253-P06,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5580,0253-2209,253.2209,Unconfirmed,242,0253-P06,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
5581,0253-2225,253.2225,Unconfirmed,242,0253-P06,Hypertension renal failure minor,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
5582,0253-2248,253.2248,Ended,242,0253-P06,Hypertension, diabetics,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5583,0253-2254,253.2254,Unconfirmed,242,0253-P06,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5584,0253-2255,253.2255,Ended,242,0253-P06,Nicotine withdrawal,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5585,0253-2256,253.2256,Ended,242,0253-P06,Premenstrual syndrome,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5586,0253-2331,253.2331,Ended,242,0253-P06,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5587,0253-2350,253.2350,Ended,242,0253-P06,Prototype comparison,Ended,MIG,Migration,I,Phase I,-  As a result of this study, a subtable prototype was selected  for further development.     ,,,000910,IS - Clin Study (MIGRATED)
5588,0253-2359,253.2359,Ended,242,0253-P06,Multiple dose PK,Ended,MIG,Migration,I,Phase I,-  Final report circulated for signatures.     ,,,000910,IS - Clin Study (MIGRATED)
5589,0253-2362,253.2362,Ended,242,0253-P06,Single dose PK,Ended,MIG,Migration,I,Phase I,-  Final report circulated for signatures.     ,,,000910,IS - Clin Study (MIGRATED)
5590,0253-2363,253.2363,Ended,242,0253-P06,Hypertension,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5591,0253-2388,253.2388,Ended,242,0253-P06,Pharmacodynamic trial,Ended,MIG,Migration,II,Phase II,-  Draft report 9/15/91     ,,,000910,IS - Clin Study (MIGRATED)
5592,0260-0691,260.691,Unconfirmed,243,0260-P09,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5593,0260-0701,260.701,Ended,243,0260-P09,Efficacy, low dose,Ended,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5594,0260-0702,260.702,Ended,243,0260-P09,Prophylact. effect, low dose,Ended,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5595,0260-0703,260.703,Ended,243,0260-P09,Low dose, curativ, acute,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5596,0260-0704,260.704,Ended,243,0260-P09,Beta-Recept./lymphoc, DNCG,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5597,0260-0705,260.705,Ended,243,0260-P09,Protective effect, histamine challenge,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5598,0260-0706,260.706,Ended,243,0260-P09,Protective effect, metachol. challenge,Ended,MIG,Migration,III,Phase III,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5599,0260-0707,260.707,Ended,243,0260-P09,Protective effect, Carbacholprovokation,Ended,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5600,0260-0708,260.708,Ended,243,0260-P09,Protective effect,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5601,0260-0709,260.709,Ended,243,0260-P09,Protective effect,Ended,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5602,0260-0710,260.710,Ended,243,0260-P09,Protective effect,Ended,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5603,0260-0711,260.711,Ended,243,0260-P09,Protective effect, allergen challenge,Ended,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5604,0260-0712,260.712,Preparing,243,0260-P09,Protective effect, allergen provocation,Preparing,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5605,0260-0713,260.713,Preparing,243,0260-P09,Protective effect, allergen provocation,Preparing,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5606,0260-0714,260.714,Ended,243,0260-P09,Low dose, curative, acute,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5607,0260-0715,260.715,Ended,243,0260-P09,Low dose, curative, acute,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5608,0260-0716,260.716,Ended,243,0260-P09,Beta-recept./Lymphoc,Ended,MIG,Migration,III,Phase III,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5609,0260-0717,260.717,Unconfirmed,243,0260-P09,Beta-recept./Lymphoc,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5610,0260-0718,260.718,Unconfirmed,243,0260-P09,Cumulative dose-effect, time course,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5611,0260-1001,260.1001,Ended,243,0260-P09,Effectiveness,Ended,MIG,Migration,IV,Phase IV,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5612,0260-1002,260.1002,Preparing,243,0260-P09,Effectiveness,Preparing,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5613,0260-1003,260.1003,Ended,243,0260-P09,Effectiveness,Ended,MIG,Migration,IV,Phase IV,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5614,0260-3006,260.3006,Unconfirmed,243,0260-P09,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- PLanned patients:5-10 * *,,,000910,IS - Clin Study (MIGRATED)
5615,0260-3016,260.3016,Ended,243,0260-P09,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5616,0260-3018,260.3018,Ended,243,0260-P09,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5617,0260-3020,260.3020,Unconfirmed,243,0260-P09,Asthma;Bronchitis;Emphysema pulmonary,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5618,0260-3021,260.3021,Unconfirmed,243,0260-P09,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5619,0260-3022,260.3022,Unconfirmed,243,0260-P09,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5620,0260-3023,260.3023,Unconfirmed,243,0260-P09,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5621,0260-3027,260.3027,Unconfirmed,243,0260-P09,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5622,0260-3028,260.3028,Unconfirmed,243,0260-P09,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5623,0260-3030,260.3030,Unconfirmed,243,0260-P09,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5624,0260-3038,260.3038,Ended,243,0260-P09,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5625,0260-3039,260.3039,Ended,243,0260-P09,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5626,0260-3040,260.3040,Ended,243,0260-P09,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5627,0260-3043,260.3043,Ended,243,0260-P09,Asthma;Cold,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5628,0260-3044,260.3044,Ended,243,0260-P09,ASTHMA/BRONCHITIS,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
5629,0260-3046,260.3046,Unconfirmed,243,0260-P09,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5630,0260-3049,260.3049,Unconfirmed,243,0260-P09,Asthma;Bronchitis;Emphysema pulmonary,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5631,0260-3050,260.3050,Unconfirmed,243,0260-P09,Bronchitis chronic obstructive,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5632,0260-3052,260.3052,Ended,243,0260-P09,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5633,0260-3058,260.3058,Unconfirmed,243,0260-P09,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5634,0260-3060,260.3060,Unconfirmed,243,0260-P09,Asthma chronic;Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5635,0260-3076,260.3076,Ended,243,0260-P09,Bronchitis chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5636,0260-3083,260.3083,Unconfirmed,243,0260-P09,Bronchitis chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5637,0260-3086,260.3086,Unconfirmed,243,0260-P09,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5638,0260-3091,260.3091,Unconfirmed,243,0260-P09,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5639,0260-3102,260.3102,Ended,243,0260-P09,ASTHMA/BRONCHITIS,Ended,MIG,Migration,III,Phase III,-  PILOT STUDY     ,,,000910,IS - Clin Study (MIGRATED)
5640,0260-3103,260.3103,Ended,243,0260-P09,ASTHMA/BRONCHITIS,Ended,MIG,Migration,III,Phase III,-  PILOT STUDY     ,,,000910,IS - Clin Study (MIGRATED)
5641,0260-3106,260.3106,Ended,243,0260-P09,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5642,0260-3108,260.3108,Unconfirmed,243,0260-P09,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5643,0260-3110,260.3110,Ended,243,0260-P09,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5644,0260-3114,260.3114,Unconfirmed,243,0260-P09,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5645,0260-3115,260.3115,Unconfirmed,243,0260-P09,Asthma;Cold,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5646,0260-3118,260.3118,Ended,243,0260-P09,COLD;Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5647,0260-3120,260.3120,Ended,243,0260-P09,Asthma, acute,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5648,0260-3124,260.3124,Ended,243,0260-P09,Bronchitis, acute,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5649,0260-3126,260.3126,Ended,243,0260-P09,Assessment efficacy/safety (inh. vs oral,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5650,0260-3134,260.3134,Ended,243,0260-P09,Effect on wheezing at night,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5651,0260-3137,260.3137,Ended,243,0260-P09,BRONCHIAL HYPERRESPONS.,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5652,0260-3138,260.3138,Ended,243,0260-P09,Clinical trial of Berotec aerosol,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5653,0260-3150,260.3150,Ended,243,0260-P09,Asthma,Ended,MIG,Migration,IV,Phase IV,- no statistics, trial to small.,,,,
5654,0260-3151,260.3151,Unconfirmed,243,0260-P09,Acute resitent asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- Final Report 10/92,,,000910,IS - Clin Study (MIGRATED)
5655,0260-3162,260.3162,Ended,243,0260-P09,Effic. inhalation fenoterol vs. salbut.,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5656,0260-3163,260.3163,Ended,243,0260-P09,Equivalent study CFCs vs HFA-134a,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5657,0054-0301,54.301,Ended,244,0054-P07,Efficacy, Bronchospasmolysis,Ended,MIG,Migration,II,Phase II,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5658,0054-0401,54.401,Ended,244,0054-P07,Efficacy & optimum dosage,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
5659,0054-0409,54.409,Unconfirmed,244,0054-P07,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5660,0054-0411,54.411,Unconfirmed,244,0054-P07,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5661,0054-0446,54.446,Ended,244,0054-P07,COLD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5662,0054-0460,54.460,Ended,244,0054-P07,Comparison with Alupent,Ended,MIG,Migration,II,Phase II,-  Formerly IIa3a. Studies IIa3a & b in conjunction with IIIb4 and  IIIc4 will support the indication in COPD.     ,,,000910,IS - Clin Study (MIGRATED)
5663,0054-0482,54.482,Ended,244,0054-P07,Safety & efficacy in asthma,Ended,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
5664,0054-0497,54.497,Ended,244,0054-P07,Single dose - eye,Ended,MIG,Migration,I,Phase I,-  Dates are obtainable if resources are available.     ,,,000910,IS - Clin Study (MIGRATED)
5665,0054-0499,54.499,Ended,244,0054-P07,COPD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5666,0054-0504,54.504,Ended,244,0054-P07,Comparison with albuterol,Ended,MIG,Migration,III,Phase III,-  Results to be pooled with IIIc4.     ,,,000910,IS - Clin Study (MIGRATED)
5667,0054-0505,54.505,Ended,244,0054-P07,Comparison with albuterol,Ended,MIG,Migration,III,Phase III,-  Same as IIIb3 except sputum testing is included.     ,,,000910,IS - Clin Study (MIGRATED)
5668,0054-0511,54.511,Ended,244,0054-P07,Mucocilliary clearance,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
5669,0054-0512,54.512,Ended,244,0054-P07,Comparison with albuterol,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
5670,0054-0513,54.513,Ended,244,0054-P07,Comparison with placebo,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
5671,0054-0514,54.514,Ended,244,0054-P07,Comparison with placebo,Ended,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
5672,0054-0518,54.518,Ended,244,0054-P07,Dose ranging,Ended,MIG,Migration,I,Phase I,-  An interim analysis will be provided for in the protocol to allow  early ordering of clinical supplies for phase II trials.   FORMERLY Ia4.     ,,,000910,IS - Clin Study (MIGRATED)
5673,0054-0519,54.519,Ended,244,0054-P07,EFFECT ON LUNG FUNCTION/EXERCISE TOL'CE/,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5674,0054-0523,54.523,Ended,244,0054-P07,Comparison with Alupent,Ended,MIG,Migration,II,Phase II,-  Dr. Rennard's study had addendum to study the effect of  BA 253 MDI on sputum. FORMERLY IIa3b.     ,,,000910,IS - Clin Study (MIGRATED)
5675,0054-0524,54.524,Ended,244,0054-P07,SALBUTAMOL/SALB.+ OXI.IN COPD IN ELDERLY,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5676,0054-0525,54.525,Ended,244,0054-P07,SAFETY, EFFICACY STUDY IN COPD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5677,0054-0526,54.526,Ended,244,0054-P07,3 MONTHS EXERCISE IN COPD,Ended,MIG,Migration,IV,Phase IV,- ,,,,
5678,0054-0528,54.528,Ended,244,0054-P07,TER-Exercise tolerance (Phase IV),Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5679,0054-0530,54.530,Ended,244,0054-P07,TER QOL study,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
5680,0054-0531,54.531,Ended,244,0054-P07,TER Add on study,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5681,0054-0532,54.532,Ended,244,0054-P07,TER Shimonoseki Study,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5682,0054-0533,54.533,Ended,244,0054-P07,TER-Fukuchi Study,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
5683,0054-0549,54.549,Ended,244,0054-P07,EFFECT ON EXERCISE CAPACITY,Ended,MIG,Migration,I,Phase I,- ,,,,
5684,0054-0551,54.551,Ended,244,0054-P07,Keio University,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
5685,0054-0552,54.552,Ended,244,0054-P07,Clinical evaluation for COPD,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
5686,0054-0554,54.554,Ended,244,0054-P07,Vertr¬¶glichkeit und Wirksamkeit bei COLD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5687,0054-0555,54.555,Ended,244,0054-P07,COPD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5688,0054-0556,54.556,Ended,244,0054-P07,COPD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5689,0072-0620,72.620,Unconfirmed,245,0072-P00,Gilles de la Tourette Syndrome,Unconfirmed,MIG,Migration,II,Phase II,-  No formal report is expected from Dr. Goetz. Dr Goetz indicated that no treatment effect was observed.     ,,,,
5690,0018-0042,18.42,Unconfirmed,246,0018-P05,Ambroxol bei Schocklunge,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5691,0018-0043,18.43,Unconfirmed,246,0018-P05,"Schocklunge", Koreuber, Berlin,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5692,0018-0044,18.44,Unconfirmed,246,0018-P05,"Schocklunge", Multicenter-Pr√ºfung,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5693,0018-0077,18.77,Unconfirmed,246,0018-P05,Lungenreifef√∂rderung, Multicenter I,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5694,0018-0086,18.86,Ended,246,0018-P05,Infusionsvertr√§glichkeit bei Probanden,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5695,0018-0088,18.88,Unconfirmed,246,0018-P05,Lungenreifef√∂rderung, Multicenter II,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5696,0018-0089,18.89,Unconfirmed,246,0018-P05,Lungenreifef√∂rderung, Prof. Brandau,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5697,0018-0090,18.90,Ended,246,0018-P05,Lungenreifef√∂rderung, Dr. Knitza,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5698,0018-0091,18.91,Ended,246,0018-P05,Lungenreifef√∂rderung, L√ºbeck,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5699,0018-0092,18.92,Unconfirmed,246,0018-P05,Lungenreifef√∂rderung, Multicenter III,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
5700,0018-0101,18.101,Unconfirmed,246,0018-P05,Lungenreifef√∂rderung, Multicenter DDR,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5701,0018-0105,18.105,Ended,246,0018-P05,Lungenreifef√∂rderung, Multicenter Ungarn,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
5702,0018-0115,18.115,Ended,246,0018-P05,Schocklungenprophylaxe,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
5703,0018-0118,18.118,Ended,246,0018-P05,Schocklungenprophylaxe Dr. Heikenw√§lder,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
5704,0018-0121,18.121,Unconfirmed,246,0018-P05,Therapie d. idiopath. Atemnotsyndroms,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5705,0018-0129,18.129,Ended,246,0018-P05,Ambroxol Infus.-Konzentrat, Prof. Eckart,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5706,0018-0130,18.130,Unconfirmed,246,0018-P05,Atemnotsyndrom, retrosp. Dr. Niemeyer,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
5707,0018-0137,18.137,Ended,246,0018-P05,Hyal. Membrankr. Neugeb. Dr. Wauer, DDR,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
5708,0018-0140,18.140,Unconfirmed,246,0018-P05,Prevention of post-oper. lung volume imp,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
5709,0018-0143,18.143,Ended,246,0018-P05,Infusionskonzentrat, Vertr√§glk., Kinetik,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5710,0018-0162,18.162,Ended,246,0018-P05,RDS b. Neugeborenen in Polen LA Amp/Pl 1,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
5711,0018-0163,18.163,Ended,246,0018-P05,none,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5712,0018-0214,18.214,Unconfirmed,246,0018-P05,Prematurity risk,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5713,0018-0216,18.216,Unconfirmed,246,0018-P05,Respiratory distress syndrome,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5714,0018-0224,18.224,Unconfirmed,246,0018-P05,Prematurity risk,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5715,0018-0248,18.248,Ended,246,0018-P05,Prematurity risk,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5716,0018-0249,18.249,Unconfirmed,246,0018-P05,Prematurity risk,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5717,0018-0287,18.287,Unconfirmed,246,0018-P05,Prematurity risk,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5718,0018-0291,18.291,Ended,246,0018-P05,Premature labour,Ended,MIG,Migration,II,Phase II,- Phase II-III ** *,,,000910,IS - Clin Study (MIGRATED)
5719,0018-0292,18.292,Ended,246,0018-P05,Premature labour,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5720,0018-0333,18.333,Ended,246,0018-P05,Premature labour,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5721,0018-0343,18.343,Ended,246,0018-P05,Prematurity risk,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5722,0018-0346,18.346,Unconfirmed,246,0018-P05,Respiratory distress syndrome,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5723,0018-0355,18.355,Unconfirmed,246,0018-P05,Respiratory distress syndrome,Unconfirmed,MIG,Migration,NONE,Not Classified,- planned patients: 60-90 * *,,,000910,IS - Clin Study (MIGRATED)
5724,0018-0360,18.360,Unconfirmed,246,0018-P05,Prematurity risk,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5725,0018-0396,18.396,Ended,246,0018-P05,Prematurity risk;Respiratory distress sy,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5726,0018-0400,18.400,Ended,246,0018-P05,POST MARKETING SURVEILLANCE,Ended,MIG,Migration,IV,Phase IV,- Report expected 11/92 (Letter Daniotti 06.10.92),,,000910,IS - Clin Study (MIGRATED)
5727,0018-0404,18.404,Ended,246,0018-P05,Respiratory tract diseases,Ended,MIG,Migration,III,Phase III,- Report available 3/93 (Letter Maria 09.10.92),,,000910,IS - Clin Study (MIGRATED)
5728,0018-0413,18.413,Ended,246,0018-P05,Prevention,Ended,MIG,Migration,IV,Phase IV,- EF Study,,,000910,IS - Clin Study (MIGRATED)
5729,0018-0416,18.416,Ended,246,0018-P05,PHARMACOKINETICS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5730,0018-0442,18.442,Ended,246,0018-P05,Ambroxol in IRDS (RDS type I),Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5731,0018-0457,18.457,Ended,246,0018-P05,Ambroxol,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5732,0018-0464,18.464,Ended,246,0018-P05,Mucosolvan Infusion for ARDS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5733,0018-0469,18.469,Ended,246,0018-P05,Effect of Mucosolvan for RDS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5734,0018-0477,18.477,Preparing,246,0018-P05,Mucosolvan iv in intensive care patients,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5735,0135-0012,135.12,Unconfirmed,247,0135-P00,Verschlu√ü der Augenarterie, K√∂ln,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5736,0135-0013,135.13,Ended,247,0135-P00,Verschlu√ü einer Augenvene, K√∂ln,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5737,0135-0018,135.18,Ended,247,0135-P00,Verschlu√ü der Augenarterie, Aachen,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5738,0135-0019,135.19,Ended,247,0135-P00,Verschlu√ü einer Augenvene, Aachen,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5739,0135-0041,135.41,Ended,247,0135-P00,Sudden loss of hearing, W√ºrzburg,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
5740,0135-0066,135.66,Unconfirmed,247,0135-P00,rt-PA vs Placebo in SAH SF-2-91,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
5741,0135-0102,135.102,Unconfirmed,247,0135-P00,Graft occlusion,Unconfirmed,MIG,Migration,I,Phase I,- OPU: Genentech USA * *,,,000910,IS - Clin Study (MIGRATED)
5742,0135-0106,135.106,Unconfirmed,247,0135-P00,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
5743,0135-0111,135.111,Ended,247,0135-P00,none,Ended,MIG,Migration,NONE,Not Classified,- OPU: Genentech USA ** *,,,000910,IS - Clin Study (MIGRATED)
5744,0135-0112,135.112,Ended,247,0135-P00,Vascular diseases,Ended,MIG,Migration,NONE,Not Classified,- OPU: Genentech USA * *,,,000910,IS - Clin Study (MIGRATED)
5745,0135-0116,135.116,Unconfirmed,247,0135-P00,LV function,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5746,0135-0118,135.118,Unconfirmed,247,0135-P00,Arteriosclerosis,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
5747,0135-0121,135.121,Unconfirmed,247,0135-P00,Arterial occlusive diseases graft occlus,Unconfirmed,MIG,Migration,II,Phase II,- OPU: Genentech USA * *,,,000910,IS - Clin Study (MIGRATED)
5748,0135-0122,135.122,Unconfirmed,247,0135-P00,Angina-Pectoris unstable,Unconfirmed,MIG,Migration,NONE,Not Classified,- OPU: Genentech USA * *,,,000910,IS - Clin Study (MIGRATED)
5749,0135-0123,135.123,Ended,247,0135-P00,Angina-Pectoris unstable,Ended,MIG,Migration,NONE,Not Classified,- OPU: Genentech USA * *,,,000910,IS - Clin Study (MIGRATED)
5750,0135-0132,135.132,Unconfirmed,247,0135-P00,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- OPU: Genentech USA ** *,,,000910,IS - Clin Study (MIGRATED)
5751,0135-0133,135.133,Unconfirmed,247,0135-P00,Angina-Pectoris unstable,Unconfirmed,MIG,Migration,NONE,Not Classified,- OPU: Genentech USA ** *,,,000910,IS - Clin Study (MIGRATED)
5752,0135-0138,135.138,Ended,247,0135-P00,Arterial thrombosis,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5753,0135-0140,135.140,Ended,247,0135-P00,Investigation of the effect of rt-PA + h,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5754,0135-0149,135.149,Unconfirmed,247,0135-P00,Arterial occlusive diseases,Unconfirmed,MIG,Migration,NONE,Not Classified,- OPU: Genentech USA ** *,,,000910,IS - Clin Study (MIGRATED)
5755,0135-0157,135.157,Ended,247,0135-P00,LV thrombosis,Ended,MIG,Migration,II,Phase II,- Report is prep. no date available (Letter van Gellecum 22.09.92) / Report requested 30.03.93 (Letter EAG),,,,
5756,0135-0160,135.160,Ended,247,0135-P00,Angina Pectoris, unstable,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5757,0135-0167,135.167,Ended,247,0135-P00,Angina Pectoris, unstable,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5758,0135-0170,135.170,Ended,247,0135-P00,PILOT STUDY IN ACUTE DIGITAL ISCHAEMIA,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5759,0135-0171,135.171,Ended,247,0135-P00,COMPARISON OF EFFECTS IN PERIPHERAL ARTE,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5760,0135-0175,135.175,Ended,247,0135-P00,ASSESSING EFFECTIVENESS OF THROM. THPY I,Ended,MIG,Migration,II,Phase II,- Summary,,,000910,IS - Clin Study (MIGRATED)
5761,0135-0177,135.177,Ended,247,0135-P00,Angina Pectoris, unstable,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5762,0135-0190,135.190,Ended,247,0135-P00,Angina Pectoris, unstable,Ended,MIG,Migration,IV,Phase IV,- old contract, payed by BIGmbH / Report available 10/92 (Letter Maria 09.10.92),,,000910,IS - Clin Study (MIGRATED)
5763,0135-0193,135.193,Unconfirmed,247,0135-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- Only abstract available and published. *,,,000910,IS - Clin Study (MIGRATED)
5764,0135-0195,135.195,Ended,247,0135-P00,Angina Pectoris, unstable,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5765,0135-0196,135.196,Ended,247,0135-P00,Clinical pharmacology,Ended,MIG,Migration,I,Phase I,- Only Abstract for publication. Not accepted. *,,,000910,IS - Clin Study (MIGRATED)
5766,0135-0198,135.198,Ended,247,0135-P00,EVALUATION IN PATIENTS WITH UNSTABLE ANG,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5767,0135-0199,135.199,Ended,247,0135-P00,Angina Pectoris, unstable,Ended,MIG,Migration,II,Phase II,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
5768,0135-0204,135.204,Ended,247,0135-P00,Hemiplegia, cerebral, ischemia,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5769,0135-0213,135.213,Ended,247,0135-P00,Angina Pectoris, unstable,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5770,0135-0215,135.215,Ended,247,0135-P00,Angina Pectoris, unstable,Ended,MIG,Migration,II,Phase II,- NZ Trial,,,000910,IS - Clin Study (MIGRATED)
5771,0135-0221,135.221,Ended,247,0135-P00,none,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5772,0135-0222,135.222,Unconfirmed,247,0135-P00,Platelets,Unconfirmed,MIG,Migration,III,Phase III,- OPU: Genentech USA, BI Canada monitoring, Contract cancelled, status is analysing, but set to 'ended without report' *,,,000910,IS - Clin Study (MIGRATED)
5773,0135-0223,135.223,Ended,247,0135-P00,Tumor diagnosis,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5774,0135-0224,135.224,Ended,247,0135-P00,Tumor diagnosis,Ended,MIG,Migration,II,Phase II,- no monitoring capacity required,,,000910,IS - Clin Study (MIGRATED)
5775,0135-0225,135.225,Ended,247,0135-P00,Angina Pectoris, unstable,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5776,0135-0226,135.226,Ended,247,0135-P00,Ischaemia, limbs,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5777,0135-0231,135.231,Ended,247,0135-P00,Postop.subararachnoid.haemorrhage,Ended,MIG,Migration,II,Phase II,- ,,,,
5778,0135-0233,135.233,Unconfirmed,247,0135-P00,Angina Pectoris, unstable,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5779,0135-0237,135.237,Ended,247,0135-P00,DRUG DEVELOPMENT,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5780,0135-0243,135.243,Unconfirmed,247,0135-P00,zzz,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5781,0135-0249,135.249,Ended,247,0135-P00,TROMBOLITIC EFFECTS OF RT-PA,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5782,0135-0250,135.250,Ended,247,0135-P00,ACTILYSE IN HEPARIN IN UNSTABLE ANGINA,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5783,0135-0251,135.251,Ended,247,0135-P00,PROSPECTIVE STUDY OF RT-PA IN ACUTE OR C,Ended,MIG,Migration,II,Phase II,- Summary,,,000910,IS - Clin Study (MIGRATED)
5784,0135-0257,135.257,Ended,247,0135-P00,SK-Ab serology,Ended,MIG,Migration,IV,Phase IV,- NZ Trial,,,000910,IS - Clin Study (MIGRATED)
5785,0135-0258,135.258,Ended,247,0135-P00,rt-PA in refractory unstable angina pect,Ended,MIG,Migration,III,Phase III,- Published *,,,000910,IS - Clin Study (MIGRATED)
5786,0135-0261,135.261,Ended,247,0135-P00,Subacute arterial occlusion,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5787,0135-0264,135.264,Ended,247,0135-P00,RT-PA IN SUBARACHNOID HAEMORRHAGE,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5788,0135-0270,135.270,Ended,247,0135-P00,Femoro-Distal Reconstruction (Grafts),Ended,MIG,Migration,III,Phase III,- ,,,,
5789,0135-0273,135.273,Ended,247,0135-P00,Ischaemia, myocardial, recurrent,Ended,MIG,Migration,II,Phase II,- (Dr. Barbasch, Israel),,,000910,IS - Clin Study (MIGRATED)
5790,0135-0274,135.274,Ended,247,0135-P00,Thrombolysis of thrombosed dialysis eath,Ended,MIG,Migration,IV,Phase IV,- ,,,,
5791,0135-0278,135.278,Ended,247,0135-P00,Pilot study,Ended,MIG,Migration,II,Phase II,- ,,,,
5792,0135-0281,135.281,Unconfirmed,247,0135-P00,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- Similar organization to GUSTO study: t-PA+Hirudin vs. t-PA+Heparin,,,000910,IS - Clin Study (MIGRATED)
5793,0135-0293,135.293,Ended,247,0135-P00,fibrinolysis with rt-PA after ophthalmo,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5794,0135-0300,135.300,Preparing,247,0135-P00,Local tPA admin in PTCA (CAIRO),Preparing,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5795,0135-0327,135.327,Preparing,247,0135-P00,MIST 3 Alteplase Intrapleural Sepsis,Preparing,IIS,Investigator Initiated Study,III,Phase III,,,,,
5796,0135-0329,135.329,Unconfirmed,247,0135-P00,FLUSH Graft liver arterial perfusion,Unconfirmed,MIG,Migration,III,Phase III,,,,,
5797,0205-0134,205.134,Ended,248,0205-P00,PK of Tiotropium in Renal Impairment ,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5798,0215-0101,215.101,Unconfirmed,250,0215-P00,SD-Pharmakokinetics,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5799,0215-0301,215.301,Ended,250,0215-P00,Inhal. or oral, basistherapy,Ended,MIG,Migration,IV,Phase IV,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5800,0215-0302,215.302,Unconfirmed,250,0215-P00,Combination rational,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
5801,0215-0601,215.601,Ended,250,0215-P00,Bioequivalence, efficacy,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5802,0215-0702,215.702,Ended,250,0215-P00,Drug Monitoring,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5803,0215-1001,215.1001,Unconfirmed,250,0215-P00,PMS Berodual,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5804,0215-1300,215.1300,Ended,250,0215-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5805,0215-1301,215.1301,Ended,250,0215-P00,COLD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5806,0215-1302,215.1302,Ended,250,0215-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5807,0215-1303,215.1303,Unconfirmed,250,0215-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5808,0215-1304,215.1304,Unconfirmed,250,0215-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5809,0215-1305,215.1305,Unconfirmed,250,0215-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5810,0215-1306,215.1306,Unconfirmed,250,0215-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5811,0215-1307,215.1307,Unconfirmed,250,0215-P00,Asthma;Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
5812,0215-1308,215.1308,Unconfirmed,250,0215-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5813,0215-1309,215.1309,Unconfirmed,250,0215-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5814,0215-1310,215.1310,Unconfirmed,250,0215-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5815,0215-1311,215.1311,Ended,250,0215-P00,COLD. To check efficacy and experience t,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5816,0215-1312,215.1312,Unconfirmed,250,0215-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5817,0215-1313,215.1313,Unconfirmed,250,0215-P00,Asthma exercise induced,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5818,0215-1314,215.1314,Unconfirmed,250,0215-P00,Asthma;Hypersensitivity respiratory,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5819,0215-1315,215.1315,Unconfirmed,250,0215-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5820,0215-1316,215.1316,Unconfirmed,250,0215-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5821,0215-1317,215.1317,Unconfirmed,250,0215-P00,Bronchitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5822,0215-1318,215.1318,Unconfirmed,250,0215-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5823,0215-1319,215.1319,Unconfirmed,250,0215-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5824,0215-1320,215.1320,Ended,250,0215-P00,non asthmatic bronchial obstruction,Ended,MIG,Migration,IV,Phase IV,- Report 1/93 (Letter VELICITAT 21.09.92),,,000910,IS - Clin Study (MIGRATED)
5825,0215-1321,215.1321,Unconfirmed,250,0215-P00,Asthma;Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5826,0215-1322,215.1322,Ended,250,0215-P00,Asthma chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5827,0215-1323,215.1323,Ended,250,0215-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5828,0215-1324,215.1324,Ended,250,0215-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5829,0215-1325,215.1325,Ended,250,0215-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5830,0215-1326,215.1326,Unconfirmed,250,0215-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5831,0215-1327,215.1327,Ended,250,0215-P00,Asthma;Hypersensitivity respiratory,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5832,0215-1328,215.1328,Unconfirmed,250,0215-P00,Bronchospasm,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5833,0215-1329,215.1329,Unconfirmed,250,0215-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5834,0215-1330,215.1330,Ended,250,0215-P00,Dose response,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5835,0215-1331,215.1331,Ended,250,0215-P00,Berodual vs salbutamol MDI, 90 days,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5836,0215-1332,215.1332,Ended,250,0215-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5837,0215-1333,215.1333,Ended,250,0215-P00,Berodual powder versus MDI,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5838,0215-1334,215.1334,Ended,250,0215-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5839,0215-1335,215.1335,Ended,250,0215-P00,Berodual powder versus MDI,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5840,0215-1336,215.1336,Ended,250,0215-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5841,0215-1337,215.1337,Ended,250,0215-P00,Bronchodual in children.,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5842,0215-1338,215.1338,Ended,250,0215-P00,Berodual Asthma bronchiale/COPD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5843,0215-1339,215.1339,Ended,250,0215-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5844,0215-1340,215.1340,Ended,250,0215-P00,Efficacy in asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5845,0215-1341,215.1341,Unconfirmed,250,0215-P00,DRF-Study/B100,Unconfirmed,MIG,Migration,III,Phase III,- Confirm,,,000910,IS - Clin Study (MIGRATED)
5846,0215-1342,215.1342,Ended,250,0215-P00,Bad coordinator,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5847,0215-1343,215.1343,Ended,250,0215-P00,FO2 vs ventodisk - manipulation,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5848,0215-1344,215.1344,Ended,250,0215-P00,FO2 vs AEM - manipulation,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5849,0215-1345,215.1345,Ended,250,0215-P00,FO2 vs AEM - manipulation,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5850,0215-1346,215.1346,Ended,250,0215-P00,Bronchodil response as function of age,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5851,0215-1350,215.1350,Ended,250,0215-P00,Efficacy and tolerability,Ended,MIG,Migration,IV,Phase IV,- inserted by gerken at 22.06.93,,,000940,Post Marketing Study (MIGRATED)
5852,0215-1351,215.1351,Ended,250,0215-P00,Chronisch obstruktive Atemwegserkrankung,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5853,0215-1352,215.1352,Ended,250,0215-P00,Tolerability and Efficacy,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5854,0215-1353,215.1353,Ended,250,0215-P00,Tolerability and Efficacy,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5855,0215-1358,215.1358,Ended,250,0215-P00,Berodual DA, 6 weeks, Safety + Efficacy,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5856,0215-1368,215.1368,Unconfirmed,250,0215-P00,UDVs for patients with COPD and BA,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
5857,0215-1369,215.1369,Preparing,250,0215-P00,UDVs for patients with COPD and BA,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
5858,0188-0006,188.6,Ended,251,0188-P00,Denan in high risk patients,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5859,0188-0007,188.7,Ended,251,0188-P00,Nonresponders a. lipid lowering therapy,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5860,0188-0008,188.8,Ended,251,0188-P00,Denan V - Hypercholesterolemia,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5861,0188-0009,188.9,Ended,251,0188-P00,DENAN in high risk patients,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5862,0188-0010,188.10,Ended,251,0188-P00,PMS in patients with comb. hyperlipemia,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5863,0188-0011,188.11,Ended,251,0188-P00,Denan in high risk patients,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5864,0188-0012,188.12,Ended,251,0188-P00,Denan in post MI patients,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5865,0188-0013,188.13,Ended,251,0188-P00,Denan in post MI patients,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5866,0188-0014,188.14,Unconfirmed,251,0188-P00,Denan I - Hypercholesterin√§mie,Unconfirmed,MIG,Migration,IV,Phase IV,13000 Centren ,,,000940,Post Marketing Study (MIGRATED)
5867,0188-0015,188.15,Ended,251,0188-P00,Denan II - Hypercholesterin√§mie,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5868,0188-0016,188.16,Ended,251,0188-P00,Denan III - Hypercholesterin√§mie,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5869,0188-0017,188.17,Ended,251,0188-P00,Denan IV - Hypercholesterolemia,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
5870,0233-0001,233.1,Unconfirmed,252,0233-P00,Hypotension orthostatic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5871,0233-0002,233.2,Unconfirmed,252,0233-P00,Hypotension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5872,0233-0003,233.3,Unconfirmed,252,0233-P00,Hypotension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5873,0233-0004,233.4,Ended,252,0233-P00,Obesity,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5874,0233-0005,233.5,Unconfirmed,252,0233-P00,Hypotension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5875,0233-0006,233.6,Ended,252,0233-P00,IN HYPOTENSION,Ended,MIG,Migration,II,Phase II,- ,,,,
5876,0233-0007,233.7,Ended,252,0233-P00,Hypotension in elderly,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5877,0233-0008,233.8,Unconfirmed,252,0233-P00,Orthostatic Hypotension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
5878,0233-0009,233.9,Ended,252,0233-P00,Efficacy and tolerance,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5879,0233-0010,233.10,Ended,252,0233-P00,VASIS,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
5880,0233-0011,233.11,Ended,252,0233-P00,Efficacy and Tolerance,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
5881,0233-0012,233.12,Unconfirmed,252,0233-P00,Bioequivalence,Unconfirmed,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
5882,0233-0013,233.13,Ended,252,0233-P00,Effortil perlongettes 25mg - hypotension,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5883,0233-0014,233.14,Ended,252,0233-P00,Relative bioavailability of etilefrine,Ended,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
5884,0233-0015,233.15,Unconfirmed,252,0233-P00,Pharmacokinetics of Effortil Perlongette,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5885,0233-0201,233.201,Preparing,252,0233-P00,Orthostatic problems, organic dementia,Preparing,MIG,Migration,IV,Phase IV,- , EStatus = X, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5886,0233-0202,233.202,Preparing,252,0233-P00,Efficacy and Tolerability,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
5887,0233-0203,233.203,Preparing,252,0233-P00,Efficacy and tolerability (main study),Preparing,MIG,Migration,IV,Phase IV,Main study to follow pilot study 233.202 ,,,000910,IS - Clin Study (MIGRATED)
5888,0233-0204,233.204,Unconfirmed,252,0233-P00,Pharmacodynamic study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
5889,0352-0001,352.1,Unconfirmed,253,0352-P00,Pilotstudie zu Methodenvergleich 352.4,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5890,0352-0002,352.2,Unconfirmed,253,0352-P00,Pilotstudie alpha 2 - Konzept,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5891,0352-0003,352.3,Unconfirmed,253,0352-P00,Handhbk. u. Acceptanz HLT b. Probanden,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5892,0352-0004,352.4,Unconfirmed,253,0352-P00,Methodenvergleich Insulinresistenz,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5893,0352-0005,352.5,Unconfirmed,253,0352-P00,Strahlenpneumonitis b. Ca-Patienten,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5894,0352-0006,352.6,Unconfirmed,253,0352-P00,Testserenauswertung, Chinoin 123,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5895,0352-0007,352.7,Unconfirmed,253,0352-P00,Idiopat. Atemnotsyndrom NRW 1982-84,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5896,0352-0008,352.8,Ended,253,0352-P00,Blutungszeit: Methodenvalid. interindiv.,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5897,0352-0009,352.9,Ended,253,0352-P00,Blutungszeit: Methodenvalid. intraindiv.,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5898,0352-0010,352.10,Unconfirmed,253,0352-P00,Thomapyrin: HPLC-Methode (s.IP-Nr 155.1),Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5899,0352-0011,352.11,Ended,253,0352-P00,Blutungszeit: Tages-,Wochenrhythmus,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5900,0352-0012,352.12,Ended,253,0352-P00,Blutungszeit bei hoher Aspirindosis,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5901,0352-0013,352.13,Unconfirmed,253,0352-P00,Befragungs-Durchf√úhrbarkt. NA872-NAC,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5902,0352-0014,352.14,Unconfirmed,253,0352-P00,Hemmung Thrombozytenaggr. durch BM13.177,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5903,0352-0015,352.15,Unconfirmed,253,0352-P00,Thrombozyten-Cyclooxygenase-Hemm. d. ASS,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5904,0352-0016,352.16,Unconfirmed,253,0352-P00,Thromboz.-Cyclooxygenase-Hemm. d. ASS II,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5905,0352-0017,352.17,Ended,253,0352-P00,Comp. Ambroxol GC/HPLC/GC-MS plasmalevel,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5906,0352-0018,352.18,Ended,253,0352-P00,Ausscheidung v.PGE2,6-keto-PGF1 alpha I,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5907,0352-0019,352.19,Unconfirmed,253,0352-P00,Me√ümethodik v. PGE2 u. PGF-1a (Vorvers.),Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5908,0352-0020,352.20,Ended,253,0352-P00,Validation: HR from tape - CRF (175.2),Ended,MIG,Migration,NONE,Not Classified,Data from Trial No. 175.2- ,,,000910,IS - Clin Study (MIGRATED)
5909,0352-0021,352.21,Ended,253,0352-P00,Validation of ICG/Tremometer,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5910,0352-0022,352.22,Unconfirmed,253,0352-P00,PFOB as Oral Contrast Agent in MRI (USA),Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5911,0352-0023,352.23,Ended,253,0352-P00,Bleeding time - 2 incision methods/ASA,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5912,0352-0024,352.24,Unconfirmed,253,0352-P00,Ausscheidung von PGE2 (Vorversuch),Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5913,0352-0025,352.25,Ended,253,0352-P00,Validation: HR from tape (IP-No. 140.53),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5914,0352-0026,352.26,Ended,253,0352-P00,Slow and fast metabolizer,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5915,0352-0027,352.27,Ended,253,0352-P00,Evaluation of Finapres,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5916,0352-0028,352.28,Ended,253,0352-P00,Effect of 200mg ASA on platelet function,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5917,0352-0029,352.29,Ended,253,0352-P00,Eval. of BP response to Hypertensin/FINA,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5918,0352-0030,352.30,Unconfirmed,253,0352-P00,Intraduodenal administration DTTX 30 SE,Unconfirmed,MIG,Migration,I,Phase I,see also trial 504.000.110 (identical) Notice Dr. Narjes - 12.05.95,,,000910,IS - Clin Study (MIGRATED)
5919,0352-0101,352.101,Ended,253,0352-P00,Methodenstudie, Mess-Validierung,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5920,0352-0102,352.102,Ended,253,0352-P00,Study of methods, Vigilanzkontrolle,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5921,0352-0103,352.103,Ended,253,0352-P00,Study of methods, Vigilance control,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5922,0352-0104,352.104,Ended,253,0352-P00,Vigilance control, optim. of methods,Ended,MIG,Migration,I,Phase I,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5923,0352-0105,352.105,Ended,253,0352-P00,Selection, Study of methods,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5924,0352-0301,352.301,Ended,253,0352-P00,NONE,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5925,0352-0402,352.402,Ended,253,0352-P00,Dyn. Pupillometry, Reliability test,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5926,0352-0501,352.501,Ended,253,0352-P00,METHODENSTUDIE,Ended,MIG,Migration,I,Phase I,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5927,0352-0502,352.502,Ended,253,0352-P00,Pharmakodynamik, Methodenstudie,Ended,MIG,Migration,I,Phase I,- , EStatus = ?, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5928,0352-0701,352.701,Ended,253,0352-P00,Haemodynamik, pos.inotrope Wirkung,Ended,MIG,Migration,I,Phase I,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5929,0352-0801,352.801,Ended,253,0352-P00,Bestimmungsmethode, Plasma und Urin,Ended,MIG,Migration,I,Phase I,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5930,0352-0901,352.901,Preparing,253,0352-P00,Methodenstudie, PAF-induzierte,Preparing,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5931,0352-1001,352.1001,Ended,253,0352-P00,Tofranil, Methods,Ended,MIG,Migration,I,Phase I,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5932,0352-1201,352.1201,Unconfirmed,253,0352-P00,No Legacy Data,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5933,0352-1301,352.1301,Ended,253,0352-P00,Acceptance,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5934,0352-1302,352.1302,Ended,253,0352-P00,Acceptance,Ended,MIG,Migration,I,Phase I,- , Jugendliche, EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5935,0352-1303,352.1303,Ended,253,0352-P00,Acceptance,Ended,MIG,Migration,I,Phase I,- , Kinder, EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5936,0352-1401,352.1401,Ended,253,0352-P00,Safety of glucose,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5937,0352-1402,352.1402,Ended,253,0352-P00,Safety of glucose,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5938,0352-1403,352.1403,Ended,253,0352-P00,Safety of lactose,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5939,0352-1411,352.1411,Preparing,253,0352-P00,Efficacy, Equivalence,Preparing,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5940,0352-1421,352.1421,Preparing,253,0352-P00,Efficacy, Equivalence,Preparing,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5941,0352-1431,352.1431,Preparing,253,0352-P00,Efficacy, Equivalence,Preparing,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5942,0352-1441,352.1441,Preparing,253,0352-P00,Bioequivalence, Efficacy,Preparing,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5943,0352-1501,352.1501,Ended,253,0352-P00,Bioequivalence, acceptance,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5944,0352-1502,352.1502,Ended,253,0352-P00,Bioequivalence, acceptance,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5945,0352-1503,352.1503,Ended,253,0352-P00,Bioequivalence, acceptance,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5946,0352-1504,352.1504,Ended,253,0352-P00,Bioequivalence, acceptance,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5947,0352-1601,352.1601,Ended,253,0352-P00,Efficacy, handling,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5948,0352-1701,352.1701,Unconfirmed,253,0352-P00,Respiratory Muscle Trainer,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5949,0352-1801,352.1801,Ended,253,0352-P00,Methodenuntersuchung, Psychometrie,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5950,0352-1805,352.1805,Ended,253,0352-P00,Normierung, Validierung,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5951,0352-1806,352.1806,Ended,253,0352-P00,Reliability, validity,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5952,0352-1807,352.1807,Ended,253,0352-P00,Reaction time inhib., Study of methods,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5953,0352-1808,352.1808,Ended,253,0352-P00,Reaction time, Study of methods,Ended,MIG,Migration,I,Phase I,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5954,0352-1813,352.1813,Unconfirmed,253,0352-P00,Reaction time, Study of methods,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5955,0352-1816,352.1816,Ended,253,0352-P00,Study of methods, AAMI,Ended,MIG,Migration,I,Phase I,- , Alter > 60, EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5956,0352-1817,352.1817,Ended,253,0352-P00,Study of methods,Ended,MIG,Migration,I,Phase I,- , Alter > 60, EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5957,0352-1818,352.1818,Ended,253,0352-P00,Study of methods,Ended,MIG,Migration,I,Phase I,- , Alter > 60, EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
5958,0352-1819,352.1819,Ended,253,0352-P00,Study of methods,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5959,0352-1821,352.1821,Ended,253,0352-P00,coffeine-test,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5960,0352-2000,352.2000,Unconfirmed,253,0352-P00,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
5961,0352-2001,352.2001,Ended,253,0352-P00,Collagen in varicous ulcers,Ended,MIG,Migration,III,Phase III,- EE Study   Only safety summary will be done.,,,000910,IS - Clin Study (MIGRATED)
5962,0352-2002,352.2002,Ended,253,0352-P00,Menopausal symptoms,Ended,MIG,Migration,III,Phase III,- Own responsibility study. / Status E (letter Dr. Placheta    13-1-93),,,,
5963,0352-2003,352.2003,Ended,253,0352-P00,Dermatitis, diaper,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
5964,0352-2004,352.2004,Ended,253,0352-P00,Asthma Clinical Field study,Ended,MIG,Migration,IV,Phase IV,- Report expected end '92,,,,
5965,0352-2005,352.2005,Ended,253,0352-P00,Fensol,Ended,MIG,Migration,IV,Phase IV,- ,,,,
5966,0352-2007,352.2007,Ended,253,0352-P00,Double-blind clinical study for testing,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
5967,0352-2009,352.2009,Ended,253,0352-P00,Nasal Tolerance Carboxymethylcellulose,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5968,0352-2010,352.2010,Ended,253,0352-P00,Acetylsalicylic acid bioavailability,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
5969,0352-2011,352.2011,Ended,253,0352-P00,Observational treatment of depression wi,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
5970,0352-2012,352.2012,Unconfirmed,253,0352-P00,Retrospective study,Unconfirmed,MIG,Migration,NONE,Not Classified,- No clinical study, no patients,,,000910,IS - Clin Study (MIGRATED)
5971,0352-2013,352.2013,Ended,253,0352-P00,I.CO.P.E.R.,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
5972,0352-2014,352.2014,Ended,253,0352-P00,Therap.strategy in pulm. embol. STEP,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
5973,0352-2015,352.2015,Ended,253,0352-P00,PEF evaluation : correlation / 2 technic,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
5974,0352-2016,352.2016,Ended,253,0352-P00,Method. of intragastric pH-measurement,Ended,MIG,Migration,I,Phase I,- Old No: 352.216, damit Etikettendruckprogramm auf CTMD zugreifen kann.,,,000910,IS - Clin Study (MIGRATED)
5975,0352-2017,352.2017,Ended,253,0352-P00,24h v/s 72h of Heparin on Thrombus size,Ended,MIG,Migration,II,Phase II,R&D Study Study was initiated and monitored by R&D BI Germany,,,000910,IS - Clin Study (MIGRATED)
5976,0352-2018,352.2018,Ended,253,0352-P00,STIM-pre-hospital,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
5977,0352-2019,352.2019,Ended,253,0352-P00,Airway inflammation in COPD,Ended,MIG,Migration,IV,Phase IV,- ,,,,
5978,0352-2020,352.2020,Ended,253,0352-P00,DENAIN study,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
5979,0352-2021,352.2021,Ended,253,0352-P00,AGATE,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
5980,0352-2023,352.2023,Unconfirmed,253,0352-P00,Strategy in benign prostatic hypertrophy,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
5981,0352-2024,352.2024,Unconfirmed,253,0352-P00,GEPETTO,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
5982,0352-2025,352.2025,Recruiting,253,0352-P00,ADME genotyping of healthy volunteers,Recruiting,MIG,Migration,I,Phase I,,,,000300,IS - Methodological Studies
5983,0352-2026,352.2026,Ended,253,0352-P00,Prospective survey,  COPD, Gen. Pract.,Ended,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
5984,0352-2027,352.2027,Ended,253,0352-P00,EDICT study,Ended,MIG,Migration,NONE,Not Classified,Demographic study of COPD prevalence. ,,,,
5985,0352-2028,352.2028,Ended,253,0352-P00,RUSIC-Resource Utilization Study in COPD,Ended,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
5986,0352-2029,352.2029,Ended,253,0352-P00,Survey quality of life COPD,Ended,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
5987,0352-2031,352.2031,Ended,253,0352-P00,Validation of the Ingelheim Psychometrie,Ended,MIG,Migration,I,Phase I,,,,000300,IS - Methodological Studies
5988,0352-2032,352.2032,Ended,253,0352-P00,Action High Blood Pressr. in the Morning,Ended,MIG,Migration,NONE,Not Classified, Values from CTMS: Planned Subjects Screened: 100000, Planned Subjects Randomized: 100000, Planned Subjects Completed Treatment: ,,,000300,IS - Methodological Studies
5989,0352-2033,352.2033,Preparing,253,0352-P00,Action High Blood Pres. Morning Screen.,Preparing,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
5990,0352-2034,352.2034,Ended,253,0352-P00,surr. markers of glucocorticoid efficacy,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
5991,0352-2035,352.2035,Analysis,253,0352-P00,Diff. mRNA and surrogate marker expres.,Analysis,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
5992,0352-2036,352.2036,Ended,253,0352-P00,Toxicogenomics - methodological study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
5993,0352-2039,352.2039,Preparing,253,0352-P00,Protective effect of ipratropium-bromide,Preparing,MIG,Migration,I,Phase I,,,,000300,IS - Methodological Studies
5994,0352-2040,352.2040,Ended,253,0352-P00,Action High Blood Pres. Morning Scr. II,Ended,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
5995,0352-2041,352.2041,Preparing,253,0352-P00,LPS-challenge in healthy volunteers,Preparing,MIG,Migration,I,Phase I,,2005-003532-22,,000910,IS - Clin Study (MIGRATED)
5996,0352-2042,352.2042,Ended,253,0352-P00,Metastudie QT Interval,Ended,MIG,Migration,I,Phase I,,,,000300,IS - Methodological Studies
5997,0352-2043,352.2043,Ended,253,0352-P00,Questionnaire to Assess Dyspnea in COPD,Ended,MIG,Migration,NONE,Not Classified,FDA feedback will influence all dates ,,,000300,IS - Methodological Studies
5998,0352-2044,352.2044,Preparing,253,0352-P00,New dyspnoea tool used in Rehab,Preparing,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
5999,0352-2045,352.2045,Unconfirmed,253,0352-P00,Effects of resp. physiotherapy on cough,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,,
6000,0352-2046,352.2046,Ended,253,0352-P00,ICS Withdrawal Study,Ended,MIG,Migration,IV,Phase IV,,2007-002522-29,,000910,IS - Clin Study (MIGRATED)
6001,0352-2047,352.2047,Ended,253,0352-P00,Diagnosis, therapy drug skin reactions,Ended,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
6002,0352-2048,352.2048,Ended,253,0352-P00,Continous ECG Validation,Ended,MIG,Migration,I,Phase I,,2006-005067-25,,000300,IS - Methodological Studies
6003,0352-2049,352.2049,Ended,253,0352-P00,COPD-Quality of life & physical fitness,Ended,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
6004,0352-2050,352.2050,Ended,253,0352-P00,Smoking and treatment of asthma,Ended,MIG,Migration,IV,Phase IV,,,,,
6005,0352-2051,352.2051,Ended,253,0352-P00,Sec. Stroke Prevention in Franken (D),Ended,MIG,Migration,IV,Phase IV,,,,,
6006,0352-2053,352.2053,Ended,253,0352-P00,Retrospective patient chart review,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
6007,0352-2054,352.2054,Ended,253,0352-P00,NSCLC Register,Ended,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
6008,0352-2055,352.2055,Ended,253,0352-P00,Methods to validate new biomarkers,Ended,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
6009,0352-2056,352.2056,Ended,253,0352-P00,Exacerbation & physical activity in COPD,Ended,MIG,Migration,III,Phase III,,,,,
6010,0352-2057,352.2057,Preparing,253,0352-P00,BI Employee Study (BI Fit im Leben),Preparing,MIG,Migration,NONE,Not Classified,cancelled-not intended as a CTMS study ,,,000300,IS - Methodological Studies
6011,0352-2058,352.2058,Ended,253,0352-P00,Human Pain Model: Pilot study,Ended,MIG,Migration,I,Phase I,,2012-003202-26,,000910,IS - Clin Study (MIGRATED)
6012,0352-2059,352.2059,Preparing,253,0352-P00,COPD/CAD,Preparing,MIG,Migration,NONE,Not Classified,,,,,
6013,0352-2060,352.2060,Ended,253,0352-P00,Patient's preference in NSCLC,Ended,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
6014,0352-2061,352.2061,Unconfirmed,253,0352-P00,COPD Illness perception-an intervention,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,,
6015,0352-2062,352.2062,Unconfirmed,253,0352-P00,Integrated care model Asthma and COPD,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,,
6016,0352-2063,352.2063,Analysis,253,0352-P00,Responsiveness of DIRECT and CRT3,Analysis,MIG,Migration,NONE,Not Classified,,,,,
6017,0352-2064,352.2064,Analysis,253,0352-P00,COPD Biomarker,Analysis,MIG,Migration,IV,Phase IV,,,,,
6018,0352-2065,352.2065,First Subject Randomised,253,0352-P00,COPDGene/ Lung Cancer Registry,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000420,NISnd ‚Äì Study - Cohort
6019,0352-2068,352.2068,Recruiting,253,0352-P00,Trajectory of Physical Activity,Recruiting,MIG,Migration,IV,Phase IV,compliant with iis SOP (B Hassemer) ,,,000150,IS - Clin Study - Explore
6020,0352-2081,352.2081,Recruiting,253,0352-P00,POAF risk factors and outcome,Recruiting,MIG,Migration,NONE,Not Classified,,,,,
6021,0352-2083,352.2083,Unconfirmed,253,0352-P00,Lung ca diag in UK prim or second care,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000980,Not Classified (MIGRATED)
6022,0352-2084,352.2084,First Subject Randomised,253,0352-P00,MURDOCK Cohort Study,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000450,NISed ‚Äì Study - Other
6023,0352-2085,352.2085,Ended,253,0352-P00,Metabolic effects with ICS use in COPD,Ended,MIG,Migration,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
6024,0352-2086,352.2086,Ended,253,0352-P00,The burden of monotherapy in COPD,Ended,MIG,Migration,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
6025,0352-2088,352.2088,Preparing,253,0352-P00,Yale CRTH2 biomarker study,Preparing,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6026,0352-2090,352.2090,Recruiting,253,0352-P00,ExOS study,Recruiting,MIG,Migration,NONE,Not Classified,,,,,
6027,0352-2093,352.2093,Analysis,253,0352-P00,Pilot study methacholine challenge,Analysis,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
6028,1093-0001,1093.1,Ended,254,1093-P00,Thoracic trauma, Pain,Ended,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
6029,1093-0002,1093.2,Ended,254,1093-P00,Pain,Ended,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
6030,1093-0003,1093.3,Ended,254,1093-P00,Pain, Oncologie,Ended,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
6031,1093-0004,1093.4,Ended,254,1093-P00,Pain, postoperative,Ended,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
6032,1093-0005,1093.5,Ended,254,1093-P00,Pharmacokinetics of Metamizol,Ended,MIG,Migration,II,Phase II,- EE Study,,,000910,IS - Clin Study (MIGRATED)
6033,1093-0006,1093.6,Ended,254,1093-P00,Pain after biliary surgery,Ended,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
6034,1093-0007,1093.7,Ended,254,1093-P00,Pain after vascular surgery,Ended,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
6035,1093-0008,1093.8,Ended,254,1093-P00,Metamizol in nephritic colic pain,Ended,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
6036,1093-0009,1093.9,Ended,254,1093-P00,Circadian rhythmus,Ended,MIG,Migration,II,Phase II,- EE Study,,,000910,IS - Clin Study (MIGRATED)
6037,1093-0010,1093.10,Ended,254,1093-P00,Metamizol in inguinal hernia surgery,Ended,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
6038,1093-0011,1093.11,Ended,254,1093-P00,PCA,Ended,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
6039,1093-0012,1093.12,Ended,254,1093-P00,Metamizol after third molar surgery,Ended,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
6040,1093-0013,1093.13,Ended,254,1093-P00,Bioavailability of three Different Metam,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6041,1093-0014,1093.14,Ended,254,1093-P00,Metamizol - neoplasic chronic pain,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6042,1093-0015,1093.15,Ended,254,1093-P00,Antithermic in stroke,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6043,1093-0016,1093.16,Ended,254,1093-P00,Efficacy in episodical moderate headache,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6044,1093-0017,1093.17,Preparing,254,1093-P00,Relative bioavailability sodium metamizo,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6045,1093-0018,1093.18,Ended,254,1093-P00,Postsurgical Pain in Children,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6046,1133-0001,1133.1,Ended,255,1133-P00,Safety & tolerability Valeriana/Melissa,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6047,1133-0002,1133.2,Preparing,255,1133-P00,Psychophysiological Insomnia,Preparing,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6048,0107-0115,107.115,Unconfirmed,256,0107-P13,Effectiveness of Meloxicam in AD,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
6049,0107-0142,107.142,Unconfirmed,256,0107-P13,Meloxicam in Cerebrospinal Fluid,Unconfirmed,MIG,Migration,I,Phase I,Trial cancelled (Tel. Dr.Hanft 04.11.94) ,,,000910,IS - Clin Study (MIGRATED)
6050,0001-0001,1.1,Ended,257,0001-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6051,0001-0002,1.2,Unconfirmed,257,0001-P00,Asthma allergic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6052,0001-0003,1.3,Ended,257,0001-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6053,0001-0004,1.4,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6054,0001-0005,1.5,Ended,257,0001-P00,Affective disorders,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6055,0001-0006,1.6,Ended,257,0001-P00,Depression,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6056,0001-0007,1.7,Ended,257,0001-P00,Depression endogenous,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6057,0001-0009,1.9,Unconfirmed,257,0001-P00,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6058,0001-0010,1.10,Unconfirmed,257,0001-P00,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6059,0001-0011,1.11,Unconfirmed,257,0001-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6060,0001-0012,1.12,Unconfirmed,257,0001-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6061,0001-0013,1.13,Unconfirmed,257,0001-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6062,0001-0014,1.14,Unconfirmed,257,0001-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6063,0001-0015,1.15,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6064,0001-0016,1.16,Unconfirmed,257,0001-P00,Depression,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6065,0001-0017,1.17,Ended,257,0001-P00,Rhinitis allergic,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6066,0001-0018,1.18,Unconfirmed,257,0001-P00,Bronchitis chronic obstructive,Unconfirmed,MIG,Migration,III,Phase III,- planned patients:10-12 ** *,,,000910,IS - Clin Study (MIGRATED)
6067,0001-0019,1.19,Unconfirmed,257,0001-P00,Abortion,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6068,0001-0020,1.20,Unconfirmed,257,0001-P00,Fever,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6069,0001-0021,1.21,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6070,0001-0022,1.22,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6071,0001-0023,1.23,Ended,257,0001-P00,COLD,Ended,MIG,Migration,III,Phase III,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6072,0001-0024,1.24,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6073,0001-0025,1.25,Ended,257,0001-P00,Asthma,Ended,MIG,Migration,II,Phase II,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6074,0001-0026,1.26,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6075,0001-0027,1.27,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6076,0001-0028,1.28,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6077,0001-0029,1.29,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6078,0001-0030,1.30,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6079,0001-0031,1.31,Unconfirmed,257,0001-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6080,0001-0032,1.32,Unconfirmed,257,0001-P00,Pneumoconiosis;Emphysema pulmonary;Bronc,Unconfirmed,MIG,Migration,III,Phase III,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6081,0001-0033,1.33,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6082,0001-0034,1.34,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6083,0001-0035,1.35,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6084,0001-0036,1.36,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6085,0001-0037,1.37,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6086,0001-0038,1.38,Unconfirmed,257,0001-P00,Premature labour,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6087,0001-0039,1.39,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6088,0001-0040,1.40,Unconfirmed,257,0001-P00,Premature labour,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6089,0001-0041,1.41,Unconfirmed,257,0001-P00,Premature labour,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6090,0001-0042,1.42,Ended,257,0001-P00,COLD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6091,0001-0043,1.43,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6092,0001-0044,1.44,Unconfirmed,257,0001-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6093,0001-0045,1.45,Unconfirmed,257,0001-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6094,0001-0046,1.46,Unconfirmed,257,0001-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6095,0001-0047,1.47,Unconfirmed,257,0001-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6096,0001-0048,1.48,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6097,0001-0049,1.49,Unconfirmed,257,0001-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6098,0001-0050,1.50,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6099,0001-0051,1.51,Unconfirmed,257,0001-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6100,0001-0052,1.52,Ended,257,0001-P00,none,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6101,0001-0053,1.53,Unconfirmed,257,0001-P00,Asthma allergic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6102,0001-0054,1.54,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6103,0001-0055,1.55,Unconfirmed,257,0001-P00,Pertussis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6104,0001-0056,1.56,Unconfirmed,257,0001-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6105,0001-0057,1.57,Unconfirmed,257,0001-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6106,0001-0058,1.58,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6107,0001-0059,1.59,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6108,0001-0060,1.60,Ended,257,0001-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6109,0001-0061,1.61,Unconfirmed,257,0001-P00,Depression,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6110,0001-0062,1.62,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6111,0001-0063,1.63,Ended,257,0001-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6112,0001-0064,1.64,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6113,0001-0065,1.65,Unconfirmed,257,0001-P00,Rhinitis allergic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6114,0001-0066,1.66,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6115,0001-0067,1.67,Unconfirmed,257,0001-P00,Depression endogenous,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6116,0001-0068,1.68,Ended,257,0001-P00,Pertussis,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6117,0001-0069,1.69,Ended,257,0001-P00,Asthma chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6118,0001-0070,1.70,Unconfirmed,257,0001-P00,Asthma eczema atopic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6119,0001-0071,1.71,Unconfirmed,257,0001-P00,Allergy,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6120,0001-0072,1.72,Unconfirmed,257,0001-P00,Eczema atopic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6121,0001-0073,1.73,Ended,257,0001-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- Report requested (Letter LV/DI 26.08.92) no answer / Report requested (Dr. DI 12/02/93) / Report requested (Letter DIE 13.05.93),,,000910,IS - Clin Study (MIGRATED)
6122,0001-0074,1.74,Ended,257,0001-P00,Asthma, nocturnal,Ended,MIG,Migration,IV,Phase IV,- EE Study   (Letter DI)/final Report end 92 (Letter Kuhlmann 11/92)/Report Date requested (Letter DI 10/92),,,000910,IS - Clin Study (MIGRATED)
6123,0001-0075,1.75,Unconfirmed,257,0001-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6124,0001-0076,1.76,Ended,257,0001-P00,Clinical Utility of Clenbuterol,Ended,MIG,Migration,III,Phase III,- Company was Teijin/Japan. Substance licenced out. Status was  A 10/92.,,,000910,IS - Clin Study (MIGRATED)
6125,0001-0077,1.77,Ended,257,0001-P00,Clinical evaluation of Clenbuterol,Ended,MIG,Migration,III,Phase III,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6126,0001-0078,1.78,Ended,257,0001-P00,Clinical Evaluation of Clenbuterol,Ended,MIG,Migration,III,Phase III,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6127,0001-0079,1.79,Ended,257,0001-P00,Long-term use in incontinence,Ended,MIG,Migration,II,Phase II,- Company was Teijin/Japan. Substance licenced out. Status was  A 10/92.,,,000910,IS - Clin Study (MIGRATED)
6128,0001-0080,1.80,Ended,257,0001-P00,Double blind trial in stress incontinenc,Ended,MIG,Migration,III,Phase III,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
6129,0001-0081,1.81,Unconfirmed,257,0001-P00,Determining optimal dose in stress incon,Unconfirmed,MIG,Migration,II,Phase II,- Company was Teijin/Japan. Substance licenced out. Status was  O 10/92,,,000910,IS - Clin Study (MIGRATED)
6130,0001-0082,1.82,Ended,257,0001-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6131,0001-0101,1.101,Unconfirmed,257,0001-P00,Kinderpr√ºfung (72068),Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6132,0001-0102,1.102,Unconfirmed,257,0001-P00,Vergleich N139 / N139A (301),Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6133,0001-0103,1.103,Unconfirmed,257,0001-P00,Vergl. Tabl./Kaps. N116/N139 (302),Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6134,0001-0104,1.104,Unconfirmed,257,0001-P00,Aerosol-Spr√ºhkopf-Vergleich (303),Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6135,0001-0105,1.105,Unconfirmed,257,0001-P00,Vergleich SCH 1000 - Berotec (304),Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6136,0001-0106,1.106,Unconfirmed,257,0001-P00,Insulin - Glucose - Fetts√§ure (306),Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6137,0001-0107,1.107,Unconfirmed,257,0001-P00,Hochdruck-Patienten (307),Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6138,0001-0108,1.108,Unconfirmed,257,0001-P00,Langzeit Phase III,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6139,0001-0109,1.109,Unconfirmed,257,0001-P00,CPK-Langzeitpr√ºfung,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6140,0001-0110,1.110,Unconfirmed,257,0001-P00,Kinderpr√ºfung Transaminasen,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6141,0001-0111,1.111,Unconfirmed,257,0001-P00,Einflu√ü auf diab. Stoffwechsellage,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6142,0001-0112,1.112,Unconfirmed,257,0001-P00,bei spastischen L√§hmungen,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6143,0001-0113,1.113,Unconfirmed,257,0001-P00,Vergleich HCL-Base - Aerosol,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6144,0001-0114,1.114,Unconfirmed,257,0001-P00,Vergleich Reins. Kapsel - Tablette,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6145,0001-0115,1.115,Unconfirmed,257,0001-P00,Vergleichspr√ºfung Anfallsasthma,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6146,0001-0116,1.116,Unconfirmed,257,0001-P00,NAB 365 + Bisolvon-Saft Kinder,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6147,0001-0117,1.117,Unconfirmed,257,0001-P00,Alupent-Vergleich, Pump-Dos. Spr.,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6148,0001-0118,1.118,Unconfirmed,257,0001-P00,SCH 1000-Vergleich, Dos.-Aerosol,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6149,0001-0119,1.119,Unconfirmed,257,0001-P00,Alupent-Vergleich, Handvernebler,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6150,0001-0120,1.120,Unconfirmed,257,0001-P00,PB 89 und Kombination, Lacktabl.,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6151,0001-0121,1.121,Unconfirmed,257,0001-P00,Dosis-Wirkungs-Pr√ºfung, EDB,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6152,0001-0122,1.122,Unconfirmed,257,0001-P00,Dosis und Applikationsh√§ufigkeit,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6153,0001-0123,1.123,Unconfirmed,257,0001-P00,Dosis-Wirkung bei Rhin. Pollinosa,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6154,0001-0124,1.124,Unconfirmed,257,0001-P00,Rhin. Pollinosa, Feldstudie,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6155,0001-0125,1.125,Unconfirmed,257,0001-P00,Dosis-Wirkung bei Rhin. Vasomotoria,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6156,0001-0126,1.126,Unconfirmed,257,0001-P00,Bei vorzeitigen Wehen,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6157,0001-0127,1.127,Unconfirmed,257,0001-P00,Rhinitis vasomot., Tabletten / Spray *,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6158,0001-0128,1.128,Unconfirmed,257,0001-P00,Rhin. pollinosa, Feldstudie '78,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6159,0001-0129,1.129,Unconfirmed,257,0001-P00,Exercise Induced Asthma,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6160,0001-0130,1.130,Unconfirmed,257,0001-P00,vs. Salbutamol, Br√ºssel B 674/78 *,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6161,0001-0131,1.131,Unconfirmed,257,0001-P00,bei vorzeitigen Wehen, Prof.Baumgarten *,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6162,0001-0132,1.132,Unconfirmed,257,0001-P00,Induziertes allergisches Asthma *,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6163,0001-0133,1.133,Unconfirmed,257,0001-P00,Vorzeitige Wehen, III,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6164,0001-0134,1.134,Unconfirmed,257,0001-P00,NAB365+NA872 Mucoziliare Clearance *,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6165,0001-0135,1.135,Unconfirmed,257,0001-P00,Allergeninhalation, Kinder, Frankfurt,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6166,0001-0136,1.136,Unconfirmed,257,0001-P00,Dosiswirkung, Kantonspital Basel NPRA,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6167,0001-0137,1.137,Unconfirmed,257,0001-P00,Harninkontinenz, Prof. Naber,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6168,0001-0138,1.138,Unconfirmed,257,0001-P00,vs. Berotec, cross-over B 620/80,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6169,0001-0139,1.139,Unconfirmed,257,0001-P00,vs. Salbutamol, Antwerpen B 1030/80,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6170,0001-0140,1.140,Unconfirmed,257,0001-P00,Reizblase - Multicenterpr√ºfung,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6171,0001-0141,1.141,Unconfirmed,257,0001-P00,Dranginkontinenz - Multicenterpr√ºfung,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6172,0001-0142,1.142,Unconfirmed,257,0001-P00,Tremorstudie, Dr. Schaffler,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6173,0001-0143,1.143,Unconfirmed,257,0001-P00,Flavoxat bei Harninkontinenz,Gr√ºneberger,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6174,0001-0144,1.144,Unconfirmed,257,0001-P00,Tropfen, Vertr√§glichkeit und Wirksamkeit,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6175,0001-0145,1.145,Unconfirmed,257,0001-P00,Saft, Vertr√§glichkeit und Wirksamkeit,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6176,0001-0146,1.146,Unconfirmed,257,0001-P00,Harninkontinenz, Dr. Gr√ºneberger,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6177,0001-0147,1.147,Unconfirmed,257,0001-P00,Prim√§re Dysmenorrhoe,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6178,0001-0148,1.148,Unconfirmed,257,0001-P00,Protekt. Wirk.b.asthm. Kindern CS 923/81,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6179,0001-0149,1.149,Unconfirmed,257,0001-P00,Methodische Untersuchung zur Urodynamik,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6180,0001-0150,1.150,Unconfirmed,257,0001-P00,Endogene Depressionen, Prof. Matussek,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6181,0001-0151,1.151,Unconfirmed,257,0001-P00,Dosis-Wirkungspr√ºfung, Dosieraerosol,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6182,0001-0152,1.152,Unconfirmed,257,0001-P00,St√∂rung der Reservoirfunktion der Blase,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6183,0001-0153,1.153,Unconfirmed,257,0001-P00,Beeinflussung der Blasenkapazit√§t,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6184,0001-0154,1.154,Unconfirmed,257,0001-P00,Meth.findg. GC-MS Bestimmung/Humanplasma,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6185,0001-0201,1.201,Unconfirmed,257,0001-P00,FRUEHGEBURTSBESTR.,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
6186,0001-0202,1.202,Unconfirmed,257,0001-P00,Tokolyse, Cerclage,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
6187,0001-0203,1.203,Unconfirmed,257,0001-P00,Tokolyse, Plazentapassage,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
6188,0001-0204,1.204,Unconfirmed,257,0001-P00,Herz-Kreislaufeinfl.,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
6189,0001-0205,1.205,Unconfirmed,257,0001-P00,Metabolismus,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
6190,0001-0206,1.206,Unconfirmed,257,0001-P00,Berufstaetige,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
6191,0001-0207,1.207,Unconfirmed,257,0001-P00,Oxytoxinspiegel, PGE-2-Induktion,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
6192,0001-0209,1.209,Analysis,257,0001-P00,Vertraeglichkeit, ADH-Spiegel, Wasser-,Analysis,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
6193,0001-0210,1.210,Analysis,257,0001-P00,Wirksamkeit, Vertraeglichkeit,Analysis,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
6194,0001-0211,1.211,Analysis,257,0001-P00,Wirksamkeit, Vertraeglichkeit,Analysis,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
6195,0001-0212,1.212,Unconfirmed,257,0001-P00,Wirksamkeit, Vertraeglichkeit,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
6196,0001-0230,1.230,Preparing,257,0001-P00,Tokolyt. Wirksamkeit, Vertraeglichkeit,Preparing,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
6197,0006-0001,6.1,Ended,258,0006-P01,Tranquilizer (3x25) (72060),Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6198,0006-0002,6.2,Ended,258,0006-P01,Tranquilizer (3x25,3x50) (72070),Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6199,0006-0003,6.3,Ended,258,0006-P01,Tranquilizer (3x50 mg Kapseln) (501),Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6200,0006-0004,6.4,Ended,258,0006-P01,Anxiolyse + Sedation (1x50) (503),Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6201,0006-0005,6.5,Ended,258,0006-P01,bei Depressionen jeder Genese (506),Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6202,0006-0006,6.6,Ended,258,0006-P01,bei Depressionen und Neurosen (507),Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6203,0006-0007,6.7,Ended,258,0006-P01,bei neurotischen Depressionen,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6204,0006-0012,6.12,Ended,258,0006-P01,Neurosen und Angst,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6205,0006-0015,6.15,Unconfirmed,258,0006-P01,Reaktive Depressionen, L√ºttich B 776/76,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6206,0006-0018,6.18,Ended,258,0006-P01,Tropfinfusion bei endog. Depr., Erlangen,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6207,0006-0021,6.21,Ended,258,0006-P01,Morbus Parkinson, Prof.Dr. Steinbrecher,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6208,0006-0025,6.25,Ended,258,0006-P01,Psychogeriatrische St√∂rungen, Eckmann,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6209,0006-0028,6.28,Ended,258,0006-P01,Lebervertr√§glichkeit, Dr. Henning *,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6210,0006-0029,6.29,Unconfirmed,258,0006-P01,Wechselwirkung mit Alkohol *,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6211,0006-0030,6.30,Ended,258,0006-P01,Vergleich Trazodon - Amitriptylin,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6212,0006-0031,6.31,Ended,258,0006-P01,Depres. Syndrom in der Jugendpsychiatrie,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6213,0006-0032,6.32,Ended,258,0006-P01,Praxiserhebung, retrospektiv,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6214,0006-0033,6.33,Ended,258,0006-P01,Alkoholiker mit depress. Syndrom, Haar,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6215,0006-0034,6.34,Ended,258,0006-P01,Alkoholiker, Defektsyndrom, Dr. Stolberg,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6216,0006-0035,6.35,Ended,258,0006-P01,Altersdepression und Tremor, Dr. Foltyn,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6217,0006-0036,6.36,Ended,258,0006-P01,Vergleich gegen Doxepin, Prof. P√∂ldinger,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6218,0006-0037,6.37,Ended,258,0006-P01,P√§dopsychiatr. Ambulanz (Kapseln), Wolff,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6219,0006-0038,6.38,Unconfirmed,258,0006-P01,Parkinson-Tremor, Prof.Dr. M√ºller,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6220,0006-0039,6.39,Ended,258,0006-P01,p√§dopsychiatr. Ambulanz (Tropfen), Wolff,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6221,0006-0040,6.40,Unconfirmed,258,0006-P01,bei Pruritus sine materia, Dr. Wittmann,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6222,0006-0041,6.41,Ended,258,0006-P01,in der Geriatrie, Dr. Wittmann,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6223,0006-0042,6.42,Ended,258,0006-P01,in der kinder√§rztl. Praxis, Dr. Palmie,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6224,0006-0043,6.43,Ended,258,0006-P01,Depress. verschied. Genese, Dr.Bibracher,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6225,0006-0044,6.44,Ended,258,0006-P01,organ. Depression nach Hirntrauma,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6226,0006-0045,6.45,Ended,258,0006-P01,Pilot-Studie, Einsparung von Opiaten,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6227,0006-0046,6.46,Unconfirmed,258,0006-P01,Wirksamkeit station√§r, Wien,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6228,0006-0047,6.47,Unconfirmed,258,0006-P01,Wirksamk. & Abh√§ngigkeit, ambulant, Wien,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6229,0006-0048,6.48,Unconfirmed,258,0006-P01,Stumpf-/Phantomschmerz,Prof.Gerbershagen,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6230,0006-0049,6.49,Ended,258,0006-P01,Antinociception, Probanden, Elger,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6231,0006-0050,6.50,Unconfirmed,258,0006-P01,Antidepressive Wirkung, Lindenberg,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6232,0006-0051,6.51,Ended,258,0006-P01,Depression 12.5-200mg p.inf., Berzewski,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6233,0006-0052,6.52,Unconfirmed,258,0006-P01,Wirkungsspektrum, Walcher,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6234,0006-0053,6.53,Unconfirmed,258,0006-P01,Wirksamkeit bei Tremor, Haan,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6235,0006-0054,6.54,Ended,258,0006-P01,psychisch Kranke, Dr. Klieser,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6236,0006-0055,6.55,Unconfirmed,258,0006-P01,Feldstudie,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6237,0006-0056,6.56,Ended,258,0006-P01,bei ambulanten Depressiven, Kempf,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6238,0006-0057,6.57,Ended,258,0006-P01,Tremor unterschiedl. Genese,Dr. Greulich,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6239,0006-0058,6.58,Ended,258,0006-P01,Bio√§quivalenz Oblongtabletten-Liquidform,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6240,0006-0059,6.59,Unconfirmed,258,0006-P01,bei Herz-/Kreislauferkrank.,Dr. Martius,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6241,0006-0060,6.60,Unconfirmed,258,0006-P01,bei Parkinsontremor, Dr. Dengler,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6242,0006-0061,6.61,Unconfirmed,258,0006-P01,b. erektiler Dysfunkt., Herbst/Rupprecht,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6243,0006-0062,6.62,Unconfirmed,258,0006-P01,Kurzzeit- vs Langzeit-Response, Galluska,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6244,0006-0063,6.63,Unconfirmed,258,0006-P01,Vergleichspr√ºfung b.Kopfschmerzen,Taneri,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6245,0006-0064,6.64,Unconfirmed,258,0006-P01,Depressive Verstimmung mit Schlafst√∂rung,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6246,0009-0001,9.1,Ended,259,0009-P00,bei Angina Pektoris,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6247,0009-0002,9.2,Ended,259,0009-P00,DVT, Tilsener Hamburg,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6248,0009-0003,9.3,Unconfirmed,259,0009-P00,DVT, Zekert Wien,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6249,0009-0004,9.4,Ended,259,0009-P00,Prim√§re Verschlu√üprophylaxe, Aggertalkl.,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6250,0009-0005,9.5,Unconfirmed,259,0009-P00,Rethrombosierungsrate, Zeitler,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6251,0009-0006,9.6,Ended,259,0009-P00,nach Dotter-Operationen, Hess,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6252,0009-0007,9.7,Ended,259,0009-P00,DVT, Heidelberg, Encke/Stock,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6253,0009-0008,9.8,Unconfirmed,259,0009-P00,PLZ, Weinfeld,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6254,0009-0009,9.9,Ended,259,0009-P00,Femoralis By-Pass, Kuijpers,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6255,0009-0010,9.10,Unconfirmed,259,0009-P00,Red. v. Rethrombos., Z√ºrich, Bollinger,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6256,0009-0011,9.11,Ended,259,0009-P00,Beinvenenthrombosen n.Myokardinfarkt, NL,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6257,0009-0012,9.12,Ended,259,0009-P00,DVT nach Myokardinfarkt, Gottstein,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6258,0009-0013,9.13,Ended,259,0009-P00,bei Arhythmien, Rotterdam,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6259,0009-0014,9.14,Unconfirmed,259,0009-P00,und Diabet. Neuropathien, Ottolander,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6260,0009-0015,9.15,Ended,259,0009-P00,Prim√§re Verschlu√üprophyl. offen P/A,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6261,0009-0016,9.16,Ended,259,0009-P00,Prim√§re Verschlu√üprophyl. offen Placebo,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6262,0009-0017,9.17,Ended,259,0009-P00,Arteriosklerose-Prophylaxe, Prof. Hess,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6263,0009-0018,9.18,Ended,259,0009-P00,Einflu√ü auf Blutzucker,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6264,0009-0019,9.19,Ended,259,0009-P00,Reverschlu√üprophyl.n.Rekanalisation,Hess,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6265,0009-0020,9.20,Ended,259,0009-P00,Bei Nierentransplation, Prof. Schimpf,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6266,0009-0021,9.21,Ended,259,0009-P00,Koronargef√§√üe, operierte Pat., Hannover,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6267,0009-0022,9.22,Ended,259,0009-P00,Koronargef√§√üe, nicht OP-Pat., Hannover,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6268,0009-0023,9.23,Ended,259,0009-P00,PLZ-By-Pass, Ostendorf,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6269,0009-0024,9.24,Ended,259,0009-P00,Pl√§ttchen IV, Bl√§ttler (1),Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6270,0009-0025,9.25,Ended,259,0009-P00,Dotterstudie, Prof. Roth,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6271,0009-0026,9.26,Ended,259,0009-P00,Einflu√ü Pl√§ttchenfaktor IV (2), Bl√§ttler,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6272,0009-0027,9.27,Ended,259,0009-P00,nach periph. u. art. Bypass, Helsinki,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6273,0009-0028,9.28,Unconfirmed,259,0009-P00,Sick Sinus Syndr.,Schweden, Abdon,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6274,0009-0029,9.29,Ended,259,0009-P00,Reverschlu√üprophylaxe, Prof. Just,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6275,0009-0030,9.30,Unconfirmed,259,0009-P00,Pl√§ttchenfaktoren n. Dotterung, Bl√§ttler,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6276,0009-0031,9.31,Ended,259,0009-P00,TXA2 und PGI2-Metaboliten, Finnland,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6277,0009-0032,9.32,Ended,259,0009-P00,Thromboseprophylaxe nach Bauchoperation,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6278,0009-0033,9.33,Unconfirmed,259,0009-P00,Depot, Reverschlu√üprophylaxe, Prof. Roth,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6279,0009-0034,9.34,Ended,259,0009-P00,Depot, Reverschlu√üprophylaxe, Hess,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6280,0009-0035,9.35,Unconfirmed,259,0009-P00,Depot, Coronary-bypass B 326/81,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6281,0009-0036,9.36,Ended,259,0009-P00,Depot, Thrombozytenproteine, Bl√§ttler,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6282,0009-0037,9.37,Unconfirmed,259,0009-P00,Depot, Hypothermia B 325/81,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6283,0009-0038,9.38,Ended,259,0009-P00,Dep.,Recurrent Venous Thrombosis B312/81,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6284,0009-0039,9.39,Ended,259,0009-P00,Dialysator-Thrombosierung, Dr.Graben,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6285,0009-0040,9.40,Unconfirmed,259,0009-P00,Depot, √üThromboglob. u. PF4, Bremer,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6286,0009-0041,9.41,Unconfirmed,259,0009-P00,Depot, PLZ, Bremer,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6287,0009-0042,9.42,Ended,259,0009-P00,Depot - Persantin Depot, Sinzinger 8/82,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6288,0009-0043,9.43,Unconfirmed,259,0009-P00,Reverschl√ºsse nach Dotterlyse, Krause,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6289,0009-0044,9.44,Unconfirmed,259,0009-P00,Asymptomatische Karotisstenose,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6290,0009-0045,9.45,Unconfirmed,259,0009-P00,Asasantin - trial norway N 339/83,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6291,0009-0046,9.46,Unconfirmed,259,0009-P00,Depot (200/25) CVI-Prophylaxe, Dr.Kremer,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6292,0009-0047,9.47,Unconfirmed,259,0009-P00,Depot, Post-Phlebitic-Syndrom B 900/83,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6293,0009-0048,9.48,Ended,259,0009-P00,Arteriosklerose-Prophylaxe, Dr.Rudofsky,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6294,0009-0049,9.49,Ended,259,0009-P00,Ret., Verschl.v.Bypass-Grafts CH 163/84,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6295,0009-0050,9.50,Ended,259,0009-P00,Arteriosklerose-Therapie Dr.Rudofsky,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6296,0009-0051,9.51,Ended,259,0009-P00,Angiopl.of the arteries of the lower ext,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6297,0009-0052,9.52,Ended,259,0009-P00,Angiopl.of the arteries of the lower ext,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6298,0009-0053,9.53,Unconfirmed,259,0009-P00,Dep.,TXB2,PGI2/Y Prot.i.Aort./Ilber.Kunz,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6299,0009-0054,9.54,Unconfirmed,259,0009-P00,Depot, Arterioskler.-Prophylaxe,Heinrich,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6300,0009-0055,9.55,Ended,259,0009-P00,Depot, Arterioskler.-Prophylaxe,Heinrich,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6301,0009-0056,9.56,Unconfirmed,259,0009-P00,Depot, Rezidivproph. n. PTA CH 905/84,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6302,0009-0059,9.59,Ended,259,0009-P00,Depot, Thromboseprophyl. bei AV-Shunt,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6303,0009-0060,9.60,Unconfirmed,259,0009-P00,Depot, Rezidivproph. n. PTA S 788/85,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6304,0009-0061,9.61,Unconfirmed,259,0009-P00,Restenoseprophyl.n.koronar. PTCA, Erbel,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6305,0009-0062,9.62,Ended,259,0009-P00,Asasantin Depot, Blutungszeit,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6306,0009-0063,9.63,Unconfirmed,259,0009-P00,Depot, 200/25 mg PACART-Study NL 728/86,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6307,0009-0064,9.64,Unconfirmed,259,0009-P00,Depot,200/25 mg Risik.Schwangsch.S 14/87,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6308,0009-0065,9.65,Unconfirmed,259,0009-P00,Depot, 200/25 mg PAVK Stad.I-IV A 90/87,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6309,0009-0066,9.66,Ended,259,0009-P00,Depot, Aggregation m. SEM, High-dose ASS,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6310,0009-0067,9.67,Ended,259,0009-P00,Depot, Aggregation m. SEM, Low-dose ASS,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6311,0009-0069,9.69,Ended,259,0009-P00,Kinetik Vergl.:Asasantin,Persantin,ASS,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6312,0009-0071,9.71,Ended,259,0009-P00,Aggregation: 10,25mg ASS,Asasantin-Depot,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6313,0009-0100,9.100,Ended,259,0009-P00,Peritoneal dialysis,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6314,0009-0101,9.101,Unconfirmed,259,0009-P00,Retinopathy, diabetes-mellitus,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6315,0009-0102,9.102,Unconfirmed,259,0009-P00,Platelet cerebrovascular,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6316,0009-0103,9.103,Unconfirmed,259,0009-P00,Deep vein thrombosis,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6317,0009-0104,9.104,Unconfirmed,259,0009-P00,Infarction,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6318,0009-0106,9.106,Unconfirmed,259,0009-P00,Arterial reconstruction,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6319,0009-0107,9.107,Unconfirmed,259,0009-P00,Arterial construction,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6320,0009-0108,9.108,Unconfirmed,259,0009-P00,Diabetes-mellitus,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6321,0009-0109,9.109,Unconfirmed,259,0009-P00,Diabetes-mellitus, albuminuria,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6322,0009-0110,9.110,Unconfirmed,259,0009-P00,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6323,0009-0111,9.111,Unconfirmed,259,0009-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6324,0009-0112,9.112,Unconfirmed,259,0009-P00,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
6325,0009-0113,9.113,Unconfirmed,259,0009-P00,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6326,0009-0114,9.114,Ended,259,0009-P00,Previous pregnancy complications,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6327,0009-0115,9.115,Ended,259,0009-P00,UNSTABLE ANGINA,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6328,0009-0116,9.116,Ended,259,0009-P00,Asasantin in diabetic retinopathy,Ended,MIG,Migration,IV,Phase IV,- ,,,,
6329,0009-0117,9.117,Ended,259,0009-P00,Platelet aggregation ex vivo,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6330,0009-0118,9.118,Ended,259,0009-P00,Hemolex vs. Haemocult test sensitivity f,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6331,0009-0119,9.119,Ended,259,0009-P00,Asasantin in Diabetic Nephropathy,Ended,MIG,Migration,IV,Phase IV,- ,,,,
6332,0009-0120,9.120,Unconfirmed,259,0009-P00,Pharmacokinetics of Asasantin ER/Persant,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6333,0009-0179,9.179,Preparing,259,0009-P00,Early Treatment,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
6334,0009-0180,9.180,Ended,259,0009-P00,Pharmacokinetics of Aggrenox,Ended,MIG,Migration,IV,Phase IV,,,,,
6335,0009-0181,9.181,Ended,259,0009-P00,Aggrenox in Aspirin resistant patients,Ended,MIG,Migration,IV,Phase IV,,,,,
6336,0009-0184,9.184,Ended,259,0009-P00,Aggrenox in Diabetes patients,Ended,MIG,Migration,IV,Phase IV,,2007-006971-19,,,
6337,0012-0005,12.5,Unconfirmed,260,0012-P02,offene Pr√ºfung Ulcus-Behandlung,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6338,0012-0015,12.15,Unconfirmed,260,0012-P02,Ulcus ventriculi, Prof. Sch√∂ffling,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6339,0012-0016,12.16,Unconfirmed,260,0012-P02,Ulcus duodeni, Prof. Sch√∂ffling,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6340,0012-0017,12.17,Ended,260,0012-P02,Wirkung U. ventriculi, Prof. Schmid,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6341,0012-0021,12.21,Unconfirmed,260,0012-P02,Vergleich gegen Cimetidine,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6342,0012-0022,12.22,Ended,260,0012-P02,Ulcus duodeni, ambulant,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6343,0012-0025,12.25,Unconfirmed,260,0012-P02,Magen-Darm-Ulcera, Prof. Goebell,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6344,0012-0026,12.26,Unconfirmed,260,0012-P02,Saft, Magen-Darm-Ulcera, Ruhrgebiet,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6345,0012-0029,12.29,Ended,260,0012-P02,U. ventriculi, Dr. Belohlavek,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6346,0012-0031,12.31,Ended,260,0012-P02,Prosp. Studie Ulcus duodeni,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6347,0012-0033,12.33,Unconfirmed,260,0012-P02,K√∂lner Studie,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6348,0012-0034,12.34,Ended,260,0012-P02,Magen-Darm-Ulcera,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6349,0012-0037,12.37,Unconfirmed,260,0012-P02,U. duodeni stat., Prof. v.Oldershausen,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6350,0012-0040,12.40,Unconfirmed,260,0012-P02,Blutung oberer Gastrointest.-Trakt,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6351,0012-0041,12.41,Unconfirmed,260,0012-P02,Eintrag fehlt; bitte updaten,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6352,0012-0042,12.42,Unconfirmed,260,0012-P02,Ulcus duodeni, T√ºbingen,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6353,0012-0049,12.49,Unconfirmed,260,0012-P02,Gallesekretion, Prof. Kaess, M√ºnchen,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6354,0012-0050,12.50,Unconfirmed,260,0012-P02,Ulcus duodeni, ambulante Patienten,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6355,0012-0051,12.51,Unconfirmed,260,0012-P02,Ulcus duodeni, Leuven,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6356,0012-0052,12.52,Unconfirmed,260,0012-P02,U. duodeni, Dr. Gassmann 2, Z√ºrich,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6357,0012-0055,12.55,Unconfirmed,260,0012-P02,Stress-Ulcus, Prof. Herfarth,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6358,0012-0056,12.56,Ended,260,0012-P02,Egazil Sekretionshemmung, G√∂teborg,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6359,0012-0057,12.57,Unconfirmed,260,0012-P02,Intragastrale Titration, Dr. Mairose,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6360,0012-0058,12.58,Unconfirmed,260,0012-P02,Therapeutische Studie, Polen,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6361,0012-0059,12.59,Ended,260,0012-P02,Prosp. Studie bei Ulcus duodeni, Multic.,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6362,0012-0060,12.60,Unconfirmed,260,0012-P02,Multicenter-Studie, M√ºnchen,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6363,0012-0061,12.61,Ended,260,0012-P02,Prosp. Studie bei Ulcus duodeni, M√ºnchen,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6364,0012-0062,12.62,Unconfirmed,260,0012-P02,Skandinavische Multicenter-Studie,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6365,0012-0065,12.65,Ended,260,0012-P02,Nahvisus nach i.v.-Applikation,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6366,0012-0066,12.66,Ended,260,0012-P02,Nahvisus nach p.o.-Applikation,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6367,0012-0067,12.67,Unconfirmed,260,0012-P02,U. duodeni - Prophylaxe B 1007/79,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6368,0012-0068,12.68,Unconfirmed,260,0012-P02,Akupunktur bei U. duodeni,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6369,0012-0069,12.69,Unconfirmed,260,0012-P02,Glaukompr√ºfung, Dr. Mertz,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6370,0012-0070,12.70,Unconfirmed,260,0012-P02,Langzeit, Prof. Brassine B 1037/80,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6371,0012-0071,12.71,Unconfirmed,260,0012-P02,Langzeit, Prof. Vantrappen B 1039/80,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6372,0012-0072,12.72,Unconfirmed,260,0012-P02,Bakteriologische Pr√ºfung, Beythien,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6373,0012-0073,12.73,Unconfirmed,260,0012-P02,Short term trial, Maingguet B 116/81,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6374,0012-0074,12.74,Unconfirmed,260,0012-P02,Stressblutung, Dr. Gyr CH 187/81,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6375,0012-0075,12.75,Unconfirmed,260,0012-P02,IOP-Senkung, Prof. Dannheim,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6376,0012-0076,12.76,Ended,260,0012-P02,Protektion nach Nierentransplantation,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6377,0012-0077,12.77,Unconfirmed,260,0012-P02,Multicenter CH 464/81,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6378,0012-0078,12.78,Unconfirmed,260,0012-P02,Dr. Knoblauch CH 507/81,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6379,0012-0079,12.79,Unconfirmed,260,0012-P02,Ulcus duodeni VR China 574/81,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6380,0012-0080,12.80,Unconfirmed,260,0012-P02,IOP-Beeinflu√üung, Prof. Dannheim,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6381,0012-0081,12.81,Unconfirmed,260,0012-P02,Chron. duod. &. gastric U. HK 723/81,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6382,0012-0082,12.82,Unconfirmed,260,0012-P02,Stressl√§sionen, -ulcusblutung CH 600/81,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6383,0012-0083,12.83,Unconfirmed,260,0012-P02,Stressl√§sionen, -ulcusblutung CH 600/81,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6384,0012-0084,12.84,Ended,260,0012-P02,Colon irritabile, Dr. H√ºttemann,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6385,0012-0085,12.85,Unconfirmed,260,0012-P02,Stressulcus-Prophylaxe, Jugoslawien,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6386,0012-0086,12.86,Ended,260,0012-P02,Narbenqualit√§t und Rezidivrate (Ranitid),Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6387,0012-0087,12.87,Ended,260,0012-P02,Narbenqualit√§t und Rezidivrate (Cimet.),Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6388,0012-0088,12.88,Ended,260,0012-P02,Blutungsprophylaxe,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6389,0012-0089,12.89,Ended,260,0012-P02,Ver√§nderungen von Parietal- und Gastrinz,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6390,0012-0090,12.90,Ended,260,0012-P02,Pepsinogen-Stoffwechsel,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6391,0012-0091,12.91,Unconfirmed,260,0012-P02,Langzeit, Dr. Laukens B 298/82,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6392,0012-0092,12.92,Unconfirmed,260,0012-P02,Langzeit, Prof. de Vis B 299/82,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6393,0012-0093,12.93,Ended,260,0012-P02,Non-Ulcer-Dyspepsia,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6394,0012-0094,12.94,Unconfirmed,260,0012-P02,Langzeit, Prof. Van Maercke B 579/82,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6395,0012-0095,12.95,Ended,260,0012-P02,Mannit-L√∂sung Erstanwendung,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6396,0012-0096,12.96,Ended,260,0012-P02,Sekretionsvergleichsstudie, Dr. Londong,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6397,0012-0097,12.97,Unconfirmed,260,0012-P02,Remissionszeiten/Rezidivraten CH 690/82,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6398,0012-0098,12.98,Ended,260,0012-P02,Pilotstudie,Frequenzsteigerung,Dr.Preiss,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6399,0012-0099,12.99,Ended,260,0012-P02,Frequenzsteigerung, Dr.Preiss,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6400,0012-0100,12.100,Unconfirmed,260,0012-P02,Vergleichsstudie, Finnland SF 875/82,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6401,0012-0101,12.101,Unconfirmed,260,0012-P02,Intervallprophylaxe Ulcus duodeni, Polen,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6402,0012-0102,12.102,Ended,260,0012-P02,Colon irritabile, Dr. Bilger,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6403,0012-0103,12.103,Ended,260,0012-P02,Sekretionshemmung, Dr. Londong,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6404,0012-0104,12.104,Ended,260,0012-P02,Stress-Ulcus, Hannover,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6405,0012-0105,12.105,Unconfirmed,260,0012-P02,Prophylaxe Mendelson-Syndr.,Huchzermeyer,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6406,0012-0106,12.106,Ended,260,0012-P02,Hemmung der sham-feeding induz.Sekretion,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6407,0012-0107,12.107,Ended,260,0012-P02,Motilit√§t von Sigma u.Rektum,Dr.v.Kleist,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6408,0012-0108,12.108,Ended,260,0012-P02,Motilit√§tsst√∂rungen, Dr. H√ºttemann,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6409,0012-0109,12.109,Ended,260,0012-P02,Leberdurchblutung, PD B√ºtzow,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6410,0012-0110,12.110,Ended,260,0012-P02,Kinetik-Pilotstudie, Dr. Krakamp,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6411,0012-0111,12.111,Unconfirmed,260,0012-P02,Kinetik b. Niereninsuffizienz,Dr.Krakamp,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6412,0012-0112,12.112,Unconfirmed,260,0012-P02,bei Reflux-√ñsophagitis SF 824/83,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6413,0012-0113,12.113,Ended,260,0012-P02,Orientierende Vertr√§glichkeit, Thomae,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6414,0012-0114,12.114,Unconfirmed,260,0012-P02,Retrospektive Erhebung bei Kindern,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6415,0012-0115,12.115,Unconfirmed,260,0012-P02,Praxispr√ºfung bei Ausl√§ndern, Frankfurt,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6416,0012-0116,12.116,Ended,260,0012-P02,i.v. Pr√ºfung Fertig- / Trockenampulle,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6417,0012-0117,12.117,Ended,260,0012-P02,i.m. Pr√ºfung Fertig- / Trockenampulle,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6418,0012-0118,12.118,Ended,260,0012-P02,Bioverf√ºgbarkeit oraler Antibiotika,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6419,0012-0119,12.119,Ended,260,0012-P02,Wirksamkeit Fertig-/Mannitamp., Londong,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6420,0012-0120,12.120,Unconfirmed,260,0012-P02,Colon irritabile, Pinneberg,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6421,0012-0121,12.121,Ended,260,0012-P02,Ulcus ventriculi,retrospektiv,Dr.Panijel,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6422,0012-0122,12.122,Unconfirmed,260,0012-P02,Non-ulcer Dyspepsia HK 74/84,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6423,0012-0123,12.123,Unconfirmed,260,0012-P02,Ulcus duodeni H 414,415/84,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6424,0012-0124,12.124,Ended,260,0012-P02,Stre√üulcus-Prophylaxe, Glaxo,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6425,0012-0125,12.125,Unconfirmed,260,0012-P02,Langzeitpr√ºfung, Prof.Mainguet B 508/84,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6426,0012-0126,12.126,Unconfirmed,260,0012-P02,Norwegen N 658/84,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6427,0012-0127,12.127,Unconfirmed,260,0012-P02,Mendelson-Syndrom,Pilotstudie,Wei√üenberg,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6428,0012-0128,12.128,Ended,260,0012-P02,Laktatbestimmungen, Dr. Tympner,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6429,0012-0129,12.129,Unconfirmed,260,0012-P02,Mendelson-Syndrom, Dr. Paronen-Mylius,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6430,0012-0130,12.130,Unconfirmed,260,0012-P02,multicenter-Studie, BIZ /85,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6431,0012-0131,12.131,Unconfirmed,260,0012-P02,Doppelblindstudie S 124/85,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6432,0012-0132,12.132,Ended,260,0012-P02,Stre√üblutungsprophylaxe, Dr. Tryba,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6433,0012-0133,12.133,Unconfirmed,260,0012-P02,Doppelblindstudie, Dr. Szanto S 237/85,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6434,0012-0134,12.134,Ended,260,0012-P02,Colon irritabile, Dr. Kruis,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6435,0012-0135,12.135,Unconfirmed,260,0012-P02,Sekretion, Probanden, Dr. Wellmann,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6436,0012-0136,12.136,Ended,260,0012-P02,Depotentwicklung (100 mg),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6437,0012-0137,12.137,Ended,260,0012-P02,bei Pankreatitis, Drs. Janisch, Kleist,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6438,0012-0138,12.138,Ended,260,0012-P02,komb. Anwendung mit Ranitidin, Londong,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6439,0012-0139,12.139,Ended,260,0012-P02,bei Niereninsuffizienz, Dr. Krakamp,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6440,0012-0140,12.140,Ended,260,0012-P02,bei Leber-und Niereninsuff., Dr. Krakamp,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6441,0012-0141,12.141,Ended,260,0012-P02,Bioverf./ Kinetik Depotentwickl.100 mg I,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6442,0012-0142,12.142,Unconfirmed,260,0012-P02,irritable bowel syndrome S 748/85,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6443,0012-0144,12.144,Ended,260,0012-P02,Bioverf./Kinetik Depotentwickl.100 mg II,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6444,0012-0145,12.145,Unconfirmed,260,0012-P02,Non-ulcer Dyspepsia N 138/86,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6445,0012-0146,12.146,Unconfirmed,260,0012-P02,Reflux Oesophagitis N 137/86,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6446,0012-0147,12.147,Unconfirmed,260,0012-P02,Gastrointestinale Peptide bei Ulcuspat.,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6447,0012-0148,12.148,Ended,260,0012-P02,Dosisfindung f√ºr i.v.-Infusion an Prob.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6448,0012-0149,12.149,Unconfirmed,260,0012-P02,hpGRF1-40 stimulierte Sekretion von HGH,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6449,0012-0150,12.150,Unconfirmed,260,0012-P02,hpGRF1-40 stimulierte Sekretion von HGH,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6450,0012-0151,12.151,Ended,260,0012-P02,Schlaf-assoziierte Sekretion von HGH,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6451,0012-0152,12.152,Unconfirmed,260,0012-P02,Belastungs-induzierte Sekretion von HGH,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6452,0012-0153,12.153,Unconfirmed,260,0012-P02,Hypoglyk√§mie-induzier. Sekretion von HGH,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6453,0012-0154,12.154,Ended,260,0012-P02,Prophylaxe v. Stre√üulcera u.-blut.,Meier,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6454,0012-0155,12.155,Ended,260,0012-P02,Wirkung auf den Magensaft-pH, Dr. Salm,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6455,0012-0156,12.156,Unconfirmed,260,0012-P02,u.Sucralfat als Mono- und Komb.beh,Tryba,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6456,0012-0157,12.157,Ended,260,0012-P02,Urinspiegel versch. Nachahmer 100 mg p.o,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6457,0012-0158,12.158,Ended,260,0012-P02,Bioverf./Kinetik Depotentw. 100 mg III,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6458,0012-0159,12.159,Ended,260,0012-P02,Bioverf./Kinetik Depotentwickl.100 mg IV,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6459,0012-0160,12.160,Unconfirmed,260,0012-P02,bei bronch. Hyperreaktion(i.v.) PL 99/87,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6460,0012-0161,12.161,Unconfirmed,260,0012-P02,LS 519 in erosive Duodenitis SF 89/87,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6461,0012-0162,12.162,Ended,260,0012-P02,Bioverf./Kinetik Depot 100 mg 4 Tage,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6462,0012-0163,12.163,Unconfirmed,260,0012-P02,bei dyspept. Symptomen o. Ulcus S 209/87,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6463,0012-0164,12.164,Ended,260,0012-P02,Bioverf./Kinetik 3 Depot Formen 100mg 5T,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6464,0012-0165,12.165,Ended,260,0012-P02,Vergleich HPLC-Methode mit ELISA-Test,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6465,0012-0166,12.166,Ended,260,0012-P02,Sekretionshemmung von Gastrozepin-Retard,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6466,0012-0170,12.170,Ended,260,0012-P02,Kinetics compar. slow release caps./tbl.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6467,0012-0171,12.171,Ended,260,0012-P02,Proph.of Pirenc.in ERCP-ind.Pancr.-dam.,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6468,0012-0200,12.200,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6469,0012-0205,12.205,Unconfirmed,260,0012-P02,Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6470,0012-0209,12.209,Unconfirmed,260,0012-P02,Intensive care,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6471,0012-0213,12.213,Unconfirmed,260,0012-P02,Dyspepsia chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6472,0012-0214,12.214,Unconfirmed,260,0012-P02,Dyspepsia;Ulcer gastric/Duodenal haemorr,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6473,0012-0216,12.216,Unconfirmed,260,0012-P02,Renal failure minor;Dyspepsia;Duodenitis,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6474,0012-0218,12.218,Unconfirmed,260,0012-P02,Ulcer peptic,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6475,0012-0220,12.220,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6476,0012-0221,12.221,Unconfirmed,260,0012-P02,Ulcer gastric,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6477,0012-0226,12.226,Unconfirmed,260,0012-P02,Ulcer gastric;Ulcer duodenal;Dyspepsia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6478,0012-0227,12.227,Unconfirmed,260,0012-P02,Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6479,0012-0237,12.237,Unconfirmed,260,0012-P02,Rheumatism minor,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6480,0012-0245,12.245,Unconfirmed,260,0012-P02,Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6481,0012-0248,12.248,Unconfirmed,260,0012-P02,Ulcer stress,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6482,0012-0250,12.250,Ended,260,0012-P02,Glaucoma minor,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6483,0012-0252,12.252,Unconfirmed,260,0012-P02,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6484,0012-0254,12.254,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6485,0012-0256,12.256,Unconfirmed,260,0012-P02,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6486,0012-0258,12.258,Unconfirmed,260,0012-P02,Dyspepsia chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6487,0012-0260,12.260,Ended,260,0012-P02,Dyspepsia,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6488,0012-0263,12.263,Unconfirmed,260,0012-P02,Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6489,0012-0264,12.264,Unconfirmed,260,0012-P02,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6490,0012-0266,12.266,Unconfirmed,260,0012-P02,Gastric acid hypersecretion,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6491,0012-0267,12.267,Unconfirmed,260,0012-P02,Lymphatic diseases,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6492,0012-0270,12.270,Ended,260,0012-P02,Ulcer duodenal healed,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6493,0012-0272,12.272,Unconfirmed,260,0012-P02,Surgery gastric postoperative pre-Operat,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6494,0012-0273,12.273,Unconfirmed,260,0012-P02,Ulcer,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6495,0012-0274,12.274,Unconfirmed,260,0012-P02,Dyspepsia;Ulcer;Dialysis minor,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6496,0012-0276,12.276,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6497,0012-0288,12.288,Unconfirmed,260,0012-P02,Ulcer stress,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6498,0012-0289,12.289,Unconfirmed,260,0012-P02,Ulcer stress,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6499,0012-0290,12.290,Unconfirmed,260,0012-P02,Ulcer peptic;Dyspepsia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6500,0012-0295,12.295,Unconfirmed,260,0012-P02,Prostatic hypertrophy minor,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6501,0012-0296,12.296,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6502,0012-0297,12.297,Ended,260,0012-P02,Dyspepsia,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6503,0012-0299,12.299,Unconfirmed,260,0012-P02,Ulcer stress,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6504,0012-0300,12.300,Unconfirmed,260,0012-P02,Ulcer stress,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6505,0012-0301,12.301,Unconfirmed,260,0012-P02,Ulcer stress;Haemorrhage gastro-Intestin,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6506,0012-0302,12.302,Unconfirmed,260,0012-P02,Haemorrhage gastro-Intestinal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6507,0012-0304,12.304,Unconfirmed,260,0012-P02,Ulcer peptic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6508,0012-0309,12.309,Unconfirmed,260,0012-P02,Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6509,0012-0311,12.311,Unconfirmed,260,0012-P02,Ulcer gastric,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6510,0012-0312,12.312,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6511,0012-0313,12.313,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6512,0012-0314,12.314,Unconfirmed,260,0012-P02,Haemorrhage gastric,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6513,0012-0315,12.315,Unconfirmed,260,0012-P02,Ulcer stress,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6514,0012-0316,12.316,Unconfirmed,260,0012-P02,Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6515,0012-0317,12.317,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6516,0012-0327,12.327,Unconfirmed,260,0012-P02,Gastric acid hypersecretion,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6517,0012-0328,12.328,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6518,0012-0329,12.329,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6519,0012-0338,12.338,Unconfirmed,260,0012-P02,Haemorrhage gastro-Intestinal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6520,0012-0339,12.339,Ended,260,0012-P02,Peptic Ulcer Disease, relapse,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6521,0012-0340,12.340,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6522,0012-0341,12.341,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6523,0012-0342,12.342,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6524,0012-0343,12.343,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6525,0012-0344,12.344,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6526,0012-0345,12.345,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6527,0012-0346,12.346,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6528,0012-0348,12.348,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6529,0012-0349,12.349,Unconfirmed,260,0012-P02,Gastric acid hypersecretion,Unconfirmed,MIG,Migration,III,Phase III,- planned patients: 12-16 * *,,,000910,IS - Clin Study (MIGRATED)
6530,0012-0350,12.350,Unconfirmed,260,0012-P02,Ulcer peptic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6531,0012-0351,12.351,Unconfirmed,260,0012-P02,Ulcer peptic;Dyspepsia;Duodenitis,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6532,0012-0352,12.352,Unconfirmed,260,0012-P02,Rheumatism minor,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6533,0012-0355,12.355,Unconfirmed,260,0012-P02,Ulcer peptic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6534,0012-0362,12.362,Unconfirmed,260,0012-P02,Ulcer;Surgery renal minor,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6535,0012-0363,12.363,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6536,0012-0365,12.365,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6537,0012-0372,12.372,Unconfirmed,260,0012-P02,Ulcer stress healed,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6538,0012-0373,12.373,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6539,0012-0374,12.374,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6540,0012-0375,12.375,Unconfirmed,260,0012-P02,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6541,0012-0378,12.378,Unconfirmed,260,0012-P02,Ulcer peptic;Dyspepsia haemorrhagic;Oeso,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6542,0012-0386,12.386,Unconfirmed,260,0012-P02,Ulcer peptic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6543,0012-0391,12.391,Unconfirmed,260,0012-P02,Ulcer peptic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6544,0012-0394,12.394,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6545,0012-0396,12.396,Unconfirmed,260,0012-P02,Oesophagitis;Dyspepsia;Duodenitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6546,0012-0399,12.399,Unconfirmed,260,0012-P02,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6547,0012-0400,12.400,Unconfirmed,260,0012-P02,Haemorrhage gastro-Intestinal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6548,0012-0401,12.401,Unconfirmed,260,0012-P02,Dyspepsia erosive;Dyspepsia congestive;D,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6549,0012-0412,12.412,Unconfirmed,260,0012-P02,Colon irritable,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6550,0012-0418,12.418,Unconfirmed,260,0012-P02,Vagal hypertonia;Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6551,0012-0425,12.425,Unconfirmed,260,0012-P02,Intensive care;Ulcer stress,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6552,0012-0427,12.427,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6553,0012-0428,12.428,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6554,0012-0429,12.429,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6555,0012-0431,12.431,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6556,0012-0433,12.433,Unconfirmed,260,0012-P02,Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6557,0012-0434,12.434,Unconfirmed,260,0012-P02,Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6558,0012-0437,12.437,Unconfirmed,260,0012-P02,Oesophagitis;Dyspepsia;Duodenitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6559,0012-0444,12.444,Unconfirmed,260,0012-P02,Colon irritable,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6560,0012-0445,12.445,Unconfirmed,260,0012-P02,Haemorrhage gastric;Haemorrhage duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6561,0012-0447,12.447,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6562,0012-0448,12.448,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,NONE,Not Classified,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
6563,0012-0455,12.455,Unconfirmed,260,0012-P02,Intolerance drug minor,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6564,0012-0457,12.457,Ended,260,0012-P02,none,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6565,0012-0468,12.468,Unconfirmed,260,0012-P02,Surgery gastric postoperative,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6566,0012-0472,12.472,Unconfirmed,260,0012-P02,Oesophagitis,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6567,0012-0473,12.473,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6568,0012-0474,12.474,Ended,260,0012-P02,Arthritis minor,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6569,0012-0475,12.475,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6570,0012-0481,12.481,Unconfirmed,260,0012-P02,Arthritis minor,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6571,0012-0482,12.482,Unconfirmed,260,0012-P02,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6572,0012-0485,12.485,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6573,0012-0494,12.494,Unconfirmed,260,0012-P02,Ulcer peptic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6574,0012-0503,12.503,Unconfirmed,260,0012-P02,Colon irritable,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6575,0012-0504,12.504,Unconfirmed,260,0012-P02,Colon irritable,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6576,0012-0509,12.509,Unconfirmed,260,0012-P02,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- NZ Trial,,,000910,IS - Clin Study (MIGRATED)
6577,0012-0510,12.510,Unconfirmed,260,0012-P02,Renal failure chronic dialysis haemo min,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6578,0012-0512,12.512,Unconfirmed,260,0012-P02,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6579,0012-0513,12.513,Unconfirmed,260,0012-P02,Colon irritable,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6580,0012-0516,12.516,Unconfirmed,260,0012-P02,Colon irritable,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6581,0012-0518,12.518,Unconfirmed,260,0012-P02,Dyspepsia;Ulcer gastric;Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6582,0012-0519,12.519,Unconfirmed,260,0012-P02,Oesophagitis;Dyspepsia;Duodenitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6583,0012-0520,12.520,Unconfirmed,260,0012-P02,Ulcer haemorrhagic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6584,0012-0522,12.522,Unconfirmed,260,0012-P02,Haemorrhage gastric;Haemorrhage duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6585,0012-0524,12.524,Unconfirmed,260,0012-P02,Duodenitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6586,0012-0526,12.526,Unconfirmed,260,0012-P02,Surgery urologic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6587,0012-0528,12.528,Unconfirmed,260,0012-P02,Arthritis minor,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6588,0012-0531,12.531,Unconfirmed,260,0012-P02,Haemorrhage stress,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6589,0012-0532,12.532,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6590,0012-0533,12.533,Unconfirmed,260,0012-P02,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6591,0012-0534,12.534,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6592,0012-0535,12.535,Unconfirmed,260,0012-P02,Intensive care,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6593,0012-0536,12.536,Unconfirmed,260,0012-P02,Colon irritable,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6594,0012-0540,12.540,Unconfirmed,260,0012-P02,Ulcer stress prevention,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6595,0012-0543,12.543,Unconfirmed,260,0012-P02,Ulcer peptic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6596,0012-0548,12.548,Unconfirmed,260,0012-P02,Haemorrhage gastro-Intestinal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6597,0012-0549,12.549,Unconfirmed,260,0012-P02,Haemorrhage gastro-Intestinal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6598,0012-0552,12.552,Unconfirmed,260,0012-P02,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6599,0012-0553,12.553,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6600,0012-0554,12.554,Unconfirmed,260,0012-P02,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6601,0012-0562,12.562,Unconfirmed,260,0012-P02,No Legacy Data,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6602,0012-0563,12.563,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6603,0012-0564,12.564,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,II,Phase II,- planned patients:28-32 * *,,,000910,IS - Clin Study (MIGRATED)
6604,0012-0565,12.565,Unconfirmed,260,0012-P02,Intensive care;Ulcer stress,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6605,0012-0566,12.566,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6606,0012-0568,12.568,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6607,0012-0569,12.569,Ended,260,0012-P02,Gastric ulcer,Ended,MIG,Migration,IV,Phase IV,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
6608,0012-0571,12.571,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6609,0012-0572,12.572,Unconfirmed,260,0012-P02,Ulcer peptic,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6610,0012-0573,12.573,Unconfirmed,260,0012-P02,Ulcer peptic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6611,0012-0574,12.574,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6612,0012-0575,12.575,Unconfirmed,260,0012-P02,Ulcer peptic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6613,0012-0576,12.576,Unconfirmed,260,0012-P02,Ulcer peptic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6614,0012-0577,12.577,Unconfirmed,260,0012-P02,Ulcer peptic,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6615,0012-0578,12.578,Unconfirmed,260,0012-P02,Ulcer peptic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6616,0012-0583,12.583,Unconfirmed,260,0012-P02,Pancreatitis,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6617,0012-0586,12.586,Unconfirmed,260,0012-P02,Hernia hiatal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6618,0012-0593,12.593,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6619,0012-0596,12.596,Unconfirmed,260,0012-P02,Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6620,0012-0597,12.597,Unconfirmed,260,0012-P02,No Legacy Data,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6621,0012-0598,12.598,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6622,0012-0601,12.601,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6623,0012-0602,12.602,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6624,0012-0604,12.604,Unconfirmed,260,0012-P02,Cholelithiasis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6625,0012-0606,12.606,Unconfirmed,260,0012-P02,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6626,0012-0607,12.607,Unconfirmed,260,0012-P02,Surgery,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6627,0012-0608,12.608,Unconfirmed,260,0012-P02,Duodenitis gastritis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6628,0012-0609,12.609,Unconfirmed,260,0012-P02,Gastric erosions,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6629,0012-0610,12.610,Unconfirmed,260,0012-P02,Dyspepsia acute;Dyspepsia chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6630,0012-0611,12.611,Unconfirmed,260,0012-P02,Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6631,0012-0613,12.613,Unconfirmed,260,0012-P02,Dyspepsia;Haemorrhage gastric,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6632,0012-0614,12.614,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6633,0012-0617,12.617,Unconfirmed,260,0012-P02,No Legacy Data,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6634,0012-0620,12.620,Unconfirmed,260,0012-P02,Intensive care,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6635,0012-0621,12.621,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6636,0012-0622,12.622,Unconfirmed,260,0012-P02,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6637,0012-0623,12.623,Unconfirmed,260,0012-P02,Gastric erosions,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6638,0012-0625,12.625,Unconfirmed,260,0012-P02,Pulmonary acid aspiration,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6639,0012-0626,12.626,Unconfirmed,260,0012-P02,Ulcer;Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6640,0012-0627,12.627,Unconfirmed,260,0012-P02,Gastroenterology,Unconfirmed,MIG,Migration,IV,Phase IV,- NZ Trial,,,000910,IS - Clin Study (MIGRATED)
6641,0012-0630,12.630,Unconfirmed,260,0012-P02,Ulcer gastric,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6642,0012-0631,12.631,Ended,260,0012-P02,Intensive care;Ulcer stress,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6643,0012-0633,12.633,Unconfirmed,260,0012-P02,Ulcer gastric,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6644,0012-0637,12.637,Unconfirmed,260,0012-P02,Haemorrhage gastroduodenal,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6645,0012-0638,12.638,Ended,260,0012-P02,Gastroduodenitis,Ended,MIG,Migration,IV,Phase IV,- 2) 20 PATIENTS (13 M *,,,000910,IS - Clin Study (MIGRATED)
6646,0012-0639,12.639,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- Published in Minerva Dietologica E Gastroenterologica, 34, 4, 265-268, 1988.* *,,,000910,IS - Clin Study (MIGRATED)
6647,0012-0640,12.640,Ended,260,0012-P02,Gastric erosions,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6648,0012-0641,12.641,Ended,260,0012-P02,Gastric erosions,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6649,0012-0642,12.642,Ended,260,0012-P02,Dyspepsia,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6650,0012-0643,12.643,Ended,260,0012-P02,Gastric erosions,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6651,0012-0644,12.644,Ended,260,0012-P02,Gastro-Intestinal disease,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6652,0012-0645,12.645,Unconfirmed,260,0012-P02,Gastric erosions,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6653,0012-0646,12.646,Unconfirmed,260,0012-P02,Gastric erosions neoplasm brain minor,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6654,0012-0647,12.647,Unconfirmed,260,0012-P02,Gastric erosions neoplasm brain minor,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6655,0012-0648,12.648,Ended,260,0012-P02,Ulcer stress,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6656,0012-0650,12.650,Ended,260,0012-P02,Non-ulcer dyspepsia,Ended,MIG,Migration,III,Phase III,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
6657,0012-0652,12.652,Ended,260,0012-P02,Dyspepsia,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6658,0012-0654,12.654,Unconfirmed,260,0012-P02,Rheumatism minor,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6659,0012-0656,12.656,Unconfirmed,260,0012-P02,Ulcer stress,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6660,0012-0657,12.657,Unconfirmed,260,0012-P02,Ulcer stress,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6661,0012-0658,12.658,Unconfirmed,260,0012-P02,Dyspepsia chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6662,0012-0661,12.661,Ended,260,0012-P02,NUD,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6663,0012-0665,12.665,Ended,260,0012-P02,Gastric bleeding,Ended,MIG,Migration,IV,Phase IV,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
6664,0012-0667,12.667,Ended,260,0012-P02,Ulcer gastric,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6665,0012-0669,12.669,Ended,260,0012-P02,Duodenitis,Ended,MIG,Migration,III,Phase III,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
6666,0012-0673,12.673,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6667,0012-0675,12.675,Ended,260,0012-P02,HEALING RATE VS.SUCRALFATE,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6668,0012-0676,12.676,Ended,260,0012-P02,EFFECTS ON NIGHTLY GH SECRETION,Ended,MIG,Migration,IV,Phase IV,- Report expected 12/92 (Letter Daniotti 06.10.92),,,000910,IS - Clin Study (MIGRATED)
6669,0012-0677,12.677,Unconfirmed,260,0012-P02,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- Trial finished in Oct.88. Published in: Min.Dietol.           Gastroenterol. 34 (1988),257-263 *,,,000910,IS - Clin Study (MIGRATED)
6670,0012-0678,12.678,Unconfirmed,260,0012-P02,POSTOPERATIVE,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6671,0012-0680,12.680,Unconfirmed,260,0012-P02,UPPER GI-BLEEDING,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6672,0012-0681,12.681,Ended,260,0012-P02,Gastroduodenitis,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6673,0012-0682,12.682,Ended,260,0012-P02,GASTRITIS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6674,0012-0683,12.683,Ended,260,0012-P02,GASTRITIS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6675,0012-0684,12.684,Ended,260,0012-P02,GASTRITIS,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6676,0012-0685,12.685,Ended,260,0012-P02,GASTRITIS,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6677,0012-0686,12.686,Unconfirmed,260,0012-P02,Gastric bleeding,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6678,0012-0687,12.687,Ended,260,0012-P02,Pirenzepine in NSAID-induced upper GI er,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6679,0012-0688,12.688,Ended,260,0012-P02,Clinical trial of Gastrozepin tablet,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6680,0012-0690,12.690,Ended,260,0012-P02,Nippon Univ. Study,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
6681,0012-0691,12.691,Ended,260,0012-P02,METABOLIC EFFICACY OF SINGLE DOSE,Ended,MIG,Migration,II,Phase II,- ,,,,
6682,0012-0692,12.692,Ended,260,0012-P02,Nagoya City Univ. Study,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
6683,0012-0693,12.693,Ended,260,0012-P02,Jikei Univ. Study,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
6684,0012-0694,12.694,Ended,260,0012-P02,Nagoya Univ. Study,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
6685,0012-0695,12.695,Ended,260,0012-P02,Minoo HP,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
6686,0012-0696,12.696,Ended,260,0012-P02,Comparison of relapse rate and plasma,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
6687,0012-0697,12.697,Ended,260,0012-P02,JR Sendai Hosp,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
6688,0012-0698,12.698,Ended,260,0012-P02,Showa Univ. Fujigaoka Hospital,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
6689,0012-0699,12.699,Ended,260,0012-P02,Yokohama Rosai Hospital,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
6690,0012-0700,12.700,Ended,260,0012-P02,METABOLIC EFFICACY OF MULTIPLE DOSE,Ended,MIG,Migration,II,Phase II,- ,,,,
6691,0012-0702,12.702,Ended,260,0012-P02,Phase IV Effect of GAi for prophylaxis,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
6692,0012-0703,12.703,Ended,260,0012-P02,Gastrozepin - Stre√üulcusprophylaxe,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
6693,0019-0001,19.1,Unconfirmed,261,0019-P01,bei Herzinfarkt, Prof. Schmid,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6694,0019-0002,19.2,Unconfirmed,261,0019-P01,pr√§- und postop. Chirurgie, Prof. Meyer,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6695,0019-0003,19.3,Ended,261,0019-P01,postoperativ, Urologie, Dr. Miller,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6696,0019-0004,19.4,Ended,261,0019-P01,in der Psychiatrie, Dr. v. Hanxleden,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6697,0019-0005,19.5,Ended,261,0019-P01,bei chronischem Alkoholismus, Dr. Guthy,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6698,0019-0006,19.6,Ended,261,0019-P01,cardioph. Angstneurosen, Dr. Bibracher,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6699,0019-0007,19.7,Unconfirmed,261,0019-P01,bei cardioph. Angstneurosen, Dr. Wilke,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6700,0019-0008,19.8,Ended,261,0019-P01,Interferenz mit Cumarin, Dr. Schneider,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6701,0019-0009,19.9,Ended,261,0019-P01,Psychosen Zusatzmedikation, Dr. Eckmann,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6702,0019-0010,19.10,Ended,261,0019-P01,im autogenen Training, Dr. Eberlein,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6703,0019-0011,19.11,Ended,261,0019-P01,Okulodynamischer Test, Dr. Schaffler,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6704,0019-0012,19.12,Ended,261,0019-P01,bei Enuresis nocturna,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6705,0019-0013,19.13,Ended,261,0019-P01,Pilot-Studie, Einsparung von Opiaten,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6706,0019-0014,19.14,Ended,261,0019-P01,Pilot-Studie, Schlafst. bei Karzinompat.,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6707,0019-0015,19.15,Ended,261,0019-P01,HWS-, LWS- Syndrom, Dr. Sch√∂pp,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6708,0019-0016,19.16,Ended,261,0019-P01,√Ñnderungen im EEG, Prof. Bente,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6709,0019-0017,19.17,Ended,261,0019-P01,Psychische Erkrankungen, Zick/Hertting,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6710,0019-0018,19.18,Ended,261,0019-P01,Wirkung bei Engwinkelglaukom, Schneider,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6711,0019-0019,19.19,Ended,261,0019-P01,bei experimentellem Stre√ü, Prof. Ehrly,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6712,0019-0020,19.20,Ended,261,0019-P01,Kinetik Handelsform/Oblongtablette,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6713,0019-0021,19.21,Ended,261,0019-P01,Psychische u. somat. Effekte b. Phobien,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6714,0019-0022,19.22,Ended,261,0019-P01,bei neurotischen Depressionen, Radmayer,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6715,0019-0023,19.23,Unconfirmed,261,0019-P01,Quart vs Thombran in Geriatrie, Radmayer,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6716,0019-0024,19.24,Unconfirmed,261,0019-P01,Quart in Geriatrie, Langer/Sch√∂nbeck,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6717,0023-0004,23.4,Ended,262,0023-P01,Lokale Anwendung bei Dermatosen,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6718,0023-0005,23.5,Ended,262,0023-P01,Lokale Anwendung bei Dermatosen,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6719,0023-0006,23.6,Ended,262,0023-P01,Pharmakokinetik v. Fucidine DR (Vorvers),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6720,0023-0007,23.7,Ended,262,0023-P01,Pharmakokinetik nach p.o. u. i.v. Appl.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6721,0023-0008,23.8,Ended,262,0023-P01,Penetrationsuntersuchung, Prof. St√ºttgen,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6722,0023-0009,23.9,Unconfirmed,262,0023-P01,Penetratat. in Eiter, Prof. Ruckdeschel,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6723,0023-0010,23.10,Unconfirmed,262,0023-P01,Penetration von Fucidin-S√§ure, Battelle,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6724,0023-0011,23.11,Ended,262,0023-P01,bei Osteomyelitis, Dr. Arens,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6725,0023-0012,23.12,Ended,262,0023-P01,Wundkleber-Spr√ºhverband bei Infektionen,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6726,0023-0013,23.13,Ended,262,0023-P01,Fucidine Puderspray bei Infektionen,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6727,0023-0014,23.14,Ended,262,0023-P01,Vergleichende Pharmakokinetik,Tabl.250mg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6728,0023-0015,23.15,Unconfirmed,262,0023-P01,Wirksamkeit bei AIDS, Pilotstudie,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6729,0023-0016,23.16,Ended,262,0023-P01,Efficacy/safety in osteomyelitis,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6730,0023-0017,23.17,Ended,262,0023-P01,Fucidine-Lotion vs Erythmycin b.Akne,LEO,Ended,MIG,Migration,III,Phase III,Initiating OPU: Leo ,,,000910,IS - Clin Study (MIGRATED)
6731,0023-0018,23.18,Ended,262,0023-P01,vs Nebacetin-Salbe b. Pyodermien, BWK,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6732,0023-0019,23.19,Ended,262,0023-P01,Einflu√ü von Fucidine auf P450,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6733,0023-0030,23.30,Ended,262,0023-P01,Fucidine - local application,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
6734,0023-0031,23.31,Ended,262,0023-P01,Fucidine - gauze,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
6735,0023-0032,23.32,Ended,262,0023-P01,Drug monitoring - Fucidine gauze,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
6736,0023-0033,23.33,Ended,262,0023-P01,PMS in Fucidine plus,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
6737,0029-0003,29.3,Unconfirmed,263,0029-P00,Hypertension,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6738,0029-0004,29.4,Unconfirmed,263,0029-P00,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6739,0029-0005,29.5,Unconfirmed,263,0029-P00,Hypertension,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6740,0029-0006,29.6,Ended,263,0029-P00,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6741,0029-0007,29.7,Ended,263,0029-P00,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6742,0029-0008,29.8,Ended,263,0029-P00,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,II,Phase II,- Dev.Prot.: STUDY STOPPED DUE TO LACH OF APPROPRIATE PATIENT POPULATION AND NO EFFICACY ANALYSIS WAS PERFORMED IN CENTRE *,,,000910,IS - Clin Study (MIGRATED)
6743,0029-0009,29.9,Ended,263,0029-P00,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6744,0029-0010,29.10,Ended,263,0029-P00,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6745,0029-0011,29.11,Ended,263,0029-P00,Hypertension mild;Hypertension moderate,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6746,0029-0013,29.13,Unconfirmed,263,0029-P00,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6747,0029-0014,29.14,Unconfirmed,263,0029-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6748,0029-0015,29.15,Ended,263,0029-P00,Hypertension,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6749,0029-0016,29.16,Unconfirmed,263,0029-P00,Hypertension,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6750,0029-0017,29.17,Unconfirmed,263,0029-P00,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6751,0029-0018,29.18,Unconfirmed,263,0029-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6752,0029-0019,29.19,Unconfirmed,263,0029-P00,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6753,0029-0020,29.20,Unconfirmed,263,0029-P00,Cough chronic,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6754,0029-0021,29.21,Unconfirmed,263,0029-P00,Cough chronic,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6755,0029-0022,29.22,Unconfirmed,263,0029-P00,Cough chronic,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6756,0029-0023,29.23,Ended,263,0029-P00,Surgery cardiovascular,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6757,0029-0024,29.24,Unconfirmed,263,0029-P00,Angina-Pectoris,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6758,0029-0025,29.25,Ended,263,0029-P00,Hypertension,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6759,0029-0026,29.26,Unconfirmed,263,0029-P00,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6760,0029-0027,29.27,Unconfirmed,263,0029-P00,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6761,0029-0029,29.29,Unconfirmed,263,0029-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6762,0029-0030,29.30,Unconfirmed,263,0029-P00,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6763,0029-0031,29.31,Unconfirmed,263,0029-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6764,0029-0032,29.32,Unconfirmed,263,0029-P00,Hypertension moderate,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6765,0029-0033,29.33,Unconfirmed,263,0029-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6766,0029-0034,29.34,Unconfirmed,263,0029-P00,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6767,0029-0035,29.35,Unconfirmed,263,0029-P00,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6768,0029-0043,29.43,Unconfirmed,263,0029-P00,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6769,0029-0045,29.45,Unconfirmed,263,0029-P00,Hypertension mild bronchitis chronic min,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6770,0029-0101,29.101,Unconfirmed,263,0029-P00,Vertr√§glichkeitspr√ºfung,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6771,0029-0102,29.102,Unconfirmed,263,0029-P00,EEG-Beeinflu√üung,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6772,0029-0103,29.103,Unconfirmed,263,0029-P00,storniert, siehe 29.18,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6773,0029-0104,29.104,Unconfirmed,263,0029-P00,Vergleich gegen 15 mg Codein,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6774,0029-0105,29.105,Unconfirmed,263,0029-P00,Husten-Tonband-Vergleich gegen Codein,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6775,0029-0106,29.106,Unconfirmed,263,0029-P00,Blutgase und Lungenfunktion,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6776,0029-0107,29.107,Unconfirmed,263,0029-P00,Dosis-Wirkungspr√ºfung mit Tussomat,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6777,0029-0108,29.108,Unconfirmed,263,0029-P00,Angina pectoris, Dr. Schrott,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6778,0029-0109,29.109,Unconfirmed,263,0029-P00,Dosis-Wirkung oral, mit Tussomat,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6779,0029-0110,29.110,Unconfirmed,263,0029-P00,Protrahierte Form gegen Codein,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6780,0029-0111,29.111,Unconfirmed,263,0029-P00,Blutdruckwirkung,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6781,0029-0112,29.112,Unconfirmed,263,0029-P00,Einflu√ü auf IOP und Pupillendurchmesser,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6782,0029-0113,29.113,Unconfirmed,263,0029-P00,CO2-R√ºckatmungsversuch, Siemon,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6783,0029-0114,29.114,Unconfirmed,263,0029-P00,Dosis-Wirkungspr√ºfung, Tussomat, 2,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6784,0029-0115,29.115,Unconfirmed,263,0029-P00,Kreislaufwirkung, Vergleich Catapresan,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6785,0029-0116,29.116,Unconfirmed,263,0029-P00,Vertr√§glichkeitspr√ºfung 2,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6786,0029-0117,29.117,Unconfirmed,263,0029-P00,Schlafverhalten und Erholung,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6787,0029-0118,29.118,Unconfirmed,263,0029-P00,Angina pectoris, Dr. Niederberger,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6788,0029-0119,29.119,Unconfirmed,263,0029-P00,Wirkungsdauer Kapsel / Tablette,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6789,0029-0120,29.120,Unconfirmed,263,0029-P00,Viskosimetrie und Lungenfunktion,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6790,0029-0121,29.121,Unconfirmed,263,0029-P00,Lungenfunktion beim Husten,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6791,0029-0122,29.122,Unconfirmed,263,0029-P00,Hustensedation, Bronchoskopie,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6792,0029-0123,29.123,Ended,263,0029-P00,Vergleich gegen Dociton, Prof. Stauch,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6793,0029-0124,29.124,Unconfirmed,263,0029-P00,Vergleich gegen Depot-Codein,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6794,0029-0125,29.125,Unconfirmed,263,0029-P00,Vgl. zu Dociton, Dr. Wojaczek, Pasing,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6795,0029-0126,29.126,Unconfirmed,263,0029-P00,Blutdruckwirkung, Mexiko,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6796,0029-0127,29.127,Unconfirmed,263,0029-P00,Husten, 3*9 mg eine Woche,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6797,0029-0128,29.128,Unconfirmed,263,0029-P00,BHT 933 + LS 519, Vertr√§glichkeit,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6798,0029-0129,29.129,Unconfirmed,263,0029-P00,Angina pectoris, Dr. Schinz,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6799,0033-0013,33.13,Ended,264,0033-P01,Wirkungspr√ºfung, Dr. Sucic,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6800,0033-0014,33.14,Ended,264,0033-P01,Niere, Mrzliak, Zagreb,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6801,0033-0015,33.15,Ended,264,0033-P01,Vergleich mit Glibenclamid, Uglesic,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6802,0033-0016,33.16,Ended,264,0033-P01,Online-Studie IIA, Zagreb 79,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6803,0033-0017,33.17,Unconfirmed,264,0033-P01,Online-Studie IIB, Zagreb 79,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6804,0033-0019,33.19,Ended,264,0033-P01,bei Insulinpflichtigen, Uglesic,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6805,0033-0021,33.21,Ended,264,0033-P01,Probanden, Proinsulin, Pharmakokinetik,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6806,0033-0022,33.22,Unconfirmed,264,0033-P01,Insulin-Ery-Rezeptorenbindung, Probanden,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6807,0033-0023,33.23,Unconfirmed,264,0033-P01,Insulin-Ery-Rezeptorenbindung, Patienten,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6808,0033-0024,33.24,Ended,264,0033-P01,Proinsulin unter i.v.-GTT, Dr. Zilker,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6809,0033-0025,33.25,Ended,264,0033-P01,Dosis-Wirkung p.o., Bottermann, Zilker,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6810,0033-0026,33.26,Ended,264,0033-P01,"neu", Pilotstudie Probanden,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6811,0033-0027,33.27,Ended,264,0033-P01,"neu", Pilotstudie Patienten,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6812,0033-0028,33.28,Ended,264,0033-P01,"new", UK 1 - Clinical Pilot Study,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6813,0033-0029,33.29,Ended,264,0033-P01,"neu", YU 1 - Profilstudie,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6814,0033-0030,33.30,Ended,264,0033-P01,SD - 30 mg, 4 Wochen, Profozic,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6815,0033-0031,33.31,Ended,264,0033-P01,SD Dosis-Wirkung, Probanden,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6816,0033-0032,33.32,Ended,264,0033-P01,SD Dosis-Wirkung, Probanden, Fortsetzung,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6817,0033-0033,33.33,Ended,264,0033-P01,SD - Handelsform, 30 mg, Turner,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6818,0033-0034,33.34,Unconfirmed,264,0033-P01,Glurenorm - Placebo, 15 mg, Dr. Drost,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6819,0033-0035,33.35,Ended,264,0033-P01,Glurenorm - Placebo, 30-90 mg, Turner,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6820,0033-0036,33.36,Ended,264,0033-P01,Therap.evaluat. with/without albuminuria,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6821,0033-0037,33.37,Ended,264,0033-P01,plasma level profile (pharmakokinetic),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6822,0033-0038,33.38,Unconfirmed,264,0033-P01,als Zusatztherapie, Dr. Profozic,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6823,0033-0039,33.39,Unconfirmed,264,0033-P01,in pat. pretreated with Glibenclamide,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6824,0033-0040,33.40,Ended,264,0033-P01,in Typ-II-diabetics, multicenter, China,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6825,0033-0041,33.41,Unconfirmed,264,0033-P01,Therap. comparison with Euglucon, China,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6826,0033-0042,33.42,Unconfirmed,264,0033-P01,Impaired renal function,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6827,0033-0100,33.100,Ended,264,0033-P01,Evaluation of Glurenorm in comparison to,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6828,0033-0101,33.101,Ended,264,0033-P01,Comcomitant use with Insulin,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6829,0041-0002,41.2,Ended,265,0041-P00,Serum-Natrium, Dr. Fleig,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6830,0041-0003,41.3,Ended,265,0041-P00,fl√ºssig, Pilotstudie, Weltzien,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6831,0041-0004,41.4,Ended,265,0041-P00,Aluminiumverhalten im Serum, Dr. Fleig,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6832,0041-0005,41.5,Ended,265,0041-P00,fl√ºssig, Wirkungsmechanismus, Weltzien,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6833,0041-0006,41.6,Ended,265,0041-P00,Suspens. und Tabl., Wirksamkeit, multic.,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
6834,0041-0007,41.7,Ended,265,0041-P00,Vergleichende Wirksamkeitspr√ºfung,Flaig,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6835,0041-0050,41.50,Unconfirmed,265,0041-P00,Gaviscon - Refluxbeschw. bei Schwangeren,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
6836,0045-0003,45.3,Unconfirmed,266,0045-P01,Vertr√§glichkeitspr√ºfung, Schweden,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6837,0045-0007,45.7,Ended,266,0045-P01,Vertr√§glichkeit Hypotoniker, Dr. Bremer,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6838,0045-0009,45.9,Ended,266,0045-P01,Metastasenhemmung, Prof. Krokowski,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6839,0045-0010,45.10,Ended,266,0045-P01,Prostatakarzinom,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6840,0045-0011,45.11,Ended,266,0045-P01,Ovarialkarzinom, Finnland,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6841,0045-0012,45.12,Ended,266,0045-P01,Hypernephrom,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6842,0045-0013,45.13,Ended,266,0045-P01,Malignes Melanom,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6843,0045-0014,45.14,Ended,266,0045-P01,Bronchial-Karzinom,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6844,0045-0015,45.15,Ended,266,0045-P01,Metastasenprophylaxe b. Strahlenbehandl.,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6845,0045-0016,45.16,Ended,266,0045-P01,Malignes Melanom, unkontrolliert,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6846,0045-0017,45.17,Ended,266,0045-P01,Urothel-Karzinom,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6847,0045-0018,45.18,Ended,266,0045-P01,Mamma-Karzinom,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6848,0045-0019,45.19,Unconfirmed,266,0045-P01,Vorversuch Knochenmetastasen,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6849,0045-0020,45.20,Unconfirmed,266,0045-P01,Metastasenprophylaxe,unkontr., Dr.Haas,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6850,0045-0021,45.21,Ended,266,0045-P01,Bioverf√ºgbarkeit versch. Formulierungen,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6851,0048-0001,48.1,Ended,267,0048-P01,Wirkungspr√ºfung 1,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6852,0048-0002,48.2,Ended,267,0048-P01,Dosis-Wirkungs-Pr√ºfung 1,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6853,0048-0003,48.3,Ended,267,0048-P01,Dosis-Wirkungs-Pr√ºfung 2,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6854,0048-0004,48.4,Ended,267,0048-P01,Pindolol - Wirkungsvergleich,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6855,0048-0005,48.5,Ended,267,0048-P01,Wirkung u. Vertr√§glichkeit oral 1, Prob.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6856,0048-0006,48.6,Ended,267,0048-P01,Vertr√§glichkeit oral 2, Probanden,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6857,0048-0007,48.7,Ended,267,0048-P01,Betablocker, Prof. Gilfrich,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6858,0048-0008,48.8,Ended,267,0048-P01,1. Dosis-Wirkungs-Pr√ºfung oral,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6859,0048-0009,48.9,Ended,267,0048-P01,Dosis-Wirkungs-Pr√ºfung, 3*Applikation,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6860,0048-0010,48.10,Ended,267,0048-P01,Vertr√§glichkeit Probanden oral, 3Tage,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6861,0048-0011,48.11,Ended,267,0048-P01,Vergl. mit Verapamil, 3 Tage, Probanden,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6862,0048-0012,48.12,Ended,267,0048-P01,I.v.-Vertr√§glichkeit, 2fach-Applikation,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6863,0048-0013,48.13,Ended,267,0048-P01,Vorversuch zur Langzeitvertr√§glichkeit,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6864,0048-0014,48.14,Ended,267,0048-P01,Different Formulations, NL 12.01.03,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6865,0048-0015,48.15,Ended,267,0048-P01,Sinustachykardie, i.v., Prof. Sack,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6866,0048-0016,48.16,Ended,267,0048-P01,Angina pectoris, i.v., Kober / Schulz,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6867,0048-0017,48.17,Unconfirmed,267,0048-P01,Sinustachykardie, Narkose, B√ºttner,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6868,0048-0018,48.18,Unconfirmed,267,0048-P01,Sinustachykardie bei Dobutamin, B√ºttner,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6869,0048-0019,48.19,Ended,267,0048-P01,Sinustachykardie bei Kardiochirurgie, BN,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6870,0048-0020,48.20,Unconfirmed,267,0048-P01,Sinustachykardie und Atemwiderstand,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6871,0048-0021,48.21,Ended,267,0048-P01,Sinustachykardie und Lungenfunktion,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6872,0048-0022,48.22,Ended,267,0048-P01,Probanden,Wirkung,Kinetik,p.o. mehrfach,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6873,0048-0023,48.23,Ended,267,0048-P01,Sinustachykardie i.v., Dr. Beythien,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6874,0048-0024,48.24,Ended,267,0048-P01,Linkskath. unter Stimulat., Prof.Leitner,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6875,0048-0025,48.25,Ended,267,0048-P01,Vergleich mit Isoptin, Dr. Isringhaus,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6876,0048-0026,48.26,Ended,267,0048-P01,Sinustachykardie, Dr. Krier,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6877,0048-0027,48.27,Ended,267,0048-P01,Normofrequenter Rhythmus, Prof. G√ºlker,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6878,0048-0028,48.28,Ended,267,0048-P01,Vergleich mit Dociton, Dr. Tryba,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6879,0048-0029,48.29,Unconfirmed,267,0048-P01,periop. Sinustachykardie, Dr. Krier,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6880,0048-0030,48.30,Unconfirmed,267,0048-P01,Sinustachykardie, Prof. Simon,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6881,0048-0031,48.31,Ended,267,0048-P01,Sinustachykardie, Dr. Eisler,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6882,0048-0032,48.32,Ended,267,0048-P01,Vergleich mit Isoptin, Dr. Demeyere,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6883,0048-0033,48.33,Ended,267,0048-P01,Sinustachyk. b. Nierenins., Prof. H√∂rl,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6884,0048-0034,48.34,Ended,267,0048-P01,Sinustachykardie, Dr. Matthes,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6885,0048-0035,48.35,Unconfirmed,267,0048-P01,Dosis-Wirkungsvergleich, Dr. Schneider,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6886,0048-0036,48.36,Ended,267,0048-P01,Sinust.,Hyperthermiebeh., Dr. Eisler,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6887,0048-0037,48.37,Ended,267,0048-P01,Wirkungsvergleich 100 mg i.v./p.o. Prob.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6888,0048-0038,48.38,Ended,267,0048-P01,Dosis-/Wirkungspr√ºfung Atropin,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6889,0048-0039,48.39,Ended,267,0048-P01,Pilotstudie zu 48.28, Dr. Tryba,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6890,0048-0040,48.40,Ended,267,0048-P01,Hyperkinet. Herzsyndrom, Prof. Kober,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6891,0048-0041,48.41,Unconfirmed,267,0048-P01,Sinustachykardie, Prof. Djonlagic,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6892,0048-0042,48.42,Unconfirmed,267,0048-P01,Dopaminind. Sinustachykardie, Djonlagic,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6893,0048-0043,48.43,Unconfirmed,267,0048-P01,Katechol.-ind. Sinustachyk., Lindlbauer,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6894,0048-0044,48.44,Ended,267,0048-P01,Langzeitinfus.,Vertr√§glichkeit, Kinetik,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6895,0048-0045,48.45,Ended,267,0048-P01,Ergometrieind. Sinustachyk., Uglesic,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6896,0048-0046,48.46,Ended,267,0048-P01,Hyperkinet. Herzsyndrom, Dr. Felder,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6897,0048-0047,48.47,Ended,267,0048-P01,Ergometrieind. Sinustachyk., Multicenter,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6898,0048-0048,48.48,Ended,267,0048-P01,Sinust. nach Myokardinfarkt, Multicenter,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6899,0048-0049,48.49,Ended,267,0048-P01,Elektrophys. u. Kinetik, Prof. S. Levy,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6900,0048-0050,48.50,Ended,267,0048-P01,nach Isoproterenol, Wien,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6901,0048-0051,48.51,Ended,267,0048-P01,Elektrophysiologie, Prof. Clementy,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6902,0048-0052,48.52,Ended,267,0048-P01,H√§modynamische Effekte, Univ. Graz,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6903,0048-0053,48.53,Ended,267,0048-P01,Sinustachyk., Vorhofflimmern, Dr. Herzog,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6904,0048-0054,48.54,Ended,267,0048-P01,Sinustachykardie, Prof.Bender+Dr.G√ºlker,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6905,0048-0055,48.55,Ended,267,0048-P01,Vorstudie zu 48.32, Dr. Demeyere,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6906,0048-0056,48.56,Ended,267,0048-P01,stim.Vorhofflimmern/flattern, Prof.Levy,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6907,0048-0057,48.57,Unconfirmed,267,0048-P01,Katechol.-ind.Sinustachyk.,2 Zentren,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6908,0048-0058,48.58,Ended,267,0048-P01,Ergometrieind. Tachykardie, Dr. Darragh,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6909,0048-0059,48.59,Unconfirmed,267,0048-P01,Vorhofflimmern/-flattern, 10 Pr√ºfstellen,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6910,0048-0060,48.60,Ended,267,0048-P01,Posttraumat.Sinustachykardie, Univ. Graz,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6911,0048-0061,48.61,Unconfirmed,267,0048-P01,Sinustachyk. in Herzchirurgie, 8 Pr√ºfst.,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6912,0048-0062,48.62,Unconfirmed,267,0048-P01,Ergometrie, 3 Tage p.o. (Prob) Broustet,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6913,0048-0063,48.63,Unconfirmed,267,0048-P01,Intraoperativ Einsatz v. Falipamil i.v.,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6914,0048-0064,48.64,Ended,267,0048-P01,Wirk.v.1x200mg p.o. Falipamil/Ang. pect.,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6915,0048-0100,48.100,Ended,267,0048-P01,Tachycardia sinus;Surgery,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6916,0048-0101,48.101,Unconfirmed,267,0048-P01,Angina-Pectoris stable,Unconfirmed,MIG,Migration,I,Phase I,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
6917,0048-0102,48.102,Unconfirmed,267,0048-P01,Extrasystoles ventricular,Unconfirmed,MIG,Migration,I,Phase I,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
6918,0048-0103,48.103,Ended,267,0048-P01,none,Ended,MIG,Migration,I,Phase I,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
6919,0048-0104,48.104,Unconfirmed,267,0048-P01,Fibrillation supraventricular,Unconfirmed,MIG,Migration,I,Phase I,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
6920,0063-0002,63.2,Unconfirmed,268,0063-P01,IOP-Beeinflussung bei Patienten,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6921,0063-0003,63.3,Ended,268,0063-P01,Beeinfl. des intraokul√§ren Druckes,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6922,0063-0004,63.4,Ended,268,0063-P01,Beeinfl. des Pupillendurchmessers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6923,0063-0005,63.5,Ended,268,0063-P01,IOP nach Mehrfachapplikation, Sch√ºtte,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6924,0063-0006,63.6,Unconfirmed,268,0063-P01,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- GREEN LANE HOSPITAL WAS RESPONSIBLE FOR DATA ENTRY BUT DID NOT RECRUIT PATIENTS. AFTER CO *,,,000910,IS - Clin Study (MIGRATED)
6925,0063-0007,63.7,Unconfirmed,268,0063-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6926,0063-0008,63.8,Unconfirmed,268,0063-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6927,0063-0009,63.9,Unconfirmed,268,0063-P01,Glaucoma,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6928,0063-0010,63.10,Unconfirmed,268,0063-P01,Glaucoma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6929,0063-0011,63.11,Unconfirmed,268,0063-P01,KOE 1366 1.0%-1.5% bei umzustell.Glaukom,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6930,0063-0012,63.12,Unconfirmed,268,0063-P01,KOE 1366 1.0%-1.5% b.neu einzust.Glaukom,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6931,0063-0013,63.13,Unconfirmed,268,0063-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6932,0063-0050,63.50,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6933,0063-0051,63.51,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6934,0063-0052,63.52,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6935,0063-0053,63.53,Unconfirmed,268,0063-P01,Coronary disease,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6936,0063-0054,63.54,Unconfirmed,268,0063-P01,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6937,0063-0055,63.55,Unconfirmed,268,0063-P01,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6938,0063-0056,63.56,Unconfirmed,268,0063-P01,Coronary disease,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6939,0063-0057,63.57,Unconfirmed,268,0063-P01,Coronary disease,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6940,0063-0058,63.58,Unconfirmed,268,0063-P01,Tetany,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6941,0063-0059,63.59,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6942,0063-0060,63.60,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6943,0063-0061,63.61,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6944,0063-0062,63.62,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6945,0063-0063,63.63,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6946,0063-0064,63.64,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6947,0063-0065,63.65,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6948,0063-0066,63.66,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6949,0063-0067,63.67,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6950,0063-0068,63.68,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6951,0063-0069,63.69,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6952,0063-0070,63.70,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6953,0063-0071,63.71,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6954,0063-0072,63.72,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6955,0063-0073,63.73,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6956,0063-0074,63.74,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6957,0063-0075,63.75,Unconfirmed,268,0063-P01,Coronary disease,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6958,0063-0076,63.76,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6959,0063-0077,63.77,Unconfirmed,268,0063-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,IV,Phase IV,- planned patients: 30-40 * *,,,000910,IS - Clin Study (MIGRATED)
6960,0063-0078,63.78,Unconfirmed,268,0063-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6961,0063-0079,63.79,Unconfirmed,268,0063-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6962,0063-0080,63.80,Unconfirmed,268,0063-P01,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6963,0063-0081,63.81,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
6964,0063-0082,63.82,Unconfirmed,268,0063-P01,Psychosomatic disorders,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6965,0063-0083,63.83,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6966,0063-0084,63.84,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6967,0063-0085,63.85,Unconfirmed,268,0063-P01,Infarction,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6968,0063-0086,63.86,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6969,0063-0087,63.87,Unconfirmed,268,0063-P01,Angina-Pectoris,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
6970,0063-0088,63.88,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6971,0063-0089,63.89,Unconfirmed,268,0063-P01,Hypotension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6972,0063-0090,63.90,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6973,0063-0091,63.91,Unconfirmed,268,0063-P01,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6974,0063-0092,63.92,Unconfirmed,268,0063-P01,Angina-Pectoris,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
6975,0063-0093,63.93,Ended,268,0063-P01,--,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6976,0063-0094,63.94,Ended,268,0063-P01,--,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6977,0063-0095,63.95,Ended,268,0063-P01,--,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6978,0063-0096,63.96,Ended,268,0063-P01,ANGINA PECTORIS,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6979,0063-0097,63.97,Ended,268,0063-P01,ANGINA PECTORIS,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6980,0063-0098,63.98,Ended,268,0063-P01,ANGINA PECTORIS,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6981,0063-0099,63.99,Ended,268,0063-P01,HYPERTENSION,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6982,0063-0100,63.100,Ended,268,0063-P01,HYPERTENSION,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6983,0063-0101,63.101,Ended,268,0063-P01,HYPERTENSION,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6984,0063-0102,63.102,Ended,268,0063-P01,HYPERTENSION,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6985,0063-0103,63.103,Ended,268,0063-P01,HYPERTENSION,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
6986,0063-0104,63.104,Ended,268,0063-P01,--,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
6987,0065-0002,65.2,Ended,269,0065-P00,Oracef-Spiegel-Beeinfl. durch Bisolvon,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6988,0065-0003,65.3,Unconfirmed,269,0065-P00,Erythromycin S 249/80,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6989,0065-0004,65.4,Ended,269,0065-P00,Nasensekret-Untersuchung, Pilot Methode,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
6990,0065-0005,65.5,Unconfirmed,269,0065-P00,Erythromycin S 248/80,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6991,0065-0006,65.6,Unconfirmed,269,0065-P00,Bisolvon-Ampullen B 816/80,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6992,0065-0007,65.7,Unconfirmed,269,0065-P00,Inhalation S 915/80,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
6993,0065-0008,65.8,Ended,269,0065-P00,Oracef-Spiegel, NH-Sekret,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6994,0065-0009,65.9,Ended,269,0065-P00,Mucosolvan, Rhinitis sicca, Dr. Klingl,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6995,0065-0010,65.10,Ended,269,0065-P00,Handhabbarkeit des HLT und Acceptanz, I,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6996,0065-0011,65.11,Ended,269,0065-P00,Handhabbarkeit des HLT und Acceptanz, II,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
6997,0065-0012,65.12,Ended,269,0065-P00,Nasensekret, -schleimhaut, Prof. Eichner,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
6998,0065-0014,65.14,Ended,269,0065-P00,Lysozymgehalt in Reiztr√§nen,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
6999,0065-0016,65.16,Ended,269,0065-P00,MCNA Bildung im Magensaft in vivo,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7000,0065-0017,65.17,Ended,269,0065-P00,MCNA Bildg. im Pentag.stimul.Magensaft,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7001,0065-0018,65.18,Ended,269,0065-P00,MCNA Bildg.im Pent.stim.Magens. in-vitro,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7002,0065-0019,65.19,Ended,269,0065-P00,Nitrit-/Nitrosaminbest.n. Bisolv ex vivo,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7003,0065-0020,65.20,Ended,269,0065-P00,Nitrit-/Nitrosaminbest.n. Bisolv ex vivo,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7004,0065-0021,65.21,Ended,269,0065-P00,Nitrit-/Nitrosaminbest.n. Bisolv ex vivo,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7005,0065-0022,65.22,Ended,269,0065-P00,Nitrit-/Nitrosaminbest.n. Bisolv ex vivo,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7006,0065-0023,65.23,Ended,269,0065-P00,Gewinnung von Magensaft als Standard,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7007,0065-0024,65.24,Ended,269,0065-P00,Gewinnung von Magensaft als Standard I,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7008,0065-0025,65.25,Ended,269,0065-P00,Gewinnung von Magensaft als Standard II,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7009,0065-0027,65.27,Ended,269,0065-P00,Nitrosamin-Folgeprodukt-Urinausscheidung,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7010,0065-0028,65.28,Ended,269,0065-P00,Akzeptanz, Vertr√§glichkeit,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7011,0065-0050,65.50,Unconfirmed,269,0065-P00,Bronchitis chronic;Bronchitis chronic OB,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7012,0065-0051,65.51,Ended,269,0065-P00,Smoking,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7013,0065-0052,65.52,Unconfirmed,269,0065-P00,Lacrimal apparatus diseases,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7014,0065-0053,65.53,Unconfirmed,269,0065-P00,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7015,0065-0054,65.54,Unconfirmed,269,0065-P00,Bronchitis chronic;Bronchitis acute,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7016,0065-0055,65.55,Unconfirmed,269,0065-P00,Bronchitis acute,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7017,0065-0056,65.56,Unconfirmed,269,0065-P00,Bronchitis acute,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7018,0065-0057,65.57,Unconfirmed,269,0065-P00,Bronchitis acute;Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7019,0065-0058,65.58,Unconfirmed,269,0065-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7020,0065-0059,65.59,Unconfirmed,269,0065-P00,Surgery,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7021,0065-0060,65.60,Unconfirmed,269,0065-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7022,0065-0061,65.61,Unconfirmed,269,0065-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7023,0065-0062,65.62,Unconfirmed,269,0065-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7024,0065-0065,65.65,Ended,269,0065-P00,High dose,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7025,0065-0066,65.66,Unconfirmed,269,0065-P00,Surgery pulmonary,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7026,0065-0067,65.67,Unconfirmed,269,0065-P00,Surgery pulmonary;Carcinoma pulmonary,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7027,0065-0068,65.68,Unconfirmed,269,0065-P00,Infection bronchopulmonary;Bronchitis ch,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7028,0065-0069,65.69,Unconfirmed,269,0065-P00,Nephropathy diabetes-Mellitus,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7029,0065-0070,65.70,Ended,269,0065-P00,Bronchitis chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7030,0065-0071,65.71,Ended,269,0065-P00,Bronchitis chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7031,0065-0072,65.72,Unconfirmed,269,0065-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7032,0065-0073,65.73,Unconfirmed,269,0065-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7033,0065-0074,65.74,Unconfirmed,269,0065-P00,Surgery postoperative,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7034,0065-0075,65.75,Unconfirmed,269,0065-P00,Bronchitis chronic;Carcinoma bronchial,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7035,0065-0076,65.76,Unconfirmed,269,0065-P00,Otitis-Media,Unconfirmed,MIG,Migration,IV,Phase IV,- NZ Trial,,,000910,IS - Clin Study (MIGRATED)
7036,0065-0077,65.77,Unconfirmed,269,0065-P00,Otitis-Media,Unconfirmed,MIG,Migration,IV,Phase IV,- Report U87-0375 ** *,,,000910,IS - Clin Study (MIGRATED)
7037,0065-0078,65.78,Unconfirmed,269,0065-P00,Keratoconjunctivitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7038,0065-0079,65.79,Unconfirmed,269,0065-P00,Respiratory tract diseases,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7039,0065-0080,65.80,Unconfirmed,269,0065-P00,Bronchitis acute;Chronic bronchitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7040,0065-0081,65.81,Unconfirmed,269,0065-P00,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7041,0065-0092,65.92,Unconfirmed,269,0065-P00,Sinusitis maxillary,Unconfirmed,MIG,Migration,IV,Phase IV,- planned patients: 50-100 * *,,,000910,IS - Clin Study (MIGRATED)
7042,0065-0093,65.93,Ended,269,0065-P00,Pneumonia;Bronchitis acute;Bronchitis ch,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7043,0065-0094,65.94,Unconfirmed,269,0065-P00,Bronchitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7044,0065-0095,65.95,Unconfirmed,269,0065-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7045,0065-0096,65.96,Unconfirmed,269,0065-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7046,0065-0097,65.97,Ended,269,0065-P00,Infection bronchopulmonary,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7047,0065-0098,65.98,Unconfirmed,269,0065-P00,Bronchitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7048,0065-0099,65.99,Unconfirmed,269,0065-P00,Common-Cold,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7049,0065-0100,65.100,Unconfirmed,269,0065-P00,Common-Cold,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7050,0065-0101,65.101,Ended,269,0065-P00,Bronchitis chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7051,0065-0102,65.102,Ended,269,0065-P00,Sinusitis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7052,0065-0103,65.103,Ended,269,0065-P00,Bronchopulmonary diseases,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7053,0065-0104,65.104,Ended,269,0065-P00,Smoking bronchitis chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7054,0065-0105,65.105,Unconfirmed,269,0065-P00,Otitis-Media secretory,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7055,0065-0106,65.106,Ended,269,0065-P00,BRONCHITIS, ACUTE,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7056,0065-0107,65.107,Unconfirmed,269,0065-P00,Bronchiectasis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7057,0065-0108,65.108,Ended,269,0065-P00,Bronchiectasis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7058,0065-0109,65.109,Unconfirmed,269,0065-P00,Bronchial pneumonia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7059,0065-0110,65.110,Ended,269,0065-P00,Bronchitis, chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7060,0065-0111,65.111,Ended,269,0065-P00,Bronchitis, chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7061,0065-0112,65.112,Ended,269,0065-P00,BRONCHITIS, CHRONIC,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7062,0065-0113,65.113,Ended,269,0065-P00,BRONCHITIS, CHRONIC,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7063,0065-0114,65.114,Ended,269,0065-P00,TUBERCULOSIS,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7064,0065-0115,65.115,Unconfirmed,269,0065-P00,Cystic Fibrosis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7065,0065-0116,65.116,Unconfirmed,269,0065-P00,Cystic Fibrosis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7066,0065-0117,65.117,Unconfirmed,269,0065-P00,Surgery,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7067,0065-0118,65.118,Ended,269,0065-P00,BRONCHITIS, CHRONIC,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7068,0065-0119,65.119,Unconfirmed,269,0065-P00,Otitis, Sinusitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7069,0065-0120,65.120,Ended,269,0065-P00,BRONCHITIS, CHRONIC,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7070,0065-0121,65.121,Ended,269,0065-P00,BRONCHITIS, ACUTE,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7071,0065-0122,65.122,Ended,269,0065-P00,POSTOPERATIVE,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7072,0065-0124,65.124,Ended,269,0065-P00,POSTOPERATIVE,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7073,0065-0125,65.125,Ended,269,0065-P00,RESPIRATORY DISEASE, ACUTE,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7074,0065-0127,65.127,Ended,269,0065-P00,Bromhexine in Cystic Fibrosis,Ended,MIG,Migration,IV,Phase IV,- BIPL only provides supples,,,,
7075,0065-0128,65.128,Unconfirmed,269,0065-P00,Chronic Obstructive Pulmonary Disease,Unconfirmed,MIG,Migration,I,Phase I,- ,,,,
7076,0065-0129,65.129,Ended,269,0065-P00,BA/BE GranuStick,Ended,MIG,Migration,I,Phase I,,2011-002733-19,,000910,IS - Clin Study (MIGRATED)
7077,0069-0001,69.1,Unconfirmed,270,0069-P01,Jontophorese, Lerner,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
7078,0069-0002,69.2,Unconfirmed,270,0069-P01,Hautvertr√§glichkeit, Probanden,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7079,0069-0003,69.3,Unconfirmed,270,0069-P01,Schultergelenkskontusionen, Dr.Mund-Hoym,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7080,0069-0004,69.4,Unconfirmed,270,0069-P01,Hand-,Sprung-,Kniegelenke, Dr.Mund-Hoym,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7081,0069-0005,69.5,Ended,270,0069-P01,Anwendungstest, Finalgon-Verreiber,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7082,0069-0006,69.6,Ended,270,0069-P01,Vertr√§glichkeit, Finalgon-Bad, Tronnier,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7083,0069-0007,69.7,Ended,270,0069-P01,Finalgon-Badezusatz, Multicenter,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7084,0069-0008,69.8,Ended,270,0069-P01,Finalgon-Pflaster, Multicenter,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7085,0069-0009,69.9,Ended,270,0069-P01,Myomechanography with Finalgon,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7086,0069-0010,69.10,Ended,270,0069-P01,Laser Doppler Scanning with Finalgon,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7087,0069-0011,69.11,Ended,270,0069-P01,LDS with Finalgon-Creme,Ended,MIG,Migration,I,Phase I,Probanden ,,,000910,IS - Clin Study (MIGRATED)
7088,0069-0050,69.50,Ended,270,0069-P01,Post herpetic neuralgia,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7089,0069-0051,69.51,Preparing,270,0069-P01,Soft tissue rheumatism (back pain),Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
7090,0069-0052,69.52,Ended,270,0069-P01,Finalgon Ointment,Ended,MIG,Migration,IIIB,Phase IIIb,,2011-003890-27,,000910,IS - Clin Study (MIGRATED)
7091,0069-0053,69.53,Ended,270,0069-P01,Finalgon cream,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7092,0074-0001,74.1,Unconfirmed,271,0074-P01,Arthrosis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7093,0074-0002,74.2,Unconfirmed,271,0074-P01,Osteo-Arthrosis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7094,0074-0003,74.3,Unconfirmed,271,0074-P01,Osteo-Arthrosis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7095,0074-0004,74.4,Unconfirmed,271,0074-P01,Osteo-Arthrosis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7096,0074-0005,74.5,Unconfirmed,271,0074-P01,Osteo-Arthrosis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7097,0074-0006,74.6,Unconfirmed,271,0074-P01,Osteo-Arthrosis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7098,0074-0007,74.7,Unconfirmed,271,0074-P01,Infection otorhinolaryngologic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7099,0074-0008,74.8,Unconfirmed,271,0074-P01,Infection urinary,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7100,0074-0009,74.9,Unconfirmed,271,0074-P01,Infection bronchopulmonary,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7101,0074-0010,74.10,Unconfirmed,271,0074-P01,Lumbago;Gout,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7102,0074-0011,74.11,Unconfirmed,271,0074-P01,Osteo-Arthrosis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7103,0074-0012,74.12,Ended,271,0074-P01,Rheumatism;Arthritis rheumatoid;Spondyli,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7104,0074-0013,74.13,Unconfirmed,271,0074-P01,Trauma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7105,0074-0014,74.14,Ended,271,0074-P01,Arthritis rheumatoid;Spondylitis,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7106,0074-0015,74.15,Ended,271,0074-P01,Pharingitis;Tonsillitis,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7107,0074-0016,74.16,Ended,271,0074-P01,Bronchitis, acute,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7108,0074-0017,74.17,Ended,271,0074-P01,Flurbiprofen in shoulder pain syndrome,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7109,0075-0001,75.1,Ended,272,0075-P01,Harnwegsinfekte, 5 Pr√ºfstellen,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7110,0075-0002,75.2,Ended,272,0075-P01,Atemwegsinfekte, Dr. Wohlrabe,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7111,0075-0003,75.3,Ended,272,0075-P01,Harnwegsinfekte, Dr. Ludwig,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7112,0075-0004,75.4,Ended,272,0075-P01,Gyn√§kologische Infekte, Weissenbacher,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7113,0075-0005,75.5,Ended,272,0075-P01,Harnwegsinfekte, Dr. Ludwig II,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7114,0075-0006,75.6,Ended,272,0075-P01,Feldstudie bei verschied. Indikationen,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7115,0075-0007,75.7,Ended,272,0075-P01,Infektionen, Prof.Lode/Prof.Hahn, Berlin,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7116,0075-0008,75.8,Ended,272,0075-P01,Pharmakokinetik bei Geriatriepat., Naber,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7117,0075-0009,75.9,Ended,272,0075-P01,HNO-Infekte, Prof. Eichner/Dr. Pilar,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7118,0075-0010,75.10,Ended,272,0075-P01,bei Atemwegsinfekten, Dr. Jentzen,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7119,0075-0011,75.11,Ended,272,0075-P01,Kinetik bei leberinsuff.Pat.,Dr.Br√ºckner,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7120,0075-0012,75.12,Unconfirmed,272,0075-P01,Infekt. bei Kindern, Dr.Wagner-Flunkert,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7121,0075-0013,75.13,Ended,272,0075-P01,Kinetik b. terminaler Niereninsuffizienz,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7122,0075-0014,75.14,Ended,272,0075-P01,Harnwegsinfekte, Prof. Bichler,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7123,0075-0015,75.15,Ended,272,0075-P01,Knochengewebs-u.Serumspiegel,Dr. Gradl,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7124,0075-0016,75.16,Ended,272,0075-P01,EEG-Ver√§nderungen, Dr. Schaffler,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7125,0075-0017,75.17,Ended,272,0075-P01,Infektionen bei Kindern, Prof. Willital,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7126,0075-0018,75.18,Ended,272,0075-P01,Gewebskinetik, Prof. Wei√üenbacher,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7127,0075-0019,75.19,Ended,272,0075-P01,Perioperat.Infekt.prophylaxe,Dr.Hartmann,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7128,0075-0020,75.20,Ended,272,0075-P01,Infektionen bei Kindern, Dr. Becker,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7129,0075-0021,75.21,Ended,272,0075-P01,Prophylaxe b.gyn.Operationen,Dr.Schr√∂ter,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7130,0075-0022,75.22,Ended,272,0075-P01,2.Feldstudie bei verschied. Indikationen,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7131,0075-0023,75.23,Ended,272,0075-P01,Gallekinetik, Prof. R√∂sch,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7132,0075-0024,75.24,Ended,272,0075-P01,Serumkinetik, Dr. Wittmann,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7133,0075-0025,75.25,Ended,272,0075-P01,H√§mostase, Prof. Renner,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7134,0075-0026,75.26,Ended,272,0075-P01,Gewebsspiegel (HNO), Prof. Schumann,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7135,0075-0027,75.27,Ended,272,0075-P01,Infektionen bei Kindern, Dr.Scharw√§chter,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7136,0075-0028,75.28,Ended,272,0075-P01,Gallekinetik, Prof. Lode,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7137,0075-0029,75.29,Ended,272,0075-P01,Wechselwirk. Lumota/Muskelrelax., Tryba,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7138,0075-0030,75.30,Ended,272,0075-P01,bei Gallenwegsinfekten, Prof. Held,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7139,0075-0031,75.31,Ended,272,0075-P01,Peritonitis bei Kindern, Dr. Kolb,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7140,0075-0032,75.32,Ended,272,0075-P01,Konz. im Prostatagewebe, Prof. Klippel,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7141,0075-0033,75.33,Unconfirmed,272,0075-P01,Pseudomonasst√§mme, Prof. Winkler,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
7142,0075-0034,75.34,Ended,272,0075-P01,periop.Prophylaxe,Gallenchirurgie,Eisele,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7143,0075-0035,75.35,Ended,272,0075-P01,versch.Lungengewebsspiegel,Dr.Isringhaus,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7144,0075-0036,75.36,Ended,272,0075-P01,bei gallenchirurg.Eingriffen, Dr.Harnoss,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7145,0075-0037,75.37,Ended,272,0075-P01,Infekt. bei Kindern,60mg/kg, Dr. Becker,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7146,0075-0038,75.38,Unconfirmed,272,0075-P01,bei postoperativer Pneumonie,Dr.Erttmann,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7147,0075-0039,75.39,Unconfirmed,272,0075-P01,Liquorspiegel, Dr. Murr,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7148,0075-0040,75.40,Ended,272,0075-P01,Harnwegsinfekte, Dr. Veitl,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7149,0075-0041,75.41,Ended,272,0075-P01,Atemwegsinfekte, Dr. Mager,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7150,0075-0042,75.42,Ended,272,0075-P01,periop. Infektionsprophylaxe, Dr.Mendel,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7151,0075-0043,75.43,Unconfirmed,272,0075-P01,Harnwegsinfekte, Prof. Peller,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7152,0075-0044,75.44,Unconfirmed,272,0075-P01,Atemwegsinfekte, Prof. Peller,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7153,0075-0045,75.45,Unconfirmed,272,0075-P01,Peritonitis, Prof. Peller,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7154,0075-0046,75.46,Ended,272,0075-P01,Periop. Infekt.prophylaxe, Prof.Husemann,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7155,0075-0047,75.47,Unconfirmed,272,0075-P01,Konz. in der Muttermilch,Prof.Kobyletzki,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7156,0075-0048,75.48,Unconfirmed,272,0075-P01,bei Mukoviszidose, Dr. Wiesemann,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7157,0075-0049,75.49,Ended,272,0075-P01,Nierenvertr√§glichkeit, Prof. Mondorf,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7158,0075-0050,75.50,Ended,272,0075-P01,Konz. im Knorpel, Kinder, Prof. Meier,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7159,0075-0051,75.51,Ended,272,0075-P01,Harnwegsinfekte, Dr. Pensel,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7160,0075-0052,75.52,Unconfirmed,272,0075-P01,Atemwegsinfekte, multizentr.,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7161,0075-0053,75.53,Unconfirmed,272,0075-P01,bei Tumorpatienten (Pilot), Dr. Riedl,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7162,0075-0054,75.54,Unconfirmed,272,0075-P01,Postoperative Infektionen, multizentr.,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7163,0075-0055,75.55,Ended,272,0075-P01,Gyn√§kologische Infektionen, Dr. Schmidt,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7164,0075-0056,75.56,Unconfirmed,272,0075-P01,Atemwegsinf. bei Beatmungspat., Dr. Rau,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7165,0075-0057,75.57,Unconfirmed,272,0075-P01,Sepsis-Studie, Prof. Lode,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7166,0075-0058,75.58,Ended,272,0075-P01,Prophylaxe bei Transplant., Dr. Buchholz,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7167,0075-0059,75.59,Ended,272,0075-P01,Harnwegsinfekte, Dr. Gutschank,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7168,0075-0060,75.60,Unconfirmed,272,0075-P01,Prophylaxe b. Appendektomie, Prof. Klaue,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7169,0075-0061,75.61,Ended,272,0075-P01,Pharmakokinetik, Prof. Lode,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7170,0075-0062,75.62,Unconfirmed,272,0075-P01,Konzentrationsbest.,Dr. Ruhland, M√ºnster,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7171,0075-0063,75.63,Ended,272,0075-P01,Wirksamk. u. Pharmakokinetik,Dr. Tassler,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7172,0075-0064,75.64,Unconfirmed,272,0075-P01,Atemwegsinf. b.Beatmungspat.,Dr.Hohlbach,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7173,0075-0100,75.100,Unconfirmed,272,0075-P01,Infection,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
7174,0075-0101,75.101,Unconfirmed,272,0075-P01,Renal failure minor,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7175,0075-0102,75.102,Unconfirmed,272,0075-P01,Infection urinary;Bronchopulmonary;Hepat,Unconfirmed,MIG,Migration,III,Phase III,- planned patients: 10-20 ** *,,,000910,IS - Clin Study (MIGRATED)
7176,0075-0103,75.103,Unconfirmed,272,0075-P01,Infection,Unconfirmed,MIG,Migration,III,Phase III,- planned patients: 10-15 ** *,,,000910,IS - Clin Study (MIGRATED)
7177,0075-0104,75.104,Unconfirmed,272,0075-P01,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7178,0075-0105,75.105,Ended,272,0075-P01,none,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7179,0075-0106,75.106,Unconfirmed,272,0075-P01,Lumota - bakterielle Infektionen,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
7180,0002-0002,2.2,Ended,273,0002-P00,Depressives Syndrom, M√ºnchen (73502),Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7181,0002-0003,2.3,Ended,273,0002-P00,Depress. Syndrom, Multicenter (73504/05),Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7182,0003-0001,3.1,Ended,274,0003-P00,Wirkung u. Vertr√§glichk., Probanden,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7183,0003-0002,3.2,Unconfirmed,274,0003-P00,Wirkungsmechanismus, U. ventriculi,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7184,0003-0003,3.3,Ended,274,0003-P00,Ulcus ventriculi, Dr. P√∂sl,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7185,0003-0004,3.4,Ended,274,0003-P00,U. duodeni, Dr. Krumpoch,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7186,0003-0005,3.5,Unconfirmed,274,0003-P00,U. ventriculi, Dr. Fleig,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7187,0015-0003,15.3,Ended,275,0015-P00,Experimentelle Wirkungspr√ºfung (Isoket),Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
7188,0020-0001,20.1,Ended,276,0020-P01,bei Oedem-Patienten,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7189,0020-0002,20.2,Ended,276,0020-P01,forcierte Diurese, D√ºsseldorf,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7190,0020-0003,20.3,Ended,276,0020-P01,bei Niereninsuffizienz,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7191,0020-0004,20.4,Ended,276,0020-P01,bei EPH-Gestose,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7192,0020-0005,20.5,Ended,276,0020-P01,bei chron. Niereninsuffizienz,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7193,0020-0006,20.6,Unconfirmed,276,0020-P01,bei medikament√∂ser Vergiftung,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7194,0020-0007,20.7,Unconfirmed,276,0020-P01,bei akuter Niereninsuffizienz,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7195,0020-0008,20.8,Ended,276,0020-P01,bei Hirnoedem,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7196,0020-0009,20.9,Unconfirmed,276,0020-P01,bei Hirnoedem nach Operation,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7197,0020-0010,20.10,Unconfirmed,276,0020-P01,bei Hirnoedem - Traumatologie,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7198,0020-0011,20.11,Unconfirmed,276,0020-P01,Hirn√∂deme, Zust√§nde nach Sch√§delhirntr.,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7199,0020-0012,20.12,Ended,276,0020-P01,Manifeste Pulmonale HYpertonie,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7200,0020-0013,20.13,Ended,276,0020-P01,Kinder mit Herzvitien, akut,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7201,0020-0014,20.14,Ended,276,0020-P01,Kinder mit Herzvitien (Langzeit),Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7202,0020-0015,20.15,Ended,276,0020-P01,Pulmonale Erkrankung,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7203,0039-0001,39.1,Unconfirmed,277,0039-P01,FCT-Arbeitsgruppe 1976,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7204,0039-0003,39.3,Unconfirmed,277,0039-P01,Psoriasis Vulgaris Langzeit,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7205,0046-0004,46.4,Unconfirmed,278,0046-P01,Postop. Reizprophylaxe, Vertr√§glichkeit,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7206,0050-0002,50.2,Unconfirmed,279,0050-P01,bei Kniegelenke-Arthrose,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
7207,0055-0015,55.15,Ended,280,0055-P00,Betamethason-Diprop. Scherwitz,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7208,0055-0020,55.20,Ended,280,0055-P00,Hautvertr√§glichkeit,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7209,0055-0021,55.21,Unconfirmed,280,0055-P00,Fettcreme Pr√ºfung,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7210,0055-0022,55.22,Unconfirmed,280,0055-P00,Fettcreme Vasokonstriktion,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7211,0055-0023,55.23,Ended,280,0055-P00,Alfason-Fettcreme bei Kindern, Dr. Kelm,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7212,0055-0024,55.24,Ended,280,0055-P00,Plasmakortisolspiegel, Prof. Leonhardi,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7213,0055-0025,55.25,Unconfirmed,280,0055-P00,CreSa b.kortikoidbed. Dermatosen, Derm.,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7214,0055-0026,55.26,Unconfirmed,280,0055-P00,CreSa b.kortikoidbed. Dermatosen, Allg.,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7215,0055-0027,55.27,Ended,280,0055-P00,bei Neurodermitis, Dr. Schulz,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7216,0055-0028,55.28,Ended,280,0055-P00,Langzeitvertr√§glichkeit, Dr. Schulz,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7217,0062-0001,62.1,Unconfirmed,281,0062-P01,qualitative Nasensekretuntersuchung,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7218,0066-0001,66.1,Ended,282,0066-P01,Salbe/Creme Vergleich mit Dermoxin,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7219,0066-0002,66.2,Unconfirmed,282,0066-P01,Florone/Ultralan, Creme - Salbe,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7220,0066-0003,66.3,Unconfirmed,282,0066-P01,Psoriasis-Plaquetest, Prof. Meigel,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7221,0066-0004,66.4,Ended,282,0066-P01,Multicenter - Feldstudie,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7222,0066-0005,66.5,Ended,282,0066-P01,Regionale, klinische Feldpr√ºfung,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7223,0066-0006,66.6,Ended,282,0066-P01,Vasokonstriktionstest, L√∂sung/Creme,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7224,0066-0007,66.7,Ended,282,0066-P01,Flor.fl√ºss.(2 Konz.)/Betnesol/Diprosalic,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7225,0066-0008,66.8,Ended,282,0066-P01,Vasokonstriktionstest, Florone-Salben,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7226,0066-0009,66.9,Unconfirmed,282,0066-P01,Florone(Sparcort)vs.Dermoxin DK 499/84,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7227,0066-0010,66.10,Ended,282,0066-P01,fl√ºssig 0.01% Grundlage Vertr√§glichkeit,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7228,0066-0011,66.11,Ended,282,0066-P01,fl√ºssig 0.05% Grundlage Vertr√§glichkeit,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7229,0076-0001,76.1,Ended,283,0076-P00,1. Vertr√§glichkeit, 0.01-4.00 mg/ml,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7230,0076-0002,76.2,Ended,283,0076-P00,2. Vertr√§glichkeit, 6-12 mg/ml,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7231,0076-0003,76.3,Ended,283,0076-P00,3. Vertr√§glichkeit, 15-30 mg/ml,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7232,0078-0001,78.1,Ended,284,0078-P01,Harnwegsinfekte bei Kindern,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7233,0078-0002,78.2,Ended,284,0078-P01,Atemwegsinfekte bei Kindern,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7234,0078-0003,78.3,Ended,284,0078-P01,als Harnwegsdesinfizienz, Prof.Stille,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7235,0078-0004,78.4,Ended,284,0078-P01,Bioverf√ºgbarkeit, Prof. Lode,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7236,0079-0001,79.1,Ended,285,0079-P01,Blutdruckwerte nach Infusion,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7237,0079-0002,79.2,Ended,285,0079-P01,Blutviskosit√§t u.H√§matologie,Dr.Borgolte,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7238,0079-0003,79.3,Unconfirmed,285,0079-P01,Blutgase und H√§matologie, Dr.Borgolte,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7239,0079-0004,79.4,Ended,285,0079-P01,Knalltrauma, Prof. Schumann,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7240,0079-0005,79.5,Ended,285,0079-P01,Hyperglob. "Pink Puffer", Dr. Borgolte,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7241,0079-0006,79.6,Ended,285,0079-P01,Hyperglob. "Blue Bloater", Dr. Borgolte,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7242,0079-0007,79.7,Ended,285,0079-P01,Kolloider Volumenersatz, Dr. Ungemach,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7243,0079-0008,79.8,Ended,285,0079-P01,Kolloider Volumenersatz, Prof. Dennhardt,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7244,0079-0009,79.9,Ended,285,0079-P01,H√∂rsturz, retrospekt. Erhebung, BWK Ulm,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7245,0079-0010,79.10,Ended,285,0079-P01,Wirksamk. u.Vertr. an Pat. mit H√∂rsch√§d.,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7246,0096-0001,96.1,Unconfirmed,286,0096-P00,None,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7247,0096-0002,96.2,Ended,286,0096-P00,Vergleich mit Atenolol p.o. einmal,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7248,0096-0003,96.3,Unconfirmed,286,0096-P00,Vertr√§glichkeit, Pharmakok. i.v.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7249,0096-0004,96.4,Ended,286,0096-P00,Kinetik, Dynamik, 125 mg - 150 mg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7250,0096-0005,96.5,Ended,286,0096-P00,Absolute Bioverf√ºgbarkeit,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7251,0096-0006,96.6,Unconfirmed,286,0096-P00,Mehrfachapplikation, Amsterdam,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7252,0096-0007,96.7,Ended,286,0096-P00,Dosiswirkung 12.5 - 400 mg p.o., Belfast,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7253,0096-0008,96.8,Ended,286,0096-P00,Lungenfunktion, Vertr√§glichkeit, Berlin,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7254,0096-0009,96.9,Ended,286,0096-P00,BORN-Test, 7 Tage Applikation,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7255,0096-0010,96.10,Ended,286,0096-P00,Dosisf. an essent. Hypertonikern station,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7256,0096-0011,96.11,Ended,286,0096-P00,Dosisf. an essent. Hypertonikern ambul.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7257,0096-0012,96.12,Ended,286,0096-P00,Wirkungsvergleich mit Atenolol, Belfast,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7258,0096-0013,96.13,Ended,286,0096-P00,Wirk.-vergl. mit Isoprenaline i.v. induz,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7259,0096-0014,96.14,Unconfirmed,286,0096-P00,Wirkung auf Kreislauf u. Lungenfunktion,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7260,0096-0015,96.15,Unconfirmed,286,0096-P00,Vertr.+Wirkung auf Lungenf. n. Provokat.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7261,0096-0016,96.16,Ended,286,0096-P00,Vertr./Wirkg.-Provok.Test(Methach.Chlor),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7262,0102-0001,102.1,Ended,287,0102-P00,Vertr√§glichkeitspr√ºfung bis 80 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7263,0102-0002,102.2,Ended,287,0102-P00,Absolute Bioverf√ºgbarkeit,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7264,0102-0003,102.3,Ended,287,0102-P00,Wirkungsnachweis, Prof. Fleischmann,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7265,0102-0004,102.4,Unconfirmed,287,0102-P00,Dosisfindung i.v., HBE, Antoni,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7266,0102-0005,102.5,Ended,287,0102-P00,Dosisfindung i.v., HBE, Neuss,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7267,0102-0006,102.6,Ended,287,0102-P00,Dosisfindung p.o., Holter-EKG, v.Leitner,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7268,0102-0007,102.7,Ended,287,0102-P00,Dosisfindung p.o., Holter-EKG, Beythien,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7269,0102-0008,102.8,Ended,287,0102-P00,Dosisfindung i.v., HBE, Steinbeck,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7270,0102-0009,102.9,Unconfirmed,287,0102-P00,Dosisfindung i.v., HBE, Klein,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7271,0102-0010,102.10,Ended,287,0102-P00,Dosisfindung i.v., HBE, G√ºlker,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7272,0103-0001,103.1,Unconfirmed,288,0103-P01,OR Vorstudie, Computerpupillographie,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7273,0103-0002,103.2,Unconfirmed,288,0103-P01,Ophthalmic rods, Kurve nach Harms,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7274,0103-0003,103.3,Unconfirmed,288,0103-P01,OR Dosistitration, Prof. Dr. Dannheim,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7275,0103-0004,103.4,Unconfirmed,288,0103-P01,OR Dosis-Wirkungsvergl., Prof. Dannheim,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7276,0103-0005,103.5,Ended,288,0103-P01,OR-Tropfen, 200-500 ug, Prof. Leydhecker,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7277,0103-0006,103.6,Ended,288,0103-P01,OR-Tropfen bei eingestellten Patienten,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7278,0106-0001,106.1,Ended,289,0106-P01,Wirkung u. Vertr√§glich. b. nasaler Appl.,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7279,0106-0002,106.2,Ended,289,0106-P01,Kinetics, tolerance of 1x10 mg /3 admin.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7280,0106-0003,106.3,Ended,289,0106-P01,Cortisol suppression after inhal.doses,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7281,0106-0050,106.50,Ended,289,0106-P01,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7282,0106-0051,106.51,Ended,289,0106-P01,Asthma-biol. tolerance,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7283,0106-0052,106.52,Ended,289,0106-P01,Asthma-biol. + clin. tol.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7284,0108-0001,108.1,Ended,290,0108-P01,Bakterielle Clearence,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7285,0108-0002,108.2,Ended,290,0108-P01,Sekretuntersuchungen, Dr. Werdermann,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7286,0108-0003,108.3,Unconfirmed,290,0108-P01,Interaktionskinetik, Prof. Dr. Kr√ºger,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7287,0108-0004,108.4,Ended,290,0108-P01,Praxispr√ºfung Dr. Vorberg,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7288,0108-0005,108.5,Ended,290,0108-P01,Vergleichende Pharmakokinetik "Alt/Neu",Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7289,0108-0006,108.6,Unconfirmed,290,0108-P01,Bioequival.: Mucotectan N/Vibramycin N,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7290,0108-0007,108.7,Unconfirmed,290,0108-P01,Bioequ.:Mucotectan N/Vibramycin N (Urin),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7291,0108-0008,108.8,Ended,290,0108-P01,Bioavail:Ambroxol 150mg/Doxycyclin 100mg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7292,0108-0009,108.9,Ended,290,0108-P01,Efficacy of mucotectan vs doxycyc.100mg,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7293,0115-0001,115.1,Ended,291,0115-P01,KP 10%-E, Wirkung/Vertr√§gl., Prof. D√∂lp,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7294,0115-0002,115.2,Ended,291,0115-P01,KP 10%, Kinetik der PAS, Dr. Kleinberger,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7295,0115-0003,115.3,Ended,291,0115-P01,10 % m.El., Vergiftungen, Dr. Zilker,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7296,0115-0004,115.4,Ended,291,0115-P01,KP 10%, Pilotversuch f√ºr Pr√ºfung 115.2,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7297,0115-0005,115.5,Ended,291,0115-P01,KP 10%-E, Wirk./Vertr√§g.,Dr.Heikenw√§lder,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7298,0115-0006,115.6,Ended,291,0115-P01,LH 8,5%, Pilotstudie Prof.H√∂rl, Freiburg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7299,0115-0007,115.7,Unconfirmed,291,0115-P01,nephro, Hauptstudie Dr. H√∂rl, W√ºrzburg,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7300,0115-0008,115.8,Ended,291,0115-P01,Alterspatienten, Prof. Platt,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7301,0115-0009,115.9,Ended,291,0115-P01,geriatrische Patienten, Dr. Profozic, YU,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7302,0115-0010,115.10,Ended,291,0115-P01,Gyn√§kologische Patienten, Dr. Philipp,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7303,0115-0011,115.11,Unconfirmed,291,0115-P01,Intensivpatienten, Dr. Milewski,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7304,0115-0012,115.12,Ended,291,0115-P01,Internistische Erkrankungen, Dr. Kult,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7305,0115-0013,115.13,Ended,291,0115-P01,Vergleichspr√ºfung auf Wirkg. u. Vertr√§gl,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7306,0115-0014,115.14,Unconfirmed,291,0115-P01,Peritonitis-Patienten, Dr. L√∂hlein,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7307,0115-0015,115.15,Ended,291,0115-P01,Neurochir. Intensivpatienten, Prof. Dick,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7308,0115-0016,115.16,Ended,291,0115-P01,bei hohem Proteinbedarf, Prof.Dr. Eckart,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7309,0115-0017,115.17,Unconfirmed,291,0115-P01,nach Verbrennungstrauma, Dr. El-Makawi,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7310,0115-0018,115.18,Ended,291,0115-P01,Need of high protein, Prof.Dr. Eckart,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7311,0115-0019,115.19,Unconfirmed,291,0115-P01,b. Patienten mit Fl√ºssigkeitsrestriktion,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7312,0115-0020,115.20,Unconfirmed,291,0115-P01,bei Patienten mit hohem Proteinbedarf,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7313,0115-0021,115.21,Unconfirmed,291,0115-P01,Parenterale Ern√§hrung b. Intensiv-Pat.,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7314,0115-0050,115.50,Unconfirmed,291,0115-P01,Thomaeamin n15% - PE bei internist. Pat.,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
7315,0117-0001,117.1,Ended,292,0117-P01,Chronische Schlafst√∂rungen, Multicenter,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7316,0117-0002,117.2,Ended,292,0117-P01,Behandlungsbed. Schlafst√∂r., Feldstudie,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7317,0117-0003,117.3,Unconfirmed,292,0117-P01,Umfrage bei Apotheken,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7318,0117-0004,117.4,Ended,292,0117-P01,Beeinflussung des Schlafprofils, Prob.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7319,0118-0001,118.1,Ended,293,0118-P00,1. Dosisfindung, Kinetik p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7320,0118-0002,118.2,Ended,293,0118-P00,1. Dosisfindung, Kinetik i.v.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7321,0118-0003,118.3,Ended,293,0118-P00,Wirksamkeit 50 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7322,0118-0004,118.4,Unconfirmed,293,0118-P00,Dosis-Wirkungspr√ºfung mit Kinetik,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7323,0118-0005,118.5,Ended,293,0118-P00,Vergleich 25 mg Kapsel / Trinkl√∂sung,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7324,0118-0006,118.6,Ended,293,0118-P00,Vertr√§glichkeit, Kinetik 60-200 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7325,0118-0007,118.7,Ended,293,0118-P00,Ergometrieinduced Tachykardie, Dr. Haehl,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7326,0122-0001,122.1,Unconfirmed,294,0122-P01,Wirkung bei verschiedener Teilchengr√∂√üe,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7327,0122-0002,122.2,Ended,294,0122-P01,Plasmaspiegel + Urinausscheidung,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7328,0122-0003,122.3,Ended,294,0122-P01,R√∂ntgenvorbereitung, Dr. Hauck,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7329,0122-0005,122.5,Ended,294,0122-P01,R√∂ntgenvorbereitung, Dr. Hauck,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7330,0122-0006,122.6,Ended,294,0122-P01,Bisacodyl:coated tablets vs pills,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7331,0122-0007,122.7,Ended,294,0122-P01,Effic.tolerab.kin.of Na-picosulf.in vol.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7332,0122-0050,122.50,Ended,294,0122-P01,Comp. safety/efficacy,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7333,0122-0051,122.51,Ended,294,0122-P01,Comparative Safety and Efficacy,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7334,0122-0052,122.52,Ended,294,0122-P01,Combination of bisacodyl and simeticone,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
7335,0122-0053,122.53,Unconfirmed,294,0122-P01,Long-term use,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,To be performed by a CRO/Study postponed ,,,000910,IS - Clin Study (MIGRATED)
7336,0122-0054,122.54,Unconfirmed,294,0122-P01,Mechanism of action,Unconfirmed,MIG,Migration,II,Phase II,To be performed by a CRO/Study postponed ,,,000910,IS - Clin Study (MIGRATED)
7337,0122-0055,122.55,Unconfirmed,294,0122-P01,Habituation to the use of bisacodyl,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,To be performed by a CRO/Study postponed ,,,000910,IS - Clin Study (MIGRATED)
7338,0122-0056,122.56,Ended,294,0122-P01,Bisacodyl vs.  placebo,Ended,MIG,Migration,IIIB,Phase IIIb,,2007-001991-34,,000910,IS - Clin Study (MIGRATED)
7339,0122-0057,122.57,Ended,294,0122-P01,PK in lactating women,Ended,MIG,Migration,I,Phase I,PK study in healthy lactating females ,2007-004407-36,,000910,IS - Clin Study (MIGRATED)
7340,0122-0058,122.58,Unconfirmed,294,0122-P01,Review on constipation in children,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,,
7341,0126-0001,126.1,Ended,295,0126-P01,Erstanwendung zur Vertr√§glichkeit,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7342,0126-0002,126.2,Ended,295,0126-P01,Gyn√§kologische Patientinnen, Dr. Traub,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7343,0126-0003,126.3,Ended,295,0126-P01,0.5g/1g/2g bei Intensivpat., Dr. Schmitz,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7344,0126-0004,126.4,Ended,295,0126-P01,PE bei postop/-traumat./internist. Pat.,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7345,0126-0005,126.5,Ended,295,0126-P01,PE bei Pankreatitis, Dr. Spiegelberg,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7346,0126-0007,126.7,Unconfirmed,295,0126-P01,Parenteral feeding in septic patients,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7347,0129-0001,129.1,Ended,296,0129-P00,Multicenter Studie, Ungarn,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7348,0129-0002,129.2,Ended,296,0129-P00,Hyperlipid√§mie, A.p., Prof. Uglesic, YU,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7349,0129-0003,129.3,Ended,296,0129-P00,Claudicatio, Keller, Budapest,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7350,0129-0004,129.4,Ended,296,0129-P00,Angina pectoris, Antaloczy, Budapest,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7351,0129-0005,129.5,Ended,296,0129-P00,Hyperlipid√§mie, Romics, Budapest,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7352,0129-0006,129.6,Ended,296,0129-P00,Claudicatio, Profozic, Zagreb,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7353,0129-0007,129.7,Ended,296,0129-P00,Relat. Bioverf√ºgbark. Kaps./L√∂sg. 300 mg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7354,0129-0008,129.8,Ended,296,0129-P00,Relat. Bioverf√ºgbark. Kaps./Tabl. 500 mg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7355,0129-0009,129.9,Ended,296,0129-P00,Angina pectoris, Prof. Uglesic, YU,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7356,0129-0010,129.10,Ended,296,0129-P00,Hyperlipid., A.p., (Koll. 129.2) Uglesic,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7357,0129-0011,129.11,Ended,296,0129-P00,Ausscheidungsbilanz, 500 mg Kapseln,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7358,0131-0001,131.1,Ended,297,0131-P00,Erstanwendung, Dosistitration,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7359,0131-0002,131.2,Ended,297,0131-P00,Wirk. im Born-Test,Vollblutaggregometrie,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7360,0131-0003,131.3,Ended,297,0131-P00,BORN-Test, 50 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7361,0131-0004,131.4,Ended,297,0131-P00,Dosisfindung und Kinetik bis 100 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7362,0131-0005,131.5,Ended,297,0131-P00,Thrombozyten-Wirkung 200 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7363,0136-0001,136.1,Ended,298,0136-P00,BS orientierende Kinetik, Dr. Haehl,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7364,0136-0002,136.2,Ended,298,0136-P00,Dosisf.,Kinetik,Vertr. bis 5.0mg i.v.Inf,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7365,0136-0003,136.3,Ended,298,0136-P00,Dosiswirkung: 0.75, 1.50 mg i.v.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7366,0143-0001,143.1,Ended,299,0143-P00,Dose finding until 80 ug p.o., solution,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7367,0143-0002,143.2,Ended,299,0143-P00,Dose finding 80-100 ug p.o., solution,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7368,0143-0003,143.3,Ended,299,0143-P00,Dose finding 2-20ug,solution, inhalant,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7369,0143-0004,143.4,Ended,299,0143-P00,Dose finding 40-100ug,solution,inhalant,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7370,0143-0005,143.5,Ended,299,0143-P00,Pharmacology/-kinetics,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7371,0143-0006,143.6,Unconfirmed,299,0143-P00,Dosisw.:10,30,60ug p.o.bei COLD (Biodes),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7372,0143-0007,143.7,Ended,299,0143-P00,Bioverf√ºg.u.Kinetik von 40ug Tabl/Trinkl,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7373,0143-0008,143.8,Unconfirmed,299,0143-P00,Dosisw.:10,30,60ug p.o.bei COLD (Berlin),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7374,0143-0009,143.9,Ended,299,0143-P00,Bioverf√ºg.u.Kinetik v. 40ug TA/45ug AEM,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7375,0143-0010,143.10,Ended,299,0143-P00,Dose resp. in bronch. asthma 143.010-TH,Ended,MIG,Migration,II,Phase II,- *Biberach trial,,,000910,IS - Clin Study (MIGRATED)
7376,0143-0011,143.11,Ended,299,0143-P00,Dose comparison and Salbutamol,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7377,0143-0012,143.12,Ended,299,0143-P00,Tol.,Pharmacokin.of 0.03/0.06 bid inh/7d,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7378,0144-0001,144.1,Ended,300,0144-P00,Dosisfindung bis 150 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7379,0144-0002,144.2,Ended,300,0144-P00,Wirkung und Kinetik bei 11 t√§g. Anwendg.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7380,0144-0003,144.3,Ended,300,0144-P00,Wirkung auf Lungenfunktion, Dr. Dorow,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7381,0144-0004,144.4,Ended,300,0144-P00,Wirkung, Vertr√§glichkeit b. mehrf. Appl.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7382,0144-0005,144.5,Ended,300,0144-P00,Dosisfindung ab 25 mg p.o., Belfast,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7383,0144-0006,144.6,Unconfirmed,300,0144-P00,√ü-Blocker-Wirkung mit HI 42 BS, Atenonol,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7384,0144-0007,144.7,Ended,300,0144-P00,Dosisfindung bis 25 mg i.v. (20 Min.Inf),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7385,0144-0008,144.8,Ended,300,0144-P00,Vergleich 75 mg HXCH/50 mg Atenolol p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7386,0144-0009,144.9,Ended,300,0144-P00,Bioverf√ºgbarkeit v. 25 mg HXCH i.v./p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7387,0145-0001,145.1,Ended,301,0145-P00,Dosisfindung, Vertr√§glichkeit (p.o.),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7388,0145-0002,145.2,Ended,301,0145-P00,Dosiswirkung 10,20,40 mg p.o., Vertr√§gl.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7389,0145-0003,145.3,Ended,301,0145-P00,Dosiswirkung, Vertr√§glichkeit, Kinetik,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7390,0145-0004,145.4,Ended,301,0145-P00,Vertr√§glichk. bei 7tg. Mehrfachapplikat.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7391,0145-0005,145.5,Ended,301,0145-P00,Dosis√§quivalenz, Dr. Profozic,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7392,0145-0006,145.6,Ended,301,0145-P00,gegen Euglucon, 1 Woche Beh., Profozic,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7393,0145-0007,145.7,Unconfirmed,301,0145-P00,gegen Euglucon, 4 Wochen Beh., Profozic,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7394,0145-0008,145.8,Ended,301,0145-P00,Cigma/Hyperglycaemic clamp, Dr. Turner,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7395,0151-0001,151.1,Ended,302,0151-P00,Dosisfindung bis 480 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7396,0151-0002,151.2,Ended,302,0151-P00,Dosisfindung: 60,120,240 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7397,0151-0003,151.3,Ended,302,0151-P00,M1/M2-Rezeptorbesetzungs-Wirkungskurve,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7398,0151-0004,151.4,Unconfirmed,302,0151-P00,Dosisfindung: 240,360,480 mg p.o.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7399,0151-0005,151.5,Ended,302,0151-P00,Dosiswirkung: 120, 240, 480 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7400,0151-0006,151.6,Ended,302,0151-P00,Dosisfindung 1 - 50 mg i.v.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7401,0151-0007,151.7,Ended,302,0151-P00,40 mg i.v. unter Beta-Blockade,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7402,0151-0008,151.8,Ended,302,0151-P00,Rel.bioavailability(sol/cap) 240 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7403,0151-0009,151.9,Ended,302,0151-P00,Multiple dosing: 120, 240 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7404,0151-0010,151.10,Ended,302,0151-P00,Influence on evacuation of the stomach,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7405,0151-0011,151.11,Ended,302,0151-P00,Metabolism, Pharmacokin. of 14C-labelled,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7406,0151-0012,151.12,Ended,302,0151-P00,Single dose 180 mg to 540 mg,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7407,0151-0013,151.13,Ended,302,0151-P00,Electrophysiological effects,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7408,0151-0014,151.14,Ended,302,0151-P00,Case studies - Dr. Pitschner,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7409,0151-0050,151.50,Ended,302,0151-P00,Dose response,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7410,0151-0052,151.52,Ended,302,0151-P00,SINGLE ADMINISTRATION,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7411,0151-0053,151.53,Ended,302,0151-P00,EFFECT OF FOOD,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7412,0151-0054,151.54,Ended,302,0151-P00,MULTIPLE ADMINISTRATION,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7413,0151-0055,151.55,Ended,302,0151-P00,Early phase II studyof AF-DX 116 cap.,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7414,0151-0056,151.56,Ended,302,0151-P00,Clinical pharmacolgical study of AF-DX,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7415,0151-0057,151.57,Ended,302,0151-P00,Phase IIa study for NMS,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
7416,0151-0058,151.58,Ended,302,0151-P00,Mental Stress test,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7417,0151-0059,151.59,Ended,302,0151-P00,Bioequivalence cap. vs tab.,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7418,0151-0060,151.60,Ended,302,0151-P00,Bioequivalence cap.vs tab.,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7419,0151-0061,151.61,Ended,302,0151-P00,Dose Titration Study,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
7420,0053-0001,53.1,Ended,303,0053-P01,Pr√§menstruelles Syndrom,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7421,0053-0002,53.2,Ended,303,0053-P01,Pr√§menstruelles Syndrom, Dr. Koch,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7422,0059-0001,59.1,Ended,304,0059-P01,Colon irritabile, Dr. Kruis,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7423,0059-0002,59.2,Ended,304,0059-P01,Colon irritabile, retrospektive Studie,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7424,0059-0003,59.3,Ended,304,0059-P01,Colon irritabile u. sekund√§res Reizcolon,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7425,0059-0004,59.4,Ended,304,0059-P01,Colon irritabile, Dr. Sch√ºtz,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7426,0067-0001,67.1,Ended,305,0067-P01,Ulcus cruris, Decubitus, Verbrennungen,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7427,0077-0001,77.1,Ended,306,0077-P01,Wirkungsverg. gegen Eniclobrat, Irsigler,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7428,0077-0002,77.2,Ended,306,0077-P01,Beclobrat-√úberpr√ºfung, Sch√∂ffling,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7429,0077-0003,77.3,Ended,306,0077-P01,Dosis-Wirkung gegen Eniclobrat,Mordasini,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7430,0077-0004,77.4,Ended,306,0077-P01,Dosis-Wirkung gegen Eniclobrat,Kaffarnik,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7431,0077-0005,77.5,Ended,306,0077-P01,Multicenterpr√ºfung in Jugoslawien,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7432,0077-0006,77.6,Ended,306,0077-P01,Dosistitration, London,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7433,0077-0007,77.7,Ended,306,0077-P01,Wirkungsvgl. gegen Bezafibrat, Dubrovnik,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7434,0077-0008,77.8,Ended,306,0077-P01,Lipoproteinprofil, London,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7435,0077-0009,77.9,Unconfirmed,306,0077-P01,Lipoproteinprofil II, London,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7436,0093-0001,93.1,Ended,307,0093-P01,Vergleich mit Erythromycin, Steigleder,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7437,0093-0002,93.2,Ended,307,0093-P01,Placebo, Erythromycin, Multicenter,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7438,0093-0003,93.3,Ended,307,0093-P01,Therapeutische Erfahrung,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7439,0093-0004,93.4,Ended,307,0093-P01,Feldstudie bei Hautinfektionen,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7440,0093-0005,93.5,Unconfirmed,307,0093-P01,Resistenzstudie Meclosorb / Tetracyclin,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7441,0080-0001,80.1,Ended,308,0080-P00,Lacalutstomatest-Winklmair, AL-Lacalut,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7442,0081-0001,81.1,Unconfirmed,309,0081-P00,Anti-Schnarchmittel, Pilot-Test,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7443,0081-0002,81.2,Ended,309,0081-P00,Anti-Schnarchmittel, Dr. Sieroslawski,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7444,0081-0003,81.3,Unconfirmed,309,0081-P00,Anti-Schnarchpr√ºfung, Dr. Steinbach,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7445,0087-0001,87.1,Ended,310,0087-P00,Nasen- u. Lungenfunktion, Probanden,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7446,0095-0001,95.1,Ended,311,0095-P00,1. Dosistitration mit Vertr√§glichkeit,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7447,0095-0002,95.2,Unconfirmed,311,0095-P00,bei unkomplizierten Harnwegsinfekten,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7448,0095-0003,95.3,Ended,311,0095-P00,Kinetik u. Vertr√§glichkeit, Dr.Schaffler,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7449,0097-0001,97.1,Ended,312,0097-P01,Feldstudie bei Dermatophytien,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7450,0098-0005,98.5,Ended,313,0098-P01,Langzeiterhebung, eingest. u. neuentd.,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7451,0098-0006,98.6,Unconfirmed,313,0098-P01,Dosiswirkungsvergl.gegen Isoglaucon 1/8%,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7452,0099-0002,99.2,Unconfirmed,314,0099-P01,Dosispr√ºfung Nasenwiderstand,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7453,0123-0001,123.1,Ended,315,0123-P01,Calciumstoffwechsel, Prof. Bichler,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7454,0130-0001,130.1,Ended,316,0130-P01,Klin. Feldpr√ºfung (mit Kopfh.applikator),Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7455,0141-0001,141.1,Ended,317,0141-P01,Praxis Pr√ºfung,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7456,0146-0001,146.1,Unconfirmed,318,0146-P01,Episiotomy,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7457,0146-0002,146.2,Ended,318,0146-P01,Efficacy and Safety of Tannolact,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7458,0146-0003,146.3,Ended,318,0146-P01,Skin tolerance,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7459,0146-0004,146.4,Ended,318,0146-P01,Skin tolerance,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7460,0146-0005,146.5,Ended,318,0146-P01,skin tolerance,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7461,0146-0006,146.6,Ended,318,0146-P01,Effic. and tolerance of Tannolact cream,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7462,0146-0007,146.7,Unconfirmed,318,0146-P01,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7463,0146-0008,146.8,Ended,318,0146-P01,Tolerance of Tannolact Fluessigcreme,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7464,0146-0009,146.9,Ended,318,0146-P01,Efficacy and tolerance of Tannolact crea,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7465,0146-0010,146.10,Ended,318,0146-P01,Dyshidrotic eczema,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7466,0146-0011,146.11,Ended,318,0146-P01,Tannolact,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7467,0146-0012,146.12,Ended,318,0146-P01,Skin tolerance of Tannolact Wassergel,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7468,0146-0013,146.13,Ended,318,0146-P01,Efficacy and Tolerability,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7469,0146-0014,146.14,Ended,318,0146-P01,Efficacy and tolerance of Iontophoresis,Ended,MIG,Migration,III,Phase III,- Abbreviated report,,,000910,IS - Clin Study (MIGRATED)
7470,0146-0015,146.15,Ended,318,0146-P01,Efficacy and tolerance of Tannolact-Flue,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7471,0155-0001,155.1,Ended,320,0155-P01,Pilotvers. z. Entwickl. f. HPLC-Methode,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7472,0155-0002,155.2,Ended,320,0155-P01,Idiopathischer Kopfschmerz, Multicenter,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7473,0155-0003,155.3,Ended,320,0155-P01,Prostaglandin-Synthese ASS/Coffein p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7474,0155-0006,155.6,Ended,320,0155-P01,Analgesic combinations in headache,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7475,0155-0007,155.7,Ended,320,0155-P01,Cold stimulus induced tooth pain,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7476,0155-0008,155.8,Ended,320,0155-P01,Main Study: Headache,Ended,MIG,Migration,III,Phase III,120 Centres, 14-42 Patients ,,,000910,IS - Clin Study (MIGRATED)
7477,0155-0009,155.9,Ended,320,0155-P01,Bioavailability of ASA+NAPAP(+Caffeine),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7478,0155-0010,155.10,Unconfirmed,320,0155-P01,Bioavailability,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7479,0155-0051,155.51,Ended,320,0155-P01,Pharmacokinetic study with Thomapyrin,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7480,0155-0052,155.52,Ended,320,0155-P01,Epidemiologic Study,Ended,MIG,Migration,NONE,Not Classified,,,,000980,Not Classified (MIGRATED)
7481,0155-0053,155.53,Unconfirmed,320,0155-P01,Bio√§quivalenz,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7482,0155-0054,155.54,Unconfirmed,320,0155-P01,Bioavailability study for TPY_ E tablets,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7483,0155-0055,155.55,Unconfirmed,320,0155-P01,THOMAPYRIN Pharmacy-based Survey,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000940,Post Marketing Study (MIGRATED)
7484,0156-0001,156.1,Ended,321,0156-P00,Komb.-Wirkung ASA+NAPAP u. Einzelsubst.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7485,0156-0002,156.2,Ended,321,0156-P00,Wirk.v.ASA,NAPAP,Kombinat.auf PGE2-Synth,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7486,0156-0003,156.3,Ended,321,0156-P00,Bioavailability of ASA,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7487,0157-0001,157.1,Ended,322,0157-P00,Urolog. Patienten mit gr. Blutverlusten,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7488,0157-0002,157.2,Ended,322,0157-P00,i.change of total prosthetic replacement,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7489,0157-0003,157.3,Ended,322,0157-P00,Severe urological operations, Dr. Vogt,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7490,0160-0001,160.1,Ended,323,0160-P00,Vorversuch - Vertr√§gl. (EKG) und Kinetik,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7491,0160-0002,160.2,Ended,323,0160-P00,Dosiswirkung 10, 20, 30 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7492,0160-0003,160.3,Ended,323,0160-P00,Dose-response, kinetics 5 - 20 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7493,0161-0001,161.1,Ended,324,0161-P00,Ausscheidung in Saliva, Pilotstudie,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7494,0162-0001,162.1,Unconfirmed,325,0162-P00,Wirkung und Vertr√§glichkeit,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7495,0162-0002,162.2,Ended,325,0162-P00,Safety,pharmacokin.of 50,100,150 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7496,0162-0003,162.3,Ended,325,0162-P00,Vertr.u.Pharmakok.3x50 u.3x100 mg,7 Tage,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7497,0164-0001,164.1,Unconfirmed,326,0164-P01,Lunalind-Inh. bei katarrh. Erkr. der OAW,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7498,0168-0001,168.1,Ended,327,0168-P01,Com. w. Betaisodona-Sol. in Pleuraempyem,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7499,0168-0002,168.2,Unconfirmed,327,0168-P01,Vgl. m. Ringer-Lsg. bei der Peritonitis,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7500,0168-0003,168.3,Ended,327,0168-P01,Einflu√ü auf k√∂rpereig. Abwehr, Keime,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7501,0168-0004,168.4,Ended,327,0168-P01,Efficacy and safety in Osteomyelitis,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7502,0168-0005,168.5,Unconfirmed,327,0168-P01,b. intraartikul√§ren Infektionen,Dr.K√ºnne,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7503,0168-0006,168.6,Unconfirmed,327,0168-P01,vs system. Antibiot. bei Pleuraempyem,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7504,0168-0007,168.7,Ended,327,0168-P01,Pilot-study endotoxin-neutralisation,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7505,0168-0008,168.8,Unconfirmed,327,0168-P01,Vergl. Taurolin-Gentamicin-PMMA-Ketten,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7506,0168-0009,168.9,Ended,327,0168-P01,Comp. w.NaCl-sol.in pat.with peritonitis,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7507,0168-0010,168.10,Unconfirmed,327,0168-P01,Vergl. m. NaCl-Lsg. bei Pleuraempyem,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7508,0168-0011,168.11,Ended,327,0168-P01,HNO-Pilotstudie,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7509,0168-0012,168.12,Ended,327,0168-P01,Comp.with H2O2 in Ulcus cruris venos.,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7510,0168-0013,168.13,Ended,327,0168-P01,Com. w. Betaisodona-sol. i. Pleuraempyem,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7511,0168-0014,168.14,Ended,327,0168-P01,Infections of angioplasties,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7512,0168-0015,168.15,Unconfirmed,327,0168-P01,Taurolin b. diff. Vierquadr.-Peritonitis,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7513,0168-0020,168.20,Unconfirmed,327,0168-P01,Taurolin - Appendektomie,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
7514,0168-0021,168.21,Unconfirmed,327,0168-P01,Taurolin - Peritonitis,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
7515,0170-0001,170.1,Ended,328,0170-P00,Dosisfindung von 0.25 bis 5 mg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7516,0170-0002,170.2,Ended,328,0170-P00,Dosiswirkung von 1, 2, 3 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7517,0170-0003,170.3,Ended,328,0170-P00,VS Placebo and Euglucon N, Profozic,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7518,0170-0004,170.4,Ended,328,0170-P00,Comparison with Semi-Euglucon N,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7519,0170-0005,170.5,Ended,328,0170-P00,Dose response,multiple adm.b.i.d.2mg p.o,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7520,0170-0006,170.6,Ended,328,0170-P00,Absolute bioavailability 1 mg: i.v./p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7521,0170-0007,170.7,Ended,328,0170-P00,Kinetik nach 14C-Markierung, p.o.und i.v,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7522,0170-0008,170.8,Ended,328,0170-P00,Relat. bioavailability of 2 mg: caps/tab,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7523,0170-0009,170.9,Unconfirmed,328,0170-P00,Infl.of food- rel.bioav. of 2mg: cap/tab,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7524,0171-0001,171.1,Unconfirmed,329,0171-P01,IP-Nr. 354.1,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
7525,0171-0002,171.2,Unconfirmed,329,0171-P01,Refluxoesophagitis,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7526,0171-0008,171.8,Ended,329,0171-P01,Ganor VIII-Ulcus duodeni sive ventriculi,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
7527,0171-0009,171.9,Unconfirmed,329,0171-P01,Ganor - Ulcus duodeni, ventriculi,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
7528,0171-0010,171.10,Ended,329,0171-P01,Ganor II - Ulcus duodeni, ventriculi,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
7529,0171-0011,171.11,Ended,329,0171-P01,Ganor IV - Ulcus duodeni sive ventriculi,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
7530,0171-0012,171.12,Ended,329,0171-P01,Ganor V - Ulcus duodeni sive ventriculi,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
7531,0171-0013,171.13,Ended,329,0171-P01,Ganor VI - Ulcus duodeni sive ventriculi,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
7532,0171-0014,171.14,Ended,329,0171-P01,Ganor (Langzeit) - Ulcus ventriculi,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
7533,0171-0015,171.15,Ended,329,0171-P01,Ganor III - Ulcus duodeni, ventriculi,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
7534,0175-0001,175.1,Ended,330,0175-P00,Dose finding: 0.25 - 10 mg capsule p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7535,0175-0002,175.2,Ended,330,0175-P00,Dose finding: 5 - 15 mg p.o./capsule,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7536,0175-0003,175.3,Ended,330,0175-P00,Dose response of 5, 10, 15 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7537,0189-0001,189.1,Ended,331,0189-P01,Common cold-Prophylaxe,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7538,0189-0002,189.2,Unconfirmed,331,0189-P01,Eleu-kokk in prev. of com. cold or influ,Unconfirmed,MIG,Migration,III,Phase III,,,,000980,Not Classified (MIGRATED)
7539,0189-0010,189.10,Unconfirmed,331,0189-P01,Flu vaccination potentation,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000980,Not Classified (MIGRATED)
7540,0189-0011,189.11,Ended,331,0189-P01,Eleu-kokk in the prevention of common co,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7541,0189-0012,189.12,Preparing,331,0189-P01,Early Acute Treatment - Sugar Coated Tab,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7542,0189-0013,189.13,Ended,331,0189-P01,Immunology - Pilot Study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7543,0189-0014,189.14,Preparing,331,0189-P01,Immunology - Confirmatory Study,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7544,0190-0001,190.1,Ended,332,0190-P01,BV-Study: Bromhexine / Oxytetracycline,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7545,0190-0002,190.2,Ended,332,0190-P01,Comparative Bioavailability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7546,0198-0001,198.1,Ended,333,0198-P01,GX vs G, Schmitz,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7547,0198-0002,198.2,Ended,333,0198-P01,Vergl. Unters. bei Intensivpat., Schmitz,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7548,0210-0105,210.105,Ended,334,0210-P01,Safety,Ended,MIG,Migration,I,Phase I,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7549,0210-0201,210.201,Preparing,334,0210-P01,Efficacy, Challenge Test,Preparing,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7550,0210-0202,210.202,Unconfirmed,334,0210-P01,CHRONIC OBSTRUCTIVE AIRWAYS DISEASE,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7551,0210-0300,210.300,Ended,334,0210-P01,Airway deposition FO-2,Ended,MIG,Migration,IV,Phase IV,- Manuscript sent to "Respiration" in May 1989. *,,,000910,IS - Clin Study (MIGRATED)
7552,0211-0219,211.219,Ended,335,0211-P01,Efficacy & safety, b.i.d.,Ended,MIG,Migration,III,Phase III,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7553,0211-0223,211.223,Ended,335,0211-P01,Efficacy & safety, b.i.d. DU 1291 SE,2x,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7554,0211-0224,211.224,Ended,335,0211-P01,Efficacy & safety, single dose DU 1219,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7555,0211-0226,211.226,Ended,335,0211-P01,Long term DU 1219 SE, b.i.d.,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7556,0211-0231,211.231,Ended,335,0211-P01,Kinetics, multipe dose,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7557,0211-0232,211.232,Analysis,335,0211-P01,bioavailability of DU 1219 in volunteers,Analysis,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7558,0211-0300,211.300,Unconfirmed,335,0211-P01,Pilotstudy, haemodynamics,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7559,0211-0301,211.301,Ended,335,0211-P01,Haemodynamics, dose-response rel.,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7560,0211-0302,211.302,Ended,335,0211-P01,Haemodynamik invasiv, Vergl. m. Captopri,Ended,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7561,0211-0303,211.303,Ended,335,0211-P01,Efficacy,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7562,0211-0305,211.305,Ended,335,0211-P01,Stress induced AP,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7563,0211-0308,211.308,Analysis,335,0211-P01,Efficay, increasing dosages,Analysis,MIG,Migration,II,Phase II,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7564,0211-0311,211.311,Unconfirmed,335,0211-P01,Wirksamkeit, Vergl. geg. Placebo,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7565,0211-0312,211.312,Unconfirmed,335,0211-P01,Wirksamkeitsvergl, Alacepril 1xtgl ggn,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7566,0211-0315,211.315,Ended,335,0211-P01,Alacepril Therapeut., effects, tolerance,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7567,0211-0317,211.317,Analysis,335,0211-P01,Efficacy, increasing dosage,Analysis,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7568,0211-0318,211.318,Ended,335,0211-P01,Haemodynamics, acut, invasive,Ended,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7569,0211-0319,211.319,Ended,335,0211-P01,Haemodynamics, inv., acut a. steady stat,Ended,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7570,0221-0201,221.201,Ended,336,0221-P01,Efficacy,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7571,0221-0301,221.301,Ended,336,0221-P01,Efficacy,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7572,0221-0400,221.400,Ended,336,0221-P01,Pain, renal colic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7573,0221-0401,221.401,Ended,336,0221-P01,Not yet coded,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
7574,0225-0201,225.201,Ended,337,0225-P00,Acceptibility,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7575,0226-0101,226.101,Ended,338,0226-P01,Bioavailability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7576,0226-0301,226.301,Ended,338,0226-P01,Efficacy & safety,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7577,0226-0302,226.302,Ended,338,0226-P01,Combination rationale,Ended,MIG,Migration,III,Phase III,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7578,0226-0303,226.303,Unconfirmed,338,0226-P01,Comparison with Sumatriptan,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7579,0234-0302,234.302,Unconfirmed,339,0234-P01,Drug monitoring, Pres and ABPM,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = R, inserted by gerken at 22.03.93,,,000940,Post Marketing Study (MIGRATED)
7580,0234-0401,234.401,Preparing,339,0234-P01,VO2IAT, EXERCISE CAP, CI AT REST/EXERCIS,Preparing,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7581,0234-0402,234.402,Unconfirmed,339,0234-P01,HEART FAILURE,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7582,0234-0403,234.403,Ended,339,0234-P01,FIRST DOSE EFFECT, BLOOD PRESSURE RESP.,Ended,MIG,Migration,IV,Phase IV,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7583,0234-0404,234.404,Ended,339,0234-P01,FIRST DOSE EFFECT, BLOOD PRESSURE,Ended,MIG,Migration,IV,Phase IV,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7584,0234-0501,234.501,Ended,339,0234-P01,Impact on exercise, capacity (sporting),Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7585,0234-0502,234.502,Unconfirmed,339,0234-P01,HANE:efficacy and, safety,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7586,0234-0503,234.503,Ended,339,0234-P01,PRES efficacy in ISH, Pilot,Ended,MIG,Migration,IV,Phase IV,- , Alter > 60, EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7587,0234-0504,234.504,Unconfirmed,339,0234-P01,ISH-Follow-up of 257.003,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7588,0234-0601,234.601,Unconfirmed,339,0234-P01,Antiischemic effects, enalapril versus,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7589,0234-0952,234.952,Unconfirmed,339,0234-P01,PMS,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
7590,0234-0953,234.953,Unconfirmed,339,0234-P01,PMS,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
7591,0234-0954,234.954,Ended,339,0234-P01,PMS,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
7592,0235-0201,235.201,Ended,340,0235-P01,Drug monitoring Pres plus,Ended,MIG,Migration,IV,Phase IV,- , EStatus = P, inserted by gerken at 22.03.93,,,000940,Post Marketing Study (MIGRATED)
7593,0235-0202,235.202,Ended,340,0235-P01,Safety and Efficacy of Pres plus,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
7594,0235-0301,235.301,Ended,340,0235-P01,24h effects of PRES plus,Ended,MIG,Migration,IV,Phase IV,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7595,0235-0302,235.302,Ended,340,0235-P01,Comparative efficacy, triple combination,Ended,MIG,Migration,IV,Phase IV,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7596,0235-0303,235.303,Ended,340,0235-P01,Efficacy in, moderate or resist.,Ended,MIG,Migration,IV,Phase IV,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7597,0235-0902,235.902,Ended,340,0235-P01,PMS,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
7598,0249-0201,249.201,Ended,341,0249-P00,COLD,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7599,0249-0203,249.203,Ended,341,0249-P00,dose-time response, ,tolerance,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7600,0249-0204,249.204,Ended,341,0249-P00,Dose-time response, tolerance,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7601,0249-0400,249.400,Unconfirmed,341,0249-P00,COLD,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7602,0249-0401,249.401,Unconfirmed,341,0249-P00,COLD,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7603,0249-0402,249.402,Unconfirmed,341,0249-P00,COLD,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7604,0018-0045,18.45,Unconfirmed,342,0018-P00,Teamstudie mit Ambroxolsaft,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7605,0018-0046,18.46,Ended,342,0018-P00,Postoperative Phase, Dr. Heil, Ulm,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7606,0018-0047,18.47,Unconfirmed,342,0018-P00,Medium Term Tolerance,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7607,0018-0049,18.49,Unconfirmed,342,0018-P00,Nebelkammer, Kinder mit Bronchitis,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7608,0018-0050,18.50,Unconfirmed,342,0018-P00,Nebelkammer, Kinder, Klingelh√∂fer,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7609,0018-0051,18.51,Ended,342,0018-P00,Wirkung Rhinitis sicca, Dr. Mann, Pilot,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7610,0018-0052,18.52,Ended,342,0018-P00,Mucoviscidose, Dr. Hofmann, I,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7611,0018-0054,18.54,Ended,342,0018-P00,Ambroxol in der Klinik I, Dr. Jorde,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7612,0018-0055,18.55,Unconfirmed,342,0018-P00,Ambroxol in der Klinik II,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7613,0018-0056,18.56,Ended,342,0018-P00,Ambroxol in der Klinik III, Dr. Petro,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7614,0018-0057,18.57,Ended,342,0018-P00,Ambroxol in der Klinik IV, Prof. Ulmer,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7615,0018-0058,18.58,Unconfirmed,342,0018-P00,Ambroxol in der Praxis, Dr. Schrader,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7616,0018-0059,18.59,Ended,342,0018-P00,Respiroph. Ger√§teaccept.,Kinder,Poloczek,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7617,0018-0060,18.60,Unconfirmed,342,0018-P00,Ambroxol, Inhalation, Dr. H√ºsen,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7618,0018-0061,18.61,Ended,342,0018-P00,Mucoviscidose, Kinder, Dr. Tillmann, II,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7619,0018-0062,18.62,Ended,342,0018-P00,Vertr√§glichkeit Depotkapseln,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7620,0018-0063,18.63,Ended,342,0018-P00,Mucosolvan im Respirator, Multicenterpr.,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7621,0018-0064,18.64,Unconfirmed,342,0018-P00,Immunglobuline b. Asthma br., Stresemann,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7622,0018-0065,18.65,Ended,342,0018-P00,Saft - Tabletten Vegleich, Dr. Kanziora,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7623,0018-0066,18.66,Ended,342,0018-P00,Mucosolvan Tropfen - Tabletten,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7624,0018-0067,18.67,Ended,342,0018-P00,Inhalation und Tabletten, Multicenter,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7625,0018-0068,18.68,Ended,342,0018-P00,Pneumosonographie, Dr. Cegla,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7626,0018-0069,18.69,Ended,342,0018-P00,Acetylcholin-Provokation, Pilot, Ferlinz,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7627,0018-0070,18.70,Ended,342,0018-P00,Mukoserotympanon, Prof. M√ºnker,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7628,0018-0071,18.71,Ended,342,0018-P00,Closing Volume, Dr. Dorow,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7629,0018-0072,18.72,Ended,342,0018-P00,Ambroxol in der Praxis, Dr. G√ºnthner,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7630,0018-0073,18.73,Ended,342,0018-P00,Wirksamkeit Depotkapseln, 3 Pr√ºfstellen,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7631,0018-0074,18.74,Unconfirmed,342,0018-P00,Ambroxol, Mucocilliare Clearance, Lichte,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7632,0018-0075,18.75,Ended,342,0018-P00,Mucoviscidose bei Kindern, IV,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7633,0018-0076,18.76,Ended,342,0018-P00,Teamstudie, Depotkapseln 75 mg,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7634,0018-0078,18.78,Ended,342,0018-P00,Mucoserotympanon - Dr. -Wellmeier,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7635,0018-0079,18.79,Ended,342,0018-P00,Mukoserotympanon - Audiogramm,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7636,0018-0080,18.80,Ended,342,0018-P00,Raucher mit Small Airway Diseases I,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7637,0018-0081,18.81,Ended,342,0018-P00,Inhalationsbehandlung bei Kurpatienten,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7638,0018-0082,18.82,Ended,342,0018-P00,Wundheilung nach Tonsillektomie,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7639,0018-0083,18.83,Unconfirmed,342,0018-P00,Internationale Langzeitstudie Bronchitis,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7640,0018-0084,18.84,Ended,342,0018-P00,Vertr√§glichkeit Depot-Kapseln 2,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7641,0018-0085,18.85,Ended,342,0018-P00,Acceptance - S√§uglingssuppositorien,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7642,0018-0087,18.87,Unconfirmed,342,0018-P00,Tablettenvergl. Scherrer CH 173/81,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7643,0018-0093,18.93,Ended,342,0018-P00,Phospholipide i.Bronchialsekret, Methode,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7644,0018-0094,18.94,Unconfirmed,342,0018-P00,Phospholipidgehalt im Lavagematerial,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7645,0018-0095,18.95,Ended,342,0018-P00,Morphologie der Bronchialschleimhaut,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7646,0018-0096,18.96,Ended,342,0018-P00,Mucoviscidose, Dr. Wiesemann,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7647,0018-0097,18.97,Ended,342,0018-P00,Mucoviscidose, Dr. Bender,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7648,0018-0098,18.98,Ended,342,0018-P00,Phospholipidgehalt im Sputum, Hertle,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7649,0018-0099,18.99,Ended,342,0018-P00,Periph. Kl√§rfunktion, Technik, Nakosteen,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
7650,0018-0100,18.100,Ended,342,0018-P00,Phospholipidgehalt im Sekret, Homburg,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7651,0018-0102,18.102,Ended,342,0018-P00,Raucher mit Small Airway Diseases II,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7652,0018-0103,18.103,Ended,342,0018-P00,Pulmonale Aerosolverteilung, Dr. Dorow,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7653,0018-0104,18.104,Ended,342,0018-P00,Oracef-Spiegel Serum, Knochen, Mucosa,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7654,0018-0106,18.106,Unconfirmed,342,0018-P00,Medizinische Erhebung, Dr. K√∂hnlein,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
7655,0018-0107,18.107,Unconfirmed,342,0018-P00,Phospholipide,Lavage,Raucher,Prof.Kr√ºger,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7656,0018-0108,18.108,Ended,342,0018-P00,Einzelfallpr√ºfung bei Sj√∂gren-Syndrom,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7657,0018-0109,18.109,Unconfirmed,342,0018-P00,Inhalationsl√∂sung, Dr. Boelcskei,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7658,0018-0110,18.110,Ended,342,0018-P00,Ambroxol bei Bestrahlungspneumonitis,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7659,0018-0111,18.111,Ended,342,0018-P00,Langzeitstudie in der Praxis,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7660,0018-0112,18.112,Ended,342,0018-P00,Ambroxol bei trapped air,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7661,0018-0113,18.113,Ended,342,0018-P00,Atemwegskomplikationen b. Kindern p.O.,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7662,0018-0114,18.114,Ended,342,0018-P00,Raucher mit Small Airway Diseases III,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7663,0018-0116,18.116,Ended,342,0018-P00,Kindersuppositorien bei Atemwegserkrgn.,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7664,0018-0117,18.117,Ended,342,0018-P00,Kindersuppositorien bei Atemwegsinfekten,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7665,0018-0119,18.119,Unconfirmed,342,0018-P00,Mukoserotympanon, LZ-Therapie, Dr.Becker,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7666,0018-0120,18.120,Ended,342,0018-P00,Hustenclearance, Prof. Matthys,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7667,0018-0122,18.122,Ended,342,0018-P00,Patientenbenefit, Dr. Schildw√§chter,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7668,0018-0123,18.123,Ended,342,0018-P00,Acceptance - Tropfen bei S√§uglingen,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7669,0018-0124,18.124,Ended,342,0018-P00,Acceptance - Tropfen bei Kindern,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7670,0018-0125,18.125,Ended,342,0018-P00,Acceptance - Tropfen bei Erwachsenen,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7671,0018-0126,18.126,Ended,342,0018-P00,Mucosolvan, Rhinitis sicca, Dr. Klingl,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7672,0018-0127,18.127,Ended,342,0018-P00,Prophylaxe der Bestrahlungspneumonitis,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7673,0018-0128,18.128,Ended,342,0018-P00,Lavageuntersuchung bei Rauchern,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7674,0018-0131,18.131,Ended,342,0018-P00,Acceptance S√§uglingssupp. ge√§nd. Rezept.,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7675,0018-0132,18.132,Ended,342,0018-P00,Kindersupp.b.Atemwegsinf., ge√§nd. Rezept,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7676,0018-0133,18.133,Ended,342,0018-P00,Ambroxol b. COLD-Pat. o. Inf. Dr.Krieger,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7677,0018-0134,18.134,Ended,342,0018-P00,Ambroxol b. COLD-Pat. m. Inf. Dr.Krieger,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7678,0018-0135,18.135,Unconfirmed,342,0018-P00,Ambroxol b. COLD-Pat.m.revers. AW-Obstr.,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7679,0018-0136,18.136,Ended,342,0018-P00,Plasmaspiegel / Bioverf√ºgbarkeit,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7680,0018-0138,18.138,Ended,342,0018-P00,Plasmaspiegel / Bioverf√ºgbarkeit (Supp.),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7681,0018-0139,18.139,Unconfirmed,342,0018-P00,Ambroxol b. COLD-Pat.m.revers. AW-Obstr.,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7682,0018-0141,18.141,Ended,342,0018-P00,Ambroxol bei Schnarchern,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7683,0018-0142,18.142,Ended,342,0018-P00,Dosislinearit√§t, Bio√§quivalenz (30/60mg),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7684,0018-0144,18.144,Ended,342,0018-P00,Ambroxol b. idiopathischer Lungenfibrose,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7685,0018-0145,18.145,Ended,342,0018-P00,Ambroxol b. Pat. mit Niereninsuffizienz,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7686,0018-0146,18.146,Ended,342,0018-P00,Granulat-Acceptance bei S√§uglingen,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7687,0018-0147,18.147,Ended,342,0018-P00,Granulat-Acceptance bei Kindern,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7688,0018-0148,18.148,Ended,342,0018-P00,Granulat-Acceptance bei Erwachsenen,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7689,0018-0149,18.149,Ended,342,0018-P00,Nahrungseinflu√ü/Bio√§quiv. versch. Formen,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7690,0018-0150,18.150,Ended,342,0018-P00,Bio√§quivalenz versch. Depot-Formen,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7691,0018-0151,18.151,Ended,342,0018-P00,Plasmasp., Vertr√§glk. nach Bolusinjekt.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7692,0018-0152,18.152,Ended,342,0018-P00,Pharmakokinetikpr√ºfung, Dr. Bender,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7693,0018-0153,18.153,Ended,342,0018-P00,Bioverf√ºgbark. versch. Formen (Urin) I,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7694,0018-0154,18.154,Ended,342,0018-P00,Bioverf√ºgbark. versch. Formen (Urin) II,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7695,0018-0155,18.155,Ended,342,0018-P00,Magensaftgewinnung als Stand. u. Vorvers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7696,0018-0156,18.156,Ended,342,0018-P00,Interaktion mit Alkohol,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7697,0018-0157,18.157,Ended,342,0018-P00,Bioverf√ºgbarkeit versch. Nachahmer Urin,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7698,0018-0158,18.158,Ended,342,0018-P00,Bioverf√ºg. u. Kinet. versch. Depotformen,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7699,0018-0159,18.159,Ended,342,0018-P00,Fertigungstoleranz und Freisetzung,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7700,0018-0160,18.160,Unconfirmed,342,0018-P00,Mucoviscidose (Langzeit), Dr. Bender,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7701,0018-0161,18.161,Ended,342,0018-P00,Rhinitis b. Septumdeviation, BWK - Ulm,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7702,0018-0164,18.164,Ended,342,0018-P00,Kinetik Vergl.:Tabl., Retardformen,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7703,0018-0165,18.165,Ended,342,0018-P00,Vertr√§glichk. 1x30 mg/3 ml (m.Xylit)i.v.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7704,0018-0166,18.166,Ended,342,0018-P00,Vertr√§glichk. 1x30 mg/3ml (m.Xylit) i.m.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7705,0018-0167,18.167,Ended,342,0018-P00,Doubling of the standard-dose,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7706,0018-0168,18.168,Unconfirmed,342,0018-P00,Inhalation bei Mucoviszidose,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
7707,0018-0169,18.169,Unconfirmed,342,0018-P00,Phospholipide in der BAL,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7708,0018-0170,18.170,Ended,342,0018-P00,Inhalation of Ambroxol,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
7709,0018-0171,18.171,Ended,342,0018-P00,Ciliary Beat Frequency in Vitro,Ended,MIG,Migration,II,Phase II,- no patient's insurance and ethics committee is necessary, only in vitro measurements,,,000910,IS - Clin Study (MIGRATED)
7710,0018-0200,18.200,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7711,0018-0201,18.201,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7712,0018-0202,18.202,Unconfirmed,342,0018-P00,Surgery postoperative,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7713,0018-0203,18.203,Unconfirmed,342,0018-P00,Surgery postoperative,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7714,0018-0206,18.206,Unconfirmed,342,0018-P00,Sinusitis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7715,0018-0207,18.207,Unconfirmed,342,0018-P00,Bronchopulmonary diseases,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7716,0018-0208,18.208,Unconfirmed,342,0018-P00,Neoplasm brain,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7717,0018-0209,18.209,Unconfirmed,342,0018-P00,Surgery postoperative;Tracheobronchial S,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7718,0018-0210,18.210,Unconfirmed,342,0018-P00,Fibrosis cystic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7719,0018-0211,18.211,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7720,0018-0212,18.212,Ended,342,0018-P00,Bronchitis chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7721,0018-0213,18.213,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7722,0018-0215,18.215,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7723,0018-0217,18.217,Unconfirmed,342,0018-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7724,0018-0218,18.218,Unconfirmed,342,0018-P00,Bronchopulmonary diseases,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7725,0018-0219,18.219,Unconfirmed,342,0018-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7726,0018-0220,18.220,Unconfirmed,342,0018-P00,Bronchiolitis,Unconfirmed,MIG,Migration,III,Phase III,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
7727,0018-0221,18.221,Unconfirmed,342,0018-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7728,0018-0222,18.222,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7729,0018-0223,18.223,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7730,0018-0225,18.225,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7731,0018-0226,18.226,Ended,342,0018-P00,Bronchitis chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7732,0018-0227,18.227,Ended,342,0018-P00,Bronchitis chronic,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
7733,0018-0228,18.228,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7734,0018-0229,18.229,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7735,0018-0230,18.230,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7736,0018-0231,18.231,Unconfirmed,342,0018-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7737,0018-0232,18.232,Unconfirmed,342,0018-P00,Intensive care;Surgery thoracal;cold,Unconfirmed,MIG,Migration,III,Phase III,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
7738,0018-0233,18.233,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
7739,0018-0234,18.234,Unconfirmed,342,0018-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
7740,0018-0235,18.235,Unconfirmed,342,0018-P00,Bronchopulmonary diseases,Unconfirmed,MIG,Migration,III,Phase III,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
7741,0018-0236,18.236,Unconfirmed,342,0018-P00,Bronchopulmonary diseases,Unconfirmed,MIG,Migration,III,Phase III,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
7742,0018-0237,18.237,Unconfirmed,342,0018-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
7743,0018-0238,18.238,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7744,0018-0239,18.239,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7745,0018-0240,18.240,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7746,0018-0241,18.241,Unconfirmed,342,0018-P00,Bronchitis chronic;Pneumoconiosis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7747,0018-0242,18.242,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7748,0018-0243,18.243,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7749,0018-0244,18.244,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7750,0018-0245,18.245,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7751,0018-0247,18.247,Ended,342,0018-P00,Trauma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7752,0018-0250,18.250,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7753,0018-0251,18.251,Ended,342,0018-P00,Bronchiolitis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7754,0018-0252,18.252,Unconfirmed,342,0018-P00,Bronchiolitis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7755,0018-0253,18.253,Unconfirmed,342,0018-P00,Miners,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7756,0018-0254,18.254,Unconfirmed,342,0018-P00,Surgery,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7757,0018-0255,18.255,Unconfirmed,342,0018-P00,Carcinoma minor,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7758,0018-0256,18.256,Unconfirmed,342,0018-P00,Bronchiolitis smoking,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7759,0018-0257,18.257,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7760,0018-0258,18.258,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7761,0018-0259,18.259,Unconfirmed,342,0018-P00,Carcinoma testicle minor,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7762,0018-0260,18.260,Unconfirmed,342,0018-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7763,0018-0261,18.261,Unconfirmed,342,0018-P00,Otitis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7764,0018-0262,18.262,Unconfirmed,342,0018-P00,Smoking,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7765,0018-0263,18.263,Unconfirmed,342,0018-P00,Smoking,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7766,0018-0264,18.264,Unconfirmed,342,0018-P00,Smoking,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7767,0018-0265,18.265,Unconfirmed,342,0018-P00,Surgery thoracal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7768,0018-0266,18.266,Ended,342,0018-P00,COLD,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7769,0018-0267,18.267,Ended,342,0018-P00,COLD,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7770,0018-0269,18.269,Ended,342,0018-P00,Bronchitis chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7771,0018-0270,18.270,Ended,342,0018-P00,Bronchiolitis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7772,0018-0271,18.271,Ended,342,0018-P00,COLD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7773,0018-0272,18.272,Ended,342,0018-P00,COLD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7774,0018-0273,18.273,Ended,342,0018-P00,COLD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7775,0018-0274,18.274,Ended,342,0018-P00,COLD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7776,0018-0275,18.275,Ended,342,0018-P00,COLD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7777,0018-0276,18.276,Ended,342,0018-P00,Bronchitis chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7778,0018-0277,18.277,Ended,342,0018-P00,COLD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7779,0018-0278,18.278,Ended,342,0018-P00,COLD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7780,0018-0279,18.279,Ended,342,0018-P00,Bronchitis chr.;Emphysema pulm.;Tebercul,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7781,0018-0280,18.280,Ended,342,0018-P00,Silicosis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7782,0018-0281,18.281,Ended,342,0018-P00,Surgery thoracal,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7783,0018-0282,18.282,Ended,342,0018-P00,COLD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7784,0018-0283,18.283,Ended,342,0018-P00,Bronchitis chronic;Dyscrinism,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7785,0018-0284,18.284,Ended,342,0018-P00,Cough chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7786,0018-0285,18.285,Unconfirmed,342,0018-P00,Bronchitis cough,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7787,0018-0286,18.286,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7788,0018-0288,18.288,Ended,342,0018-P00,Bronchopulmonary diseases,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7789,0018-0289,18.289,Ended,342,0018-P00,Bronchitis chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7790,0018-0290,18.290,Ended,342,0018-P00,Bronchopulmonary diseases,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7791,0018-0293,18.293,Ended,342,0018-P00,Cough,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7792,0018-0294,18.294,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7793,0018-0295,18.295,Unconfirmed,342,0018-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7794,0018-0296,18.296,Unconfirmed,342,0018-P00,Otitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7795,0018-0297,18.297,Unconfirmed,342,0018-P00,Bronchitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7796,0018-0298,18.298,Unconfirmed,342,0018-P00,Surgery postoperative,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7797,0018-0299,18.299,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,I,Phase I,- Phase I-II * *,,,000910,IS - Clin Study (MIGRATED)
7798,0018-0300,18.300,Unconfirmed,342,0018-P00,COLD,Unconfirmed,MIG,Migration,I,Phase I,- Phase I-II ** *,,,000910,IS - Clin Study (MIGRATED)
7799,0018-0301,18.301,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7800,0018-0302,18.302,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7801,0018-0303,18.303,Unconfirmed,342,0018-P00,Bronchiolitis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7802,0018-0304,18.304,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7803,0018-0305,18.305,Unconfirmed,342,0018-P00,Bronchopneumonia;Pneumonia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7804,0018-0306,18.306,Unconfirmed,342,0018-P00,Bronchitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7805,0018-0307,18.307,Unconfirmed,342,0018-P00,Fibrosis cystic,Unconfirmed,MIG,Migration,IV,Phase IV,- planned patients:20-30 * *,,,000910,IS - Clin Study (MIGRATED)
7806,0018-0308,18.308,Unconfirmed,342,0018-P00,Surgery postoperative,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7807,0018-0309,18.309,Unconfirmed,342,0018-P00,Bronchopulmonary disease chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7808,0018-0310,18.310,Unconfirmed,342,0018-P00,No Legacy Data,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7809,0018-0311,18.311,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7810,0018-0312,18.312,Unconfirmed,342,0018-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7811,0018-0313,18.313,Ended,342,0018-P00,Glue ear in young patients,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7812,0018-0314,18.314,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7813,0018-0315,18.315,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7814,0018-0316,18.316,Unconfirmed,342,0018-P00,Fibrosis cystic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7815,0018-0317,18.317,Unconfirmed,342,0018-P00,Surgery,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7816,0018-0318,18.318,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7817,0018-0319,18.319,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7818,0018-0320,18.320,Unconfirmed,342,0018-P00,Smoking,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7819,0018-0328,18.328,Unconfirmed,342,0018-P00,Surgery,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7820,0018-0329,18.329,Ended,342,0018-P00,Smoking,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7821,0018-0330,18.330,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7822,0018-0331,18.331,Ended,342,0018-P00,Bronchitis, chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7823,0018-0332,18.332,Unconfirmed,342,0018-P00,Pneumonia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7824,0018-0334,18.334,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7825,0018-0335,18.335,Unconfirmed,342,0018-P00,Surgery thoracal,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7826,0018-0336,18.336,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7827,0018-0337,18.337,Unconfirmed,342,0018-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7828,0018-0338,18.338,Unconfirmed,342,0018-P00,Asthma;Bronchitis chronic;Emphysema pulm,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7829,0018-0340,18.340,Unconfirmed,342,0018-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7830,0018-0344,18.344,Unconfirmed,342,0018-P00,Cough,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7831,0018-0345,18.345,Unconfirmed,342,0018-P00,COLD;Pneumonia;Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7832,0018-0347,18.347,Unconfirmed,342,0018-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
7833,0018-0348,18.348,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7834,0018-0349,18.349,Ended,342,0018-P00,Bronchitis chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7835,0018-0350,18.350,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7836,0018-0351,18.351,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7837,0018-0352,18.352,Unconfirmed,342,0018-P00,Bronchopneumonia surgery,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7838,0018-0353,18.353,Unconfirmed,342,0018-P00,Otitis-Media,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
7839,0018-0358,18.358,Unconfirmed,342,0018-P00,Smoking,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7840,0018-0359,18.359,Ended,342,0018-P00,Silicosis,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7841,0018-0363,18.363,Ended,342,0018-P00,Bronchitis chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7842,0018-0364,18.364,Ended,342,0018-P00,Bronchitis chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7843,0018-0365,18.365,Ended,342,0018-P00,Otitis-Media,Ended,MIG,Migration,IV,Phase IV,- EF Study,,,000910,IS - Clin Study (MIGRATED)
7844,0018-0366,18.366,Unconfirmed,342,0018-P00,Bronchiolitis,Unconfirmed,MIG,Migration,IV,Phase IV,- EF Study,,,000910,IS - Clin Study (MIGRATED)
7845,0018-0369,18.369,Ended,342,0018-P00,Smoking,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7846,0018-0370,18.370,Ended,342,0018-P00,COLD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7847,0018-0371,18.371,Unconfirmed,342,0018-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7848,0018-0372,18.372,Ended,342,0018-P00,Airway obstruction,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7849,0018-0373,18.373,Unconfirmed,342,0018-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7850,0018-0374,18.374,Unconfirmed,342,0018-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7851,0018-0375,18.375,Unconfirmed,342,0018-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7852,0018-0376,18.376,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7853,0018-0377,18.377,Unconfirmed,342,0018-P00,Fibrosis cystic,Unconfirmed,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
7854,0018-0378,18.378,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7855,0018-0379,18.379,Unconfirmed,342,0018-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7856,0018-0380,18.380,Ended,342,0018-P00,Bronchitis, chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7857,0018-0381,18.381,Ended,342,0018-P00,Bronchopulmonary diseases surgery postop,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7858,0018-0382,18.382,Unconfirmed,342,0018-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7859,0018-0387,18.387,Ended,342,0018-P00,Atelectasis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7860,0018-0389,18.389,Ended,342,0018-P00,Infection bronchopulmonary,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7861,0018-0390,18.390,Ended,342,0018-P00,Bronchitis, chronic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7862,0018-0391,18.391,Unconfirmed,342,0018-P00,Surgery,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7863,0018-0392,18.392,Ended,342,0018-P00,Bronchitis, chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7864,0018-0393,18.393,Ended,342,0018-P00,Glue ear,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7865,0018-0394,18.394,Ended,342,0018-P00,Alveol.capil.permeability,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7866,0018-0395,18.395,Ended,342,0018-P00,Safety,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7867,0018-0397,18.397,Ended,342,0018-P00,Otitis-Media secretory,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7868,0018-0398,18.398,Ended,342,0018-P00,Safety,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7869,0018-0401,18.401,Ended,342,0018-P00,Airways obstruction,Ended,MIG,Migration,IV,Phase IV,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
7870,0018-0402,18.402,Ended,342,0018-P00,Sinusitis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7871,0018-0403,18.403,Ended,342,0018-P00,Bioequivalence,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7872,0018-0405,18.405,Ended,342,0018-P00,Bronchial hyperreactivity,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7873,0018-0406,18.406,Ended,342,0018-P00,Chest surgery,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7874,0018-0407,18.407,Ended,342,0018-P00,Chest surgery,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7875,0018-0408,18.408,Ended,342,0018-P00,Bronchitis, chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7876,0018-0409,18.409,Ended,342,0018-P00,Bronchitis, chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7877,0018-0410,18.410,Ended,342,0018-P00,Farin. seca,Ended,MIG,Migration,IV,Phase IV,- EF Study,,,000910,IS - Clin Study (MIGRATED)
7878,0018-0412,18.412,Ended,342,0018-P00,PREVENTION IRDS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7879,0018-0414,18.414,Ended,342,0018-P00,Pulmonary function,Ended,MIG,Migration,IV,Phase IV,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
7880,0018-0417,18.417,Ended,342,0018-P00,PREV. OF RESPIRATORY FAILURE,Ended,MIG,Migration,III,Phase III,- Summary requested (Letter LV/DI 26.08.92)                    Report expected 11/92 (Letter Daniotti 06.10.92),,,000910,IS - Clin Study (MIGRATED)
7881,0018-0418,18.418,Ended,342,0018-P00,PHARMACOKINETICS STUDY,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7882,0018-0419,18.419,Ended,342,0018-P00,SINGLE ADMINISTRATION (ADDITIONAL),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7883,0018-0420,18.420,Ended,342,0018-P00,MULTIPLE ADMINISTRATION TRIAL,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7884,0018-0421,18.421,Ended,342,0018-P00,SINGLE ADMINISTRATION,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7885,0018-0422,18.422,Ended,342,0018-P00,MIURA DTS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7886,0018-0423,18.423,Ended,342,0018-P00,HARASAWA DBT, JOINT DEVELOPMENT NBI 50%,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7887,0018-0424,18.424,Ended,342,0018-P00,TAKAHASHI OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7888,0018-0426,18.426,Ended,342,0018-P00,KAITO OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7889,0018-0427,18.427,Ended,342,0018-P00,SAKURAI OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7890,0018-0428,18.428,Ended,342,0018-P00,MISHINA OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7891,0018-0429,18.429,Unconfirmed,342,0018-P00,Retrolental fibroplasia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7892,0018-0430,18.430,Unconfirmed,342,0018-P00,Tube surf. stimulat.,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7893,0018-0432,18.432,Ended,342,0018-P00,Surgery, abdominal,Ended,MIG,Migration,III,Phase III,- Report expected 1/93 (BIT) (Letter Daniotti 06.10.92),,,000910,IS - Clin Study (MIGRATED)
7894,0018-0433,18.433,Ended,342,0018-P00,ambroxol retard in chronic bronchitis,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7895,0018-0434,18.434,Ended,342,0018-P00,Ambroxol in cystic fibrosis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7896,0018-0435,18.435,Ended,342,0018-P00,Bakt. Adhaesivitaet,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
7897,0018-0436,18.436,Ended,342,0018-P00,Surgery,Ended,MIG,Migration,I,Phase I,- Company was Teijin/Japan. Substance licenced out. Status was  A 10/92,,,000910,IS - Clin Study (MIGRATED)
7898,0018-0437,18.437,Ended,342,0018-P00,Surgery,Ended,MIG,Migration,I,Phase I,- Company was Teijin/Japan. Substance licenced out. Status was  A 10/92,,,000910,IS - Clin Study (MIGRATED)
7899,0018-0438,18.438,Ended,342,0018-P00,No Legacy Data,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7900,0018-0439,18.439,Ended,342,0018-P00,Clinical trial of Mucosolvan ampoules,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7901,0018-0440,18.440,Ended,342,0018-P00,Bronchodilating and Mucokinetic effect,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7902,0018-0441,18.441,Unconfirmed,342,0018-P00,Effect on children with mucoviscidosis,Unconfirmed,MIG,Migration,II,Phase II,- ,,,,
7903,0018-0443,18.443,Ended,342,0018-P00,YAMAKIDO OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7904,0018-0445,18.445,Ended,342,0018-P00,FURUTA OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7905,0018-0446,18.446,Ended,342,0018-P00,YAMAKIDO OT (TUBERUCLOSIS),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7906,0018-0447,18.447,Ended,342,0018-P00,NAGATO OT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7907,0018-0448,18.448,Ended,342,0018-P00,EFFECT OF FOOD,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7908,0018-0449,18.449,Ended,342,0018-P00,PHARMACOKINETICS,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7909,0018-0450,18.450,Ended,342,0018-P00,Ausscheidung v. PGE2, 6-keto-PGF1 alphaI,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7910,0018-0451,18.451,Unconfirmed,342,0018-P00,Sinusitis,Unconfirmed,MIG,Migration,IV,Phase IV,- EF Study,,,000910,IS - Clin Study (MIGRATED)
7911,0018-0452,18.452,Ended,342,0018-P00,Pharmacokinetics of ambroxol,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7912,0018-0453,18.453,Ended,342,0018-P00,CHRONIC, BRONCHITIS ETC.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7913,0018-0454,18.454,Ended,342,0018-P00,JOINT DEVELOPMENT NBI 50%,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7914,0018-0455,18.455,Ended,342,0018-P00,Efficacy / Tolerance,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7915,0018-0456,18.456,Ended,342,0018-P00,Mucosolvan in severe stable COPD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7916,0018-0458,18.458,Ended,342,0018-P00,Ambroxol in acute episodes of chron.bron,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7917,0018-0459,18.459,Unconfirmed,342,0018-P00,Children,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7918,0018-0462,18.462,Ended,342,0018-P00,PREVENTION OF C.B. EXACERBATION,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7919,0018-0471,18.471,Unconfirmed,342,0018-P00,Mucosolvan S - bronchopulmonale Beschw.,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
7920,0018-0472,18.472,Unconfirmed,342,0018-P00,Mucosolvan Saft - bronchopulm. Beschw.,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
7921,0018-0473,18.473,Unconfirmed,342,0018-P00,Mucosolvan Tropfen - bronchopul. Beschw.,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
7922,0018-0474,18.474,Unconfirmed,342,0018-P00,Ambroxol in glue ear,Unconfirmed,MIG,Migration,III,Phase III,- ,,,,
7923,0018-0476,18.476,Unconfirmed,342,0018-P00,Influence on acute exacerbations,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
7924,0018-0478,18.478,Ended,342,0018-P00,Mucosolvan Syrup bioequivalent (China),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7925,0018-0480,18.480,Preparing,342,0018-P00,Mucosolvan iv for Atelectasis,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
7926,0018-0488,18.488,Ended,342,0018-P00,Relative bioavailbility of ambroxol,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7927,0018-0502,18.502,Preparing,342,0018-P00,Mucosolvan soft pastille BI study China,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7928,0018-0503,18.503,Unconfirmed,342,0018-P00,Ambroxol all dose forms all indications,Unconfirmed,MIG,Migration,III,Phase III,14.01.2009 just for testing. ,,,000910,IS - Clin Study (MIGRATED)
7929,0018-0509,18.509,Ended,342,0018-P00,Ambroxol soft pastilles15mg BA/BE Brazil,Ended,MIG,Migration,I,Phase I,Local BA/BE study (ANVISA) ,,,000910,IS - Clin Study (MIGRATED)
7930,0018-0510,18.510,Ended,342,0018-P00,PK Lasolvan Russia,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
7931,0018-0511,18.511,Preparing,342,0018-P00,Mucosolvan 1g aRCT trial,Preparing,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
7932,0261-0305,261.305,Ended,343,0261-P01,Bioavailability, multiple dose,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7933,0261-0307,261.307,Ended,343,0261-P01,Fenoterol+Theophyll., different multiinh,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7934,0261-0308,261.308,Preparing,343,0261-P01,Berodual+Theophyll., different multiinh.,Preparing,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7935,0261-0309,261.309,Ended,343,0261-P01,Kinetics,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7936,0262-0101,262.101,Analysis,344,0262-P00,Tolerance, titration,Analysis,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7937,0262-0102,262.102,Unconfirmed,344,0262-P00,Dose response,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = ?, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7938,0262-0103,262.103,Unconfirmed,344,0262-P00,Tolerance following multiple application,Unconfirmed,MIG,Migration,I,Phase I,- , EStatus = ?, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7939,0262-0108,262.108,Ended,344,0262-P00,Duration of effect, volunteers,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7940,0262-0109,262.109,Ended,344,0262-P00,Histamin Quaddel, vgl. zu Terfenadin,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7941,0262-0110,262.110,Ended,344,0262-P00,Parasympatolytisch, Speicheldruese, Auge,Ended,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7942,0262-0111,262.111,Ended,344,0262-P00,Pharmakokinetik, Metabolismus,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
7943,0262-0150,262.150,Unconfirmed,344,0262-P00,Rhinitis acute;Rhinitis allergic seasona,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7944,0262-0151,262.151,Unconfirmed,344,0262-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7945,0262-0152,262.152,Unconfirmed,344,0262-P00,Asthma allergic,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7946,0262-0153,262.153,Unconfirmed,344,0262-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7947,0262-0154,262.154,Unconfirmed,344,0262-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7948,0262-0155,262.155,Unconfirmed,344,0262-P00,Asthma;Bronchitis,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7949,0262-0156,262.156,Ended,344,0262-P00,Rhinitis seasonal allergic,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7950,0262-0157,262.157,Unconfirmed,344,0262-P00,Rhinitis allergic seasonal,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7951,0262-0158,262.158,Ended,344,0262-P00,Rhinitis allergic seasonal;Conjunctiviti,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7952,0262-0159,262.159,Ended,344,0262-P00,--,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7953,0262-0160,262.160,Ended,344,0262-P00,No Legacy Data,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7954,0262-0161,262.161,Ended,344,0262-P00,Performance,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7955,0262-0162,262.162,Ended,344,0262-P00,--,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7956,0262-0163,262.163,Ended,344,0262-P00,RHINITIS, ALLERGIC,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7957,0262-0164,262.164,Ended,344,0262-P00,URTICARIA,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7958,0262-0165,262.165,Ended,344,0262-P00,ASTHMA,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7959,0262-0166,262.166,Ended,344,0262-P00,Skin test,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7960,0262-0167,262.167,Ended,344,0262-P00,Bronchial provacation,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7961,0262-0168,262.168,Ended,344,0262-P00,Bronchial provacation (vs. placebo),Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7962,0262-0169,262.169,Ended,344,0262-P00,ASTHMA,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7963,0262-0170,262.170,Ended,344,0262-P00,RHINITIS, ALLERGIC,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7964,0262-0171,262.171,Ended,344,0262-P00,URTICARIA,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7965,0262-0172,262.172,Ended,344,0262-P00,--,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7966,0262-0173,262.173,Ended,344,0262-P00,Rhinitis,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7967,0262-0174,262.174,Ended,344,0262-P00,DBT of WAL 801 CL (vs. Azelastine),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7968,0262-0175,262.175,Ended,344,0262-P00,Effect of WAL 801 on psoriasis vulgaris.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7969,0262-0176,262.176,Ended,344,0262-P00,Effect of WAL 801 on puritic skin disord,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7970,0262-0177,262.177,Ended,344,0262-P00,DBT of WAL 801 CL for asthma (vs ketotif,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7971,0262-0178,262.178,Ended,344,0262-P00,A long-term trial of WAL 801 CL (urticar,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7972,0262-0179,262.179,Ended,344,0262-P00,Long-term trial of WAL 801 CL (Nasal All,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7973,0262-0180,262.180,Ended,344,0262-P00,Double blind study of WAL 801 Cl,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7974,0262-0181,262.181,Ended,344,0262-P00,Long-term administration study,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7975,0262-0182,262.182,Ended,344,0262-P00,Effects of WAL 801 CL on eczema e.t.c.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7976,0262-0183,262.183,Ended,344,0262-P00,Effects of WAL 801 CL on skin disorders,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7977,0262-0184,262.184,Ended,344,0262-P00,Effects of WAL 801 Cl on skin disorders,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7978,0262-0185,262.185,Ended,344,0262-P00,Long-term administr. trial of WAL 801 CL,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7979,0262-0186,262.186,Ended,344,0262-P00,BIOLOGICAL EQUIVALENCE STUDY OF WAL 801,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7980,0262-0187,262.187,Ended,344,0262-P00,Biological equivalence study of Wal 801,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7981,0262-0188,262.188,Ended,344,0262-P00,Effect of car driving performance,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7982,0262-0189,262.189,Ended,344,0262-P00,Biological equivalence study,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7983,0262-0190,262.190,Ended,344,0262-P00,Influence of food on bioavailability,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7984,0262-0191,262.191,Ended,344,0262-P00,Efficacy of WAL 801 on Urticaria fact.,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7985,0262-0192,262.192,Ended,344,0262-P00,Bioequivalence study,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7986,0262-0193,262.193,Ended,344,0262-P00,Pilot study,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
7987,0262-0196,262.196,Ended,344,0262-P00,Dose ranging study,open label,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7988,0262-0197,262.197,Ended,344,0262-P00,Tolerability in increasing doses,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7989,0262-0198,262.198,Ended,344,0262-P00,Tolerability of Epinastine Eye drops,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7990,0262-0199,262.199,Ended,344,0262-P00,Efficacy of 10 and 20 mg WAL 801 CL in,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7991,0262-0200,262.200,Ended,344,0262-P00,Epinastine HCl in Chronic Urticaria,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7992,0262-0201,262.201,Ended,344,0262-P00,Epinastine for Perennial Nasal Allergy,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7993,0262-0202,262.202,Ended,344,0262-P00,WAL 801 for Allergic Bronchial Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
7994,0262-0203,262.203,Ended,344,0262-P00,Efficacy of 0.05%,0.1% and 0.3% WAL 801,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7995,0262-0204,262.204,Ended,344,0262-P00,Efficacy and Safety,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7996,0262-0205,262.205,Ended,344,0262-P00,Skin tolerability,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
7997,0262-0206,262.206,Ended,344,0262-P00,Dose Interval Study,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7998,0262-0207,262.207,Ended,344,0262-P00,Efficacy and safety,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
7999,0262-0208,262.208,Ended,344,0262-P00,Influence to CNS in in daytime by MSLT,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8000,0262-0211,262.211,Ended,344,0262-P00,efficacy on wheal and flare reactions,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8001,0262-0212,262.212,Ended,344,0262-P00,Efficacy and safety,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8002,0262-0213,262.213,Ended,344,0262-P00,Efficacy in VCC if Epinastine 0.05%,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8003,0262-0214,262.214,Ended,344,0262-P00,Efficacy of Epinastine 0.05 %,Ended,MIG,Migration,II,Phase II,- Study to run in South Africa,,,000910,IS - Clin Study (MIGRATED)
8004,0262-0215,262.215,Unconfirmed,344,0262-P00,Epinastine eye drops, children + adults,Unconfirmed,MIG,Migration,III,Phase III,- Study running in Skandinavia,,,000910,IS - Clin Study (MIGRATED)
8005,0262-0216,262.216,Ended,344,0262-P00,Initial therapy for Ceder Pollenosis,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8006,0262-0217,262.217,Ended,344,0262-P00,effect & safety of AL for Pruritus seni,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8007,0262-0218,262.218,Ended,344,0262-P00,INITIAL THERAPY FOR CEDAR PLLENOSIS,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8008,0262-0219,262.219,Ended,344,0262-P00,EFFECT & SAFETY OF AL FOR PRURITUS SENI,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8009,0262-0221,262.221,Ended,344,0262-P00,INITIAL THERAPY FOR CEDAR POLLENOSIS,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8010,0262-0222,262.222,Ended,344,0262-P00,THERAPY FOR ITCHING WITH DIALYSIS,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8011,0262-0223,262.223,Ended,344,0262-P00,INITIAL THERAPY FOR CEDAR POLLENOSIS,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8012,0262-0224,262.224,Ended,344,0262-P00,EFFECT & SAFETY OF AL ON ATOPIC DERMATI,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8013,0262-0225,262.225,Ended,344,0262-P00,EFFECT & SAFETY OF AL ON ATOPIC DERMATI,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8014,0262-0226,262.226,Ended,344,0262-P00,EFFECTS & SAFETY OF AL ON DERMATITIS,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8015,0262-0227,262.227,Ended,344,0262-P00,Effect of Alesion for broncal asthma,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
8016,0262-0228,262.228,Ended,344,0262-P00,Tachyphylaxy,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8017,0262-0230,262.230,Ended,344,0262-P00,Ef. and safety compar. vs. Loratadine,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8018,0262-0231,262.231,Ended,344,0262-P00,Double blind t. to assess ef. & safety,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8019,0262-0232,262.232,Ended,344,0262-P00,WAL 801 20 mg for Perannial Nas. Allergy,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8020,0262-0233,262.233,Ended,344,0262-P00,Dose finding study of WAL801CL DS,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
8021,0262-0234,262.234,Ended,344,0262-P00,Dose finding study of WAL801CL DS,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
8022,0262-0235,262.235,Ended,344,0262-P00,Bioequivalence study,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8023,0262-0236,262.236,Ended,344,0262-P00,Open trial for efficacy,Ended,MIG,Migration,IV,Phase IV,- only drug and finance support. No monitoring. No Data Management. No reporting,,,,
8024,0262-0237,262.237,Preparing,344,0262-P00,Efficacy in allergic rhinitis,Preparing,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8025,0262-0240,262.240,Unconfirmed,344,0262-P00,SAR -SPRING,Unconfirmed,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
8026,0262-0241,262.241,Unconfirmed,344,0262-P00,SAR -,Unconfirmed,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
8027,0262-0242,262.242,Unconfirmed,344,0262-P00,SAR -FALL,Unconfirmed,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
8028,0262-0243,262.243,Unconfirmed,344,0262-P00,SAR -PK FOOD BIO-AVAILABILITY,Unconfirmed,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
8029,0262-0244,262.244,Unconfirmed,344,0262-P00,SAR -PK DRUG INTERACTION,Unconfirmed,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
8030,0262-0245,262.245,Unconfirmed,344,0262-P00,SAR -PK GENDER AND ETHNICITY,Unconfirmed,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
8031,0262-0246,262.246,Unconfirmed,344,0262-P00,SAR -PK RENAL INSUFFICIENCY,Unconfirmed,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
8032,0262-0247,262.247,Unconfirmed,344,0262-P00,SAR -PK HEPATIC DYSFUNCTION,Unconfirmed,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
8033,0262-0248,262.248,Unconfirmed,344,0262-P00,SAR -BIO-EQUIVALENCE,Unconfirmed,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
8034,0262-0249,262.249,Unconfirmed,344,0262-P00,SAR -PEDIATRIC DOSE RANGING,Unconfirmed,MIG,Migration,II,Phase II,        ,,,000910,IS - Clin Study (MIGRATED)
8035,0262-0250,262.250,Unconfirmed,344,0262-P00,SAR -PEDIATRIC PHASE III,Unconfirmed,MIG,Migration,III,Phase III,        ,,,000910,IS - Clin Study (MIGRATED)
8036,0262-0258,262.258,Ended,344,0262-P00,WAL801CL - DS DBT on Rhinitis,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8037,0262-0259,262.259,Ended,344,0262-P00,WAL801CL - DS DBT on A.D.,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8038,0262-0260,262.260,Ended,344,0262-P00,WAL801CL-DS Open on A.D.,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8039,0262-0267,262.267,Preparing,344,0262-P00,Epinastine OTC Mono-tab. BE study,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8040,0262-0268,262.268,Unconfirmed,344,0262-P00,Epinastine OTC Combo PK single admin.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8041,0262-0269,262.269,Unconfirmed,344,0262-P00,Epinastine OTC Combo PK multiple admin.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8042,0262-0270,262.270,Unconfirmed,344,0262-P00,Epinastine OTC Combo DBT,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8043,0262-0271,262.271,Unconfirmed,344,0262-P00,Epinastine Tab. Phase IV on asthma,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8044,0262-0272,262.272,Unconfirmed,344,0262-P00,Epinastine - DS Open on asthma,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8045,0262-0276,262.276,Unconfirmed,344,0262-P00,WAL Tab. Ph IV on Allergic Rhinitis,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8046,0262-0277,262.277,Unconfirmed,344,0262-P00,WAL Tab. Ph IV on Atopic Dermatitis,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8047,0262-0280,262.280,Unconfirmed,344,0262-P00,WAL801CL OTC Combo PK single admin. 2,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8048,0262-0281,262.281,Unconfirmed,344,0262-P00,WAL801CL OTC Combo Food effect study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8049,0262-0282,262.282,Unconfirmed,344,0262-P00,WAL801 Clinical pharmacology study on AR,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8050,0262-0283,262.283,Unconfirmed,344,0262-P00,WAL801CL OTC Combo Open study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8051,0262-0284,262.284,Ended,344,0262-P00,WAL801CL-DS new formulation BE study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8052,0262-0285,262.285,Unconfirmed,344,0262-P00,WAL801CL OTC Combo OT in skin symptoms,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8053,0262-0286,262.286,Unconfirmed,344,0262-P00,WAL801CL tab. Clinical Pharmacology,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8054,0262-0287,262.287,Unconfirmed,344,0262-P00,WAL801CL-DS Ph. IV Atopic dermatitis,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8055,0262-0288,262.288,Unconfirmed,344,0262-P00,WAL801CL-DS Ph. IV Allergic rhinitis,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8056,0262-0289,262.289,Preparing,344,0262-P00,WAL801CL-Dry Syrup preliminary BE study,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8057,0262-0290,262.290,Ended,344,0262-P00,Alesion tablets PMS study,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
8058,0262-0293,262.293,Ended,344,0262-P00,Alesion Dry Syrup 1% PMS Study,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
8059,0262-0294,262.294,Ended,344,0262-P00,Alesion Dry Syrup 1% PMS for Urticaria,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
8060,0263-0201,263.201,Ended,345,0263-P01,Effect on residual, urine,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8061,0263-0203,263.203,Unconfirmed,345,0263-P01,Influence on, physical powers,,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8062,0263-0204,263.204,Ended,345,0263-P01,Influence on, physical powers,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8063,0263-0205,263.205,Unconfirmed,345,0263-P01,Influence on, physical powers,,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8064,0263-0206,263.206,Unconfirmed,345,0263-P01,Screening, prevalence,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8065,0263-0207,263.207,Ended,345,0263-P01,Safety,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8066,0263-0300,263.300,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8067,0263-0301,263.301,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8068,0263-0302,263.302,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8069,0263-0303,263.303,Ended,345,0263-P01,Insomnia psychiatric,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8070,0263-0304,263.304,Ended,345,0263-P01,Insomnia,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8071,0263-0305,263.305,Ended,345,0263-P01,none,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8072,0263-0306,263.306,Ended,345,0263-P01,Insomnia,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8073,0263-0307,263.307,Ended,345,0263-P01,none,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8074,0263-0308,263.308,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8075,0263-0309,263.309,Unconfirmed,345,0263-P01,Insomnia chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8076,0263-0310,263.310,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8077,0263-0311,263.311,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8078,0263-0312,263.312,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8079,0263-0313,263.313,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8080,0263-0314,263.314,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8081,0263-0315,263.315,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8082,0263-0316,263.316,Unconfirmed,345,0263-P01,Surgery pre-Operative,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8083,0263-0317,263.317,Unconfirmed,345,0263-P01,Surgery pre-Operative,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8084,0263-0318,263.318,Unconfirmed,345,0263-P01,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8085,0263-0319,263.319,Unconfirmed,345,0263-P01,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8086,0263-0320,263.320,Unconfirmed,345,0263-P01,Diabetes-Mellitus minor,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8087,0263-0321,263.321,Unconfirmed,345,0263-P01,Diabetes-Mellitus minor,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8088,0263-0322,263.322,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8089,0263-0323,263.323,Ended,345,0263-P01,none,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8090,0263-0324,263.324,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8091,0263-0325,263.325,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8092,0263-0326,263.326,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8093,0263-0327,263.327,Unconfirmed,345,0263-P01,Psychiatric diseases,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8094,0263-0328,263.328,Unconfirmed,345,0263-P01,Psychiatric diseases,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8095,0263-0329,263.329,Unconfirmed,345,0263-P01,Psychiatric diseases;Insomnia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8096,0263-0330,263.330,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8097,0263-0331,263.331,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8098,0263-0332,263.332,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8099,0263-0333,263.333,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8100,0263-0334,263.334,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8101,0263-0335,263.335,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8102,0263-0336,263.336,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8103,0263-0337,263.337,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8104,0263-0338,263.338,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8105,0263-0339,263.339,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8106,0263-0340,263.340,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8107,0263-0341,263.341,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8108,0263-0342,263.342,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8109,0263-0343,263.343,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8110,0263-0344,263.344,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8111,0263-0345,263.345,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8112,0263-0346,263.346,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8113,0263-0347,263.347,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8114,0263-0348,263.348,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8115,0263-0349,263.349,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8116,0263-0350,263.350,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8117,0263-0351,263.351,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8118,0263-0352,263.352,Unconfirmed,345,0263-P01,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8119,0263-0353,263.353,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8120,0263-0354,263.354,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8121,0263-0355,263.355,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8122,0263-0356,263.356,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8123,0263-0357,263.357,Ended,345,0263-P01,Insomnia,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8124,0263-0358,263.358,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8125,0263-0359,263.359,Unconfirmed,345,0263-P01,Psychiatric diseases,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8126,0263-0360,263.360,Unconfirmed,345,0263-P01,Psychiatric diseases,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8127,0263-0361,263.361,Unconfirmed,345,0263-P01,Psychiatric diseases;Insomnia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8128,0263-0362,263.362,Unconfirmed,345,0263-P01,Psychiatric diseases;Insomnia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8129,0263-0363,263.363,Unconfirmed,345,0263-P01,Psychiatric diseases;Insomnia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8130,0263-0364,263.364,Unconfirmed,345,0263-P01,Psychiatric diseases;Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8131,0263-0365,263.365,Unconfirmed,345,0263-P01,Psychiatric diseases,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8132,0263-0366,263.366,Unconfirmed,345,0263-P01,Surgery pre-Operative,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8133,0263-0367,263.367,Unconfirmed,345,0263-P01,Surgery pre-Operative,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8134,0263-0368,263.368,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8135,0263-0369,263.369,Unconfirmed,345,0263-P01,COLD minor;Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8136,0263-0370,263.370,Unconfirmed,345,0263-P01,Renal failure minor,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8137,0263-0371,263.371,Unconfirmed,345,0263-P01,Hepatic failure minor,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8138,0263-0372,263.372,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8139,0263-0373,263.373,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8140,0263-0374,263.374,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8141,0263-0375,263.375,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8142,0263-0376,263.376,Ended,345,0263-P01,Hepatic failure minor,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8143,0263-0377,263.377,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8144,0263-0378,263.378,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8145,0263-0379,263.379,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8146,0263-0380,263.380,Unconfirmed,345,0263-P01,Psychiatric diseases,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8147,0263-0381,263.381,Unconfirmed,345,0263-P01,Psychiatric diseases,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8148,0263-0382,263.382,Unconfirmed,345,0263-P01,Psychiatric diseases,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8149,0263-0383,263.383,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8150,0263-0384,263.384,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8151,0263-0385,263.385,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8152,0263-0386,263.386,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8153,0263-0387,263.387,Unconfirmed,345,0263-P01,Insomnia chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8154,0263-0388,263.388,Unconfirmed,345,0263-P01,Insomnia chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8155,0263-0389,263.389,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8156,0263-0390,263.390,Unconfirmed,345,0263-P01,Insomnia chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8157,0263-0391,263.391,Unconfirmed,345,0263-P01,Insomnia chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8158,0263-0392,263.392,Unconfirmed,345,0263-P01,Insomnia chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8159,0263-0393,263.393,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8160,0263-0394,263.394,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8161,0263-0395,263.395,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8162,0263-0396,263.396,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8163,0263-0397,263.397,Unconfirmed,345,0263-P01,Insomnia chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8164,0263-0398,263.398,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8165,0263-0399,263.399,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8166,0263-0400,263.400,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8167,0263-0401,263.401,Unconfirmed,345,0263-P01,Insomnia chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8168,0263-0402,263.402,Unconfirmed,345,0263-P01,Insomnia chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8169,0263-0403,263.403,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8170,0263-0404,263.404,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8171,0263-0405,263.405,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8172,0263-0406,263.406,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8173,0263-0407,263.407,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8174,0263-0408,263.408,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8175,0263-0409,263.409,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8176,0263-0410,263.410,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8177,0263-0411,263.411,Unconfirmed,345,0263-P01,Insomnia;Insomnia psychiatric,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8178,0263-0412,263.412,Unconfirmed,345,0263-P01,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8179,0263-0413,263.413,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8180,0263-0414,263.414,Unconfirmed,345,0263-P01,Insomnia psychiatric,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8181,0263-0415,263.415,Unconfirmed,345,0263-P01,Insomnia psychiatric,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8182,0263-0416,263.416,Unconfirmed,345,0263-P01,Insomnia psychiatric,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8183,0263-0417,263.417,Unconfirmed,345,0263-P01,Insomnia psychiatric,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8184,0263-0418,263.418,Unconfirmed,345,0263-P01,Insomnia psychiatric,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8185,0263-0419,263.419,Unconfirmed,345,0263-P01,Insomnia psychiatric,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8186,0263-0420,263.420,Unconfirmed,345,0263-P01,Surgery pre-Operative,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8187,0263-0421,263.421,Unconfirmed,345,0263-P01,Surgery pre-Operative,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8188,0263-0422,263.422,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8189,0263-0423,263.423,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8190,0263-0424,263.424,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8191,0263-0425,263.425,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8192,0263-0426,263.426,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8193,0263-0427,263.427,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8194,0263-0428,263.428,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8195,0263-0429,263.429,Ended,345,0263-P01,Insomnia,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8196,0263-0430,263.430,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8197,0263-0431,263.431,Unconfirmed,345,0263-P01,Psychiatric diseases,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8198,0263-0432,263.432,Unconfirmed,345,0263-P01,Psychiatric diseases,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8199,0263-0433,263.433,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8200,0263-0434,263.434,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8201,0263-0435,263.435,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8202,0263-0436,263.436,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8203,0263-0437,263.437,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8204,0263-0438,263.438,Unconfirmed,345,0263-P01,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8205,0263-0439,263.439,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8206,0263-0440,263.440,Unconfirmed,345,0263-P01,Hepatic failure minor,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8207,0263-0441,263.441,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8208,0263-0442,263.442,Unconfirmed,345,0263-P01,Insomnia psychiatric,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8209,0263-0443,263.443,Unconfirmed,345,0263-P01,Insomnia trauma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8210,0263-0444,263.444,Unconfirmed,345,0263-P01,Insomnia postoperative,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8211,0263-0445,263.445,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8212,0263-0446,263.446,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8213,0263-0447,263.447,Unconfirmed,345,0263-P01,Insomnia;Sleep disorders,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8214,0263-0448,263.448,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- planned patients: 30-40 * *,,,000910,IS - Clin Study (MIGRATED)
8215,0263-0449,263.449,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8216,0263-0450,263.450,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8217,0263-0451,263.451,Unconfirmed,345,0263-P01,Insomnia psychiatric,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8218,0263-0452,263.452,Unconfirmed,345,0263-P01,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8219,0263-0453,263.453,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8220,0263-0454,263.454,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8221,0263-0455,263.455,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8222,0263-0456,263.456,Unconfirmed,345,0263-P01,Surgery pre-Operative,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8223,0263-0457,263.457,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8224,0263-0458,263.458,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8225,0263-0459,263.459,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8226,0263-0460,263.460,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,NONE,Not Classified,- planned patients: 6-8 * *,,,000910,IS - Clin Study (MIGRATED)
8227,0263-0461,263.461,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8228,0263-0462,263.462,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8229,0263-0463,263.463,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8230,0263-0464,263.464,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8231,0263-0465,263.465,Unconfirmed,345,0263-P01,Insomnia psychiatric,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8232,0263-0466,263.466,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8233,0263-0467,263.467,Unconfirmed,345,0263-P01,Surgery pre-Operative,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8234,0263-0468,263.468,Ended,345,0263-P01,Insomnia psychiatric,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8235,0263-0469,263.469,Unconfirmed,345,0263-P01,Surgery pre-Operative,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8236,0263-0470,263.470,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8237,0263-0471,263.471,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8238,0263-0472,263.472,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8239,0263-0473,263.473,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8240,0263-0474,263.474,Unconfirmed,345,0263-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8241,0263-0475,263.475,Ended,345,0263-P01,Bronchitis,chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8242,0263-0476,263.476,Ended,345,0263-P01,Insomnia,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8243,0263-0477,263.477,Ended,345,0263-P01,Insomnia,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8244,0263-0478,263.478,Ended,345,0263-P01,Insomnia,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8245,0263-0479,263.479,Ended,345,0263-P01,Insomnia,Ended,MIG,Migration,IV,Phase IV,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
8246,0263-0480,263.480,Unconfirmed,345,0263-P01,Sleep disorders,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8247,0263-0481,263.481,Unconfirmed,345,0263-P01,Insomnia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8248,0263-0482,263.482,Ended,345,0263-P01,EFFICACY VS.FLURAZEPAM,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8249,0263-0483,263.483,Ended,345,0263-P01,EFFICACY BROTIZOLAM VS.TRIAZOLAM,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8250,0263-0484,263.484,Ended,345,0263-P01,Brotizolam in psychotic children,Ended,MIG,Migration,IV,Phase IV,- Discontinued due to slow recruiting rate - 2 patients *,,,000910,IS - Clin Study (MIGRATED)
8251,0263-0485,263.485,Ended,345,0263-P01,Insomnia,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8252,0263-0486,263.486,Ended,345,0263-P01,Insomnia,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8253,0263-0487,263.487,Ended,345,0263-P01,EFFICACY IN SHIFT WORKERS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8254,0263-0488,263.488,Ended,345,0263-P01,Insomnia,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8255,0263-0489,263.489,Ended,345,0263-P01,Brotizolam VS Quazepam VS Lorazepam,Ended,MIG,Migration,III,Phase III,- No promising results. No Report =Info on page 3!) *,,,000910,IS - Clin Study (MIGRATED)
8256,0263-0490,263.490,Ended,345,0263-P01,Italian Insomnia Project '89,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8257,0263-0491,263.491,Ended,345,0263-P01,ISIDE,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8258,0263-0492,263.492,Ended,345,0263-P01,Lendormin in Sleep Disturbances,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8259,0263-0493,263.493,Ended,345,0263-P01,Brotizolam/Multiple Latency Test,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8260,0263-0494,263.494,Ended,345,0263-P01,Efficacy and safety of Brotizolam,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8261,0263-0495,263.495,Ended,345,0263-P01,The effect for Preanesthetic medication,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8262,0263-0496,263.496,Unconfirmed,345,0263-P01,Efficacy and safety of Brotizoram,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8263,0263-0497,263.497,Ended,345,0263-P01,Clinical evaluation in dermatorogic fiel,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8264,0263-0498,263.498,Ended,345,0263-P01,Clinical evaluation in psychiatric field,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8265,0263-0499,263.499,Ended,345,0263-P01,Clinical evaluation in dermatorogic fiel,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8266,0263-0500,263.500,Ended,345,0263-P01,Duration of effect,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8267,0263-0501,263.501,Ended,345,0263-P01,Efficacy and safety in dermatology,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8268,0263-0502,263.502,Ended,345,0263-P01,Effect of hypnotics on ERP.,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8269,0263-0503,263.503,Ended,345,0263-P01,Insomnia induced by Interferon,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8270,0263-0504,263.504,Ended,345,0263-P01,Insomnia with ithcy subjects in dermatol,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
8271,0263-0505,263.505,Unconfirmed,345,0263-P01,Insomnia in Hospitalized Patients,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8272,0263-0506,263.506,Ended,345,0263-P01,Absorption from oral dissolving tablet,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8273,0263-0507,263.507,Ended,345,0263-P01,Bio-equivalence study (without water),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8274,0263-0508,263.508,Ended,345,0263-P01,Bio-equivalency study (with water),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8275,0263-0509,263.509,Ended,345,0263-P01,Lendormin OD tab. PMS Study,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
8276,0263-0510,263.510,Ended,345,0263-P01,safety/efficacy Lendormin in insom pat.,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
8277,0263-0511,263.511,Ended,345,0263-P01,BE study of lendormin in Taiwanese pts,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8278,0186-0001,186.1,Ended,346,0186-P01,Bioverf√ºgbarkeit von 500 mg Tabletten,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8279,0186-0002,186.2,Ended,346,0186-P01,Blutungszeit / Methodik, Precisette,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8280,0186-0003,186.3,Ended,346,0186-P01,Blutungszeit: Methodenvalidierung,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8281,0010-0001,10.1,Ended,347,0010-P00,Blutfette,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8282,0010-0002,10.2,Ended,347,0010-P00,Blutfette und Thrombozyten,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8283,0010-0003,10.3,Ended,347,0010-P00,Persantin in Coronary Slow-Flow Syndrome,Ended,MIG,Migration,IIB,Phase IIb,,,,,
8284,0034-0007,34.7,Unconfirmed,348,0034-P00,Akute Harnwegsinfekte, Prof. H√∂ffler,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8285,0034-0008,34.8,Unconfirmed,348,0034-P00,Granulat, Harnwegsinfekte bei Kindern,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8286,0034-0009,34.9,Unconfirmed,348,0034-P00,Granulat, Vergleichspr√ºfung bei Kindern,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8287,0038-0001,38.1,Ended,349,0038-P00,Probanden mit Kapseln, Jacobi,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8288,0038-0002,38.2,Ended,349,0038-P00,Probanden mit Tabletten,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8289,0038-0003,38.3,Ended,349,0038-P00,Klin. Pharmakologie, Prof. Deutsch,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8290,0042-0001,42.1,Ended,350,0042-P01,Multicenter - Feldstudie,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8291,0042-0002,42.2,Ended,350,0042-P01,Jaikin N Akzeptanz und Vertr√§glichkeit,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8292,0042-0003,42.3,Ended,350,0042-P01,Jaikin N Wirkung und Vertr√§glichkeit,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8293,0049-0001,49.1,Ended,351,0049-P00,1. Anwendung, 3 Dosierungen je Proband,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8294,0049-0002,49.2,Ended,351,0049-P00,Dosis-Wirkung p.o. Probanden bis 500 mg,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8295,0049-0003,49.3,Ended,351,0049-P00,1. i.v.-Anwendung, Probanden,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8296,0058-0002,58.2,Ended,352,0058-P01,Morbus Meniere, Dr. Gr√ºnberg,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8297,0060-0007,60.7,Ended,353,0060-P00,1. Pr√ºfung Zagreb,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8298,0060-0010,60.10,Unconfirmed,353,0060-P00,Wirkungspr√ºfung M√únchen,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8299,0082-0001,82.1,Ended,354,0082-P00,1. Vertr√§glichkeit-Dosistitration,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8300,0082-0002,82.2,Ended,354,0082-P00,2. Vertr√§glichkeit-Dosistitration,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8301,0082-0003,82.3,Ended,354,0082-P00,3. Vertr√§glichkeit-Glukose-Toleranz-Test,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8302,0082-0004,82.4,Ended,354,0082-P00,1. Thrombozytenaggregation 80 mg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8303,0082-0005,82.5,Ended,354,0082-P00,4. Vertr√§glichkeit-Glukose-Toleranz-Test,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8304,0082-0006,82.6,Ended,354,0082-P00,Vertr√§gl. Glukose-Toleranz-T., mehrt√§gig,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8305,0082-0007,82.7,Ended,354,0082-P00,Thrombozytenaggregation 1*100, 5*20 mg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8306,0082-0008,82.8,Ended,354,0082-P00,Thrombozytenaggregation 100 mg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8307,0082-0009,82.9,Ended,354,0082-P00,Kinetik, Wirkung, 4 galenische Formen,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8308,0082-0010,82.10,Ended,354,0082-P00,Thrombozyten-Teste, 80 mg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8309,0083-0001,83.1,Unconfirmed,355,0083-P01,Wirkungsvergleich bei Patienten, Michel,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8310,0083-0002,83.2,Unconfirmed,355,0083-P01,Wirkungsvergleich bei Probanden, Michel,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8311,0083-0003,83.3,Ended,355,0083-P01,Methodik bei intranas. Provokation, I,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8312,0083-0004,83.4,Ended,355,0083-P01,Methodik bei intranas. Provokation, II,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8313,0083-0005,83.5,Unconfirmed,355,0083-P01,Festleg.der BU bei 4 Konz.v.3 Allerg.,I,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8314,0083-0006,83.6,Unconfirmed,355,0083-P01,Bestimmg.d.optimalen Quaddelgr√∂√üe,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8315,0083-0007,83.7,Unconfirmed,355,0083-P01,Varianz der Quaddelgr√∂√üe,3 Allerg.,25 BU,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8316,0083-0008,83.8,Unconfirmed,355,0083-P01,Festleg.der BU bei 4 Konz.v.3 Allerg.,II,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8317,0083-0010,83.10,Unconfirmed,355,0083-P01,Vergl.d.allerg.Potenz Rog+Ray/Derm.pter.,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8318,0083-0011,83.11,Unconfirmed,355,0083-P01,gegen Allergopharma mit 3 Allergenen,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8319,0083-0012,83.12,Unconfirmed,355,0083-P01,Bestimmg.d.optimalen Quaddelgr√∂√üe,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8320,0083-0013,83.13,Unconfirmed,355,0083-P01,Bestimmg.d.Allerg.determin.(Derm.pter.),Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8321,0083-0014,83.14,Ended,355,0083-P01,Vergleich: 4 Prick-Test-L√∂sg.v. 3 Firmen,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8322,0083-0015,83.15,Unconfirmed,355,0083-P01,Honiggras, Hasel, Birke - NaCl, Histamin,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8323,0083-0016,83.16,Ended,355,0083-P01,Histaminquaddeln versch. Konzentrationen,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8324,0083-0017,83.17,Ended,355,0083-P01,Pricktestung mit Hundeepithelien-Extrakt,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8325,0083-0018,83.18,Ended,355,0083-P01,Pricktestung mit Eichenpollen-Extrakt,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8326,0083-0019,83.19,Unconfirmed,355,0083-P01,Pricktestung eines Haselpollen-Extraktes,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8327,0083-0020,83.20,Ended,355,0083-P01,Pricktestung eines Erlenpollen-Extraktes,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8328,0083-0021,83.21,Ended,355,0083-P01,Pricktestung m. Katzenepithelien-Extrakt,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8329,0100-0001,100.1,Ended,356,0100-P00,Vertr√§glichkeitspr√ºfung bis 50 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8330,0100-0002,100.2,Ended,356,0100-P00,Vertr√§glichkeitspr√ºfung bis 200 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8331,0100-0003,100.3,Ended,356,0100-P00,Crem./Polyglykol, Vertr√§glichk.bis 20 mg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8332,0100-0004,100.4,Ended,356,0100-P00,Crem./Polyglykol, Vertr√§glichk., Wirkung,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8333,0100-0005,100.5,Ended,356,0100-P00,Crem./Polyglykol, Wirkung nach Born,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8334,0100-0006,100.6,Ended,356,0100-P00,Crem. / Polyglykol, Dosiswirkung,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8335,0100-0007,100.7,Ended,356,0100-P00,Pharmakokin., Erg√§nzung, Pr√§paration 61,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8336,0100-0008,100.8,Ended,356,0100-P00,Vertr√§glichkeit, Kinetik, 5t√§gig,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8337,0100-0009,100.9,Ended,356,0100-P00,Vertr√§glichkeit, Kinetik, Pr√§paration 23,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8338,0104-0001,104.1,Ended,357,0104-P00,Dosisfindung bis 1000 mg p.o., Trinkl√∂sg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8339,0104-0002,104.2,Ended,357,0104-P00,Wirkg. auf Insulinsekr. bei 1000 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8340,0104-0003,104.3,Ended,357,0104-P00,Vertr√§glichkeitspr. bei 7tg. Applikation,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8341,0104-0004,104.4,Ended,357,0104-P00,2. Vertr√§glichkeitspr. b. 7tg. Applikat.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8342,0104-0005,104.5,Ended,357,0104-P00,Wirkg. v. 1000 mg p.o. unter KH-Belastg.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8343,0104-0006,104.6,Ended,357,0104-P00,Wirkung u. Vertr√§glichk. b. 7tg. Anwendg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8344,0128-0001,128.1,Ended,358,0128-P00,Vertr√§glichkeit, orientierende Kinetik,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8345,0128-0002,128.2,Ended,358,0128-P00,Dosisfindung p.o., Trinkl√∂sung,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8346,0128-0003,128.3,Ended,358,0128-P00,Bioverf√ºgbarkeit, Trinkl√∂sung - Tablette,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8347,0128-0004,128.4,Unconfirmed,358,0128-P00,Wirkungsvergleich AZDF 265 - Euglucon N,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8348,0090-0001,90.1,Ended,359,0090-P00,Vertr√§glichkeitspr√ºfung I, Dr. Schaffler,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8349,0090-0002,90.2,Ended,359,0090-P00,Vertr√§glichkeitspr√ºfung II,Dr. Schaffler,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8350,0110-0001,110.1,Ended,360,0110-P01,Allergische Konjunktivitis, Multicenter,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8351,0111-0001,111.1,Ended,361,0111-P01,Juckreizstillende Wirkg.b. Neurodermitis,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8352,0223-0201,223.201,Unconfirmed,362,0223-P01,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8353,1099-0001,1099.1,Ended,363,1099-P01,Candidiasis vulvovaginal,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8354,1099-0002,1099.2,Ended,363,1099-P01,Efficacy and tolerance of Intertrigo Pas,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8355,1099-0003,1099.3,Unconfirmed,363,1099-P01,Pimafucin bei Soorkolpitis, Dr. Uher,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8356,1099-0004,1099.4,Ended,363,1099-P01,Pimafucin - Schaumovulum,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8357,1099-0005,1099.5,Unconfirmed,363,1099-P01,Partnerbehandlung, Praxiserhebung, Grobe,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8358,1099-0006,1099.6,Ended,363,1099-P01,Wirkungsdauer 5 - 10 Tage,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8359,1099-0007,1099.7,Ended,363,1099-P01,Pimafucin-Schaumovulum, Biberach,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8360,1099-0008,1099.8,Ended,363,1099-P01,Vergl. mit Canesten 1 und Gyno Travogen,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8361,1099-0009,1099.9,Ended,363,1099-P01,Vergl. 3-t√§gige und 1-t√§gige Applikation,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8362,1099-0010,1099.10,Ended,363,1099-P01,Vertr√§glichkeitsvergleich, intraindivid.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8363,1099-0011,1099.11,Ended,363,1099-P01,Vergleich zweier galen. Formulierungen,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8364,1099-0012,1099.12,Ended,363,1099-P01,b.gastro-intest.Candidosis d.Kleinkindes,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8365,1099-0013,1099.13,Ended,363,1099-P01,Feldstudie Synogil Ovula bei Cand.-Kolp.,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8366,1099-0014,1099.14,Ended,363,1099-P01,Paste / Grundlage,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8367,1099-0015,1099.15,Ended,363,1099-P01,Grundlage gegen Paste, 4 Pr√ºfstellen,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8368,0036-0001,36.1,Ended,364,0036-P00,bei klimakterischem Syndrom 72031,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8369,1068-0001,1068.1,Unconfirmed,365,1068-P01,Heart failure,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8370,1068-0002,1068.2,Unconfirmed,365,1068-P01,Heart failure,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8371,1068-0003,1068.3,Ended,365,1068-P01,COLD,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8372,1068-0004,1068.4,Unconfirmed,365,1068-P01,COLD,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8373,1068-0005,1068.5,Unconfirmed,365,1068-P01,Heart failure,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8374,1068-0006,1068.6,Unconfirmed,365,1068-P01,Heart failure,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8375,1068-0007,1068.7,Unconfirmed,365,1068-P01,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8376,1068-0008,1068.8,Unconfirmed,365,1068-P01,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8377,1068-0009,1068.9,Ended,365,1068-P01,Heart failure chronic,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8378,1068-0010,1068.10,Unconfirmed,365,1068-P01,Heart failure,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8379,1068-0011,1068.11,Unconfirmed,365,1068-P01,Heart failure surgery cardiovascular,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8380,1068-0012,1068.12,Unconfirmed,365,1068-P01,Heart failure,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8381,1068-0013,1068.13,Unconfirmed,365,1068-P01,Heart failure,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8382,1068-0014,1068.14,Ended,365,1068-P01,Heart failure acute;Infarction myocardia,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8383,1068-0015,1068.15,Unconfirmed,365,1068-P01,Heart failure;Coronary disease,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8384,1068-0016,1068.16,Unconfirmed,365,1068-P01,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8385,1068-0017,1068.17,Unconfirmed,365,1068-P01,Heart failure,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8386,1068-0018,1068.18,Unconfirmed,365,1068-P01,Heart failure,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8387,1068-0019,1068.19,Unconfirmed,365,1068-P01,Heart failure,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8388,1068-0020,1068.20,Ended,365,1068-P01,Subjektive Vertr√§glichkeit oral,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8389,1068-0021,1068.21,Unconfirmed,365,1068-P01,1. Wirkungspr√ºfung p.o., Dr. Lindlbauer,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8390,1068-0022,1068.22,Unconfirmed,365,1068-P01,Wirkungspr√ºfung, Dr. Steinbrunn,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8391,1068-0023,1068.23,Ended,365,1068-P01,Wirkung und Vertr√§glichkeit, II,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8392,1068-0024,1068.24,Unconfirmed,365,1068-P01,Wirksamkeitspr√ºfung, Dr. Weikl,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8393,1068-0025,1068.25,Ended,365,1068-P01,Pilotstudie Wirkungsnachweis, Dr. Esser,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8394,1068-0026,1068.26,Ended,365,1068-P01,Wirksamkeitspr√ºf., Linkskatheter, Stauch,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8395,1068-0027,1068.27,Ended,365,1068-P01,Systolische Zeitintervalle, Probanden,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8396,1068-0028,1068.28,Ended,365,1068-P01,Wirksamkeit i.v., Dr. Weikl,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8397,1068-0029,1068.29,Ended,365,1068-P01,Infusion-Dosis-Wirkung, Bad Krozingen,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8398,1068-0030,1068.30,Ended,365,1068-P01,Wirksamkeitspr√ºfung, Dr. Sabin,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8399,1068-0031,1068.31,Ended,365,1068-P01,Systol. Zeitintervalle, Probanden, p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8400,1068-0032,1068.32,Ended,365,1068-P01,Vertr√§gl. nach Mehrfachappl., van Wayjen,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8401,1068-0033,1068.33,Ended,365,1068-P01,Dosis-Wirkung, Infusion, Probanden,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8402,1068-0034,1068.34,Unconfirmed,365,1068-P01,Wirkungsvergl. gegen Dobutamin, M√ºnchen,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8403,1068-0035,1068.35,Ended,365,1068-P01,Akute Herzinsuffizienz, Dr. Jadraque,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8404,1068-0036,1068.36,Unconfirmed,365,1068-P01,Wirksamkeit Depot - Granulat, Fernandez,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8405,1068-0037,1068.37,Unconfirmed,365,1068-P01,Akutversuch, Dr. Fernandez,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8406,1068-0038,1068.38,Unconfirmed,365,1068-P01,Herzleistung mit Gammacamera, Spanien,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8407,1068-0039,1068.39,Ended,365,1068-P01,Wirksamkeitspr√ºfung II, Dr. Steinbrunn,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8408,1068-0040,1068.40,Ended,365,1068-P01,Patientenvergleich, Prof. Kober,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8409,1068-0041,1068.41,Ended,365,1068-P01,Belastungsversuch, Freiburg,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8410,1068-0042,1068.42,Ended,365,1068-P01,EKG und Labor bei Infusion,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8411,1068-0043,1068.43,Ended,365,1068-P01,Wirkungsnachweis i.v., Freiburg,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8412,1068-0044,1068.44,Ended,365,1068-P01,3 Std Infusion, Bad Krozingen,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8413,1068-0045,1068.45,Ended,365,1068-P01,Vergleich mit Dobutamin, Dr. Kleine,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8414,1068-0046,1068.46,Ended,365,1068-P01,Niereninsuffiziente Patienten,Dr.Stegaru,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8415,1068-0047,1068.47,Unconfirmed,365,1068-P01,Infusion mehrere Tage, Lindelbauer,Esser,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8416,1068-0048,1068.48,Unconfirmed,365,1068-P01,Nitroglycerin, Dr. Klein, M√ºnchen,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8417,1068-0049,1068.49,Unconfirmed,365,1068-P01,Dosiswirkung p.o., Sauer,Bauer, M√ºnchen,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8418,1068-0050,1068.50,Ended,365,1068-P01,Kongestive Kardiomyopathie, Klein, Graz,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8419,1068-0051,1068.51,Unconfirmed,365,1068-P01,Bei eingeschr. Nierenfunktion, Fr√∂lich,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8420,1068-0052,1068.52,Unconfirmed,365,1068-P01,Langzeitinfusion, Br√ºssel,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8421,1068-0053,1068.53,Ended,365,1068-P01,Angina pectoris, Prim.Dr. Pozenel,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8422,1068-0054,1068.54,Ended,365,1068-P01,Angina pectoris Belastung, ISD, Pozenel,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8423,1068-0055,1068.55,Ended,365,1068-P01,Infusion m. abnehmender Dosierung, Weikl,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8424,1068-0056,1068.56,Unconfirmed,365,1068-P01,Alkoholbed. Kardiomyopath., Inf.,Spanien,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8425,1068-0057,1068.57,Ended,365,1068-P01,Wirksamkeitspr√ºfung p.o., Dr. Ruffmann,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8426,1068-0058,1068.58,Ended,365,1068-P01,Wirksamkeit p.o., Dr. Thormann,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8427,1068-0059,1068.59,Ended,365,1068-P01,Wirksamkeit i.v., Dr. Thormann,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8428,1068-0060,1068.60,Unconfirmed,365,1068-P01,Vertr√§glichkeit, Probanden, Dr. Brick,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8429,1068-0061,1068.61,Ended,365,1068-P01,Wirkungspr√ºfung i.v., Dr. Esser,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8430,1068-0062,1068.62,Ended,365,1068-P01,Wirkungspr√ºfung i.v., Prof. Simon,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8431,1068-0063,1068.63,Unconfirmed,365,1068-P01,Nitroglycerin-Vergleich, Kulbertus,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8432,1068-0064,1068.64,Unconfirmed,365,1068-P01,Wirksamkeitspr√ºfung I, Lyon,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8433,1068-0065,1068.65,Ended,365,1068-P01,Dosis-Wirkungspr√ºfung, Prof. Bernard,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8434,1068-0066,1068.66,Unconfirmed,365,1068-P01,Wirksamkeitspr√ºfung II, Lyon,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8435,1068-0067,1068.67,Ended,365,1068-P01,Langzeitinfusion, Prof. Stauch,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8436,1068-0068,1068.68,Ended,365,1068-P01,Langzeitinfusion, Mexico,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8437,1068-0069,1068.69,Ended,365,1068-P01,Kinetik, Niereninsuffizienz, Wien,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8438,1068-0070,1068.70,Unconfirmed,365,1068-P01,Nierenclearance, Probanden, Dr. R√∂ckl,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8439,1068-0071,1068.71,Ended,365,1068-P01,Nitroglycerin - Vergleich, Dr. Benzo,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8440,1068-0072,1068.72,Ended,365,1068-P01,Pilotversuch mit reduzierter Dosis,Nebel,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8441,1068-0073,1068.73,Ended,365,1068-P01,Plethysmographie, England,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8442,1068-0074,1068.74,Ended,365,1068-P01,Retardform Einmal-Anwendung, Prof. Simon,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8443,1068-0075,1068.75,Unconfirmed,365,1068-P01,Retardform Einmal-Anwendung, Prof. Esser,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8444,1068-0076,1068.76,Ended,365,1068-P01,Retardform Viermal-Anwendung,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8445,1068-0077,1068.77,Unconfirmed,365,1068-P01,Retardform Viermal-Anwendung, Prof.Esser,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8446,1068-0078,1068.78,Ended,365,1068-P01,Depot-Wirkungspr.,Probanden, Sauer/Klein,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8447,1068-0079,1068.79,Unconfirmed,365,1068-P01,Vergleich i.v. und Depot oral, Beythien,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8448,1068-0080,1068.80,Ended,365,1068-P01,Nierenfunktion bei Probanden, Rosenthal,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8449,1068-0081,1068.81,Ended,365,1068-P01,Verapamil, Kerkhoff-Klinik,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8450,1068-0082,1068.82,Ended,365,1068-P01,Wirkungspr√ºfung i.v. und p.o., Stauch,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8451,1068-0083,1068.83,Unconfirmed,365,1068-P01,Dose effectiveness, Hagemeier,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8452,1068-0084,1068.84,Ended,365,1068-P01,Frequenzstimulierte Patienten, Thormann,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8453,1068-0085,1068.85,Ended,365,1068-P01,Sauerstoffverbrauch, Oeff / Schr√∂der,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8454,1068-0086,1068.86,Ended,365,1068-P01,8-Stundeninfusion, Herold,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8455,1068-0087,1068.87,Unconfirmed,365,1068-P01,Blutspiegel-Wirkungsvergleich, Valencia,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8456,1068-0088,1068.88,Unconfirmed,365,1068-P01,Blutsp.-Wirkung 5*150 p.o. Spitzer,Weikl,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8457,1068-0089,1068.89,Ended,365,1068-P01,Blutsp.-Wirkung 5*150 mg Dienstl,Schulz,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8458,1068-0090,1068.90,Ended,365,1068-P01,Blutspiegel-Wirkung,1.4 mg/min, El Allaf,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8459,1068-0091,1068.91,Ended,365,1068-P01,Blutsp.-Wirkung, 2*450 mg p.o., Bonn,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8460,1068-0092,1068.92,Unconfirmed,365,1068-P01,24 Stunden Infusion, Egre, Frankreich,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8461,1068-0093,1068.93,Unconfirmed,365,1068-P01,Herzinsuffizienz, 2x450 mg p.o.,Thormann,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8462,1068-0094,1068.94,Ended,365,1068-P01,Blutspiegel-Wirk., 3x450 mg p.o., Madrid,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8463,1068-0095,1068.95,Ended,365,1068-P01,Placebovergleich M√ºnchen,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8464,1068-0096,1068.96,Unconfirmed,365,1068-P01,450 mg Depot, oral, El Allaf, L√ºttich,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8465,1068-0097,1068.97,Ended,365,1068-P01,3 * 75 mg, 1 Woche, Ulm,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8466,1068-0098,1068.98,Ended,365,1068-P01,Langzeitinfusion Dr. Bernard, Br√ºssel,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8467,1068-0099,1068.99,Unconfirmed,365,1068-P01,Blutsp.-Wirkung 5*150 mg, Mehmel, Disse,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8468,1068-0100,1068.100,Ended,365,1068-P01,450 mg p.o., 1 Woche, Bad Krozingen,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8469,1068-0101,1068.101,Ended,365,1068-P01,Herzinsuffizienz p.o., Hauf, Schweiz,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8470,1068-0102,1068.102,Ended,365,1068-P01,Wirkungsvergl.gegen Dobutamin, Rotterdam,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8471,1068-0103,1068.103,Ended,365,1068-P01,Dosis - Wirkungsbeziehung, London,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8472,1068-0104,1068.104,Ended,365,1068-P01,Infusion √ºber 3 h Dr. Col, Br√ºssel,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8473,1068-0105,1068.105,Ended,365,1068-P01,Langzeitinfusion Dr. Col, Br√ºssel,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8474,1068-0106,1068.106,Unconfirmed,365,1068-P01,Langzeitpr√ºfung p.o., Klein,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8475,1068-0107,1068.107,Ended,365,1068-P01,Langzeitpr√ºfung p.o., Nebel,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8476,1068-0108,1068.108,Ended,365,1068-P01,Langzeitpr√ºfung p.o., Lindlbauer,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8477,1068-0109,1068.109,Unconfirmed,365,1068-P01,Wirksamkeit, Thoraxcenter NL 371/83,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8478,1068-0110,1068.110,Ended,365,1068-P01,Langzeitpr√ºfung p.o., Dortmund,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8479,1068-0111,1068.111,Unconfirmed,365,1068-P01,Langzeitpr√ºfung p.o., Dubrovnik,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8480,1068-0112,1068.112,Unconfirmed,365,1068-P01,Langzeitpr√ºfung p.o., Mexiko,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8481,1068-0113,1068.113,Unconfirmed,365,1068-P01,Kombination mit Impromidin, Dr.Baumann,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8482,1068-0114,1068.114,Ended,365,1068-P01,Langzeitpr. cross-over, Prof. Schr√∂der,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8483,1068-0115,1068.115,Unconfirmed,365,1068-P01,Vergleich 200-450 mg p.o., Dr. El Allaf,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8484,1068-0116,1068.116,Unconfirmed,365,1068-P01,Vergleich Dobutamin Infus., Prof.Bernard,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8485,1068-0117,1068.117,Unconfirmed,365,1068-P01,Wirkungsdauer nach 5x150mg p.o.,Rotterd.,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8486,1068-0118,1068.118,Ended,365,1068-P01,Langzeitanwendung 3x450 mg, Dr. El Allaf,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8487,1068-0119,1068.119,Unconfirmed,365,1068-P01,Dosisvergleich, Dr. Fernandez-Montenegro,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8488,1068-0120,1068.120,Ended,365,1068-P01,Dauerinfusion (5 Tage), Dr. El Allaf,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8489,0040-0001,40.1,Unconfirmed,366,0040-P02,Vertr√§glichkeit, entz√ºndete Augen,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8490,0040-0050,40.50,Ended,366,0040-P02,Rhinitis acute,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8491,0040-0051,40.51,Ended,366,0040-P02,Sinusitis;Rhinitis;Common-cold,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8492,0040-0052,40.52,Unconfirmed,366,0040-P02,Obstruction nasal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8493,0040-0053,40.53,Ended,366,0040-P02,none,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8494,0040-0054,40.54,Ended,366,0040-P02,RINOGUTT + ANTISTAMINIC,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8495,0040-0055,40.55,Ended,366,0040-P02,RINOGUTT ANTISTAMINIC,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8496,1060-0001,1060.1,Ended,367,1060-P01,Seborrhoe,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8497,1060-0002,1060.2,Ended,367,1060-P01,Pityriasis Simpl., Psoriasis Cap,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8498,0071-0001,71.1,Ended,368,0071-P00,1. Klinische Pr√ºfung,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8499,0084-0001,84.1,Ended,369,0084-P01,Pr√ºfung im werks√§rztlichen Dienst,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8500,0085-0001,85.1,Ended,370,0085-P00,Hautvertr√§glichkeit,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8501,0085-0002,85.2,Ended,370,0085-P00,Epicutantest, Prof. Tronnier,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8502,0085-0003,85.3,Ended,370,0085-P00,Vasokonstriktionstest, Prof. Tronnier,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8503,0085-0004,85.4,Ended,370,0085-P00,Erregernachweis und klin. Symptomatik,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8504,0085-0005,85.5,Ended,370,0085-P00,Multicenterpr√ºfung bei ambulanten Pat.,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8505,0085-0006,85.6,Ended,370,0085-P00,Erregernachweis u. klin. Symptomatik,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8506,0085-0007,85.7,Unconfirmed,370,0085-P00,Plasmacortisolspiegel, Prof. Altmeyer,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8507,0085-0008,85.8,Ended,370,0085-P00,Serum Cortisol-Spiegel, Altmeyer,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8508,1009-0001,1009.1,Ended,371,1009-P00,Surgery pulmonary,Ended,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
8509,1009-0002,1009.2,Unconfirmed,371,1009-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
8510,1009-0003,1009.3,Unconfirmed,371,1009-P00,Acne-Papulo-Pustulosa,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8511,1009-0004,1009.4,Unconfirmed,371,1009-P00,Pneumonia,Unconfirmed,MIG,Migration,II,Phase II,- planned patients: 4-20 */ trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
8512,1009-0005,1009.5,Unconfirmed,371,1009-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8513,1009-0006,1009.6,Unconfirmed,371,1009-P00,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
8514,1009-0007,1009.7,Unconfirmed,371,1009-P00,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- OPU: Dieckmann D ** *,,,000910,IS - Clin Study (MIGRATED)
8515,1009-0008,1009.8,Unconfirmed,371,1009-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
8516,1009-0009,1009.9,Unconfirmed,371,1009-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
8517,1009-0010,1009.10,Unconfirmed,371,1009-P00,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- OPU: Dieckmann D * *,,,000910,IS - Clin Study (MIGRATED)
8518,1009-0011,1009.11,Unconfirmed,371,1009-P00,Tonsillitis,Unconfirmed,MIG,Migration,NONE,Not Classified,- OPU: Dieckmann D * *,,,000910,IS - Clin Study (MIGRATED)
8519,1009-0012,1009.12,Ended,371,1009-P00,Orientierende Toleranzunters., IPHAR,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8520,1009-0013,1009.13,Unconfirmed,371,1009-P00,bei Akne, Cunliffe, Leeds,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8521,1009-0014,1009.14,Unconfirmed,371,1009-P00,Plasma- und Tonsillengewebespiegel,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8522,1009-0015,1009.15,Unconfirmed,371,1009-P00,Pharmakokinetik, Prof. Schumann,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8523,1009-0016,1009.16,Unconfirmed,371,1009-P00,bei Prostatektomie, Kinetik, Dr. Bach,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8524,1009-0017,1009.17,Unconfirmed,371,1009-P00,Gewebespiegel Nasenschleimhaut, HNO-Ulm,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8525,1009-0018,1009.18,Unconfirmed,371,1009-P00,Gewebespiegel Tonsillen, HNO-Ulm,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8526,1009-0019,1009.19,Unconfirmed,371,1009-P00,bei Infektionen, Dr. Braune,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8527,1009-0020,1009.20,Unconfirmed,371,1009-P00,Erkrankung d. unteren Atemwege, Berlin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8528,1009-0021,1009.21,Unconfirmed,371,1009-P00,Erkrankung d. oberen Atemwege, HNO-Ulm,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8529,1009-0022,1009.22,Ended,371,1009-P00,Bioverf√ºgbarkeit v. ASE 136 BS-Tabletten,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8530,1009-0023,1009.23,Ended,371,1009-P00,Bioverf√ºgbark. v. ASE 136 BS Kinderform,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8531,1009-0024,1009.24,Ended,371,1009-P00,Erythromycin Mikro-Pellets,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8532,1009-0025,1009.25,Ended,371,1009-P00,Bioverf√ºgb. v. AS-E 136 BS Kinderform,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8533,1009-0026,1009.26,Unconfirmed,371,1009-P00,Infektionen der unteren Atemwege,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8534,1009-0027,1009.27,Ended,371,1009-P00,Bioverf√ºgbarkeit von AS-E 136 BS Suppos.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8535,1009-0028,1009.28,Unconfirmed,371,1009-P00,Infektionen der oberen Atemwege,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8536,1009-0029,1009.29,Unconfirmed,371,1009-P00,AS-E 136 BS Spiegel im Tonsillengewebe,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8537,1009-0030,1009.30,Unconfirmed,371,1009-P00,Einflu√ü auf Nierenfunktion Biodesign,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8538,1009-0031,1009.31,Ended,371,1009-P00,Bioverf√ºgb. u. Pharmakokin. v. Erythrom.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8539,1009-0032,1009.32,Unconfirmed,371,1009-P00,Loading Dose Prof. Dr. Schumann, Ulm,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8540,1009-0033,1009.33,Ended,371,1009-P00,Ausscheidungsbilanz 1x500 mg p.o./Prob.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8541,1009-0034,1009.34,Unconfirmed,371,1009-P00,Loading Dose II Prof.Dr. Schumann, Ulm,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8542,1009-0035,1009.35,Unconfirmed,371,1009-P00,Vergleich m. Doxycyclin b. Pneumonie,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8543,1009-0036,1009.36,Unconfirmed,371,1009-P00,Pneumonie-Studie O.A. Dr. Schlimmer,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8544,1009-0037,1009.37,Unconfirmed,371,1009-P00,Wirksamkeit bei Hautinfektionen,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8545,1009-0038,1009.38,Ended,371,1009-P00,Absol. Bioverf√ºgbark. v. ASE 136BS(Prob),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8546,1009-0039,1009.39,Unconfirmed,371,1009-P00,Erkrankungen d. o. A.W. offene Studie,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8547,1009-0040,1009.40,Unconfirmed,371,1009-P00,Infektionen d. u. A.W. offene Studie,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8548,1009-0041,1009.41,Unconfirmed,371,1009-P00,Vergl. b. Infektionen d. oberen Atemwege,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8549,1009-0042,1009.42,Unconfirmed,371,1009-P00,Vergl. b. Infektionen d.unteren Atemwege,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8550,1009-0043,1009.43,Unconfirmed,371,1009-P00,Pilotstudie untere Atemwege B-UAW,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8551,1009-0044,1009.44,Unconfirmed,371,1009-P00,Pilotstudie obere Atemwege B-OAW,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8552,1009-0045,1009.45,Ended,371,1009-P00,Metabolisierung im Plasma (5d p.o.) Prob,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8553,1009-0046,1009.46,Unconfirmed,371,1009-P00,bei Prostatektomie, Kinetik, Dr. Tammen,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8554,1009-0047,1009.47,Unconfirmed,371,1009-P00,Lungengewebsspiegel, Dr. Macha,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8555,1009-0048,1009.48,Unconfirmed,371,1009-P00,Lungengewebsspiegel II, Dr. Macha,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8556,0088-0001,88.1,Ended,372,0088-P00,Faserstoffe zur nat√ºrlichen Entleerung,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8557,0089-0001,89.1,Ended,373,0089-P00,Berofor bei HPV-6 Trachealpapillomatose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8558,0089-0002,89.2,Ended,373,0089-P00,Abheildauer bei Keratitis dendritica,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8559,0091-0001,91.1,Ended,374,0091-P00,GYN G-WL 32/80 Vertr√§glichk. u.Akzeptanz,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8560,1034-0001,1034.1,Ended,375,1034-P00,Cardiomyopathy ischaemic,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8561,1034-0002,1034.2,Ended,375,1034-P00,Hypertension,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8562,1034-0003,1034.3,Ended,375,1034-P00,Hypertension,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8563,1034-0004,1034.4,Ended,375,1034-P00,Hypertension,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8564,1034-0005,1034.5,Ended,375,1034-P00,Erstanwendung, Dosistitr. bis 35 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8565,1034-0006,1034.6,Ended,375,1034-P00,Erstanwendung, Dosistitr.bis 500 ug i.v.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8566,1034-0007,1034.7,Ended,375,1034-P00,Erstanwendung bis 1 mg, Infusion,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8567,0094-0001,94.1,Ended,376,0094-P00,Pepti 2000, Enterale Ern√§hrung, Prob.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8568,0094-0002,94.2,Ended,376,0094-P00,Pepti 2000, Enterale Ern√§hrung, Pat. Ulm,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8569,0133-0001,133.1,Ended,377,0133-P00,4 Tr√§nenersatzfl√ºssigkeiten b.Probanden,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8570,0133-0002,133.2,Ended,377,0133-P00,7 Tr√§nenersatzfl√ºssigkeiten b.Probanden,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8571,0133-0003,133.3,Unconfirmed,377,0133-P00,gegen Oculotect bei Sicca-Symptomatik,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8572,0153-0001,153.1,Unconfirmed,378,0153-P01,Leberzirrhose (I-II), Prof.Dr. M√ºting,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8573,0153-0002,153.2,Ended,378,0153-P01,Leberzirrhose (II-IV), Multicenter,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8574,0153-0003,153.3,Unconfirmed,378,0153-P01,Parenterale Ern√§hrung b. Lebererkrankg.,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8575,0158-0001,158.1,Ended,379,0158-P01,Vertr√§glichkeit und Wirksamkeit bei COLD,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8576,0158-0002,158.2,Ended,379,0158-P01,Vergleich NAB 365/Ba253 mit Berodual,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8577,0158-0003,158.3,Ended,379,0158-P01,Vergleich NAB 365/Ba253 m. Einzelsubst.,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8578,0158-0004,158.4,Ended,379,0158-P01,Dose ranging study in patients with COPD,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8579,0158-0005,158.5,Unconfirmed,379,0158-P01,Inhalation of SIVENT in pat. with COPD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8580,0159-0001,159.1,Ended,380,0159-P00,Chr. Bronchitis m. klin. Exazerbation,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8581,0159-0002,159.2,Ended,380,0159-P00,Kinetik bei Kombination 30 u. 250 mg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8582,0159-0003,159.3,Ended,380,0159-P00,Bioavailability Ambroxol/Erythromycin po,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8583,0181-0002,181.2,Unconfirmed,381,0181-P01,Volumenersatz,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8584,0227-0201,227.201,Ended,382,0227-P00,Efficacy & safety,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8585,0227-0202,227.202,Unconfirmed,382,0227-P00,COMMON MIGRAINE,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8586,0253-2274,253.2274,Unconfirmed,383,0253-P07,Glaucoma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8587,0253-2397,253.2397,Ended,383,0253-P07,Glaucoma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8588,0253-2417,253.2417,Ended,383,0253-P07,Ocular haemodynamic and Isoglaucon 1/16%,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8589,0253-2471,253.2471,Ended,383,0253-P07,Efficacy and tolerance,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8590,0253-2481,253.2481,Ended,383,0253-P07,Ophthalmic Rods Dosiswirkung,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8591,0253-2482,253.2482,Ended,383,0253-P07,Augenst√§bchen, Restmedikation,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8592,0505-0101,505.101,Ended,384,0505-P00,DOSE TOLERANCE P.O., SINGLE DOSE,Ended,MIG,Migration,I,Phase I,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8593,0505-0102,505.102,Ended,384,0505-P00,Dose tolerance p.o., multiple dose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8594,0505-0103,505.103,Ended,384,0505-P00,DOSE TOLERANCE P.O., SINGLE DOSE,Ended,MIG,Migration,I,Phase I,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8595,0505-0201,505.201,Unconfirmed,384,0505-P00,DOSE RANGE,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8596,0505-0202,505.202,Unconfirmed,384,0505-P00,EFFICACY & SAFETY, (PIVOTAL),Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8597,0505-0203,505.203,Unconfirmed,384,0505-P00,EFFICACY & SAFETY, (PIVOTAL),Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = P, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8598,0520-0101,520.101,Ended,385,0520-P00,Bromhexin / Erythromycin (dry sirup),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8599,0520-0102,520.102,Ended,385,0520-P00,BV-Study of Bromhexin/Erythromycin-Caps,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8600,0520-0150,520.150,Ended,385,0520-P00,Bisolvon-Eritromicina vs Erythromicine,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8601,0524-0101,524.101,Unconfirmed,386,0524-P00,3months efficacystudy in vol.with Ginco.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8602,0524-0102,524.102,Unconfirmed,386,0524-P00,single dose of gincosan in the eeg,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8603,0524-0200,524.200,Ended,386,0524-P00,Gincosan in the treatment of Cerebrovasc,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8604,0524-0201,524.201,Ended,386,0524-P00,Safety and efficacy of Gincosan,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8605,0524-0202,524.202,Ended,386,0524-P00,Ability of Gincosan to imrpove Cognitive,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8606,0524-0203,524.203,Unconfirmed,386,0524-P00,Gincosan, Efficacy USA,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8607,0524-0204,524.204,Unconfirmed,386,0524-P00,Gincosan (1 dose) in the improvement of,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8608,1112-0201,1112.201,Ended,387,1112-P01,Post Marketing Surveillance,Ended,MIG,Migration,IV,Phase IV,- ,,,000940,Post Marketing Study (MIGRATED)
8609,1112-0202,1112.202,Ended,387,1112-P01,PMS,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
8610,1112-0250,1112.250,Ended,387,1112-P01,Pharmacokinetic of Bunazosin,Ended,MIG,Migration,I,Phase I,,,,000980,Not Classified (MIGRATED)
8611,1112-0251,1112.251,Ended,387,1112-P01,Efficacy and Tolerability of Bunazosin,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
8612,1112-0252,1112.252,Ended,387,1112-P01,Efficacy and Tolerability of Bunazosin,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
8613,0532-0001,532.1,Ended,388,0532-P00,BV-Study of Erythromycin-Capsules,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8614,0533-0001,533.1,Ended,389,0533-P01,Safety and efficacy,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
8615,0533-0002,533.2,Ended,389,0533-P01,PMS via Internet,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
8616,0101-0001,101.1,Ended,390,0101-P01,Erregernw., klin. Symptomatik, 3 Pr√ºfer,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8617,0101-0002,101.2,Ended,390,0101-P01,Erregernw., klin. Symptomatik, 2 Pr√ºfer,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8618,0101-0003,101.3,Ended,390,0101-P01,Erregernw.,klin. Sympt.b. Dermatomykosen,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8619,0101-0004,101.4,Ended,390,0101-P01,Erregernw.,klin. Sympt.b. Dermatomykosen,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8620,0109-0001,109.1,Ended,391,0109-P01,Vertr√§glichkeitspr√ºfung, Probanden,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8621,0109-0002,109.2,Ended,391,0109-P01,Vertr√§glichkeitspr√ºfung, Patienten,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8622,0109-0003,109.3,Ended,391,0109-P01,Vertr√§glichkeitspr√ºfung, BWK Ulm,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8623,0132-0001,132.1,Ended,392,0132-P00,Vertr√§glichkeit, orientierende Kinetik,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8624,0132-0002,132.2,Ended,392,0132-P00,Erg√§nzung Kreislaufvertr√§glich. zu 132.1,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8625,0134-0001,134.1,Ended,393,0134-P00,Dosisfindung, Kinetik bis 200 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8626,0134-0002,134.2,Ended,393,0134-P00,Wirkung, Vertr√§glichkeit, 200 mg p.o.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8627,0138-0001,138.1,Unconfirmed,394,0138-P00,Hyperhidrosis,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8628,0199-0001,199.1,Ended,395,0199-P00,Bioavailability - capsules,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8629,0199-0002,199.2,Ended,395,0199-P00,Bioavailability - dry sirup,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8630,0072-0003,72.3,Unconfirmed,396,0072-P02,Pilot-Glaukompr√ºfung, Prof. Dannheim,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8631,0072-0004,72.4,Ended,396,0072-P02,Augentropfen, Vertr√§glichkeit, Probanden,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8632,0072-0005,72.5,Ended,396,0072-P02,Pilot-Glaukompr√ºfung, Multicenter,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8633,0072-0006,72.6,Ended,396,0072-P02,orientierende i.v. Vertr√§glichkeit,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
8634,0072-0607,72.607,Ended,396,0072-P02,Glaucoma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8635,0072-0611,72.611,Ended,396,0072-P02,Chron. Glaukom., okul. Hyper.,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8636,0072-0612,72.612,Ended,396,0072-P02,Efficacy of Talipexole,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8637,0072-0613,72.613,Ended,396,0072-P02,Chron. Glaukom., okul. Hyper.,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8638,0072-0621,72.621,Ended,396,0072-P02,Chron. Glaucoma; oculare Hypertension,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8639,0072-0624,72.624,Ended,396,0072-P02,Efficacy and Tolerance,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8640,0072-0626,72.626,Ended,396,0072-P02,Efficacy in OH or OAG,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8641,0072-0627,72.627,Ended,396,0072-P02,Add-on-study,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8642,0072-0628,72.628,Ended,396,0072-P02,Open extension of Add-on-study,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8643,0072-0301,72.301,Ended,397,0072-P03,Schizophrenia,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8644,0072-0302,72.302,Ended,397,0072-P03,Schizophrenia,Ended,MIG,Migration,II,Phase II,- planned patients: 15-25 * old contract, payed by BIGmbH,,,000910,IS - Clin Study (MIGRATED)
8645,0072-0303,72.303,Unconfirmed,397,0072-P03,Schizophrenia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8646,0072-0304,72.304,Ended,397,0072-P03,Schizophrenia with-, out neuroleptics,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8647,0072-0305,72.305,Ended,397,0072-P03,Efficacy,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8648,0072-0306,72.306,Ended,397,0072-P03,Efficacy, without neuroleptics,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8649,0072-0307,72.307,Ended,397,0072-P03,Schizophrenia with-, out neuroleptics,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8650,0072-0308,72.308,Ended,397,0072-P03,Efficacy,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8651,0072-0309,72.309,Ended,397,0072-P03,Efficacy,Ended,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8652,0072-0310,72.310,Ended,397,0072-P03,Efficacy,Ended,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8653,0072-0311,72.311,Ended,397,0072-P03,Safety & efficacy,Ended,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8654,0072-0312,72.312,Preparing,397,0072-P03,Safety & efficacy,Preparing,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8655,0072-0314,72.314,Preparing,397,0072-P03,Safety & efficacy,Preparing,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8656,0072-0316,72.316,Preparing,397,0072-P03,Safety & efficacy,Preparing,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8657,0072-0317,72.317,Ended,397,0072-P03,Efficacy,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8658,0072-0318,72.318,Preparing,397,0072-P03,Safety & efficacy,Preparing,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8659,0072-0319,72.319,Ended,397,0072-P03,BHT 920 versus haloperidol,Ended,MIG,Migration,II,Phase II,- BI GmbH fin. support/ Final report will be compiled by BIKG.,,,000910,IS - Clin Study (MIGRATED)
8660,0072-0320,72.320,Preparing,397,0072-P03,Dosefinding, safety & efficacy,Preparing,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8661,0072-0321,72.321,Unconfirmed,397,0072-P03,SCHIZOPHRENIA,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = ?, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8662,0072-0322,72.322,Unconfirmed,397,0072-P03,Efficacy,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = ?, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8663,0072-0323,72.323,Ended,397,0072-P03,Safety & efficacy,Ended,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8664,0072-0324,72.324,Unconfirmed,397,0072-P03,Efficacy,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = ?, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8665,0072-0325,72.325,Preparing,397,0072-P03,Safety & efficacy,Preparing,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8666,0072-0326,72.326,Preparing,397,0072-P03,Safety & efficacy,Preparing,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8667,0072-0327,72.327,Preparing,397,0072-P03,Efficacy,Preparing,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8668,0072-0600,72.600,Ended,397,0072-P03,Schizophrenia,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8669,0072-0605,72.605,Ended,397,0072-P03,SCHIZOPHRENIA,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8670,0072-0609,72.609,Ended,397,0072-P03,ANTI-SCHIZOPHRENIC EFFECT OF B-HT-920,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8671,0072-0610,72.610,Ended,397,0072-P03,ANTI-SCHIZOPHRENIC EFFECT OF B-HT-920,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8672,0072-0501,72.501,Ended,398,0072-P04,Dyskinesia,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8673,0072-0502,72.502,Preparing,398,0072-P04,Efficacy,Preparing,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8674,0072-0503,72.503,Unconfirmed,398,0072-P04,Efficacy,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8675,0072-0504,72.504,Unconfirmed,398,0072-P04,Efficacy,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8676,0072-0505,72.505,Ended,398,0072-P04,BHT 920 in tardive Dyskinesia,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8677,0072-0506,72.506,Ended,398,0072-P04,Efficacy & safety,Ended,MIG,Migration,II,Phase II,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8678,0072-0602,72.602,Ended,398,0072-P04,Tardive dyskinesia,Ended,MIG,Migration,II,Phase II,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
8679,0022-0001,22.1,Unconfirmed,399,0022-P00,Bronchitis chr.;Tuberculosis pulm.;Carci,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8680,0022-0002,22.2,Unconfirmed,399,0022-P00,Bronchitis chr.;Tuberculosis pulm.;Carci,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8681,0022-0003,22.3,Ended,399,0022-P00,Bronchitis chr.;Tuberculosis pulm.;Carci,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8682,0022-0004,22.4,Unconfirmed,399,0022-P00,Bronchitis chr.;Tuberculosis pulm.;Carci,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8683,0022-0005,22.5,Unconfirmed,399,0022-P00,Bronchitis chr.;Tuberculosis pulm.;Carci,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8684,0022-0006,22.6,Unconfirmed,399,0022-P00,Bronchitis chr.;Tuberculosis pulm.;Carci,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8685,0022-0007,22.7,Unconfirmed,399,0022-P00,Bronchitis chr.;Tuberculosis pulm.;Carci,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8686,0022-0008,22.8,Unconfirmed,399,0022-P00,Bronchitis acute;Infection bronchopulmon,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8687,0022-0009,22.9,Unconfirmed,399,0022-P00,Bronchitis acute;Infection bronchopulmon,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8688,0022-0010,22.10,Unconfirmed,399,0022-P00,Bronchitis acute;Infection bronchopulmon,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8689,0022-0011,22.11,Unconfirmed,399,0022-P00,Infection bronchopulmonary;Bronchitis ac,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8690,0022-0012,22.12,Unconfirmed,399,0022-P00,Infection bronchopulmonary;Bronchitis ac,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8691,0022-0013,22.13,Unconfirmed,399,0022-P00,Infection bronchopulmonary;Bronchitis ac,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8692,0022-0014,22.14,Unconfirmed,399,0022-P00,Infection bronchopulmonary;Bronchitis ac,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8693,0022-0015,22.15,Unconfirmed,399,0022-P00,Infection bronchopulmonary;Bronchitis ac,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8694,0022-0016,22.16,Unconfirmed,399,0022-P00,Infection bronchopulmonary;Bronchitis ac,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8695,0022-0017,22.17,Unconfirmed,399,0022-P00,Infection bronchopulmonary;Bronchitis ac,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8696,0022-0018,22.18,Unconfirmed,399,0022-P00,Infection bronchopulmonary;Bronchitis ac,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8697,0022-0019,22.19,Unconfirmed,399,0022-P00,Pneumoconiosis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8698,0022-0020,22.20,Ended,399,0022-P00,Bronchitis chr.;Tuberculosis pulm.;Carci,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8699,0022-0021,22.21,Unconfirmed,399,0022-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8700,0022-0022,22.22,Unconfirmed,399,0022-P00,Pneumoconiosis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8701,0022-0023,22.23,Unconfirmed,399,0022-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8702,0022-0024,22.24,Unconfirmed,399,0022-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8703,0022-0025,22.25,Ended,399,0022-P00,none,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8704,0022-0026,22.26,Ended,399,0022-P00,Bronchitis, acute and chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8705,0022-0027,22.27,Ended,399,0022-P00,Respiratory disease, acute,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8706,0022-0028,22.28,Ended,399,0022-P00,Chronic resp. disease urb. & IRDS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8707,0022-0029,22.29,Ended,399,0022-P00,Cough, pediatric,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8708,0022-0030,22.30,Unconfirmed,399,0022-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8709,0022-0031,22.31,Unconfirmed,399,0022-P00,Antitusive Effect of Forminoben,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8710,1065-0001,1065.1,Ended,400,1065-P00,Bronchitis,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8711,1065-0002,1065.2,Ended,400,1065-P00,none,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8712,1065-0003,1065.3,Ended,400,1065-P00,Not yet coded,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8713,1065-0004,1065.4,Ended,400,1065-P00,Efficacy and tolerability,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8714,1065-0005,1065.5,Ended,400,1065-P00,Tracheale Kl√§rgeschwindigk., Nakhosteen,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8715,1065-0006,1065.6,Ended,400,1065-P00,COPD,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8716,1065-0007,1065.7,Ended,400,1065-P00,Mucociliare Clearance, Wien,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8717,1065-0008,1065.8,Ended,400,1065-P00,Intrinsic Asthma bei Kindern, Dr.Hofmann,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8718,1065-0009,1065.9,Ended,400,1065-P00,Chron. Bronchitis, Bad Reichenhall,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8719,1065-0010,1065.10,Ended,400,1065-P00,Wirksamkeit + Vertr√§glichk. niedr. Dosis,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8720,1065-0011,1065.11,Ended,400,1065-P00,Wirksamkeit + Vertr√§glichk. h√∂here Dosis,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8721,1065-0012,1065.12,Ended,400,1065-P00,Blutgase bei chron. obstr. Bronch.,Dorow,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8722,1065-0013,1065.13,Ended,400,1065-P00,Wirksamk. u. Vertr√§glichk., Saft, Kinder,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8723,1065-0014,1065.14,Ended,400,1065-P00,Wirksamkeit, Vertr√§glichkeit, Tropfen,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8724,1065-0015,1065.15,Ended,400,1065-P00,Blutgase bei obstruktivem Emphysem,Dorow,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8725,0222-0201,222.201,Ended,401,0222-P00,Prophylact. effect,Ended,MIG,Migration,III,Phase III,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8726,0222-0202,222.202,Unconfirmed,401,0222-P00,Ditec vs. Aarane / Allergospasm,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8727,0222-0203,222.203,Unconfirmed,401,0222-P00,Combination rational,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8728,0222-0298,222.298,Ended,401,0222-P00,Efficacy, DNCG,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8729,0222-0299,222.299,Ended,401,0222-P00,Efficacy,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8730,0222-0301,222.301,Preparing,401,0222-P00,Efficacy, equivalence,Preparing,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8731,0222-0302,222.302,Unconfirmed,401,0222-P00,EXTRINSIC BRONCHIAL ASTHMA,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8732,0222-0303,222.303,Unconfirmed,401,0222-P00,Dose Range Finding (adults),Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8733,0222-0304,222.304,Unconfirmed,401,0222-P00,Dose range finding,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8734,0222-0305,222.305,Unconfirmed,401,0222-P00,Safety,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8735,0222-0401,222.401,Ended,401,0222-P00,Efficacy and tolerability,Ended,MIG,Migration,IV,Phase IV,- inserted by gerken at 22.06.93,,,000940,Post Marketing Study (MIGRATED)
8736,0222-0402,222.402,Ended,401,0222-P00,Efficacy and tolerability,Ended,MIG,Migration,IV,Phase IV,- inserted by gerken at 22.06.93,,,000940,Post Marketing Study (MIGRATED)
8737,0222-0403,222.403,Unconfirmed,401,0222-P00,PMS Ditec,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
8738,0222-0404,222.404,Ended,401,0222-P00,PMS Ditec,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
8739,0222-0405,222.405,Ended,401,0222-P00,Efficacy and Tolerability,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
8740,0222-0504,222.504,Preparing,401,0222-P00,Safety, alt. prop.,Preparing,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8741,0222-0600,222.600,Ended,401,0222-P00,Ditec in Exercise Ind. Bronchial Asthma,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
8742,0222-0601,222.601,Ended,401,0222-P00,Ditec in exercise induced Asthma,Ended,MIG,Migration,III,Phase III,- Report for Centre in Mexico in October 1994,,,000910,IS - Clin Study (MIGRATED)
8743,0222-0602,222.602,Ended,401,0222-P00,Ditec in Exercise induced asthma, child,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8744,0222-0603,222.603,Preparing,401,0222-P00,Safety and swich effect (CFC-HFA),Preparing,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8745,0260-0102,260.102,Unconfirmed,402,0260-P00,Kinetics, bioavailability,Unconfirmed,MIG,Migration,I,Phase I,- inserted by gerken at 22.06.93,,,000910,IS - Clin Study (MIGRATED)
8746,0260-1101,260.1101,Ended,402,0260-P00,Bioequivalence, efficacy,Ended,MIG,Migration,III,Phase III,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8747,0260-1102,260.1102,Ended,402,0260-P00,Bioequivalence, efficacy,Ended,MIG,Migration,III,Phase III,- , EStatus = A, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8748,0260-1201,260.1201,Ended,402,0260-P00,Efficacy,Ended,MIG,Migration,IV,Phase IV,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8749,0260-1659,260.1659,Ended,402,0260-P00,TOKOLYSE,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8750,0260-1816,260.1816,Ended,402,0260-P00,Bioavailability, single dose,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8751,0260-1817,260.1817,Unconfirmed,402,0260-P00,E. ONSET OF DELIVERY,Unconfirmed,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8752,0260-2101,260.2101,Ended,402,0260-P00,Efficacy and tolerability,Ended,MIG,Migration,IV,Phase IV,- inserted by gerken at 22.06.93,,,000940,Post Marketing Study (MIGRATED)
8753,0260-2102,260.2102,Unconfirmed,402,0260-P00,PMS Berotec,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
8754,0260-2601,260.2601,Unconfirmed,402,0260-P00,PMS Berotec,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
8755,0260-3000,260.3000,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8756,0260-3001,260.3001,Unconfirmed,402,0260-P00,Bronchial obstruction,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8757,0260-3002,260.3002,Ended,402,0260-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8758,0260-3003,260.3003,Ended,402,0260-P00,Bronchospasm,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8759,0260-3004,260.3004,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8760,0260-3005,260.3005,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8761,0260-3007,260.3007,Ended,402,0260-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8762,0260-3008,260.3008,Unconfirmed,402,0260-P00,Premature labour,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8763,0260-3009,260.3009,Unconfirmed,402,0260-P00,Premature labour,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8764,0260-3010,260.3010,Ended,402,0260-P00,Asthma,Ended,MIG,Migration,II,Phase II,- Planned patients:15-20 * *,,,000910,IS - Clin Study (MIGRATED)
8765,0260-3011,260.3011,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8766,0260-3012,260.3012,Ended,402,0260-P00,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8767,0260-3013,260.3013,Ended,402,0260-P00,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8768,0260-3014,260.3014,Unconfirmed,402,0260-P00,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8769,0260-3015,260.3015,Unconfirmed,402,0260-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8770,0260-3017,260.3017,Ended,402,0260-P00,Silicosis,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8771,0260-3019,260.3019,Unconfirmed,402,0260-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8772,0260-3024,260.3024,Unconfirmed,402,0260-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8773,0260-3025,260.3025,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8774,0260-3026,260.3026,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8775,0260-3029,260.3029,Unconfirmed,402,0260-P00,Asthma;Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8776,0260-3031,260.3031,Unconfirmed,402,0260-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8777,0260-3032,260.3032,Unconfirmed,402,0260-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8778,0260-3033,260.3033,Unconfirmed,402,0260-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8779,0260-3034,260.3034,Ended,402,0260-P00,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8780,0260-3035,260.3035,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8781,0260-3036,260.3036,Ended,402,0260-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8782,0260-3037,260.3037,Ended,402,0260-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8783,0260-3041,260.3041,Ended,402,0260-P00,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8784,0260-3042,260.3042,Ended,402,0260-P00,none,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8785,0260-3045,260.3045,Ended,402,0260-P00,COLD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8786,0260-3047,260.3047,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8787,0260-3048,260.3048,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8788,0260-3051,260.3051,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8789,0260-3053,260.3053,Unconfirmed,402,0260-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8790,0260-3054,260.3054,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8791,0260-3055,260.3055,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8792,0260-3056,260.3056,Unconfirmed,402,0260-P00,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8793,0260-3057,260.3057,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8794,0260-3059,260.3059,Ended,402,0260-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8795,0260-3061,260.3061,Unconfirmed,402,0260-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8796,0260-3062,260.3062,Unconfirmed,402,0260-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8797,0260-3063,260.3063,Unconfirmed,402,0260-P00,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8798,0260-3064,260.3064,Unconfirmed,402,0260-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8799,0260-3065,260.3065,Unconfirmed,402,0260-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8800,0260-3066,260.3066,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8801,0260-3067,260.3067,Unconfirmed,402,0260-P00,Asthma;Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8802,0260-3068,260.3068,Unconfirmed,402,0260-P00,Asthma;Bronchitis chronic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8803,0260-3069,260.3069,Ended,402,0260-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8804,0260-3070,260.3070,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8805,0260-3071,260.3071,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8806,0260-3072,260.3072,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8807,0260-3073,260.3073,Unconfirmed,402,0260-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8808,0260-3074,260.3074,Unconfirmed,402,0260-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8809,0260-3075,260.3075,Unconfirmed,402,0260-P00,Asthma allergic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8810,0260-3077,260.3077,Unconfirmed,402,0260-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8811,0260-3078,260.3078,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,II,Phase II,- planned patients: 20-30 * *,,,000910,IS - Clin Study (MIGRATED)
8812,0260-3079,260.3079,Unconfirmed,402,0260-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8813,0260-3080,260.3080,Unconfirmed,402,0260-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8814,0260-3081,260.3081,Unconfirmed,402,0260-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8815,0260-3082,260.3082,Ended,402,0260-P00,COPD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8816,0260-3084,260.3084,Ended,402,0260-P00,Premature labour,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8817,0260-3085,260.3085,Ended,402,0260-P00,Bronchospasm,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8818,0260-3087,260.3087,Unconfirmed,402,0260-P00,Pregnancy complications,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8819,0260-3088,260.3088,Unconfirmed,402,0260-P00,Premature labour,Unconfirmed,MIG,Migration,II,Phase II,- planned patients: 120-150 * *,,,000910,IS - Clin Study (MIGRATED)
8820,0260-3089,260.3089,Unconfirmed,402,0260-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8821,0260-3090,260.3090,Unconfirmed,402,0260-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8822,0260-3092,260.3092,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- NZ Trial,,,000910,IS - Clin Study (MIGRATED)
8823,0260-3093,260.3093,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- NZ Trial,,,000910,IS - Clin Study (MIGRATED)
8824,0260-3094,260.3094,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- NZ Trial,,,000910,IS - Clin Study (MIGRATED)
8825,0260-3095,260.3095,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8826,0260-3096,260.3096,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8827,0260-3097,260.3097,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8828,0260-3098,260.3098,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8829,0260-3099,260.3099,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8830,0260-3100,260.3100,Unconfirmed,402,0260-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8831,0260-3101,260.3101,Unconfirmed,402,0260-P00,Hypersensitivity respiratory,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8832,0260-3104,260.3104,Ended,402,0260-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8833,0260-3105,260.3105,Unconfirmed,402,0260-P00,Hypersensitivity respiratory,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8834,0260-3107,260.3107,Ended,402,0260-P00,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8835,0260-3109,260.3109,Unconfirmed,402,0260-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8836,0260-3111,260.3111,Ended,402,0260-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8837,0260-3112,260.3112,Ended,402,0260-P00,Bronchoconstriction,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8838,0260-3113,260.3113,Ended,402,0260-P00,Asthma acute,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8839,0260-3116,260.3116,Ended,402,0260-P00,Efficacy new inhaler,Ended,MIG,Migration,III,Phase III,- Report forwarded 10/92 (Letter Hakansson 12.8.92) / Report expected 12/92 (Letter Sommar 10/92),,,000910,IS - Clin Study (MIGRATED)
8840,0260-3117,260.3117,Ended,402,0260-P00,Asthma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8841,0260-3119,260.3119,Unconfirmed,402,0260-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8842,0260-3121,260.3121,Ended,402,0260-P00,Aerochamber,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8843,0260-3122,260.3122,Ended,402,0260-P00,Bronchospasm/Aerochamber,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8844,0260-3123,260.3123,Ended,402,0260-P00,CREDO pilot trial,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8845,0260-3125,260.3125,Ended,402,0260-P00,Dose response,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8846,0260-3127,260.3127,Ended,402,0260-P00,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8847,0260-3128,260.3128,Unconfirmed,402,0260-P00,Asthmatic bronchitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8848,0260-3129,260.3129,Unconfirmed,402,0260-P00,Asthmatic bronchitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8849,0260-3130,260.3130,Ended,402,0260-P00,Asthmatic bronchitis,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8850,0260-3131,260.3131,Ended,402,0260-P00,Asthmatic bronchitis,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8851,0260-3132,260.3132,Ended,402,0260-P00,BPCD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8852,0260-3133,260.3133,Ended,402,0260-P00,Inhalation Aid,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8853,0260-3136,260.3136,Ended,402,0260-P00,RESPIRATORY MUSCLES,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8854,0260-3140,260.3140,Unconfirmed,402,0260-P00,RESEARCH WORK FOR BIG,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8855,0260-3141,260.3141,Ended,402,0260-P00,COMPARE SELECTIVE B2 AGONIST ACTIVITY,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8856,0260-3142,260.3142,Ended,402,0260-P00,COMPARE FENOTEROL AND SALBUTAMOL,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8857,0260-3143,260.3143,Unconfirmed,402,0260-P00,Berotec Defuse,Unconfirmed,MIG,Migration,IV,Phase IV,- Safety Report will follows (CTU deWet 07.10.92),,,000910,IS - Clin Study (MIGRATED)
8858,0260-3144,260.3144,Unconfirmed,402,0260-P00,POL.RESPIRATORY MUSCLES,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8859,0260-3145,260.3145,Ended,402,0260-P00,OBD in ICU,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8860,0260-3149,260.3149,Ended,402,0260-P00,B2-adrenoreceptor regulation,Ended,MIG,Migration,IV,Phase IV,- ,,,,
8861,0260-3152,260.3152,Ended,402,0260-P00,Fenoterol in asthmatic patients,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8862,0260-3153,260.3153,Ended,402,0260-P00,Fenoterol vs oxitropium in children,Ended,MIG,Migration,IV,Phase IV,- Abstract in CMDI,,,,
8863,0260-3154,260.3154,Unconfirmed,402,0260-P00,Efficacy of three different treatments,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8864,0260-3155,260.3155,Unconfirmed,402,0260-P00,Rationale for combination,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8865,0260-3156,260.3156,Unconfirmed,402,0260-P00,Abs. Bioavailability,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8866,0260-3157,260.3157,Preparing,402,0260-P00,The anti-oxidative effect of fenoterol,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8867,0260-3159,260.3159,Unconfirmed,402,0260-P00,Efficacy of combination vs Fenoterol,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,,
8868,0260-3160,260.3160,Ended,402,0260-P00,Protective effect in pediatric asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,,
8869,0260-3161,260.3161,Unconfirmed,402,0260-P00,Effect in preterm. neonates with RDS,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,,
8870,0260-3166,260.3166,Unconfirmed,402,0260-P00,Kinetics, bioavailability,Unconfirmed,MIG,Migration,I,Phase I,- inserted by gerken at 22.06.93,,,000910,IS - Clin Study (MIGRATED)
8871,0253-1201,253.1201,Unconfirmed,403,0253-P08,Efficacy,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8872,0253-1202,253.1202,Ended,403,0253-P08,Efficacy,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8873,0253-1203,253.1203,Ended,403,0253-P08,Efficacy,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8874,0253-1204,253.1204,Ended,403,0253-P08,Efficacy,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8875,0253-1205,253.1205,Ended,403,0253-P08,Efficacy,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8876,0253-1206,253.1206,Ended,403,0253-P08,Efficacy,Ended,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8877,0253-1207,253.1207,Ended,403,0253-P08,Safety & efficacy, add-on to Baclofen,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8878,0253-1208,253.1208,Unconfirmed,403,0253-P08,Efficacy,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8879,0253-1209,253.1209,Ended,403,0253-P08,Efficacy,Ended,MIG,Migration,II,Phase II,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8880,0253-1210,253.1210,Ended,403,0253-P08,Efficacy,Ended,MIG,Migration,II,Phase II,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8881,0253-2181,253.2181,Unconfirmed,403,0253-P08,Spasticity,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8882,0253-2182,253.2182,Unconfirmed,403,0253-P08,Spasticity,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8883,0253-2194,253.2194,Ended,403,0253-P08,Spasticity,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8884,0253-1301,253.1301,Ended,404,0253-P09,Efficacy, in-patient,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8885,0253-1302,253.1302,Ended,404,0253-P09,Efficacy,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8886,0253-1303,253.1303,Ended,404,0253-P09,Efficacy, out-patient,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8887,0253-1304,253.1304,Ended,404,0253-P09,Efficacy, out-patient,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8888,0253-1305,253.1305,Ended,404,0253-P09,Efficacy, in-patient,Ended,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8889,0253-1306,253.1306,Preparing,404,0253-P09,DELIRIUM TREMENS,Preparing,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8890,0253-1307,253.1307,Preparing,404,0253-P09,Efficacy, dosefinding,Preparing,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8891,0253-1308,253.1308,Unconfirmed,404,0253-P09,Efficacy, pilot study,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8892,0253-1309,253.1309,Unconfirmed,404,0253-P09,ALCOHOL WITHDRAWAL,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8893,0253-1310,253.1310,Ended,404,0253-P09,Efficacy & safety, dosefinding,Ended,MIG,Migration,III,Phase III,number of visits variable highest number of visits=11;,,,000910,IS - Clin Study (MIGRATED)
8894,0253-1311,253.1311,Ended,404,0253-P09,Safety and Efficacy of Paracefan,Ended,MIG,Migration,IV,Phase IV,- , EStatus = C, inserted by gerken at 22.03.93,,,000940,Post Marketing Study (MIGRATED)
8895,0253-1501,253.1501,Ended,404,0253-P09,Titration,Ended,MIG,Migration,III,Phase III,- , EStatus = I, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8896,0253-1502,253.1502,Ended,404,0253-P09,Titration,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8897,0253-1503,253.1503,Ended,404,0253-P09,Efficacy, acute,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8898,0253-1504,253.1504,Ended,404,0253-P09,Efficacy,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8899,0253-1505,253.1505,Ended,404,0253-P09,Efficacy,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8900,0253-1507,253.1507,Ended,404,0253-P09,Efficacy,Ended,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8901,0253-1901,253.1901,Analysis,404,0253-P09,Retrospective Study,Analysis,MIG,Migration,III,Phase III,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8902,0253-2006,253.2006,Unconfirmed,404,0253-P09,Withdrawal syndrome, opiate,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8903,0253-2010,253.2010,Unconfirmed,404,0253-P09,Withdrawal syndrome opiate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8904,0253-2096,253.2096,Unconfirmed,404,0253-P09,Withdrawal syndrome opiate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8905,0253-2102,253.2102,Unconfirmed,404,0253-P09,Withdrawal syndrome opiate,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8906,0253-2103,253.2103,Unconfirmed,404,0253-P09,Withdrawal syndrome opiate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8907,0253-2105,253.2105,Unconfirmed,404,0253-P09,Withdrawal syndrome nicotine,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8908,0253-2116,253.2116,Unconfirmed,404,0253-P09,Withdrawal syndrome opiate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8909,0253-2124,253.2124,Unconfirmed,404,0253-P09,Withdrawal syndrome nicotine,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8910,0253-2129,253.2129,Unconfirmed,404,0253-P09,Withdrawal syndrome opiate,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8911,0253-2183,253.2183,Unconfirmed,404,0253-P09,Withdrawal syndrome alcohol,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8912,0253-2184,253.2184,Unconfirmed,404,0253-P09,Withdrawal syndrome alcohol,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8913,0253-2185,253.2185,Unconfirmed,404,0253-P09,Withdrawal syndrome alcohol,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8914,0253-2186,253.2186,Unconfirmed,404,0253-P09,Withdrawal syndrome alcohol,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8915,0253-2195,253.2195,Ended,404,0253-P09,Withdrawal syndrome drug,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8916,0253-2196,253.2196,Unconfirmed,404,0253-P09,Withdrawal syndrome opiate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8917,0253-2197,253.2197,Unconfirmed,404,0253-P09,Withdrawal syndrome opiate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8918,0253-2198,253.2198,Unconfirmed,404,0253-P09,Withdrawal syndrome opiate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8919,0253-2199,253.2199,Unconfirmed,404,0253-P09,Withdrawal syndrome opiate,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8920,0253-2201,253.2201,Unconfirmed,404,0253-P09,Withdrawal syndrome alcohol,Unconfirmed,MIG,Migration,NONE,Not Classified,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
8921,0253-2207,253.2207,Unconfirmed,404,0253-P09,Withdrawal syndrome alcohol,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8922,0253-2224,253.2224,Unconfirmed,404,0253-P09,Withdrawal, drug,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8923,0253-2249,253.2249,Unconfirmed,404,0253-P09,Withdrawal syndrome alcohol,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8924,0253-2251,253.2251,Ended,404,0253-P09,Withdrawal syndrome opiate,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8925,0253-2281,253.2281,Unconfirmed,404,0253-P09,Withdrawal syndrome opiate,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8926,0253-2305,253.2305,Unconfirmed,404,0253-P09,Withdrawal syndrome alcohol,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8927,0253-2306,253.2306,Ended,404,0253-P09,Withdrawal syndrome, nicotine,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8928,0253-2313,253.2313,Ended,404,0253-P09,Withdrawal syndrome opiate,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8929,0253-2317,253.2317,Unconfirmed,404,0253-P09,Withdrawal syndrome opiate,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8930,0253-2318,253.2318,Ended,404,0253-P09,Withdrawal syndrome opiate,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8931,0253-2319,253.2319,Ended,404,0253-P09,Withdrawal syndrome alcohol,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8932,0253-2378,253.2378,Ended,404,0253-P09,Alcohol Withdrawal,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8933,0253-2396,253.2396,Ended,404,0253-P09,Withdrawal syndrome, alcohol,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8934,0253-2456,253.2456,Unconfirmed,404,0253-P09,Clonidine in Alcoholic Korsakoff¬¥s synd.,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,,
8935,0253-2470,253.2470,Ended,404,0253-P09,IOR study,Ended,MIG,Migration,IV,Phase IV,- ,,,,
8936,0231-0314,231.314,Ended,406,0231-P00,Effect of oral calcium and Lacidipine,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8937,0231-0317,231.317,Unconfirmed,406,0231-P00,Hypertension in diabetics,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8938,0231-0318,231.318,Ended,406,0231-P00,COMPARATIVE STUDY LACID. V LISINOPRIL,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8939,0231-0319,231.319,Ended,406,0231-P00,Effect on platelets aggregation,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8940,0231-0321,231.321,Ended,406,0231-P00,Lacidipine/ hypertension/ABPM,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8941,0231-0323,231.323,Unconfirmed,406,0231-P00,OvA minimum,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8942,0231-0337,231.337,Unconfirmed,406,0231-P00,Lacidipine in chronic Stable Angina,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8943,0231-0339,231.339,Ended,406,0231-P00,Lacidipine In Stable Angina (LISA),Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8944,0528-0019,528.19,Ended,408,0528-P02,Terbogrel in PPH,Ended,MIG,Migration,II,Phase II,-  2nd draft protocol is available.     ,,,000910,IS - Clin Study (MIGRATED)
8945,0528-0021,528.21,Ended,408,0528-P02,OL extension of 528.19,Ended,MIG,Migration,II,Phase II,-  The study will end when terbogrel is approved for marketing in the US or for other reasons,e.g.,discontinuation of the terbogrel PPH program.     ,,,000910,IS - Clin Study (MIGRATED)
8946,0528-0208,528.208,Unconfirmed,408,0528-P02,Terbogrel in PPH and SPH,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8947,0244-0201,244.201,Ended,414,0244-P26,Befindlichkeit,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
8948,0244-0202,244.202,Ended,414,0244-P26,DIGITALIS-INDUZIERTEBRADYKARDIE,Ended,MIG,Migration,IV,Phase IV,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
8949,0244-2169,244.2169,Unconfirmed,414,0244-P26,Arrhythmia,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8950,0244-2226,244.2226,Unconfirmed,414,0244-P26,Bradycardia sinus;Arrhythmia;Chagas-Dise,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8951,0244-2230,244.2230,Ended,414,0244-P26,Bradycardia sinus,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8952,0244-2231,244.2231,Ended,414,0244-P26,Itrop orally. Acute effects in patients,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8953,0244-2232,244.2232,Unconfirmed,414,0244-P26,Bradycardia sinus,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
8954,0244-2264,244.2264,Unconfirmed,414,0244-P26,Bradycardia,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
8955,1163-0001,1163.1,Unconfirmed,416,1163-P01,Recurrent Laryngeal Cancer (2),Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
8956,1163-0002,1163.2,Unconfirmed,416,1163-P01,Recurrent Laryngeal Cancer (1),Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
8957,0152-0001,152.1,Ended,417,0152-P00,Tumortherapie - Prof. Mertelsmann,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8958,0152-0002,152.2,Ended,417,0152-P00,Tumortherapie - Prof. Nagel,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8959,0152-0003,152.3,Ended,417,0152-P00,Advanced cancer,Dr.Schmiegel EBI-No.10.4,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8960,0152-0004,152.4,Ended,417,0152-P00,Colon Carcinom - Prof.Hossfeld, Hamburg,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8961,0152-0005,152.5,Unconfirmed,417,0152-P00,Non-Small Cell Lung-Ca - Dr. Bergmann,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8962,0152-0006,152.6,Ended,417,0152-P00,h√§matologische Indik. - Prof.Hossfeld,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8963,0152-0007,152.7,Ended,417,0152-P00,Solidified Tumors - Prof.Nagel,G√∂ttingen,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8964,0152-0008,152.8,Unconfirmed,417,0152-P00,rTNF bei HIV positiven Patienten,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8965,0152-0009,152.9,Ended,417,0152-P00,nicht-lymphoblast. Leuk√§mie EORTC 6872,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8966,0152-0010,152.10,Unconfirmed,417,0152-P00,Lupus nephritis,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8967,0152-0050,152.50,Ended,417,0152-P00,Cancer,advanced,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8968,0152-0051,152.51,Ended,417,0152-P00,Cancer, breast,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8969,0152-0052,152.52,Ended,417,0152-P00,Cancer,advanced,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8970,0152-0053,152.53,Ended,417,0152-P00,Cancer, colorectal,Ended,MIG,Migration,II,Phase II,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
8971,0152-0054,152.54,Ended,417,0152-P00,Cancer, colorectal,Ended,MIG,Migration,II,Phase II,- planned patients: 14-30 * *,,,000910,IS - Clin Study (MIGRATED)
8972,0152-0055,152.55,Ended,417,0152-P00,AML,Ended,MIG,Migration,II,Phase II,- Safety summary expected,,,000910,IS - Clin Study (MIGRATED)
8973,0152-0057,152.57,Unconfirmed,417,0152-P00,Cancer,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8974,0152-0058,152.58,Ended,417,0152-P00,Carcinoma,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8975,0152-0059,152.59,Ended,417,0152-P00,NHL + HL,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8976,0152-0060,152.60,Ended,417,0152-P00,Cancer,head + neck,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8977,0152-0064,152.64,Ended,417,0152-P00,malignant mesothe,Ended,MIG,Migration,II,Phase II,- ,,,,
8978,0152-0065,152.65,Ended,417,0152-P00,metastatic liver disease,Ended,MIG,Migration,II,Phase II,- ,,,,
8979,0152-0068,152.68,Ended,417,0152-P00,Palliation of refract. malign. ascites,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
8980,0152-0069,152.69,Ended,417,0152-P00,Intravesical treatm. operable bladder CA,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
8981,0212-0800,212.800,Ended,418,0212-P00,Efficacy and safety of Flunisolide,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8982,0212-0804,212.804,Ended,418,0212-P00,Cortico dependent asthmatic children,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
8983,0212-0805,212.805,Ended,418,0212-P00,Non cortic. dependent asthmatics,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
8984,0212-0806,212.806,Ended,418,0212-P00,Flunisolide in mild bronchial asthma,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
8985,0212-9998,212.9998,Ended,418,0212-P00,Flunisolide in asthma (adults),Ended,MIG,Migration,III,Phase III,high study number for historical reasons ,,,000910,IS - Clin Study (MIGRATED)
8986,1097-0004,1097.4,Ended,419,1097-P00,EFFICACY OF 1:1 WHEN CONVERTING PATIENTS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8987,1097-0006,1097.6,Ended,419,1097-P00,CONTROLLED RELEASE MORPH. IN VOLUNTEERS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
8988,0502-0269,502.269,Unconfirmed,421,0502-P00,Bioequibalance: 20mg VS 40mg KAH,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8989,0528-0209,528.209,Unconfirmed,423,0528-P00,Comparative antiaggregatory efficacy,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
8990,0040-0006,40.6,Ended,424,0040-P03,Acceptance von Rhinospray Plus,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8991,0040-0007,40.7,Ended,424,0040-P03,Nasentrockenheit bei Rhinospray plus,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8992,0040-0056,40.56,Ended,424,0040-P03,PMS activity for Rhinospray Plus,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
8993,1138-0001,1138.1,Ended,426,1138-P01,Antistax tolerance study,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
8994,1138-0002,1138.2,Ended,426,1138-P01,The ability of antistax to improve CVI,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
8995,1138-0003,1138.3,Ended,426,1138-P01,Microcirculation,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
8996,1138-0004,1138.4,Ended,426,1138-P01,Chronic Venous Insufficiency,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8997,1138-0005,1138.5,Ended,426,1138-P01,Tolerability Study - CH,Ended,MIG,Migration,IV,Phase IV,film-coated tablets 180 mg ,,,000910,IS - Clin Study (MIGRATED)
8998,1138-0006,1138.6,Ended,426,1138-P01,Safety and Efficacy - Japan,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
8999,1138-0007,1138.7,Preparing,426,1138-P01,CVI, effects on adhesion molecules,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
9000,1138-0008,1138.8,Preparing,426,1138-P01,Effects on retina,Preparing,MIG,Migration,II,Phase II,Dr. Wilhelm, Tuebingen ,,,000910,IS - Clin Study (MIGRATED)
9001,1138-0009,1138.9,Ended,426,1138-P01,Pharmacokinetic in Healthy Volunteers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9002,1138-0010,1138.10,Ended,426,1138-P01,Efficacy and Safety CVI, Study 2,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
9003,1138-0011,1138.11,Ended,426,1138-P01,Efficacy of 720 mg/day vs Placebo 3 mth,Ended,MIG,Migration,III,Phase III,Comparable studies 1138.2, -.4, -.10 ,2008-003932-40,,000910,IS - Clin Study (MIGRATED)
9004,1138-0012,1138.12,Ended,426,1138-P01,NTA project # 11124,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
9005,1114-0001,1114.1,Ended,427,1114-P01,In-house tolerance study with 4 formulat,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9006,1114-0002,1114.2,Ended,427,1114-P01,Comparison of 2 GP formulations in healt,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9007,1114-0003,1114.3,Ended,427,1114-P01,QOL and Pharmaton Capsules,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9008,1114-0004,1114.4,Ended,427,1114-P01,Pilot study on antioxidant eff. of G115,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9009,1114-0005,1114.5,Unconfirmed,427,1114-P01,Efficacy of GP on the Vitality Index,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9010,1114-0006,1114.6,Ended,427,1114-P01,Double blind study,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9011,1114-0007,1114.7,Ended,427,1114-P01,Gegorvit caps on fatigue in the elderly,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9012,1114-0008,1114.8,Ended,427,1114-P01,Safety profile of GP Film-coated tablets,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9013,1114-0009,1114.9,Ended,427,1114-P01,Safety profile of geriatric pharmaton fi,Ended,MIG,Migration,II,Phase II,- This is followup of study 1114.8,,,000910,IS - Clin Study (MIGRATED)
9014,1114-0010,1114.10,Ended,427,1114-P01,Safety and tolerablility of GP vs GP,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9015,1114-0011,1114.11,Ended,427,1114-P01,Mental performance and physical fatigue,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9016,1114-0012,1114.12,Unconfirmed,427,1114-P01,Upgrade to improve mental performance,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
9017,1160-0001,1160.1,Ended,432,1160-P01,Single dose rising - oral,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9018,1160-0002,1160.2,Ended,432,1160-P01,Multiple dose rising - oral,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9019,1160-0003,1160.3,Ended,432,1160-P01,Relative Bioavailability Sol.vsTbl.,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9020,1160-0004,1160.4,Preparing,432,1160-P01,Single Rising Dose IV,Preparing,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9021,1160-0005,1160.5,Ended,432,1160-P01,Bioavailability - solution/final tablet,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9022,1160-0006,1160.6,Ended,432,1160-P01,C14 ADME,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9023,1160-0008,1160.8,Preparing,432,1160-P01,Drug interaction - diclofenac,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9024,1160-0010,1160.10,Ended,432,1160-P01,Elderly,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9025,1160-0011,1160.11,Ended,432,1160-P01,Pilot dose range finding,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
9026,1160-0012,1160.12,Unconfirmed,432,1160-P01,Dose ranging vs enoxaparin EU,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9027,1160-0013,1160.13,Unconfirmed,432,1160-P01,Dose ranging vs enoxaparin NA,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9028,1160-0014,1160.14,Ended,432,1160-P01,Relative BA - multiple dose tablet,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9029,1160-0015,1160.15,Ended,432,1160-P01,pH dependent absorption,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9030,1160-0016,1160.16,Ended,432,1160-P01,Interaction H2 & proton pump inhibitors,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9031,1160-0017,1160.17,Ended,432,1160-P01,Experimental formulations,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9032,1160-0018,1160.18,Preparing,432,1160-P01,Relative BA of experimental formulations,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9033,1160-0019,1160.19,Ended,432,1160-P01,BISTRO-2,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9034,1160-0021,1160.21,Unconfirmed,432,1160-P01,BV final formulation +/- pantoprazole,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9035,1160-0022,1160.22,Unconfirmed,432,1160-P01,BVfinal formulation -multiple dosing,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9036,1160-0024,1160.24,Ended,432,1160-P01,REMOBILIZE,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
9037,1160-0025,1160.25,Ended,432,1160-P01,REMODEL,Ended,MIG,Migration,III,Phase III,,2004-001317-34,,000910,IS - Clin Study (MIGRATED)
9038,1160-0030,1160.30,Ended,432,1160-P01,PK profile in of BIBR 1048 in THR pats.,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
9039,1160-0031,1160.31,Ended,432,1160-P01,Absorption new formulations (pilot),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9040,1160-0032,1160.32,Ended,432,1160-P01,BV of 4 experimental formulations,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9041,1160-0033,1160.33,Ended,432,1160-P01,PK Evaluation of new formulations,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9042,1160-0034,1160.34,Ended,432,1160-P01,Pellet formulation: +/-panto, food,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
9043,1160-0037,1160.37,Unconfirmed,432,1160-P01,Single dose s.c. formulation A,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9044,1160-0038,1160.38,Unconfirmed,432,1160-P01,Single dose s.c. formulation B,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9045,1160-0039,1160.39,Unconfirmed,432,1160-P01,Multiple dose s.c. formulation A/B,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9046,1160-0040,1160.40,Ended,432,1160-P01,Rel Bioavailabilty of a new polymorph,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9047,1160-0048,1160.48,Ended,432,1160-P01,RE-NOVATE,Ended,MIG,Migration,IIIA,Phase IIIa,,2004-001988-21,,000910,IS - Clin Study (MIGRATED)
9048,1160-0050,1160.50,Ended,432,1160-P01,DVT acute prevention after TKR, Japan,Ended,MIG,Migration,IIB,Phase IIb,preliminary;to be discussed with team ,,,000910,IS - Clin Study (MIGRATED)
9049,1160-0064,1160.64,Ended,432,1160-P01,Dabigatran for VTE Prevention Post THR,Ended,MIG,Migration,III,Phase III,,2007-002630-11,,000910,IS - Clin Study (MIGRATED)
9050,1160-0065,1160.65,Unconfirmed,432,1160-P01,Dabigatran vs. warfarin post TKR,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
9051,1160-0074,1160.74,Ended,432,1160-P01,Dabigatran etexilat/verapamil DDI study,Ended,MIG,Migration,I,Phase I,,2008-001021-34,,000910,IS - Clin Study (MIGRATED)
9052,1160-0075,1160.75,Ended,432,1160-P01,Dabigatran etexilate/quinidine DDI study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9053,1160-0076,1160.76,Unconfirmed,432,1160-P01,Dabigatran etexilate/ritonavir DDI study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9054,1160-0078,1160.78,Ended,432,1160-P01,BE - LMWH switch to Dabigatran,Ended,MIG,Migration,I,Phase I,,2008-000929-19,,000910,IS - Clin Study (MIGRATED)
9055,1160-0079,1160.79,Unconfirmed,432,1160-P01,BE diff appl (capsule vs pellets),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9056,1160-0080,1160.80,Unconfirmed,432,1160-P01,PK/PD bridging stud- KR,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9057,1160-0084,1160.84,Ended,432,1160-P01,obs. study in mod. ren. impaired pts,Ended,MIG,Migration,IV,Phase IV,,,,,
9058,1160-0085,1160.85,Ended,432,1160-P01,obs. study in higher risk of bleeds pts,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
9059,1160-0086,1160.86,Ended,432,1160-P01,TT-test ev. in renally impaired pts.,Ended,MIG,Migration,IV,Phase IV,Handled according PASS prior 02Jul2012 ,2010-018723-26,,,
9060,1160-0093,1160.93,Ended,432,1160-P01,Observational study,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
9061,1160-0095,1160.95,Unconfirmed,432,1160-P01,Observ. eff/saf dab. etex. 220mg THR/TKR,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
9062,1160-0096,1160.96,Unconfirmed,432,1160-P01,Observ. eff/saf switch HEPtoDAB THR/TKR,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
9063,1160-0102,1160.102,Ended,432,1160-P01,Observ eff/saf THR/TKR DABI France,Ended,MIG,Migration,IV,Phase IV,,,,,
9064,1160-0103,1160.103,Ended,432,1160-P01,Mexican all comers PMS pVTEp,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
9065,1160-0115,1160.115,Ended,432,1160-P01,Online Strat Exploratory Qualitative Res,Ended,MIG,Migration,NONE,Not Classified,This is a market research study (NTA) With solicited AE reporting - no medical budget impact
This is a non trial activity (NTA),,,000600,Survey Patient Questionnaire
9066,1160-0118,1160.118,Ended,432,1160-P01,SWITCH PMS AUSTRIA,Ended,MIG,Migration,IV,Phase IV,marketed drug acc. to label, PASS old de ,,,,
9067,1160-0126,1160.126,Unconfirmed,432,1160-P01,Statisfaction of anticoagulation info,Unconfirmed,MIG,Migration,NONE,Not Classified,This is an NTA with the number #10290 ,,,,
9068,1160-0154,1160.154,Unconfirmed,432,1160-P01,Adherence to thrombosis prophylaxis,Unconfirmed,MIG,Migration,IV,Phase IV,cancelled ,,,,
9069,0203-0001,203.1,Unconfirmed,433,0203-P01,Arthrosis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9070,0203-0002,203.2,Ended,433,0203-P01,Lonarid mono - Tolerance study,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9071,0203-0003,203.3,Ended,433,0203-P01,Bioavailability of Lonarid mono,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9072,0203-0004,203.4,Ended,433,0203-P01,Bioavailability, Prontalgine efferv. TA,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9073,0203-0005,203.5,Ended,433,0203-P01,Bioavailability,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9074,0203-0006,203.6,Ended,433,0203-P01,Tolerance of Lonarid mono syrup/children,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9075,0203-0007,203.7,Ended,433,0203-P01,Tolerability,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9076,0206-0001,206.1,Ended,434,0206-P00,none,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9077,0239-0201,239.201,Preparing,435,0239-P00,Efficacy, Safety,Preparing,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9078,0239-0202,239.202,Preparing,435,0239-P00,Efficacy, Safety,Preparing,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9079,0239-0203,239.203,Unconfirmed,435,0239-P00,CHRONIC OBSTRUCTIVE AIRWAYS DISEASE,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9080,0239-0204,239.204,Unconfirmed,435,0239-P00,CHRONIC OBSTRUCTIVE DISEASE,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9081,0239-0205,239.205,Unconfirmed,435,0239-P00,CHRONIC OBSTRUCTIVE AIRWAYS DISEASE,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = C, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9082,0239-0206,239.206,Unconfirmed,435,0239-P00,Duration of efficacy and tolerability,Unconfirmed,MIG,Migration,III,Phase III,- inserted by gerken at 22.06.93,,,000910,IS - Clin Study (MIGRATED)
9083,0239-0301,239.301,Unconfirmed,435,0239-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9084,0239-0302,239.302,Unconfirmed,435,0239-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9085,0239-0303,239.303,Unconfirmed,435,0239-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9086,0239-0304,239.304,Unconfirmed,435,0239-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9087,0239-0401,239.401,Unconfirmed,435,0239-P00,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9088,0239-0402,239.402,Unconfirmed,435,0239-P00,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9089,0239-0403,239.403,Unconfirmed,435,0239-P00,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9090,0239-0404,239.404,Unconfirmed,435,0239-P00,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9091,0239-0405,239.405,Unconfirmed,435,0239-P00,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9092,0239-0406,239.406,Unconfirmed,435,0239-P00,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9093,0239-0407,239.407,Unconfirmed,435,0239-P00,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9094,0239-0501,239.501,Unconfirmed,435,0239-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9095,0239-0502,239.502,Unconfirmed,435,0239-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9096,0239-0503,239.503,Unconfirmed,435,0239-P00,No Legacy Data,Unconfirmed,MIG,Migration,III,Phase III,- , EStatus = B, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9097,0582-0001,582.1,Ended,436,0582-P01,Songha Night to improve sleep in patient,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9098,0582-0002,582.2,Ended,436,0582-P01,Songha Night Hangover,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9099,1001-0001,1001.1,Unconfirmed,437,1001-P00,Biliary tract disease,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9100,1001-0002,1001.2,Unconfirmed,437,1001-P00,Biliary tract disease,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9101,1001-0003,1001.3,Ended,437,1001-P00,Gallenblasenkinetik, Dr. Tympner,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
9102,1003-0001,1003.1,Ended,438,1003-P00,Tolerance of Contra Color Neu,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9103,1004-0001,1004.1,Ended,439,1004-P00,EFFICACY IN P.A.D,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9104,1005-0001,1005.1,Ended,440,1005-P01,Contraception,Ended,MIG,Migration,IV,Phase IV,- Status E (letter Dr. Placheta 13-1-93),,,,
9105,1006-0001,1006.1,Ended,441,1006-P01,Infection, ocular,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9106,1006-0002,1006.2,Ended,441,1006-P01,Bacterial infections, eye,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9107,1007-0001,1007.1,Ended,442,1007-P00,Angina Pectoris,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9108,1007-0002,1007.2,Ended,442,1007-P00,Angina Pectoris, unstable,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9109,1007-0003,1007.3,Ended,442,1007-P00,Angina Pectoris,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9110,1007-0004,1007.4,Ended,442,1007-P00,Diltiazem in silent ischemia,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9111,1007-0005,1007.5,Ended,442,1007-P00,Diltiazem in acute myocardial infarction,Ended,MIG,Migration,IV,Phase IV,- ,,,,
9112,1008-0001,1008.1,Ended,443,1008-P00,Insomnia,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9113,1010-0001,1010.1,Ended,444,1010-P01,EFFICACY/SAFETY OF ORAL CLODRONATE IN HY,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9114,1010-0002,1010.2,Ended,444,1010-P01,SAFETY/EFFICACY OF CLODRONATE IV IN HYPE,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9115,1010-0003,1010.3,Unconfirmed,444,1010-P01,Cancer, screening,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9116,1010-0004,1010.4,Ended,444,1010-P01,SAFETY/EFFICACY OF ORAL CLODRONATE,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9117,1010-0005,1010.5,Ended,444,1010-P01,SAFETY/EFFICACY STUDY OF CLODRONATE IV I,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9118,1010-0006,1010.6,Ended,444,1010-P01,ORAL CLODRONATE IN TREATMENT OF BONE PAI,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9119,1010-0007,1010.7,Ended,444,1010-P01,EFFICACY/SAFETY STUDY IN HYPERCALCAEMIA,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9120,1010-0008,1010.8,Ended,444,1010-P01,SAFETY/EFFICACY STUDY IN BONE PAIN,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9121,1010-0009,1010.9,Ended,444,1010-P01,FAILURE OF RESPONSE/RELAPSE,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9122,1010-0010,1010.10,Ended,444,1010-P01,Comparative Bioavailability,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9123,1011-0001,1011.1,Ended,445,1011-P00,Climacteric, complaints,Ended,MIG,Migration,III,Phase III,- Status E (letter Dr. Placheta 13-1-93),,,,
9124,1013-0001,1013.1,Ended,446,1013-P00,Osteo-Arthrosis;Arthritis rheumatoid;Spo,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9125,1014-0001,1014.1,Unconfirmed,447,1014-P00,No Legacy Data,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9126,1014-0002,1014.2,Unconfirmed,447,1014-P00,000,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9127,1015-0001,1015.1,Ended,448,1015-P00,Bronchitis,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9128,1015-0002,1015.2,Unconfirmed,448,1015-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9129,1015-0003,1015.3,Unconfirmed,448,1015-P00,Arthrosis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9130,1015-0004,1015.4,Unconfirmed,448,1015-P00,Laryngitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9131,1015-0005,1015.5,Unconfirmed,448,1015-P00,Pharyngitis;Rhinopharyngitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9132,1015-0006,1015.6,Unconfirmed,448,1015-P00,Rhinitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9133,1015-0007,1015.7,Ended,448,1015-P00,PHARMACODYNAMICS OF FEPRAZONE,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9134,1015-0008,1015.8,Preparing,448,1015-P00,Marketing support for OTC shift,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
9135,1016-0001,1016.1,Unconfirmed,449,1016-P00,Hypercolest.,Unconfirmed,MIG,Migration,IV,Phase IV,- EF Study,,,000910,IS - Clin Study (MIGRATED)
9136,1016-0002,1016.2,Unconfirmed,449,1016-P00,Hyperlipemias,Unconfirmed,MIG,Migration,IV,Phase IV,- EF Study,,,000910,IS - Clin Study (MIGRATED)
9137,1016-0003,1016.3,Ended,449,1016-P00,Hypertension,Ended,MIG,Migration,IV,Phase IV,- EF Study   Only safety summary will be done,,,000910,IS - Clin Study (MIGRATED)
9138,1016-0004,1016.4,Ended,449,1016-P00,Effect of fish oil on rheumatoid arthrit,Ended,MIG,Migration,II,Phase II,- ,,,,
9139,1016-0005,1016.5,Ended,449,1016-P00,Hypertriglicerides,Ended,MIG,Migration,IV,Phase IV,- EF Study,,,000910,IS - Clin Study (MIGRATED)
9140,1017-0001,1017.1,Ended,450,1017-P00,LONG TERM IN ELDERLY,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9141,1017-0002,1017.2,Ended,450,1017-P00,Pharmacokinetics,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9142,1017-0003,1017.3,Ended,450,1017-P00,DOSE RANGE FINDING STUDY,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9143,1017-0005,1017.5,Ended,450,1017-P00,Single Dose in Elderly,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9144,1017-0006,1017.6,Ended,450,1017-P00,EFFICACY VS.KETAZOLAM VS.PLACEBO,Ended,MIG,Migration,III,Phase III,- Centre of Prof. Marchesi (Ancona) never started.              Report expected 3/93 (Letter Daniotti 06.10.92),,,000910,IS - Clin Study (MIGRATED)
9145,1017-0007,1017.7,Ended,450,1017-P00,EFFECTS ON EEG VS DIAZEPAM,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9146,1017-0008,1017.8,Ended,450,1017-P00,EFFICACY IN LONG TERM STUDY,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9147,1017-0009,1017.9,Ended,450,1017-P00,Single and Multiple dose in healthy,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9148,1021-0001,1021.1,Ended,451,1021-P01,none,Ended,MIG,Migration,I,Phase I,- Data cannot be used because of defect in measuring instrumen ts *,,,000910,IS - Clin Study (MIGRATED)
9149,1021-0002,1021.2,Ended,451,1021-P01,Vasoconstriction,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9150,1021-0003,1021.3,Ended,451,1021-P01,Atopic dermatitis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9151,1021-0004,1021.4,Ended,451,1021-P01,none,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9152,1021-0005,1021.5,Ended,451,1021-P01,Psoriasis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9153,1021-0006,1021.6,Ended,451,1021-P01,Eczema,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9154,1021-0007,1021.7,Ended,451,1021-P01,Efficacy and safety of Pandel CreLo.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9155,1021-0008,1021.8,Ended,451,1021-P01,Dermatitis, atopic,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9156,1021-0009,1021.9,Ended,451,1021-P01,Skin thinning by topical corticoids,Ended,MIG,Migration,I,Phase I,- Publication in preperation,,,000910,IS - Clin Study (MIGRATED)
9157,1022-0001,1022.1,Unconfirmed,452,1022-P01,Vaginitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9158,1022-0002,1022.2,Unconfirmed,452,1022-P01,Eczema,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9159,1023-0001,1023.1,Unconfirmed,453,1023-P01,Dermatitis allergic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9160,1023-0002,1023.2,Ended,453,1023-P01,Efficacy and tolerance of Hydroxizin,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9161,1026-0001,1026.1,Ended,454,1026-P01,Cancer, lung,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9162,1026-0002,1026.2,Ended,454,1026-P01,Neoplasm lymphocytic;Neoplasm histiocyti,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9163,1026-0003,1026.3,Ended,454,1026-P01,Carcinoma mamma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9164,1026-0004,1026.4,Ended,454,1026-P01,Carcinoma pulmonary,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9165,1026-0005,1026.5,Ended,454,1026-P01,RANDOMISED TRIAL IN NEOADJUVANT CHEMOTHE,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9166,1026-0006,1026.6,Ended,454,1026-P01,Carcinoma bronchial,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9167,1026-0007,1026.7,Ended,454,1026-P01,Carcinoma ovarian,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9168,1026-0008,1026.8,Unconfirmed,454,1026-P01,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9169,1026-0009,1026.9,Ended,454,1026-P01,Carcinoma cervical,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9170,1026-0010,1026.10,Ended,454,1026-P01,Sarcoma osteogenic,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9171,1026-0011,1026.11,Ended,454,1026-P01,Cancer, lung,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9172,1026-0012,1026.12,Ended,454,1026-P01,Carcinoma pulmonary,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9173,1026-0013,1026.13,Unconfirmed,454,1026-P01,Carcinoma cervical,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9174,1026-0014,1026.14,Ended,454,1026-P01,Carcinoma bronchial,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9175,1026-0015,1026.15,Ended,454,1026-P01,Carcinoma pulmonary,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9176,1026-0016,1026.16,Ended,454,1026-P01,Carcinoma cervical,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9177,1026-0017,1026.17,Ended,454,1026-P01,Carcinoma pulmonary,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9178,1026-0018,1026.18,Ended,454,1026-P01,Carcinoma uterine,Ended,MIG,Migration,II,Phase II,- Local study numbers: FC-648a # CT-359 * *,,,000910,IS - Clin Study (MIGRATED)
9179,1026-0019,1026.19,Ended,454,1026-P01,Carcinoma pulmonary,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9180,1026-0020,1026.20,Unconfirmed,454,1026-P01,Lymphoma non-Hodgkin;Hodgkins-Disease;LE,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9181,1026-0021,1026.21,Ended,454,1026-P01,Carcinoma pulmonary,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9182,1026-0022,1026.22,Unconfirmed,454,1026-P01,Carcinoma ovarian,Unconfirmed,MIG,Migration,II,Phase II,- planned patients: 30-40 ** *,,,000910,IS - Clin Study (MIGRATED)
9183,1026-0023,1026.23,Ended,454,1026-P01,Carcinoma ovarian,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9184,1026-0024,1026.24,Unconfirmed,454,1026-P01,Cancer, Pancreatic,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9185,1026-0025,1026.25,Ended,454,1026-P01,Cancer, lung,Ended,MIG,Migration,II,Phase II,- No report, no patient's records, no publication. Trial stopped. * *,,,000910,IS - Clin Study (MIGRATED)
9186,1026-0026,1026.26,Ended,454,1026-P01,Lymphoma,Ended,MIG,Migration,II,Phase II,- Study abandoned. * *,,,000910,IS - Clin Study (MIGRATED)
9187,1026-0027,1026.27,Ended,454,1026-P01,Cancer, lung,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9188,1026-0028,1026.28,Ended,454,1026-P01,Cancer, lung,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9189,1026-0029,1026.29,Ended,454,1026-P01,Carcinoma pulmonary,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9190,1026-0030,1026.30,Unconfirmed,454,1026-P01,Cancer, Pancreatic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9191,1026-0031,1026.31,Unconfirmed,454,1026-P01,Cancer, gastric,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9192,1026-0032,1026.32,Ended,454,1026-P01,Carcinoma gastric,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9193,1026-0033,1026.33,Ended,454,1026-P01,Cancer, lung,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9194,1026-0034,1026.34,Ended,454,1026-P01,Carcinoma pulmonary,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9195,1026-0035,1026.35,Ended,454,1026-P01,Hodgkins Disease,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9196,1026-0036,1026.36,Ended,454,1026-P01,Cancer, lung,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9197,1026-0037,1026.37,Ended,454,1026-P01,Cancer, colonic,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9198,1026-0038,1026.38,Ended,454,1026-P01,Cancer, lung,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9199,1026-0039,1026.39,Ended,454,1026-P01,STUDY IN RELAPSED RESISTANT NON-HODGKINS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9200,1026-0040,1026.40,Ended,454,1026-P01,Cancer, colonic,Ended,MIG,Migration,II,Phase II,- Only abstract and summary available. *,,,000910,IS - Clin Study (MIGRATED)
9201,1026-0041,1026.41,Ended,454,1026-P01,Cancer, breast,Ended,MIG,Migration,II,Phase II,- Stopped due to slow recruitment. Patient data of poor quality. * *,,,000910,IS - Clin Study (MIGRATED)
9202,1026-0042,1026.42,Ended,454,1026-P01,EVALUATION OF IFOS/CISPLATIN IN STAGES I,Ended,MIG,Migration,II,Phase II,- Data difficult to retrieve from investigator, therefore trial stopped. * *,,,000910,IS - Clin Study (MIGRATED)
9203,1026-0043,1026.43,Ended,454,1026-P01,Cancer, breast,Ended,MIG,Migration,II,Phase II,- No full report, summary and abstract only.  * *,,,000910,IS - Clin Study (MIGRATED)
9204,1026-0044,1026.44,Ended,454,1026-P01,LYMPHOMA,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9205,1026-0045,1026.45,Ended,454,1026-P01,Cancer, lung,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9206,1026-0046,1026.46,Ended,454,1026-P01,Carcinoma bronchial,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9207,1030-0001,1030.1,Ended,455,1030-P00,Depression,Ended,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
9208,1030-0002,1030.2,Unconfirmed,455,1030-P00,Postconcussional syndrome,Unconfirmed,MIG,Migration,III,Phase III,- EE Study,,,000910,IS - Clin Study (MIGRATED)
9209,1030-0003,1030.3,Unconfirmed,455,1030-P00,Hepatitis,Unconfirmed,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
9210,1030-0004,1030.4,Unconfirmed,455,1030-P00,Depression,Unconfirmed,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
9211,1030-0005,1030.5,Unconfirmed,455,1030-P00,Alcohol amnestic disorder,Unconfirmed,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
9212,1030-0006,1030.6,Unconfirmed,455,1030-P00,Depression,Unconfirmed,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
9213,1030-0007,1030.7,Ended,455,1030-P00,Arthritis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9214,1030-0008,1030.8,Ended,455,1030-P00,Hepatitis, acute,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9215,1030-0009,1030.9,Ended,455,1030-P00,Depression,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9216,1030-0010,1030.10,Ended,455,1030-P00,Ademetionine in Alcoholic cirrhosis,Ended,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
9217,1030-0011,1030.11,Ended,455,1030-P00,Depression,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9218,1030-0012,1030.12,Ended,455,1030-P00,Depression,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9219,1030-0013,1030.13,Ended,455,1030-P00,Hepatic steatosis,Ended,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
9220,1030-0014,1030.14,Ended,455,1030-P00,Ademetionine in depression,Ended,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
9221,1030-0015,1030.15,Ended,455,1030-P00,S-Adenosyl-L-Methionine dosing and Depre,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9222,1030-0016,1030.16,Ended,455,1030-P00,Antidrepressive effect of oral SAMe.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9223,1030-0017,1030.17,Unconfirmed,455,1030-P00,Depression,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9224,1030-0018,1030.18,Ended,455,1030-P00,Pharmacokinetics of Metionine,Ended,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
9225,1030-0019,1030.19,Ended,455,1030-P00,Hepatitis C,Ended,MIG,Migration,IV,Phase IV,- EE Study,,,000910,IS - Clin Study (MIGRATED)
9226,1030-0020,1030.20,Ended,455,1030-P00,SAME in alcoholic hapatits,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9227,1032-0001,1032.1,Unconfirmed,456,1032-P01,Contraception,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9228,1032-0002,1032.2,Unconfirmed,456,1032-P01,Contraception,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9229,1032-0003,1032.3,Ended,456,1032-P01,Contraception,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9230,1032-0004,1032.4,Unconfirmed,456,1032-P01,Contraception,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9231,1032-0005,1032.5,Unconfirmed,456,1032-P01,Contraception,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9232,1033-0001,1033.1,Unconfirmed,457,1033-P00,Gastritis,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9233,1033-0002,1033.2,Ended,457,1033-P00,HEALING RATE VS.RANITIDINE,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9234,1033-0003,1033.3,Ended,457,1033-P00,HEALING VS.PLACEBO,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9235,1033-0004,1033.4,Ended,457,1033-P00,HEALING RATE VS.RANITIDINE,Ended,MIG,Migration,IV,Phase IV,- Samle size not reached. *,,,000910,IS - Clin Study (MIGRATED)
9236,1033-0005,1033.5,Ended,457,1033-P00,Aluminium resorption,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9237,1033-0006,1033.6,Ended,457,1033-P00,Aluminium resorption,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9238,1033-0007,1033.7,Ended,457,1033-P00,In vitro/in vivo comparison o. Phosphalu,Ended,MIG,Migration,IV,Phase IV,- Summary info. BIG 12/92 (Letter Maria 09.10.92)/ Report expected 7/93,,,000910,IS - Clin Study (MIGRATED)
9239,1033-0008,1033.8,Ended,457,1033-P00,Interactions Phosphalugel and Diclofenac,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9240,1033-0009,1033.9,Ended,457,1033-P00,Interactions Phosphalugel and Piroxicam,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9241,1033-0010,1033.10,Ended,457,1033-P00,Efficacy,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
9242,1036-0001,1036.1,Unconfirmed,458,1036-P00,Macular degeneration,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9243,1036-0002,1036.2,Unconfirmed,458,1036-P00,Vascular diseases,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9244,1036-0003,1036.3,Unconfirmed,458,1036-P00,Cerebrovascular disorders,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9245,1037-0001,1037.1,Ended,459,1037-P01,Ance-Vulgaris,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9246,1037-0002,1037.2,Ended,459,1037-P01,Efficacy, Tolerability,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9247,1037-0003,1037.3,Ended,459,1037-P01,Feldstudie verschiedener Zubereitungen,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
9248,1037-0004,1037.4,Ended,459,1037-P01,2 Farbt√∂nungen, Acceptance,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9249,1037-0005,1037.5,Unconfirmed,459,1037-P01,2 Farbt√∂nungen, Acceptance, Dr. Wacker,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9250,1037-0006,1037.6,Ended,459,1037-P01,Propylenglykolgehalt 5.25 und 7.5 %,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9251,1037-0007,1037.7,Ended,459,1037-P01,gegen aknefug-oxid 3% bei Akne vulgaris,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
9252,1037-0008,1037.8,Unconfirmed,459,1037-P01,Bestimmung der Lichtschutzwirkung,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
9253,1038-0001,1038.1,Ended,460,1038-P00,Postonsillectomy,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9254,1038-0002,1038.2,Ended,460,1038-P00,Antiinflamatory effect of Benzydamine,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9255,1038-0003,1038.3,Ended,460,1038-P00,Antiinflamatory effect Benzydamine,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9256,1038-0004,1038.4,Ended,460,1038-P00,Surgery, dental,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9257,1038-0005,1038.5,Ended,460,1038-P00,Antiinflamatory effect of Benzidamine D.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9258,1038-0006,1038.6,Ended,460,1038-P00,Antiinflamatory effect of Benzydamine D.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9259,1038-0007,1038.7,Ended,460,1038-P00,Antiinflamatory effect of Benzydamine,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9260,1039-0001,1039.1,Ended,461,1039-P00,Inflammation skin incontinence urinary/f,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9261,1042-0001,1042.1,Ended,462,1042-P00,Pharmacokinetics,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9262,1043-0001,1043.1,Ended,463,1043-P00,Bisolvon-Ampicilina vs Ampicilina,Ended,MIG,Migration,IV,Phase IV,- Span. man. avail. 01/93 (engl. transl. planned) (Letter Promeco 11/92)/ Report requested (Letter DIE 13.05.93),,,000910,IS - Clin Study (MIGRATED)
9263,1043-0002,1043.2,Ended,463,1043-P00,Bisolvon - Ampicilina vs Ampicillin,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9264,1043-0003,1043.3,Ended,463,1043-P00,Bisolvon - Ampicillin vs Ampicillin,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9265,1044-0001,1044.1,Ended,464,1044-P00,FDC Multicenter Study,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9266,1044-0002,1044.2,Ended,464,1044-P00,Amoxicillin plus Bromhexine in Pneumonia,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9267,1045-0001,1045.1,Ended,465,1045-P00,CONSTIPATION PATS.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9268,1045-0002,1045.2,Ended,465,1045-P00,--,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9269,1048-0001,1048.1,Ended,466,1048-P00,Ceftizoxime in serious respiratory inf.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9270,1048-0002,1048.2,Ended,466,1048-P00,ceftizoxime in child with RTI,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9271,1048-0003,1048.3,Ended,466,1048-P00,Ceftizoxime in serious infections,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9272,1048-0004,1048.4,Ended,466,1048-P00,Antiinfective effect of ceftizoxime,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9273,1048-0005,1048.5,Ended,466,1048-P00,Ceftizoxime in acute Peritoneal infectio,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9274,1049-0001,1049.1,Ended,467,1049-P00,Angina-Pectoris stable,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9275,1049-0002,1049.2,Ended,467,1049-P00,Arteriosclerosis,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9276,1050-0001,1050.1,Unconfirmed,468,1050-P00,Hypertension mild,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9277,1050-0002,1050.2,Unconfirmed,468,1050-P00,Hypertension mild,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9278,1050-0003,1050.3,Unconfirmed,468,1050-P00,Hypertension mild,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9279,1050-0004,1050.4,Ended,468,1050-P00,Hypertension mild,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9280,1050-0005,1050.5,Unconfirmed,468,1050-P00,Hypertension,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9281,1051-0001,1051.1,Unconfirmed,469,1051-P01,No Legacy Data,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9282,1052-0001,1052.1,Unconfirmed,470,1052-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9283,1052-0002,1052.2,Unconfirmed,470,1052-P01,Gastro-Intestinal disease,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9284,1052-0003,1052.3,Unconfirmed,470,1052-P01,Biliary tract diseases;Pancreatic DUCT D,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9285,1052-0004,1052.4,Unconfirmed,470,1052-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9286,1052-0005,1052.5,Unconfirmed,470,1052-P01,Colon irritable,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9287,1052-0006,1052.6,Unconfirmed,470,1052-P01,Colon irritable,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9288,1052-0007,1052.7,Unconfirmed,470,1052-P01,none,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9289,1052-0008,1052.8,Unconfirmed,470,1052-P01,Colon irritable,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9290,1052-0009,1052.9,Unconfirmed,470,1052-P01,none,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9291,1052-0010,1052.10,Unconfirmed,470,1052-P01,Biliary tract diseases,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9292,1052-0011,1052.11,Unconfirmed,470,1052-P01,Biliary tract diseases,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9293,1052-0012,1052.12,Unconfirmed,470,1052-P01,Ulcer gastric;Ulcer duodenal;Premedicati,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9294,1052-0013,1052.13,Unconfirmed,470,1052-P01,Colon irritable,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9295,1052-0014,1052.14,Unconfirmed,470,1052-P01,Gastro-Intestinal disease,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9296,1052-0015,1052.15,Unconfirmed,470,1052-P01,Achalasia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9297,1052-0016,1052.16,Unconfirmed,470,1052-P01,Colon irritable,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9298,1052-0017,1052.17,Unconfirmed,470,1052-P01,Premedication radiology,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9299,1052-0018,1052.18,Ended,470,1052-P01,Colon irritable,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9300,1052-0019,1052.19,Ended,470,1052-P01,Premedication radiology,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9301,1052-0020,1052.20,Ended,470,1052-P01,Premedication endoscopy,Ended,MIG,Migration,III,Phase III,- 31-85 34-86 *,,,000910,IS - Clin Study (MIGRATED)
9302,1052-0021,1052.21,Ended,470,1052-P01,Nephrolithiasis,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9303,1052-0022,1052.22,Unconfirmed,470,1052-P01,No Legacy Data,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9304,1052-0023,1052.23,Ended,470,1052-P01,No Legacy Data,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9305,1052-0024,1052.24,Unconfirmed,470,1052-P01,Colon irritable,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9306,1052-0025,1052.25,Unconfirmed,470,1052-P01,Colon irritable,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9307,1052-0026,1052.26,Ended,470,1052-P01,EFFECTS ON ANORECTAL MOTILITY,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9308,1052-0027,1052.27,Ended,470,1052-P01,PAIN RELIEF VS. PLACEBO,Ended,MIG,Migration,IV,Phase IV,- Calculated samlpe size not reached. *,,,000910,IS - Clin Study (MIGRATED)
9309,1052-0028,1052.28,Ended,470,1052-P01,OROCECAL TRANSIT EVALUATION,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9310,1052-0029,1052.29,Ended,470,1052-P01,Infantile colics,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9311,1052-0030,1052.30,Ended,470,1052-P01,Colon irritable,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9312,1052-0031,1052.31,Ended,470,1052-P01,Renal colics,Ended,MIG,Migration,IV,Phase IV,- Too many missing data. *,,,000910,IS - Clin Study (MIGRATED)
9313,1052-0032,1052.32,Ended,470,1052-P01,Colon irritable,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9314,1052-0033,1052.33,Ended,470,1052-P01,--,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9315,1052-0034,1052.34,Unconfirmed,470,1052-P01,GASTRIC EMPTYING VS.ATROPINE,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9316,1052-0035,1052.35,Ended,470,1052-P01,BILIARY DRUG EXCRETION,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9317,1052-0036,1052.36,Ended,470,1052-P01,Biliary tract diseases,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9318,1052-0037,1052.37,Unconfirmed,470,1052-P01,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9319,1052-0038,1052.38,Ended,470,1052-P01,SIMPTOMS RELIEF,Ended,MIG,Migration,IV,Phase IV,- Just descriptive statistics will be done, no report. *,,,000910,IS - Clin Study (MIGRATED)
9320,1052-0039,1052.39,Ended,470,1052-P01,PREMEDICATION IN ERCP,Ended,MIG,Migration,IV,Phase IV,- Short medical report,,,000910,IS - Clin Study (MIGRATED)
9321,1052-0040,1052.40,Ended,470,1052-P01,Esophageal motility disorders,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9322,1052-0041,1052.41,Ended,470,1052-P01,Efficacy of Alginor in gastrointestinal,Ended,MIG,Migration,III,Phase III,- ,,,,
9323,1052-0042,1052.42,Unconfirmed,470,1052-P01,Diverticulosis,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9324,1052-0043,1052.43,Ended,470,1052-P01,--,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9325,1052-0044,1052.44,Ended,470,1052-P01,Phase II of DA3177 tab.,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9326,1052-0045,1052.45,Ended,470,1052-P01,--,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9327,1052-0046,1052.46,Ended,470,1052-P01,GASTROINTESTINAL DISEASE,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9328,1052-0047,1052.47,Ended,470,1052-P01,Early phase II of DA 3177 amp.-premedica,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9329,1052-0048,1052.48,Ended,470,1052-P01,An effect of Algiron for IBS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9330,1052-0049,1052.49,Ended,470,1052-P01,An effect of Algiron for IBS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9331,1052-0050,1052.50,Ended,470,1052-P01,CIMETROPIUM-BRO IN PRIMARY ACHALASIA,Ended,MIG,Migration,IV,Phase IV,- Report expected 11/92 (Letter Daniotti 06.10.92),,,000910,IS - Clin Study (MIGRATED)
9332,1052-0051,1052.51,Ended,470,1052-P01,An effect of cimetropium bromide for IBS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9333,1052-0052,1052.52,Ended,470,1052-P01,Effects of DA3177 Amp. for pain with ure,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9334,1052-0053,1052.53,Ended,470,1052-P01,Early phase II study of DA 3177 tab.,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9335,1052-0054,1052.54,Ended,470,1052-P01,Late phase II study of DA 3177 tab. abdo,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9336,1052-0055,1052.55,Ended,470,1052-P01,Late phase II study(dose finding),Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
9337,1052-0056,1052.56,Ended,470,1052-P01,Additional late phase II study,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
9338,1052-0057,1052.57,Ended,470,1052-P01,PhaseIII study of DA3177 tab.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9339,1052-0058,1052.58,Ended,470,1052-P01,The effect of Algiron for IBS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9340,1052-0059,1052.59,Ended,470,1052-P01,CIMETROPIUM-BROMIDE IN INFANTILE COLIC,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9341,1052-0060,1052.60,Ended,470,1052-P01,PhaseIII study of DA3177 tab.(Open),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9342,1052-0061,1052.61,Ended,470,1052-P01,Clinical pharmacology of DA3177tab.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9343,1052-0062,1052.62,Ended,470,1052-P01,Pharmacokinetics of DA3177tab.,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9344,1052-0063,1052.63,Ended,470,1052-P01,Phase III study of DA3177 Tab.,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9345,1052-0064,1052.64,Ended,470,1052-P01,Influence of food,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9346,1052-0065,1052.65,Ended,470,1052-P01,Late phase II study(dose finding),Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
9347,1052-0066,1052.66,Ended,470,1052-P01,Phase III study of DA3177 Tab.(Open),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9348,1052-0067,1052.67,Ended,470,1052-P01,Phase III study (DBT),Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9349,1052-0068,1052.68,Ended,470,1052-P01,Pharmacokinetics in elderly patients,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9350,1052-0069,1052.69,Ended,470,1052-P01,Pharmacokinetics of DA3177 tab.,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9351,1052-0070,1052.70,Ended,470,1052-P01,Use of Cimetropium in Irritable Bowel,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9352,1052-0071,1052.71,Ended,470,1052-P01,Phase I study,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9353,1053-0001,1053.1,Unconfirmed,471,1053-P01,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9354,1053-0002,1053.2,Unconfirmed,471,1053-P01,Oesophagitis reflux,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9355,1053-0003,1053.3,Unconfirmed,471,1053-P01,Dyspepsia,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9356,1053-0004,1053.4,Unconfirmed,471,1053-P01,Colon irritable,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9357,1054-0001,1054.1,Ended,472,1054-P01,Psoriasis;Seborrhoea-Oleosa,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9358,1054-0002,1054.2,Ended,472,1054-P01,Seborrhoea,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9359,1054-0003,1054.3,Ended,472,1054-P01,Safety of Berniter Kopfhaut-Gel,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9360,1054-0004,1054.4,Ended,472,1054-P01,Efficacy and Tolerability,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9361,1054-0005,1054.5,Ended,472,1054-P01,Effic.,Tolera.,Accept. for Coal-tar gel,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9362,1054-0006,1054.6,Ended,472,1054-P01,Efficacy, Tolerability,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9363,1054-0007,1054.7,Ended,472,1054-P01,Skin tolerability of Berniter Body-gel,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9364,1056-0001,1056.1,Unconfirmed,473,1056-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9365,1057-0001,1057.1,Ended,474,1057-P01,Herpes-simplex,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9366,1057-0002,1057.2,Unconfirmed,474,1057-P01,Ecthyma contagious,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9367,1057-0003,1057.3,Unconfirmed,474,1057-P01,Herpes-zoster,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9368,1057-0004,1057.4,Ended,474,1057-P01,Warts,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9369,1018-0001,1018.1,Ended,475,1018-P00,JOINT DEVELOPMENT, NBI 25%,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9370,1058-0001,1058.1,Unconfirmed,476,1058-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9371,1058-0002,1058.2,Unconfirmed,476,1058-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9372,1059-0001,1059.1,Ended,477,1059-P01,EFFECTS ON 24H GASTRIC PH,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9373,1059-0002,1059.2,Ended,477,1059-P01,SHORT-TERM TREATMENT,Ended,MIG,Migration,III,Phase III,- Report expected 3/93 (Letter Daniotti 06.10.92),,,000910,IS - Clin Study (MIGRATED)
9374,1059-0003,1059.3,Ended,477,1059-P01,PHARMACOKINETIC IN HEPATOPATIC PATIENTS,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9375,1061-0001,1061.1,Ended,478,1061-P01,Dry Eye,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9376,1062-0001,1062.1,Unconfirmed,479,1062-P00,Constipation,Unconfirmed,MIG,Migration,NONE,Not Classified,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
9377,1062-0002,1062.2,Unconfirmed,479,1062-P00,Premedication radiology,Unconfirmed,MIG,Migration,NONE,Not Classified,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
9378,1062-0003,1062.3,Unconfirmed,479,1062-P00,Premedication radiology;Premedication EN,Unconfirmed,MIG,Migration,NONE,Not Classified,- Company was Teijin/Japan. Substance licenced out.,,,000910,IS - Clin Study (MIGRATED)
9379,1062-0004,1062.4,Ended,479,1062-P00,DOSE RANGING STUDY IN OPIOD INDUCED CONS,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9380,1062-0005,1062.5,Ended,479,1062-P00,r, m-c, p-c, d-b, efficacy, safety,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9381,1062-0006,1062.6,Unconfirmed,479,1062-P00,bei chronischer Obstipation,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
9382,1062-0007,1062.7,Ended,479,1062-P00,Picosulfate vs. placebo,Ended,MIG,Migration,IIIB,Phase IIIb,,2007-002087-10,,000910,IS - Clin Study (MIGRATED)
9383,1062-0008,1062.8,Unconfirmed,479,1062-P00,Children Study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
9384,1063-0002,1063.2,Ended,480,1063-P01,Warts,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9385,1063-0004,1063.4,Ended,480,1063-P01,Warts;Keratosis actinic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9386,1063-0006,1063.6,Ended,480,1063-P01,Molluscum contagiosum,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9387,1063-0007,1063.7,Ended,480,1063-P01,Condylomata acuminata,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9388,1063-0008,1063.8,Ended,480,1063-P01,unit dose system Solco Derman,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9389,1064-0005,1064.5,Unconfirmed,481,1064-P00,No Legacy Data,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9390,1064-0006,1064.6,Unconfirmed,481,1064-P00,No Legacy Data,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9391,1064-0007,1064.7,Unconfirmed,481,1064-P00,No Legacy Data,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9392,1064-0008,1064.8,Ended,481,1064-P00,No Legacy Data,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9393,1066-0001,1066.1,Ended,482,1066-P00,None,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9394,1066-0002,1066.2,Unconfirmed,482,1066-P00,No indication,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9395,1066-0003,1066.3,Unconfirmed,482,1066-P00,No indication,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9396,1067-0001,1067.1,Unconfirmed,483,1067-P00,Anxiety,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9397,1069-0001,1069.1,Ended,484,1069-P01,Snoring,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9398,1069-0002,1069.2,Ended,484,1069-P01,Snoring,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9399,1074-0001,1074.1,Ended,485,1074-P00,Psychomotor agitation,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9400,1075-0001,1075.1,Unconfirmed,486,1075-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9401,1076-0001,1076.1,Ended,487,1076-P00,Dermal tolerability of tretinoin gel,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9402,1077-0001,1077.1,Ended,488,1077-P01,Model of "sucking bubbles",Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9403,1080-0001,1080.1,Ended,489,1080-P01,Breast,Ended,MIG,Migration,III,Phase III,- ,,,,
9404,1080-0002,1080.2,Ended,489,1080-P01,Adeno,Ended,MIG,Migration,III,Phase III,- ,,,,
9405,1080-0003,1080.3,Ended,489,1080-P01,NSCLC,Ended,MIG,Migration,II,Phase II,- ,,,,
9406,1080-0004,1080.4,Ended,489,1080-P01,Metastatic breast,Ended,MIG,Migration,IV,Phase IV,- ,,,,
9407,1080-0006,1080.6,Ended,489,1080-P01,NVB-Mammaca,Ended,MIG,Migration,II,Phase II,- ,,,,
9408,1080-0007,1080.7,Ended,489,1080-P01,Vinorelbine/Ifosfamice,Ended,MIG,Migration,III,Phase III,- ,,,,
9409,1081-0001,1081.1,Ended,490,1081-P00,Vitamine D supplementation in pregnancy,Ended,MIG,Migration,IV,Phase IV,- Report forwarded end 1992 (Letter Jirou-Najou 29.09.92),,,000910,IS - Clin Study (MIGRATED)
9410,1082-0001,1082.1,Unconfirmed,491,1082-P00,No indication,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9411,1082-0002,1082.2,Unconfirmed,491,1082-P00,No Legacy Data,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9412,1083-0001,1083.1,Unconfirmed,492,1083-P01,Ulcer duodenal,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9413,1083-0002,1083.2,Ended,492,1083-P01,none,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9414,1083-0003,1083.3,Unconfirmed,492,1083-P01,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9415,1083-0004,1083.4,Ended,492,1083-P01,DFS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9416,1083-0005,1083.5,Unconfirmed,492,1083-P01,Ulcer peptic,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9417,1083-0006,1083.6,Unconfirmed,492,1083-P01,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9418,1083-0007,1083.7,Ended,492,1083-P01,Ulcer, duodenal,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9419,1083-0008,1083.8,Unconfirmed,492,1083-P01,Peptic ulcer/Pharmacokinetics,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9420,1083-0009,1083.9,Unconfirmed,492,1083-P01,Ulcer peptic,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9421,1086-0001,1086.1,Ended,493,1086-P00,ISDN v.s. 5-ISMN in Angor Pectoris,Ended,MIG,Migration,IV,Phase IV,- (Letter EAG),,,000910,IS - Clin Study (MIGRATED)
9422,1087-0001,1087.1,Ended,494,1087-P01,KETOPROFEN EFFICACY-SAFETY/NIMESULIDE,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
9423,1087-0002,1087.2,Ended,494,1087-P01,EFFICACY IN SINUSITIS/NIMESULIDE,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9424,1087-0003,1087.3,Ended,494,1087-P01,EFFICACY IN PHARINGITIS/NIMESULIDE,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9425,1087-0004,1087.4,Ended,494,1087-P01,Ketoprofen: Italian Pediatric Study,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9426,1087-0005,1087.5,Unconfirmed,494,1087-P01,Use of NSAIDS in Childhood,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9427,1087-0006,1087.6,Unconfirmed,494,1087-P01,SEAK-Analgesy in volunteers,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9428,1087-0007,1087.7,Ended,494,1087-P01,Mouthwash KLS in ENT- MISTRAL -,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9429,1088-0001,1088.1,Ended,495,1088-P00,BRONCHOGENIC CARCINOMA,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9430,1089-0001,1089.1,Ended,496,1089-P00,Clinical and bacteriological efficacy,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9431,1090-0001,1090.1,Ended,497,1090-P01,Lacrimal apparatus diseases,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9432,1090-0002,1090.2,Ended,497,1090-P01,Testing four different tear substitutes,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9433,1091-0001,1091.1,Unconfirmed,498,1091-P00,Cardiovascular diseases,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9434,1091-0002,1091.2,Unconfirmed,498,1091-P00,Arthritis rheumatoid,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9435,1091-0003,1091.3,Ended,498,1091-P00,Arthritis rheumatoid,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9436,1092-0001,1092.1,Ended,499,1092-P01,NONE,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9437,1092-0002,1092.2,Unconfirmed,499,1092-P01,Glaucoma,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9438,1092-0003,1092.3,Ended,499,1092-P01,Double-blind clinical trial in order to,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9439,1094-0001,1094.1,Unconfirmed,500,1094-P00,Debility postoperative,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9440,1094-0002,1094.2,Ended,500,1094-P00,Debility,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9441,1095-0001,1095.1,Unconfirmed,501,1095-P01,UVA SCREENING TESTS,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9442,1095-0002,1095.2,Ended,501,1095-P01,SUNSCREEN STUDY-PHOTODERMATOSIS PATIENTS,Ended,MIG,Migration,IV,Phase IV,- Publication,,,000910,IS - Clin Study (MIGRATED)
9443,1098-0001,1098.1,Unconfirmed,502,1098-P01,Surgery postoperative,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9444,1102-0001,1102.1,Ended,503,1102-P01,Alopecia-Areata,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9445,1103-0001,1103.1,Ended,504,1103-P00,Urinary Incontinence,Ended,MIG,Migration,IV,Phase IV,- Status E (letter Dr. Placheta 13.1.93),,,,
9446,1106-0001,1106.1,Ended,505,1106-P00,Creon Forte vs Cotazym S,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9447,1106-0002,1106.2,Unconfirmed,505,1106-P00,Cystic fibrosis,Unconfirmed,MIG,Migration,IV,Phase IV,- NZ Trial,,,000910,IS - Clin Study (MIGRATED)
9448,1108-0001,1108.1,Ended,506,1108-P00,none,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9449,1109-0001,1109.1,Unconfirmed,507,1109-P01,Eczema,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9450,1110-0001,1110.1,Ended,508,1110-P00,Urol.pats.with high blood losses,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9451,1111-0001,1111.1,Ended,509,1111-P00,TO COMPARE EFFECTIVENESS OF NEW FORMULA,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9452,1115-0001,1115.1,Ended,510,1115-P00,Effficacy & Safety in the Treatment of M,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9453,1119-0001,1119.1,Unconfirmed,511,1119-P01,Duodenal Ulcer,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9454,1119-0002,1119.2,Unconfirmed,511,1119-P01,Reflux Oesophagitis,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9455,1121-0001,1121.1,Ended,512,1121-P01,Efficacy and security of BDP vs. Amoxi,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9456,1121-0002,1121.2,Ended,512,1121-P01,Efficacy and security of BDP vs. Norflox,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9457,1121-0003,1121.3,Ended,512,1121-P01,Efficacy and security of BDP vs. Co-trim,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9458,1121-0004,1121.4,Ended,512,1121-P01,Efficacy and security of BDP,Ended,MIG,Migration,IV,Phase IV,- No report because of insufficient accuracy of data (e-mail Dr. Segovia to Dr. Mueller, 13.10.97),,,000910,IS - Clin Study (MIGRATED)
9459,1121-0005,1121.5,Ended,512,1121-P01,Efficacy and security,Ended,MIG,Migration,IV,Phase IV,- No report because of insufficient accuracy of data (e-mail Dr. Segovia to Dr. Mueller, 13.10.97),,,000910,IS - Clin Study (MIGRATED)
9460,1121-0006,1121.6,Ended,512,1121-P01,Efficacy and security of BDP,Ended,MIG,Migration,IV,Phase IV,- No report because of insufficient accuracy of data (e-mail Dr. Segovia to Dr. Mueller, 13.10.97),,,000910,IS - Clin Study (MIGRATED)
9461,1122-0001,1122.1,Ended,513,1122-P00,Efficacy and security of Cefixime vs Amo,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9462,1129-0001,1129.1,Ended,514,1129-P00,Safety profile of Kiddi effervescent tab,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
9463,1129-0002,1129.2,Ended,514,1129-P00,Safety and tolerability study-Kiddi Fizz,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9464,1129-0003,1129.3,Unconfirmed,514,1129-P00,Kiddi Chewable, Tolerance study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9465,1129-0004,1129.4,Unconfirmed,514,1129-P00,Kiddi Extemporary Syrup, Tolerance Study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9466,1129-0005,1129.5,Unconfirmed,514,1129-P00,Kiddi New Generation /Tolerability study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9467,1129-0006,1129.6,Ended,514,1129-P00,3-month Kiddi in school-children,Ended,MIG,Migration,IIA,Phase IIa,,,,,
9468,1135-0001,1135.1,Ended,515,1135-P00,Seresis acceptance study,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9469,1135-0002,1135.2,Ended,515,1135-P00,To determine the time of peak activity,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9470,1135-0003,1135.3,Ended,515,1135-P00,Seresis, anti-ageing and skin protection,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
9471,1135-0004,1135.4,Ended,515,1135-P00,Pharmacokinetic study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9472,1137-0001,1137.1,Ended,516,1137-P00,Pharmaton Young tolerance study,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9473,1137-0002,1137.2,Ended,516,1137-P00,Pharmaton Young tolerance study,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9474,1147-0001,1147.1,Ended,517,1147-P00,Dose-finding for twilight vision,Ended,MIG,Migration,IA,Phase Ia,- ,,,000910,IS - Clin Study (MIGRATED)
9475,1147-0002,1147.2,Ended,517,1147-P00,Efficacy and Safety,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
9476,1147-0003,1147.3,Ended,517,1147-P00,Efficacy in improving night vision,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9477,1147-0004,1147.4,Unconfirmed,517,1147-P00,Anthocyane, Computer Fatigue,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9478,1164-0001,1164.1,Ended,518,1164-P01,Adjuvant to radiation therapy,Ended,MIG,Migration,III,Phase III,See extended comment field. Enrollment in the trial has been put on hold.  Patients will continue to be seen for follow up visits and Safety issues.  Once 300 end points are obtained, an analysis will be done on the data.,,,000910,IS - Clin Study (MIGRATED)
9479,1164-0002,1164.2,Preparing,518,1164-P01,Non-small cell lung cancer,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9480,1164-0003,1164.3,Ended,518,1164-P01,PK Study - Head & Neck Cancer,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9481,1164-0004,1164.4,Ended,518,1164-P01,Safety, efficacy head & neck ca post op,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
9482,1164-0005,1164.5,Preparing,518,1164-P01,Esophageal Cancer,Preparing,MIG,Migration,II,Phase II,Centers not determined, (US, Europe) ,,,000910,IS - Clin Study (MIGRATED)
9483,1164-0006,1164.6,Unconfirmed,518,1164-P01,Cervical cancer,Unconfirmed,MIG,Migration,II,Phase II,Centers not determined, (US,Mex,Ar,Ven) ,,,000910,IS - Clin Study (MIGRATED)
9484,1164-0007,1164.7,Unconfirmed,518,1164-P01,Safety, efficacy head & neck ca,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
9485,1164-0008,1164.8,Unconfirmed,518,1164-P01,Safety, population PK-H & N cancer,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9486,1164-0009,1164.9,Unconfirmed,518,1164-P01,Safety, pharmaco- H & N and other cancer,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9487,1164-0010,1164.10,Unconfirmed,518,1164-P01,Safety, efficacy, NSCLC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
9488,1164-0011,1164.11,Ended,518,1164-P01,Safety, efficacy H & N + Acc. RT,Ended,MIG,Migration,I,Phase I,Conducted by Bruce G. Haffty ,,,,
9489,1164-0012,1164.12,Unconfirmed,518,1164-P01,Safety, for Cervical Cancer,Unconfirmed,MIG,Migration,I,Phase I,Conducted by Kenneth B. Roberts ,,,,
9490,1164-0013,1164.13,Unconfirmed,518,1164-P01,14C-metabolic study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9491,1164-0014,1164.14,Unconfirmed,518,1164-P01,Safety, H&N cancer (triple Rx),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9492,1164-0015,1164.15,Unconfirmed,518,1164-P01,Efficacy, RT + porf for advanced Sarcoma,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9493,0600-0001,600.1,Ended,521,0600-P01,Tolerability and pharmacokinetics,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9494,0600-0002,600.2,Ended,521,0600-P01,Maintenance Dose in Healthy Volunteers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9495,0600-0003,600.3,Preparing,521,0600-P01,Tolerability in Patients,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9496,0600-0005,600.5,Preparing,521,0600-P01,ADME in Man,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9497,0600-0006,600.6,Ended,521,0600-P01,Elderly healthy volunteers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9498,0600-0007,600.7,Unconfirmed,521,0600-P01,First efficacy study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9499,0599-0001,599.1,Ended,522,0599-P01,Loading dose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9500,0599-0002,599.2,Ended,522,0599-P01,Maintenance dose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9501,0599-0003,599.3,Ended,522,0599-P01,Tolerability in Patients,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
9502,0599-0005,599.5,Preparing,522,0599-P01,ADME in Man,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9503,0599-0006,599.6,Preparing,522,0599-P01,Signal of efficacy in stroke patients,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9504,0599-0007,599.7,Ended,522,0599-P01,PET study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9505,0599-0008,599.8,Unconfirmed,522,0599-P01,MRI Stroke study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9506,0599-0010,599.10,Unconfirmed,522,0599-P01,1 hour infusion - PK bridging study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9507,0599-0011,599.11,Ended,522,0599-P01,Interaction - Desipramine,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9508,0599-0012,599.12,Ended,522,0599-P01,Interaction - Midazolam,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9509,0599-0013,599.13,Unconfirmed,522,0599-P01,Interaction - labetolol,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9510,0599-0014,599.14,Unconfirmed,522,0599-P01,Interaction - Metoprolol,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9511,0599-0015,599.15,Unconfirmed,522,0599-P01,Interaction - Captopril,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9512,0599-0016,599.16,Unconfirmed,522,0599-P01,Interaction - Nifedipine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9513,0599-0017,599.17,Unconfirmed,522,0599-P01,Interaction - Haloperidol,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9514,0599-0018,599.18,Unconfirmed,522,0599-P01,Interaction - Clonidine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9515,0599-0019,599.19,Unconfirmed,522,0599-P01,Interaction - Digitoxine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9516,0599-0020,599.20,Unconfirmed,522,0599-P01,Interaction - Theophylline,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9517,0599-0021,599.21,Unconfirmed,522,0599-P01,Interaction - Warfarin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9518,0599-0022,599.22,Unconfirmed,522,0599-P01,Formulation switch - PK/safety,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9519,0599-0023,599.23,Preparing,522,0599-P01,Interaction - Itraconazole,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9520,0599-0024,599.24,Unconfirmed,522,0599-P01,Haemorrhage Safety,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9521,0599-0025,599.25,Unconfirmed,522,0599-P01,Formulation switch - Patients PK/Safety,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9522,0599-0026,599.26,Unconfirmed,522,0599-P01,6 hour infusion - PK bridge,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9523,0599-0027,599.27,Unconfirmed,522,0599-P01,Efficacy bridge - IIb,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9524,0116-0126,116.126,Ended,525,0116-P00,CLINICAL PHARMACOLOGICAL TRIAL,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9525,0116-0127,116.127,Ended,525,0116-P00,CLINICAL PHARMACOLOGICAL TRIAL,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9526,0116-0131,116.131,Ended,525,0116-P00,PHASE I STUDY (MULTIPLE ADMIN.),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9527,0116-0132,116.132,Ended,525,0116-P00,PILOT STUDY,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9528,0116-0133,116.133,Ended,525,0116-P00,CLINICAL PHARMACOLOGICAL TRIAL,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9529,0116-0134,116.134,Ended,525,0116-P00,CLINICAL PHARMACOLOGICAL TRIAL,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9530,0116-0135,116.135,Ended,525,0116-P00,DTS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9531,0116-0136,116.136,Ended,525,0116-P00,CLINICAL PHARMACOLOGICAL TRIAL,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9532,0116-0137,116.137,Ended,525,0116-P00,CLINICAL PHARMACOLOGICAL TRIAL,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9533,0116-0139,116.139,Ended,525,0116-P00,CLINICAL PHARMACOLOGICAL STUDY,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9534,0116-0140,116.140,Ended,525,0116-P00,CLIN. EVAL. OF PIMOBENDAN ON AHF BY DBT,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9535,0116-0149,116.149,Ended,525,0116-P00,OT ON A,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9536,0116-0150,116.150,Ended,525,0116-P00,Cardiomyopathy / Heart failure,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9537,0116-0153,116.153,Ended,525,0116-P00,Phase I study (Antacid),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9538,0116-0154,116.154,Ended,525,0116-P00,Pilot study,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
9539,0116-0155,116.155,Ended,525,0116-P00,Hemodynamic effect by repeate iv Pim,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
9540,0116-0156,116.156,Ended,525,0116-P00,Pilot study,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
9541,0116-0157,116.157,Ended,525,0116-P00,Effects of Pimo in circulatory failure,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
9542,0116-0158,116.158,Ended,525,0116-P00,Maintenance of postope. hemodynamics,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
9543,0116-0160,116.160,Ended,525,0116-P00,clinical pharmacol.,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
9544,0116-0161,116.161,Ended,525,0116-P00,pilot study,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
9545,0116-0171,116.171,Ended,525,0116-P00,Acute effect on hemodynamics,Ended,MIG,Migration,IV,Phase IV,- ,,,000920,NISnd - Study (MIGRATED)
9546,0116-0173,116.173,Ended,525,0116-P00,Dose titration study,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
9547,0116-0174,116.174,Ended,525,0116-P00,Dose titration study,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
9548,0116-0159,116.159,Ended,526,0116-P02,Skin tolerability,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9549,0116-0162,116.162,Ended,526,0116-P02,Skin tolerance (Duhringkammer-Test),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9550,0116-0165,116.165,Unconfirmed,526,0116-P02,Tolerance of UDCG 115 Eye drops,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9551,0116-0168,116.168,Ended,526,0116-P02,Tolerance of UDCG 115 Eye drops,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9552,0116-0263,116.263,Ended,526,0116-P02,Tolerance of UDCG 115 Eye drops,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9553,0116-0264,116.264,Ended,526,0116-P02,Efficacy, tolerability,Ended,MIG,Migration,IIA,Phase IIa,- ,,,000910,IS - Clin Study (MIGRATED)
9554,0137-0100,137.100,Ended,527,0137-P02,Carcinoma renal cell,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9555,0137-0101,137.101,Unconfirmed,527,0137-P02,CAHB,Unconfirmed,MIG,Migration,II,Phase II,- Dev.Prot.: 0.05 MG/M2 BODY SURFACE-DOSAGE, NOT APPLIED. TRIAL PERFORMED IN 8 PATIENTS (4 + 4), APPLYING TO 4 PATIENTS 0 *,,,000910,IS - Clin Study (MIGRATED)
9556,0137-0111,137.111,Unconfirmed,527,0137-P02,Cancer ovarian,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9557,0137-0112,137.112,Ended,527,0137-P02,Malignant melanoma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9558,0137-0113,137.113,Ended,527,0137-P02,RCC,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9559,0137-0114,137.114,Ended,527,0137-P02,Melanoma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9560,0137-0115,137.115,Ended,527,0137-P02,Carcinoma ovarian,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9561,0137-0116,137.116,Ended,527,0137-P02,Melanoma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9562,0137-0117,137.117,Ended,527,0137-P02,Bowens Disease,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9563,0137-0119,137.119,Ended,527,0137-P02,Carcinoma mamma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9564,0137-0122,137.122,Ended,527,0137-P02,Multiple myeloma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9565,0137-0123,137.123,Ended,527,0137-P02,SCLC,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9566,0137-0128,137.128,Ended,527,0137-P02,Recombinant tumor necrosis factor,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9567,0137-0132,137.132,Ended,527,0137-P02,Cancer, basal cell,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9568,0137-0141,137.141,Ended,527,0137-P02,Renal cell carcinoma / melanoma,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9569,0137-0159,137.159,Ended,527,0137-P02,RCC,Ended,MIG,Migration,II,Phase II,- ,,,,
9570,0137-0160,137.160,Ended,527,0137-P02,NSCLC,Ended,MIG,Migration,III,Phase III,- ,,,,
9571,0137-0161,137.161,Ended,527,0137-P02,Ovarian Ca,Ended,MIG,Migration,III,Phase III,- ,,,,
9572,0137-0162,137.162,Ended,527,0137-P02,comp. use,Ended,MIG,Migration,III,Phase III,- comp. use,,,000500,Compassionate Use Program (CUP)
9573,0137-0164,137.164,Ended,527,0137-P02,Vulva Ca,Ended,MIG,Migration,III,Phase III,- ,,,,
9574,0137-0165,137.165,Ended,527,0137-P02,VIN II+III,Ended,MIG,Migration,III,Phase III,- ,,,,
9575,0137-0166,137.166,Ended,527,0137-P02,Sclerodermia,Ended,MIG,Migration,II,Phase II,- ,,,,
9576,0137-0169,137.169,Ended,527,0137-P02,Head and neck,Ended,MIG,Migration,II,Phase II,- ,,,,
9577,0137-0170,137.170,Ended,527,0137-P02,Systemic scleroderma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9578,0137-0171,137.171,Ended,527,0137-P02,Advanced colorectal carcinoma,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9579,0137-0172,137.172,Ended,527,0137-P02,Non-Hodgkins Lymphoma,Ended,MIG,Migration,III,Phase III,- ,,,,
9580,0137-0178,137.178,Unconfirmed,527,0137-P02,SCLC,Unconfirmed,MIG,Migration,III,Phase III,- ,,,,
9581,0137-0179,137.179,Ended,527,0137-P02,RCC,Ended,MIG,Migration,II,Phase II,- ,,,,
9582,0137-0183,137.183,Ended,527,0137-P02,IFN-gamma and MIBG captation by neurobla,Ended,MIG,Migration,I,Phase I,- ,,,,
9583,0137-0184,137.184,Ended,527,0137-P02,REFRACTORY CROHNS DISEASE,Ended,MIG,Migration,III,Phase III,- ,,,,
9584,0137-0185,137.185,Ended,527,0137-P02,Malignant Melanoma,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9585,0137-0197,137.197,Ended,527,0137-P02,IOR study,Ended,MIG,Migration,II,Phase II,- ,,,,
9586,0137-0198,137.198,Ended,527,0137-P02,Chronic granulomatous disease,Ended,MIG,Migration,III,Phase III,- ,,,000500,Compassionate Use Program (CUP)
9587,0137-0199,137.199,Ended,527,0137-P02,Chronic granulomatouse disease,Ended,MIG,Migration,III,Phase III,- ,,,000500,Compassionate Use Program (CUP)
9588,0137-0102,137.102,Unconfirmed,528,0137-P03,Leprosy,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9589,0137-0103,137.103,Ended,528,0137-P03,CAHB-Vaccination,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9590,0137-0105,137.105,Unconfirmed,528,0137-P03,MDS,Unconfirmed,MIG,Migration,II,Phase II,- Status E agreed by Dr. Hertkorn, 10.06.1997.,,,000910,IS - Clin Study (MIGRATED)
9591,0137-0106,137.106,Unconfirmed,528,0137-P03,MDS,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9592,0137-0107,137.107,Ended,528,0137-P03,Rheum. arthritis,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9593,0137-0108,137.108,Ended,528,0137-P03,Herpes-zoster,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9594,0137-0109,137.109,Ended,528,0137-P03,Psoriasis,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9595,0137-0118,137.118,Ended,528,0137-P03,Hepatitis, CAHB (vaccination),Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9596,0137-0120,137.120,Ended,528,0137-P03,HPV (CIN),Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9597,0137-0121,137.121,Ended,528,0137-P03,Hepatitis, CAHB,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9598,0137-0125,137.125,Ended,528,0137-P03,Leprosy,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9599,0137-0126,137.126,Unconfirmed,528,0137-P03,Leishmaniasis cut.,Unconfirmed,MIG,Migration,II,Phase II,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
9600,0137-0127,137.127,Ended,528,0137-P03,Leishmaniasis syst.,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9601,0137-0130,137.130,Unconfirmed,528,0137-P03,MDS,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9602,0137-0131,137.131,Ended,528,0137-P03,Condylomata accuminata,Ended,MIG,Migration,III,Phase III,- started int'l,,,000910,IS - Clin Study (MIGRATED)
9603,0137-0135,137.135,Unconfirmed,528,0137-P03,Leishmaniasis syst.,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9604,0137-0137,137.137,Ended,528,0137-P03,Thrombocythaemia,Ended,MIG,Migration,II,Phase II,- Report expected 3/93 (verb. Wilson 10/92),,,000910,IS - Clin Study (MIGRATED)
9605,0137-0138,137.138,Ended,528,0137-P03,AML,Ended,MIG,Migration,II,Phase II,- Status set to E following e-mail Mr. Zentragf from 31.07.96.,,,000910,IS - Clin Study (MIGRATED)
9606,0137-0139,137.139,Ended,528,0137-P03,Condylomata accuminata,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9607,0137-0142,137.142,Ended,528,0137-P03,CML,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9608,0137-0146,137.146,Ended,528,0137-P03,Leishmaniasis syst.,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9609,0137-0147,137.147,Ended,528,0137-P03,Leishmaniasis cut.,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9610,0137-0155,137.155,Ended,528,0137-P03,Gamma-Interferon in Lepromatous Lepra,Ended,MIG,Migration,II,Phase II,- payed by BI GmbH,,,000910,IS - Clin Study (MIGRATED)
9611,0137-0167,137.167,Ended,528,0137-P03,OMF-Study,Ended,MIG,Migration,II,Phase II,- ,,,,
9612,0137-0168,137.168,Ended,528,0137-P03,pilot study, relapses after IFN-alpha,Ended,MIG,Migration,I,Phase I,- ,,,,
9613,0137-0173,137.173,Ended,528,0137-P03,IFN-gamma in CAV,Ended,MIG,Migration,IV,Phase IV,- ,,,,
9614,0137-0174,137.174,Ended,528,0137-P03,Inflam.cytokines & growth factors in OSF,Ended,MIG,Migration,III,Phase III,- ,,,,
9615,0137-0177,137.177,Ended,528,0137-P03,Atopic Dermatits,Ended,MIG,Migration,III,Phase III,- ,,,,
9616,0137-0180,137.180,Ended,528,0137-P03,Chron. interstitial lung disease,Ended,MIG,Migration,II,Phase II,- ,,,,
9617,0137-0181,137.181,Ended,528,0137-P03,radionuclide imaging,Ended,MIG,Migration,II,Phase II,- ,,,,
9618,0137-0182,137.182,Ended,528,0137-P03,Imukin in Dupuytren's contractures IOR,Ended,MIG,Migration,IV,Phase IV,- ,,,,
9619,0137-1202,137.1202,Ended,528,0137-P03,Reaktive Arthritis,Ended,MIG,Migration,II,Phase II,,,,,
9620,0202-0301,202.301,Ended,529,0202-P00,Kinetics,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9621,0202-0302,202.302,Ended,529,0202-P00,Kinetics,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9622,0202-0303,202.303,Ended,529,0202-P00,Tolerance, dose-effectiveness,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9623,0202-0304,202.304,Ended,529,0202-P00,Bioavailability, Tolerance,Ended,MIG,Migration,I,Phase I,- , EStatus = D, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9624,0202-0502,202.502,Ended,529,0202-P00,Efficacy & safety,Ended,MIG,Migration,III,Phase III,- , EStatus = R, inserted by gerken at 22.03.93,,,000910,IS - Clin Study (MIGRATED)
9625,0202-0800,202.800,Ended,529,0202-P00,Choledocholithiasis;Cholelithiasis;pain,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9626,0202-0801,202.801,Unconfirmed,529,0202-P00,COLIC urologic diseases;Colic biliary TR,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9627,0202-0802,202.802,Unconfirmed,529,0202-P00,Colon irritable,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9628,0202-0803,202.803,Unconfirmed,529,0202-P00,Pain pelvic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9629,0202-0804,202.804,Ended,529,0202-P00,Dysmenorrhoea psychogenic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9630,0202-0805,202.805,Ended,529,0202-P00,Scopolamine in biliary lithiasis,Ended,MIG,Migration,IV,Phase IV,- Group A: Study on the Oddi sphincter                          Group B: Study on the biliary bladder *,,,000910,IS - Clin Study (MIGRATED)
9631,0202-0808,202.808,Ended,529,0202-P00,GASTROINTESTINAL DISEASE,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9632,0202-0814,202.814,Ended,529,0202-P00,Buscopan Ibuprofen tablets, bioavailabi,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9633,0202-0817,202.817,Unconfirmed,529,0202-P00,Onset and duration of action,Unconfirmed,MIG,Migration,II,Phase II,To be performed by a CRO ,,,000910,IS - Clin Study (MIGRATED)
9634,0202-0818,202.818,Unconfirmed,529,0202-P00,Efficacy of Buscopan Mono,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,To be performed by CRO ,,,000910,IS - Clin Study (MIGRATED)
9635,0202-0819,202.819,Unconfirmed,529,0202-P00,Tolerability vs hyoscyamine,Unconfirmed,MIG,Migration,I,Phase I,To be performed by CRO ,,,000910,IS - Clin Study (MIGRATED)
9636,0202-0820,202.820,Unconfirmed,529,0202-P00,Efficacy in premenstrual syndrome,Unconfirmed,MIG,Migration,II,Phase II,To be performed by CRO ,,,000910,IS - Clin Study (MIGRATED)
9637,0202-0822,202.822,Unconfirmed,529,0202-P00,Rectal tone and tresholds,Unconfirmed,MIG,Migration,II,Phase II,To be performed by CRO ,,,000910,IS - Clin Study (MIGRATED)
9638,0202-0823,202.823,Unconfirmed,529,0202-P00,Induced esophageal contractions,Unconfirmed,MIG,Migration,II,Phase II,To be performed by CRO ,,,000910,IS - Clin Study (MIGRATED)
9639,0202-0824,202.824,Unconfirmed,529,0202-P00,Pain gas insufflation small intestine,Unconfirmed,MIG,Migration,II,Phase II,To be performed by CRO ,,,000910,IS - Clin Study (MIGRATED)
9640,0202-0825,202.825,Unconfirmed,529,0202-P00,Pain gas production colon,Unconfirmed,MIG,Migration,II,Phase II,To be performed by CRO ,,,000910,IS - Clin Study (MIGRATED)
9641,0202-0826,202.826,Unconfirmed,529,0202-P00,Duodenal contractions ERCP,Unconfirmed,MIG,Migration,II,Phase II,To be performed by CRO ,,,000910,IS - Clin Study (MIGRATED)
9642,0202-0827,202.827,Unconfirmed,529,0202-P00,Post-colonoscopy crampy pain,Unconfirmed,MIG,Migration,II,Phase II,To be performed by CRO ,,,000910,IS - Clin Study (MIGRATED)
9643,0202-0828,202.828,Unconfirmed,529,0202-P00,Proctalgia fugax,Unconfirmed,MIG,Migration,II,Phase II,To be performed by CRO ,,,000910,IS - Clin Study (MIGRATED)
9644,0202-0830,202.830,Unconfirmed,529,0202-P00,Buscopan in colonoscopy,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
9645,0202-0833,202.833,Ended,529,0202-P00,Pharmacokinetics, oral administration,Ended,MIG,Migration,IA,Phase Ia,,2006-004691-12,,000910,IS - Clin Study (MIGRATED)
9646,0202-0838,202.838,Ended,529,0202-P00,Bioequivalence tablets / capsule China,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
9647,0202-0844,202.844,Ended,529,0202-P00,CHC Market Research, NTA UK,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
9648,0202-0845,202.845,Preparing,529,0202-P00,Perfomance of colonoscopy after 20 mg iv,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
9649,0202-0846,202.846,Ended,529,0202-P00,Buscopan pilot BE study,Ended,MIG,Migration,I,Phase I,,2012-003720-20,,000910,IS - Clin Study (MIGRATED)
9650,0202-0847,202.847,Unconfirmed,529,0202-P00,Pivotal bioequivalence study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9651,0202-0848,202.848,Ended,529,0202-P00,Buscopan ampoules registration China,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
9652,0202-0849,202.849,Preparing,529,0202-P00,HBB vs No-Spa in biliary colic-Russia,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
9653,0202-0850,202.850,Ended,529,0202-P00,BE Canada,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9654,0202-0851,202.851,Unconfirmed,529,0202-P00,BUSCAPINA COMP N PASS,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
9655,0220-1301,220.1301,Ended,530,0220-P00,Acceptance-study,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9656,0220-1500,220.1500,Unconfirmed,530,0220-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9657,0220-1501,220.1501,Unconfirmed,530,0220-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9658,0220-1502,220.1502,Unconfirmed,530,0220-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9659,0220-1503,220.1503,Unconfirmed,530,0220-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9660,0220-1504,220.1504,Unconfirmed,530,0220-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9661,0220-1505,220.1505,Unconfirmed,530,0220-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9662,0220-1506,220.1506,Unconfirmed,530,0220-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9663,0220-1507,220.1507,Ended,530,0220-P00,Bronchitis chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9664,0220-1508,220.1508,Unconfirmed,530,0220-P00,Hypersensitivity respiratory,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9665,0220-1509,220.1509,Unconfirmed,530,0220-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9666,0220-1510,220.1510,Unconfirmed,530,0220-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9667,0220-1511,220.1511,Unconfirmed,530,0220-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9668,0220-1512,220.1512,Unconfirmed,530,0220-P00,Bronchitis chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9669,0220-1513,220.1513,Unconfirmed,530,0220-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9670,0220-1514,220.1514,Unconfirmed,530,0220-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9671,0220-1515,220.1515,Unconfirmed,530,0220-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9672,0220-1516,220.1516,Ended,530,0220-P00,COLD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9673,0220-1517,220.1517,Unconfirmed,530,0220-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9674,0220-1518,220.1518,Unconfirmed,530,0220-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9675,0220-1519,220.1519,Unconfirmed,530,0220-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9676,0220-1520,220.1520,Unconfirmed,530,0220-P00,Bronchospasm,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9677,0220-1521,220.1521,Unconfirmed,530,0220-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9678,0220-1522,220.1522,Unconfirmed,530,0220-P00,COLD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9679,0220-1523,220.1523,Unconfirmed,530,0220-P00,Asthma,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9680,0220-1524,220.1524,Unconfirmed,530,0220-P00,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9681,0220-1525,220.1525,Unconfirmed,530,0220-P00,Asthma;Bronchitis chronic,Unconfirmed,MIG,Migration,II,Phase II,- NZ Trial,,,000910,IS - Clin Study (MIGRATED)
9682,0220-1526,220.1526,Unconfirmed,530,0220-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9683,0220-1527,220.1527,Ended,530,0220-P00,COLD,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9684,0220-1528,220.1528,Unconfirmed,530,0220-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9685,0220-1529,220.1529,Unconfirmed,530,0220-P00,COLD,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9686,0220-1530,220.1530,Ended,530,0220-P00,COLD,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9687,0220-1531,220.1531,Ended,530,0220-P00,ASTHMA,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9688,0220-1532,220.1532,Unconfirmed,530,0220-P00,COPD,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9689,0220-1533,220.1533,Unconfirmed,530,0220-P00,Asthma;Cold,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9690,0220-1534,220.1534,Ended,530,0220-P00,Asthma,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9691,0220-1535,220.1535,Ended,530,0220-P00,Comparison of Duovent UD with Salbutamol,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9692,0220-1536,220.1536,Ended,530,0220-P00,Bronchitis, chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9693,0220-1537,220.1537,Unconfirmed,530,0220-P00,Asthma chronic,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9694,0220-1538,220.1538,Ended,530,0220-P00,Seeding study,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9695,0220-1539,220.1539,Ended,530,0220-P00,SAFETY STUDY IN REVERSIBLE AIRWAYS OBSTR,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9696,0220-1540,220.1540,Ended,530,0220-P00,SAFETY STUDY IN REVERSIBLE AIRWAYS OBSTR,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9697,0220-1541,220.1541,Ended,530,0220-P00,Duovent vs. Berotec 100 spray in treatme,Ended,MIG,Migration,IV,Phase IV,- prot. requested (Letter LV/SCH 21.08.92),,,,
9698,0220-1542,220.1542,Ended,530,0220-P00,Duovent MDI Versus Inhalets,Ended,MIG,Migration,III,Phase III,- Clinical Report expected 10/92 (Letter deWet 07.09.92),,,000910,IS - Clin Study (MIGRATED)
9699,0220-1543,220.1543,Ended,530,0220-P00,Bronchitis, chronic,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9700,0220-1544,220.1544,Ended,530,0220-P00,Duovent and Fenoterol in COPD,Ended,MIG,Migration,IV,Phase IV,- ,,,,
9701,0254-0001,254.1,Unconfirmed,531,0254-P00,Coronary disease;Angina-Pectoris,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9702,0254-0002,254.2,Unconfirmed,531,0254-P00,Coronary disease,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9703,0254-0003,254.3,Ended,531,0254-P00,Tachycardia,after catech.,Ended,MIG,Migration,II,Phase II,- Substance development discontinued *,,,000910,IS - Clin Study (MIGRATED)
9704,0254-0004,254.4,Ended,531,0254-P00,Effects of Alinidine on hemodynamics,Ended,MIG,Migration,II,Phase II,- old contract -> I (EWOE, see CTU III/91 letter),,,000910,IS - Clin Study (MIGRATED)
9705,0254-0005,254.5,Ended,531,0254-P00,Coronary disease;Angina-Pectoris,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9706,0254-0006,254.6,Ended,531,0254-P00,Effect of Alinidine on hemodynamy,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9707,0254-0007,254.7,Unconfirmed,531,0254-P00,Infarction myocardial acute,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9708,0254-0008,254.8,Unconfirmed,531,0254-P00,Angina-Pectoris,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9709,0254-0009,254.9,Unconfirmed,531,0254-P00,Tachycardia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9710,0254-0010,254.10,Unconfirmed,531,0254-P00,Infarction myocardial acute hyperkinesis,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9711,0254-0011,254.11,Ended,531,0254-P00,Coronary disease,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9712,0254-0012,254.12,Unconfirmed,531,0254-P00,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9713,0254-0013,254.13,Unconfirmed,531,0254-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9714,0254-0014,254.14,Unconfirmed,531,0254-P00,Angina-Pectoris stable,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9715,0254-0015,254.15,Unconfirmed,531,0254-P00,Coronary disease,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9716,0254-0016,254.16,Unconfirmed,531,0254-P00,Angina-Pectoris stable,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9717,0254-0017,254.17,Unconfirmed,531,0254-P00,none,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9718,0254-0018,254.18,Unconfirmed,531,0254-P00,Renal failure minor,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9719,0254-0019,254.19,Unconfirmed,531,0254-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9720,0254-0020,254.20,Unconfirmed,531,0254-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9721,0254-0021,254.21,Unconfirmed,531,0254-P00,Angina-Pectoris stable;Coronary disease,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9722,0254-0022,254.22,Unconfirmed,531,0254-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9723,0254-0023,254.23,Unconfirmed,531,0254-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9724,0254-0024,254.24,Unconfirmed,531,0254-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9725,0254-0025,254.25,Unconfirmed,531,0254-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9726,0254-0026,254.26,Unconfirmed,531,0254-P00,Angina-Pectoris stable,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9727,0254-0027,254.27,Unconfirmed,531,0254-P00,Angina-Pectoris,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9728,0254-0028,254.28,Ended,531,0254-P00,none,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9729,0254-0029,254.29,Ended,531,0254-P00,Coronary spasm,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9730,0254-0030,254.30,Unconfirmed,531,0254-P00,COLD,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9731,0254-0031,254.31,Unconfirmed,531,0254-P00,CHD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9732,0254-0032,254.32,Unconfirmed,531,0254-P00,Infarction, myocardial, acute,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9733,0254-0033,254.33,Unconfirmed,531,0254-P00,Tachycardia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9734,0254-0034,254.34,Unconfirmed,531,0254-P00,No Legacy Data,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9735,0254-0035,254.35,Unconfirmed,531,0254-P00,Tachycardia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9736,0254-0036,254.36,Unconfirmed,531,0254-P00,Infarction, myocardial, acute,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9737,0254-0037,254.37,Ended,531,0254-P00,Tachycardia,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9738,0254-0038,254.38,Unconfirmed,531,0254-P00,Tachycardia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9739,0254-0039,254.39,Ended,531,0254-P00,Tachycardia,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9740,0254-0040,254.40,Unconfirmed,531,0254-P00,CHD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9741,0254-0041,254.41,Ended,531,0254-P00,Infarction, myocardial,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9742,0254-0042,254.42,Unconfirmed,531,0254-P00,Infarction, myocardial,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9743,0254-0043,254.43,Ended,531,0254-P00,Pharmacokinetics,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9744,0254-0044,254.44,Ended,531,0254-P00,Pharmacokinetics,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9745,0254-0045,254.45,Unconfirmed,531,0254-P00,Pharmacokinetics,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9746,0254-0046,254.46,Ended,531,0254-P00,Angina Pectoris,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9747,0254-0047,254.47,Ended,531,0254-P00,Angina Pectoris,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9748,0254-0048,254.48,Ended,531,0254-P00,Tachycardia,Ended,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9749,0254-0049,254.49,Unconfirmed,531,0254-P00,Arrhythmia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9750,0254-0050,254.50,Ended,531,0254-P00,Dose-response relationship of Alinidine,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9751,0254-0051,254.51,Unconfirmed,531,0254-P00,Tachycardia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9752,0254-0052,254.52,Ended,531,0254-P00,Infarction, myocardial, acute,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9753,0254-0053,254.53,Unconfirmed,531,0254-P00,Infarction, myocardial, acute,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9754,0254-0054,254.54,Unconfirmed,531,0254-P00,Infarction, myocardial, acute,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9755,0254-0055,254.55,Unconfirmed,531,0254-P00,Infarction, myocardial,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9756,0254-0056,254.56,Unconfirmed,531,0254-P00,Angina pectoris, unstable,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9757,0254-0057,254.57,Unconfirmed,531,0254-P00,Angina pectoris, unstable,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9758,0254-0058,254.58,Ended,531,0254-P00,CHD,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9759,0254-0059,254.59,Ended,531,0254-P00,Angina Pectoris,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9760,0254-0060,254.60,Ended,531,0254-P00,Tachycardia,after surgery,Ended,MIG,Migration,II,Phase II,- Substance development discontinued. *,,,000910,IS - Clin Study (MIGRATED)
9761,0254-0061,254.61,Unconfirmed,531,0254-P00,Surgery, cardiac,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9762,0254-0062,254.62,Unconfirmed,531,0254-P00,Surgery, cardiac,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9763,0254-0063,254.63,Unconfirmed,531,0254-P00,Angina, unstable,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9764,0254-0064,254.64,Ended,531,0254-P00,PHARMACOKINETICS,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9765,0254-0065,254.65,Unconfirmed,531,0254-P00,Tachycardia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9766,0254-0066,254.66,Unconfirmed,531,0254-P00,Tachycardia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9767,0254-0067,254.67,Ended,531,0254-P00,Tachycardia,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9768,0254-0068,254.68,Ended,531,0254-P00,ANGINA PECTORIS,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9769,0254-0069,254.69,Ended,531,0254-P00,Tachycardia,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9770,0254-0070,254.70,Unconfirmed,531,0254-P00,COLD,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9771,0254-0071,254.71,Unconfirmed,531,0254-P00,Surgery, cardiac,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9772,0254-0072,254.72,Unconfirmed,531,0254-P00,Tachycardia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9773,0254-0073,254.73,Unconfirmed,531,0254-P00,Tachycardia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9774,0254-0074,254.74,Unconfirmed,531,0254-P00,Tachycardia,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9775,0254-0075,254.75,Ended,531,0254-P00,Sinus tachycardia,Ended,MIG,Migration,II,Phase II,- intenational?,,,000910,IS - Clin Study (MIGRATED)
9776,0254-0076,254.76,Unconfirmed,531,0254-P00,Alinidine in acute Myocardial infarction,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9777,0254-0077,254.77,Unconfirmed,531,0254-P00,Infarction, myocardial, acute,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9778,0254-0078,254.78,Unconfirmed,531,0254-P00,Surgery, cardiac,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9779,0254-0079,254.79,Unconfirmed,531,0254-P00,Surgery, cardiac,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9780,0254-0080,254.80,Unconfirmed,531,0254-P00,Surgery, cardiac,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9781,0254-0081,254.81,Unconfirmed,531,0254-P00,Surgery, cardiac,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9782,0254-0082,254.82,Unconfirmed,531,0254-P00,Angina pectoris, unstable,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9783,0254-0083,254.83,Unconfirmed,531,0254-P00,Angina pectoris, unstable,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9784,0254-0084,254.84,Ended,531,0254-P00,AMI,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9785,0254-0085,254.85,Ended,531,0254-P00,SINUS RHYTHM,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9786,0254-0086,254.86,Ended,531,0254-P00,Surgery, cardiac,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9787,1031-0001,1031.1,Unconfirmed,532,1031-P00,Hypertension moderate,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9788,1031-0002,1031.2,Ended,532,1031-P00,No Legacy Data,Ended,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9789,1031-0003,1031.3,Unconfirmed,532,1031-P00,Hypertension,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9790,1031-0004,1031.4,Unconfirmed,532,1031-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9791,1031-0005,1031.5,Unconfirmed,532,1031-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9792,1031-0006,1031.6,Unconfirmed,532,1031-P00,Hypertension,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9793,1031-0007,1031.7,Unconfirmed,532,1031-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9794,1031-0010,1031.10,Unconfirmed,532,1031-P00,Hypertension,Unconfirmed,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
9795,1031-0011,1031.11,Unconfirmed,532,1031-P00,Hypertension,Unconfirmed,MIG,Migration,II,Phase II,- / trial performed by: BI France Sarl Div. Biotherax/LFT *,,,000910,IS - Clin Study (MIGRATED)
9796,1031-0012,1031.12,Unconfirmed,532,1031-P00,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9797,1031-0013,1031.13,Unconfirmed,532,1031-P00,none,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9798,1031-0014,1031.14,Unconfirmed,532,1031-P00,Hypertension,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9799,1031-0015,1031.15,Unconfirmed,532,1031-P00,Coronary disease,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9800,1031-0016,1031.16,Unconfirmed,532,1031-P00,Hypertension,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9801,1031-0017,1031.17,Unconfirmed,532,1031-P00,Hypertension,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9802,1031-0018,1031.18,Unconfirmed,532,1031-P00,Hypertension mild;Hypertension moderate,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9803,1031-0019,1031.19,Unconfirmed,532,1031-P00,Hypertension,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9804,1031-0021,1031.21,Unconfirmed,532,1031-P00,Angina-Pectoris,Unconfirmed,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9805,1031-0027,1031.27,Unconfirmed,532,1031-P00,none,Unconfirmed,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9806,1071-0001,1071.1,Unconfirmed,533,1071-P02,Asthma,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9807,1071-0002,1071.2,Ended,533,1071-P02,--,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9808,1071-0003,1071.3,Ended,533,1071-P02,--,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9809,1071-0004,1071.4,Ended,533,1071-P02,--,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9810,1071-0005,1071.5,Ended,533,1071-P02,--,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9811,1071-0006,1071.6,Ended,533,1071-P02,--,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9812,1071-0007,1071.7,Ended,533,1071-P02,--,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9813,1071-0008,1071.8,Ended,533,1071-P02,--,Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
9814,1071-0010,1071.10,Ended,533,1071-P02,Theophylline bioavailability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9815,1105-0003,1105.3,Unconfirmed,534,1105-P07,Asthma acute,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9816,1105-0004,1105.4,Unconfirmed,534,1105-P07,Asthma,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9817,1105-0008,1105.8,Unconfirmed,534,1105-P07,Asthma;Cold,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9818,1105-0009,1105.9,Unconfirmed,534,1105-P07,Asthma;Cold,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9819,1105-0011,1105.11,Unconfirmed,534,1105-P07,Asthma acute,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9820,1105-0013,1105.13,Unconfirmed,534,1105-P07,Bronchitis chronic,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9821,1105-0025,1105.25,Ended,534,1105-P07,Asthma,Ended,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9822,1120-0003,1120.3,Ended,535,1120-P02,Eschscholtzia dental pain,Ended,MIG,Migration,II,Phase II,- ,,,000910,IS - Clin Study (MIGRATED)
9823,1029-0001,1029.1,Unconfirmed,536,1029-P01,Arthritis rheumatoid,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9824,1029-0002,1029.2,Unconfirmed,536,1029-P01,Rheumatism;Arthritis,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9825,1029-0003,1029.3,Unconfirmed,536,1029-P01,Arthritis rheumatoid,Unconfirmed,MIG,Migration,III,Phase III,- ,,,000910,IS - Clin Study (MIGRATED)
9826,1029-0004,1029.4,Unconfirmed,536,1029-P01,Spondylitis ankylosing;Arthritis rheumat,Unconfirmed,MIG,Migration,NONE,Not Classified,- ,,,000910,IS - Clin Study (MIGRATED)
9827,1029-0005,1029.5,Unconfirmed,536,1029-P01,Tendosynovitis;Bursitis;Epicondylitis ac,Unconfirmed,MIG,Migration,IV,Phase IV,- ,,,000910,IS - Clin Study (MIGRATED)
9828,1100-1220,1100.1220,Ended,537,1100-P03,HIV eradication protocol,Ended,MIG,Migration,IV,Phase IV,-  DR. LANGE (NETHERLANDS) INVESTIGATOR. No CRF data expected. Investigator to write report.     ,,,,
9829,1100-1221,1100.1221,Ended,537,1100-P03,ACTG 366, f/u to ACTG245,Ended,MIG,Migration,II,Phase II,-  Dr. Burchett Investigator.  Some Suspension, some tablets. Drug approved, payment for virology under discussion. Glaxo pulled out of trial. Plans under review. June 1997, revised protocol submitted with renewed interest to start up in July.   ,,,,
9830,1100-1222,1100.1222,Ended,537,1100-P03,ACTG 356 ZDV/3TC/NVP peds<2yrs,Ended,MIG,Migration,II,Phase II,        ,,,,
9831,1100-1224,1100.1224,Ended,537,1100-P03,Pk d4T/nelfinavir/NVP,Ended,MIG,Migration,I,Phase I,-  Joint funding with Agouron     ,,,000910,IS - Clin Study (MIGRATED)
9832,1100-1232,1100.1232,Ended,537,1100-P03,ACTG 373 (Rollover from ACTG 347),Ended,MIG,Migration,II,Phase II,-  BIPI will supply drugs only (tablets).     ,,,,
9833,1100-1233,1100.1233,Ended,537,1100-P03,ACTG 377 PRAM study,Ended,MIG,Migration,IIA,Phase IIa,-  BIPI will supply drugs only (tablets). Final protocol expected by 7/21. Expect 50 evaluable patients per arm (200 total, Age 4 mo. to 17 yrs) up to 48 weeks of therapy. Nevirapine will potentially be used  in 3 of the 4 arms.   ,,,,
9834,1100-1234,1100.1234,Ended,537,1100-P03,ACTG 341: Pathogenesis of MAC with HAART,Ended,MIG,Migration,IIA,Phase IIa,-  BIPI will supply drugs only (tablets). Lead investigator is Rob McGregor.     ,,,,
9835,1100-1235,1100.1235,Ended,537,1100-P03,HIVNET 012A,Ended,MIG,Migration,III,Phase III,-  BIPI will supply drugs only (tablets). Protocol & monitoring by DAIDS. Lead investigator is Brooks Jackson     ,,,,
9836,1100-1237,1100.1237,Ended,537,1100-P03,Quadruplex Rx,Ended,MIG,Migration,II,Phase II,-  BIPI will supply drugs only to the France OPU. Investigator is Jaques Leibowitch     ,,,,
9837,1100-1238,1100.1238,Ended,537,1100-P03,QD dosing,Ended,MIG,Migration,II,Phase II,Terminated early-Adefovir safety issues BIPI will supply drugs and money. To be conducted n Canada as a collaboration with BMS/Gilead. BIPI splitting the cost of the trial.     ,,,,
9838,1100-1240,1100.1240,Preparing,537,1100-P03,QD vs BID - Argentina,Preparing,MIG,Migration,II,Phase II,-  BIPI will supply drugs only to the Argentina OPU Investigator is D Rouleau     ,,,000910,IS - Clin Study (MIGRATED)
9839,1100-1242,1100.1242,Unconfirmed,537,1100-P03,NIH,Unconfirmed,MIG,Migration,II,Phase II,-  BIPI will supply drugs only Investigator is Robert Yarchoan     ,,,,
9840,1100-1243,1100.1243,Preparing,537,1100-P03,ICC-601,Preparing,MIG,Migration,II,Phase II,-  Monitoring by Parexel Investigator is M. Odorisio     ,,,,
9841,1100-1244,1100.1244,Ended,537,1100-P03,Amprenavir + Abacavir + NVP,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
9842,1100-1245,1100.1245,Ended,537,1100-P03,Oral Contraceptive PK,Ended,MIG,Migration,I,Phase I,        ,,,000910,IS - Clin Study (MIGRATED)
9843,1100-1246,1100.1246,Unconfirmed,537,1100-P03,ACTG 384,Unconfirmed,MIG,Migration,NONE,Not Classified,-  Investigator: Hirsch Merigan     ,,,,
9844,1100-1247,1100.1247,Ended,537,1100-P03,Pk interaction with NVP/ABT-378/RIT,Ended,MIG,Migration,I,Phase I,Abbott Study.  Investigator is T. Japour Investigator is T. Japour     ,,,000910,IS - Clin Study (MIGRATED)
9845,1100-1248,1100.1248,Ended,537,1100-P03,OZCombo2,Ended,MIG,Migration,IV,Phase IV,-  Investigator is D. Cooper     ,,,,
9846,1100-1249,1100.1249,Ended,537,1100-P03,ACTG 338: PRAM I,Ended,MIG,Migration,II,Phase II,-  Investigator is S. Nachman     ,,,,
9847,1100-1251,1100.1251,Ended,537,1100-P03,ACTG 387 PR 168 Concept,Ended,MIG,Migration,IV,Phase IV,-  Investigator is Johnson,M.     ,,,,
9848,1100-1253,1100.1253,Ended,537,1100-P03,bioequivalence study,Ended,MIG,Migration,I,Phase I,-  Investigator is Johnson,M.     ,,,,
9849,1100-1254,1100.1254,Ended,537,1100-P03,d4T+ddl+nvp Era,Ended,MIG,Migration,IV,Phase IV,-  Investigator is Charles B. Hicks     ,,,,
9850,1100-1255,1100.1255,Preparing,537,1100-P03,Induction/Maintenence Study,Preparing,MIG,Migration,IV,Phase IV,-  Induction + Maintenance     ,,,000910,IS - Clin Study (MIGRATED)
9851,1100-1256,1100.1256,Ended,537,1100-P03,ICC Trimeris,Ended,MIG,Migration,II,Phase II,-  T-20 + NVP PK Interaction     ,,,,
9852,1100-1264,1100.1264,Ended,537,1100-P03,NVP+FTC in HIV Naive Pts,Ended,MIG,Migration,I,Phase I,,,,,
9853,1100-1265,1100.1265,Ended,537,1100-P03,ACTG 403 - Peds multiple combination,Ended,MIG,Migration,II,Phase II,-  BIPI will supply drugs only.     ,,,,
9854,1100-1267,1100.1267,Ended,537,1100-P03,1204 CSF Sub-study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9855,1100-1268,1100.1268,Ended,537,1100-P03,1224 Sub-study,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
9856,1100-1271,1100.1271,Ended,537,1100-P03,ABT-378/Ritonavir/nuc/NVP PK,Ended,MIG,Migration,I,Phase I,Abbott Study ,,,,
9857,1100-1273,1100.1273,Unconfirmed,537,1100-P03,NONPRO1,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
9858,1100-1274,1100.1274,Unconfirmed,537,1100-P03,NONPRO2,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
9859,1100-1275,1100.1275,Ended,537,1100-P03,EFV/NVP PK,Ended,MIG,Migration,I,Phase I,,,,,
9860,1100-1276,1100.1276,Ended,537,1100-P03,1229 Viral Dynamics Sub-study,Ended,MIG,Migration,IV,Phase IV,,,,,
9861,1100-1277,1100.1277,Ended,537,1100-P03,1253 NVP QD PK Sub-study,Ended,MIG,Migration,I,Phase I,,,,,
9862,1100-1280,1100.1280,Ended,537,1100-P03,SAQsg/NVP PK,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
9863,1100-1281,1100.1281,Preparing,537,1100-P03,HIVNAT-006,Preparing,MIG,Migration,II,Phase II,,,,,
9864,1100-1285,1100.1285,Ended,537,1100-P03,HIVNET 023 - Breast Feeding Transmission,Ended,MIG,Migration,I,Phase I,,,,,
9865,1100-1297,1100.1297,Ended,537,1100-P03,d4T/ddI/NELF/NVP Triple Arm in Naive Pts,Ended,MIG,Migration,IV,Phase IV,Looks at induction- maintenance strategy for HIV naive patients including NVP or EFV as first line drugs which are maintained as back bone with the 4th drug (PI) is dropped,,,,
9866,1100-1298,1100.1298,Preparing,537,1100-P03,PI 1st line failure - NVP vs EFV,Preparing,MIG,Migration,IV,Phase IV,,,,,
9867,1100-1303,1100.1303,Ended,537,1100-P03,PI or NNRTI Switch Upon Failure,Ended,MIG,Migration,IV,Phase IV,,,,,
9868,1100-1344,1100.1344,Ended,537,1100-P03,ACTG 1007 Multidrug Rx in Trted Peds Pts,Ended,MIG,Migration,I,Phase I,,,,,
9869,1100-1349,1100.1349,Unconfirmed,537,1100-P03,PK and Safety of Dual NNRTI Rx,Unconfirmed,MIG,Migration,I,Phase I,,,,,
9870,1100-1356,1100.1356,Ended,537,1100-P03,Botswana - Harvard MTCT Study,Ended,MIG,Migration,III,Phase III,,,,,
9871,1100-1357,1100.1357,Ended,537,1100-P03,Perinatal HIV Prevention in Thailand,Ended,MIG,Migration,III,Phase III,,,,,
9872,1100-1358,1100.1358,Ended,537,1100-P03,ARES - Open-label, 4-arm,Ended,MIG,Migration,IV,Phase IV,Awaiting P-number of publication. ,,,,
9873,1100-1360,1100.1360,Ended,537,1100-P03,SIMBA,Ended,MIG,Migration,III,Phase III,,,,,
9874,1100-1361,1100.1361,Ended,537,1100-P03,PK interaction fluconazole and NVP,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
9875,1100-1365,1100.1365,Ended,537,1100-P03,Correlation NVP levels plasma vs saliva,Ended,MIG,Migration,I,Phase I,,,,,
9876,1100-1366,1100.1366,Ended,537,1100-P03,LFT changes vs NVP plasma levels,Ended,MIG,Migration,IV,Phase IV,,,,,
9877,1100-1369,1100.1369,Unconfirmed,537,1100-P03,PK validation of 150 mg/m2 dose children,Unconfirmed,MIG,Migration,II,Phase II,,,,,
9878,1100-1371,1100.1371,Ended,537,1100-P03,Peadiatric roll-over study from SIMBA,Ended,MIG,Migration,IV,Phase IV,,,,,
9879,1100-1372,1100.1372,Ended,537,1100-P03,ACTG 5095 - switch EFV to NVP,Ended,MIG,Migration,IV,Phase IV,,,,,
9880,1100-1373,1100.1373,Ended,537,1100-P03,ACTG 5110 - reversal lipoatrophy of NRTI,Ended,MIG,Migration,IV,Phase IV,,,,,
9881,1100-1382,1100.1382,Ended,537,1100-P03,MTCTantibiotic treatment plus NVP/HIV024,Ended,MIG,Migration,III,Phase III,,,,,
9882,1100-1384,1100.1384,Unconfirmed,537,1100-P03,Metabolic and immune aspects SJS & TEN,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,,
9883,1100-1385,1100.1385,Unconfirmed,537,1100-P03,Immunological mech. of hepatitis,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,,
9884,1100-1386,1100.1386,Unconfirmed,537,1100-P03,Pharmaco-epidemio study : livertox,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
9885,1100-1387,1100.1387,Unconfirmed,537,1100-P03,Baseline phenotype and clinical response,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
9886,1100-1388,1100.1388,Ended,537,1100-P03,Athena cohort liver tox NVP,Ended,MIG,Migration,IV,Phase IV,,,,,
9887,1100-1389,1100.1389,Ended,537,1100-P03,Methadone PK interaction (pilot),Ended,MIG,Migration,IV,Phase IV,Data to be collected retrospectively. ,,,,
9888,1100-1390,1100.1390,Ended,537,1100-P03,Methadone PK interaction,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
9889,1100-1391,1100.1391,Ended,537,1100-P03, PACTG P1022 NVP vs NFV in preg. women,Ended,MIG,Migration,III,Phase III,,,,,
9890,1100-1392,1100.1392,Ended,537,1100-P03,ACTG 5093,Ended,MIG,Migration,IV,Phase IV,,,,,
9891,1100-1394,1100.1394,Preparing,537,1100-P03,PI vs NVP vs ABC in switch (Viragen),Preparing,MIG,Migration,III,Phase III,,,,,
9892,1100-1397,1100.1397,Ended,537,1100-P03,HPTN 040 Intrapartum Prev.,Ended,MIG,Migration,IV,Phase IV,No DMU - no data in house ,,,,
9893,1100-1398,1100.1398,Ended,537,1100-P03,HPTN 046 prevent MTCT in breastfeeding,Ended,MIG,Migration,III,Phase III,Sponsor of trial is DAIDS -no DMU needed ,,,,
9894,1100-1408,1100.1408,Ended,537,1100-P03,Montaner NVP effect on Lipids in PIs,Ended,MIG,Migration,IV,Phase IV,,,,,
9895,1100-1409,1100.1409,Ended,537,1100-P03,Montaner-Abbot:Nuc Sparing w Kaletra,Ended,MIG,Migration,IV,Phase IV,,,,,
9896,1100-1410,1100.1410,Ended,537,1100-P03,Conway Dot Study,Ended,MIG,Migration,IV,Phase IV,,,,,
9897,1100-1411,1100.1411,Preparing,537,1100-P03,Peters-Lipids w Kaletra/NVP vs CBV/NVP,Preparing,MIG,Migration,IV,Phase IV,,,,,
9898,1100-1412,1100.1412,Ended,537,1100-P03,Immune Response w/ NVP/TZV,Ended,MIG,Migration,IV,Phase IV,,,,,
9899,1100-1413,1100.1413,Ended,537,1100-P03,MTCT TOPS - NVP+ CBV,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
9900,1100-1414,1100.1414,Ended,537,1100-P03,Late Response to MTCT - NVP+CBV,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
9901,1100-1415,1100.1415,Ended,537,1100-P03,NNRTI Resistance Surveillance - S Africa,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
9902,1100-1417,1100.1417,Preparing,537,1100-P03,Brutus - Mod ARV Rx - Lipid Abnorm.,Preparing,MIG,Migration,IV,Phase IV,,,,,
9903,1100-1418,1100.1418,Ended,537,1100-P03,Higgins - Mod. ARV Rx - Lipid Abnorm.,Ended,MIG,Migration,IV,Phase IV,,,,,
9904,1100-1419,1100.1419,Ended,537,1100-P03,Montana - Mod. ARV Rx - Lipid Abnorn.,Ended,MIG,Migration,IV,Phase IV,,,,,
9905,1100-1420,1100.1420,Preparing,537,1100-P03,Glaser - NVP as Alternative Rx,Preparing,MIG,Migration,IV,Phase IV,,,,,
9906,1100-1421,1100.1421,Ended,537,1100-P03,Lymphocite Proliferation,Ended,MIG,Migration,IV,Phase IV,,,,,
9907,1100-1422,1100.1422,Ended,537,1100-P03,Mitochondrial Toxicity,Ended,MIG,Migration,IV,Phase IV,,,,,
9908,1100-1423,1100.1423,Unconfirmed,537,1100-P03,Reactive Metabolites Analyisis (1090 Sa),Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
9909,1100-1424,1100.1424,Ended,537,1100-P03,Nevirapine FTC Tenofovir  Study,Ended,MIG,Migration,IV,Phase IV,,,,,
9910,1100-1425,1100.1425,Unconfirmed,537,1100-P03,Nevirapine Atazanavir PK Study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
9911,1100-1426,1100.1426,Ended,537,1100-P03,N.I.L.E. Study,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
9912,1100-1427,1100.1427,Unconfirmed,537,1100-P03,P.R.O.T.O.N.S. Study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
9913,1100-1428,1100.1428,Unconfirmed,537,1100-P03,Lipid Profiling Study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
9914,1100-1429,1100.1429,Ended,537,1100-P03,NVP Switch in NNRTI-Naive Pts,Ended,MIG,Migration,IV,Phase IV,,,,,
9915,1100-1430,1100.1430,Ended,537,1100-P03,D.A.R.T.,Ended,MIG,Migration,IV,Phase IV,MRC study Drug supply only ,,,,
9916,1100-1431,1100.1431,Ended,537,1100-P03,PACTG 1032,Ended,MIG,Migration,IV,Phase IV,,,,,
9917,1100-1432,1100.1432,Unconfirmed,537,1100-P03,NVP/TFV PK Interaction,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
9918,1100-1433,1100.1433,Ended,537,1100-P03,AUC Variations of Nevirapine by Weight,Ended,MIG,Migration,IV,Phase IV,,,,,
9919,1100-1434,1100.1434,Ended,537,1100-P03,REGISCAR,Ended,MIG,Migration,IV,Phase IV,,,,,
9920,1100-1435,1100.1435,Ended,537,1100-P03,SIROCCO,Ended,MIG,Migration,IV,Phase IV,,,,,
9921,1100-1436,1100.1436,Ended,537,1100-P03,FOTOV,Ended,MIG,Migration,IV,Phase IV,,,,,
9922,1100-1437,1100.1437,Preparing,537,1100-P03,AIEDRP QD HARTin Zambia,Preparing,MIG,Migration,IV,Phase IV,,,,,
9923,1100-1438,1100.1438,Ended,537,1100-P03,NVP vs. PI HAART Impact on HDL,Ended,MIG,Migration,IV,Phase IV,,,,,
9924,1100-1439,1100.1439,Ended,537,1100-P03,Peri HAART in Kenya/KiBS,Ended,MIG,Migration,IV,Phase IV,CDC sponsored in Kenya (KiBS) ,,,,
9925,1100-1440,1100.1440,Ended,537,1100-P03,EFV Switch to NVP,Ended,MIG,Migration,IV,Phase IV,,,,,
9926,1100-1441,1100.1441,Ended,537,1100-P03,NVP-Induced Mutations in HIV Pts on NVP,Ended,MIG,Migration,IV,Phase IV,,,,,
9927,1100-1442,1100.1442,Ended,537,1100-P03,Eval SubCl Atherosclerosis/Long-Term NVP,Ended,MIG,Migration,IV,Phase IV,,,,,
9928,1100-1448,1100.1448,Ended,537,1100-P03,NVP Levels in Hepatically Impaired Pts,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
9929,1100-1449,1100.1449,Ended,537,1100-P03,HPTN 052,Ended,MIG,Migration,III,Phase III,,,,,
9930,1100-1450,1100.1450,Preparing,537,1100-P03,Mitocare Trial,Preparing,MIG,Migration,IV,Phase IV,Study cancelled ,,,,
9931,1100-1451,1100.1451,Ended,537,1100-P03,Maternal-Infant Health HIV Interventions,Ended,MIG,Migration,IV,Phase IV,Trial conducted by UNC/CDC. BAN ,,,,
9932,1100-1452,1100.1452,Ended,537,1100-P03, NVP Case/Control Toxicogenomics Study,Ended,MIG,Migration,IV,Phase IV,REmoved from the registry 2009 ,2005-004321-26,,000910,IS - Clin Study (MIGRATED)
9933,1100-1453,1100.1453,Unconfirmed,537,1100-P03,PI or EFV Switch to NVP,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
9934,1100-1454,1100.1454,Ended,537,1100-P03,2NN LT F-U,Ended,MIG,Migration,IV,Phase IV,,2004-000623-16,,,
9935,1100-1455,1100.1455,Unconfirmed,537,1100-P03,2NN Early Lipid Changes,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
9936,1100-1456,1100.1456,Unconfirmed,537,1100-P03,HAART MTCT Prevention (NIH),Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
9937,1100-1457,1100.1457,Ended,537,1100-P03,PMS Mexico,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
9938,1100-1458,1100.1458,Preparing,537,1100-P03,PREVIHNE3-GESIDA,Preparing,MIG,Migration,IV,Phase IV,,,,,
9939,1100-1459,1100.1459,Ended,537,1100-P03,MULTINEKA,Ended,MIG,Migration,IV,Phase IV,,,,,
9940,1100-1460,1100.1460,Preparing,537,1100-P03,ESPADA,Preparing,MIG,Migration,IV,Phase IV,,,,,
9941,1100-1461,1100.1461,Ended,537,1100-P03,QUALVI,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
9942,1100-1462,1100.1462,Preparing,537,1100-P03,PMS-Peru-VIRAMUNE,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
9943,1100-1463,1100.1463,Preparing,537,1100-P03,EFV Switch to NVP,Preparing,MIG,Migration,IV,Phase IV,IIR Study funded by BI Canada Marketing ,,,,
9944,1100-1464,1100.1464,Ended,537,1100-P03,DAUFIN,Ended,MIG,Migration,III,Phase III,,,,,
9945,1100-1465,1100.1465,Preparing,537,1100-P03,TENEVA,Preparing,MIG,Migration,IV,Phase IV,,,,,
9946,1100-1466,1100.1466,Ended,537,1100-P03,HEPATOX,Ended,MIG,Migration,IV,Phase IV,,,,,
9947,1100-1467,1100.1467,Ended,537,1100-P03,NODy,Ended,MIG,Migration,IV,Phase IV,,,,,
9948,1100-1468,1100.1468,Ended,537,1100-P03,TRIMUNE,Ended,MIG,Migration,IV,Phase IV,,,,,
9949,1100-1469,1100.1469,Preparing,537,1100-P03,NELFINE,Preparing,MIG,Migration,IV,Phase IV,,,,,
9950,1100-1470,1100.1470,Ended,537,1100-P03,ARTEN,Ended,MIG,Migration,IIIB,Phase IIIb,,2005-004330-40,,000910,IS - Clin Study (MIGRATED)
9951,1100-1471,1100.1471,Ended,537,1100-P03,VIHDASEX,Ended,MIG,Migration,IV,Phase IV,,,,,
9952,1100-1472,1100.1472,Ended,537,1100-P03,D.O.T.,Ended,MIG,Migration,IV,Phase IV,,,,,
9953,1100-1473,1100.1473,Ended,537,1100-P03,NVP for CTAP,Ended,MIG,Migration,NONE,Not Classified,donation program to provide Nevirapine donation program to provide Nevirapine to Cambodian patients,,,000500,Compassionate Use Program (CUP)
9954,1100-1474,1100.1474,Ended,537,1100-P03,RI.CO,Ended,MIG,Migration,IV,Phase IV,,,,,
9955,1100-1475,1100.1475,Ended,537,1100-P03,VENICE,Ended,MIG,Migration,IV,Phase IV,,,,,
9956,1100-1476,1100.1476,Ended,537,1100-P03,GEPETO,Ended,MIG,Migration,IV,Phase IV,,,,,
9957,1100-1477,1100.1477,Preparing,537,1100-P03,Mallolas,Preparing,MIG,Migration,IV,Phase IV,,,,,
9958,1100-1478,1100.1478,Preparing,537,1100-P03,COMETA,Preparing,MIG,Migration,IV,Phase IV,,,,,
9959,1100-1479,1100.1479,Preparing,537,1100-P03,CIPRA Project 4,Preparing,MIG,Migration,IV,Phase IV,,,,,
9960,1100-1480,1100.1480,Preparing,537,1100-P03,CHARM LTF,Preparing,MIG,Migration,IV,Phase IV,,,,,
9961,1100-1481,1100.1481,Ended,537,1100-P03,Oxidant Stress,Ended,MIG,Migration,IV,Phase IV,,,,,
9962,1100-1482,1100.1482,Ended,537,1100-P03,A5207/Comp. 3 ARV Txs. to Red. NVP Resi.,Ended,MIG,Migration,IV,Phase IV,,,,,
9963,1100-1487,1100.1487,Ended,537,1100-P03,A5208/OCTANE,Ended,MIG,Migration,IV,Phase IV,,,,,
9964,1100-1488,1100.1488,Ended,537,1100-P03,PACTG P1060,Ended,MIG,Migration,II,Phase II,,,,,
9965,1100-1491,1100.1491,Ended,537,1100-P03,CIPRA TH001,Ended,MIG,Migration,IV,Phase IV,,,,,
9966,1100-1493,1100.1493,Ended,537,1100-P03,PEDSA,Ended,MIG,Migration,IV,Phase IV,,,,,
9967,1100-1494,1100.1494,Ended,537,1100-P03,ProCaViNa,Ended,MIG,Migration,IV,Phase IV,,,,,
9968,1100-1495,1100.1495,Ended,537,1100-P03,NEVIATAZ,Ended,MIG,Migration,IV,Phase IV,,,,,
9969,1100-1497,1100.1497,Preparing,537,1100-P03,Viramune Revitalization Project,Preparing,MIG,Migration,NONE,Not Classified,This is a survey. In CTMS to allow solicited reporting.,,,000600,Survey Patient Questionnaire
9970,1100-1500,1100.1500,Ended,537,1100-P03,Meta-Analysis,Ended,MIG,Migration,IV,Phase IV,,,,,
9971,1100-1501,1100.1501,Preparing,537,1100-P03,NEVAT,Preparing,MIG,Migration,IV,Phase IV,Must comply/w BI-approved CD4 parameters ,,,,
9972,1100-1502,1100.1502,Ended,537,1100-P03,NADIR-02 SNODO,Ended,MIG,Migration,IIIB,Phase IIIb,,2006-002582-39,,,
9973,1100-1504,1100.1504,Ended,537,1100-P03,LPV/r Switch to ATV/r or NVP-based Rx,Ended,MIG,Migration,IV,Phase IV,,2006-006716-30,,,
9974,1100-1505,1100.1505,Preparing,537,1100-P03,ALUMNI,Preparing,MIG,Migration,IV,Phase IV,,,,,
9975,1100-1506,1100.1506,Unconfirmed,537,1100-P03,NEVIH,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
9976,1100-1507,1100.1507,Ended,537,1100-P03,TOSCANA,Ended,MIG,Migration,IV,Phase IV,,,,,
9977,1100-1508,1100.1508,Unconfirmed,537,1100-P03,3TC/NVP/TDF vs. 3TC/EFV/TDF,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
9978,1100-1509,1100.1509,Ended,537,1100-P03,CogNaive,Ended,MIG,Migration,IV,Phase IV,,2007-002405-47,,,
9979,1100-1510,1100.1510,Ended,537,1100-P03,Nuke Sparing,Ended,MIG,Migration,IV,Phase IV,,,,,
9980,1100-1512,1100.1512,Ended,537,1100-P03,NVP vs boosted Atazanavir/NEwArT,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
9981,1100-1513,1100.1513,Preparing,537,1100-P03,TDF/FTC/NVP vs 2-dose NVP Prev. MTCT HIV,Preparing,MIG,Migration,III,Phase III,NIAID sponsored study ,,,,
9982,1100-1514,1100.1514,Ended,537,1100-P03,Trianon genomic sub-analysis,Ended,MIG,Migration,IV,Phase IV,Retrospective Sub-analysis of TRIANON ,,,,
9983,1100-1515,1100.1515,Ended,537,1100-P03,PHPT-5,Ended,MIG,Migration,IV,Phase IV,,,,,
9984,1100-1516,1100.1516,Ended,537,1100-P03,Effects of NVP and EFV on adipocytes,Ended,MIG,Migration,IV,Phase IV,,,,,
9985,1100-1519,1100.1519,Ended,537,1100-P03,Lymphocyte Elispot Assay,Ended,MIG,Migration,IV,Phase IV,,,,,
9986,1100-1520,1100.1520,Ended,537,1100-P03,Winston Data Collection,Ended,MIG,Migration,IV,Phase IV,,,,,
9987,1100-1521,1100.1521,Ended,537,1100-P03,Taylor Data Collection,Ended,MIG,Migration,IV,Phase IV,,,,,
9988,1100-1522,1100.1522,Ended,537,1100-P03,PSYCONEV Study,Ended,MIG,Migration,IV,Phase IV,,,,,
9989,1100-1523,1100.1523,Ended,537,1100-P03,Depression Study: Detecting and Treating,Ended,MIG,Migration,IV,Phase IV,,,,,
9990,1100-1524,1100.1524,Ended,537,1100-P03,PMS with Viramune plus ARV,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
9991,1100-1525,1100.1525,Ended,537,1100-P03,BIOCOMBO II,Ended,MIG,Migration,IV,Phase IV,,,,,
9992,1100-1528,1100.1528,Ended,537,1100-P03,NEVADA,Ended,MIG,Migration,IV,Phase IV,,,,,
9993,1100-1529,1100.1529,Ended,537,1100-P03,NVP + NRTIs - LPV/r + NRTIs,Ended,MIG,Migration,IV,Phase IV,,,,,
9994,1100-1530,1100.1530,Ended,537,1100-P03,CONNECT Study,Ended,MIG,Migration,IV,Phase IV,,,,,
9995,1100-1532,1100.1532,Ended,537,1100-P03,NELT,Ended,MIG,Migration,IV,Phase IV,Retrospective, multicenter, descriptive ,,,,
9996,1100-1533,1100.1533,Ended,537,1100-P03,VIRA-C,Ended,MIG,Migration,IV,Phase IV,Retrospective, observational cohort ,,,,
9997,1100-1535,1100.1535,Ended,537,1100-P03,Nevirapine long-term durability,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
9998,1100-1536,1100.1536,Ended,537,1100-P03,Viramune, gender specific evaluation,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
9999,1100-1537,1100.1537,Unconfirmed,537,1100-P03,PACTG 1077/PROMISE,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
10000,1100-1538,1100.1538,Ended,537,1100-P03,NEVICOR,Ended,MIG,Migration,IV,Phase IV,,,,,
10001,1100-1540,1100.1540,Ended,537,1100-P03,NVP +TDF/FTC vs. EFV + TDF/FTC,Ended,MIG,Migration,IV,Phase IV,,,,,
10002,1100-1541,1100.1541,Analysis,537,1100-P03,NVP on HCV,Analysis,MIG,Migration,IV,Phase IV,,,,,
10003,1100-1542,1100.1542,Ended,537,1100-P03,Residual Viremia: TDF+FTC+NVP or EFV,Ended,MIG,Migration,IV,Phase IV,,,,,
10004,1100-1543,1100.1543,Preparing,537,1100-P03,Sleep Distrubance Prevalence in HIV+ Pts,Preparing,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
10005,1100-1544,1100.1544,Ended,537,1100-P03,NVP Dose Escalation,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
10006,1100-1545,1100.1545,Ended,537,1100-P03,RELAX Study,Ended,MIG,Migration,IV,Phase IV,,,,,
10007,1100-1546,1100.1546,Ended,537,1100-P03,KIVI Study,Ended,MIG,Migration,IV,Phase IV,,,,,
10008,1100-1547,1100.1547,Ended,537,1100-P03,NVP-DBS,Ended,MIG,Migration,IV,Phase IV,,,,,
10009,1100-1548,1100.1548,Ended,537,1100-P03,Residual Viraemia Study,Ended,MIG,Migration,IV,Phase IV,,,,000930,NISed - Study (MIGRATED)
10010,1100-1549,1100.1549,Unconfirmed,537,1100-P03,NVP Hypersensitivity,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,,
10011,1100-1550,1100.1550,Ended,537,1100-P03,NVP XR PMS,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
10012,1168-0001,1168.1,Preparing,543,1168-P01,Efficacy and Safety in Acute Diarrhoea,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10013,1169-0001,1169.1,Ended,545,1169-P01,ORLAAM implementation in primary care,Ended,MIG,Migration,III,Phase III,- ,,,,
10014,1170-0001,1170.1,Ended,546,1170-P01,Phase I dose escalation in HNSCC (MAG3),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10015,1170-0002,1170.2,Ended,546,1170-P01,Phase I uptake in Breast cancer (MAG3),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10016,1170-0003,1170.3,Ended,546,1170-P01,Phase I uptake in NSCLC (MAG3),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10017,1170-0004,1170.4,Preparing,546,1170-P01,Phase II BIWA4 in HNSCC (EU),Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10018,1170-0005,1170.5,Preparing,546,1170-P01,Phase II BIWA4 in HNSCC (USA),Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10019,1170-0006,1170.6,Unconfirmed,546,1170-P01,Phase I BIWA4+Taxol in Breast ca.(USA),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10020,1170-0007,1170.7,Preparing,546,1170-P01,Phase II BIWA4+Taxol in Breast ca (USA),Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10021,1170-0008,1170.8,Preparing,546,1170-P01,Phase II BIWA 4 in NSCLC (EU),Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10022,1170-0009,1170.9,Preparing,546,1170-P01,Phase II BIWA 4 in NSCLC (USA),Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10023,1170-0010,1170.10,Preparing,546,1170-P01,Phase I BIWA 4 in H & N Cancer (EU),Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10024,1170-0011,1170.11,Initiated,546,1170-P01,Phase I BIWA 4 in NSCLC (EU),Initiated,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10025,1170-0012,1170.12,Preparing,546,1170-P01,Safety and efficacy of repeated BIWA4,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10026,1170-0013,1170.13,Preparing,546,1170-P01,Phase I BIWA4 + Taxol in HNSCC (EU),Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10027,1170-0014,1170.14,Preparing,546,1170-P01,Phase I BIWA4 + Taxol in NSCLC (EU),Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10028,1170-0015,1170.15,Preparing,546,1170-P01,Phase II BIWA 4 + Taxol in HNSCC (EU),Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10029,1170-0016,1170.16,Preparing,546,1170-P01,Phase II BIWA 4 + Taxol in NSCLC (EU),Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10030,1170-0017,1170.17,Unconfirmed,546,1170-P01,Phase III H&N ca at risk of relapse (EU),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10031,1170-0018,1170.18,Unconfirmed,546,1170-P01,Phase III NSCLC at risk of relapse (EU),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10032,1170-0019,1170.19,Unconfirmed,546,1170-P01,Phase III H&N risk of relapse+Taxol(USA),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10033,1170-0020,1170.20,Unconfirmed,546,1170-P01,Phase III NSCLC risk of relap+Taxol(USA),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10034,0262-0252,262.252,Ended,547,0262-P01,Bioequivalence tabl./syrup,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10035,0262-0253,262.253,Ended,548,0262-P02,Epinastine vs.loratadine syrup children,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10036,0262-0257,262.257,Unconfirmed,548,0262-P02,Pharmacokinetic in children,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10037,0262-0266,262.266,Unconfirmed,548,0262-P02,Pediatric patients with asthma,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10038,0262-0254,262.254,Ended,549,0262-P03,Epinast. vs. Epinast./Pseudoephedrin,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10039,0262-0255,262.255,Ended,549,0262-P03,Epinastine+Pseudoephedrine: PKN,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10040,0262-0256,262.256,Preparing,549,0262-P03,Epinastine+Pseudoephedrine,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10041,1172-0001,1172.1,Ended,551,1172-P01,Stress Incontinence,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10042,1172-0002,1172.2,Ended,551,1172-P01,Single rising dose in H.V.-males+females,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10043,1172-0003,1172.3,Preparing,551,1172-P01,Multiple rising dose, H.V.-males+females,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10044,1172-0004,1172.4,Unconfirmed,551,1172-P01,Single rising dose in female HV,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10045,1172-0005,1172.5,Unconfirmed,551,1172-P01,Multiple dose in female HV,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10046,1172-0006,1172.6,Unconfirmed,551,1172-P01,Cross-over bioavailability,  HV,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10047,1172-0007,1172.7,Unconfirmed,551,1172-P01,Dose finding in female patients,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10048,1172-0008,1172.8,Preparing,551,1172-P01,Proof of concept,Preparing,MIG,Migration,IIA,Phase IIa,Dose dependent upon Phase I study ,,,000910,IS - Clin Study (MIGRATED)
10049,1172-0009,1172.9,Preparing,551,1172-P01,Single rising dose i.v. in H.V.,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10050,1172-0010,1172.10,Unconfirmed,551,1172-P01,Multiple rising dose i.v. in H.V.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10051,1172-0011,1172.11,Preparing,551,1172-P01,Proof of concept study, i.v.,Preparing,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10052,1159-0001,1159.1,Unconfirmed,552,1159-P01,Single Rising Dose S.C.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10053,1159-0002,1159.2,Unconfirmed,552,1159-P01,Multiple Rising Dose S.C.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10054,1159-0003,1159.3,Unconfirmed,552,1159-P01,s.c. PK profile in orthop-surgery pts,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10055,1173-0001,1173.1,Ended,554,1173-P01,Oral single rising dose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10056,1173-0002,1173.2,Ended,554,1173-P01,Pharmacokinetics of the components,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10057,1173-0003,1173.3,Ended,554,1173-P01,PK and QT dispersion in hypertensive pat,Ended,MIG,Migration,II,Phase II,by Glaxo-Wellcome, study no. TLA 1003 ,,,000910,IS - Clin Study (MIGRATED)
10058,1173-0004,1173.4,Preparing,554,1173-P01,Dose finding,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10059,1173-0005,1173.5,Preparing,554,1173-P01,Longterm safety,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10060,1173-0006,1173.6,Ended,554,1173-P01,Bioavailability of FDC vs. single subst.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10061,1149-0031,1149.31,Ended,555,1149-P02,Safety and Tolerability: subcutaneous,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10062,1149-0032,1149.32,Preparing,555,1149-P02,SC:Safety, Tolerability, Efficacy in pts,Preparing,MIG,Migration,II,Phase II,1dose,self-admin at home during H/A. ,,,000910,IS - Clin Study (MIGRATED)
10063,1149-0033,1149.33,Unconfirmed,555,1149-P02,PK Bridging study for  devices,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10064,1149-0039,1149.39,Preparing,555,1149-P02,Safety, tolerability: new subcut,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10065,1149-0037,1149.37,Ended,556,1149-P03,Safety/ tolerability/PK: inhalative form,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10066,1149-0038,1149.38,Unconfirmed,556,1149-P03,Ih: Safety tolerability, efficacy in Pts,Unconfirmed,MIG,Migration,II,Phase II,formulation will be base; active control ,,,000910,IS - Clin Study (MIGRATED)
10067,1149-0040,1149.40,Unconfirmed,556,1149-P03,Safety/tol./PK: inhal form/new excipient,Unconfirmed,MIG,Migration,I,Phase I,-lactose excipient and plastic calpsule ,,,000910,IS - Clin Study (MIGRATED)
10068,1149-0042,1149.42,Unconfirmed,556,1149-P03,Safety/tolerability/PK: ih/Japan,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10069,1149-0044,1149.44,Ended,556,1149-P03,Safety/Tolerability/PK:SD BIBN 4096 BS,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10070,1149-0045,1149.45,Unconfirmed,556,1149-P03,Safety/Tolerability/PK:SD BIBN CL,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10071,1149-0046,1149.46,Unconfirmed,556,1149-P03,SD  Inhlative :Poc  in Aura,Unconfirmed,MIG,Migration,IIB,Phase IIb,Formulation will  be Base ,,,000910,IS - Clin Study (MIGRATED)
10072,1149-0047,1149.47,Unconfirmed,556,1149-P03,ADME trial,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10073,0605-0001,605.1,Ended,557,0605-P01,Phase Ia: PK Study for BILN 2061,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10074,0605-0002,605.2,Preparing,557,0605-P01,Multiple escalating doses for 2w in HV,Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10075,0605-0003,605.3,Unconfirmed,557,0605-P01,Pivotal - Combination 2061/PegIFN/RBV NR,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
10076,0605-0004,605.4,Preparing,557,0605-P01,Bioavailability of two oral formulations,Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10077,0605-0005,605.5,Ended,557,0605-P01,Ultra short term PK/PD study,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10078,0605-0006,605.6,Preparing,557,0605-P01,Interaction study with Peg IFN in HV,Preparing,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10079,0605-0007,605.7,Preparing,557,0605-P01,Interaction with Peg IFN / RBV in HCVNaive Patients,Preparing,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10080,0605-0008,605.8,Preparing,557,0605-P01,Multiple dose 4 wk mono in HCV patients,Preparing,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10081,0605-0009,605.9,Ended,557,0605-P01,Ultra short term PK/PD in cirrhotics,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10082,0605-0010,605.10,Unconfirmed,557,0605-P01,Pretreatment f/by PegIFN/RBV HCV NRs,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
10083,0605-0011,605.11,Unconfirmed,557,0605-P01,BILN 2061 C14 ADME,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10084,0605-0012,605.12,Unconfirmed,557,0605-P01,Pivotal-Combo 2061+PegIFN+RBV Naive,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10085,0605-0013,605.13,Unconfirmed,557,0605-P01,Pivotal - Monotherapy in HCV NRs,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
10086,0605-0014,605.14,Preparing,557,0605-P01,Monotherapy Dose & Duration Exploratory HCV NRs,Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
10087,0605-0015,605.15,Unconfirmed,557,0605-P01,Biln2061 Interaction - Antacids and PPI,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10088,0605-0016,605.16,Unconfirmed,557,0605-P01,Combination 2061+PegIFN+RBV in HCV Naive,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10089,0605-0017,605.17,Unconfirmed,557,0605-P01,Combination Dose & Duration Exploratory HCV NRs,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10090,0605-0018,605.18,Unconfirmed,557,0605-P01,Pediatric HCV single dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10091,0605-0019,605.19,Unconfirmed,557,0605-P01,Pediatric HCV multi dose,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10092,0605-0020,605.20,Unconfirmed,557,0605-P01,Liver transplant patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10093,0605-0021,605.21,Preparing,557,0605-P01,Single escalating dose in Japanese HV,Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10094,0605-0022,605.22,Unconfirmed,557,0605-P01,Bioavailability 2 formul. (Japanese HV),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10095,0605-0023,605.23,Unconfirmed,557,0605-P01,Multi escalating dose (Japanese HIV),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10096,0605-0024,605.24,Unconfirmed,557,0605-P01,Food Effect (Japan Volunteers),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10097,0605-0025,605.25,Ended,557,0605-P01,PEG400-ethanol x 4weeks in healthy volun,Ended,MIG,Migration,IA,Phase Ia,PPD trial CRO ,,,000300,IS - Methodological Studies
10098,0605-0026,605.26,Preparing,557,0605-P01,MD 2,4 wks safety/PK in HCV pts,Preparing,MIG,Migration,IIA,Phase IIa,Replaces Study 605.8 ,,,000910,IS - Clin Study (MIGRATED)
10099,0605-0027,605.27,Unconfirmed,557,0605-P01,Interaction 2061 +1941 (or other),Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10100,0605-0028,605.28,Unconfirmed,557,0605-P01,Intensive ECG Healthy Volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10101,0543-0015,543.15,Initiated,558,0543-P02,Neutrophil Trafficking,Initiated,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10102,0543-0027,543.27,Ended,558,0543-P02,3 mth therapy BIIL 284 BS in RA,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10103,0543-0029,543.29,Unconfirmed,558,0543-P02,Single-dose Study in Normal Volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10104,0543-0030,543.30,Unconfirmed,558,0543-P02,Multiple-dose Study in Normal Volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10105,0543-0032,543.32,Unconfirmed,558,0543-P02,Food Effect Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10106,0543-0035,543.35,Preparing,558,0543-P02,BIIL 284 BS Long-term safety study in RA,Preparing,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
10107,0543-0046,543.46,Unconfirmed,558,0543-P02,BIIL 284 vs Placebo on top of MTX in RA,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10108,0543-0047,543.47,Unconfirmed,558,0543-P02,BIIL 284 in active RA despite anti-TNF,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10109,0543-0048,543.48,Unconfirmed,558,0543-P02,Dose proportionality study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10110,0543-0049,543.49,Preparing,558,0543-P02,Safety, tolerability and PK,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10111,0543-0050,543.50,Unconfirmed,558,0543-P02,BIIL 284 vs Leflunomide,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10112,0262-0194,262.194,Ended,559,0262-P04,Phase I study (single administration),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
10113,0262-0195,262.195,Ended,559,0262-P04,Phase I study (multiple administration),Ended,MIG,Migration,I,Phase I,- ,,,000910,IS - Clin Study (MIGRATED)
10114,0262-0229,262.229,Ended,559,0262-P04,Safety of Epinastine eye drops,Ended,MIG,Migration,IIIB,Phase IIIb,- ,,,000910,IS - Clin Study (MIGRATED)
10115,0262-0278,262.278,Unconfirmed,559,0262-P04,WAL801 Eye-drop Phase III DBT,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10116,0262-0279,262.279,Unconfirmed,559,0262-P04,WAL801 Eye-drop PD study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10117,1175-0001,1175.1,Ended,560,1175-P01,Escalated single oral doses of BIRB 796,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10118,1175-0002,1175.2,Preparing,560,1175-P01,Single Rising Dose above Trial 1175.1,Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10119,1175-0003,1175.3,Ended,560,1175-P01,Rising Multiple Doses,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10120,1175-0004,1175.4,Ended,560,1175-P01,I.V. Endotoxin Challenge,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10121,1175-0005,1175.5,Unconfirmed,560,1175-P01,LacTabl./BCD  Bioequiv. plus Food Effect,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10122,1175-0006,1175.6,Ended,560,1175-P01,C14 Metabolism,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10123,1175-0007,1175.7,Unconfirmed,560,1175-P01,Drug Interaction,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10124,1175-0008,1175.8,Unconfirmed,560,1175-P01,Endotox. Inhal. Challenge Health. Volun.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10125,1175-0009,1175.9,Unconfirmed,560,1175-P01,COPD Induced Sputum Trial,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10126,1175-0011,1175.11,Ended,560,1175-P01,BIRB 796 short term efficacy in RA,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10127,1175-0013,1175.13,Unconfirmed,560,1175-P01,Absolute ADME IV/PO BIRB 796,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10128,1175-0014,1175.14,Ended,560,1175-P01,BID Normal Volunteer Tolerance Trial,Ended,MIG,Migration,I,Phase I,backup for phase IIA trials ,,,000910,IS - Clin Study (MIGRATED)
10129,1175-0015,1175.15,Preparing,560,1175-P01, Japanese, Normal Vol, Single Dose,Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10130,1175-0016,1175.16,Preparing,560,1175-P01,phase I Japanese multiple dose,Preparing,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10131,1175-0017,1175.17,Ended,560,1175-P01,assessment of effect of pH on absorption,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10132,1175-0018,1175.18,Ended,560,1175-P01,Efficay and safety  in RA over 12 weeks,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10133,1175-0020,1175.20,Preparing,560,1175-P01,Phase I Study Congestive Heart Failure,Preparing,MIG,Migration,IB,Phase Ib,On HOLD pending pre-clin data (4Q2003) ,,,000910,IS - Clin Study (MIGRATED)
10134,1175-0021,1175.21,Ended,560,1175-P01,Safety Dose Extension Study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10135,1175-0025,1175.25,Unconfirmed,560,1175-P01,Methotrexate add-on in RA,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
10136,0502-0319,502.319,Unconfirmed,562,0502-P04,Telmisartan vs placebo in diab. retinop.,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10137,1177-0001,1177.1,Ended,563,1177-P01,Tolerability Norforms+MYRJ49 vs original,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10138,1174-0001,1174.1,Ended,564,1174-P01,Assent Plus in Myocardial Infarction,Ended,MIG,Migration,II,Phase II,Due to a change of the lytic agent used from TNK to rt-PA this study belongs to the project 135.P1,,,000910,IS - Clin Study (MIGRATED)
10139,1178-0001,1178.1,Ended,565,1178-P01,single rising dose Phase I study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10140,1178-0002,1178.2,Ended,565,1178-P01,multiple rising dose Phase I study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10141,1178-0003,1178.3,Preparing,565,1178-P01,8-week dose-ranging trial,Preparing,MIG,Migration,IIA,Phase IIa,Program was cancelled in 2002. ,,,000910,IS - Clin Study (MIGRATED)
10142,1178-0004,1178.4,Unconfirmed,565,1178-P01,Effect in Familial Hypercholesterolemia,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10143,1178-0005,1178.5,Preparing,565,1178-P01,Resin drug-drug interaction trial,Preparing,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10144,1178-0006,1178.6,Unconfirmed,565,1178-P01,Long-term Cataract Surveillance Trial,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10145,1178-0007,1178.7,Unconfirmed,565,1178-P01,statin factorial design trial,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10146,1178-0008,1178.8,Unconfirmed,565,1178-P01,NIDDM/IGT trial,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10147,1178-0009,1178.9,Unconfirmed,565,1178-P01,lipoprotein turnover mechanistic trial,Unconfirmed,MIG,Migration,IIB,Phase IIb,Program on HOLD ,,,000910,IS - Clin Study (MIGRATED)
10148,1178-0010,1178.10,Unconfirmed,565,1178-P01,diet control trial,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10149,1178-0011,1178.11,Unconfirmed,565,1178-P01,Statin drug interaction trial,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10150,1178-0012,1178.12,Unconfirmed,565,1178-P01,Fibrate/niacin drug interaction trial,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10151,1178-0013,1178.13,Unconfirmed,565,1178-P01,separate statin factorial design trial,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10152,1178-0014,1178.14,Unconfirmed,565,1178-P01,renal insufficiency special study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10153,1178-0015,1178.15,Preparing,565,1178-P01,BIBB 1464 1x4mg vs 2x2mg vs 4x1mg,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10154,1178-0016,1178.16,Unconfirmed,565,1178-P01,Japanese Phase I Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10155,1180-0001,1180.1,Ended,567,1180-P01,single rising dose and cross over,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10156,1180-0002,1180.2,Ended,567,1180-P01,multiple dose oral formulation,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10157,1180-0003,1180.3,Ended,567,1180-P01,single rising dose i.v,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10158,1180-0004,1180.4,Preparing,567,1180-P01,Titration back to bolus & absolute F,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10159,1180-0005,1180.5,Preparing,567,1180-P01,Food interaction study with tablet form.,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10160,1180-0006,1180.6,Preparing,567,1180-P01,AMI in high risk patients,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10161,1180-0007,1180.7,Unconfirmed,567,1180-P01,Mechanistic imaging study in AMI,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10162,1180-0008,1180.8,Preparing,567,1180-P01,Registry of cardiac surgery centres,Preparing,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10163,1180-0009,1180.9,Unconfirmed,567,1180-P01,BIIB 722 in high risk CABG patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10164,1180-0010,1180.10,Preparing,567,1180-P01,Captisol and HPBCD bioequivalence,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10165,1180-0011,1180.11,Preparing,567,1180-P01,Haemodynamic safety study,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10166,1180-0012,1180.12,Unconfirmed,567,1180-P01,oral MRD PK/ PD/safety/ tolerability,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10167,1157-0011,1157.11,Preparing,568,1157-P02,Dose-ranging I,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10168,1157-0012,1157.12,Preparing,568,1157-P02,Dose-ranging II,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10169,1157-0027,1157.27,Preparing,568,1157-P02, MDD Flexible dose study,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10170,1157-0028,1157.28,Preparing,568,1157-P02,MDD Flexible dose study,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10171,1157-0029,1157.29,Unconfirmed,568,1157-P02,Pk male vs female,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10172,1181-0001,1181.1,Ended,569,1181-P01,BIWH-3:  MCP-1 Phase I Study in PAOD/CLI,Ended,MIG,Migration,I,Phase I,see comment TB31may2002: most likely soon IND, protocol am needed on minor issues, will be made after Inv. Meeting (9-10June)



TB18oct2001: FDA requires more data on dose, duration and safety profile (more minipig studies); FDA wants less sites (2 max), this will be discussed ??4 sites (2US and 2 EU)

First trial, multicenter (6) perhaps 2 US, 2 netherlands, 2 W Eur.

TB 9Apr2001: more sites 8?, 
US 2, NL 1, Ch 1, GE 3, DK 1

patient population to be decided (less severe PAOD?)
and efficacy as endpoint?,,,000910,IS - Clin Study (MIGRATED)
10173,1181-0002,1181.2,Ended,569,1181-P01,BIWH 3 in healthy volunteers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10174,1181-0003,1181.3,Unconfirmed,569,1181-P01,Dose ranging study of BIWH 3 for PAOD,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10175,0602-0001,602.1,Unconfirmed,570,0602-P01,Tolerability in colorectal cancer,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10176,0602-0002,602.2,Unconfirmed,570,0602-P01,combination with chemotherapy,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10177,0603-0001,603.1,Unconfirmed,571,0603-P01,Tolerability and PK,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10178,0603-0002,603.2,Unconfirmed,571,0603-P01,Safety, PK and MTD in cancer patients,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10179,0603-0003,603.3,Unconfirmed,571,0603-P01,Combination with paclitaxel,Unconfirmed,MIG,Migration,IB,Phase Ib,BIBU 1361 may be replaced by BIBX 1542 ,,,000910,IS - Clin Study (MIGRATED)
10180,0603-0004,603.4,Unconfirmed,571,0603-P01,BIBU 1361 in head and neck cancer,Unconfirmed,MIG,Migration,IIA,Phase IIa,BIBU 1361 may be replaced by BIBX 1542 ,,,000910,IS - Clin Study (MIGRATED)
10181,0603-0005,603.5,Unconfirmed,571,0603-P01,BIBU 1361 in NSCLC,Unconfirmed,MIG,Migration,IIA,Phase IIa,BIBU 1361 may be replaced by BIBX 1542 ,,,000910,IS - Clin Study (MIGRATED)
10182,0603-0006,603.6,Unconfirmed,571,0603-P01,BIBU 1361 in prostate cancer,Unconfirmed,MIG,Migration,IIA,Phase IIa,>BIBU 1361 may be replaced by BIBX 1542 ,,,000910,IS - Clin Study (MIGRATED)
10183,0603-0007,603.7,Unconfirmed,571,0603-P01,BIBU 1361 in ovarian cancer,Unconfirmed,MIG,Migration,IIA,Phase IIa,BIBU 1361 may be replaced by BIBX 1542 ,,,000910,IS - Clin Study (MIGRATED)
10184,0603-0008,603.8,Unconfirmed,571,0603-P01,BIBU 1361 in pancreatic cancer,Unconfirmed,MIG,Migration,IIA,Phase IIa,BIBU 1361 may be replaced by BIBX 1542 ,,,000910,IS - Clin Study (MIGRATED)
10185,0604-0001,604.1,Unconfirmed,572,0604-P01,Tolerability and PK,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10186,0604-0002,604.2,Unconfirmed,572,0604-P01,Safety and PK,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10187,1182-0001,1182.1,Ended,573,1182-P01,P&U 004:TPV Safe., PK, Effic. in HIV pts,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10188,1182-0002,1182.2,Ended,573,1182-P01,P&U 006:TPV-500 vs 1000 mg BID,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10189,1182-0003,1182.3,Ended,573,1182-P01,P&U 015:TPV-SEDDS at Different Doses,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10190,1182-0004,1182.4,Ended,573,1182-P01,P&U 016:TPV vs TPV+RTV vs SQV+RTV,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10191,1182-0005,1182.5,Ended,573,1182-P01,Phase I PK Study: GRID Design w/TPV,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10192,1182-0006,1182.6,Ended,573,1182-P01,TPV/RTV PK interaction,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10193,1182-0007,1182.7,Unconfirmed,573,1182-P01,Phase I PK Study w/ TPV and ????,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10194,1182-0008,1182.8,Unconfirmed,573,1182-P01,Phase I PK Study w/ TPV and ???,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10195,1182-0009,1182.9,Unconfirmed,573,1182-P01,Phase I PK Study w/ TPV and ???,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10196,1182-0010,1182.10,Ended,573,1182-P01,Phase I PK Study w/ TPV and fluconazole,Ended,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10197,1182-0011,1182.11,Ended,573,1182-P01,Phase I PK Study w/ TPV & clarithromycin,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10198,1182-0012,1182.12,Ended,573,1182-P01,Multiple PI Failure Pivotal Trial,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10199,1182-0013,1182.13,Preparing,573,1182-P01,TPV/RTV + 2nd PI vs 2nd PI/3rd PI/RTV,Preparing,MIG,Migration,IIIB,Phase IIIb,Trial is a Phase IIIB/IV study ,,,000910,IS - Clin Study (MIGRATED)
10200,1182-0015,1182.15,Unconfirmed,573,1182-P01,Pediatric Dose Finding Study,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10201,1182-0016,1182.16,Ended,573,1182-P01,TPV Expanded Access for PI Failures,Ended,MIG,Migration,IV,Phase IV,,,,000500,Compassionate Use Program (CUP)
10202,1182-0017,1182.17,Ended,573,1182-P01,TPV Roll-Over Study,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10203,1182-0018,1182.18,Unconfirmed,573,1182-P01,TPV Multiple PI Failure,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10204,1182-0019,1182.19,Preparing,573,1182-P01,TPV Pediatric Efficacy,Preparing,MIG,Migration,II,Phase II,On hold. TCM Kevin Curry 10 Sept 2002 ,,,000910,IS - Clin Study (MIGRATED)
10205,1182-0020,1182.20,Preparing,573,1182-P01,Phase I PK Study w/TPV and Rifampin,Preparing,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10206,1182-0021,1182.21,Ended,573,1182-P01,Phase I PK Study w/TPV and Atorvastatin,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10207,1182-0022,1182.22,Ended,573,1182-P01,PK of TPV with ethinyl estradiol,Ended,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10208,1182-0023,1182.23,Preparing,573,1182-P01,PK of TPV + High Fat and Antacid,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10209,1182-0024,1182.24,Ended,573,1182-P01,ADME Study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10210,1182-0025,1182.25,Unconfirmed,573,1182-P01,PK Study of TPV with Rifabutin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10211,1182-0026,1182.26,Ended,573,1182-P01,PK Study of TPV with Methadone,Ended,MIG,Migration,I,Phase I,,2004-002325-44,,000910,IS - Clin Study (MIGRATED)
10212,1182-0027,1182.27,Unconfirmed,573,1182-P01,PK Study of TPV with Indinavir,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10213,1182-0028,1182.28,Unconfirmed,573,1182-P01,PK Study of TPV with Nelfinavir,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10214,1182-0029,1182.29,Unconfirmed,573,1182-P01,PK Study of TPV with Lopinavir,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10215,1182-0030,1182.30,Unconfirmed,573,1182-P01,PK Study of TPV with Saquinavir,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10216,1182-0031,1182.31,Unconfirmed,573,1182-P01,PK Study of TPV with Amprenavir,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10217,1182-0032,1182.32,Ended,573,1182-P01,PK of TPV in Hepatic Impaired,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10218,1182-0033,1182.33,Ended,573,1182-P01,ARV Naive Subjects,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10219,1182-0034,1182.34,Unconfirmed,573,1182-P01,Bioequivalence,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10220,1182-0035,1182.35,Unconfirmed,573,1182-P01,PK Assessment of TPV w/P450 Inhibitors,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10221,1182-0036,1182.36,Preparing,573,1182-P01,TPV Multiple PI Failure,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10222,1182-0037,1182.37,Ended,573,1182-P01,TPV/ZDV PK in Healthy Volunteers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10223,1182-0038,1182.38,Preparing,573,1182-P01,TPV/RTV PK w/3TC in Healthy Volunteers,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10224,1182-0039,1182.39,Preparing,573,1182-P01,TPV/RTV PK w/d4T in Healthy Volunteers,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10225,1182-0040,1182.40,Preparing,573,1182-P01,TPV/RTV PK w/NVP in HIV Pts,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10226,1182-0041,1182.41,Ended,573,1182-P01,TPV/RTV PK w/EFV in Healthy Volunteers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10227,1182-0042,1182.42,Ended,573,1182-P01,TPV/RTV PK w/ddI in Healthy Volunteers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10228,1182-0043,1182.43,Preparing,573,1182-P01,TPV/RTV PK w/ABC in Healthy Volunteers,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10229,1182-0044,1182.44,Ended,573,1182-P01,TPV/RTV PK w/RFB in Healthy Volunteers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10230,1182-0045,1182.45,Ended,573,1182-P01,TPV/RTV PK w/BIO in Healthy Volunteers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10231,1182-0046,1182.46,Ended,573,1182-P01,TPV/RTV PK w/TFV in Healthy Volunteers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10232,1182-0047,1182.47,Preparing,573,1182-P01,TPV/RTV PK w/DRH in Healthy Volunteers,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10233,1182-0048,1182.48,Ended,573,1182-P01,Multiple PI Failure Pivotal (Europe),Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10234,1182-0049,1182.49,Unconfirmed,573,1182-P01,TPV/RTV + 2nd PI vs 2nd PI/3rd PI/RTV,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10235,1182-0050,1182.50,Preparing,573,1182-P01,PK Study of TPV with T-20/T-1249,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10236,1182-0051,1182.51,Ended,573,1182-P01,PK, safety of TPV/RTV w/ SQV, APV or LPV,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10237,1182-0052,1182.52,Ended,573,1182-P01,3 TPV/RTV Doses in Multiple ARV Pts.,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10238,1182-0053,1182.53,Preparing,573,1182-P01,GI Transit Study,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10239,1182-0054,1182.54,Preparing,573,1182-P01,TPV in Naive Patients,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10240,1182-0055,1182.55,Ended,573,1182-P01,PDPK interaction of TPV/RTV & loperamide,Ended,MIG,Migration,I,Phase I,approved by IDC November 14, 2001 ,,,000910,IS - Clin Study (MIGRATED)
10241,1182-0056,1182.56,Preparing,573,1182-P01,Pediatric Rollover Safety Trial,Preparing,MIG,Migration,II,Phase II,canceled as: Canceled as patients will be entered into the rollover portion of the 1182.14,,,000910,IS - Clin Study (MIGRATED)
10242,1182-0057,1182.57,Preparing,573,1182-P01,Rollover Trial for Phase III Program,Preparing,MIG,Migration,III,Phase III,The primary efficacy follow-up after 48W ,,,000910,IS - Clin Study (MIGRATED)
10243,1182-0058,1182.58,Ended,573,1182-P01,Emergency Use Program for HTE Patients,Ended,MIG,Migration,IV,Phase IV,So Africa Reg: 16 May 2014:HR2014-156 ,,,000500,Compassionate Use Program (CUP)
10244,1182-0059,1182.59,Ended,573,1182-P01,TPV/r in Child Pugh A &  B subjects,Ended,MIG,Migration,I,Phase I,Includes Pk analysis with RBV and IFN2A ,2005-001918-41,,000910,IS - Clin Study (MIGRATED)
10245,1182-0060,1182.60,Ended,573,1182-P01,Evaluation of QT Interval with TPV/r,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10246,1182-0061,1182.61,Ended,573,1182-P01,TPV & TAZ PK Interaction,Ended,MIG,Migration,I,Phase I,See Extended Remarks Changed from Phase IV to I by TCM Sept 5, 2008.  Reason: Phase in CTMS was incorrect originally- Change required to align with Protocol & CTR for purposes of disclosure.  JDC/ME,,,000910,IS - Clin Study (MIGRATED)
10247,1182-0062,1182.62,Preparing,573,1182-P01,NRTI-Sparing Anti-HIV Regimen,Preparing,MIG,Migration,IV,Phase IV,,,,,
10248,1182-0063,1182.63,Unconfirmed,573,1182-P01,TPV/r Efficacy Using TDM,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
10249,1182-0064,1182.64,Preparing,573,1182-P01,TPV/r or LPV/r + T-20 or T-1249,Preparing,MIG,Migration,IV,Phase IV,,,,,
10250,1182-0065,1182.65,Preparing,573,1182-P01,TPV/r + Fusion Inhibitor in HTE Patients,Preparing,MIG,Migration,IV,Phase IV,,,,,
10251,1182-0066,1182.66,Preparing,573,1182-P01,TPV/r and F.I. in T-20 Failure Patients,Preparing,MIG,Migration,IV,Phase IV,,,,,
10252,1182-0067,1182.67,Ended,573,1182-P01,Expanded Access Program--France,Ended,MIG,Migration,III,Phase III,,,,000500,Compassionate Use Program (CUP)
10253,1182-0068,1182.68,Ended,573,1182-P01,Expanded Access Program-Germany,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
10254,1182-0069,1182.69,Unconfirmed,573,1182-P01,TPV/r Pharmacogenomics,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
10255,1182-0070,1182.70,Ended,573,1182-P01,Expanded Access Program in United States,Ended,MIG,Migration,IV,Phase IV,,,,000500,Compassionate Use Program (CUP)
10256,1182-0071,1182.71,Ended,573,1182-P01,TPV vs DRV in  pts with >1PI resistance,Ended,MIG,Migration,IV,Phase IV,,2005-001866-15,,000910,IS - Clin Study (MIGRATED)
10257,1182-0072,1182.72,Unconfirmed,573,1182-P01,TPV in first line failures LPV/r naives,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
10258,1182-0073,1182.73,Ended,573,1182-P01,Study of tipranavir resistance profile,Ended,MIG,Migration,IV,Phase IV,,,,,
10259,1182-0074,1182.74,Unconfirmed,573,1182-P01,ACTG HAART Simplification study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
10260,1182-0075,1182.75,Preparing,573,1182-P01,PK Study of TPV/r with Fos-Amprenavir,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
10261,1182-0076,1182.76,Ended,573,1182-P01,PK Study TPV/r with TMC125 (NNRTI),Ended,MIG,Migration,I,Phase I,Tibotec Study BI co-sponsor ,,,000910,IS - Clin Study (MIGRATED)
10262,1182-0077,1182.77,Unconfirmed,573,1182-P01,PK study TPV/r with TMC114 (PI),Unconfirmed,MIG,Migration,I,Phase I,US ACTG study ,,,,
10263,1182-0078,1182.78,Unconfirmed,573,1182-P01,PK study TPV/r with capravirine  (NRTI),Unconfirmed,MIG,Migration,IV,Phase IV,Pfizer Study BI co-sponsor ,,,000910,IS - Clin Study (MIGRATED)
10264,1182-0079,1182.79,Unconfirmed,573,1182-P01,TPV/r/UK-427857,Unconfirmed,MIG,Migration,I,Phase I,Pfizer study, BI co-sponsor ,,,000910,IS - Clin Study (MIGRATED)
10265,1182-0080,1182.80,Ended,573,1182-P01,PK study TPV/r with carbamacepin,Ended,MIG,Migration,I,Phase I,,2005-000673-22,,000910,IS - Clin Study (MIGRATED)
10266,1182-0081,1182.81,Unconfirmed,573,1182-P01,PK study TPV/r with Ribavirin,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
10267,1182-0082,1182.82,Unconfirmed,573,1182-P01,PH study TPV/r with Interferon alpha 2-b,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
10268,1182-0083,1182.83,Ended,573,1182-P01,PK TPV/r/tadalafil,Ended,MIG,Migration,I,Phase I,,2005-001920-35,,000910,IS - Clin Study (MIGRATED)
10269,1182-0084,1182.84,Ended,573,1182-P01,PK  TPV/r with proton pump inhibitor,Ended,MIG,Migration,I,Phase I,,2005-001921-27,,000910,IS - Clin Study (MIGRATED)
10270,1182-0085,1182.85,Ended,573,1182-P01,PK TPV/r with buprenorphine,Ended,MIG,Migration,IV,Phase IV,,,,,
10271,1182-0086,1182.86,Preparing,573,1182-P01,TPV/r + GW695634 PK interaction,Preparing,MIG,Migration,IV,Phase IV,Study conducted by GSK ,,,,
10272,1182-0087,1182.87,Unconfirmed,573,1182-P01,Intracellular DDI & Platelet Function,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10273,1182-0088,1182.88,Ended,573,1182-P01,TPV/r/GW873140,Ended,MIG,Migration,I,Phase I,GSK study, BI co-sponsor ,,,,
10274,1182-0089,1182.89,Ended,573,1182-P01,TPV/r/GW640385,Ended,MIG,Migration,I,Phase I,GSK study, BI co-sponsor ,,,,
10275,1182-0090,1182.90,Ended,573,1182-P01,TPV/r/Reverset,Ended,MIG,Migration,I,Phase I,Incyte trial, BI co-sponsor ,,,,
10276,1182-0091,1182.91,Unconfirmed,573,1182-P01,TPV/r/IDV,Unconfirmed,MIG,Migration,IV,Phase IV,Will be conducted by CRO ,,,000910,IS - Clin Study (MIGRATED)
10277,1182-0092,1182.92,Preparing,573,1182-P01,PK Interaction TPV/r/NVP,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
10278,1182-0093,1182.93,Ended,573,1182-P01,TPV Bioequivalence of RT Supplies,Ended,MIG,Migration,I,Phase I,Tris analysis for EMEA ,,,000910,IS - Clin Study (MIGRATED)
10279,1182-0094,1182.94,Preparing,573,1182-P01,TPV/r/SCH 417690,Preparing,MIG,Migration,I,Phase I,Study will be performed by Shering ,,,000910,IS - Clin Study (MIGRATED)
10280,1182-0095,1182.95,Ended,573,1182-P01,PK TPV/r/bupropion,Ended,MIG,Migration,I,Phase I,,,,,
10281,1182-0096,1182.96,Preparing,573,1182-P01,TPV/r concentrations in genital fluids,Preparing,MIG,Migration,IV,Phase IV,Invest.: Alain LAFEUILLADE, Toulon, Fra ,,,,
10282,1182-0098,1182.98,Ended,573,1182-P01,SPRING Diversity + TDM,Ended,MIG,Migration,IIIB,Phase IIIb,TDM = delayed final protocol ,2005-005264-86,,000910,IS - Clin Study (MIGRATED)
10283,1182-0099,1182.99,Ended,573,1182-P01,TICINO TPV in hepatitis coinfected+TDM,Ended,MIG,Migration,IIIB,Phase IIIb,,2005-005023-33,,000910,IS - Clin Study (MIGRATED)
10284,1182-0101,1182.101,Ended,573,1182-P01,TPV cocktail study,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10285,1182-0102,1182.102,Ended,573,1182-P01,TPV/r 500/200 interaction efv,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10286,1182-0104,1182.104,Ended,573,1182-P01,TPV/r/Valaciclovir,Ended,MIG,Migration,I,Phase I,,2006-001932-35,,000910,IS - Clin Study (MIGRATED)
10287,1182-0105,1182.105,Ended,573,1182-P01,TPV/r/rosuvastatin,Ended,MIG,Migration,I,Phase I,,,,,
10288,1182-0106,1182.106,Preparing,573,1182-P01,TPV/r/Bactrim,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10289,1182-0107,1182.107,Ended,573,1182-P01,TPV/r Low Dose Effic, PK,Ended,MIG,Migration,IIB,Phase IIb,,2006-005256-33,,000910,IS - Clin Study (MIGRATED)
10290,1182-0108,1182.108,Unconfirmed,573,1182-P01,Safety & efficacy of TPV/r < 500/100,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10291,1182-0109,1182.109,Ended,573,1182-P01,TPV on intracellular TP abacavir and AZT,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10292,1182-0110,1182.110,Ended,573,1182-P01,PK Interaction TPV/r/GW873140,Ended,MIG,Migration,I,Phase I,Follow-up study to 1182.88 done by GSK ,,,,
10293,1182-0111,1182.111,Unconfirmed,573,1182-P01,TPV/r/GW640385X (PI),Unconfirmed,MIG,Migration,I,Phase I,Study will be conducted by GSK alone ,,,000910,IS - Clin Study (MIGRATED)
10294,1182-0112,1182.112,Ended,573,1182-P01,AWB Aptivus,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
10295,1182-0113,1182.113,Unconfirmed,573,1182-P01,PK interaction TPV/r/GS-9137,Unconfirmed,MIG,Migration,II,Phase II,Conducted by Gilead, no BI resources ,,,,
10296,1182-0114,1182.114,Ended,573,1182-P01,HIV/AIDS Symptom Management Manual,Ended,MIG,Migration,IV,Phase IV,Substudy Study will be nested in a large, non BI funded multinational research study,,,,
10297,1182-0115,1182.115,Preparing,573,1182-P01,Herpes zoster,Preparing,MIG,Migration,IV,Phase IV,Case control ,,,,
10298,1182-0116,1182.116,Ended,573,1182-P01,Resistance test to optimize HAART,Ended,MIG,Migration,IV,Phase IV,Open label Randomization among three arms: Pheno/Geno+Pheno/Geno,,,000940,Post Marketing Study (MIGRATED)
10299,1182-0117,1182.117,Ended,573,1182-P01,Effect of TPV/r on platelet aggregation,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10300,1182-0118,1182.118,Unconfirmed,573,1182-P01,TPV in low susceptebility to LPV,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
10301,1182-0119,1182.119,Initiated,573,1182-P01,TPV/r iin HIV-1 sub-type G,Initiated,MIG,Migration,IV,Phase IV,,,,,
10302,1182-0120,1182.120,Unconfirmed,573,1182-P01,TPVvs.  LPV,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
10303,1182-0121,1182.121,Unconfirmed,573,1182-P01,TPV vs. LPV in stable viraemia,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
10304,1182-0122,1182.122,Preparing,573,1182-P01,TPV/r + raltegravir,Preparing,MIG,Migration,IV,Phase IV,TX is 24 wks w 4 wks of f/u after EOT this is not an IND study,,,000910,IS - Clin Study (MIGRATED)
10305,1182-0123,1182.123,Unconfirmed,573,1182-P01,TPV vs DRV,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
10306,1182-0125,1182.125,Ended,573,1182-P01,TPV 500/100 simplification,Ended,MIG,Migration,IV,Phase IV,Lead Investigator: Adriano Lazzarin ,2006-006117-32,,,
10307,1182-0126,1182.126,Ended,573,1182-P01,French cohort analysis NADIS,Ended,MIG,Migration,IV,Phase IV,,,,,
10308,1182-0127,1182.127,Ended,573,1182-P01,French PMS - target population,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
10309,1182-0128,1182.128,Unconfirmed,573,1182-P01,Aptivus Market Research,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
10310,1182-0129,1182.129,Ended,573,1182-P01,Pharmacoepidemiol descrip study,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
10311,1182-0130,1182.130,Ended,573,1182-P01,Ital propect. patient characterization,Ended,MIG,Migration,IV,Phase IV,,,,000930,NISed - Study (MIGRATED)
10312,1182-0131,1182.131,Ended,573,1182-P01,TPV Virtiual IQ in Spain,Ended,MIG,Migration,IV,Phase IV,Study will be conducted by Prof Gatell ,,,,
10313,1182-0132,1182.132,Ended,573,1182-P01,RETROSIP Database analysis,Ended,MIG,Migration,IV,Phase IV,Epidem study by Dr. Llibre Non-interventional, epidemiological, retrospective, multicenter study. Patients will not be followed-up. Only one retrospective basal visit planned,,,000600,Survey Patient Questionnaire
10314,1182-0133,1182.133,Preparing,573,1182-P01,TPV therapy simplification,Preparing,MIG,Migration,IV,Phase IV,Study conducted by Vincent Soriano Investigator davices to lower the phenotypic cut-off for TPV to < 1.2 for patients with plannd RTV reduction,,,,
10315,1182-0134,1182.134,Ended,573,1182-P01,PRONNTO RTV simplification,Ended,MIG,Migration,IV,Phase IV,Conducted by Dr. Santiago Moreno ,,,,
10316,1182-0135,1182.135,Ended,573,1182-P01,Retrospective cohort analysis,Ended,MIG,Migration,IV,Phase IV,Study conducted by Dr. Berenguer ,,,,
10317,1182-0136,1182.136,Unconfirmed,573,1182-P01,Market research - Aptivus Evolution,Unconfirmed,MIG,Migration,NONE,Not Classified,Solicited reporting This is a program interviewing physicians on certain messages for which solicited AE reporting has been decided,,,000600,Survey Patient Questionnaire
10318,1182-0138,1182.138,Ended,573,1182-P01,Hepatic safety in HCV coinfected,Ended,MIG,Migration,IV,Phase IV,Retrospective, observational, multicentr Retrospective, observational, multicentre study of patients who started a rescue regimen with Tipranavir from September 2004 to 31 July 2006,,,,
10319,1182-0140,1182.140,Ended,573,1182-P01,ACTG OPTIONS,Ended,MIG,Migration,IV,Phase IV,,,,,
10320,1182-0141,1182.141,Ended,573,1182-P01,Belgian patient population charact,Ended,MIG,Migration,IV,Phase IV,,,,000930,NISed - Study (MIGRATED)
10321,1182-0142,1182.142,Ended,573,1182-P01,HIV TALK Patient survey,Ended,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
10322,1182-0143,1182.143,Ended,573,1182-P01,RTV simplification pilot,Ended,MIG,Migration,IV,Phase IV,Dr. B Clotet, Barcelona Pilot, open-label, non-randomised, clinical trial in HIV-infected patients whose antiretroviral treatment includes tipranavir/ritonavir at a dose of 500/200 mg every 12 hours and who present an HIV plasma viral load inferior to 50 copies/ml and an IQ of tipranavir ¬ø 60,,,,
10323,1182-0144,1182.144,Preparing,573,1182-P01,SCOLTA Long term ARV tox cohort Italy,Preparing,MIG,Migration,IV,Phase IV,Also done on other ARVs The SCOLTA team has conducted and published similar analysis with other ARVs. Further this collaboration could fit into our safety database collaborations mentioned in the Pharmacovigilance Plan,,,000920,NISnd - Study (MIGRATED)
10324,1182-0145,1182.145,Unconfirmed,573,1182-P01,CHUM and RAMQ database analysis for ICH,Unconfirmed,MIG,Migration,IV,Phase IV,retrospective data review no interventional study,,,000980,Not Classified (MIGRATED)
10325,1182-0146,1182.146,Unconfirmed,573,1182-P01,DRV reduced susceptibility,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
10326,1182-0147,1182.147,Ended,573,1182-P01,PMS on safety of TPV/r,Ended,MIG,Migration,IV,Phase IV,Observation of therapeutic use, PMS ,,,000940,Post Marketing Study (MIGRATED)
10327,0563-0001,563.1,Ended,574,0563-P01,Menopausal complaints,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10328,0563-0002,563.2,Ended,574,0563-P01,Menopausal symptoms, confirm study 40 mg,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10329,0563-0003,563.3,Ended,574,0563-P01,Endometrial Safety,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
10330,0563-0004,563.4,Preparing,574,0563-P01,Tolerability of Menofem Plus,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10331,1183-0001,1183.1,Ended,575,1183-P01,Premenstrual syndrome - Czech Republic,Ended,MIG,Migration,III,Phase III,40 mg, 100 mg, 200 mg, Placebo ,,,000910,IS - Clin Study (MIGRATED)
10332,1184-0001,1184.1,Preparing,585,1184-P01,Additivity Study in COPD,Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
10333,1184-0002,1184.2,Ended,585,1184-P01,Formoterol on top of PD steady state tio,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10334,1184-0003,1184.3,Ended,585,1184-P01,Tio+Form vs. components,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10335,1184-0004,1184.4,Unconfirmed,585,1184-P01,SD safety and PK study/healthy subjects,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10336,1184-0005,1184.5,Unconfirmed,585,1184-P01,MD safety and PK study/healthy subjects,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10337,1184-0006,1184.6,Unconfirmed,585,1184-P01,LABA dosing and performance COPD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10338,1184-0007,1184.7,Ended,585,1184-P01,Tio. + Salm. vs components,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10339,1184-0008,1184.8,Ended,585,1184-P01,SD PK study of Salm. MDI vs Salm. Diskus,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10340,1184-0009,1184.9,Ended,585,1184-P01,Dose selection Tio PE capsule,Ended,MIG,Migration,II,Phase II,,2005-001686-34,,000910,IS - Clin Study (MIGRATED)
10341,1184-0010,1184.10,Ended,585,1184-P01,24-h dose selection Salm. PE capsule,Ended,MIG,Migration,II,Phase II,,2004-005238-37,,000910,IS - Clin Study (MIGRATED)
10342,1184-0011,1184.11,Ended,585,1184-P01,Combo PK study,Ended,MIG,Migration,I,Phase I,,2005-000916-28,,000910,IS - Clin Study (MIGRATED)
10343,1184-0012,1184.12,Ended,585,1184-P01,12-h dose selection Salm. PE caps,Ended,MIG,Migration,II,Phase II,,2005-000918-13,,000910,IS - Clin Study (MIGRATED)
10344,1184-0013,1184.13,Ended,585,1184-P01,Combination justification study,Ended,MIG,Migration,IIIA,Phase IIIa,,2007-005135-28,,000910,IS - Clin Study (MIGRATED)
10345,1184-0014,1184.14,Ended,585,1184-P01,1-yr TioSal combo vs mono therapies,Ended,MIG,Migration,IIIA,Phase IIIa,,2007-005134-36,,000910,IS - Clin Study (MIGRATED)
10346,1184-0015,1184.15,Ended,585,1184-P01,1-yr TioSal combo vs mono therapies,Ended,MIG,Migration,IIIA,Phase IIIa,,2007-005107-17,,000910,IS - Clin Study (MIGRATED)
10347,1184-0016,1184.16,Preparing,585,1184-P01,Effect on QTc,Preparing,MIG,Migration,I,Phase I,,2007-000206-73,,000910,IS - Clin Study (MIGRATED)
10348,1184-0017,1184.17,Ended,585,1184-P01,SD PK study of Salm. PE vs Salm. Diskus,Ended,MIG,Migration,I,Phase I,,2005-001871-36,,000910,IS - Clin Study (MIGRATED)
10349,1184-0018,1184.18,Preparing,585,1184-P01,Tio+Salm vs free combo marketed products,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10350,1184-0019,1184.19,Preparing,585,1184-P01,Tio+Salm vs mark. prod. vs free combo,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10351,1184-0020,1184.20,Preparing,585,1184-P01,1-yr: Tio+Salm vs Spiriva+ Serevent,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10352,1184-0021,1184.21,Preparing,585,1184-P01,Tio+Salm vs Components,Preparing,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10353,1184-0022,1184.22,Unconfirmed,585,1184-P01,Exercise study vs tiotropium,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10354,1184-0023,1184.23,Unconfirmed,585,1184-P01,exercise study versus salmeterol,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10355,1184-0024,1184.24,Ended,585,1184-P01,TioSal PK study in COPD,Ended,MIG,Migration,III,Phase III,,2007-000207-15,,000910,IS - Clin Study (MIGRATED)
10356,1184-0025,1184.25,Preparing,585,1184-P01,Tiotropium PE dose confirmation study,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10357,1185-0001,1185.1,Unconfirmed,586,1185-P01,Escalated single oral doses of BIRT,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10358,1185-0002,1185.2,Unconfirmed,586,1185-P01,Oral multiple doses,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10359,1185-0003,1185.3,Unconfirmed,586,1185-P01,Food interaction,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10360,1186-0001,1186.1,Unconfirmed,590,1186-P01,Phase I Single Rising Dose,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10361,1186-0002,1186.2,Unconfirmed,590,1186-P01,Phase I Multiple Rising Dose,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10362,1187-0001,1187.1,Ended,591,1187-P01,Single dose, normal volunteer safety,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10363,1187-0002,1187.2,Preparing,591,1187-P01,BA of Solid Form and MRD in HMV,Preparing,MIG,Migration,IB,Phase Ib,,2006-000037-35,,000910,IS - Clin Study (MIGRATED)
10364,1187-0003,1187.3,Unconfirmed,591,1187-P01,Psoriasis, 4 week mono,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10365,1187-0004,1187.4,Unconfirmed,591,1187-P01,RA, 12  Week mono and MTX add on in RA,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10366,1187-0005,1187.5,Initiated,591,1187-P01,Single rising dose extension in NHV,Initiated,MIG,Migration,I,Phase I,plac.contr.double-blind.each dose level ,2005-004957-89,,000910,IS - Clin Study (MIGRATED)
10367,1187-0006,1187.6,Unconfirmed,591,1187-P01,Relative BA of New Solid Formulations,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10368,1187-0007,1187.7,Unconfirmed,591,1187-P01,RA, 52-week (mainly EU-centres),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10369,1187-0008,1187.8,Unconfirmed,591,1187-P01,RA 52 week (US),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10370,1187-0009,1187.9,Unconfirmed,591,1187-P01,Psoriasis 12 week Clinical Endpoints,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
10371,1187-0010,1187.10,Unconfirmed,591,1187-P01,Psoriasis 26/52 weeks Clinical Endpoints,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10372,1187-0011,1187.11,Unconfirmed,591,1187-P01,Psoriasis 26/52 week clinical endpoints,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10373,1188-0001,1188.1,Ended,592,1188-P01,Phase I Single Dose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10374,1188-0002,1188.2,Ended,592,1188-P01,MD Dose Escalation,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10375,1188-0003,1188.3,Preparing,592,1188-P01,Dose Finding Phase II Study,Preparing,MIG,Migration,II,Phase II,,2005-001868-30,,000910,IS - Clin Study (MIGRATED)
10376,1188-0004,1188.4,Ended,592,1188-P01,Effect of Ritonavir on SD of BILR 355,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10377,1188-0005,1188.5,Ended,592,1188-P01,Relative Bioavailability,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10378,1188-0006,1188.6,Ended,592,1188-P01,BILR 355 Single Dose Boosting Study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10379,1188-0007,1188.7,Ended,592,1188-P01,PK interaction study - TPV-r and BILR 355,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10380,1188-0008,1188.8,Ended,592,1188-P01,PK interaction study with Lopinivir-r and BILR 355,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10381,1188-0009,1188.9,Ended,592,1188-P01,PK Interaction between CBV and BILR 355+RTV,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10382,1188-0010,1188.10,Ended,592,1188-P01,BILR 355 Interaction with Truvada,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10383,1188-0011,1188.11,Preparing,592,1188-P01,BILR 355 BS+RTV Proof of Activity Trial,Preparing,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10384,1188-0012,1188.12,Unconfirmed,592,1188-P01,PK Interaction Trial - ATV/r,Unconfirmed,MIG,Migration,I,Phase I,tentative - not yet approved ,,,000910,IS - Clin Study (MIGRATED)
10385,1188-0013,1188.13,Unconfirmed,592,1188-P01,Rollover trial to continue BILR 355,Unconfirmed,MIG,Migration,II,Phase II,No longer planned to capture PhII pts ,,,000910,IS - Clin Study (MIGRATED)
10386,1188-0014,1188.14,Unconfirmed,592,1188-P01,Pivotal Comparative Trial in Naive Patients,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10387,1188-0015,1188.15,Unconfirmed,592,1188-P01,Pivotal Comparative Trial in Rx Experienced Patients,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10388,1188-0016,1188.16,Unconfirmed,592,1188-P01,Alternative Pivotal Trial in Patients with >2 NN Mutations,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10389,1188-0017,1188.17,Unconfirmed,592,1188-P01,ADME Trial,Unconfirmed,MIG,Migration,I,Phase I,tentative - not yet approved ,,,000910,IS - Clin Study (MIGRATED)
10390,1188-0018,1188.18,Unconfirmed,592,1188-P01,Emergency Use - Named Patient,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10391,1188-0019,1188.19,Unconfirmed,592,1188-P01,Expanded Access Study,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
10392,1188-0020,1188.20,Unconfirmed,592,1188-P01,Relative Bioequivalence of Pediatric Formulation,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10393,1188-0021,1188.21,Unconfirmed,592,1188-P01,Pediatric PK Dose Finding and Safety Trial,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10394,1188-0022,1188.22,Unconfirmed,592,1188-P01,PK Interaction Study with FTC,Unconfirmed,MIG,Migration,I,Phase I,tentative - not yet approved ,,,000910,IS - Clin Study (MIGRATED)
10395,1188-0023,1188.23,Unconfirmed,592,1188-P01,PK study with d4T,Unconfirmed,MIG,Migration,I,Phase I,tentative - not yet approved ,,,000910,IS - Clin Study (MIGRATED)
10396,1188-0024,1188.24,Unconfirmed,592,1188-P01,PK Study with ddI,Unconfirmed,MIG,Migration,I,Phase I,tentative - not yet approved ,,,000910,IS - Clin Study (MIGRATED)
10397,1188-0025,1188.25,Unconfirmed,592,1188-P01,PK Study with FosAPV,Unconfirmed,MIG,Migration,I,Phase I,tentative - not yet approved ,,,000910,IS - Clin Study (MIGRATED)
10398,1188-0026,1188.26,Unconfirmed,592,1188-P01,PK with ABC,Unconfirmed,MIG,Migration,I,Phase I,tentative - not yet approved ,,,000910,IS - Clin Study (MIGRATED)
10399,1188-0027,1188.27,Unconfirmed,592,1188-P01,SD PK Study with Food and Antacids,Unconfirmed,MIG,Migration,I,Phase I,tentative - not yet approved ,,,000910,IS - Clin Study (MIGRATED)
10400,1188-0028,1188.28,Unconfirmed,592,1188-P01,PK with Fluconazole,Unconfirmed,MIG,Migration,I,Phase I,tentative - not yet approved ,,,000910,IS - Clin Study (MIGRATED)
10401,1188-0029,1188.29,Unconfirmed,592,1188-P01,BILR355 in Rx Naive HIV Patients - PhII,Unconfirmed,MIG,Migration,II,Phase II,pending approval ,,,000910,IS - Clin Study (MIGRATED)
10402,1188-0030,1188.30,Unconfirmed,592,1188-P01,MD Rel BA Study - Final Formulation,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10403,1188-0031,1188.31,Initiated,592,1188-P01,Mono/Combo Rx Pilot - NNRTI Resist Pts,Initiated,MIG,Migration,IIA,Phase IIa,Pending IMC and IDC discussion ,2005-004698-39,,000910,IS - Clin Study (MIGRATED)
10404,1188-0032,1188.32,Ended,592,1188-P01,Single Dose Escalation BILR355(SDS),Ended,MIG,Migration,IA,Phase Ia,Propose as RDC study ,,,000910,IS - Clin Study (MIGRATED)
10405,1188-0033,1188.33,Ended,592,1188-P01,Rel BA Tab / Caps SDS Formulation,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10406,1189-0001,1189.1,Unconfirmed,593,1189-P01,BIBF 1000 in pat. with various cancers,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10407,1190-0001,1190.1,Ended,594,1190-P01,Clotrimazole Bioequivalence,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10408,0262-0261,262.261,Ended,595,0262-P05,Tolerability and Safety, single-dose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10409,0262-0262,262.262,Preparing,595,0262-P05,Tolerability and Safety, multiple dose,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10410,0262-0263,262.263,Preparing,595,0262-P05,Pharmacodynamics I,Preparing,MIG,Migration,II,Phase II,endpoint: total nasal symptom score ,,,000910,IS - Clin Study (MIGRATED)
10411,0262-0264,262.264,Preparing,595,0262-P05,Pharmacodynamics II,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10412,0262-0265,262.265,Unconfirmed,595,0262-P05,Pharmacodynamics III,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10413,0262-0273,262.273,Unconfirmed,595,0262-P05,Efficacy/safety Epi N in Ragweed season,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10414,0262-0274,262.274,Unconfirmed,595,0262-P05,Eff/Safety of Epi N in cedar season,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10415,0262-0275,262.275,Unconfirmed,595,0262-P05,Eff/Safety of Epi N in PAR,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10416,1191-0001,1191.1,Ended,596,1191-P01,Breast Cancer, monotherapy (1/3w),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10417,1191-0002,1191.2,Ended,596,1191-P01,HNSCC, monotherapy (1/3w),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10418,1191-0003,1191.3,Ended,596,1191-P01,Breast Cancer, monotherapy (1/w x 3),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10419,1191-0004,1191.4,Ended,596,1191-P01,H&N, esoph.ca, monotherapy (1/w x 3),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10420,1191-0005,1191.5,Unconfirmed,596,1191-P01,Breast Cancer, monotherapy,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10421,1191-0006,1191.6,Unconfirmed,596,1191-P01,HNSCC, monotherapy,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10422,1191-0007,1191.7,Unconfirmed,596,1191-P01,NSCLC, monotherapy,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10423,1191-0008,1191.8,Unconfirmed,596,1191-P01,Breast Cancer, combo docetaxel (1/w x 3),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10424,1191-0009,1191.9,Unconfirmed,596,1191-P01,NSCLC, combo docetaxel (1/w x 3),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10425,1191-0010,1191.10,Unconfirmed,596,1191-P01,Breast Cancer,combo paclitaxel (1/w x 3),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10426,1191-0011,1191.11,Unconfirmed,596,1191-P01,HNSCC, combo paclitaxel (1/w x 3),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10427,1191-0012,1191.12,Unconfirmed,596,1191-P01,Breast Cancer, combo docetaxel,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10428,1191-0013,1191.13,Unconfirmed,596,1191-P01,NSCLC, combo docetaxel,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10429,1191-0014,1191.14,Unconfirmed,596,1191-P01,Breast Cancer, combo paclitaxel,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10430,1191-0015,1191.15,Unconfirmed,596,1191-P01,HNSCC, combo paclitaxel,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10431,1191-0016,1191.16,Unconfirmed,596,1191-P01,Breast Cancer, combo taxane,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10432,1191-0017,1191.17,Unconfirmed,596,1191-P01,HNSCC, combo taxane,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10433,1191-0018,1191.18,Unconfirmed,596,1191-P01,NSCLC, combo taxane,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10434,1191-0019,1191.19,Ended,596,1191-P01,Phase I extension study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10435,1191-0020,1191.20,Unconfirmed,596,1191-P01,Monotherapy BIWI 1head & neck cancer,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10436,1191-0021,1191.21,Unconfirmed,596,1191-P01,Phase III monotherapy breast cancer,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10437,1192-0001,1192.1,Ended,597,1192-P01,Single dose escalation,Ended,MIG,Migration,I,Phase I,Single dose escalation study to investigate safety, PK, PD after intravenous administration;,,,000910,IS - Clin Study (MIGRATED)
10438,1192-0002,1192.2,Ended,597,1192-P01,Multiple dose escalation,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10439,1192-0003,1192.3,Unconfirmed,597,1192-P01,Formulation development study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10440,1192-0004,1192.4,Unconfirmed,597,1192-P01,AMI: adjunct thrombolysis, dose finding,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10441,1192-0005,1192.5,Unconfirmed,597,1192-P01,AMI: adjunt thrombolysis, pivotal trial,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10442,1192-0006,1192.6,Unconfirmed,597,1192-P01,ACS: NSTEMI, dose finding,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10443,1192-0007,1192.7,Unconfirmed,597,1192-P01,ACS: NSTEMI, pivotal trial,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10444,1192-0008,1192.8,Unconfirmed,597,1192-P01,Acute DIC / Sepsis: dose finding,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10445,1192-0009,1192.9,Unconfirmed,597,1192-P01,Acute DIC / Sepsis: pivotal trial 1,Unconfirmed,MIG,Migration,III,Phase III,x Patients with sepsis syndrome showing laboratory and clinical signs of initial phase of DIC;,,,000910,IS - Clin Study (MIGRATED)
10446,1192-0010,1192.10,Unconfirmed,597,1192-P01,Acute DIC / Sepsis: pivotal trial 2,Unconfirmed,MIG,Migration,III,Phase III,x Patients with sepsis syndrome showing laboratory and clinical signs of initial phase of DIC;,,,000910,IS - Clin Study (MIGRATED)
10447,1192-0011,1192.11,Ended,597,1192-P01,LPS challenge study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10448,1192-0012,1192.12,Ended,597,1192-P01,PK in patients with renal insufficiency,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10449,1192-0013,1192.13,Unconfirmed,597,1192-P01,anticoagulation during haemodialysis,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10450,1192-0014,1192.14,Unconfirmed,597,1192-P01,ADME-study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10451,1192-0017,1192.17,Unconfirmed,597,1192-P01,PK in patients with liver failure,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10452,1192-0018,1192.18,Unconfirmed,597,1192-P01,Coagulation test evaluation study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10453,1193-0001,1193.1,Ended,598,1193-P01,Single dose escalation,drinking solution,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10454,1193-0002,1193.2,Preparing,598,1193-P01,Drug interaction, CYP 3A4,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10455,1193-0003,1193.3,Unconfirmed,598,1193-P01,Multiple dose escalation, tablet,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10456,1193-0004,1193.4,Unconfirmed,598,1193-P01,Food-effect study, tablet, TF 1,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10457,1193-0005,1193.5,Unconfirmed,598,1193-P01,Formulation development study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10458,1193-0006,1193.6,Unconfirmed,598,1193-P01,Drug interaction, CYP model drug,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10459,1193-0007,1193.7,Unconfirmed,598,1193-P01,Prevention arterial events, dose finding,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10460,1193-0008,1193.8,Unconfirmed,598,1193-P01,Prev arterial events, pivotal trial 1,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10461,1193-0009,1193.9,Unconfirmed,598,1193-P01,Prev arterial events, pivotal trial 2,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10462,1193-0010,1193.10,Unconfirmed,598,1193-P01,Latent DIC, dose finding,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10463,1193-0011,1193.11,Unconfirmed,598,1193-P01,Latent DIC, pivotal trial 1,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10464,1193-0012,1193.12,Unconfirmed,598,1193-P01,Latent DIC, pivotal trial 2,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10465,1193-0013,1193.13,Unconfirmed,598,1193-P01,Drug interaction, ASS,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10466,1193-0014,1193.14,Unconfirmed,598,1193-P01,Drug interaction, metabolism 1,Unconfirmed,MIG,Migration,I,Phase I,Co-medication: dep on preclin invest Co-medication to be defined: depending on further preclinical and clinical investigations, i. e. drug metabolismus and excretion;,,,000910,IS - Clin Study (MIGRATED)
10467,1193-0015,1193.15,Unconfirmed,598,1193-P01,Influence of Age-Gender on PK/PD,Unconfirmed,MIG,Migration,I,Phase I,to investigate the influence of age and gender on PK and PD of BIBT 1011; 
,,,000910,IS - Clin Study (MIGRATED)
10468,0352-2030,352.2030,Ended,599,0352-P01,Multiple oral rising dose of PEG 400,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10469,1195-0001,1195.1,Ended,601,1195-P01,Single rising dose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10470,1195-0002,1195.2,Preparing,601,1195-P01,multiple rising dose,Preparing,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10471,1195-0003,1195.3,Ended,601,1195-P01,Delayed type hypersenstivity (Mantoux),Ended,MIG,Migration,IA,Phase Ia,,,,000300,IS - Methodological Studies
10472,0248-0515,248.515,Ended,603,0248-P06,dose finding study,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
10473,0248-0518,248.518,Ended,603,0248-P06,comparator study to Madopar DR,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10474,0248-0519,248.519,Preparing,603,0248-P06,Comparator trial to Madopar IR,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10475,0248-0520,248.520,Ended,603,0248-P06,european placebo. contr. trial,Ended,MIG,Migration,IIIA,Phase IIIa,interim analysis after period 1 ,,,000910,IS - Clin Study (MIGRATED)
10476,0248-0521,248.521,Unconfirmed,603,0248-P06,??????????,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10477,0248-0522,248.522,Unconfirmed,603,0248-P06,Japanese bridging study,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10478,0248-0531,248.531,Preparing,603,0248-P06,Longterm efficacy of PPX in RLS,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10479,0248-0541,248.541,Preparing,603,0248-P06,GLORIA I,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
10480,0248-0542,248.542,Unconfirmed,603,0248-P06,GLORIA II,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
10481,0248-0543,248.543,Ended,603,0248-P06,12 week plb, contr. backup study,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10482,0248-0546,248.546,Ended,603,0248-P06,Longterm efficacy of PPX in RLS,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10483,0248-0557,248.557,Ended,603,0248-P06,Japanese pilot study in RLS patients,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10484,0248-0573,248.573,Unconfirmed,603,0248-P06,528E-CNS-0072-131,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
10485,0248-0591,248.591,Unconfirmed,603,0248-P06,Time to symptom relief study 1,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10486,0248-0592,248.592,Unconfirmed,603,0248-P06,Time to symptom relief study 2,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10487,0248-0603,248.603,Preparing,603,0248-P06,Study in RLS patients with depressive Sx,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
10488,0248-0604,248.604,Ended,603,0248-P06,PPX on RLS symtoms and mood disturbances,Ended,MIG,Migration,IV,Phase IV,,2005-006128-13,,000910,IS - Clin Study (MIGRATED)
10489,0248-0615,248.615,Ended,603,0248-P06,Effects of PPX on RLS symptoms and sleep,Ended,MIG,Migration,IV,Phase IV,1 week follow-up after end of treatment ,2005-005225-54,,000910,IS - Clin Study (MIGRATED)
10490,0248-0616,248.616,Ended,603,0248-P06,Easy titration study and onset of action,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
10491,0248-0618,248.618,Ended,603,0248-P06,German observation RLS,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
10492,0248-0623,248.623,Ended,603,0248-P06,PPX in RLS,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
10493,0248-0627,248.627,Ended,603,0248-P06,Japanese Phase III study  in RLS,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
10494,0248-0629,248.629,Ended,603,0248-P06,European Longterm Study,Ended,MIG,Migration,IV,Phase IV,,2006-006431-42,,000910,IS - Clin Study (MIGRATED)
10495,0248-0630,248.630,Ended,603,0248-P06,Chinese RLS study,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
10496,0248-0632,248.632,Ended,603,0248-P06,Frequency of RLS in chronic insomnia,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
10497,0248-0638,248.638,Ended,603,0248-P06,RLS-PMS-QoL-D,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
10498,0248-0643,248.643,Preparing,603,0248-P06,RLS and cardiovascular system,Preparing,MIG,Migration,IV,Phase IV,,,,,
10499,0248-0646,248.646,Unconfirmed,603,0248-P06,US Early afternoon coverage of RLS,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
10500,0248-0647,248.647,Unconfirmed,603,0248-P06,Prescribing Dynam. Study,Unconfirmed,MIG,Migration,NONE,Not Classified,Non clinical trial activity ,,,000300,IS - Methodological Studies
10501,0248-0652,248.652,Ended,603,0248-P06,Prevalence of RLS in pat with leg probl,Ended,MIG,Migration,NONE,Not Classified,Survey Trial Non-drug trial,,,000600,Survey Patient Questionnaire
10502,0248-0653,248.653,Ended,603,0248-P06,Mirapex RLS PMS study,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
10503,0248-0654,248.654,Ended,603,0248-P06,Epidemiol RLS Germany Berger,Ended,MIG,Migration,NONE,Not Classified,No BI Drug used ,,,,
10504,0248-0655,248.655,Ended,603,0248-P06,Sifrol Observational RLS Study,Ended,MIG,Migration,IV,Phase IV,Observation in therapeutic Use - Austria Anwendungsbeobachtung according to local law AMG ¬ß2a,,,000940,Post Marketing Study (MIGRATED)
10505,0248-0656,248.656,Initiated,603,0248-P06,RLS Epidemiology in Italy,Initiated,MIG,Migration,IV,Phase IV,Interventional diagnostic procedures ,,,,
10506,0248-0659,248.659,Ended,603,0248-P06,Influence of PPX on pain in RLS,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
10507,0248-0664,248.664,Ended,603,0248-P06,single dose PK study in Chinese subjects,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10508,0248-0667,248.667,Unconfirmed,603,0248-P06,Sifrol plus ferroglycinsulfa in RLS,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
10509,0248-0668,248.668,Ended,603,0248-P06,RLS and Cardiovascular System,Ended,MIG,Migration,IV,Phase IV,IIS Study - Dr. Montplasir no active drug in study. comparing RLS patients to matched controls,,,,
10510,0248-0678,248.678,Ended,603,0248-P06,Survey on Long-Term Use for  RLS,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
10511,0543-0036,543.36,Ended,604,0543-P03,Safety,Tolerability & PK in CF (SD),Ended,MIG,Migration,IB,Phase Ib,U# - U03-3049 ,,,000910,IS - Clin Study (MIGRATED)
10512,0543-0037,543.37,Ended,604,0543-P03,Safety, Tolerability & PK in CF (MD),Ended,MIG,Migration,IB,Phase Ib,U# - U03-3277 ,,,000910,IS - Clin Study (MIGRATED)
10513,0543-0045,543.45,Ended,604,0543-P03,6 months treatment with BIIL 284 in CF,Ended,MIG,Migration,II,Phase II,Final CTR archived as: U07-3355 ,,,000910,IS - Clin Study (MIGRATED)
10514,0557-0001,557.1,Unconfirmed,605,0557-P02,Artichoke and Sylimarin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10515,0511-0056,511.56,Unconfirmed,606,0511-P02,Renal Insufficiency Study,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10516,0511-0057,511.57,Unconfirmed,606,0511-P02,Dose strength equivalence study,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10517,0511-0058,511.58,Unconfirmed,606,0511-P02,Beta blocker drug interaction study,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10518,0511-0059,511.59,Unconfirmed,606,0511-P02,Warfarin drug interaction study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10519,0511-0060,511.60,Unconfirmed,606,0511-P02,Digoxin drug interaction study,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10520,0511-0061,511.61,Unconfirmed,606,0511-P02,Lithium Drug Interaction Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10521,0511-0062,511.62,Unconfirmed,606,0511-P02,Desipramine drug interaction study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10522,0511-0063,511.63,Unconfirmed,606,0511-P02,SSRI safety study,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10523,0511-0064,511.64,Unconfirmed,606,0511-P02,Phase I,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10524,0511-0065,511.65,Unconfirmed,606,0511-P02,Phase 1,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10525,0511-0066,511.66,Unconfirmed,606,0511-P02,Phase 1,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10526,0511-0067,511.67,Ended,606,0511-P02,Hepatic Insufficiency Study,Ended,MIG,Migration,IB,Phase Ib,,2006-000778-59,,000910,IS - Clin Study (MIGRATED)
10527,0511-0068,511.68,Ended,606,0511-P02,Flibanserin vs. placebo in HSDD,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10528,0511-0069,511.69,Ended,606,0511-P02,Flibanserin vs. placebo in FHSDD,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10529,0511-0070,511.70,Ended,606,0511-P02,25 & 50mg BID/50mg qhs/pbo premeno NA,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10530,0511-0071,511.71,Ended,606,0511-P02,QHS 50 mg v100 mg v pbo premeno,  NA,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10531,0511-0072,511.72,Ended,606,0511-P02,SIDI Validation Study,Ended,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
10532,0511-0073,511.73,Ended,606,0511-P02,Validation of SIDI and PED Diary,Ended,MIG,Migration,IIA,Phase IIa,no drug, no treatment, methodology study ,,,000910,IS - Clin Study (MIGRATED)
10533,0511-0074,511.74,Ended,606,0511-P02,Sustained efficacy, younger HSDD, NA,Ended,MIG,Migration,IIIA,Phase IIIa,RDC equivalent to 70 CRF pages ,,,000910,IS - Clin Study (MIGRATED)
10534,0511-0075,511.75,Ended,606,0511-P02,Best tol:50bid/100qhs uptit,25bid,pbo,NA,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10535,0511-0076,511.76,Unconfirmed,606,0511-P02,Independent 12-mo safety in women in NA,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10536,0511-0077,511.77,Ended,606,0511-P02,Flibanserin in EU women with HSDD,Ended,MIG,Migration,IIIA,Phase IIIa,,2007-000032-68,,000910,IS - Clin Study (MIGRATED)
10537,0511-0078,511.78,Unconfirmed,606,0511-P02,Fixed doses FLI v pbo premeno HSDD EU,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10538,0511-0079,511.79,Unconfirmed,606,0511-P02,QD 50mg v 100mg v pbo in younger in EU,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10539,0511-0080,511.80,Unconfirmed,606,0511-P02,Up-titration 50bid/100mg qd/pbo young EU,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10540,0511-0083,511.83,Unconfirmed,606,0511-P02,Up-titration 50bid/100mg qd/pbo older NA,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10541,0511-0084,511.84,Ended,606,0511-P02,Worldwide open label safety study,Ended,MIG,Migration,IIIA,Phase IIIa,RDC equivalent to 100 CRF pages ,,,000910,IS - Clin Study (MIGRATED)
10542,0511-0085,511.85,Ended,606,0511-P02,European Validation of SIDI & eDiary,Ended,MIG,Migration,IIB,Phase IIb,U06-1401 ,,,000910,IS - Clin Study (MIGRATED)
10543,0511-0086,511.86,Ended,606,0511-P02,3A4 interaction with rifampicin,Ended,MIG,Migration,I,Phase I,,2006-006960-46,,000910,IS - Clin Study (MIGRATED)
10544,0511-0087,511.87,Ended,606,0511-P02,paroxetine & 2D6 PM vs flibanserin PK,Ended,MIG,Migration,IA,Phase Ia,,2006-000779-14,,000910,IS - Clin Study (MIGRATED)
10545,0511-0088,511.88,Ended,606,0511-P02,flibanserin vs bupropion PK & PD,Ended,MIG,Migration,I,Phase I,,2007-001455-19,,000910,IS - Clin Study (MIGRATED)
10546,0511-0089,511.89,Unconfirmed,606,0511-P02,Flibanserin-buspirone potentiation,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10547,0511-0090,511.90,Ended,606,0511-P02,Thorough QT study of flibanserin,Ended,MIG,Migration,I,Phase I,,2006-000780-28,,000910,IS - Clin Study (MIGRATED)
10548,0511-0091,511.91,Ended,606,0511-P02,N. Am. Patient Input About SIDI content,Ended,MIG,Migration,IIA,Phase IIa,,,,000600,Survey Patient Questionnaire
10549,0511-0092,511.92,Unconfirmed,606,0511-P02,Alcohol interaction study,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10550,0511-0093,511.93,Ended,606,0511-P02,PK interaction with oral contraceptives,Ended,MIG,Migration,IA,Phase Ia,,2006-006959-12,,000910,IS - Clin Study (MIGRATED)
10551,0511-0094,511.94,Unconfirmed,606,0511-P02,PK/safety with benzodiazepines,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10552,0511-0095,511.95,Preparing,606,0511-P02,Japanese Phase 1 multiple dose study,Preparing,MIG,Migration,IA,Phase Ia,Treatment time/pt assumes 3 doses x ... 1 wk each (25, 50, 100 mg) + 1 wk washout between doses,,,000910,IS - Clin Study (MIGRATED)
10553,0511-0096,511.96,Ended,606,0511-P02,Renal insufficiency study,Ended,MIG,Migration,IB,Phase Ib,,2006-000782-11,,000910,IS - Clin Study (MIGRATED)
10554,0511-0097,511.97,Ended,606,0511-P02,Dose strength equivalence 25/50/100mg,Ended,MIG,Migration,I,Phase I,,2007-001456-39,,000910,IS - Clin Study (MIGRATED)
10555,0511-0098,511.98,Unconfirmed,606,0511-P02,beta-blocker/2D6 substrate interaction,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10556,0511-0099,511.99,Preparing,606,0511-P02,Warfarin drug interaction,Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10557,0511-0100,511.100,Unconfirmed,606,0511-P02,Digoxin drug interaction,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10558,0511-0101,511.101,Preparing,606,0511-P02,SSRI safety study,Preparing,MIG,Migration,IA,Phase Ia,Study deleted--will do 511.87 instead ,,,000910,IS - Clin Study (MIGRATED)
10559,0511-0102,511.102,Unconfirmed,606,0511-P02,PK/sedative PD 25/50/100mg/pbo,women,Unconfirmed,MIG,Migration,IA,Phase Ia,Study deleted ,,,000910,IS - Clin Study (MIGRATED)
10560,0511-0104,511.104,Unconfirmed,606,0511-P02,Tolerability study of 100 mg qhs,Unconfirmed,MIG,Migration,IA,Phase Ia,study deleted ,,,000910,IS - Clin Study (MIGRATED)
10561,0511-0105,511.105,Ended,606,0511-P02,PK of flibanserin in female HSDD,Ended,MIG,Migration,IB,Phase Ib,lo-dose, washout, high-dose, washout ,,,000910,IS - Clin Study (MIGRATED)
10562,0511-0106,511.106,Ended,606,0511-P02,Utility of a simple diagnostic & eDiary,Ended,MIG,Migration,II,Phase II,,,,000300,IS - Methodological Studies
10563,0511-0107,511.107,Preparing,606,0511-P02,ASA-FLI bleeding PD study,Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10564,0511-0108,511.108,Ended,606,0511-P02,Rel bioavail of 100 mg by dissol rate,Ended,MIG,Migration,IA,Phase Ia,,2006-000443-26,,000910,IS - Clin Study (MIGRATED)
10565,0511-0109,511.109,Unconfirmed,606,0511-P02,Bioequiv w pearlcoat,Unconfirmed,MIG,Migration,IA,Phase Ia,required if FDA denies bio-waiver 9/05 ,,,000910,IS - Clin Study (MIGRATED)
10566,0511-0111,511.111,Ended,606,0511-P02,thoro 3A inhib study,Ended,MIG,Migration,I,Phase I,,2007-002757-23,,000910,IS - Clin Study (MIGRATED)
10567,0511-0114,511.114,Ended,606,0511-P02,Safety in Depression with SSRIs/SNRIs,Ended,MIG,Migration,IIIB,Phase IIIb,+1 wk  post-treatment (withdrawal) screening may be 14 to 28 days,,,000910,IS - Clin Study (MIGRATED)
10568,0511-0117,511.117,Ended,606,0511-P02,SRD+MRD Tolerance & PK in Japan,Ended,MIG,Migration,IA,Phase Ia,Doses, blinding tbd; rising-dose design assuming doses = 25, 50, and 100 mg + 6 day washout between doses + 1 wk final followup,,,000910,IS - Clin Study (MIGRATED)
10569,0511-0118,511.118,Ended,606,0511-P02,7-month safety of flibanserin in Europe,Ended,MIG,Migration,IIIA,Phase IIIa,Replaces participation in 511.84 for EU ,2007-004076-38,,000910,IS - Clin Study (MIGRATED)
10570,0511-0119,511.119,Unconfirmed,606,0511-P02,efficacy 25 mg FLI v Pbo premeno HSDD,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10571,0511-0120,511.120,Unconfirmed,606,0511-P02,6-MO ext for completers of .119,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,Only for 511.119 pts (not yet approved) ,,,000910,IS - Clin Study (MIGRATED)
10572,0511-0121,511.121,Ended,606,0511-P02,FSDS-R Content validity study,Ended,MIG,Migration,NONE,Not Classified,Screening = Diagnosis and in/exclusions CRO named UBC conducts cognitive debriefing interviews of pts,,,000300,IS - Methodological Studies
10573,0511-0122,511.122,Preparing,606,0511-P02,New sex. distress scale: concept/content,Preparing,MIG,Migration,NONE,Not Classified,screen: diagnosis & in/exclusions UBC asks pts what sexual distress means, creates new scale, asks its clarity & relevance.,,,000300,IS - Methodological Studies
10574,0511-0123,511.123,Analysis,606,0511-P02,Brain activity in women with HSDD,Analysis,MIG,Migration,IB,Phase Ib,goals and design tbd,2008-001103-38,,000910,IS - Clin Study (MIGRATED)
10575,0511-0126,511.126,Preparing,606,0511-P02,Brain Imaging of HSDD pts on flibanserin,Preparing,MIG,Migration,IB,Phase Ib,none none,,,000910,IS - Clin Study (MIGRATED)
10576,0511-0127,511.127,Preparing,606,0511-P02,Pivotal Trial FLI for HSDD in East Asia,Preparing,MIG,Migration,IIIA,Phase IIIa,More entered in China than Korea? 13 wk "treatment" includes 1 week post-treatment evaluation,,,000910,IS - Clin Study (MIGRATED)
10577,0511-0128,511.128,Unconfirmed,606,0511-P02,Ph II Pilot Study of FHSDD pts in Japan,Unconfirmed,MIG,Migration,IIA,Phase IIa,design and objectives highly tentative Depends on feasibility of indication to PDMA tbd early 2008,,,000910,IS - Clin Study (MIGRATED)
10578,0511-0129,511.129,Ended,606,0511-P02,HSDD Registry,Ended,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
10579,0511-0138,511.138,Unconfirmed,606,0511-P02,Relationship assessment,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
10580,0511-0139,511.139,Unconfirmed,606,0511-P02,Flibanserin and behavioral therapy,Unconfirmed,MIG,Migration,IV,Phase IV,either cross from Rx/pbo->Rx/pbo+CBT... or randomize to CBT/no CBT at the start,,,000910,IS - Clin Study (MIGRATED)
10581,0511-0140,511.140,Unconfirmed,606,0511-P02,Validation of FSD measures in Japan,Unconfirmed,MIG,Migration,II,Phase II,,,,000300,IS - Methodological Studies
10582,0511-0144,511.144,Ended,606,0511-P02,Content valildation study of FSFI,Ended,MIG,Migration,NONE,Not Classified,recommended by external experts June 4 to aid approvability of premenopausal NDA,,,000300,IS - Methodological Studies
10583,0511-0145,511.145,Preparing,606,0511-P02,Recall study of FSFI,Preparing,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
10584,0511-0147,511.147,Ended,606,0511-P02,Fixed 100mg vs Plb/ HSDD,Ended,MIG,Migration,IIIA,Phase IIIa,NDA approvability may hinge on this trial,,,000910,IS - Clin Study (MIGRATED)
10585,0511-0150,511.150,Unconfirmed,606,0511-P02,Flex vs fixed dose pivotal #2,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,Recommended for CTMS by  Dr. Voigt... ...in case FDA requires on 8 Jan '09 a second such trial,,,000910,IS - Clin Study (MIGRATED)
10586,0511-0151,511.151,Ended,606,0511-P02,2nd FSFI content validity study,Ended,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
10587,0511-0154,511.154,Unconfirmed,606,0511-P02,Outside US HSCD prevalence Study,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
10588,0511-0155,511.155,Ended,606,0511-P02,US Prevalence of HSDD in Women,Ended,MIG,Migration,NONE,Not Classified,sample to match most recent census Data 1 visit; dx of HSDD per DSDS.  Please add Sexual Symptoms Checklist to dx FSAD, FOD, sexual pain dis.,,,000600,Survey Patient Questionnaire
10589,0511-0159,511.159,Unconfirmed,606,0511-P02,FLI 100 mg v pbo for EU premeno HSDD,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,12 wk treatment sought; 24=worst case No. of EU countries tbd, but at least 6,,,000910,IS - Clin Study (MIGRATED)
10590,0511-0162,511.162,Preparing,606,0511-P02,Bioequivalence study,Preparing,MIG,Migration,IA,Phase Ia,,2010-018951-89,,000910,IS - Clin Study (MIGRATED)
10591,0511-0163,511.163,Unconfirmed,606,0511-P02,Efficacy/Safety in Indian women w HSDD,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10592,0511-0164,511.164,Unconfirmed,606,0511-P02,Validating endpoints for India,Unconfirmed,MIG,Migration,NONE,Not Classified,cognitive debriefing -> content validity nontreatment study, 1 visit, max 30 women,,,000600,Survey Patient Questionnaire
10593,0511-0165,511.165,Unconfirmed,606,0511-P02,Validating HSDD endpoints in China,Unconfirmed,MIG,Migration,NONE,Not Classified,single-visit study (interview) ,,,000600,Survey Patient Questionnaire
10594,0511-0166,511.166,Unconfirmed,606,0511-P02,Validating HSDD endpoints in Korea,Unconfirmed,MIG,Migration,NONE,Not Classified,single-visit interview study ,,,000600,Survey Patient Questionnaire
10595,0511-0167,511.167,Unconfirmed,606,0511-P02,Efficacy in SSRI/SNRI users,Unconfirmed,MIG,Migration,IV,Phase IV,Release, design depend on NDA and .114 Go if NDA approved and .114 SSRI users safety study results favorable,,,000910,IS - Clin Study (MIGRATED)
10596,0511-0168,511.168,Unconfirmed,606,0511-P02,Efficacy on relationship distress,Unconfirmed,MIG,Migration,IV,Phase IV,Relationship measure already developed No more validation studies needed before initiation of this trial,,,000910,IS - Clin Study (MIGRATED)
10597,0511-0169,511.169,Unconfirmed,606,0511-P02,FLI PK with mod CYP3A inhibitor,Unconfirmed,MIG,Migration,IA,Phase Ia,Design tbd by MST June 4 ,,,000910,IS - Clin Study (MIGRATED)
10598,0511-0170,511.170,Unconfirmed,606,0511-P02,Alcohol-FLI interaction,Unconfirmed,MIG,Migration,I,Phase I,no conceivable benefit to subjects 4 txs: FLI 100 mg, FLI pbo, 0.7 g/kg ethyl alcohol, pbo-alcohol solution,,,000910,IS - Clin Study (MIGRATED)
10599,0511-0171,511.171,Unconfirmed,606,0511-P02,Supratherapeutic exposure RE orthostasis,Unconfirmed,MIG,Migration,IA,Phase Ia,QT relevant but not a thoro QT study PK, VAS drowsy, routine labs also to help interpret overall safety,,,000910,IS - Clin Study (MIGRATED)
10600,1024-0005,1024.5,Ended,607,1024-P03,Bioavailability, under influence of food,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10601,1024-0006,1024.6,Preparing,607,1024-P03,Safety Study Ibuprofen Meltrex f-c tabl,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10602,1197-0001,1197.1,Unconfirmed,608,1197-P01,Escalated single oral doses,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
10603,1197-0002,1197.2,Unconfirmed,608,1197-P01,Escalated multiple oral doses,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10604,1197-0003,1197.3,Unconfirmed,608,1197-P01,IV Endotoxin Challenge,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10605,0107-0256,107.256,Unconfirmed,609,0107-P14,Mel 3.75 and 7.5 vs Placebo, OA hip/knee,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10606,0107-0257,107.257,Unconfirmed,609,0107-P14,Mel 3.75,7.5 vs Placebo in OA Hip/Knee,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10607,0107-0261,107.261,Unconfirmed,609,0107-P14,Onset of Action Trial,Unconfirmed,MIG,Migration,III,Phase III,preliminary info based on current info ,,,000910,IS - Clin Study (MIGRATED)
10608,0107-0263,107.263,Unconfirmed,609,0107-P14,Actual Use Trial,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
10609,1198-0001,1198.1,Ended,610,1198-P01,Single dose I (1253/116),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10610,1198-0002,1198.2,Ended,610,1198-P01,Single dose II (1253/122),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10611,1198-0003,1198.3,Ended,610,1198-P01,Single dose, food interaction (1253/130),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10612,1198-0004,1198.4,Ended,610,1198-P01,Single dose elderly (1253/131),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10613,1198-0005,1198.5,Ended,610,1198-P01,Multiple dose, healthy subj. (1253/141),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10614,1198-0006,1198.6,Ended,610,1198-P01,Metoprolol CYP2D6 inhibition (Q21125),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10615,1198-0007,1198.7,Unconfirmed,610,1198-P01,CYP2D6 interaction trial II,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10616,1198-0008,1198.8,Ended,610,1198-P01,Effect 3A4 interaction with Itraconazol,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10617,1198-0009,1198.9,Unconfirmed,610,1198-P01,Cimetidine interaction, pts w/t low CrCl,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10618,1198-0010,1198.10,Unconfirmed,610,1198-P01,Interaction study V,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10619,1198-0011,1198.11,Ended,610,1198-P01,14C ADME microdose of 3 mg (PBR 013081),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10620,1198-0012,1198.12,Ended,610,1198-P01,Safety, tolerability, PK - i.v.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10621,1198-0013,1198.13,Unconfirmed,610,1198-P01,Bioavailability & inhibition,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10622,1198-0014,1198.14,Ended,610,1198-P01,PC in decreased kidney funtion (Q21150),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10623,1198-0015,1198.15,Ended,610,1198-P01,PET dopamine transp. occupancy (Q21149),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10624,1198-0016,1198.16,Unconfirmed,610,1198-P01,Specific ECG investigation,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10625,1198-0017,1198.17,Ended,610,1198-P01,Abuse liability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10626,1198-0018,1198.18,Unconfirmed,610,1198-P01,Hepatic dysfunction,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10627,1198-0019,1198.19,Unconfirmed,610,1198-P01,L-Dopa (Kinetics),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10628,1198-0020,1198.20,Unconfirmed,610,1198-P01,Pramipexole,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10629,1198-0021,1198.21,Unconfirmed,610,1198-P01,Selegeline,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10630,1198-0023,1198.23,Unconfirmed,610,1198-P01,Interaction w/t Dopamine Ag. (Kinetics),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10631,1198-0024,1198.24,Unconfirmed,610,1198-P01,Interaction w anticholin. (Kinetics),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10632,1198-0025,1198.25,Ended,610,1198-P01,0.75 mg tolerability in healthy elderly,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10633,1198-0026,1198.26,Ended,610,1198-P01,Single dose Phase I Japan,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10634,1198-0027,1198.27,Unconfirmed,610,1198-P01,Multiple dose Phase I Japan,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10635,1198-0028,1198.28,Unconfirmed,610,1198-P01,Dose strength equivalence,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10636,1198-0029,1198.29,Unconfirmed,610,1198-P01,PK in different Ethnic population,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10637,1198-0030,1198.30,Unconfirmed,610,1198-P01,Desipramin interaction,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10638,1198-0031,1198.31,Unconfirmed,610,1198-P01,Rifampin interaction,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10639,1198-0032,1198.32,Unconfirmed,610,1198-P01,Itraconazol steady state,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10640,1198-0033,1198.33,Unconfirmed,610,1198-P01,Warfarin interaction,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10641,1198-0034,1198.34,Unconfirmed,610,1198-P01,Digoxin interaction,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10642,1198-0035,1198.35,Unconfirmed,610,1198-P01,dummy 35,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10643,1198-0036,1198.36,Unconfirmed,610,1198-P01,dummy 36,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10644,1198-0037,1198.37,Unconfirmed,610,1198-P01,dummy 37,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10645,1198-0038,1198.38,Unconfirmed,610,1198-P01,dummy 38,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10646,1198-0039,1198.39,Unconfirmed,610,1198-P01,dummy 39,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10647,1198-0040,1198.40,Unconfirmed,610,1198-P01,dummy 40,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10648,1198-0041,1198.41,Unconfirmed,610,1198-P01,dummy 41,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10649,1198-0042,1198.42,Unconfirmed,610,1198-P01,dummy 42,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10650,1198-0043,1198.43,Unconfirmed,610,1198-P01,dummy 43,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10651,1198-0044,1198.44,Unconfirmed,610,1198-P01,dummy 44,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10652,1198-0045,1198.45,Unconfirmed,610,1198-P01,dummy 45,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10653,1198-0046,1198.46,Unconfirmed,610,1198-P01,dummy 46,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10654,1198-0047,1198.47,Unconfirmed,610,1198-P01,dummy 47,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10655,1198-0048,1198.48,Unconfirmed,610,1198-P01,dummy 48,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10656,1198-0049,1198.49,Unconfirmed,610,1198-P01,dummy 49,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10657,1198-0100,1198.100,Ended,610,1198-P01,Early proof of concept & dose finding,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10658,1198-0101,1198.101,Ended,610,1198-P01,Advanced PD POC trial (ADVANS),Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10659,1198-0102,1198.102,Unconfirmed,610,1198-P01,Pivotal trial against Plac. in early PD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10660,1198-0103,1198.103,Unconfirmed,610,1198-P01,Pivotal ag. Plac. and L-Dopa in early PD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10661,1198-0104,1198.104,Unconfirmed,610,1198-P01,Imaging study in early PD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10662,1198-0105,1198.105,Unconfirmed,610,1198-P01,Pivotal comp. ag. Plac. in advanced PD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10663,1198-0106,1198.106,Unconfirmed,610,1198-P01,Pivotal comp. ag. plac. & DA in adv. PD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10664,1198-0107,1198.107,Unconfirmed,610,1198-P01,Comp. trial ag. Entacapone in adv. PD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10665,1198-0108,1198.108,Unconfirmed,610,1198-P01,Long term open label extension,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10666,1198-0109,1198.109,Unconfirmed,610,1198-P01,L-Dopa Sparing Effect,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10667,1198-0110,1198.110,Ended,610,1198-P01,First admin. in PD (safety experience),Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10668,1198-0111,1198.111,Preparing,610,1198-P01,Pivotal trial against Placebo,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10669,1198-0112,1198.112,Preparing,610,1198-P01,Pivotal trial against Ropinirole and Plb,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10670,1198-0113,1198.113,Preparing,610,1198-P01,pivotal trial against Placebo in adv. PD,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10671,1198-0114,1198.114,Preparing,610,1198-P01,Pivotal trial 2against Plb in adv. PD,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10672,1198-0115,1198.115,Preparing,610,1198-P01,Piv.l trial 3 vrs Rop and Plb (adv PD),Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10673,1198-0116,1198.116,Preparing,610,1198-P01,Open label follow up study in early PD,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10674,1198-0117,1198.117,Preparing,610,1198-P01,Open label follow-up study in adv PD,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10675,1198-0022,1198.22,Ended,611,1198-P02,NS 2330 safety add-on Donepezil,Ended,MIG,Migration,IIA,Phase IIa,,2004-001100-12,,000910,IS - Clin Study (MIGRATED)
10676,1198-0050,1198.50,Ended,611,1198-P02,Multiple dose saf. & tol. (AD 2330-003),Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10677,1198-0051,1198.51,Ended,611,1198-P02,Safety & tolerabil. study (AD 2330-004),Ended,MIG,Migration,II,Phase II,+Neurosearch ,,,000910,IS - Clin Study (MIGRATED)
10678,1198-0052,1198.52,Ended,611,1198-P02,Proof of concept study (AD 2330-007),Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10679,1198-0053,1198.53,Preparing,611,1198-P02,Piv trail II NSvsPl&DPZ, 6mon, MMS 10-26,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10680,1198-0054,1198.54,Preparing,611,1198-P02,Piv trial I NS vs Pl, 6 mon, MMS 10-26,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10681,1198-0055,1198.55,Unconfirmed,611,1198-P02,Pivl trial III vs Pl, 6 mon, MMS 4-18,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10682,1198-0056,1198.56,Unconfirmed,611,1198-P02,Head-to-head DPZ (12 month),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10683,1198-0057,1198.57,Preparing,611,1198-P02,Combination treatment with DZP, add on,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10684,1198-0058,1198.58,Preparing,611,1198-P02,Open label extension (1-3 years),Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10685,1198-0059,1198.59,Unconfirmed,611,1198-P02,Behaviour in moderate DAT (6 month),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10686,1198-0060,1198.60,Unconfirmed,611,1198-P02,Pivl trial IV vs Pl, 6 mon, MMS 10-26,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10687,1198-0061,1198.61,Unconfirmed,611,1198-P02,dummy 61,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10688,1198-0062,1198.62,Unconfirmed,611,1198-P02,dummy 62,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10689,1198-0063,1198.63,Unconfirmed,611,1198-P02,dummy 63,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10690,1198-0064,1198.64,Unconfirmed,611,1198-P02,dummy 64,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10691,1198-0065,1198.65,Unconfirmed,611,1198-P02,dummy 65,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10692,1198-0066,1198.66,Unconfirmed,611,1198-P02,dummy 66,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10693,1198-0067,1198.67,Unconfirmed,611,1198-P02,dummy 67,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10694,1198-0068,1198.68,Unconfirmed,611,1198-P02,dummy 68,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10695,1198-0069,1198.69,Unconfirmed,611,1198-P02,dummy 69,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10696,1198-0070,1198.70,Unconfirmed,611,1198-P02,dummy 70,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10697,1198-0071,1198.71,Unconfirmed,611,1198-P02,dummy 71,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10698,1198-0072,1198.72,Unconfirmed,611,1198-P02,dummy 72,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10699,1198-0073,1198.73,Unconfirmed,611,1198-P02,dummy 73,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10700,1198-0074,1198.74,Unconfirmed,611,1198-P02,dummy 74,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10701,1198-0075,1198.75,Unconfirmed,611,1198-P02,dummy 75,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10702,1198-0076,1198.76,Unconfirmed,611,1198-P02,dummy 76,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10703,1198-0077,1198.77,Unconfirmed,611,1198-P02,dummy 77,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10704,1198-0078,1198.78,Unconfirmed,611,1198-P02,dummy 78,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10705,1198-0079,1198.79,Unconfirmed,611,1198-P02,dummy 79,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10706,1198-0080,1198.80,Unconfirmed,611,1198-P02,dummy 80,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10707,1198-0081,1198.81,Unconfirmed,611,1198-P02,dummy 81,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10708,1198-0082,1198.82,Unconfirmed,611,1198-P02,dummy 82,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10709,1198-0083,1198.83,Unconfirmed,611,1198-P02,dummy 83,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10710,1198-0084,1198.84,Unconfirmed,611,1198-P02,dummy 84,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10711,1198-0085,1198.85,Unconfirmed,611,1198-P02,dummy 85,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10712,1198-0086,1198.86,Unconfirmed,611,1198-P02,dummy 86,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10713,1198-0087,1198.87,Unconfirmed,611,1198-P02,dummy 87,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10714,1198-0088,1198.88,Unconfirmed,611,1198-P02,dummy 88,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10715,1198-0089,1198.89,Unconfirmed,611,1198-P02,dummy 89,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10716,1198-0090,1198.90,Unconfirmed,611,1198-P02,dummy 90,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10717,1198-0091,1198.91,Unconfirmed,611,1198-P02,dummy 91,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10718,1198-0092,1198.92,Unconfirmed,611,1198-P02,dummy 92,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10719,1198-0093,1198.93,Unconfirmed,611,1198-P02,dummy 93,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10720,1198-0094,1198.94,Unconfirmed,611,1198-P02,dummy 94,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10721,1198-0095,1198.95,Unconfirmed,611,1198-P02,dummy 95,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10722,1198-0096,1198.96,Unconfirmed,611,1198-P02,dummy 96,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10723,1198-0097,1198.97,Unconfirmed,611,1198-P02,dummy 97,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10724,1198-0098,1198.98,Unconfirmed,611,1198-P02,dummy 98,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10725,1198-0099,1198.99,Unconfirmed,611,1198-P02,dummy 99,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10726,1199-0001,1199.1,Ended,613,1199-P01,Phase I Study in Various Cancers,Ended,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10727,1199-0002,1199.2,Ended,613,1199-P01,Phase I in Refractory Multiple Myeloma,Ended,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10728,1199-0003,1199.3,Ended,613,1199-P01,Phase I continous dosing in var. cancers,Ended,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10729,1199-0004,1199.4,Ended,613,1199-P01,Phase I comb. w. docetaxel,Ended,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10730,1199-0006,1199.6,Ended,613,1199-P01,Phase I comb. w. paclitaxel/carboplatin,Ended,MIG,Migration,I,Phase I,,2005-001467-55,,000910,IS - Clin Study (MIGRATED)
10731,1199-0007,1199.7,Unconfirmed,613,1199-P01,Phase I comb. in advanced lung cancer,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10732,1199-0008,1199.8,Unconfirmed,613,1199-P01,Phase II high-risk stage D0 rising PSA,Unconfirmed,MIG,Migration,IIA,Phase IIa,Monitoring Visits: 2 days every 4 weeks ,,,000910,IS - Clin Study (MIGRATED)
10733,1199-0009,1199.9,Ended,613,1199-P01,Phase II ovarian cancer w. rising CA-125,Ended,MIG,Migration,IIA,Phase IIa,Monitoring Visits:approx 1 day/4 weeks ,2005-002427-14,,000910,IS - Clin Study (MIGRATED)
10734,1199-0011,1199.11,Ended,613,1199-P01,Phase II in advanced prostate cancer,Ended,MIG,Migration,IIA,Phase IIa,,2005-002426-55,,000910,IS - Clin Study (MIGRATED)
10735,1199-0012,1199.12,Unconfirmed,613,1199-P01,Phase III in refract. prostate ca.,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10736,1199-0015,1199.15,Analysis,613,1199-P01,Phase III advanced ovarian cancer,Analysis,MIG,Migration,IIIA,Phase IIIa,,2008-006831-10,,000910,IS - Clin Study (MIGRATED)
10737,1199-0016,1199.16,Ended,613,1199-P01,Phase I/ II extension study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10738,1199-0017,1199.17,Ended,613,1199-P01,Food Effect Study Phase I,Ended,MIG,Migration,IA,Phase Ia,open, randomised intra-individual crossover,2005-003695-37,,000910,IS - Clin Study (MIGRATED)
10739,1199-0020,1199.20,Ended,613,1199-P01,Human ADME Study in Healthy Volunteers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10740,1199-0021,1199.21,Ended,613,1199-P01,Bioavailability Solution vs. SGC,Ended,MIG,Migration,I,Phase I,open, randomized, intra-individual, cros sover, comparison design,2006-002518-36,,000910,IS - Clin Study (MIGRATED)
10741,1199-0022,1199.22,Unconfirmed,613,1199-P01,Phase I/II BIBF 1120 + Bevacizumab,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10742,1199-0023,1199.23,Unconfirmed,613,1199-P01,Phase I/II BIBF 1120 + FOLFIRI,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
10743,1199-0024,1199.24,Unconfirmed,613,1199-P01,Phase III CRC BIBF1120/ BIBW2992,Unconfirmed,MIG,Migration,III,Phase III,Pivotal study (accelerated approval) ,,,000910,IS - Clin Study (MIGRATED)
10744,1199-0025,1199.25,Unconfirmed,613,1199-P01,Phase III CRC BIBF 1120/BIBW 2992,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10745,1199-0038,1199.38,Unconfirmed,613,1199-P01,BIBF 1120 and Everolimus in RCC,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10746,1199-0076,1199.76,Unconfirmed,613,1199-P01,BIBF 1120 + dose dense C/P in OC,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10747,1199-0083,1199.83,Unconfirmed,613,1199-P01,BIBF1120 maintenance for Pt resistant OC,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
10748,1199-0127,1199.127,Unconfirmed,613,1199-P01,BIBF1120+chemo 1st line endometrial CA,Unconfirmed,MIG,Migration,III,Phase III,details of study to be determined ,,,000910,IS - Clin Study (MIGRATED)
10749,1199-0149,1199.149,Unconfirmed,613,1199-P01,BIBF 1120 + PLD forPt  resistant OC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10750,1199-0198,1199.198,Unconfirmed,613,1199-P01,Nintedanib in low risk 1st line OC,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
10751,0205-0112,205.112,Ended,614,0205-P03,Multiple increasing dose tolerance study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10752,0205-0127,205.127,Ended,614,0205-P03,Dose ranging Respimat,Ended,MIG,Migration,IIB,Phase IIb,- ,,,000910,IS - Clin Study (MIGRATED)
10753,0205-0138,205.138,Ended,614,0205-P03,Ocular Safety of Tiotropium,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10754,0205-0209,205.209,Unconfirmed,614,0205-P03,3 month safety and efficacy (Respimat),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10755,0205-0210,205.210,Unconfirmed,614,0205-P03,Respimat dose ranging study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10756,0205-0212,205.212,Unconfirmed,614,0205-P03,Respimat tiotropium vs Atrovent,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10757,0205-0213,205.213,Unconfirmed,614,0205-P03,Respimat tiotropium vs salmeterol,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10758,0205-0225,205.225,Unconfirmed,614,0205-P03,Tiotropium Respimat Phase II trial,Unconfirmed,MIG,Migration,III,Phase III,Phase III placeholder for Tio Respimat ,,,000910,IS - Clin Study (MIGRATED)
10759,0205-0248,205.248,Ended,614,0205-P03,Tolerability of low pH in asthma patient,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10760,0205-0249,205.249,Ended,614,0205-P03,Respimat 4-week crossover trial,Ended,MIG,Migration,III,Phase III,Paired study with 205.250 ,,,000910,IS - Clin Study (MIGRATED)
10761,0205-0250,205.250,Ended,614,0205-P03,Respimat 6-week capsule cont trial 2,Ended,MIG,Migration,III,Phase III,Paired study with 205.249 ,,,000910,IS - Clin Study (MIGRATED)
10762,0205-0251,205.251,Ended,614,0205-P03,Respimat 12-week Atrovent cont trial 1,Ended,MIG,Migration,IIIA,Phase IIIa,Paired study with 205.252 ,,,000910,IS - Clin Study (MIGRATED)
10763,0205-0252,205.252,Ended,614,0205-P03,Respimat 12-week Atrovent cont trial 2,Ended,MIG,Migration,IIIA,Phase IIIa,Paired study with 205.251 ,,,000910,IS - Clin Study (MIGRATED)
10764,0205-0253,205.253,Unconfirmed,614,0205-P03,Respimat 12-week Atrovent cont trial 2,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10765,0205-0254,205.254,Ended,614,0205-P03,Respimat one-year placebo cont trial 1,Ended,MIG,Migration,III,Phase III,Paired study with 205.255 ,,,000910,IS - Clin Study (MIGRATED)
10766,0205-0255,205.255,Ended,614,0205-P03,Respimat one-year placebo cont trial 2,Ended,MIG,Migration,III,Phase III,Paired study with 205.254 ,,,000910,IS - Clin Study (MIGRATED)
10767,0205-0260,205.260,Unconfirmed,614,0205-P03,Phase I Respimat in Japan,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10768,0205-0291,205.291,Ended,614,0205-P03,Tiotropium Respimat Ph2 crossover study,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
10769,0205-0310,205.310,Unconfirmed,614,0205-P03,Spiriva respimat vs Atrovent MDI in COPD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10770,0205-0353,205.353,Unconfirmed,614,0205-P03,New dyspnoea tool in COPD on Tio RMT,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10771,0205-0372,205.372,Ended,614,0205-P03,Efficacy/safety of 5mcg tio. in COPD,Ended,MIG,Migration,III,Phase III,,2006-001009-27,,000910,IS - Clin Study (MIGRATED)
10772,0205-0392,205.392,Ended,614,0205-P03,Retro.Vital Status Ascertainm. COPD Pat,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10773,0205-0426,205.426,Ended,614,0205-P03,German Spiriva Respimat PMS,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
10774,0205-0452,205.452,Ended,614,0205-P03,TIOSPIR,Ended,MIG,Migration,IIIB,Phase IIIb,Trial duration is event-driven BI only study. - Although the trial design is in principle event-driven a minimum treatment duration of two years will apply for the individual.,2009-015713-51,,,
10775,0205-0458,205.458,Ended,614,0205-P03,PK & Dose Ranging in COPD,Ended,MIG,Migration,II,Phase II,,2009-016251-21,,000910,IS - Clin Study (MIGRATED)
10776,0205-0463,205.463,Ended,614,0205-P03,Drug use survey of RESPIMAT,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
10777,0205-0471,205.471,Ended,614,0205-P03,Respimat PIC evaluation,Ended,MIG,Migration,IV,Phase IV,Alliance study, GPV # 10137 ,,,000600,Survey Patient Questionnaire
10778,0205-0509,205.509,Unconfirmed,614,0205-P03,Tiotropium RMT twin I,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10779,0205-0510,205.510,Preparing,614,0205-P03,Tio RMT 6 months pbo cont trial 1,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10780,0205-0511,205.511,Preparing,614,0205-P03,Tio RMT 6 months pbo cont trial 2,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10781,0205-0514,205.514,Ended,614,0205-P03,Patient Device Satisfaction Study,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
10782,0205-0524,205.524,Unconfirmed,614,0205-P03,Respimat handling Germany-NIS,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
10783,0205-0532,205.532,Unconfirmed,614,0205-P03,Inhaler training/behavioral intervention,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000920,NISnd - Study (MIGRATED)
10784,0205-0535,205.535,Unconfirmed,614,0205-P03,Anti-inflammatory effects of tiotropium,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
10785,1123-0018,1123.18,Ended,615,1123-P02,Cardiac Arrest,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10786,0503-0203,503.203,Ended,616,0503-P02,Pharmacodynamic dose finding study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10787,0503-0204,503.204,Ended,616,0503-P02,Safety confirmatory study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10788,0503-0205,503.205,Preparing,616,0503-P02,Food interaction study,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10789,0503-0206,503.206,Unconfirmed,616,0503-P02,PFF - cilobradine vs zatebradine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10790,0503-0207,503.207,Preparing,616,0503-P02,Safety & Heart Rate verification,Preparing,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
10791,0503-0208,503.208,Unconfirmed,616,0503-P02,Proof of concept in systolic HF,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
10792,0503-0209,503.209,Ended,616,0503-P02,C14 ADME study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10793,0503-0210,503.210,Preparing,616,0503-P02,Digoxin Interaction Study,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10794,0503-0211,503.211,Unconfirmed,616,0503-P02,Warfarin Interaction Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10795,0503-0212,503.212,Unconfirmed,616,0503-P02,Diastolic HF -Preliminary efficacy,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10796,0503-0213,503.213,Ended,616,0503-P02,Itraconazole interaction study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10797,0503-0214,503.214,Unconfirmed,616,0503-P02,Statin interaction study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10798,0503-0215,503.215,Unconfirmed,616,0503-P02,Nicardipine interaction study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10799,0503-0216,503.216,Unconfirmed,616,0503-P02,Driving and operating machinery trial,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10800,0248-0524,248.524,Ended,617,0248-P07,Pivotal study in early PD patients,Ended,MIG,Migration,IIIA,Phase IIIa,test export again ,2007-000073-39,,000910,IS - Clin Study (MIGRATED)
10801,0248-0525,248.525,Ended,617,0248-P07,Pivotal study in advanced PD patients,Ended,MIG,Migration,IIIA,Phase IIIa,,2007-000074-23,,000910,IS - Clin Study (MIGRATED)
10802,0248-0526,248.526,Unconfirmed,617,0248-P07,Dose finding study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10803,0248-0528,248.528,Unconfirmed,617,0248-P07,PPX XR tablet food effect study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10804,0248-0529,248.529,Ended,617,0248-P07,Bioavailability study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10805,0248-0530,248.530,Ended,617,0248-P07,multiple rising dose study,Ended,MIG,Migration,I,Phase I,,2005-005954-34,,000910,IS - Clin Study (MIGRATED)
10806,0248-0532,248.532,Ended,617,0248-P07,Single Dose Formulation Finding Study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10807,0248-0545,248.545,Ended,617,0248-P07,Specific ECG study,Ended,MIG,Migration,I,Phase I,,2007-000970-21,,000910,IS - Clin Study (MIGRATED)
10808,0248-0560,248.560,Ended,617,0248-P07,in vivo-in vitro correlation study,Ended,MIG,Migration,I,Phase I,,2005-001666-14,,000910,IS - Clin Study (MIGRATED)
10809,0248-0561,248.561,Unconfirmed,617,0248-P07,iv/iv correlation study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10810,0248-0607,248.607,Ended,617,0248-P07,Phase I Japanese multiple dose study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10811,0248-0608,248.608,Unconfirmed,617,0248-P07,Japanese multiple rising dose study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10812,0248-0609,248.609,Ended,617,0248-P07,Magnetic monitoring study,Ended,MIG,Migration,I,Phase I,,2005-005953-23,,000910,IS - Clin Study (MIGRATED)
10813,0248-0610,248.610,Ended,617,0248-P07,Japanese safety, PK  APD study,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
10814,0248-0624,248.624,Unconfirmed,617,0248-P07,Japanese bridging study in early PD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10815,0248-0633,248.633,Ended,617,0248-P07,open label extension in early PD,Ended,MIG,Migration,III,Phase III,Am 3; duration extended with 48 weeks ,2007-004234-16,,000910,IS - Clin Study (MIGRATED)
10816,0248-0634,248.634,Ended,617,0248-P07,open label extension in advanced PD,Ended,MIG,Migration,III,Phase III,,2007-004235-37,,000910,IS - Clin Study (MIGRATED)
10817,0248-0636,248.636,Ended,617,0248-P07,Phase III switch trial,Ended,MIG,Migration,IIIA,Phase IIIa,,2007-003353-90,,000910,IS - Clin Study (MIGRATED)
10818,0248-0650,248.650,Unconfirmed,617,0248-P07,open label extension of trial 248.610,Unconfirmed,MIG,Migration,III,Phase III,trial implemented following PMDA request PMDA meeting held on May 10, 2007,,,000910,IS - Clin Study (MIGRATED)
10819,0248-0660,248.660,Unconfirmed,617,0248-P07,Add-on study of PPX ER in PD,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
10820,0248-0662,248.662,Unconfirmed,617,0248-P07,PPX ER PD Positioning Mafo,Unconfirmed,MIG,Migration,NONE,Not Classified,Non clinical trial activity, no BI drug market research,,,000600,Survey Patient Questionnaire
10821,0248-0663,248.663,Unconfirmed,617,0248-P07,Open label switch study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
10822,0248-0665,248.665,Ended,617,0248-P07,PK and BE study in China,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10823,0248-0666,248.666,Unconfirmed,617,0248-P07,PPX ER BE study in Chinese HVs,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10824,0248-0669,248.669,Preparing,617,0248-P07,Observ. Study of Sifrol retard in PD,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
10825,0248-0671,248.671,Ended,617,0248-P07,Phase III study in Parkinson disease,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10826,0248-0674,248.674,Ended,617,0248-P07,Infl of PPX ER on medication adherence,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
10827,0248-0675,248.675,Ended,617,0248-P07,PPX ER in routine clinical practice,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
10828,0248-0676,248.676,Preparing,617,0248-P07,Routine practice of PPX adm. in Greece,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
10829,0248-0677,248.677,Ended,617,0248-P07, BE and PK in Japanese HVs,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10830,0248-0680,248.680,Ended,617,0248-P07,Drug Use Result Survey of Mirapex LA,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
10831,1160-0007,1160.7,Ended,618,1160-P02,Drug interaction - diclofenac,Ended,MIG,Migration,I,Phase I,,2006-001188-40,,000910,IS - Clin Study (MIGRATED)
10832,1160-0009,1160.9,Unconfirmed,618,1160-P02,Food interaction,Unconfirmed,MIG,Migration,I,Phase I,BIPI will not participate in this trial. ,,,000910,IS - Clin Study (MIGRATED)
10833,1160-0020,1160.20,Ended,618,1160-P02,PETRO Prevention of Thrombosis in A Fib,Ended,MIG,Migration,IIB,Phase IIb,Modified study approved at Jan 2003 IDC ,,,000910,IS - Clin Study (MIGRATED)
10834,1160-0023,1160.23,Ended,618,1160-P02,PK in patients with renal insufficiency,Ended,MIG,Migration,I,Phase I,,2004-005280-20,,000910,IS - Clin Study (MIGRATED)
10835,1160-0026,1160.26,Ended,618,1160-P02,RELY,Ended,MIG,Migration,IIIA,Phase IIIa,,2005-003894-26,,000910,IS - Clin Study (MIGRATED)
10836,1160-0027,1160.27,Preparing,618,1160-P02,PETRO-2b,Preparing,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
10837,1160-0028,1160.28,Ended,618,1160-P02,PK and PD in Japanese and Caucasian,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10838,1160-0029,1160.29,Ended,618,1160-P02,PK and PD in Asians,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10839,1160-0035,1160.35,Unconfirmed,618,1160-P02,PETRO-1B Dose-titration in AF patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
10840,1160-0036,1160.36,Unconfirmed,618,1160-P02,BIBR 1048 Pk in elderly,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10841,1160-0041,1160.41,Unconfirmed,618,1160-P02,Open label Follow-up Treatment in A Fib.,Unconfirmed,MIG,Migration,IIA,Phase IIa,duplicate of 1160.42--PLEASE IGNORE ,,,000910,IS - Clin Study (MIGRATED)
10842,1160-0042,1160.42,Ended,618,1160-P02,Open Label Follow-up Treatment in A Fib,Ended,MIG,Migration,IIA,Phase IIa,Trial extended by 2 yrs Nov 05 ,,,000910,IS - Clin Study (MIGRATED)
10843,1160-0043,1160.43,Unconfirmed,618,1160-P02,Food Effects in Japanese,Unconfirmed,MIG,Migration,I,Phase I,requested by Mr. Tomimori ,,,000910,IS - Clin Study (MIGRATED)
10844,1160-0044,1160.44,Unconfirmed,618,1160-P02,PK in Japanese Elderly Population,Unconfirmed,MIG,Migration,I,Phase I,requested by Mr Tomimori May 7, 2003 ,,,000910,IS - Clin Study (MIGRATED)
10845,1160-0049,1160.49,Ended,618,1160-P02,Phase II pilot study, Japan,Ended,MIG,Migration,IIA,Phase IIa,preliminary description ,,,000910,IS - Clin Study (MIGRATED)
10846,1160-0051,1160.51,Ended,618,1160-P02,Kinetics of dabigatran in liver failure,Ended,MIG,Migration,I,Phase I,,2004-005281-20,,000910,IS - Clin Study (MIGRATED)
10847,1160-0052,1160.52,Ended,618,1160-P02,Polymorphs 1 and 2: Comparative BA,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10848,1160-0054,1160.54,Ended,618,1160-P02,Effect of dabigatran on QT-Interval,Ended,MIG,Migration,I,Phase I,A randomised, placebo controlled, double three-way crossover study with an open label positive control (moxifloxacin),2005-006154-13,,000910,IS - Clin Study (MIGRATED)
10849,1160-0055,1160.55,Ended,618,1160-P02,Phase I Japanese multiple dose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10850,1160-0056,1160.56,Ended,618,1160-P02,Bioequivalence Polym. I and II, elderly,Ended,MIG,Migration,I,Phase I,,2006-000455-18,,000910,IS - Clin Study (MIGRATED)
10851,1160-0057,1160.57,Ended,618,1160-P02,Amiodarone Interaction with Dabigatran,Ended,MIG,Migration,I,Phase I,,2006-001189-19,,000910,IS - Clin Study (MIGRATED)
10852,1160-0058,1160.58,Ended,618,1160-P02,Atorvastatin Interaction with Dabigatran,Ended,MIG,Migration,I,Phase I,,2006-001190-26,,000910,IS - Clin Study (MIGRATED)
10853,1160-0059,1160.59,Ended,618,1160-P02,Digoxin Interaction with Dabigatran,Ended,MIG,Migration,I,Phase I,,2006-001191-20,,000910,IS - Clin Study (MIGRATED)
10854,1160-0060,1160.60,Ended,618,1160-P02,Single Rising Dose for QT Study,Ended,MIG,Migration,I,Phase I,,2005-005042-39,,000910,IS - Clin Study (MIGRATED)
10855,1160-0061,1160.61,Ended,618,1160-P02,Japanese Caucasian PK Comparison,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10856,1160-0062,1160.62,Unconfirmed,618,1160-P02,ASA superiority study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
10857,1160-0066,1160.66,Ended,618,1160-P02,Polymorph I/II Bioequivalence,Ended,MIG,Migration,I,Phase I,,2007-005764-27,,000910,IS - Clin Study (MIGRATED)
10858,1160-0068,1160.68,Ended,618,1160-P02, IVAX warfarin vs Coumadin BE study,Ended,MIG,Migration,I,Phase I,probably 2 doses of warfarin each cohort receives 1 dose, 3 week washout, same dose of other brand,,,000910,IS - Clin Study (MIGRATED)
10859,1160-0070,1160.70,Ended,618,1160-P02,1st vs 2nd Generation Drug Product BE,Ended,MIG,Migration,I,Phase I,use replicate design as for 1160.56 ,2007-005765-35,,000910,IS - Clin Study (MIGRATED)
10860,1160-0071,1160.71,Ended,618,1160-P02,RELY-ABLE,Ended,MIG,Migration,IIIB,Phase IIIb,Observation period is up to 28-53 mo ,2008-005248-17,,,
10861,1160-0072,1160.72,Unconfirmed,618,1160-P02,Anticoagulant-Naive study,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,necessity of blinding not yet clear ,,,000910,IS - Clin Study (MIGRATED)
10862,1160-0073,1160.73,Ended,618,1160-P02,Safety in Cardiac Catheterization,Ended,MIG,Migration,II,Phase II,support for safety of dabigatran in the cath lab using doses of 110 and 150 mg bid,2007-007536-25,,000910,IS - Clin Study (MIGRATED)
10863,1160-0077,1160.77,Preparing,618,1160-P02,A Fib Registry,Preparing,MIG,Migration,NONE,Not Classified,observational only ,,,000600,Survey Patient Questionnaire
10864,1160-0081,1160.81,Ended,618,1160-P02,PK in Chinese Subjects,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10865,1160-0082,1160.82,Ended,618,1160-P02,clarithromycin dabigatran Inx,Ended,MIG,Migration,I,Phase I,,2008-001063-10,,000910,IS - Clin Study (MIGRATED)
10866,1160-0090,1160.90,Ended,618,1160-P02,quinidine-dabigatran safety study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10867,1160-0091,1160.91,Unconfirmed,618,1160-P02,rifampin-dabigatran interaction study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10868,1160-0092,1160.92,Unconfirmed,618,1160-P02,ritonavir-dabigatran interaction study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10869,1160-0094,1160.94,Ended,618,1160-P02,Atrial Fibrilation registry USA,Ended,MIG,Migration,NONE,Not Classified,2500 pts observed for 6 months;250 sites 1250 pts observed for 1 day,,,000600,Survey Patient Questionnaire
10870,1160-0107,1160.107,Ended,618,1160-P02,AF Registry in Greece (RAFTING study),Ended,MIG,Migration,IV,Phase IV,A registry of patients suffering from AF Recruitment from Emergency Departments of participating hospitals/investigational sites.,,,,
10871,1160-0110,1160.110,Ended,618,1160-P02,ACT-AF,Ended,MIG,Migration,NONE,Not Classified,Non-trial activity ,,,000600,Survey Patient Questionnaire
10872,1160-0112,1160.112,Ended,618,1160-P02,Dronedarone DDI study,Ended,MIG,Migration,I,Phase I,,2010-024009-11,,000910,IS - Clin Study (MIGRATED)
10873,1160-0116,1160.116,Preparing,618,1160-P02,Charcoal filtration in man (DABI),Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10874,1160-0120,1160.120,Ended,618,1160-P02,Patient flow for AF patients in Denmark,Ended,MIG,Migration,NONE,Not Classified,This is an NTA with the number #10131 ,,,000930,NISed - Study (MIGRATED)
10875,1160-0121,1160.121,Ended,618,1160-P02,Hemodialysis in man (DABI),Ended,MIG,Migration,I,Phase I,,2010-021819-16,,000910,IS - Clin Study (MIGRATED)
10876,1160-0122,1160.122,Ended,618,1160-P02,Dabigatran on atrial fibrosis,Ended,MIG,Migration,IV,Phase IV,,,,,
10877,1160-0123,1160.123,Ended,618,1160-P02,IMPACT Market Research Emerging Markets,Ended,MIG,Migration,NONE,Not Classified,This is an NTA with the number #10298 ,,,000600,Survey Patient Questionnaire
10878,1160-0124,1160.124,Preparing,618,1160-P02,Pradaxa Product Familiarisation Program,Preparing,MIG,Migration,NONE,Not Classified,This is an NTA with the number #10179 ,,,000980,Not Classified (MIGRATED)
10879,1160-0125,1160.125,Ended,618,1160-P02,Dabigatran in Ablation of AF - DAPPAR-AF,Ended,MIG,Migration,IV,Phase IV,,,,,
10880,1160-0127,1160.127,Unconfirmed,618,1160-P02,Cardioversion,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
10881,1160-0128,1160.128,Ended,618,1160-P02,GI Adverse Events,Ended,MIG,Migration,IV,Phase IV,,,,,
10882,1160-0130,1160.130,Ended,618,1160-P02,PMS-Japan-Efficacy and Safety Dabi SPAF,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
10883,1160-0131,1160.131,Ended,618,1160-P02,Survey on VKA challenges in AF,Ended,MIG,Migration,NONE,Not Classified,NTA #10006; C. Eschenfelder ,,,000600,Survey Patient Questionnaire
10884,1160-0132,1160.132,Ended,618,1160-P02,AFTER3,Ended,MIG,Migration,IV,Phase IV,,,,,
10885,1160-0133,1160.133,Preparing,618,1160-P02,BA of 150mg Dabi in renally impaired sub,Preparing,MIG,Migration,I,Phase I,,2011-000231-83,,000910,IS - Clin Study (MIGRATED)
10886,1160-0134,1160.134,Unconfirmed,618,1160-P02,Medical Need Program,Unconfirmed,MIG,Migration,NONE,Not Classified,This is an NTA from Belgium ,,,000980,Not Classified (MIGRATED)
10887,1160-0135,1160.135,Ended,618,1160-P02,Nordic Chart Pull,Ended,MIG,Migration,NONE,Not Classified,This is an NTA with the number #11008 ,,,000930,NISed - Study (MIGRATED)
10888,1160-0137,1160.137,Unconfirmed,618,1160-P02,Global Patients Adherence Program,Unconfirmed,MIG,Migration,NONE,Not Classified, NTA, GPVCEU#:10274; S. Formella ,,,000980,Not Classified (MIGRATED)
10889,1160-0139,1160.139,Analysis,618,1160-P02,Pradaxa NIS in Korean AF patients,Analysis,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
10890,1160-0143,1160.143,Recruiting,618,1160-P02,MANAGE Trial,Recruiting,MIG,Migration,IV,Phase IV,hybrid IIS study with PHRI ,,,,
10891,1160-0144,1160.144,Initiated,618,1160-P02,Study to evaluate pot. off-label use,Initiated,MIG,Migration,IV,Phase IV,Epi-study ,,,,
10892,1160-0146,1160.146,Ended,618,1160-P02,AF Stroke Prophylaxis Management Review,Ended,MIG,Migration,NONE,Not Classified,NTA number #11193; Responsible: M. Khera ,,,000980,Not Classified (MIGRATED)
10893,1160-0147,1160.147,Unconfirmed,618,1160-P02,Expert-AF NTA,Unconfirmed,MIG,Migration,NONE,Not Classified,NTA #11187 ,,,000980,Not Classified (MIGRATED)
10894,1160-0148,1160.148,Unconfirmed,618,1160-P02,Drive Treatment Innovation (DTI),Unconfirmed,MIG,Migration,NONE,Not Classified,NTA - BR0002 (Luciana Giangrande) ,,,000980,Not Classified (MIGRATED)
10895,1160-0149,1160.149,Ended,618,1160-P02,FUM 026/risk minimization activities,Ended,MIG,Migration,IV,Phase IV,Budget by Marketing. PASS acc. old def. ,,,,
10896,1160-0150,1160.150,Ended,618,1160-P02,TITAN Study,Ended,MIG,Migration,IV,Phase IV,NTA #11186 / Bernat Arino ,,,000300,IS - Methodological Studies
10897,1160-0151,1160.151,Preparing,618,1160-P02,Characterize US Patients with Atr.Fibr.,Preparing,MIG,Migration,NONE,Not Classified, Values from CTMS: Planned Subjects Screened: 440000, Planned Subjects Randomized: 440000, Planned Subjects Completed Treatment: ,,,000980,Not Classified (MIGRATED)
10898,1160-0152,1160.152,Unconfirmed,618,1160-P02,Health Tracker Market Research,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000980,Not Classified (MIGRATED)
10899,1160-0153,1160.153,Ended,618,1160-P02,CAFE Registry,Ended,MIG,Migration,NONE,Not Classified,NTA: #11241 - Paola Guallini ,,,000930,NISed - Study (MIGRATED)
10900,1160-0155,1160.155,Unconfirmed,618,1160-P02,Burden of AF in India,Unconfirmed,MIG,Migration,NONE,Not Classified,NTA2011-PM-PRA-IN03 / S. Bhure ,,,000600,Survey Patient Questionnaire
10901,1160-0157,1160.157,Ended,618,1160-P02,Comp.effectiveness f.oral anticoagulants,Ended,MIG,Migration,IV,Phase IV,,,,,
10902,1160-0158,1160.158,Ended,618,1160-P02,Examination of AF Patient Characteristic,Ended,MIG,Migration,IV,Phase IV,,,,000980,Not Classified (MIGRATED)
10903,1160-0161,1160.161,Ended,618,1160-P02,UK Pilot: Pradaxa Heartmind programme,Ended,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
10904,1160-0162,1160.162,Ended,618,1160-P02,Bleeding management in AF patients,Ended,MIG,Migration,IV,Phase IV,,,,000450,NISed ‚Äì Study - Other
10905,1160-0163,1160.163,Unconfirmed,618,1160-P02,Prospective bleeding management,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
10906,1160-0164,1160.164,Unconfirmed,618,1160-P02,Guideline Optimization for Afib (Go4AF),Unconfirmed,MIG,Migration,NONE,Not Classified,NTA #12NL001 - Jitske Evertse ,,,000980,Not Classified (MIGRATED)
10907,1160-0165,1160.165,Recruiting,618,1160-P02,Continued versus Interrupted Dabigatran,Recruiting,MIG,Migration,IV,Phase IV,,,,,
10908,1160-0166,1160.166,Ended,618,1160-P02,DABIRENAL,Ended,MIG,Migration,IB,Phase Ib,,2011-003081-32,,,
10909,1160-0167,1160.167,Ended,618,1160-P02,Dabigatran for AF Ablation,Ended,MIG,Migration,IV,Phase IV,,,,,
10910,1160-0168,1160.168,Unconfirmed,618,1160-P02,Asian Patients Risks and Treatment,Unconfirmed,MIG,Migration,NONE,Not Classified,NTA 12TW002 ,,,000600,Survey Patient Questionnaire
10911,1160-0169,1160.169,Last Subject Randomised,618,1160-P02,Find-AF,Last Subject Randomised,MIG,Migration,NONE,Not Classified,,,,,
10912,1160-0170,1160.170,Ended,618,1160-P02,Dabigatran in renally impaired patients,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
10913,1160-0172,1160.172,Recruiting,618,1160-P02,Pulse measurements for detection of AF,Recruiting,MIG,Migration,NONE,Not Classified,,,,,
10914,1160-0173,1160.173,Ended,618,1160-P02,75 mg PK study in NVAF renal pts,Ended,MIG,Migration,IV,Phase IV,,,,,
10915,1160-0174,1160.174,Ended,618,1160-P02,ROTEM and Multiplate Study,Ended,MIG,Migration,NONE,Not Classified,,,,,
10916,1160-0175,1160.175,Ended,618,1160-P02,Renal function in anticoagulated pat,Ended,MIG,Migration,NONE,Not Classified,,,,,
10917,1160-0176,1160.176,Ended,618,1160-P02,Perioperative Laboratory Testing,Ended,MIG,Migration,IV,Phase IV,,,,,
10918,1160-0177,1160.177,Recruiting,618,1160-P02,Anticoagulant utilization patterns,Recruiting,MIG,Migration,IV,Phase IV, Values from CTMS: Planned Subjects Screened: 100000, Planned Subjects Randomized: 100000, Planned Subjects Completed Treatment: 100000,,,000930,NISed - Study (MIGRATED)
10919,1160-0178,1160.178,Unconfirmed,618,1160-P02,Comparison of bleeding-associated..,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000930,NISed - Study (MIGRATED)
10920,1160-0179,1160.179,Unconfirmed,618,1160-P02,Drug Utilization Study Denmark,Unconfirmed,NISED,Non Interventional Study Existing Data,NONE,Not Classified,Responsibilty liegt in GEpi ,,,000930,NISed - Study (MIGRATED)
10921,1160-0180,1160.180,Preparing,618,1160-P02,Managem.of Warfarin-associated bleedings,Preparing,MIG,Migration,NONE,Not Classified,Responsibilty liegt in GEpi ,,,000930,NISed - Study (MIGRATED)
10922,1160-0181,1160.181,Unconfirmed,618,1160-P02,Head to head trial in AF,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
10923,1160-0183,1160.183,Ended,618,1160-P02,Safety, Effective of Pradaxa in DoD Pts,Ended,MIG,Migration,IV,Phase IV,,,,,
10924,1160-0185,1160.185,Unconfirmed,618,1160-P02,US RE-DUAL PCI,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
10925,1160-0186,1160.186,Analysis,618,1160-P02,RE-DUAL PCI,Analysis,MIG,Migration,III,Phase III,,2013-003201-26,,000910,IS - Clin Study (MIGRATED)
10926,1160-0187,1160.187,First Subject Randomised,618,1160-P02,Prevent. of TEE after AF cath. ablation,First Subject Randomised,MIG,Migration,IV,Phase IV,,2013-003492-35,,000150,IS - Clin Study - Explore
10927,1160-0190,1160.190,Unconfirmed,618,1160-P02,Pradaxa post ischemic stroke (SITS-1),Unconfirmed,MIG,Migration,IV,Phase IV,,,,000930,NISed - Study (MIGRATED)
10928,1160-0191,1160.191,Unconfirmed,618,1160-P02,Ischemic stroke in Pradaxa pts (SITS-2),Unconfirmed,MIG,Migration,IV,Phase IV,,,,000930,NISed - Study (MIGRATED)
10929,1160-0192,1160.192,Analysis,618,1160-P02,Safety and Effectiveness  Humana,Analysis,MIG,Migration,IV,Phase IV,,,,000460,NISed ‚Äì Study - Cohort
10930,1160-0193,1160.193,Ended,618,1160-P02,Chinese Auricular Fibrillation Registry,Ended,MIG,Migration,NONE,Not Classified,,,,,
10931,1160-0195,1160.195,Analysis,618,1160-P02,VIKTOR-FA French cohort,Analysis,MIG,Migration,NONE,Not Classified,,,,000920,NISnd - Study (MIGRATED)
10932,1160-0197,1160.197,Preparing,618,1160-P02,Channeling assessment after Riva launch,Preparing,MIG,Migration,IV,Phase IV,CDep GEpi: Dalia Shash ,,,000930,NISed - Study (MIGRATED)
10933,1160-0198,1160.198,Preparing,618,1160-P02,Assessment of bleeding in the real world,Preparing,MIG,Migration,IV,Phase IV,CDep GEpi: Dalia Shash ,,,000930,NISed - Study (MIGRATED)
10934,1160-0199,1160.199,Ended,618,1160-P02,Humana untreated NVAF patients,Ended,MIG,Migration,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
10935,1160-0200,1160.200,Analysis,618,1160-P02,Bleed Management NVAF Pradaxa patients,Analysis,MIG,Migration,IV,Phase IV,,,,,
10936,1160-0201,1160.201,First Subject Randomised,618,1160-P02,PRODAST,First Subject Randomised,MIG,Migration,NONE,Not Classified,,,,000420,NISnd ‚Äì Study - Cohort
10937,1160-0202,1160.202,Recruiting,618,1160-P02,CPASS Study,Recruiting,MIG,Migration,IV,Phase IV,,,,,
10938,1160-0203,1160.203,Analysis,618,1160-P02,Dabireversal by PCC-healthy volunteers,Analysis,MIG,Migration,I,Phase I,,,,,
10939,1160-0204,1160.204,Ended,618,1160-P02,RE-CIRCUIT Trial,Ended,MIG,Migration,IV,Phase IV,,2014-003890-40,,,
10940,1160-0205,1160.205,First Subject Randomised,618,1160-P02,RELATED AF,First Subject Randomised,MIG,Migration,IV,Phase IV,IIS ,2013-005364-26,,000150,IS - Clin Study - Explore
10941,1160-0206,1160.206,Initiated,618,1160-P02,AF-ThrombusUL,Initiated,MIG,Migration,IV,Phase IV,IIS Dr. Miriam Bach ,,,,
10942,1160-0207,1160.207,Initiated,618,1160-P02,Sequential Comp.Effectiven. of Anticoag,Initiated,MIG,Migration,IV,Phase IV, Values from CTMS: Planned Subjects Screened: 120000, Planned Subjects Randomized: 120000, Planned Subjects Completed Treatment: ,,,,
10943,1160-0208,1160.208,Recruiting,618,1160-P02,Stroke Prevention and Anticoagulants,Recruiting,MIG,Migration,NONE,Not Classified,Dr Oliviu CRISAN ,,,000400,NISnd ‚Äì Study - Case Control
10944,1160-0209,1160.209,Preparing,618,1160-P02,QUASAR,Preparing,MIG,Migration,NONE,Not Classified,Jitske Evertse, M.Sc. ,,,,
10945,1160-0210,1160.210,Last Subject Randomised,618,1160-P02,Dabigatran vs Warfarin in AF ablation,Last Subject Randomised,MIG,Migration,IV,Phase IV,Daisuke Nakayama,Ph.D. ,,,,
10946,1160-0211,1160.211,Last Subject Randomised,618,1160-P02,IMPACT AF,Last Subject Randomised,MIG,Migration,NONE,Not Classified,,,,000410,NISnd ‚Äì Study - Other
10947,1160-0213,1160.213,First Subject Randomised,618,1160-P02,RASUNOA-Prime,First Subject Randomised,MIG,Migration,NONE,Not Classified,Dr. Christoph Eschenfelder ,,,000420,NISnd ‚Äì Study - Cohort
10948,1160-0214,1160.214,First Subject Randomised,618,1160-P02,Acute Heart Failure Registry,First Subject Randomised,MIG,Migration,NONE,Not Classified,Dr. Miriam Bach ,,,000420,NISnd ‚Äì Study - Cohort
10949,1160-0216,1160.216,Recruiting,618,1160-P02,AF Related Cognitive Impairment Trial,Recruiting,MIG,Migration,IV,Phase IV,Thais Melo ,,,,
10950,1160-0218,1160.218,Last Subject Randomised,618,1160-P02,AVANTI,Last Subject Randomised,MIG,Migration,NONE,Not Classified,Pradaxa/VKA Persist./Adherence in SPAF,,,000400,NISnd ‚Äì Study - Case Control
10951,1160-0219,1160.219,Preparing,618,1160-P02,Validation of predictors of OAC initiat.,Preparing,MIG,Migration,IV,Phase IV,,,,000470,NISed ‚Äì Study - Cross Sectional
10952,1160-0220,1160.220,Preparing,618,1160-P02,EU Initiative NIS,Preparing,MIG,Migration,NONE,Not Classified,,,,000920,NISnd - Study (MIGRATED)
10953,1160-0221,1160.221,Ended,618,1160-P02,Epi study with warfarin in AF pts in Slo,Ended,MIG,Migration,NONE,Not Classified,DIRECT Process; TCM: Dalia Shash ,,,000930,NISed - Study (MIGRATED)
10954,1160-0222,1160.222,Ended,618,1160-P02,Dabi concentration in breast milk,Ended,MIG,Migration,II,Phase II,,,,,
10955,1160-0223,1160.223,First Subject Randomised,618,1160-P02,SAFFO Study,First Subject Randomised,MIG,Migration,NONE,Not Classified,,,,,
10956,1160-0224,1160.224,Analysis,618,1160-P02,Endothelial thromb.in AF patients,Analysis,MIG,Migration,NONE,Not Classified,,,,,
10957,1160-0225,1160.225,Preparing,618,1160-P02,RADOA-Registry,Preparing,MIG,Migration,NONE,Not Classified,Dr. Miriam Bach ,,,,
10958,1160-0226,1160.226,Preparing,618,1160-P02,Epidemiology Study AF in India,Preparing,MIG,Migration,NONE,Not Classified,,,,,
10959,1160-0227,1160.227,Recruiting,618,1160-P02,Effect of dabi on platelet aggregation,Recruiting,MIG,Migration,NONE,Not Classified,,,,,
10960,1160-0228,1160.228,Ended,618,1160-P02,Thrombosis Treatment in Estonia-Survey,Ended,MIG,Migration,NONE,Not Classified,,,,,
10961,1160-0229,1160.229,First Subject Randomised,618,1160-P02,SWITCH IIS Switzerland,First Subject Randomised,MIG,Migration,NONE,Not Classified,,,,,
10962,1160-0230,1160.230,Preparing,618,1160-P02,Outcomes of Dabigatran vs. Warfarin,Preparing,MIG,Migration,IV,Phase IV,,,,,
10963,1160-0232,1160.232,Ended,618,1160-P02,FinFib2,Ended,MIG,Migration,NONE,Not Classified,,,,,
10964,1160-0233,1160.233,Preparing,618,1160-P02,STUdy of Dabi in ablation atrial Flutter,Preparing,MIG,Migration,NONE,Not Classified,,,,,
10965,1160-0234,1160.234,Preparing,618,1160-P02,Dabigatran in sICAS,Preparing,MIG,Migration,III,Phase III,,,,,
10966,1160-0235,1160.235,Preparing,618,1160-P02,Pradaxa Init Post Stroke Study:SITS-AF 1,Preparing,NISED,Non Interventional Study Existing Data,IV,Phase IV,,,,000930,NISed - Study (MIGRATED)
10967,1160-0236,1160.236,Preparing,618,1160-P02,Isch stroke in Pradaxa pat: SITS-AF 2,Preparing,NISED,Non Interventional Study Existing Data,IV,Phase IV,,,,000930,NISed - Study (MIGRATED)
10968,1160-0238,1160.238,Recruiting,618,1160-P02,Thrombin Inhib. in Pulmonary Fibrosis,Recruiting,MIG,Migration,I,Phase I,This is a preclinical study that was assigned a CTMS number due to technical reasons.,,,000300,IS - Methodological Studies
10969,1160-0239,1160.239,Analysis,618,1160-P02,Quality of Anticoag w. VKA for 2nd SPAF,Analysis,MIG,Migration,NONE,Not Classified,,,,,
10970,1160-0240,1160.240,First Subject Randomised,618,1160-P02,non-prescr. of oacs in patients w/ NV AF,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000410,NISnd ‚Äì Study - Other
10971,1160-0241,1160.241,Preparing,618,1160-P02,Left Atrial Thrombus with Dabi,Preparing,MIG,Migration,IV,Phase IV,,,,,
10972,1160-0242,1160.242,Preparing,618,1160-P02,RE-SOUND Study,Preparing,MIG,Migration,IV,Phase IV,,,,,
10973,1160-0243,1160.243,First Subject Randomised,618,1160-P02,Dabigatran in the early phase of stroke,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000430,NISnd ‚Äì Study - Cross Sectional
10974,1160-0244,1160.244,Unconfirmed,618,1160-P02,dabigatran in HD patients,Unconfirmed,MIG,Migration,I,Phase I,,,,,
10975,1160-0245,1160.245,Unconfirmed,618,1160-P02,dabigatran vs VKAs,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
10976,1160-0246,1160.246,Ended,618,1160-P02,Exploratory relative BA study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10977,1160-0247,1160.247,Analysis,618,1160-P02,MIDI NIS,Analysis,MIG,Migration,IV,Phase IV,,,,000400,NISnd ‚Äì Study - Case Control
10978,1160-0249,1160.249,Analysis,618,1160-P02,RCV NIS RE-SONANCE,Analysis,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
10979,1160-0250,1160.250,Analysis,618,1160-P02,Pradaxa and Bone,Analysis,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
10980,1160-0251,1160.251,First Subject Randomised,618,1160-P02,INFORM-AF,First Subject Randomised,MIG,Migration,IV,Phase IV,Site sumbitted an amendment stating that the full reach of the study was 25 pt interviews and 25 physician interviews.  Site reported that they have received saturation at this point and that the study is completed.,,,000410,NISnd ‚Äì Study - Other
10981,1160-0252,1160.252,First Subject Randomised,618,1160-P02,Sleep apnoe and AF,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000410,NISnd ‚Äì Study - Other
10982,1160-0253,1160.253,First Subject Randomised,618,1160-P02,RE-SONANCE NIS SPAIN,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000420,NISnd ‚Äì Study - Cohort
10983,1160-0254,1160.254,Ended,618,1160-P02,Length of stay - NIS(SHORT-J),Ended,MIG,Migration,IV,Phase IV,,,,000930,NISed - Study (MIGRATED)
10984,1160-0255,1160.255,Unconfirmed,618,1160-P02,Gene marker of AF study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000700,Pharmacogenetic Research Program
10985,1160-0256,1160.256,Unconfirmed,618,1160-P02,EDICTS (electronic decision support),Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
10986,1160-0257,1160.257,Unconfirmed,618,1160-P02,EDICTS- Elecotrnic Decisions Support,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
10987,1160-0258,1160.258,Unconfirmed,618,1160-P02,RE-SONANCE France,Unconfirmed,NISND,NISND incl. Chart Abstractions,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
10988,1160-0260,1160.260,Recruiting,618,1160-P02,Surveillance study of costs of bleeding,Recruiting,MIG,Migration,IV,Phase IV,,,,,
10989,1160-0261,1160.261,Recruiting,618,1160-P02,NIS RELATE,Recruiting,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
10990,1160-0262,1160.262,First Subject Randomised,618,1160-P02,Impact of Anticoagulation Therapy,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
10991,1160-0263,1160.263,Recruiting,618,1160-P02,Engel 2 aNticoaGulants bEnefit-risk,Recruiting,MIG,Migration,NONE,Not Classified,,,,000460,NISed ‚Äì Study - Cohort
10992,1160-0264,1160.264,Unconfirmed,618,1160-P02,Engel 1 VKA aNticoaGulants bEnefit risk,Unconfirmed,NISED,Non Interventional Study Existing Data,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
10993,1160-0265,1160.265,Recruiting,618,1160-P02,Smart Phone monitoring in Stroke,Recruiting,MIG,Migration,NONE,Not Classified,,,,,
10994,1160-0266,1160.266,First Subject Randomised,618,1160-P02,EDICTS - (an ACT study),First Subject Randomised,MIG,Migration,NONE,Not Classified,,,,000410,NISnd ‚Äì Study - Other
10995,1160-0267,1160.267,First Subject Randomised,618,1160-P02,AFIB in Ischemic Stroke,First Subject Randomised,MIG,Migration,NONE,Not Classified,,,,000410,NISnd ‚Äì Study - Other
10996,1160-0268,1160.268,First Subject Randomised,618,1160-P02,Improving Pt Outcomes (an ACT study),First Subject Randomised,MIG,Migration,NONE,Not Classified,,,,000410,NISnd ‚Äì Study - Other
10997,1160-0269,1160.269,Unconfirmed,618,1160-P02,Stroke Prevention in Atrial Enlargement,Unconfirmed,MIG,Migration,III,Phase III,,,,,
10998,1160-0270,1160.270,Analysis,618,1160-P02,Pradaxa tablet PPI study in Japan,Analysis,FULL,Full functionality,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
10999,1160-0271,1160.271,Analysis,618,1160-P02,Pradaxa tablet BE study in Japan,Analysis,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11000,1160-0272,1160.272,Unconfirmed,618,1160-P02,DABIGATRAN SPAF RWE,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
11001,1160-0273,1160.273,Preparing,618,1160-P02,Provision of care reality in AF patients,Preparing,MIG,Migration,NONE,Not Classified,Observation of PR and education measures on AF detection. Supported by grant. No classical IIS, no classical NISnd.,,,000410,NISnd ‚Äì Study - Other
11002,1160-0274,1160.274,Initiated,618,1160-P02,DoD study,Initiated,MIG,Migration,IV,Phase IV,,,,000460,NISed ‚Äì Study - Cohort
11003,1160-0275,1160.275,First Subject Randomised,618,1160-P02,DEvsVKA-prev. silent CI in Val. AF pts,First Subject Randomised,MIG,Migration,III,Phase III,,,,,
11004,1160-0276,1160.276,Unconfirmed,618,1160-P02,EAP of Idarucizumab,Unconfirmed,MIG,Migration,III,Phase III,,,,000500,Compassionate Use Program (CUP)
11005,1160-0277,1160.277,Recruiting,618,1160-P02,Dabigatran adherence in Korea,Recruiting,MIG,Migration,IV,Phase IV,,,,,
11006,1160-0278,1160.278,Recruiting,618,1160-P02,Benefit Risk Assessment of NOACs vs. VKA,Recruiting,MIG,Migration,NONE,Not Classified, Values from CTMS: Planned Subjects Screened: 1200000, Planned Subjects Randomized: 1200000, Planned Subjects Completed Treatment: 0,,,000420,NISnd ‚Äì Study - Cohort
11007,1160-0279,1160.279,Ended,618,1160-P02,Treatment Pattern of OAC in Japan,Ended,NISND,NISND incl. Chart Abstractions,,, Values from CTMS: Planned Subjects Screened: 80000, Planned Subjects Randomized: 300000, Planned Subjects Completed Treatment: 0,,,000930,NISed - Study (MIGRATED)
11008,1200-0001,1200.1,Ended,621,1200-P01,Phase I in Patients with Solid Tumors,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11009,1200-0002,1200.2,Ended,621,1200-P01,Phase I in Patients with Solid Tumors,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11010,1200-0003,1200.3,Ended,621,1200-P01,Phase I Solid Tumors Continuous Dosing,Ended,MIG,Migration,I,Phase I,,2004-000656-16,,000910,IS - Clin Study (MIGRATED)
11011,1200-0004,1200.4,Ended,621,1200-P01,Phase I Solid Tumors Continuous Dosing,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11012,1200-0005,1200.5,Ended,621,1200-P01,Phase II in HR metastatic Breast cancer,Ended,MIG,Migration,IIA,Phase IIa,,2006-002814-37,,000910,IS - Clin Study (MIGRATED)
11013,1200-0006,1200.6,Ended,621,1200-P01,Phase I in Combination with Docetaxel,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11014,1200-0007,1200.7,Unconfirmed,621,1200-P01,Phase I in Combination with Capecitabine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11015,1200-0008,1200.8,Unconfirmed,621,1200-P01,Phase I in Combination with CPT11 5FU/LV,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11016,1200-0009,1200.9,Unconfirmed,621,1200-P01,Phase I in Comb. with Oxalipl., 5FU/LV,Unconfirmed,MIG,Migration,I,Phase I,Fallback if BIBW 2992 monodevelop. CRC ,,,000910,IS - Clin Study (MIGRATED)
11017,1200-0010,1200.10,Ended,621,1200-P01,Phase II in Her2-negative breast cancer,Ended,MIG,Migration,II,Phase II,,2006-002018-36,,000910,IS - Clin Study (MIGRATED)
11018,1200-0011,1200.11,Ended,621,1200-P01,Phase II in Trastuzumab Failures,Ended,MIG,Migration,II,Phase II,,2007-004805-80,,000910,IS - Clin Study (MIGRATED)
11019,1200-0012,1200.12,Ended,621,1200-P01,Ph I comb  paclitaxel/bevacizumab/carbo,Ended,MIG,Migration,IB,Phase Ib,,2006-005005-55,,000910,IS - Clin Study (MIGRATED)
11020,1200-0013,1200.13,Unconfirmed,621,1200-P01,Phase II in Refractory Colorectal Cancer,Unconfirmed,MIG,Migration,II,Phase II,Back-up trial if BIBW mono CRC develop ,,,000910,IS - Clin Study (MIGRATED)
11021,1200-0014,1200.14,Unconfirmed,621,1200-P01,Phase IIb/III in HR refractory BC,Unconfirmed,MIG,Migration,III,Phase III,ER low, HER2 negative patients are to benefit most from this treatment,,,000910,IS - Clin Study (MIGRATED)
11022,1200-0015,1200.15,Unconfirmed,621,1200-P01,Phase IIb / III in Prostate Cancer,Unconfirmed,MIG,Migration,III,Phase III,Fallback if BIBW mono development ,,,000910,IS - Clin Study (MIGRATED)
11023,1200-0016,1200.16,Unconfirmed,621,1200-P01,Phase IIb / III in Colorectal Cancer,Unconfirmed,MIG,Migration,III,Phase III,Fallback if BIBW mono development ,,,000910,IS - Clin Study (MIGRATED)
11024,1200-0017,1200.17,Ended,621,1200-P01,Extension study for 1200.1 and 1200.2,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11025,1200-0018,1200.18,Preparing,621,1200-P01,Extension study for 1200.3 and 1200.4,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11026,1200-0019,1200.19,Unconfirmed,621,1200-P01,Phase IIb/III in Her2 neg. Breast Cancer,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11027,1200-0020,1200.20,Ended,621,1200-P01,Pulsatile therapy in comb. with taxane,Ended,MIG,Migration,IB,Phase Ib,,2005-000034-20,,000910,IS - Clin Study (MIGRATED)
11028,1200-0024,1200.24,Ended,621,1200-P01,Ph II in solid tumours, QTc trial,Ended,MIG,Migration,IIA,Phase IIa,To be performed in phase I centers Duration of QTc interval as coprimary endpoint next to efficacy,2008-006288-36,,000910,IS - Clin Study (MIGRATED)
11029,1200-0025,1200.25,Ended,621,1200-P01,BIBW 2992 ADME trial,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11030,1200-0031,1200.31,Unconfirmed,621,1200-P01,Food effect study HPZ,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11031,1200-0035,1200.35,Ended,621,1200-P01,Rel. bioavailability tab vs. solution,Ended,MIG,Migration,I,Phase I,Design dicussed with FDA ducted in healthy volounteers ongoing,2008-005150-20,,000910,IS - Clin Study (MIGRATED)
11032,1200-0044,1200.44,Ended,621,1200-P01,neoadjuvant BIBW2992 in HER2+ breast ca,Ended,MIG,Migration,IIA,Phase IIa,Trial Design was discussed with the TMM All three drugs need to be introduced as IMPs,,,000910,IS - Clin Study (MIGRATED)
11033,1200-0067,1200.67,Ended,621,1200-P01,Afatinib in Brain metastases,Ended,MIG,Migration,II,Phase II, recurrence or progression of brain mets during or after trastuzumab and/or lapatinib based therapy,2010-021415-16,,000910,IS - Clin Study (MIGRATED)
11034,1200-0068,1200.68,Ended,621,1200-P01,BIBW 2992 combination with herceptin,Ended,MIG,Migration,I,Phase I,None ,2009-010003-89,,000910,IS - Clin Study (MIGRATED)
11035,1200-0069,1200.69,Ended,621,1200-P01,BIBW 2992 in comb. with vinorelbine,Ended,MIG,Migration,I,Phase I,i.v. vinorelbine cohort will be filled first, vinorelbine oral cohort secondly,2008-006290-32,,000910,IS - Clin Study (MIGRATED)
11036,1200-0073,1200.73,Unconfirmed,621,1200-P01,Afatinib combinations in solid tumours,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11037,1200-0075,1200.75,Last Subject Randomised,621,1200-P01,BIBW 2992+Vinor. vs Herceptin+Vinor.,Last Subject Randomised,MIG,Migration,III,Phase III,patients with mBC after failure of prior Herceptin treatment will be eligible; 2:1 randomisation planned,2009-015476-98,,000910,IS - Clin Study (MIGRATED)
11038,1200-0078,1200.78,Unconfirmed,621,1200-P01,BIBW 2992 interaction with digoxin,Unconfirmed,MIG,Migration,I,Phase I,HV phase I trial to be discussed with authorities,,,000910,IS - Clin Study (MIGRATED)
11039,1200-0079,1200.79,Ended,621,1200-P01,BIBW 2992 interaction with ritonavir,Ended,MIG,Migration,I,Phase I,to be discussed with authorities 20 mg BIBW dose in HV should suffice,2009-011909-16,,000910,IS - Clin Study (MIGRATED)
11040,1200-0080,1200.80,Ended,621,1200-P01,BA of BIBW 2992 phase III formulations,Ended,MIG,Migration,I,Phase I,Single groups, staggered design design preferable to parallel-group
To be discussed with authorities,2009-011910-35,,000910,IS - Clin Study (MIGRATED)
11041,1200-0081,1200.81,Unconfirmed,621,1200-P01,BIBW 2992 interaction with rifampicin,Unconfirmed,MIG,Migration,I,Phase I,to be discussed with authorities 20 mg BIBW in HV,,,000910,IS - Clin Study (MIGRATED)
11042,1200-0083,1200.83,Unconfirmed,621,1200-P01,BIBW 2992 and paclitaxel in Japan,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11043,1200-0084,1200.84,Ended,621,1200-P01,BIBW 2992 with vinorelbine in Japan,Ended,MIG,Migration,I,Phase I,Phase I trial to determine DLTs and MTD of combination of BIBW 2992 and i.v. vinorelbine,,,000910,IS - Clin Study (MIGRATED)
11044,1200-0086,1200.86,Ended,621,1200-P01,Afatinib in hepatic impairment,Ended,MIG,Migration,I,Phase I,Trial outsourced; 30 to 50 mg BIBW 2992 as single dose plus control group at highest dose level,2010-021140-18,,000910,IS - Clin Study (MIGRATED)
11045,1200-0087,1200.87,Unconfirmed,621,1200-P01,Afatinib and TDM1 in Breast Cancer,Unconfirmed,MIG,Migration,IA,Phase Ia,biomarkers ,,,000910,IS - Clin Study (MIGRATED)
11046,1200-0088,1200.88,Unconfirmed,621,1200-P01,Afatinib and herceptin in brain mets,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11047,1200-0089,1200.89,Ended,621,1200-P01,Afatinib in inflammatory breast cancer,Ended,MIG,Migration,II,Phase II,HER2-pos. pts: no prior Lapatinib HER2-pos IBC, naive and prior trastuzumab treatment,2010-024454-10,,000910,IS - Clin Study (MIGRATED)
11048,1200-0097,1200.97,Unconfirmed,621,1200-P01,Afatinib in HER2-pos mBC patients,Unconfirmed,MIG,Migration,II,Phase II,support 1200.75 afatinib+pacli combi to gain safety and efficacy data for BIBW and paclitaxel in mBC,,,000910,IS - Clin Study (MIGRATED)
11049,1200-0098,1200.98,Analysis,621,1200-P01,Afatinib in HER2-treatment failures,Analysis,MIG,Migration,II,Phase II,Afatinib monotherapy paclitaxel or vinorelbine added upon progression,2010-021945-29,,000910,IS - Clin Study (MIGRATED)
11050,1200-0134,1200.134,Ended,621,1200-P01,Phase I combination with Trastuzumab,Ended,MIG,Migration,IB,Phase Ib,epirubicine or doxorubicine allowed,2012-001753-10,,000910,IS - Clin Study (MIGRATED)
11051,1200-0169,1200.169,Unconfirmed,621,1200-P01,metastatic breast cancer Her2+,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
11052,1201-0001,1201.1,Ended,622,1201-P01,Single escalating dose in HV,Ended,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
11053,1201-0002,1201.2,Ended,622,1201-P01,1 day,  rising doses bid/tid HCV patient,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11054,1201-0003,1201.3,Unconfirmed,622,1201-P01,2 weeks, multiple escalating doses in HV,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11055,1201-0004,1201.4,Unconfirmed,622,1201-P01,2-4 w multiple escalat. doses in HCV pat,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
11056,1201-0005,1201.5,Unconfirmed,622,1201-P01,Comparison of two formulations in HV,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11057,1201-0006,1201.6,Unconfirmed,622,1201-P01,Interaction studies in HV,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11058,1201-0007,1201.7,Unconfirmed,622,1201-P01,Interaction studies PegIFN/RBV SS HCV,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11059,1201-0008,1201.8,Unconfirmed,622,1201-P01,Monotherapy Exploratory in HCV NRs,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11060,1201-0009,1201.9,Unconfirmed,622,1201-P01,Combination PegIFN/RBV Explor HCV NRs,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
11061,1201-0010,1201.10,Unconfirmed,622,1201-P01,CombinationExplor in HCV Treatment NAIVE,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
11062,1201-0011,1201.11,Unconfirmed,622,1201-P01,Pivotal - Monotherapy in NRs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11063,1201-0012,1201.12,Unconfirmed,622,1201-P01,Pivotal - Combination HCV NRs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11064,1201-0013,1201.13,Unconfirmed,622,1201-P01,Pivotal - Combination HCV  NAiVE,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11065,1201-0014,1201.14,Ended,622,1201-P01,Five day antiviral PK-PD in HCV Patients,Ended,MIG,Migration,IB,Phase Ib,,2004-001212-31,,000910,IS - Clin Study (MIGRATED)
11066,1204-0001,1204.1,Preparing,624,1204-P01,C(O)B db, random,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11067,1205-0001,1205.1,Ended,625,1205-P01,SD-tolerance (Respimat),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11068,1205-0002,1205.2,Ended,625,1205-P01,MD-tolerance (Respimat),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11069,1205-0003,1205.3,Ended,625,1205-P01,Single Dose in COPD Patients (PoC qd),Ended,MIG,Migration,IIA,Phase IIa,PD steadystate only in MD, PoC in IIb? ,,,000910,IS - Clin Study (MIGRATED)
11070,1205-0004,1205.4,Ended,625,1205-P01,Chronic dose ranging study in COPD,Ended,MIG,Migration,IIB,Phase IIb,USA lead, RDC trial ,2005-000650-79,,000910,IS - Clin Study (MIGRATED)
11071,1205-0005,1205.5,Ended,625,1205-P01,i.v. tolerance BEA 2180 in HV,Ended,MIG,Migration,IA,Phase Ia,to be done before hADME, CO i.h. for  BA ,2006-001884-50,,000910,IS - Clin Study (MIGRATED)
11072,1205-0006,1205.6,Ended,625,1205-P01,high dose comparison study in COPD,Ended,MIG,Migration,IIB,Phase IIb,Final design in discussion, RDC ,,,000910,IS - Clin Study (MIGRATED)
11073,1205-0007,1205.7,Unconfirmed,625,1205-P01,QTc analysis BEA pbc & active control,Unconfirmed,MIG,Migration,I,Phase I,tbd at EoPhII meeting ,,,000910,IS - Clin Study (MIGRATED)
11074,1205-0008,1205.8,Ended,625,1205-P01,14C human ADME study i.v.+ p.o.,Ended,MIG,Migration,I,Phase I,CML DE, conduct most likely by CRO (NL?) ,2006-004125-28,,000910,IS - Clin Study (MIGRATED)
11075,1205-0009,1205.9,Unconfirmed,625,1205-P01,PK in elderly,Unconfirmed,MIG,Migration,I,Phase I,to be discussed ,,,000910,IS - Clin Study (MIGRATED)
11076,1205-0010,1205.10,Unconfirmed,625,1205-P01,Liver function impairment,Unconfirmed,MIG,Migration,I,Phase I,to be discussed ,,,000910,IS - Clin Study (MIGRATED)
11077,1205-0011,1205.11,Unconfirmed,625,1205-P01,Renal function impairment,Unconfirmed,MIG,Migration,I,Phase I,to be discussed ,,,000910,IS - Clin Study (MIGRATED)
11078,1205-0012,1205.12,Preparing,625,1205-P01,Exercise tolerance in COPD  (CN),Preparing,MIG,Migration,III,Phase III,To be discussed at EoPhII meeting ,,,000910,IS - Clin Study (MIGRATED)
11079,1205-0013,1205.13,Preparing,625,1205-P01,Exercise tolerance in COPD (EU),Preparing,MIG,Migration,III,Phase III,To be discussed at EoPhII meeting ,,,000910,IS - Clin Study (MIGRATED)
11080,1205-0014,1205.14,Ended,625,1205-P01,24 week treatment of BEA 2180 BR,Ended,MIG,Migration,IIB,Phase IIb,extended phase II is under discussion,2007-001946-42,,000910,IS - Clin Study (MIGRATED)
11081,1205-0015,1205.15,Preparing,625,1205-P01,1-y treatment of BEA 2180 BR (EU),Preparing,MIG,Migration,III,Phase III,trial design in discussion ,,,000910,IS - Clin Study (MIGRATED)
11082,1205-0016,1205.16,Preparing,625,1205-P01,a.m. vs p.m., onset of action,Preparing,MIG,Migration,IIIA,Phase IIIa,to be discussed ,,,000910,IS - Clin Study (MIGRATED)
11083,1205-0017,1205.17,Preparing,625,1205-P01,Safety, PD, PK in Japanese, SRD,Preparing,MIG,Migration,I,Phase I,await PhII b data ,,,000910,IS - Clin Study (MIGRATED)
11084,1205-0018,1205.18,Ended,625,1205-P01,Safety, PD, PK in Japanese, MRD,Ended,MIG,Migration,I,Phase I,Depends on progress of tio RMT ,,,000910,IS - Clin Study (MIGRATED)
11085,1205-0019,1205.19,Preparing,625,1205-P01,Dose finding PoC in Japanese,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11086,1205-0020,1205.20,Ended,625,1205-P01,p.o. tolerance BEA 2180 in HV,Ended,MIG,Migration,I,Phase I,,2006-002643-88,,000910,IS - Clin Study (MIGRATED)
11087,1205-0021,1205.21,Unconfirmed,625,1205-P01,Absolute bioavailability,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11088,1205-0022,1205.22,Unconfirmed,625,1205-P01,Atrovent interaction,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11089,1205-0023,1205.23,Unconfirmed,625,1205-P01,Corticosteroide interaction,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11090,1205-0024,1205.24,Unconfirmed,625,1205-P01,CYP 2D6 interaction,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11091,1205-0025,1205.25,Unconfirmed,625,1205-P01,24h profile steady-state,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11092,1205-0026,1205.26,Unconfirmed,625,1205-P01,Onset of action,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11093,1205-0027,1205.27,Unconfirmed,625,1205-P01,Mucocilliary clearance,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11094,1205-0028,1205.28,Unconfirmed,625,1205-P01,Flexible dose I (PoC),Unconfirmed,MIG,Migration,II,Phase II,modification of study design details might occur during update of CTP draft in course of study preperation,,,000910,IS - Clin Study (MIGRATED)
11095,1205-0029,1205.29,Unconfirmed,625,1205-P01,Flexible dose II (pivotal),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11096,1205-0030,1205.30,Preparing,625,1205-P01,Flexible Dose in mild COPD,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11097,1175-0010,1175.10,Ended,626,1175-P02,Short term BIRB 796 in mod-sev psoriasis,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11098,1175-0019,1175.19,Ended,626,1175-P02,Psoriasis efficacy and safety,Ended,MIG,Migration,IIB,Phase IIb,Study discotinued on 19th November 2003 ,,,000910,IS - Clin Study (MIGRATED)
11099,1175-0023,1175.23,Preparing,626,1175-P02,Rollover Longterm Psoriasis trial,Preparing,MIG,Migration,II,Phase II,Study discontinued on the 19th Nov 03 ,,,000910,IS - Clin Study (MIGRATED)
11100,1175-0012,1175.12,Ended,627,1175-P03,Short term efficacy in Crohn's disease,Ended,MIG,Migration,IIA,Phase IIa,8 weeks treatment followed by a 18 weeks treatment extension in patients with clinical remission or at least partial response after 8 weeks treatment,,,000910,IS - Clin Study (MIGRATED)
11101,1175-0022,1175.22,Unconfirmed,627,1175-P03,Phase III Crohn's disease,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11102,0527-0043,527.43,Unconfirmed,628,0527-P02,Food interaction study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11103,0527-0044,527.44,Unconfirmed,628,0527-P02,Steady state study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11104,0527-0045,527.45,Unconfirmed,628,0527-P02,Efficacy and Safety of TOCAS 0.8 mg,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
11105,0527-0048,527.48,Unconfirmed,628,0527-P02,Orthostatic Hypotension,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11106,0527-0054,527.54,Unconfirmed,628,0527-P02,Interaction with ketoconazole,Unconfirmed,MIG,Migration,I,Phase I,Pre-requisite (identification of maximum possible exposure) to the QTc study,,,000910,IS - Clin Study (MIGRATED)
11107,0527-0055,527.55,Unconfirmed,628,0527-P02,Effect on QTc,Unconfirmed,MIG,Migration,I,Phase I,To be conducted in sequence to 527.55, which will identify the highest possible exposure to tamsulosin OCAS,,,000910,IS - Clin Study (MIGRATED)
11108,0527-0061,527.61,Unconfirmed,628,0527-P02,TOCAS 0.4 and 0.8 mg safey and efficacy,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11109,0527-0062,527.62,Unconfirmed,628,0527-P02,FDC Tamsulosin + finasteride,Unconfirmed,MIG,Migration,III,Phase III,This study is included in 527.P2 because part of life cycle planning. It will be allocated to a separate project as soon as it is released,,,000910,IS - Clin Study (MIGRATED)
11110,0527-0071,527.71,Unconfirmed,628,0527-P02,Tamsulosin OCAS in Dysmenorrhea - POC,Unconfirmed,MIG,Migration,NONE,Not Classified,Proof of concept study ,,,000910,IS - Clin Study (MIGRATED)
11111,0527-0072,527.72,Unconfirmed,628,0527-P02,TOCAS in Dysmenorrhea - Dose finding,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
11112,0527-0074,527.74,Preparing,628,0527-P02,WOWtab 0.4 mg alcohol dissolution study,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11113,0527-0033,527.33,Unconfirmed,629,0527-P03,Tamsulosin OTC -1,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11114,0527-0034,527.34,Unconfirmed,629,0527-P03,Tamsulosin OTC-2,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11115,0527-0039,527.39,Unconfirmed,629,0527-P03,Actual Use Study,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
11116,0527-0042,527.42,Unconfirmed,629,0527-P03,OTC Feasibility Pre- Study,Unconfirmed,MIG,Migration,III,Phase III,,,,000300,IS - Methodological Studies
11117,0527-0082,527.82,Ended,629,0527-P03,Exploratory use study,Ended,MIG,Migration,II,Phase II,Exploratory actual use study for Flomax "Paul Carter, Corporate Head of CHC Medical-DRA approves of this study as there is no TAH or CEG."  Also regarding the phase of this trial, IIIb is not a choice on the form,,,000910,IS - Clin Study (MIGRATED)
11118,0527-0083,527.83,Ended,629,0527-P03,self-selection study for OTC tamsulosin,Ended,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
11119,0527-0085,527.85,Analysis,629,0527-P03,Pivotal Actual Use Study,Analysis,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11120,0527-0086,527.86,Ended,629,0527-P03,Final Label Comprehension study,Ended,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
11121,0527-0087,527.87,Analysis,629,0527-P03,Male LUTS: real world data,Analysis,MIG,Migration,IV,Phase IV,Retrospective patient chart review ,,,000930,NISed - Study (MIGRATED)
11122,0527-0088,527.88,Ended,629,0527-P03,tamsulosin bioequivalence study fasted,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11123,0527-0089,527.89,Ended,629,0527-P03,Bio-equivalence in fed state,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11124,0527-0090,527.90,Ended,629,0527-P03,Self-selection study for tamsulosin OTC,Ended,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
11125,0527-0091,527.91,Preparing,629,0527-P03,Fasting BE study,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11126,0527-0092,527.92,Unconfirmed,629,0527-P03,Fed BE study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11127,1206-0001,1206.1,Ended,630,1206-P01,Single rising dose,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11128,1206-0002,1206.2,Ended,630,1206-P01,Multiple rising dose,Ended,MIG,Migration,I,Phase I,,2004-004161-15,,000910,IS - Clin Study (MIGRATED)
11129,1206-0003,1206.3,Preparing,630,1206-P01,Drug interaction ibuprofen / naproxen,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11130,1206-0004,1206.4,Unconfirmed,630,1206-P01,US 8 wk psoriasis safety study,Unconfirmed,MIG,Migration,IIA,Phase IIa,Study proposed to meet FDA request ,,,000910,IS - Clin Study (MIGRATED)
11131,1206-0005,1206.5,Ended,630,1206-P01,12+12 wk PoC Psoriasis study,Ended,MIG,Migration,IIA,Phase IIa,Previous trial on same indic. = 1175.19 ,2005-005368-10,,000910,IS - Clin Study (MIGRATED)
11132,1206-0006,1206.6,Unconfirmed,630,1206-P01,Pivotal study 1 in psoriasis AM,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11133,1206-0007,1206.7,Unconfirmed,630,1206-P01,Pivotal study 2 in psoriasis EU,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11134,1206-0008,1206.8,Unconfirmed,630,1206-P01,Roll over study in Psoriasis,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11135,1206-0009,1206.9,Ended,630,1206-P01,Drug interaction with Midazolam,Ended,MIG,Migration,I,Phase I,open-label, randomized ,2005-001394-98,,000910,IS - Clin Study (MIGRATED)
11136,1206-0010,1206.10,Ended,630,1206-P01,PK "cocktail study",Ended,MIG,Migration,I,Phase I,open-label, single-group, multiple-dose ,2005-002876-14,,000910,IS - Clin Study (MIGRATED)
11137,1206-0011,1206.11,Preparing,630,1206-P01,Drug interaction with sertraline,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11138,1206-0012,1206.12,Ended,630,1206-P01,Drug interaction with amitryptilline,Ended,MIG,Migration,I,Phase I,,2006-002137-20,,000910,IS - Clin Study (MIGRATED)
11139,1206-0013,1206.13,Unconfirmed,630,1206-P01,4 wk MS safety study (fall-back),Unconfirmed,MIG,Migration,IIA,Phase IIa,Placeholder study if required by agency ,,,000910,IS - Clin Study (MIGRATED)
11140,1206-0014,1206.14,Unconfirmed,630,1206-P01,12 wk MS PoC-study (fall-back),Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11141,1206-0015,1206.15,Preparing,630,1206-P01,24 wk MRI safety study in MS,Preparing,MIG,Migration,IIB,Phase IIb,,2005-005985-35,,000910,IS - Clin Study (MIGRATED)
11142,1206-0016,1206.16,Unconfirmed,630,1206-P01,Pivotal trial 1 in MS monotherapy AM,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11143,1206-0017,1206.17,Unconfirmed,630,1206-P01,Pivotal Study 2 in MS monotherapy, + INF,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11144,1206-0018,1206.18,Unconfirmed,630,1206-P01,Pivotal add-on study in MS,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11145,1206-0019,1206.19,Unconfirmed,630,1206-P01,Roll-over study in MS,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11146,1206-0020,1206.20,Unconfirmed,630,1206-P01,ADME-Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11147,1206-0021,1206.21,Preparing,630,1206-P01,Bioequivalence of final drug formulation,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11148,1206-0022,1206.22,Unconfirmed,630,1206-P01,Drug interaction with acetaminophen,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11149,1206-0023,1206.23,Unconfirmed,630,1206-P01,Interaction with oral contraceptive,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11150,1206-0024,1206.24,Unconfirmed,630,1206-P01,Interaction with ketoconazole,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11151,1207-0001,1207.1,Ended,631,1207-P01,Single Rising Dose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11152,1207-0002,1207.2,Ended,631,1207-P01,Colonic site absorption,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11153,1207-0003,1207.3,Ended,631,1207-P01,Multiple Rising Dose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11154,1207-0004,1207.4,Ended,631,1207-P01,Urodynamic Spinal Cord Injured Patients,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11155,1207-0005,1207.5,Preparing,631,1207-P01,Proof-of-efficacy dose-ranging study,Preparing,MIG,Migration,IIA,Phase IIa,,2004-004590-28,,000910,IS - Clin Study (MIGRATED)
11156,1207-0006,1207.6,Ended,631,1207-P01,High Dose Extension Of SRD-Study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11157,1207-0007,1207.7,Unconfirmed,631,1207-P01,PK in renal impairment,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11158,1207-0008,1207.8,Unconfirmed,631,1207-P01,Relative bioavailability final form.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11159,1207-0009,1207.9,Unconfirmed,631,1207-P01,14 C ADME man,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11160,1207-0010,1207.10,Unconfirmed,631,1207-P01,Drug/drug interaction with Antacids,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11161,1207-0011,1207.11,Unconfirmed,631,1207-P01,Drug/drug interaction with charcoal,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11162,1207-0012,1207.12,Preparing,631,1207-P01,MRD high dose extension,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11163,1207-0013,1207.13,Unconfirmed,631,1207-P01,Metabolic effects in diabetic patients,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11164,1207-0014,1207.14,Unconfirmed,631,1207-P01,Interaction with renal transporters,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11165,1207-0015,1207.15,Unconfirmed,631,1207-P01,Phase II dose finding /PoC/Pop PK,Unconfirmed,MIG,Migration,II,Phase II,,,,000980,Not Classified (MIGRATED)
11166,1207-0016,1207.16,Unconfirmed,631,1207-P01,PK in hepatic impairment,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11167,1207-0017,1207.17,Unconfirmed,631,1207-P01,Food effect,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
11168,1207-0018,1207.18,Unconfirmed,631,1207-P01,Phase III pivotal efficacy #1,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11169,1207-0019,1207.19,Unconfirmed,631,1207-P01,long-term extens. (pivotal efficacy #1),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11170,1207-0020,1207.20,Unconfirmed,631,1207-P01,Pivotal efficacy #2,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11171,1207-0021,1207.21,Unconfirmed,631,1207-P01,long-term extens. (piv. efficacy #2),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11172,1207-0022,1207.22,Ended,631,1207-P01,Preliminary QT Study,Ended,MIG,Migration,I,Phase I,,2005-002170-29,,000910,IS - Clin Study (MIGRATED)
11173,1207-0023,1207.23,Unconfirmed,631,1207-P01,Pop PK (tbd),Unconfirmed,MIG,Migration,III,Phase III,,,,000980,Not Classified (MIGRATED)
11174,1207-0024,1207.24,Unconfirmed,631,1207-P01,Phase IIa PoE trial,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11175,1207-0025,1207.25,Preparing,631,1207-P01,Dose-proportionality study I,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11176,1207-0026,1207.26,Ended,631,1207-P01,in-vivo beta-3 selectivity,Ended,MIG,Migration,I,Phase I,,2005-002988-89,,000910,IS - Clin Study (MIGRATED)
11177,1207-0027,1207.27,Preparing,631,1207-P01,PoE trial in OAB,Preparing,MIG,Migration,IIA,Phase IIa,,2005-005958-48,,000910,IS - Clin Study (MIGRATED)
11178,1207-0028,1207.28,Unconfirmed,631,1207-P01,Backup 12-w efficacy trial,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11179,1207-0029,1207.29,Unconfirmed,631,1207-P01,UDX ph III study in neurogenic OAB,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11180,1207-0030,1207.30,Unconfirmed,631,1207-P01,Pediatric study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11181,1207-0031,1207.31,Unconfirmed,631,1207-P01,Definitive QT study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11182,1207-0032,1207.32,Unconfirmed,631,1207-P01,QT study in Japeneses,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11183,1208-0001,1208.1,Ended,632,1208-P01,Combined max doses pharmacology trial,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11184,1208-0002,1208.2,Preparing,632,1208-P01,Study in severely depressed in-patients,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11185,1208-0007,1208.7,Unconfirmed,632,1208-P01,PCP-Study,Unconfirmed,MIG,Migration,IV,Phase IV, study has been cancelled in April 2004 Study plannd under the asumption the BI would be the sponsor of that trial. BI would contribute 100% of the patients and responsible for all functions within the trial.
This needs to be discussed with Lilly.,,,000910,IS - Clin Study (MIGRATED)
11186,1208-0008,1208.8,Unconfirmed,632,1208-P01,DVD-Study,Unconfirmed,MIG,Migration,IV,Phase IV,see remarks Study planed under the asumption that BI contributes 50% of the total number of patients planned for EU (2.200 of 4.400). It is intended to split the trial and BI to act as Sponsor in its branch of the trial.
This proposal needs to be discussed with Lilly.,,,000910,IS - Clin Study (MIGRATED)
11187,1208-0009,1208.9,Unconfirmed,632,1208-P01,Pure Pain study,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,see remarks Planned under the asuption BI to be the sponsor and contributes all patients (100%) and covers all functions within that trial.
This needs to be discussed with Lilly.,,,000910,IS - Clin Study (MIGRATED)
11188,1208-0010,1208.10,Ended,632,1208-P01,Pain enriched depressed patient study,Ended,MIG,Migration,IIIB,Phase IIIb,see remarks Planned under the assumption BI to be the sponsor of that trail, cobvering all functions and contribtung 100% patients.
Needs to be discussed with Lilly.,2004-003742-18,,000910,IS - Clin Study (MIGRATED)
11189,1208-0011,1208.11,Unconfirmed,632,1208-P01,AWB Psychiater Cymbalta,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
11190,1208-0012,1208.12,Unconfirmed,632,1208-P01,AWB GPs Cymbalta,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
11191,1208-0021,1208.21,Ended,632,1208-P01,Duloxetine in Melancoholic Depression,Ended,MIG,Migration,IIIB,Phase IIIb,BI-EL trial in Australia also in Canada ,,,000910,IS - Clin Study (MIGRATED)
11192,1208-0023,1208.23,Ended,632,1208-P01,FINDER,Ended,MIG,Migration,IV,Phase IV,FINDER is a Lilly study This study is a Lilly health outcome study and will be conducted according to Lilly protocol and SOPs. Main purpose of the filing into CTMS is the Documentation of OPU contribution form Austria and Ireland, where BI is conducting the FINDER study.,,,000910,IS - Clin Study (MIGRATED)
11193,1208-0024,1208.24,Ended,632,1208-P01,Duloxetine severe depression study,Ended,MIG,Migration,IV,Phase IV,registry done by Lilly severe depression incl. suicidal patients,2006-001618-34,,000910,IS - Clin Study (MIGRATED)
11194,1208-0025,1208.25,Preparing,632,1208-P01,IIT-Smeraldi-Italy,Preparing,MIG,Migration,IV,Phase IV,,,,,
11195,1208-0026,1208.26,Ended,632,1208-P01,IIT-Cardoner-Spain,Ended,MIG,Migration,IV,Phase IV,,2005-003846-33,,,
11196,1208-0029,1208.29,Ended,632,1208-P01,Spain: depression and pain - HO survey:,Ended,MIG,Migration,IV,Phase IV,prelaunch  health-outcome crossectional ,,,000600,Survey Patient Questionnaire
11197,1208-0030,1208.30,Ended,632,1208-P01,Come to me + Come to me GP,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
11198,1208-0033,1208.33,Unconfirmed,632,1208-P01,STAR - Overcoming Depression,Unconfirmed,MIG,Migration,IV,Phase IV,Non-trial activity !! 28 June 2007: not yet approved,,,000600,Survey Patient Questionnaire
11199,1208-0035,1208.35,Unconfirmed,632,1208-P01,CNS comorbidities in Greece,Unconfirmed,MIG,Migration,IV,Phase IV,This study was not a approved by BI internal and BI /Lilly processes,,,000940,Post Marketing Study (MIGRATED)
11200,0502-0241,502.241,Unconfirmed,633,0502-P05,? / Japan,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
11201,0502-0421,502.421,Ended,633,0502-P05,High Strength FDC vs. Diovan HCT (US),Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11202,0502-0422,502.422,Unconfirmed,633,0502-P05,High Strength FDC versus Diovan HCT (CN),Unconfirmed,MIG,Migration,III,Phase III,422 and 421 are identical studies ,,,000910,IS - Clin Study (MIGRATED)
11203,0502-0434,502.434,Preparing,633,0502-P05,Pivotal BE study,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11204,0502-0476,502.476,Ended,633,0502-P05,High-Dose FDC II,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11205,0502-0480,502.480,Ended,633,0502-P05,Non-Responder-Study,Ended,MIG,Migration,III,Phase III,,2005-002442-19,,000910,IS - Clin Study (MIGRATED)
11206,0502-0491,502.491,Ended,633,0502-P05,Open label extension T80/H25 in EU,Ended,MIG,Migration,III,Phase III,,2005-003000-11,,000910,IS - Clin Study (MIGRATED)
11207,0502-0550,502.550,Ended,633,0502-P05,T+H25 First line in moderate/ severe HTN,Ended,MIG,Migration,IV,Phase IV,,2008-007711-32,,000910,IS - Clin Study (MIGRATED)
11208,0502-0551,502.551,Preparing,633,0502-P05,T+H25 in non-control. BP with ARB/H 12.5,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11209,0502-0552,502.552,Unconfirmed,633,0502-P05,T+H25 vs. V320+H25 (I),Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11210,0502-0553,502.553,Unconfirmed,633,0502-P05,T+H25 vs. V320 + H25 (II),Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11211,0502-0592,502.592,Ended,633,0502-P05,Eff on BP+CV Risk Fact in high risk pat,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
11212,0502-0415,502.415,Ended,634,0502-P06,Sodium Salt Bioavailability,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11213,0502-0432,502.432,Preparing,634,0502-P06,Bioequivalence study,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11214,1208-0003,1208.3,Ended,635,1208-P02,PURE Study (SBCB),Ended,MIG,Migration,IIIB,Phase IIIb,This is an Eli Lilly study. handling the budgets.  Lilly is running the study in Germany, UK, Austria, Norway, Fonland, Switzerland, Belgium and Denmark,,,000300,IS - Methodological Studies
11215,1208-0004,1208.4,Unconfirmed,635,1208-P02,SBCD US,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000940,Post Marketing Study (MIGRATED)
11216,1208-0005,1208.5,Unconfirmed,635,1208-P02,German  Study,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,Approved by German CCC - Study protocol still under preparation,,,000910,IS - Clin Study (MIGRATED)
11217,1208-0006,1208.6,Ended,635,1208-P02,SUIT: SUI Treatment (SBBS), Cost effect.,Ended,MIG,Migration,IV,Phase IV,To be conducted in the 10 major markets. OpU committment under evaluation,,,000940,Post Marketing Study (MIGRATED)
11218,1208-0013,1208.13,Unconfirmed,635,1208-P02,PMS Study in Germany,Unconfirmed,MIG,Migration,IV,Phase IV,Post-launch study in Germany ,,,000940,Post Marketing Study (MIGRATED)
11219,1208-0014,1208.14,Preparing,635,1208-P02,RoW (or  ICR) study (SBCL),Preparing,MIG,Migration,IIIB,Phase IIIb,ICR stands for Inter-Continental Region, i.e.: Rest od World (suggested OpUs: Canada, Australia, Brazil, Mexico,,,000910,IS - Clin Study (MIGRATED)
11220,1208-0017,1208.17,Ended,635,1208-P02,6 months,prospective,UI cost study,Ended,MIG,Migration,IV,Phase IV,,,,000300,IS - Methodological Studies
11221,1208-0022,1208.22,Ended,635,1208-P02,Duloxetine in SUI and MUI females > =65,Ended,MIG,Migration,IV,Phase IV,The CTR will be written by Lilly. ,2005-001021-28,,000910,IS - Clin Study (MIGRATED)
11222,1208-0027,1208.27,Analysis,635,1208-P02,GynaeFlow Italian Survey on female LUTS,Analysis,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
11223,1208-0028,1208.28,Unconfirmed,635,1208-P02,DUROSA expansion study in Mexico,Unconfirmed,MIG,Migration,IV,Phase IV,ExpLilly German trial.Partial intl fund ,,,000940,Post Marketing Study (MIGRATED)
11224,1209-0001,1209.1,Ended,636,1209-P01,tolerance study with PHL 00747,Ended,MIG,Migration,III,Phase III,safety and tolerance study ,,,000910,IS - Clin Study (MIGRATED)
11225,1210-0001,1210.1,Unconfirmed,637,1210-P01,Escalated single oral doses of BIRB 1297,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11226,1210-0002,1210.2,Unconfirmed,637,1210-P01,Rising multiple doses of BIRB 1297 BS,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11227,1175-0024,1175.24,Unconfirmed,638,1175-P04,PK/tolerability in COPD patients,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
11228,1211-0001,1211.1,Ended,639,1211-P01,Dose ranging study,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11229,1211-0002,1211.2,Preparing,639,1211-P01,Alovudine interaction with tenofovir,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11230,1211-0003,1211.3,Preparing,639,1211-P01,Alovudine interaction with didanosine,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11231,1211-0004,1211.4,Preparing,639,1211-P01,Alovudine interaction with tipranavir/r,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11232,1211-0005,1211.5,Unconfirmed,639,1211-P01,Alovudine interaction with bactrim,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11233,1211-0006,1211.6,Preparing,639,1211-P01,Alovudine dose-finding study,Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
11234,1211-0007,1211.7,Unconfirmed,639,1211-P01,Alovudine interaction with lopinavir,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11235,1211-0008,1211.8,Preparing,639,1211-P01,Alovudine interaction with abacavir,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11236,1211-0009,1211.9,Unconfirmed,639,1211-P01,Alovudine interaction with lamivudine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11237,1211-0010,1211.10,Preparing,639,1211-P01,Alovudine interaction with efavirenz,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11238,1211-0011,1211.11,Unconfirmed,639,1211-P01,Alovudine interaction with fosamprenavir,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11239,1211-0012,1211.12,Unconfirmed,639,1211-P01,Alovudine interaction with atazanavir,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11240,1213-0001,1213.1,Unconfirmed,642,1213-P01,Dose tolerance p.o., single dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11241,1213-0002,1213.2,Unconfirmed,642,1213-P01,Dose tolerance p.o., multiple dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11242,1213-0003,1213.3,Unconfirmed,642,1213-P01,PK/PD in diabetics (CRO),Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11243,1213-0004,1213.4,Unconfirmed,642,1213-P01,Drug Interaction in diabetics (CRO),Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11244,1213-0005,1213.5,Unconfirmed,642,1213-P01,Safety in combination with SUs,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11245,1213-0006,1213.6,Unconfirmed,642,1213-P01,PoC, dose range finding,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11246,0018-0482,18.482,Unconfirmed,643,0018-P06,PoC study of ambroxol in NP,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11247,0018-0483,18.483,Unconfirmed,643,0018-P06,PK study OAD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11248,0018-0484,18.484,Unconfirmed,643,0018-P06,Dose/range study,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
11249,0018-0485,18.485,Unconfirmed,643,0018-P06,ambroxol in hepatic impaired,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11250,0018-0486,18.486,Unconfirmed,643,0018-P06,Ambroxol in renal impaired,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11251,1214-0001,1214.1,Ended,645,1214-P01,Safety, Tolerability, PK,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11252,1214-0002,1214.2,Unconfirmed,645,1214-P01,PK/PD Forearm BF Trial,Unconfirmed,MIG,Migration,IA,Phase Ia,CRO; a Phase I unit in a University ,,,000910,IS - Clin Study (MIGRATED)
11253,1214-0003,1214.3,Preparing,645,1214-P01,Safety,Tolerability, Efficacy in Pts,Preparing,MIG,Migration,IIB,Phase IIb, single attack; active control ,,,000910,IS - Clin Study (MIGRATED)
11254,1214-0004,1214.4,Unconfirmed,645,1214-P01,PoC  in Acute Prevention (Aura),Unconfirmed,MIG,Migration,IIA,Phase IIa,PoC in Acute prevention ,,,000910,IS - Clin Study (MIGRATED)
11255,1214-0005,1214.5,Preparing,645,1214-P01,ADME Study,Preparing,MIG,Migration,IA,Phase Ia,To be performed at CRO in NL (PBR) ,,,000910,IS - Clin Study (MIGRATED)
11256,1214-0006,1214.6,Preparing,645,1214-P01,CYP 3A4 DDI inhibitor,Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11257,1214-0007,1214.7,Preparing,645,1214-P01,CYP 3A4 DDI substrate,Preparing,MIG,Migration,IA,Phase Ia,performed at HPZ-I or CRO ,,,000910,IS - Clin Study (MIGRATED)
11258,1214-0008,1214.8,Preparing,645,1214-P01,Japanese Phase I Bridging,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11259,1214-0009,1214.9,Unconfirmed,645,1214-P01,P-gp DDI substrate,Unconfirmed,MIG,Migration,IA,Phase Ia,to be performed at CRO ,,,000910,IS - Clin Study (MIGRATED)
11260,0352-2037,352.2037,Ended,646,0352-P02,RMT-2 IR/SDur Optimization Pilot Study,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11261,0352-2038,352.2038,Preparing,646,0352-P02,RMT-2 IR Optimization Main Study in COPD,Preparing,MIG,Migration,II,Phase II,,2005-003905-10,,000910,IS - Clin Study (MIGRATED)
11262,0352-2052,352.2052,Preparing,646,0352-P02,Characterize supervised/unsupervised PFT,Preparing,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
11263,0502-0403,502.403,Ended,647,0502-P07,Pediatric PK/PD Study,Ended,MIG,Migration,II,Phase II,Those randomized to PK have 3 add days ,,,000910,IS - Clin Study (MIGRATED)
11264,0502-0405,502.405,Unconfirmed,647,0502-P07,Pediatric Microalbuminuria,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11265,0502-0416,502.416,Preparing,647,0502-P07,Pediatric Formulation,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11266,0502-0558,502.558,Preparing,647,0502-P07,Migraine Prophylaxis,Preparing,MIG,Migration,III,Phase III,,2008-007511-32,,000910,IS - Clin Study (MIGRATED)
11267,0502-0561,502.561,Preparing,647,0502-P07,Safety  Migraine Prophylaxis in children,Preparing,MIG,Migration,III,Phase III,,2008-007512-15,,000910,IS - Clin Study (MIGRATED)
11268,0502-0577,502.577,Preparing,647,0502-P07,Telmisartan in adults with migraine,Preparing,MIG,Migration,II,Phase II,28d base, 6 month db tx, 3-6 mon open ex 24 weeks db tx followed by 3 to 6 months of open label safety.,2008-007513-74,,000910,IS - Clin Study (MIGRATED)
11269,0502-0578,502.578,Preparing,647,0502-P07,Safety in normotensive ped. migraineurs,Preparing,MIG,Migration,II,Phase II,Single center study in US ,,,000910,IS - Clin Study (MIGRATED)
11270,0502-0583,502.583,Unconfirmed,647,0502-P07,Migraine Prophylaxis in Adults,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11271,1215-0001,1215.1,Unconfirmed,648,1215-P01,CLL once weekly,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11272,1215-0002,1215.2,Unconfirmed,648,1215-P01,CLL biweekly,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11273,1215-0003,1215.3,Unconfirmed,648,1215-P01,NHLonce weekly,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11274,1215-0004,1215.4,Unconfirmed,648,1215-P01,NHL biweekly,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11275,1215-0005,1215.5,Unconfirmed,648,1215-P01,CLL monotherapy,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11276,1215-0006,1215.6,Unconfirmed,648,1215-P01,CLL monotherapy,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11277,1215-0007,1215.7,Unconfirmed,648,1215-P01,NHL monotherapy,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11278,1215-0008,1215.8,Unconfirmed,648,1215-P01,NHL monotherapy,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11279,1215-0009,1215.9,Unconfirmed,648,1215-P01,NHL Rituxan combination,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11280,1215-0010,1215.10,Unconfirmed,648,1215-P01,NHL rituxan combination,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11281,1215-0011,1215.11,Unconfirmed,648,1215-P01,NHL rituxan combination,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11282,1215-0012,1215.12,Unconfirmed,648,1215-P01,CLL Fludara-combination,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11283,1215-0013,1215.13,Unconfirmed,648,1215-P01, CLL Fludara-combination,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11284,1215-0014,1215.14,Unconfirmed,648,1215-P01,CLL Fludara-combination,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11285,1216-0001,1216.1,Ended,649,1216-P01,Solid tumor single dose,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11286,1216-0002,1216.2,Ended,649,1216-P01,Solid tumor weekly,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11287,1216-0003,1216.3,Ended,649,1216-P01,BI 2536 in NHL,Ended,MIG,Migration,I,Phase I,07-MAR-2008  This trial wil be closed soon due to project closure.  We have seen 3 CR and one near CR.  3 out of 4 patient had T-Cell Lymphoma.  We have treated only 5 patients with T cell lymphoma. As such we are evaluating possible development plan for BI 2536 in T cell Lymphomas.  TCM met with 3 investigators and is gathering clinical data on the 3 patients to be presented at CEG.  (07-JAN-2008),,,000910,IS - Clin Study (MIGRATED)
11288,1216-0004,1216.4,Unconfirmed,649,1216-P01,Lung cancer 2d on/5d off,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11289,1216-0007,1216.7,Unconfirmed,649,1216-P01,Solid Tumor combo,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11290,1216-0008,1216.8,Ended,649,1216-P01,Pancreas Combo Gemcitabine,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11291,1216-0010,1216.10,Ended,649,1216-P01,Pancreas mono,Ended,MIG,Migration,II,Phase II,,2005-005253-22,,000910,IS - Clin Study (MIGRATED)
11292,1216-0011,1216.11,Ended,649,1216-P01,Small Cell Lung Cancer mono,Ended,MIG,Migration,II,Phase II,07-MAR-2008  Negative trial, No PR or CR Closing the trial.  Notice was sent to the sites. DRA advising FDA.  4 patients remain on trial.  We need to revise our consent form and reconsent these patients.,,,000910,IS - Clin Study (MIGRATED)
11293,1216-0012,1216.12,Unconfirmed,649,1216-P01,NHL Phase II mono,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11294,1216-0013,1216.13,Unconfirmed,649,1216-P01,NHL Phase II mono,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11295,1216-0016,1216.16,Unconfirmed,649,1216-P01,Pancreatic Adeno-Ca,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11296,1216-0017,1216.17,Unconfirmed,649,1216-P01,Hormone Refractory Prostate Cancer,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11297,1216-0018,1216.18,Ended,649,1216-P01,EORTC basket study,Ended,MIG,Migration,II,Phase II,non-randomized, multicenter various solid tumours,2006-004529-27,,000910,IS - Clin Study (MIGRATED)
11298,1216-0019,1216.19,Ended,649,1216-P01,Prostate BI 2536 Monotherapy,Ended,MIG,Migration,II,Phase II,,2005-005255-18,,000910,IS - Clin Study (MIGRATED)
11299,1216-0020,1216.20,Ended,649,1216-P01,AML mono,Ended,MIG,Migration,II,Phase II,Treatment arm B day1-3 discontinued; new treatment arm C: day 1+8 (CTP Amendm. 3),2006-000613-38,,000910,IS - Clin Study (MIGRATED)
11300,1216-0021,1216.21,Unconfirmed,649,1216-P01,Phase I and II Roll Over Trial,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11301,1216-0022,1216.22,Unconfirmed,649,1216-P01,Phase I study in Japanese patients,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11302,1216-0023,1216.23,Unconfirmed,649,1216-P01,ADME Trial in Patients,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11303,1216-0024,1216.24,Unconfirmed,649,1216-P01,DDI Ketoconazole (CYP 3A4 inhibitor),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11304,1216-0025,1216.25,Unconfirmed,649,1216-P01,DDI Study warfarin (CYP2 C9 substrate),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11305,1217-0001,1217.1,Unconfirmed,650,1217-P01,Finalgel efficacy and safety,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11306,1218-0001,1218.1,Ended,652,1218-P01,Single Rising Dose,Ended,MIG,Migration,I,Phase I,,2004-001919-66,,000910,IS - Clin Study (MIGRATED)
11307,1218-0002,1218.2,Ended,652,1218-P01,Dose tolerance p.o., multiple dose,Ended,MIG,Migration,IB,Phase Ib,,2004-004979-11,,000910,IS - Clin Study (MIGRATED)
11308,1218-0003,1218.3,Ended,652,1218-P01,PK/PD in diabetics (CRO),Ended,MIG,Migration,IB,Phase Ib,,2005-001265-34,,000910,IS - Clin Study (MIGRATED)
11309,1218-0004,1218.4,Ended,652,1218-P01,Interaction with metformin,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11310,1218-0005,1218.5,Ended,652,1218-P01,Plcb controlled, BI1356 vs. metformin,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11311,1218-0006,1218.6,Ended,652,1218-P01,Efficacy vs. placebo in combination,Ended,MIG,Migration,IIB,Phase IIb,,2005-004597-24,,000910,IS - Clin Study (MIGRATED)
11312,1218-0007,1218.7,Ended,652,1218-P01,Human ADME Study,Ended,MIG,Migration,IB,Phase Ib,,2006-000100-17,,000910,IS - Clin Study (MIGRATED)
11313,1218-0008,1218.8,Ended,652,1218-P01,Relative Bioavailability,Ended,MIG,Migration,I,Phase I,,2005-001266-13,,000910,IS - Clin Study (MIGRATED)
11314,1218-0009,1218.9,Ended,652,1218-P01,Clinical PK Interaction With Simvastatin,Ended,MIG,Migration,I,Phase I,,2005-002648-24,,000910,IS - Clin Study (MIGRATED)
11315,1218-0010,1218.10,Ended,652,1218-P01,Tolerability of intravenous formulation,Ended,MIG,Migration,I,Phase I,,2006-000099-34,,000910,IS - Clin Study (MIGRATED)
11316,1218-0011,1218.11,Ended,652,1218-P01,SRD and MRD (combined P1) in Japanese HV,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11317,1218-0012,1218.12,Ended,652,1218-P01,PK/PD in Japanese T2D,Ended,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
11318,1218-0013,1218.13,Ended,652,1218-P01,Drug-drug interaction with pioglitazone,Ended,MIG,Migration,I,Phase I,,2006-005918-12,,000910,IS - Clin Study (MIGRATED)
11319,1218-0014,1218.14,Unconfirmed,652,1218-P01,Efficacy of once weekly posology,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11320,1218-0015,1218.15,Ended,652,1218-P01,Initial combination with pioglitazone,Ended,MIG,Migration,III,Phase III,,2007-002456-41,,000910,IS - Clin Study (MIGRATED)
11321,1218-0016,1218.16,Ended,652,1218-P01,Efficacy vs. Placebo Monotherapy 24wk,Ended,MIG,Migration,III,Phase III,,2007-002448-10,,000910,IS - Clin Study (MIGRATED)
11322,1218-0017,1218.17,Ended,652,1218-P01,Efficacy vs. PBO as add-on to metformin,Ended,MIG,Migration,III,Phase III,,2007-002457-24,,000910,IS - Clin Study (MIGRATED)
11323,1218-0018,1218.18,Ended,652,1218-P01,Efficacy vs PBO: add-on to metformin/SU,Ended,MIG,Migration,III,Phase III,,2007-002450-28,,000910,IS - Clin Study (MIGRATED)
11324,1218-0019,1218.19,Preparing,652,1218-P01,Efficacy vs. TZD as add-on to metformin,Preparing,MIG,Migration,III,Phase III,,2007-002451-17,,000910,IS - Clin Study (MIGRATED)
11325,1218-0020,1218.20,Ended,652,1218-P01,Eff.vs glimepiride as addon to metformin,Ended,MIG,Migration,III,Phase III,,2007-004585-40,,000910,IS - Clin Study (MIGRATED)
11326,1218-0021,1218.21,Unconfirmed,652,1218-P01,Beta Cell Function Study vs. SU,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11327,1218-0022,1218.22,Last Subject Randomised,652,1218-P01,CARMELINA,Last Subject Randomised,MIG,Migration,IV,Phase IV,,2011-004148-23,,000200,IS - Clin Study - Outcome
11328,1218-0023,1218.23,Ended,652,1218-P01,Japanese P III vs Voglibose and Placebo,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
11329,1218-0024,1218.24,Unconfirmed,652,1218-P01,Combination with alpha-GI vs. SU,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11330,1218-0025,1218.25,Ended,652,1218-P01,Relative BA trial formulations vs. iFF,Ended,MIG,Migration,I,Phase I,,2006-005069-21,,000910,IS - Clin Study (MIGRATED)
11331,1218-0026,1218.26,Ended,652,1218-P01,PK/PD/safety in renal insufficiency,Ended,MIG,Migration,I,Phase I,,2007-006309-26,,000910,IS - Clin Study (MIGRATED)
11332,1218-0027,1218.27,Ended,652,1218-P01,PK/PD/safety in hepatic insufficiency,Ended,MIG,Migration,I,Phase I,,2008-000922-38,,000910,IS - Clin Study (MIGRATED)
11333,1218-0028,1218.28,Ended,652,1218-P01,Interaction with warfarin,Ended,MIG,Migration,I,Phase I,,2008-002375-26,,000910,IS - Clin Study (MIGRATED)
11334,1218-0029,1218.29,Ended,652,1218-P01,Interaction with digoxin,Ended,MIG,Migration,I,Phase I,,2007-007073-23,,000910,IS - Clin Study (MIGRATED)
11335,1218-0030,1218.30,Ended,652,1218-P01,Interaction with glyburide,Ended,MIG,Migration,I,Phase I,,2008-000336-41,,000910,IS - Clin Study (MIGRATED)
11336,1218-0031,1218.31,Ended,652,1218-P01,Interaction with ritonavir,Ended,MIG,Migration,I,Phase I,,2007-007074-34,,000910,IS - Clin Study (MIGRATED)
11337,1218-0032,1218.32,Ended,652,1218-P01,Formal QT prolongation study,Ended,MIG,Migration,I,Phase I,,2007-004220-21,,000910,IS - Clin Study (MIGRATED)
11338,1218-0033,1218.33,Ended,652,1218-P01,Assessment of dose proportionality,Ended,MIG,Migration,I,Phase I,,2009-011780-36,,000910,IS - Clin Study (MIGRATED)
11339,1218-0034,1218.34,Ended,652,1218-P01,Food effect of final formulation,Ended,MIG,Migration,I,Phase I,,2008-002111-40,,000910,IS - Clin Study (MIGRATED)
11340,1218-0035,1218.35,Ended,652,1218-P01,Safety in combination with sulfonylureas,Ended,MIG,Migration,IIIB,Phase IIIb,,2008-003118-86,,000910,IS - Clin Study (MIGRATED)
11341,1218-0036,1218.36,Ended,652,1218-P01,Combination with insulin,Ended,MIG,Migration,III,Phase III,,2008-008296-33,,000910,IS - Clin Study (MIGRATED)
11342,1218-0037,1218.37,Ended,652,1218-P01,Infl. of Pbo, BI 1356 and sita on biom.,Ended,MIG,Migration,IIA,Phase IIa,,2007-007865-19,,000910,IS - Clin Study (MIGRATED)
11343,1218-0038,1218.38,Unconfirmed,652,1218-P01,PD and biomarker profiling,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11344,1218-0039,1218.39,Unconfirmed,652,1218-P01,Efficacy in poorly controlled patients,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11345,1218-0040,1218.40,Ended,652,1218-P01,Safety BI1356 as monotherapy or in combi,Ended,MIG,Migration,IIIB,Phase IIIb,,2008-000750-13,,000910,IS - Clin Study (MIGRATED)
11346,1218-0041,1218.41,Unconfirmed,652,1218-P01,Open label extension of 1218.16,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11347,1218-0042,1218.42,Unconfirmed,652,1218-P01,open label extension of 1218.17,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11348,1218-0043,1218.43,Ended,652,1218-P01,Safety in renally impaired T2D pat,Ended,MIG,Migration,III,Phase III,,2008-001569-27,,000910,IS - Clin Study (MIGRATED)
11349,1218-0044,1218.44,Ended,652,1218-P01,Effect on PK of oral contraceptives,Ended,MIG,Migration,I,Phase I,,2008-000953-37,,000910,IS - Clin Study (MIGRATED)
11350,1218-0048,1218.48,Unconfirmed,652,1218-P01,Non-inferiority vs. sitagliptin,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,Exact design based on results of 1218.37 ,,,000910,IS - Clin Study (MIGRATED)
11351,1218-0049,1218.49,Unconfirmed,652,1218-P01,Open label extension of 1218.18,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11352,1218-0050,1218.50,Ended,652,1218-P01,Metformin ineligible patients,Ended,MIG,Migration,III,Phase III,,2007-007485-38,,000910,IS - Clin Study (MIGRATED)
11353,1218-0054,1218.54,Unconfirmed,652,1218-P01,Open label extension to 1218.35,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11354,1218-0055,1218.55,Ended,652,1218-P01,Effect of Race  on PK/PD,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11355,1218-0058,1218.58,Ended,652,1218-P01,PK in Chinese volunteers,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11356,1218-0060,1218.60,Ended,652,1218-P01,safety and efficacy BI 1356+Metformin qd,Ended,MIG,Migration,IV,Phase IV,,2011-002276-16,,000910,IS - Clin Study (MIGRATED)
11357,1218-0061,1218.61,Ended,652,1218-P01,Efficacy vs Pbo add-on to met and pio,Ended,MIG,Migration,III,Phase III,,2009-013289-20,,000910,IS - Clin Study (MIGRATED)
11358,1218-0063,1218.63,Ended,652,1218-P01,Safety and efficacy in elderly patients,Ended,MIG,Migration,III,Phase III,,2009-015255-25,,000910,IS - Clin Study (MIGRATED)
11359,1218-0064,1218.64,Ended,652,1218-P01,Safety+effic.in pts with renal imp.,Ended,MIG,Migration,III,Phase III,,2009-016971-31,,000910,IS - Clin Study (MIGRATED)
11360,1218-0065,1218.65,Ended,652,1218-P01,Add on to metformin in China,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11361,1218-0066,1218.66,Ended,652,1218-P01,Efficacy+safety in T2D patients in China,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11362,1218-0067,1218.67,Ended,652,1218-P01,DDI with Rifampicin,Ended,MIG,Migration,I,Phase I,,2009-012946-22,,000910,IS - Clin Study (MIGRATED)
11363,1218-0068,1218.68,Unconfirmed,652,1218-P01,safety+eff. afro-americans vs caucasians,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11364,1218-0072,1218.72,Unconfirmed,652,1218-P01,PK/PD in mild/mod. renal impairment,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11365,1218-0073,1218.73,Unconfirmed,652,1218-P01,PK/PD of 1 mg in severe ren. imp.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11366,1218-0074,1218.74,First Subject Randomised,652,1218-P01,safety and efficacy linagliptin vs SU,First Subject Randomised,MIG,Migration,III,Phase III,,2009-013157-15,,000200,IS - Clin Study - Outcome
11367,1218-0075,1218.75,Ended,652,1218-P01,Linagliptin in Black/ African Americans,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11368,1218-0076,1218.76,Unconfirmed,652,1218-P01,SU non responder study in Japan,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11369,1218-0077,1218.77,Unconfirmed,652,1218-P01,alpha-GI non responder study in Japan,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11370,1218-0078,1218.78,Ended,652,1218-P01,Comprehensive add on study in Japan,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
11371,1218-0079,1218.79,Unconfirmed,652,1218-P01,American College of Cardiology registry,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
11372,1218-0080,1218.80,Ended,652,1218-P01,Cross sectional prevalence CKD in US T2D,Ended,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
11373,1218-0081,1218.81,Unconfirmed,652,1218-P01,ESRD requiring hemodialysis,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11374,1218-0082,1218.82,Unconfirmed,652,1218-P01,Renal Transplantation NODAT study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11375,1218-0083,1218.83,Ended,652,1218-P01,Newly diagnosed T2DM patients,Ended,MIG,Migration,IV,Phase IV,,2011-004158-24,,000910,IS - Clin Study (MIGRATED)
11376,1218-0084,1218.84,Preparing,652,1218-P01,Efficacy+Safety vs. SU during Ramadan,Preparing,MIG,Migration,IV,Phase IV,,2012-003783-42,,000910,IS - Clin Study (MIGRATED)
11377,1218-0085,1218.85,Unconfirmed,652,1218-P01,H2H vs. Comparator in mild/ moderate RI,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11378,1218-0086,1218.86,Preparing,652,1218-P01,H2H vs. SU in elderly T2DM patients,Preparing,MIG,Migration,IV,Phase IV,,2014-001212-18,,000910,IS - Clin Study (MIGRATED)
11379,1218-0087,1218.87,Unconfirmed,652,1218-P01,H2H vs. SU in BOT,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11380,1218-0088,1218.88,Unconfirmed,652,1218-P01,Mechanistic BOT study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11381,1218-0089,1218.89,Ended,652,1218-P01,MARLINA T2DM -  Patients at risk of RI,Ended,MIG,Migration,IIIB,Phase IIIb,,2012-002603-17,,000910,IS - Clin Study (MIGRATED)
11382,1218-0090,1218.90,Ended,652,1218-P01,Prevalence of CKD in T2DM in Germany,Ended,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
11383,1218-0094,1218.94,Ended,652,1218-P01,PMS on Linagliptin Among Filipinos,Ended,MIG,Migration,IV,Phase IV,,,,,
11384,1218-0095,1218.95,Last Subject Randomised,652,1218-P01,PMS of Trazenta on Long Term Use,Last Subject Randomised,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
11385,1218-0096,1218.96,Ended,652,1218-P01,EPI: Characterization of pat. with T2DM,Ended,MIG,Migration,NONE,Not Classified, Values from CTMS: Planned Subjects Screened: 200000, Planned Subjects Randomized: 200000, Planned Subjects Completed Treatment: 200000,,,000980,Not Classified (MIGRATED)
11386,1218-0097,1218.97,Preparing,652,1218-P01,EPI-PMR: Hypersensitivity and Skin,Preparing,MIG,Migration,IV,Phase IV,,,,000980,Not Classified (MIGRATED)
11387,1218-0098,1218.98,Ended,652,1218-P01,Prevalence of renal impairm. in diabetes,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
11388,1218-0099,1218.99,Unconfirmed,652,1218-P01,Japanese add onto insulin study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11389,1218-0100,1218.100,Ended,652,1218-P01,Critical Evaluation of the Literature,Ended,MIG,Migration,NONE,Not Classified, Values from CTMS: Planned Subjects Screened: 200000, Planned Subjects Randomized: 200000, Planned Subjects Completed Treatment: ,,,000930,NISed - Study (MIGRATED)
11390,1218-0101,1218.101,Analysis,652,1218-P01,EPI: Pregnancy,Analysis,MIG,Migration,IV,Phase IV, Values from CTMS: Planned Subjects Screened: 200000, Planned Subjects Randomized: 200000, Planned Subjects Completed Treatment: ,,,000930,NISed - Study (MIGRATED)
11391,1218-0102,1218.102,First Subject Randomised,652,1218-P01,Add on to insulin study in China,First Subject Randomised,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11392,1218-0103,1218.103,Ended,652,1218-P01,STONE: NEphropathy in T2D in Finland.,Ended,MIG,Migration,IV,Phase IV,Non-interventional, cross-sectional ,,,000300,IS - Methodological Studies
11393,1218-0104,1218.104,Recruiting,652,1218-P01,Regulatory requisite PMS in Korea,Recruiting,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
11394,1218-0105,1218.105,Ended,652,1218-P01,Endothelial function pilot study,Ended,MIG,Migration,I,Phase I,,2012-003317-33,,000910,IS - Clin Study (MIGRATED)
11395,1218-0106,1218.106,Unconfirmed,652,1218-P01,Plaque inflammation study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11396,1218-0107,1218.107,Unconfirmed,652,1218-P01,Coronary flow reserve study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11397,1218-0108,1218.108,Unconfirmed,652,1218-P01,Endothelial function Full scale trial,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11398,1218-0109,1218.109,Unconfirmed,652,1218-P01,Microvascular coronary reactivity EPCs,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11399,1218-0110,1218.110,Unconfirmed,652,1218-P01,Renal endothelial function study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11400,1218-0111,1218.111,Unconfirmed,652,1218-P01,Prevention of heart failure in early LVD,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11401,1218-0112,1218.112,Unconfirmed,652,1218-P01,Linagliptin vascular effects,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11402,1218-0113,1218.113,Unconfirmed,652,1218-P01,Linagliptin inflammatory response,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11403,1218-0114,1218.114,Preparing,652,1218-P01,MRI study on macrovascular reactivity,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11404,1218-0119,1218.119,Unconfirmed,652,1218-P01,DARLINA T2DM renal risk pts study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11405,1218-0124,1218.124,Unconfirmed,652,1218-P01,Trajenta STP study (CN12003) China,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
11406,1218-0125,1218.125,Preparing,652,1218-P01,Prevalence of CKD in Long term care,Preparing,MIG,Migration,NONE,Not Classified,see extended remarks This was an HEOR study. It was initially entered per global's request for budget tracking. However, this plan was cancelled and it was requested to delete these studies from CTMS.,,,000980,Not Classified (MIGRATED)
11407,1218-0126,1218.126,Preparing,652,1218-P01,OADs,polypharmacy, HE in T2DM in CKD,Preparing,MIG,Migration,NONE,Not Classified,See extended remarks This was an HEOR study. It was initially entered per global's request for budget tracking. However, this plan was cancelled and it was requested to delete these studies from CTMS.,,,000980,Not Classified (MIGRATED)
11408,1218-0127,1218.127,Preparing,652,1218-P01,Long-term care T2M (Analyticare),Preparing,MIG,Migration,NONE,Not Classified,See extended remarks This was an HEOR study. It was initially entered per global's request for budget tracking. However, this plan was cancelled and it was requested to delete these studies from CTMS.,,,000980,Not Classified (MIGRATED)
11409,1218-0128,1218.128,Preparing,652,1218-P01,Thomson database study T2D,Preparing,MIG,Migration,NONE,Not Classified,See extended remarks. This was an HEOR study. It was initially entered per global's request for budget tracking. However, this plan was cancelled and it was requested to delete these studies from CTMS. Values from CTMS: Planned Subjects Screened: 100000, Planned Subjects Randomized: 100000, Planned Subjects Completed Treatment: ,,,000980,Not Classified (MIGRATED)
11410,1218-0129,1218.129,Ended,652,1218-P01,TONY-T2DM and diabetic CKD in GP,Ended,MIG,Migration,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
11411,1218-0145,1218.145,Analysis,652,1218-P01,EPI :SU and CV Risk,Analysis,MIG,Migration,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
11412,1218-0147,1218.147,Last Subject Randomised,652,1218-P01,Japanese PMS (add on therapy),Last Subject Randomised,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
11413,1218-0148,1218.148,Unconfirmed,652,1218-P01,US Jentaduetto study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11414,1218-0149,1218.149,Analysis,652,1218-P01,add-on to basal insulin in the elderly,Analysis,MIG,Migration,IV,Phase IV,,2014-000904-88,,000910,IS - Clin Study (MIGRATED)
11415,1218-0154,1218.154,Preparing,652,1218-P01,Hispanic T2DM study,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11416,1218-0161,1218.161,Ended,652,1218-P01,EPI:Channelling assesment 1218.100Part 2,Ended,MIG,Migration,IV,Phase IV, Values from CTMS: Planned Subjects Screened: 200000, Planned Subjects Randomized: 200000, Planned Subjects Completed Treatment: ,,,,
11417,1218-0162,1218.162,Analysis,652,1218-P01,EPI:Validation study (part III 1218.100),Analysis,MIG,Migration,IV,Phase IV, Values from CTMS: Planned Subjects Screened: 166613, Planned Subjects Randomized: 492963, Planned Subjects Completed Treatment: 166613,,,000930,NISed - Study (MIGRATED)
11418,1218-0163,1218.163,Recruiting,652,1218-P01,EPI:Surveillance System 1218.100 Part 4,Recruiting,MIG,Migration,IV,Phase IV, Values from CTMS: Planned Subjects Screened: 500000, Planned Subjects Randomized: 500000, Planned Subjects Completed Treatment: 450000,,,,
11419,1218-0164,1218.164,Preparing,652,1218-P01,EPI:Background ratesT2DM.1218.96-Part2,Preparing,MIG,Migration,NONE,Not Classified, Values from CTMS: Planned Subjects Screened: 200000, Planned Subjects Randomized: 200000, Planned Subjects Completed Treatment: ,,,000980,Not Classified (MIGRATED)
11420,1218-0169,1218.169,Preparing,652,1218-P01,Hypoclamp-Study,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11421,1218-0172,1218.172,Analysis,652,1218-P01,Maccabi Epidemiological Study,Analysis,MIG,Migration,IV,Phase IV,focus on treatment patterns only in patients with T2DM and impaired renal function; linagliptin data will not be collected, and it is not a PASS,,,000930,NISed - Study (MIGRATED)
11422,1218-0174,1218.174,Recruiting,652,1218-P01,Treatment pattern of old T2DM patinets in China,Recruiting,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
11423,1218-0175,1218.175,Ended,652,1218-P01,UK MAPOR proposal,Ended,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
11424,1218-0178,1218.178,Analysis,652,1218-P01,o-CLS Japan,Analysis,MIG,Migration,IV,Phase IV,,,,000930,NISed - Study (MIGRATED)
11425,1219-0001,1219.1,Ended,653,1219-P01,SD-tolerance,Ended,MIG,Migration,I,Phase I,,2004-004383-74,,000910,IS - Clin Study (MIGRATED)
11426,1219-0002,1219.2,Ended,653,1219-P01,Cough and sputum validation study,Ended,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
11427,1219-0003,1219.3,Ended,653,1219-P01,multiple rising dose study,Ended,MIG,Migration,I,Phase I,,2005-005133-35,,000910,IS - Clin Study (MIGRATED)
11428,1219-0004,1219.4,Ended,653,1219-P01,Safety and efficacy in COB,Ended,MIG,Migration,II,Phase II,,2007-003742-15,,000910,IS - Clin Study (MIGRATED)
11429,1219-0005,1219.5,Ended,653,1219-P01,Effect of BIBW 2948 BS on Mucus staining,Ended,MIG,Migration,IIA,Phase IIa,,2006-001975-40,,000910,IS - Clin Study (MIGRATED)
11430,1219-0006,1219.6,Unconfirmed,653,1219-P01,Effect of BIBW 2948 BS on PRO,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11431,1219-0007,1219.7,Ended,653,1219-P01,CASA-Q during exacerbation,Ended,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
11432,0527-0049,527.49,Ended,654,0527-P04,Pediatric Pharmacokinetic,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11433,0527-0050,527.50,Preparing,654,0527-P04,Pediatric Dose Ranging Study,Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
11434,0527-0051,527.51,Ended,654,0527-P04,Multiple dose efficacy in pediatric NGB,Ended,MIG,Migration,IIIB,Phase IIIb,,2006-003048-52,,000910,IS - Clin Study (MIGRATED)
11435,0527-0063,527.63,Unconfirmed,654,0527-P04,Bioequivalence study,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11436,0527-0065,527.65,Unconfirmed,654,0527-P04,?,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000980,Not Classified (MIGRATED)
11437,0527-0066,527.66,Ended,654,0527-P04,Pediatric Open-Label Safety Study,Ended,MIG,Migration,II,Phase II,,2006-004423-11,,000910,IS - Clin Study (MIGRATED)
11438,1200-0021,1200.21,Unconfirmed,655,1200-P02,Phase I combination trial,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
11439,1200-0022,1200.22,Ended,655,1200-P02,Phase II in mutation +ve NSCLC,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11440,1200-0023,1200.23,Ended,655,1200-P02,Ph IIb/III NSCLC in pts with prior  EGFR,Ended,MIG,Migration,III,Phase III,,2007-005983-28,,000910,IS - Clin Study (MIGRATED)
11441,1200-0033,1200.33,Ended,655,1200-P02,Japanese Phase I/II (LUX-Lung 4),Ended,MIG,Migration,IIB,Phase IIb,Based on Phase II step Entered informaton based on the phase II step,,,000910,IS - Clin Study (MIGRATED)
11442,1200-0039,1200.39,Preparing,655,1200-P02,Phase II never-smoker NSCLC,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11443,1200-0040,1200.40,Ended,655,1200-P02,Phase II EGFR FISH+ NSCLC,Ended,MIG,Migration,IIA,Phase IIa,,2008-001264-37,,000910,IS - Clin Study (MIGRATED)
11444,1200-0041,1200.41,Ended,655,1200-P02,Phase II in EGFR/HER2 mutated NSCLC,Ended,MIG,Migration,IIA,Phase IIa,,2008-001546-67,,000910,IS - Clin Study (MIGRATED)
11445,1200-0042,1200.42,Ended,655,1200-P02,BIBW & Taxol in EGFR TKI Failures,Ended,MIG,Migration,III,Phase III,,2009-014563-39,,000910,IS - Clin Study (MIGRATED)
11446,1200-0070,1200.70,Ended,655,1200-P02,Phase Ib of BIBW 2992 + mTOR inhibitor,Ended,MIG,Migration,IB,Phase Ib,This is a Phase Ib trial The length of the treatment has been estimated as 6 months on average, but it will vary depending on each individual¬¥s response to treatment.,2009-010432-18,,000910,IS - Clin Study (MIGRATED)
11447,1200-0072,1200.72,Ended,655,1200-P02,BIBW 2992 in non-mutated NSCLC,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11448,1200-0121,1200.121,Ended,655,1200-P02,afatinib in T790M,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11449,1123-0020,1123.20,Ended,656,1123-P03,TIPES - TNK Italian PE Study,Ended,MIG,Migration,II,Phase II,,,,,
11450,1123-0023,1123.23,Preparing,656,1123-P03,TIPES - TNK Italian PE Study,Preparing,MIG,Migration,II,Phase II,,,,,
11451,1123-0024,1123.24,Analysis,656,1123-P03,PEITHO - International PE study,Analysis,MIG,Migration,III,Phase III,,,,,
11452,1208-0015,1208.15,Preparing,657,1208-P03,European study of duloxetine in UUI,Preparing,MIG,Migration,IIIA,Phase IIIa,,2004-002143-27,,000910,IS - Clin Study (MIGRATED)
11453,1208-0016,1208.16,Preparing,657,1208-P03,N. American Study of duloxetine in UUI,Preparing,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
11454,1208-0018,1208.18,Preparing,657,1208-P03,UUI open label extension to 1208.15,Preparing,MIG,Migration,III,Phase III,Open label extension of 1208.15; continued until approval in each country,,,000910,IS - Clin Study (MIGRATED)
11455,1208-0019,1208.19,Preparing,657,1208-P03,UUI open label extension of 1208.16,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11456,1208-0020,1208.20,Unconfirmed,657,1208-P03,Duloxetine in Mixed Incontinence,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11457,1199-0005,1199.5,Ended,658,1199-P02,Phase I  w. paclitaxel / carboplatin,Ended,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
11458,1199-0010,1199.10,Ended,658,1199-P02,Phase II non small cell lung cancer,Ended,MIG,Migration,IIA,Phase IIa,,2005-000317-35,,000910,IS - Clin Study (MIGRATED)
11459,1199-0013,1199.13,Last Subject Randomised,658,1199-P02,Phase III in advanced NSCLC (2nd line),Last Subject Randomised,MIG,Migration,III,Phase III,,2007-004803-36,,000910,IS - Clin Study (MIGRATED)
11460,1199-0014,1199.14,Ended,658,1199-P02,pemetrexed vs pemetrexed/BIBF1120,Ended,MIG,Migration,IIIA,Phase IIIa,target opinion leaders/specialists ,2008-002072-10,,000910,IS - Clin Study (MIGRATED)
11461,1199-0018,1199.18,Ended,658,1199-P02,BIBF1120 ES and Pemetrexed in NSCLC,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11462,1199-0019,1199.19,Ended,658,1199-P02,Phase I study in Japanese patients,Ended,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
11463,1199-0027,1199.27,Unconfirmed,658,1199-P02,BIBF 1120 in Neuroendocrine Tumors,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11464,1199-0075,1199.75,Ended,658,1199-P02,BIBF 1120 absolute bioavailability,Ended,MIG,Migration,I,Phase I,i.v. tolerability run in phase ,2009-011129-15,,000910,IS - Clin Study (MIGRATED)
11465,1199-0078,1199.78,Unconfirmed,658,1199-P02,Ph I/II BIBF1120+Pem/Cisplatin 1st line,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11466,1199-0079,1199.79,Unconfirmed,658,1199-P02,Ph II BIBF1120 + Pem/Cisplatin 1st line,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11467,1199-0081,1199.81,Unconfirmed,658,1199-P02,Ph II w. Carboplatin/Taxol 1st line,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11468,1199-0082,1199.82,Analysis,658,1199-P02,Phase I/II study in squamous cell NSCLC,Analysis,MIG,Migration,I,Phase I,,2010-019707-32,,000910,IS - Clin Study (MIGRATED)
11469,1199-0089,1199.89,Unconfirmed,658,1199-P02,BIBF 1120 + docetaxel Japanese Phase III,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11470,1199-0128,1199.128,Analysis,658,1199-P02, Phase III,Analysis,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11471,1199-0147,1199.147,Unconfirmed,658,1199-P02,BIBF 1120 in large cell NSCLC,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11472,1199-0148,1199.148,Unconfirmed,658,1199-P02,BIBF 1120 in bevacizumab pretreated pat,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11473,1199-0243,1199.243,Preparing,658,1199-P02,Pharmacogenomics Research Project,Preparing,MIG,Migration,III,Phase III,,,,000700,Pharmacogenetic Research Program
11474,1220-0001,1220.1,Ended,659,1220-P01,SRD, safety, PK in HV (ZW),Ended,MIG,Migration,IA,Phase Ia,#Subject Visits in food effect line: 4 ,,,000910,IS - Clin Study (MIGRATED)
11475,1220-0002,1220.2,Ended,659,1220-P01,MRD, safety, PK, efficacy in HCV GT-1,Ended,MIG,Migration,IB,Phase Ib,Part 1 (20, 48, 120, 240mg QD) Part 2 (240mg QD, 240mg BID),2007-001158-19,,000910,IS - Clin Study (MIGRATED)
11476,1220-0003,1220.3,Ended,659,1220-P01,SRD, safety, PK in HV (NA, lip form.),Ended,MIG,Migration,IA,Phase Ia,,2006-001873-12,,000910,IS - Clin Study (MIGRATED)
11477,1220-0004,1220.4,Unconfirmed,659,1220-P01,DDI polym inhibitor and Food Effect/HCV,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
11478,1220-0005,1220.5,Ended,659,1220-P01,Efficacy, safety TN HCV GT-1,Ended,MIG,Migration,II,Phase II,,2008-003538-11,,000910,IS - Clin Study (MIGRATED)
11479,1220-0006,1220.6,Ended,659,1220-P01,MRD, safety, PK in HV and Gilbert¬¥s,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11480,1220-0007,1220.7,Ended,659,1220-P01,Pivotal trial in TE HCV patients GT-1,Ended,MIG,Migration,III,Phase III,,2010-021715-17,,000910,IS - Clin Study (MIGRATED)
11481,1220-0008,1220.8,Preparing,659,1220-P01,TN and TE HCV patients GT-1,Preparing,MIG,Migration,III,Phase III,,2012-001242-18,,000910,IS - Clin Study (MIGRATED)
11482,1220-0009,1220.9,Ended,659,1220-P01,DDI (raltegravir) in HV and food effect,Ended,MIG,Migration,I,Phase I,,2009-012429-12,,000910,IS - Clin Study (MIGRATED)
11483,1220-0010,1220.10,Ended,659,1220-P01,Rel BA PIB vx. SGC in HV,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11484,1220-0013,1220.13,Ended,659,1220-P01,SRD, safety, PK in Japanese HV,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11485,1220-0014,1220.14,Ended,659,1220-P01,MRD, safety, PK in Japanese HCV patients,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11486,1220-0015,1220.15,Ended,659,1220-P01,Safety, PK non-HCV cirrhosis,Ended,MIG,Migration,I,Phase I,,2007-007776-42,,000910,IS - Clin Study (MIGRATED)
11487,1220-0016,1220.16,Ended,659,1220-P01,Thorough QT/QTc,Ended,MIG,Migration,IB,Phase Ib,,2007-007850-79,,000910,IS - Clin Study (MIGRATED)
11488,1220-0017,1220.17,Unconfirmed,659,1220-P01,Liver transplant in HCV patients GT-1,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11489,1220-0019,1220.19,Ended,659,1220-P01,Init HCV GT-1 treatment in HIV/HCV pts,Ended,MIG,Migration,III,Phase III,,2010-021734-59,,000910,IS - Clin Study (MIGRATED)
11490,1220-0020,1220.20,Ended,659,1220-P01,DDI (Efavirenz) in HV,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11491,1220-0021,1220.21,Unconfirmed,659,1220-P01,Efficacy, safety polym. I combo in HCV,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11492,1220-0022,1220.22,Unconfirmed,659,1220-P01,Efficacy, PK, safety Albferon in TN HCV,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11493,1220-0023,1220.23,Unconfirmed,659,1220-P01,Efficacy,safety in HCV p. GT-4 TN+TE,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11494,1220-0024,1220.24,Unconfirmed,659,1220-P01,Pivotal trial with Albferon in HCV,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11495,1220-0025,1220.25,Unconfirmed,659,1220-P01,Efficacy, safety Albferon  in TE HCV,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11496,1220-0026,1220.26,Preparing,659,1220-P01,Efficacy in African American HCV GT-1 TN,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11497,1220-0027,1220.27,Unconfirmed,659,1220-P01,Pivotal low dose SOC TN QD + BID,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11498,1220-0028,1220.28,Preparing,659,1220-P01,24 weeks  in HCV TE (Fall-back .2 AM),Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11499,1220-0029,1220.29,Unconfirmed,659,1220-P01,HCV GT-2/3 TE BID/TN QD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11500,1220-0030,1220.30,Ended,659,1220-P01,European pivotal in TN HCV GT-1,Ended,MIG,Migration,III,Phase III,,2010-021716-42,,000910,IS - Clin Study (MIGRATED)
11501,1220-0031,1220.31,Unconfirmed,659,1220-P01,Pivotal trial poly In combo in HCV GT-1,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11502,1220-0032,1220.32,Ended,659,1220-P01,DDI cocktail study (CYP3A4, 2C9),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11503,1220-0033,1220.33,Ended,659,1220-P01,ADME in HV,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11504,1220-0034,1220.34,Unconfirmed,659,1220-P01,HBV - HCV co-inefection TE 75BD TN 75QD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11505,1220-0035,1220.35,Unconfirmed,659,1220-P01,Telaprevir Failures TE BID,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11506,1220-0036,1220.36,Unconfirmed,659,1220-P01,W/o RBV TN BID RBV contra,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11507,1220-0037,1220.37,Unconfirmed,659,1220-P01,Low dose w/o PegIFN TN QD + BID,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11508,1220-0040,1220.40,Ended,659,1220-P01,12-week in BI 201335 in TN,Ended,MIG,Migration,II,Phase II,,2009-012579-90,,000910,IS - Clin Study (MIGRATED)
11509,1220-0041,1220.41,Unconfirmed,659,1220-P01,24 weeks in HCV TE (Fall-back .5 AM),Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11510,1220-0042,1220.42,Unconfirmed,659,1220-P01,Comparison Telapravir,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11511,1220-0043,1220.43,Unconfirmed,659,1220-P01,Comparison Brocepravir,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11512,1220-0044,1220.44,Unconfirmed,659,1220-P01,Comparison TMC 435,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11513,1220-0045,1220.45,Unconfirmed,659,1220-P01,Hermodialysis TE BID TN QD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11514,1220-0047,1220.47,Ended,659,1220-P01,American pivotal trial TN HCV GT1,Ended,MIG,Migration,III,Phase III,CRO and Drug supply costs are pending ,2010-021716-42,,000910,IS - Clin Study (MIGRATED)
11515,1220-0048,1220.48,Ended,659,1220-P01,Roll over trial,Ended,MIG,Migration,III,Phase III,,2011-000141-20,,000910,IS - Clin Study (MIGRATED)
11516,1220-0049,1220.49,Ended,659,1220-P01,DDI (Darunavir/ritonavir) in HV,Ended,MIG,Migration,I,Phase I,,2011-000505-41,,000910,IS - Clin Study (MIGRATED)
11517,1220-0050,1220.50,Ended,659,1220-P01,DDI Tenofovir in HV,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11518,1220-0051,1220.51,Unconfirmed,659,1220-P01,DDI (Atazanavir) in pat,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11519,1220-0052,1220.52,Ended,659,1220-P01,PK in Chinese HV,Ended,MIG,Migration,I,Phase I,local registration of soft capsule ,,,000910,IS - Clin Study (MIGRATED)
11520,1220-0053,1220.53,Ended,659,1220-P01,Rel. BA 3 x 40mg vs. 120 mg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11521,1220-0054,1220.54,Ended,659,1220-P01,Japanese HCV with PegIntron,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
11522,1220-0055,1220.55,Unconfirmed,659,1220-P01,PegIntron vs Pegasys,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11523,1220-0056,1220.56,Ended,659,1220-P01,DDI with oral contraceptives in women,Ended,MIG,Migration,IB,Phase Ib,,2011-006061-17,,000910,IS - Clin Study (MIGRATED)
11524,1220-0057,1220.57,Ended,659,1220-P01,Methad-Bupren-BI201335 DDI in patients,Ended,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
11525,1220-0058,1220.58,Ended,659,1220-P01,BI 201335 in renal impairment,Ended,MIG,Migration,IB,Phase Ib,excludes patients on hemodialysis ,2011-005442-35,,000910,IS - Clin Study (MIGRATED)
11526,1220-0059,1220.59,Ended,659,1220-P01,Food effect on BI 201335 in HVs,Ended,MIG,Migration,IB,Phase Ib,,2012-002941-39,,000910,IS - Clin Study (MIGRATED)
11527,1220-0060,1220.60,Unconfirmed,659,1220-P01,Comparative Trial with telaprevir,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11528,1220-0061,1220.61,Ended,659,1220-P01,DDI with ketoconazole and statins,Ended,MIG,Migration,I,Phase I,,2012-005518-20,,000910,IS - Clin Study (MIGRATED)
11529,1220-0062,1220.62,Unconfirmed,659,1220-P01,DDI with Statin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11530,1220-0063,1220.63,Preparing,659,1220-P01,DDI with Alisporivir,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11531,1220-0064,1220.64,Unconfirmed,659,1220-P01, Case control pharmacogenomics study,Unconfirmed,MIG,Migration,II,Phase II,,,,000700,Pharmacogenetic Research Program
11532,1220-0065,1220.65,Ended,659,1220-P01,DDI with Raltegravir in HV (2),Ended,MIG,Migration,I,Phase I,repeat of 1220.9 (GCP issue at Lab21) ,2012-004872-21,,000910,IS - Clin Study (MIGRATED)
11533,1220-0067,1220.67,Unconfirmed,659,1220-P01,Faldaprevir US EAP,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
11534,1220-0068,1220.68,Preparing,659,1220-P01,follow up registry trial,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11535,1220-0069,1220.69,Preparing,659,1220-P01,Japanese PMS study of Faldaprevir,Preparing,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
11536,1220-0074,1220.74,Unconfirmed,659,1220-P01,HCV background study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
11537,1220-0075,1220.75,Ended,659,1220-P01,HCV Background study,Ended,MIG,Migration,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
11538,1221-0001,1221.1,Preparing,660,1221-P01,SD-tolerance (Respimat),Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11539,1222-0001,1222.1,Ended,661,1222-P01,Single rising dose Phase I,Ended,MIG,Migration,IA,Phase Ia,,2004-003926-92,,000910,IS - Clin Study (MIGRATED)
11540,1222-0002,1222.2,Ended,661,1222-P01,Multiple dose Phase I,Ended,MIG,Migration,IB,Phase Ib,,2005-004877-11,,000910,IS - Clin Study (MIGRATED)
11541,1222-0003,1222.3,Ended,661,1222-P01,SD dose-ranging COPD,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11542,1222-0005,1222.5,Ended,661,1222-P01,Phase IIb 4wk dose-finding in COPD,Ended,MIG,Migration,IIB,Phase IIb,,2006-004828-36,,000910,IS - Clin Study (MIGRATED)
11543,1222-0007,1222.7,Ended,661,1222-P01,i.v. tolerance,Ended,MIG,Migration,I,Phase I,,2006-003414-18,,000910,IS - Clin Study (MIGRATED)
11544,1222-0008,1222.8,Ended,661,1222-P01,Thorough QT Study,Ended,MIG,Migration,I,Phase I,,2006-006920-21,,000910,IS - Clin Study (MIGRATED)
11545,1222-0009,1222.9,Ended,661,1222-P01,Human ADME Study,Ended,MIG,Migration,I,Phase I,,2007-006013-16,,000910,IS - Clin Study (MIGRATED)
11546,1222-0010,1222.10,Unconfirmed,661,1222-P01,Absolute BA study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11547,1222-0011,1222.11,Ended,661,1222-P01,12 / 48 wk pivotal PFT vs PBO in COPD I,Ended,MIG,Migration,III,Phase III,changed to non scope 9/10 ,2008-003647-36,,000910,IS - Clin Study (MIGRATED)
11548,1222-0012,1222.12,Ended,661,1222-P01,12 / 48 wk pivotal PFT vs PBO in COPD II,Ended,MIG,Migration,III,Phase III,changed to non-scope 9/10 ,2008-003704-67,,000910,IS - Clin Study (MIGRATED)
11549,1222-0013,1222.13,Ended,661,1222-P01,24/48 wk pivotal PFT vs active COPD I,Ended,MIG,Migration,III,Phase III,,2008-001933-84,,000910,IS - Clin Study (MIGRATED)
11550,1222-0014,1222.14,Ended,661,1222-P01,24/48 wk pivotal PFT vs active COPD II,Ended,MIG,Migration,III,Phase III,,2008-001934-28,,000910,IS - Clin Study (MIGRATED)
11551,1222-0019,1222.19,Ended,661,1222-P01,oral tolerance in HV,Ended,MIG,Migration,I,Phase I,,2006-006472-38,,000910,IS - Clin Study (MIGRATED)
11552,1222-0020,1222.20,Ended,661,1222-P01,Hepatic impairment,Ended,MIG,Migration,I,Phase I,,2009-010822-21,,000910,IS - Clin Study (MIGRATED)
11553,1222-0021,1222.21,Ended,661,1222-P01,Phase I in Japan,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11554,1222-0022,1222.22,Ended,661,1222-P01,Japan Phase II in COPD,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
11555,1222-0024,1222.24,Ended,661,1222-P01,24 hr PFT Registration study in COPD I,Ended,MIG,Migration,III,Phase III,24 hour PFT study Sites must have infrastructure to support overnight stay of patients,,,000910,IS - Clin Study (MIGRATED)
11556,1222-0025,1222.25,Ended,661,1222-P01,24 hr PFT Registration Study in COPD II,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11557,1222-0026,1222.26,Ended,661,1222-P01,exploratory qd dosing vs bid dosing,Ended,MIG,Migration,IIB,Phase IIb,,2008-006334-10,,000910,IS - Clin Study (MIGRATED)
11558,1222-0034,1222.34,Unconfirmed,661,1222-P01,12 week twice daily (placeholder) COPD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11559,1222-0035,1222.35,Ended,661,1222-P01,Renal impairment,Ended,MIG,Migration,I,Phase I,,2009-010823-15,,000910,IS - Clin Study (MIGRATED)
11560,1222-0036,1222.36,Unconfirmed,661,1222-P01,Multiple dose QT study (placeholder),Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
11561,1222-0037,1222.37,Ended,661,1222-P01,Exercise Label Claim 1,Ended,MIG,Migration,III,Phase III,,2009-014395-21,,000910,IS - Clin Study (MIGRATED)
11562,1222-0038,1222.38,Ended,661,1222-P01,Exercise Label Claim 2,Ended,MIG,Migration,III,Phase III,,2009-014416-35,,000910,IS - Clin Study (MIGRATED)
11563,1222-0039,1222.39,Ended,661,1222-P01,24 Hr PFT vs Tio HH Reg Study in COPD 1,Ended,MIG,Migration,III,Phase III,,2009-014417-27,,000910,IS - Clin Study (MIGRATED)
11564,1222-0040,1222.40,Ended,661,1222-P01,24 Hr PFT vs Tio HH Reg Study in COPD 2,Ended,MIG,Migration,III,Phase III,,2009-014418-86,,000910,IS - Clin Study (MIGRATED)
11565,1222-0041,1222.41,Unconfirmed,661,1222-P01,Exacerbation Study (1),Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11566,1222-0042,1222.42,Unconfirmed,661,1222-P01,Exacerbation Study (2),Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11567,1222-0043,1222.43,Unconfirmed,661,1222-P01,1 year vs. Tiotropium HH,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11568,1222-0044,1222.44,Unconfirmed,661,1222-P01,12 wk tio+olo free combo study (1),Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11569,1222-0045,1222.45,Unconfirmed,661,1222-P01,12 wk  tio+olo free combo study (2),Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11570,1222-0046,1222.46,Preparing,661,1222-P01,Japan Phase III,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11571,1222-0047,1222.47,Ended,661,1222-P01,DDI study (Pgp),Ended,MIG,Migration,I,Phase I,,2010-018527-25,,000910,IS - Clin Study (MIGRATED)
11572,1222-0048,1222.48,Ended,661,1222-P01,DDI study (CYP 2C9),Ended,MIG,Migration,I,Phase I,,2010-018528-18,,000910,IS - Clin Study (MIGRATED)
11573,1222-0049,1222.49,Ended,661,1222-P01,PRP UGT and Olodaterol PK,Ended,MIG,Migration,NONE,Not Classified,,,,000700,Pharmacogenetic Research Program
11574,1222-0050,1222.50,Unconfirmed,661,1222-P01,ADRB2 haplotype analysis,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000700,Pharmacogenetic Research Program
11575,1222-0051,1222.51,Ended,661,1222-P01, Olodaterol Respimat & Tiotropium HH (1),Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11576,1222-0052,1222.52,Ended,661,1222-P01,Olodaterol and  Tiotropium HH (2),Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11577,1222-0053,1222.53,Preparing,661,1222-P01,Drug Utilization Study,Preparing,MIG,Migration,IV,Phase IV,,,,000470,NISed ‚Äì Study - Cross Sectional
11578,1222-0054,1222.54,Preparing,661,1222-P01,PASS Longterm Use of Olol & CV events,Preparing,MIG,Migration,IV,Phase IV,,,,,
11579,1222-0055,1222.55,Last Subject Randomised,661,1222-P01,NPU Brazil,Last Subject Randomised,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
11580,1222-0056,1222.56,Ended,661,1222-P01,Changes i phy funct in pats w COPD,Ended,MIG,Migration,NONE,Not Classified,,,,000920,NISnd - Study (MIGRATED)
11581,1223-0001,1223.1,Unconfirmed,663,1223-P01,Single rising dose study (SRD),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11582,1223-0002,1223.2,Unconfirmed,663,1223-P01,Multiple rising dose study (MRD),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11583,1224-0001,1224.1,Ended,664,1224-P01,Single Rising Dose,Ended,MIG,Migration,I,Phase I,,2006-000712-25,,000910,IS - Clin Study (MIGRATED)
11584,1224-0002,1224.2,Ended,664,1224-P01,BA trial liquid vs solid formulation,Ended,MIG,Migration,I,Phase I,,2006-004723-11,,000910,IS - Clin Study (MIGRATED)
11585,1224-0003,1224.3,Ended,664,1224-P01,Multiple rising dose in DM 2 patients,Ended,MIG,Migration,I,Phase I,,2006-004724-36,,000910,IS - Clin Study (MIGRATED)
11586,1224-0004,1224.4,Ended,664,1224-P01,Four weeks treatment in DM type 2 pts.,Ended,MIG,Migration,I,Phase I,performed at specialized CRO's ,2007-000373-35,,000910,IS - Clin Study (MIGRATED)
11587,1224-0005,1224.5,Unconfirmed,664,1224-P01,SRD i.v. formulation,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11588,1224-0006,1224.6,Unconfirmed,664,1224-P01,Human ADME study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11589,1224-0007,1224.7,Unconfirmed,664,1224-P01,Renal insufficiency,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11590,1224-0008,1224.8,Unconfirmed,664,1224-P01,Hepatic insufficiency study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11591,1224-0009,1224.9,Unconfirmed,664,1224-P01,Dose finding/Ph 2b - monotherapy,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11592,1224-0010,1224.10,Unconfirmed,664,1224-P01,Dose-finding study / Ph 2b, add-on,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
11593,1224-0011,1224.11,Ended,664,1224-P01,SRD in Japanese healthy subjects,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11594,1224-0012,1224.12,Unconfirmed,664,1224-P01,MRD in Japanese healthy subjects,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11595,1224-0013,1224.13,Unconfirmed,664,1224-P01,Ph3 Combination with insulin vs. placebo,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11596,1224-0014,1224.14,Unconfirmed,664,1224-P01,Formal QT-study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11597,1224-0015,1224.15,Unconfirmed,664,1224-P01,Drug-drug interaction study - Warfarin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11598,1224-0016,1224.16,Unconfirmed,664,1224-P01,drug interaction study with pioglitazone,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11599,1224-0017,1224.17,Unconfirmed,664,1224-P01,drug-drug interaction metformin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11600,1224-0018,1224.18,Unconfirmed,664,1224-P01,drug-drug interaction sulfonylurea,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11601,1224-0019,1224.19,Unconfirmed,664,1224-P01,Comparison of TF2 vs. iFF,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11602,1224-0020,1224.20,Unconfirmed,664,1224-P01,Drug-drug interaction with Acarbose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11603,1224-0021,1224.21,Unconfirmed,664,1224-P01,DDI Study BI 44847 vs. Sitagliptin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11604,1224-0022,1224.22,Ended,664,1224-P01,PK-evaluation of ethnic differences,Ended,MIG,Migration,I,Phase I,,2008-003061-76,,000910,IS - Clin Study (MIGRATED)
11605,1225-0001,1225.1,Unconfirmed,665,1225-P01,Single dose, normal volunteer study,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11606,1226-0001,1226.1,Unconfirmed,666,1226-P01,BI-1230 - Rising Single Doses in HV,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11607,1228-0001,1228.1,Ended,668,1228-P01,T+S free combination study,Ended,MIG,Migration,III,Phase III,,2005-002851-41,,000910,IS - Clin Study (MIGRATED)
11608,1228-0002,1228.2,Ended,668,1228-P01,Pilot BA study T+S formulation Zydus(1),Ended,MIG,Migration,I,Phase I,Study performed  under ZC responsibility ,,,000910,IS - Clin Study (MIGRATED)
11609,1228-0005,1228.5,Unconfirmed,668,1228-P01,Bioequivalence T40/S10 (Zydus),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11610,1228-0006,1228.6,Unconfirmed,668,1228-P01,Bioequivalence T80/S40 (Zydus),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11611,1228-0007,1228.7,Preparing,668,1228-P01,FDC Food effect T80/S40 FDC (Cipla),Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11612,1228-0008,1228.8,Ended,668,1228-P01,Pilot BA study T+S Cipla formulation(1),Ended,MIG,Migration,I,Phase I,Sponsor Cipla, conduct CRO Sitec India ,,,000910,IS - Clin Study (MIGRATED)
11613,1228-0009,1228.9,Preparing,668,1228-P01,Drug interaction trial T80 / S40 mg,Preparing,MIG,Migration,I,Phase I,,2007-005044-25,,000910,IS - Clin Study (MIGRATED)
11614,1228-0010,1228.10,Preparing,668,1228-P01,Bioequivalence T40/S10 (Cipla),Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11615,1228-0011,1228.11,Preparing,668,1228-P01,Bioequivalence T80/S40 (Cipla),Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11616,1228-0012,1228.12,Ended,668,1228-P01,BA study Zydus formulation (2),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11617,1228-0017,1228.17,Unconfirmed,668,1228-P01,BA study Zydus formulation (3),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11618,1228-0018,1228.18,Preparing,668,1228-P01,Bioequivalence bridging study Zocor,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11619,1229-0001,1229.1,Unconfirmed,669,1229-P01,Phase I dose escalation,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11620,1229-0002,1229.2,Unconfirmed,669,1229-P01,Phase I dose escalation,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11621,1229-0003,1229.3,Unconfirmed,669,1229-P01,Phase I trial of BI 7325 in combination,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11622,1230-0001,1230.1,Last Subject Randomised,670,1230-P01,Various solid tumours,Last Subject Randomised,MIG,Migration,I,Phase I,,2005-002500-42,,000910,IS - Clin Study (MIGRATED)
11623,1230-0005,1230.5,Ended,670,1230-P01,Phase II in NSCLC,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11624,1230-0007,1230.7,Ended,670,1230-P01,Phase I combo BI6727/BIBF 1120,Ended,MIG,Migration,I,Phase I,,2008-008304-41,,000910,IS - Clin Study (MIGRATED)
11625,1230-0008,1230.8,Unconfirmed,670,1230-P01,Phase II NSCLC first line,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11626,1230-0009,1230.9,Unconfirmed,670,1230-P01,Phase III NSCLC combination BIBF 1120,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11627,1230-0010,1230.10,Unconfirmed,670,1230-P01,Phase III combo with TKI in  NSCLC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11628,1230-0011,1230.11,Unconfirmed,670,1230-P01,Phase III first line NSCLC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11629,1230-0019,1230.19,Preparing,670,1230-P01,Volasertib Phase II SCC NSCLC,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11630,1230-0020,1230.20,Ended,670,1230-P01,BI 6727 + BIBW 2992 combination,Ended,MIG,Migration,I,Phase I,,2010-019437-97,,000910,IS - Clin Study (MIGRATED)
11631,1231-0001,1231.1,Unconfirmed,671,1231-P01,Phase I dose escalation study,Unconfirmed,MIG,Migration,IB,Phase Ib,,2006-003729-99,,000910,IS - Clin Study (MIGRATED)
11632,1231-0002,1231.2,Unconfirmed,671,1231-P01,Phase I Single Rising Dose,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11633,1231-0003,1231.3,Unconfirmed,671,1231-P01,Phase I Formulation Finding,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11634,1232-0001,1232.1,Ended,672,1232-P01,to improve mental performance,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11635,1233-0001,1233.1,Ended,673,1233-P01,Single rising dose,Ended,MIG,Migration,I,Phase I,,2005-004615-30,,000910,IS - Clin Study (MIGRATED)
11636,1233-0002,1233.2,Ended,673,1233-P01,Multiple rising dose+4w trt in patients,Ended,MIG,Migration,I,Phase I,,2006-000707-42,,000910,IS - Clin Study (MIGRATED)
11637,1233-0003,1233.3,Ended,673,1233-P01,BA of BI 14332 CL as PIB and tablets,Ended,MIG,Migration,I,Phase I,,2006-000709-46,,000910,IS - Clin Study (MIGRATED)
11638,0248-0600,248.600,Ended,674,0248-P08,PK study in children with RLS,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11639,0248-0601,248.601,Preparing,674,0248-P08,Safety and effic. of PPX in RLS children,Preparing,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
11640,0248-0602,248.602,Unconfirmed,674,0248-P08,OL safety study in RLS children,Unconfirmed,MIG,Migration,III,Phase III,this study is cancelled- ,,,000910,IS - Clin Study (MIGRATED)
11641,0248-0645,248.645,Ended,674,0248-P08,Ped. RLS Validation Program-MAPI,Ended,MIG,Migration,NONE,Not Classified,this is not a drug study ,,,000300,IS - Methodological Studies
11642,1234-0001,1234.1,Ended,675,1234-P01,Single rising dose study,Ended,MIG,Migration,I,Phase I,,2005-004213-15,,000910,IS - Clin Study (MIGRATED)
11643,1234-0002,1234.2,Ended,675,1234-P01,Multiple rising dose study,Ended,MIG,Migration,I,Phase I,,2007-001265-15,,000910,IS - Clin Study (MIGRATED)
11644,1234-0003,1234.3,Preparing,675,1234-P01,P-gp interaction study with ritonavir,Preparing,MIG,Migration,I,Phase I,BI 11634 alone vs BI 11634+ritonavir ,2008-004806-16,,000910,IS - Clin Study (MIGRATED)
11645,1234-0004,1234.4,Unconfirmed,675,1234-P01,SRD of IV solution,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11646,1234-0005,1234.5,Unconfirmed,675,1234-P01,Absolute bioavailability Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11647,1234-0006,1234.6,Unconfirmed,675,1234-P01,Elderly PK trial,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
11648,1234-0007,1234.7,Ended,675,1234-P01,Relative BA of SR prototype A,Ended,MIG,Migration,IB,Phase Ib,,2007-003283-21,,000910,IS - Clin Study (MIGRATED)
11649,1234-0008,1234.8,Preparing,675,1234-P01,Relative BA if SR Prototype B,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11650,1234-0009,1234.9,Preparing,675,1234-P01,MRD of sustained release dosage form,Preparing,MIG,Migration,I,Phase I,To utilize reformulated SR dose form ,,,000910,IS - Clin Study (MIGRATED)
11651,1234-0010,1234.10,Unconfirmed,675,1234-P01,Dose escalation in orthopedic surgery,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11652,1234-0011,1234.11,Unconfirmed,675,1234-P01,Reletive BA of SR formulation,Unconfirmed,MIG,Migration,I,Phase I,Assessment of reformulated SR ,,,000910,IS - Clin Study (MIGRATED)
11653,1234-0012,1234.12,Ended,675,1234-P01,Drinking solution to tablet crossover,Ended,MIG,Migration,I,Phase I,Trial replaces activities originally intended for 1234.1 and 1234.2,2007-001266-33,,000910,IS - Clin Study (MIGRATED)
11654,1234-0013,1234.13,Unconfirmed,675,1234-P01,DDI Study atorvastatin and verapamil,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11655,1235-0001,1235.1,Ended,676,1235-P01,Telmisartan and Amlodipine FDC,Ended,MIG,Migration,IIIA,Phase IIIa,16 ,2008-000874-19,,000910,IS - Clin Study (MIGRATED)
11656,1235-0002,1235.2,Ended,676,1235-P01,PK interaction study T+A,Ended,MIG,Migration,I,Phase I,,2006-000159-16,,000910,IS - Clin Study (MIGRATED)
11657,1235-0003,1235.3,Ended,676,1235-P01,BE T+A FDC low dose,Ended,MIG,Migration,I,Phase I,,2007-001308-19,,000910,IS - Clin Study (MIGRATED)
11658,1235-0004,1235.4,Ended,676,1235-P01,BE T+A FDC high dose,Ended,MIG,Migration,I,Phase I,,2007-001310-16,,000910,IS - Clin Study (MIGRATED)
11659,1235-0005,1235.5,Ended,676,1235-P01,Amlo 5 filter study pivotal efficacy FDC,Ended,MIG,Migration,III,Phase III,,2007-002409-36,,000910,IS - Clin Study (MIGRATED)
11660,1235-0006,1235.6,Ended,676,1235-P01,Amlo10 filter study pivotal efficacy FDC,Ended,MIG,Migration,III,Phase III,,2007-002421-68,,000910,IS - Clin Study (MIGRATED)
11661,1235-0007,1235.7,Ended,676,1235-P01,26 w open-label follow up (FDC Amlo 5),Ended,MIG,Migration,III,Phase III,,2007-002410-19,,000910,IS - Clin Study (MIGRATED)
11662,1235-0008,1235.8,Ended,676,1235-P01,26 week open-label follow up (FDC T+A10),Ended,MIG,Migration,III,Phase III,Interim cut off 'LPO' 26Mar09 EU CTD ,2007-002422-29,,000910,IS - Clin Study (MIGRATED)
11663,1235-0011,1235.11,Ended,676,1235-P01,Pilot BA Study T+A Cipla,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11664,1235-0012,1235.12,Ended,676,1235-P01,Food effect study,Ended,MIG,Migration,I,Phase I,,2007-001311-36,,000910,IS - Clin Study (MIGRATED)
11665,1235-0020,1235.20,Ended,676,1235-P01,8 week T+A vs. A in severe hypertension,Ended,MIG,Migration,III,Phase III,,2008-000873-40,,000910,IS - Clin Study (MIGRATED)
11666,1235-0021,1235.21,Ended,676,1235-P01,8 week T+A v A in diabetic hypertensives,Ended,MIG,Migration,III,Phase III,,2008-000874-19,,000910,IS - Clin Study (MIGRATED)
11667,1235-0022,1235.22,Unconfirmed,676,1235-P01,10w T+A vs V+A mod/sev HTN,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11668,1235-0023,1235.23,Unconfirmed,676,1235-P01,10w T+A vs Valsartan+A T2DM sister,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11669,1235-0024,1235.24,Unconfirmed,676,1235-P01,10w T+A vs O+A mod/sev HTN,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11670,1235-0025,1235.25,Unconfirmed,676,1235-P01,10w T+A vs O+A mod/sev HTN (US sister),Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11671,1235-0026,1235.26,Unconfirmed,676,1235-P01,Food effect of T+A,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11672,1235-0029,1235.29,Ended,676,1235-P01,Pivotal A5 non-responder study China,Ended,MIG,Migration,IIIA,Phase IIIa,regional trial China, Korea, Philippines clinical trial protocol submission to Chinese authorities planned for March 2009,,,000910,IS - Clin Study (MIGRATED)
11673,1235-0030,1235.30,Ended,676,1235-P01,PK-study random open-label comb China,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11674,1235-0031,1235.31,Ended,676,1235-P01,Open-Label ABPM-Study T80/A5 China,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11675,1235-0032,1235.32,Preparing,676,1235-P01,TplusA vs A in overweight hypertens. pts,Preparing,MIG,Migration,IV,Phase IV,,,,,
11676,1235-0033,1235.33,Ended,676,1235-P01,TEAMSTA switch,Ended,MIG,Migration,IIIB,Phase IIIb,,2009-017336-40,,000910,IS - Clin Study (MIGRATED)
11677,1235-0034,1235.34,Ended,676,1235-P01,TEAMSTA protect I,Ended,MIG,Migration,IV,Phase IV,,2009-017010-68,,,
11678,1235-0035,1235.35,Unconfirmed,676,1235-P01,TEAMSTA protect II,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11679,1235-0039,1235.39,Unconfirmed,676,1235-P01,PMS on Filipino Hypertensive Patients,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
11680,1235-0040,1235.40,Analysis,676,1235-P01,Regulatory requisite PMS in Korea,Analysis,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
11681,1235-0041,1235.41,Ended,676,1235-P01,canadian bioequivalence study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11682,1235-0042,1235.42,Analysis,676,1235-P01,Twynsta OS in Korean patients,Analysis,MIG,Migration,IV,Phase IV,Protocol amendment_04Aug2011 ,,,000920,NISnd - Study (MIGRATED)
11683,1235-0043,1235.43,Preparing,676,1235-P01,BA/BE T40/A5 Cipla vs BI,Preparing,MIG,Migration,I,Phase I,,2011-004467-77,,000910,IS - Clin Study (MIGRATED)
11684,1235-0044,1235.44,Preparing,676,1235-P01,BA/BE T80/A10 Cipla vs BI,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11685,1236-0001,1236.1,Ended,677,1236-P01,Telmisartan and Ramipril FDC,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
11686,1236-0002,1236.2,Ended,677,1236-P01,Pilot BA study T+R (Zydus),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11687,1236-0003,1236.3,Ended,677,1236-P01,Food effect study (Cipla Formulation),Ended,MIG,Migration,I,Phase I,,2006-004059-39,,000910,IS - Clin Study (MIGRATED)
11688,1236-0004,1236.4,Ended,677,1236-P01,BE Study, low dose T40/R2.5 mg (Cipla),Ended,MIG,Migration,I,Phase I,,2006-004060-31,,000910,IS - Clin Study (MIGRATED)
11689,1236-0005,1236.5,Ended,677,1236-P01,BE high dose T80+R10 (Cipla),Ended,MIG,Migration,I,Phase I,,2006-004371-35,,000910,IS - Clin Study (MIGRATED)
11690,1236-0006,1236.6,Ended,677,1236-P01,Interaction Study T vs R vs T+R,Ended,MIG,Migration,I,Phase I,,2006-004372-12,,000910,IS - Clin Study (MIGRATED)
11691,1236-0007,1236.7,Ended,677,1236-P01,Pilot BA T+R (Cipla),Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11692,1236-0008,1236.8,Preparing,677,1236-P01,BE Low Dose (Zydus),Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11693,1236-0009,1236.9,Preparing,677,1236-P01,BE Study High Dose (Zydus),Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11694,1236-0010,1236.10,Preparing,677,1236-P01,Food effect study (Zydus Formulation),Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11695,1236-0011,1236.11,Preparing,677,1236-P01,BE of Delix 2.5mg vs Tritace 2 x 1.25mg,Preparing,MIG,Migration,I,Phase I,,2007-002057-22,,000910,IS - Clin Study (MIGRATED)
11696,1236-0012,1236.12,Preparing,677,1236-P01,BE Study of Cipla FDC vs monocomponents,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11697,1236-0013,1236.13,Preparing,677,1236-P01,BE Low Dose Cipla T40/R2.5 FDC,Preparing,MIG,Migration,I,Phase I,6 weeks washout between treatments ,2007-006223-12,,000910,IS - Clin Study (MIGRATED)
11698,1236-0014,1236.14,Unconfirmed,677,1236-P01,Interaction Study T40 vs R2.5 vs T+R,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11699,1237-0001,1237.1,Ended,678,1237-P01,SRD in Healthy Volunteers,Ended,MIG,Migration,IA,Phase Ia,,2005-005787-84,,000910,IS - Clin Study (MIGRATED)
11700,1237-0002,1237.2,Ended,678,1237-P01,MRD fixed combo in HV,Ended,MIG,Migration,I,Phase I,,2006-006921-14,,000910,IS - Clin Study (MIGRATED)
11701,1237-0003,1237.3,Ended,678,1237-P01,PK interaction FDC vs compenents,Ended,MIG,Migration,I,Phase I,,2008-000813-31,,000910,IS - Clin Study (MIGRATED)
11702,1237-0004,1237.4,Ended,678,1237-P01,Chronic dose finding,Ended,MIG,Migration,II,Phase II,,2007-005087-26,,000910,IS - Clin Study (MIGRATED)
11703,1237-0005,1237.5,Ended,678,1237-P01,52 wk Pivotal in COPD (TOnadoTM 1),Ended,MIG,Migration,IIIA,Phase IIIa,12 wk efficacy for US; 24 wk efficacy for EU ; 48 wk safety (US/EU),2009-010668-40,,000910,IS - Clin Study (MIGRATED)
11704,1237-0006,1237.6,Ended,678,1237-P01,52 wk Pivotal in COPD (TOnadoTM 2),Ended,MIG,Migration,III,Phase III,12 wk efficacy for US; 24 wk efficacy for EU; 48 wk safety (US/EU),2009-010669-22,,000910,IS - Clin Study (MIGRATED)
11705,1237-0007,1237.7,Ended,678,1237-P01,T+O FDC vs. T+O free combo vs. Placebo,Ended,MIG,Migration,II,Phase II,The study has been requested by the MEB ,2013-002652-32,,000910,IS - Clin Study (MIGRATED)
11706,1237-0008,1237.8,Unconfirmed,678,1237-P01,24 hr PFT Registration COPD (2),Unconfirmed,MIG,Migration,III,Phase III,,2009-010667-16,,000910,IS - Clin Study (MIGRATED)
11707,1237-0009,1237.9,Ended,678,1237-P01,Phase IIb cross-over dose-finding,Ended,MIG,Migration,IIB,Phase IIb,,2008-000562-23,,000910,IS - Clin Study (MIGRATED)
11708,1237-0010,1237.10,Unconfirmed,678,1237-P01,24 hr PFT  vs. Seretide [promotion EU],Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11709,1237-0011,1237.11,Ended,678,1237-P01,24 hr PFT vs. ICS/LABA FDC,Ended,MIG,Migration,IIIB,Phase IIIb,,2013-000808-41,,000910,IS - Clin Study (MIGRATED)
11710,1237-0012,1237.12,Unconfirmed,678,1237-P01,iCS on-top of T+O FDC: exercise,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11711,1237-0013,1237.13,Ended,678,1237-P01,Exercise Label Claim (1),Ended,MIG,Migration,III,Phase III,,2011-004659-37,,000910,IS - Clin Study (MIGRATED)
11712,1237-0014,1237.14,Ended,678,1237-P01,Exercise Label Claim (2),Ended,MIG,Migration,III,Phase III,,2011-004660-30,,000910,IS - Clin Study (MIGRATED)
11713,1237-0015,1237.15,Ended,678,1237-P01,T+O FDC and Functional Capacity,Ended,MIG,Migration,III,Phase III,,2011-004253-11,,000910,IS - Clin Study (MIGRATED)
11714,1237-0016,1237.16,Ended,678,1237-P01,T+O FDC+exerc. training+beh. modific.,Ended,MIG,Migration,IIIB,Phase IIIb,,2013-002671-18,,000910,IS - Clin Study (MIGRATED)
11715,1237-0017,1237.17,Unconfirmed,678,1237-P01,Japan Phase III,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11716,1237-0018,1237.18,Ended,678,1237-P01,Phase II dose-finding (tiotropium),Ended,MIG,Migration,IIB,Phase IIb,,2009-014880-38,,000910,IS - Clin Study (MIGRATED)
11717,1237-0019,1237.19,Analysis,678,1237-P01,Exacerbations (1),Analysis,MIG,Migration,IIIB,Phase IIIb,,2014-002275-28,,000010,IS - Clin Study - Clin Pharm - SRD
11718,1237-0020,1237.20,Ended,678,1237-P01,Comprehensive lung function assessment,Ended,MIG,Migration,III,Phase III,,2011-004710-42,,000910,IS - Clin Study (MIGRATED)
11719,1237-0021,1237.21,Preparing,678,1237-P01,Exacerbations (2),Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11720,1237-0022,1237.22,Ended,678,1237-P01,Japan long-term safety,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
11721,1237-0023,1237.23,Ended,678,1237-P01,FPI-SF content validation,Ended,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
11722,1237-0024,1237.24,Ended,678,1237-P01,PK of T+O FDC in Japanese COPD patients,Ended,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
11723,1237-0025,1237.25,Ended,678,1237-P01,T+O FDC vs. tio and pbo: PFT / SGRQ (1),Ended,MIG,Migration,IIIB,Phase IIIb,,2013-002243-29,,000910,IS - Clin Study (MIGRATED)
11724,1237-0026,1237.26,Ended,678,1237-P01,T+O FDC vs. tio and pbo: PFT / SGRQ (2),Ended,MIG,Migration,IIIB,Phase IIIb,,2013-002264-24,,000910,IS - Clin Study (MIGRATED)
11725,1237-0027,1237.27,Unconfirmed,678,1237-P01,Comb Bronchodil in COPD & CardPulm AEs,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
11726,1237-0028,1237.28,Last Subject Randomised,678,1237-P01,Activity-related breathlessness,Last Subject Randomised,FULL,Full functionality,IV,Phase IV,,2015-002974-20,,000910,IS - Clin Study (MIGRATED)
11727,1237-0029,1237.29,Unconfirmed,678,1237-P01,Exercise endurance 24 hr profile (2),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11728,1237-0030,1237.30,Analysis,678,1237-P01,China PK Study,Analysis,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11729,1237-0031,1237.31,Preparing,678,1237-P01,LFT and Work,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11730,1237-0033,1237.33,Analysis,678,1237-P01,Japanese Physical Activity Study,Analysis,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11731,1237-0034,1237.34,Recruiting,678,1237-P01,Japanese PMS in COPD,Recruiting,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
11732,1237-0035,1237.35,Preparing,678,1237-P01,Long-term benefits of early intervention,Preparing,FULL,Full functionality,IV,Phase IV,update,,,000910,IS - Clin Study (MIGRATED)
11733,1237-0036,1237.36,First Subject Randomised,678,1237-P01,Cardiovascular function in COPD patients,First Subject Randomised,FULL,Full functionality,IV,Phase IV,,2015-002641-66,,000160,IS - Clin Study - Explore- Subpopulation
11734,1237-0037,1237.37,Unconfirmed,678,1237-P01,COPD with asthma,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11735,1237-0038,1237.38,Unconfirmed,678,1237-P01,Non inferiority to triple,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11736,1237-0039,1237.39,Unconfirmed,678,1237-P01,Head to head LABA/ICS sister,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11737,1237-0040,1237.40,Unconfirmed,678,1237-P01,FDC Tio/Olo on lung funct i AfroAm/Hisps,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11738,1237-0041,1237.41,Unconfirmed,678,1237-P01,FDC Tio/Olo on lung funct vs Advair,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11739,1237-0042,1237.42,Analysis,678,1237-P01,Effic,Handl,Tolerab of Spiolto Respimat,Analysis,MIG,Migration,NONE,Not Classified,,,,000420,NISnd ‚Äì Study - Cohort
11740,1237-0043,1237.43,Initiated,678,1237-P01,Eff+handl of Spiolto Resp i COPD pat - I,Initiated,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
11741,1237-0044,1237.44,Analysis,678,1237-P01,RCV NIS OTIVACTO,Analysis,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
11742,1237-0045,1237.45,Recruiting,678,1237-P01,MIDI NIS Spiolto OTIVACTO,Recruiting,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
11743,1237-0048,1237.48,First Subject Randomised,678,1237-P01,Jpns PMS baseline assessment,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
11744,1237-0049,1237.49,Analysis,678,1237-P01,Free vs FDC HtH T+O comparison,Analysis,MIG,Migration,IV,Phase IV,,2015-003879-29,,000910,IS - Clin Study (MIGRATED)
11745,1237-0050,1237.50,Unconfirmed,678,1237-P01,Extension of study 1237.35,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11746,1237-0051,1237.51,First Subject Randomised,678,1237-P01,SATisfaction+adherence to COPD treatment,First Subject Randomised,MIG,Migration,NONE,Not Classified,NA ,,,000920,NISnd - Study (MIGRATED)
11747,1237-0053,1237.53,Recruiting,678,1237-P01,US database review,Recruiting,MIG,Migration,IV,Phase IV,,,,000410,NISnd ‚Äì Study - Other
11748,1237-0056,1237.56,Unconfirmed,678,1237-P01,Spirometry Study-HUMANA,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
11749,1237-0057,1237.57,Unconfirmed,678,1237-P01,Comp effectiveness of COPD treatments,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000930,NISed - Study (MIGRATED)
11750,1237-0058,1237.58,Initiated,678,1237-P01,Spain NIS OTIVACTO,Initiated,NISND,NISND incl. Chart Abstractions,IV,Phase IV,,,,000420,NISnd ‚Äì Study - Cohort
11751,1237-0060,1237.60,Recruiting,678,1237-P01,Vahelva Respimat rPMS in Korean COPD pts,Recruiting,MIG,Migration,IV,Phase IV,,,,000410,NISnd ‚Äì Study - Other
11752,1237-0061,1237.61,Preparing,678,1237-P01,Baseline Survey,Preparing,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
11753,1237-0063,1237.63,Preparing,678,1237-P01,LAMA/LABA vs ICS/LABA: 24 h PFT,Preparing,FULL,Full functionality,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11754,1208-0031,1208.31,Ended,680,1208-P05,DNP postlaunch safety - Philippines,Ended,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
11755,1208-0032,1208.32,Unconfirmed,680,1208-P05,DLX safety in DNP - Philippines,Unconfirmed,MIG,Migration,IV,Phase IV,approved by Lilyl / BI alliance (CTWG) local Lilly to contact local authorities,,,000940,Post Marketing Study (MIGRATED)
11756,1208-0034,1208.34,Ended,680,1208-P05,DLX in DPNP patients +/- depression,Ended,MIG,Migration,IV,Phase IV,CCC approval 17.03.2008 ,2008-002731-32,,000910,IS - Clin Study (MIGRATED)
11757,1208-0036,1208.36,Ended,680,1208-P05,EMPATHY 6 mth obs on treat patterns,Ended,MIG,Migration,IV,Phase IV,Lilly Germany lead OPU BI  France sponsor for France,,,000940,Post Marketing Study (MIGRATED)
11758,1208-0037,1208.37,Ended,680,1208-P05,MIRA Project,Ended,MIG,Migration,IV,Phase IV,,,,,
11759,1208-0038,1208.38,Unconfirmed,680,1208-P05,Duloxetine Pregabalin combo study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11760,1100-1484,1100.1484,Ended,682,1100-P04,Human absorption study,Ended,MIG,Migration,I,Phase I,,2005-001482-34,,000910,IS - Clin Study (MIGRATED)
11761,1100-1485,1100.1485,Ended,682,1100-P04,Relative bioavailability,Ended,MIG,Migration,I,Phase I,,2005-004322-12,,000910,IS - Clin Study (MIGRATED)
11762,1100-1486,1100.1486,Ended,682,1100-P04,VERxVE: Nevirapine XR in Naive HIV Pts,Ended,MIG,Migration,III,Phase III,A long term extension is included. Patients will remain in their assigned blinded treatment arm until they reach week 144, then they will enter an extension phase where they will receive NVP XR until LPO week 144.,2007-003654-29,,000910,IS - Clin Study (MIGRATED)
11763,1100-1489,1100.1489,Ended,682,1100-P04,Multiple dose PK study,Ended,MIG,Migration,IB,Phase Ib,,2006-002458-31,,000910,IS - Clin Study (MIGRATED)
11764,1100-1490,1100.1490,Preparing,682,1100-P04,Food effect study,Preparing,MIG,Migration,I,Phase I,will be included in 1100.1489 study ,,,000910,IS - Clin Study (MIGRATED)
11765,1100-1498,1100.1498,Unconfirmed,682,1100-P04,VERSUS: nevirapine ER versus SUSTIVA,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11766,1100-1499,1100.1499,Unconfirmed,682,1100-P04,Induction bridging study,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
11767,1100-1511,1100.1511,Unconfirmed,682,1100-P04,PK in Asian population,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11768,1100-1517,1100.1517,Ended,682,1100-P04,single dose PK in HV,Ended,MIG,Migration,IA,Phase Ia,,2008-000851-85,,000910,IS - Clin Study (MIGRATED)
11769,1100-1518,1100.1518,Ended,682,1100-P04,MD study in HIV infected children,Ended,MIG,Migration,IB,Phase Ib,Scope affect interim date only ,2008-005855-61,,000910,IS - Clin Study (MIGRATED)
11770,1100-1526,1100.1526,Ended,682,1100-P04,Transition study,Ended,MIG,Migration,IIIA,Phase IIIa,Patients will be offered 96 wk extension ,2008-004681-55,,000910,IS - Clin Study (MIGRATED)
11771,1100-1531,1100.1531,Ended,682,1100-P04,50mg tablets: PK study,Ended,MIG,Migration,IA,Phase Ia,,2009-014465-37,,000910,IS - Clin Study (MIGRATED)
11772,1100-1534,1100.1534,Unconfirmed,682,1100-P04,NVP XR+Truvada - AA,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11773,0205-0341,205.341,Ended,683,0205-P05,Tiotropium bromide in severe asthmatics,Ended,MIG,Migration,II,Phase II,,2005-005615-21,,000910,IS - Clin Study (MIGRATED)
11774,0205-0342,205.342,Ended,683,0205-P05,Tiotropium versus salmeterol in asthma,Ended,MIG,Migration,IIA,Phase IIa,,2005-005616-25,,000910,IS - Clin Study (MIGRATED)
11775,0205-0380,205.380,Ended,683,0205-P05,TinA dose confirmation in GINA 3/4,Ended,MIG,Migration,II,Phase II,,2010-018471-26,,000910,IS - Clin Study (MIGRATED)
11776,0205-0416,205.416,Ended,683,0205-P05,TinA in Severe Asthma 1,Ended,MIG,Migration,IIIA,Phase IIIa,48 wks double-blind + 4 wks. follow-up ,2008-001413-14,,000910,IS - Clin Study (MIGRATED)
11777,0205-0417,205.417,Ended,683,0205-P05,TinA Severe Asthma Trial 2,Ended,MIG,Migration,IIIA,Phase IIIa,48 wks double-blind + 30 days follow-up ,2008-001414-25,,000910,IS - Clin Study (MIGRATED)
11778,0205-0418,205.418,Ended,683,0205-P05,TinA in moderate persistent asthma 1,Ended,MIG,Migration,IIIA,Phase IIIa,24 weeks treatment + 21 days follow-up ,2009-018004-18,,000910,IS - Clin Study (MIGRATED)
11779,0205-0419,205.419,Ended,683,0205-P05,TinA in moderate persistent asthma 2,Ended,MIG,Migration,IIIA,Phase IIIa,24 weeks treatment + 21 days follow-up ,2009-018005-43,,000910,IS - Clin Study (MIGRATED)
11780,0205-0420,205.420,Ended,683,0205-P05,TinA posology testing,Ended,MIG,Migration,II,Phase II,,2009-018006-21,,000910,IS - Clin Study (MIGRATED)
11781,0205-0424,205.424,Ended,683,0205-P05,DRF in adolescents (12-17 y) in mod. a.,Ended,MIG,Migration,II,Phase II,difficult recruitment in pediatrics ,2009-017745-55,,000910,IS - Clin Study (MIGRATED)
11782,0205-0425,205.425,Ended,683,0205-P05,DRF in ped. (6-11yrs) in moderate a.,Ended,MIG,Migration,II,Phase II,difficult recruitment in pediatrics PK evaluation in 6-11 year olds adds complexity,2010-022458-18,,000910,IS - Clin Study (MIGRATED)
11783,0205-0441,205.441,Ended,683,0205-P05,TinA Posology Testing in moderate asthma,Ended,MIG,Migration,II,Phase II,8 weeks treatment + 21 days follow up ,2012-001873-10,,000910,IS - Clin Study (MIGRATED)
11784,0205-0442,205.442,Ended,683,0205-P05,TinA in mild asthmatics,Ended,MIG,Migration,III,Phase III,12 weeks treatment +21 days follow up ,2010-023112-14,,000910,IS - Clin Study (MIGRATED)
11785,0205-0443,205.443,Ended,683,0205-P05,Safety/Efficacy in pediatrics under 6y,Ended,MIG,Migration,II,Phase II,Difficult recruitment in pediatrics ,2011-005512-28,,000910,IS - Clin Study (MIGRATED)
11786,0205-0444,205.444,Ended,683,0205-P05,Conf. of adolescents in moderate a.,Ended,MIG,Migration,III,Phase III,,2010-021093-11,,000910,IS - Clin Study (MIGRATED)
11787,0205-0445,205.445,Ended,683,0205-P05,Conf. of 6-11 yrs peds. in moderate a.,Ended,MIG,Migration,III,Phase III,,2011-001758-26,,000910,IS - Clin Study (MIGRATED)
11788,0205-0446,205.446,Ended,683,0205-P05,Conf. of 6-11 yrs peds. in severe a.,Ended,MIG,Migration,III,Phase III,,2011-001777-43,,000910,IS - Clin Study (MIGRATED)
11789,0205-0456,205.456,Ended,683,0205-P05,Conf. of adolescents in severe a.,Ended,MIG,Migration,III,Phase III,,2010-021778-13,,000910,IS - Clin Study (MIGRATED)
11790,0205-0457,205.457,Unconfirmed,683,0205-P05,TinA in GINA step 1 (placeholder),Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11791,0205-0464,205.464,Ended,683,0205-P05,TinA - local Japan registration trial,Ended,MIG,Migration,IIIB,Phase IIIb,52 weeks treatment + 3 weeks follow-up ,,,000910,IS - Clin Study (MIGRATED)
11792,0205-0521,205.521,Preparing,683,0205-P05,Add-on study TinA,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11793,0205-0522,205.522,First Subject Randomised,683,0205-P05,SIENA,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
11794,0205-0523,205.523,Preparing,683,0205-P05,SIENA,Preparing,MIG,Migration,IV,Phase IV,,,,,
11795,0205-0525,205.525,Last Subject Randomised,683,0205-P05,PMS of Tiotropium in asthmatics,Last Subject Randomised,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
11796,0205-0527,205.527,Unconfirmed,683,0205-P05,Characterization of asthmatics...,Unconfirmed,MIG,Migration,NONE,Not Classified,Obs study based on existing data ,,,000980,Not Classified (MIGRATED)
11797,0205-0533,205.533,Last Subject Randomised,683,0205-P05,Japanese patient' characteristic survey,Last Subject Randomised,MIG,Migration,IV,Phase IV,,,,000600,Survey Patient Questionnaire
11798,1238-0001,1238.1,Preparing,684,1238-P01,Single rising dose trial of BI 607812,Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11799,1238-0002,1238.2,Unconfirmed,684,1238-P01,Multiple rising dose,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
11800,1238-0003,1238.3,Unconfirmed,684,1238-P01,12 week RA study,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11801,1238-0004,1238.4,Unconfirmed,684,1238-P01,4 week safety study in RA,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11802,1238-0005,1238.5,Unconfirmed,684,1238-P01,Phase IIb in RA,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
11803,1238-0006,1238.6,Unconfirmed,684,1238-P01,Pivotal trial 1,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11804,1238-0007,1238.7,Unconfirmed,684,1238-P01,Pivotal trial 2,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11805,1238-0008,1238.8,Unconfirmed,684,1238-P01,Rollover extension of 1238.6,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11806,1238-0009,1238.9,Unconfirmed,684,1238-P01,Drug interaction cocktail study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11807,1238-0010,1238.10,Unconfirmed,684,1238-P01,Interaction with ketoconazole,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11808,1238-0011,1238.11,Unconfirmed,684,1238-P01,Interaction with methotrexate,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11809,0205-0338,205.338,Ended,685,0205-P06,Safety, Tolerability & PK in CFpatients,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11810,0205-0339,205.339,Ended,685,0205-P06,Phase II Dose Ranging,Ended,MIG,Migration,II,Phase II,,2008-001156-43,,000910,IS - Clin Study (MIGRATED)
11811,0205-0438,205.438,Ended,685,0205-P06,Phase III, 6 month efficacy and safety,Ended,MIG,Migration,III,Phase III,,2010-019802-17,,000910,IS - Clin Study (MIGRATED)
11812,1239-0001,1239.1,Ended,686,1239-P01,BIBF 1120 / BIBW 2992 concomitant Ph 1,Ended,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
11813,1239-0002,1239.2,Ended,686,1239-P01,BIBF 1120 / BIBW 2992 sequential CRC,Ended,MIG,Migration,IIA,Phase IIa,,2006-000893-56,,000910,IS - Clin Study (MIGRATED)
11814,1239-0003,1239.3,Ended,686,1239-P01,3-arm Ph II BIBF,BIBW or sequ. BIBF&BIBW,Ended,MIG,Migration,IIA,Phase IIa,Review of efficacy at 12, 24, 36 and 48 ,2005-005249-21,,000910,IS - Clin Study (MIGRATED)
11815,1239-0004,1239.4,Preparing,686,1239-P01,BIBF 1120/ BIBW 2992 Ph Icomb docetaxel,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11816,1239-0005,1239.5,Unconfirmed,686,1239-P01,BIBF/BIBW PhII CRC 2nd line,Unconfirmed,MIG,Migration,II,Phase II,Back-up option to allow for CRC 2nd line ,,,000910,IS - Clin Study (MIGRATED)
11817,1239-0006,1239.6,Preparing,686,1239-P01,BIBF1120/BIBW 2992 Ph II CRC 1st line,Preparing,MIG,Migration,II,Phase II,,2006-004528-35,,000910,IS - Clin Study (MIGRATED)
11818,1239-0007,1239.7,Unconfirmed,686,1239-P01,BIBF/BIBW Ph III HRPC 1st line,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11819,1239-0008,1239.8,Unconfirmed,686,1239-P01,BIBF/BIBW Ph III in refractory CRC,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11820,1239-0009,1239.9,Unconfirmed,686,1239-P01,BIBF/BIBW Ph III in refractory CRC US,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11821,1239-0010,1239.10,Unconfirmed,686,1239-P01,BIBF/BIBW Ph III in 1st line CRC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11822,1239-0011,1239.11,Unconfirmed,686,1239-P01,BIBF1120 monotherapy CRC,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11823,1239-0012,1239.12,Unconfirmed,686,1239-P01,BIBF+ BIBW+ 5FU maintenance therapy CRC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11824,1239-0013,1239.13,Unconfirmed,686,1239-P01,concomitant BIBF 1120  + BIBW 2992,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11825,1239-0014,1239.14,Ended,686,1239-P01,BIBF 1120 + BIBW 2992,Ended,MIG,Migration,I,Phase I,,2009-011321-14,,000910,IS - Clin Study (MIGRATED)
11826,1240-0001,1240.1,Ended,687,1240-P01,Single IV dose in psoriasis,Ended,MIG,Migration,I,Phase I,Trial to be performed by dermatologists with access to infusion centers and experienced with biologic trials,,,000910,IS - Clin Study (MIGRATED)
11827,1240-0002,1240.2,Unconfirmed,687,1240-P01,Multiple rising IV doses in psoriasis,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
11828,1240-0003,1240.3,Unconfirmed,687,1240-P01,Route of administration of AbGn-168,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11829,1240-0004,1240.4,Unconfirmed,687,1240-P01,Phase II in moderate to severe psoriasis,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11830,1240-0005,1240.5,Unconfirmed,687,1240-P01,Phase III in psoriasis US/CN,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11831,1240-0006,1240.6,Unconfirmed,687,1240-P01,Phase III in psoriasis EU/Asia,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11832,1240-0007,1240.7,Unconfirmed,687,1240-P01,Phase III psoriasis vs placebo,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11833,1240-0008,1240.8,Unconfirmed,687,1240-P01,Ph IIa in Rheum.Arthritis,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11834,1228-0003,1228.3,Unconfirmed,688,1228-P02,Single rising dose Japan,Unconfirmed,MIG,Migration,I,Phase I,T+S in JPN is tentative [depend PMDA] ,,,000910,IS - Clin Study (MIGRATED)
11835,1228-0004,1228.4,Unconfirmed,688,1228-P02,Multiple rising dose Japan,Unconfirmed,MIG,Migration,I,Phase I,T+S in JPN is tentative [depend PMDA] ,,,000910,IS - Clin Study (MIGRATED)
11836,1228-0013,1228.13,Unconfirmed,688,1228-P02,Drug-drug interaction T+S,Unconfirmed,MIG,Migration,I,Phase I,T+S in JPN is tentative [depend PMDA] ,,,000910,IS - Clin Study (MIGRATED)
11837,1228-0014,1228.14,Preparing,688,1228-P02,Factorial design FDC vs monotreatments,Preparing,MIG,Migration,III,Phase III,T+S in JPN is tentative [depend PMDA] final formulation will be used in this study, timeline is limited by CMC and CTS,,,000910,IS - Clin Study (MIGRATED)
11838,1228-0015,1228.15,Unconfirmed,688,1228-P02,Long term study,Unconfirmed,MIG,Migration,III,Phase III,T+S in JPN is tentative [depend PMDA] ,,,000910,IS - Clin Study (MIGRATED)
11839,1228-0016,1228.16,Preparing,688,1228-P02,Telmisartan evening dosing tolerability,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11840,1228-0019,1228.19,Preparing,688,1228-P02,pilot BA study FDC,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11841,1228-0020,1228.20,Unconfirmed,688,1228-P02,pilot BA study FDC,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11842,1241-0001,1241.1,Ended,689,1241-P01,Single rising doses of BI 7127 in HV,Ended,MIG,Migration,I,Phase I,,2006-004404-38,,000910,IS - Clin Study (MIGRATED)
11843,1241-0002,1241.2,Ended,689,1241-P01,Multiple rising dose in HCV,Ended,MIG,Migration,IB,Phase Ib,2 and 4 week part cancelled (new tox) ,2007-004068-38,,000910,IS - Clin Study (MIGRATED)
11844,1241-0003,1241.3,Unconfirmed,689,1241-P01,PK and safety in cirrhotic patients,Unconfirmed,MIG,Migration,IB,Phase Ib,2w treatment duration due to co+wash-out ,,,000910,IS - Clin Study (MIGRATED)
11845,1241-0004,1241.4,Unconfirmed,689,1241-P01,Randomized, placebo-controlled,Unconfirmed,MIG,Migration,IIB,Phase IIb,study is unlikely due to hi resistance ,,,000910,IS - Clin Study (MIGRATED)
11846,1241-0005,1241.5,Unconfirmed,689,1241-P01,Roll-over Quadrupel in PI failure,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
11847,1241-0006,1241.6,Preparing,689,1241-P01,quadruple therapy  in PI-Failure,Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
11848,1241-0007,1241.7,Ended,689,1241-P01,4-week combination with Peg-IFN + RBV,Ended,MIG,Migration,IB,Phase Ib,former "part C" of 1241.2  according DRA-feedback separate study,2008-008292-34,,000910,IS - Clin Study (MIGRATED)
11849,1241-0008,1241.8,Ended,689,1241-P01,Pan Asian Phase I,Ended,MIG,Migration,IA,Phase Ia,planned to be performed at SNUH/Seoul each dose 6+2 Chinese and 6+2 Japanese HV,,,000910,IS - Clin Study (MIGRATED)
11850,1241-0009,1241.9,Ended,689,1241-P01,Bioavailability different formulations,Ended,MIG,Migration,I,Phase I,,2009-009923-12,,000910,IS - Clin Study (MIGRATED)
11851,1241-0010,1241.10,Unconfirmed,689,1241-P01,Randomized, placebo-controlled,Unconfirmed,MIG,Migration,III,Phase III,study unlikely due to resistance ,,,000910,IS - Clin Study (MIGRATED)
11852,1241-0011,1241.11,Unconfirmed,689,1241-P01,quadruple combination in PI failures,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11853,1241-0012,1241.12,Unconfirmed,689,1241-P01,O2/ Treatment-experienced,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
11854,1241-0013,1241.13,Unconfirmed,689,1241-P01,Randomized, parallel group,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
11855,1241-0014,1241.14,Unconfirmed,689,1241-P01,Randomized, parallel group,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
11856,1241-0015,1241.15,Unconfirmed,689,1241-P01,Randomized, parallel group,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11857,1241-0016,1241.16,Unconfirmed,689,1241-P01,Randomized, parallel group,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11858,1241-0017,1241.17,Preparing,689,1241-P01,Thorough QT Study,Preparing,MIG,Migration,I,Phase I,,2013-001210-15,,000910,IS - Clin Study (MIGRATED)
11859,1241-0018,1241.18,Ended,689,1241-P01,PK DDI 1335/7127,Ended,MIG,Migration,I,Phase I,,2009-010881-49,,000910,IS - Clin Study (MIGRATED)
11860,1241-0019,1241.19,Unconfirmed,689,1241-P01,O2/RBV in HCV pts with PegIFN intol./CIs,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11861,1241-0020,1241.20,Ended,689,1241-P01,HCVerso1,Ended,MIG,Migration,III,Phase III,,2012-003533-41,,000910,IS - Clin Study (MIGRATED)
11862,1241-0021,1241.21,Ended,689,1241-P01,Interferon free for 4 up to 40 weeks,Ended,MIG,Migration,IIA,Phase IIa,,2009-018197-66,,000910,IS - Clin Study (MIGRATED)
11863,1241-0022,1241.22,Ended,689,1241-P01,Human ADME Study in HV,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11864,1241-0023,1241.23,Unconfirmed,689,1241-P01,Pediatric Study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11865,1241-0024,1241.24,Unconfirmed,689,1241-P01,Phase III / treatment-naive,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11866,1241-0025,1241.25,Ended,689,1241-P01,Japanese MRD in HCV patients,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11867,1241-0026,1241.26,Ended,689,1241-P01,reIBA Study,Ended,MIG,Migration,IA,Phase Ia,,2011-005346-36,,000910,IS - Clin Study (MIGRATED)
11868,1241-0027,1241.27,Ended,689,1241-P01,DDI Study,Ended,MIG,Migration,IB,Phase Ib,,2012-004102-10,,000910,IS - Clin Study (MIGRATED)
11869,1241-0028,1241.28,Preparing,689,1241-P01,HIV Co-infected study,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11870,1241-0029,1241.29,Preparing,689,1241-P01,DDI study methadone/buprenorphine,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11871,1241-0030,1241.30,Ended,689,1241-P01,BI 207127 in hepatic impairment patients,Ended,MIG,Migration,IIB,Phase IIb,,2012-003534-17,,000910,IS - Clin Study (MIGRATED)
11872,1241-0031,1241.31,Ended,689,1241-P01,DDI study oral contraceptives,Ended,MIG,Migration,IB,Phase Ib,,2013-000298-62,,000910,IS - Clin Study (MIGRATED)
11873,1241-0032,1241.32,Ended,689,1241-P01,O2 in renal impairment patients,Ended,MIG,Migration,IB,Phase Ib,,2013-001075-21,,000910,IS - Clin Study (MIGRATED)
11874,1241-0033,1241.33,Preparing,689,1241-P01,Genotype 4 infection,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11875,1241-0034,1241.34,Unconfirmed,689,1241-P01,Post-Liver Transplant,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11876,1241-0035,1241.35,Ended,689,1241-P01,BI 207127 MD in HVs (previous DDI/ARV),Ended,MIG,Migration,IA,Phase Ia,,2012-003697-10,,000910,IS - Clin Study (MIGRATED)
11877,1241-0036,1241.36,Ended,689,1241-P01,BI 207127 in HCV patients,Ended,MIG,Migration,IIIA,Phase IIIa,,2012-003535-27,,000910,IS - Clin Study (MIGRATED)
11878,1241-0037,1241.37,Initiated,689,1241-P01,open label vs Telaprevir in HCV patients,Initiated,MIG,Migration,IIIA,Phase IIIa,,2012-004544-30,,000910,IS - Clin Study (MIGRATED)
11879,1241-0038,1241.38,Preparing,689,1241-P01,DDI with Statins,Preparing,MIG,Migration,IB,Phase Ib,,2013-000299-13,,000910,IS - Clin Study (MIGRATED)
11880,1241-0039,1241.39,Unconfirmed,689,1241-P01,O2 in GT-1a patients,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11881,1241-0040,1241.40,Ended,689,1241-P01,TQT in HV,Ended,MIG,Migration,I,Phase I,,2013-002741-11,,000910,IS - Clin Study (MIGRATED)
11882,1241-0041,1241.41,Preparing,689,1241-P01,TN patients in Asia,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11883,1241-0042,1241.42,Ended,689,1241-P01,O2 and photosensitivity potential,Ended,MIG,Migration,IB,Phase Ib,,2013-000767-88,,000910,IS - Clin Study (MIGRATED)
11884,1241-0043,1241.43,Unconfirmed,689,1241-P01,BE study with BI 207127 300 mg tablets,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11885,1241-0044,1241.44,Ended,689,1241-P01,Food effect and DDI w/ antiacids and PPI,Ended,MIG,Migration,IA,Phase Ia,,2013-003967-74,,000910,IS - Clin Study (MIGRATED)
11886,1241-0045,1241.45,Preparing,689,1241-P01,DDI with ARV therapy,Preparing,MIG,Migration,IB,Phase Ib,,2013-001209-99,,000910,IS - Clin Study (MIGRATED)
11887,1241-0046,1241.46,Preparing,689,1241-P01,Phase 3 O2 in China,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11888,1241-0054,1241.54,Unconfirmed,689,1241-P01,DDI with antidepresants,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11889,1241-0055,1241.55,Unconfirmed,689,1241-P01,DDI with ARV: Stribild and rilpivirine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11890,1241-0057,1241.57,Unconfirmed,689,1241-P01,Background AE rate de-/compensated cirr,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
11891,1241-0061,1241.61,Ended,689,1241-P01,DDI with immunosuppressants,Ended,MIG,Migration,IB,Phase Ib,,2013-003435-30,,000910,IS - Clin Study (MIGRATED)
11892,1241-0062,1241.62,Unconfirmed,689,1241-P01,TQT in Japan,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11893,1241-0063,1241.63,Unconfirmed,689,1241-P01,Treatment-experience in Japan,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11894,1241-0064,1241.64,Preparing,689,1241-P01,DDI with Itraconazole,Preparing,MIG,Migration,I,Phase I,,2013-004413-40,,000910,IS - Clin Study (MIGRATED)
11895,1241-0065,1241.65,Preparing,689,1241-P01,Ribavirin BE study (Canada),Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11896,1199-0030,1199.30,Ended,690,1199-P03,Effect of BIBF 1120 on FVC in  IPF,Ended,MIG,Migration,IIB,Phase IIb,,2006-002875-42,,000910,IS - Clin Study (MIGRATED)
11897,1199-0031,1199.31,Ended,690,1199-P03,Safety and PK Study in Japan,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11898,1199-0032,1199.32,Ended,690,1199-P03,Effect BIBF 1120 on FVC (pivotal),Ended,MIG,Migration,III,Phase III,,2010-024251-87,,000910,IS - Clin Study (MIGRATED)
11899,1199-0033,1199.33,First Subject Randomised,690,1199-P03,Extension Study,First Subject Randomised,MIG,Migration,III,Phase III,,2011-002766-21,,000910,IS - Clin Study (MIGRATED)
11900,1199-0034,1199.34,Ended,690,1199-P03,Effect BIBF 1120 on FVC (pivotal),Ended,MIG,Migration,III,Phase III,,2010-024252-29,,000910,IS - Clin Study (MIGRATED)
11901,1199-0035,1199.35,Ended,690,1199-P03,Roll over study from 1199.30,Ended,MIG,Migration,II,Phase II,no established duration trial would run until all patients withdraw,2009-013788-21,,000910,IS - Clin Study (MIGRATED)
11902,1199-0036,1199.36,First Subject Randomised,690,1199-P03,Nintedanib + sildenafil in advanced IPF,First Subject Randomised,MIG,Migration,IIIB,Phase IIIb,,2015-002619-14,,000910,IS - Clin Study (MIGRATED)
11903,1199-0040,1199.40,Ended,690,1199-P03,Follow up study from 1199.31 Japan,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11904,1199-0143,1199.143,Ended,690,1199-P03,Patient interview - no study,Ended,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
11905,1199-0161,1199.161,Ended,690,1199-P03,DDI study with a P-gp Inhibitor in HV,Ended,MIG,Migration,I,Phase I,pilot and main part ,2012-001009-26,,000910,IS - Clin Study (MIGRATED)
11906,1199-0162,1199.162,Ended,690,1199-P03,DDI study with a P-gp Inducer in HV,Ended,MIG,Migration,I,Phase I,,2012-002507-18,,000910,IS - Clin Study (MIGRATED)
11907,1199-0174,1199.174,First Subject Randomised,690,1199-P03,DCRI Registry Study,First Subject Randomised,MIG,Migration,IV,Phase IV,Protocol Amendment 1 - January 25, 2016 ,,,000600,Survey Patient Questionnaire
11908,1199-0181,1199.181,Analysis,690,1199-P03,PRP Pharmacogenetic analysis of MUC5B,Analysis,MIG,Migration,NONE,Not Classified,,,,000700,Pharmacogenetic Research Program
11909,1199-0187,1199.187,Analysis,690,1199-P03,Effects on Disease Progression in IPF,Analysis,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11910,1199-0188,1199.188,Unconfirmed,690,1199-P03,Effects on Disease Progression in IPF 2,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11911,1199-0193,1199.193,Ended,690,1199-P03,Characterization of patients with IPF,Ended,MIG,Migration,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
11912,1199-0200,1199.200,Ended,690,1199-P03,Nintedanib in hepatic impairment,Ended,MIG,Migration,I,Phase I,,2014-000690-39,,000910,IS - Clin Study (MIGRATED)
11913,1199-0202,1199.202,Recruiting,690,1199-P03,Japanese PMS of Nintedanib in IPF,Recruiting,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
11914,1199-0207,1199.207,Unconfirmed,690,1199-P03,INPULSIS-3,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11915,1199-0209,1199.209,Analysis,690,1199-P03,UGT1A1, UGT1A7 and UGT1A8,Analysis,MIG,Migration,NONE,Not Classified,,,,000700,Pharmacogenetic Research Program
11916,1199-0210,1199.210,Unconfirmed,690,1199-P03,MUC5B,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000700,Pharmacogenetic Research Program
11917,1199-0222,1199.222,Analysis,690,1199-P03,Combination Nintedanib and Pirfenidone,Analysis,MIG,Migration,IV,Phase IV,,2015-000640-42,,000910,IS - Clin Study (MIGRATED)
11918,1199-0227,1199.227,First Subject Randomised,690,1199-P03,Effect of nintedanib on biomarkers,First Subject Randomised,MIG,Migration,IV,Phase IV,,2015-003148-38,,000910,IS - Clin Study (MIGRATED)
11919,1199-0229,1199.229,Analysis,690,1199-P03,Nintedanib-pifenidone DDI study,Analysis,MIG,Migration,IV,Phase IV,Study to be conducted per RMP committmen ,2015-000732-15,,000910,IS - Clin Study (MIGRATED)
11920,1199-0240,1199.240,Unconfirmed,690,1199-P03,PMO Clinical Trial in patients,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
11921,1199-0245,1199.245,Unconfirmed,690,1199-P03,Japanese baseline characteristic in IPF,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000920,NISnd - Study (MIGRATED)
11922,1199-0252,1199.252,Recruiting,690,1199-P03,INDULGE IPF,Recruiting,MIG,Migration,NONE,Not Classified,,,,000920,NISnd - Study (MIGRATED)
11923,1199-0262,1199.262,Last Subject Randomised,690,1199-P03,IPF Italian Observational Study,Last Subject Randomised,MIG,Migration,NONE,Not Classified,,,,000920,NISnd - Study (MIGRATED)
11924,1199-0265,1199.265,Unconfirmed,690,1199-P03,IPF-PRO Biomarker Profiling,Unconfirmed,PRP,Pharmacogenomic Research Project,IV,Phase IV,,,,000700,Pharmacogenetic Research Program
11925,1199-0267,1199.267,Unconfirmed,690,1199-P03,TOLLIP PRP INPULSIS,Unconfirmed,MIG,Migration,III,Phase III,,,,000700,Pharmacogenetic Research Program
11926,1199-0270,1199.270,Preparing,690,1199-P03,Chinese Extension of study 1199.36,Preparing,PRELIM,Preliminary,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11927,1199-0280,1199.280,First Subject Randomised,690,1199-P03,PMS in Indian patients with IPF,First Subject Randomised,FULL,Full functionality,NONE,Not Classified,None. ,,,000420,NISnd ‚Äì Study - Cohort
11928,1199-0283,1199.283,Preparing,690,1199-P03,PROOF Registry Netherlands,Preparing,MIG,Migration,NONE,Not Classified,,,,000920,NISnd - Study (MIGRATED)
11929,1199-0287,1199.287,Unconfirmed,690,1199-P03,IPF Management Brazil,Unconfirmed,NISED,Non Interventional Study Existing Data,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
11930,1242-0001,1242.1,Unconfirmed,691,1242-P01,Single rising dose in HMV,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11931,1243-0001,1243.1,Unconfirmed,692,1243-P01,Single rising doses of BIRC 1915 in HV,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11932,1216-0005,1216.5,Ended,693,1216-P02,NSCLC Pemetrexed combo,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11933,1216-0006,1216.6,Preparing,693,1216-P02,NSCL + Head & Neck Ca combo Cisplatin,Preparing,MIG,Migration,I,Phase I,Study Cancelled ,,,000910,IS - Clin Study (MIGRATED)
11934,1216-0009,1216.9,Ended,693,1216-P02,NSCLC monotherapy,Ended,MIG,Migration,II,Phase II,,2005-004005-28,,000910,IS - Clin Study (MIGRATED)
11935,1216-0014,1216.14,Unconfirmed,693,1216-P02,NSCLC EU,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11936,1216-0015,1216.15,Unconfirmed,693,1216-P02,NSCLC US,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11937,1244-0001,1244.1,Unconfirmed,694,1244-P01,Single rising dose of BI609001 in HV,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11938,1244-0002,1244.2,Unconfirmed,694,1244-P01,Multiple-dosing of BI609001 in HV,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
11939,1244-0003,1244.3,Unconfirmed,694,1244-P01,Phase Ib study in active RA,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
11940,1245-0001,1245.1,Ended,695,1245-P01,Single rising dose,Ended,MIG,Migration,I,Phase I,,2006-002804-32,,000910,IS - Clin Study (MIGRATED)
11941,1245-0002,1245.2,Ended,695,1245-P01,Multiple rising dose in T2DM patients,Ended,MIG,Migration,I,Phase I,,2007-000654-32,,000910,IS - Clin Study (MIGRATED)
11942,1245-0003,1245.3,Ended,695,1245-P01,Food Effect study,Ended,MIG,Migration,I,Phase I,,2007-002684-26,,000910,IS - Clin Study (MIGRATED)
11943,1245-0004,1245.4,Ended,695,1245-P01,4 weeks treatment in T2DM patients,Ended,MIG,Migration,I,Phase I,performed at specialized CROs ,2007-002685-36,,000910,IS - Clin Study (MIGRATED)
11944,1245-0005,1245.5,Ended,695,1245-P01,SRD in Japanese healthy subjects,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
11945,1245-0006,1245.6,Ended,695,1245-P01,Interaction of BI 10773 with metformin,Ended,MIG,Migration,I,Phase I,,2008-006059-38,,000910,IS - Clin Study (MIGRATED)
11946,1245-0007,1245.7,Ended,695,1245-P01,Interaction of BI 10773 with glimepiride,Ended,MIG,Migration,I,Phase I,,2008-006060-11,,000910,IS - Clin Study (MIGRATED)
11947,1245-0008,1245.8,Ended,695,1245-P01,Human ADME study,Ended,MIG,Migration,I,Phase I,,2007-006310-42,,000910,IS - Clin Study (MIGRATED)
11948,1245-0009,1245.9,Ended,695,1245-P01,Dose finder vs placebo as monotherapy,Ended,MIG,Migration,IIB,Phase IIb,,2008-000640-14,,000910,IS - Clin Study (MIGRATED)
11949,1245-0010,1245.10,Ended,695,1245-P01,Dose finder vs placebo as add on therapy,Ended,MIG,Migration,IIB,Phase IIb,,2008-000641-54,,000910,IS - Clin Study (MIGRATED)
11950,1245-0011,1245.11,Unconfirmed,695,1245-P01,Dose finder for combination with insulin,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
11951,1245-0012,1245.12,Ended,695,1245-P01,BI 10773 in renal impairment/failure,Ended,MIG,Migration,I,Phase I,,2008-006086-86,,000910,IS - Clin Study (MIGRATED)
11952,1245-0013,1245.13,Ended,695,1245-P01,BI 10773 in hepatic insufficiency,Ended,MIG,Migration,I,Phase I,,2009-017202-36,,000910,IS - Clin Study (MIGRATED)
11953,1245-0014,1245.14,Unconfirmed,695,1245-P01,MRD in healthy volunteers in Japan,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11954,1245-0015,1245.15,Ended,695,1245-P01,4 week treatment in T2DM in Japan,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
11955,1245-0016,1245.16,Ended,695,1245-P01,Formal QT study,Ended,MIG,Migration,I,Phase I,,2010-018609-13,,000910,IS - Clin Study (MIGRATED)
11956,1245-0017,1245.17,Ended,695,1245-P01,Interaction with pioglitazone,Ended,MIG,Migration,I,Phase I,,2008-006087-11,,000910,IS - Clin Study (MIGRATED)
11957,1245-0018,1245.18,Ended,695,1245-P01,interaction of BI 10773 with warfarin,Ended,MIG,Migration,I,Phase I,,2009-018088-29,,000910,IS - Clin Study (MIGRATED)
11958,1245-0019,1245.19,Ended,695,1245-P01,Efficacy v placebo as TZD add on +/- met,Ended,MIG,Migration,III,Phase III,Roll-over trial 1245.31 Patients (75%) will roll-over into extension trial 1245.31,2009-016154-40,,000910,IS - Clin Study (MIGRATED)
11959,1245-0020,1245.20,Ended,695,1245-P01,Ph III, 24 wk, mono vs. placebo,Ended,MIG,Migration,IIIA,Phase IIIa,Add to rollover study 1245.31 Will roll over into 104-week double blind placebo controlled extension trial for CV safety (no re-randomisation). Naive patients only (no tx for 8 weeks prior to run-in),2009-016243-20,,000910,IS - Clin Study (MIGRATED)
11960,1245-0021,1245.21,Unconfirmed,695,1245-P01,Head to head v Januvia as monotherapy,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11961,1245-0022,1245.22,Preparing,695,1245-P01,H2H v DPP-IV- on background of metformin,Preparing,MIG,Migration,IIIB,Phase IIIb,,2013-000060-29,,000910,IS - Clin Study (MIGRATED)
11962,1245-0023,1245.23,Ended,695,1245-P01,BI 10773 vs  placebo as add on to MFN/SU,Ended,MIG,Migration,III,Phase III,,2009-016258-41,,000910,IS - Clin Study (MIGRATED)
11963,1245-0024,1245.24,Ended,695,1245-P01,Ph IIb open-label extension Trial,Ended,MIG,Migration,IIB,Phase IIb, OLE of 1245.9, 1245.10 Re-randomisation to two selected BI 10773 doses or comparator,2008-007938-21,,000910,IS - Clin Study (MIGRATED)
11964,1245-0025,1245.25,Ended,695,1245-P01,Cardiovascular safety in high risk pts,Ended,MIG,Migration,IIIA,Phase IIIa, FDA requirement ,2009-016178-33,,000910,IS - Clin Study (MIGRATED)
11965,1245-0026,1245.26,Unconfirmed,695,1245-P01,combination with insulin v placebo,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11966,1245-0027,1245.27,Ended,695,1245-P01,Interaction of BI 10773 with sitagliptin,Ended,MIG,Migration,I,Phase I,,2008-006088-35,,000910,IS - Clin Study (MIGRATED)
11967,1245-0028,1245.28,Ended,695,1245-P01,Effect+ safety BI 10773 + met vs SU+met,Ended,MIG,Migration,III,Phase III,,2009-016244-39,,000910,IS - Clin Study (MIGRATED)
11968,1245-0029,1245.29,First Subject Randomised,695,1245-P01,African Americans with T2DM ABPM study,First Subject Randomised,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11969,1245-0030,1245.30,Ended,695,1245-P01,BI 1356 drug-drug interaction trial,Ended,MIG,Migration,I,Phase I,Preliminary to FDC consideration ,2008-006089-27,,000910,IS - Clin Study (MIGRATED)
11970,1245-0031,1245.31,Ended,695,1245-P01,Ph III min. 52-wk extension trial,Ended,MIG,Migration,III,Phase III,Treatment period is 52-130 weeks (max) ,2010-022718-17,,000910,IS - Clin Study (MIGRATED)
11971,1245-0032,1245.32,Unconfirmed,695,1245-P01,Ph III 24-wk add  BI 10773  to Januvia,Unconfirmed,MIG,Migration,III,Phase III,roll into extension trial This study is cancelled because it is redundent with study 1245.20,,,000910,IS - Clin Study (MIGRATED)
11972,1245-0033,1245.33,Ended,695,1245-P01,Ph IIb add on to LA insulin,Ended,MIG,Migration,II,Phase II,,2009-013668-38,,000910,IS - Clin Study (MIGRATED)
11973,1245-0034,1245.34,Unconfirmed,695,1245-P01,Add-on to GLP-1 analogues,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,consider active control - metformin since GLP-1 impacts hepatic glucose I question the overall impact of MET.  Perhaps a noninferiority study of MET v. 10773?,,,000910,IS - Clin Study (MIGRATED)
11974,1245-0035,1245.35,Ended,695,1245-P01,Japanese PPG study,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11975,1245-0036,1245.36,Ended,695,1245-P01,52-wk renal safety study,Ended,MIG,Migration,III,Phase III,safety requirement This may be negotiable with FDA regarding the timing of completion ( by 4-mnth update?),2009-016179-31,,000910,IS - Clin Study (MIGRATED)
11976,1245-0037,1245.37,Unconfirmed,695,1245-P01,add-on to ONDERO,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
11977,1245-0038,1245.38,Ended,695,1245-P01,Dose finder study plus extension Japan,Ended,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
11978,1245-0039,1245.39,Ended,695,1245-P01,Phase II mechanistic study,Ended,MIG,Migration,II,Phase II,3 OPUs with Ferrannini as the CI goal is to better define how renal loss of glucose impacts glucose balance,2010-018708-99,,000910,IS - Clin Study (MIGRATED)
11979,1245-0040,1245.40,Ended,695,1245-P01,Digoxin PK interaction study,Ended,MIG,Migration,I,Phase I,,2010-023170-40,,000910,IS - Clin Study (MIGRATED)
11980,1245-0041,1245.41,Ended,695,1245-P01,oral contraceptives PK interaction study,Ended,MIG,Migration,I,Phase I,,2010-023432-16,,000910,IS - Clin Study (MIGRATED)
11981,1245-0042,1245.42,Ended,695,1245-P01,Diuretics PK/PD interaction study,Ended,MIG,Migration,I,Phase I,,2010-019624-31,,000910,IS - Clin Study (MIGRATED)
11982,1245-0043,1245.43,Ended,695,1245-P01,P-gp PK interaction study,Ended,MIG,Migration,I,Phase I,,2010-023059-27,,000910,IS - Clin Study (MIGRATED)
11983,1245-0044,1245.44,Ended,695,1245-P01,PK in Chinese subjects,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11984,1245-0045,1245.45,Ended,695,1245-P01,ACE-Inhibitor PK DDI study,Ended,MIG,Migration,I,Phase I,,2010-022717-25,,000910,IS - Clin Study (MIGRATED)
11985,1245-0046,1245.46,Ended,695,1245-P01,RAAS interaction and add-on to insulin,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
11986,1245-0047,1245.47,Unconfirmed,695,1245-P01,multidose PK in Chinese T2DM pts,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11987,1245-0048,1245.48,Ended,695,1245-P01,ABPM study,Ended,MIG,Migration,IIIA,Phase IIIa,,2011-000347-25,,000910,IS - Clin Study (MIGRATED)
11988,1245-0049,1245.49,Ended,695,1245-P01,BI 10773 add-on to MDI insulin regimen,Ended,MIG,Migration,IIIA,Phase IIIa,,2010-019968-37,,000910,IS - Clin Study (MIGRATED)
11989,1245-0050,1245.50,Ended,695,1245-P01,DDI with Pioglitazone,Ended,MIG,Migration,I,Phase I,,2009-018089-36,,000910,IS - Clin Study (MIGRATED)
11990,1245-0051,1245.51,Ended,695,1245-P01,BA TF2 vs FF,Ended,MIG,Migration,I,Phase I,FDA request Bridge data from two clinical trials with different formulations,2010-022469-81,,000910,IS - Clin Study (MIGRATED)
11991,1245-0052,1245.52,Ended,695,1245-P01,Comprehensive safety trial in Japan,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
11992,1245-0053,1245.53,Ended,695,1245-P01,Renal impairment/failure study in Japan,Ended,MIG,Migration,IA,Phase Ia,Japanese study under HPC auspices ,,,000910,IS - Clin Study (MIGRATED)
11993,1245-0054,1245.54,Unconfirmed,695,1245-P01,Patients with multiple metabolic traits,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11994,1245-0057,1245.57,Unconfirmed,695,1245-P01,CHF trial,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11995,1245-0058,1245.58,Ended,695,1245-P01,DDI BI 10773 and Gemfibrozil,Ended,MIG,Migration,I,Phase I,,2010-023152-85,,000910,IS - Clin Study (MIGRATED)
11996,1245-0059,1245.59,Unconfirmed,695,1245-P01,DDI study with voglibose or glinide,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
11997,1245-0060,1245.60,Unconfirmed,695,1245-P01,add-on to basal insulin (TTT),Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11998,1245-0061,1245.61,Unconfirmed,695,1245-P01,Mechanistic DM clamp study,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
11999,1245-0062,1245.62,Analysis,695,1245-P01,PGx trial,Analysis,MIG,Migration,IIIB,Phase IIIb,,,,000700,Pharmacogenetic Research Program
12000,1245-0063,1245.63,Ended,695,1245-P01,DDI with Simvastatin,Ended,MIG,Migration,I,Phase I,,2010-023680-18,,000910,IS - Clin Study (MIGRATED)
12001,1245-0064,1245.64,Unconfirmed,695,1245-P01,Pre-diabetes study,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
12002,1245-0065,1245.65,Unconfirmed,695,1245-P01,H2H vs aGI,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
12003,1245-0066,1245.66,Ended,695,1245-P01,Stepwise clamp study,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12004,1245-0079,1245.79,Ended,695,1245-P01,Food effect study (final formulation),Ended,MIG,Migration,I,Phase I,,2011-002836-13,,000910,IS - Clin Study (MIGRATED)
12005,1245-0080,1245.80,Unconfirmed,695,1245-P01,PMO placeholder study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12006,1245-0083,1245.83,Ended,695,1245-P01,DDI with rifampicin (rifa as OATP1B1inh),Ended,MIG,Migration,I,Phase I,,2012-000971-17,,000910,IS - Clin Study (MIGRATED)
12007,1245-0088,1245.88,Preparing,695,1245-P01,HEOR US clin burden,Preparing,MIG,Migration,IV,Phase IV,See extended remmarks This was an HEOR study. It was initially entered per global's request for budget tracking. However, this plan was cancelled and it was requested to delete these studies from CTMS.,,,000980,Not Classified (MIGRATED)
12008,1245-0089,1245.89,Preparing,695,1245-P01,Economic bruden among pts with T2DM,Preparing,MIG,Migration,IV,Phase IV,See extended remarks This was an HEOR study. It was initially entered per global's request for budget tracking. However, this plan was cancelled and it was requested to delete these studies from CTMS.,,,000980,Not Classified (MIGRATED)
12009,1245-0090,1245.90,Preparing,695,1245-P01,clinical & economic burden of UTI,Preparing,MIG,Migration,IV,Phase IV,See extended remarks This was an HEOR study. It was initially entered per global's request for budget tracking. However, this plan was cancelled and it was requested to delete these studies from CTMS.,,,000980,Not Classified (MIGRATED)
12010,1245-0091,1245.91,Last Subject Randomised,695,1245-P01,Renal urogenital other conditions,Last Subject Randomised,NISED,Non Interventional Study Existing Data,IV,Phase IV,,,,000930,NISed - Study (MIGRATED)
12011,1245-0092,1245.92,Unconfirmed,695,1245-P01,Empagliflozin CER study,Unconfirmed,NISED,Non Interventional Study Existing Data,IV,Phase IV,,,,000460,NISed ‚Äì Study - Cohort
12012,1245-0093,1245.93,Unconfirmed,695,1245-P01,cancer in diabetes EPI study,Unconfirmed,NISED,Non Interventional Study Existing Data,IV,Phase IV, Values from CTMS: Planned Subjects Screened: 100000, Planned Subjects Randomized: 100000, Planned Subjects Completed Treatment: ,,,000930,NISed - Study (MIGRATED)
12013,1245-0094,1245.94,Last Subject Randomised,695,1245-P01,PMS of Empagliflozin on long term use,Last Subject Randomised,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
12014,1245-0095,1245.95,Unconfirmed,695,1245-P01,Empa - H2H vs. Metformin,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
12015,1245-0096,1245.96,Recruiting,695,1245-P01,PASS renal, hepatic injury, infections,Recruiting,MIG,Migration,IV,Phase IV,,,,000460,NISed ‚Äì Study - Cohort
12016,1245-0097,1245.97,Preparing,695,1245-P01,Empa PASS on urinary tract malignancies,Preparing,NISED,Non Interventional Study Existing Data,IV,Phase IV,Includes feasibility study ,,,000460,NISed ‚Äì Study - Cohort
12017,1245-0098,1245.98,Ended,695,1245-P01,Japanese PMS, elderly patients,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
12018,1245-0106,1245.106,Analysis,695,1245-P01,Empa add-on to GLP-1 (Japan),Analysis,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
12019,1245-0107,1245.107,Last Subject Randomised,695,1245-P01,Empa add-on to Insulin (Japan),Last Subject Randomised,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
12020,1245-0112,1245.112,Recruiting,695,1245-P01,Israel CUP 1245.25 patient use programme,Recruiting,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
12021,1245-0116,1245.116,Recruiting,695,1245-P01,postmarketing study  in Korean with T2DM,Recruiting,MIG,Migration,IV,Phase IV,,,,000410,NISnd ‚Äì Study - Other
12022,1245-0122,1245.122,Ended,695,1245-P01,Empa DUS in UK,Ended,MIG,Migration,IV,Phase IV,,,,000470,NISed ‚Äì Study - Cross Sectional
12023,1245-0146,1245.146,Unconfirmed,695,1245-P01,Empa, 5-year Ketoacidosis Surveillance,Unconfirmed,NISED,Non Interventional Study Existing Data,IV,Phase IV,,,,000930,NISed - Study (MIGRATED)
12024,1245-0149,1245.149,Unconfirmed,695,1245-P01,Regulatory requirement study in KSA,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
12025,1245-0150,1245.150,Analysis,695,1245-P01,Epi of lower limb amputations in DM,Analysis,NISED,Non Interventional Study Existing Data,IV,Phase IV,,,,000930,NISed - Study (MIGRATED)
12026,1246-0001,1246.1,Ended,696,1246-P01,FIH SRD study,Ended,MIG,Migration,I,Phase I,,2006-003499-36,,000910,IS - Clin Study (MIGRATED)
12027,1246-0002,1246.2,Ended,696,1246-P01,Food effect study,Ended,MIG,Migration,I,Phase I,,2007-003079-38,,000910,IS - Clin Study (MIGRATED)
12028,1246-0003,1246.3,Ended,696,1246-P01,Drug-drug interaction study,Ended,MIG,Migration,I,Phase I,,2007-003108-37,,000910,IS - Clin Study (MIGRATED)
12029,1246-0004,1246.4,Ended,696,1246-P01,PoC / dose-finding study,Ended,MIG,Migration,II,Phase II,,2008-000079-31,,000910,IS - Clin Study (MIGRATED)
12030,1246-0005,1246.5,Unconfirmed,696,1246-P01,Acute pain single attack study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12031,1246-0006,1246.6,Unconfirmed,696,1246-P01,Acute pain multiple attacks study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12032,1246-0007,1246.7,Unconfirmed,696,1246-P01,Acute pain early intervention study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12033,1246-0008,1246.8,Unconfirmed,696,1246-P01,Acute pain adolescents study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12034,1246-0009,1246.9,Unconfirmed,696,1246-P01,Acute prevention single attack study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12035,1246-0010,1246.10,Unconfirmed,696,1246-P01,Acute prevention multiple attacks study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12036,1246-0011,1246.11,Unconfirmed,696,1246-P01,Safety extension study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12037,1246-0012,1246.12,Ended,696,1246-P01,single rising dose intravenous tolerance,Ended,MIG,Migration,I,Phase I,,2008-001460-37,,000910,IS - Clin Study (MIGRATED)
12038,1246-0013,1246.13,Unconfirmed,696,1246-P01,absolute BA,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12039,1246-0014,1246.14,Ended,696,1246-P01,Human ADME,Ended,MIG,Migration,I,Phase I,,2008-001461-28,,000910,IS - Clin Study (MIGRATED)
12040,1246-0015,1246.15,Ended,696,1246-P01,MRD,Ended,MIG,Migration,I,Phase I,,2008-005946-21,,000910,IS - Clin Study (MIGRATED)
12041,1246-0016,1246.16,Preparing,696,1246-P01,J-SRD study,Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12042,1246-0017,1246.17,Unconfirmed,696,1246-P01,J-MRD study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12043,1246-0018,1246.18,Unconfirmed,696,1246-P01,J-Acute Treatment Bridging study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12044,1246-0019,1246.19,Unconfirmed,696,1246-P01,J-Long term safety extension study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12045,1246-0020,1246.20,Unconfirmed,696,1246-P01,J-Acute prevention efficacy study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12046,1246-0021,1246.21,Ended,696,1246-P01, BI 44370 during/between migraine attack,Ended,MIG,Migration,I,Phase I,,2008-001356-42,,000910,IS - Clin Study (MIGRATED)
12047,1246-0022,1246.22,Preparing,696,1246-P01,D/D-I study with quinidine and ritonavir,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12048,1246-0023,1246.23,Unconfirmed,696,1246-P01,PK in adolescents,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12049,1246-0024,1246.24,Unconfirmed,696,1246-P01,D/D-Interaction with digoxin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12050,1246-0025,1246.25,Unconfirmed,696,1246-P01,D/D-I with rifampin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12051,1246-0026,1246.26,Unconfirmed,696,1246-P01,D/D-I with repaglinide,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12052,1246-0027,1246.27,Unconfirmed,696,1246-P01,Hepatic impairment,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12053,1246-0028,1246.28,Unconfirmed,696,1246-P01,Severe renal impairment / ESRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12054,1246-0029,1246.29,Unconfirmed,696,1246-P01,Drug/Drug-Interaction with warfarin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12055,1246-0030,1246.30,Unconfirmed,696,1246-P01,Formal FE study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12056,1246-0031,1246.31,Unconfirmed,696,1246-P01,T QT study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12057,1246-0032,1246.32,Unconfirmed,696,1246-P01,dose proportionality of final form,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12058,1246-0033,1246.33,Unconfirmed,696,1246-P01,IVIVC study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12059,1246-0034,1246.34,Unconfirmed,696,1246-P01,Single attack non-inferiority study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12060,1246-0035,1246.35,Unconfirmed,696,1246-P01,BI 44370 HEPM study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12061,1246-0036,1246.36,Unconfirmed,696,1246-P01,Pan-Asian SRD/MRD study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12062,1246-0037,1246.37,Unconfirmed,696,1246-P01,DDI with contraceptives,Unconfirmed,MIG,Migration,I,Phase I,estimated 24 subjects in total ,,,000910,IS - Clin Study (MIGRATED)
12063,1246-0038,1246.38,Unconfirmed,696,1246-P01,DDI with midazolam,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12064,1246-0039,1246.39,Unconfirmed,696,1246-P01,DDI with statins,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12065,1246-0040,1246.40,Unconfirmed,696,1246-P01,DDI with glibenclamide,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12066,1246-0041,1246.41,Unconfirmed,696,1246-P01,Drug-drug interaction with amplodipine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12067,1246-0042,1246.42,Unconfirmed,696,1246-P01,Drug-drug interaction with budesonide,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12068,1246-0043,1246.43,Unconfirmed,696,1246-P01,Drug-drug interaction with loperamide,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12069,1246-0044,1246.44,Unconfirmed,696,1246-P01,DDI with codeine / dihydrocodeine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12070,1246-0045,1246.45,Unconfirmed,696,1246-P01,Safety during 4-wk daily treatment,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12071,1247-0001,1247.1,Ended,697,1247-P01,Phase I in various solid tumours,Ended,MIG,Migration,I,Phase I,,2007-000191-17,,000910,IS - Clin Study (MIGRATED)
12072,1247-0002,1247.2,Preparing,697,1247-P01,Phase I/II in NSCLC, combi schedules,Preparing,MIG,Migration,IIA,Phase IIa,This trial is being discussed by the management in light of other NSCLC trials.   Trial was approved by IMC on 05-SEP-2007, however as of this date (17-Sept-2007), it is still being discussed by upper management and may not proceed as planned due to other large scale NSCLC trials that have been approved by management and being developed.,,,000910,IS - Clin Study (MIGRATED)
12073,1247-0003,1247.3,Ended,697,1247-P01,Phase I/II in AML, 1st line, combi,Ended,MIG,Migration,IIA,Phase IIa,,2007-005684-10,,000910,IS - Clin Study (MIGRATED)
12074,1247-0004,1247.4,Unconfirmed,697,1247-P01,Phase II in PAC, monotherapy,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12075,1247-0005,1247.5,Unconfirmed,697,1247-P01,Phase II additional TPP indication,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12076,1247-0006,1247.6,Unconfirmed,697,1247-P01,Ph II basket trial,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12077,1247-0007,1247.7,Unconfirmed,697,1247-P01,Phase I/IIa study in various cancers,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12078,1247-0008,1247.8,Unconfirmed,697,1247-P01,Phase II NSCLC second line,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12079,1247-0009,1247.9,Unconfirmed,697,1247-P01,Phase II Refract/Relapsed AML Mono,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12080,1247-0010,1247.10,Unconfirmed,697,1247-P01,Phase I Combo with Platinum,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12081,1247-0011,1247.11,Unconfirmed,697,1247-P01,Phase I Combo with BIBF 1120,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12082,1247-0012,1247.12,Unconfirmed,697,1247-P01,Phase I  triple combo,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12083,1247-0013,1247.13,Unconfirmed,697,1247-P01,Phase I combo with taxane,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12084,1247-0014,1247.14,Unconfirmed,697,1247-P01,Phase I with hADME,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12085,1230-0003,1230.3,Unconfirmed,698,1230-P02,BI 6727 p.o. in various solid tumours,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12086,1249-0001,1249.1,Ended,699,1249-P01,Ciclesonide/fluticasone+tio+salm in COPD,Ended,MIG,Migration,II,Phase II,,2007-003169-42,,000910,IS - Clin Study (MIGRATED)
12087,1249-0002,1249.2,Preparing,699,1249-P01,Tio bridging (EIS/AIS),Preparing,MIG,Migration,II,Phase II,ethanolic inhalation spray (EIS), aqueous inhalation spray (AIS),,,000910,IS - Clin Study (MIGRATED)
12088,1249-0003,1249.3,Preparing,699,1249-P01,PK interaction TFDC vs free combo,Preparing,MIG,Migration,I,Phase I,,2011-003492-11,,000910,IS - Clin Study (MIGRATED)
12089,1249-0004,1249.4,Preparing,699,1249-P01,PK interaction TFDC vs monos,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12090,1249-0005,1249.5,Preparing,699,1249-P01,BI54903 QD PM or BID on top of BI1744,Preparing,MIG,Migration,IIB,Phase IIb,,2011-004721-27,,000910,IS - Clin Study (MIGRATED)
12091,1249-0006,1249.6,Preparing,699,1249-P01,BI54903 DF on top of BI1744,Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12092,1249-0007,1249.7,Ended,699,1249-P01,BI1744 bridging (EIS/AIS),Ended,MIG,Migration,II,Phase II,aqueous inhalation spray (AIS),2011-000935-98,,000910,IS - Clin Study (MIGRATED)
12093,1250-0001,1250.1,Ended,700,1250-P01,SRD in HV,Ended,MIG,Migration,IA,Phase Ia,,2006-006922-24,,000910,IS - Clin Study (MIGRATED)
12094,1160-0047,1160.47,Ended,701,1160-P03,RE-MEDY (Secondary VTE  prevention),Ended,MIG,Migration,IIIA,Phase IIIa,24 months of accrual enrollment ,2005-002536-94,,000910,IS - Clin Study (MIGRATED)
12095,1160-0063,1160.63,Ended,701,1160-P03,Secondary VTE Prevention (plac. control),Ended,MIG,Migration,III,Phase III,,2007-002586-12,,000910,IS - Clin Study (MIGRATED)
12096,1160-0196,1160.196,Analysis,701,1160-P03,Pulmonary Embolism French Registry,Analysis,MIG,Migration,NONE,Not Classified,,,,,
12097,1160-0215,1160.215,Preparing,701,1160-P03,Prospective cohort on ven.thromb.outcome,Preparing,MIG,Migration,NONE,Not Classified,Dr. Oliviu Crisan ,,,,
12098,1160-0231,1160.231,Recruiting,701,1160-P03,PEITHO 2 - Andante PE,Recruiting,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
12099,1160-0045,1160.45,Preparing,702,1160-P04,RE-SOLVE (DVT Treatment Dose Finding),Preparing,MIG,Migration,II,Phase II,,2004-002635-85,,000910,IS - Clin Study (MIGRATED)
12100,1160-0046,1160.46,Ended,702,1160-P04,DVT Treatment, Definitive,Ended,MIG,Migration,IIIA,Phase IIIa,,2007-002631-86,,000910,IS - Clin Study (MIGRATED)
12101,1160-0053,1160.53,Ended,702,1160-P04,RE-COVER,Ended,MIG,Migration,IIIA,Phase IIIa,,2005-001999-12,,000910,IS - Clin Study (MIGRATED)
12102,1160-0111,1160.111,Preparing,702,1160-P04,RECOVER III,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12103,1160-0188,1160.188,Recruiting,702,1160-P04,Obs Study for acute DVT and PE treatment,Recruiting,MIG,Migration,IV,Phase IV,Angelegt f√ºr Az Ahmad und Martin Feuring ,,,000450,NISed ‚Äì Study - Other
12104,1160-0217,1160.217,Recruiting,702,1160-P04,Inpatient vs Outpatient Mgmt of VTE,Recruiting,MIG,Migration,IV,Phase IV,non-drug study ,,,000930,NISed - Study (MIGRATED)
12105,1160-0237,1160.237,Recruiting,702,1160-P04,Prevalence  of PTS following DVT,Recruiting,MIG,Migration,IV,Phase IV,,,,,
12106,1160-0248,1160.248,First Subject Randomised,702,1160-P04,RE-SPECT CVT,First Subject Randomised,MIG,Migration,III,Phase III,,2015-004412-38,,000150,IS - Clin Study - Explore
12107,1160-0259,1160.259,First Subject Randomised,702,1160-P04,RE-SPIRE study,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,,
12108,1251-0001,1251.1,Unconfirmed,703,1251-P01,1251.1,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12109,1251-0002,1251.2,Unconfirmed,703,1251-P01,1251.2,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12110,0511-0103,511.103,Ended,704,0511-P03,Colonic absorption study,Ended,MIG,Migration,IA,Phase Ia,,2005-001014-40,,000910,IS - Clin Study (MIGRATED)
12111,0511-0110,511.110,Ended,704,0511-P03,MR form 1st PK,Ended,MIG,Migration,IA,Phase Ia,,2006-000783-86,,000910,IS - Clin Study (MIGRATED)
12112,0511-0112,511.112,Unconfirmed,704,0511-P03,MR FLI v pbo, efficacy in HSDD, #1,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
12113,0511-0113,511.113,Unconfirmed,704,0511-P03,MR FLI vs pbo for women w/ HSDD, #2,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
12114,0511-0115,511.115,Ended,704,0511-P03,PK/ PD of chosen form MR FLI,Ended,MIG,Migration,I,Phase I,,2008-001115-38,,000910,IS - Clin Study (MIGRATED)
12115,0511-0116,511.116,Unconfirmed,704,0511-P03,Feasibility of MR osmotic tab,Unconfirmed,MIG,Migration,IA,Phase Ia,design tbd; number of treatments tbd ,,,000910,IS - Clin Study (MIGRATED)
12116,0511-0135,511.135,Unconfirmed,704,0511-P03,Flib MR MRD chosen form,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12117,1252-0001,1252.1,Unconfirmed,705,1252-P01,Single rising dose study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12118,1252-0002,1252.2,Unconfirmed,705,1252-P01,Rel. BA liquid vs. solid formulation,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12119,1252-0003,1252.3,Unconfirmed,705,1252-P01,Multiple rising dose study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12120,1252-0004,1252.4,Unconfirmed,705,1252-P01,four-week treatment in DM 2 patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12121,1253-0001,1253.1,Ended,707,1253-P01,Efficacy and tolerability of Glucomannan,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
12122,0248-0637,248.637,Ended,708,0248-P09,PoC trial PPX ER in fibromyalgia,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12123,0248-0640,248.640,Unconfirmed,708,0248-P09,Pivotal study in Fibromyalgia,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12124,1254-0001,1254.1,Preparing,709,1254-P01,Macrogol 4000, efficacy and safety,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12125,1182-0014,1182.14,Ended,710,1182-P02,Tipranavir Pediatric Safety and PK Trial,Ended,MIG,Migration,I,Phase I,Initiation may be delayed until JAN 04 ,,,000910,IS - Clin Study (MIGRATED)
12126,1182-0097,1182.97,Preparing,710,1182-P02,TPV in children under 2 years,Preparing,MIG,Migration,II,Phase II,,,,,
12127,1182-0100,1182.100,Ended,710,1182-P02,TPV bioequivalence oral sol and caps,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12128,1182-0124,1182.124,Ended,710,1182-P02,BE of 2 TPV liquid formulations,Ended,MIG,Migration,I,Phase I,,2007-007627-40,,000910,IS - Clin Study (MIGRATED)
12129,1182-0148,1182.148,Ended,710,1182-P02,Thailand Pediatric Donation Program,Ended,MIG,Migration,IV,Phase IV,Study is taking place in Thailand ,,,,
12130,1235-0009,1235.9,Ended,711,1235-P02,Telmisartan+amlodipine  SRD & MRD,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12131,1235-0010,1235.10,Unconfirmed,711,1235-P02,Telmisartan+amlodipine Multiple,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12132,1235-0013,1235.13,Ended,711,1235-P02,Amlodipine 5mg non-responder study,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
12133,1235-0014,1235.14,Ended,711,1235-P02,Telmisartan 40mg non-responder study,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
12134,1235-0015,1235.15,Unconfirmed,711,1235-P02,Telmisartan 80mg non-responder study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12135,1235-0016,1235.16,Ended,711,1235-P02,Long term study,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
12136,1235-0017,1235.17,Ended,711,1235-P02,BA T40/A5,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12137,1235-0018,1235.18,Ended,711,1235-P02,BA T80/A5,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12138,1235-0027,1235.27,Ended,711,1235-P02,Food effect of T+A,Ended,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12139,1235-0028,1235.28,Ended,711,1235-P02,BE study in Japan for T80/A5,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12140,1235-0036,1235.36,Ended,711,1235-P02,Telmisartan 80 mg non-responder study,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
12141,1235-0037,1235.37,Ended,711,1235-P02,Comparison in Japan T80/A5 and T40/A5,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
12142,1235-0038,1235.38,Ended,711,1235-P02,MICAMLO Combi Japan Tablets PMS,Ended,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
12143,1235-0045,1235.45,Unconfirmed,711,1235-P02,Long-term use of T80/A5 Japan PMS,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
12144,1255-0001,1255.1,Unconfirmed,712,1255-P01,SRD in healthy male volunteers,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12145,1255-0002,1255.2,Unconfirmed,712,1255-P01,BI 605,906 for 14 days in male HV,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12146,1255-0003,1255.3,Unconfirmed,712,1255-P01,BI 605906 MRD in RA patients on  MTX,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12147,1222-0004,1222.4,Ended,713,1222-P02,SD dose-ranging asthma,Ended,MIG,Migration,IIA,Phase IIa,No EUDRACT Number - Not applicable ,,,000910,IS - Clin Study (MIGRATED)
12148,1222-0006,1222.6,Ended,713,1222-P02,Phase IIb 4 wk dose-finding in Asthma,Ended,MIG,Migration,IIB,Phase IIb,Objective/Rationale modified 4/25/07 CM requested that Objective be modified to remove reference to dosage frequency,2006-004829-29,,000910,IS - Clin Study (MIGRATED)
12149,1222-0015,1222.15,Unconfirmed,713,1222-P02,tbd,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12150,1222-0016,1222.16,Unconfirmed,713,1222-P02,tbd,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12151,1222-0017,1222.17,Unconfirmed,713,1222-P02,48 wk piv PFT ( pbo, act comp) asthma,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12152,1222-0018,1222.18,Unconfirmed,713,1222-P02,24/48 wk piv PFT(pbo, act c) asthma II,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12153,1222-0023,1222.23,Unconfirmed,713,1222-P02,Japan Phase II in Asthma,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12154,1222-0027,1222.27,Ended,713,1222-P02,Dose selection study,Ended,MIG,Migration,IIB,Phase IIb,,2009-013395-48,,000910,IS - Clin Study (MIGRATED)
12155,1222-0028,1222.28,Unconfirmed,713,1222-P02,tbd,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12156,1222-0029,1222.29,Ended,713,1222-P02,Posology dosing asthma,Ended,MIG,Migration,IIB,Phase IIb,two full cross-overs in parrallel ,2008-006625-14,,000910,IS - Clin Study (MIGRATED)
12157,1222-0030,1222.30,Unconfirmed,713,1222-P02,4 wk safety,efficacy, pk in 12-18y,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12158,1222-0031,1222.31,Unconfirmed,713,1222-P02,6 months safety efficacy in 12-18y,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12159,1222-0032,1222.32,Unconfirmed,713,1222-P02,safety, efficacy, PK in 5-11y,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12160,1222-0033,1222.33,Unconfirmed,713,1222-P02,efficacy, long term safety 5-11y,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12161,1256-0001,1256.1,Ended,714,1256-P01,Multiple rising dose Saf+Tol BHT,Ended,MIG,Migration,I,Phase I,,2007-003168-23,,000910,IS - Clin Study (MIGRATED)
12162,1256-0002,1256.2,Ended,714,1256-P01,PK HD ICS DFDC vs free combo of monos,Ended,MIG,Migration,I,Phase I,DFDC = double fixed dose combination ,2008-007340-34,,000910,IS - Clin Study (MIGRATED)
12163,1256-0003,1256.3,Ended,714,1256-P01,PK HD ICS DFDC vs monos,Ended,MIG,Migration,I,Phase I,DFDC = double fixed dose combination ,2008-007341-31,,000910,IS - Clin Study (MIGRATED)
12164,1256-0004,1256.4,Preparing,714,1256-P01,BI 54903 dose finding (Ahrens),Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12165,1256-0005,1256.5,Preparing,714,1256-P01,BI 1744 bridging (EIS/AIS),Preparing,MIG,Migration,II,Phase II,EIS = ethanolic inhalation solution, AIS = aqueous inhalation solution, DFDC = double fixed dose combination,,,000910,IS - Clin Study (MIGRATED)
12166,1256-0006,1256.6,Preparing,714,1256-P01,BI54903 dosed qd PM vs bid in asthma,Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12167,1256-0007,1256.7,Preparing,714,1256-P01,Efficacy & safety compared to Alvesco,Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12168,1256-0008,1256.8,Unconfirmed,714,1256-P01,DFDC vs. free combo of substances, 12-we,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12169,1256-0009,1256.9,Unconfirmed,714,1256-P01,DFDC vs. monosubstances, 12 weeks,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12170,1256-0010,1256.10,Unconfirmed,714,1256-P01,24-we DFDC vs. free combination I,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12171,1256-0011,1256.11,Unconfirmed,714,1256-P01,24-we DFDC vs. free combination II,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12172,1256-0012,1256.12,Unconfirmed,714,1256-P01,Longterm safety,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12173,1256-0013,1256.13,Ended,714,1256-P01,BHT tolerability asthma,Ended,MIG,Migration,I,Phase I,,2009-013278-42,,000910,IS - Clin Study (MIGRATED)
12174,0248-0641,248.641,Preparing,715,0248-P10,PPX in children with Tourette Syndrome,Preparing,MIG,Migration,III,Phase III,,2008-000343-33,,000910,IS - Clin Study (MIGRATED)
12175,0248-0642,248.642,Ended,715,0248-P10,OL extension PPX in children with TS,Ended,MIG,Migration,III,Phase III,,2008-000342-32,,000910,IS - Clin Study (MIGRATED)
12176,0248-0644,248.644,Ended,715,0248-P10,Pilot Study with PPX in Tourette Syn.,Ended,MIG,Migration,II,Phase II,,2008-004460-39,,000910,IS - Clin Study (MIGRATED)
12177,1257-0001,1257.1,Ended,716,1257-P01,Ph I in patients with adv. solid tumors,Ended,MIG,Migration,I,Phase I,,2008-001631-36,,000910,IS - Clin Study (MIGRATED)
12178,1160-0067,1160.67,Ended,717,1160-P05,Dose finding in ACS biomarkers/bleeds,Ended,MIG,Migration,II,Phase II,,2007-004301-99,,000910,IS - Clin Study (MIGRATED)
12179,1160-0069,1160.69,Unconfirmed,717,1160-P05,RE-DEEM 2,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12180,1160-0083,1160.83,Ended,717,1160-P05,Clopidogrel interaction study,Ended,MIG,Migration,I,Phase I,,2008-006436-36,,000910,IS - Clin Study (MIGRATED)
12181,1160-0097,1160.97,Unconfirmed,717,1160-P05,RE-PLY 1 (Early PCI patients),Unconfirmed,MIG,Migration,IIIA,Phase IIIa,Event driven study ,,,000910,IS - Clin Study (MIGRATED)
12182,1160-0098,1160.98,Unconfirmed,717,1160-P05,Prasugrel DDI,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12183,1160-0099,1160.99,Preparing,717,1160-P05,1st Gen vs 2nd Gen BE confirmatory study,Preparing,MIG,Migration,IA,Phase Ia,,2009-011011-20,,000910,IS - Clin Study (MIGRATED)
12184,1160-0100,1160.100,Ended,717,1160-P05,Rifampicin drug interaction study,Ended,MIG,Migration,IA,Phase Ia,,2009-011765-93,,000910,IS - Clin Study (MIGRATED)
12185,1160-0101,1160.101,Ended,717,1160-P05,Ketoconazole drug interaction study,Ended,MIG,Migration,IA,Phase Ia,,2009-011764-10,,000910,IS - Clin Study (MIGRATED)
12186,1160-0109,1160.109,Unconfirmed,717,1160-P05,BA of DE pellet on food vs other forms,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12187,1160-0119,1160.119,Preparing,717,1160-P05,New BE study comparing two capsules,Preparing,MIG,Migration,IA,Phase Ia,,2010-020434-25,,000910,IS - Clin Study (MIGRATED)
12188,1160-0156,1160.156,Preparing,717,1160-P05,Dabigatran on endoth. cells in CAD,Preparing,MIG,Migration,NONE,Not Classified,,2012-005107-41,,,
12189,1218-0045,1218.45,Ended,718,1218-P02,PK/PD of BI 1356 5 mg qd vs 2.5 mg bid,Ended,MIG,Migration,I,Phase I,Twice daily dosing regimen for FDC ,2007-006734-34,,000910,IS - Clin Study (MIGRATED)
12190,1218-0046,1218.46,Ended,718,1218-P02,Fact.design free combo BI1356+Metf,Ended,MIG,Migration,III,Phase III,Open label arm open label:  pts. with HbA1c equal or more than 11 %,2008-001640-40,,000910,IS - Clin Study (MIGRATED)
12191,1218-0047,1218.47,Ended,718,1218-P02,Pilot BA BI1356 2.5+Metformin 1000,Ended,MIG,Migration,I,Phase I,,2008-002112-18,,000910,IS - Clin Study (MIGRATED)
12192,1218-0051,1218.51,Unconfirmed,718,1218-P02,Pivotal BE/food interaction FDC 2.5/1000,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12193,1218-0052,1218.52,Ended,718,1218-P02,54w extension 2.5/500/1000, met 1000 bid,Ended,MIG,Migration,III,Phase III,Blinded randomised extension to 1218.46 Interim cut off for US NDA: LPO 08Jun10, DBL 06Jul10, first results 09Jul, stat ana 20Jul, final CTR archived 17Aug10,2008-008494-59,,000910,IS - Clin Study (MIGRATED)
12194,1218-0053,1218.53,Unconfirmed,718,1218-P02,Food Study BI 1356 2.5+Metformin 1000,Unconfirmed,MIG,Migration,I,Phase I,35 days wash-out between treatments ,,,000910,IS - Clin Study (MIGRATED)
12195,1218-0057,1218.57,Ended,718,1218-P02,BE study US vs. EU Glucophage,Ended,MIG,Migration,I,Phase I,,2008-003964-20,,000910,IS - Clin Study (MIGRATED)
12196,1218-0059,1218.59,Unconfirmed,718,1218-P02,Pivotal BE BI 1356 2.5+Metformin 500,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12197,1218-0062,1218.62,Ended,718,1218-P02,12 week BI 1356 bid vs qd,Ended,MIG,Migration,II,Phase II,,2009-013549-27,,000910,IS - Clin Study (MIGRATED)
12198,1218-0069,1218.69,Unconfirmed,718,1218-P02,Pivotal BE BI 1356 2.5+Metformin 850,Unconfirmed,MIG,Migration,I,Phase I,study may be required for Japan as well ,,,000910,IS - Clin Study (MIGRATED)
12199,1218-0070,1218.70,Unconfirmed,718,1218-P02,Metformin non-responder study Japan,Unconfirmed,MIG,Migration,III,Phase III,registration study Japan ,,,000910,IS - Clin Study (MIGRATED)
12200,1218-0071,1218.71,Unconfirmed,718,1218-P02,52 week open-label study Japan,Unconfirmed,MIG,Migration,III,Phase III,may be conducted as extension to 1218.70 safety exposure for submission in Japan,,,000910,IS - Clin Study (MIGRATED)
12201,1218-0093,1218.93,Unconfirmed,718,1218-P02,Factorial design China,Unconfirmed,MIG,Migration,III,Phase III,FDC tablet China, pending CA feedb ,,,000910,IS - Clin Study (MIGRATED)
12202,1258-0001,1258.1,Ended,719,1258-P01,FIH / SRD,Ended,MIG,Migration,I,Phase I,,2007-004718-15,,000910,IS - Clin Study (MIGRATED)
12203,1258-0002,1258.2,Unconfirmed,719,1258-P01,Drug-drug-interaction,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12204,1258-0003,1258.3,Unconfirmed,719,1258-P01,Acute Pain PoC / DF,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12205,1258-0004,1258.4,Unconfirmed,719,1258-P01,Acute Pain Single Attack,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12206,1258-0005,1258.5,Unconfirmed,719,1258-P01,Acute Pain Multiple Attacks,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12207,1258-0006,1258.6,Unconfirmed,719,1258-P01,Acute Pain Early Intervention,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12208,1258-0007,1258.7,Unconfirmed,719,1258-P01,Acute Pain Adolescents,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12209,1258-0008,1258.8,Unconfirmed,719,1258-P01,Acute Prevention Single Attack,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12210,1258-0009,1258.9,Unconfirmed,719,1258-P01,Acute Prevention Multiple Attacks,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12211,1258-0010,1258.10,Unconfirmed,719,1258-P01,Safety Extension,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12212,1258-0011,1258.11,Unconfirmed,719,1258-P01,IV Tolerance Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12213,1258-0012,1258.12,Unconfirmed,719,1258-P01,Absolute BA study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12214,1258-0013,1258.13,Unconfirmed,719,1258-P01,Human ADME,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12215,1258-0014,1258.14,Unconfirmed,719,1258-P01,PK during and between migraine attacks,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12216,1258-0015,1258.15,Unconfirmed,719,1258-P01,MRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12217,1258-0016,1258.16,Unconfirmed,719,1258-P01,Single migraine attack non-inferiority,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12218,0511-0081,511.81,Unconfirmed,720,0511-P04,Flex dose FLI v pbo in older women NA,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,contingent on success in premeno Ph 3 ,,,000910,IS - Clin Study (MIGRATED)
12219,0511-0082,511.82,Unconfirmed,720,0511-P04,2 fixed doses FLI v pbo, meno women,NA,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,contingent on Ph 3 success in pre-meno. ,,,000910,IS - Clin Study (MIGRATED)
12220,0511-0130,511.130,Ended,720,0511-P04,FLI vs Pbo in nat pm women USA,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
12221,0511-0131,511.131,Preparing,720,0511-P04,2nd efficacy study of menol patients,Preparing,MIG,Migration,IIIB,Phase IIIb,Trial in Europe; supportive safety. Unknown if required but would give either an EU database on postmenos are a rand w/d trial,,,000910,IS - Clin Study (MIGRATED)
12222,0511-0132,511.132,Ended,720,0511-P04,New sex distress scale concept/content,Ended,MIG,Migration,NONE,Not Classified,Methodology study ,,,000300,IS - Methodological Studies
12223,0511-0133,511.133,Ended,720,0511-P04,Extension for pre- and postmeno. w HSDD,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
12224,0511-0134,511.134,Unconfirmed,720,0511-P04,Rand withdrawal postmeno,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
12225,0511-0142,511.142,Ended,720,0511-P04,New sex distress scale/cogn. debriefing,Ended,MIG,Migration,NONE,Not Classified,Methodology study ,,,000300,IS - Methodological Studies
12226,0511-0143,511.143,Ended,720,0511-P04,New sex distress scale/validation,Ended,MIG,Migration,NONE,Not Classified,Methodology study ,,,000300,IS - Methodological Studies
12227,0511-0146,511.146,Ended,720,0511-P04,PK of flibanserin in pm women with HSDD,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12228,0511-0148,511.148,Unconfirmed,720,0511-P04,FSFI content validationin pm women,Unconfirmed,MIG,Migration,NONE,Not Classified,Recommended by experts in June 2008 to aid approvability of FSFI desire domain as co-primary endpoint,,,000300,IS - Methodological Studies
12229,0511-0149,511.149,Unconfirmed,720,0511-P04,FSFI recall trial/pm women,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
12230,0511-0152,511.152,Unconfirmed,720,0511-P04,Sexual function in pm women/Russia.,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
12231,0511-0156,511.156,Ended,720,0511-P04,2nd FLI vs Pbo in nat pm women N Am,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
12232,0511-0157,511.157,Preparing,720,0511-P04,FLI vs Pbo in nat pm women in EU,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
12233,0511-0158,511.158,Ended,720,0511-P04,PK interaction with digoxin,Ended,MIG,Migration,I,Phase I,,2010-018950-11,,000910,IS - Clin Study (MIGRATED)
12234,0511-0160,511.160,Unconfirmed,720,0511-P04,Ext. pre/postmeno w with HSDD in EU,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
12235,0511-0161,511.161,Unconfirmed,720,0511-P04,Effects of flib on PK of estr./prog.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12236,1259-0001,1259.1,Unconfirmed,721,1259-P01,Phase I Single Rising Dose in HV,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12237,1260-0001,1260.1,Unconfirmed,722,1260-P01,SRD in healthy volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12238,1260-0002,1260.2,Unconfirmed,722,1260-P01,MRD in T2DM patients,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12239,1260-0003,1260.3,Unconfirmed,722,1260-P01,4 weeks treatment in T2DM patients,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12240,1261-0001,1261.1,Preparing,723,1261-P01,Phase I trial in solid tumours,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12241,1261-0002,1261.2,Preparing,723,1261-P01,Phase I trial in solid tumours,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12242,1261-0003,1261.3,Unconfirmed,723,1261-P01,Phase I trial in pediatric solid tumours,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12243,1261-0004,1261.4,Unconfirmed,723,1261-P01,Phase I/IIa combination trial in NSCLC,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12244,1261-0005,1261.5,Unconfirmed,723,1261-P01,Phase I/IIa combination trial in NSCLC,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12245,1261-0006,1261.6,Unconfirmed,723,1261-P01,Phase I/IIa combination trial in HCC,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12246,1261-0007,1261.7,Unconfirmed,723,1261-P01,Phase II basket trial in solid tumours,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12247,1261-0008,1261.8,Unconfirmed,723,1261-P01,Phase II  basket trial in solid tumours,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12248,1261-0009,1261.9,Unconfirmed,723,1261-P01,Phase III trial in NSCLC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12249,1261-0010,1261.10,Unconfirmed,723,1261-P01,Phase III trial in NSCLC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12250,1261-0011,1261.11,Unconfirmed,723,1261-P01,Phase III trial in HCC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12251,1262-0001,1262.1,Ended,724,1262-P01,Single rising dose in healthy volunteers,Ended,MIG,Migration,IA,Phase Ia,,2008-004809-34,,000910,IS - Clin Study (MIGRATED)
12252,1262-0002,1262.2,Ended,724,1262-P01,Multiple rising dose,Ended,MIG,Migration,IB,Phase Ib,,2009-014466-26,,000910,IS - Clin Study (MIGRATED)
12253,1262-0003,1262.3,Preparing,724,1262-P01,Proof of concept in RA,Preparing,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12254,1262-0004,1262.4,Unconfirmed,724,1262-P01,Safety and Efficacy in RA with extension,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12255,1262-0005,1262.5,Unconfirmed,724,1262-P01,Pivotal trial I in RA,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
12256,1262-0006,1262.6,Unconfirmed,724,1262-P01,Pivotal trial II in RA,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
12257,1262-0007,1262.7,Unconfirmed,724,1262-P01,Roll-over Phase III extension study,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
12258,1262-0008,1262.8,Preparing,724,1262-P01,Phase I SRD+MRD in Asian subjects,Preparing,MIG,Migration,IA,Phase Ia,SRD and MRD study ,,,000910,IS - Clin Study (MIGRATED)
12259,1262-0009,1262.9,Ended,724,1262-P01,In vivo endotoxin challenge,Ended,MIG,Migration,IB,Phase Ib,,2009-017127-26,,000910,IS - Clin Study (MIGRATED)
12260,1262-0010,1262.10,Preparing,724,1262-P01,Drug interaction cocktail study,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12261,1262-0011,1262.11,Preparing,724,1262-P01,Bridging PK and food effect,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12262,1262-0012,1262.12,Unconfirmed,724,1262-P01,BI 653048 pediatric study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12263,1262-0013,1262.13,Unconfirmed,724,1262-P01,ADME study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12264,1262-0014,1262.14,Unconfirmed,724,1262-P01,Safety and efficacy in lupus,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12265,0511-0124,511.124,Preparing,726,0511-P05,Proof of concept male HSDD,Preparing,MIG,Migration,IIA,Phase IIa,Pool w PoC II re primary EP ,,,000910,IS - Clin Study (MIGRATED)
12266,0511-0125,511.125,Unconfirmed,726,0511-P05,PoC in male HSDD trial II,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12267,0511-0136,511.136,Ended,726,0511-P05,Male HSDD PRO -Qual,Ended,MIG,Migration,NONE,Not Classified,This study is out-sourced, non-treatment ,,,000300,IS - Methodological Studies
12268,0511-0137,511.137,Preparing,726,0511-P05,Male HSDD PRO Validation,Preparing,MIG,Migration,IIB,Phase IIb,,,,000300,IS - Methodological Studies
12269,0511-0141,511.141,Unconfirmed,726,0511-P05,150mg relative BA,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12270,0511-0153,511.153,Ended,726,0511-P05,Qualitative characterization of HSDD,Ended,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
12271,1199-0049,1199.49,Unconfirmed,727,1199-P04,BIBF1120 monotherapy CRC,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12272,1199-0050,1199.50,Unconfirmed,727,1199-P04,BIBF 1120 monotherapy CRC,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12273,1199-0051,1199.51,Ended,727,1199-P04,BIBF 1120 versus Bevacizumab in  CRC,Ended,MIG,Migration,II,Phase II,,2008-005364-14,,000910,IS - Clin Study (MIGRATED)
12274,1199-0052,1199.52,Ended,727,1199-P04,BIBF 1120 vs placebo in refractrory mCRC,Ended,MIG,Migration,III,Phase III,,2012-000095-42,,000910,IS - Clin Study (MIGRATED)
12275,1199-0111,1199.111,Unconfirmed,727,1199-P04,BIBF 1120 and Folfox ph I for Japanese,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12276,1199-0112,1199.112,Unconfirmed,727,1199-P04,BIBF 1120 + Folfox in CRC/ China,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12277,1199-0113,1199.113,Unconfirmed,727,1199-P04,BIBF 1120 + Folfiri  in CRC,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12278,1199-0156,1199.156,Preparing,727,1199-P04,Maintenance for resected stage 4 CRC,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12279,1199-0234,1199.234,Unconfirmed,727,1199-P04,BIBF 1120 in CRC w/ optional pre-treatm.,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12280,1199-0235,1199.235,Preparing,727,1199-P04,Nintedanib CRC Bridging Study for India,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12281,1199-0251,1199.251,Analysis,727,1199-P04, Nindedanib or Nintedanib + Capecitabine,Analysis,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12282,1199-0275,1199.275,Preparing,727,1199-P04,Patient characteristics of refra CRC-US,Preparing,NISED,Non Interventional Study Existing Data,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
12283,1199-0276,1199.276,Unconfirmed,727,1199-P04,Best Supp Care cost in US mCRC patients,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
12284,1199-0286,1199.286,Unconfirmed,727,1199-P04,Nintedanib/TAS 102 vs TAS 102 in mCRC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12285,1134-0002,1134.2,Ended,728,1134-P02,Rel. Bioavail DMP Soft Pastille vs Syrup,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12286,1134-0003,1134.3,Ended,728,1134-P02,Safety study with  emphasis on ECG,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12287,1134-0004,1134.4,Preparing,728,1134-P02,DX Pastilles vs. Syrup BE study in China,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12288,1264-0001,1264.1,Ended,729,1264-P01,Ralative BA Linagliptin5+Pioglitazone45,Ended,MIG,Migration,I,Phase I,,2008-005092-10,,000910,IS - Clin Study (MIGRATED)
12289,1264-0002,1264.2,Preparing,729,1264-P01,Pioglitazone non responder study,Preparing,MIG,Migration,III,Phase III,study replaced by 1264.15 (EMA fu-SA) 2:1 randomisation to BI 1356 and Placebo, 70% screening failure rate assumed,2008-007418-31,,000910,IS - Clin Study (MIGRATED)
12290,1264-0003,1264.3,Ended,729,1264-P01,Parallel group study BI 1356 + Pio Combi,Ended,MIG,Migration,III,Phase III,6 w forced titration Pio 30 to  Pio 45 ,2008-008127-15,,000910,IS - Clin Study (MIGRATED)
12291,1264-0004,1264.4,Preparing,729,1264-P01,58 w extension 5/30, 5/45 qd vs Pio 30,Preparing,MIG,Migration,III,Phase III,rand. db extension to 1264.3 interim cut off for submission; 6 w forced titration Pio 30 to Pio45,,,000910,IS - Clin Study (MIGRATED)
12292,1264-0005,1264.5,Preparing,729,1264-P01,Pivotal BE BI 1356+Pio 45mg,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12293,1264-0006,1264.6,Unconfirmed,729,1264-P01,Kinetic Food Interaction Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12294,1264-0007,1264.7,Preparing,729,1264-P01,Pivotal BE BI 1356+Pio 15mg,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12295,1264-0008,1264.8,Unconfirmed,729,1264-P01,Extension BI 1356+Pio (5/30) Japan,Unconfirmed,MIG,Migration,III,Phase III,Extension for 1264.3 in Japan ,,,000910,IS - Clin Study (MIGRATED)
12296,1264-0009,1264.9,Preparing,729,1264-P01,Pioglitazone non responder study Japan,Preparing,MIG,Migration,IIIA,Phase IIIa,1:1 allocation to pio 15/30 screening 2:1 randomisation to linagliptin/pioglitazone FDC or pioglitazone mono,,,000910,IS - Clin Study (MIGRATED)
12297,1264-0010,1264.10,Unconfirmed,729,1264-P01,Piovotal BE BI 1356 5mg+Pio30mg Japan,Unconfirmed,MIG,Migration,I,Phase I,conduct in Japanese patients required ,,,000910,IS - Clin Study (MIGRATED)
12298,1264-0011,1264.11,Unconfirmed,729,1264-P01,Food interaction BI 1356+Pio30 Japan,Unconfirmed,MIG,Migration,I,Phase I,Study required in Japanese patients ,,,000910,IS - Clin Study (MIGRATED)
12299,1264-0012,1264.12,Unconfirmed,729,1264-P01,Relative BA study Lina/Pio FDC,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12300,1264-0013,1264.13,Preparing,729,1264-P01,Linagliptin filter study Japan,Preparing,MIG,Migration,IIIA,Phase IIIa,pivotal trial for registration in Japan ,,,000910,IS - Clin Study (MIGRATED)
12301,1264-0014,1264.14,Ended,729,1264-P01,Piovotal BE lina5mg/pio30mg FDC,Ended,MIG,Migration,I,Phase I,required for EU approval (switch claim) four period cross-over study (repilcate design),2010-022649-29,,000910,IS - Clin Study (MIGRATED)
12302,1264-0015,1264.15,Preparing,729,1264-P01,Pioglitazone 30mg filter, met ineligible,Preparing,MIG,Migration,III,Phase III,replacement for trial 1264.2 (EMA fu-SA) ,2010-024545-79,,000910,IS - Clin Study (MIGRATED)
12303,1265-0001,1265.1,Ended,731,1265-P01,ECG study pentoxyverine citrate,Ended,MIG,Migration,I,Phase I,,2009-012277-35,,000910,IS - Clin Study (MIGRATED)
12304,1160-0087,1160.87,Ended,732,1160-P06,Relative BA Study,Ended,MIG,Migration,I,Phase I,,2008-003702-34,,000910,IS - Clin Study (MIGRATED)
12305,1160-0088,1160.88,Ended,732,1160-P06,Safety and  tolerability in adolescents,Ended,MIG,Migration,IIA,Phase IIa,dose determined by weight adjusted by TT ,,,000910,IS - Clin Study (MIGRATED)
12306,1160-0089,1160.89,Ended,732,1160-P06,Safety & tolerability: 1 to under 12 yrs,Ended,MIG,Migration,IIA,Phase IIa,,2009-013618-29,,000910,IS - Clin Study (MIGRATED)
12307,1160-0104,1160.104,Unconfirmed,732,1160-P06,Dose finding 1 to less than 18 years,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12308,1160-0105,1160.105,Ended,732,1160-P06,Dose confirmation 0 to 12 months,Ended,MIG,Migration,IIA,Phase IIa,,2014-001259-22,,000910,IS - Clin Study (MIGRATED)
12309,1160-0106,1160.106,First Subject Randomised,732,1160-P06,Phase IIb/III efficacy and safety study,First Subject Randomised,MIG,Migration,III,Phase III,Incidence: 0.07-0.14 VTE / 10K children ,2013-002114-12,,000910,IS - Clin Study (MIGRATED)
12310,1160-0108,1160.108,First Subject Randomised,732,1160-P06,Prevention of secVT 0 to less than 18yrs,First Subject Randomised,MIG,Migration,III,Phase III,,2014-000583-18,,000910,IS - Clin Study (MIGRATED)
12311,1160-0117,1160.117,Ended,732,1160-P06,BE Study Qualicps vs Capsugel in adults,Ended,MIG,Migration,I,Phase I,Study requested(and paid) by Development Study will support adult indications,2010-022966-28,,000910,IS - Clin Study (MIGRATED)
12312,1160-0145,1160.145,Initiated,732,1160-P06,Safety &Tolerability PK study,Initiated,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12313,1160-0159,1160.159,Ended,732,1160-P06,CHD+IART Retrospective Chart Review,Ended,MIG,Migration,NONE,Not Classified,,,,,
12314,1160-0160,1160.160,Ended,732,1160-P06,CHD+ Fontan Chart Review,Ended,MIG,Migration,NONE,Not Classified,,,,,
12315,1160-0194,1160.194,Ended,732,1160-P06,BA of pellets, OLF relative to caps,Ended,MIG,Migration,I,Phase I,,2013-002498-23,,000910,IS - Clin Study (MIGRATED)
12316,0202-0829,202.829,Preparing,733,0202-P05,Efficacy of Buscopan,Preparing,MIG,Migration,III,Phase III,to be performed by a CRO ,,,000910,IS - Clin Study (MIGRATED)
12317,0202-0831,202.831,Ended,733,0202-P05,Patient questionnaire through pharmacist,Ended,MIG,Migration,IV,Phase IV,Support from CRO ,,,000600,Survey Patient Questionnaire
12318,0202-0832,202.832,Ended,733,0202-P05,Onset of action - proof of principle,Ended,MIG,Migration,II,Phase II, By CRO ,,,000910,IS - Clin Study (MIGRATED)
12319,0202-0834,202.834,Preparing,733,0202-P05,Validation of outcome measures,Preparing,MIG,Migration,NONE,Not Classified,CRO: RTI-hs,  Res Triangle Park, NC, USA ,,,000300,IS - Methodological Studies
12320,0202-0835,202.835,Preparing,733,0202-P05,Actual use study,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
12321,0202-0836,202.836,Preparing,733,0202-P05,ECG study,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12322,0202-0839,202.839,Ended,733,0202-P05,Pilot study Buscopan US,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12323,0202-0840,202.840,Preparing,733,0202-P05,Dose Ranging Study,Preparing,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12324,0202-0841,202.841,Preparing,733,0202-P05,Phase I Clinical Study - ADME,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12325,0202-0842,202.842,Preparing,733,0202-P05,Phase III clinical efficacy study 2,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12326,0202-0843,202.843,Unconfirmed,733,0202-P05,Phase III pivotal efficacy trial 2,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12327,1266-0001,1266.1,Unconfirmed,734,1266-P01,SRD of BI 631950 in  HV,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12328,1266-0002,1266.2,Unconfirmed,734,1266-P01,MRD of BI 631,950 for 14 days,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12329,1266-0003,1266.3,Unconfirmed,734,1266-P01,CYP 3A4 interaction,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12330,1266-0004,1266.4,Unconfirmed,734,1266-P01,Bioavailibility SOF TF1,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12331,1200-0026,1200.26,Ended,735,1200-P03,BIBW 2992 in EGFR Amplified Tumors,Ended,MIG,Migration,IIA,Phase IIa,Trial expanded to multiple sites. 01-APR-08 Our legal dept. disapproved of using site specific ICF, as such the protocol has to be amended.  This will seriously slow down the enrollment.    07-MAR-2008.  Protocol is in signature stage now.  ICFs are being reviewed by DRA.   (5-FEB-2008) The budget well reflected under OPU/Grants.  CTMS does not recognize pre-screening from enrolled, and i need to find a solution to resove this issue so that i can adjust TCM budget items. 

(5-FEB-2008)  Final draft of protocol was submitted to PRC on 4-FEB-2008.  Budget was revised based on current assumptions, taking into consideration the worst case scenario of needing to prescreen 1200 patients at a 5% FISH positive rate overall.
Design of this trial has been very much dependent on the logistics of the pre-screening.   After much brainstorming, the trial team, along with TMM chose to limit this trial to two to three sites at most, MGH, Dana Farber and Beth Isreal NYC, reduced the number of patients to 48 from original 60.   This will still pose several issues, most importantly MGH's ability to enroll patients, along with Dana Farber in 18 months.   Enrolling 48 patients requires pre-screening of 600-1200 patients to find those who test positive for EGFR/HER2 gene amplification.

STIM took place on 02-NOV-2007.  
,,,000910,IS - Clin Study (MIGRATED)
12332,1200-0027,1200.27,Unconfirmed,735,1200-P03,Ph II in ovarian cancer,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12333,1200-0029,1200.29,Unconfirmed,735,1200-P03,Ph II in pancreatic cancer,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12334,1200-0030,1200.30,Unconfirmed,735,1200-P03,Ph II in hepatocellular cancer,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12335,1200-0036,1200.36,Ended,735,1200-P03,Phase I/II in glioma,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12336,1200-0038,1200.38,Last Subject Randomised,735,1200-P03,Phase I in newly diagnosed GBM,Last Subject Randomised,MIG,Migration,I,Phase I,,2008-007284-17,,000910,IS - Clin Study (MIGRATED)
12337,1200-0076,1200.76,Unconfirmed,735,1200-P03,gh,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12338,1200-0077,1200.77,Unconfirmed,735,1200-P03,Phase III GBM,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12339,1200-0090,1200.90,Unconfirmed,735,1200-P03,Newly diagnosed, unmethylated GBM,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12340,1267-0001,1267.1,Ended,736,1267-P01,SINGLE RISING DOSE STUDY,Ended,MIG,Migration,I,Phase I,,2008-006789-27,,000910,IS - Clin Study (MIGRATED)
12341,1267-0002,1267.2,Unconfirmed,736,1267-P01,DDI Study with Ketoconazol,Unconfirmed,MIG,Migration,I,Phase I,BI 60732 alone vs BI 60732 + Ketoconazol ,,,000910,IS - Clin Study (MIGRATED)
12342,1267-0003,1267.3,Unconfirmed,736,1267-P01,MRD Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12343,0502-0563,502.563,Preparing,737,0502-P08,Dose-ranging in patients aged 6-17.25 y,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12344,0502-0564,502.564,Preparing,737,0502-P08,Open-label, long-term (26-weeks) study,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12345,0502-0565,502.565,Preparing,737,0502-P08,BA of oral liquid in adults,Preparing,MIG,Migration,I,Phase I,,2008-003750-15,,000910,IS - Clin Study (MIGRATED)
12346,0502-0566,502.566,Preparing,737,0502-P08,Oral liquid in children 2 to under 6 y,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12347,1268-0001,1268.1,Ended,738,1268-P01,MRD study of BI 671800 in atopic adults,Ended,MIG,Migration,IB,Phase Ib,Study performed under IND 77,496 held and sponsored by Actimis and Beckloff,,,000910,IS - Clin Study (MIGRATED)
12348,1268-0002,1268.2,Unconfirmed,738,1268-P01,Relative Bioavail.  EDA formulations,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12349,1268-0003,1268.3,Unconfirmed,738,1268-P01,Relative Bioavail.  IR formulations,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12350,1268-0004,1268.4,Ended,738,1268-P01,Relative Bioavail. ERF formulations,Ended,MIG,Migration,IB,Phase Ib,,2009-013040-36,,000910,IS - Clin Study (MIGRATED)
12351,1268-0005,1268.5,Unconfirmed,738,1268-P01,Relative Bioavail.  final formulation,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12352,1268-0006,1268.6,Unconfirmed,738,1268-P01,IV toleran / absolute Bioavail,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12353,1268-0007,1268.7,Ended,738,1268-P01,Mass balance metabolic,Ended,MIG,Migration,IB,Phase Ib,,2009-016370-32,,000910,IS - Clin Study (MIGRATED)
12354,1268-0008,1268.8,Unconfirmed,738,1268-P01,Effect of renal impairment,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12355,1268-0009,1268.9,Unconfirmed,738,1268-P01,Effect of hepatic impairment,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12356,1268-0010,1268.10,Unconfirmed,738,1268-P01,Drug drug interaction prednisone,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12357,1268-0011,1268.11,Unconfirmed,738,1268-P01,Drug drug interaction theophylline,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12358,1268-0012,1268.12,Unconfirmed,738,1268-P01,Drug drug interaction montelukast,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12359,1268-0013,1268.13,Unconfirmed,738,1268-P01,Thorough QT,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12360,1268-0014,1268.14,Unconfirmed,738,1268-P01,Relative Bioavail paed formulations,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12361,1268-0015,1268.15,Ended,738,1268-P01,Pan Asian phase I study,Ended,MIG,Migration,IA,Phase Ia,Two part study, single rising dose and multiple rising dose part,,,000910,IS - Clin Study (MIGRATED)
12362,1268-0016,1268.16,Ended,738,1268-P01,Symptomatic asthmatic pts on ICS (PoC),Ended,MIG,Migration,IIA,Phase IIa,,2009-014551-80,,000910,IS - Clin Study (MIGRATED)
12363,1268-0017,1268.17,Ended,738,1268-P01,Asthma dose ranging PoC,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12364,1268-0018,1268.18,Unconfirmed,738,1268-P01,Asthma allergen challenge,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12365,1268-0019,1268.19,Unconfirmed,738,1268-P01,Asthma PoC optimal formulation,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12366,1268-0020,1268.20,Preparing,738,1268-P01,Adult add-on iCS +   taper,Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12367,1268-0021,1268.21,Unconfirmed,738,1268-P01,Non-atopic asthma,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12368,1268-0022,1268.22,Unconfirmed,738,1268-P01,EIB > 12 yrs pivotal USA,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12369,1268-0023,1268.23,Unconfirmed,738,1268-P01,EIB > 12 yrs pivotal EU,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12370,1268-0024,1268.24,Unconfirmed,738,1268-P01,Asthma mild > 12 yrs pivotal USA,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12371,1268-0025,1268.25,Unconfirmed,738,1268-P01,Asthma mild > 12 yrs pivotalI EU,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12372,1268-0026,1268.26,Unconfirmed,738,1268-P01,Asthma add-on / taper > 12 yrs USA,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12373,1268-0027,1268.27,Unconfirmed,738,1268-P01,Asthma add-on / taper > 12 yr EU,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12374,1268-0028,1268.28,Unconfirmed,738,1268-P01,Voluntary OL roll over adolescents,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
12375,1268-0029,1268.29,Unconfirmed,738,1268-P01,Montelukast comparison Ph III b,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
12376,1268-0030,1268.30,Unconfirmed,738,1268-P01,Registry for pregnancy and lactation,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12377,1268-0031,1268.31,Preparing,738,1268-P01,Adolescent bridging asthma,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12378,1268-0032,1268.32,Unconfirmed,738,1268-P01,Adolescent hyper-reactivity asthma,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12379,1268-0033,1268.33,Unconfirmed,738,1268-P01,5-11 yrs asthma bridging PK,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12380,1268-0034,1268.34,Unconfirmed,738,1268-P01,EIB 5-11 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12381,1268-0035,1268.35,Unconfirmed,738,1268-P01,Asthma mild 5-11 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12382,1268-0036,1268.36,Unconfirmed,738,1268-P01,Asthma add-on / taper 5-11 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12383,1268-0037,1268.37,Unconfirmed,738,1268-P01,Asthma roll-over 1-11 yrs,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
12384,1268-0038,1268.38,Unconfirmed,738,1268-P01,2-4 yrs asthma bridging PK,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12385,1268-0039,1268.39,Unconfirmed,738,1268-P01,1-2 yrs asthma bridging PK,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12386,1268-0040,1268.40,Unconfirmed,738,1268-P01,Asthma add-on 1-4 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12387,1268-0053,1268.53,Ended,738,1268-P01,Bid vs qd in asthmatics on low dose iCS,Ended,MIG,Migration,IIA,Phase IIa,scope is only for bottom line results ,,,000910,IS - Clin Study (MIGRATED)
12388,1268-0054,1268.54,Preparing,738,1268-P01,am vs pm dosing in mod to severe asthma,Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12389,1268-0055,1268.55,Preparing,738,1268-P01,Mild asthma dose ranging PoC in Japan,Preparing,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12390,1268-0056,1268.56,Ended,738,1268-P01,Relative Bioavail. HEA vs. EDA IR,Ended,MIG,Migration,I,Phase I,,2009-013280-19,,000910,IS - Clin Study (MIGRATED)
12391,1268-0057,1268.57,Unconfirmed,738,1268-P01,HEA b.i.d. bridging in asthma,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12392,1268-0058,1268.58,Unconfirmed,738,1268-P01,HEA qd in mild asthma,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12393,1268-0059,1268.59,Ended,738,1268-P01,HEA IR md in healthy adults,Ended,MIG,Migration,IB,Phase Ib,,2009-016369-27,,000910,IS - Clin Study (MIGRATED)
12394,1268-0060,1268.60,Ended,738,1268-P01,Colonic absorption study,Ended,MIG,Migration,IB,Phase Ib,,2009-016368-35,,000910,IS - Clin Study (MIGRATED)
12395,1268-0061,1268.61,Preparing,738,1268-P01,Add on ICS plus LABA,Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12396,1268-0062,1268.62,Unconfirmed,738,1268-P01,iCS naive asthmatics (smoking),Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12397,1268-0063,1268.63,Preparing,738,1268-P01,DDI study CYP 2C8 substrates,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12398,1268-0064,1268.64,Preparing,738,1268-P01,DDI Study CYP 2C9 Substrates,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12399,1268-0065,1268.65,Unconfirmed,738,1268-P01,Relative Bioavail paed formulations,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12400,1268-0067,1268.67,Preparing,738,1268-P01,DDI study CYP 3A4 inhibitor,Preparing,MIG,Migration,I,Phase I,,2010-023929-38,,000910,IS - Clin Study (MIGRATED)
12401,1268-0041,1268.41,Ended,739,1268-P02,SAR EEC PoC adult,Ended,MIG,Migration,IIA,Phase IIa,,2009-013269-24,,000910,IS - Clin Study (MIGRATED)
12402,1268-0042,1268.42,Unconfirmed,739,1268-P02,Cross-over study opt formulation,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12403,1268-0043,1268.43,Unconfirmed,739,1268-P02,SAR relief PoC adult,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12404,1268-0044,1268.44,Unconfirmed,739,1268-P02,PAR relief PoC adult,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12405,1268-0045,1268.45,Unconfirmed,739,1268-P02,SAR relief > 12 yrs pivotal,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12406,1268-0046,1268.46,Unconfirmed,739,1268-P02,SAR control  > 12 yrs pivotal,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12407,1268-0047,1268.47,Unconfirmed,739,1268-P02,PAR relief > 12 yrs pivotal,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12408,1268-0048,1268.48,Unconfirmed,739,1268-P02,SAR relief > 12 yrs pivotal,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12409,1268-0049,1268.49,Unconfirmed,739,1268-P02,SAR 5-11 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12410,1268-0050,1268.50,Unconfirmed,739,1268-P02,PAR 5-11 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12411,1268-0051,1268.51,Unconfirmed,739,1268-P02,AR 2-4 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12412,1268-0052,1268.52,Unconfirmed,739,1268-P02,AR 0,5-2 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12413,1268-0066,1268.66,Unconfirmed,739,1268-P02,Japanese dose ranging SAR study,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
12414,1144-0001,1144.1,Preparing,740,1144-P02,Bioequivalence Ranitidine ODT 75 mg,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12415,1144-0002,1144.2,Preparing,740,1144-P02,Pivotal BE Ranitidine ODT,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12416,1144-0003,1144.3,Ended,740,1144-P02,BA ranitidine ODT 150 mg,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12417,1144-0004,1144.4,Preparing,740,1144-P02,Pivotal BE ranitidine ODT standard meal,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12418,1144-0005,1144.5,Ended,740,1144-P02,BE Ranitidine 150 mg FCT - Europe,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12419,1144-0006,1144.6,Preparing,740,1144-P02,Ranitidine ODT versus Zantic (150 mg),Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12420,1144-0007,1144.7,Unconfirmed,740,1144-P02,Zantac BE study_new flavor,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12421,0135-0318,135.318,Preparing,741,0135-P08,Catheter Clearance with Actilyse 2mg,Preparing,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
12422,0135-0323,135.323,Ended,741,0135-P08,Actilyse treatment of CVAD occlusion,Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12423,1269-0001,1269.1,Unconfirmed,742,1269-P01,BI 836842 Phase I, weekly schedule,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12424,1269-0002,1269.2,Unconfirmed,742,1269-P01,BI 836842 Phase I, three-weekly schedule,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12425,1270-0001,1270.1,Analysis,743,1270-P01,BI 836826 Phase I in CLL patients,Analysis,MIG,Migration,I,Phase I,,2010-021488-34,,000910,IS - Clin Study (MIGRATED)
12426,1270-0003,1270.3,Unconfirmed,743,1270-P01,BI 836826 combination with bendamustine,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12427,1270-0004,1270.4,Preparing,743,1270-P01,BI 836826 combination with chlorambucil,Preparing,MIG,Migration,II,Phase II,,2014-001982-29,,000910,IS - Clin Study (MIGRATED)
12428,1270-0006,1270.6,Unconfirmed,743,1270-P01,BI 836826 + venetoclax in relapse/refractory CLL,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12429,1270-0007,1270.7,Unconfirmed,743,1270-P01,BI 836826 + ibrutinib in CLL,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12430,1270-0013,1270.13,Preparing,743,1270-P01,BI 836826 in CLL R/R to BCR inhibition,Preparing,MIG,Migration,IB,Phase Ib,no randomization but dates entered for subject randomized corresponds to date when the subject enters the combination treatment after the 5-week ramp-up period for venetoclax alone,2014-004957-16,,000910,IS - Clin Study (MIGRATED)
12431,1270-0014,1270.14,Preparing,743,1270-P01,BI836826 + idelalisib in CLL,Preparing,MIG,Migration,I,Phase I,,,,,
12432,1270-0015,1270.15,First Subject Randomised,743,1270-P01,BI 836826 + ibrutinib in relapsed CLL,First Subject Randomised,MIG,Migration,I,Phase I,Trial will be a Phase Ib/II design Phase Ib will determine the MTD of BI 836826 in combination with SOC ibrutinib.  Phase II will be an expansion phase of the MTD dose of BI 836826 confirmed in Phase Ib in combination with ibrutinib.,,,000910,IS - Clin Study (MIGRATED)
12433,1271-0001,1271.1,Preparing,744,1271-P01,BI 836830 Phase I dose escalation in CLL,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12434,1271-0002,1271.2,Unconfirmed,744,1271-P01,Ph1 dose escalation NHL,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12435,1271-0003,1271.3,Unconfirmed,744,1271-P01,Ph2 CLL relapsed with bendamustine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12436,1271-0004,1271.4,Unconfirmed,744,1271-P01,Ph2 First line CLL with chlorambucil,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12437,1271-0005,1271.5,Unconfirmed,744,1271-P01,Ph2 relapsed NHL with R-DHAP,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12438,1271-0006,1271.6,Unconfirmed,744,1271-P01,Ph3 relapsed CLL BI+Benda vs benda,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12439,1271-0007,1271.7,Unconfirmed,744,1271-P01,Ph3 1st L CLL BI+chlor vs ofa+chlor,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12440,1271-0008,1271.8,Unconfirmed,744,1271-P01,Ph3 relapsed NHL BI+R-ICE vs R-ICE,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12441,1271-0009,1271.9,Unconfirmed,744,1271-P01,Ph3 BI+R-ICE vs R-ICE relapsed NHL,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12442,1272-0001,1272.1,Ended,745,1272-P01,single rising dose study,Ended,MIG,Migration,I,Phase I,,2009-014890-42,,000910,IS - Clin Study (MIGRATED)
12443,1272-0002,1272.2,Ended,745,1272-P01,Multiple Rising Dose study,Ended,MIG,Migration,IB,Phase Ib,,2010-018541-62,,000910,IS - Clin Study (MIGRATED)
12444,1272-0003,1272.3,Preparing,745,1272-P01,SRD study in Asian healthy subjects,Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12445,1272-0004,1272.4,Preparing,745,1272-P01,Phase II PoC and Dose finding study,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12446,1272-0005,1272.5,Ended,745,1272-P01,Ketokonazole interaction study,Ended,MIG,Migration,IB,Phase Ib,,2010-018542-31,,000910,IS - Clin Study (MIGRATED)
12447,1272-0006,1272.6,Unconfirmed,745,1272-P01,Absolute bioavailability study,Unconfirmed,MIG,Migration,IB,Phase Ib,preliminary placeholder ,,,000910,IS - Clin Study (MIGRATED)
12448,1272-0007,1272.7,Unconfirmed,745,1272-P01,Human ADME study,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12449,1272-0008,1272.8,Unconfirmed,745,1272-P01,Efficacy in painful OA of the knee,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12450,1272-0009,1272.9,Unconfirmed,745,1272-P01,Efficacy in painful OA of the hip,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12451,1272-0010,1272.10,Unconfirmed,745,1272-P01,Study in patients with CV risks,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12452,1272-0011,1272.11,Unconfirmed,745,1272-P01,Efficacy in painful OA of the hand,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12453,1272-0012,1272.12,Unconfirmed,745,1272-P01,Open label extension study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12454,1272-0013,1272.13,Unconfirmed,745,1272-P01,MRD study in Asian OA patients,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12455,1272-0014,1272.14,Preparing,745,1272-P01,DDI Study - moderate CYP 3A4 inhibitor,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12456,1273-0001,1273.1,Unconfirmed,746,1273-P01,PK-DDI 1335/7127 in HVs,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12457,1273-0002,1273.2,Unconfirmed,746,1273-P01,10-day dual combination of 1335/7127,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12458,1274-0001,1274.1,Unconfirmed,747,1274-P01,8 week proof on clinical concept RA,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12459,1199-0026,1199.26,Last Subject Randomised,748,1199-P05,Phase II in RCC (BIBF1120 versus Sutent),Last Subject Randomised,MIG,Migration,IIB,Phase IIb,Treat until clinical relapse of cancer ,2009-009516-44,,000910,IS - Clin Study (MIGRATED)
12460,1199-0037,1199.37,Ended,748,1199-P05,BIBF 1120 in hepatocellular cancer,Ended,MIG,Migration,IIA,Phase IIa,study has two compoments: phase I and II phase I in UK only (two sites),2009-011925-14,,000200,IS - Clin Study - Outcome
12461,1199-0039,1199.39,Ended,748,1199-P05,BIBF 1120, HCC (Asia),Ended,MIG,Migration,IIA,Phase IIa,Phase I with two sites in Taiwan. ,,,000910,IS - Clin Study (MIGRATED)
12462,1199-0085,1199.85,Unconfirmed,748,1199-P05,Phase III for HCC in Caucasians,Unconfirmed,MIG,Migration,III,Phase III,see below total observation period determined by overall survival (expected median overall survival for HCC patients on BIBF 1120 arm is 15 months,,,000910,IS - Clin Study (MIGRATED)
12463,1199-0086,1199.86,Unconfirmed,748,1199-P05,Phase III for HCC in Asians,Unconfirmed,MIG,Migration,III,Phase III,see below total observation period estimated from overall survival,,,000910,IS - Clin Study (MIGRATED)
12464,1199-0092,1199.92,Unconfirmed,748,1199-P05,Phase III  in RCC (BIBF 1120 vs Sutent),Unconfirmed,MIG,Migration,III,Phase III,study will only go if 1199.26 positive ,,,000910,IS - Clin Study (MIGRATED)
12465,1199-0120,1199.120,Ended,748,1199-P05,Phase I of BIBF 1120 in HCC in Japan,Ended,MIG,Migration,I,Phase I,final design will depend on outcome of 1199.37 and 39 expected in Q2 2011,,,000910,IS - Clin Study (MIGRATED)
12466,1199-0204,1199.204,Unconfirmed,748,1199-P05,Relative bio availabilty study,Unconfirmed,MIG,Migration,I,Phase I,90 patients will be included ,2014-002719-40,,000910,IS - Clin Study (MIGRATED)
12467,1199-0205,1199.205,Unconfirmed,748,1199-P05,Relative Bioavailabilty study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12468,1199-0237,1199.237,Ended,748,1199-P05,Bioequiv.1x200 vs 2x100mg Nintedanib,Ended,MIG,Migration,I,Phase I,,2015-001348-12,,000910,IS - Clin Study (MIGRATED)
12469,1275-0001,1275.1,Ended,749,1275-P01,BI10773/BI1356 FDC vs BI10773 or BI1356,Ended,MIG,Migration,IIIA,Phase IIIa,,2011-000383-10,,000910,IS - Clin Study (MIGRATED)
12470,1275-0002,1275.2,Unconfirmed,749,1275-P01,Food Effect Study  BI10773+BI1356 FDC,Unconfirmed,MIG,Migration,I,Phase I,35 days wash-out between treatments ,,,000910,IS - Clin Study (MIGRATED)
12471,1275-0003,1275.3,Ended,749,1275-P01,Pilot BA BI10773+BI1356FDC,Ended,MIG,Migration,I,Phase I,,2010-019211-38,,000910,IS - Clin Study (MIGRATED)
12472,1275-0004,1275.4,Unconfirmed,749,1275-P01,Pivotal BE of BI10773+BI1356 FDC,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12473,1275-0005,1275.5,Unconfirmed,749,1275-P01,52 W extension BI10773+BI1356FDC,Unconfirmed,MIG,Migration,III,Phase III,Blinded randomized extension to 1275.1 ,,,000910,IS - Clin Study (MIGRATED)
12474,1275-0006,1275.6,Unconfirmed,749,1275-P01,PK/PD of BI10773 QD vs BI10773 1/2 BID,Unconfirmed,MIG,Migration,I,Phase I,Twice daily regimen for FDC ,,,000910,IS - Clin Study (MIGRATED)
12475,1275-0007,1275.7,Unconfirmed,749,1275-P01,BI 10773 drug-drug interaction,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12476,1275-0008,1275.8,Unconfirmed,749,1275-P01,Add-on to BI1356,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12477,1275-0009,1275.9,Ended,749,1275-P01,Empagliflozin add-on to linagliptin,Ended,MIG,Migration,III,Phase III,,2012-002270-31,,000910,IS - Clin Study (MIGRATED)
12478,1275-0010,1275.10,Ended,749,1275-P01,Linagliptin add-on to BI 10773,Ended,MIG,Migration,IIIB,Phase IIIb,,2012-002271-34,,000910,IS - Clin Study (MIGRATED)
12479,1275-0011,1275.11,Preparing,749,1275-P01,H2H BI10773+Linagliptin vs GLP-1,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12480,1275-0012,1275.12,Preparing,749,1275-P01,Empa+Lina FDC PMO study,Preparing,MIG,Migration,III,Phase III,,2012-000560-25,,000910,IS - Clin Study (MIGRATED)
12481,1275-0013,1275.13,Analysis,749,1275-P01,Japanese Lina add-on to Empa,Analysis,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
12482,1275-0014,1275.14,Unconfirmed,749,1275-P01,Japanese Lina add-on to Empa 25 mg,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
12483,1275-0015,1275.15,Unconfirmed,749,1275-P01,PK in Chinese subjects,Unconfirmed,MIG,Migration,I,Phase I,local registration of FDC ,,,000910,IS - Clin Study (MIGRATED)
12484,1275-0016,1275.16,Unconfirmed,749,1275-P01,Comprehensive safety trial in Japan,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
12485,1275-0017,1275.17,Ended,749,1275-P01,Food effect study Japan,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12486,1275-0018,1275.18,Unconfirmed,749,1275-P01,Japanese BE study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12487,1275-0019,1275.19,Ended,749,1275-P01,Japanese Empa add on to Lina study,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
12488,1275-0020,1275.20,Unconfirmed,749,1275-P01,EmpaLina CKD outcome study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12489,1275-0021,1275.21,Ended,749,1275-P01,BE Empa 10mg and Lina 5mg and FDC,Ended,MIG,Migration,I,Phase I,,2015-004234-98,,000910,IS - Clin Study (MIGRATED)
12490,1275-0022,1275.22,Preparing,749,1275-P01,EmpaLina Mechanistic FDC Study,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
12491,1275-0023,1275.23,Preparing,749,1275-P01,EmpaLina Goal Attainment Study,Preparing,MIG,Migration,III,Phase III,,2015-001829-17,,000910,IS - Clin Study (MIGRATED)
12492,1275-0024,1275.24,Preparing,749,1275-P01,BE Empa 25 Lina 5mg and FDC,Preparing,MIG,Migration,I,Phase I,,2016-004006-34,29-SEP-16,000090,IS - Clin Study - Clin Pharm - BA/BE
12493,1276-0001,1276.1,Ended,750,1276-P01, Fact Design free combo Empa+Met,Ended,MIG,Migration,III,Phase III,,2010-021375-92,,000910,IS - Clin Study (MIGRATED)
12494,1276-0002,1276.2,Unconfirmed,750,1276-P01,BI10773+Met FDC v.BI1356 +/- Met,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12495,1276-0003,1276.3,Unconfirmed,750,1276-P01,Long term extension BI10773+Met FDC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12496,1276-0004,1276.4,Unconfirmed,750,1276-P01, Food effect BI10773+Met 1000 mg FDC,Unconfirmed,MIG,Migration,I,Phase I,35 days washout between treatments ,,,000910,IS - Clin Study (MIGRATED)
12497,1276-0005,1276.5,Ended,750,1276-P01,Pilot BA + Food Eff. 10773+Met 1000 FDC,Ended,MIG,Migration,I,Phase I,,2010-018589-22,,000910,IS - Clin Study (MIGRATED)
12498,1276-0006,1276.6,Ended,750,1276-P01,Pivotal BE BI10773+Met500 mg,Ended,MIG,Migration,I,Phase I,,2012-000082-20,,000910,IS - Clin Study (MIGRATED)
12499,1276-0007,1276.7,Ended,750,1276-P01,Pivotal BE Empagliflozin + Met 850 mg,Ended,MIG,Migration,I,Phase I,,2012-002277-65,,000910,IS - Clin Study (MIGRATED)
12500,1276-0008,1276.8,Ended,750,1276-P01,BE BI10773+Met 1000 mg FDC + food effect,Ended,MIG,Migration,I,Phase I,,2012-005156-42,,000910,IS - Clin Study (MIGRATED)
12501,1276-0009,1276.9,Ended,750,1276-P01,PK/PD BI10773 QD vs BI10773 1/2 BID,Ended,MIG,Migration,I,Phase I,Twice daily regimen for FDC ,2009-012524-90,,000910,IS - Clin Study (MIGRATED)
12502,1276-0010,1276.10,Ended,750,1276-P01,16 Week BI10773 QD vs BID,Ended,MIG,Migration,IIB,Phase IIb,,2012-000905-53,,000910,IS - Clin Study (MIGRATED)
12503,1276-0011,1276.11,Unconfirmed,750,1276-P01,PK/PD BI10773 QD v BI10773 BID,Unconfirmed,MIG,Migration,I,Phase I,Twice daily regimen for FDC ,,,000910,IS - Clin Study (MIGRATED)
12504,1276-0012,1276.12,Unconfirmed,750,1276-P01,Efficacy of BI 10773 QD vs BI 10773 BID,Unconfirmed,MIG,Migration,II,Phase II,Study to be conducted if requested by HA ,,,000910,IS - Clin Study (MIGRATED)
12505,1276-0022,1276.22,Unconfirmed,750,1276-P01,China empa bid vs qd add on to met+SU,Unconfirmed,MIG,Migration,III,Phase III,internal preparation as fall back option ,,,000910,IS - Clin Study (MIGRATED)
12506,1276-0023,1276.23,Ended,750,1276-P01,BI10773/Metformin FDC local (China) PK,Ended,MIG,Migration,I,Phase I,local registration of FDC ,,,000910,IS - Clin Study (MIGRATED)
12507,1276-0024,1276.24,Ended,750,1276-P01,Local (Canadian) PK study,Ended,MIG,Migration,I,Phase I,local regulatory requirement (HC) ,,,000910,IS - Clin Study (MIGRATED)
12508,1276-0027,1276.27,Ended,750,1276-P01,Local BE Russia FDC vs empa+local met,Ended,MIG,Migration,I,Phase I,required by Russian CA for FDC approval ,,,000910,IS - Clin Study (MIGRATED)
12509,1276-0039,1276.39,Preparing,750,1276-P01,Regulatory request NIS in Korea,Preparing,NISND,NISND incl. Chart Abstractions,IV,Phase IV,,,,000410,NISnd ‚Äì Study - Other
12510,1230-0002,1230.2,Ended,752,1230-P03,Phase II trial in solid tumours/bladder,Ended,MIG,Migration,IIA,Phase IIa,Trial will be used to open  US IND ,,,000910,IS - Clin Study (MIGRATED)
12511,1230-0006,1230.6,Ended,752,1230-P03,Phase I combo platinum,Ended,MIG,Migration,I,Phase I,,2008-003926-40,,000910,IS - Clin Study (MIGRATED)
12512,1230-0012,1230.12,Unconfirmed,752,1230-P03,Phase III Urothelial Ca second line,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12513,1230-0013,1230.13,Unconfirmed,752,1230-P03,Phase IIb/III Urothelial Ca 1st line,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12514,1230-0018,1230.18,Ended,752,1230-P03,BI 6727phase II in ovarian cancer,Ended,MIG,Migration,II,Phase II,,2009-015770-35,,000910,IS - Clin Study (MIGRATED)
12515,1230-0021,1230.21,Unconfirmed,752,1230-P03,BI 6727 Phase III ovarian CA 2nd line,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12516,1230-0022,1230.22,Unconfirmed,752,1230-P03,BI 6727 phase III ovarian CA 1st line,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12517,1277-0001,1277.1,Ended,753,1277-P01,1st in human volunteers, SRD study,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12518,1277-0002,1277.2,Initiated,753,1277-P01,MRD in Healthy volunteers with PIB soln,Initiated,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12519,1277-0003,1277.3,Unconfirmed,753,1277-P01,colonic absorption study,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12520,1277-0004,1277.4,Unconfirmed,753,1277-P01,rel BA of prototype TFII CR formulations,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12521,1277-0005,1277.5,Unconfirmed,753,1277-P01,DDI study with FDC partner drug(s),Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12522,1277-0006,1277.6,Unconfirmed,753,1277-P01,DDI study with CYP-probe drug,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12523,1277-0007,1277.7,Unconfirmed,753,1277-P01,Proof-of--clinical concept in ARV-naive,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12524,1277-0008,1277.8,Unconfirmed,753,1277-P01,Dose finding in ARV-naive patients,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12525,1277-0009,1277.9,Unconfirmed,753,1277-P01,Dose finding in ARV-experienced,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12526,1278-0001,1278.1,Unconfirmed,754,1278-P01,Single Rising Dose Study in HV,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12527,1278-0002,1278.2,Unconfirmed,754,1278-P01,Multiple Rising Dose Study in HV,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12528,1278-0003,1278.3,Unconfirmed,754,1278-P01,Single Dose in Patients with COPD,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12529,1278-0004,1278.4,Unconfirmed,754,1278-P01,PoC,  Efficacy Profiling,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12530,1278-0005,1278.5,Unconfirmed,754,1278-P01,Supportive LPS Challenge,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12531,1278-0006,1278.6,Unconfirmed,754,1278-P01,Final Dose Finding Study,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12532,1278-0007,1278.7,Unconfirmed,754,1278-P01,Active Comparator (1),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12533,1278-0008,1278.8,Unconfirmed,754,1278-P01,Active Comparator (2),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12534,1278-0009,1278.9,Unconfirmed,754,1278-P01,Add on LABA+ICS (1),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12535,1278-0010,1278.10,Unconfirmed,754,1278-P01, Add on LABA+ICS (2),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12536,1278-0011,1278.11,Unconfirmed,754,1278-P01,Add on LABA+LAMA (1),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12537,1278-0012,1278.12,Unconfirmed,754,1278-P01,Add on LABA+LAMA (2),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12538,1279-0001,1279.1,Ended,755,1279-P01,SRD study in HV,Ended,MIG,Migration,IB,Phase Ib,,2010-021187-15,,000910,IS - Clin Study (MIGRATED)
12539,1279-0002,1279.2,Unconfirmed,755,1279-P01,Phase Ib DDI tbd,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12540,1279-0003,1279.3,Unconfirmed,755,1279-P01,MRD  in HV after BA with food-effect,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12541,1279-0004,1279.4,Unconfirmed,755,1279-P01,4 weeks safety in RA patients,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12542,1279-0005,1279.5,Unconfirmed,755,1279-P01,SRD in Panasian healthy volunteers,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12543,1279-0006,1279.6,Unconfirmed,755,1279-P01,MRD in Panasian healthy volunteers,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12544,1279-0007,1279.7,Unconfirmed,755,1279-P01,12 wks efficacy, safety, PK in RA,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12545,1279-0008,1279.8,Unconfirmed,755,1279-P01,26 wks efficacy, safety in RA patients,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12546,1279-0009,1279.9,Unconfirmed,755,1279-P01,12 wks effic., saf. in anti-TNF failurs,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12547,1279-0010,1279.10,Unconfirmed,755,1279-P01,Effic., saf. in RA pat. odd-on to MTX,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12548,1279-0011,1279.11,Unconfirmed,755,1279-P01,Effic., saf. in RA pat. add-on to MTX,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12549,1279-0012,1279.12,Unconfirmed,755,1279-P01,Roll-over trial,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12550,1279-0013,1279.13,Unconfirmed,755,1279-P01,Rel bioavail. of diff. form. children,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12551,1279-0014,1279.14,Unconfirmed,755,1279-P01,BI 638683 children w juvenile arthritis,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12552,1200-0071,1200.71,Ended,756,1200-P04,BIBW 2992(afatinib)+Cetuximab in NSCLC,Ended,MIG,Migration,IB,Phase Ib,,2009-015911-42,,000910,IS - Clin Study (MIGRATED)
12553,1200-0074,1200.74,Ended,756,1200-P04,Phase II Afatinib vs cetuximab in CRC,Ended,MIG,Migration,II,Phase II,CTARR still pending ,2009-011996-59,,000910,IS - Clin Study (MIGRATED)
12554,1200-0085,1200.85,Unconfirmed,756,1200-P04,BIBW2922 maintenance in 1st line mCRC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12555,1200-0122,1200.122,Ended,756,1200-P04,Phase Ib   of afatinib and cetuximab,Ended,MIG,Migration,IB,Phase Ib,,2012-005230-10,,000910,IS - Clin Study (MIGRATED)
12556,1200-0130,1200.130,Unconfirmed,756,1200-P04,Afatinib Targeted Combination,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12557,1200-0151,1200.151,Ended,756,1200-P04,BA Afatinib timed coadmin of P-gp inhib,Ended,MIG,Migration,I,Phase I,,2011-001803-11,,000910,IS - Clin Study (MIGRATED)
12558,1200-0152,1200.152,Ended,756,1200-P04,BA afatinib with P-gp inducers,Ended,MIG,Migration,I,Phase I,,2011-001804-37,,000910,IS - Clin Study (MIGRATED)
12559,1280-0001,1280.1,Analysis,757,1280-P01,BI 836845 phase I q1wk,Analysis,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12560,1280-0002,1280.2,Ended,757,1280-P01,BI 836845 phase I q3wk,Ended,MIG,Migration,I,Phase I,To be performed in phase I centres ,2010-021714-29,,000910,IS - Clin Study (MIGRATED)
12561,1280-0003,1280.3,Unconfirmed,757,1280-P01,BI836845 peadiatric ph I dose escalation,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12562,1280-0005,1280.5,Preparing,757,1280-P01,Ph II BI836845+Platinum-based NSCLC,Preparing,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12563,1280-0006,1280.6,Unconfirmed,757,1280-P01,Ph II BI836845 +sorafenib HCC Asia,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12564,1280-0007,1280.7,Unconfirmed,757,1280-P01,Ph II BI836845 + nintedanib non-Asia HCC,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12565,1280-0008,1280.8,First Subject Randomised,757,1280-P01,Ph Ib/II BI836845 + enzalutamide CRPC,First Subject Randomised,MIG,Migration,IB,Phase Ib,,2013-004011-41,,000910,IS - Clin Study (MIGRATED)
12566,1280-0009,1280.9,Unconfirmed,757,1280-P01,Ph II BI 836845 metastatic sarcoma,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12567,1280-0010,1280.10,Unconfirmed,757,1280-P01,Ph III BI 836845  in NSCLC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12568,1280-0011,1280.11,Unconfirmed,757,1280-P01,Ph III BI 836845 in HCC Asia,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12569,1280-0012,1280.12,Unconfirmed,757,1280-P01,Ph III BI836845 + nintedanib non-Asia,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12570,1280-0014,1280.14,Unconfirmed,757,1280-P01,Ph III Xentuzumab + enzalutamide or abiraterone CRPC,Unconfirmed,PRELIM,Preliminary,III,Phase III,CRPC: Castration-resistant prostate cancer,,,000910,IS - Clin Study (MIGRATED)
12571,1280-0015,1280.15,Last Subject Randomised,757,1280-P01,Phase I dose escalation Japan,Last Subject Randomised,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12572,1280-0017,1280.17,Unconfirmed,757,1280-P01,BI 836845 plus Abiraterone Phase 2,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12573,1280-0018,1280.18,First Subject Randomised,901,1280-P02,Phase I Abemaciclib + BI 836845,First Subject Randomised,FULL,Full functionality,I,Phase I,,,,000100,IS - Clin Study - Clin Pharm - Other
12574,1280-0019,1280.19,Unconfirmed,901,1280-P02,Phase II Abemaciclib + BI 836845 in mBC,Unconfirmed,FULL,Full functionality,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12575,1280-0020,1280.20,Unconfirmed,757,1280-P01,Ph III Abemaciclib+BI836845 mBC 1st line,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12576,1281-0001,1281.1,Unconfirmed,758,1281-P01,BI 837841 Phase I in melanoma,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12577,1281-0002,1281.2,Unconfirmed,758,1281-P01,BI 837841 phase I in solid tumours,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12578,1282-0001,1282.1,Unconfirmed,759,1282-P01,BI 839671 phase I 1wk on 1wk off,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12579,1282-0002,1282.2,Unconfirmed,759,1282-P01,BI 839671 phase I 3 wk on 1wk off,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12580,1283-0001,1283.1,Ended,760,1283-P01,SRD in Healthy Volunteers,Ended,MIG,Migration,I,Phase I,,2010-018856-28,,000910,IS - Clin Study (MIGRATED)
12581,1283-0002,1283.2,Ended,760,1283-P01,MRD in patients with T2DM,Ended,MIG,Migration,IB,Phase Ib,adipose  tissue biopsies ,2010-022698-32,,000910,IS - Clin Study (MIGRATED)
12582,1283-0003,1283.3,Ended,760,1283-P01,Food Effect,Ended,MIG,Migration,I,Phase I,,2010-022697-14,,000910,IS - Clin Study (MIGRATED)
12583,1283-0004,1283.4,Preparing,760,1283-P01,6 week safety and efficacy in patients,Preparing,MIG,Migration,I,Phase I,double-blind within dose levels ,2010-022174-13,,000910,IS - Clin Study (MIGRATED)
12584,1283-0005,1283.5,Ended,760,1283-P01,SRD in Asian subjects,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12585,1283-0006,1283.6,Unconfirmed,760,1283-P01,MRD in Chinese subjects,Unconfirmed,MIG,Migration,I,Phase I,Adipose tissue biopsy included ,,,000910,IS - Clin Study (MIGRATED)
12586,1283-0007,1283.7,Preparing,760,1283-P01,DDI with Metformin,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12587,1283-0008,1283.8,Unconfirmed,760,1283-P01,Human ADME,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12588,1283-0009,1283.9,Unconfirmed,760,1283-P01,Dose Finder vs placebo,Unconfirmed,MIG,Migration,IIB,Phase IIb,combined Phase IIb ,,,000910,IS - Clin Study (MIGRATED)
12589,1283-0010,1283.10,Unconfirmed,760,1283-P01,Phase I placeholder,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12590,1283-0011,1283.11,Unconfirmed,760,1283-P01,Phase IIb Extension,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12591,1283-0012,1283.12,Unconfirmed,760,1283-P01,DDI with CYP3A4 substrate,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12592,1283-0013,1283.13,Preparing,760,1283-P01,MRD study in Japanese patients,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12593,1283-0014,1283.14,Unconfirmed,760,1283-P01,Paediatric dose finding,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12594,1283-0015,1283.15,Unconfirmed,760,1283-P01,Paediatric safety and efficacy,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12595,1283-0016,1283.16,Unconfirmed,760,1283-P01,Rel. BA of TF-II,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12596,1283-0017,1283.17,Unconfirmed,760,1283-P01,Tolerability of iv formulation,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12597,1283-0018,1283.18,Unconfirmed,760,1283-P01,DDI placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12598,1283-0019,1283.19,Unconfirmed,760,1283-P01,PK in T2DM pat with renal impairment,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12599,1283-0020,1283.20,Unconfirmed,760,1283-P01,Thorough QT study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12600,1283-0021,1283.21,Unconfirmed,760,1283-P01,24w Phase III + 54 LT extension,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12601,1283-0022,1283.22,Unconfirmed,760,1283-P01,24w Phase III + 54 LT extension,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12602,1283-0023,1283.23,Unconfirmed,760,1283-P01,24w Phase III + 54 LT extension,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12603,1283-0024,1283.24,Unconfirmed,760,1283-P01,24w Phase III + 54 LT extension,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12604,1283-0025,1283.25,Unconfirmed,760,1283-P01,24w Phase III + 54 LT extension,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12605,1283-0026,1283.26,Unconfirmed,760,1283-P01,Phase III H2H trial 104 weeks,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12606,1283-0027,1283.27,Unconfirmed,760,1283-P01,Phase III H2H trial 52 weeks,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12607,1283-0028,1283.28,Unconfirmed,760,1283-P01,Phase III in pat with renal impairment,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12608,1283-0029,1283.29,Unconfirmed,760,1283-P01,CV safety trial,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12609,1283-0030,1283.30,Unconfirmed,760,1283-P01,Add-on safety trial - Japan,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12610,1283-0031,1283.31,Unconfirmed,760,1283-P01,DDI Placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12611,1283-0032,1283.32,Unconfirmed,760,1283-P01,DDI Placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12612,1283-0033,1283.33,Unconfirmed,760,1283-P01,Mechanistic Study,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12613,1283-0034,1283.34,Ended,760,1283-P01,PK and PD of 200mg BI 135585 single dose,Ended,MIG,Migration,I,Phase I,,2012-000844-85,,000910,IS - Clin Study (MIGRATED)
12614,1230-0004,1230.4,Last Subject Randomised,761,1230-P04,BI 6727 in AML,Last Subject Randomised,MIG,Migration,II,Phase II,,2008-003617-27,,000910,IS - Clin Study (MIGRATED)
12615,1230-0014,1230.14,Last Subject Randomised,761,1230-P04,Phase III AML 1st line combo,Last Subject Randomised,MIG,Migration,III,Phase III,,2012-002487-27,,000910,IS - Clin Study (MIGRATED)
12616,1230-0015,1230.15,Ended,761,1230-P04,Phase I trial in Japanese patients,Ended,MIG,Migration,I,Phase I,Phase I trial to determine MTD ,,,000910,IS - Clin Study (MIGRATED)
12617,1230-0016,1230.16,Ended,761,1230-P04,Dose escalation weekly in asian patients,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12618,1230-0017,1230.17,Unconfirmed,761,1230-P04,BI 6727 QT study in patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12619,1230-0023,1230.23,Ended,761,1230-P04,BI 6727 Human ADME in patients,Ended,MIG,Migration,I,Phase I,,2009-018199-32,,000910,IS - Clin Study (MIGRATED)
12620,1230-0024,1230.24,Analysis,761,1230-P04,BI 6727 DDI itraconazole,Analysis,MIG,Migration,I,Phase I,,2011-002367-23,,000910,IS - Clin Study (MIGRATED)
12621,1230-0025,1230.25,Preparing,761,1230-P04,BI 6727 Relapsed refractory AML,Preparing,MIG,Migration,IIB,Phase IIb,Changed to Phase II/III (CR+OS) ,2010-023499-25,,000910,IS - Clin Study (MIGRATED)
12622,1230-0026,1230.26,Ended,761,1230-P04,Japanese phase I for AML,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12623,1230-0027,1230.27,Ended,761,1230-P04,Phase I pediatric,Ended,MIG,Migration,I,Phase I,,2013-001291-38,,000910,IS - Clin Study (MIGRATED)
12624,1230-0028,1230.28,Preparing,761,1230-P04,pediatric AML Phase I/IIa,Preparing,MIG,Migration,I,Phase I,,2015-004625-14,,000910,IS - Clin Study (MIGRATED)
12625,1230-0029,1230.29,Unconfirmed,761,1230-P04,pediatric AML Phase IIb/III,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12626,1230-0030,1230.30,Analysis,761,1230-P04,Volasertib+decitabine in AML,Analysis,MIG,Migration,I,Phase I,CTP Amendment V 4.0 dated 23 Oct 2015 ,2013-001752-36,,000910,IS - Clin Study (MIGRATED)
12627,1230-0031,1230.31,Unconfirmed,761,1230-P04,Volasertib + Decitabine phase III,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
12628,1230-0032,1230.32,Ended,761,1230-P04,AML patient emotional insights research,Ended,PRP,Pharmacogenomic Research Project,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
12629,1230-0038,1230.38,Preparing,761,1230-P04,East Asia AML Volasertib+LDAC,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12630,1230-0042,1230.42,Unconfirmed,761,1230-P04,Safety of alternate LDAC R/R AML,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12631,1200-0032,1200.32,Analysis,762,1200-P05,PhIII NSCLC with EGFR mutation,Analysis,MIG,Migration,IIIA,Phase IIIa,,2008-005615-18,,000170,IS - Clin Study - Confirmatory/Pivotal
12632,1200-0034,1200.34,Analysis,762,1200-P05,BIBW 2992 vs. gem-cis in 1st line NSCLC,Analysis,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12633,1200-0092,1200.92,Ended,762,1200-P05, BIBW 2992 phase I Pemetrexed combo,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12634,1200-0093,1200.93,Ended,762,1200-P05,Afatinib ph I gemcitabine&docetaxel,Ended,MIG,Migration,I,Phase I,,2010-020560-37,,000910,IS - Clin Study (MIGRATED)
12635,1200-0123,1200.123,Last Subject Randomised,762,1200-P05,Afatinib vs. Iressa in EGFR mut,Last Subject Randomised,MIG,Migration,IIB,Phase IIb,,2011-001814-33,,000910,IS - Clin Study (MIGRATED)
12636,1200-0216,1200.216,Ended,762,1200-P05,Afatinib in renal impairment,Ended,MIG,Migration,I,Phase I,,2013-004825-98,,000910,IS - Clin Study (MIGRATED)
12637,1284-0001,1284.1,Ended,763,1284-P01,Single Rising Dose, First in Human,Ended,MIG,Migration,IA,Phase Ia,,2009-015995-90,,000910,IS - Clin Study (MIGRATED)
12638,1284-0002,1284.2,Preparing,763,1284-P01,Multiple Rising Dose,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12639,1284-0003,1284.3,Preparing,763,1284-P01,Single Rising Dose in Asia,Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12640,1284-0004,1284.4,Unconfirmed,763,1284-P01,Pediatric patients with neuropathic pain,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12641,1284-0005,1284.5,Unconfirmed,763,1284-P01,Pediatric PK,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12642,1284-0006,1284.6,Unconfirmed,763,1284-P01,Open label safety in pediatric patients,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12643,1284-0007,1284.7,Preparing,763,1284-P01,Flex dose  in DNP,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12644,1284-0008,1284.8,Preparing,763,1284-P01,Fixed dose in DNP,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12645,1284-0009,1284.9,Preparing,763,1284-P01,Proof of concept in LSR,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12646,1284-0010,1284.10,Preparing,763,1284-P01,Pivotal trial in DNP, Fixed dose,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12647,1284-0011,1284.11,Preparing,763,1284-P01,Pivotal trial in DNP, flex dose,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12648,1284-0012,1284.12,Preparing,763,1284-P01,Pivotal trial in DNP, fixed OR flex, TBD,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12649,1284-0013,1284.13,Preparing,763,1284-P01,Pivotal trial in PHN, fixed dose,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12650,1284-0014,1284.14,Preparing,763,1284-P01,Pivotal trial in PHN, flex dose,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12651,1284-0015,1284.15,Preparing,763,1284-P01,Pivotal trial in PHN, fixed OR flex, TBD,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12652,1284-0016,1284.16,Preparing,763,1284-P01,Pivotal trial in LSR, fixed dose,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12653,1284-0017,1284.17,Preparing,763,1284-P01,Pivotal trial in LSR, flex dose,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12654,1284-0018,1284.18,Unconfirmed,763,1284-P01,Pivotal trial in LSR, fixed OR flex, TBD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12655,1284-0019,1284.19,Preparing,763,1284-P01,Pivotal trial in SCI,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12656,1284-0020,1284.20,Preparing,763,1284-P01,open-label extension trial in DNP,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12657,1284-0021,1284.21,Preparing,763,1284-P01,Open-label extension trial in PHN,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12658,1284-0022,1284.22,Preparing,763,1284-P01,Open-label extension trial in LSR,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12659,1284-0023,1284.23,Unconfirmed,763,1284-P01,MRD Study in Chinese Subjects,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12660,1284-0024,1284.24,Preparing,763,1284-P01,DDI Study of CYP3A4 Induction Potential,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12661,1286-0001,1286.1,Unconfirmed,765,1286-P01,Single rising dose trial in HV,Unconfirmed,MIG,Migration,I,Phase I,treatment duration ranges from 1 day in SRD to approximately 15 days in MRD.,,,000910,IS - Clin Study (MIGRATED)
12662,1286-0002,1286.2,Unconfirmed,765,1286-P01,Multiple rising dose trial in HV,Unconfirmed,MIG,Migration,I,Phase I,Duration of treatment and obsrvation TBD ,,,000910,IS - Clin Study (MIGRATED)
12663,1286-0003,1286.3,Unconfirmed,765,1286-P01,Multiple dose trial in HCV Pt,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12664,1286-0004,1286.4,Unconfirmed,765,1286-P01,BA of PIB and SOF,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12665,1286-0005,1286.5,Unconfirmed,765,1286-P01,Oral-Oral DDI in healthy subjects,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12666,1286-0006,1286.6,Unconfirmed,765,1286-P01,MRD in Asian healthy volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12667,1286-0007,1286.7,Unconfirmed,765,1286-P01,SRD in Asian Healthy Volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12668,1286-0008,1286.8,Unconfirmed,765,1286-P01,Human ADME Study in Healthy Volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12669,1286-0009,1286.9,Unconfirmed,765,1286-P01,Absolute BA & single IV rising dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12670,1286-0010,1286.10,Unconfirmed,765,1286-P01,Safety and Efficacy (03) in TN G1 Pts,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12671,1286-0011,1286.11,Unconfirmed,765,1286-P01,Safety and Efficacy (03) in TE G1 Pts,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12672,1287-0001,1287.1,Ended,766,1287-P01,Monotherapy dose finding solid tumors,Ended,MIG,Migration,I,Phase I,,2010-023832-18,,000910,IS - Clin Study (MIGRATED)
12673,1287-0002,1287.2,Unconfirmed,766,1287-P01,Phase I scheduling, food effect study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12674,1287-0003,1287.3,Unconfirmed,766,1287-P01,Phase I combi study in metastatic CRC,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12675,1287-0004,1287.4,Unconfirmed,766,1287-P01,Phase I combi study in metastatic CRC(b),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12676,1287-0005,1287.5,Unconfirmed,766,1287-P01,Phase I combi in metastatic melanoma,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12677,1287-0006,1287.6,Unconfirmed,766,1287-P01,Phase II in KRAS mutated metastatic CRC,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12678,1287-0007,1287.7,Unconfirmed,766,1287-P01,Phase II in KRAS wildtype metastatic CRC,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12679,1287-0008,1287.8,Unconfirmed,766,1287-P01,Phase II in metastatic melanoma 1st line,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12680,1287-0009,1287.9,Unconfirmed,766,1287-P01,Phase II in pancreatic cancer 1st line,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12681,1287-0010,1287.10,Unconfirmed,766,1287-P01,Phase II study of a non-TPP (NSCLC),Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12682,1287-0011,1287.11,Unconfirmed,766,1287-P01,Phase III in KRAS mutated CRC last line,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12683,1287-0012,1287.12,Unconfirmed,766,1287-P01,Ph III in metastatic melanoma 1st line,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12684,1287-0013,1287.13,Unconfirmed,766,1287-P01,Ph III met pancreatic cancer 1st line,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12685,1287-0014,1287.14,Unconfirmed,766,1287-P01,Phase II QTc study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12686,1287-0015,1287.15,Unconfirmed,766,1287-P01,Phase I DDI with digoxin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12687,1287-0016,1287.16,Unconfirmed,766,1287-P01,Phase II study in hepatic impaired pts,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12688,1287-0017,1287.17,Unconfirmed,766,1287-P01,Human ADME study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12689,1287-0018,1287.18,Unconfirmed,766,1287-P01,Phase III in metastatic CRC last line,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12690,1287-0019,1287.19,Unconfirmed,766,1287-P01,Phase I DDI study (CYP) (a),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12691,1287-0020,1287.20,Unconfirmed,766,1287-P01,Phase I DDI study (CYP) (b),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12692,1287-0021,1287.21,Unconfirmed,766,1287-P01,Phase I study in Asian patients,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12693,1287-0022,1287.22,Unconfirmed,766,1287-P01,Phase I combi in Asian/Japanese pts,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12694,1287-0023,1287.23,Unconfirmed,766,1287-P01,Phase I study in Japanese patients,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12695,1287-0024,1287.24,Unconfirmed,766,1287-P01,Absolute bioavailability study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12696,1288-0001,1288.1,Ended,767,1288-P01,Pivotal BE FDC 2.5/1000,Ended,MIG,Migration,I,Phase I,,2009-015655-24,,000910,IS - Clin Study (MIGRATED)
12697,1288-0002,1288.2,Ended,767,1288-P01,Pivotal BE BI 1356 2.5+Metformin 500,Ended,MIG,Migration,I,Phase I,,2009-015676-95,,000910,IS - Clin Study (MIGRATED)
12698,1288-0003,1288.3,Ended,767,1288-P01,Pivotal BE BI 1356 2.5+Metformin 850,Ended,MIG,Migration,I,Phase I,,2009-015677-13,,000910,IS - Clin Study (MIGRATED)
12699,1288-0004,1288.4,Ended,767,1288-P01,Food Study FDC BI1356 2.5+Metformin 1000,Ended,MIG,Migration,I,Phase I,,2009-016642-13,,000910,IS - Clin Study (MIGRATED)
12700,1288-0005,1288.5,Ended,767,1288-P01,Local PK Linagliptin/Metformin FDC China,Ended,MIG,Migration,I,Phase I,local registration of FDC ,,,000910,IS - Clin Study (MIGRATED)
12701,1288-0006,1288.6,Ended,767,1288-P01,relative BA lina/met FDC side batch,Ended,MIG,Migration,I,Phase I,confirm release kinetics linagliptin avoid shelf life limitations for regulatory approval,2010-019291-75,,000910,IS - Clin Study (MIGRATED)
12702,1288-0018,1288.18,Ended,767,1288-P01,24 w reduced factorial China,Ended,MIG,Migration,IIIB,Phase IIIb,replaces trial 1218.93 (now FDC) ,,,000910,IS - Clin Study (MIGRATED)
12703,1288-0019,1288.19,Ended,767,1288-P01,BE 2.5/1000 or /500 lina/met FDC Canada,Ended,MIG,Migration,I,Phase I,conduct trial per Health Canada request ,,,000910,IS - Clin Study (MIGRATED)
12704,1288-0020,1288.20,Ended,767,1288-P01,BE lina2.5/met500 (fed),Ended,MIG,Migration,I,Phase I, required acc to BRA local reg guidance ,2011-005423-41,,000910,IS - Clin Study (MIGRATED)
12705,1288-0021,1288.21,Ended,767,1288-P01,Local BE study Russia,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12706,1288-0022,1288.22,Analysis,767,1288-P01,Regulatory requisite NIS in Korea,Analysis,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
12707,1289-0001,1289.1,Ended,768,1289-P01,SRD in healthy volunteers,Ended,MIG,Migration,I,Phase I,,2010-023604-27,,000910,IS - Clin Study (MIGRATED)
12708,1289-0002,1289.2,Ended,768,1289-P01,MRD in healthy volunteers,Ended,MIG,Migration,I,Phase I,,2011-002369-39,,000910,IS - Clin Study (MIGRATED)
12709,1289-0003,1289.3,Ended,768,1289-P01,PoM study in healthy volunteers,Ended,MIG,Migration,I,Phase I,,2011-003749-16,,000910,IS - Clin Study (MIGRATED)
12710,1289-0004,1289.4,Ended,768,1289-P01,SRD in healthy Asian subjects,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12711,1289-0005,1289.5,First Subject Randomised,768,1289-P01,Ph. II PoC/dose finding in prodromal AD,First Subject Randomised,MIG,Migration,II,Phase II,,2013-005031-24,,000131,IS - Clin Study - POCC
12712,1289-0007,1289.7,First Subject Randomised,768,1289-P01,PoC and dose finding in patients with AD,First Subject Randomised,MIG,Migration,II,Phase II,,2013-005040-28,,000131,IS - Clin Study - POCC
12713,1289-0008,1289.8,Unconfirmed,768,1289-P01,Mild AD - NA,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12714,1289-0009,1289.9,Unconfirmed,768,1289-P01,Mild AD - EU,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12715,1289-0010,1289.10,Unconfirmed,768,1289-P01,Phase III safety extension ,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12716,1289-0011,1289.11,Unconfirmed,768,1289-P01,Moderate AD,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12717,1289-0012,1289.12,Unconfirmed,768,1289-P01,Prodromal AD pivotal/EPAD,Unconfirmed,PRELIM,Preliminary,III,Phase III,May be run via EPAD consortium ,,,000910,IS - Clin Study (MIGRATED)
12718,1289-0016,1289.16,Preparing,768,1289-P01,MRD Asia,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12719,1289-0017,1289.17,Ended,768,1289-P01,MRD in PM and EM,Ended,MIG,Migration,I,Phase I,,2012-000052-34,,000910,IS - Clin Study (MIGRATED)
12720,1289-0022,1289.22,Ended,768,1289-P01,food effect and PK study,Ended,MIG,Migration,I,Phase I,,2014-001934-28,,000910,IS - Clin Study (MIGRATED)
12721,1289-0023,1289.23,Ended,768,1289-P01,DDI with strong CYP3A4 inhibitor,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12722,1289-0024,1289.24,Ended,768,1289-P01,DDI with donepezil,Ended,MIG,Migration,I,Phase I,,2015-001694-40,,000910,IS - Clin Study (MIGRATED)
12723,1289-0025,1289.25,Unconfirmed,768,1289-P01,Absolute BA trial,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,2016-000751-27,,000910,IS - Clin Study (MIGRATED)
12724,1289-0026,1289.26,Ended,768,1289-P01,Human ADME,Ended,MIG,Migration,I,Phase I,,2015-001877-42,,000910,IS - Clin Study (MIGRATED)
12725,1289-0033,1289.33,Unconfirmed,768,1289-P01,Cognitive remediation in early AD,Unconfirmed,PRELIM,Preliminary,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
12726,1289-0034,1289.34,Unconfirmed,768,1289-P01,DDI with sensitive OAT substrate,Unconfirmed,PRELIM,Preliminary,I,Phase I,placeholder: EMA req. pre clin threshold ,,,000910,IS - Clin Study (MIGRATED)
12727,1289-0035,1289.35,Ended,768,1289-P01,DDI with CYP 1A inhibitor,Ended,MIG,Migration,I,Phase I,,2016-000752-10,17-FEB-16,000910,IS - Clin Study (MIGRATED)
12728,1289-0036,1289.36,Unconfirmed,768,1289-P01,Mild to moderate AD dose-finding Japan,Unconfirmed,PRELIM,Preliminary,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12729,1289-0038,1289.38,Preparing,768,1289-P01,Thorough QT Study,Preparing,PRELIM,Preliminary,I,Phase I,,2016-000753-12,,000910,IS - Clin Study (MIGRATED)
12730,1289-0040,1289.40,Preparing,768,1289-P01,DDI; Mod CYP1A2 inhib (CYP2C19 PMs),Preparing,FULL,Full functionality,I,Phase I,,,,000030,IS - Clin Study - Clin Pharm - DDI
12731,1289-0041,1289.41,Unconfirmed,768,1289-P01,Renal Impairment,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12732,1289-0042,1289.42,Unconfirmed,768,1289-P01,Hepatic Impairment,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12733,1289-0043,1289.43,Unconfirmed,768,1289-P01,DDI; alpha blocker(perp, safety),Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12734,1289-0044,1289.44,Analysis,768,1289-P01,DDI with Rifampicin (victim),Analysis,PIHPZ,Phase I HPZ,I,Phase I,,2016-004828-37 ,29-NOV-16,000030,IS - Clin Study - Clin Pharm - DDI
12735,1289-0045,1289.45,Unconfirmed,768,1289-P01,DDI with Risperidone (perpetrator),Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12736,1289-0046,1289.46,Unconfirmed,768,1289-P01,Driving Simulation,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12737,1289-0047,1289.47,Unconfirmed,768,1289-P01,Additional DDI study,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12738,1289-0048,1289.48,Unconfirmed,768,1289-P01,MRD mainland China,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12739,1248-0001,1248.1,Preparing,769,1248-P01,BI 54903 dose finding GINA 3/4 (1256.4),Preparing,MIG,Migration,II,Phase II,double dummy design ,,,000910,IS - Clin Study (MIGRATED)
12740,1248-0002,1248.2,Initiated,769,1248-P01,Posology, LD range, sympt. on SABA only,Initiated,MIG,Migration,IIB,Phase IIb,Comparator deleted acc. CEG 11-Mar-10 ,2010-023165-22,,000910,IS - Clin Study (MIGRATED)
12741,1248-0003,1248.3,Initiated,769,1248-P01,Posology, MD range, sympt. on LD ICS,Initiated,MIG,Migration,IIB,Phase IIb,Trial 1248.3 should be performed at the same sites!!! CTRF adapted according CEG recommendations of 11-May-10,2010-023166-51,,000910,IS - Clin Study (MIGRATED)
12742,1248-0004,1248.4,Initiated,769,1248-P01,Posology, HD range, sympt. on MD ICS,Initiated,MIG,Migration,IIB,Phase IIb,Trial 1248.4 should be performed at ,2011-002638-38,,000910,IS - Clin Study (MIGRATED)
12743,1248-0005,1248.5,Ended,769,1248-P01,dose finding, LD range, symptomatic SABA,Ended,MIG,Migration,IIB,Phase IIb,Trials 1248.5/.6/.7 should be performed at the same sites,2010-023167-17,,000910,IS - Clin Study (MIGRATED)
12744,1248-0006,1248.6,Ended,769,1248-P01,dose finding, MD range, sympt. on LD ICS,Ended,MIG,Migration,IIB,Phase IIb,Trials 1248.5/.6/.7 should be performed at the same sites, CTRF adapted according CEG recommendations 11-May-10,2010-023168-41,,000910,IS - Clin Study (MIGRATED)
12745,1248-0007,1248.7,Ended,769,1248-P01,dose finding, HD range, sympt. on MD ICS,Ended,MIG,Migration,IIB,Phase IIb,Trials 1248.5/.6/.7 should be performed at the same sites; CTP adapted according CEG recommendations 11-Mar-10,2010-023169-23,,000910,IS - Clin Study (MIGRATED)
12746,1200-0094,1200.94,Preparing,770,1200-P06,Afatinib / cetuximab in refractory NSCLC,Preparing,MIG,Migration,III,Phase III,,,,,
12747,1200-0111,1200.111,Last Subject Randomised,770,1200-P06,TIMELY,Last Subject Randomised,MIG,Migration,II,Phase II,,2011-003608-19,,000150,IS - Clin Study - Explore
12748,1200-0112,1200.112,Ended,770,1200-P06,T790M mutations in CTC + BIBW treatment,Ended,MIG,Migration,IIB,Phase IIb,study conducted in USA ,,,000150,IS - Clin Study - Explore
12749,1200-0113,1200.113,Ended,770,1200-P06,BIBW 2992 +/- simvastatin in NSCLC,Ended,MIG,Migration,II,Phase II,,,,,
12750,1200-0118,1200.118,Ended,770,1200-P06,CTC in NSCLC with EGFR T790M Mutation,Ended,MIG,Migration,IA,Phase Ia,IIS substudy 1200.32 ,,,,
12751,1200-0124,1200.124,Recruiting,770,1200-P06,randomized +cetuximab vs afa alone,Recruiting,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
12752,1200-0136,1200.136,Analysis,770,1200-P06,Window of Opportunity neoadjuvant NSCLC,Analysis,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
12753,1200-0139,1200.139,Last Subject Randomised,770,1200-P06,2nd line NSCLC Pemetrexed+/-Afatinib-RK,Last Subject Randomised,MIG,Migration,IIB,Phase IIb,,,,000100,IS - Clin Study - Clin Pharm - Other
12754,1200-0140,1200.140,Initiated,770,1200-P06,Neoadjuvant Stage I/II NSCLC - CA,Initiated,MIG,Migration,II,Phase II,,,,,
12755,1200-0143,1200.143,Last Subject Randomised,770,1200-P06,2nd line all-comers NSCLC - MX,Last Subject Randomised,MIG,Migration,IIIB,Phase IIIb,,,,000100,IS - Clin Study - Clin Pharm - Other
12756,1200-0155,1200.155,Preparing,770,1200-P06,Safety, toleability and MTD - DE,Preparing,MIG,Migration,I,Phase I,,,,,
12757,1200-0157,1200.157,Recruiting,770,1200-P06,PET biodistribution study of afatinib,Recruiting,MIG,Migration,I,Phase I,,2012-002849-38,,000160,IS - Clin Study - Explore- Subpopulation
12758,1200-0158,1200.158,Last Subject Randomised,770,1200-P06,stage III treatment EGFRmutation - US,Last Subject Randomised,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
12759,1200-0164,1200.164,Ended,770,1200-P06,open label window of opportunity - UK,Ended,MIG,Migration,II,Phase II,,2012-004537-16,,000150,IS - Clin Study - Explore
12760,1200-0166,1200.166,Recruiting,770,1200-P06,Dasatinib combi wt irrevers EGFR - US,Recruiting,MIG,Migration,I,Phase I,,,,000150,IS - Clin Study - Explore
12761,1200-0167,1200.167,Ended,770,1200-P06,ADAM-Afatinib Diarrhea Management-US,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
12762,1200-0172,1200.172,Unconfirmed,770,1200-P06,NSCLC registry,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
12763,1200-0173,1200.173,Preparing,770,1200-P06,Uptake radiolabeled afatinib NSCLC - NL,Preparing,MIG,Migration,NONE,Not Classified,,,,,
12764,1200-0175,1200.175,Ended,770,1200-P06,mNSCLC Patient Diary Study March 2012-UK,Ended,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
12765,1200-0176,1200.176,Ended,770,1200-P06,Effect afatinib immuneresponse NSCLC AUS,Ended,MIG,Migration,IV,Phase IV,,,,,
12766,1200-0181,1200.181,Analysis,770,1200-P06,Long-term observation PMS for afatinib,Analysis,MIG,Migration,IV,Phase IV,,,,,
12767,1200-0183,1200.183,Preparing,770,1200-P06,PhI afatinib+temsirolimus NSCLC - USA,Preparing,MIG,Migration,I,Phase I,,,,,
12768,1200-0185,1200.185,Initiated,770,1200-P06,Afatinib + CRT in EGFR-mutant NSCLC,Initiated,MIG,Migration,I,Phase I,see extended remarks There is a specific IND for this trial being conducted under a request for proposal grant to the NCCN from BI.  For the purpose of reporting safety infromation that would normally go to BI Trials and IIS trials defined by BI SAPs, this trial is classified as an IIS trial,,,,
12769,1200-0186,1200.186,First Subject Randomised,770,1200-P06,Adjuvant afatinib for EGFR NSCLC,First Subject Randomised,MIG,Migration,II,Phase II,see extended remarks There is a specific IND for this trial being conducted under a request for proposal grant to the NCCN from BI.  For the purpose of reporting safety infromation that would normally go to BI Trials and IIS trials defined by BI SAPs, this trial is classified as an IIS trial,,,000150,IS - Clin Study - Explore
12770,1200-0187,1200.187,Preparing,770,1200-P06,Lung Cancer Genomic Evolution,Preparing,MIG,Migration,II,Phase II,,,,,
12771,1200-0189,1200.189,Ended,770,1200-P06,phIb afatinib+nimotuzumab NSCLC - Korea,Ended,MIG,Migration,IB,Phase Ib,,,,,
12772,1200-0190,1200.190,Preparing,770,1200-P06,phI afatinib+cisplatin/radiation NSCLC,Preparing,MIG,Migration,I,Phase I,,,,,
12773,1200-0191,1200.191,Unconfirmed,770,1200-P06,Health conditions in advanced NSCLC,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
12774,1200-0197,1200.197,Preparing,770,1200-P06,+fulvestrant pts restistant EGFR TKIs-US,Preparing,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
12775,1200-0201,1200.201,Preparing,770,1200-P06,phII afatinib neoadjuv EGFR mut NSCLC,Preparing,MIG,Migration,II,Phase II,,,,,
12776,1200-0208,1200.208,Analysis,770,1200-P06,Tolerability/Efficacy in Poor PS NSCLC,Analysis,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
12777,1200-0209,1200.209,First Subject Randomised,770,1200-P06,Afatinib in elderly EGFR M+ NSCLC,First Subject Randomised,MIG,Migration,IV,Phase IV,NPCC requested changes frm Nov 17 draft ,,,000940,Post Marketing Study (MIGRATED)
12778,1200-0210,1200.210,Preparing,770,1200-P06,Prophyl.diarrhea treatment w loperamide,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
12779,1200-0211,1200.211,Preparing,770,1200-P06,MTD + activity afa w c-MET inhibitor,Preparing,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12780,1200-0212,1200.212,Preparing,770,1200-P06,HER2 pos BC and EGFR pos lung canc - US,Preparing,MIG,Migration,I,Phase I,,,,,
12781,1200-0214,1200.214,First Subject Randomised,770,1200-P06,+Cetuximab for EGFR-Mutant NSCLC - FF,First Subject Randomised,MIG,Migration,II,Phase II,,2015-003390-15,,000150,IS - Clin Study - Explore
12782,1200-0219,1200.219,Recruiting,770,1200-P06,MARBLE,Recruiting,MIG,Migration,II,Phase II,,2014-001983-36,,000910,IS - Clin Study (MIGRATED)
12783,1200-0221,1200.221,Preparing,770,1200-P06,PhII Pem+Afa EGFR Mut positive NSCLC,Preparing,MIG,Migration,II,Phase II,,,,,
12784,1200-0224,1200.224,Initiated,770,1200-P06,DARWIN phII afatinib 1st line rec NSCLC,Initiated,MIG,Migration,II,Phase II,,2014-002197-36,,000150,IS - Clin Study - Explore
12785,1200-0230,1200.230,Last Subject Randomised,770,1200-P06,phII afatinib adv NSCLC HER2 exon 20 mut,Last Subject Randomised,MIG,Migration,II,Phase II,ETOP trial ,2014-005098-35,,000150,IS - Clin Study - Explore
12786,1200-0233,1200.233,Ended,770,1200-P06,PhI afa+peme+carbo EGFR mut,Ended,MIG,Migration,I,Phase I,,,,000010,IS - Clin Study - Clin Pharm - SRD
12787,1200-0237,1200.237,First Subject Randomised,770,1200-P06,ph I afatinib+MK3475 EGFR+ NSCLC,First Subject Randomised,MIG,Migration,I,Phase I,,,,000150,IS - Clin Study - Explore
12788,1200-0238,1200.238,Recruiting,770,1200-P06,+selumetinib KRASm+colorectal, NSCLC, PC,Recruiting,MIG,Migration,II,Phase II,,2014-001855-22,,000080,IS - Clin Study - Clin Pharm - Explore
12789,1200-0239,1200.239,Preparing,770,1200-P06,Clinical activity of Afatinib,Preparing,MIG,Migration,II,Phase II,,,,000100,IS - Clin Study - Clin Pharm - Other
12790,1200-0240,1200.240,First Subject Randomised,770,1200-P06,Genomic landscape of EGFR mut NSCLC,First Subject Randomised,MIG,Migration,I,Phase I,,,,000150,IS - Clin Study - Explore
12791,1200-0241,1200.241,Last Subject Randomised,770,1200-P06,Assessment of the cytogenetic response,Last Subject Randomised,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
12792,1200-0246,1200.246,Preparing,770,1200-P06,ph II afa induction stage IIIA pN2 NSCLC,Preparing,IIS,Investigator Initiated Study,II,Phase II,,,,,
12793,1200-0250,1200.250,Analysis,770,1200-P06,potential biomarkers EGFR-TKIs,Analysis,MIG,Migration,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
12794,1200-0251,1200.251,Preparing,770,1200-P06,+ Ganetespib NSCLC EGRF Mutations,Preparing,MIG,Migration,II,Phase II,,,,,
12795,1200-0255,1200.255,First Subject Randomised,770,1200-P06,epidem growth factor receptor mut,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000160,IS - Clin Study - Explore- Subpopulation
12796,1200-0256,1200.256,Preparing,770,1200-P06,Resistance to Afa via plasma DNA,Preparing,MIG,Migration,IV,Phase IV,,,,000470,NISed ‚Äì Study - Cross Sectional
12797,1200-0257,1200.257,Preparing,770,1200-P06,pilot study 18F-afa wt 188Rhenium-HEDP,Preparing,MIG,Migration,NONE,Not Classified,,,,,
12798,1200-0259,1200.259,Last Subject Randomised,770,1200-P06,+ bevacizumab after acquired resistance,Last Subject Randomised,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
12799,1200-0260,1200.260,Preparing,770,1200-P06,+ beva first-line therapy adv EGFR mut,Preparing,MIG,Migration,IIB,Phase IIb,,,,,
12800,1200-0263,1200.263,Recruiting,770,1200-P06,CRISP Registry,Recruiting,MIG,Migration,NONE,Not Classified,,,,000410,NISnd ‚Äì Study - Other
12801,1200-0264,1200.264,Preparing,770,1200-P06,Precision 2 explorative open label,Preparing,MIG,Migration,II,Phase II,,,,000100,IS - Clin Study - Clin Pharm - Other
12802,1200-0270,1200.270,First Subject Randomised,770,1200-P06,Real World Data on dose adjustment,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000450,NISed ‚Äì Study - Other
12803,1200-0271,1200.271,First Subject Randomised,770,1200-P06,Anti-tumour activity of Afatinib,First Subject Randomised,MIG,Migration,II,Phase II,,,,000100,IS - Clin Study - Clin Pharm - Other
12804,1200-0273,1200.273,Preparing,770,1200-P06,Predictive Value Cf Tumor DNA NSCLC,Preparing,MIG,Migration,NONE,Not Classified,,,,,
12805,1200-0275,1200.275,Preparing,770,1200-P06,CNS mets and LMD NSCLC,Preparing,MIG,Migration,II,Phase II,,,,000930,NISed - Study (MIGRATED)
12806,1200-0278,1200.278,Preparing,770,1200-P06,+bevacizumab NSCLC EGFR mutations,Preparing,IIS,Investigator Initiated Study,II,Phase II,,,,000150,IS - Clin Study - Explore
12807,1200-0279,1200.279,Preparing,770,1200-P06,Advanced SCLC EGFR sensitive mutation,Preparing,IIS,Investigator Initiated Study,II,Phase II,,,,000450,NISed ‚Äì Study - Other
12808,1200-0280,1200.280,Preparing,770,1200-P06,Detection of genomic mutations,Preparing,MIG,Migration,NONE,Not Classified,,,,000470,NISed ‚Äì Study - Cross Sectional
12809,1200-0281,1200.281,Preparing,770,1200-P06,efficacy+safety after failure CS-LUNG-3,Preparing,MIG,Migration,II,Phase II,,,,,
12810,1200-0282,1200.282,Preparing,770,1200-P06,+necitumumab NSCLC (NCCN),Preparing,MIG,Migration,I,Phase I,,,,000150,IS - Clin Study - Explore
12811,1200-0285,1200.285,Preparing,770,1200-P06,Physician¬øs knowledge newer genomic data,Preparing,MIG,Migration,NONE,Not Classified,,,,000410,NISnd ‚Äì Study - Other
12812,1199-0080,1199.80,Unconfirmed,771,1199-P06,BIBF1120 + Pemetrexed/Cisplatin 1st line,Unconfirmed,MIG,Migration,II,Phase II,,,,,
12813,1199-0087,1199.87,Ended,771,1199-P06,BIBF 1120 in endometrial Ca,Ended,MIG,Migration,II,Phase II,,,,,
12814,1199-0094,1199.94,Ended,771,1199-P06,ph II trial of BIBF 1120 in relapsed GBM,Ended,MIG,Migration,II,Phase II,,,,,
12815,1199-0114,1199.114,Analysis,771,1199-P06,NONK 3 ,Analysis,MIG,Migration,II,Phase II,,2011-000921-61,,000080,IS - Clin Study - Clin Pharm - Explore
12816,1199-0115,1199.115,Analysis,771,1199-P06,TRICC-C,Analysis,MIG,Migration,II,Phase II,,2010-023050-37,,000150,IS - Clin Study - Explore
12817,1199-0116,1199.116,Preparing,771,1199-P06,Ph II BIBF Mono in 2nd line OC,Preparing,MIG,Migration,II,Phase II,,,,,
12818,1199-0121,1199.121,Ended,771,1199-P06,Ph I/II BIBF + Doxil in 2nd line OC,Ended,MIG,Migration,II,Phase II,This is an investigator initiated study IND number TBD,,,,
12819,1199-0122,1199.122,Ended,771,1199-P06,Ph II BIBF Mono in 3rd line Glioma,Ended,MIG,Migration,II,Phase II,,2010-021407-24,,,
12820,1199-0123,1199.123,Last Subject Randomised,771,1199-P06,OC 2nd line + cyclo-phosphamide,Last Subject Randomised,MIG,Migration,II,Phase II,,2011-005814-12,,000150,IS - Clin Study - Explore
12821,1199-0124,1199.124,Recruiting,771,1199-P06,AML,Recruiting,MIG,Migration,II,Phase II,,2011-001086-41,,000150,IS - Clin Study - Explore
12822,1199-0125,1199.125,Ended,771,1199-P06,SCLC 2nd line / Korea,Ended,MIG,Migration,IIB,Phase IIb,,,,,
12823,1199-0126,1199.126,Preparing,771,1199-P06,NSCLC 1st line (non-SCC) /  US,Preparing,MIG,Migration,I,Phase I,,,,,
12824,1199-0129,1199.129,Preparing,771,1199-P06,NSCLC 1st line non-squamous,Preparing,MIG,Migration,I,Phase I,,,,,
12825,1199-0136,1199.136,Ended,771,1199-P06,BARIS-BIBF1120 & RAD001 in solid tumors,Ended,MIG,Migration,I,Phase I,,2010-023578-38,,,
12826,1199-0139,1199.139,Analysis,771,1199-P06,VENUS I,Analysis,MIG,Migration,I,Phase I,,2011-003094-28,,000150,IS - Clin Study - Explore
12827,1199-0140,1199.140,Analysis,771,1199-P06,VENUS II,Analysis,MIG,Migration,I,Phase I,,2011-002141-36,,000150,IS - Clin Study - Explore
12828,1199-0141,1199.141,Ended,771,1199-P06,Neoadjuvant BIBF+paclitaxel in BC - ES,Ended,MIG,Migration,II,Phase II,,2011-001649-34,,,
12829,1199-0142,1199.142,Unconfirmed,771,1199-P06,+paclitaxel in BC - SP,Unconfirmed,MIG,Migration,II,Phase II,,,,,
12830,1199-0144,1199.144,First Subject Randomised,771,1199-P06,Ph II BIBF Mono in 2nd line OC,First Subject Randomised,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
12831,1199-0145,1199.145,Ended,771,1199-P06,Adv FGFR3 mutated / FGFR3 wild type / TW,Ended,MIG,Migration,II,Phase II,,,,,
12832,1199-0146,1199.146,Preparing,771,1199-P06,advanced solid tumor malignancies / USA,Preparing,MIG,Migration,I,Phase I,study has been put on indefinite "hold" ,,,,
12833,1199-0151,1199.151,Initiated,771,1199-P06,Recurrent & Platinum-Sensitive SCLC - CA,Initiated,MIG,Migration,II,Phase II,,,,,
12834,1199-0152,1199.152,Recruiting,771,1199-P06,BIBF in recurrent CCC Ovary/Endometrium,Recruiting,MIG,Migration,II,Phase II,,2013-002109-73,,000150,IS - Clin Study - Explore
12835,1199-0153,1199.153,Recruiting,771,1199-P06,in addition to 1st line chemo - FR,Recruiting,MIG,Migration,II,Phase II,,2011-006288-23,,000150,IS - Clin Study - Explore
12836,1199-0154,1199.154,Preparing,771,1199-P06,Combo wt Carboplatin/Paclitaxel - AU,Preparing,MIG,Migration,II,Phase II,,,,,
12837,1199-0155,1199.155,Analysis,771,1199-P06,+/-Docetaxel HER-metastatic BC - FR,Analysis,MIG,Migration,II,Phase II,,2012-002214-38,,000150,IS - Clin Study - Explore
12838,1199-0163,1199.163,Preparing,771,1199-P06,Preop. chemo + BIBF in Her2neg IBC - AU,Preparing,MIG,Migration,I,Phase I,,,,,
12839,1199-0164,1199.164,Recruiting,771,1199-P06,PhII BIBF1120 2nd line thyroid cancer,Recruiting,MIG,Migration,IIA,Phase IIa,,2012-004295-19,,000150,IS - Clin Study - Explore
12840,1199-0165,1199.165,Preparing,771,1199-P06,Ph II BIBF 1120 1st line thyroid cancer,Preparing,MIG,Migration,IIA,Phase IIa,,,,,
12841,1199-0166,1199.166,Ended,771,1199-P06,Ph II BIBF 1120 2nd and 3rd line NSCLC,Ended,MIG,Migration,II,Phase II,,,,,
12842,1199-0167,1199.167,Recruiting,771,1199-P06,PhII neoadjuv BIBF Bladder 1st line - UK,Recruiting,MIG,Migration,II,Phase II,,2012-004895-21,,000150,IS - Clin Study - Explore
12843,1199-0168,1199.168,Recruiting,771,1199-P06,PhII nintedanib+carbo/pacli cervix - BE,Recruiting,MIG,Migration,II,Phase II,,2012-004076-19,,000100,IS - Clin Study - Clin Pharm - Other
12844,1199-0169,1199.169,Preparing,771,1199-P06,PhI nintedanib+capecitabine/radio Rectal,Preparing,MIG,Migration,I,Phase I,,2013-003140-23,,,
12845,1199-0172,1199.172,Preparing,771,1199-P06,phII nintedanib metast HER2neg IBC - USA,Preparing,MIG,Migration,II,Phase II,,,,,
12846,1199-0173,1199.173,Preparing,771,1199-P06,phII nintedanib+cyclophosphamide OC,Preparing,MIG,Migration,II,Phase II,,2011-005814-12,,,
12847,1199-0175,1199.175,Recruiting,771,1199-P06,NIPAWILMA,Recruiting,MIG,Migration,II,Phase II,,2013-004458-34,,000150,IS - Clin Study - Explore
12848,1199-0176,1199.176,Recruiting,771,1199-P06,malignant pleural mesothelioma-US,Recruiting,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
12849,1199-0178,1199.178,Preparing,771,1199-P06,PhII nintedanib adv+recurr cervical canc,Preparing,MIG,Migration,II,Phase II,,,,,
12850,1199-0179,1199.179,First Subject Randomised,771,1199-P06,PhI +cisplat/docetax stage IB-IIIA NSCLC,First Subject Randomised,MIG,Migration,I,Phase I,,,,000150,IS - Clin Study - Explore
12851,1199-0180,1199.180,Preparing,771,1199-P06,PhII +cisplat/docetax stageIB-IIIA NSCLC,Preparing,IIS,Investigator Initiated Study,II,Phase II,,,,000150,IS - Clin Study - Explore
12852,1199-0182,1199.182,Preparing,771,1199-P06,phII safety/efficacy nintedanib DTC/MTC,Preparing,MIG,Migration,IIA,Phase IIa,,,,,
12853,1199-0183,1199.183,Recruiting,771,1199-P06,phII nintedanib FGFR1-gene ampl NSCLC,Recruiting,MIG,Migration,II,Phase II,,2013-004324-11,,000160,IS - Clin Study - Explore- Subpopulation
12854,1199-0186,1199.186,Preparing,771,1199-P06,randomized study of EORTC Group - UK,Preparing,IIS,Investigator Initiated Study,II,Phase II,,,,000150,IS - Clin Study - Explore
12855,1199-0194,1199.194,Recruiting,771,1199-P06,radiation pneumonitis - USA,Recruiting,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
12856,1199-0195,1199.195,Last Subject Randomised,771,1199-P06,phII nintedanib adv refrac/rec EG ca,Last Subject Randomised,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
12857,1199-0196,1199.196,Ended,771,1199-P06,phII nintedanib rec/met sal gland HNSCC,Ended,MIG,Migration,II,Phase II,,,,,
12858,1199-0201,1199.201,First Subject Randomised,771,1199-P06,ENGOT-EN1-A,First Subject Randomised,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
12859,1199-0203,1199.203,First Subject Randomised,771,1199-P06,Nintedanib+docetaxel angiogen biomarker,First Subject Randomised,MIG,Migration,II,Phase II,,2014-003891-22,,000150,IS - Clin Study - Explore
12860,1199-0206,1199.206,First Subject Randomised,771,1199-P06,Nin+letrozole post-menopausal BC,First Subject Randomised,MIG,Migration,IA,Phase Ia,,2014-005227-27,,000150,IS - Clin Study - Explore
12861,1199-0208,1199.208,Recruiting,771,1199-P06,ph II nintedanib met HER2neg IBC,Recruiting,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
12862,1199-0213,1199.213,Recruiting,771,1199-P06,2nd line nintedanib NSCLC - SENECA,Recruiting,MIG,Migration,IIB,Phase IIb,,,,,
12863,1199-0217,1199.217,Recruiting,771,1199-P06,BIBF1120 vs PBO prophyl XRT pneumonitis,Recruiting,MIG,Migration,II,Phase II,see extended remarks There is a specific IND for this trial being conducted under a request for proposal grant to the NCCN from BI.  For the purpose of reporting safety infromation that would normally go to BI Trials and IIS trials (as defined by BI SOPs), this trial is classified as an IIS trial,,,000150,IS - Clin Study - Explore
12864,1199-0218,1199.218,Recruiting,771,1199-P06,PhI/II  BIBF 1120 + capecitabine in CRC,Recruiting,MIG,Migration,II,Phase II,see extended remarks There is a specific IND for this trial being conducted under a request for proposal grant to the NCCN from BI.  For the purpose of reporting safety information that would normally go to BI Trials and IIS trials (as defined by BI SOPs), this trial is classified as an IIS trial.,,,000150,IS - Clin Study - Explore
12865,1199-0219,1199.219,Recruiting,771,1199-P06,BIBF1120 in selected patients with NSCLC,Recruiting,MIG,Migration,I,Phase I,see extended remarks There is no IND for this trial being conducted under a request for proposal grant to the NCCN from BI.  An IND exemption was granted by the FDA.  For the purpose of reporting safety information that would normally go to BI Trials and IIS trials (as defined by BI SOPs), this trial is classified as an IIS trial.,,,000150,IS - Clin Study - Explore
12866,1199-0220,1199.220,Recruiting,771,1199-P06,BIBF1120 in Carcinoid tumors,Recruiting,MIG,Migration,II,Phase II,see extended remarkds There is a specific IND for this trial being conducted under a request for proposal grant to the NCCN from BI.  For the purpose of reporting safety information that would normally go to BI Trials and IIS trials (as defined by BI SOPs), this trial is classified as an IIS trial.,,,000150,IS - Clin Study - Explore
12867,1199-0221,1199.221,Preparing,771,1199-P06,Ph II nin+pemetrexed urothelial cancer,Preparing,MIG,Migration,II,Phase II,,,,,
12868,1199-0228,1199.228,Preparing,771,1199-P06,nin+paclitaxel esophageal and gastric,Preparing,MIG,Migration,II,Phase II,,,,,
12869,1199-0230,1199.230,Preparing,771,1199-P06,BILIVE,Preparing,MIG,Migration,III,Phase III,,,,,
12870,1199-0231,1199.231,Last Subject Randomised,771,1199-P06,CRC pat intolerant standard therapy,Last Subject Randomised,MIG,Migration,II,Phase II,,,,000131,IS - Clin Study - POCC
12871,1199-0232,1199.232,Preparing,771,1199-P06,Pancreatic ca+gemictabine-nab paclitaxel,Preparing,IIS,Investigator Initiated Study,I,Phase I,,,,000150,IS - Clin Study - Explore
12872,1199-0233,1199.233,Recruiting,771,1199-P06,REFRACT,Recruiting,MIG,Migration,II,Phase II,,2015-000475-27,,000150,IS - Clin Study - Explore
12873,1199-0236,1199.236,Preparing,771,1199-P06,anti-tumor efficacy A549 and Calu-6,Preparing,MIG,Migration,NONE,Not Classified,,,,,
12874,1199-0241,1199.241,First Subject Randomised,771,1199-P06,cytarabine+idarubicin myeloid leukemia,First Subject Randomised,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
12875,1199-0242,1199.242,Initiated,771,1199-P06,Soft tissue for inoperable disease,Initiated,MIG,Migration,II,Phase II,,,,000100,IS - Clin Study - Clin Pharm - Other
12876,1199-0244,1199.244,Preparing,771,1199-P06,EORTC,Preparing,IIS,Investigator Initiated Study,II,Phase II,,,,,
12877,1199-0246,1199.246,Preparing,771,1199-P06,Analysis matched tumor and biopsis,Preparing,MIG,Migration,NONE,Not Classified,,,,,
12878,1199-0257,1199.257,Preparing,771,1199-P06,after 1st line chemo,Preparing,MIG,Migration,II,Phase II,,,,,
12879,1199-0258,1199.258,Last Subject Randomised,771,1199-P06,+ bevacizumab dose escalation open label,Last Subject Randomised,MIG,Migration,I,Phase I,,,,000150,IS - Clin Study - Explore
12880,1199-0259,1199.259,Preparing,771,1199-P06,+ irinotecan 2nd line dose escalation,Preparing,MIG,Migration,IB,Phase Ib,,,,,
12881,1199-0260,1199.260,First Subject Randomised,771,1199-P06,PEMBIB,First Subject Randomised,MIG,Migration,IB,Phase Ib,,2015-004511-21,,000080,IS - Clin Study - Clin Pharm - Explore
12882,1199-0263,1199.263,Initiated,771,1199-P06,metastatic appendi carcinom - drug only,Initiated,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
12883,1199-0271,1199.271,Preparing,771,1199-P06,Nintedanib + Pembro gastric ca,Preparing,MIG,Migration,II,Phase II,,,,,
12884,1199-0273,1199.273,Preparing,771,1199-P06,Nintedanib+MEDI4736+tremelimumab,Preparing,IIS,Investigator Initiated Study,I,Phase I,,,,,
12885,1199-0274,1199.274,Preparing,771,1199-P06,N3 NSCLC,Preparing,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
12886,1199-0279,1199.279,Preparing,771,1199-P06,NintNivo (Reck),Preparing,IIS,Investigator Initiated Study,I,Phase I,Nintedanib+Nivolumab NSCLC w/o EGFR/ALK ,,,000150,IS - Clin Study - Explore
12887,1199-0285,1199.285,Preparing,771,1199-P06,biomarker driven SCC Head and Neck,Preparing,IIS,Investigator Initiated Study,II,Phase II,,,,000100,IS - Clin Study - Clin Pharm - Other
12888,1199-0291,1199.291,Preparing,771,1199-P06,PMS of Ofev¬Æ Capsules in pts with CRC,Preparing,MIG,Migration,NONE,Not Classified,,,,000920,NISnd - Study (MIGRATED)
12889,1199-0292,1199.292,Preparing,771,1199-P06,+5-azacitidine by HOX overexpression,Preparing,IIS,Investigator Initiated Study,IB,Phase Ib,,,,000150,IS - Clin Study - Explore
12890,1290-0001,1290.1,Preparing,772,1290-P01,SRD FIM study,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12891,1290-0002,1290.2,Unconfirmed,772,1290-P01,MRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12892,1290-0003,1290.3,Preparing,772,1290-P01,Tablet bridging study,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12893,1290-0004,1290.4,Unconfirmed,772,1290-P01,pan-Asian SRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12894,1290-0005,1290.5,Unconfirmed,772,1290-P01,PoC in IBS,Unconfirmed,MIG,Migration,II,Phase II,IND opening study ,,,000910,IS - Clin Study (MIGRATED)
12895,1290-0006,1290.6,Unconfirmed,772,1290-P01,DF study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12896,1290-0007,1290.7,Unconfirmed,772,1290-P01,DDI with midazolam,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12897,1290-0008,1290.8,Unconfirmed,772,1290-P01,hADME,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12898,1290-0009,1290.9,Unconfirmed,772,1290-P01,i.v. tolerance and absolute BA,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12899,1290-0010,1290.10,Unconfirmed,772,1290-P01,IVIVC,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12900,1290-0011,1290.11,Unconfirmed,772,1290-P01,pan-Asian MRD study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12901,1290-0012,1290.12,Unconfirmed,772,1290-P01,Pivotal study 1,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12902,1290-0013,1290.13,Unconfirmed,772,1290-P01,DDI with ketoconazole,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12903,1290-0014,1290.14,Unconfirmed,772,1290-P01,Pivotal study 2,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12904,1290-0015,1290.15,Unconfirmed,772,1290-P01,Pivotal study in men,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12905,1290-0016,1290.16,Unconfirmed,772,1290-P01,Phase III for EU submission,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12906,1290-0017,1290.17,Unconfirmed,772,1290-P01,Extension safety trial,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12907,1290-0018,1290.18,Unconfirmed,772,1290-P01,DDI with a Pgp substrate,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12908,1291-0001,1291.1,Ended,773,1291-P01,SRD in healthy volunteers,Ended,MIG,Migration,IA,Phase Ia,,2011-006184-22,,000910,IS - Clin Study (MIGRATED)
12909,1291-0002,1291.2,Unconfirmed,773,1291-P01,MRD in patients with T2DM,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12910,1291-0003,1291.3,Unconfirmed,773,1291-P01,Food Effect,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12911,1291-0004,1291.4,Unconfirmed,773,1291-P01,6 week safety and efficacy in patients,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12912,1291-0005,1291.5,Unconfirmed,773,1291-P01,SRD in Asian subjects,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12913,1291-0006,1291.6,Unconfirmed,773,1291-P01,MRD in heatly Chinese Volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12914,1291-0007,1291.7,Unconfirmed,773,1291-P01,DDI with Metformin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12915,1291-0008,1291.8,Unconfirmed,773,1291-P01,Human ADME,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12916,1291-0009,1291.9,Unconfirmed,773,1291-P01,Dose Finder vs placebo as monotherapy,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12917,1291-0010,1291.10,Unconfirmed,773,1291-P01,Dose finder vs placebo added to Metf.,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12918,1291-0011,1291.11,Unconfirmed,773,1291-P01,Phase I placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12919,1291-0012,1291.12,Unconfirmed,773,1291-P01,Phase I placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12920,1291-0013,1291.13,Unconfirmed,773,1291-P01,6 week safety and efficacy in Japan,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12921,1024-0007,1024.7,Ended,774,1024-P04,rel. bioavailability vs. Rhinadvil,Ended,MIG,Migration,I,Phase I,,2010-019052-45,,000910,IS - Clin Study (MIGRATED)
12922,1024-0009,1024.9,Analysis,774,1024-P04,Bioequivalence Study,Analysis,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12923,1293-0001,1293.1,Ended,777,1293-P01,Single rising dose,Ended,MIG,Migration,I,Phase I,,2011-002251-34,,000910,IS - Clin Study (MIGRATED)
12924,1293-0002,1293.2,Ended,777,1293-P01,MRD in HV+POC in RA patients,Ended,MIG,Migration,IB,Phase Ib,,2012-004090-16,,000910,IS - Clin Study (MIGRATED)
12925,1293-0003,1293.3,Preparing,777,1293-P01,Dose finding in MTX-failures,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12926,1293-0004,1293.4,Preparing,777,1293-P01,Dose finding study in anti-TNF failures,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12927,1293-0005,1293.5,Unconfirmed,777,1293-P01,MTX failures pivotal sup. to anti-TNF,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12928,1293-0006,1293.6,Unconfirmed,777,1293-P01,TNF-failures pivotal sup. to Orencia,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12929,1293-0007,1293.7,Ended,777,1293-P01,POM in ITP,Ended,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12930,1293-0008,1293.8,Ended,777,1293-P01,PanAsian SRD,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12931,1293-0009,1293.9,Ended,777,1293-P01,Chinese MRD,Ended,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
12932,1293-0012,1293.12,Unconfirmed,777,1293-P01,Roll-over in phase II,Unconfirmed,MIG,Migration,II,Phase II,responders from 1293.3, all from 1293.4 open label extension with BI 65504,,,000910,IS - Clin Study (MIGRATED)
12933,1218-0056,1218.56,Ended,778,1218-P03,Effic. PK + safety in paed. patients,Ended,MIG,Migration,IIB,Phase IIb,,2009-017004-91,,000910,IS - Clin Study (MIGRATED)
12934,1218-0091,1218.91,Preparing,778,1218-P03,52 wks Eff. & Saf. Ph III in Paediatrics,Preparing,FULL,Full functionality,III,Phase III,,2016-000669-21,,000180,IS - Clin Study - Confirmatory - Subpop
12935,1218-0092,1218.92,Unconfirmed,778,1218-P03,Effic & Safety 52 wks in Paediatrics,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
12936,1218-0141,1218.141,Preparing,778,1218-P03,Epidemiology study in pediatric T2DM,Preparing,MIG,Migration,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
12937,1294-0001,1294.1,Ended,779,1294-P01,SRD i.v. and s.c. in healthy volunteers,Ended,MIG,Migration,IA,Phase Ia,,2011-004987-30,,000910,IS - Clin Study (MIGRATED)
12938,1294-0002,1294.2,Preparing,779,1294-P01,MRD in mild COPD,Preparing,MIG,Migration,IB,Phase Ib,,2013-001307-37,,000910,IS - Clin Study (MIGRATED)
12939,1294-0004,1294.4,Unconfirmed,779,1294-P01, Clinical PoP in mod to sev COPD 24 week,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
12940,1294-0005,1294.5,Preparing,779,1294-P01,Mechanistic PoP,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12941,1294-0007,1294.7,Preparing,779,1294-P01,Japanese SRD sc in HV,Preparing,MIG,Migration,IA,Phase Ia,FPI was postponed to 2015 ,,,000910,IS - Clin Study (MIGRATED)
12942,1294-0008,1294.8,Unconfirmed,779,1294-P01,Handling of self-injection in COPD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12943,1294-0010,1294.10,Unconfirmed,779,1294-P01,Placeholder,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12944,1294-0013,1294.13,Unconfirmed,779,1294-P01,Pivotal 52 week COPD,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
12945,1294-0014,1294.14,Unconfirmed,779,1294-P01,Pivotal 52 week COPD,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
12946,1294-0018,1294.18,Unconfirmed,779,1294-P01,Disease modification COPD,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
12947,1294-0020,1294.20,Unconfirmed,779,1294-P01,MRD Japan,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12948,1294-0021,1294.21,Ended,779,1294-P01,Biomarker Study,Ended,MIG,Migration,NONE,Not Classified,Further indication: COPD, healthy subjec ,2012-003475-19,,000300,IS - Methodological Studies
12949,1294-0022,1294.22,Unconfirmed,779,1294-P01,Pan Asian SRD iv/sc in HV (excl. Japan),Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12950,1295-0001,1295.1,Unconfirmed,780,1295-P01,SRD study in healthy volunteers,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12951,1296-0001,1296.1,Ended,781,1296-P01,Single Rising Dose, First in Human,Ended,MIG,Migration,I,Phase I,,2010-022465-96,,000910,IS - Clin Study (MIGRATED)
12952,1296-0002,1296.2,Preparing,781,1296-P01,Multiple rising Dose,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12953,1296-0003,1296.3,Preparing,781,1296-P01,SIngle Rising Dose in Asia,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12954,1296-0004,1296.4,Unconfirmed,781,1296-P01,Pediatric patients with neuropathic pain,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12955,1296-0005,1296.5,Unconfirmed,781,1296-P01,Pediatric PK,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12956,1296-0006,1296.6,Unconfirmed,781,1296-P01,Pediatric Study #2,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12957,1296-0007,1296.7,Unconfirmed,781,1296-P01,Flex Dose in DNP,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12958,1296-0008,1296.8,Unconfirmed,781,1296-P01,Fixed Dose in DNP,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12959,1296-0009,1296.9,Unconfirmed,781,1296-P01,Proof of concept in LSR,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
12960,1296-0010,1296.10,Unconfirmed,781,1296-P01,Pivotal trial in DNP, fixed dose,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12961,1296-0011,1296.11,Unconfirmed,781,1296-P01,Pivotal trial in DNP, Flex dose,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12962,1296-0012,1296.12,Unconfirmed,781,1296-P01,Pivotal trial in DNP, fixed OR flex, TBD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12963,1296-0013,1296.13,Unconfirmed,781,1296-P01,Pivotal trial in PHN, fixed dose,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12964,1296-0014,1296.14,Unconfirmed,781,1296-P01,Pivotal trial in PHN, flex dose,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12965,1296-0015,1296.15,Unconfirmed,781,1296-P01,Pivotal trial in PHN, fixed OR flex, TBD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12966,1296-0016,1296.16,Unconfirmed,781,1296-P01,Pivotal trial in LSR, fixed dose,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12967,1296-0017,1296.17,Unconfirmed,781,1296-P01,Pivotal trial in LSR, flex dose,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12968,1296-0018,1296.18,Unconfirmed,781,1296-P01,Pivotal trial in LSR, fixed OR flex, TBD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12969,1296-0019,1296.19,Unconfirmed,781,1296-P01,Pivotal trial in SCI,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12970,1296-0020,1296.20,Unconfirmed,781,1296-P01,Open-label extension trial in DNP,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12971,1296-0021,1296.21,Unconfirmed,781,1296-P01,Open-label extension trial in PHN,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12972,1296-0022,1296.22,Unconfirmed,781,1296-P01,Open-label extension trial in LSR,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12973,1296-0023,1296.23,Unconfirmed,781,1296-P01,Multiple rising dose in Chinese subjects,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12974,1296-0024,1296.24,Preparing,781,1296-P01,DDI Study of CYP3A4 Induction Potential,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12975,1296-0025,1296.25,Unconfirmed,781,1296-P01,Laser sensory evoked pain model,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12976,1296-0026,1296.26,Unconfirmed,781,1296-P01,PK MRD in DNP Patients,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12977,1296-0027,1296.27,Unconfirmed,781,1296-P01,CYP3A4 Ketoconazole DDI,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12978,1296-0028,1296.28,Unconfirmed,781,1296-P01,CNS Imaging Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12979,1297-0001,1297.1,Ended,782,1297-P01,Single dose in healthy volunteers,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
12980,1297-0002,1297.2,Ended,782,1297-P01,Multiple dose in RA,Ended,MIG,Migration,III,Phase III,,2012-002945-40,,000910,IS - Clin Study (MIGRATED)
12981,1297-0003,1297.3,First Subject Randomised,782,1297-P01,Rollover study in RA,First Subject Randomised,MIG,Migration,IIIB,Phase IIIb,Fully outsourced to CRO exept US IND-sub ,2015-002634-41,,000910,IS - Clin Study (MIGRATED)
12982,1297-0004,1297.4,Recruiting,782,1297-P01,Crohn's Disease Ph III study,Recruiting,FULL,Full functionality,III,Phase III,,2016-000612-14,,000910,IS - Clin Study (MIGRATED)
12983,1297-0005,1297.5,Preparing,782,1297-P01,Rollover study in Crohn's,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12984,1297-0006,1297.6,Ended,782,1297-P01,Bioequivalence PFS to autoinjector,Ended,MIG,Migration,I,Phase I,,2015-003029-32,,000910,IS - Clin Study (MIGRATED)
12985,1297-0007,1297.7,Unconfirmed,782,1297-P01,Comparative dose response in Psoriasis,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12986,1297-0008,1297.8,Ended,782,1297-P01,Single dose in HV BE formulation comp.,Ended,MIG,Migration,I,Phase I,,2013-003722-84,,000910,IS - Clin Study (MIGRATED)
12987,1297-0009,1297.9,Preparing,782,1297-P01,Comparative study in Psoriasis,Preparing,OUT,Fully Outsourced,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
12988,1297-0010,1297.10,Unconfirmed,782,1297-P01,BI 695501 real life data with PFS,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
12989,1297-0011,1297.11,Analysis,782,1297-P01,BI 695501 self administ. auto-injector,Analysis,MIG,Migration,II,Phase II,,2015-003030-27,,000910,IS - Clin Study (MIGRATED)
12990,1297-0012,1297.12,Recruiting,782,1297-P01,BI 695501 in Plaque Psoriasis Efficacy,Recruiting,MIG,Migration,III,Phase III,,2016-000613-79,,000910,IS - Clin Study (MIGRATED)
12991,1297-0013,1297.13,Ended,782,1297-P01,AI vs PFS pharmacokinetic Study,Ended,MIG,Migration,I,Phase I,,2016-003158-34,,000910,IS - Clin Study (MIGRATED)
12992,1160-0113,1160.113,Ended,783,1160-P07,Dabigatran in pts.with mech.heart valves,Ended,MIG,Migration,II,Phase II,,2010-022685-27,,000910,IS - Clin Study (MIGRATED)
12993,1160-0138,1160.138,Ended,783,1160-P07,Long term observ.in pts w. heart valves,Ended,MIG,Migration,II,Phase II,follow on study to 1160.113 ,2011-002285-21,,000910,IS - Clin Study (MIGRATED)
12994,1160-0140,1160.140,Unconfirmed,783,1160-P07,Thromboemb.event prevention heart valve,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12995,1160-0141,1160.141,Ended,783,1160-P07,Drug-drug interaction with ticagrelor,Ended,MIG,Migration,I,Phase I,,2012-000874-42,,,
12996,1160-0142,1160.142,Ended,783,1160-P07,Steady state interaction with ticagrelor,Ended,MIG,Migration,I,Phase I,,2012-002656-16,,,
12997,1160-0182,1160.182,Unconfirmed,783,1160-P07,Dabigatran in congestive heart failure,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
12998,1298-0001,1298.1,Preparing,784,1298-P01,FDC TIC vs free combo, monos, safety+PK,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
12999,1298-0002,1298.2,Ended,784,1298-P01,FDC TIC vs free combo of monos safety+PK,Ended,MIG,Migration,I,Phase I,,2010-023780-18,,000910,IS - Clin Study (MIGRATED)
13000,1298-0003,1298.3,Preparing,784,1298-P01,Tio bridging (EIS/AIS),Preparing,MIG,Migration,II,Phase II,ethanolic inhalation spray (EIS) aqueous inhalation spray (AIS),2011-001801-29,,000910,IS - Clin Study (MIGRATED)
13001,0018-0504,18.504,Ended,785,0018-P07,Dose Finding Trial,Ended,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13002,0018-0505,18.505,Preparing,785,0018-P07,Efficacy and Safety trial (Phase III),Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13003,0018-0506,18.506,Preparing,785,0018-P07,Efficacy and safety trial (Phase III),Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13004,1299-0001,1299.1,Preparing,786,1299-P01,SRD study in healthy volunteers,Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
13005,1299-0002,1299.2,Unconfirmed,786,1299-P01,MRD study in healthy volunteers,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13006,1299-0003,1299.3,Unconfirmed,786,1299-P01,Safety and tolerability in COPD patients,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13007,1299-0004,1299.4,Unconfirmed,786,1299-P01,PoC and dose ranging vs placebo in COPD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13008,1299-0005,1299.5,Unconfirmed,786,1299-P01,PoC vs active comparator,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13009,1300-0001,1300.1,Preparing,787,1300-P01,BI 853520 Phase I 3 wk on 1 wk off,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13010,1300-0002,1300.2,Ended,787,1300-P01,BI 853520 Ph I 4 wk on continuous dosing,Ended,MIG,Migration,I,Phase I,,2010-024609-10,,000910,IS - Clin Study (MIGRATED)
13011,1300-0003,1300.3,Unconfirmed,787,1300-P01,BI 853520 with gemcitabine,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13012,1300-0004,1300.4,Unconfirmed,787,1300-P01,BI 853520 with pegylated doxorubicin,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13013,1300-0005,1300.5,Unconfirmed,787,1300-P01,BI 853520 with docetaxel,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13014,1300-0006,1300.6,Unconfirmed,787,1300-P01,BI 853520 with chemotherapy,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13015,1300-0007,1300.7,Unconfirmed,787,1300-P01,BI 853520 in breast cancer,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13016,1300-0008,1300.8,Unconfirmed,787,1300-P01,BI 853520 in colon cancer,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13017,1300-0009,1300.9,Unconfirmed,787,1300-P01,BI 853520 with platinum/taxane,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13018,1300-0010,1300.10,Unconfirmed,787,1300-P01,BI 853520 in pancreatic adenocarcinoma,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13019,1300-0011,1300.11,Unconfirmed,787,1300-P01,BI 853520 in platinum refractory OC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13020,1300-0012,1300.12,Unconfirmed,787,1300-P01,BI 853520 in HRPC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13021,1300-0013,1300.13,Unconfirmed,787,1300-P01,BI 853520 with Platinum/Taxane in OC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13022,1300-0014,1300.14,Unconfirmed,787,1300-P01,BI 853520 Ph I in Asian population,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13023,1300-0015,1300.15,Ended,787,1300-P01,BI 853520 Ph I in Japanese and Taiwanese,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13024,1301-0001,1301.1,Recruiting,788,1301-P01,Anti-CD20 in rheumatoid arthritis,Recruiting,MIG,Migration,III,Phase III,,2011-002894-48,,000910,IS - Clin Study (MIGRATED)
13025,1301-0004,1301.4,Recruiting,788,1301-P01,BI 695500 in RA open label extension,Recruiting,MIG,Migration,III,Phase III,,2013-002622-23,,000910,IS - Clin Study (MIGRATED)
13026,1302-0001,1302.1,Ended,789,1302-P01,PK BE of BI 695502,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13027,1302-0002,1302.2,Preparing,789,1302-P01,BI695502 vs bevacizumab in CRC,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13028,1302-0003,1302.3,Recruiting,789,1302-P01,Efficacy and safety in colorectal cancer,Recruiting,MIG,Migration,IIIB,Phase IIIb,,2015-003718-25,,000910,IS - Clin Study (MIGRATED)
13029,1302-0004,1302.4,Preparing,789,1302-P01,BE in healthy Asian subjects,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13030,1302-0005,1302.5,Last Subject Randomised,789,1302-P01,BI 695502 vs. Avastin in NSCLC,Last Subject Randomised,MIG,Migration,III,Phase III,,2014-002161-30,,000910,IS - Clin Study (MIGRATED)
13031,1302-0006,1302.6,Unconfirmed,789,1302-P01,1302.6,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
13032,1303-0001,1303.1,Preparing,790,1303-P01,PK equivalence study,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13033,1303-0002,1303.2,Unconfirmed,790,1303-P01,efficacy and safety comparative study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13034,1303-0003,1303.3,Unconfirmed,790,1303-P01,Bridging study in GC,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13035,1270-0002,1270.2,First Subject Randomised,791,1270-P02,BI 836826 Phase I in NHL patients,First Subject Randomised,MIG,Migration,I,Phase I,,2010-024456-29,,000910,IS - Clin Study (MIGRATED)
13036,1270-0005,1270.5,Preparing,791,1270-P02,BI 836826 relaps aggr NHL eligible HD tx,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13037,1270-0008,1270.8,Unconfirmed,791,1270-P02,BI 836826 relaps aggr NHL eligible HD tx,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13038,1270-0009,1270.9,Unconfirmed,791,1270-P02,Asian Ph 1 in NHL,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13039,1270-0010,1270.10,Unconfirmed,791,1270-P02,Asia/Japan Ph 1,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13040,1270-0011,1270.11,First Subject Randomised,791,1270-P02,Relapsed DLBCL inelig HD tx comb GemOx,First Subject Randomised,MIG,Migration,I/II,Phase I/II,,2014-004794-16,,000910,IS - Clin Study (MIGRATED)
13041,1270-0012,1270.12,Unconfirmed,791,1270-P02,relaps aggr NHL ineligible HD tx,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13042,1270-0016,1270.16,Unconfirmed,791,1270-P02,Lymphoma immunohistochemistry study,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
13043,1304-0001,1304.1,Ended,792,1304-P01,Single rising dose in healthy volunteers,Ended,MIG,Migration,IA,Phase Ia,,2011-000713-39,,000910,IS - Clin Study (MIGRATED)
13044,1304-0002,1304.2,Preparing,792,1304-P01,Adaptiv Ph Ib/II in mod./ sev psoriasis,Preparing,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13045,1304-0003,1304.3,Unconfirmed,792,1304-P01,Roll-overfrom phase II and phase III,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13046,1304-0004,1304.4,Unconfirmed,792,1304-P01,Non-inferiority versus active comparator,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13047,1304-0005,1304.5,Unconfirmed,792,1304-P01,Non-inferiority versus active comparator,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13048,1304-0006,1304.6,Unconfirmed,792,1304-P01,Adaptive phase IIa/IIb in RA,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13049,1304-0007,1304.7,Unconfirmed,792,1304-P01,POC in psoriatic arthritis,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13050,1304-0008,1304.8,Unconfirmed,792,1304-P01,PanAsian SRD,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
13051,1304-0009,1304.9,Unconfirmed,792,1304-P01,PanAsian MRD,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13052,1305-0001,1305.1,Ended,793,1305-P01,Single Rising Dose in Healthy Volunteers,Ended,MIG,Migration,IA,Phase Ia,Back Up to BI 137882 ,2012-000405-68,,000910,IS - Clin Study (MIGRATED)
13053,1305-0002,1305.2,Ended,793,1305-P01,Multiple Rising Dose Healthy Volunteers,Ended,MIG,Migration,IB,Phase Ib,,2012-005614-19,,000910,IS - Clin Study (MIGRATED)
13054,1305-0003,1305.3,Preparing,793,1305-P01,BA - food effect in HV,Preparing,MIG,Migration,I,Phase I,,2013-002679-16,,000910,IS - Clin Study (MIGRATED)
13055,1305-0004,1305.4,Unconfirmed,793,1305-P01,LPS In vivo challenge in HV,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13056,1305-0005,1305.5,Unconfirmed,793,1305-P01,PoC 6 weeks in COPD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13057,1305-0006,1305.6,Unconfirmed,793,1305-P01,Pan-Asian SRD in HV,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13058,1305-0007,1305.7,Unconfirmed,793,1305-P01,Pan-Asian MRD in HV,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13059,1305-0010,1305.10,Unconfirmed,793,1305-P01,Multiple Rising Dose (2) HVs,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13060,1306-0001,1306.1,Ended,794,1306-P01,FIH SRD in HV,Ended,MIG,Migration,IA,Phase Ia,,2010-023462-52,,000910,IS - Clin Study (MIGRATED)
13061,1306-0002,1306.2,Unconfirmed,794,1306-P01,MRD in HV,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13062,1306-0003,1306.3,Unconfirmed,794,1306-P01, Food Effect in HV,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13063,1306-0004,1306.4,Unconfirmed,794,1306-P01,Multiple Dose in COPD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13064,1306-0005,1306.5,Unconfirmed,794,1306-P01,Pan-Asian SRD in HV,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
13065,1306-0006,1306.6,Unconfirmed,794,1306-P01,Pan-Asian MRD in HV,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13066,1306-0007,1306.7,Unconfirmed,794,1306-P01,PoC and Dose Finding,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13067,1200-0119,1200.119,First Subject Randomised,795,1200-P07,Post op BIBW  maintenance therapy HNSCC,First Subject Randomised,MIG,Migration,III,Phase III,,2010-023265-22,,000150,IS - Clin Study - Explore
13068,1200-0132,1200.132,Unconfirmed,795,1200-P07,Phase I combination with AIs,Unconfirmed,MIG,Migration,I,Phase I,parellel recruitment into combination with anastrozole or with exemestane,,,000910,IS - Clin Study (MIGRATED)
13069,1200-0133,1200.133,Unconfirmed,795,1200-P07,Phase I combination with HR antagonists,Unconfirmed,MIG,Migration,I,Phase I,parallel recruitment into cohorts tamoxifen and fulvestrant allowed, expanded MTD cohort for tamoxifen,,,000910,IS - Clin Study (MIGRATED)
13070,1200-0135,1200.135,Unconfirmed,795,1200-P07,Afatinib in HR-refractory BC,Unconfirmed,MIG,Migration,II,Phase II,ER-low, HER2-neg patients to benefit most; phase II R design,,,,
13071,1200-0137,1200.137,Ended,795,1200-P07,BIBW 2992 in Intermediate Her2 breast Ca,Ended,MIG,Migration,II,Phase II,,2011-001765-41,,,
13072,1200-0138,1200.138,Ended,795,1200-P07,Her2-positive prostate cancer - Germany,Ended,MIG,Migration,II,Phase II,,2010-024164-18,,,
13073,1200-0144,1200.144,Analysis,795,1200-P07,Resectable HNSCC neoadjuvant - FR,Analysis,MIG,Migration,IIA,Phase IIa,,2010-024046-29,,000150,IS - Clin Study - Explore
13074,1200-0146,1200.146,Ended,795,1200-P07,BIBW 2992 as add-on to Gem/Cis in advanced biliary tract can,Ended,MIG,Migration,I,Phase I,First patient in: 24-AUG-2012
Last patient out: 16-JUL-2015
Report Date: 21-NOV-2016,2011-004163-80,,,
13075,1200-0147,1200.147,Unconfirmed,795,1200-P07,Afatinib in HR-refractory BC,Unconfirmed,MIG,Migration,III,Phase III,ER-low, HER2-neg patients to benefit most; phase III design with an interim for futility at 25% of total events needed (330) after 200 pts acrrued,,,000910,IS - Clin Study (MIGRATED)
13076,1200-0149,1200.149,Ended,795,1200-P07,Na√Øve pts with HER2-postive Adv GC - USA,Ended,MIG,Migration,II,Phase II,,,,,
13077,1200-0150,1200.150,Ended,795,1200-P07,Neoadj HNSCC EORTC NOCI-HNCG - Belgium,Ended,MIG,Migration,IIA,Phase IIa,,2011-005820-17,,,
13078,1200-0153,1200.153,Preparing,795,1200-P07,+ Paclitaxel in Metastatic Esophago - US,Preparing,MIG,Migration,II,Phase II,,,,,
13079,1200-0154,1200.154,Last Subject Randomised,795,1200-P07,ACCEPT,Last Subject Randomised,MIG,Migration,II,Phase II,,2011-004063-77,,000910,IS - Clin Study (MIGRATED)
13080,1200-0156,1200.156,Last Subject Randomised,795,1200-P07,evaluating dual targeting EGFR - FF,Last Subject Randomised,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
13081,1200-0159,1200.159,Ended,795,1200-P07,+ trastuzumab BC taxane-anthracycline-DE,Ended,MIG,Migration,II,Phase II,,2011-004704-38,,,
13082,1200-0160,1200.160,Last Subject Randomised,795,1200-P07,1st line 5-fu+cisplatin chemo in GC - GB,Last Subject Randomised,MIG,Migration,II,Phase II,,2011-006198-25,,000910,IS - Clin Study (MIGRATED)
13083,1200-0163,1200.163,Unconfirmed,795,1200-P07,EGFR combi of Cetu and BIBW vs Cetu mono,Unconfirmed,MIG,Migration,II,Phase II,,,,,
13084,1200-0168,1200.168,Last Subject Randomised,795,1200-P07,1st line adv. ER+, HER2- post-meno BC-US,Last Subject Randomised,MIG,Migration,II,Phase II,1st line trt ER+ HER2- letrozole ,2013-002192-18,,000150,IS - Clin Study - Explore
13085,1200-0171,1200.171,First Subject Randomised,795,1200-P07,Afatinib advanced refractory UC - USA,First Subject Randomised,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
13086,1200-0177,1200.177,Recruiting,795,1200-P07,PhII afatinib vs. iv methotrexate OCSCC,Recruiting,MIG,Migration,IIB,Phase IIb,in betel quid chewers amonst endemic are ,,,000150,IS - Clin Study - Explore
13087,1200-0178,1200.178,Recruiting,795,1200-P07,PhI afatinib postop radiation HNSCC - US,Recruiting,MIG,Migration,I,Phase I,see extended remarks There is a specific IND for this trial being conducted under a request for proposal grant to the NCCN from BI.  For the purpose of reporting safety infromation that would normally go to BI Trials and IIS trials defined by BI SAPs, this trial is classified as an IIS trial,,,000150,IS - Clin Study - Explore
13088,1200-0179,1200.179,Last Subject Randomised,795,1200-P07,PhI/II afatinib/carbopl/pacli HNSCC - US,Last Subject Randomised,MIG,Migration,I,Phase I,see extended remarks There is a specific IND for this trial being conducted under a request for proposal grant to the NCCN from BI.  For the purpose of reporting safety infromation that would normally go to BI Trials and IIS trials defined by BI SAPs, this trial is classified as an IIS trial,,,000150,IS - Clin Study - Explore
13089,1200-0180,1200.180,Ended,795,1200-P07,PhI afatinib/ribav/carbopl/pacli OPSCC,Ended,MIG,Migration,I,Phase I,see extended remarks There is a specific IND for this trial being conducted under a request for proposal grant to the NCCN from BI.  For the purpose of reporting safety infromation that would normally go to BI Trials and IIS trials defined by BI SAPs, this trial is classified as an IIS trial,,,,
13090,1200-0182,1200.182,Ended,795,1200-P07,phI TP-afatinib combo vs TPF HNSCC -  FR,Ended,MIG,Migration,I,Phase I,,2013-002876-42,,,
13091,1200-0184,1200.184,Preparing,795,1200-P07,pre-op afatinib HER2+ esophag-GC - USA,Preparing,MIG,Migration,I,Phase I,,,,,
13092,1200-0188,1200.188,Preparing,795,1200-P07,Afatinib and metformin in breast ca,Preparing,MIG,Migration,II,Phase II,,,,,
13093,1200-0196,1200.196,First Subject Randomised,795,1200-P07,+ruxolitinib adv solid tumors - Korea,First Subject Randomised,MIG,Migration,IB,Phase Ib,,,,000100,IS - Clin Study - Clin Pharm - Other
13094,1200-0198,1200.198,Preparing,795,1200-P07,PhII biomarker vs cetuximab HNSCC,Preparing,MIG,Migration,II,Phase II,,,,,
13095,1200-0199,1200.199,Preparing,795,1200-P07,PhII AfaCetPac recurr/metast HNSCC,Preparing,MIG,Migration,II,Phase II,,,,,
13096,1200-0200,1200.200,First Subject Randomised,795,1200-P07,PhI/Ib afa+capecitabine solid tumors,First Subject Randomised,MIG,Migration,IB,Phase Ib,,,,000150,IS - Clin Study - Explore
13097,1200-0203,1200.203,Ended,795,1200-P07,PhII afatinib + paclitaxel 2nd line GC,Ended,MIG,Migration,II,Phase II,,,,,
13098,1200-0206,1200.206,Recruiting,795,1200-P07,proof-of-principle randomised study-UK,Recruiting,MIG,Migration,II,Phase II,,2013-002398-23,,000150,IS - Clin Study - Explore
13099,1200-0207,1200.207,Ended,795,1200-P07,PhII adjuvant afatinib mono LA HNSCC,Ended,MIG,Migration,II,Phase II,,,,,
13100,1200-0213,1200.213,Preparing,795,1200-P07,Afa + Pac/Cis in r/mSCCHN - DE,Preparing,MIG,Migration,IB,Phase Ib,,2014-002293-37,,,
13101,1200-0215,1200.215,Recruiting,795,1200-P07,open label,pac,neoadj, triple BC - TW,Recruiting,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
13102,1200-0218,1200.218,Preparing,795,1200-P07,phII afatinib+BSC met/rec HNSCC,Preparing,MIG,Migration,II,Phase II,,,,,
13103,1200-0225,1200.225,Preparing,795,1200-P07,Ph I Dose CNS PK Gliomas,Brain Metas.,Preparing,MIG,Migration,I,Phase I,,,,,
13104,1200-0226,1200.226,Preparing,795,1200-P07,Ph I squamous cell ca of esophagus,Preparing,MIG,Migration,II,Phase II,,,,,
13105,1200-0228,1200.228,Last Subject Randomised,795,1200-P07,phII afatinib met/rec esophageal,Last Subject Randomised,MIG,Migration,II,Phase II,,,,000100,IS - Clin Study - Clin Pharm - Other
13106,1200-0229,1200.229,First Subject Randomised,795,1200-P07,phI afatinib rec glioma + brain mets,First Subject Randomised,MIG,Migration,I,Phase I,,,,000150,IS - Clin Study - Explore
13107,1200-0231,1200.231,Recruiting,795,1200-P07,phII afatinib adv penile (PSCC),Recruiting,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
13108,1200-0242,1200.242,First Subject Randomised,795,1200-P07,phII persist./recurr. HER2+ endometrial,First Subject Randomised,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
13109,1200-0243,1200.243,Recruiting,795,1200-P07,EGFR activ mut/HER2 kinase activ mut,Recruiting,MIG,Migration,I,Phase I,,,,000150,IS - Clin Study - Explore
13110,1200-0245,1200.245,Preparing,795,1200-P07,post op. afa+radiation cutaneous HNSCC,Preparing,MIG,Migration,II,Phase II,,,,,
13111,1200-0248,1200.248,Preparing,795,1200-P07,Ph II HER2 EGFR NSCC Cervix,Preparing,MIG,Migration,II,Phase II,,,,,
13112,1200-0249,1200.249,First Subject Randomised,795,1200-P07,Molekular Basket Trial,First Subject Randomised,MIG,Migration,NONE,Not Classified,IIS study molecular basket trial ,,,000160,IS - Clin Study - Explore- Subpopulation
13113,1200-0252,1200.252,Recruiting,795,1200-P07,Na√Øve pts with HER2-postive Adv GC - USA,Recruiting,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
13114,1200-0253,1200.253,Preparing,795,1200-P07,WINTHER,Preparing,MIG,Migration,NONE,Not Classified,,,,,
13115,1200-0254,1200.254,First Subject Randomised,795,1200-P07,refract gastric ca afatinib+paclitaxel,First Subject Randomised,MIG,Migration,II,Phase II,,,,000100,IS - Clin Study - Clin Pharm - Other
13116,1200-0258,1200.258,Recruiting,795,1200-P07,AFFECT,Recruiting,MIG,Migration,IB,Phase Ib,,2015-004065-86,,000910,IS - Clin Study (MIGRATED)
13117,1200-0262,1200.262,First Subject Randomised,795,1200-P07,matched therapies selected tumor types,First Subject Randomised,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
13118,1200-0267,1200.267,Preparing,795,1200-P07,+cetuximab wt CRC,Preparing,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
13119,1200-0268,1200.268,Recruiting,795,1200-P07,+post docetaxel, cisplatin HNSCC,Recruiting,MIG,Migration,I,Phase I,,,,000150,IS - Clin Study - Explore
13120,1200-0274,1200.274,Preparing,795,1200-P07,HNSCC - Basket trial BE,Preparing,IIS,Investigator Initiated Study,II,Phase II,,,,000100,IS - Clin Study - Clin Pharm - Other
13121,1200-0276,1200.276,Preparing,795,1200-P07,MET + HER in EGFR targeted therapy SCCHN,Preparing,IIS,Investigator Initiated Study,I,Phase I,,,,000150,IS - Clin Study - Explore
13122,1200-0277,1200.277,Preparing,795,1200-P07,Afatinib chordoma EGFR overex,Preparing,MIG,Migration,II,Phase II,,,,000160,IS - Clin Study - Explore- Subpopulation
13123,1200-0028,1200.28,Ended,796,1200-P08,randomized Ph II in HNSCC,Ended,MIG,Migration,II,Phase II,IVRS was changed to 'yes' on 21Jun07(mb) Bio-imaging vendor, eRT will also be used,2008-007097-38,,000910,IS - Clin Study (MIGRATED)
13124,1200-0037,1200.37,Ended,796,1200-P08,Phase I study with platinum/5FU/taxane,Ended,MIG,Migration,IB,Phase Ib,,2008-002613-43,,000910,IS - Clin Study (MIGRATED)
13125,1200-0043,1200.43,Analysis,796,1200-P08,LUX-H&N 1, afatinib vs MTX in R/M HNSCC,Analysis,MIG,Migration,III,Phase III,,2011-000391-34,,000910,IS - Clin Study (MIGRATED)
13126,1200-0131,1200.131,Ended,796,1200-P08,LUX H&N 2, afatinib/placebo in L/A HNSCC,Ended,MIG,Migration,IIIA,Phase IIIa,,2011-000392-14,,000910,IS - Clin Study (MIGRATED)
13127,1200-0161,1200.161,First Subject Randomised,796,1200-P08,Asian Phase III (LUX H&N 3),First Subject Randomised,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13128,1200-0162,1200.162,Ended,796,1200-P08,Asian Phase III (LUX H&N 4),Ended,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13129,1294-0003,1294.3,Preparing,797,1294-P02,MRD in mild asthma,Preparing,MIG,Migration,IB,Phase Ib,,2013-001311-75,,000910,IS - Clin Study (MIGRATED)
13130,1294-0006,1294.6,Unconfirmed,797,1294-P02,Proof of Principle in asthma 24 weeks,Unconfirmed,MIG,Migration,IIA,Phase IIa,women of childbearing potential with aeq uate contraception, active competitor (ICS tbc),,,000910,IS - Clin Study (MIGRATED)
13131,1294-0009,1294.9,Unconfirmed,797,1294-P02,s.c. self-injection in asthma,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13132,1294-0011,1294.11,Unconfirmed,797,1294-P02,placeholder,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13133,1294-0012,1294.12,Unconfirmed,797,1294-P02,8 week adolescent asthma,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13134,1294-0015,1294.15,Unconfirmed,797,1294-P02,Pivotal 52 week asthma,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
13135,1294-0016,1294.16,Unconfirmed,797,1294-P02,Pivotal 52 week asthma,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
13136,1294-0017,1294.17,Unconfirmed,797,1294-P02,Placeholder- adolescent or pediatric,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13137,1294-0019,1294.19,Unconfirmed,797,1294-P02,24 week OCS sparing,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
13138,1307-0001,1307.1,Ended,798,1307-P01,SRD in healthy male volunteers,Ended,MIG,Migration,IA,Phase Ia,,2011-006183-45,,000910,IS - Clin Study (MIGRATED)
13139,1307-0002,1307.2,Ended,798,1307-P01,MRD in patients with T2DM,Ended,MIG,Migration,IB,Phase Ib,,2013-000312-21,,000910,IS - Clin Study (MIGRATED)
13140,1307-0003,1307.3,Ended,798,1307-P01,Relative BA/Food effect,Ended,MIG,Migration,I,Phase I,,2013-004627-37,,000910,IS - Clin Study (MIGRATED)
13141,1307-0004,1307.4,Ended,798,1307-P01,4 week safety and efficacy in patients,Ended,MIG,Migration,IIA,Phase IIa,,2013-003646-16,,000910,IS - Clin Study (MIGRATED)
13142,1307-0005,1307.5,Unconfirmed,798,1307-P01,SRD in Japanese and Chinese subjects,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
13143,1307-0006,1307.6,Unconfirmed,798,1307-P01,MRD in Chinese obese patients with T2DM,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13144,1307-0007,1307.7,Ended,798,1307-P01,DDI metformin,Ended,MIG,Migration,I,Phase I,,2013-004628-13,,000910,IS - Clin Study (MIGRATED)
13145,1307-0008,1307.8,Preparing,798,1307-P01,Human ADME,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13146,1307-0009,1307.9,Unconfirmed,798,1307-P01,Dose finder vs placebo as monotherapy,Unconfirmed,MIG,Migration,IIB,Phase IIb,,2014-004710-29,,000910,IS - Clin Study (MIGRATED)
13147,1307-0010,1307.10,Unconfirmed,798,1307-P01,Dose finder vs Plc add-on Met/SGLT2i,Unconfirmed,MIG,Migration,IIB,Phase IIb,,2014-004773-16,,000910,IS - Clin Study (MIGRATED)
13148,1307-0011,1307.11,Unconfirmed,798,1307-P01,DDI Prednison,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13149,1307-0012,1307.12,Unconfirmed,798,1307-P01,DDI Empagliflozin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13150,1307-0013,1307.13,Unconfirmed,798,1307-P01,Ph2b Japan 12 wks dose finding,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13151,1307-0014,1307.14,Unconfirmed,798,1307-P01,MRD in Japanese obese patients with T2DM,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13152,1307-0015,1307.15,Unconfirmed,798,1307-P01,PK in T2DM pat with renal impairment,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13153,1307-0016,1307.16,Unconfirmed,798,1307-P01,Thorough QT study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13154,1307-0017,1307.17,Unconfirmed,798,1307-P01,Phase II mechanistic clamp study,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13155,1307-0018,1307.18,Unconfirmed,798,1307-P01,Absolute BA / iv formulation,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13156,1307-0019,1307.19,Ended,798,1307-P01,DDI CYP Cocktail,Ended,MIG,Migration,I,Phase I,,2013-005029-22,,000910,IS - Clin Study (MIGRATED)
13157,1307-0020,1307.20,Ended,798,1307-P01,DDI CYP2B6, 2C8,Ended,MIG,Migration,I,Phase I,,2013-005030-38,,000910,IS - Clin Study (MIGRATED)
13158,1307-0021,1307.21,Unconfirmed,798,1307-P01,DDI Glimepiride,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13159,1307-0022,1307.22,Unconfirmed,798,1307-P01,DDI Sitagliptin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13160,1307-0023,1307.23,Unconfirmed,798,1307-P01,DDI Placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13161,1307-0024,1307.24,Unconfirmed,798,1307-P01,Insulin dose recovery OR athero imaging,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13162,1307-0025,1307.25,Unconfirmed,798,1307-P01,Phase III Mono 52+52 weeks,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13163,1307-0026,1307.26,Unconfirmed,798,1307-P01,Phase III in pat with renal impairment,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13164,1307-0027,1307.27,Unconfirmed,798,1307-P01,Phase III H2H trial 152 wks,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13165,1307-0028,1307.28,Unconfirmed,798,1307-P01,Phase III CV safety trial,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13166,1307-0029,1307.29,Unconfirmed,798,1307-P01,Ph3 Japan Add-on safety,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13167,1307-0030,1307.30,Unconfirmed,798,1307-P01,Paediatric dose finding,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13168,1307-0031,1307.31,Unconfirmed,798,1307-P01,Paediatric safety and efficacy,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13169,1307-0032,1307.32,Unconfirmed,798,1307-P01,PK in hepatic impairment,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13170,1307-0033,1307.33,Unconfirmed,798,1307-P01,Ph3 Japan Monotherapy,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13171,1307-0034,1307.34,Unconfirmed,798,1307-P01,Effect of combined CYP3A and P-gp induc.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13172,1307-0035,1307.35,Unconfirmed,798,1307-P01,Effect of P-gp inhibition (cyclosporine),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13173,1307-0036,1307.36,Unconfirmed,798,1307-P01,Effect on oral and iv midazolam,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13174,1307-0037,1307.37,Unconfirmed,798,1307-P01,Effect of PPI/gastric pH on relative bio,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13175,1307-0038,1307.38,Unconfirmed,798,1307-P01,DDI ethinylestratdiol+levonorgestrel,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13176,1307-0039,1307.39,Unconfirmed,798,1307-P01,DDI atorvastatin+rosuvastatin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13177,1307-0040,1307.40,Unconfirmed,798,1307-P01,DDI tadalafil,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13178,1307-0041,1307.41,Unconfirmed,798,1307-P01,DDI calcium channel blocker(s),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13179,1307-0042,1307.42,Unconfirmed,798,1307-P01,DDI SSRI,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13180,1307-0043,1307.43,Unconfirmed,798,1307-P01,DDI colchicine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13181,1307-0044,1307.44,Preparing,798,1307-P01,DDI Canagliflozin,Preparing,MIG,Migration,I,Phase I,,2015-001140-11,,000910,IS - Clin Study (MIGRATED)
13182,1307-0045,1307.45,Unconfirmed,798,1307-P01,DDI Linagliptin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13183,1307-0046,1307.46,Unconfirmed,798,1307-P01,Ph3 Japan Add-on to insulin vs. insulin,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13184,1307-0047,1307.47,Unconfirmed,798,1307-P01,Food effect with final form. in Jap,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13185,1307-0048,1307.48,Unconfirmed,798,1307-P01,Local PK in China,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13186,1308-0001,1308.1,Ended,799,1308-P01,SRD study in healthy volunteers,Ended,MIG,Migration,I,Phase I,,2011-004840-23,,000910,IS - Clin Study (MIGRATED)
13187,1308-0002,1308.2,Unconfirmed,799,1308-P01,MRD study in healthy volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13188,1308-0003,1308.3,Unconfirmed,799,1308-P01,PoM study in healthy volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13189,1308-0004,1308.4,Unconfirmed,799,1308-P01,SRD in healthy Asian volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13190,1308-0005,1308.5,Unconfirmed,799,1308-P01,PoC and dose finding study in AD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13191,1289-0006,1289.6,Ended,800,1289-P02,Phase II PoC and dose finding study,Ended,MIG,Migration,II,Phase II,,2013-005015-28,,000910,IS - Clin Study (MIGRATED)
13192,1289-0013,1289.13,Preparing,800,1289-P02,Efficacy and Safety - NA,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13193,1289-0014,1289.14,Preparing,800,1289-P02,Efficacy and Safety - EU,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13194,1289-0015,1289.15,Unconfirmed,800,1289-P02,OL extension,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13195,1289-0018,1289.18,Ended,800,1289-P02,BI 409306 in patients with schizophrenia,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13196,1289-0019,1289.19,Ended,800,1289-P02,PRO for CIAS: Qualitative Dev,Ended,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
13197,1289-0020,1289.20,Analysis,800,1289-P02,PRO for CIAS;  Quant validation study,Analysis,MIG,Migration,NONE,Not Classified,,,,000920,NISnd - Study (MIGRATED)
13198,1289-0021,1289.21,Unconfirmed,800,1289-P02,Impulsivity charaterization study,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
13199,1289-0027,1289.27,First Subject Randomised,768,1289-P01,PK and ophthalmologic assessment,First Subject Randomised,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13200,1289-0028,1289.28,Ended,800,1289-P02,CV Assessment in HVs,Ended,MIG,Migration,I,Phase I,,2014-005132-34,,000910,IS - Clin Study (MIGRATED)
13201,1289-0029,1289.29,Unconfirmed,800,1289-P02,SRD Adolescents,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13202,1289-0030,1289.30,Unconfirmed,800,1289-P02,Adolescent CIAS phase II,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13203,1289-0031,1289.31,Preparing,800,1289-P02,CogRem in CIAS,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13204,1289-0037,1289.37,Unconfirmed,768,1289-P01,Human Abuse Liability,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13205,1289-0039,1289.39,Unconfirmed,800,1289-P02,Pan-Asian Phase III,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13206,1301-0002,1301.2,Preparing,801,1301-P02, Efficacy and safety in NHL,Preparing,MIG,Migration,III,Phase III,,2011-002908-33,,000910,IS - Clin Study (MIGRATED)
13207,1301-0003,1301.3,Unconfirmed,801,1301-P02,Phase I PK/PD study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13208,1301-0005,1301.5,Ended,801,1301-P02,Phase I PK/PD study in NHL,Ended,MIG,Migration,I,Phase I,,2013-001904-12,,000910,IS - Clin Study (MIGRATED)
13209,1301-0006,1301.6,Ended,801,1301-P02,BI 695500 vs Rituxan in LTBFL,Ended,MIG,Migration,III,Phase III,Biosimilar study ,2014-004544-36,,000910,IS - Clin Study (MIGRATED)
13210,1301-0007,1301.7,Unconfirmed,801,1301-P02,BI 695500 in DLBCL,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
13211,1160-0114,1160.114,Ended,802,1160-P08,GLORIA-AF Registry Program, Phase I,Ended,MIG,Migration,IV,Phase IV,The study will start sequentially dependent on the dabigatran approval in each participating country - therefore the long trial duration.,,,000940,Post Marketing Study (MIGRATED)
13212,1160-0129,1160.129,First Subject Randomised,802,1160-P08,GLORIA-AF Registry Phase II/III (Core),First Subject Randomised,MIG,Migration,IV,Phase IV,See Notes -> 05-SEP-2014 - Study changed to non-imposed PASS at request of PVWG. 

---
Handled according PASS prior 02Jul2012.
Study will start sequentially dependent on approval of dabigatran in participating countries -,,,000420,NISnd ‚Äì Study - Cohort
13213,1160-0136,1160.136,First Subject Randomised,802,1160-P08,GLORIA-AF Registry, Phase II/III (EU),First Subject Randomised,MIG,Migration,IV,Phase IV,Handled according PASS prior 02Jul2012 ,,,000420,NISnd ‚Äì Study - Cohort
13214,1160-0171,1160.171,Last Subject Randomised,802,1160-P08,GLORIA-AF Phase II/III,Last Subject Randomised,MIG,Migration,IV,Phase IV,,,,000420,NISnd ‚Äì Study - Cohort
13215,1309-0001,1309.1,Unconfirmed,803,1309-P01,Ph I  BI 837279 in advanced cancer pts,Unconfirmed,MIG,Migration,IA,Phase Ia,expanded MTD cohorts foreseen potential expanded MTD cohorts: refr. BC, refr. OC, refr. NHL,,,000910,IS - Clin Study (MIGRATED)
13216,1309-0002,1309.2,Unconfirmed,803,1309-P01,Ph I  BI 837279 in advanced cancer pts,Unconfirmed,MIG,Migration,IA,Phase Ia,an expanded MTD cohort ,,,000910,IS - Clin Study (MIGRATED)
13217,1309-0003,1309.3,Unconfirmed,803,1309-P01,Ph I of BI 837279 in combination with CT,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13218,1309-0004,1309.4,Unconfirmed,803,1309-P01,Ph I of BI 837279 novel combo,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13219,1309-0005,1309.5,Unconfirmed,803,1309-P01,Ph I of BI837279 with RT,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13220,1309-0006,1309.6,Unconfirmed,803,1309-P01,Ph II R of BI837279 with a.i. vs a.i.,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13221,1309-0007,1309.7,Unconfirmed,803,1309-P01,Ph II R of BI837279 with CT vs CT,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13222,1309-0008,1309.8,Unconfirmed,803,1309-P01,Ph III R of BI837279+ai vs ai+everolimus,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13223,1310-0001,1310.1,Ended,804,1310-P01,SRD study of BI 1021958 in HV,Ended,MIG,Migration,IA,Phase Ia,,2011-003483-70,,000910,IS - Clin Study (MIGRATED)
13224,1310-0002,1310.2,Ended,804,1310-P01,MRD study of BI 1021958 in asthmatics,Ended,MIG,Migration,IB,Phase Ib,,2012-000926-23,,000910,IS - Clin Study (MIGRATED)
13225,1310-0003,1310.3,Ended,804,1310-P01,Pan Asian phase I SRD study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13226,1310-0004,1310.4,Unconfirmed,804,1310-P01,Relative F TF I and TFII,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13227,1310-0005,1310.5,Unconfirmed,804,1310-P01,Single dose absolute bio-availability,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13228,1310-0006,1310.6,Unconfirmed,804,1310-P01,Radioactive mass balance single dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13229,1310-0007,1310.7,Unconfirmed,804,1310-P01,Renal impairment effect,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13230,1310-0008,1310.8,Unconfirmed,804,1310-P01,Hepatic impairment effect,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13231,1310-0009,1310.9,Unconfirmed,804,1310-P01,DDI CYP 2C8,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13232,1310-0010,1310.10,Unconfirmed,804,1310-P01,DDI theophylline as per 1310.9,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13233,1310-0011,1310.11,Unconfirmed,804,1310-P01,DDI montelukast as per 1310.9,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13234,1310-0012,1310.12,Unconfirmed,804,1310-P01,Thorough QT study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13235,1310-0013,1310.13,Unconfirmed,804,1310-P01,Relative Bioavail paed formulations,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13236,1310-0014,1310.14,Preparing,804,1310-P01,8 week dose ranging,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13237,1310-0015,1310.15,Preparing,804,1310-P01,12 week dose ranging add on iCS +/- LABA,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13238,1310-0016,1310.16,Preparing,804,1310-P01,12 week controller taper/withdrawal,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13239,1310-0017,1310.17,Unconfirmed,804,1310-P01,6 week efficay Japanese asthmatics,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13240,1310-0018,1310.18,Unconfirmed,804,1310-P01,EIB > 12 yrs pivotal USA,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13241,1310-0019,1310.19,Unconfirmed,804,1310-P01,EIB > 12 yrs pivotal EU,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13242,1310-0020,1310.20,Unconfirmed,804,1310-P01,Mild > 12 yrs pivotal MT superiority,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13243,1310-0021,1310.21,Unconfirmed,804,1310-P01, mild > 12 years pivotal MT superiority,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13244,1310-0022,1310.22,Unconfirmed,804,1310-P01,mild > 12yrs pivotal  FP non-inferiority,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13245,1310-0023,1310.23,Unconfirmed,804,1310-P01,mild > 12yrs pivotal  non-inferiority,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13246,1310-0024,1310.24,Unconfirmed,804,1310-P01,severe > 12yrs pivotal,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
13247,1310-0025,1310.25,Unconfirmed,804,1310-P01,Adolescent bridging study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13248,1310-0028,1310.28,Unconfirmed,804,1310-P01,Phase III SAR control > 12 years pivotal,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13249,1310-0030,1310.30,Unconfirmed,804,1310-P01,5-11 yrs asthma bridging,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13250,1310-0031,1310.31,Unconfirmed,804,1310-P01,EIB 5-11 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13251,1310-0032,1310.32,Unconfirmed,804,1310-P01,Asthma mild 5-11 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13252,1310-0033,1310.33,Unconfirmed,804,1310-P01,Asthma add on/ taper 5-11 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13253,1310-0034,1310.34,Unconfirmed,804,1310-P01,Asthma roll over 2-11 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13254,1310-0035,1310.35,Unconfirmed,804,1310-P01,2-4 yrs asthma bridging PK,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13255,1310-0036,1310.36,Unconfirmed,804,1310-P01,Asthma add on 2-4 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13256,1310-0040,1310.40,Unconfirmed,804,1310-P01,Roll over 12-17 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13257,1310-0043,1310.43,Unconfirmed,804,1310-P01,Pgp inhibition/substrate,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13258,1310-0044,1310.44,Unconfirmed,804,1310-P01,Posology controller naive,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13259,1310-0045,1310.45,Unconfirmed,804,1310-P01,iCS Taper study,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13260,1310-0046,1310.46,Unconfirmed,804,1310-P01,Pivotal severe > 12 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13261,1310-0047,1310.47,Unconfirmed,804,1310-P01,Japanese pivtol mild,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13262,1310-0048,1310.48,Unconfirmed,804,1310-P01,Japanese pivotal severe,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13263,1310-0049,1310.49,Unconfirmed,804,1310-P01,Pan-Asian MRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13264,1310-0050,1310.50,Unconfirmed,804,1310-P01,BA - food effect in HV,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13265,1310-0051,1310.51,Unconfirmed,804,1310-P01,Renal Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13266,1311-0001,1311.1,Ended,805,1311-P01,SRD (IV and SC) in Psoriasis,Ended,MIG,Migration,IB,Phase Ib,,2012-000081-37,,000910,IS - Clin Study (MIGRATED)
13267,1311-0002,1311.2,Ended,805,1311-P01,Randomized dose finding trial,Ended,MIG,Migration,II,Phase II,,2012-004384-48,,000910,IS - Clin Study (MIGRATED)
13268,1311-0003,1311.3,Last Subject Randomised,805,1311-P01,Pivotal efficacy trial,Last Subject Randomised,MIG,Migration,III,Phase III,,2014-005117-23,,000910,IS - Clin Study (MIGRATED)
13269,1311-0004,1311.4,Last Subject Randomised,805,1311-P01,Pivotal Efficacy & Randomized Withdrawal,Last Subject Randomised,MIG,Migration,III,Phase III,,2014-005102-38,,000910,IS - Clin Study (MIGRATED)
13270,1311-0012,1311.12,Unconfirmed,805,1311-P01,HCLF bridging PK study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13271,1311-0013,1311.13,Last Subject Randomised,805,1311-P01,Open label extension to 1311.2,Last Subject Randomised,MIG,Migration,II,Phase II,,2014-001687-36,,000910,IS - Clin Study (MIGRATED)
13272,1311-0028,1311.28,Last Subject Randomised,805,1311-P01,Induction and maintenance vs Stelara,Last Subject Randomised,MIG,Migration,III,Phase III,,2015-003622-13,,000910,IS - Clin Study (MIGRATED)
13273,1311-0029,1311.29,Unconfirmed,805,1311-P01,Auto Injector Real World Use Study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13274,1311-0030,1311.30,Last Subject Randomised,805,1311-P01,safety and efficacy versus adalimumab,Last Subject Randomised,MIG,Migration,III,Phase III,,2015-003623-65,,000910,IS - Clin Study (MIGRATED)
13275,1311-0031,1311.31,Preparing,805,1311-P01,roll over for phase 3 in psoriasis,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13276,1311-0032,1311.32,Unconfirmed,805,1311-P01,Nail psoriasis,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13277,1311-0033,1311.33,Unconfirmed,805,1311-P01,Palmoplantar psoriasis,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13278,1311-0034,1311.34,Unconfirmed,805,1311-P01,Psoriasis dosing frequency refinement,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13279,1311-0036,1311.36,Last Subject Randomised,805,1311-P01,DDI,Last Subject Randomised,MIG,Migration,I,Phase I,,2015-005523-31,,000910,IS - Clin Study (MIGRATED)
13280,1311-0037,1311.37,Unconfirmed,805,1311-P01,BA - pre-filled syringe to autoinjector,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13281,1311-0038,1311.38,First Subject Randomised,805,1311-P01,Japanese efficacy and safety study,First Subject Randomised,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13282,1311-0039,1311.39,Preparing,805,1311-P01,Japanese open label study,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13283,1311-0041,1311.41,Unconfirmed,805,1311-P01,Duration of effect,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13284,1312-0001,1312.1,Ended,806,1312-P01,SRD in HV,Ended,MIG,Migration,I,Phase I,,2011-004615-23,,000910,IS - Clin Study (MIGRATED)
13285,1312-0002,1312.2,Unconfirmed,806,1312-P01,Multiple rising dose study in HVs,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13286,1312-0003,1312.3,Unconfirmed,806,1312-P01,Single dose study in AD patients,Unconfirmed,MIG,Migration,I,Phase I,Follow-up: 2 months ,,,000910,IS - Clin Study (MIGRATED)
13287,1312-0004,1312.4,Preparing,806,1312-P01,Phase I MRD in mild to moderate AD,Preparing,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13288,1312-0005,1312.5,Unconfirmed,806,1312-P01,Phase III #1 in mild AD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13289,1312-0006,1312.6,Unconfirmed,806,1312-P01,Phase III #2 in mild AD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13290,1312-0007,1312.7,Unconfirmed,806,1312-P01,Phase IIIl #1 in prodromal AD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13291,1312-0008,1312.8,Unconfirmed,806,1312-P01,Phase III #2 in prodromal AD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13292,1312-0009,1312.9,Unconfirmed,806,1312-P01,Asian SRD trial,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13293,1312-0010,1312.10,Unconfirmed,806,1312-P01,Asian MRD trial,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13294,1312-0011,1312.11,Unconfirmed,806,1312-P01,SRD Phase I in HV (plasma+CSF),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13295,1312-0012,1312.12,Unconfirmed,806,1312-P01,Phase II in Mild AD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13296,1312-0013,1312.13,Unconfirmed,806,1312-P01,Phase II in Prodromal AD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13297,1312-0014,1312.14,Unconfirmed,806,1312-P01,MRD in HVs (PoM),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13298,1313-0001,1313.1,Ended,807,1313-P01,SRD in Healthy Males,Ended,MIG,Migration,IA,Phase Ia,HPZ study first in man ,2011-002560-24,,000910,IS - Clin Study (MIGRATED)
13299,1313-0002,1313.2,Ended,807,1313-P01,Multiple Rising Dose (MRD),Ended,MIG,Migration,IB,Phase Ib,mild asthma, otherwise healthy subjects ,2012-001615-23,,000910,IS - Clin Study (MIGRATED)
13300,1313-0003,1313.3,Unconfirmed,807,1313-P01,Induced Sputum PoM Study,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13301,1313-0004,1313.4,Unconfirmed,807,1313-P01,Allergen Challenge out of Season Grass,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13302,1313-0005,1313.5,Unconfirmed,807,1313-P01,Thorough QTc,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13303,1313-0007,1313.7,Ended,807,1313-P01,DDI with Ketoconazole,Ended,MIG,Migration,I,Phase I,,2012-003225-21,,000910,IS - Clin Study (MIGRATED)
13304,1313-0008,1313.8,Unconfirmed,807,1313-P01,Hepatic Impairment Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13305,1313-0009,1313.9,Ended,807,1313-P01,Relative Bioavailability study,Ended,MIG,Migration,I,Phase I,,2013-000258-23,,000910,IS - Clin Study (MIGRATED)
13306,1313-0010,1313.10,Unconfirmed,807,1313-P01,6 wk Safety and Efficacy study,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13307,1313-0011,1313.11,Unconfirmed,807,1313-P01,18 wk safety/efficacy/steroid titration,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13308,1313-0012,1313.12,Unconfirmed,807,1313-P01,6 wk posology crossover,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13309,1313-0013,1313.13,Unconfirmed,807,1313-P01,18 wk safety/ efficacy (ICS / LABA),Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13310,1313-0014,1313.14,Unconfirmed,807,1313-P01,Pediatric Formulation Bridging,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13311,1313-0015,1313.15,Unconfirmed,807,1313-P01,6 week efficacy and safety (JPN),Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13312,1313-0016,1313.16,Unconfirmed,807,1313-P01,6wk Adolescent Efficacy Bridging,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13313,1313-0017,1313.17,Unconfirmed,807,1313-P01,DDI with a CYP 3A4 inhibitor,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13314,1313-0018,1313.18,Unconfirmed,807,1313-P01,DDI with a PgP inhibitor,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13315,1313-0019,1313.19,Unconfirmed,807,1313-P01,mass balance/  human ADME,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13316,1199-0028,1199.28,Ended,808,1199-P07,BIBF 1120+Pem (JPN), Ph I/II,Ended,MIG,Migration,IB,Phase Ib,Japanese patients; Phase I/II trial ,,,000910,IS - Clin Study (MIGRATED)
13317,1199-0029,1199.29,Ended,808,1199-P07,BIBF 1120 + Docetaxel(Japan), Phase I,Ended,MIG,Migration,IB,Phase Ib,Japanese NSCLC patients ,,,000910,IS - Clin Study (MIGRATED)
13318,1199-0088,1199.88,Unconfirmed,808,1199-P07,BIBF 1120+pemetrexed Japanese Phase III,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13319,1199-0090,1199.90,Analysis,808,1199-P07,Appropriateness of N200+D75 for RD,Analysis,MIG,Migration,IB,Phase Ib,Trial 1199.29 released in Sept 2008 as Phase I/II. IMC decision (December 2008) to split into Phase I (1199.29) and Phase II (1199.90) after PMDA interaction. 1199.90 will enroll the remaining patients needed for registration in Japan, in case that not a sufficient number of Japanese patients has been entered into the Phase III trial 1199.13 (competitive recruitment).,,,000080,IS - Clin Study - Clin Pharm - Explore
13320,1199-0223,1199.223,First Subject Randomised,808,1199-P07,Biomarker study in patients with NSCLC,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
13321,1199-0224,1199.224,First Subject Randomised,808,1199-P07,Safety of nintedanib + weekly docetaxel,First Subject Randomised,MIG,Migration,I,Phase I,,2015-000317-52,,000910,IS - Clin Study (MIGRATED)
13322,1199-0261,1199.261,Unconfirmed,808,1199-P07,East Asian patients NSCLC Adenos,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13323,1199-0272,1199.272,First Subject Randomised,808,1199-P07,Safety in Indian NSCLC pts,First Subject Randomised,MIG,Migration,NONE,Not Classified,,,,000410,NISnd ‚Äì Study - Other
13324,1314-0001,1314.1,Ended,809,1314-P01,SRD in Healthy Volunteers,Ended,MIG,Migration,IA,Phase Ia,,2011-005034-19,,000910,IS - Clin Study (MIGRATED)
13325,1314-0002,1314.2,Ended,809,1314-P01,MRD study in Healthy Volunteers,Ended,MIG,Migration,IB,Phase Ib,,2012-002536-82,,000910,IS - Clin Study (MIGRATED)
13326,1314-0003,1314.3,Ended,809,1314-P01,Relative BA and food effect in HV,Ended,MIG,Migration,I,Phase I,,2012-002537-11,,000910,IS - Clin Study (MIGRATED)
13327,1314-0004,1314.4,Preparing,809,1314-P01,PoC and dose ranging,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13328,1314-0005,1314.5,Ended,809,1314-P01,Safety & Tolerability in COPD,Ended,MIG,Migration,I,Phase I,,2012-005451-16,,000910,IS - Clin Study (MIGRATED)
13329,1314-0006,1314.6,Preparing,809,1314-P01,PoC versus active comparator,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13330,1314-0007,1314.7,Ended,809,1314-P01,DDI with ketoconazole (¬± voriconazole),Ended,MIG,Migration,I,Phase I,,2012-002538-36,,000910,IS - Clin Study (MIGRATED)
13331,1314-0008,1314.8,Unconfirmed,809,1314-P01,Pan-Asian SRD trial,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
13332,1314-0009,1314.9,Ended,809,1314-P01,Pan-Asian SRD/MRD trial,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13333,1314-0010,1314.10,Unconfirmed,809,1314-P01,2nd DDI trial (verap, diltiaz, cipro),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13334,1314-0011,1314.11,Unconfirmed,809,1314-P01,PIvotal phase III vs pbo #1,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13335,1314-0012,1314.12,Unconfirmed,809,1314-P01,Pivotal phase III vs pbo #2,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13336,1314-0013,1314.13,Unconfirmed,809,1314-P01,Pivotal head to head vs roflumilast #1,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13337,1314-0014,1314.14,Unconfirmed,809,1314-P01,PIvotal head to head vs roflumilast #2,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13338,1314-0015,1314.15,Unconfirmed,809,1314-P01,Effects on mucociliary clearance,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13339,1314-0016,1314.16,Unconfirmed,809,1314-P01,Effect on EGFR internalization,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13340,1314-0017,1314.17,Unconfirmed,809,1314-P01,BI 113608 effect on virus replication,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13341,1314-0018,1314.18,Unconfirmed,809,1314-P01,Thorough QT trial,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13342,1314-0019,1314.19,Unconfirmed,809,1314-P01,BI 113608 14C ADME study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13343,1314-0020,1314.20,Unconfirmed,809,1314-P01,PK in patients with hepatic impairment,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13344,1314-0021,1314.21,Unconfirmed,809,1314-P01,PK in patients with renal impairment,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13345,1314-0022,1314.22,Unconfirmed,809,1314-P01,Absolute BA after iv.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13346,1314-0023,1314.23,Unconfirmed,809,1314-P01,Alternative posology trial (placeholder),Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13347,1314-0024,1314.24,Unconfirmed,809,1314-P01,DDI trial with P-gp/BCRP substrate,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13348,1314-0025,1314.25,Unconfirmed,809,1314-P01,4th DDI trial (placeholder),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13349,1314-0026,1314.26,Unconfirmed,809,1314-P01,Confirmatory trial on food effect,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13350,1314-0027,1314.27,Unconfirmed,809,1314-P01,Photosensitivity evaluation in man,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13351,1314-0028,1314.28,Preparing,809,1314-P01,BI 113608 Proof of concept in COPD/CB,Preparing,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13352,1315-0001,1315.1,First Subject Randomised,810,1315-P01,Phase I monotherapy in leukemia,First Subject Randomised,MIG,Migration,I,Phase I,Planned number of subjects updated to reflect new subject population (AML patients in CR) planned recruitment (screened: +35 and randomized/entered: +27),,,000910,IS - Clin Study (MIGRATED)
13353,1315-0002,1315.2,First Subject Randomised,810,1315-P01,BI 836858 combi vs decitabine,First Subject Randomised,MIG,Migration,II,Phase II,,2015-002892-30,,000910,IS - Clin Study (MIGRATED)
13354,1315-0003,1315.3,Unconfirmed,810,1315-P01,BI 836858 combi vs 5 - Aza,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13355,1315-0004,1315.4,Unconfirmed,810,1315-P01,BI 836858 maintenence in AML,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13356,1315-0005,1315.5,Unconfirmed,810,1315-P01,Bi836858 mono vs placebo,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13357,1315-0006,1315.6,Preparing,810,1315-P01,Asian Phase I,Preparing,FULL,Full functionality,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13358,1315-0007,1315.7,First Subject Randomised,810,1315-P01,Phase I/II monotherapy of low risk MDS,First Subject Randomised,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13359,1315-0008,1315.8,Preparing,810,1315-P01,PH-F16IL2CD33-03/15 TeleukinBI836858 AML,Preparing,MIG,Migration,I,Phase I,Sponsor Philogen; PH-F16IL2CD33-03/15 ,,,,
13360,1315-0009,1315.9,First Subject Randomised,810,1315-P01,BAML-16-001-S2/BI 836858 with 5-Aza,First Subject Randomised,MIG,Migration,II,Phase II,Sponsor LLS: BAML-16-001-S2 ,,,,
13361,1317-0001,1317.1,Preparing,812,1317-P01,Single dose PK in healthy volunteers,Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
13362,1317-0002,1317.2,Unconfirmed,812,1317-P01,Comparative dose trial in Crohn's,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13363,1317-0003,1317.3,Unconfirmed,812,1317-P01,Rollover in Crohn's,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13364,1317-0004,1317.4,Unconfirmed,812,1317-P01,Comparative dose trial in RA,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13365,1288-0007,1288.7,Unconfirmed,813,1288-P02,US Pilot Study Linagliptin+Met XR,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13366,1288-0008,1288.8,Ended,813,1288-P02,US Pilot BA study (fed, fasted),Ended,MIG,Migration,I,Phase I,pilot study, in healthy subjects ,,,000910,IS - Clin Study (MIGRATED)
13367,1288-0009,1288.9,Ended,813,1288-P02,Pivotal BE 5 Lina/1000 Met XR FDC,Ended,MIG,Migration,I,Phase I,,2013-005142-11,,000910,IS - Clin Study (MIGRATED)
13368,1288-0010,1288.10,Ended,813,1288-P02,Pivotal BE 2.5 Lina/750 Met XR FDC,Ended,MIG,Migration,I,Phase I,,2013-005143-85,,000910,IS - Clin Study (MIGRATED)
13369,1288-0011,1288.11,Ended,813,1288-P02,Pivotal BE 2.5Lina/1000 Met XR FDC,Ended,MIG,Migration,I,Phase I,,2013-005144-28,,000910,IS - Clin Study (MIGRATED)
13370,1288-0012,1288.12,Preparing,813,1288-P02,MD Study 5 Lina/1000 Met XR FDC, fed,Preparing,MIG,Migration,I,Phase I,,2014-003314-85,,000910,IS - Clin Study (MIGRATED)
13371,1288-0013,1288.13,Preparing,813,1288-P02,MD Study 2.5 Lina/750 Met XR FDC, fed,Preparing,MIG,Migration,I,Phase I,,2014-003315-11,,000910,IS - Clin Study (MIGRATED)
13372,1288-0014,1288.14,Preparing,813,1288-P02,MD Study 2.5 Lina/1000 Met (Met XR), fed,Preparing,MIG,Migration,I,Phase I,,2014-003316-37,,000910,IS - Clin Study (MIGRATED)
13373,1288-0015,1288.15,Unconfirmed,813,1288-P02,XR Claim Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13374,1288-0016,1288.16,Unconfirmed,813,1288-P02,Pediatric PK Rel BA,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13375,1288-0017,1288.17,Unconfirmed,813,1288-P02,Pediatric 54 week study (Met XR),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13376,1288-0023,1288.23,Unconfirmed,813,1288-P02,BE study Australia,Unconfirmed,MIG,Migration,I,Phase I,needed for submission of LIna/MetXR in A ,,,000910,IS - Clin Study (MIGRATED)
13377,1288-0024,1288.24,Unconfirmed,813,1288-P02,BE study Brazil,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13378,1288-0025,1288.25,Unconfirmed,813,1288-P02,BE study Canada,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13379,1288-0026,1288.26,Unconfirmed,813,1288-P02,BE study Russia,Unconfirmed,MIG,Migration,I,Phase I,to be conducted in Russia ,,,000910,IS - Clin Study (MIGRATED)
13380,1276-0013,1276.13,Ended,814,1276-P02,Pilot BA 25 mg BI 10773/ Met XR 1000 mg,Ended,MIG,Migration,I,Phase I,pilot study in healthy subjects ,,,000910,IS - Clin Study (MIGRATED)
13381,1276-0014,1276.14,Ended,814,1276-P02,Pilot BA FDC 10 mg BI 10773/ Met XR, US,Ended,MIG,Migration,I,Phase I,pilot study in healthy volunteers ,,,000910,IS - Clin Study (MIGRATED)
13382,1276-0015,1276.15,Ended,814,1276-P02,Pivotal BE BI 10773 25/Met 1000 XR FDC,Ended,MIG,Migration,I,Phase I,,2014-002016-17,,000910,IS - Clin Study (MIGRATED)
13383,1276-0016,1276.16,Unconfirmed,814,1276-P02,Pivotal BE BI10773 12.5/Metformin 1000,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13384,1276-0017,1276.17,Unconfirmed,814,1276-P02,Pivotal BE 12.5 BI10773/Met XR 750,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13385,1276-0018,1276.18,Preparing,814,1276-P02,MD Pivotal 25 BI10773/Met XR 1000,Preparing,MIG,Migration,I,Phase I,,2014-005218-53,,000910,IS - Clin Study (MIGRATED)
13386,1276-0019,1276.19,Unconfirmed,814,1276-P02,MD Pivotal BI10773 12.5/Metformin 1000,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13387,1276-0020,1276.20,Unconfirmed,814,1276-P02,MD Pivotal BI10773 12.5/Metformin 750 XR,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13388,1276-0021,1276.21,Unconfirmed,814,1276-P02,Pediatric PK Study,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13389,1276-0025,1276.25,Unconfirmed,814,1276-P02,XR Claim Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13390,1276-0026,1276.26,Unconfirmed,814,1276-P02,Pediatric 54 week study,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13391,1276-0028,1276.28,Ended,814,1276-P02,Pivotal BE 10773 10/Met 1000 XR FDC,Ended,MIG,Migration,I,Phase I,,2014-002360-32,,000910,IS - Clin Study (MIGRATED)
13392,1276-0029,1276.29,Unconfirmed,814,1276-P02,Pivotal BE 5 BI10773/Met XR 750,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13393,1276-0030,1276.30,Unconfirmed,814,1276-P02, Pivotal BE 5mg BI10773/ 1000mg/Met XR,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13394,1276-0031,1276.31,Preparing,814,1276-P02,MD Pivotal 10mg BI 10773/1000mg MetXR,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13395,1276-0032,1276.32,Unconfirmed,814,1276-P02,MD pivotal 5mg BI 10773 / 1000 mg MetXR,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13396,1276-0033,1276.33,Unconfirmed,814,1276-P02,MD pivotal 5mg BI 10773 / 750 mg MetXR,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13397,1276-0034,1276.34,Unconfirmed,814,1276-P02,BE study Australia,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13398,1276-0035,1276.35,Unconfirmed,814,1276-P02,BE study Brazil,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13399,1276-0036,1276.36,Unconfirmed,814,1276-P02,BE study Canada,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13400,1276-0037,1276.37,Unconfirmed,814,1276-P02,BE study Russia,Unconfirmed,MIG,Migration,I,Phase I,to be conducted in Russia ,,,000910,IS - Clin Study (MIGRATED)
13401,1276-0038,1276.38,Unconfirmed,814,1276-P02,Empa 25 mg evening dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13402,1318-0001,1318.1,Preparing,815,1318-P01,Phase I trial in solid tumors patients,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13403,1318-0002,1318.2,Unconfirmed,815,1318-P01,Phase II in Breast cancer patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13404,1318-0003,1318.3,Unconfirmed,815,1318-P01,Phase II in Pnacreas cancer patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13405,1318-0004,1318.4,Unconfirmed,815,1318-P01,Phase II in ovarian cancer patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13406,1318-0005,1318.5,Unconfirmed,815,1318-P01,Phase II in Renal cancer patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13407,1319-0001,1319.1,Unconfirmed,816,1319-P01,Single Rising Dose Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13408,1319-0002,1319.2,Unconfirmed,816,1319-P01,Multiple Rising Dose Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13409,1245-0067,1245.67,Preparing,817,1245-P02,EASE-M study,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13410,1245-0068,1245.68,Unconfirmed,817,1245-P02,PhIIb T1DM all comers study, N-America,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13411,1245-0069,1245.69,Last Subject Randomised,817,1245-P02,EASE-2 (52w eff/safety) T1DM pat,Last Subject Randomised,MIG,Migration,III,Phase III,,2014-001922-14,,000170,IS - Clin Study - Confirmatory/Pivotal
13412,1245-0070,1245.70,Unconfirmed,817,1245-P02,PhIIb, 9-month safety ext. of 1245.69,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13413,1245-0071,1245.71,Unconfirmed,817,1245-P02,EASE-4 Eff. and saf. in all comers trial,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13414,1245-0072,1245.72,First Subject Randomised,817,1245-P02,EASE-3 Eff. and saf. in all comers trial,First Subject Randomised,MIG,Migration,III,Phase III,,2014-005256-26,,000910,IS - Clin Study (MIGRATED)
13415,1245-0073,1245.73,Unconfirmed,817,1245-P02,T1DM microvascular outcome trial,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
13416,1245-0074,1245.74,Unconfirmed,817,1245-P02,Insulin secretion preservation study,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
13417,1245-0075,1245.75,Unconfirmed,817,1245-P02,Poorly controlled study (HbA1c > 8.5%),Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
13418,1245-0076,1245.76,Preparing,817,1245-P02,Pediatric study PK (6-18 years),Preparing,FULL,Full functionality,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13419,1245-0077,1245.77,Unconfirmed,817,1245-P02,Pediatric study (6 - 18 years),Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13420,1245-0078,1245.78,Ended,817,1245-P02,EASE-1 4-w PK and dose finding study,Ended,MIG,Migration,IIA,Phase IIa,,2011-004354-25,,000910,IS - Clin Study (MIGRATED)
13421,1245-0081,1245.81,Unconfirmed,817,1245-P02,Pediatric study PK (Age 2-6 years),Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13422,1245-0082,1245.82,Unconfirmed,817,1245-P02,Pediatric study Age 2-6,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13423,1245-0100,1245.100,First Subject Randomised,817,1245-P02,BETWEEN-T1DM Study,First Subject Randomised,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13424,1245-0113,1245.113,Ended,817,1245-P02,4-week PK/PD trial in Japanese patient,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13425,1245-0114,1245.114,Unconfirmed,817,1245-P02,52-w safety/efficacy in Jap. patients,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13426,1320-0001,1320.1,Ended,818,1320-P01,SRD study in healthy volunteers,Ended,MIG,Migration,I,Phase I,,2012-002366-12,,000910,IS - Clin Study (MIGRATED)
13427,1320-0002,1320.2,Ended,818,1320-P01,MRD study in OA patients,Ended,MIG,Migration,IB,Phase Ib,,2012-005690-31,,000910,IS - Clin Study (MIGRATED)
13428,1320-0003,1320.3,Ended,818,1320-P01,Human Pain Model,Ended,MIG,Migration,IB,Phase Ib,,2012-005691-33,,000910,IS - Clin Study (MIGRATED)
13429,1320-0004,1320.4,Unconfirmed,818,1320-P01,Pan Asian SRD study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13430,1320-0005,1320.5,Unconfirmed,818,1320-P01,Dose finding study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13431,1320-0006,1320.6,Unconfirmed,818,1320-P01,human pain model pilot study,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000300,IS - Methodological Studies
13432,1320-0007,1320.7,Preparing,818,1320-P01,DDI Itraconazole in interaction study,Preparing,MIG,Migration,I,Phase I,,2012-005692-13,,000910,IS - Clin Study (MIGRATED)
13433,1320-0008,1320.8,Unconfirmed,818,1320-P01,Celebrex BE study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13434,1320-0009,1320.9,Unconfirmed,818,1320-P01,Phase III OA of the knee,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13435,1320-0010,1320.10,Unconfirmed,818,1320-P01,Phase III OA of the hip,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13436,1320-0011,1320.11,Unconfirmed,818,1320-P01,Phase III OA of the hand,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13437,1320-0012,1320.12,Unconfirmed,818,1320-P01,Open label extension study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13438,1320-0013,1320.13,Ended,818,1320-P01,Dental pain study,Ended,MIG,Migration,IB,Phase Ib,,2013-003580-62,,000910,IS - Clin Study (MIGRATED)
13439,1320-0014,1320.14,Unconfirmed,818,1320-P01,Asian MRD,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
13440,1320-0015,1320.15,Unconfirmed,818,1320-P01,Relative BA,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13441,1310-0026,1310.26,Unconfirmed,819,1310-P02,Phase II SAR PoC/ DR Adult,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13442,1310-0027,1310.27,Unconfirmed,819,1310-P02,Phase III SAR relief > 12 years pivotal,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13443,1310-0029,1310.29,Unconfirmed,819,1310-P02,Phase III PAR relief > 12 years pivotal,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13444,1310-0037,1310.37,Unconfirmed,819,1310-P02,SAR 5-11 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13445,1310-0038,1310.38,Unconfirmed,819,1310-P02,PAR 5-11 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13446,1310-0039,1310.39,Unconfirmed,819,1310-P02,AR 2-4 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13447,1310-0041,1310.41,Unconfirmed,819,1310-P02,SAR Japanese,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13448,1310-0042,1310.42,Unconfirmed,819,1310-P02,SAR 12-17 yrs,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13449,1321-0001,1321.1,Ended,820,1321-P01,Safety and tolerability,Ended,MIG,Migration,IB,Phase Ib,,2012-003611-66,,000910,IS - Clin Study (MIGRATED)
13450,1321-0002,1321.2,Ended,820,1321-P01,Safety & Efficacy in healthy volunteers,Ended,MIG,Migration,IB,Phase Ib,,2013-003616-52,,000910,IS - Clin Study (MIGRATED)
13451,1321-0003,1321.3,Ended,820,1321-P01,Bleeding or emerg.surgery/procedure,Ended,MIG,Migration,III,Phase III,,2013-004813-41,,000910,IS - Clin Study (MIGRATED)
13452,1321-0004,1321.4,Unconfirmed,820,1321-P01,BI 655075 in emergency surgery,Unconfirmed,MIG,Migration,II,Phase II,case series, no control group ,,,000910,IS - Clin Study (MIGRATED)
13453,1321-0005,1321.5,Ended,820,1321-P01,BI 655075 Japanese Phase I study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13454,1321-0006,1321.6,Last Subject Randomised,820,1321-P01,Chinese PK study,Last Subject Randomised,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13455,1321-0007,1321.7,First Subject Randomised,820,1321-P01,Bleeding in paediatric patients,First Subject Randomised,MIG,Migration,III,Phase III,,2015-002177-37,,000910,IS - Clin Study (MIGRATED)
13456,1321-0008,1321.8,Unconfirmed,820,1321-P01,Standalone dabigatran reversal protocol,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
13457,1321-0009,1321.9,Unconfirmed,820,1321-P01,Reversal of Dabigatran in AF Patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13458,1321-0010,1321.10,Preparing,820,1321-P01,Post approval registry,Preparing,MIG,Migration,IV,Phase IV,This is an NTA. NTA # 150076 ,,,000600,Survey Patient Questionnaire
13459,1321-0011,1321.11,Preparing,820,1321-P01,Idarucizumab safety study in pediatrics,Preparing,MIG,Migration,IV,Phase IV,angelegt f√ºr Dr. Gr√ºnenfelder JAN 2015 ,,,000920,NISnd - Study (MIGRATED)
13460,1321-0012,1321.12,Unconfirmed,820,1321-P01,Idarucizumab noninterv.case-series study,Unconfirmed,MIG,Migration,IV,Phase IV,Created for F. Gr√ºnenfelder ,,,000920,NISnd - Study (MIGRATED)
13461,1321-0013,1321.13,Recruiting,820,1321-P01,IDA ATU,Recruiting,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13462,1321-0014,1321.14,Analysis,820,1321-P01,CU prog. of ida. for Jap. patients,Analysis,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13463,1321-0015,1321.15,First Subject Randomised,820,1321-P01,PMS for idarucizumab in Japan,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
13464,1321-0016,1321.16,Unconfirmed,820,1321-P01,Portugal PAP Praxbind,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13465,1321-0017,1321.17,Preparing,820,1321-P01,Idarucizumab early access program,Preparing,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13466,1144-0008,1144.8,Unconfirmed,821,1144-P03,BE Fasted Zantac SGC,Unconfirmed,MIG,Migration,I,Phase I,outsourcing study ,,,000910,IS - Clin Study (MIGRATED)
13467,1144-0009,1144.9,Unconfirmed,821,1144-P03,BE Fed Zantac SGC,Unconfirmed,MIG,Migration,I,Phase I,outsourcing study ,,,000910,IS - Clin Study (MIGRATED)
13468,1322-0001,1322.1,Unconfirmed,822,1322-P01,SRD in healthy volunteers,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
13469,1324-0001,1324.1,Preparing,826,1324-P01,SRD/MRD study in patients with T2D,Preparing,MIG,Migration,I,Phase I,BI not sponsor of this study ,,,000910,IS - Clin Study (MIGRATED)
13470,1324-0002,1324.2,Unconfirmed,826,1324-P01,Potential Ic study for uptitration,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13471,1324-0003,1324.3,Unconfirmed,826,1324-P01,efficacy and safety in T2D patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13472,1324-0004,1324.4,Unconfirmed,826,1324-P01,DDI study metformin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13473,1324-0005,1324.5,Unconfirmed,826,1324-P01,Dose finding study placebo liraglutide,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13474,1324-0006,1324.6,Unconfirmed,826,1324-P01,controlled extension in T2D patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13475,1324-0007,1324.7,Unconfirmed,826,1324-P01,Human ADME,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13476,1324-0008,1324.8,Unconfirmed,826,1324-P01,2 week liver mechanistic study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13477,1324-0009,1324.9,Unconfirmed,826,1324-P01,Mechanistic hypoglycemic clamp,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13478,1324-0010,1324.10,Unconfirmed,826,1324-P01,Absolute BA,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13479,1324-0011,1324.11,Unconfirmed,826,1324-P01,SRD in Asian patients,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13480,1324-0012,1324.12,Unconfirmed,826,1324-P01,4 week treatment in Japanese patients,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13481,1324-0013,1324.13,Unconfirmed,826,1324-P01,MRD in healthy Chinese volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13482,1324-0014,1324.14,Unconfirmed,826,1324-P01,Mechanistic graded glucose infusion,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13483,1324-0015,1324.15,Unconfirmed,826,1324-P01,Rel BA TF1 vs TF2 single dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13484,1324-0016,1324.16,Unconfirmed,826,1324-P01,Dose strength equivalence,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13485,1324-0017,1324.17,Unconfirmed,826,1324-P01,DDI digoxin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13486,1324-0018,1324.18,Unconfirmed,826,1324-P01,DDI warfarin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13487,1324-0019,1324.19,Unconfirmed,826,1324-P01,DDI oral contraceptives,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13488,1324-0020,1324.20,Unconfirmed,826,1324-P01,DDI sumatriptan,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13489,1324-0021,1324.21,Unconfirmed,826,1324-P01,DDI dummy,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13490,1324-0022,1324.22,Unconfirmed,826,1324-P01,4-6 wk ABPM study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13491,1324-0023,1324.23,Unconfirmed,826,1324-P01,24 wk, ZP2929 mono vs placebo,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13492,1324-0024,1324.24,Unconfirmed,826,1324-P01,104w, ZP2929+met vs liraglutide,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13493,1324-0025,1324.25,Unconfirmed,826,1324-P01,24w, ZP2929 vs placebo MFN+SGLT2,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13494,1324-0026,1324.26,Unconfirmed,826,1324-P01,24w, ZP2929 vs placebo MFN+TZD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13495,1324-0027,1324.27,Unconfirmed,826,1324-P01,24w, ZP2929 vs placebo as add on to MFN,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13496,1324-0028,1324.28,Unconfirmed,826,1324-P01,24w, ZP2929 vs placebo combi insulin,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13497,1324-0029,1324.29,Unconfirmed,826,1324-P01,24w, ZP2929 vs placebo combi MDI insulin,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13498,1324-0030,1324.30,Unconfirmed,826,1324-P01,Cardiovascular safety in high risk pts,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13499,1324-0031,1324.31,Unconfirmed,826,1324-P01,Ph III min. 52-wk extension trial,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13500,1324-0032,1324.32,Unconfirmed,826,1324-P01,52wk Japanese OL safety trial,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13501,1324-0033,1324.33,Unconfirmed,826,1324-P01,PK in RI,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13502,1324-0034,1324.34,Unconfirmed,826,1324-P01,PK in HI,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13503,1324-0035,1324.35,Unconfirmed,826,1324-P01,tQT,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13504,1324-0036,1324.36,Unconfirmed,826,1324-P01,DDI pioglitazone,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13505,1324-0037,1324.37,Unconfirmed,826,1324-P01,PK/PD special populations ethnic diff,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13506,1324-0038,1324.38,Unconfirmed,826,1324-P01,Site absorption study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13507,1324-0039,1324.39,Unconfirmed,826,1324-P01,PK study in mainland China,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13508,1324-0040,1324.40,Unconfirmed,826,1324-P01,Magnetic marker monitoring-study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13509,1323-0001,1323.1,Unconfirmed,827,1323-P02,SRD HV,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
13510,1323-0002,1323.2,Unconfirmed,827,1323-P02,MRD in OA patients,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13511,1323-0003,1323.3,Unconfirmed,827,1323-P02,CYP3A4 DDI,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13512,1323-0004,1323.4,Unconfirmed,827,1323-P02,LEP pain model in HVs,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13513,1323-0005,1323.5,Unconfirmed,827,1323-P02,Pan-Asian SRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13514,1323-0006,1323.6,Unconfirmed,827,1323-P02,Early PoCC,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13515,1323-0007,1323.7,Unconfirmed,827,1323-P02,DF+early PoCC,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13516,1323-0008,1323.8,Unconfirmed,827,1323-P02,Knee OA pivotal study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13517,1323-0009,1323.9,Unconfirmed,827,1323-P02,Hip OA pivotal study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13518,1323-0010,1323.10,Unconfirmed,827,1323-P02,Hand OA pivotal study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13519,1323-0011,1323.11,Unconfirmed,827,1323-P02,OL extension,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13520,1325-0001,1325.1,Analysis,828,1325-P01,Ph I in advanced cancer pts,Analysis,MIG,Migration,I,Phase I,,2013-000765-36,,000910,IS - Clin Study (MIGRATED)
13521,1325-0002,1325.2,Preparing,828,1325-P01,Ph I  BI 860585+BI 836845,Preparing,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
13522,1325-0003,1325.3,Unconfirmed,828,1325-P01,Ph 1 BI 860585 in combination with PLD,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13523,1325-0004,1325.4,Preparing,828,1325-P01,Ph I of BI 860585 in Asian patients,Preparing,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13524,1325-0005,1325.5,Unconfirmed,828,1325-P01,Ph II R of BI860585 with ai vs ai,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13525,1325-0006,1325.6,Unconfirmed,828,1325-P01,Ph II R of BI 860585 with CT in Ovarian,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13526,1325-0007,1325.7,Unconfirmed,828,1325-P01,Ph III R BI860585+IGF+ET,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13527,1325-0008,1325.8,Unconfirmed,828,1325-P01,Ph III of BI 860585 with CT vs CT in OC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13528,1325-0009,1325.9,Unconfirmed,828,1325-P01,Ph II BI 860585 with CT in BC,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13529,1325-0010,1325.10,Unconfirmed,828,1325-P01,Ph II BI 860585+BI836845+Fulvestrant,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13530,1325-0011,1325.11,Unconfirmed,828,1325-P01,Ph I/II BI 860585 with CT in SCLC,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
13531,1325-0012,1325.12,Unconfirmed,828,1325-P01,PhIII trial of BI860585 with pacli in BC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13532,1325-0013,1325.13,Unconfirmed,828,1325-P01,PhIII BI 860585 with chemo in SCLC,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
13533,1325-0014,1325.14,Unconfirmed,828,1325-P01,Ph III BI860585+BI 836845 in BC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13534,1326-0001,1326.1,Ended,829,1326-P01,Efficacy of Bisolviral in common cold,Ended,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
13535,1199-0093,1199.93,First Subject Randomised,830,1199-P08,Ph II/III BIBF1120 in mesothelioma,First Subject Randomised,MIG,Migration,III,Phase III,,2012-005201-48,,000910,IS - Clin Study (MIGRATED)
13536,1199-0157,1199.157,Unconfirmed,830,1199-P08,Nintedanib + CT in Flt3-ITD Ped AML,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13537,1199-0158,1199.158,Unconfirmed,830,1199-P08,Ph3 BIBF 1120+CT in Flt3+ Pediatric AML,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13538,1220-0018,1220.18,Unconfirmed,831,1220-P03,Paediatric HCV patients GT-1,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13539,1220-0046,1220.46,Ended,831,1220-P03,Relative BA 40 mg SGC vs Ped,Ended,MIG,Migration,I,Phase I,,2012-000687-22,,000910,IS - Clin Study (MIGRATED)
13540,1327-0001,1327.1,Unconfirmed,832,1327-P01,Phase I Single Rising Dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13541,1327-0002,1327.2,Unconfirmed,832,1327-P01,Phase I Multiple Rising Dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13542,1328-0001,1328.1,Unconfirmed,833,1328-P01,FTIM - Phase I study with exp. cohorts,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13543,1328-0002,1328.2,Unconfirmed,833,1328-P01,Ph II Colorectal Cancer 3rd line,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13544,1328-0003,1328.3,Unconfirmed,833,1328-P01,Ph II Pancreatic Adeno Ca 1st line,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13545,1328-0004,1328.4,Unconfirmed,833,1328-P01,Ph III Colorectal Cancer 3rd line,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13546,1328-0005,1328.5,Unconfirmed,833,1328-P01,Ph III Pancreatic Adeno Ca  1st line,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13547,1328-0006,1328.6,Unconfirmed,833,1328-P01,Ph I food effect/PD study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13548,1328-0007,1328.7,Unconfirmed,833,1328-P01,Rand Ph II KRASm+ Met CRC 1st L run-in,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13549,1328-0008,1328.8,Unconfirmed,833,1328-P01,PhII K-RASm+ M+ NSCLC1st Line R+Run-in,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13550,1328-0009,1328.9,Unconfirmed,833,1328-P01,Rand PhIII KRASm+ M+ CRC 1st Line,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13551,1328-0010,1328.10,Unconfirmed,833,1328-P01,Human ADME study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13552,1328-0011,1328.11,Unconfirmed,833,1328-P01,PhII QT study in patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13553,1328-0012,1328.12,Unconfirmed,833,1328-P01,Ph I DDI interaction with digoxin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13554,1328-0013,1328.13,Unconfirmed,833,1328-P01,Ph I CYP DDI 1,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13555,1328-0014,1328.14,Unconfirmed,833,1328-P01,Ph I CYP DDI 2,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13556,1328-0015,1328.15,Unconfirmed,833,1328-P01,Ph II in hepatic impaired patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13557,1328-0016,1328.16,Unconfirmed,833,1328-P01,Absolute bioavailability study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13558,1328-0017,1328.17,Unconfirmed,833,1328-P01,Asian Ph I with exp coh. PAC-CRC-NSCLC,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13559,1328-0018,1328.18,Unconfirmed,833,1328-P01,Japan PhI with exp.coh. CRC-PAC-NSCLC,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13560,1328-0019,1328.19,Unconfirmed,833,1328-P01,Asia/Jap PhI/II comb 1stL M+ CRC run-in,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13561,1230-0036,1230.36,Ended,834,1230-P05,AMLSG 20-13,Ended,MIG,Migration,II,Phase II,,2014-000477-39,,,
13562,1230-0037,1230.37,Preparing,834,1230-P05,Ph I Vol+Chemo untreated AML patients,Preparing,MIG,Migration,I,Phase I,,,,,
13563,1230-0039,1230.39,Preparing,834,1230-P05,Polo-Like Kinase Inhibitor + Chemo,Preparing,MIG,Migration,I,Phase I,,,,,
13564,1230-0046,1230.46,Preparing,834,1230-P05,RELAZA-003,Preparing,MIG,Migration,I,Phase I,,,,000080,IS - Clin Study - Clin Pharm - Explore
13565,1230-0047,1230.47,Preparing,834,1230-P05,Volasertib+azacitidine MDS,Preparing,MIG,Migration,II,Phase II,,,,,
13566,1230-0048,1230.48,Unconfirmed,834,1230-P05,PhI volasertib+romidepsin R/R PTCL CTCL,Unconfirmed,MIG,Migration,I,Phase I,,,,,
13567,1230-0049,1230.49,Unconfirmed,834,1230-P05,PhI volasertib plus VSLI in R/R ALL,Unconfirmed,MIG,Migration,I,Phase I,,,,,
13568,1230-0050,1230.50,Unconfirmed,834,1230-P05,PhI volasertib+Belinostat R/R lymphoma,Unconfirmed,MIG,Migration,I,Phase I,,,,,
13569,1218-0115,1218.115,Ended,835,1218-P05,IIS-1-002-IT Avogaro,Ended,MIG,Migration,IV,Phase IV,,2013-002311-10,,,
13570,1218-0117,1218.117,Ended,835,1218-P05,IIS-1-008-GLB_Forst,Ended,MIG,Migration,IV,Phase IV,,,,,
13571,1218-0122,1218.122,Ended,835,1218-P05,IIS-1-007-GLB_Schmieder,Ended,MIG,Migration,IV,Phase IV,,2012-002278-30,,,
13572,1218-0130,1218.130,Analysis,835,1218-P05,IIS-1-011R-AT_Sourij,Analysis,MIG,Migration,IV,Phase IV,,2013-000330-35,,000150,IS - Clin Study - Explore
13573,1218-0131,1218.131,Ended,835,1218-P05,00/0594-LINARI (Meier),Ended,MIG,Migration,IV,Phase IV,,2013-000364-28,,000150,IS - Clin Study - Explore
13574,1218-0132,1218.132,Recruiting,835,1218-P05,IIS-1-018-US_Bajaj,Recruiting,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
13575,1218-0133,1218.133,Ended,835,1218-P05,IIS-1-019-GLB_Marx,Ended,MIG,Migration,IV,Phase IV,,2012-003858-81,,,
13576,1218-0134,1218.134,Ended,835,1218-P05,IIS-1-020-GLB_Marx,Ended,MIG,Migration,III,Phase III,,2012-003859-12,,,
13577,1218-0135,1218.135,Ended,835,1218-P05,IIS-1-015R-JP_Watada,Ended,MIG,Migration,IV,Phase IV,,,,,
13578,1218-0137,1218.137,Ended,835,1218-P05,IIS-1-016-US_Veves,Ended,MIG,Migration,IV,Phase IV,,,,,
13579,1218-0139,1218.139,Ended,835,1218-P05,IIS-1-025R-NL_Kamphuisen,Ended,MIG,Migration,IV,Phase IV,,2012-005220-15,,,
13580,1218-0140,1218.140,Ended,835,1218-P05,IIS-1-024-GLB_Forst,Ended,MIG,Migration,IIIB,Phase IIIb,,2012-004300-35,,,
13581,1218-0144,1218.144,Ended,835,1218-P05,IIS-0-006-SP_Sangr√≥s,Ended,MIG,Migration,NONE,Not Classified,,,,,
13582,1218-0146,1218.146,First Subject Randomised,835,1218-P05,IIS-1-035-IT_Giorda,First Subject Randomised,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
13583,1218-0150,1218.150,Ended,835,1218-P05,IIS-1-032-JP_Sato,Ended,MIG,Migration,IV,Phase IV,,,,,
13584,1218-0151,1218.151,Ended,835,1218-P05,IIS-0-007-SP_Franch,Ended,MIG,Migration,NONE,Not Classified, Values from CTMS: Planned Subjects Screened: 200000, Planned Subjects Randomized: 200000, Planned Subjects Completed Treatment: 200000,,,,
13585,1218-0152,1218.152,Last Subject Randomised,835,1218-P05,IIS-1-054-JP_Miyagawa,Last Subject Randomised,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
13586,1218-0155,1218.155,Preparing,835,1218-P05,IIS-1-046-US_Raj,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,,
13587,1218-0156,1218.156,Analysis,835,1218-P05,IIS-1-047R-NL_Kramer,Analysis,MIG,Migration,IV,Phase IV,,2013-002493-47,,000150,IS - Clin Study - Explore
13588,1218-0157,1218.157,Ended,835,1218-P05,IIS-1-053_US_Dandona,Ended,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
13589,1218-0158,1218.158,Analysis,835,1218-P05,IIS-1-055-JP_Hirose,Analysis,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
13590,1218-0159,1218.159,Analysis,835,1218-P05,IIS-1-037-US_Umpierrez,Analysis,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
13591,1218-0160,1218.160,Ended,835,1218-P05,IIS-0-010-CN_Chan,Ended,MIG,Migration,IV,Phase IV,,,,,
13592,1218-0165,1218.165,Recruiting,835,1218-P05,IIS-1-065-JP_Kamada,Recruiting,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
13593,1218-0166,1218.166,First Subject Randomised,835,1218-P05,ePREDICE,First Subject Randomised,MIG,Migration,IIIB,Phase IIIb,,,,000150,IS - Clin Study - Explore
13594,1218-0167,1218.167,Ended,835,1218-P05,IIS-1-066-JP_Yabe,Ended,MIG,Migration,IV,Phase IV,,,,,
13595,1218-0168,1218.168,Analysis,835,1218-P05,IIS-1-071-US_Umpierrez,Analysis,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
13596,1218-0170,1218.170,Recruiting,835,1218-P05,IIS-1-073-US_Sen,Recruiting,MIG,Migration,I,Phase I,,,,000150,IS - Clin Study - Explore
13597,1218-0171,1218.171,First Subject Randomised,835,1218-P05,IIS-1-072-UK_Frankel,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
13598,1218-0173,1218.173,First Subject Randomised,835,1218-P05,IIS-0-013-SP_Galceran,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000410,NISnd ‚Äì Study - Other
13599,1218-0176,1218.176,Recruiting,835,1218-P05,IIS-1-082-JP_Watada,Recruiting,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
13600,1218-0177,1218.177,Preparing,835,1218-P05,IIS-1-083-CN_Li,Preparing,IIS,Investigator Initiated Study,IV,Phase IV,,,,000150,IS - Clin Study - Explore
13601,1304-0010,1304.10,Unconfirmed,836,1304-P02,Roll-over in RA,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13602,1304-0011,1304.11,Unconfirmed,836,1304-P02,AbGn-168H in TNF naive patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13603,1329-0001,1329.1,Preparing,837,1329-P01,SRD + itraconazole (2-part study),Preparing,MIG,Migration,I,Phase I,Part I: SRD; Part II: DDI ,2015-002193-20,,000910,IS - Clin Study (MIGRATED)
13604,1329-0002,1329.2,Unconfirmed,837,1329-P01,SRD-CSF,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13605,1329-0003,1329.3,Unconfirmed,837,1329-P01,MRD with CSF,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13606,1329-0004,1329.4,Unconfirmed,837,1329-P01,DDI (digoxin),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13607,1329-0005,1329.5,Unconfirmed,837,1329-P01,Phase II safety and PoM in AD patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13608,1329-0006,1329.6,Unconfirmed,837,1329-P01,Asian Phase1 SRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13609,1329-0007,1329.7,Unconfirmed,837,1329-P01,DDI placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13610,1329-0008,1329.8,Unconfirmed,837,1329-P01,DDI placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13611,1329-0009,1329.9,Unconfirmed,837,1329-P01,FE + relBA,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13612,1329-0010,1329.10,Unconfirmed,837,1329-P01,TQT,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13613,1329-0011,1329.11,Unconfirmed,837,1329-P01,Renal impairment,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13614,1329-0012,1329.12,Unconfirmed,837,1329-P01,absBA and ADME,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13615,1329-0013,1329.13,Unconfirmed,837,1329-P01,Asian MRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13616,1329-0014,1329.14,Unconfirmed,837,1329-P01,Safety in early AD patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13617,1330-0001,1330.1,Unconfirmed,838,1330-P01,Phase I in advanced cancer pts,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13618,1330-0002,1330.2,Unconfirmed,838,1330-P01,Ph I of BI 862142 in combo with CT,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13619,1330-0003,1330.3,Unconfirmed,838,1330-P01,Ph I of BI 862142 novel combo,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13620,1330-0004,1330.4,Unconfirmed,838,1330-P01,Ph I of BI 862142 in combo with RT,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13621,1330-0005,1330.5,Unconfirmed,838,1330-P01,Ph II R of BI 862142 with ai vs ai,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13622,1330-0006,1330.6,Unconfirmed,838,1330-P01,Ph II R of BI 862142 with CT vs CT,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13623,1330-0007,1330.7,Unconfirmed,838,1330-P01,Ph III R of BI862142+ai vs ai+everolimus,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13624,1330-0008,1330.8,Unconfirmed,838,1330-P01,Phase III R of BI 862142 with CT vs CT,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13625,1245-0055,1245.55,Preparing,839,1245-P03,Pediatric dose finding study,Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13626,1245-0056,1245.56,Unconfirmed,839,1245-P03,Pediatric efficacy and safety study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13627,1245-0087,1245.87,Ended,839,1245-P03,Paediatric PK single dose trial,Ended,MIG,Migration,I,Phase I,Trial replacing 1245.55 ,2013-002304-14,,000910,IS - Clin Study (MIGRATED)
13628,1324-0041,1324.41,Unconfirmed,840,1324-P02,Ph IIb dose finding vs placebo & AC,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13629,1324-0042,1324.42,Unconfirmed,840,1324-P02,Ph IIb extension,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13630,1324-0043,1324.43,Unconfirmed,840,1324-P02,Ph III 52w Obese Px,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13631,1324-0044,1324.44,Unconfirmed,840,1324-P02,Ph III 104w Obese Px,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13632,1324-0045,1324.45,Unconfirmed,840,1324-P02,Ph III Cardiovascular outcome study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13633,1331-0001,1331.1,Unconfirmed,841,1331-P01,SRD in healthy volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13634,1331-0002,1331.2,Unconfirmed,841,1331-P01,MRD in healthy volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13635,1331-0004,1331.4,Unconfirmed,841,1331-P01,First dose guiding IIa study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13636,1331-0005,1331.5,Unconfirmed,841,1331-P01,Pan-Asian SRD Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13637,1331-0006,1331.6,Unconfirmed,841,1331-P01,Multicentre Imaging Trial (24 Mo) IIb-1,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13638,1331-0007,1331.7,Unconfirmed,841,1331-P01,Single Ctr Vascular React. Trial IIb-2,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13639,1331-0008,1331.8,Unconfirmed,841,1331-P01,Phase IIb-1 Rollover Extension,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13640,1331-0009,1331.9,Unconfirmed,841,1331-P01,DDI Statin Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13641,1331-0010,1331.10,Unconfirmed,841,1331-P01,DDI ketoconazole,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13642,1331-0011,1331.11,Unconfirmed,841,1331-P01,DDI PPI and food interaction,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13643,1331-0012,1331.12,Unconfirmed,841,1331-P01,DDI Rosuvastatin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13644,1331-0013,1331.13,Unconfirmed,841,1331-P01,DDI atorvastatin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13645,1331-0014,1331.14,Unconfirmed,841,1331-P01,Relative bioavailability TFI vs TFII,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13646,1331-0015,1331.15,Unconfirmed,841,1331-P01,Human ADME and absolute BA,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13647,1331-0016,1331.16,Unconfirmed,841,1331-P01,DDI rifampicin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13648,1331-0017,1331.17,Unconfirmed,841,1331-P01,DDI warfarin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13649,1331-0018,1331.18,Unconfirmed,841,1331-P01,MRD in Chinese healthy volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13650,1331-0019,1331.19,Unconfirmed,841,1331-P01,DDI digoxin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13651,1331-0020,1331.20,Unconfirmed,841,1331-P01,Formal QT prolongation study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13652,1331-0021,1331.21,Unconfirmed,841,1331-P01,PK/PD/Safety in renal insufficiency,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13653,1331-0022,1331.22,Unconfirmed,841,1331-P01,PK/PD/Safety in hepatic insufficiency,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13654,1331-0023,1331.23,Unconfirmed,841,1331-P01,Relative bioavailability TFF vs. iFF,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13655,1331-0024,1331.24,Unconfirmed,841,1331-P01,Food effect of final formulation,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13656,1331-0025,1331.25,Unconfirmed,841,1331-P01,DDI oral contraceptive,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13657,1331-0026,1331.26,Unconfirmed,841,1331-P01,Dose strength equivalence,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13658,1331-0027,1331.27,Unconfirmed,841,1331-P01,DDI placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13659,1331-0028,1331.28,Unconfirmed,841,1331-P01,PK/PD in special populations placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13660,1331-0029,1331.29,Unconfirmed,841,1331-P01,PK study in mainland China,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13661,1331-0030,1331.30,Unconfirmed,841,1331-P01, 8-wk treatment in Japanese patients IIa,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13662,1332-0001,1332.1,Unconfirmed,842,1332-P01,Single Rising Dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13663,1332-0002,1332.2,Unconfirmed,842,1332-P01,Multiple Rising Dose Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13664,1333-0001,1333.1,Ended,843,1333-P01,SRD in healthy volunteers,Ended,MIG,Migration,IA,Phase Ia,,2013-001475-20,,000910,IS - Clin Study (MIGRATED)
13665,1333-0002,1333.2,Ended,843,1333-P01,MRD in mild asthma,Ended,MIG,Migration,IB,Phase Ib,,2013-005463-10,,000910,IS - Clin Study (MIGRATED)
13666,1333-0003,1333.3,Ended,843,1333-P01,SRD in healthy Asian volunteers,Ended,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
13667,1333-0004,1333.4,Ended,843,1333-P01,Relative F TF I and TF II,Ended,MIG,Migration,I,Phase I,,2014-005507-24,,000910,IS - Clin Study (MIGRATED)
13668,1333-0005,1333.5,Unconfirmed,843,1333-P01,Single dose absolute bio-availability,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13669,1333-0006,1333.6,Unconfirmed,843,1333-P01,Radioactive mass balance single dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13670,1333-0007,1333.7,Unconfirmed,843,1333-P01,Renal impairment effect,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13671,1333-0008,1333.8,Unconfirmed,843,1333-P01,Hepatic impairment effect,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13672,1333-0009,1333.9,Unconfirmed,843,1333-P01,DDI statin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13673,1333-0010,1333.10,Unconfirmed,843,1333-P01,DDI theophylline as per 1268.10,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13674,1333-0011,1333.11,Unconfirmed,843,1333-P01,DDI montelukast as per 1268.10,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13675,1333-0012,1333.12,Unconfirmed,843,1333-P01,Thorough QT study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13676,1333-0013,1333.13,Unconfirmed,843,1333-P01,Relative Bioavail paed formulations,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13677,1333-0014,1333.14,Preparing,843,1333-P01,8 week dose ranging,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13678,1333-0015,1333.15,Preparing,843,1333-P01,13 week dose ranging add on iCS,Preparing,MIG,Migration,II,Phase II,,2014-002025-35,,000910,IS - Clin Study (MIGRATED)
13679,1333-0016,1333.16,Preparing,843,1333-P01,12 week controller taper/withdrawal,Preparing,MIG,Migration,II,Phase II,,2014-002026-12,,000910,IS - Clin Study (MIGRATED)
13680,1333-0017,1333.17,Unconfirmed,843,1333-P01,6 week efficay Japanese asthmatics,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13681,1333-0018,1333.18,Unconfirmed,843,1333-P01,EIB > 12 yrs pivotal USA,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13682,1333-0019,1333.19,Unconfirmed,843,1333-P01,EIB > 12 yrs pivotal EU,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13683,1333-0020,1333.20,Unconfirmed,843,1333-P01,Mild > 12 yrs pivotal MTs ICS study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13684,1333-0021,1333.21,Unconfirmed,843,1333-P01, mild > 12 yrs pivotal MTs ICS study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13685,1333-0022,1333.22,Unconfirmed,843,1333-P01,mild > 12yrs pivotal  FP non-inferiority,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13686,1333-0023,1333.23,Unconfirmed,843,1333-P01,mild > 12yrs pivotal  non-inferiority,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13687,1333-0024,1333.24,Unconfirmed,843,1333-P01,severe > 12yrs pivotal,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13688,1333-0025,1333.25,Unconfirmed,843,1333-P01,severe > 12yrs pivotal,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13689,1333-0026,1333.26,Unconfirmed,843,1333-P01,Adolescent bridging study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13690,1333-0027,1333.27,Unconfirmed,843,1333-P01,5-11 yrs asthma bridging,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13691,1333-0028,1333.28,Unconfirmed,843,1333-P01,EIB 5-11 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13692,1333-0029,1333.29,Unconfirmed,843,1333-P01,Asthma mild 5-11 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13693,1333-0030,1333.30,Unconfirmed,843,1333-P01,Asthma add on/ taper 5-11 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13694,1333-0031,1333.31,Unconfirmed,843,1333-P01,Asthma roll over 2-11 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13695,1333-0032,1333.32,Unconfirmed,843,1333-P01,2-4 yrs asthma bridging PK,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13696,1333-0033,1333.33,Unconfirmed,843,1333-P01,Asthma add on 2-4 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13697,1333-0034,1333.34,Unconfirmed,843,1333-P01,Roll over 12-17 yrs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13698,1333-0043,1333.43,Ended,843,1333-P01,Renal GFR  study,Ended,MIG,Migration,I,Phase I,,2014-000320-20,,000910,IS - Clin Study (MIGRATED)
13699,1333-0044,1333.44,Ended,843,1333-P01,Additional Food Effect Study,Ended,MIG,Migration,I,Phase I,,2014-001960-37,,000910,IS - Clin Study (MIGRATED)
13700,1333-0045,1333.45,Unconfirmed,843,1333-P01,DDI OCT2,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13701,1333-0046,1333.46,Unconfirmed,843,1333-P01,MAG3 study,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
13702,1333-0047,1333.47,Preparing,843,1333-P01,Pan Asian Phase I MRD,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13703,1334-0001,1334.1,Ended,844,1334-P01,SRD in healthy volunteers,Ended,MIG,Migration,I,Phase I,,2012-005721-67,,000910,IS - Clin Study (MIGRATED)
13704,1334-0002,1334.2,Ended,844,1334-P01,MRD in healthy volunteers,Ended,MIG,Migration,I,Phase I,,2013-003813-17,,000910,IS - Clin Study (MIGRATED)
13705,1334-0003,1334.3,Preparing,844,1334-P01,Ph IIa 8 w treatment,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13706,1334-0004,1334.4,Unconfirmed,844,1334-P01,PIIb 18 mo treatment,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13707,1334-0005,1334.5,Ended,844,1334-P01,PAN-Asian SRD Study,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13708,1334-0006,1334.6,Unconfirmed,844,1334-P01,Multi Ctr Imaging Trial IIb-1,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13709,1334-0007,1334.7,Unconfirmed,844,1334-P01,Single Ctr Vascular React. Trial IIb-2,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13710,1334-0008,1334.8,Unconfirmed,844,1334-P01,Phase IIb-1 Rollover Extension,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13711,1334-0009,1334.9,Unconfirmed,844,1334-P01,DDI Statin Study,Unconfirmed,MIG,Migration,I,Phase I,,2014-002420-27,,000910,IS - Clin Study (MIGRATED)
13712,1334-0010,1334.10,Ended,844,1334-P01,DDI Itraconazole,Ended,MIG,Migration,I,Phase I,,2013-003814-42,,000910,IS - Clin Study (MIGRATED)
13713,1334-0011,1334.11,Preparing,844,1334-P01,MRD in Chin. & Japan. healthy volunteers,Preparing,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13714,1334-0012,1334.12,Unconfirmed,844,1334-P01,DDI atorvastatin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13715,1334-0013,1334.13,Unconfirmed,844,1334-P01,Relative bioavailabilityTFI vs. TFII,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13716,1334-0014,1334.14,Unconfirmed,844,1334-P01,DDI rifampicin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13717,1334-0015,1334.15,Unconfirmed,844,1334-P01,DDI warfarin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13718,1334-0016,1334.16,Unconfirmed,844,1334-P01,DDI Rosuvastatin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13719,1334-0017,1334.17,Unconfirmed,844,1334-P01,DDI digoxin,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13720,1334-0018,1334.18,Unconfirmed,844,1334-P01,Formal QT prolongation study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13721,1334-0019,1334.19,Unconfirmed,844,1334-P01,Human ADME an absolute BA,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13722,1334-0020,1334.20,Unconfirmed,844,1334-P01,PK/PD/safety in hepatic insufficiency,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13723,1334-0021,1334.21,Unconfirmed,844,1334-P01,PK/PD/safetyin renal insufficiency,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13724,1334-0022,1334.22,Unconfirmed,844,1334-P01,Food effect of final formulation,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13725,1334-0023,1334.23,Unconfirmed,844,1334-P01,DDI oral contraceptive,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13726,1334-0024,1334.24,Unconfirmed,844,1334-P01,Dose strength equivalence,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13727,1334-0025,1334.25,Unconfirmed,844,1334-P01,Relative bioavailability TFI vs. iFF,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13728,1334-0026,1334.26,Unconfirmed,844,1334-P01,PK/PD in special populations placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13729,1334-0027,1334.27,Unconfirmed,844,1334-P01,PK study in mainland China,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13730,1334-0028,1334.28,Preparing,844,1334-P01,Exploratory food effect,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13731,1334-0029,1334.29,Unconfirmed,844,1334-P01,DDI placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13732,1334-0030,1334.30,Unconfirmed,844,1334-P01,IIa 8-wk treatment in Japanese patients,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13733,1334-0031,1334.31,Unconfirmed,844,1334-P01,Phase III Pivotal Trial,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13734,1200-0047,1200.47,Analysis,845,1200-P09,EAP BIBW in Non small cell lung cancer,Analysis,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13735,1200-0051,1200.51,Ended,845,1200-P09,CUP BIBW in NSCLC / Germany,Ended,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13736,1200-0052,1200.52,First Subject Randomised,845,1200-P09,NPU BIBW in NSCLC / UK,First Subject Randomised,MIG,Migration,NONE,Not Classified,NAMED PATIENT SUPPLY PROGRAMME IN UK ,,,000500,Compassionate Use Program (CUP)
13737,1200-0054,1200.54,Preparing,845,1200-P09,EAP afatinib in NSCLC / France,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13738,1200-0056,1200.56,Ended,845,1200-P09,NPU BIBW 2992 in NSCLC / Ireland,Ended,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13739,1200-0057,1200.57,Ended,845,1200-P09,NPU BIBW in NSCLC / Switzerland,Ended,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13740,1200-0058,1200.58,Ended,845,1200-P09,LUX-Lung NPU AT BIBW 2992,Ended,MIG,Migration,NONE,Not Classified,Austria: NPU (named patient use) ,,,000500,Compassionate Use Program (CUP)
13741,1200-0059,1200.59,Ended,845,1200-P09,NPU BIBW in NSCLC / Denmark,Ended,MIG,Migration,NONE,Not Classified,,2010-019450-40,,000500,Compassionate Use Program (CUP)
13742,1200-0060,1200.60,Ended,845,1200-P09,NPU BIBW in NSCLC / Netherlands,Ended,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13743,1200-0061,1200.61,Recruiting,845,1200-P09,CUP BIBW in NSCLC / Belgium / Luxembourg,Recruiting,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13744,1200-0062,1200.62,Ended,845,1200-P09,BIBW 2992 NPU last line NSCLC/ Portugal,Ended,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13745,1200-0064,1200.64,Ended,845,1200-P09,EAP BIBW in NSCLC / Finland,Ended,MIG,Migration,NONE,Not Classified,,2010-020733-93,,000500,Compassionate Use Program (CUP)
13746,1200-0065,1200.65,Ended,845,1200-P09,NPU BIBW in NSCLC / Norway,Ended,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13747,1200-0082,1200.82,Ended,845,1200-P09,NPU BIBW in NSCLC / Sweden,Ended,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13748,1200-0095,1200.95,Ended,845,1200-P09,LUX-Lung NPU SK BIBW 2992,Ended,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13749,1200-0102,1200.102,Preparing,845,1200-P09,LUX-Lung NPU PL BIBW 2992,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13750,1200-0103,1200.103,Preparing,845,1200-P09,LUX-Lung NPU EE BIBW 2992,Preparing,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13751,1200-0104,1200.104,Ended,845,1200-P09,LUX-Lung CUP SLO BIBW 2992,Ended,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13752,1200-0105,1200.105,Preparing,845,1200-P09,LUX-Lung NPU RO BIBW 2992,Preparing,MIG,Migration,NONE,Not Classified,RO: NPU (named patient use) ,,,000500,Compassionate Use Program (CUP)
13753,1200-0106,1200.106,Preparing,845,1200-P09,LUX-Lung NPU HR BIBW 2992,Preparing,MIG,Migration,NONE,Not Classified,Croatia: NPU (named patient use) ,,,000500,Compassionate Use Program (CUP)
13754,1200-0107,1200.107,Analysis,845,1200-P09,NPU BIBW in NSCLC / France,Analysis,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13755,1200-0109,1200.109,Last Subject Randomised,845,1200-P09,NPU BIBW in NSCLC / Turkey,Last Subject Randomised,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13756,1200-0114,1200.114,Recruiting,845,1200-P09,NPU BIBW in NSCLC / South Africa,Recruiting,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13757,1200-0116,1200.116,Preparing,845,1200-P09,LUX-Lung CUP LV BIBW 2992,Preparing,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13758,1200-0129,1200.129,Analysis,845,1200-P09,NPU BIBW in NSCLC / Canada,Analysis,MIG,Migration,IIIB,Phase IIIb,No protocol used for this study - SAP ,,,000500,Compassionate Use Program (CUP)
13759,1200-0148,1200.148,First Subject Randomised,845,1200-P09,Afatinib Named Patient Use,First Subject Randomised,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13760,1200-0195,1200.195,Ended,845,1200-P09,Afatinib CUP in NSCLC,Ended,MIG,Migration,NONE,Not Classified,,,,,
13761,1200-0234,1200.234,Preparing,845,1200-P09,IIS retrospec HER2 gene copy No analysis,Preparing,MIG,Migration,NONE,Not Classified,,,,,
13762,1200-0045,1200.45,Ended,846,1200-P10,LUX-Lung EAP US,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
13763,1200-0046,1200.46,Unconfirmed,846,1200-P10,EAP BIBW in NSCLC / Japan,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13764,1200-0048,1200.48,Ended,846,1200-P10,Afatinib Phase III b  in NSCLC / Canada,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
13765,1200-0049,1200.49,Preparing,846,1200-P10,LUX LUNG EAP BR,Preparing,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13766,1200-0050,1200.50,Preparing,846,1200-P10,EAP BIBW in NSCLC / Mexico,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13767,1200-0053,1200.53,Preparing,846,1200-P10,EAP BIBW in NSCLC / Spain,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13768,1200-0055,1200.55,Last Subject Randomised,846,1200-P10,Afatinib in mut +NSCLC,Last Subject Randomised,MIG,Migration,IIIB,Phase IIIb,,2009-017661-34,,000910,IS - Clin Study (MIGRATED)
13769,1200-0066,1200.66,First Subject Randomised,846,1200-P10,Afatinib in mut+ NSCLC / Asia,First Subject Randomised,MIG,Migration,IIIB,Phase IIIb,includes Asia Korea's study number: 1200.193,,,000910,IS - Clin Study (MIGRATED)
13770,1200-0091,1200.91,Preparing,846,1200-P10,EAP BIBW in NSCLC/Greece,Preparing,MIG,Migration,IIIB,Phase IIIb,Enrolment stops when commercially availa ,2010-019458-42,,000500,Compassionate Use Program (CUP)
13771,1200-0096,1200.96,Preparing,846,1200-P10,LUX-Lung NPU HU BIBW 2992,Preparing,MIG,Migration,IIIB,Phase IIIb,,2010-019658-42,,000500,Compassionate Use Program (CUP)
13772,1200-0099,1200.99,Preparing,846,1200-P10,EAP BIBW in NSCLC / Argentina,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13773,1200-0100,1200.100,Preparing,846,1200-P10,EAP BIBW in NSCLC / Columbia,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13774,1200-0101,1200.101,Preparing,846,1200-P10,EAP BIBW in NSCLC / Venezuela,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13775,1200-0108,1200.108,Preparing,846,1200-P10,LUX-Lung NPU CZ BIBW 2992,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13776,1200-0110,1200.110,Preparing,846,1200-P10,LUX-Lung NPU RF BIBW 2992,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13777,1200-0115,1200.115,Preparing,846,1200-P10,LUX-Lung NPU SRB BIBW 2992,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13778,1200-0126,1200.126,Preparing,846,1200-P10,EAP BIBW in NSCLC / Chile,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13779,1200-0127,1200.127,Preparing,846,1200-P10,EAP BIBW in NSCLC /  Peru,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13780,1200-0128,1200.128,Preparing,846,1200-P10,EAP BIBW in NSCLC / Ecuador,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13781,1200-0193,1200.193,Last Subject Randomised,846,1200-P10,LUX Lung EAP Korea,Last Subject Randomised,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
13782,1200-0205,1200.205,Last Subject Randomised,846,1200-P10,GIDEON,Last Subject Randomised,MIG,Migration,NONE,Not Classified,,,,000420,NISnd ‚Äì Study - Cohort
13783,1200-0217,1200.217,Analysis,846,1200-P10,Ph IV NSCLC with EGFR mutation,Analysis,MIG,Migration,IV,Phase IV,,2014-001077-14,,000910,IS - Clin Study (MIGRATED)
13784,1200-0222,1200.222,First Subject Randomised,846,1200-P10,PhII afatinib adv NSCLC HER2 mutation,First Subject Randomised,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13785,1200-0227,1200.227,First Subject Randomised,846,1200-P10,PARTAGE Study,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
13786,1200-0235,1200.235,First Subject Randomised,846,1200-P10,Korea PMS safety & efficacy NSCLC EGFR,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000940,Post Marketing Study (MIGRATED)
13787,1200-0244,1200.244,Last Subject Randomised,846,1200-P10,Chinese sub study to 1200.66,Last Subject Randomised,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
13788,1200-0247,1200.247,First Subject Randomised,846,1200-P10,SYM-Less Study,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
13789,1200-0266,1200.266,Preparing,846,1200-P10,Afatinib Registration Trial in Vietnam,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
13790,1199-0053,1199.53,Preparing,847,1199-P09,EAP BIBF 1120 2nd line NSCLC / USA,Preparing,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13791,1199-0054,1199.54,Preparing,847,1199-P09,EAP BIBF 1120 2nd line NSCLC / Japan,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13792,1199-0055,1199.55,Recruiting,847,1199-P09,NPU BIBF 1120 2nd line NSCLC,Recruiting,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13793,1199-0056,1199.56,Preparing,847,1199-P09,EAP BIBF 1120 2nd line NSCLC / France,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13794,1199-0057,1199.57,Preparing,847,1199-P09,IIIb BIBF 1120 2nd line NSCLC / Italy,Preparing,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13795,1199-0058,1199.58,Preparing,847,1199-P09,NPP for BIBF 1120 2nd line NSCLC / UK,Preparing,MIG,Migration,NONE,Not Classified,Named pat supply programme in UK ,,,000500,Compassionate Use Program (CUP)
13796,1199-0059,1199.59,Preparing,847,1199-P09,NPU BIBF 1120 2nd line NSCLC/Australia,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13797,1199-0060,1199.60,Preparing,847,1199-P09,EAP BIBF 1120 2nd line NSCLC / Brazil,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13798,1199-0061,1199.61,Preparing,847,1199-P09,Phase IIIb BIBF 1120 2nd line NSCLC/CDN,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13799,1199-0062,1199.62,Preparing,847,1199-P09,EAP BIBF 1120 2nd line NSCLC / Mexico,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13800,1199-0063,1199.63,Preparing,847,1199-P09,IIIB BIBF 1120 2nd line NSCLC / Spain,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13801,1199-0064,1199.64,Preparing,847,1199-P09,EAP BIBF 1120 2nd line NSCLC / Austria,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13802,1199-0065,1199.65,Preparing,847,1199-P09,NPU BIBF 1120 2nd line NSCLC / Netherl.,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13803,1199-0066,1199.66,Preparing,847,1199-P09,CUP BIBF 1120 2nd line NSCLC / Belgium,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13804,1199-0067,1199.67,Preparing,847,1199-P09,EAP BIBF 1120 2nd line NSCLC / Denmark,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13805,1199-0068,1199.68,Preparing,847,1199-P09,EAP BIBF 1120 2nd line NSCLC / Finland,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13806,1199-0069,1199.69,Preparing,847,1199-P09,NPU BIBF 1120 2nd line NSCLC / Ireland,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13807,1199-0070,1199.70,Preparing,847,1199-P09,EAP BIBF 1120 2nd line NSCLC / Norway,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13808,1199-0071,1199.71,Preparing,847,1199-P09,EAP BIBF 1120 2nd line NSCLC / Korea,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13809,1199-0072,1199.72,Preparing,847,1199-P09,NPU BIBF 1120 in 2nd line NSCLC/CH,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13810,1199-0073,1199.73,Preparing,847,1199-P09,PhIIIb BIBF1120 2nd line NSCLC/Portugal,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13811,1199-0074,1199.74,Preparing,847,1199-P09,EAP BIBF 1120 2nd line NSCLC / Asia,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13812,1199-0077,1199.77,Preparing,847,1199-P09,EAP BIBF 1120 2nd line NSCLC / Sweden,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13813,1199-0091,1199.91,Preparing,847,1199-P09,EAP BIBF 1120 2nd line NSCLC / Greece,Preparing,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13814,1199-0095,1199.95,Preparing,847,1199-P09,EAP BIBF 1120 2nd line NSCLC / Poland,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13815,1199-0096,1199.96,Preparing,847,1199-P09,NPU BIBF 1120 2nd line NSCLC / France,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13816,1199-0097,1199.97,Preparing,847,1199-P09,EAP BIBF 1120 2nd line NSCLC / Russia,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13817,1199-0098,1199.98,Preparing,847,1199-P09,Phase IIIb-BIBF1120 2nd line NSCLC/Latam,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13818,1199-0099,1199.99,Preparing,847,1199-P09,NPU BIBF 1120 in NSCLC / South Africa,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13819,1199-0100,1199.100,Preparing,847,1199-P09,EAP BIBF 1120 in NSCLC / Czech Republic,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13820,1199-0101,1199.101,Preparing,847,1199-P09,EAP BIBF 1120 in NSCLC / Slovakia,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13821,1199-0102,1199.102,Preparing,847,1199-P09,NPU BIBF 1120 in NSCLC / Croatia,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13822,1199-0103,1199.103,Preparing,847,1199-P09,EAP BIBF 1120 in NSCLC / Latvia,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13823,1199-0104,1199.104,Preparing,847,1199-P09,EAP BIBF 1120 in NSCLC / Serbia,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13824,1199-0105,1199.105,Preparing,847,1199-P09,EAP BIBF 1120 in NSCLC / Hungary,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13825,1199-0106,1199.106,Preparing,847,1199-P09,EAP BIBF 1120 in NSCLC / Kazakhstan,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13826,1199-0107,1199.107,Preparing,847,1199-P09,CUP BIBF 1120 in NSCLC / Estonia,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13827,1199-0108,1199.108,Preparing,847,1199-P09,EAP BIBF 1120 in NSCLC / Slovenia,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13828,1199-0109,1199.109,Preparing,847,1199-P09,EAP BIBF 1120 in NSCLC / Romania,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13829,1199-0110,1199.110,Unconfirmed,847,1199-P09,EAP BIBF 1120 in NSCLC / China,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13830,1199-0130,1199.130,Preparing,847,1199-P09,EAP BIBF 1120 in NSCLC / Chile,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13831,1199-0131,1199.131,Preparing,847,1199-P09,EAP BIBF 1120 in NSCLC / Columbia,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13832,1199-0132,1199.132,Preparing,847,1199-P09,EAP BIBF 1120 in NSCLC / Ecuador,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13833,1199-0133,1199.133,Preparing,847,1199-P09,EAP BIBF 1120 in NSCLC / Peru,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13834,1199-0134,1199.134,Preparing,847,1199-P09,IIIB BIBF 1120 2nd line NSCLC / Turkey,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13835,1199-0135,1199.135,Preparing,847,1199-P09,EAP BIBF 1120 in NSCLC / Venezuela,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000500,Compassionate Use Program (CUP)
13836,1199-0190,1199.190,Unconfirmed,847,1199-P09,EAP BIBF 1199 in OC / US,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13837,1199-0226,1199.226,Ended,847,1199-P09,MNP Nintedanib in Belgium,Ended,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13838,1199-0269,1199.269,Preparing,847,1199-P09,EAP Nintedanib CRC / USA,Preparing,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13839,1199-0281,1199.281,Unconfirmed,847,1199-P09,EAP of nintedanib mCRC / Japan,Unconfirmed,MIG,Migration,III,Phase III,,,,000500,Compassionate Use Program (CUP)
13840,1199-0282,1199.282,Preparing,847,1199-P09,CUP Nintedanib CRC,Preparing,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13841,1199-0289,1199.289,Unconfirmed,847,1199-P09,CUP Nintedanib CRC 2,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13842,1199-0214,1199.214,First Subject Randomised,848,1199-P10,Systemic Sclerosis (ILD) pivotal study,First Subject Randomised,MIG,Migration,III,Phase III,,2015-000392-28,,000170,IS - Clin Study - Confirmatory/Pivotal
13843,1199-0215,1199.215,Unconfirmed,848,1199-P10,Systemic Sclerosis,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13844,1199-0225,1199.225,Preparing,848,1199-P10, Extension,Preparing,FULL,Full functionality,III,Phase III,,2016-003403-66,19-AUG-16,000100,IS - Clin Study - Clin Pharm - Other
13845,1199-0238,1199.238,First Subject Randomised,848,1199-P10,DDI oral contraceptives,First Subject Randomised,MIG,Migration,I,Phase I,,2015-005664-41,,000910,IS - Clin Study (MIGRATED)
13846,1199-0239,1199.239,Ended,848,1199-P10,DDI Bosentan,Ended,MIG,Migration,I,Phase I,,2015-003819-38,,000910,IS - Clin Study (MIGRATED)
13847,1335-0001,1335.1,Ended,849,1335-P01,Efficacy and Safety in dental pain,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
13848,1335-0002,1335.2,Ended,849,1335-P01,Bioavailability versus monodrugs,Ended,MIG,Migration,I,Phase I,,2013-000990-66,,000910,IS - Clin Study (MIGRATED)
13849,1335-0003,1335.3,Analysis,849,1335-P01,Bioavailibility under fed conditions,Analysis,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13850,1335-0004,1335.4,Unconfirmed,849,1335-P01,rBA versus ibuprofen and caffeine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13851,1335-0005,1335.5,First Subject Randomised,849,1335-P01,Low Back Pain Trial,First Subject Randomised,MIG,Migration,III,Phase III,,2016-000902-12,,000150,IS - Clin Study - Explore
13852,1336-0001,1336.1,First Subject Randomised,850,1336-P01,Phase I FIM in solid tumor patients,First Subject Randomised,MIG,Migration,I,Phase I,,2014-005395-28,,000120,IS - Clin Study - Clin Pharm - Other/IV
13853,1336-0002,1336.2,Unconfirmed,850,1336-P01,Phase II in NSCLC cancer patients,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13854,1336-0003,1336.3,Unconfirmed,850,1336-P01,Phase II in pancreas cancer patients,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13855,1336-0004,1336.4,Unconfirmed,850,1336-P01,Phase II in ovarian cancer patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13856,1336-0005,1336.5,Unconfirmed,850,1336-P01,Phase II in renal cancer patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13857,1336-0006,1336.6,First Subject Randomised,850,1336-P01,Phase I trial weekly in solid tumor,First Subject Randomised,MIG,Migration,I,Phase I,,2015-001132-38,,,
13858,1338-0001,1338.1,Unconfirmed,852,1338-P01,Phase I Dose Escalation,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13859,1338-0002,1338.2,Unconfirmed,852,1338-P01,randomised phase II in 2nd line melanoma,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13860,1338-0003,1338.3,Unconfirmed,852,1338-P01,randomised phase II in BRAFmut CRC,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13861,1338-0004,1338.4,Unconfirmed,852,1338-P01,randomised PH III in 2nd line melanoma,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13862,1338-0005,1338.5,Unconfirmed,852,1338-P01,randomised PH 3 in BRAFmut CRC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13863,1333-0035,1333.35,Unconfirmed,853,1333-P02,Dose Ranging Allergic Rhinitis,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13864,1333-0036,1333.36,Unconfirmed,853,1333-P02,Dose Ranging Allergic Rhinitis Japanese,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13865,1333-0037,1333.37,Unconfirmed,853,1333-P02,Pivotal SAR > 12,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13866,1333-0038,1333.38,Unconfirmed,853,1333-P02,Pivotal SAR > 12,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13867,1333-0039,1333.39,Unconfirmed,853,1333-P02,Pivotal PAR > 12,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13868,1333-0040,1333.40,Unconfirmed,853,1333-P02,Pivotal 6 - 11 SAR,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13869,1333-0041,1333.41,Unconfirmed,853,1333-P02,Pivotal 6 - 11 PAR,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13870,1333-0042,1333.42,Unconfirmed,853,1333-P02,Pivotal 2 - 4 PAR / SAR,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13871,1199-0084,1199.84,Preparing,854,1199-P11,Nintedanib in plt sensitive ROC,Preparing,MIG,Migration,IIIB,Phase IIIb,,2013-001641-14,,000910,IS - Clin Study (MIGRATED)
13872,1199-0117,1199.117,Ended,854,1199-P11,BIBF1120+CBDCA/PLD (Japan), Phase I,Ended,MIG,Migration,IB,Phase Ib,BIBF 1120 in combination with CBDCA/PLD doxil/carbo wii be used commercially availble drug in trial sites,,,000910,IS - Clin Study (MIGRATED)
13873,1199-0118,1199.118,Unconfirmed,854,1199-P11,Japanese 1st line OC bridging trial,Unconfirmed,MIG,Migration,II,Phase II,Re-assigned from earlier phase I concept ,,,000910,IS - Clin Study (MIGRATED)
13874,1199-0119,1199.119,Analysis,854,1199-P11,Ph I BIBF 1120 + Carbo/PLDCaucasian Pts,Analysis,MIG,Migration,I,Phase I,OPU = Spain ,2010-022523-30,,000910,IS - Clin Study (MIGRATED)
13875,1199-0150,1199.150,Unconfirmed,854,1199-P11,BIBF 1120 + chemo in Pt resistant OC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13876,1199-0159,1199.159,Unconfirmed,854,1199-P11,ph I Nintedanib + weekly paclitaxel,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13877,1199-0160,1199.160,Unconfirmed,854,1199-P11,Ph I Nintedanib added to Carbo Gem,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13878,1199-0189,1199.189,Unconfirmed,854,1199-P11,Nintedanib in Asian OC patients,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13879,1220-0066,1220.66,Unconfirmed,855,1220-P04,NPU Compassionate Use for Brazilian Pat,Unconfirmed,MIG,Migration,III,Phase III,,,,000500,Compassionate Use Program (CUP)
13880,1220-0072,1220.72,Preparing,855,1220-P04,EAP BRAZIL iBASED coinfection,Preparing,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13881,1220-0073,1220.73,Unconfirmed,855,1220-P04,NPU GLOBAL iBASED coinfection,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
13882,1245-0084,1245.84,Unconfirmed,856,1245-P04,DDI with Olanzapine,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13883,1245-0085,1245.85,Unconfirmed,856,1245-P04,DDI with Risperidone,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13884,1245-0086,1245.86,Unconfirmed,856,1245-P04,Proof of concept study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13885,1220-0070,1220.70,Preparing,857,1220-P05,FDV + FDC SOF/LDV in TN,Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13886,1220-0071,1220.71,Unconfirmed,857,1220-P05,DCV & FDV study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13887,1220-0076,1220.76,Unconfirmed,857,1220-P05,FDV/SOF/LDV 4wks vs SOF/LDV 8wks in HCV,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
13888,1339-0002,1339.2,Unconfirmed,858,1339-P01,Multiple Rising Dose Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13889,1339-0003,1339.3,Unconfirmed,858,1339-P01,Site specific absorption study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13890,1339-0004,1339.4,Unconfirmed,858,1339-P01,PAN-Asian SRD study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13891,1339-0005,1339.5,Unconfirmed,858,1339-P01,MRD study, Chinese ex China,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13892,1341-0001,1341.1,Unconfirmed,860,1341-P01,Allergen Challenge in Mild Asthma,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13893,1341-0002,1341.2,Unconfirmed,860,1341-P01,HPA Stress Challenge,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13894,1341-0003,1341.3,Unconfirmed,860,1341-P01,4 wk PoM study (Segmental challenge),Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13895,1341-0004,1341.4,Unconfirmed,860,1341-P01,Relative Bioavailability / Food Effect,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
13896,1341-0005,1341.5,Unconfirmed,860,1341-P01,Definitive QTc,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13897,1341-0006,1341.6,Unconfirmed,860,1341-P01,Pan Asian PK Bridging,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13898,1341-0007,1341.7,Unconfirmed,860,1341-P01,Renal Impairment,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13899,1341-0008,1341.8,Unconfirmed,860,1341-P01,12wk safety/efficacy controller na√ØveDRF,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13900,1341-0009,1341.9,Unconfirmed,860,1341-P01,12wk on low dose iCS+LABA,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13901,1341-0010,1341.10,Unconfirmed,860,1341-P01,Steroid withdrawal  (ICS/ LABA) 16 wk,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13902,1341-0011,1341.11,Unconfirmed,860,1341-P01,6 week efficacy and safety (JPN),Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13903,1341-0012,1341.12,Unconfirmed,860,1341-P01,6 wk  Adolescent Efficacy Bridging,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13904,1341-0013,1341.13,Unconfirmed,860,1341-P01,Non-inferiority iCS 12 wk,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13905,1341-0014,1341.14,Unconfirmed,860,1341-P01,Non-inferiority iCS 12 wk,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13906,1341-0015,1341.15,Unconfirmed,860,1341-P01,Pivotal study MTL Superiority 24 wk,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13907,1341-0016,1341.16,Unconfirmed,860,1341-P01,Pivotal study MTL Superiority 52wk,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13908,1341-0017,1341.17,Unconfirmed,860,1341-P01,Pivotal study in Moderate-Serve Asthma,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13909,1341-0018,1341.18,Unconfirmed,860,1341-P01,Pivotal study in Moderate- Serve Asthma,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13910,1341-0019,1341.19,Unconfirmed,860,1341-P01,Pivotal study in EIB (Adult*) acute,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13911,1341-0020,1341.20,Unconfirmed,860,1341-P01,Pivotal study in EIB (Adult*),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13912,1342-0001,1342.1,Unconfirmed,861,1342-P01,PK in healthy volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13913,1342-0002,1342.2,Unconfirmed,861,1342-P01,Efficacy and safety in pts with asthma,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13914,1343-0001,1343.1,Preparing,862,1343-P01,Phase I in advanced cancer pts,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13915,1344-0001,1344.1,Ended,863,1344-P01,Single rising dose,Ended,MIG,Migration,I,Phase I,,2013-002868-88,,000910,IS - Clin Study (MIGRATED)
13916,1344-0002,1344.2,Ended,863,1344-P01,Multiple rising dose / PoM in healthy,Ended,MIG,Migration,I,Phase I,,2014-002482-30,,000910,IS - Clin Study (MIGRATED)
13917,1344-0003,1344.3,Preparing,863,1344-P01,DDI cocktail,Preparing,MIG,Migration,I,Phase I,,2014-004329-42,,000910,IS - Clin Study (MIGRATED)
13918,1344-0004,1344.4,Unconfirmed,863,1344-P01,Phase II safety and PoM in patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13919,1344-0005,1344.5,Preparing,863,1344-P01,Asian SRD,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13920,1344-0006,1344.6,Preparing,863,1344-P01,CV study,Preparing,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13921,1344-0007,1344.7,Unconfirmed,863,1344-P01,DDI placeholder A,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13922,1344-0008,1344.8,Unconfirmed,863,1344-P01,DDI placeholder B,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13923,1344-0009,1344.9,Unconfirmed,863,1344-P01,DDI placeholder C,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13924,1344-0010,1344.10,Unconfirmed,863,1344-P01,DDI placeholder D,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13925,1344-0011,1344.11,Unconfirmed,863,1344-P01,DDI placeholder E,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13926,1344-0012,1344.12,Unconfirmed,863,1344-P01,ADME study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13927,1344-0013,1344.13,Unconfirmed,863,1344-P01,exploratory QTc,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13928,1344-0014,1344.14,Unconfirmed,863,1344-P01,EPAD Phase 2,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13929,1344-0015,1344.15,Unconfirmed,863,1344-P01,DDI donepezil,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13930,1344-0016,1344.16,Unconfirmed,863,1344-P01,DDI with itraconazole,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13931,1344-0017,1344.17,Unconfirmed,863,1344-P01,DDI with statins,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13932,1344-0018,1344.18,Unconfirmed,863,1344-P01,DDI with Ca-antagonists,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13933,1344-0019,1344.19,Unconfirmed,863,1344-P01,DDI with Quetiapine (Seroquel),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13934,1344-0020,1344.20,Ended,863,1344-P01,PoM study,Ended,MIG,Migration,I,Phase I,,2013-004563-32,,000910,IS - Clin Study (MIGRATED)
13935,1344-0021,1344.21,Unconfirmed,863,1344-P01,EPAD extension,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13936,1345-0001,1345.1,Ended,864,1345-P01,Single rising dose,Ended,MIG,Migration,I,Phase I,,2013-003560-31,,000910,IS - Clin Study (MIGRATED)
13937,1345-0002,1345.2,Unconfirmed,864,1345-P01,MRD in OA patients,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13938,1345-0003,1345.3,Unconfirmed,864,1345-P01,Human Pain Model,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13939,1345-0004,1345.4,Unconfirmed,864,1345-P01,Dental pain study,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13940,1345-0005,1345.5,Unconfirmed,864,1345-P01,Proof of Concept and Dose Range Finding,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13941,1345-0006,1345.6,Unconfirmed,864,1345-P01,Pan Asian SRD,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
13942,1345-0007,1345.7,Unconfirmed,864,1345-P01,Pilot trial vs. Tramadol,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13943,1241-0047,1241.47,Preparing,865,1241-P02,Relative BA of OS vs. tablet,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13944,1241-0048,1241.48,Unconfirmed,865,1241-P02,Pediatric PK of Oral drugs,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13945,1241-0049,1241.49,Unconfirmed,865,1241-P02,Pivotal Pediatric Trial,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13946,1241-0066,1241.66,Unconfirmed,865,1241-P02,Taste test of solution and sprinkles,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13947,1346-0006,1346.6,Unconfirmed,869,1346-P01,Safety&Tolerability in Alzheimer's pts,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13948,1346-0008,1346.8,Unconfirmed,869,1346-P01,PoCC/dose-finding in prodromal AD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
13949,1346-0023,1346.23,First Subject Randomised,869,1346-P01,PoCC/dose-finding in Mild to Moderate AD,First Subject Randomised,MIG,Migration,II,Phase II,,2015-005438-24,,000910,IS - Clin Study (MIGRATED)
13950,1346-0024,1346.24,Unconfirmed,869,1346-P01,Pivotal Study in Mild AD,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13951,1346-0025,1346.25,Unconfirmed,869,1346-P01,Pivotal Study in Mild AD,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13952,1346-0026,1346.26,Unconfirmed,869,1346-P01,EPAD study in prodromal AD,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13953,1346-0027,1346.27,Unconfirmed,869,1346-P01,Pan-Asian Pivotal in Mild to Moderate AD,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13954,1346-0028,1346.28,Unconfirmed,869,1346-P01,Safety extension study,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13955,1346-0029,1346.29,Preparing,869,1346-P01,DDI with donepezil,Preparing,PRELIM,Preliminary,I,Phase I,,2015-004226-34,,000910,IS - Clin Study (MIGRATED)
13956,1346-0030,1346.30,Unconfirmed,869,1346-P01,DDI with Simvastatin,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13957,1346-0031,1346.31,Unconfirmed,869,1346-P01,Cognitive remediation in early AD,Unconfirmed,PRELIM,Preliminary,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13958,1346-0037,1346.37,Unconfirmed,869,1346-P01,EEG biomarke in AD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13959,1024-0008,1024.8,Preparing,870,1024-P05,Bioequivalence Trial Russia,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13960,1341-0021,1341.21,Unconfirmed,871,1341-P02,12 wk PoC DRF COPD GOLD II-III,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13961,1341-0022,1341.22,Unconfirmed,871,1341-P02,24 wk Safety/ Efficacy COPD II-IV,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13962,1341-0023,1341.23,Unconfirmed,871,1341-P02,24 wk safety/ efficacy COPD GOLD IV,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13963,1341-0024,1341.24,Unconfirmed,871,1341-P02,52 wk COPD Exacerbation GOLD II-IV,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13964,1341-0025,1341.25,Unconfirmed,871,1341-P02,52 wk COPD Exacerbation GOLD IV,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13965,1347-0001,1347.1,Preparing,873,1347-P01,PK in healthy volunteers,Preparing,MIG,Migration,I,Phase I,No indication as in healthy volunteers ,,,000910,IS - Clin Study (MIGRATED)
13966,1347-0002,1347.2,Unconfirmed,873,1347-P01,Efficacy and safety in patients with RA,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13967,1347-0003,1347.3,Unconfirmed,873,1347-P01,Open label extension study in RA,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13968,1347-0004,1347.4,Unconfirmed,873,1347-P01,Bioequivalence PFS to autoinjector,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13969,1347-0005,1347.5,Unconfirmed,873,1347-P01,PK in healthy volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13970,1348-0001,1348.1,Ended,874,1348-P01,Add-on to Micamlo BP,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
13971,1348-0002,1348.2,Ended,874,1348-P01,Add-on to Micombi BP,Ended,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
13972,1348-0003,1348.3,Ended,874,1348-P01,BE Micamlo+H vs MicTC,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13973,1348-0004,1348.4,Ended,874,1348-P01,BE Micombi+A vs MicTC,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13974,1348-0005,1348.5,Ended,874,1348-P01,DDIstudy T/A/HFDC vs. Micomb vs. Micamlo,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13975,1348-0006,1348.6,First Subject Randomised,874,1348-P01,PMS on long-term use of Micatrio,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
13976,1348-0007,1348.7,Unconfirmed,874,1348-P01,PMS on long-term use of Micatrio,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
13977,1311-0006,1311.6,Analysis,875,1311-P02,Dose finding trial in Crohn's Disease,Analysis,MIG,Migration,IIB,Phase IIb,,2013-002902-29,,000910,IS - Clin Study (MIGRATED)
13978,1311-0007,1311.7,Unconfirmed,875,1311-P02,Pivotal controlled induction trial in CD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13979,1311-0011,1311.11,Preparing,875,1311-P02,Pivotal induction trial in CD,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13980,1311-0020,1311.20,Analysis,875,1311-P02,Long-term extension trial,Analysis,MIG,Migration,II,Phase II,,2015-001834-15,,000910,IS - Clin Study (MIGRATED)
13981,1311-0022,1311.22,Unconfirmed,875,1311-P02,BI 655066 maintenance treatment in aTNF,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13982,1311-0040,1311.40,Unconfirmed,875,1311-P02,Pediatric Crohn's Disease,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13983,1349-0001,1349.1,Unconfirmed,876,1349-P01,Single rising dose + Rel. BA,Unconfirmed,MIG,Migration,IA,Phase Ia,,2014-001364-36,,000910,IS - Clin Study (MIGRATED)
13984,1349-0002,1349.2,Unconfirmed,876,1349-P01,Multiple rising dose,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
13985,1349-0003,1349.3,Unconfirmed,876,1349-P01,BA Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13986,1349-0004,1349.4,Unconfirmed,876,1349-P01,Phase IIa Monotherapy study,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13987,1349-0005,1349.5,Unconfirmed,876,1349-P01,Phase IIa Add-on therapy study,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
13988,1349-0006,1349.6,Unconfirmed,876,1349-P01,Pan Asia Single rising dose study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13989,1349-0007,1349.7,Unconfirmed,876,1349-P01,Pan Asia MRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
13990,1349-0008,1349.8,Unconfirmed,876,1349-P01,Phase IIb Monotherapy study,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13991,1349-0009,1349.9,Unconfirmed,876,1349-P01,Phase IIb Add-on therapy study,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
13992,1349-0010,1349.10,Unconfirmed,876,1349-P01,Phase III Monotherpay study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13993,1349-0011,1349.11,Unconfirmed,876,1349-P01,Phase III add-on to metformin study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13994,1349-0012,1349.12,Unconfirmed,876,1349-P01,Phase III Add-on to basal insulin study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13995,1349-0013,1349.13,Unconfirmed,876,1349-P01,Phase III add-on to 2+OAD vs. insulin,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13996,1349-0014,1349.14,Unconfirmed,876,1349-P01,Phase III add-on to 2+OAD vs. GLP-1,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13997,1349-0015,1349.15,Unconfirmed,876,1349-P01,Phase III CV study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
13998,0502-0608,502.608,Preparing,877,0502-P09,Consumer Use study,Preparing,MIG,Migration,IV,Phase IV,,,,000910,IS - Clin Study (MIGRATED)
13999,0502-0609,502.609,Preparing,877,0502-P09,Self-selection study,Preparing,MIG,Migration,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
14000,1293-0010,1293.10,First Subject Randomised,878,1293-P02,Phase II in lupus nephritis,First Subject Randomised,MIG,Migration,IIA,Phase IIa,,2015-001750-15,,000910,IS - Clin Study (MIGRATED)
14001,1293-0011,1293.11,Unconfirmed,878,1293-P02,Phase III induction in lupus nephritis,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14002,1293-0013,1293.13,Preparing,878,1293-P02,Exploratory maintenance study in LN,Preparing,FULL,Full functionality,II,Phase II,,,,000150,IS - Clin Study - Explore
14003,1311-0008,1311.8,Ended,879,1311-P03,POC, dose finding in AS,Ended,MIG,Migration,II,Phase II,,2013-003666-13,,000910,IS - Clin Study (MIGRATED)
14004,1311-0009,1311.9,Unconfirmed,879,1311-P03,Radiographic and non-radiographic SpA,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14005,1311-0021,1311.21,Preparing,879,1311-P03,Open label extension to SpA study,Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14006,1311-0023,1311.23,Unconfirmed,879,1311-P03,AS radiographic,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
14007,1313-0006,1313.6,Preparing,882,1313-P02,Pan Asian Bridging,Preparing,MIG,Migration,I,Phase I,South Korean phase I unit, Seoul ,,,000910,IS - Clin Study (MIGRATED)
14008,1313-0020,1313.20,Ended,882,1313-P02,IIa/ PoM wAMD,Ended,MIG,Migration,IIA,Phase IIa,,2013-004567-30,,000910,IS - Clin Study (MIGRATED)
14009,1313-0021,1313.21,Unconfirmed,882,1313-P02,IIb/ PoC and Dose Range Finder,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14010,1313-0022,1313.22,Unconfirmed,882,1313-P02,IIb/52 wk Open label PoC Extension,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14011,1313-0023,1313.23,Unconfirmed,882,1313-P02,I/ Geriatric Safety PK,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14012,1313-0024,1313.24,Unconfirmed,882,1313-P02,I/ Definitive QTc,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14013,1313-0025,1313.25,Unconfirmed,882,1313-P02,I/ MENA MRD Safety Bridging,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14014,1313-0026,1313.26,Unconfirmed,882,1313-P02,Renal Impairment,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14015,1313-0027,1313.27,Unconfirmed,882,1313-P02,Hepatic Impairment,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14016,1313-0028,1313.28,Unconfirmed,882,1313-P02,DDI with a CYP 3A4 inhibitor,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14017,1313-0029,1313.29,Unconfirmed,882,1313-P02,DDI with a PgP inhibitor,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14018,1313-0030,1313.30,Unconfirmed,882,1313-P02,Radioactive human ADME,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14019,1313-0031,1313.31,Unconfirmed,882,1313-P02,Pivotal Study-non inferiority to aVEGF I,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14020,1313-0032,1313.32,Unconfirmed,882,1313-P02,Pivotal study-non inferiority to aVEGFII,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14021,1313-0033,1313.33,Unconfirmed,882,1313-P02,Rollover Study-2yr extens. from 1313.31,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
14022,1313-0034,1313.34,Unconfirmed,882,1313-P02,Pivotal study Add on to VEGF Adjunct I,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14023,1313-0035,1313.35,Unconfirmed,882,1313-P02,Pivotal study Add on to VEGF Adjunct II,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14024,1313-0036,1313.36,Unconfirmed,882,1313-P02,Absolute BA (incl SRD iv),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14025,1313-0037,1313.37,Unconfirmed,882,1313-P02,Relative BA (TF II vs iFF),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14026,1313-0038,1313.38,Unconfirmed,882,1313-P02,Relative BA (FF vs iFF),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14027,1313-0039,1313.39,Unconfirmed,882,1313-P02,Confirmatory Food effect with FF,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14028,1313-0040,1313.40,Unconfirmed,882,1313-P02,DDI with CYP3A4/P-gp inducer,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14029,1313-0041,1313.41,Unconfirmed,882,1313-P02,DDIs with moderate/weak CYP3A4 inhibit.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14030,1313-0042,1313.42,Unconfirmed,882,1313-P02,DDIs with moderate/weak CYP3A4 inhibit.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14031,1313-0043,1313.43,Unconfirmed,882,1313-P02,DDIs with moderate/weak CYP3A4 inhibit.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14032,1313-0044,1313.44,Unconfirmed,882,1313-P02,DDIs with moderate/weak CYP3A4 inhibit.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14033,1313-0045,1313.45,Unconfirmed,882,1313-P02,DDIs with moderate/weak CYP3A4 inhibit.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14034,1313-0046,1313.46,Unconfirmed,882,1313-P02,DDIs with moderate/weak CYP3A4 inhibit.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14035,1313-0047,1313.47,Unconfirmed,882,1313-P02,DDIs with moderate/weak CYP3A4 inhibit.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14036,1313-0048,1313.48,Unconfirmed,882,1313-P02,DDIs with BCRP substrate,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14037,1313-0049,1313.49,Unconfirmed,882,1313-P02,DDIs with OCT2 inhibitor (cimetedine),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14038,1313-0050,1313.50,Unconfirmed,882,1313-P02,MRD in mainland China,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14039,1313-0051,1313.51,Unconfirmed,882,1313-P02,Food effect in Japanese with FF,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14040,1305-0008,1305.8,Unconfirmed,883,1305-P03,PK, Safety/ tolerability study in IPF,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14041,1305-0009,1305.9,Unconfirmed,883,1305-P03,Effect of BI1015550 on FVC in IPF pts,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14042,1351-0001,1351.1,First Subject Randomised,884,1351-P01,Ph I mono. civ last line MM,First Subject Randomised,FULL,Full functionality,I,Phase I,,2014-004896-22,,000100,IS - Clin Study - Clin Pharm - Other
14043,1351-0002,1351.2,Unconfirmed,884,1351-P01,Ph II single arm trial in refractory MM,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14044,1351-0003,1351.3,Unconfirmed,884,1351-P01,Randomised Ph III in refractory MM,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14045,1351-0004,1351.4,Unconfirmed,884,1351-P01,Pomalidomide/dex Ph I combo,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14046,1351-0005,1351.5,Unconfirmed,884,1351-P01,Lenalidomide/dex Ph I combo,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14047,1351-0006,1351.6,Unconfirmed,884,1351-P01,Proteasome inhibitor Ph I combo,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14048,1351-0007,1351.7,Unconfirmed,884,1351-P01,Ph III in relapsed MM,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14049,1351-0008,1351.8,Unconfirmed,884,1351-P01,Asian/Japanese Ph I,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14050,1351-0009,1351.9,Unconfirmed,884,1351-P01,Ph II consolidation in MRD + MM,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14051,1351-0010,1351.10,Unconfirmed,884,1351-P01,Ph III ind/consol in ASCT patients,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14052,1241-0053,1241.53,Unconfirmed,885,1241-P03,FDV/BI207127/PPI668 in GT1a for 12 weeks,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14053,1241-0056,1241.56,Unconfirmed,885,1241-P03,Triple DAA in HCV - phase IIb,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14054,1241-0058,1241.58,Preparing,886,1241-P04,iFree EAP US,Preparing,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
14055,1241-0059,1241.59,Preparing,886,1241-P04,iFree NPU Global,Preparing,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
14056,1241-0060,1241.60,Preparing,886,1241-P04,iFree EAP Brazil,Preparing,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
14057,1352-0001,1352.1,Preparing,887,1352-P01,SRD in healthy volunteers,Preparing,MIG,Migration,IA,Phase Ia,,2014-001061-27,,000910,IS - Clin Study (MIGRATED)
14058,1352-0002,1352.2,Unconfirmed,887,1352-P01,Formulation Selection + food effect,Unconfirmed,MIG,Migration,I,Phase I,Study planned to run at Quotient (UK) ,,,000910,IS - Clin Study (MIGRATED)
14059,1352-0003,1352.3,Unconfirmed,887,1352-P01,Combined MRD in HV  and POC in RA,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14060,1352-0004,1352.4,Unconfirmed,887,1352-P01,24 weeks dose finding in RA patients,Unconfirmed,MIG,Migration,II,Phase II,placebo switch to active after 12 weeks ,,,000910,IS - Clin Study (MIGRATED)
14061,1199-0177,1199.177,Ended,888,1199-P12,Expanded Access Program/Phase IIIb,Ended,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
14062,1199-0192,1199.192,Analysis,888,1199-P12,IPF EAP Brazil,Analysis,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
14063,1199-0191,1199.191,First Subject Randomised,889,1199-P13,NPU / CUP IPF,First Subject Randomised,MIG,Migration,NONE,Not Classified,,,,000500,Compassionate Use Program (CUP)
14064,1346-0001,1346.1,Ended,890,1346-P02,FIH, SIngle Rising Dose,Ended,MIG,Migration,I,Phase I,,2013-004937-34,,000910,IS - Clin Study (MIGRATED)
14065,1346-0002,1346.2,Ended,890,1346-P02,Multiple Rising Dose,Ended,MIG,Migration,I,Phase I,,2014-004390-16,,000910,IS - Clin Study (MIGRATED)
14066,1346-0003,1346.3,Ended,890,1346-P02,Proof of Mechanism,Ended,MIG,Migration,I,Phase I,,2014-005652-26,,000910,IS - Clin Study (MIGRATED)
14067,1346-0004,1346.4,Ended,890,1346-P02,Pan-Asian SRD,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14068,1346-0005,1346.5,Unconfirmed,890,1346-P02,Chinese MRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14069,1346-0007,1346.7,Unconfirmed,890,1346-P02,biomarker trial in CIAS,Unconfirmed,PRELIM,Preliminary,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14070,1346-0009,1346.9,Recruiting,890,1346-P02,Proof of Concept in Schizophrenia,Recruiting,MIG,Migration,II,Phase II,,2016-000285-28,,000910,IS - Clin Study (MIGRATED)
14071,1346-0010,1346.10,Ended,890,1346-P02,DDI with Itraconazole,Ended,MIG,Migration,I,Phase I,,2014-004855-29,,000910,IS - Clin Study (MIGRATED)
14072,1346-0011,1346.11,Unconfirmed,890,1346-P02,Pivotal efficacy - North America,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14073,1346-0012,1346.12,Unconfirmed,890,1346-P02,Pivotal efficacy - EU,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14074,1346-0013,1346.13,Unconfirmed,890,1346-P02,Pivotal efficacy - placeholder,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14075,1346-0014,1346.14,Unconfirmed,890,1346-P02,Open-label extension study,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14076,1346-0015,1346.15,Unconfirmed,890,1346-P02,Absolute BA,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14077,1346-0016,1346.16,Unconfirmed,890,1346-P02,Human ADME,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14078,1346-0017,1346.17,Unconfirmed,890,1346-P02,DDI moderate CYP3A4 inhibitor,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14079,1346-0018,1346.18,Analysis,890,1346-P02,DDI strong CYP3A4 inducer,Analysis,PIHPZ,Phase I HPZ,I,Phase I,,2016-004862-24,01-DEC-16,000910,IS - Clin Study (MIGRATED)
14080,1346-0019,1346.19,Unconfirmed,890,1346-P02,Relative BA TF2 vs iFF,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14081,1346-0020,1346.20,Unconfirmed,890,1346-P02,DDI with atypical antipsychotic #1,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14082,1346-0021,1346.21,Unconfirmed,890,1346-P02,DDI with atypical antipsychotic #2,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14083,1346-0022,1346.22,Ended,890,1346-P02,DDI cocktail induction study,Ended,MIG,Migration,I,Phase I,,2015-001371-41,,000910,IS - Clin Study (MIGRATED)
14084,1346-0032,1346.32,Unconfirmed,890,1346-P02,DDI with amlodipine,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14085,1346-0033,1346.33,Unconfirmed,890,1346-P02,Human Abuse Liability trial,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14086,1346-0034,1346.34,Unconfirmed,890,1346-P02,drug vs. cognitive stimulation,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14087,1346-0035,1346.35,Unconfirmed,890,1346-P02,DDI with midazolam at therapeutic dose,Unconfirmed,PRELIM,Preliminary,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14088,1346-0036,1346.36,Unconfirmed,890,1346-P02,DDI with oral contraceptive,Unconfirmed,PRELIM,Preliminary,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14089,1346-0038,1346.38,Unconfirmed,890,1346-P02,Add-on to cognitive training,Unconfirmed,FULL,Full functionality,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14090,1241-0050,1241.50,Preparing,891,1241-P05,iFree in elderly and co-morbid pat,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14091,1241-0051,1241.51,Preparing,891,1241-P05,Evaluation of shorter iFree treatm. dur.,Preparing,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
14092,1241-0052,1241.52,Preparing,891,1241-P05, act drug abusers&meth/buprenorphin sub,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14093,1241-0067,1241.67,Unconfirmed,891,1241-P05,Genet. characterist. GT1a pts iFree comb,Unconfirmed,MIG,Migration,NONE,Not Classified,Investigator Initiated Study ,,,,
14094,1353-0001,1353.1,Ended,892,1353-P01,BA poweder in cap to tab PPI668 formula.,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14095,1353-0002,1353.2,Ended,892,1353-P01,FDV+BI207127+BI 238630 in GT1a for 12wks,Ended,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
14096,1353-0003,1353.3,Preparing,892,1353-P01,FDV+BI207127+BI238630 in TN GT1 pts,Preparing,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14097,1353-0004,1353.4,Preparing,892,1353-P01,BI238630 human ADME,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14098,1353-0005,1353.5,Unconfirmed,892,1353-P01,FDV/DLV/PPI668 in GT1a for 12 weeks,Unconfirmed,MIG,Migration,IIA,Phase IIa,The POP for the trial is Presidio pharma ,,,000910,IS - Clin Study (MIGRATED)
14099,1353-0008,1353.8,Unconfirmed,892,1353-P01,DDI with OC,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14100,1353-0009,1353.9,Unconfirmed,892,1353-P01,TQT Trial,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14101,1353-0010,1353.10,Unconfirmed,892,1353-P01,Effect of renal impairmnt on PK BI238630,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14102,1353-0011,1353.11,Unconfirmed,892,1353-P01,Effect of hepatic impair on PK,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14103,1353-0012,1353.12,Unconfirmed,892,1353-P01,Effect of food on PK of BI238630,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14104,1353-0013,1353.13,Unconfirmed,892,1353-P01,DDI with meth and bup,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14105,1353-0014,1353.14,Unconfirmed,892,1353-P01,DDI with antidepressants,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14106,1353-0015,1353.15,Unconfirmed,892,1353-P01,Asian PK,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14107,1353-0016,1353.16,Unconfirmed,892,1353-P01,DDI with immunosuppressants,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14108,1353-0017,1353.17,Unconfirmed,892,1353-P01,Absolute BA,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14109,1353-0018,1353.18,Unconfirmed,892,1353-P01,Triple DAA in GT1 TN pts,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14110,1353-0019,1353.19,Unconfirmed,892,1353-P01,Triple DAA in GT1 TN pts,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14111,1353-0020,1353.20,Unconfirmed,892,1353-P01,Dual DAA in GT1b TN pts,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14112,1354-0001,1354.1,Unconfirmed,893,1354-P01,Single Rising Dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14113,1354-0002,1354.2,Unconfirmed,893,1354-P01,Multiple Rising Dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14114,1354-0003,1354.3,Unconfirmed,893,1354-P01,PhIIa 8 wks Treatment,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
14115,1354-0004,1354.4,Unconfirmed,893,1354-P01,Ph IIb (24m treatment),Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14116,1354-0005,1354.5,Unconfirmed,893,1354-P01,DDI CYP3A4 inhibitor (itraconazole),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14117,1354-0006,1354.6,Unconfirmed,893,1354-P01,Ph IIb (24m treatment),Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14118,1355-0001,1355.1,Preparing,894,1355-P01,Single Rising Dose, First in Human,Preparing,MIG,Migration,IA,Phase Ia,,2014-000474-19,,000910,IS - Clin Study (MIGRATED)
14119,1355-0002,1355.2,Unconfirmed,894,1355-P01,Multiple Rising Dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14120,1355-0003,1355.3,Unconfirmed,894,1355-P01,Pan-Asian Single Rising Dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14121,1355-0004,1355.4,Unconfirmed,894,1355-P01,Healthy volunteer pain model LEP,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14122,1355-0005,1355.5,Unconfirmed,894,1355-P01,Healthy Volunteer Dental Pain Model,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14123,1355-0006,1355.6,Unconfirmed,894,1355-P01,Pan-Asian MRD,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14124,1355-0007,1355.7,Unconfirmed,894,1355-P01,PoCC in PHN Flex Dose,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
14125,1355-0008,1355.8,Unconfirmed,894,1355-P01,PoCC and dose-finding in DNP,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14126,1355-0009,1355.9,Unconfirmed,894,1355-P01,DDI with strong CYP3A4 inhibitor,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14127,1356-0001,1356.1,Preparing,895,1356-P01,SRD,Preparing,MIG,Migration,I,Phase I,,2014-000475-72,,000910,IS - Clin Study (MIGRATED)
14128,1356-0002,1356.2,Unconfirmed,895,1356-P01,MRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14129,1356-0003,1356.3,Unconfirmed,895,1356-P01,DDI study (itraconazole),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14130,1356-0004,1356.4,Unconfirmed,895,1356-P01,Human Pain Model,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14131,1356-0005,1356.5,Unconfirmed,895,1356-P01,Dental Pain Study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14132,1356-0006,1356.6,Unconfirmed,895,1356-P01,PoC & dose finding in OA,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14133,1356-0007,1356.7,Unconfirmed,895,1356-P01,POC & dose finding in DPNP,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14134,1356-0008,1356.8,Unconfirmed,895,1356-P01,POC in cancer pain,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14135,1356-0009,1356.9,Unconfirmed,895,1356-P01,Pan-Asian SRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14136,1356-0010,1356.10,Unconfirmed,895,1356-P01,Pan-Asian MRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14137,1356-0011,1356.11,Unconfirmed,895,1356-P01,Food Effect (FE),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14138,1356-0012,1356.12,Unconfirmed,895,1356-P01,DPNP confirmatory trial,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14139,1356-0013,1356.13,Unconfirmed,895,1356-P01,confirmatory trial in DPNP,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14140,1356-0014,1356.14,Unconfirmed,895,1356-P01,PHN,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14141,1356-0015,1356.15,Unconfirmed,895,1356-P01,3rd peripheral NeP model,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14142,1356-0016,1356.16,Unconfirmed,895,1356-P01,open-label extension study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14143,1160-0189,1160.189,First Subject Randomised,896,1160-P09,Secondary Prevention of Stroke,First Subject Randomised,MIG,Migration,III,Phase III,,2013-003444-24,,000910,IS - Clin Study (MIGRATED)
14144,1160-0212,1160.212,Unconfirmed,896,1160-P09,ASA bioavailability study Phase I,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14145,1357-0001,1357.1,Unconfirmed,897,1357-P01,PK in healthy volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14146,1357-0002,1357.2,Unconfirmed,897,1357-P01,Comparative efficacy study in RA,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14147,1357-0003,1357.3,Unconfirmed,897,1357-P01,Open label extension study in RA,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14148,1357-0004,1357.4,Unconfirmed,897,1357-P01,BE IV BI 695507 in Healthy Volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14149,1123-0031,1123.31,Recruiting,898,1123-P04,TASTE Tenecteplase in AIS,Recruiting,MIG,Migration,III,Phase III,,,,,
14150,1123-0032,1123.32,Recruiting,898,1123-P04,EXTEND I.A. TNK,Recruiting,MIG,Migration,II,Phase II,,,,,
14151,1123-0034,1123.34,Unconfirmed,898,1123-P04,TEMPO 2 Minor stroke with occlusion,Unconfirmed,MIG,Migration,III,Phase III,,,,,
14152,1123-0035,1123.35,Unconfirmed,898,1123-P04,DIVA,Unconfirmed,IIS,Investigator Initiated Study,II,Phase II,,,,,
14153,1123-0036,1123.36,Preparing,898,1123-P04,ATTEST 2,Preparing,MIG,Migration,III,Phase III,,,,,
14154,1123-0037,1123.37,Unconfirmed,898,1123-P04,TWIST,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,,
14155,1230-0033,1230.33,Analysis,899,1230-P06,Ph I MDS/ CMML 1st line Volasertib+Aza,Analysis,MIG,Migration,I,Phase I,,2013-001290-24,,000150,IS - Clin Study - Explore
14156,1230-0034,1230.34,Unconfirmed,899,1230-P06,Ph III MDS 1st line Volasertib+Aza,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14157,1230-0035,1230.35,Ended,899,1230-P06,Volasertib+ Azacitidine Ph I in JP MDS,Ended,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14158,1230-0043,1230.43,Ended,899,1230-P06,volasertib - MDS - HMA failures,Ended,MIG,Migration,I,Phase I,,2015-004490-32,08-OCT-15,000130,IS - Clin Study - POC
14159,1230-0044,1230.44,Unconfirmed,899,1230-P06,Volasertib - MDS - HMA  failures,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14160,1230-0045,1230.45,Unconfirmed,899,1230-P06,Ph II MDS/ CMML 1st line Volasertib+Aza,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14161,1245-0099,1245.99,Recruiting,900,1245-P05,EMPATROPHY (Jordan),Recruiting,MIG,Migration,IV,Phase IV,,2014-003313-28,,000150,IS - Clin Study - Explore
14162,1245-0101,1245.101,Ended,900,1245-P05,CRC2014EMPA (Schmieder),Ended,MIG,Migration,IIIB,Phase IIIb,,2014-003053-34,,,
14163,1245-0104,1245.104,Ended,900,1245-P05,IIS-3-001-NO_Eriksen,Ended,MIG,Migration,NONE,Not Classified,,,,,
14164,1245-0105,1245.105,Ended,900,1245-P05,EMLIN-001 (Forst),Ended,MIG,Migration,IV,Phase IV,,2014-004895-48,,,
14165,1245-0108,1245.108,Recruiting,900,1245-P05,EmLiFa001 (Roden),Recruiting,MIG,Migration,IV,Phase IV,,2015-000077-12,,000150,IS - Clin Study - Explore
14166,1245-0111,1245.111,First Subject Randomised,900,1245-P05,IIS-2-012-UK_Davies,First Subject Randomised,MIG,Migration,IV,Phase IV,,2015-001594-40,,000150,IS - Clin Study - Explore
14167,1245-0115,1245.115,Preparing,900,1245-P05,IIS-2-015-IT_Ferrannini,Preparing,IIS,Investigator Initiated Study,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14168,1245-0117,1245.117,Preparing,900,1245-P05,IIS-2-016-IT_Del_Prato,Preparing,IIS,Investigator Initiated Study,IV,Phase IV,,2016-002268-15,,000150,IS - Clin Study - Explore
14169,1245-0118,1245.118,Recruiting,900,1245-P05,IIS-2-017-SWE_Ryden,Recruiting,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
14170,1245-0119,1245.119,Preparing,900,1245-P05,00/0764-Empa2 - Empagliflozin and sympathetic nerve traffic,Preparing,IIS,Investigator Initiated Study,IV,Phase IV,,2017-002175-25,,000080,IS - Clin Study - Clin Pharm - Explore
14171,1245-0120,1245.120,Recruiting,900,1245-P05,SUPER-Trial (Schindler),Recruiting,MIG,Migration,IV,Phase IV,,2016-000825-38,,000150,IS - Clin Study - Explore
14172,1245-0123,1245.123,First Subject Randomised,900,1245-P05,IIS-2-026-CAN_Zinman,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14173,1245-0124,1245.124,Recruiting,900,1245-P05,EFFORT (Seufert),Recruiting,MIG,Migration,IV,Phase IV,,2016-000214-30,,000150,IS - Clin Study - Explore
14174,1245-0125,1245.125,First Subject Randomised,900,1245-P05,CRC2016ELMI (Schmieder),First Subject Randomised,MIG,Migration,IV,Phase IV,,2016-000242-57,,000150,IS - Clin Study - Explore
14175,1245-0126,1245.126,First Subject Randomised,900,1245-P05,IIS-2-024-SWE_Ryden,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14176,1245-0127,1245.127,First Subject Randomised,900,1245-P05,IIS-2-028-CH_Burnier,First Subject Randomised,MIG,Migration,IIA,Phase IIa,Methodology study - short name EMMY,,,000150,IS - Clin Study - Explore
14177,1245-0128,1245.128,Preparing,900,1245-P05,IIS-2-029-IT_Ferrannini,Preparing,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14178,1245-0129,1245.129,First Subject Randomised,900,1245-P05,IIS-2-030-US_Kosiborod,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14179,1245-0130,1245.130,Initiated,900,1245-P05,IIS-2-033-JP_Node,Initiated,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14180,1245-0131,1245.131,Unconfirmed,900,1245-P05,IIS-2-034-JP_Kario,Unconfirmed,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14181,1245-0132,1245.132,Preparing,900,1245-P05,IIS-2-035-AUS_Schlaich,Preparing,IIS,Investigator Initiated Study,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14182,1245-0133,1245.133,Preparing,900,1245-P05,IIS-2-036-UK_Sattar,Preparing,IIS,Investigator Initiated Study,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14183,1245-0134,1245.134,First Subject Randomised,900,1245-P05,EmDia (Wild),First Subject Randomised,MIG,Migration,IV,Phase IV,,2016-001264-11,,000150,IS - Clin Study - Explore
14184,1245-0135,1245.135,Preparing,900,1245-P05,IIS-2-031-US_Ballantyne,Preparing,IIS,Investigator Initiated Study,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14185,1245-0136,1245.136,First Subject Randomised,900,1245-P05,IIS-2-039-NL_Heerspink,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14186,1245-0138,1245.138,Unconfirmed,900,1245-P05,IIS-2-042-CH_Christ-Crain,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
14187,1245-0139,1245.139,First Subject Randomised,900,1245-P05,IIS-2-044-AUT_Saemann,First Subject Randomised,MIG,Migration,II,Phase II,,2016-002935-14,,000150,IS - Clin Study - Explore
14188,1245-0140,1245.140,Recruiting,900,1245-P05,IIS-2-047-DK_Poulsen,Recruiting,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14189,1245-0141,1245.141,First Subject Randomised,900,1245-P05,IIS-2-048-US_Testani,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14190,1245-0142,1245.142,Unconfirmed,900,1245-P05,IIS-2-050-SP_Lago,Unconfirmed,MIG,Migration,IV,Phase IV,,,,,
14191,1245-0143,1245.143,Preparing,900,1245-P05,IIS-2-051-FR_Dutour,Preparing,IIS,Investigator Initiated Study,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14192,1245-0144,1245.144,Recruiting,900,1245-P05,Empabrain01 (Heni),Recruiting,IIS,Investigator Initiated Study,II,Phase II,,2016-003477-18,,000150,IS - Clin Study - Explore
14193,1245-0145,1245.145,Preparing,900,1245-P05,IIS-2-045-AUS_Cooper,Preparing,IIS,Investigator Initiated Study,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14194,1245-0147,1245.147,Recruiting,900,1245-P05,EMPA Hemodynamics (Marx),Recruiting,MIG,Migration,II,Phase II,,2016-000172-19,,000150,IS - Clin Study - Explore
14195,1245-0151,1245.151,First Subject Randomised,900,1245-P05,IIS-2-054-AUT_Sourij,First Subject Randomised,MIG,Migration,II/III,Phase II/III,,,,000150,IS - Clin Study - Explore
14196,1245-0152,1245.152,Initiated,900,1245-P05,IIS-2-055-SK_Lee,Initiated,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14197,1280-0004,1280.4,Last Subject Randomised,901,1280-P02,BI836845+Everolimus+Exemestane ER+ BrCa,Last Subject Randomised,MIG,Migration,IB,Phase Ib,,2013-001110-15,,000910,IS - Clin Study (MIGRATED)
14198,1280-0013,1280.13,Unconfirmed,901,1280-P02,Ph III Xentuzumab ER+ breast ca,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14199,1280-0016,1280.16,First Subject Randomised,901,1280-P02,PhIb BI845 + Afatinib in EGFRmut cancer,First Subject Randomised,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14200,1358-0001,1358.1,First Subject Randomised,902,1358-P01,Diclo/Capsaicin Gel Back/Neck Pain,First Subject Randomised,MIG,Migration,III,Phase III,,2015-000404-25,,000910,IS - Clin Study (MIGRATED)
14201,1358-0002,1358.2,Analysis,902,1358-P01,Relative Bioavailability Trial,Analysis,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14202,1360-0001,1360.1,Unconfirmed,904,1360-P01,BI 695511 in neovascular AMD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14203,0352-2066,352.2066,Preparing,905,0352-P03,Imaging in AD Patients - Berkeley,Preparing,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
14204,0352-2067,352.2067,First Subject Randomised,905,0352-P03,fMRI in Borderline Personality Disorder,First Subject Randomised,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
14205,0352-2069,352.2069,First Subject Randomised,905,0352-P03,Emphysema Progression Biomarker Study,First Subject Randomised,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
14206,0352-2070,352.2070,Analysis,905,0352-P03,mucus/perfusion MRI,Analysis,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
14207,0352-2071,352.2071,Unconfirmed,905,0352-P03,MRI to assess pulm. alterations in COPD,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
14208,0352-2072,352.2072,Analysis,905,0352-P03,biomarkers in induced sputum in COPD/HV,Analysis,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
14209,0352-2073,352.2073,First Subject Randomised,905,0352-P03,Fingerprinting in Impulsivity,First Subject Randomised,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
14210,0352-2074,352.2074,Preparing,905,0352-P03,anti CX3CR1 nanobody imaging tool,Preparing,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
14211,0352-2075,352.2075,Unconfirmed,905,0352-P03,Autoimmune disease 1,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
14212,0352-2076,352.2076,Unconfirmed,905,0352-P03,Autoimmune disease 2,Unconfirmed,METHOD,Method,NONE,Not Classified,,,,000300,IS - Methodological Studies
14213,0352-2077,352.2077,Analysis,905,0352-P03,Investigation in PLS patients,Analysis,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
14214,0352-2078,352.2078,Unconfirmed,905,0352-P03,multiplex assays for translat. studies,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
14215,0352-2079,352.2079,Ended,905,0352-P03,RNA seq. analyses from translat. samples,Ended,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
14216,0352-2080,352.2080,Preparing,905,0352-P03,biomarker study (Prof. Howarth),Preparing,MIG,Migration,NONE,Not Classified,,,,,
14217,0352-2082,352.2082,Ended,905,0352-P03,Transporter DDI Study in HV,Ended,MIG,Migration,I,Phase I,,2014-001940-40,,000300,IS - Methodological Studies
14218,0352-2087,352.2087,Analysis,905,0352-P03,Biomarker study in asthma,Analysis,MIG,Migration,NONE,Not Classified,,,,000920,NISnd - Study (MIGRATED)
14219,0352-2089,352.2089,Preparing,905,0352-P03,Charcterization surgically resected pat,Preparing,MIG,Migration,NONE,Not Classified,No patients treated, no BI substance use ,,,,
14220,0352-2094,352.2094,Ended,905,0352-P03,Transporter drug-drug interaction,Ended,MIG,Migration,I,Phase I,,2015-003052-46,,000300,IS - Methodological Studies
14221,0352-2095,352.2095,Unconfirmed,905,0352-P03,SYK BM in asthma pat blood samp at NJH,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
14222,0352-2096,352.2096,Ended,905,0352-P03,Transporter cocktail mutual interaction,Ended,MIG,Migration,I,Phase I,,2016-001893-14,,000300,IS - Methodological Studies
14223,0352-2097,352.2097,Unconfirmed,905,0352-P03,sVAP-1 in NASH,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
14224,0352-2098,352.2098,Preparing,905,0352-P03,Imaging in NASH patients,Preparing,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
14225,1361-0001,1361.1,Ended,906,1361-P01,BA (25/5/1000;10/5/1000) Triple FDC,Ended,MIG,Migration,I,Phase I,pilot study in healthy subjects ,2015-005082-23,05-NOV-15,000090,IS - Clin Study - Clin Pharm - BA/BE
14226,1361-0002,1361.2,Unconfirmed,906,1361-P01,BA (10/5/1000;5/2.5/750 Triple FDC),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14227,1361-0003,1361.3,Preparing,906,1361-P01,BE study (25/5/1000mg (HD1),Preparing,PIHPZ,Phase I HPZ,I,Phase I,,2017‚Äê000425‚Äê12,26-JAN-17,000090,IS - Clin Study - Clin Pharm - BA/BE
14228,1361-0004,1361.4,Unconfirmed,906,1361-P01,BE study  12.5/2.5/1000mg (HD2),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14229,1361-0005,1361.5,Unconfirmed,906,1361-P01,BE study  12.5/2.5/750mg (HD3),Unconfirmed,MIG,Migration,I,Phase I,dose strength most likely not developped ,,,000910,IS - Clin Study (MIGRATED)
14230,1361-0006,1361.6,Unconfirmed,906,1361-P01,BE study  10/5/1000mg (LD1),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14231,1361-0007,1361.7,Unconfirmed,906,1361-P01,BE study 5/2.5/1000mg (LD2),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14232,1361-0008,1361.8,Unconfirmed,906,1361-P01,BE study 5/2.5/750mg (LD3),Unconfirmed,MIG,Migration,I,Phase I,dose strength most likely not developped ,,,000910,IS - Clin Study (MIGRATED)
14233,1361-0009,1361.9,Unconfirmed,906,1361-P01,MD study HD1 vs empa, lina & Glumetza,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14234,1361-0010,1361.10,Unconfirmed,906,1361-P01,MD study LD1 vs empa, lina & Glumetza,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14235,1362-0001,1362.1,Unconfirmed,907,1362-P01,Ph. 1 in advanced cancer patients,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
14236,1362-0002,1362.2,Unconfirmed,907,1362-P01,Phase Ib/II BI 878382 + Volasertib,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
14237,1362-0003,1362.3,Unconfirmed,907,1362-P01,Ph II R study of BI878382 + CT in TNBC,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14238,1362-0004,1362.4,Unconfirmed,907,1362-P01,Phase III R of BI 878382 with CT in TNBC,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14239,1362-0005,1362.5,Unconfirmed,907,1362-P01,Ph III BI 878382 with volasertib in AML,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14240,1311-0014,1311.14,First Subject Randomised,908,1311-P04,PoC in Severe Asthma (24 wks),First Subject Randomised,MIG,Migration,IIA,Phase IIa,,2014-004932-20,,000910,IS - Clin Study (MIGRATED)
14241,1311-0015,1311.15,Unconfirmed,908,1311-P04,DRF in Severe Asthma (26 wks),Unconfirmed,PRELIM,Preliminary,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14242,1311-0016,1311.16,Analysis,908,1311-P04,PAPI in Japanese, Chinese and Caucasian,Analysis,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
14243,1311-0017,1311.17,Unconfirmed,908,1311-P04,CHN SRD/ MRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14244,1311-0018,1311.18,Preparing,908,1311-P04,Biomarker Study (Prof. Howarth),Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14245,1311-0019,1311.19,Preparing,908,1311-P04,Biomarker Study Quintiles,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14246,1311-0025,1311.25,Unconfirmed,908,1311-P04,Posology Finding Asthma,Unconfirmed,PRELIM,Preliminary,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14247,1363-0001,1363.1,Ended,909,1363-P01,SRD in healthy volunteers,Ended,MIG,Migration,I,Phase I,,2015-004395-30,,000910,IS - Clin Study (MIGRATED)
14248,1363-0002,1363.2,First Subject Randomised,909,1363-P01,MRD in HV and CF patients,First Subject Randomised,FULL,Full functionality,IB,Phase Ib,,2016-001504-31,,000020,IS - Clin Study - Clin Pharm - MRD
14249,1363-0003,1363.3,Unconfirmed,909,1363-P01,PoM (radioscintigraphy) in CF patients,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
14250,1363-0006,1363.6,Unconfirmed,909,1363-P01,MRD in healthy volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14251,1363-0007,1363.7,First Subject Randomised,909,1363-P01,MRD in Asthma (Methacholine),First Subject Randomised,FULL,Full functionality,I,Phase I,,2016-001506-42,,000910,IS - Clin Study (MIGRATED)
14252,1363-0008,1363.8,Preparing,909,1363-P01,6 wk dose finding,Preparing,FULL,Full functionality,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14253,1363-0009,1363.9,Unconfirmed,909,1363-P01,Add on effect Hypertonic Saline,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14254,1363-0010,1363.10,Unconfirmed,909,1363-P01,CF >12 yrs pivotal,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14255,1363-0011,1363.11,Unconfirmed,909,1363-P01,CF >12 yrs pivotal,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14256,1363-0017,1363.17,Unconfirmed,909,1363-P01,Relative bioavailability,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,2017‚Äê000855‚Äê24,22-FEB-17,000910,IS - Clin Study (MIGRATED)
14257,1363-0018,1363.18,Unconfirmed,909,1363-P01,Human 14C ADME,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14258,1363-0019,1363.19,Unconfirmed,909,1363-P01,DDI with CYP perpetrator,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14259,1363-0020,1363.20,Unconfirmed,909,1363-P01,Pivotal 6 - 11 years,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14260,1363-0021,1363.21,Unconfirmed,909,1363-P01,Pivotal below 6 years,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14261,1363-0022,1363.22,Unconfirmed,909,1363-P01,Bridging study,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14262,1364-0001,1364.1,Unconfirmed,910,1364-P01,SRD for BI689794 in Healthy Volunteers,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
14263,1364-0002,1364.2,Unconfirmed,910,1364-P01,SRD for BI689794 in DN Patients,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
14264,1364-0003,1364.3,Unconfirmed,910,1364-P01,MRD for BI689794 in Healthy Volunteers,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14265,1364-0004,1364.4,Unconfirmed,910,1364-P01,MRD for BI689794 in DN Patients,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14266,1364-0005,1364.5,Unconfirmed,910,1364-P01,Phase II DF/PoCC for BI689794 in DN,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14267,1365-0001,1365.1,Unconfirmed,911,1365-P01,SRD in HV,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14268,1365-0002,1365.2,Unconfirmed,911,1365-P01,Multiple rising dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14269,1365-0003,1365.3,Unconfirmed,911,1365-P01,Open labeled safety study in patients,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14270,1366-0001,1366.1,Ended,912,1366-P01,SRD for BI 685509 Healthy Volunteers,Ended,PIHPZ,Phase I HPZ,I,Phase I,,2014-004455-31,,000910,IS - Clin Study (MIGRATED)
14271,1366-0002,1366.2,Unconfirmed,912,1366-P01,SRD for BI 685509 in DN Patients,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
14272,1366-0003,1366.3,First Subject Randomised,912,1366-P01,MRD-study of BI 685509 in healthy subjects,First Subject Randomised,PIHPZ,Phase I HPZ,IB,Phase Ib,,2014‚Äê004540‚Äê35,16-OCT-14,000020,IS - Clin Study - Clin Pharm - MRD
14273,1366-0004,1366.4,Preparing,912,1366-P01,MRD for BI 685509 in DN Patients,Preparing,FULL,Full functionality,IB,Phase Ib,,2014-004541-27,,000020,IS - Clin Study - Clin Pharm - MRD
14274,1366-0005,1366.5,Unconfirmed,912,1366-P01,Phase II DF/PoCC for BI 685509 in DN,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14275,1366-0006,1366.6,Unconfirmed,912,1366-P01,Bi 685509 Food Effect,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14276,1366-0007,1366.7,Unconfirmed,912,1366-P01,Food Effect,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14277,1366-0008,1366.8,Unconfirmed,912,1366-P01,Mass Balance,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14278,1366-0009,1366.9,Unconfirmed,912,1366-P01,DDI with CYP2C8 substrate,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14279,1366-0010,1366.10,Analysis,912,1366-P01,DDI with a P-gp inhibitor, OATP-inhibitor, food effect,Analysis,PIHPZ,Phase I HPZ,I,Phase I,,2016-003310-27,10-AUG-16,000910,IS - Clin Study (MIGRATED)
14280,1366-0011,1366.11,Unconfirmed,912,1366-P01,Interaction with statins,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14281,1366-0012,1366.12,Unconfirmed,912,1366-P01,Through QTc,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14282,1366-0013,1366.13,Preparing,912,1366-P01,pan-Asian SRD/MRD study,Preparing,FULL,Full functionality,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14283,1366-0014,1366.14,Unconfirmed,912,1366-P01,MRD Pan-Asian,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14284,1366-0015,1366.15,Unconfirmed,912,1366-P01,Phase III renal outcome study,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14285,1366-0016,1366.16,Unconfirmed,912,1366-P01,Phase III CV outcome trial,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14286,1366-0017,1366.17,Preparing,912,1366-P01,FE/BA study for BI 685509,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14287,1366-0018,1366.18,Unconfirmed,912,1366-P01,Investigation of effects on FMD,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14288,1366-0019,1366.19,Unconfirmed,912,1366-P01,UACR reduction on top of SGLT2i,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14289,1367-0001,1367.1,First Subject Randomised,913,1367-P01,Phase I dose escalation FIM,First Subject Randomised,MIG,Migration,I,Phase I,,2015-001111-12,,000910,IS - Clin Study (MIGRATED)
14290,1367-0002,1367.2,Unconfirmed,913,1367-P01,Phase I/II in AML and MDS,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14291,1367-0003,1367.3,Unconfirmed,913,1367-P01,Phase I study in lymphoma,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14292,1367-0004,1367.4,Unconfirmed,913,1367-P01,Phase II single arm trial in AML,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14293,1367-0005,1367.5,Unconfirmed,913,1367-P01,Phase II in relapsed/refractory myeloma,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14294,1367-0006,1367.6,Unconfirmed,913,1367-P01,Phase I in Asian patients,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14295,1367-0007,1367.7,Unconfirmed,913,1367-P01,Phase III in relapsed/refractory myeloma,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14296,1367-0008,1367.8,Unconfirmed,913,1367-P01,Phase III in treatment-naive AML,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14297,1367-0009,1367.9,Unconfirmed,913,1367-P01,Ph II/III 1st line Double-Hit Lymphoma,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14298,1367-0010,1367.10,Unconfirmed,913,1367-P01,Phase IIb/III 2nd line DLBCL,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14299,1367-0011,1367.11,Unconfirmed,913,1367-P01,Ph IIb/III r/r AML/MDS,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14300,1367-0012,1367.12,Unconfirmed,913,1367-P01,Ph I treatment-naive AML, BET/DAC in USA,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14301,1367-0013,1367.13,Unconfirmed,913,1367-P01,Ph I/II treatment-naive high-risk MDS,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14302,1367-0014,1367.14,Unconfirmed,913,1367-P01,Ph III treatment-naive high-risk MDS,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14303,1367-0015,1367.15,Unconfirmed,913,1367-P01,Phase I Human ADME study,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14304,1367-0016,1367.16,Unconfirmed,913,1367-P01,Absolute bioavailability study,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14305,1363-0004,1363.4,Unconfirmed,914,1363-P02,Proof of Concept in COPD,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14306,1363-0005,1363.5,Unconfirmed,914,1363-P02,Pan Asia Bridging Study,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14307,1363-0012,1363.12,Unconfirmed,914,1363-P02,26 wk dose ranging,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14308,1363-0013,1363.13,Unconfirmed,914,1363-P02,18 yrs pivotal COPD,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14309,1363-0014,1363.14,Unconfirmed,914,1363-P02,18 yrs pivotal COPD,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14310,1363-0015,1363.15,Unconfirmed,914,1363-P02,PD on top of LAMA in COPD patients,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14311,1363-0016,1363.16,Unconfirmed,914,1363-P02,Safety/PD on top of standard care COPD,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14312,1200-0141,1200.141,Ended,915,1200-P11,Epidem Trial in CA Population - CA,Ended,MIG,Migration,NONE,Not Classified,,,,,
14313,1200-0142,1200.142,Ended,915,1200-P11,Epidem of EGFR/HER2/k-ras mutations-MX,Ended,MIG,Migration,IIIB,Phase IIIb,,,,,
14314,1200-0145,1200.145,Recruiting,915,1200-P11,Molecular Epidemiology of NSCLC - Brazil,Recruiting,MIG,Migration,NONE,Not Classified,,,,000410,NISnd ‚Äì Study - Other
14315,1200-0165,1200.165,Ended,915,1200-P11,INSIGHT - NSCLC EGFR epidem,Ended,MIG,Migration,NONE,Not Classified,,,,,
14316,1200-0170,1200.170,Ended,915,1200-P11,Lungscape epidem - CH,Ended,MIG,Migration,NONE,Not Classified,,2013-002397-50,,,
14317,1200-0174,1200.174,Ended,915,1200-P11,Epidem Prevalence low levelsVit D BC,Ended,MIG,Migration,II,Phase II,,,,,
14318,1200-0192,1200.192,Ended,915,1200-P11,Epidem HER2/HER4 mut NSCLC wt EGFR-China,Ended,MIG,Migration,NONE,Not Classified,,,,,
14319,1200-0223,1200.223,Last Subject Randomised,915,1200-P11,Biomarker afatinib EGFR mut+ adv NSCLC,Last Subject Randomised,MIG,Migration,NONE,Not Classified,,,,000150,IS - Clin Study - Explore
14320,1200-0232,1200.232,Ended,915,1200-P11,Characteristics of Patients with NSCLC,Ended,MIG,Migration,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
14321,1200-0236,1200.236,Unconfirmed,915,1200-P11,Freq of Test EGFR+ in NSCLC,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000980,Not Classified (MIGRATED)
14322,1200-0272,1200.272,Preparing,915,1200-P11,Treatment patterns patients with NSCLC,Preparing,MIG,Migration,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
14323,1199-0211,1199.211,Recruiting,916,1199-P14,VARGADO,Recruiting,MIG,Migration,NONE,Not Classified,,,,000420,NISnd ‚Äì Study - Cohort
14324,1199-0212,1199.212,Analysis,916,1199-P14,Angiogenese-Projekt,Analysis,MIG,Migration,NONE,Not Classified,No patients treated, no BI substance use ,,,000700,Pharmacogenetic Research Program
14325,1199-0288,1199.288,Preparing,916,1199-P14,Early progressors,Preparing,MIG,Migration,NONE,Not Classified,,,,000930,NISed - Study (MIGRATED)
14326,1368-0001,1368.1,Ended,917,1368-P01,Phase I SRD iv Hv,Ended,MIG,Migration,I,Phase I,,2015-001931-19,,000910,IS - Clin Study (MIGRATED)
14327,1368-0002,1368.2,Last Subject Randomised,917,1368-P01,Phase I MRD in hv,Last Subject Randomised,MIG,Migration,I,Phase I,,2016-001235-12,,000910,IS - Clin Study (MIGRATED)
14328,1368-0003,1368.3,Last Subject Randomised,917,1368-P01,s.c. formulation study in hv,Last Subject Randomised,PIHPZ,Phase I HPZ,I,Phase I,,2016-004557-32,08-NOV-16,000090,IS - Clin Study - Clin Pharm - BA/BE
14329,1368-0004,1368.4,First Subject Randomised,917,1368-P01,Study to investigate MoA of BI 655130 in UC pts,First Subject Randomised,FULL,Full functionality,IIA,Phase IIa,,2017-000100-20,04-JAN-17,000910,IS - Clin Study (MIGRATED)
14330,1368-0005,1368.5,Preparing,917,1368-P01,Phase II/III in UC patients,Preparing,FULL,Full functionality,II,Phase II,this is a three-part adaptive, operationally seamless  phase 2/3 trial of 12 weeks induction with BI 655130
part 1: phase 2 POC and dose finding (PBO controlled parallel group, double blind design with 2 active dose groups)
part 2: between LPI part 1 and FPI part 2 - active feeder( non-controlled parallel group with 2 active dose groups)
part 3: phase 3 confirmatory trial of efficacy and safety of 12 weeks induction with BI 655130 (PBO controlled, double blind parallel group design with 2 active dose groups)
,,,000910,IS - Clin Study (MIGRATED)
14331,1368-0006,1368.6,Unconfirmed,917,1368-P01,Adaptive Phase III induction and maintenance treatment in CD,Unconfirmed,PRELIM,Preliminary,III,Phase III,2 part combined induction / maintenance trial:
part 1: combined induction treatment in CD with sample size re-adjustment (double blind, PBO controlled, randomized parallel group design with 2 active doses of BI 655130); roll-over into maintenance secition either directly into randomized withdrawal (RW) phase, or via a re-induction treament with high dose IV;
part 2: active feeder of the maintenance part: randomized parallel group design with 2 active doses of BI 655130 with responders rolling-over into the RW phase.,,,000910,IS - Clin Study (MIGRATED)
14332,1368-0007,1368.7,Unconfirmed,917,1368-P01,Ph. III open label long-term extension CD,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14333,1368-0008,1368.8,Unconfirmed,917,1368-P01,PoCC and PoCM in fistulizing CD,Unconfirmed,PRELIM,Preliminary,I,Phase I,,2017-003090-34,19-JUL-17,000910,IS - Clin Study (MIGRATED)
14334,1368-0009,1368.9,First Subject Randomised,917,1368-P01,Pan-Asian Phase I trial in HV,First Subject Randomised,FULL,Full functionality,I,Phase I,,,,000010,IS - Clin Study - Clin Pharm - SRD
14335,1368-0010,1368.10,Recruiting,917,1368-P01,Phase IIa trial in UC,Recruiting,FULL,Full functionality,II,Phase II,,2016-004572-21,14-NOV-16,000131,IS - Clin Study - POCC
14336,1368-0017,1368.17,Unconfirmed,917,1368-P01,Phase 2 longterm Open Label Extension Study in UC,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14337,1368-0018,1368.18,Unconfirmed,917,1368-P01,Ph.3: BI655130 or PBO induction in BIO naive UC,Unconfirmed,PRELIM,Preliminary,III,Phase III,identical sites as in 1368.5/17 and 1368.6,,,000910,IS - Clin Study (MIGRATED)
14338,1368-0019,1368.19,Unconfirmed,917,1368-P01,BI655130/PBO ind in BIO naive/exp. UC,Unconfirmed,PRELIM,Preliminary,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
14339,1368-0020,1368.20,Unconfirmed,917,1368-P01,BI655130 Ph.3 Maintenance (incl OL feeder) in UC,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14340,1368-0021,1368.21,Unconfirmed,917,1368-P01,BI655130 or vedolizumab in BIO expUC pts,Unconfirmed,PRELIM,Preliminary,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
14341,1368-0022,1368.22,Unconfirmed,917,1368-P01,Phase 3: longterm OL Extension safety study in UC,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14342,1369-0001,1369.1,Unconfirmed,918,1369-P01,Phase I SRD in hv iv only,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14343,1369-0002,1369.2,Unconfirmed,918,1369-P01,Phase 1b in CD iv only,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14344,1369-0003,1369.3,Unconfirmed,918,1369-P01,Bridging study in hv,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14345,1370-0001,1370.1,Last Subject Randomised,919,1370-P01,BI1482694 in second line T790M+ NSCLC,Last Subject Randomised,MIG,Migration,II,Phase II,See Notes -> The sponsor for this study is Hanmi.
Advised by CAS (after their consultation with CTMS expert) to change trial type to IIS.
---
We will be creating a single (CN) OPU, and a single dummy site to receive recruitment actuals.

Last subject screened on 27 May 2016
Last subject enrolled on 5 Jul 2016

A total of 68 sites from 10 countries (Australia, Canada, Germany, Italy, Korea, Malaysia, Philippines, Spain, Taiwan, USA) participated in this study and 47 sites from 9 countries enrolled at least 1 subject. 3 sites in Germany were initiated but couldn't recruit any subjects. ,,,,
14346,1370-0002,1370.2,Preparing,919,1370-P01,BI1482694 v Chemo, 2nd line T790M NSCLC,Preparing,MIG,Migration,III,Phase III,,2015-005079-26,,000910,IS - Clin Study (MIGRATED)
14347,1370-0004,1370.4,Preparing,919,1370-P01,Phase I/II of BI1482694 in JP NSCLC pts,Preparing,MIG,Migration,I,Phase I,screen failures, reg. bridging  study ,,,000910,IS - Clin Study (MIGRATED)
14348,1370-0006,1370.6,Preparing,919,1370-P01,BI1482694 in T790M+ pts in US,Preparing,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14349,1230-0040,1230.40,Preparing,920,1230-P07,CUP Volasertib AML,Preparing,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
14350,1230-0041,1230.41,Preparing,920,1230-P07,Volasertib EAP US,Preparing,MIG,Migration,IIIB,Phase IIIb,Indication per BIRDS dictionary ,,,000910,IS - Clin Study (MIGRATED)
14351,1371-0001,1371.1,Preparing,921,1371-P01,Phase I Single Rising Dose,Preparing,PIHPZ,Phase I HPZ,I,Phase I,,2016‚Äê003470‚Äê40,19-AUG-16,000910,IS - Clin Study (MIGRATED)
14352,1371-0002,1371.2,Unconfirmed,921,1371-P01,MRD healthy volunteers ,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14353,1371-0003,1371.3,Unconfirmed,921,1371-P01,Ph I Pan Asian study SRD,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14354,1371-0004,1371.4,Unconfirmed,921,1371-P01,DDI CYP3A4 inhib,Unconfirmed,PRELIM,Preliminary,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
14355,1371-0005,1371.5,Unconfirmed,921,1371-P01,DDI CYP3A4 iduced study,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14356,1371-0006,1371.6,Unconfirmed,921,1371-P01,Ph I Pan Asian study MRD,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14357,1372-0001,1372.1,Preparing,922,1372-P01,SRD in HV,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14358,1372-0002,1372.2,Unconfirmed,922,1372-P01,MRD in HV,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14359,1372-0003,1372.3,Unconfirmed,922,1372-P01,DDI with itraconazole in HV,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14360,1372-0004,1372.4,Unconfirmed,922,1372-P01,PET occupancy study HV,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14361,1372-0005,1372.5,Unconfirmed,922,1372-P01,Pan-Asian SRD in HV,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14362,1372-0006,1372.6,Unconfirmed,922,1372-P01,Phase Ic in HV/AD/CIAS,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14363,1372-0007,1372.7,Unconfirmed,922,1372-P01,Ph II mild to moderate AD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14364,1372-0008,1372.8,Unconfirmed,922,1372-P01,Ph II prodromal AD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14365,1372-0009,1372.9,Unconfirmed,922,1372-P01,DDI with donepezil and risperidone,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14366,1372-0010,1372.10,Unconfirmed,922,1372-P01,Pivotal Ph III in mild to moderate AD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14367,1372-0011,1372.11,Unconfirmed,922,1372-P01,Pivotal Ph III in mild to moderate AD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14368,1372-0012,1372.12,Unconfirmed,922,1372-P01,Ph III in Prodromal AD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14369,1372-0013,1372.13,Unconfirmed,922,1372-P01,Pan-Asian Ph III in mild to moderate AD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14370,1372-0014,1372.14,Unconfirmed,922,1372-P01,Open-label extension,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14371,1372-0015,1372.15,Unconfirmed,922,1372-P01,Ph III prodromal AD with Cognitive Rem,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14372,1373-0001,1373.1,Preparing,923,1373-P01,Ph I/II tu-vaccine + afatinib NSCLC,Preparing,MIG,Migration,II,Phase II,Phase I / Phase II trial ,2015-001477-41,,000910,IS - Clin Study (MIGRATED)
14373,1373-0002,1373.2,Unconfirmed,923,1373-P01,Ph III tu-vaccine+afatinib NSCLC,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14374,1373-0003,1373.3,Preparing,923,1373-P01,BI 1361849 vs plac in NSCLC after CRT,Preparing,MIG,Migration,II,Phase II,,2014-004959-30,,000910,IS - Clin Study (MIGRATED)
14375,1373-0004,1373.4,Unconfirmed,923,1373-P01,BI1361849 postchemorad maintenance,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14376,1373-0005,1373.5,Unconfirmed,923,1373-P01,BI 1361849 + durvalumab and tremelimumab,Unconfirmed,MIG,Migration,I,Phase I,,,,,
14377,1373-0006,1373.6,Preparing,923,1373-P01,Phase I/II BI 1361849 & Nivolumab,Preparing,FULL,Full functionality,II,Phase II,,2016-002867-33,07-JUL-16,000200,IS - Clin Study - Outcome
14378,1373-0007,1373.7,Unconfirmed,923,1373-P01,Ph III BI 1361849 & CPI NSCLC,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14379,1374-0001,1374.1,Unconfirmed,925,1374-P01,SRD in healthy volunteers + Relative BA,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
14380,1374-0002,1374.2,Unconfirmed,925,1374-P01,MRD in T2DM patients,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14381,1374-0003,1374.3,Unconfirmed,925,1374-P01,Pan Asia SRD in healthy volunteers,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
14382,1374-0004,1374.4,Unconfirmed,925,1374-P01,Global Ph2a (4 weeks),Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14383,1374-0005,1374.5,Unconfirmed,925,1374-P01,Chinese MRD in patients with T2DM,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14384,1374-0006,1374.6,Unconfirmed,925,1374-P01,Japanese Phase IIa (4 wks),Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14385,1374-0007,1374.7,Unconfirmed,925,1374-P01,Food effect study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14386,1374-0008,1374.8,Unconfirmed,925,1374-P01,DDI study with CYP2C8 + CYP2C9,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14387,1374-0009,1374.9,Unconfirmed,925,1374-P01,Ph IIb (12w + 66w; mono),Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14388,1374-0010,1374.10,Unconfirmed,925,1374-P01,Ph IIb (12w + 66w; add-on),Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14389,1374-0011,1374.11,Unconfirmed,925,1374-P01,Ph II (12w) clamp study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14390,1374-0012,1374.12,Unconfirmed,925,1374-P01,DDI study with SGLT2i,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14391,1374-0013,1374.13,Unconfirmed,925,1374-P01,DDI study with BI transporter cocktail,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14392,1374-0014,1374.14,Unconfirmed,925,1374-P01,DDI DPP4i,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14393,1374-0015,1374.15,Unconfirmed,925,1374-P01,Absolute BA (incl. SRD iv),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14394,1374-0016,1374.16,Unconfirmed,925,1374-P01,Human ADME,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14395,1374-0017,1374.17,Unconfirmed,925,1374-P01,PK in hepatic impairment,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14396,1374-0018,1374.18,Unconfirmed,925,1374-P01,Thorough QT study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14397,1374-0019,1374.19,Unconfirmed,925,1374-P01,PK in renal impairment,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14398,1374-0020,1374.20,Unconfirmed,925,1374-P01,Confirmatory Food Effect study (FF),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14399,1374-0021,1374.21,Unconfirmed,925,1374-P01,Chinese PK study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14400,1374-0022,1374.22,Unconfirmed,925,1374-P01,Ph III (24w; mono vs Plc),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14401,1374-0023,1374.23,Unconfirmed,925,1374-P01,Ph III (52 wk renal insuff),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14402,1374-0024,1374.24,Unconfirmed,925,1374-P01,Ph III (52w; add-on basal insulin),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14403,1374-0025,1374.25,Unconfirmed,925,1374-P01,Ph I Placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14404,1374-0026,1374.26,Unconfirmed,925,1374-P01,Ph III (52w, H2H vs insulin),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14405,1374-0027,1374.27,Unconfirmed,925,1374-P01,Ph III (52w;add-on met vs Plc, SU, DPP4),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14406,1374-0028,1374.28,Unconfirmed,925,1374-P01,Ph III CV safety,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14407,1374-0029,1374.29,Unconfirmed,925,1374-P01,Relative BA (TFI vs TFII) - placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14408,1374-0030,1374.30,Unconfirmed,925,1374-P01,Relative BA (TFII vs IFF),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14409,1374-0031,1374.31,Unconfirmed,925,1374-P01,DDIs with other relevant Co-Med,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14410,1374-0032,1374.32,Unconfirmed,925,1374-P01,DDI study with UGTi inducer,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14411,1374-0033,1374.33,Unconfirmed,925,1374-P01,Ph III HbA1c durability (4 yrs),Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
14412,1374-0034,1374.34,Unconfirmed,925,1374-P01,Japanese Phase III (add on; 52 wks),Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14413,1374-0035,1374.35,Unconfirmed,925,1374-P01,Japanese PhIII add-on to insulin,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14414,1375-0001,1375.1,Unconfirmed,926,1375-P01,Ph I SRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14415,1375-0002,1375.2,Unconfirmed,926,1375-P01,Ph I MRD: T2D pts w BMI >27,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14416,1375-0003,1375.3,Unconfirmed,926,1375-P01,Placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14417,1375-0004,1375.4,Unconfirmed,926,1375-P01,Placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14418,1375-0005,1375.5,Unconfirmed,926,1375-P01,2 week liver mechanistic study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14419,1375-0006,1375.6,Unconfirmed,926,1375-P01,Absolute BA,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14420,1375-0007,1375.7,Unconfirmed,926,1375-P01,MRD in healthy Chines volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14421,1375-0008,1375.8,Unconfirmed,926,1375-P01,4 week treatment in Japanese patients,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14422,1375-0009,1375.9,Unconfirmed,926,1375-P01,Placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14423,1375-0010,1375.10,Unconfirmed,926,1375-P01,Placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14424,1375-0011,1375.11,Unconfirmed,926,1375-P01,tQT,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14425,1375-0012,1375.12,Unconfirmed,926,1375-P01,PK/PD special populations ethnic diff,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14426,1375-0013,1375.13,Unconfirmed,926,1375-P01,Site absorption study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14427,1375-0014,1375.14,Unconfirmed,926,1375-P01,PK study in mainland China,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14428,1375-0015,1375.15,Unconfirmed,926,1375-P01,Potential Ic study for uptitration,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14429,1375-0016,1375.16,Unconfirmed,926,1375-P01,Pediatric development phase 1 (+PK),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14430,1375-0017,1375.17,Unconfirmed,926,1375-P01,Pediatric development phase 3,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14431,1375-0018,1375.18,Unconfirmed,926,1375-P01,Placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14432,1375-0019,1375.19,Unconfirmed,926,1375-P01,Placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14433,1375-0020,1375.20,Unconfirmed,926,1375-P01,Placeholder,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14434,1375-0021,1375.21,Unconfirmed,926,1375-P01,SRD in Asian patients,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14435,1375-0022,1375.22,Unconfirmed,926,1375-P01,weekly vs daily in T2D patients 2a 6wk,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
14436,1375-0023,1375.23,Unconfirmed,926,1375-P01,Dose finding study monotherapy (+ext.),Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14437,1375-0024,1375.24,Unconfirmed,926,1375-P01,Mechanistic study (6wk) energy exp.,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
14438,1375-0025,1375.25,Unconfirmed,926,1375-P01,Dose finding study add-on (+ext.),Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14439,1375-0026,1375.26,Unconfirmed,926,1375-P01,52 wk, BI 1225575 mono vs placebo in T2D,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14440,1375-0027,1375.27,Unconfirmed,926,1375-P01,Placeholder,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14441,1375-0028,1375.28,Unconfirmed,926,1375-P01,24w,BI 1225575 vs placebo MFN+SGLT2,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14442,1375-0029,1375.29,Unconfirmed,926,1375-P01,24w, BI 1225575 vs placebo MFN+ SUs,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14443,1375-0030,1375.30,Unconfirmed,926,1375-P01,24w, BI 1225575 vs pl Insulin + OADS,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14444,1375-0031,1375.31,Unconfirmed,926,1375-P01,52wk Japanese add-on to ...,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14445,1375-0032,1375.32,Unconfirmed,926,1375-P01,Cardiovaskular safety in high risk pts,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14446,1375-0033,1375.33,Unconfirmed,926,1375-P01,52wk Asian add-on to ....,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14447,1375-0034,1375.34,Unconfirmed,926,1375-P01,Placeholder,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14448,1375-0041,1375.41,Unconfirmed,926,1375-P01,104w, BI 1225575 vs liraglutide H2H in,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14449,1320-0016,1320.16,Ended,927,1320-P02,Safety and Tolerability in COPD,Ended,MIG,Migration,I,Phase I,,2015-002123-25,,000910,IS - Clin Study (MIGRATED)
14450,1320-0017,1320.17,Analysis,927,1320-P02,LPS in vivo challenge in smoking HVs,Analysis,MIG,Migration,I,Phase I,,2015-001789-25,,000910,IS - Clin Study (MIGRATED)
14451,1320-0018,1320.18,Preparing,927,1320-P02,PoC and Dose Finding in COPD,Preparing,FULL,Full functionality,II,Phase II,,2016-002693-13 ,21-JUN-16,000130,IS - Clin Study - POC
14452,1320-0019,1320.19,Unconfirmed,927,1320-P02,PanAsian SRD,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
14453,1320-0020,1320.20,Ended,927,1320-P02,DDI Itraconazole in interaction study,Ended,MIG,Migration,I,Phase I,,2015-002140-14,,000910,IS - Clin Study (MIGRATED)
14454,1320-0021,1320.21,Unconfirmed,927,1320-P02,PanAsian MRD,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14455,1320-0023,1320.23,Analysis,927,1320-P02,SRD/MRD PanAsian,Analysis,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14456,1320-0024,1320.24,Unconfirmed,935,1320-P03,DDI Diltiazem in interaction study,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14457,1320-0025,1320.25,Unconfirmed,927,1320-P02,DDI Rifampicin in interaction study,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14458,1320-0029,1320.29,Unconfirmed,927,1320-P02,Pivotal Phase III vs Pbo #1,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14459,1320-0030,1320.30,Unconfirmed,927,1320-P02,Pivotal Phase III vs Pbo # 2,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14460,0352-2091,352.2091,Recruiting,928,0352-P04,MCID dyspnoea 3-MST and 3-MWT,Recruiting,MIG,Migration,I,Phase I,,,,,
14461,0352-2092,352.2092,Preparing,928,0352-P04,iLaennec Phase II,Preparing,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
14462,1245-0103,1245.103,Unconfirmed,929,1245-P06,Secondary prevention of CV disease,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14463,1245-0110,1245.110,First Subject Randomised,929,1245-P06,Empagliflozin and heart failure (HFpEF),First Subject Randomised,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14464,1245-0121,1245.121,First Subject Randomised,929,1245-P06,Empagliflozin and Heart failure (HFrEF),First Subject Randomised,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14465,1245-0148,1245.148,Preparing,929,1245-P06,A study that looks at the function of the heart in patients,Preparing,OUT,Fully Outsourced,III,Phase III,,2017-000376-28 ,25-JAN-17,000150,IS - Clin Study - Explore
14466,1378-0001,1378.1,Analysis,933,1378-P01,Single rising dose study in HV,Analysis,MIG,Migration,I,Phase I,,2015-003642-10,,000910,IS - Clin Study (MIGRATED)
14467,1378-0002,1378.2,Recruiting,933,1378-P01,MRD in HV including a FE part,Recruiting,PIHPZ,Phase I HPZ,IB,Phase Ib,,2017-000104-18,04-JAN-17,000020,IS - Clin Study - Clin Pharm - MRD
14468,1378-0003,1378.3,Initiated,933,1378-P01,pan-Asian SRD,Initiated,FULL,Full functionality,IA,Phase Ia,,,,000010,IS - Clin Study - Clin Pharm - SRD
14469,1378-0004,1378.4,Unconfirmed,933,1378-P01,pan-Asian MRD,Unconfirmed,PRELIM,Preliminary,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14470,1378-0005,1378.5,Unconfirmed,933,1378-P01,Phase II dose finding/PoCC,Unconfirmed,PRELIM,Preliminary,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14471,1378-0006,1378.6,Unconfirmed,933,1378-P01,Phase III Renal Outcomes,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14472,1378-0007,1378.7,Unconfirmed,933,1378-P01,Phase III CV outcomes,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14473,1378-0008,1378.8,Preparing,933,1378-P01,MRD in patients,Preparing,FULL,Full functionality,I,Phase I,,2017-000563-32,02-FEB-17,000910,IS - Clin Study (MIGRATED)
14474,1378-0009,1378.9,Unconfirmed,933,1378-P01,Extension of 1378.5 Ph II dose finding,Unconfirmed,PRELIM,Preliminary,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14475,1378-0010,1378.10,Unconfirmed,933,1378-P01,Phase II endothelial function study,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14476,1378-0011,1378.11,Unconfirmed,933,1378-P01,Phase II on top of new SoC study,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14477,1379-0001,1379.1,Preparing,934,1379-P01,Ph1 mono/combi+PD1 in advanced tumours,Preparing,OUT,Fully Outsourced,I,Phase I,,2017-000465-74,31-JAN-17,000910,IS - Clin Study (MIGRATED)
14478,1379-0002,1379.2,Unconfirmed,934,1379-P01,PhIb BI891065+PD-1 in hem-onc,Unconfirmed,PRELIM,Preliminary,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14479,1379-0003,1379.3,Unconfirmed,934,1379-P01,PhII BI891065+anti PD1 in solid tumors,Unconfirmed,MIG,Migration,IIA,Phase IIa,Indication to be defined ,,,000910,IS - Clin Study (MIGRATED)
14480,1379-0004,1379.4,Unconfirmed,934,1379-P01,Ph. III BI 891065+ anti PD-1 in MM,Unconfirmed,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
14481,1379-0005,1379.5,Unconfirmed,934,1379-P01,seamless PhII/III in later line NSCLC,Unconfirmed,PRELIM,Preliminary,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
14482,1379-0006,1379.6,Unconfirmed,934,1379-P01,Phase I in Asian patients,Unconfirmed,PRELIM,Preliminary,IA,Phase Ia,Updated as discussed on 1379.6 PanAsian TC on 14-July-2017.
Please note: We need 21 patients enrolled. I have entered 25 (Randomized) considering about 4 repleacement patients.,,,000910,IS - Clin Study (MIGRATED)
14483,1379-0007,1379.7,Unconfirmed,934,1379-P01,PhIII BI891065 + PD1 in NSCLC first line,Unconfirmed,PRELIM,Preliminary,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
14484,1379-0008,1379.8,Unconfirmed,934,1379-P01,PhI BI891065+targeted therapy in hemato,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14485,1320-0022,1320.22,First Subject Randomised,935,1320-P03,Ph2a in patients with DME over 12 weeks,First Subject Randomised,MIG,Migration,IIA,Phase IIa,,2015-003529-33,,000132,IS - Clin Study - POCP
14486,1320-0026,1320.26,Preparing,935,1320-P03,Ph2b POCC in DME, 12 months,Preparing,FULL,Full functionality,IIB,Phase IIb,updated on 02 nov 2016 ,,,000132,IS - Clin Study - POCP
14487,1320-0027,1320.27,Unconfirmed,935,1320-P03,Ph3 H2H BI 1026706 vs VEGF in DME 12m,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14488,1320-0028,1320.28,Unconfirmed,935,1320-P03,Ph3 BI 102706 vs Plc in DME event driven,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14489,1200-0120,1200.120,First Subject Randomised,936,1200-P12,Phase I/II trial in paediatric tumours,First Subject Randomised,MIG,Migration,I/II,Phase I/II,90% screening failures in MTD expansion ,2014-002123-10,16-MAY-14,000910,IS - Clin Study (MIGRATED)
14490,1200-0204,1200.204,Unconfirmed,936,1200-P12,Afatinib in neuroectodermal tumours,Unconfirmed,FULL,Full functionality,IIA,Phase IIa,Biomarker driven; ph II  may be ph 1/2 ,,,000910,IS - Clin Study (MIGRATED)
14491,1200-0220,1200.220,Unconfirmed,936,1200-P12,Relative BA in adult HV,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,HPC, HV ,,,000910,IS - Clin Study (MIGRATED)
14492,1200-0261,1200.261,First Subject Randomised,936,1200-P12,Afatinib in metastatic Urothelial Cancer,First Subject Randomised,MIG,Migration,IIB,Phase IIb,2 stage, biomarker selection ,2015-005427-10,,000910,IS - Clin Study (MIGRATED)
14493,1380-0001,1380.1,Unconfirmed,937,1380-P01,single rising dose in healthy volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14494,1381-0001,1381.1,First Subject Randomised,938,1381-P01,BI 754091 first-in-man dose escalation,First Subject Randomised,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14495,1381-0002,1381.2,Recruiting,938,1381-P01,BI754111 & BI754091/BI75411 combination,Recruiting,OUT,Fully Outsourced,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14496,1381-0003,1381.3,Unconfirmed,938,1381-P01,Bio-Distribution Study,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14497,1382-0001,1382.1,Unconfirmed,939,1382-P01,BI 729802 - RORC Inhibitor,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
14498,1382-0002,1382.2,Unconfirmed,939,1382-P01,BI 729802 - MRD in HV and PsO,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14499,1382-0003,1382.3,Unconfirmed,939,1382-P01,BI 729802 - POCC in AS,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
14500,1383-0001,1383.1,Unconfirmed,940,1383-P01,Single rising dose in HV,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14501,1383-0002,1383.2,Unconfirmed,940,1383-P01,MRD in HV,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14502,1383-0003,1383.3,Unconfirmed,940,1383-P01,Pan-Asian Ph 1 SRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14503,1383-0004,1383.4,Unconfirmed,940,1383-P01,Relative BA,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14504,1383-0005,1383.5,Unconfirmed,940,1383-P01,PoCC in nonrenal lupus,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14505,1384-0001,1384.1,Preparing,941,1384-P01,Single Rising Dose Phase I,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14506,1384-0002,1384.2,Unconfirmed,941,1384-P01,Ph I MRD COPD and Bronchiectasis,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14507,1384-0003,1384.3,Unconfirmed,941,1384-P01,PH II challenge study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14508,1384-0004,1384.4,Unconfirmed,941,1384-P01,Pan-Asian SRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14509,1384-0005,1384.5,Unconfirmed,941,1384-P01,Pan-Asian MRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14510,1384-0006,1384.6,Unconfirmed,941,1384-P01,26-52w A1AT deficiency study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14511,1384-0007,1384.7,Unconfirmed,941,1384-P01,26w COPD study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14512,1384-0008,1384.8,Unconfirmed,941,1384-P01,COPD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14513,1384-0009,1384.9,Unconfirmed,941,1384-P01,COPD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14514,1384-0010,1384.10,Unconfirmed,941,1384-P01,DDI Itraconazole,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14515,1199-0197,1199.197,Ended,942,1199-P15,In-patient rehabilitation in IPF,Ended,MIG,Migration,NONE,Not Classified,,,,,
14516,1199-0216,1199.216,Recruiting,942,1199-P15,IPF Registry RCV,Recruiting,MIG,Migration,NONE,Not Classified,International, multicentre, observational, non-interventional registry of IPF patients in the Czech Republic and Central and Eastern Europe.
'EMPIRE' Agreement has been prolonged till 31-Dec-2019 according to Amendment no. 2.,,,000410,NISnd ‚Äì Study - Other
14517,1199-0249,1199.249,First Subject Randomised,942,1199-P15,Etiology and pathogenesis of AE-IPF,First Subject Randomised,MIG,Migration,NONE,Not Classified,,,,,
14518,1199-0250,1199.250,Recruiting,942,1199-P15,1199-0250 Sleep disorders in IPF,Recruiting,MIG,Migration,NONE,Not Classified,,,,000980,Not Classified (MIGRATED)
14519,1199-0253,1199.253,Recruiting,942,1199-P15,HOPE-IPF Study,Recruiting,MIG,Migration,IV,Phase IV,,,,,
14520,1199-0254,1199.254,First Subject Randomised,942,1199-P15,Cognitive Behavioral Therapy in IPF,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14521,1199-0255,1199.255,First Subject Randomised,942,1199-P15,VA Database IPF study,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000450,NISed ‚Äì Study - Other
14522,1199-0256,1199.256,First Subject Randomised,942,1199-P15,Nintedanib in patients with LAM pilot,First Subject Randomised,MIG,Migration,II,Phase II,,,,000150,IS - Clin Study - Explore
14523,1199-0264,1199.264,Preparing,942,1199-P15,Prognostic value of FDG-PET-CT in IPF,Preparing,MIG,Migration,NONE,Not Classified,,,,,
14524,1199-0266,1199.266,Preparing,942,1199-P15,MR imaging in monitoring of IPF,Preparing,MIG,Migration,IV,Phase IV,,,,,
14525,1199-0277,1199.277,Initiated,942,1199-P15, Viral Infections in Natural IPF History,Initiated,MIG,Migration,NONE,Not Classified,,,,000910,IS - Clin Study (MIGRATED)
14526,1199-0278,1199.278,Recruiting,942,1199-P15,Nebulized Fentanyl in IPF,Recruiting,MIG,Migration,NONE,Not Classified,,,,,
14527,1199-0284,1199.284,Preparing,942,1199-P15,Predictors of ILD in SSc,Preparing,IIS,Investigator Initiated Study,NONE,Not Classified,,,,000460,NISed ‚Äì Study - Cohort
14528,1199-0290,1199.290,First Subject Randomised,942,1199-P15,ILA Progression in COPD Gene,First Subject Randomised,MIG,Migration,NONE,Not Classified,,,,000450,NISed ‚Äì Study - Other
14529,1199-0293,1199.293,Unconfirmed,942,1199-P15,Cryobiopsy in ILD,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,,
14530,1199-0294,1199.294,First Subject Randomised,942,1199-P15,Japanese IIP Registry,First Subject Randomised,MIG,Migration,NONE,Not Classified,,,,000920,NISnd - Study (MIGRATED)
14531,1385-0001,1385.1,Unconfirmed,943,1385-P01,SRD (HV),Unconfirmed,MIG,Migration,I,Phase I,,2016-000688-17,,000910,IS - Clin Study (MIGRATED)
14532,1385-0002,1385.2,Unconfirmed,943,1385-P01,MRD (4w in patients),Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14533,1385-0003,1385.3,Unconfirmed,943,1385-P01,Pan-Asian SRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14534,1385-0004,1385.4,Unconfirmed,943,1385-P01,Pan-Asian MRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14535,1385-0005,1385.5,Unconfirmed,943,1385-P01,Challenge study,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14536,1385-0006,1385.6,Unconfirmed,943,1385-P01,26w COPD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14537,1385-0007,1385.7,Unconfirmed,943,1385-P01,52w A1AT deficiency,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14538,1385-0008,1385.8,Unconfirmed,943,1385-P01,52w/2y extension COPD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14539,1385-0009,1385.9,Unconfirmed,943,1385-P01,52w/2y extension COPD,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14540,1385-0010,1385.10,Unconfirmed,943,1385-P01,52w/2y extension A1AT deficiency,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14541,1289-0032,1289.32,Preparing,945,1289-P03,FEP / CHR PoC,Preparing,FULL,Full functionality,II,Phase II,,2016-004973-42,06-DEC-16,000131,IS - Clin Study - POCC
14542,1199-0247,1199.247,First Subject Randomised,946,1199-P16,Nintedanib - PF-ILD,First Subject Randomised,FULL,Full functionality,III,Phase III,,2015-003360-37,,000170,IS - Clin Study - Confirmatory/Pivotal
14543,1199-0248,1199.248,Unconfirmed,946,1199-P16,Nintedanib in PF-ILD (extension/EAP/CUP),Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14544,1375-0035,1375.35,Unconfirmed,947,1375-P02,52wk, BI 1225575vs rel GLP-1 comp H2H,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
14545,1375-0036,1375.36,Unconfirmed,947,1375-P02,Ph IIb dose finding vs placebo & AC,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14546,1375-0037,1375.37,Unconfirmed,947,1375-P02,placeholder ext. (subgroup prediabetes),Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14547,1375-0038,1375.38,Unconfirmed,947,1375-P02,PhIII 52w Obese non-d vs Pl vs GLP-1,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14548,1375-0039,1375.39,Unconfirmed,947,1375-P02,PhIII 52w Obese T2D vs Pl vs GLP-1 comp.,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14549,1375-0040,1375.40,Unconfirmed,947,1375-P02,Ph III Cardiovascular outcome study,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14550,1375-0042,1375.42,Unconfirmed,947,1375-P02,Placeholder,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14551,1375-0043,1375.43,Unconfirmed,947,1375-P02,PhIII 52w Obe. non-di.vs Pl vs rel GLP-1,Unconfirmed,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14552,1200-0125,1200.125,Recruitment Completed,948,1200-P13,Afatinib vs. erlotinib in NSCLC,Recruitment Completed,MIG,Migration,III,Phase III,,2011-002380-24,,000910,IS - Clin Study (MIGRATED)
14553,1200-0265,1200.265,Unconfirmed,948,1200-P13,Afatinib Ph-2 in Japanese Squamous NSCLC,Unconfirmed,MIG,Migration,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14554,1222-0057,1222.57,Preparing,949,1222-P03,Ph 2 dose-ranging in CF 12 and older,Preparing,FULL,Full functionality,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14555,1222-0058,1222.58,Unconfirmed,949,1222-P03,Ph 3 A/A in CF 12 and older,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14556,1222-0059,1222.59,Unconfirmed,949,1222-P03,Ph 3 in CF peds 6-11 years,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14557,1222-0060,1222.60,Unconfirmed,949,1222-P03,Ph 2/3 safety in CF 5 years and less,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14558,1222-0061,1222.61,Unconfirmed,949,1222-P03,Ph 2 dose-ranging in CF 6-11 years,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14559,1222-0062,1222.62,Unconfirmed,949,1222-P03,12 week Phase 3 Study in A/A CF patients,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14560,1311-0005,1311.5,First Subject Randomised,950,1311-P05,PoC PsA trial,First Subject Randomised,MIG,Migration,IIA,Phase IIa,,2015-003625-34,,000910,IS - Clin Study (MIGRATED)
14561,1311-0010,1311.10,Preparing,950,1311-P05,Pivotal PsA trial,Preparing,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
14562,1311-0024,1311.24,Unconfirmed,950,1311-P05,PsA radiographic progression trial,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
14563,1311-0026,1311.26,Unconfirmed,950,1311-P05,PsA Auto-injector Real Life Handling,Unconfirmed,MIG,Migration,IIIB,Phase IIIb,,,,000910,IS - Clin Study (MIGRATED)
14564,1311-0027,1311.27,Preparing,950,1311-P05,PsA Roll-Over,Preparing,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
14565,1311-0035,1311.35,Preparing,950,1311-P05,Translational Medicine study in PsA,Preparing,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14566,1237-0032,1237.32,Ended,951,1237-P02,Prop.pat. who meet incl/excl crit in CTs,Ended,MIG,Migration,NONE,Not Classified,Observational (non-interventional) IIS ,,,,
14567,1237-0046,1237.46,Recruiting,951,1237-P02,Airway effects Resp vs Handih,Recruiting,MIG,Migration,IV,Phase IV,,,,,
14568,1237-0047,1237.47,Preparing,951,1237-P02,COPD screening health need ass.,Preparing,MIG,Migration,IV,Phase IV,,,,,
14569,1237-0052,1237.52,Recruiting,951,1237-P02,WHISPER,Recruiting,MIG,Migration,IV,Phase IV,,,,,
14570,1237-0054,1237.54,First Subject Randomised,951,1237-P02,Cardiopulmonary Interactions,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,,
14571,1237-0055,1237.55,First Subject Randomised,951,1237-P02,eff on centr and periph comp of fatigue,First Subject Randomised,MIG,Migration,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14572,1237-0059,1237.59,Ended,951,1237-P02,aerosol transfer velocity Spiolto Resp,Ended,MIG,Migration,NONE,Not Classified,,,,,
14573,1237-0062,1237.62,Preparing,951,1237-P02,RETROPOPE,Preparing,MIG,Migration,IV,Phase IV,,,,000460,NISed ‚Äì Study - Cohort
14574,1386-0001,1386.1,Unconfirmed,952,1386-P01,PK/PD MRD in target patient population,Unconfirmed,MIG,Migration,I,Phase I,,2015-002951-90,,000910,IS - Clin Study (MIGRATED)
14575,1386-0002,1386.2,Preparing,952,1386-P01,Renal Impairment trial,Preparing,PIHPZ,Phase I HPZ,I,Phase I,,2017‚Äê002180‚Äê18,22-MAY-17,000910,IS - Clin Study (MIGRATED)
14576,1386-0003,1386.3,Unconfirmed,952,1386-P01,tQT trial,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14577,1386-0004,1386.4,Recruiting,952,1386-P01,PoM in target population,Recruiting,FULL,Full functionality,IIA,Phase IIa,,2016-000499-83 ,05-SEP-16,000130,IS - Clin Study - POC
14578,1386-0005,1386.5,Unconfirmed,952,1386-P01,PoCC in target population,Unconfirmed,PRELIM,Preliminary,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14579,1386-0006,1386.6,Unconfirmed,952,1386-P01,Registration trial in target population,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14580,1386-0007,1386.7,Initiated,952,1386-P01,Pan Asian Phase 1 SRD/MRD,Initiated,FULL,Full functionality,I,Phase I,,,,000020,IS - Clin Study - Clin Pharm - MRD
14581,1386-0008,1386.8,Analysis,952,1386-P01,PK/PD in HV,Analysis,MIG,Migration,IB,Phase Ib,,2015-005049-29,,000910,IS - Clin Study (MIGRATED)
14582,1386-0009,1386.9,Unconfirmed,952,1386-P01,Pan Asian Phase 1 MRD,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14583,1386-0010,1386.10,Unconfirmed,952,1386-P01,Hepatic Impairment study,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14584,1386-0011,1386.11,Unconfirmed,952,1386-P01,hADME,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,2017-002879-26,06-JUL-17,000910,IS - Clin Study (MIGRATED)
14585,1386-0016,1386.16,Unconfirmed,952,1386-P01,DDI cocktail study,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14586,1386-0017,1386.17,Analysis,952,1386-P01,Food Effect and Relative BA,Analysis,MIG,Migration,I,Phase I,,2016-001534-97,05-APR-16,000910,IS - Clin Study (MIGRATED)
14587,1387-0001,1387.1,Analysis,953,1387-P01,Japanese phase  III trial of IP-TN,Analysis,MIG,Migration,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
14588,1388-0001,1388.1,Preparing,954,1388-P01,Safety of Macrogol 3350 oral concentrate,Preparing,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14589,1339-0001,1339.1,First Subject Randomised,955,1339-P02,Single Rising Dose study,First Subject Randomised,MIG,Migration,I,Phase I,,2014-002413-29,,000910,IS - Clin Study (MIGRATED)
14590,1339-0006,1339.6,Unconfirmed,955,1339-P02,MRD,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14591,1339-0007,1339.7,Unconfirmed,955,1339-P02,SRD with SC formulation,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14592,1339-0008,1339.8,Unconfirmed,955,1339-P02,MRD in patients (SC),Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14593,1389-0001,1389.1,Unconfirmed,956,1389-P01,SRD in HVs,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
14594,1389-0002,1389.2,Unconfirmed,956,1389-P01,MRD in HVs,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14595,1389-0003,1389.3,Unconfirmed,956,1389-P01,MRD in Pts.,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14596,1389-0004,1389.4,Unconfirmed,956,1389-P01,pan-Asian SRD in HVs,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14597,1389-0005,1389.5,Unconfirmed,956,1389-P01,pan-Asian MRD in HVs,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14598,1390-0001,1390.1,Unconfirmed,957,1390-P01,SRD in HV,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
14599,1390-0002,1390.2,Unconfirmed,957,1390-P01,MRD in HVs,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14600,1390-0003,1390.3,Unconfirmed,957,1390-P01,pan-Asian SRD,Unconfirmed,FULL,Full functionality,IA,Phase Ia,,,,000010,IS - Clin Study - Clin Pharm - SRD
14601,1390-0004,1390.4,Unconfirmed,957,1390-P01,pan-Asian MRD,Unconfirmed,PRELIM,Preliminary,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14602,1390-0005,1390.5,Unconfirmed,957,1390-P01,Phase II dose finding/PoCC,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14603,1370-0003,1370.3,Preparing,958,1370-P02,BI1482694 vs afatinib, 1st line EGFRM+LC,Preparing,MIG,Migration,III,Phase III,high screen fail ,2015-005080-16,,000910,IS - Clin Study (MIGRATED)
14604,1370-0007,1370.7,Ended,958,1370-P02,hADME study of BI1482694 in HV,Ended,MIG,Migration,I,Phase I,,2016-000190-20,,000910,IS - Clin Study (MIGRATED)
14605,1370-0010,1370.10,Preparing,958,1370-P02,BI1482694/bev vs afa in EGFRmut+ NSCLC,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14606,1370-0011,1370.11,Unconfirmed,958,1370-P02,DDI study with ritonavir in HV,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14607,1370-0012,1370.12,Unconfirmed,958,1370-P02,DDI  with Cyp3A4, 1A2, Pgp substrates,Unconfirmed,MIG,Migration,IB,Phase Ib,Study still in planning phase ,,,000910,IS - Clin Study (MIGRATED)
14608,1370-0005,1370.5,Preparing,959,1370-P03,BI1482694 and pembrolizumab in NSCLC,Preparing,MIG,Migration,IIA,Phase IIa,Joined development with Merck ,2015-005270-37,,000910,IS - Clin Study (MIGRATED)
14609,1370-0008,1370.8,Preparing,959,1370-P03,BI 1482694 with afatinib or BI 836845,Preparing,MIG,Migration,IB,Phase Ib,,2016-001734-97,,000910,IS - Clin Study (MIGRATED)
14610,1370-0009,1370.9,Preparing,959,1370-P03,Ph I BI1482694 +nintedanib EGFR+ NSCLC,Preparing,MIG,Migration,IB,Phase Ib,Expansion arm B consists of 2 subgroups ,2015-005305-37,,000910,IS - Clin Study (MIGRATED)
14611,1391-0001,1391.1,Unconfirmed,960,1391-P01,BE for Anador flex,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14612,1392-0001,1392.1,Preparing,961,1392-P01,Efficacy and Safety of Rhubarb,Preparing,MIG,Migration,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14613,1393-0001,1393.1,Unconfirmed,963,1393-P01,SRD in Healthy Volunteers,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
14614,1393-0002,1393.2,Unconfirmed,963,1393-P01,MRD in Healthy Volunteers,Unconfirmed,MIG,Migration,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14615,1393-0003,1393.3,Unconfirmed,963,1393-P01,Safety and tolerability in COPD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14616,1393-0004,1393.4,Unconfirmed,963,1393-P01,LPS in vivo challenge in smoking HVs,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14617,1393-0005,1393.5,Unconfirmed,963,1393-P01,Dose finding study in COPD,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14618,1393-0006,1393.6,Unconfirmed,963,1393-P01,DDI study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14619,1393-0007,1393.7,Unconfirmed,963,1393-P01,SRD/MRD PanAsian,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14620,1386-0012,1386.12,Preparing,966,1386-P02,Ph2a PoM in NPDR BI 1467335 vs Plc 12 wk,Preparing,FULL,Full functionality,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
14621,1386-0013,1386.13,Unconfirmed,966,1386-P02,Ph2b PoCC in NPDR, 6m+6m extension,Unconfirmed,PRELIM,Preliminary,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14622,1386-0014,1386.14,Unconfirmed,966,1386-P02,Ph3 event-driven BI 1467335 in NPDR,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14623,1386-0015,1386.15,Unconfirmed,966,1386-P02,Ph3 noninf BI1467335 vs PRP in PDR,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14624,1386-0018,1386.18,Unconfirmed,966,1386-P02,Ph2a BI1467335 in DME,Unconfirmed,PRELIM,Preliminary,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
14625,1395-0001,1395.1,Unconfirmed,967,1395-P01,PK Single dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14626,1395-0002,1395.2,Unconfirmed,967,1395-P01,PK Multiple dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14627,1397-0001,1397.1,Unconfirmed,969,1397-P01,SRD in HV and Food effect,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14628,1397-0002,1397.2,Unconfirmed,969,1397-P01,MRD in patients,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14629,1397-0003,1397.3,Unconfirmed,969,1397-P01,Pan-Asian SRD,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14630,1397-0004,1397.4,Unconfirmed,969,1397-P01,Pan-Asian MRD,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14631,1397-0005,1397.5,Unconfirmed,969,1397-P01,Challenge study,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14632,1397-0006,1397.6,Unconfirmed,969,1397-P01,26w COPD study,Unconfirmed,PRELIM,Preliminary,IIA,Phase IIa,,,,000132,IS - Clin Study - POCP
14633,1397-0007,1397.7,Unconfirmed,969,1397-P01,52w A1AT deficiency,Unconfirmed,PRELIM,Preliminary,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
14634,1398-0001,1398.1,Unconfirmed,970,1398-P01,Phase I - Single Rising Dose,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14635,1398-0002,1398.2,Unconfirmed,970,1398-P01,Multiple rising dose healthy volunteers,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14636,1398-0003,1398.3,Unconfirmed,970,1398-P01,Ph I Pan Asian study SRD,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14637,1398-0004,1398.4,Unconfirmed,970,1398-P01,DDI CYP3A4 inhib,Unconfirmed,MIG,Migration,IA,Phase Ia,,,,000910,IS - Clin Study (MIGRATED)
14638,1398-0005,1398.5,Unconfirmed,970,1398-P01,DDI CYP3A4 induced study,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14639,1399-0001,1399.1,Preparing,971,1399-P01,SRD in Healthy Volunteers,Preparing,PIHPZ,Phase I HPZ,I,Phase I,,2017‚Äê001106‚Äê15,09-MAR-17,000010,IS - Clin Study - Clin Pharm - SRD
14640,1399-0002,1399.2,Preparing,971,1399-P01,MRD ,Preparing,PIHPZ,Phase I HPZ,I,Phase I,,2017‚Äê001107‚Äê71,09-MAR-17,000020,IS - Clin Study - Clin Pharm - MRD
14641,1400-0001,1400.1,Recruiting,972,1400-P01,BI 473494 - Safety, tolerability, PK & PD of SRD,Recruiting,PIHPZ,Phase I HPZ,I,Phase I,,2016-003224-24,01-AUG-16,000010,IS - Clin Study - Clin Pharm - SRD
14642,1400-0002,1400.2,Unconfirmed,972,1400-P01,Ph I MRD: Phase II T2D,Unconfirmed,PRELIM,Preliminary,I/II,Phase I/II,,,,000910,IS - Clin Study (MIGRATED)
14643,1400-0003,1400.3,Unconfirmed,972,1400-P01,Gastric Emptying iHV,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14644,1400-0004,1400.4,Unconfirmed,972,1400-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14645,1400-0005,1400.5,Unconfirmed,972,1400-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14646,1400-0006,1400.6,Unconfirmed,972,1400-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14647,1400-0007,1400.7,Unconfirmed,972,1400-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14648,1400-0008,1400.8,Unconfirmed,972,1400-P01,Dose finding study in Japanese patients (12 wks),Unconfirmed,PRELIM,Preliminary,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14649,1400-0009,1400.9,Unconfirmed,972,1400-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14650,1400-0010,1400.10,Unconfirmed,972,1400-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14651,1400-0011,1400.11,Unconfirmed,972,1400-P01,tQT,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14652,1400-0012,1400.12,Unconfirmed,972,1400-P01,PK/PD special populations ethnic diff,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14653,1400-0013,1400.13,Unconfirmed,972,1400-P01,Site absorption study,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14654,1400-0014,1400.14,Unconfirmed,972,1400-P01,PK study in mainland China,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14655,1400-0015,1400.15,Unconfirmed,972,1400-P01,Potential Ic study for uptitration,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14656,1400-0016,1400.16,Unconfirmed,972,1400-P01,Pediatric development phase 1 (+PK),Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14657,1400-0017,1400.17,Unconfirmed,972,1400-P01,Pediatric development phase 3,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14658,1400-0018,1400.18,Unconfirmed,972,1400-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14659,1400-0019,1400.19,Unconfirmed,972,1400-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14660,1400-0020,1400.20,Unconfirmed,972,1400-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14661,1400-0021,1400.21,Unconfirmed,972,1400-P01,SRD in Japanese & Chinese HV,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14662,1400-0022,1400.22,Unconfirmed,972,1400-P01,DDI,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14663,1400-0023,1400.23,Unconfirmed,972,1400-P01,Mechanistic study (12wk) energy exp.,Unconfirmed,PRELIM,Preliminary,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14664,1400-0024,1400.24,Unconfirmed,972,1400-P01,DDI,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14665,1400-0025,1400.25,Unconfirmed,972,1400-P01,52 wk, BI 473494 mono Phase III,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14666,1400-0026,1400.26,Unconfirmed,972,1400-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14667,1400-0027,1400.27,Unconfirmed,972,1400-P01,24w,BI 473494 vs placebo MFN+SGLT2,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14668,1400-0028,1400.28,Unconfirmed,972,1400-P01,24w, BI 473494 vs placebo MFN+ SUs,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14669,1400-0029,1400.29,Unconfirmed,972,1400-P01,24w, BI 1473494 vs pl Insulin + OADS,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14670,1400-0030,1400.30,Unconfirmed,972,1400-P01,52wk Japanese add-on to ...,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14671,1400-0031,1400.31,Unconfirmed,972,1400-P01,LAMY CV outcome,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14672,1400-0032,1400.32,Unconfirmed,972,1400-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14673,1400-0033,1400.33,Unconfirmed,972,1400-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14674,1400-0034,1400.34,Unconfirmed,972,1400-P01,104w, BI 473494 vs GLP1 comp H2H in,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14675,1400-0035,1400.35,Unconfirmed,973,1400-P02,52wk, BI 473494 vs rel GLP-1 comp H2H,Unconfirmed,PRELIM,Preliminary,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
14676,1400-0036,1400.36,Unconfirmed,973,1400-P02,Ph IIb dose finding vs placebo & AC,Unconfirmed,PRELIM,Preliminary,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
14677,1400-0037,1400.37,Unconfirmed,973,1400-P02,placeholder ext. (subgroup prediabetes),Unconfirmed,PRELIM,Preliminary,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14678,1400-0038,1400.38,Unconfirmed,973,1400-P02,PhIII 52w Obese non-d vs Pl vs GLP1 comp,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14679,1400-0039,1400.39,Unconfirmed,973,1400-P02,PhIII 52w Obese T2D vs Pl vs GLP1 comp,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14680,1400-0040,1400.40,Unconfirmed,973,1400-P02,Ph III Cardiovascular outcome study,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14681,1400-0041,1400.41,Unconfirmed,973,1400-P02,Dose finding study in Japanese patients (12 wks),Unconfirmed,PRELIM,Preliminary,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14682,1400-0042,1400.42,Unconfirmed,973,1400-P02,PhIII 52w Obe. non-di.vs Pl vs rel GLP1,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14683,1401-0001,1401.1,Unconfirmed,974,1401-P01,First in man dose escalation,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14684,1401-0002,1401.2,Unconfirmed,974,1401-P01,Phase I in combination with chemotherapy,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14685,1393-0008,1393.8,Unconfirmed,975,1393-P02,Ph2a in patients with DME over 12 weeks,Unconfirmed,MIG,Migration,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
14686,1368-0011,1368.11,First Subject Randomised,976,1368-P02,Single dose i.v. in GPP,First Subject Randomised,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14687,1368-0012,1368.12,Unconfirmed,976,1368-P02,Multiple dose in GPP,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14688,1368-0013,1368.13,Preparing,976,1368-P02,Flare Treatment Phase III Trial in GPP,Preparing,FULL,Full functionality,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14689,1368-0014,1368.14,Unconfirmed,976,1368-P02,SRD bridging trial to Japanese hv,Unconfirmed,MIG,Migration,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14690,1368-0015,1368.15,First Subject Randomised,976,1368-P02,Multiple dosing trial in PPP,First Subject Randomised,FULL,Full functionality,IIA,Phase IIa,,2016-004573-40,08-NOV-16,000131,IS - Clin Study - POCC
14691,1368-0016,1368.16,Unconfirmed,976,1368-P02,Seamless Phase II/III Trial in PPP,Unconfirmed,PRELIM,Preliminary,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14692,0018-0512,18.512,Preparing,977,0018-P08,Efficacy/safety ambroxol lozenges 20mg,Preparing,MIG,Migration,III,Phase III,,2016-001649-17,,000910,IS - Clin Study (MIGRATED)
14693,1402-0001,1402.1,First Subject Randomised,979,1402-P01,Single Rising Dose,First Subject Randomised,PIHPZ,Phase I HPZ,IA,Phase Ia,,2017-000143-40 ,09-JAN-17,000010,IS - Clin Study - Clin Pharm - SRD
14694,1402-0002,1402.2,Unconfirmed,979,1402-P01,Multiple rising dose,Unconfirmed,PRELIM,Preliminary,IB,Phase Ib,,,,000020,IS - Clin Study - Clin Pharm - MRD
14695,1402-0003,1402.3,Unconfirmed,979,1402-P01,fMRI study in Depressed/Dysphorics,Unconfirmed,PRELIM,Preliminary,IB,Phase Ib,Physiological response / circuit engagement in the brain by using functional MR Imaging (fMRI) in an emotional processing task in unmedicated depressed subjects ( = PoCP )  
,,,000100,IS - Clin Study - Clin Pharm - Other
14696,1402-0004,1402.4,Unconfirmed,979,1402-P01,Safety study in patients with MDD,Unconfirmed,PRELIM,Preliminary,IB,Phase Ib,,,,000910,IS - Clin Study (MIGRATED)
14697,1404-0001,1404.1,Initiated,981,1404-P01,Ph I SRD,Initiated,PIHPZ,Phase I HPZ,I,Phase I,,2017‚Äê000295‚Äê29,19-JAN-17,000910,IS - Clin Study (MIGRATED)
14698,1404-0002,1404.2,Unconfirmed,981,1404-P01,Ph I MRD: Phase II T2D,Unconfirmed,PRELIM,Preliminary,I/II,Phase I/II,,,,000910,IS - Clin Study (MIGRATED)
14699,1404-0003,1404.3,Unconfirmed,981,1404-P01,Gastric Emtying iHV,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14700,1404-0004,1404.4,Unconfirmed,981,1404-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14701,1404-0005,1404.5,Unconfirmed,981,1404-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14702,1404-0006,1404.6,Unconfirmed,981,1404-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14703,1404-0007,1404.7,Unconfirmed,981,1404-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14704,1404-0008,1404.8,Unconfirmed,981,1404-P01,Dose finding study in Japanese patients (12 weeks),Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14705,1404-0009,1404.9,Unconfirmed,981,1404-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14706,1404-0010,1404.10,Unconfirmed,981,1404-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14707,1404-0011,1404.11,Unconfirmed,981,1404-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14708,1404-0012,1404.12,Unconfirmed,981,1404-P01,PK/PD special populations ethnic diff,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14709,1404-0013,1404.13,Unconfirmed,981,1404-P01,Site absorption study,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14710,1404-0014,1404.14,Unconfirmed,981,1404-P01,PK study in mainland China,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14711,1404-0015,1404.15,Unconfirmed,981,1404-P01,Potential Ic study for uptitration,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14712,1404-0016,1404.16,Unconfirmed,981,1404-P01,Pediatric development phase 1 (+PK),Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14713,1404-0017,1404.17,Unconfirmed,981,1404-P01,Pediatric development phase 3,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14714,1404-0018,1404.18,Unconfirmed,981,1404-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14715,1404-0019,1404.19,Unconfirmed,981,1404-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14716,1404-0020,1404.20,Unconfirmed,981,1404-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14717,1404-0021,1404.21,Unconfirmed,981,1404-P01,SRD in Asian patients,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14718,1404-0022,1404.22,Unconfirmed,981,1404-P01,Dose finding study vs. GLP-1,Unconfirmed,PRELIM,Preliminary,IIA,Phase IIa,,,,000910,IS - Clin Study (MIGRATED)
14719,1404-0023,1404.23,Unconfirmed,981,1404-P01,Mechanistic study (12wk) energy exp.,Unconfirmed,PRELIM,Preliminary,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14720,1404-0024,1404.24,Unconfirmed,981,1404-P01,DDI,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14721,1404-0025,1404.25,Unconfirmed,981,1404-P01,52 wk, BI 456906 mono vs placebo in T2D,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14722,1404-0026,1404.26,Unconfirmed,981,1404-P01,CV outcome,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14723,1404-0027,1404.27,Unconfirmed,981,1404-P01,24w,BI 456906 vs placebo MFN+SGLT2,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14724,1404-0028,1404.28,Unconfirmed,981,1404-P01,24w, BI 456906 vs placebo MFN+ SUs,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14725,1404-0029,1404.29,Unconfirmed,981,1404-P01,24w, BI 456906 vs pl Insulin + OADS,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14726,1404-0030,1404.30,Unconfirmed,981,1404-P01,52wk Japanese add-on to ...,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14727,1404-0031,1404.31,Unconfirmed,981,1404-P01,Cardiovaskular safety in high risk pts,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14728,1404-0032,1404.32,Unconfirmed,981,1404-P01,52wk Asian add-on to ....,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14729,1404-0033,1404.33,Unconfirmed,981,1404-P01,Placeholder,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14730,1404-0034,1404.34,Unconfirmed,981,1404-P01,104w, BI 456906 vs GLP1 comp H2H in,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14731,1404-0035,1404.35,Unconfirmed,982,1404-P02,52wk, BI 456906 vs rel GLP1 comp H2H,Unconfirmed,PRELIM,Preliminary,IIIA,Phase IIIa,,,,000910,IS - Clin Study (MIGRATED)
14732,1404-0036,1404.36,Unconfirmed,982,1404-P02,Ph IIb dose finding vs placebo & AC,Unconfirmed,PRELIM,Preliminary,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14733,1404-0037,1404.37,Unconfirmed,982,1404-P02,placeholder ext. (subgroup prediabetes),Unconfirmed,PRELIM,Preliminary,IIB,Phase IIb,,,,000910,IS - Clin Study (MIGRATED)
14734,1404-0038,1404.38,Unconfirmed,982,1404-P02,PhIII 52w Obese non-d vs Pl vs GLP1 comp,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14735,1404-0039,1404.39,Unconfirmed,982,1404-P02,PhIII 52w Obese T2D vs Pl vs GLP1 comp.,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14736,1404-0040,1404.40,Unconfirmed,982,1404-P02,Ph III Cardiovascular outcome study,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14737,1404-0041,1404.41,Unconfirmed,982,1404-P02,Placeholder,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14738,1404-0042,1404.42,Unconfirmed,982,1404-P02,PhIII 52w Obe. non-di.vs Pl vs rel GLP-1,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14739,1405-0001,1405.1,Unconfirmed,983,1405-P01,SRD in HV,Unconfirmed,PRELIM,Preliminary,IA,Phase Ia,,,,000010,IS - Clin Study - Clin Pharm - SRD
14740,1405-0002,1405.2,Unconfirmed,983,1405-P01,MRD in patients,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000020,IS - Clin Study - Clin Pharm - MRD
14741,1336-0007,1336.7,Unconfirmed,985,1336-P02,SRD/MRD/PoCM in wAMD,Unconfirmed,FULL,Full functionality,I,Phase I,,2017-001221-40 ,17-MAR-17,000910,IS - Clin Study (MIGRATED)
14742,1336-0008,1336.8,Unconfirmed,985,1336-P02,Ph2 PoCC in DME,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14743,1336-0009,1336.9,Unconfirmed,985,1336-P02,Ph3 in DME (study 1),Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14744,1336-0010,1336.10,Unconfirmed,985,1336-P02,Ph3 in DME (study 2),Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14745,1407-0001,1407.1,First Subject Randomised,986,1407-P01,BI 730357 - Safety, tolerability, PK & PD of SRD,First Subject Randomised,PIHPZ,Phase I HPZ,I,Phase I,,2016-003047-11,18-JUL-16,000010,IS - Clin Study - Clin Pharm - SRD
14746,1407-0002,1407.2,Preparing,986,1407-P01,BI 730357 MRD/PoCC Psoriasis,Preparing,FULL,Full functionality,II,Phase II,,2017-001653-14,19-APR-17,000131,IS - Clin Study - POCC
14747,1407-0003,1407.3,Unconfirmed,986,1407-P01,BI 730357 - PoCC in AS,Unconfirmed,PRELIM,Preliminary,IB,Phase Ib,,,,000131,IS - Clin Study - POCC
14748,1407-0005,1407.5,Unconfirmed,986,1407-P01,BI 730357 - Psoriasis Open Label Extension,Unconfirmed,MIG,Migration,II,Phase II,12 month open label extension for patients upon (24 week) completion of Phase II (PoC) part of 1407-0002 study.,,,000910,IS - Clin Study (MIGRATED)
14749,1408-0001,1408.1,First Subject Randomised,987,1408-P01,SRD in HV,First Subject Randomised,PIHPZ,Phase I HPZ,I,Phase I,,2017-000324-98,18-JAN-17,000910,IS - Clin Study (MIGRATED)
14750,1408-0002,1408.2,Unconfirmed,987,1408-P01,MRD in HV,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14751,1408-0003,1408.3,Unconfirmed,987,1408-P01,PoCP in RA,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14752,1408-0004,1408.4,Unconfirmed,987,1408-P01,Safety of BI 705564 in lupus,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14753,1245-0137,1245.137,Unconfirmed,988,1245-P07,Renal outcome study in CKD,Unconfirmed,FULL,Full functionality,III,Phase III,,2017-002971-24 ,12-JUL-17,000910,IS - Clin Study (MIGRATED)
14754,1407-0004,1407.4,Unconfirmed,990,1407-P03,BI 730357 Phase 2 PoC Psoriatic Arthritis,Unconfirmed,PRELIM,Preliminary,IIB,Phase IIb,,,,000131,IS - Clin Study - POCC
14755,1409-0001,1409.1,Unconfirmed,992,1409-P01,Ph I SRD,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14756,1409-0002,1409.2,Unconfirmed,992,1409-P01,Ph I MRD incl obese (4w treatment),Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14757,1409-0003,1409.3,Unconfirmed,992,1409-P01,Ph II (12w treatment),Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14758,1409-0004,1409.4,Unconfirmed,992,1409-P01,CYP 3A4 induction,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14759,1409-0005,1409.5,Unconfirmed,992,1409-P01,CYP 3A4 metabolism,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14760,1409-0006,1409.6,Unconfirmed,992,1409-P01,Ph I Pan-Asian,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14761,1409-0007,1409.7,Unconfirmed,992,1409-P01,Absolute BA (incl SRD iv),Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14762,1409-0008,1409.8,Unconfirmed,992,1409-P01,Hepatic/renal impairment trial,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000910,IS - Clin Study (MIGRATED)
14763,1409-0009,1409.9,Unconfirmed,992,1409-P01,Ph III (52w treatment),Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000910,IS - Clin Study (MIGRATED)
14764,0352-2099,352.2099,Unconfirmed,994,0352-P05,Asthma and Cough assessment devices,Unconfirmed,MIG,Migration,NONE,Not Classified,,,,000300,IS - Methodological Studies
14765,1200-0283,1200.283,Preparing,995,1200-P14,afatinib+pembrolizumab in squamous NSCLC,Preparing,FULL,Full functionality,II,Phase II,,2016-005042-37,12-DEC-16,000910,IS - Clin Study (MIGRATED)
14766,1200-0284,1200.284,Unconfirmed,995,1200-P14,afatinib+pembrolizumab in SCCHN,Unconfirmed,MIG,Migration,II,Phase II,,,,000910,IS - Clin Study (MIGRATED)
14767,1402-0005,,Unconfirmed,979,1402-P01,Physiological response in CCK-4 challenge,Unconfirmed,FULL,Full functionality,I,Phase I,Physiological response by compound effect in the cholecystokinin tetrapeptide (CCK-4) challenge model in healthy volunteers (HV) ( = PoCP )  


,,,000100,IS - Clin Study - Clin Pharm - Other
14768,1402-0006,,Unconfirmed,979,1402-P01,fMRI study in BPD,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000150,IS - Clin Study - Explore
14769,1321-0018,,Unconfirmed,820,1321-P01,EAP of Idarucizumab,Unconfirmed,COMP,Compassionate Use,IIIB,Phase IIIb,,,,,
14770,1402-0007,,Unconfirmed,979,1402-P01,DDI placeholder study 1,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000030,IS - Clin Study - Clin Pharm - DDI
14771,1402-0008,,Unconfirmed,979,1402-P01,Pan Asian Phase I,Unconfirmed,PIHPZ,Phase I HPZ,I/II,Phase I/II,,,,000020,IS - Clin Study - Clin Pharm - MRD
14772,1237-0064,,Preparing,678,1237-P01,COPD pragmatic randomised clinical trial,Preparing,OUT,Fully Outsourced,,,,,,000200,IS - Clin Study - Outcome
14773,1336-0011,,Preparing,850,1336-P01,Phase Ib/expansion BI836880 in combination with CPI,Preparing,FULL,Full functionality,,,,,,,
14774,1407-0006,,Unconfirmed,991,1407-P04,BI 730357 PoCP Asthma,Unconfirmed,FULL,Full functionality,IIA,Phase IIa,,,,000080,IS - Clin Study - Clin Pharm - Explore
14775,1407-0007,,Unconfirmed,991,1407-P04,BI 730357 Bronchoscopy study Asthma,Unconfirmed,FULL,Full functionality,IIA,Phase IIa,,,,000080,IS - Clin Study - Clin Pharm - Explore
14776,1237-0065,,Recruiting,678,1237-P01,AERIAL,Recruiting,NISND,NISND incl. Chart Abstractions,NONE,Not Classified,,,,000420,NISnd ‚Äì Study - Cohort
14777,1237-0066,,Recruiting,951,1237-P02,INCOGNITO,Recruiting,IIS,Investigator Initiated Study,,,,,,000150,IS - Clin Study - Explore
14778,1390-0006,,Unconfirmed,957,1390-P01,MRD in patients,Unconfirmed,FULL,Full functionality,I/II,Phase I/II,okay,,,000020,IS - Clin Study - Clin Pharm - MRD
14779,1200-0286,,Preparing,770,1200-P06,Afatinib Osimertinib sequencing NIS,Preparing,NISED,Non Interventional Study Existing Data,IV,Phase IV,,,,000450,NISed ‚Äì Study - Other
14780,1245-0153,,Preparing,900,1245-P05,IIS-2-057-AUS_Lim,Preparing,IIS,Investigator Initiated Study,,,,,,000150,IS - Clin Study - Explore
14781,1245-0154,,Preparing,900,1245-P05,IIS-2-061-ISR_Caspi,Preparing,IIS,Investigator Initiated Study,IV,Phase IV,,,,000150,IS - Clin Study - Explore
14782,1245-0155,,Preparing,900,1245-P05,IIS-2-072-NL_vanRaalte,Preparing,IIS,Investigator Initiated Study,,,,,,000150,IS - Clin Study - Explore
14783,1245-0156,,Unconfirmed,900,1245-P05,IIS-2-063-JP_Kuwahara,Unconfirmed,IIS,Investigator Initiated Study,,,,,,000150,IS - Clin Study - Explore
14784,1245-0157,,Preparing,900,1245-P05,IIS-2-066-CAN_Cherney,Preparing,IIS,Investigator Initiated Study,,,,,,000150,IS - Clin Study - Explore
14785,1245-0158,,Recruiting,900,1245-P05,CRC2017ELSI (Schmieder),Recruiting,IIS,Investigator Initiated Study,III,Phase III,,2017-000055-88,06-MAR-17,000150,IS - Clin Study - Explore
14786,1245-0159,,Unconfirmed,900,1245-P05,IIS-2-073-JP_Tsutsui,Unconfirmed,IIS,Investigator Initiated Study,,,,,,000150,IS - Clin Study - Explore
14787,1199-0295,,Preparing,690,1199-P03,BROAD Study,Preparing,NISED,Non Interventional Study Existing Data,IV,Phase IV,,,,000460,NISed ‚Äì Study - Cohort
14788,1160-0280,,Recruiting,618,1160-P02,RE-QUOL NISnd Spain,Recruiting,NISND,NISND incl. Chart Abstractions,IV,Phase IV,,,,000430,NISnd ‚Äì Study - Cross Sectional
14789,1371-0007,,Unconfirmed,921,1371-P01,Allergen Challenge Study,Unconfirmed,FULL,Full functionality,IB,Phase Ib,,,,000132,IS - Clin Study - POCP
14790,0205-0536,,Recruiting,683,0205-P05,Specific Use-Result of Spiriva Respimat¬Æ in asthmatics ,Recruiting,NISND,NISND incl. Chart Abstractions,IV,Phase IV,,,,000420,NISnd ‚Äì Study - Cohort
14791,1289-0049,,Preparing,999,1289-P04,PoC in Prevention of Relapse,Preparing,FULL,Full functionality,II,Phase II,,2017-002369-23 ,02-JUN-17,000131,IS - Clin Study - POCC
14792,1381-0004,,Preparing,938,1381-P01,Pan Asian BI 754091/BI 754111 phase I,Preparing,FULL,Full functionality,I,Phase I,,,,000150,IS - Clin Study - Explore
14793,1245-0160,,Unconfirmed,695,1245-P01,Study of Health Care Resources Use in higH CV risk in Spain ,Unconfirmed,NISED,Non Interventional Study Existing Data,IV,Phase IV,,,,000460,NISed ‚Äì Study - Cohort
14794,1199-0296,,Preparing,690,1199-P03,OASIS-IPF Study,Preparing,NISND,NISND incl. Chart Abstractions,IV,Phase IV,,,,000410,NISnd ‚Äì Study - Other
14795,1199-0297,,Unconfirmed,690,1199-P03,PROSPECT-IPF Study,Unconfirmed,NISND,NISND incl. Chart Abstractions,IV,Phase IV,,,,000410,NISnd ‚Äì Study - Other
14796,1199-0298,,Preparing,690,1199-P03,IPF Algorithm Validation in a US Population,Preparing,NISED,Non Interventional Study Existing Data,,,,,,000450,NISed ‚Äì Study - Other
14797,1199-0299,,Preparing,690,1199-P03,IPF in Elderly US Patients ,Preparing,NISED,Non Interventional Study Existing Data,,,,,,000460,NISed ‚Äì Study - Cohort
14798,1405-0003,,Unconfirmed,983,1405-P01,Pan-Asian SRD,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000010,IS - Clin Study - Clin Pharm - SRD
14799,1321-0019,,Preparing,820,1321-P01,Chinese Phase 3 Idarucizumab ,Preparing,FULL,Full functionality,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14800,1412-0001,,Unconfirmed,997,1412-P01,BI 905711: FIH phase Ia/Ib dose finding in CRC,Unconfirmed,PRELIM,Preliminary,I/II,Phase I/II,,,,000150,IS - Clin Study - Explore
14801,1289-0050,,Unconfirmed,999,1289-P04,Phase III - Americas,Unconfirmed,FULL,Full functionality,,,,,,,
14802,1289-0051,,Unconfirmed,999,1289-P04,Phase III - ROW,Unconfirmed,FULL,Full functionality,,,,,,,
14803,1289-0052,,Unconfirmed,999,1289-P04,Phase III - OL Safety Extension,Unconfirmed,FULL,Full functionality,,,,,,,
14804,1416-0001,,Unconfirmed,1001,1416-P01,SRD evaluation of safety and PK of BI 730460 in HVs,Unconfirmed,PIHPZ,Phase I HPZ,IA,Phase Ia,,,,000010,IS - Clin Study - Clin Pharm - SRD
14805,1416-0002,,Unconfirmed,1001,1416-P01,BI 730460 MRD in HVs,Unconfirmed,FULL,Full functionality,IB,Phase Ib,,,,000020,IS - Clin Study - Clin Pharm - MRD
14806,1405-0004,,Unconfirmed,983,1405-P01,Pan-Asian MRD,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000020,IS - Clin Study - Clin Pharm - MRD
14807,1405-0005,,Unconfirmed,983,1405-P01,26w COPD study,Unconfirmed,PRELIM,Preliminary,IIA,Phase IIa,,,,000132,IS - Clin Study - POCP
14808,1405-0006,,Unconfirmed,983,1405-P01,52w A1AT deficiency study,Unconfirmed,PRELIM,Preliminary,IIA,Phase IIa,,,,,
14809,1402-0009,,Unconfirmed,979,1402-P01,DDI placeholder 2,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000030,IS - Clin Study - Clin Pharm - DDI
14810,1402-0010,,Unconfirmed,979,1402-P01,Rel BA placeholder TFI to TFII,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000090,IS - Clin Study - Clin Pharm - BA/BE
14811,1402-0011,,Unconfirmed,979,1402-P01,Proof of concept and DRF in MDD,Unconfirmed,FULL,Full functionality,II,Phase II,,,,000140,IS - Clin Study - DRF
14812,1402-0012,,Unconfirmed,979,1402-P01,Proof of concept and DRF in BPD,Unconfirmed,FULL,Full functionality,II,Phase II,,,,000140,IS - Clin Study - DRF
14813,1339-0009,,Unconfirmed,955,1339-P02,Phase I Pan-Asian Study,Unconfirmed,COMP,Compassionate Use,I,Phase I,,,,,
14814,1339-0010,,Unconfirmed,955,1339-P02,BI 655088 Phase IIb Study CKD,Unconfirmed,COMP,Compassionate Use,IIB,Phase IIb,,,,,
14815,1276-0040,,Unconfirmed,750,1276-P01,local ph 3 study India,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000190,IS - Clin Study - Confirmatory - Other
14816,1280-0021,,Unconfirmed,757,1280-P01,window trial prostate cancer,Unconfirmed,IIS,Investigator Initiated Study,,,,,,,
14817,1160-0281,,Unconfirmed,618,1160-P02,Electronic Decision Making Tool,Unconfirmed,NISED,Non Interventional Study Existing Data,NONE,Not Classified,,,,000600,Survey Patient Questionnaire
14818,1321-0020,,Preparing,820,1321-P01,Ida-rtPA PRODAST Registry,Preparing,IIS,Investigator Initiated Study,NONE,Not Classified,,,,000300,IS - Methodological Studies
14819,1200-0287,,Initiated,795,1200-P07,+Cetuximab Recurrent or Metastatic SCC of Head and Neck,Initiated,IIS,Investigator Initiated Study,,,,,,000150,IS - Clin Study - Explore
14820,1123-0038,,Unconfirmed,898,1123-P04,TWIST Tenecteplase in wake up stroke,Unconfirmed,IIS,Investigator Initiated Study,,,,,,,
14821,0248-0686,,Unconfirmed,617,0248-P07,Efficacy&safety of Prami SR vs Prami IR on nocturnal symptom,Unconfirmed,FULL,Full functionality,,,,,,,
14822,1200-0288,,Preparing,770,1200-P06,+ cetuximab EGFR exon 20,Preparing,IIS,Investigator Initiated Study,I/II,Phase I/II,,,,000160,IS - Clin Study - Explore- Subpopulation
14823,1160-0282,,Unconfirmed,717,1160-P05,IIS MATADOR-PCI,Unconfirmed,IIS,Investigator Initiated Study,,,,,,,
14824,1363-0023,,Unconfirmed,909,1363-P01,Taste acceptability,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000100,IS - Clin Study - Clin Pharm - Other
14825,1199-0300,,Preparing,690,1199-P03,Treatment of patients with ILD in Germany,Preparing,NISED,Non Interventional Study Existing Data,,,,,,000470,NISed ‚Äì Study - Cross Sectional
14826,1199-0301,,Unconfirmed,690,1199-P03,Premier Database Analysis In-hospital mortality in IPF,Unconfirmed,NISED,Non Interventional Study Existing Data,,,,,,000450,NISed ‚Äì Study - Other
14827,1373-0008,,Unconfirmed,923,1373-P01,CureVac sponsored Phase Ib BI 1361849 (CV9202),Unconfirmed,OUT,Fully Outsourced,,,,,,,
14828,1199-0302,,Preparing,942,1199-P15,China IPF Registry,Preparing,IIS,Investigator Initiated Study,,,,,,000400,NISnd ‚Äì Study - Case Control
14829,1199-0303,,Preparing,690,1199-P03,NICEFIT Taiwan,Preparing,NISND,NISND incl. Chart Abstractions,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
14830,1199-0304,,Recruiting,942,1199-P15,INSIGHTS IPF Registry,Recruiting,IIS,Investigator Initiated Study,,,,,,000410,NISnd ‚Äì Study - Other
14831,1245-0161,,Unconfirmed,695,1245-P01,Empagliflozin Genome Wide Association Study,Unconfirmed,PRP,Pharmacogenomic Research Project,II,Phase II,,,,000100,IS - Clin Study - Clin Pharm - Other
14832,1160-0283,,Unconfirmed,618,1160-P02,RE-ELECT ,Unconfirmed,IIS,Investigator Initiated Study,IV,Phase IV,RE-ELECT: Dabigatran vs warfarin in AF patients with T2D and CKD,,,,
14833,1237-0067,,Preparing,678,1237-P01,Comparative effectiveness of COPD treatments,Preparing,NISED,Non Interventional Study Existing Data,,,,,,000420,NISnd ‚Äì Study - Cohort
14834,1275-0025,,Unconfirmed,749,1275-P01,Local Phase 3 study India,Unconfirmed,FULL,Full functionality,IIIB,Phase IIIb,,,,000190,IS - Clin Study - Confirmatory - Other
14835,1417-0001,,Unconfirmed,1002,1417-P01,Single Rising Dose ,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,2017-001287-37,22-MAR-17,000010,IS - Clin Study - Clin Pharm - SRD
14836,1417-0002,,Unconfirmed,1002,1417-P01,Multiple Rising Dose ,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000020,IS - Clin Study - Clin Pharm - MRD
14837,1417-0003,,Unconfirmed,1002,1417-P01,Proof of Clinical Principal in Crohn‚Äôs Disease,Unconfirmed,PRELIM,Preliminary,IIA,Phase IIa,,,,000132,IS - Clin Study - POCP
14838,1320-0031,,Unconfirmed,935,1320-P03,ADME,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,2017‚Äê001453‚Äê14,05-APR-17,000110,IS - Clin Study - Clin Pharm - Other/ADME
14839,1160-0284,,Recruiting,618,1160-P02,Japanese Pradaxa PMS, long term,Recruiting,NISND,NISND incl. Chart Abstractions,IV,Phase IV,,,,000420,NISnd ‚Äì Study - Cohort
14840,1199-0305,,Recruiting,942,1199-P15,Nintedanib for IPF associated with advanced NSCLC,Recruiting,IIS,Investigator Initiated Study,,,,,,000160,IS - Clin Study - Explore- Subpopulation
14841,1199-0306,,Preparing,942,1199-P15,Pulmonary rehabilitation in IPF patients on nintedanib,Preparing,IIS,Investigator Initiated Study,,,,,,000150,IS - Clin Study - Explore
14842,1199-0307,,Unconfirmed,942,1199-P15,IPF clinical practice: RaDiCo-PID Cohort,Unconfirmed,IIS,Investigator Initiated Study,,,,,,,
14843,1199-0308,,Recruiting,942,1199-P15,Transbronchial lung cryobiopsy in the diagnosis of ILD,Recruiting,IIS,Investigator Initiated Study,NONE,Not Classified,,,,000410,NISnd ‚Äì Study - Other
14844,1199-0309,,Unconfirmed,942,1199-P15,Parenchymal and Vascular Analysis in ILD,Unconfirmed,IIS,Investigator Initiated Study,,,,,,000460,NISed ‚Äì Study - Cohort
14845,1245-0162,,Preparing,900,1245-P05,IIS-2-062-JP_Kumashiro,Preparing,IIS,Investigator Initiated Study,,,,,,000150,IS - Clin Study - Explore
14846,1200-0289,,Preparing,795,1200-P07,afatinib+nivolumab SCCHN,Preparing,IIS,Investigator Initiated Study,I,Phase I,,,,000150,IS - Clin Study - Explore
14847,1199-0310,,Unconfirmed,942,1199-P15,Microsatellite alter. in exhaled breath condensate in IPF   ,Unconfirmed,IIS,Investigator Initiated Study,,,,,,000410,NISnd ‚Äì Study - Other
14848,1199-0311,,Unconfirmed,942,1199-P15,Longitudinal changes in breath biomarkers in IPF,Unconfirmed,IIS,Investigator Initiated Study,,,,,,000150,IS - Clin Study - Explore
14849,1199-0312,,Recruiting,942,1199-P15,Lungcast- Lung disease progression forecast,Recruiting,IIS,Investigator Initiated Study,,,,,,000450,NISed ‚Äì Study - Other
14850,1160-0285,,Unconfirmed,618,1160-P02,Assessment of stroke in Japan,Unconfirmed,IIS,Investigator Initiated Study,NONE,Not Classified,,,,,
14851,1245-0163,,Unconfirmed,817,1245-P02,Pediatric T1DM PK/PD study in 2-5 year olds ,Unconfirmed,FULL,Full functionality,,,,,,000100,IS - Clin Study - Clin Pharm - Other
14852,1245-0164,,Unconfirmed,817,1245-P02,Pediatric T1DM phase 3 study in 2-5 year olds,Unconfirmed,FULL,Full functionality,,,,,,000150,IS - Clin Study - Explore
14853,1245-0165,,Unconfirmed,817,1245-P02,Relative BA study in adults - liquid formulation ,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000090,IS - Clin Study - Clin Pharm - BA/BE
14854,1403-0001,,Preparing,980,1403-P01,Phase I BI907828 in advanced TP53WT/MDM2-amplified tumors ,Preparing,FULL,Full functionality,I,Phase I,,,,000150,IS - Clin Study - Explore
14855,1403-0002,,Unconfirmed,980,1403-P01,Ph. I BI 907828+BI 754091 (PD-1 mAb) and BI 754111 (LAG-3),Unconfirmed,FULL,Full functionality,IB,Phase Ib,,,,000132,IS - Clin Study - POCP
14856,1407-0008,,Unconfirmed,991,1407-P04,Dose range finding study,Unconfirmed,FULL,Full functionality,IIB,Phase IIb,,,,000130,IS - Clin Study - POC
14857,1407-0009,,Unconfirmed,991,1407-P04,Pivotal efficacy study,Unconfirmed,FULL,Full functionality,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14858,1407-0010,,Unconfirmed,991,1407-P04,Pivotal efficacy study II,Unconfirmed,FULL,Full functionality,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14859,1245-0166,,Preparing,900,1245-P05,IIS-2-078-NL_Voors,Preparing,IIS,Investigator Initiated Study,,,,,,000150,IS - Clin Study - Explore
14860,1218-0179,,Preparing,835,1218-P05,IIS-1-088-DK_Vilsboll,Preparing,IIS,Investigator Initiated Study,II,Phase II,,,,000150,IS - Clin Study - Explore
14861,1218-0180,,Preparing,835,1218-P05,IIS-0-014-SK_Park,Preparing,IIS,Investigator Initiated Study,,,,,,000450,NISed ‚Äì Study - Other
14862,1199-0313,,Unconfirmed,690,1199-P03,NI PASS of Nintedanib in IPF in Argentina ,Unconfirmed,NISND,NISND incl. Chart Abstractions,IV,Phase IV,,,,000410,NISnd ‚Äì Study - Other
14863,1305-0011,,Preparing,883,1305-P03,Phase I SRD/MRD in Healthy Volunteers,Preparing,PIHPZ,Phase I HPZ,I,Phase I,,2017-002003-10,11-MAY-17,000020,IS - Clin Study - Clin Pharm - MRD
14864,1305-0012,,Unconfirmed,883,1305-P03,Phase I MRD in IPF patients,Unconfirmed,FULL,Full functionality,IB,Phase Ib,,,,000020,IS - Clin Study - Clin Pharm - MRD
14865,1160-0286,,Recruiting,618,1160-P02,PASSION,Recruiting,NISND,NISND incl. Chart Abstractions,IV,Phase IV,,,,000920,NISnd - Study (MIGRATED)
14866,1320-0032,,Unconfirmed,927,1320-P02,Phase II on triple therapy in COPD,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000130,IS - Clin Study - POC
14867,1320-0033,,Unconfirmed,927,1320-P02,Phase II on triple therapy in COPD,Unconfirmed,PRELIM,Preliminary,,,,,,,
14868,1321-0021,,Unconfirmed,820,1321-P01,PRAXBIND - ICB,Unconfirmed,IIS,Investigator Initiated Study,NONE,Not Classified,,,,000300,IS - Methodological Studies
14869,1237-0068,,Recruiting,951,1237-P02,COPD maintenance na√Øve patients in Japan,Recruiting,IIS,Investigator Initiated Study,,,,,,000200,IS - Clin Study - Outcome
14870,1200-0290,,Preparing,770,1200-P06,effects proton pump inhibitor esomeprazole on the bioavailib,Preparing,IIS,Investigator Initiated Study,IV,Phase IV,,,,000030,IS - Clin Study - Clin Pharm - DDI
14871,1200-0291,,Preparing,770,1200-P06,Potential Efficacy in Treatment with Known Molecular Profile,Preparing,IIS,Investigator Initiated Study,II,Phase II,,,,000160,IS - Clin Study - Explore- Subpopulation
14872,1305-0013,,Unconfirmed,883,1305-P03,Phase II dose finding/PoCP,Unconfirmed,FULL,Full functionality,II,Phase II,,,,000132,IS - Clin Study - POCP
14873,1305-0014,,Unconfirmed,883,1305-P03,Phase III confirmatory trials /PoCC,Unconfirmed,FULL,Full functionality,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14874,1237-0069,,Unconfirmed,678,1237-P01,GOLD adherence,Unconfirmed,NISED,Non Interventional Study Existing Data,,,,,,,
14875,1386-0019,,Unconfirmed,952,1386-P01,BI 1467335 - bioavailability,Unconfirmed,OUT,Fully Outsourced,I,Phase I,,,,000090,IS - Clin Study - Clin Pharm - BA/BE
14876,1245-0167,,Preparing,929,1245-P06,Exercise capacity study in HFpEF,Preparing,FULL,Full functionality,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14877,1245-0168,,Preparing,929,1245-P06,Exercise capacity study in HFrEF,Preparing,FULL,Full functionality,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14878,1199-0314,,Initiated,916,1199-P14,Clinical profile of early progression on first-line chemothe,Initiated,NISED,Non Interventional Study Existing Data,NONE,Not Classified,,,,000450,NISed ‚Äì Study - Other
14879,1245-0169,,Preparing,900,1245-P05,OXIDISE (Birkenfeld),Preparing,IIS,Investigator Initiated Study,IV,Phase IV,,2017-003296-60,03-AUG-17,000150,IS - Clin Study - Explore
14880,1200-0292,,Preparing,770,1200-P06,NSCLC retrospective analysis,Preparing,IIS,Investigator Initiated Study,,,,,,000300,IS - Methodological Studies
14881,1368-0023,,Unconfirmed,976,1368-P02,Phase II OLE,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000100,IS - Clin Study - Clin Pharm - Other
14882,1399-0003,,Unconfirmed,971,1399-P01,6-w dose-ranging in A/A with CF,Unconfirmed,FULL,Full functionality,II,Phase II,,,,000140,IS - Clin Study - DRF
14883,0352-2100,,Unconfirmed,905,0352-P03,Investigation of pharmacokinetic changes of digoxin, furosem,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,2017-001549-29 ,10-APR-17,000100,IS - Clin Study - Clin Pharm - Other
14884,1381-0005,,Unconfirmed,938,1381-P01,BI PD1+LAG3 in first line NSCLC,Unconfirmed,FULL,Full functionality,,,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14885,1381-0006,,Unconfirmed,938,1381-P01,BI PD1+LAG3 in second Line NSCLC,Unconfirmed,FULL,Full functionality,,,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14886,1407-0011,,Unconfirmed,986,1407-P01,Pivotal Phase 3 Efficacy Trial (1) vs Apremilast,Unconfirmed,FULL,Full functionality,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14887,1407-0012,,Unconfirmed,986,1407-P01,Pivotal Phase 3 Efficacy Trial (2) vs Apremilast,Unconfirmed,FULL,Full functionality,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14888,1160-0287,,Unconfirmed,618,1160-P02,RE-CONOCE,Unconfirmed,NISND,NISND incl. Chart Abstractions,IV,Phase IV,,,,000430,NISnd ‚Äì Study - Cross Sectional
14889,1237-0070,,Unconfirmed,678,1237-P01,OPTI Study,Unconfirmed,NISND,NISND incl. Chart Abstractions,IV,Phase IV,,,,000430,NISnd ‚Äì Study - Cross Sectional
14890,1237-0071,,Unconfirmed,951,1237-P02,ICS step-down in primary care for patients with COPD,Unconfirmed,IIS,Investigator Initiated Study,,,,,,,
14891,1305-0015,,Unconfirmed,883,1305-P03,DDI study,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000030,IS - Clin Study - Clin Pharm - DDI
14892,1305-0016,,Unconfirmed,883,1305-P03,Human ADME,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000110,IS - Clin Study - Clin Pharm - Other/ADME
14893,1305-0017,,Unconfirmed,883,1305-P03,PanAsian SRD,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000010,IS - Clin Study - Clin Pharm - SRD
14894,1305-0018,,Unconfirmed,883,1305-P03,DDI with CYP3A inhibitor,Unconfirmed,PIHPZ,Phase I HPZ,,,,,,,
14895,1305-0019,,Unconfirmed,883,1305-P03,Human ADME,Unconfirmed,PIHPZ,Phase I HPZ,,,,,,,
14896,1199-0315,,Preparing,942,1199-P15,Mechanisms of Familial Pulmonary Fibrosis,Preparing,IIS,Investigator Initiated Study,,,,,,,
14897,1422-0001,,Unconfirmed,1012,1422-P01,Ph I: SRD,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,000010,IS - Clin Study - Clin Pharm - SRD
14898,1368-0024,,Unconfirmed,976,1368-P02,5 Years OLE Phase III Trial in PPP,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000100,IS - Clin Study - Clin Pharm - Other
14899,1368-0025,,Unconfirmed,976,1368-P02,5 Years OLE Phase III Trial in GPP,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000100,IS - Clin Study - Clin Pharm - Other
14900,1417-0004,,Unconfirmed,1002,1417-P01,PoCC dose finding study,Unconfirmed,FULL,Full functionality,IIB,Phase IIb,,,,000131,IS - Clin Study - POCC
14901,1417-0005,,Unconfirmed,1002,1417-P01,Pivotal TNFi failures,Unconfirmed,FULL,Full functionality,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14902,1417-0006,,Unconfirmed,1002,1417-P01,Pivotal TNFi naive and non-failure,Unconfirmed,FULL,Full functionality,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14903,1417-0007,,Unconfirmed,1002,1417-P01,Pvital mantenance ,Unconfirmed,FULL,Full functionality,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14904,1200-0293,,Preparing,770,1200-P06,Evaluation of EGFR TKIs resistance mechanism beyond T790M mu,Preparing,IIS,Investigator Initiated Study,,,,,,,
14905,1199-0316,,Preparing,771,1199-P06,A Phase I/II Trial of Nintedanib and Nivolumab in Advanced N,Preparing,IIS,Investigator Initiated Study,,,,,,000150,IS - Clin Study - Explore
14906,1160-0288,,Preparing,618,1160-P02,Warfarin and Dabigatran Comparison,Preparing,FULL,Full functionality,NONE,Not Classified,,,,000420,NISnd ‚Äì Study - Cohort
14907,0352-2101,,Unconfirmed,905,0352-P03,Performance of [18F]AraG PET in Head and Neck cancer patient,Unconfirmed,METHOD,Method,NONE,Not Classified,Stanford Cancer Inst., D.Colevas ,,,000300,IS - Methodological Studies
14908,1245-0170,,Preparing,900,1245-P05,IIS-2-082-DK_Madsbad,Preparing,IIS,Investigator Initiated Study,,,,,,000150,IS - Clin Study - Explore
14909,1245-0171,,Preparing,695,1245-P01,SAP for a Meta-Analysis of Amputation Risk,Preparing,FULL,Full functionality,,,,,,,
14910,0352-2102,,Unconfirmed,905,0352-P03,Inv of COPD markers in spontaneous and induced sputum,Unconfirmed,METHOD,Method,NONE,Not Classified,,,,000300,IS - Methodological Studies
14911,1293-0014,,Unconfirmed,878,1293-P02,Phase 3 Maintenance in LN,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14912,1407-0013,,Unconfirmed,991,1407-P04,BI 730357 PoCP Asthma,Unconfirmed,FULL,Full functionality,,,,,,,
14913,1416-0003,,Unconfirmed,1005,1416-P04,BI 730460 PoCP Asthma,Unconfirmed,FULL,Full functionality,IIA,Phase IIa,,,,000132,IS - Clin Study - POCP
14914,1416-0004,,Unconfirmed,1005,1416-P04,BI 730460 Bronchoscopy study Asthma,Unconfirmed,FULL,Full functionality,IIA,Phase IIa,,,,000150,IS - Clin Study - Explore
14915,1416-0005,,Unconfirmed,1005,1416-P04,Dose range finding study,Unconfirmed,FULL,Full functionality,IIB,Phase IIb,,,,000140,IS - Clin Study - DRF
14916,1416-0006,,Unconfirmed,1005,1416-P04,Pivotal efficacy study,Unconfirmed,FULL,Full functionality,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14917,1416-0007,,Unconfirmed,1005,1416-P04,Pivotal efficacy study II,Unconfirmed,FULL,Full functionality,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14918,1289-0053,,Unconfirmed,945,1289-P03,Cognitive debriefing of the Scale of Psychosis-Risk Symptoms,Unconfirmed,OUT,Fully Outsourced,,,,,,,
14919,0205-0537,,Unconfirmed,683,0205-P05,Characteristics of pts initiating Spiriva Respimat in Asthma,Unconfirmed,NISND,NISND incl. Chart Abstractions,,,,,,,
14920,1381-0007,,Unconfirmed,938,1381-P01,PD1/LAG3 isolation of effect trial,Unconfirmed,FULL,Full functionality,II,Phase II,,,,000150,IS - Clin Study - Explore
14921,1407-0014,,Unconfirmed,986,1407-P01,BI 730357 Drug-Drug Interaction Study,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000030,IS - Clin Study - Clin Pharm - DDI
14922,1407-0015,,Unconfirmed,986,1407-P01,BI 730357 PanAsian SRD Study,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000010,IS - Clin Study - Clin Pharm - SRD
14923,1321-0022,,Preparing,820,1321-P01,Medical Need of OAC Reversal,Preparing,FULL,Full functionality,NONE,Not Classified,,,,000420,NISnd ‚Äì Study - Cohort
14924,1381-0008,,Unconfirmed,938,1381-P01,BI 754091+BI 754111 in IO pretreated NSCLC patients ,Unconfirmed,FULL,Full functionality,II,Phase II,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14925,0352-2103,,Unconfirmed,905,0352-P03,Immunomonitoring for Cancer Vaccines Development,Unconfirmed,METHOD,Method,NONE,Not Classified,,,,000300,IS - Methodological Studies
14926,1321-0023,,Unconfirmed,820,1321-P01,Idarucizumab India PMS program,Unconfirmed,NISND,NISND incl. Chart Abstractions,NONE,Not Classified,,,,000410,NISnd ‚Äì Study - Other
14927,1305-0020,,Preparing,883,1305-P03,Food effect trial,Preparing,PIHPZ,Phase I HPZ,I,Phase I,,2017-002271-26,30-MAY-17,000100,IS - Clin Study - Clin Pharm - Other
14928,1321-0024,,Unconfirmed,820,1321-P01,Feasibility of early tx on MSU,Unconfirmed,IIS,Investigator Initiated Study,IV,Phase IV,,,,,
14929,1218-0181,,Preparing,835,1218-P05,IIS-1-093-CN_Yu ,Preparing,IIS,Investigator Initiated Study,,,,,,000150,IS - Clin Study - Explore
14930,1321-0025,,Unconfirmed,820,1321-P01,Praxbind on the MSU ischemic,Unconfirmed,IIS,Investigator Initiated Study,IV,Phase IV,,,,,
14931,1199-0317,,Unconfirmed,690,1199-P03,Response to ninterdanib by TOLLIP genotype,Unconfirmed,PRELIM,Preliminary,IIIB,Phase IIIb,,,,,
14932,0352-2104,,Unconfirmed,905,0352-P03,Pilot technology evaluation,Unconfirmed,METHOD,Method,NONE,Not Classified,,,,000300,IS - Methodological Studies
14933,0205-0538,,Unconfirmed,614,0205-P03,Comparative effectiveness of COPD treatments,Unconfirmed,NISED,Non Interventional Study Existing Data,,,,,,,
14934,1407-0016,,Unconfirmed,991,1407-P04,Target population study,Unconfirmed,FULL,Full functionality,IIB,Phase IIb,,,,000180,IS - Clin Study - Confirmatory - Subpop
14935,1407-0017,,Unconfirmed,991,1407-P04,BI 730357 in moderate asthma,Unconfirmed,FULL,Full functionality,IIIB,Phase IIIb,,,,000190,IS - Clin Study - Confirmatory - Other
14936,1408-0005,,Unconfirmed,987,1408-P01,SRD in Japanese healthy volunteers,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000010,IS - Clin Study - Clin Pharm - SRD
14937,1368-0026,,Unconfirmed,917,1368-P01,BI 655130 OL Extension in fistulizing Crohn`s Disease,Unconfirmed,PRELIM,Preliminary,IB,Phase Ib,,,,,
14938,1245-0172,,Preparing,900,1245-P05,IIS-2-085-CAN_Kramer,Preparing,IIS,Investigator Initiated Study,,,,,,000150,IS - Clin Study - Explore
14939,0352-2105,,Unconfirmed,905,0352-P03,Exploratory fMRI study in BPD,Unconfirmed,METHOD,Method,NONE,Not Classified,,,,000300,IS - Methodological Studies
14940,0107-0277,,Unconfirmed,182,0107-P00,1New Bioequivalence 15 mg cap/tab - Russia,Unconfirmed,OUT,Fully Outsourced,,,,,,,
14941,1199-0318,,Preparing,847,1199-P09,Global Compassionate Use Program Mesothelioma,Preparing,COMP,Compassionate Use,,,,,,,
14942,1199-0319,,Unconfirmed,847,1199-P09,EAP Japan Mesothelioma,Unconfirmed,COMP,Compassionate Use,,,,,,,
14943,1280-0022,,Preparing,1027,1280-P03,Phase 3 HR+ breast cancer Xentuzumab + Everolimus/Exemestane,Preparing,FULL,Full functionality,III,Phase III,global pivotal trial: US, EU, China
Japan under discussion,2017-003131-11,24-JUL-17,000170,IS - Clin Study - Confirmatory/Pivotal
14944,1289-0054,,Unconfirmed,768,1289-P01,Memantine Interaction,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000030,IS - Clin Study - Clin Pharm - DDI
14945,1407-0018,,Unconfirmed,1019,1407-P05,Phase 1 PoC evaluation of BI 730357 in patients with IBD,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000131,IS - Clin Study - POCC
14946,1408-0006,,Unconfirmed,987,1408-P01,DDI with prednisone,Unconfirmed,PIHPZ,Phase I HPZ,,,,,,,
14947,1381-0009,,Unconfirmed,938,1381-P01,PD1 + longitudinal study,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,,
14948,0352-2106,,Preparing,928,0352-P04,iLaennec Phase I,Preparing,FULL,Full functionality,NONE,Not Classified,,,,000400,NISnd ‚Äì Study - Case Control
14949,0352-2107,,Unconfirmed,253,0352-P00,Recovery of impairments after stroke - an exploratory study,Unconfirmed,IIS,Investigator Initiated Study,IV,Phase IV,,,,,
14950,1160-0289,,Unconfirmed,618,1160-P02,Pradaxa tablet BA study in Japan,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000090,IS - Clin Study - Clin Pharm - BA/BE
14951,1275-0026,,Preparing,749,1275-P01,Japanese EmpaLina PMS, long term,Preparing,NISND,NISND incl. Chart Abstractions,IV,Phase IV,,,,000420,NISnd ‚Äì Study - Cohort
14952,1245-0173,,Unconfirmed,929,1245-P06,Epidemiology of HF by subtype,Unconfirmed,NISND,NISND incl. Chart Abstractions,NONE,Not Classified,,,,000460,NISed ‚Äì Study - Cohort
14953,1346-0039,,Unconfirmed,869,1346-P01,Memantine Interaction,Unconfirmed,PIHPZ,Phase I HPZ,,,,,,,
14954,1245-0174,,Unconfirmed,900,1245-P05,EMPA Acute Heart Failure (Lehrke),Unconfirmed,IIS,Investigator Initiated Study,III,Phase III,,,,000150,IS - Clin Study - Explore
14955,1245-0175,,Preparing,900,1245-P05,IIS-2-084-JP_Shimizu,Preparing,IIS,Investigator Initiated Study,,,,,,000150,IS - Clin Study - Explore
14956,0352-2108,,Unconfirmed,253,0352-P00,3 MST:evaluation of exertional breathlessness in COPD,Unconfirmed,IIS,Investigator Initiated Study,,,,,,,
14957,1289-0055,,Unconfirmed,768,1289-P01,Add-on to Memantine in Moderte AD,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000180,IS - Clin Study - Confirmatory - Subpop
14958,1289-0056,,Unconfirmed,768,1289-P01,Pan-Asian mild and moderate AD,Unconfirmed,PRELIM,Preliminary,IIIB,Phase IIIb,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14959,1419-0001,,Unconfirmed,1010,1419-P01,SRD + MRD study in healthy subjects,Unconfirmed,PIHPZ,Phase I HPZ,,,,,,,
14960,1419-0002,,Unconfirmed,1010,1419-P01,Renail impairment study in CKD patients,Unconfirmed,PIHPZ,Phase I HPZ,,,,,,,
14961,1160-0290,,Preparing,618,1160-P02,Prediction of AF following Stroke,Preparing,IIS,Investigator Initiated Study,NONE,Not Classified,,,,,
14962,0205-0539,,Unconfirmed,683,0205-P05,UNTWIST 2,Unconfirmed,NISED,Non Interventional Study Existing Data,,,,,,,
14963,0352-2109,,Unconfirmed,905,0352-P03,AERO (Acute Exacerbations of COPD),Unconfirmed,METHOD,Method,,,,,,000300,IS - Methodological Studies
14964,1199-0320,,Preparing,942,1199-P15,QST to assess and quantify thoracic pain in patients with IL,Preparing,IIS,Investigator Initiated Study,,,,,,000300,IS - Methodological Studies
14965,1418-0001,,Unconfirmed,1008,1418-P01,Phase I SRD/MRD ,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000010,IS - Clin Study - Clin Pharm - SRD
14966,1371-0008,,Unconfirmed,921,1371-P01,MRD moderate Asthma ,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000020,IS - Clin Study - Clin Pharm - MRD
14967,1371-0009,,Unconfirmed,921,1371-P01,16 wks ad on /dose ranging,Unconfirmed,FULL,Full functionality,II,Phase II,,,,000131,IS - Clin Study - POCC
14968,1371-0010,,Unconfirmed,921,1371-P01,12wks dose ranging on top ICS  ,Unconfirmed,FULL,Full functionality,II,Phase II,,,,000140,IS - Clin Study - DRF
14969,1371-0011,,Unconfirmed,921,1371-P01,Japanese bridging study,Unconfirmed,FULL,Full functionality,II,Phase II,,,,000140,IS - Clin Study - DRF
14970,1371-0012,,Unconfirmed,921,1371-P01,Human ADME study,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000110,IS - Clin Study - Clin Pharm - Other/ADME
14971,1371-0013,,Unconfirmed,921,1371-P01,ped. adolescent PK/PD & safety,Unconfirmed,FULL,Full functionality,II,Phase II,,,,000140,IS - Clin Study - DRF
14972,1371-0014,,Unconfirmed,921,1371-P01,52wks asthma exacerbation study,Unconfirmed,FULL,Full functionality,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14973,1371-0015,,Unconfirmed,921,1371-P01,52wks asthma exacerbation study,Unconfirmed,FULL,Full functionality,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14974,1371-0016,,Unconfirmed,921,1371-P01,Absolute BA (incl. SRD) study,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000090,IS - Clin Study - Clin Pharm - BA/BE
14975,1371-0017,,Unconfirmed,921,1371-P01,Hepatic Impairment trial,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000040,IS - Clin Study - Clin Pharm - Hep
14976,1367-0017,,Unconfirmed,913,1367-P01,Phase II study in lymphoma,Unconfirmed,FULL,Full functionality,I/II,Phase I/II,,,,000131,IS - Clin Study - POCC
14977,1367-0018,,Unconfirmed,913,1367-P01,Phase II study in HGBL,Unconfirmed,FULL,Full functionality,II,Phase II,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14978,1367-0019,,Unconfirmed,913,1367-P01,Phase III study in lymphoma,Unconfirmed,FULL,Full functionality,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14979,1367-0020,,Unconfirmed,913,1367-P01,Phase II study in solid tumours,Unconfirmed,FULL,Full functionality,I/II,Phase I/II,,,,000131,IS - Clin Study - POCC
14980,1367-0021,,Unconfirmed,913,1367-P01,Phase III study in solid tumours,Unconfirmed,FULL,Full functionality,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14981,1199-0321,,Unconfirmed,942,1199-P15,Prospective multicentre NIS on IPF(nat Russian IPF registry),Unconfirmed,IIS,Investigator Initiated Study,,,,,,,
14982,1245-0176,,Unconfirmed,695,1245-P01,SDB in T2DM in real world setting,Unconfirmed,NISED,Non Interventional Study Existing Data,,,,,,,
14983,0502-0612,,Unconfirmed,93,0502-P03,Comparison of the medication adherence,Unconfirmed,NISED,Non Interventional Study Existing Data,,,,,,,
14984,1336-0012,,Unconfirmed,850,1336-P01,Phsae I/Ib in japanese patients,Unconfirmed,FULL,Full functionality,,,,,,,
14985,1200-0294,,Unconfirmed,936,1200-P12,Afatinib confirmatory trial in paediatrics,Unconfirmed,FULL,Full functionality,,,,,,,
14986,1200-0295,,Preparing,770,1200-P06,efficacy+safety Afa starting dose 30mg OD in Caucasian pts,Preparing,IIS,Investigator Initiated Study,,,,,,,
14987,1371-0018,,Unconfirmed,921,1371-P01,Renal Impairment trial,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000050,IS - Clin Study - Clin Pharm - Renal
14988,1371-0019,,Unconfirmed,921,1371-P01,QTc study,Unconfirmed,FULL,Full functionality,I,Phase I,,,,000070,IS - Clin Study - Clin Pharm - QT
14989,0135-0335,,Unconfirmed,20,0135-P05,Revision,Unconfirmed,IIS,Investigator Initiated Study,,,,,,,
14990,1237-0072,,Unconfirmed,678,1237-P01,Changes in health status in COPD patients,Unconfirmed,NISND,NISND incl. Chart Abstractions,,,,,,000410,NISnd ‚Äì Study - Other
14991,1199-0322,,Unconfirmed,946,1199-P16,Prevalence & Cost Burden Analysis in PF-ILD,Unconfirmed,NISND,NISND incl. Chart Abstractions,,,,,,,
14992,0135-0336,,Unconfirmed,20,0135-P05,Gauteng (SA) Registry,Unconfirmed,NISND,NISND incl. Chart Abstractions,IV,Phase IV,,,,,
14993,1245-0177,,Unconfirmed,695,1245-P01,Insulin Usage in the Treatment of Diabetes in Germany,Unconfirmed,NISED,Non Interventional Study Existing Data,,,,,,000450,NISed ‚Äì Study - Other
14994,1346-0040,,Unconfirmed,869,1346-P01,Pivotal Study in Moderate AD,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14995,1346-0041,,Unconfirmed,869,1346-P01,Add-on to Memantine in Moderate AD,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14996,1399-0004,,Unconfirmed,971,1399-P01,Pivotal phase III in A/A,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14997,1399-0005,,Unconfirmed,971,1399-P01,Pivotal phase III in A/A,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
14998,1399-0006,,Unconfirmed,971,1399-P01,Pivotal 6 - 11 years,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000180,IS - Clin Study - Confirmatory - Subpop
14999,1399-0007,,Unconfirmed,971,1399-P01,Pivotal <6 years.,Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000180,IS - Clin Study - Confirmatory - Subpop
15000,1399-0008,,Unconfirmed,1028,1399-P02,Pan-Asian phase I trial,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000020,IS - Clin Study - Clin Pharm - MRD
15001,1399-0009,,Unconfirmed,1028,1399-P02,Phase IIa PoC in COPD,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000132,IS - Clin Study - POCP
15002,1399-0010,,Unconfirmed,1028,1399-P02,Phase IIb dose-ranging in COPD,Unconfirmed,PRELIM,Preliminary,II,Phase II,,,,000140,IS - Clin Study - DRF
15003,1399-0011,,Unconfirmed,1028,1399-P02,Pivotal phase III in COPD (I),Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
15004,1399-0012,,Unconfirmed,1028,1399-P02,Pivotal phase III in COPD (II),Unconfirmed,PRELIM,Preliminary,III,Phase III,,,,000170,IS - Clin Study - Confirmatory/Pivotal
15005,1399-0013,,Unconfirmed,971,1399-P01,ADME trial,Unconfirmed,PRELIM,Preliminary,I,Phase I,,,,000110,IS - Clin Study - Clin Pharm - Other/ADME
15006,1399-0014,,Unconfirmed,971,1399-P01,Relative BA trial,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,2017‚Äê000855‚Äê24,22-FEB-17,000090,IS - Clin Study - Clin Pharm - BA/BE
15007,1386-0020,,Unconfirmed,966,1386-P02,Characterization of patients with DR and DME,Unconfirmed,NISED,Non Interventional Study Existing Data,,,,,,,
15008,1419-0003,,Unconfirmed,1010,1419-P01,PanAsian SRD+MRD HV,Unconfirmed,PIHPZ,Phase I HPZ,I,Phase I,,,,,
15009,1368-0027,,Unconfirmed,976,1368-P02,Flare Prevention Phase III Trial in GPP,Unconfirmed,FULL,Full functionality,III,Phase III,,,,,
15010,1416-0008,,Unconfirmed,1001,1416-P01,BI 730460 PoCC Psoriasis,Unconfirmed,FULL,Full functionality,,,,,,,
15011,1416-0009,,Unconfirmed,1001,1416-P01,BI 730460 Pivotal Phase 3 Efficacy Trial (1) vs Apremilast,Unconfirmed,FULL,Full functionality,,,,,,,
15012,1416-0010,,Unconfirmed,1001,1416-P01,BI 730460 Pivotal Phase 3 Efficacy Trial (2) vs Apremilast,Unconfirmed,FULL,Full functionality,,,,,,,
15013,1416-0011,,Unconfirmed,1001,1416-P01,BI 730460 - Psoriasis Open Label Extension,Unconfirmed,FULL,Full functionality,,,,,,,
15014,1407-0019,,Unconfirmed,990,1407-P03,BI 730357 Pivotal Phase 3 Trial (1) in PsA,Unconfirmed,FULL,Full functionality,,,,,,,
15015,1407-0020,,Unconfirmed,990,1407-P03,BI 730357 Pivotal Phase 3 Trial (2) in PsA,Unconfirmed,FULL,Full functionality,,,,,,,
15016,1407-0021,,Unconfirmed,990,1407-P03,BI 730357 Long-term Extension Trial in PsA,Unconfirmed,FULL,Full functionality,,,,,,,
15017,1379-0009,,Unconfirmed,934,1379-P01,BI 891065 + BI 754091 in MM (dose escalation + expansion),Unconfirmed,PRELIM,Preliminary,,,,,,,
15018,1199-0323,,Unconfirmed,942,1199-P15,Prospective multicentre non-interventional study on IPF,Unconfirmed,IIS,Investigator Initiated Study,,,,,,,
15019,0352-2110,,Unconfirmed,905,0352-P03,Global Atrophie Biomarker Evaluation Study (GABiE),Unconfirmed,METHOD,Method,,,,,,000300,IS - Methodological Studies
15020,0352-2111,,Unconfirmed,905,0352-P03,Single Cell COPD Study,Unconfirmed,OUT,Fully Outsourced,,,,,,000300,IS - Methodological Studies
15021,1407-0022,,Unconfirmed,1019,1407-P05,Phase II Dose-finding Trial in Patients with CD,Unconfirmed,FULL,Full functionality,,,,,,,
15022,1407-0023,,Unconfirmed,1019,1407-P05,Pivotal Phase III Trial (1) in CD,Unconfirmed,FULL,Full functionality,,,,,,,
15023,1407-0024,,Unconfirmed,1019,1407-P05,Pivotal Phase 3 Trial (2) in Patients with CD,Unconfirmed,FULL,Full functionality,,,,,,,
15024,1407-0025,,Unconfirmed,1019,1407-P05,Maintenance of Remission in Patients with CD,Unconfirmed,FULL,Full functionality,,,,,,,
15025,1407-0026,,Unconfirmed,989,1407-P02,Phase II Dose-finding Trial in Patients with AS,Unconfirmed,FULL,Full functionality,,,,,,,
15026,1407-0027,,Unconfirmed,989,1407-P02,Phase III Pivotal Evaluation in Patients with AS (1),Unconfirmed,FULL,Full functionality,,,,,,,
15027,1407-0028,,Unconfirmed,989,1407-P02,Phase III Pivotal Evaluation in Patients with AS (2),Unconfirmed,FULL,Full functionality,,,,,,,
15028,1199-0324,,Unconfirmed,690,1199-P03,Pulmonary Rehabilitation and Nintedanib in IPF,Unconfirmed,PRELIM,Preliminary,,,,,,,
15029,1199-0325,,Unconfirmed,942,1199-P15,Self monitoring of spirometry and syptoms in patients with I,Unconfirmed,IIS,Investigator Initiated Study,,,,,,,
15030,1245-0178,,Unconfirmed,900,1245-P05,IIS-2-087-GER_Schulze,Unconfirmed,IIS,Investigator Initiated Study,,,,,,000150,IS - Clin Study - Explore
15031,1245-0179,,Unconfirmed,900,1245-P05,IIS-2-092-US_Badimon,Unconfirmed,IIS,Investigator Initiated Study,,,,,,000150,IS - Clin Study - Explore
